

0001655759-24-00013110-Q ARVINAS, INC. 2024103020241030170104170104170104 0 0001655759-24-000131 10-Q 91 20240930 20241030 20241030
ARVINAS, INC. 0001655759 2834 472566120 DE 1231 10-Q 34 001-38672 241411260 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511
203-535-1456 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511 ARVINAS INC. 20181001 ARVINAS HOLDING COMPANY, LLC 20151015
10-Q 1 arvn-20240930.htm 10-Q arvn-20240930false2024Q30001655759--12-
31311111xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:sgftarvn:product00016557592024-01-012024-09-3000016557592024-10-
2500016557592024-09-3000016557592023-12-3100016557592024-07-012024-09-3000016557592023-07-012023-09-3000016557592023-01-012023-09-
300001655759us-gaap:CommonStockMember2024-06-300001655759us-gaap:RetainedEarningsMember2024-06-300001655759us-
gaap:AdditionalPaidInCapitalMember2024-06-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000016557592024-06-
300001655759us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001655759us-gaap:RetainedEarningsMember2024-07-012024-09-
300001655759us-gaap:CommonStockMember2024-07-012024-09-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-
012024-09-300001655759us-gaap:CommonStockMember2024-09-300001655759us-gaap:RetainedEarningsMember2024-09-300001655759us-
gaap:AdditionalPaidInCapitalMember2024-09-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001655759us-
gaap:CommonStockMember2023-06-300001655759us-gaap:RetainedEarningsMember2023-06-300001655759us-
gaap:AdditionalPaidInCapitalMember2023-06-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000016557592023-06-
300001655759us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001655759us-gaap:RetainedEarningsMember2023-07-012023-09-
300001655759us-gaap:CommonStockMember2023-07-012023-09-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-
012023-09-300001655759us-gaap:CommonStockMember2023-09-300001655759us-gaap:RetainedEarningsMember2023-09-300001655759us-
gaap:AdditionalPaidInCapitalMember2023-09-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000016557592023-09-
300001655759us-gaap:CommonStockMember2023-12-310001655759us-gaap:RetainedEarningsMember2023-12-310001655759us-
gaap:AdditionalPaidInCapitalMember2023-12-310001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001655759us-
gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001655759us-gaap:RetainedEarningsMember2024-01-012024-09-300001655759us-
gaap:CommonStockMember2024-01-012024-09-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-
300001655759us-gaap:CommonStockMember2022-12-310001655759us-gaap:RetainedEarningsMember2022-12-310001655759us-
gaap:AdditionalPaidInCapitalMember2022-12-310001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100016557592022-12-
310001655759us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001655759us-gaap:RetainedEarningsMember2023-01-012023-09-
300001655759us-gaap:CommonStockMember2023-01-012023-09-300001655759us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-
012023-09-300001655759arvn:NovartisPharmaAGMemberus-gaap:LicenseMember2024-05-310001655759arvn:NovartisPharmaAGMemberus-
gaap:LicenseMember2021-08-012024-09-300001655759arvn:NovartisPharmaAGMemberus-gaap:LicenseMember2024-01-012024-09-
300001655759arvn:NovartisPharmaAGMemberus-gaap:LicenseMember2024-09-300001655759arvn:NovartisPharmaAGMemberus-
gaap:LicenseMember2024-04-300001655759arvn:PfizerIncorporationMemberarvn:CollaborationAgreementMember2021-07-
310001655759arvn:PfizerIncorporationMembersrt:MaximumMemberarvn:RegulatoryAndSalesBasedMilestonesMember2021-07-
310001655759arvn:PfizerIncorporationMemberarvn:RegulatoryMilestonePaymentsMember2021-07-
310001655759arvn:PfizerIncorporationMemberarvn:SalesBasedMilestonesMember2021-07-
310001655759arvn:PfizerIncorporationMemberarvn:SalesBasedMilestonePaymentsMember2021-08-012024-09-
300001655759arvn:PfizerIncorporationMemberarvn:RegulatoryMilestonePaymentsMember2021-08-012024-09-
300001655759arvn:PfizerIncorporationMemberarvn:CollaborationAgreementMember2024-01-012024-09-
300001655759arvn:PfizerIncorporationMemberarvn:CollaborationAgreementMember2024-09-300001655759arvn:BayerAGMember2019-06-
300001655759arvn:BayerAGMemberarvn:ResearchFundingPaymentsMember2023-12-
310001655759arvn:BayerAGMemberarvn:ResearchFundingPaymentsMember2023-01-012023-09-
300001655759arvn:BayerAGMembersrt:MaximumMemberarvn:DevelopmentMilestonePaymentsMember2019-06-
300001655759arvn:BayerAGMembersrt:MaximumMemberarvn:SalesBasedMilestonePaymentsMember2019-06-
300001655759arvn:BayerAGMemberarvn:SalesBasedMilestonePaymentsMember2024-01-012024-09-
300001655759arvn:BayerAGMemberarvn:DevelopmentMilestonePaymentsMember2024-01-012024-09-
300001655759arvn:PfizerIncorporationMember2018-01-012018-12-
310001655759arvn:PfizerIncorporationMembersrt:MaximumMemberarvn:OptionPaymentsToLicenseAgreementMember2024-09-
300001655759arvn:PfizerIncorporationMembersrt:MaximumMemberarvn:DevelopmentMilestonePaymentsMember2024-09-
300001655759arvn:PfizerIncorporationMembersrt:MaximumMemberarvn:SalesBasedMilestonePaymentsMember2024-09-
300001655759arvn:PfizerIncorporationMember2023-01-012023-09-
300001655759arvn:PfizerIncorporationMemberarvn:SalesBasedMilestonePaymentsMember2024-01-012024-09-
300001655759arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember2017-11-012017-11-
300001655759arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMembersrt:MaximumMemberarvn:DevelopmentMilestonePaymentsMember2024-
09-300001655759arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMemberarvn:RegulatoryMilestonePaymentsMember2024-09-
300001655759arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMemberarvn:CommercialMilestonesMember2024-09-
300001655759arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember2024-01-012024-09-
300001655759arvn:UpdatedResearchTimelinesMember2023-01-012023-09-3000016557592024-10-012024-09-3000016557592025-01-012024-09-
3000016557592026-01-012024-09-3000016557592027-01-012024-09-3000016557592028-01-012024-09-3000016557592029-01-012024-09-
300001655759us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-
09-300001655759us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentDebtSecuritiesMember2024-09-300001655759us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember2024-09-300001655759us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001655759us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-
310001655759us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-
310001655759arvn:LaboratoryEquipmentMember2024-09-300001655759arvn:LaboratoryEquipmentMember2023-12-310001655759us-
gaap:LeaseholdImprovementsMember2024-09-300001655759us-gaap:LeaseholdImprovementsMember2023-12-310001655759us-
gaap:OfficeEquipmentMember2024-09-300001655759us-gaap:OfficeEquipmentMember2023-12-310001655759arvn:A101CollegeStreetLLCMemberus-
gaap:LeaseholdImprovementsMember2024-07-012024-09-300001655759arvn:A101CollegeStreetLLCMemberus-
gaap:LeaseholdImprovementsMember2024-01-012024-09-300001655759srt:MinimumMember2024-09-300001655759srt:MaximumMember2024-09-
3000016557592021-05-310001655759arvn:OneTimeCashTerminationFeeMember2024-08-152024-08-
150001655759arvn:WriteoffOfPrepaidRentMember2024-08-152024-08-150001655759us-gaap:AssetPledgedAsCollateralMemberus-
gaap:LetterOfCreditMember2024-09-300001655759arvn:TwoThousandAndEighteenAssistanceAgreementMember2024-09-
300001655759arvn:TwoThousandAndEighteenAssistanceAgreementMember2023-12-
310001655759srt:CTarvn:TwoThousandAndEighteenAssistanceAgreementMember2018-09-
300001655759srt:CTarvn:TwoThousandAndEighteenAssistanceAgreementMember2018-09-012018-09-
300001655759arvn:AtTheMarketOfferingMemberarvn:PiperSandlerAndCantorMemberarvn:EquityDistributionAgreementMember2023-11-
300001655759arvn:AtTheMarketOfferingMemberarvn:PiperSandlerAndCantorMemberarvn:EquityDistributionAgreementMember2024-01-012024-09-
300001655759us-gaap:EmployeeStockMember2018-09-300001655759us-gaap:EmployeeStockMember2018-09-300001655759us-
gaap:EmployeeStockMember2024-09-300001655759us-gaap:EmployeeStockMember2024-01-012024-09-300001655759us-
gaap:EmployeeStockMember2023-01-012023-09-300001655759arvn:TwoThousandEighteenStockIncentivePlanMember2018-09-
300001655759arvn:TwoThousandEighteenStockIncentivePlanMembersrt:MaximumMember2018-09-
300001655759arvn:TwoThousandEighteenStockIncentivePlanMembersrt:MinimumMember2019-01-012019-12-
310001655759arvn:TwoThousandEighteenStockIncentivePlanMember2019-01-012019-12-
310001655759arvn:TwoThousandEighteenStockIncentivePlanMember2024-09-300001655759us-gaap:EmployeeStockMember2024-07-012024-09-
300001655759us-gaap:EmployeeStockMember2023-07-012023-09-300001655759us-gaap:EmployeeStockOptionMember2024-01-012024-09-
300001655759us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001655759us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-
01-012024-09-300001655759us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-300001655759us-
gaap:EmployeeStockOptionMembersrt:MinimumMember2023-01-012023-09-300001655759us-
gaap:EmployeeStockOptionMembersrt:MaximumMember2023-01-012023-09-300001655759us-
gaap:EmployeeStockOptionMembersrt:MinimumMember2024-09-300001655759us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-09-
300001655759us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-09-300001655759us-
gaap:EmployeeStockOptionMembersrt:MaximumMember2023-09-300001655759arvn:TwoThousandEighteenStockIncentivePlanMember2023-12-
310001655759arvn:TwoThousandEighteenStockIncentivePlanMember2023-01-012023-12-
310001655759arvn:TwoThousandEighteenStockIncentivePlanMember2024-01-012024-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2024-
01-012024-09-300001655759us-gaap:ShareBasedPaymentArrangementEmployeeMemberarvn:TwoThousandEighteenStockIncentivePlanMemberus-
gaap:RestrictedStockUnitsRSUMember2023-12-310001655759us-
gaap:ShareBasedPaymentArrangementEmployeeMemberarvn:TwoThousandEighteenStockIncentivePlanMemberus-

gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001655759us-gaap:ShareBasedPaymentArrangementEmployeeMemberarvn:TwoThousandEighteenStockIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2024-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001655759arvn:PreFundedWarrantMember2023-11-300001655759us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001655759us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001655759us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001655759us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001655759us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMemberarvn:BayerCropScienceLPMember2019-07-310001655759arvn:OerthBioLimitedLiabilityCorporationMember2019-07-310001655759arvn:OerthBioLimitedLiabilityCorporationMemberarvn:BayerCropScienceLPMember2024-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMemberarvn:BayerCropScienceLPMember2023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2024-07-012024-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2023-07-012023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2024-07-012024-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2023-07-012023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2023-07-012023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2024-01-012024-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2023-01-012023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2023-01-012023-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2024-01-012024-09-300001655759arvn:OerthBioLimitedLiabilityCorporationMember2023-01-012023-09-300001655759arvn:YaleUniversityMemberarvn:UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember2024-06-012024-06-300001655759arvn:YaleUniversityMemberarvn:MilestonePaymentOnFirstAnniversaryOfSigningMember2024-06-300001655759arvn:YaleUniversityMembersrt:MaximumMemberarvn:MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember2024-06-300001655759arvn:YaleUniversityMembersrt:MinimumMember2013-07-052013-07-050001655759arvn:YaleUniversityMembersrt:LicenseFirstLicensedProductMemberarvn:SuccessBasedMilestonePaymentsMember2013-07-052013-07-050001655759arvn:YaleUniversityMembersrt:LicenseSecondLicensedProductMemberarvn:SuccessBasedMilestonePaymentsMember2013-07-052013-07-050001655759arvn:YaleUniversityMembersrt:MaximumMember2013-07-052013-07-050001655759arvn:FoundationMedicineIncMembersrt:MaximumMemberarvn:SuccessBasedMilestonePaymentsMember2022-06-042022-06-04Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-Q (Mark One)A1/2QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024 ORoTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to .Commission File Number: 001-38672 ARVINAS, INC. (Exact name of registrant as specified in its Charter) Delaware47-2566120(State or other jurisdiction of incorporation or organization).(I.R.S. EmployerIdentification No.)5 Science Park 395 Winchester Ave. New Haven, Connecticut 06511(Address of principal executive offices)(Zip Code)Registrant's telephone number, including area code: (203) 535-1456 Securities registered pursuant to Section 12(b) of the Act:Title of each classA TradingSymbol(s)A Name of each exchange on which registeredCommon stock, par value \$0.001 per shareA ARVNThe Nasdaq Stock Market LLCIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes A1/2 No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes A1/2 No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.Large accelerated filerA1/2Accelerated filerNon-accelerated filerSmaller reporting companyoEmerging growth companyoIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes A No A1/2As of OctoberA 25, 2024, the registrant had 68,713,098 shares of common stock, \$0.001 par value per share, outstanding.Table of ContentsTable of ContentsPagePART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations and Comprehensive Loss3Condensed Consolidated Statements of Changes in Stockholders' Equity4Condensed Consolidated Statements of Cash Flows5Notes to Condensed Consolidated Financial Statements6Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk36Item 4.Controls and Procedures36PART II.OTHER INFORMATION37Item 1.Legal Proceedings37Item 1A.Risk Factors37Item 2.Unregistered Sales of Equity Securities and Use of Proceeds38Item 5.Other Information38Item 6.Exhibits39Signatures40iTable of ContentsCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "goals," "will," "would," "could," "should," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:the initiation, timing, progress and results of our current and any future clinical trials of vepdegestrant, ARV-102 and ARV-393 and current trials of ARV-766, which we are transitioning to Novartis Pharma AG, and bavdegalutamide (ARV-110), including statements regarding the period during which the results of the clinical trials will become available;the timing of, and our ability to obtain, marketing approval of our product candidates and the ability of our product candidates to meet existing or future regulatory standards;the potential receipt of payments based on achievement of milestones under our collaborations, including our collaboration with Pfizer Inc. entered into in July 2021;the potential receipt of payments based on the achievement of milestones related to ARV-766 and future royalties under our license agreement with Novartis Pharma AG; our plans to pursue research and development of other product candidates;the filing of an investigational new drug application for our kirsten rat sarcoma GD12 program;the potential advantages of our platform technology and our product candidates;the extent to which our scientific approach and platform technology may potentially address a broad range of diseases and disease targets;the potential receipt of revenue from future sales of our product candidates;the rate and degree of market acceptance and clinical utility of our product candidates;our estimates regarding the potential market opportunity for our product candidates;our sales, marketing and distribution capabilities and strategy;our ability to establish and maintain arrangements for manufacture of our product candidates;our ability to enter into additional collaborations with third parties;our intellectual property position;our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;the impact of government laws and regulations; andour competitive position.We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended DecemberA 31, 2023, filed on February 27, 2024, and this Quarterly Report on Form 10-Q, particularly in the "Risk Factors" sections, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do iTable of Contentsnot reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may differ materially from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law.Throughout this Quarterly Report on Form 10-Q, references to the "Company," "Arvinas," "we," "us," "our," "its" and "our," refer to Arvinas, Inc. and its consolidated subsidiaries, except where the context requires otherwise, or any one or more of them as the context may require, and "board of directors" refers to the board of directors of Arvinas, Inc.The Arvinas name and logo are our trademarks. We also own the service mark and the registered U.S. trademark for PROTAC®. This Quarterly Report on Form 10-Q contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q, including logos, artwork and other visual displays, may appear without the ® or ®, ¢ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.iiiTable of ContentsPART Iâ"FINANCIAL INFORMATIONItem 1. Financial Statements.ARVINAS, INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets (unaudited)(dollars and shares in millions, except per share amounts)September 30, 2024December 31, 2023AssetsCurrent assets:Cash and cash equivalents\$85.2A \$311.7A Restricted cashA 5.5A Marketable securities1,036.4A 949.3A Accounts receivable7.3A A Other receivables7.5A 7.2A Prepaid expenses and other current assets13.1A 6.5A Total current assets1,149.5A 1,280.2A Property, equipment and leasehold improvements, net6.8A 11.5A Operating lease right of use assets1.0A 2.5A Collaboration contract asset and other assets9.8A 10.4A Total assets\$1,167.1A \$1,304.6A Liabilities and stockholders' equityCurrent liabilities:Accounts payable and accrued liabilities\$75.9A \$92.2A Deferred revenue199.2A 163.0A Current portion of operating lease liabilities0.8A 1.9A Total current

liabilities275.1Â 257.1Â Deferred revenue304.5Â 386.2Â Long-term debt0.6Â 0.8Â Operating lease liabilities0.1Â 0.5Â Total liabilities581.9Â 644.6Â Commitments and Contingencies (Note 13)Stockholdersâ€™ equity:Preferred stock, \$0.001 par value, zero shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectivelyâ€”Â 0.0Â Common stock, \$0.001 par value; 68.7 and 68.0 shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively0.1Â 0.1Â Accumulated deficit(1,486.5)(1,332.7)Additional paid-in capital2,068.3Â 1,995.7Â Accumulated other comprehensive income (loss)4.1Â (3.1)Total stockholdersâ€™ equity586.0Â 660.0Â Total liabilities and stockholdersâ€™ equity\$1,167.1Â \$1,304.6Â See accompanying notes to the condensed consolidated financial statementsTable of ContentsARVINAS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)(dollars and shares in millions, except per share amounts)For the Three Months EndedSeptember 30,For the Nine Months EndedSeptember 30,Consolidated Statements of Operations2024202320242023Revenue\$102.4Â \$34.6Â \$204.2Â \$121.6Â Operating expenses:Research and development86.9Â 85.9Â 264.9Â 284.5Â General and administrative75.8Â 22.6Â 131.3Â 73.3Â Total operating expenses162.7Â 108.5Â 396.2Â 357.8Â Loss from operations(60.3)(73.9)(192.0)(236.2)Other (expense) incomeOther expense, net(2.6)â€”(2.7)(1.1)Interest income, net14.3Â 10.0Â 41.9Â 26.6Â Total other (expense) income11.7Â 10.0Â 39.2Â 25.5Â Net loss before income taxes and loss from equity method investment(48.6)(63.9)(152.8)(210.7)Income tax (expense) benefit(0.6)â€”(1.0)0.7Â Loss from equity method investmentâ€”(0.1)â€”(2.5)Net loss\$(49.2)\$(64.0)\$(153.8)\$(212.5)Net loss per common share, basic and diluted\$(0.68)\$(1.18)\$(2.14)\$(3.97)Weighted average common shares outstanding, basic and diluted72.1Â 54.1Â 71.9Â 53.6Â (dollars in millions)For the Three Months EndedSeptember 30,For the Nine Months EndedSeptember 30,Consolidated Statements of Comprehensive Loss2024202320242023Net loss\$(49.2)\$(64.0)\$(153.8)\$(212.5)Other comprehensive loss:Unrealized gain on available-for-sale securities7.9Â 3.0Â 7.2Â 10.0Â Comprehensive loss\$(41.3)\$(61.0)\$(146.6)\$(202.5)See accompanying notes to the condensed consolidated financial statements3Table of ContentsARVINAS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Changes in Stockholdersâ€™ Equity (unaudited) (dollars and shares in millions)CommonAccumulated DeficitAdditional Paid-inCapitalAccumulated Other Comprehensive (Loss) Income Total Stockholders' EquityFor the Three Months Ended September 30, 2024 and 2023SharesAmountBalance as of June 30, 202468.6Â 0.1Â \$(1,437.3)\$2,041.2Â \$(3.8)\$600.2Â Stock-based compensationâ€”Â 0.0Â 24.7Â 24.7Â Net lossâ€”(49.2)â€”(49.2)â€”(49.2)Issuance of common stock under equity incentive plans0.1Â 0.1Â 2.4Â 2.4Â Unrealized gain on available-for-sale securitiesâ€”Â 0.0Â 7.9Â 7.9Â Balance as of SeptemberÂ 30, 202468.7Â 0.1Â \$(1,486.5)\$2,068.3Â \$4.1Â \$586.0Â Balance as of June 30, 202353.4Â 0.1Â \$(1,113.9)\$1,589.6Â \$(12.2)\$463.6Â Stock-based compensationâ€”Â 0.0Â 16.7Â 16.7Â Net lossâ€”(64.0)â€”(64.0)â€”(64.0)Issuance of common stock under equity incentive plans0.1Â 0.1Â 1.9Â 1.9Â Common stock issued, net of issuance costs of \$1.11.5Â 0.0Â 36.0Â 36.0Â Unrealized gain on available-for-sale securitiesâ€”Â 0.0Â 3.0Â 3.0Â Balance as of SeptemberÂ 30, 202355.0Â 0.1Â \$(1,177.9)\$1,644.2Â \$(9.2)\$457.2Â (dollars and shares in millions)CommonAccumulated Deficit Additional Paid-in Capital Accumulated Other Comprehensive (Loss) Income Total Stockholders' Equity For the Nine Months Ended September 30, 2024 and 2023SharesAmountBalance as of DecemberÂ 31, 202368.0Â 0.1Â \$(1,332.7)\$1,995.7Â \$(3.1)\$660.0Â Stock-based compensationâ€”Â 0.0Â 64.9Â 64.9Â Net lossâ€”(153.8)â€”(153.8)â€”(153.8)Issuance of common stock under equity incentive plans0.7Â 0.0Â 7.7Â 7.7Â Unrealized gain on available-for-sale securitiesâ€”Â 0.0Â 7.2Â 7.2Â Balance as of SeptemberÂ 30, 202468.7Â 0.1Â \$(1,486.5)\$2,068.3Â \$4.1Â \$586.0Â Balance as of DecemberÂ 31, 202353.2Â 0.1Â \$(965.4)\$1,549.4Â \$(19.2)\$564.9Â Stock-based compensationâ€”Â 0.0Â 54.9Â 54.9Â Net lossâ€”(212.5)â€”(212.5)â€”(212.5)Issuance of common stock under equity incentive plans0.3Â 0.0Â 3.9Â 3.9Â Common stock issued, net of issuance costs of \$1.11.5Â 0.0Â 36.0Â 36.0Â Unrealized gain on available-for-sale securitiesâ€”Â 0.0Â 10.0Â 10.0Â Balance as of SeptemberÂ 30, 202355.0Â 0.1Â \$(1,177.9)\$1,644.2Â \$(9.2)\$457.2Â See accompanying notes to the condensed consolidated financial statements4Table of ContentsARVINAS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows (unaudited)For the Nine Months EndedSeptember 30,(dollars in millions)20242023Cash flows from operating activities:Net loss\$(153.8)\$(212.5)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization3.5Â 3.6Â Net accretion of bond discounts/premiums(17.1)(11.6)Loss on sale of marketable securitiesâ€”Â 0.9Â Amortization of right-of-use assets1.5Â 1.4Â Amortization of collaboration contract asset3.6Â 2.0Â Net loss on disposal of property, plant and equipment2.6Â 0.0Â Stock-based compensation64.9Â 54.9Â Changes in operating assets and liabilities:Accounts receivable(7.3)(14.7)Other receivables(0.3)2.2Â Prepaid expenses and other current assets(6.4)12.3Â Collaboration contract asset(3.0)â€”Â Accounts payable and accrued liabilities(16.3)16.0Â Operating lease liability(1.6)(1.5)Deferred revenue(45.5)(117.7)Net cash used in operating activities(175.2)(264.7)Cash flows from investing activities:Purchases of marketable securities(600.8)(665.7)Maturities of marketable securities538.0Â 873.4Â Sales of marketable securitiesâ€”Â 52.3Â Purchases of property, equipment and leasehold improvements(1.5)(2.8)Proceeds from disposal of property, equipment and leaseholds improvements0.1Â 1.0Â Net cash (used in) provided by investing activities(64.2)257.2Â Cash flows from financing activities:Repayments of long-term debt(0.3)â€”Â Proceeds from issuance of common stockâ€”Â 37.1Â Payment of common stock issuance costsâ€”(1.1)Proceeds from exercise of stock options and issuance of ESPP shares7.7Â 3.9Â Net cash provided by financing activities7.4Â 39.9Â Net (decrease) increase in cash, cash equivalents and restricted cash(232.0)32.4Â Cash, cash equivalents and restricted cash, beginning of the period317.2Â 86.8Â Cash, cash equivalents and restricted cash, end of the period\$85.2Â \$119.2Â Supplemental disclosure of cash flow information:Cash paid for taxes\$1.6Â \$9.1Â See accompanying notes to the condensed consolidated financial statements5Table of ContentsARVINAS, INC. AND SUBSIDIARIESNotes to Condensed Consolidated Financial Statements (unaudited)1. Nature of Business and Basis of PresentationArvinas, Inc. and its subsidiaries (â€œArvinasâ€”the "Companyâ€”) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (â€œSECâ€”) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of DecemberÂ 31, 2023 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended DecemberÂ 31, 2023, forming part of Arvinasâ€™ 2023 Annual Report on Form 10-K filed with the SEC on FebruaryÂ 27, 2024. The preparation of the Companyâ€™s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.Risks and UncertaintiesThe Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Companyâ€™s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately \$1.1 billion as of SeptemberÂ 30, 2024.2. Summary of Accounting Pronouncements and Significant Accounting PoliciesAccounting PronouncementsRecently Adopted Accounting Pronouncements There have been no recently adopted accounting pronouncements that have had a material impact on the Company's unaudited condensed consolidated financial statements.Recently Issued Accounting Pronouncements Not Yet AdoptedSegment Reporting (Topic 280) - In November 2023, the Financial Accounting Standards Board (â€œFASBâ€”) issued Accounting Standards Update (â€œASUâ€”) No. 2023-07, â€œSegment Reporting - Improvements to Reportable Segment Disclosures,â€” which requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures 6Table of Contentsrequired by this ASU and all existing segment disclosures in Accounting Standard Codification (â€œASCâ€”) 280, â€œSegment Reporting.â€” The requirements of the ASU are effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact ASU No. 2023-07 will have on its condensed consolidated financial statements.Income Taxes (Topic 740) - In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.Significant Accounting PoliciesThere were no changes to the Companyâ€™s significant accounting policies during the nine months ended SeptemberÂ 30, 2024.Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the nine months ended SeptemberÂ 30, 2024 and 2023:(dollars in millions)September 30,2024September 30,2023Cash and cash equivalents\$85.2Â \$113.7Â Restricted cashâ€”Â 5.5Â Cash, cash equivalents and restricted cash\$85.2Â \$119.2Â Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as was required under the terms of the Terminated Lease, as discussed below in Note 6, Right-of-Use Assets and Liabilities.3. Research Collaboration and License Agreements Novartis License and Asset AgreementsIn April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of ARV-766, the Company's second generation PROTACÂ® androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of ARV-766 and has all research, development, manufacturing, and

commercialization rights with respect to the Company’s PROTAC® protein degrader targeting AR-V7, a splice variant of the AR. In May 2024, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Novartis Transaction (the “HSR Termination”). As a result of the HSR Termination and satisfaction of other closing conditions, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of \$150.0 million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional \$1.01 billion as contingent payments based on specified development, regulatory and commercial milestones for ARV-766 being met, as well as tiered royalties based on worldwide net sales of ARV-766, subject to reduction under certain circumstances as provided in the Table of ContentsNovartis License Agreement. There were no development, regulatory or commercial milestone payments, or sales-based royalties received through September 30, 2024.The Novartis License Agreement will expire on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be evaluated as a combined contract in accordance with ASC 606, Revenue from Contracts with Customers. The Company determined the fair value of the assets sold under the Novartis Asset Agreement to be \$20.0 million, which was recognized at the time of sale as revenue, and the fair value of the Novartis License Agreement to be \$130.0 million, which is being recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred.As a direct result of the Company’s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling \$3.0 million. In accordance with ASC 340, Other Assets and Deferred Costs, the Company recognized an asset of \$3.0 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the Novartis License Agreement and the Novartis Asset Agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the Novartis License Agreement and the Novartis Asset Agreement.Vepdegestrant (ARV-471) Collaboration AgreementIn July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (“Pfizer”) (the “Vepdegestrant (ARV-471) Collaboration Agreement”) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company’s proprietary compound vepdegestrant (the “Licensed Products”). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of \$650.0 million. In addition, the Company is eligible to receive up to an additional \$1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, \$400.0 million in regulatory milestones are related to marketing approvals and \$1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through September 30, 2024.The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.As a direct result of the Company’s entry into the Vepdegestrant (ARV-471) Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling \$12.9 million. In accordance with ASC 340, Other Assets and Deferred Costs, the Company recognized an asset of \$12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the Vepdegestrant (ARV-471) Collaboration Agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the Vepdegestrant (ARV-471) Collaboration Agreement.8Table of ContentsBayer Collaboration AgreementIn June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the “Bayer Collaboration Agreement”) setting forth the Company’s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras (“PROTAC® targeted protein degraders”) that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of \$17.5 million in exchange for the use of the Company’s technology license. The Company also received an additional \$12.0 million from Bayer AG from inception through 2023, including \$1.5 million received during the nine months ended September 30, 2023. These payments are being recognized over the total estimated period of performance.The Company was also eligible to receive up to \$197.5 million in development milestone payments and up to \$490.0 million in sales-based milestone payments for all designated target proteins. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. There were no development or sales-based milestone payments or royalties received through September 30, 2024. Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024. Pfizer Research Collaboration AgreementIn December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the “Pfizer Research Collaboration Agreement”). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling \$28.0 million in 2018 in exchange for use of the Company’s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional \$37.5 million in non-refundable option payments if Pfizer exercises its options for all target proteins under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to \$225.0 million in development milestone payments and up to \$550.0 million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the nine months ended September 30, 2023, the Company received payments totaling \$1.0 million for additional target proteins and services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received through September 30, 2024.Restated Genentech AgreementIn November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the “Restated Genentech Agreement”) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together “Genentech”), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of \$34.5 million (in addition to \$11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period. The Company is eligible to receive up to \$44.0 million per target protein in development milestone payments, \$52.5 million in regulatory milestone payments and \$60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through September 30, 2024.9Table of ContentsChanges in the Company's contract balances for the nine months ended September 30, 2024 and 2023 were as follows:(dollars in millions)September 30, 2024September 30, 2023Accounts receivable related to collaborationsBeginning balance\$1.0Additions8.721.7Payments received(1.4)(7.0)Ending balance\$7.3\$15.7Accounts payable related to collaborationsBeginning balance\$13.1\$5.0Additions43.531.0Payments made(42.3)(6.7)Ending balances\$14.3\$29.3Contract assets: Collaboration contract assetBeginning balance\$9.4\$10.7Additions3.0\$0Amortization(3.6)(2.0)Ending balance\$8.8\$8.7Contract liabilities: Deferred revenueBeginning balance\$549.2\$623.7Additions to collaboration agreements130.01.5Revenue recognized from balances held at the beginning of the period(82.0)(119.1)Revenue recognized from new collaborations(93.5)\$0Ending balance\$503.7\$506.1During the nine months ended September 30, 2023, the Company changed its estimate of the duration of the performance period under the Bayer Collaboration Agreement and Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and net income of \$8.2 million and a decrease in net loss per share of \$0.15 for the nine months ended September 30, 2023. The reversed revenue related to the Bayer Collaboration Agreement was fully recognized through September 30, 2024. The reversed revenue related to the Pfizer Research Collaboration Agreement will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline. During each of the three months ended September 30, 2024 and 2023 and the nine months ended September 30, 2024, no changes in accounting estimates related to the Company's collaborations were recorded.The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of September 30, 2024 totaled \$503.7 million, which is expected to be recognized in the following periods:(dollars in millions)Remainder of 2024\$84.1A 2025153.4A 2026105.0A 202757.6A 202859.8A 202943.8A Total\$503.7A 10Table of Contents4. Marketable Securities and Fair Value MeasurementsThe Company’s marketable securities consist of corporate bonds and government securities which are adjusted to fair value as of each balance sheet date based on quoted prices, which are considered Level 2 inputs.The following is a summary of the Company’s available-for-sale marketable securities measured at fair value on a recurring basis. September 30, 2024(dollars in millions)ValuationHierarchyAmortizedCostGrossUnrealizedGainsGross UnrealizedLossesFair ValueCorporate bondsLevel 2\$1,028.8\$4.4\$(0.3)\$1,032.9A Government securitiesLevel 23.5\$0\$0\$3.5Totals\$1,032.3\$4.4\$(0.3)\$1,036.4A December 31, 2023(dollars in millions)ValuationHierarchyAmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair ValueCorporate bondsLevel 2\$934.4\$1.5\$(4.6)\$931.3A Government securitiesLevel 218.0\$0\$0\$18.0Totals\$952.4\$1.5\$(4.6)\$949.3A The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.The carrying values of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these assets and liabilities.5. Property, Equipment and Leasehold Improvements Property, equipment and leasehold improvements consist of the following:(dollars in millions)September 30, 2024December 31, 2023Laboratory equipments19.4\$18.5Leasehold improvements9.3A 11.5A Office equipment2.6A 2.6A Total property, equipment and leasehold improvements31.3A 32.6A Less: accumulated depreciation and amortization(24.5)(21.1)Property, equipment and leasehold improvements, net\$6.8A \$11.5A During the three and nine months ended September 30, 2024, the Company wrote-off leasehold improvements totaling \$2.4 million resulting from the termination of the lease for its laboratory and office space at 101 College Street, as discussed below in Note 6, Right-of-Use Assets and Liabilities. During the three months ended September 30, 2024 and 2023, the

Company recognized depreciation and amortization expense of \$1.1 million and \$1.2 million, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized depreciation and amortization expense of \$3.5 million and \$3.6 million, respectively.

Table of Contents

6. Right-of-Use Assets and Liabilities

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments, which ranges from 3.0% - 7.5%. Lease expense is recognized on a straight-line basis over the lease term. The Company considers options to extend or terminate leases in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised.

In August 2024, the Company entered into a Lease Termination Agreement with 101 College Street LLC (the "Landlord"). Under the terms of the Lease Termination Agreement, the lease, by and between the Company and the Landlord, dated May 4, 2021 (as amended, the "Terminated Lease"), for certain leased premises of approximately 160,000 square feet of laboratory and office space, was terminated in full, effective August 15, 2024. The leased premises were expected to be occupied by the Company in 2025. In connection with the Lease Termination Agreement and as consideration for the Landlord's agreement to terminate the lease for its laboratory and office space at 101 College Street in full, the Company agreed to pay to the Landlord a one-time cash termination fee in the amount of \$41.5 million and wrote-off \$1.9 million of prepaid rent, both of which are recognized in "Lease termination costs" on the condensed consolidated statements of operations. The Company also cancelled its previously issued letter of credit in the amount of \$5.5 million.

The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than October 2025. The leases have a weighted average remaining term of approximately nine months. The components of lease expense were as follows:

Three Months Ended September 30,	Nine Months Ended September 30,
(dollars in millions)	(dollars in millions)
2024	2023
Operating lease costs	\$0.5
\$0.5	\$1.5
\$1.5	\$1.5

Supplemental cash flow information related to leases was as follows:

Nine Months Ended September 30,	
(dollars in millions)	
2024	
2023	
Cash paid for amounts included in the measurement of lease liabilities	\$1.6
\$1.6	\$1.5

Maturities of operating lease liabilities as of September 30, 2024, were as follows:

(dollars in millions)	
Remainder of 2024	\$0.4
\$0.4	\$250.5

Total lease payments

0.9	
Less: imputed interest	\$0.9
\$0.9	\$12

Table of Contents

7. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

(dollars in millions)	
September 30, 2024	December 31, 2023
Accounts payable	\$17.7
\$17.7	\$17.8

Accrued liabilities

Research and development expenses	29.1	43.1
Employee expenses	19.9	25.7
Income taxes	4.1	0.7

General and administrative and commercial expenses

2.7	2.4
Professional fees	2.4
2.4	2.5

Total accounts payable and accrued liabilities

\$75.9	\$92.2
8. Long-Term Debt	

Debt obligations consisted of the following:

(dollars in millions)	Maturity Date	Interest Rate
September 30, 2024	December 31, 2023	2018 Assistance Agreement
Debt	09/283.25%	\$0.8
\$1.0	Less: current installments	(0.2)
(0.2)	Total long-term debt	\$0.6

\$0.8

In June 2018, the Company entered into an assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed \$2.0 million under the 2018 Assistance Agreement in September 2018, of which \$1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of \$2.0 million plus liquidated damages of 7.5% of the total amount of funding received. Minimum future principal payments on long-term debt are as follows:

(dollars in millions)	
Remainder of 2024	\$2.0
\$2.0	\$2060.2

\$2060.2

During the three and nine months ended September 30, 2024 and 2023, interest expense was immaterial.

Table of Contents

9. Equity

Equity Distribution Agreements

In November 2023, the Company amended and restated the Equity Distribution Agreement with Piper Sandler & Company (the "Piper Sandler") and Cantor Fitzgerald & Co. (the "Cantor"), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately \$262.8 million of the common stock registered under a universal shelf registration statement pursuant to one or more "at-the-market" offerings. During the nine months ended September 30, 2024, no shares were issued under this agreement.

Stock-based Compensation

2018 Employee Stock Purchase Plan

In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company's then-outstanding common stock, effective as of January 1 of each year. As of September 30, 2024, 3,035,594 shares remained available for purchase. During the nine months ended September 30, 2024 and 2023, the Company issued 85,119 and 78,528 shares of common stock, respectively, under the 2018 ESPP.

2018 Stock Incentive Plan

In September 2018, the Company's board of directors adopted, and the Company's stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company's initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Fourth Amendment to the Company's Incentive Share Plan, which was terminated in September 2018, that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company's common stock, 4% of the number of shares of the Company's common stock outstanding on the first day of the year or an amount determined by the Company's board of directors. As of September 30, 2024, 3,434,422 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.

Table of Contents

Compensation Expense

During the three months ended September 30, 2024 and 2023, the Company recognized compensation expense of \$24.7 million and \$16.7 million, respectively, related to the issuance of incentive awards, including \$0.1 million and \$0.2 million, respectively, related to the 2018 ESPP. During the nine months ended September 30, 2024 and 2023, the Company recognized compensation expense of \$64.9 million and \$54.9 million, respectively, relating to the issuance of incentive awards, including \$0.6 million and \$0.7 million, respectively, related to the 2018 ESPP. As of September 30, 2024, there was \$75.1 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.2 years.

Stock Options

The fair value of the stock options granted during the nine months ended September 30, 2024 and 2023 was determined using the Black-Scholes option pricing model with the following assumptions:

September 30, 2024	September 30, 2023
Expected volatility	(1) 72.8 - 75.6%
71.5 - 74.2%	Expected term (years)
(2) 5.4 - 5.55	5 - 7.0
Risk free interest rate	(3) 3.5% - 4.6%
3.4% - 4.3%	Expected dividend yield
0%	Exercise price
\$24.85 - \$47.00	\$23.23 - \$36.27

(1) Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.

(2) Expected term is calculated based on the Company's historical experience.

(3) Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.

A summary of the stock option activity during the nine months ended September 30, 2024 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

(dollars in millions, except weighted average exercise price)			
Options	Weighted Average	Exercise Price	Weighted Average
Remaining Contractual Term (Years)	Aggregate Intrinsic Value	Outstanding as of December 31,	
2023	933,794	\$45.22	7.2
\$62.6	Granted	1,45,629	\$41.74
Exercised	(269,028)	\$21.53	Forfeited
(855,007)	\$56.63	Outstanding as of September 30,	
2024	955,388	\$44.32	6.9
\$12.2	Vested and exercisable as of September 30,	2024	5,219,887
\$44.42	6.0	\$11.8	Vested and expected to vest as of September 30,
2024	724,552	\$44.45	6.9
\$12.2	Table of Contents	The weighted-average grant date fair value per share of options granted during the nine months ended September 30,	2024 and 2023 was \$27.69 and \$22.51, respectively. The total intrinsic value of options exercised during the nine months ended September 30,
2024 and 2023 was \$3.6 million and \$0.9 million, respectively.	Restricted Stock Units ("RSUs")	A summary of RSU activity during the nine months ended September 30,	2024 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).
Shares	Weighted Average	Grant Date	Fair Value
Per Share	Unvested RSUs as of December 31,	2023	1,151,856
\$38.16	Granted	1,722,239	\$44.69
Vested	(316,065)	\$39.01	Forfeited
(201,028)	\$42.62	Unvested RSUs as of September 30,	2024
357,002	\$42.43	The total fair value of RSUs vested during the nine months ended September 30,	2024 and 2023 was \$12.3 million and \$6.2 million, respectively.
10. Income Taxes	For the three months ended September 30,	2024, the Company recognized income tax expense of \$0.6 million, resulting in an effective tax rate of (1.3)%, as compared to no income tax expense or benefit recognized in the same period for 2023, resulting in an effective tax rate of 0.0%. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended September 30,	2024 and the Company's overall effective tax rate of (1.3)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended September 30,
2023 and the Company's overall effective tax rate of 0.0% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. For the nine months ended September 30,	2024, the Company recognized income tax expense of \$1.0 million resulting in an effective tax rate of (0.6)%, as compared to income tax benefit of \$0.7 million resulting in an effective tax rate of 0.3% in the same period for 2023. The primary reconciling items between the federal statutory rate of 21.0% for the nine months ended September 30,	2024 and the Company's overall effective tax rate of (0.6)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the nine months ended September 30,	2023 and the Company's overall effective tax rate of 0.3% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The

Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.

16Table of Contents11. Net Loss Per Share Basic and diluted loss per common share was calculated as follows:For the Three Months EndedSeptember 30,For the Nine Months EndedSeptember 30,(dollars and shares in millions, except per share amounts)2024202320242023Net loss\$(49.2)\$(64.0)\$(153.8)\$(212.5)Weighted average number of common shares outstanding - basic and diluted72.1 54.1 71.9 53.6 Net loss per common share - basic and diluted\$(0.68)\$(1.18)\$(2.14)\$(3.97)The weighted average number of common shares included in the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2024 gives effect to pre-funded warrants issued in November 2023 which allow holders to acquire up to 3,422,380 shares of common stock at a nominal exercise price of \$0.001 per share and are classified as equity. The shares underlying the pre-funded warrants are exercisable for little or no consideration and therefore the underlying shares are considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted average number of common shares outstanding in basic and diluted net loss per share for common share.The Company reported net losses for each of the three and nine months ended September 30, 2024 and 2023, and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:For the Three and Nine Months EndedSeptember 30,20242023Stock options8.0 8.0 RSUs2.4 1.1 10.4 9.1 12. Equity Method InvestmentsIn July 2019, the Company and Bayer CropScience LP (the "Bayer LP") formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 44.3% and 45.2% as of September 30, 2024 and 2023, respectively, as a result of vested incentive units.Net loss of Oerth Bio for the three months ended September 30, 2024 and 2023 totaled \$1.2 million and \$3.2 million, respectively. The Company recognized equity method losses of zero and \$0.1 million for the three months ended September 30, 2024 and 2023, respectively. Net loss of Oerth Bio for the nine months ended September 30, 2024 and 2023 totaled \$2.7 million and \$8.5 million, respectively. The Company recognized equity method losses of zero and \$2.5 million for the nine months ended September 30, 2024 and 2023, respectively.As of September 30, 2024 and 2023, the Company's carrying value of the investment was zero. The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and nine months ended September 30, 2024 and 2023 were immaterial.17Table of Contents13. Commitments and ContingenciesFrom time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred. The Company's accrual for such matters totaled \$5.0 million and \$10.0 million as of September 30, 2024 and 2023, respectively, related to the Amended License Agreement with Yale University ("Yale"), as further described below.Clinical and Preclinical Development and Licensing ArrangementsFrom time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.Yale University License AgreementIn June 2024, the Company entered into an Amended and Restated License Agreement (the "Amended License Agreement") with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of \$14.95 million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, Research Collaboration and License Agreements, for a description of the agreements). The Company will make another \$5.0 million payment on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to \$15.0 million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined collaboration products, and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined meaningfully involved products. The Company's obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the requirement to pay to Yale a minimum license maintenance royalty totaling \$0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately \$3.0 million for the first licensed product and approximately \$1.5 million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from \$0.2 million to \$0.5 million.FMI AgreementIn June 2022, the Company entered into a Master In Vitro Diagnostics Agreement with Foundation Medicine, Inc. (the "FMI Agreement") for the development and commercialization of one or more of Foundation Medicine, Inc.'s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine, Inc. may terminate the FMI Agreement with respect to an applicable program, (a) if a reasonably necessary third party license is not secured by Foundation Medicine, Inc. or if the Company does not consent to payments for such license, (b) if Foundation Medicine, Inc. reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain licensing and other rights and certain obligations of Foundation Medicine, Inc. survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine, Inc. and may also be required to pay a termination fee, if applicable.ARV-766In exchange for the development of Foundation One® Liquid CDx as a companion diagnostic for use with ARV-766 for androgen receptor (the "AR") metastatic castration-resistant prostate cancer in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars in addition to certain validation fees per sample and related pass-through costs.19Table of ContentsItem 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amount and certainty of cash flows from operations and from outside sources, so as to allow investors to better view our company from management's perspective. You should read the following discussion and analysis of financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and the related notes and discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the year ended December 31, 2023 filed on February 27, 2024. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 27, 2024 and elsewhere in this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. OverviewOur Business We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROTAC Discovery Engine, our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, we are pioneering the development of protein degradation therapies designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. We are currently progressing multiple product candidates through clinical development programs, including vepdegestrant, targeting the estrogen receptor, or ER, for the treatment of locally advanced or metastatic ER positive / human epidermal growth factor receptor 2, or HER2, negative, or ER+/HER2-, breast cancer; ARV-102, targeting the leucine-rich repeat kinase 2, or LRRK2, protein for the treatment of neurodegenerative disorders; and ARV-393, targeting the B-cell lymphoma 6, or BCL6 protein for the treatment of relapsed/refractory non-Hodgkin Lymphoma. In addition to the programs above and our early-stage collaborations, including with Pfizer, Inc., or Pfizer, and Genentech, Inc. and F. Hoffman-La Roche Ltd., or Genentech, we are conducting exploratory research and development work on multiple other undisclosed targets.Estrogen Receptor Program: Vepdegestrant Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. We are co-developing vepdegestrant with Pfizer, pursuant to a collaboration agreement entered into in July 2021. We granted Pfizer worldwide co-exclusive rights to develop and commercialize vepdegestrant.In preclinical studies, vepdegestrant demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models and showed superior anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a cyclin-dependent kinase, or CDK, 4/6 inhibitor.We, along with Pfizer, have several ongoing clinical trials of vepdegestrant, designed to potentially position vepdegestrant as a backbone ER-targeting therapy in breast cancer, including: Study lead-in of VERITAC-3, a Phase 3 first-line clinical trial of vepdegestrant in combination with IBRANCE® (palbociclib), targeting metastatic breast cancer, for which we completed enrollment of patients in the second quarter of 2024; VERITAC-2, a Phase 3 second-line clinical trial of vepdegestrant as a monotherapy, targeting metastatic breast cancer, for which we are currently enrolling patients; VERITAC, a Phase 2 second-line dose expansion clinical trial of vepdegestrant as a monotherapy, targeting metastatic breast cancer, for which enrollment of patients is complete;20Table of ContentsTACTIVE-N, a Phase 2 clinical trial of vepdegestrant as a monotherapy in the neoadjuvant setting, to inform a potential

adjuvant trial, for which we completed enrollment of patients in the first quarter of 2024;â€¢TACTIVE-U, a Phase 1b/2 clinical trial of vepdegestrant in combination with multiple targeted therapies including abemaciclib, ribociclib or Carrick Therapeutics, Inc.'s, or Carrick, cyclin-dependent kinase 7, or CDK7, inhibitor, samuraciclib, for which we are currently enrolling patients globally;â€¢TACTIVE-E, a Phase 1 clinical trial of vepdegestrant in combination with everolimus, for which enrollment of patients is complete; andâ€¢TACTIVE-K, a Phase 1b/2 clinical trial of vepdegestrant in combination with Pfizer's cyclin-dependent kinase 4, or CDK4, inhibitor, atirromociclib (PF-07220060), for which we are currently enrolling patients globally.In the first quarter of 2024, we initiated an additional arm of TACTIVE-U, the Phase 1b combination umbrella trial with Carrick's CDK7 inhibitor and initiated dosing for TACTIVE-K. In addition, in the first quarter of 2024, the U.S. Food and Drug Administration, or the FDA, granted Fast Track designation for the investigation of vepdegestrant as a monotherapy in the treatment of adults with ER+/HER- locally advanced or metastatic breast cancer previously treated with endocrine based therapy, and we announced the inclusion of an additional arm in the I-SPY-2 Endocrine Optimization Platform (EOP) study that will evaluate vepdegestrant in combination with abemaciclib. Vepdegestrant is also being evaluated in a monotherapy arm and in combination with letrozole arm in the ongoing I-SPY TRIAL endocrine optimization program sponsored by Quantum Leap.In the second quarter of 2024, we, along with Pfizer, evaluated enrollment and blinded event rates in the ongoing VERITAC-2 Phase 3 monotherapy clinical trial in patients with metastatic breast cancer. We expect to complete enrollment for this clinical trial in the fourth quarter of 2024 and provide top-line data in the fourth quarter of 2024 or the first quarter of 2025.Additionally, in the second quarter of 2024, we, along with Pfizer, presented updated clinical data from a Phase 1b clinical trial combination cohort evaluating vepdegestrant in combination with palbociclib (IBRANCEÂ®) at the 2024 European Society for Medical Oncology, or ESMO, Breast Cancer Annual Congress. After six months of additional follow-up (data cutoff of December 18, 2023), these data were consistent with data presented at the 2023 San Antonio Breast Cancer Symposium, or SABCS, in the fourth quarter of 2023 (data cutoff of June 6, 2023), and show that vepdegestrant in combination with palbociclib continued to demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of prior therapy with locally advanced or metastatic ER+/HER2- breast cancer.Specifically, after six months of additional follow-up, updated data from the trial continued to demonstrate an encouraging clinical benefit rate (63% across all dose levels (n=46)), objective response rate (42% in evaluable patients with measurable disease at baseline (n=31)) and median progression-free survival (11.2 months (95% CI: 8.2 - 16.5) based on 27 (59%) events across all dose levels), and consistent safety profile of vepdegestrant in combination with palbociclib as previously reported at SABCS in December 2023. In addition, at the recommended Phase 3 dose, or RP3D, of 200 mg vepdegestrant in combination with 125 mg palbociclib, patients (n=21) achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR). Further, across all vepdegestrant dose groups, circulating tumor DNA analyses showed marked reduction in tumor fraction after one treatment cycle, regardless of ESR1 gene mutation status, and at the 200 mg vepdegestrant dose, robust on-treatment decreases in mutant ESR1 circulating tumor DNA were sustained through multiple treatment cycles.The Phase 1b cohort of the ARV-471-mBC-101 is designed to assess the safety, tolerability, and anti-tumor activity of vepdegestrant in combination with palbociclib among 46 patients with heavily pre-treated locally advanced or metastatic ER+/HER2- breast cancer. Patients in the study received a median of four prior therapies (median of three in the metastatic setting); 87% were previously treated with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor; 80% were previously treated with fulvestrant; and 78% were previously treated with chemotherapy, including 48% in the metastatic setting. Patients were treated once daily with oral doses of vepdegestrant at 180 mg (n=2), the RP3D of 200 mg (n=21), 400 mg (n=3) or 500 mg (n=20), plus 125 mg of palbociclib given orally once daily for 21 days, followed by seven days off treatment in 28-day cycles. Detailed data presented at the 2024 ESMO Breast Cancer Annual Congress included:21Table of ContentsClinical Benefit Rate, or CBR:â€¢CBR, defined as the rate of confirmed complete response, partial response, or stable disease â€¢24 weeks across all dose levels (n = 46) was 63% (95% CI: 47.5 - 76.8), with a CBR of 72% in patients with mutant ESR1 (n=29; 95% CI: 52.8 - 87.3) and a CBR of 53% in patients with wild-type ESR1 (n=15; 95% CI: 26.6 â€¢ 78.7).â€¢CBR in patients dosed at the RP3D of 200 mg (n=21) was 67% (95% CI: 43.0 - 85.4) with a CBR of 79% in patients with mutant ESR1 (n=14; 95% CI: 49.2 - 95.3) and a CBR of 43% in patients with wild-type ESR1 (n=7; 95% CI: 9.9 - 81.6).Objective Response Rate, or ORR, and Duration of Response, or DOR:â€¢The ORR in evaluable patients with measurable disease at baseline (n=31) was 42% (95% CI: 24.5 - 60.9) with a median DOR in 13 responders of 14.6 months (95% CI: 9.5 â€¢ not reached). At the RP3D of 200 mg (n=15), the ORR was 53% (95% CI: 25.6 â€¢ 78.7).â€¢ORR in patients with mutant ESR1 (n=17): 47% (95% CI: 23.0 - 72.2).â€¢ORR at the RP3D of 200 mg (n=10): 60% (95% CI: 26.2 - 87.8).â€¢ORR in patients with wild-type ESR1 (n=12): 42% (95% CI: 15.2 - 72.3).â€¢ORR at the RP3D of 200 mg (n=5): 40% (95% CI: 5.3 - 85.3).Progression-free Survival, or PFS:â€¢Median PFS, or mPFS, based on 27 (59%) events across all dose levels was 11.2 months (95% CI: 8.2 â€¢ 16.5) with a mPFS of 13.7 months (95% CI: 8.2 - NR) in patients with ESR1 mutation (n=29) and mPFS of 11.1 months (95% CI: 2.8 - 19.3) in patients with wild-type ESR1 (n=15).â€¢mPFS in patients dosed at the RP3D of 200 mg (n=21) based on 12 events (57%) was 13.9 months (95% CI: 8.1 - NR) with a mPFS of 13.9 months (95% CI: 8.1 - NR) in patients with ESR1 mutation (n=14) and mPFS of 11.2 months (95% CI: 1.8 - NR) in patients with wild-type ESR1 (n=7).Circulating Tumor DNA, or ctDNA:â€¢Exploratory ctDNA analyses found marked reduction (median change, â€¢98.9% in tumor fraction after one treatment cycle (all dose groups) regardless of ESR1 mutant status and robust on-treatment decreases in mutant ESR1 ctDNA levels sustained through cycle 7 (evaluated in patients in 200 mg dose cohort), as presented in the poster session.Safety Profile:â€¢The safety profile of vepdegestrant in combination with palbociclib was consistent with what was previously reported with Grade 3/4 treatment-related adverse events, or TRAEs, â€¢10% of neutropenia (91%) and decreased white blood cell count (15%); no grade 5 TRAEs or febrile neutropenia were reported.â€¢The majority of Grade 4 neutropenia events occurred in the first cycle of treatment and occurrences of Grade 3/4 neutropenia decreased following palbociclib dose reductions as described in the prescribing label.â€¢The safety profile of vepdegestrant in combination with palbociclib was otherwise consistent with the profile of palbociclib and what has been observed in other clinical trials for vepdegestrant. Three of 46 patients discontinued palbociclib due to neutropenia including one out of 21 patients treated with the RP3D of vepdegestrant (200 mg) plus palbociclib 125 mg.As part of our global collaboration with Pfizer, in the second half of 2024, we and Pfizer plan to evaluate data from the study-lead in of the VERITAC-3 Phase 3 clinical trial of vepdegestrant in combination with palbociclib. We also expect to continue enrollment and evaluate preliminary data from the ongoing TACTIVE-K clinical trial and, pending emerging data and regulatory feedback, in 2025, we plan to initiate, with Pfizer, Phase 3 combination trials in the first- and second-line settings: the first-line setting with vepdegestrant plus atirromociclib or palbociclib, and the second-line setting with vepdegestrant plus palbociclib and/or another CDK4/6 inhibitor.22Table of ContentsIn addition, in the fourth quarter of 2024, we and Pfizer expect to present initial safety and pharmacokinetic data from the TACTIVE-U sub-study of abemaciclib at the 2024 SABCS and we expect to otherwise continue enrollment in TACTIVE-U, the ongoing Phase 1b/2 combination umbrella trial evaluating combinations of vepdegestrant with abemaciclib, ribociclib, or samuraciclib. We also expect to present data from the Phase 1 pharmacokinetic trial of vepdegestrant in combination with midazolam to assess potential for drug-drug interaction at the 2024 SABCS in the fourth quarter of 2024. Neuroscience Program: ARV-102 ARV-102 is our first oral PROTAC protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade LRRK2, which is a large multidomain scaffolding kinase. In human genetics, increased activity and expression of LRRK2 are genetically involved in the pathogenesis of neurological diseases including Parkinsonâ€™s Disease and progressive supranuclear palsy.In the second quarter of 2024, we presented preclinical data at the Biennial International LRRK2 Meeting, which further supported the potential of PROTACA®-induced LRRK2 degradation as a potential treatment for neurodegenerative diseases. The preclinical data presented at the Biennial International LRRK2 Meeting highlighted, with our PROTAC LRRK2 degrader, near complete LRRK2 target engagement, as well as LRRK2 degradation, in mouse and non-human primate lung and brain. The preclinical data also showed differing effects of the LRRK2 PROTAC degraders in the lungs compared to kinase inhibitors, suggesting reduced pulmonary function risk, including: â€¢substantially less Type II pneumocyte enlargement compared to MLI-2, an experimental LRRK2 kinase inhibitor; â€¢surfactant protein accumulation in mouse lung was observed after treatment with the LRRK2 kinase inhibitor MLI-2, but not after treatment with the PROTAC LRRK2 degrader; and â€¢no evidence of collagen deposition in lung to date with PROTAC LRRK2 degraders in non-human primates, or NHPs.In October 2024, we presented preclinical data at the 2024 Michael J. Fox Foundation Parkinsonâ€™s Disease Conference further supporting the potential of PROTAC-induced LRRK2 degradation as a potential treatment for patients with neurodegenerative diseases. New findings presented included data demonstrating:â€¢orally delivered ARV-102 crosses the blood-brain barriers and degrades LRRK2 in the cerebrospinal fluid, or CSF, of NHPs; â€¢degradation of LRRK2 by ARV-102 induces changes in pathway (lysosomal and inflammation) biomarkers in the CSF of NHPs, which has not previously been demonstrated by kinase inhibitors of LRRK2; andâ€¢in murine tauopathy models, oral PROTAC LRRK2 degrader treatment led to ~50% pathologic tau reduction.The European Medicines Agency cleared our clinical trial application for ARV-102 in the fourth quarter of 2023. We initiated the first-in-human Phase 1 clinical trial for ARV-102 in the first quarter of 2024. The trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-102, including the evaluation of LRRK2 degradation and exploratory LRRK2 pathway biomarkers. We completed enrollment in the single ascending dose portion of the Phase 1 clinical trial in healthy volunteers with the PROTAC LRRK2 degrader ARV-102 at the Centre for Human Drug Research in Leiden, the Netherlands. In the second quarter of 2024, we received health authority approval to initiate the multiple ascending dose portion of the ongoing Phase 1 clinical trial in healthy volunteers with the PROTAC LRRK2 degrader ARV-102, and we initiated the multiple ascending dose portion of this clinical trial in the third quarter of 2024. Going forward, we expect to complete enrollment in this ongoing clinical trial, and expect to present data from the Phase 1 clinical trial in 2025.Hematology Program: ARV-393ARV-393 is an investigational PROTAC designed to degrade BCL6, a transcriptional repressor and major driver of B-cell lymphomas. The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA 23Table of Contentsdamage response. We believe that PROTAC-mediated degradation has the potential to address the traditional undruggable nature of BCL6.In the second quarter of 2024, we presented preclinical data for ARV-393 at the European Hematology Association 2024 Annual Congress, which showed anti-tumor activity in preclinical models of B-cell lymphoma. In these preclinical models, ARV-393 potently and rapidly degraded the BCL6 protein and inhibited cell growth in diffuse large B-cell lymphoma, or DLBCL, and Burkitt cell lines. ARV-393 showed tumor growth inhibition, including tumor regression, in various DLBCL cell line-derived xenograft models and in multiple patient-derived xenograft models of non-Hodgkin lymphoma, or NHL, including germinal center B-cell-like, or GCB, activated B-cell, or ABC, GCB/ABC, and BCL not otherwise specified subtypes of DLBCL, and Burkitt lymphoma.In the first quarter of 2024, we announced that the FDA cleared our investigational new drug application, or IND, for ARV-393. We initiated our first-in-human Phase 1 clinical trial in patients with B-cell lymphomas with PROTAC BCL6 degrader ARV-393 in the second quarter of 2024 and we continued recruiting patients for this clinical trial in the third quarter of 2024. Going forward, we expect to continue recruiting patients for this clinical trial.Other Programs: KRAS G12D, ARV-766 and bavdegalutamide (ARV-110)Kirsten rat sarcoma, or KRAS, is a driver oncogene in several major tumor types and is associated with poor prognosis and resistance to standards of care. Our KRAS G12D program is currently in preclinical development and we anticipate filing an IND application for our KRAS G12D program

in 2025. ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide (ARV-110), as a potential treatment for men with metastatic castration resistant prostate cancer, or mCRPC, and metastatic castration-sensitive prostate cancer. Bavdegalutamide is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the AR for the treatment of men with mCRPC. Based on signs of superior tolerability and efficacy of ARV-766 in clinical settings to date as compared to bavdegalutamide (ARV-110), early in the fourth quarter of 2023, we prioritized the initiation of a Phase 3 clinical trial with ARV-766 in mCRPC instead of the previously planned Phase 3 clinical trial for bavdegalutamide. While we expect to continue ongoing trial activities with bavdegalutamide (ARV-110-101 and ARV-110-103), we will not be enrolling new patients in these clinical trials and expect to wind down our bavdegalutamide program after completion of these clinical trials. In the second quarter of 2024, we entered into and closed a transaction, or the Novartis Transaction, including both a license agreement, or the Novartis License Agreement, and an asset purchase agreement, or the Novartis Asset Agreement, with Novartis. The Novartis Transaction closed in the second quarter of 2024. Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and commercialization of ARV-766, our second generation PROTAC[®] AR degrader for patients with prostate cancer and are currently in the process of transitioning our ongoing and planned clinical trials of ARV-766 to Novartis, including: a Phase 2 dose expansion clinical trial in the post-novel hormonal agent, or NHA setting; a Phase 1 dose escalation clinical trial in the post-NHA setting; and a Phase 1/2 clinical trial in combination with abiraterone in the pre-NHA setting. Our Operations We commenced operations in 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations and a licensing arrangement, grant funding and debt financing. Since inception through September 30, 2024, we raised approximately \$1.7 billion in total gross proceeds from the sale of assets and equity interests and the exercise of stock options and had received an aggregate of \$913.0 million in payments primarily from collaboration partners and a licensing arrangement. We are a clinical-stage company, with product candidates in clinical development and other drug discovery activities in the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since inception, we have incurred significant operating losses and expect to incur increasing operating losses for at least the next several years due to costs associated with our ongoing and anticipated preclinical and clinical activities, development activities, research activities in oncology, neurological and other disease areas to expand our pipeline, hiring additional personnel in research, clinical trials, quality and other functional areas, including general and administrative, sales and commercial as we move towards potential commercialization, increased expenses incurred with CMOs to supply us with product for our preclinical and clinical studies and expenses incurred with contract research organizations, or CROs, for the synthesis of compounds in our preclinical development activities, as well as other associated costs including the management of our intellectual property portfolio. We do not expect to generate any revenue from product sales in the near future, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Financial Operations Overview Revenue To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. Our revenues to date have been generated through research collaborations, a licensing arrangement and an asset sale. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue recognized in the near term will be derived from our current collaboration agreements and licensing arrangement and any additional arrangements that we may enter into in the future. To date, we have not received any development, regulatory and commercial milestone payments or royalties under any of the collaboration agreements or licensing arrangement. Novartis Transaction In April 2024, we entered into the Novartis Transaction, including both the Novartis License Agreement and the Novartis Asset Agreement, with Novartis. The Novartis Transaction closed in May 2024 upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, at which time the Novartis License Agreement and the Novartis Asset Agreement became effective. Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and commercialization of ARV-766, our second generation PROTAC[®] AR degrader for patients with prostate cancer. Pursuant to the Novartis Asset Agreement, we sold to Novartis all of our rights, title and interest in our PROTAC[®] protein degrader targeting AR-V7, a splice variant of the AR. Under the terms of and as consideration for entering into the Novartis Transaction, we received a one-time, upfront payment in the aggregate amount of \$150.0 million from Novartis. Under the Novartis License Agreement, we are also eligible to receive up to an additional \$1.01 billion as contingent payments based on specified development, regulatory, and commercial milestones for ARV-766 being met, as well as tiered royalties based upon worldwide net sales of ARV-766, subject to reduction under certain circumstances as provided in the Novartis License Agreement. The Novartis License Agreement will expire on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event of the other party's insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue. Genentech License Agreement In September 2015, we entered into an Option and License Agreement with Genentech focused on PROTAC targeted protein degrader discovery and research for target proteins based on our proprietary platform technology, other than excluded target proteins as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. Under the Restated Genentech Agreement, Genentech has the right to designate up to ten target proteins for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a target any protein to which a PROTAC targeted protein degrader, by design, binds to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a target protein from the collaboration and substitute a different target protein that is not an excluded target protein at any time prior to us commencing research on such target protein or in certain circumstances following commencement of research by us. At the time we entered into the original agreement with Genentech, we received an upfront payment of \$11.0 million, and at the time we entered into the Restated Genentech Agreement, we received an additional \$34.5 million in upfront and expansion target payments. We are eligible to receive payments aggregating up to \$44.0 million per target protein upon the achievement of specified development milestones; payments aggregating up to \$52.5 million per target protein (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to \$60.0 million per PROTAC targeted protein degrader directed against the applicable target protein, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. Pfizer Research Collaboration Agreement In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of target proteins, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement. Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial target proteins. For each identified target protein, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial target proteins candidates, subject to the stage of research for such target protein. In the year ended December 31, 2018, we received an upfront non-refundable payment and certain additional payments totaling \$28.0 million in exchange for use of our technology license and to fund Pfizer-related research, as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional \$37.5 million in non-refundable option payments if Pfizer exercises its options for all target proteins under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to \$225.0 million in development milestone payments and up to \$550.0 million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products. Bayer Collaboration Agreement In June 2019, we entered into a Collaboration and License Agreement, or the Bayer Collaboration Agreement, with Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of target proteins, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations. The Bayer Collaboration Agreement became effective in July 2019. Under the Bayer Collaboration Agreement, we and Bayer conducted a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each target protein selected by Bayer. During the term of the Bayer Collaboration Agreement, we were not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any target protein selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities. Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront non-refundable payment of \$17.5 million and an additional \$12.0 million in aggregate from inception through 2023. We were also eligible to receive up to \$197.5 million in development milestone payments and up to \$490.0 million in sales-based milestone payments for all designated target proteins. In addition, we were eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated, effective August 12, 2024. Pfizer Vepdegestrant (ARV-471) Collaboration Agreement In July 2021, we entered into a Collaboration Agreement with Pfizer, or the Vepdegestrant (ARV-471) Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471, or the Licensed Products. Under the Vepdegestrant (ARV-471) Collaboration Agreement, we received an upfront, non-refundable payment of \$650.0 million. In addition, we are eligible to receive up to an additional \$1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, \$400 million in regulatory milestones are related to marketing approvals and \$1.0 billion are related to sales-based milestones. We and Pfizer share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions.

for certain regions described below, we will also share equally (50/50) all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. We will be the marketing authorization holder and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. We will determine with Pfizer which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of all profits and losses for the Licensed Products based on the role each party will be performing. Unless earlier terminated in accordance with its terms, the Vepdegestrant (ARV-471) Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Products are no longer commercialized or developed for commercialization in such country. Pfizer may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for the other party's unsecured material breach or insolvency. Subject to applicable terms of the Vepdegestrant (ARV-471) Collaboration Agreement, including certain payments to Pfizer upon termination for our unsecured material breach, effective upon termination of the Vepdegestrant (ARV-471) Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products. Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the Vepdegestrant (ARV-471) Collaboration Agreement anywhere in the world during the term of the Vepdegestrant (ARV-471) Collaboration Agreement.

Table of Contents
Operating Expenses Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. Research and Development Expenses Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; expenses incurred under agreements with third parties, including CROs and other third parties that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; costs of outside consultants, including their fees, stock-based compensation and related travel expenses; the costs of laboratory supplies and developing preclinical studies and clinical trial materials; facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and third-party licensing fees. We expense research and development costs as incurred. We typically use our employee and infrastructure resources across our development programs and as such do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for the three and nine months ended September 30, 2024 and 2023:

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024	For the Three Months Ended September 30, 2023	For the Nine Months Ended September 30, 2023
Program-specific external expenses	\$19.6	\$20.0	\$63.8	\$78.1
ARV-7664	7.8	1.1	1.1	1.1
ARV-1024	5.2	2.0	7.5	2.2
ARV-1102	7.4	4.3	6.8	22.3
ARV-3931	7.0	3.4	4.6	0.4
Other programs	0.8	1.1	1.1	1.1
Total program-specific external expenses	\$34.0	\$35.1	\$101.7	\$119.4
Non-program specific external expenses	\$13.7	\$14.8	\$43.4	\$57.3
Unallocated internal expenses				
Compensation and personnel expenses (including stock-based compensation)	\$35.8	\$33.0	\$110.4	\$85.7
Other expenses	\$3.4	\$3.0	\$9.4	\$9.1
Total unallocated internal expenses	\$39.2	\$36.0	\$119.8	\$107.8
Total research and development expenses	\$86.9	\$85.9	\$264.9	\$284.5

(*) ARV-4 includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement.

Table of Contents
Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials of vepdegestrant and ARV-102, initiate clinical trials of ARV-393, and continue to discover and develop additional product candidates. Research and development expenses related to vepdegestrant are shared equally with Pfizer since July 22, 2021, the effective date of the Vepdegestrant (ARV-471) Collaboration Agreement. We may receive reimbursement from, or make payments to, Pfizer to satisfy the cost sharing requirements. These payments are accounted for pursuant to ASC 808, which are recorded as an offset or an increase to research and development expenses. We cannot determine with certainty the duration and costs of future clinical trials of vepdegestrant, ARV-102, ARV-393, or unexpected costs of ongoing clinical trials of bavdegalutamide and ARV-766, prior to the transition of such trials and their associated expenses to Novartis, or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: successful completion of preclinical studies and clinical trials; receipt and related terms of marketing approvals from applicable regulatory authorities; obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; establishing sales, marketing, market access and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; acceptance of our products, if and when approved, by patients, the medical community and third-party payors; obtaining and maintaining third-party coverage and adequate reimbursement; maintaining a continued acceptable safety profile of the products following approval; and effectively competing with other therapies. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. General and Administrative Expenses General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to our product candidates and develop our commercial operations. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services.

Table of Contents
Results of Operations Comparison of the Three and Nine Months Ended September 30, 2024 and 2023

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024	For the Three Months Ended September 30, 2023	For the Nine Months Ended September 30, 2023
Revenue	\$102.4	\$34.6	\$67.8	\$204.2
Research and development expenses	(86.9)	(85.9)	(264.9)	(284.5)
General and administrative expenses	(75.8)	(72.6)	(225.2)	(213.3)
Other income	11.7	10.0	1.7	39.2
Income tax (expense) benefit	(0.6)	(0.6)	(0.6)	(0.6)
Loss from equity method investments	(0.1)	(0.1)	(0.1)	(0.1)
Net loss	\$(49.2)	\$(64.0)	\$(153.8)	\$(212.5)

\$58.7 Revenue Revenue for the three months ended September 30, 2024 totaled \$102.4 million, compared to \$34.6 million for the three months ended September 30, 2023. The increase of \$67.8 million was primarily due to revenue from the Novartis License Agreement, which was entered into during the second quarter of 2024, of \$76.7 million, offset by a decrease in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer totaling \$7.6 million related to timing differences in clinical trials and program expenses and a decrease in revenue from Bayer of \$1.1 million related to the termination of the Bayer Collaboration Agreement in August 2024. Revenue for the nine months ended September 30, 2024 totaled \$204.2 million, compared to \$121.6 million for the nine months ended September 30, 2023. The increase of \$82.6 million was primarily due to revenue from the Novartis License Agreement and the Novartis Asset Agreement of \$122.1 million and year over year increases in revenue of \$4.5 million and \$2.4 million from the Bayer Collaboration Agreement and the Pfizer Research Collaboration Agreement, respectively, primarily due to changes in estimates in 2023 of the performance period duration under the agreements resulting from updated research timelines, offset by a decrease in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer totaling \$42.2 million related to timing differences in clinical trials and program expenses, a decrease of \$2.5 million of previously constrained deferred revenue related to our Oerth Bio joint venture, and a decrease of \$1.8 million of revenue under the Genentech Amended and Restated Option. License, and Collaboration Agreement as the performance period has concluded. Research and Development

ExpensesResearch and development expenses for the three months ended September 30, 2024 totaled \$86.9 million, compared to \$85.9 million for the three months ended September 30, 2023. The increase of \$1.0 million was primarily due to an increase in compensation and related personnel expenses of \$2.8 million, which are not allocated by program, partially offset by a decrease in external expenses of \$2.2 million. External expenses include program-specific expenses, which decreased by \$1.1 million, primarily driven by decreases in our ARV-766 and ARV-110 programs of \$3.8 million and \$1.6 million, respectively, partially offset by increases in our ARV-102 and ARV-393 programs of \$2.5 million and \$1.4 million, respectively, and our non-program specific expenses, which decreased by \$1.1 million. Research and development expenses for the nine months ended September 30, 2024 totaled \$264.9 million, compared to \$284.5 million for the nine months ended September 30, 2023. The decrease of \$19.6 million was primarily due to a decrease in external expenses of \$31.6 million, partially offset by an increase in compensation and related personnel expenses of \$11.7 million, which are not allocated by program. External expenses include program-specific expenses, which decreased by \$17.7 million, driven by decreases in Table of Contents in our ARV-110 and ARV-471 programs of \$15.5 million and \$14.3 million, respectively, partially offset by increases in our ARV-102 and ARV-393 programs of \$5.3 million and \$4.1 million, respectively, and our non-program specific expenses, which decreased by \$13.9 million. General and Administrative Expenses General and administrative expenses totaled \$75.8 million for the three months ended September 30, 2024, compared to \$22.6 million for the three months ended September 30, 2023. The increase of \$53.2 million was primarily due to a loss on the termination of our laboratory and office space lease with 101 College Street LLC in August 2024 of \$43.4 million as well as increases in personnel and infrastructure related costs of \$5.0 million, professional fees of \$3.4 million and costs related to developing our commercial operations of \$1.2 million. General and administrative expenses totaled \$131.3 million for the nine months ended September 30, 2024, compared to \$73.3 million for the nine months ended September 30, 2023. The increase of \$58.0 million was primarily due to a loss on the termination of our laboratory and office space lease with 101 College Street LLC in August 2024 of \$43.4 million as well as increased spending in personnel and infrastructure related costs of \$6.8 million, professional fees of \$6.3 million and costs related to developing our commercial operations of \$1.4 million. Other Income Other income totaled \$11.7 million for the three months ended September 30, 2024, compared to \$10.0 million for the three months ended September 30, 2023. The increase of \$1.7 million was primarily due to an increase in interest income of \$4.3 million, partially offset by a loss on the disposal of fixed assets of \$2.4 million related to the termination of our laboratory and office space lease with 101 College Street LLC in August 2024. Other income totaled \$39.2 million for the nine months ended September 30, 2024, compared to \$25.5 million for the nine months ended September 30, 2023. The increase of \$13.7 million was primarily due to an increase in interest income of \$15.3 million and realized losses on the sale of our marketable securities in 2023 of \$0.9 million which did not recur in 2024, partially offset by a loss on the disposal of fixed assets of \$2.4 million related to the termination of our laboratory and office space lease with 101 College Street LLC in August 2024. Income Tax (Expense) Benefit Income tax expense totaled \$0.6 million for the three months ended September 30, 2024, compared to no income tax expense or benefit for the three months ended September 30, 2023. The current year tax expense was driven by the effect of equity compensation and the valuation allowance recorded against the full amount of our net deferred tax assets. Prior year tax expense was driven by expected benefits from state net operating loss carryback claims. Income tax expense totaled \$1.0 million for the nine months ended September 30, 2024, compared to an income tax benefit of \$0.7 million for the nine months ended September 30, 2023. The current year tax expense was driven by the effect of equity compensation and the valuation allowance recorded against the full amount of our net deferred tax assets. Prior year tax expense was driven by expected benefits from state net operating loss carryback claims. Loss from Equity Method Investment Loss from equity method investment totaled zero for the three months ended September 30, 2024, compared to \$0.1 million for the three months ended September 30, 2023. The decrease of \$0.1 million was due to fully recognizing the remaining constrained revenue and the equity method losses during 2023. Loss from equity method investment totaled zero for the nine months ended September 30, 2024, compared to \$2.5 million for the nine months ended September 30, 2023. The decrease of \$2.5 million was due to fully recognizing the remaining constrained revenue and the equity method losses during 2023. 32 Table of Contents Liquidity and Capital Resources Overview We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of our equity interests, proceeds from our collaborations and a license arrangement, grant funding and debt financing. Since inception through September 30, 2024, we had received an aggregate of \$913.0 million in payments from collaboration partners and a licensing arrangement, grant funding and forgivable and partially forgivable loans from the State of Connecticut, and raised approximately \$1.7 billion in gross proceeds from the sale of assets and equity interests, and the exercise of stock options, including: • October 2018: completion of our initial public offering in which we issued and sold an aggregate of 7,700,482 shares of common stock, for aggregate gross proceeds of \$123.2 million before fees and expenses; • July 2019: sale of 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of \$32.5 million; • November 2019: completion of a follow-on offering in which we issued and sold 5,227,273 shares of common stock for aggregate gross proceeds of \$115.0 million before fees and expenses; • September – December 2020: sale of 2,593,637 shares of common stock in an at-the-market offering for aggregate gross proceeds of \$65.6 million before fees and expenses; • December 2020: completion of a follow-on offering in which we issued and sold 6,571,428 shares of common stock for aggregate gross proceeds of \$460.0 million before fees and expenses; • September 2021: issuance of 3,457,815 shares of common stock to Pfizer for aggregate gross proceeds of \$350.0 million; • July – September 2023: sale of 1,449,275 shares of common stock in an at-the-market offering for aggregate gross proceeds of \$37.2 million before fees and expenses; • November 2023: sale of 12,963,542 shares of common stock and pre-funded warrants to purchase 3,422,380 shares of common stock in a private placement for aggregate gross proceeds of \$350.0 million before fees and expenses; and • April 2024: sale of AR-V7 to Novartis under the Novartis Asset Agreement for \$20.0 million. In November 2023, we amended and restated the Equity Distribution Agreement with Piper Sandler & Company and Cantor Fitzgerald & Co., pursuant to which we may offer and sell from time to time, through the agents, up to approximately \$262.8 million of the common stock registered under our universal shelf registration statement pursuant to one or more at-the-market" offering. During the nine months ended September 30, 2024, no shares were issued under the amended and restated agreement. Cash Flows Our cash, cash equivalents, restricted cash and marketable securities totaled \$1.1 billion and \$1.3 billion as of September 30, 2024 and December 31, 2023, respectively. We had an outstanding loan balance of \$0.8 million and \$1.0 million as of September 30, 2024 and December 31, 2023, respectively. 33 Table of Contents The following table summarizes our sources and uses of cash for the period presented: • For the Nine Months Ended September 30, (dollars in millions) 2024 2023 \$ change Net cash used in operating activities \$(175.2) \$(264.7) \$89.5 Net cash (used in) provided by investing activities (64.2) 257.2 (321.4) Net cash provided by financing activities 7.4 39.9 (32.5) Net (decrease) increase in cash, cash equivalents and restricted cash \$(232.0) \$32.4 \$(264.4) Operating Activities Net cash used in operating activities for the nine months ended September 30, 2024 decreased by \$89.5 million, compared with the nine months ended September 30, 2023, primarily due to changes in deferred revenue of \$72.2 million, accounts receivable of \$7.4 million, and non-cash charges of \$7.8 million, as well as a decrease in our net loss of \$58.7 million, inclusive of a one-time cash termination fee in the amount of \$41.5 million related to the termination of our laboratory and office space lease with 101 College Street LLC in August 2024, partially offset by changes in accounts payable and accrued liabilities of \$32.3 million, prepaid expenses and other current assets of \$18.7 million, collaboration contract asset of \$3.0 million related to the Novartis License Agreement and other receivables of \$2.5 million. The change in non-cash charges was primarily due to an increase in stock-based compensation of \$10.0 million, partially offset by net accretion of bond discounts/premiums of \$5.5 million. Investing Activities Net cash from investing activities for the nine months ended September 30, 2024 decreased by \$321.4 million, compared with the nine months ended September 30, 2023, primarily due to a net decrease in maturities and net sales of marketable securities and increase in purchases of \$322.8 million, partially offset by a decrease in purchases of property and equipment of \$1.3 million. Financing Activities Net cash provided by financing activities for the nine months ended September 30, 2024 decreased by \$32.5 million, compared with the nine months ended September 30, 2023, due to net proceeds from the issuance of common stock under our "at the market" offering program in 2023 of \$36.0 million, offset by increased proceeds from the exercise of stock options of \$3.8 million. Funding Requirements Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses in the foreseeable future as we advance the preclinical and clinical development of our product candidates. Specifically, we anticipate that our expenses will increase substantially if, and as we: • continue our ongoing and planned clinical trials of our product candidates, including vepdegestrant, for the treatment of locally advanced or metastatic ER+/HER2- breast cancer, ARV-102, our PROTAC degrader designed to target the LRRK2 protein, and ARV-393, our PROTAC protein degrader designed to target the BCL6 protein; • continue to transition our ongoing clinical trials of ARV-766 for the treatment of men with mCRPC to Novartis, and continue our ongoing current clinical trials of bavdegalutamide (ARV-110) for the treatment of men with mCRPC; • progress additional PROTAC protein degrader programs into IND- or CTA-enabling studies, including our KRAS G12D program; • apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development; 34 Table of Contents • expand the capabilities of our PROTAC Discovery Engine; • seek marketing approvals for any product candidates that successfully complete clinical trials; • ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval; • expand, maintain and protect our intellectual property portfolio; • hire additional development, including clinical and regulatory, and scientific personnel; and • add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and continue to support our operations as a public company. We had cash, cash equivalents and marketable securities totaling approximately \$1.1 billion as of September 30, 2024. We believe that our cash, cash equivalents and marketable securities as of September 30, 2024 will enable us to fund our planned operating expenses and capital expenditure requirements into 2027. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: • the progress, costs and results of our ongoing and planned clinical trials of vepdegestrant ARV-102 and ARV-393, and our ongoing clinical trials of bavdegalutamide; • the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs, including our KRAS G12D program; • the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; • the success of our collaborations, including with Pfizer and Genentech; • the costs, timing and outcome of regulatory review of our product candidates; • the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; • the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; • the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and • our ability to establish additional collaboration arrangements with other biotechnology or

pharmaceutical companies on favorable terms, if at all, or enter into license, marketing and royalty arrangements, and similar transactions for the development or commercialization of our product candidates. As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations, including with Pfizer and Genentech, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our 35Table of Contentscommon stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. BorrowingsIn June 2018, we entered into an additional assistance agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space. We borrowed \$2.0 million under the 2018 Assistance Agreement in September 2018, of which \$1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that we be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of \$2.0 million plus liquidated damages of 7.5% of the total amount of funding received. As of September 30, 2024, \$0.8 million remains outstanding under the 2018 Assistance Agreement.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and marketable securities. Interest income earned on these assets totaled \$41.9 million and \$26.6 million for the nine months ended September 30, 2024 and 2023, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. As of September 30, 2024, our cash equivalents consisted of bank deposits and money market funds, and our marketable securities included interest-earning securities. Our outstanding debt totaled \$0.8 million and \$1.0 million as of September 30, 2024 and December 31, 2023, respectively, and carries a fixed interest rate of 3.25% per annum.

Item 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresOur management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in Internal Control over Financial ReportingNo change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

36Table of ContentsPART II“OTHER INFORMATION”Item 1. Legal Proceedings.From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business and regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material litigation or legal proceedings.

Item 1A. Risk Factors.Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties discussed in “Part I, Item 1A, Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 27, 2024, together with all of the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. New or revised risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. The risk factor disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023 are qualified by the information that is described in this Quarterly Report on Form 10-Q. If any of the risks in our Annual Report on Form 10-K for the year ended December 31, 2023 actually occur, our business, prospects, operating results and financial condition could suffer materially. In such an event, the trading price of our common stock could decline and you might lose all or part of your investment. The revised risk described below and the risks described in our Annual Report on Form 10-K for the year ended December 31, 2023 are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

The risk factor included in our Annual Report on Form 10-K for the year ended December 31, 2023 “We rely and expect to continue to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.” is replaced in its entirety by the risk factor below.We rely and expect to continue to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.We currently rely and expect to continue to rely on third-party CROs to conduct our ongoing and planned clinical trials. We currently do not plan to independently conduct any clinical trials of vevdegestrant, and ARV-766 or of our other product candidates, including ARV-393 and ARV-102 and have not independently conducted any clinical trials of our product candidates, including bavdegalutamide, to date. Agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our product development activities.Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.Furthermore, these third parties may have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.

37Table of ContentsIn addition, we currently rely on foreign CROs, CMOs and vendors, including Wuxi AppTec, and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Act, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China’s public health, economic, political, and social conditions and the uncertainty around China’s relationship with other governments, such as the United States and the U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.Sales of Unregistered SecuritiesWe did not issue any securities that were not registered under the Securities Act during the three months ended September 30, 2024.

Item 5. Other InformationDirector and Officer Trading ArrangementsNone of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.

38Table of ContentsItem 6. Exhibits.ExhibitNumberDescription3.1Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).3.2Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on June 21, 2023).10.1+Promotion Letter for Angela Cacace, Ph.D., dated July 8, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 10-Q (File No. 001-38672) filed with the SEC on July 30, 2024).10.2*“Lease Termination Agreement, dated August 15, 2024, by and among Arvinas Operations, Inc. and 101 College Street, LLC.31.1*Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2**Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCH*Inline XBRL Taxonomy Extension Schema Document.101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF*Inline XBRL Taxonomy Extension

link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Marketable Securities and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Long-Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Equity - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Equity - Summary of Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Net Loss Per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 arvn-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 arvn-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 arvn-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Repayments of long-term debt Repayments of Long-Term Debt Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Components of Lease Expense Lease, Cost [Table Text Block] Cover [Abstract] Cover [Abstract] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Trading Symbol Trading Symbol Ownership interest, percentage Equity Method Investment, Ownership Percentage Updated Research Timelines Updated Research Timelines [Member] Updated Research Timelines All Trading Arrangements All Trading Arrangements [Member] Pledged Status [Domain] Pledged Status [Domain] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] One-Time Cash Termination Fee One-Time Cash Termination Fee [Member] One-Time Cash Termination Fee Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Loss per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Cash paid for taxes Income Taxes Paid, Net Equity method investments Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Income Statement And Statement Of Comprehensive Income [Abstract] Income Statement And Statement Of Comprehensive Income Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Employees Share-Based Payment Arrangement, Employee [Member] Operating lease liability Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Marketable Securities and Fair Value Measurements Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Right-of-Use Assets and Liabilities Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Other receivables Other Receivables, Net, Current Annual payment for license Annual License Fee Payment Annual License Fee Payment Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Common stock, shares remained available for purchase (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities Operating Lease, Liability, Noncurrent Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies Deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Pledged Status [Axis] Pledged Status [Axis] Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Corporate bonds Corporate Bond Securities [Member] Sales Based Milestone Payments Sales Based Milestone Payments [Member] Sales-based milestone payments. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Future grant of incentive units to service providers percentage Future Grant Of Incentive Units To Service Providers Percentage Future grant of incentive units to service providers, percentage. Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Proceeds from exercise of stock options and issuance of ESPP shares Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares Award Timing Method Award Timing Method [Text Block] Office equipment Office Equipment [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Fair Value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Additions Accounts Receivable, After Allowance For Credit Loss, Current, Additions Accounts Receivable, After Allowance For Credit Loss, Current, Additions Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Beginning balance Ending balance Accounts Payable, Contract Balances, Current Accounts Payable, Contract Balances, Current Unrealized gain on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Entity Small Business Entity Small Business Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Oerth Oerth Bio Limited Liability Corporation [Member] Oerth Bio LLC. Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Warrants to be purchased (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Lease for laboratory and office space (in sq feet) Land Subject to Ground Leases Loss contingency Loss Contingency Accrual Common stock, shares issued (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Antidilutive securities excluded from computation of diluted net loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Additional upfront non-refundable amount received under previous agreement Additional Upfront Non Refundable Amount Received Under Previous Agreement Additional upfront non-refundable amount received under previous agreement. Asset Pledged as Collateral Asset Pledged as Collateral [Member] Schedule of Transaction Price Allocated to Performance Obligations Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Debt instrument interest payments term (in months) Debt Instrument Interest Payments Term Debt instrument interest payments term. Cash, cash equivalents and restricted cash, beginning of the period Cash, cash equivalents and restricted cash, end of the period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net accretion of bond discounts/premiums Accretion (Amortization) of Discounts and Premiums, Investments Compensation expense not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Development Milestone Payments Development Milestone Payments [Member] Development milestone payments. Equity Distribution Agreement Equity Distribution Agreement [Member] Equity distribution agreement. Letter of credit for collateralized by certificate of deposit Debt Securities Required milestone payments Required Milestone Payments Required Milestone Payments Contract liabilities: Deferred revenue Change in

Contract with Customer, Liability [Roll Forward] Change in Contract with Customer, Liability Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Amortization Capitalized Contract Cost, Amortization During Period Capitalized Contract Cost, Amortization During Period Product and Service [Domain] Product and Service [Domain] Stock options Share-Based Payment Arrangement, Option [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Marketable securities Marketable Securities, Current 2025 Lessee, Operating Lease, Liability, to be Paid, Year One License License [Member] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income taxes Accrued Income Taxes, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Other receivables Increase (Decrease) in Other Receivables Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Contract Termination [Domain] Contract Termination [Domain] Contract Termination [Domain] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property, equipment and leasehold improvements, net Property, equipment and leasehold improvements, net Property, Plant and Equipment, Net Total liabilities Liabilities Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Available-for-Sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Piper Sandler and Cantor Piper Sandler And Cantor [Member] Piper sandler and cantor. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] 101 College Street LLC 101 College Street LLC [Member] 101 College Street LLC Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] License Second Licensed Product License Second Licensed Product [Member] License Second Licensed Product Contingent payments Revenue, Remaining Performance Obligation, Contingent Payments Revenue, Remaining Performance Obligation, Contingent Payments Current portion of operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Restricted Stock Grant Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Novartis Pharma AG Novartis Pharma AG [Member] Novartis Pharma AG Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Number of inducement grants (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants Total property, equipment and leasehold improvements Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Collaboration agreement direct and incremental costs incurred Direct And Incremental Costs Incurred To Obtain The Contract Direct and incremental costs incurred to obtain the contract. Aggregate Intrinsic Value Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Payments for collaboration Payments For Collaboration Payments For Collaboration Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted average number of common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Cash, cash equivalents, restricted cash and marketable securities Cash, Cash Equivalents, Restricted Cash and Marketable Securities Cash, Cash Equivalents, Restricted Cash and Marketable Securities MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Research Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Property, Equipment and Leasehold Improvements Property, Plant and Equipment Disclosure [Text Block] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable Beginning balance Ending balance Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Total Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Expected dividend yield (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Restricted cash Restricted Cash, Current Document Type Document Type Foundation Medicine, Inc. Foundation Medicine, Inc. [Member] Foundation Medicine, Inc. Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Vested and exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 2018 Assistance Agreement Two Thousand And Eighteen Assistance Agreement [Member] Two thousand and eighteen assistance agreement. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost License First Licensed Product License First Licensed Product [Member] License First Licensed Product Schedule of Contract Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Maximum Maximum Maximum [Member] Contract with customer, liability Beginning balance Ending balance Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Annual increase in reserved shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period Leasehold improvements Leasehold Improvements [Member] Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Capitalized costs Capitalized Contract Cost, Gross Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Commercial Milestones Commercial Milestones [Member] Commercial milestones. Collaboration contract asset and other assets Collaboration Contract Asset And Other Assets Collaboration contract asset and other assets. Accounts payable related to collaborations Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward] Change in Accounts Payable, after Allowance for Credit Loss Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Success-Based Milestone Payments Success-Based Milestone Payments [Member] Success-Based Milestone Payments Grantee Status [Domain] Grantee Status [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Issuance of common stock under equity incentive plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] 2018 Plan 2018 Plan Two Thousand Eighteen Stock Incentive Plan [Member] Two thousand eighteen stock incentive plan. Collaboration contract asset Increase (Decrease) in Contract with Customer, Asset Revenue recognized from new collaborations Contract with Customer, Liability, Revenue Recognized From New Collaboration Contract with Customer, Liability, Revenue Recognized From New Collaboration Investment, Name [Axis] Investment, Name [Axis] Additions to collaboration agreements Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net loss per common share, diluted (in dollars per share) Net loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Amortization of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vested and expected to vest (in Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Total fair value of RSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Proceeds from disposal of property, equipment and leaseholds improvements Proceeds from Sale of Property, Plant, and Equipment Income tax (expense) benefit Income Tax Expense (Benefit) Interest Rate Debt instrument bearing interest rate Debt Instrument, Interest Rate, Stated Percentage Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Compensation expense not yet recognized, period of recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Total other (expense) income Nonoperating Income (Expense) Research Funding Payments Research Funding Payments [Member] Research funding payments. Condensed Consolidated Statements of Comprehensive Loss Statement of Comprehensive Income [Abstract] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net cash (used in) provided by

investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Interest expense Interest Expense, Operating and Nonoperating Total liabilities and stockholders' equity Liabilities and Equity Leasehold improvement written-off Property, Plant And Equipment, Writeoff Property, Plant And Equipment, Writeoff Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Employee expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Maturities of marketable securities Proceeds From Maturities Of Marketable Securities Proceeds from maturities of marketable securities. Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income, net Investment Income, Interest Schedule of Minimum Future Payments on Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Schedule Of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Loan forgiveness Debt Instrument Loan Forgiveness Debt instrument loan forgiveness. General and administrative and commercial expenses Accrued General And Administrative And Commercial, Current Accrued General And Administrative And Commercial, Current Genentech Genentech Incorporation And F Hoffman La Roche Limited [Member] Genentech, Incorporation, and F. Hoffman-La Roche Limited. Research Collaboration And License Agreements [Line Items] Research Collaboration And License Agreements [Line Items] Research collaboration and license agreements. Operating expenses: Operating Expenses [Abstract] Percentage of liquidated damages Percentage Of Liquidated Damages Percentage of liquidated damages. Schedule of Property, Equipment and Leasehold Improvements Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders' equity Liabilities and Equity [Abstract] Milestone Payment Upon Approval of First and Second Royalty Products Milestone Payment Upon Approval Of First And Second Royalty Products [Member] Milestone Payment Upon Approval Of First And Second Royalty Products Pledging Purpose [Axis] Pledging Purpose [Axis] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Deferred revenue Contract with Customer, Liability, Noncurrent State of Connecticut CONNECTICUT Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right of use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Federal statutory rate, percentage Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Collaboration Agreement Collaboration Agreement [Member] Collaboration agreement. Net Loss Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Stockholders' equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Payments made Accounts Payable, Contract Balances, Current Payments Accounts Payable, Contract Balances, Current Payments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Common stock aggregate offering price Maximum Aggregate Offering Price Of Common Stock Maximum aggregate offering price of common stock. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Loss from equity method investment Income (Loss) from Equity Method Investments Remainder of 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Net loss before income taxes and loss from equity method investment Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Sales of marketable securities Proceeds From Sale Of Marketable Securities Proceeds from sale of marketable securities. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other (expense) income Other Nonoperating Income (Expense) [Abstract] Yale University Yale University [Member] Yale University Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Research Collaboration And License Agreements [Abstract] Research Collaboration And License Agreements Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Payments received Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received Total operating expenses Operating Expenses Schedule Of Equity Method Investments [Table] Equity Method Investment [Table] Risk free interest rate, maximum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Weighted Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Components of Accounts Payable and Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Contract assets: Collaboration contract asset Change in Collaboration Contract Asset And Other Assets [Roll Forward] Change in Collaboration Contract Asset And Other Assets Payment of common stock issuance costs Payments of Stock Issuance Costs Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Common Stock [Member] Measure: Measure [Axis] Inducement grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants Issuance of common stock under equity incentive plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Common stock issued, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Issuance of common stock, offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Entity Central Index Key Entity Central Index Key Bayer LP Bayer Crop Science L P [Member] Bayer CropScience LP. Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Research and development expenses Accrued Research And Development Expense Current Accrued research and development expense current. Accrued liabilities Accrued Liabilities [Abstract] Lessee Lease Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Option Payments To License Agreement Option Payments To License Agreement [Member] Option payments to license agreement. Accounts receivable related to collaborations Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward] Change in Accounts Receivable, after Allowance for Credit Loss Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Regulatory and Sales-Based Milestones Regulatory And Sales Based Milestones [Member] Regulatory and sales-based milestones. Expected volatility, minimum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Schedule of Supplemental Cash Flow Information Related to Leases Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block] Supplemental cash flow information related to leases. Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Contract Termination [Axis] Contract Termination [Axis] Contract Termination Financial Instrument [Axis] Financial Instrument [Axis] Less: current installments Long-Term Debt, Current Maturities Bayer Collaboration Agreement Bayer A G [Member] Bayer AG. Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Lease termination costs Gain (Loss) on Contract Termination Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Accounting Pronouncements and Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Writeoff of Prepaid Rent Writeoff Of Prepaid Rent [Member] Writeoff Of Prepaid Rent Vested and exercisable, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2027 Long-Term Debt, Maturity, Year Three Debt Instrument [Table] Schedule of Long-Term Debt

Instruments [Table] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Weighted Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average grant date fair value of options (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) General and administrative General and Administrative Expense Sales-Based Milestones Sales Based Milestones [Member] Sales-based milestones. 2026 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Common stock reserved for issuance represented as percentage on outstanding common stock Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock. Additions Accounts Payable, Contract Balances, Current Additions Accounts Payable, Contract Balances, Current Additions Amendment Flag Amendment Flag Pledging Purpose [Domain] Pledging Purpose [Domain] Entity Registrant Name Entity Registrant Name Net loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Milestone payment the Company will make Collaborative Arrangement, Rights And Obligations, Milestone Payment Collaborative Arrangement, Rights And Obligations, Milestone Payment Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Schedule of Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Long-Term Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Amortization of collaboration contract asset Capitalized Contract Cost, Amortization Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument face amount Debt Instrument, Face Amount Common stock issued, net of issuance costs Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock, \$0.001 par value; 68.7 and 68.0 shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Government securities US Government Debt Securities [Member] Pfizer, Inc. Pfizer Incorporation [Member] Pfizer, Incorporation. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Grantee Status [Axis] Grantee Status [Axis] Research Collaboration And License Agreements [Table] Research Collaboration And License Agreements [Table] Research collaboration and license agreements. Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, \$0.001 par value, zero shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Preferred Stock, Value, Issued Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] ESPP Employee Stock [Member] Depreciation and amortization Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Net loss per common share, basic (in dollars per share) Net loss per common share - basic (in dollars per share) Earnings Per Share, Basic Number of licensed products Number of Licensed Products Number of Licensed Products Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Operating cash flows from operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Upfront Payment for Amended License Agreement and Novartis License and Asset Agreements Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements [Member] Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property, equipment and leasehold improvements Payments to Acquire Property, Plant, and Equipment Annual increase in reserved shares as percentage of outstanding common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Commitments and Contingencies (Note 13) Commitments and Contingencies Risk free interest rate, minimum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Termination Date Trading Arrangement Termination Date Milestone Payment on First Anniversary of Signing Milestone Payment On First Anniversary Of Signing [Member] Milestone Payment On First Anniversary Of Signing Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Expected volatility, maximum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Nature of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Warrant exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Revenue Revenues 2025 Long-Term Debt, Maturity, Year One Equity Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Payments received Proceeds from Collaborators Debt Instrument [Axis] Debt Instrument [Axis] Regulatory Milestone Related to Marketing Approvals Regulatory Milestone Payments [Member] Regulatory milestone payments. Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net income (loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Milestone payments the Company is entitled to (up to) Collaborative Arrangement, Milestone Payments Collaborative Arrangement, Milestone Payments Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Percentage of incremental borrowing for lease payments Percentage Of Incremental Borrowing For Lease Payments Percentage of incremental borrowing for lease payments. Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Operating lease, weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Additions Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Contract revenue receivable if milestones achieved Beginning balance Ending balance Contract with Customer, Asset, after Allowance for Credit Loss Royalty payment Payments for Royalties Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. At-the-Market Offering At The Market Offering [Member] At the market offering. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Revenue recognized from balances held at the beginning of the period Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted average common shares outstanding, basic (in shares) Weighted average number of common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] RSUs Restricted Stock Units (RSUs) [Member] Loss on sale of marketable securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Increase (Decrease) in

[illegible]

&C7\$UKYK1P=^#G^4@#.#U:/@!~#VFR:X=::&7^T3#]G\X7\$@=YS MMP&QC/3KS6>W@/PV^G+8^3W^@SK< ;%VF7^:3Q% MXE-
,6,WIC:=HY74L4*E2^&^4Y5D MD8)@R!(^9196D=@N^H+,2<#]P.G\$]35DW\$*W26QD3N WC2^F>2]D GZ LOYT7^Q%;6TMQ<2+^#1=W8X"@?
27L8I+&XW>=)%EO-+^9B>2Q/.XG. M>]5KOQ&MIXNTWP^UE,6OX994N=R[!Y8!(QG.?F4#;.W* ,/0?^!^@^&K>:#2 MK!8DF4+Y)DC2EE^1/@?
P!=%F87V4ATZ>7S!(#>=2]6?=NR?F5]GZ\UOQK%\$L:EBJ C M W,6/XD\G!:=10!SFF^ O^&CZP^J^V&DQP7;.7!5W**QX+*A.U3CC(JU/X4T M.YT>
[TFXM7EL;N4RSQ27\$C8Q(0)8MG] <9G6K<2%;2R11&:1\$+&+I D#H+ M G@9Z5%I]Q/=Z=;7%S/:3RQJ^XEN\!C\$Q*DC@X^H R-4\$^!;.M+&VU?Q;9;
M^ CVD-Q\j8 82!M^Q\Y\Q;Y)Z>=Z=9;?+98M^+19;>:**5XPCJ!; ^\^;+J.KOZ!:=6A>|BB\2^9UWQYSM< M X<9YPP-53X#^@.H^?HJ?EI 94GFGQBB1PT;YSN5\
[@@]@LBUU<0B^".6>9YFD09&+DYX)Y/-1.%X&^-^&KQ[O2=,6WF;(1)QW^ M]0@8D)G_9Q6Y/<0VR^*|BQJ\$K&"QZLQ"]J/20*EH Y>?X=>%KD7JR:8?)O9 M/-
N(N)N5A=@|O@+0;0V0.0,UTD<@?<=NL\$:[8U7: ">|>]M^;W\$-U")8^%DC) M*AE.02^0?
U!j]6@#^!B^Z^!8ZA91VLRVHLL[W.WH9H]B".>%P4BAT8="",@T@#^+ P^\$=TPZU?#K!BE- #Y^Y^3&XD M.\$[KC=@@D G(Y/-2^ZQHVGZ]IS6&IVXGMF97*
[BI*#<@@J0001U!j 10!CQ^% MM(AU2/4XK:1+R.#[,DBW\$@Q%G.W&[&^`^Y YZU !/7A!^QKS2^TX26%Y(99X9 M97D#.#3DL^\$S\$@YYR,%=%\4V\,LV^W(@??
\$P=D>=O564@CMWJ5L52M+RZG0)T^?3Y+>+^W=5AG; M16%P^N20!R^,^CF@^K!X8TBU@T^&WM%#^!AEMT29P%ZFENWV\N)0)=H(!/TR14M
&!) A +1+:=#1+R+9BUO0%<221P\$9 M1&8]G!(X QDXZU8@T#3;6KG6(H%)=(SFD,SZ.HZ.J3MP,C^&'.TZ*^,S1/ M#^E^~;5K;2K06T+~NV!V;^!).N)P,DX
X&3QS3+WPUI= j?]I2PS1WIC\I| M>XDA9T!*Q1AN^/?.*UJ* ,?4?"VAZKH2Z)>Z9!)Ij ;(-H3^0J1@J?<<^FH M^7P?
H%GH4^B1.;&VGW&Z/BE9I#+^TY9F)8G@8.>.#^2MRB@# TWP3X=TG3+K3 MK335%K=Q^5.LLCRET1M+.2=HR<#!.1FF6G@7PW8W%A<0://L 1,2/-
((#C MC+,<@8& <@=L5T59>K:U!SM8621B^~U^1H!\$MM#4+L6;P !UP>HXH S+ MCX>^%
[H7RS:9OC0!GB,FPON@%@N[!DD8^4^0\&KL A/1[B2X=|>8>8U MBG1+F54E11M 90V&#.1R,YZU^X?UW4]7GN([!P[>:4L(\$EQ(C^1]Q!^X.2 M.
0W<^&G2:)/\$;.^%TUGLIIKA;Z^AL@R,H\$;2,%!);SCZ_ A0!KG@CP[!XBGMI^] M3TU!)K5=D,L *M7%Q#~.6!EQ<2+^%&S.QP *KW-Y=0ZG8VT6GR3V\ F>=..E
%1 "<D2:A?7^VSMY8SR8DCP1M(W8 P3C XSQ4E MCX>6M7%GBR>?"5I88C#\$\j)Q,8T.^JN]CM!P,XZX^H^U*PXO\$>R>-]O^9LIHY M([!7HG9EVNI?8
"3U!XZX>+^NK;+!^N6T@OJ-OYJ1R^".AV1HW^1E92^K# M^Y)KBRT^PLG\$;9KC9R3.TKR@#^#Y)(X)P^OUS5_XP^CXJ\A.IHVH7 M-Y-
;FYC:%H0AC!P3EI!W[8(T 6\A)Z+I;P&TM75+~B]O\$\\CQP\$YR8T9B]= M2. .9..M+~+X4T6;4KW46LR+N]C\$=Q(DSKO 7:#@\$;QN^..U!8^+~[+YUT:
M^=VUWJN\,ADBM[Q%G*.IC9696H)Q.^N@H P\A #^!- L 3#!+~]ETZ59K M2,74N(77!^S=LG^IFM>^L^K?4>=N+&Z\$EO<+1%*A_B5A@C\C5BLQ/XC7PI
MX?GU>2REFNX6162)EY&Y@H)/3^0&@^O>^!(SPLAO786N[61%@P2L@N MUX4MM(.< .ATSTJ35]!_M<?L;HRZ5:1S^W^QD])VQ
MP5.UBIQ[8\$("L"<)/#^XTBTTH64@L;436\@NIO(W!R"/FSP>1Z5T%Q%&/=^M%)O-0: D@E2]>(OR2P7,D32H.BN48;>^:=?^&=&U.QL[^YL4^SV3]JLD3-
M^Y)48&T]01P<8Z5K5%<7\$-I,2W%Q(L<L,2EW=C@^R2: &SV<^%Q8O9.A%NZ>6 M4C8\N,8!4@CCTK^/@S03IMAIWV246EA*LUK\$+j4")U^Z1\|V>.WIVK?
HH Q; MCPGHEW^W5]:KV?@7PW8W-A75O>V.,,GR7.,\C+~.LBj+F\$;2<#^!M^OVK^")NIWFW+, M=-0QVK>?(&1#P4)W99<#&ULBM^LWQ!JXT#0+
[5FM9;E+2G1GCB^ABJ(C)\$S\$ MH* [, A!/#7D2.DKIBK87, WG30\JLV=|V;H^R#R^J !70D^>C(B&YD^Y) &H.-0!&EVEZ\$**X4243G;N4&?<
QJS0!R\7PZ\^0P00I^~5!j\ MHA4S2\$1/SJW+~*O)RH^4]Q5U?".BHNjJMM*!j>?M@^U2_OLC^/S<<<<8XXZ5 MMT4 <=>?"#Y8Z?9RV3^7IN/L;I<2I+
,8PL@8.!@ 8SC@5;TCPUI&A3W4^ MFV@AENWWSN9&5]3N7]Y\$>#^!(XQZU<50OX0L9-1UF]>ZO#^K M^N+Z=^0<4]NM^Y! 8X.>.._L6?
AZ^VU^49[NZOKN^IK>+6Y\$*QHQ18?j^ MJYVKDG)X^N0FBOB19!<AX.9I;A-VNQ!13N@P8Y^T4CG@8/4VLOT8V1>VF^RM^Y!>?EO?U|<|
<|JAK_AZS\16UK%=R7\$36MREU!+ M;R^CD7(!!Y[\$C\:@M _UM:Z)/K\$-|>K=36RVK9=6 C7.WJl.023DDDDYS0! MPVA>~*6U#PSX^L9[DRW.J274<|[\SF%I1 7
7S%!(+8!)VGGGFNR+;?K>F7 M>J0:I217%FVB2V,1N7GE@0@]E9W4%AD^*3D]1GBJ C _?0Y/!"OH^R7IMK68W M^K.)@LUO(6+;D<
8.6)YSU^E>:AZ%!H5L<=S>7DTA!EN;VP[8 M^!j]30!R>K>Q%!j58=3OM!O_ \$WAN@M.O;NIOBD^CRSSL>8.B5!SQY(_%OB>QUR,0KZP72\$FCA?
4(/D>1*~HR2.0.9KJL \$FMZ1U]H5 M\$J \$EW]!XBBT^& N)-KF&01P&?^~^,Rl<|<AZ5N:G9W%U8K^>,ZE,0QZ!)^] MK(MR4\$AE4A\$(3.45R>?
0=ZWKCP7HMYX=N]N^H^GMKN1IYY?jY)*3GS-PZ-D M#&.!@ #'% %?0M,UW3?\$MVUS>Q^2+BW#16@^ ^YXSG J760#EGK=Q97Y.^H^W5V2O MFR?
+MZ[=PHHP .W/-3%HL^A_1]?2[6:>2VMD\$<0F(0)51T0!G!> .>EN; MAB?%Z/3QJ\$S]BET^686^X;\$D\$R+N QUP>^>M<5>ZU#^~0^2Q^J];VWFZIL
M,V\$95N@FUU ^<3C1X^& _IOARV83KX@^U727j6QM%!"LNP1DX?@?P! MS!>G%9C?# 3^,W7AJKR_A=3FEF\$6W8B^~\MR 6Y^M01E^>)M-
BN/BQX4 MW37:^=;7I;R[F1.,5CQMP?E]8SWI=+GN &-KXHN/[1O+Y.LM1GL;(6[1K! MY0&UF4^#DL2QW C!Q7277AB^UW3]9EO[W[981O^ OR!<. 'R-N#G
+^C%12 M^#!([C^?WEK=WMB=1%>%2\$G.,,CE25;^9!^_I^F@#A;7/-94A/IY-4O+ M_Q:W80I[9@>8BQ >")!R1UQD8Y&:UH! B^M(MOX=?Q%K\$M@-
,K^YJ@<3 M^N[< #N[C]D>>:Z:2PCIFH:->0R7L%="1DLH^HCC5EVL,3G0+^M^G;5_ MARW^Q0Q\$S(NK!T6IM %!&W8P5_OZ M?%W\$%H G8WK%-
<@>;Q^~)!W9&,<=2>E\3W=S/=:QY&I7LLMOI(ELM;&5H19. M0[>;(X8!LX&%3A3Q@DUKGKP^IK>^M2T-KR :RU&=[BX!=-S,YW/@[> 3S_+ %M.F\!Z9/J-
S>O=ZB^N[9;6!1+C8MRJ@Jl<*!R <<8?#S0!R-UYFNWNGPMO[VX MN3<7D+^j,T4Q|@L;0L6 4@ Y^Y^...E:TVLWVD>./%3=7-U:6.AI>Q6KOE58 M&0D
^UV#DY/O6P/ 6E#2]&L5N=03^~H^#6DZW\$]J C;L^!00KQ@>^V^00>+&# MQ#;GOGGG_#ZG>IZ=^=^;VV174VH[+ M6ZN8FF8PW^RLH>+R[5 WX!4
C;UZU=2WU#5 ^/C#3)>=>2&TM[!^TDZ^81F M]G60 ^0,9@;KQG.^W+!P/IEC;0V^3WDFEP3B>3!)>#&@>VY,
G^T^/]"#MO#>B6^DV4DSVMN^L7G.&95SG&0!G;IMX1L?|8U/5(KF)[GU]%6X M6.;\$A@<^*01NV\>G?&>.: /= "-
jH_@WX=!:I;K>YKNKU!;S/W#0R!@1LZ M9&=QYS^<% QGJVH6.D^@M4T 5,VYNK^CJVG6D>=O9@&.&%EW;96Y;RG[P MR1@"NM^@33AHVD:4MY?
BUTF+=BT =J29V9.WD#J\KXSF+WX.Z+?!Q!< MBMKJTIGN+&^YQB4XD Q U) !1=~*#6\$; ^!G,MT/^)!LV%N9 NX7&.8! MQMX&5Z^KBI?B_
LOPWU!R]F.6 CRY&3.9D4YP>1@G@_7M6X_A.P;7++6/O M5O+6W^S%A<~^CW;P).![-S_#XXJ[KVB6?B/1+K2;\.;X4!_+;P((8\$^L M00#^%
&'<=..S1)|C%="W429^0!E\$!>7&(R1Q0)]Jl]0.F.9EKXC/2M U M6Q_..T/B<:3!>74V7CANZ=XIN)]V+^&QJBV^2SDOI^F5)U89=6D4\$5(9/><52;R^A_P)
M7X2M+35;NS@O.F:&=(& #*(6;3KQV^!QD5M>O^MMX>#_M,j6H3%/+6;4+ MDS;B?W5Z @^9P,G SG J350#EMK&f;j\$US=13:=(5;<0LH4,1M).5.
<@D4 M^!>T&J7UIP;9M8PAV !7)VAF&.G7DUT7B^P5IOB+4+74GN+ZPU& MV4QQWFGS^3+L)R4)P;@;MjA/ 9L/F+I4S.&^41AF968\$^L^5#\$G(SZ9JN
MNjZX/ O@_5!ZAJMJ;^69=3BLYV6Z?.>XD7!#/@DY_1.Z5I^!^JN;J.JA75O M\$UL8+&UGB6WG^LC%GZ\$@/?+SG)/%K:SUJ\U:"] MOENKN!
^"75@0\$9^B^C^Y&3R&61F M3>;R#<=I^S?/(FZCG4UZW=VB/L,UH7F>=24W+PDQCKO!W9\YK 3P!l,?A
MFQT@+B^6VT^Y6YM)!*!+>3?=-E>QKMN9;Z8RRR=&=,MQC^48Q\J234ECX8 M+BTN M^J]ZJOIK-
[22.2.17:7^@+3+G2;>REN M]2>>?"Z62_Y+7/G*!BYI|<8QC^:GQ>!(CFUF1Y+V;^V(!|>++QW[=L4
>~Mj.B^& #5Q96FIZCIZV 4++>TNF^TQIOM=^F#J_ E_1U!7 M5>+&^TU/PQ=W=Cj\$U_9R^RD^?QO;Y6SSN7[I^E16WA&&SBT];75=4CDL8W
MBCE,RNSHP0&4j0\N!<CjT]TFUT33UL[-6\$+YJ-9CEG=V+ ,QJ22?3T MH \W7Mj\$C17B+5+~5;VYN;4A^!~(8|>T7=&|@9-VV5OF;<=I^]R01BM+
MOKJU|I&KW4VHQZH^N@26JQQ7^F2MFPE^<L:D\$CE#D@&@8QCUDJ7GPVT6]AU> MWDN-22UU2^Z+^-"I2XB0)((X89!^O7CB7/B/A!>:-T\
M3:D^IV>Z4PO/(F03E2CKCYFLN>G &7!LL45OIFGQPPQF.VMHPB)&I;JC M R3P*^j^/AC[5V/M,]J7.I)^TDNFW42^EIO\$K.N0R!RN=K8SC[2]M0!(;74
MM=>^<Mz8_B#5K.S2QM+F.VE5C&C=F?(V)EP1C[FK6D+j&Jz_XZTB75[X+ M#- EK^="K6^<^\$-E=N_,JL+APX: [6!;^JFC./[L.E9UB;5M0L2]M02U6]NYH-
>^S;X#=-.IFJ27!<=E%>O-J.H.F+=,+3S,YW>7]>><9QP^..+Q^U^X,M>!M4U>T^T01JL989^LJ@8COC^G^R>DO^Q^VL>=]FQGN^N^5+1).O;(B=
MI1)YBL1^Q.Pj5)^7 P>E=Gj%A:ZKJ|Q87T^SVPACEC;HRG!^RMA^6MBjB M9;RJO5T\$62W;jP@RNW(PH+;D L6(lj; :A^V>HZOJ^M7%YXAU5TTO7YX
MH81^H1T^)(CC^*_T&8SU)K:5ZM+^;UX;T9)WMX=5NY(YIT;^P5(V?8I|^%MF^C(YQG^/-A^+&0)M0DMKFZE- &TLKV\J]5F>R^N+^B=IOFV^EE0N3M(P<
M@<\$=jVHOI^VE V^>3?=-E>QKMN9;Z8RRR=&=,MQC^48Q\J234ECX8 M+BTN M^J]ZJOIK-
H[5[MD8P!A@D;5&6P;,FR<9YY.0#S2ZNM:3P!XHUS_A(M4^V:/J MURMKB;[8Y0_ 'S CC!X]_<)]XKL(KSXD^~7>6Z3SQ>;A!>+>=?0-
3^T5R_!SU^>XN075+O&Z;|874R^EU)AO&A6Z^C^S^..@&@^]7U+6G% ^F6K376H_*K]2 OKNYET[7?L<<[M3;,D1;M4&@C<=I]J]P#U&:}[5WNM-
^(/@VQMMOOL5R+Q9H^F^KJLBW^6^9 MB^3U|>E7?) A M^AW4=&DGO9+2^N#>=26!_64N^+*P48.X_ E6Y?^EK-J> MD.@J]?<-&4)(910V3(.6RIR2/R[8H
X?7=6U^T@DU.RU6]NY(j)?CA-S^8 M[9(C^J&WLMAR <%@O7/S9&^Z%?^2X2_JBVG I2U/E^&FBRVEW9 :M32UGN_MMBP)=!)&0^DH,
<9([YQDXQ6Q#X9M8\$SHUY;F[-V+066UI R&(^< !K3G4 M P^VT>];jX0@9E/^C;FI-^NKWQ;H/B74UU^*L[RTO;FWLQ^;R+;^3PNY=K MDD9;<#j]"%=9I_A?
3K#57U9A=ZFZ>6;NZD,CjGU>R#V4^JLG@RP-YJ,UM M=7MG%j9WU^M;R^YV(P6Y4E6(X)Oj3]>.:6T/Q^J.L:P^!KR6:5=6TNYF
33K=7/ENZ^F&^)!U) &6L;Q^>W=S-^_!%Q:MX0T[4GTj]2^6ZT^72@4M+&01E\$A2G(VL>8<|<543XZ?&NF;QIS_&R2
MVU;^;SJA7N6/SY4AE/8Y53DY)QR30!DW,6j>=&P&X?2+6j]0O/66GANK[<.<\$ M9(RXDC_=",\$#C#8MCK5QH GASQ1;..LE>AV?
A^&V08KZY>+N_O8(C#&#/=)%8E.VT^J^C;G&G3CK5^P#&I TC5^N M3<7=GJTJ^W-U^P.97(j92H!!R 1ZXHX BTC2]>T]Q4\H\$^-'GMMILY;Z6YD M\$X.=Z-
H(&W@KG^>IO%[+^Z+;B GC6=JUC.Y6:PA[PJN&78JG#\$Y X^YY MF<7^GJ7P22R7^IW@>3RXY-0NC,8DX^5.X^X^P;^!4FN>&+^/K7W3KJ>:[MK
MO3W=K>>UEV, X=3P<@@#^/TH XG3-2\W/A#5TM!<7MSI^ORV_V=KK\$^EjC MF)9>I?!(SG) ZUF>)M2L-=^%FOS6EYJH>"_@WV=[+
(DUHQ>3\$X+98>?89)& M6j]1QW=KX^TVQ6X^QWFIVj37WV_>MR6^2D8)&X\$&^j.^+&*^1.;j37TLI);63<6@9^=1(2H M^<#j;_@D^'=3j_@+3-
873Y);S4X+^P^"4>Z^7.&^~^!<.0?3&IVP^EN?I6 MGW-KIEN;J_4:==^BDX\,S[C/[QV8\$F/7^CGITH P1M[P]X^E^Z?#KFJ7 M5O/>7^3^ZF#F4>4[,@,0 6P<
9!|56ZUNYTIQ4UIXA;4[%9]34Z?j4\$S-9RQ[MQM@=0=J,0^IR.3DYKLM4,6VK-IIFHSW-TDVFNTEN(V4+N&8;22^ISD\$BjJGA M&SF^R*>|O9)]S[;..1T,?
F>9Y@QNX+OP=NI^ZY_!76?L7Q%(4:2LUC#j] MNHVMN=20X\$#?9D(4\$=^?HI^/7KT/2^++B T^YLjDLJ4U#088)NUL;I_M,3D MKME.&#.H
<8SQG/85H77@+2KU<2ZGNYEUHH;LDRD>0^*5^7Y2^!CZ]>:N1 M^&?&)DMI8M:U1K>#^.[3]Q&C=Y&=>30!/X7N[>^~\;=Q00Q3LB11Q!E^&+& M \$DL^?
FXQ>5Z5I.E6FB7;Z=8Q^>7;0+^A9R>3DDGN222?K77/P]Tj:35Q#> M.E:6NKA_MK;3A89<89\$SACWP<^N^*.:QO[SA=OTGPY^<QO>[!>+>+R
M6K2,QV9#H18A=HXR!EN<^8JZ@GBC2;3PK8W_(B=KN36Q9RRVL@;?"R.ZB0E M1EP_.HP>"0GSP:7%jIOE_LVX^UQ/YH9WFF^~V8\$^F/7CGZ4
<==^(-2^M^C^B^J CT MNUM;FSY9(Y96C>56!Y/4\$ Xj&AX6X2QU^N^Q>7U097L4[2]<);.M;PL.8^D>#<G^2NC^A+3CjJNK7\
[SW!U^:8+N&4&4W100jX"C Q|j^!9I A^ MRL%L(WNjVM);=9074BLL!P5!&1%8A2O.Q&.&_!LKO#-I2-M7N)+FQO
M9#&);B1UR88^%E)P^">_88Z5T]EIFOPZ_I6iOZE\$.->DO8IM1DN/M.YI48-5O#O@330#[NVD8M@1C]VO;@D9.2 2.YH ZBBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN;9_-H M5EIL=j56YU/48-.BE89\$1D)R^Y^"AL^UQ6?JFJZ+X^T[0IK^2\lJ8M9VMY9
MHD/RWF8 8 <50RE3T(SGOB@M^M^AC2^*Q,K+Q^VN!KF*]4MMJECQ^U=KS>Q2^<(W&Q^?Q^Sj) MN[+6I;5S:PjYHMHY0K&-
.8+!#3M.N;TP7^P(VD..O^OD? SA5[GJV]6^7S M|>*(8Z^1 VR1=K+D9P1V>?2>^IKKX^>);T+Q^jK-I\$^L#36Z^6W^QY;.IM M7G(/)0]ZT(-?
O=4^1Z3X>CNWMG?15U.ZN(TONY+^BjNX0,EB>0/0#^?T5 MY1K7+4QK^IWAQOG+?^4V3P^7>^0A.T,NTIN^7.T.2^0<#<BNCCO^];TSXBV
M&EW>J?;[4K&?>R3 D8@DC?<(&L;OV;..2?>@#M^M^j)*^*K5M=K.U+K^F MRUN+>[2+R!\$^C^C!PT#^H6jN]O;(/+C MB#8W-MW^+13D<# R.W:*
(^PQX%^A3^UY/LHN/\R!RYF^;^!^7^W_ ;MIQ6O+XGW%O:Z MU(DLVI/j(F@<^Y)=,X*^,=<\$^LDB>\$^BGO|^#4?L^j7US#<37\$ \$5/W0V
MjNPND\$YR23D)CC^444 ^EWMK^=SP;5^"A015).^#GDD MjGZ^GR^<Q^0]T^4;74#jJVF6_V5;GRO23PX^Y(F1D<@ \$8/M/74T4
_2j]=~101\$G1X1^76BS:Ej/YWKM^#799# \$D8E-F9&R= MW!Z^M^j]P3G@^<D6Q^UjM+M^=ZE-J^O.BR2HjE^8Y^~B^=T^T^ "BBB@ HHHH M**** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****

[illegible]

(Y,N1ANZ~9LCY2N1CJ:Q=;U63Q9F?PJUJ&XGM%OM4 M@8PH\$(C?RY,=JZ]+PA+8W.L#2]3-K9:M(TUQ T&Q|RL,.\3;AM M+=<\$,)\^U-
U'P6L^1A'ZUT2]2RL;#FCF@A,F;F12H#<.,??:. HB1HXD M11&D95 +L "Q]3Q?2*W\?6L7BB/5H\$;X%Q|<(&G%V")P*]1QM1,]
MMT@KT:19FMF6.1\$G*X5V0E0WKMR./;4M#TV?2=(BLI[M;J5"Q?:RMAD9B6+ M,.,GDDDG&.004 ?8#F@#. MU/Q7K9\^)=8LIEAN]*U)K.WL6B5ED"LJ@-
QN+<NR,\$=5X\,=J35-4M?2B%I6 MCR7GF6MWIT]J&1B1&0 @1]X]9<+;WR7&M:A=1^-8,.*2^E8:?.CI+= M1X8]B@G#L-H& N<
XYKNI_#NI:Q=<#KK:B-.UBS@>+8I,ATD23;N78QIRH(MY..AS0!C9VB7;7SH.O2CS[U]/UY[(R6]NK3):KLW,J 89P&(\,.,5F>)=9GU3 MX?7] _IOBA[VT.HVT44D*
(D@C:2-6CE&P\$)9]8%R",9]ZK3;1EYH7GV+Q,] MYMS];.BS2P*PV1@~" P-/>G3@M#]P/AU+2?P]P/_XUM0S00T406K6@M
MS!G*,P9CNW=IW<&I: #XA?3+VVB...JX\$EADRO2&!&1G: MHR.F.E6 !VMW7B#PS;7U_,"VO@TD\$S"OW5EC=HWQ[94U]>Z;K4NK?:+/7OL] MDT81[5K)-
I!|SH^003GN&2]J6L?2V AVVL/#!FI2Z<=0S"17\$ F_,S"0 MGH&8R.C;Z^N*. .CFBCGA>&5%>-U*LC#(8']#7,^(1/7Q|KFB64>/^9?)J-Q*
M! _]JBML3]/YBPX_NJ<11GH]Y;26.VF\$\$(ODI3>8/]2V]P;6\$<GRC.F!<>@GICKZ4 0>|RT_B;QS)<#.,IU41=_ _UA0(M/I@GZ9!)Y8Q+!))O;IE7RHHHQ-
(<8A25PO)Z *!^5;MSX)+##(" @4;5BC+|UW\$;VXR W(R, M5SVA>)O#C?%RU:VUJ]"[:YT

0*(JUND*Q@9SA5ZDYZGT%|VQ_)DOB/SSY@T\V/D[>,&0/NSZ]8Q0!C % M" N+P-)?"M[ID4BQW#A9+>1NB2HP="?;^""",@%@+&%SGVQ[>D6D^~
M5N]#T*VF4S:K?7UU9R2VZ(I9 M8"^YU5R%#\$*O!X&2<^&*Z2\$PS>0^+V\0OJJ2RG3UL#&]MC*ABX8D,.=Q/;&
M/>>L4 _#./X>BTXTZS+>6M^~^H65 _P|'[@E=BS#18AE^8C" % &YX:F1&U.WU M]VD%G&Z-
87,QB\$LBDD?>KX\$Q4%3T(QD?I75DZL!= IT#M]FL2ZK>283#/"D* MJHZ47@=22>2?7@ :U 11110 4444 %%% % !1110 4444 %%% % !1110 444 M4 %%% %
!1110 4444 %%% % !1110 4444 %%% % !4,MU'## =S2S\$[549. ! MC)/H!D<^X^4B]JR=8.V>M7FFW=Q)=13:?.YL+6\QCW="5;'WE.UZG-'.]G9EO.DC3. N=Q
SD@\$\$'I5; A*];^RTU,V&H 8FC683"#[(MV\$9# \$ YQ@YZ<"L/Q3X-[JTDN2=0L]B>6.68NB-L8G8!^Z'23Q 05: MT'377/^&XEL;#[\$]O;K<,)V=S\$8Q_4
YXSSTSUH Z'4=7 RAZ?."V\N6XO+& M.T%M#MWR!|EB-Q &1U(ZCUK3Q9YSZ<;FUTW5)YT@-Q-9+;A,B%]\R,P MRXC R3M.,UCZU SR_ MF1740?
3;MEV+&=@=19 RAX?2.3Z55%1ZRVGQ2\6 M74NHW;1VVGVDSKMC^=1YIVGY. Q@P<8P>?2: _ M+ F \LX+J;.(YHUD4.15L\$9 M&0>0>>AJ:O/M-
U;Q=J^GZ#K6GPSNEVT4UW;S&W%6\G<9.P@^9N4\$8SUP*|U>+J]T+48K2YL]1DM+6WF13"XB8*WFG:7^;YCVI& 5]R0#MBZ"01E
MEWD@N>2!C)Q^~(_J.DZ]JNK17+K9WEKY#R]N1=0^67*G&J?5#V/>>N1@ANF^~
M%VIU.ZV#1(1A%)A09F8%0"O" *#QS[U#1^H>==8) %*OLFJ.D:QIV]74%GMO M^AUB VQE2I"/KUR>M 'HE%#O M# =Q_JV%9NG:SXLUK3-
#US3;(ATNGCFN;:4VPM _L]JOA|\P,HQ@GJOVVHV4-Y93QW%M,H>_ M6-MRL#W!J>O'O!5Y>Z;H'B*3[R"TTR#Q/+;P2RQKI=HLUI!GVMM7 &5XX#8/8T
>F(Z2QK)&PZ MNC ,K^<@@"|!"#67X@|1Z?X9M(+K4C,L,TZPAHHF?2."9P[L[00>X];-6:;Q[HEFE9=@W^A%[@#MD\GN>/0 M8YX?]
73EO\$NF\$DPZ=K4\5N.R1MAPH]@6;|MB@#HSJ]JG3UTC[?>5%FMC:E%[/EJ,2"5\$SNB@GCWK^V^); M^\06>FZOJ5QI^L"/64W6E74"/+/%?;:=PN6
.T >|P#F@#T*BN>|6ZY-HUO MIL5L&XU^&CLT*!2RY#,-2-Q"YPA SQDCKT.#?7WZ 3-+3W,CRQV=M[W=A< MW2P-.DJ*2R,L?RE> 02,]=V^L>(<2 \
!=S= M:N+N#F6U\$5Q: 9D14)@.@=6 W9R."P& 0.#H^ /5]*Y&U X2M?=\$-NN+IM)F@=;A[W~O@E RC1B M(_,">#"GL?6N6TOQ1XGA^'P|97^KPWS;)/#|C-
JBAY#<#&*.0L",8Z\$#<@#OD MT>KUD>?{5\$IX:L(R)[BN^BDF2>2F|].P49Y R16&EWXFT[6H][X2[ET]; M65[1TWOV+;C4=9^&F]|J-#JE[=6-P]F\$3RT1YD
M*]#MW9&5R2>?<CD 'K';&BZJ]NM:5#?K9WEF)=W|FA]J>5<CE>W3[|B*NR M\$1,J|<@<C.#ZXKRN'Q5XDD^&F@ZM_4?|HEW.KBTGD-NI61#=-
'C'8;0!Q MS[YYH]61%=7&58,,D9!SR#@ _K7#0W>M0^~=3\,7>M37\$SD^_ AG6&..2W?S M^A5,+@CH1NR1ZUA>%M M<\$ \$]7K(UOQ%::#-IL5U<
<,-=ONTLX6B3J^1^FXYP+P!RQK'M]7U+2_B%#X=O+ MI[ZRO()J]VFD1\$DB=& =&L_4@|@&XR#Q\$57XF"5K?PNL#HDQ|OV@1W7<%/SX M)&1GZ9%
'TU>^36+8&5]5E1,"Q.CHP4QL\$P"N64 MYZUMUO'Q9_!MAL^V|<|,I>M= 90T+?>DDA|O.>>"&R,8JZ_.O5T?>M96VG|P M(#\,=7NM)UF|;5(|R|>'S4BD\QDF?
@Y3)+ 8ZV\&.#BM"Z]9 MR_VMX1U&UU"8Z]J2(MXGEQD1M*I\$)9MN1EU93CCCMW /1:XF\0W\~WIUM!
M+@T5Q)G|6VMS]JSN9UTL>:T\$]X+VM;JT^S(J\$2QD|@&@P(SP0/84 M>FR2)M\$&TDCJD: LS.< =R:Q="!8:'XFOM0M~O5NVL"@G=%P.%MV _B^Z>
MG%;E>1_"7 DHGQ+ _PFO HR>@#N;WQSH=A=7P4UPYBL(XKVY5=7]FBPDN&+4+4B?L\$\$.;/(WW2Y#D,1%)M9P(9)9?4A1
MT'7DX'!YK2N[2" M9+;YCSD+CYE/UR/U->+.#)B; P#H4U _L[L5&4&8&9B#&3!*32*.215>9BDH]Y9L%M M#%) "O&O@C _C\0^ ^O]/_
\$9/0|ZQKFM6WA|29]4O4E-I;KNE:)=Q1?7' M4CZ5@Q?*\$21Y _# _L;JLFEI6?|2EDS+M4D,>.< @Y/M2?S\$V:OAOXEAS9 M\$L6+*#H!Z?R-
%K&6UA_L66S0=TBREC_ G8"NN ,%G|2-G24> QJ#E" 6;0^P|'O3?&WBOP X M*?'.C^H!?:76?M,<-RVV*2.+>+& <& M<<@ 6I?^
^\$OLDU.QT^XLM3M\$;V0Q0~..J,P|;|[H#M@]'|Q'<=DWMPMX>D6-M7?N0KCI'R'K7H^BZZA>:AK9|06\$ M;V-K55F+HJ"]>.(7J2V>!SD4 ==
M74%C:375U,D-O"ADDD%\$FK'BS2;?7O"VH:3=7/V:.\C\@3?W68@+]?F(X[UXS#XB9?#?\$6 MVB^~M/&J^&-Z0Q7L?S&-0 <*< XK' M^,
<<5;|IGI6G1BK2\$&B|VJB MW|O|9"0PA7#&C|J5L\$]. #7B7A'Q+>=>M3^~^JVL6FDG44@U_,BK+L,8R;#8 M.5'?0?CCM @CHEMI @B?5(=1CO)-5E,\HB4JL+
8,>#SD?'P|1ED0 =9GWG|H3NS^~ '5?)YIHLK.^>RU5;[.8BN#9M ML(DP(\$ Z Y)';74 _VD:2^1^1:~8=0.6F,JW<|=J\$1QD@,|NZ\$X9>GK6/X\$?4 M;W3--
L=4M(%TP:~9;-)|BXD./F+9 VL,)QSCU-6/BK"GP|1/]J 2PAV9?X MB67GWX H T+|>:3J _9KVT&H" #4G*6MP|]JRQNP#&[H.%KZ5U<~\)|H8Y M?
A5X<B,*Q2)G7(^Z=|=-Z1XM=~/7BW@7_DXX MQI_U|M \$%78 %K4Y[X:Z]]@F*W@MTR/S+&|BHQ|OE+< 6@#4M0&DZC>7 M%OI*7F]V;9/-90%XHV]-
YQ&/LN36EHVO?K|S5+|AKNMN;..?7\$?960*K%2 MK \$S\$!AG(ZUR?P7B@B^&^BF #YO*SD=W\U@< _EC*[*>WL>|UEN98(@CW4OG3 M?
QOM5,]JH _"@>BHKIY|(29X3&5)5C8IYIPF|&X]AZUY|IWB35H \$/A_V MU2 AU5|D0^A'MS(L6 _#158J]">001SGF@#N-9U6WT2KC4|J.5K:V0R3 M-
\$NXH@&2V.X&_U94OC?2K;2X=4O(&^VT29%=-;J2U8QA6Y#,5SM|R:3@4OC _M))UXD_|IEQ Z+!_#44_@31X9T5X9,@617&593\$ 0?;% &S#-%BO*?
AWXAO[3P MAH&6CPGD6]O|V.UECV&?%<|EL|YA"YW"> >_>.F-SQ&W?>AYXUAUW-FM\$M7 M-A/,8O.= "AW+((SMRIX!&,@T>D6\RW-M%.@(61
X|ZX(S4E7.H)+N64! JLK 1@%\$DL<8.W) //-G?QXBD^%VF^>^OMCK+9WC+J_ M21PQ_OK=)VCG.0#NZR8\$/-|XGN= M 6*X6[M[9;EF9,(49BHP.E2)XBC5;N.X=
(I 4W30Y^1V"\$] MK\$! XR*Q80Q^~^!6VL?#&#&C.#Y\E '3Z1]BZO9&Y6TN[4'5X_+NXC& _RL
M5SCT..@&E7Z\KN?7B)A7.M]J2 |P|HVNIO;B4VZ?,@N1\$|C&^|IZX:;\$]S MXCM?"_AG7O,M=2L);A7-I&#M71E!OCD\$- _NQ[T ==K.IKHVDW&H~7=VL
M(!,%G%YDKY('RKWZY^/F:MB12\$).T|O|U6X).XQZ|:PN?%B^V^&GBJ|_ M)6 MU30|0FM\$O/LZ9E5"N"5QM|P_ 88XK4UF.[E^*WAM\$U2|ABEL+I_39L4KY?
(M4)G<8'KGXSX[R6.W@? M|_+1.(Y2A60L?),(4G(Q@D8XY.O:~G|B/6M;L|_ ^DTV+2S;@1(CLS|8M MN!|^4:E QG#<|,
&UX>UVU|2Z%:ZQ8K*MM<@M&5'M@_5Y))TZXKQX29 X5 M9H6>OE/G OXU=K0 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1 M110 4444
%% % !1110 4444 %%% % !110 445C^|(\$-OX|@AOT:W>2UL9+IPK*Y M&M*?Y7H[?0X=)|@U?6H8HH%MUFCL^W0E"J N02A _!UQ7=G4V&O#2_LYM-M|
MH^V>7^X\$S;=F|W/^<=,*OT >:3;K1+*= /UN&76(EL+9K6V+P\$?%NRGEMC. M3LSGY1CZ=6\$SU?2K;Q?7J6N/<Q- _\$4< \$ULWAZZ"!\$SMP<F<_D M(>(<?
6-2U:QBM[B&3)EAF\X*-Q90P*X)XP1UQ4|_J;6-|IJ+>^|N|>2-9H(C |M]R087.ZOY^4'I: _/;#72- F^S6NM^*SH2R&2/2FT6X*USG;YGE;JF?X01G
MOGG*QKHGU?_?9K|B]PL=I^F-Q>V\$BW&V20 >96_Y,V|H|Q1CT.P|16^H M>(-6T9+;YCN-.6)I6D"[7\$@8KMP3GA3U?J2=6&IZ/#J.MG=-<),Y@OD\N1
M,5^89XSX(C|B* _'FU31@N@Q^~1F@U^SN="M"EFMG+;H;RR2QJY=1DQ97D^H M>|6T9+.#MZ1X=&I SZU=?;|V2|BT4 >>>|6|+>? M%U0+>#_WULI?
73W+^*C79";CG8O|OA02Q _P!HUC:(ND:|F^&K;O(-:10V<\$0A62#P|<)/M_WS&P|P,UZG10|Y5>CPN? M#^E5H|: I7]E72W=K+^HEU(?,&|<-
'V=S9S1#+HBWNSSZCXEN|UNT6WN MT?0IQDA"F\$0?)*W _UKU6B@#Q^>?W>XT;1X#K#>/5-XL=2BT*X1HTVA=
MA41892%&0>3ZXKXN|U]#2W|R@.1&S MGA,|J|A5^H=10%|O@R>|):Q>?|?;6CLSR9? _*4QE@P;@-<[MP|IVJM;^\$ MI"=74|4> 72)!+;.\(65G"% 7<D _>
!GC);MQ|\$M=06I)>YGR8XDY8] M,|FE|&1DGU ZD QC58&MXID25EFE" N,0!.5YZ81.3C@9Z8R 40%/AFT6 M.;=NY9H&619X+B!MLD\$|J]ZGU']SE|
(7TV@:AIVI>(|O4+B|)MGM#3Q## U-+9"EFEU&FV^+<(- M0#<CD|S2:9X&M+3P3/X3OKAKI3Y1|(L@1P'0>H9L@XXXZUTE|7QS8/I7A[41:7GD[-
'#;G|O|MG|!_ FXX|Z9Z4_T M'P=(M0UBTBOQV%Y]T (I4]=Q4;G.TD1E^..)/;?>=|10!&4D%N427|J|MP?7/_I QG\5Q4? MP|>+PK8: NLOY-
E?"]28VXWLXD,H|YQC<3VZ8M&H.U2<=\$X&<#J;Y?B'I879 M-5EL|12W^_ |]BP&|]HFOD,[S20\$&TYH NCPW?&|]127P9P|L+6XAPICW;\
MYW9SN/Y<8|UDVGPY@|@^VNA3:M=S+831/IUP\$17M&1B4(P/F)!SU'I6POBR MR;5-3T_+?B;3@K2YMF =#C+1_WP,C..>>
:.VH|XKFVCG@D26&50Z2'D|OVMF MANI+::RO(|VWE10P\$B9Q|NZCD|W=%A,C%F&0,MR3U MJD|A]I |):IX<C|Q+ _EDF+@ _\$S/N79Z!#MP;|WK6V|>(+?
Q8SW5M|L- MS-NDX 8V&VUNA(Z^~.KJ*68@*IDD" _.'1>#+7+M'L+*YV~|GTUTD|; MJV.'@91@8SU&.".0]7@+;+5?
#EWI>NZM>ZE/=,"UXP2)XRARAC5 %7!R>A)R M"3|.SF(\$(&^&,\$YQC/M6CHOC/1)>O|([3K1YE.U MS|HLIXS'*OO@|\$=.0<602,?>R>1 MCC-
'3N)#\$P1E63'#.N0#|,C^=Y;6)O.NHY|_NRS# M80>_7/7|YULMX@3^WIM'33KZ2YA@6X9E5|+V,2%.XL258 _G@|JS/#Q_T MOQH?
#33|TZU;I=2P<C\=Q?VJL L MZ-N1)1OX0Q W<V(K0>8>#H %GAK (1W?V*P(SB#-A"")H!P!P.U1^\$ B M)X?9W?Z7-
*MU;|R07>2>9QD#|/|X|QZUL5:K2;K>P|9W4+6G- \$FBZ?|I6CVFGR7 N/LT2PKY|>PLJ@ 9&3SQVQ|*R/O M?3%QLY|B2:TU&Q\$MI?6Q
DB8\$N"'"@!_2M:XUNPM=5,;OY_H?2C6M:L= TU|_43)"K*BA1N9W8X55 Y+\$\ 4 5+?2-49H/[2UQ M|F.%@^R" 0>:0022,C!M!
[Y%4]9\$V.I^|(+&Q):S26&MV@V|&^?0^~|71XD@34K3KRRO; ZOF9;=)HU(H?<A< _C,H,P%|!?.M>:>>@U MMY+BXE2&2]R.V\$50,DDGH* _.;_.\$+@O?
%6MXCUJY^WUWFFRTC6M/RT(Y8 M)DDM|DGMZ'L_7/AVVM^+ _Q'6=9DM|RQ01V:6ZE H+G)Y|SGT|]X|TJ2B M26+>QU*|TF
MNO881L(7|S*K,'8#!Y"GH?2KS>+==*PJ_B2SE:~TQ(FF:2V M)"**6."0>,'(Z^U %5?#H.R>(<75|S7Y+EK2.1;>W-LJ1\$C|8@').?&JQ
M#GPVG|+KJVV;XAE6;5)/N%DM49=VYF&|GCEV|>Xj^&W]T]PU.X^VVFF7| MIA@O9X/W41<\$@&E22O*G|P'0FKNO^L';.W8:1>VJZUJ! "VGDQJRSD<
'= MQR0.<4 Y_UQ=Z|K>F7FNSW,FL2;KBYD/71Q|UGV/Q?T4M;U1K13M3EO_3L_.81\$F4P<C<9?#AF@!^J _# M_2-;ZV15]P9=,2,6M|&VV>-U &@G
)SD\$ A5'Q1|)/&MC96&OZTTE MK:R^~#;VPBDD;3,2PZ\$|%%; AOQ9H BRUFGTfy,OD2>5/\$Z,DD3^C*P!| M-8U:U+6|TFYT^WO9UBDU^X^S6X\3[2M
'>|A|)X]M[*VNM2D MM+>T?S\$6&(<%BV,2""V5!48,%|V9C@> "N>7XD:8 B23PZNFZ]=6CCQKQ;R4 MW|T:73|I88YJNZ2%L.N&#?*>QXZ|JRJ3)MKG%I
MNLZB;S3B24D:(PA9)BIRHD<!&0,[57-43])VB:X>M=V4M M Z2]SY49=V0?W;=NU;+>H>+?T;P\;U>8Z?9E0?WX&_GH %R3Z#)H|A8^& M?
&^O\$O7S(Y77C6MM<?-= (PSP#8 9.R|IV-3>)&?PYX;MM&BNQ.M|Y\$4Q M8.ITW 'G;5GWGCS3M+L[6^U>RU?3;Z8+>=7.'[6^|O 163^M U>^>D]5
M^~)=|':=;ZCJ27+V.PP1+BV02+N(O) ZYY]|Z4 9_A7X>Q>=|6UJ|&HM>)&K, MADNX9H %))8_+@#YSP<5^X7^~(I&W&J?V)K\$|=G?2,6%G-\$)\$A;L5YIR!QS MU
&F5;>GAF+Q#;."^TZ1%=7M5#M^Q|G|I(X(ZC#3KOQ);6NH6NF^W MN)M4N8C.ME|M_LBQ@X+2P51DXR6Y3'>.>|AS-X(TNZL-U+P|N?>9|5
M796P|D<@=AU!HU3X;2VQX?PY>Y<? MI|U0M/'^F7G??"PK';7PU6!>L;1H%1< [MV|&I&XR>BMOB3H\$WC%O^LYN M;5/@=HBN8Y9J0
P)!|R/6@#3|)>?^\$5\6VB+>=06P*Q2-'M?!)|.#@ M]?:L3X<>%KGPM#K\$#W=|/8SWF^T^VMF3;M&YB.V6S[X />ND&M(??\$-|BN _M.6\$3F;|OE;"
<9SNSU&,8S^~9]SXUTM=DT2QCNCM3U.(9FM|*~Y|VW8A@^ MA;|M0!F+>?A2?|/B>+2M9DU:2TFTMTQ):K% I 8,&RV3SRH]#T9#6i7>LZ;?W
M_B'6>#PD:5+9+9(XW+37Y\$O|QC&AM5,>5. "@-[.# MIYD@DE6\$ _JMAV%!(|O)JO>+,#2I|>/6+> M|TQ;AQ~AY MKE;|P|=1RZ#-
(XEO)IM#+>+;MY\$2CRS^Y97.&N4^Y "NVK|U[Q#;^!AIYN;> MXE6^O(MK)&B'D(C|5+9(XY[924 A1:0VO!>Z2+G|EY\$T,L^3R?% 'Y4|Y
M+@"(3GY41<^O4^O4YSQC]]*. 3?P;< VSI^JV^O7%M=6]B+^")K37;+5[C3]]*V M:TE\$<22"2(L&P-P(4Y'7GZ5T=% '"')-S#I4&G1:|<>1;ZH-3B|R!6*N)#(%
MSQD9)SGKQC'./Q+X _MZ]L=5N+UFQ4|>6R@>|R,C9#>+GG|Z5U%M M%2=|DTVR\$U|>W#'?>Z0#=#O+&G&\9!<0< M8W=NG%\$;SWAR>?
Q98Z^~H+YMI;./;?0?(RN06/WLYRHQZ]>|=10!Q_ P_X| M/ZH|ZL|?UJ|>[G<6XW[S[=P7Y18U>5>9SW _2U#PK;?ZOHN]C5I;]>JTV.2%G
MBA7\$R.W%#9VGY1S725G:MJPTO29K^*SN|0M@OD6*21CO"G R.ASGTP: _
M;C^~|V>LWMSIGB+4;#3;&8SW60G&C.WWBC6\$HJW?;SZ\$<8MS>?S%XEGUGD- M7N=+~Y+D=|!#&C|L/&%8;@<C <9Y5U0Y%&
&X2\X3.6NC17DUW;|MK MS!01DDX&|TR3UR?>MNB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH ****
"BBB@ KBOB;_ _@2 _L-6/ M_HY|6L3Q/X<7Q-9VUM)>S6J07,=T#\$JDLZ-N7.X'C(H SFU+4\$^<^>E&9M M.DT9[K|47"R"5\$SNQGH3U/>NM>ZP+^>|&-?

```

13**"Q M$J&W.F:/F&1D")=-?+X76?Q8FOR7/QD6R-B8 BA&C8AF9R2.N:PX?AFL.EZ9 MIW "1ZHT&E7:7-B"L7/G;"<";[Q&6SCMRWR
9EEI]>L:IXM:~I.NR:5*MY M4>.:!)-S &=-;MP/R^P /OVIVF>+;]U6U\ WTEQYIU2XFMI\ZW1?V2&-.02, MC+>G@UU*=%&MM7U2_L=6NK;^U-
AND"HQ"*@0.C$94Z ZY*M3;GP79N^<"/RP) M+&WVL,2J03M*G<6R3P[YSO;G:(C/4?&R)(T);+> Z@]@>SD/CG7
M*7>HZGKOPH;:E>ZG<_YM8@69XMJ"3 $HJ,@# P.G'(>AVGAIKP@+JV MN1:C-Y"1IQRRIM&11!& "$X(DS;DU;:S$^MM'X(A,+JEWY=M.MQ;76U/B
M=9;/I28/S9ZCH: [J2OM2\>.-]-Y]JS-H.HJUH5E2("ZQE"SI!< ,P SUK MHJ"-Q+I VJXN990M+M-$)
H\N(G+&P! #C.PVPLVV*CEA*JZGK@<"/"1J0Q!0XUM&O [K>C>](<1JK MTQ!14ERL*;J,R( S+CY25?D+CGIC-;&=>3XAS^?^$DNFM+K2_MWF&"S(&
M$H0K+&F #D?>+&F0;4YK4A MG->+&C@;B60A]$ZA&DFGWG]JS9&.H' '0 =M*NGPTQ61XB M'47*V1LO*M=A0L&)]<[ @#U] .&G3>
(8 AQ<7B;JWJH6& MMG3C<V%&,SQBY$>6&,[3 #C16R]YXB\>.K#3[K61J5AK%O<GVF%( LLT2[ M\@H1'^(.)&.&OKD^-/#T?AWP!>V,>HSS-
?&O<C;XDU9)&? 1+98AMCV%&-A 7!4XW M'1^E6$!<HNB^<(+JW+1-Y+<+&8TW(T)"N$XX&N<4 4K %K4\;0^<=&5
MN;^5~U0%MY[<(<FR"X=08VV;=VUCE>O!Q*?ZOVN)K66\FNI9DN96D>5PH< M6?D P>1ANWVQ")6W!Q@;<@%XQU;OC MN418T5$4JC &!O!Q?
ABX?4/B)XRN)B2;1[:R@! @C$9>GA;V&?3KBN+OKFR\ M:AU6XTK7-.U.TU- %< VZ...770YT-N(VWKL B O8)SG;!Z4 :>EZOJ3>[/[ M$%]?
O8W.CM=<QRWD;-R+(LBK04Q;00"&R1P7,55ECK B<+.-63Z.J).J] M#<60V>)8IHWN+Q6OVN2ZAXOGU+*T>U>1]E"R*6# M#Y1" N"HZ8)[FJZ6^C)X-
L_*R>+OLEK<+.DAT&?S"5D[P GRL8W>U '2C4+ MOQ,OBGRM0V!391+&.&.%4RSI&+9WW YR6P.P.U#U+6 P#R3KX6?JA6R
M1ZE8S^+;#^T4"ZA.P:'.8[A(N-^&B)1B.17'X'FHHXM(BT/0* MCF6/>3HERES S:%,69T1"AOW7W<.>.0/6@#J;6]U#Q1J/B*#&TU2;3ETRY^Q6 M E(C?O
BL9**=PRV.![>IXYJW7Z KUGX.F@O\,GU*|N+*^C2)70M&L@+ MKN1/5<@9QT!S5[^U-.M];OM4TQ[SMC+^J]+M%T&X=)&48$@!C^5\<9Y!XR#5
M65!4Z"M*CXFLXM$=I+>~M#&WLP(8N6CR<[FSTY]&_YI5QJEWX@N/50QK< MTC:19Q/C(OXK<+M%06E97U182:TZ&Y?>Y;T]X\.(Q8A"R*6YZ\G,T
=4EK&MW)<_TKJ]QRSM M4=<W.W)]P&2.2^ETS1>-(M-QB#3;N;N>W Z+&2^CV!<@>V*VZVN5M+&YF5W MVCA(UW,Q[ #N.XA?6]P^>9X?;
4K03;OJ0?49Y+(K K7)/EDD8V .03WV\ MX{V]T\D=G.31+(L.%&E.%!QP6/IZUYIWB#5X $/A"W;4I[V5HYTO)FB0 M02R+&O#0?*K;00<'&"14UWVHZ?
j]NDW>FW18PW4#P2E#>[64j<+&P.Y-W M'1-HDDWB+4IYJ&8UD98AB,H4*#<?Y?XCEO<4 M!@VIV.JV6LWMCJ=M."TEN8%CVFs= Z.17(!"!*?
PK22+PYJ4@H K\<H"K"FK2V-KNO>I9Y69+>9KEP.12i>|.P#<$9&QL>[ M4S5KB,M?VDJL"S6N8!)+.M+Y2F8C\;Y\;YBNJU:X>6^1^..3C( *K8GE;-
NW&.9Z=IT M<3( (\5>-. $7C>YG&J2]F^*F12#;)\H!8GIV1&IT'<.(HO&G %O?C-I'B) M/W>EZP/LM^1PJMP"Q #8WN4.N7X>6%KXID\6Z?
75C=SKM8N(MIAGI=P(I\X MIX\49ZUKV) "F^F^+=+CT 5(R).<O^<#?7*G'T(RI[F. #O#RM;RZK*^A674 M7\A@K%G3<_WR $CLS-
EWI/7'KXH Z.U DU>S2H1.L36V,*WV\PKCO M|WP@&)]Z;JMW(+YA( GHG;7&+1@#UZK@&#S7QJ.O1]T3O BXJ3IBU&SM8
MWOH4$!]>7QWXX8=QSV.??2AKXBA5:J&NQ1- EU>EC&Q^XPAB5AGN.@^E M='H>DG1M&@TOKN2]1=B23*H8KVIV@
_E61#X'LK#PWJ>A.3=3Z=:WTDI_M7=$ #?F00!P<>F>* /(OB)JA35^<(>G3S/=6=]M\@QN%#H#A.2.8;#$\
M7:~03O&AVGQ%$6509ZD+62ZDCN\GYPT@1F4"/W=WTQGMBMW6/>D>M^<M^ M] NK@<^3/;Y.DBOJ#M$#H".<=JO\,^<^&G>]-I-
T8:UJ4D&FW7VTTDP(LD3 M:7&W(TE2G)P0?3IQ0!P AGOCXL?Q?IA7X@Z<I>VFFVZ2IOP3OVE =PX<: M9ANYZUTOQS:17X5ZCJEW.3)s]O
#SWC/X9VUTI>&%O-8L-2U6>^ETLUJ M&8U1$=A@N0/O-C\IV&:V+RSM]0LJK.IA2.VG0QRON.AE(P0: .^&R0#X8^ MEC"^4;|<V2/F 7->
"EIC A5?Q$CROL1M3!GIN;+L2@&KU^Q"O"2M F MT#3=V BCQ+>1Y07&17<+Q6ICJ]D*M5@P;R#GP@>M[!X7>JETIY #00ZBFX7?""?
*]Y">2"N>O!7DNFZU?|AWXK?75: #20 D2:VB\QX]Y;:0RY(^4YU(XX)KJ #U=U:Y8:E;1>3K9.SQ6OEQ!79&3< MP"Y)8HR:SI"
0:~XNUO"Q"J=U=:EGJ3*B;""&=9U2 T'5:VOCU'F6JJC11GL5!7@<DX\,MXZ5O6'AY:PLN@ .FGA6 P>;+&I9E(P=PZ$GG)IYH B(Z);>+ ">EZTJ(3-
M&^9<9N495@/H=P^E>:VGJU- |> |$17>^!2? L'@.PGL+&4RZM9D!Q M5SM.O\ $Q!U' %00 #Y#"X@2^O!5NFU"5/+HGE:H7&.9Z
L@<K^O"C&28Y2312367?>.DU?P%;W&2I>+>52;)\;=&#G @X M^IKTWOUXM?NG6^GWL<6]M\JP+<+&DN R4D@885;UCP2@H/PU'HFMAK
MN*+LFX21648#1]T:;X=>* .XO+&WPGU]S;.*C/KYB8 6N<|<:>NN?"WP M)I^MP>?#<7$T3QR=XO(N@GT+4@|L"NOU3P./$&F6VE:YK-Y?;=
ZNT6U8VN M-Q02NH^8=^~N3SGK?Z#|IFTIK6>RATR3S(888DVGY&CP*."UUU")AF2>"5?O1.IR"U'YUJ M.X\;
[O$4VNVN175M>2P1B.X)D0L1NOCGECSD$=CR<@*^&+QM>+>W5-.U M 20I/A16"1I=5$5J MM.MT(W'V.(XZ>CUOVI^!=NM*0?;[V:UF-5N] MF
2E4V+H&C I&C.EWLC27%0M;>^XKDDA<|IH(7C MCB@#S71"/3IO$ 7@A T7$5IOQV1XS&B\T />ZO&JA&V*GRX3.B1: #?
QM]7BIM1^UYSIKNEZ;.>8.N,D# M-M..Q)&"/4&JO\;+H&O7]I_7K6 M/RKJ_A2.X"=6)Z]P3@8.3CBL#0=90 MS(O;K19)[V73VTJ.JA^W1JL@;S"A(P 0I&.&
(Z 50^> #T'B?0Y=>GGFM) MSI+>^1IOC=&#*PSQJ JA8^WMW\6S0S:W2W5X+J\.)%C"S*+&#*H/1<< M^><@&7/6 P#D3I; +^EG Z-6M/XCQVK
M7BOPPGBK3X.;*FM88YTG_UJIG@Z+7Q%QKFI7=191N'.EAX M&9R!R'X50S'G\!;@#E?#6NZQ?66B;$ VP7$>@6IY\#QK*Y1WIN7VO+&A MR18D8OGL
!@ # % &XKU:5.63Q(IKJL>@>OL1/9V]BBL8"$9F>X+KMY(&W9 M*^X&::>: JUJ=^"M.FOG72-56.WOK9438DTL>8V1*[@<"V0><=<OTKOP%>=7^
MMS+K_!;:U!0Q.60)M=O+Q<^&EEEXZ@<GZ<5OQZ5EWG@_!U/6]A=8OX+36H]MY9Q\K-Y M2E[@Q4LOR]@>?
IOQIC76K^<3UKPE:V>KFO36=JENID\ (W$<#9+&D9SESP3 MCVI<7^OZC=OHUI>7DEYI4-OJK@<5$2FSM$KF5U?I!+#Y1OP?PTI/P|DOM! MN [9NY9-
&MVMH0<=>)$8*1#87T5<8QT[TFK>I[|WQ.@OZ=K6HZ1>SOK%=&T RM"MPJ#<4C6>1 M;7Q%IF
```

```

[!UJDC%O&J8_HR9_(53)=W\BOX=Z_XAMF+Z.M.%9+#8!11F9E?VE3V*OZT>J6.TUS8PSSP!#+( @8QH^+!GMG S^56*XO4
M&2U 2=.$TIS) 9K2G34>|ZF@#U^H;YBL[62YG;.&#&NYCC)^ M@<^@UB>KRVU^ZG\06$ R!SDL^QM&0#5*>=(%)4^'+.6$MGME
MG:11$[!BNR1DYI(G;G>I+.;J(SL0%49)/85Y \_N_>Z\ V#6%W;K!+B6 M95"2I!H#F"2<=#D#GUKT@&#BKOQW>Z9:76I^H;NTT.XF2%:.JIT+QESA&DB
M**21WR\@/BMJ\UUIU^U^O.M%N4Y+?I5.FAM(D)VKEMK?Q.P!P= 22..O: MY9)XD>+2CAK&XCGO6I-Y;!UB'N6"D^@&XA/6H"/%60&E' P"7BTLJ8#ZQ
MA9%?<#>0!JXL6^U^T.T0!TJ2T24+BI+*EKN6.OLAPXD8+M(P>O..9S2>&O=&M: W?2.C1=IILNF:MIY0SVKR"12CC*NLCCA@<'Z5$ #>46N4)
(+V=MEI)KMI+>"QZ.M.;/QOZ_#_T!UT&C:68I6U'6I\ EYJ&Q%G/*&$.&(I\LS'W'..D_9H_B;^U MO$NM;.=/GM7TM8"SRL\WS Q!4G POKGGH.5OUQ7Al_
)*KXT ZB\ /0) M*!6@ HKD $+)=>*M^T!B>>3[-.=<C>_B@#U6BN6\#>A9ZA MIM;O\A"=XR3V>H%G+C+>OM7..>23E>XP<8/2NIH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M1HH S->T&P2Z3+I>II)9RX\>)&3=@Y)!Z@\'CB\>.=/%I4 P#I+R:6 MKI:M)H>=-U/6I;6+&W8OK562".2.Z=!&&&& (<'>KNA:@VK M>I'-
U)XQ&IW:Q3L6G(4N@>_ .K1&*WA:3)FNC=<"XN M5LUIP+FY>0>4WWE M) ^7I&2;.@>E4+>X>Z\;ITBK?<I-Q\>+>?2LZ>5VI.EON8XV\I;DYLVB"X
MNO&VJ;I+>11QV=M#<I+>(6.WDJO6*IG=NW P\I2L6/>><F\TXD?>54** QOQPO>0 MCDY/1ZEX2TG5- M<@UBXCG6IBB\>O 5AD\ M34I *Q?
#SP!|96EG#=#=1VIG= .+>:-.N0+>+>DD$#=#P 2<#IR?4UH\P!I>XO> M:G+>+>7D'V:X$LK.DD7/R/"=N.3VIUM44_YQ7657:IMUU".Q.J_9(FF6//12H) -
U_K%&.:^%I.MM2$5OKT7VG^T+AI"!7#E64=%VDPX/14#B#P5H2B:IMKS4+>47EL"1L5S:SO# M*JGJNY""1>Y\T(9J3:7-J&:SA33$B1H+D39=W.=RE.<
<+>+8131?V42UH(IW41L<@<DX/S$Y.2!K MAV\LOL(&'E*P&X').5T$OE6%C B/*I\JNY52?<@<'Y&N1V^+>M92>$80%AH5 MILF21H\|=I08.O1F7^JODE3CZT
7H? VC07T^<GVXWL4=6 VEI\Y5I'0D^H6 MRV".1.W08:/6A+X?M=&6.Z&G6L\PFAB9U\U\CAMP.L>#RIFM..ZU276(4%G M$NEI/>8UPTN)F$IS9CIG:>=
&.OAG34I'1756<7SOK#(PG<@)(%SM+H#M8C M)P2*77?#6G>(<?LC7ISK-9R&6WGMYWADC8C!PRD'D<&M6L@EMYE#ON0I9/OCVH YR3X=^);?4KZG:"3I
M..36A\ A72-T1-U6W:ZM8R0R2-YB..C\I@IZYK1U"@"ATSFC#N21#>:QM M<@<'DX S@#N?>?AK7K?Q\X-L9M1MCNH@Y0G)1NC*?<$?A0 [0I
L/>UFUM M8K+ACN>2>9I9\NSD^PZ"?NUTC3)K_XJZ7=FWOTM8-EA-W KJL2LZD#<.- MH_U'K7=T4 <I>^!=#O( 2TL)8)E5+K!L:LT<[K.] ^>GF
[MW..YZ<=A4+>= M 9M0/DW0.HP+>W>+>N7\H!&6^EB"06//YY=-/10!BW7A32KIPO P(YU_X1+2 [1TV )O&N=-5EMI'NY&(&?#?SD_6I
MDYK=KG)I07&H>+>M>T6:TBB33%MVCD20L91&*.2"XC<T<@ 6@<"N P\>KTV ML?86GXG<23QI.ZPS.\XGC\VL2J.'O5VYU*Z9=37KRBY:..@&X3P.#
M!)ZDU#KGA3I_!>:1.17ZS?Z..MO#)#.T3QR $ AE(X\U'X<^W6W\HBPY3= M&(S>4#R8RD@<R>/7I*L4 8MMX5TJVU>ZU[4EW=0K$1N374.4484
$X&G M&*S4^'\AV*UTZWABO(1IS.UK)%>R)D&'74.&W:6[C-7%07/ "P&\>O:1+! M 9IODN!*2S?O FTK@=3W\N@H Y@>?#_..#3-5TU:.1:35)/-N(A.^W'D<
MHS\URH.1UP/05OV-E%I\UE:PM*R1C :65I'N268DD^Y.M(6M26UY)=1VRR: MR^3-M.=CJ5:??#^+>=6*.8M?AIX.LM'+*QN8 M+2*X6XOH+1\A4H)"[ @
<GKTR?Z">@#( P$S:TX>(<DUY5G6 2#I.K+>P019S MLV9VXSSTJO<^#=$O-50I1AGX7EU"R+N\SW$GMRN<9.$(C
M5(5#<0 RJ.O\#>+I=K:6I@MW:I.Q\I\KNY.QESE@<2N P"R">.<AUTEPE"1.M:1GMY\IH_9EY8^<^YYN?..C"7SCUDUWYV:O?MTXK1T70K#0+>VUBD@5CN
M>26519)Z\LI$D_GO6E10\AZMX1TC6-6M15N(YXK^!#&MQ:W.D#M&3DHO0@E? M8U0/PY\_-
C38K&*VN(8X\LWD+Q755R4GZII^ *G75S+Y@Z2>83NW>^?>I02Z.X.TC2M875H1=OJ M$Q&>>@EE9T!)PVYCNY/
M2..&5.OUBZUJ\NIVLRNCZ\ _C&#%?S90I%&N<#>X.22#>_ 'HWGMKAX9(IPPP#0<Q<=&J4?@<0(6N3#<1<1"XN5NG$5W* MH$J@<N.X\>I)
(ZXY55?3/'MG<>%)5UG4I6737TB62" MG8.8Y$.%X.X8/ M&-OE&UP#GC(&XYX_-+3I'M--FN M:B(2/7/.#GGDI^I2T>.+5+WPU+>X>>5$>:
T/C5V"K\A.WA(+>Q1X?MM7MHI(4FW*T4HPTJQ5E/T<:]&=9Z):65I>W<:3M)>D-.)9F M=6( 4?*>3<@ #BJ=
IX/T6^I.X2_!OK>P>D\&00:;X6.S7D-!+>79 MKK$5JO<8$AB<(2S"^^AX)\<C+X@N(O'MMX>:TB^SSV$EVMP)"6RKJNTKC ^I MUR?
PK0:ZVTZU\YNYEBB!"[F/4D@ #W\)( ^M $B$5IH>B66EVP AM85B7 Q MG Y.KGW07">/H?#K6D0MY=>I>16X$A+$JZKM*XP/O?PKH* .;/O
M\NDOX0;PU#>R?V>6+^(7+H03(9"2X.[&XDUN6UJ8-AM'FDE,<*Q&5F.JL#& MXGU/7-
2S316$D\B1QI\J7=W.4%#DDGL*;;7$=W:P.W+>+>HID$B&^&C(H Y0 M?
#+PZ%$ZJT;SEHV6X*MDY.1OPZO)9R$SD@<V..D.N!..N6Y58ZA:C4TTWSE^UM"TXB'7 M8&"DGTY8#WYI* *5EXIWC%; M:TA:;0J.G:HR<#UH
.-TJUNT.9:9&W3R&6:1V+>Y/Y &YB>IP /8 <#"KE2RNJAF&P @>@3M) $E2?>?MJN@>=I+H(WNI6*#D4 MY"EE#8'YT 72*** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6\7/#)?Z%8O-.L\ITY33XB M MV%<C8D2.3PBY#*KG
&#D5U-9.M^&M*0FT4&#&EMO#);RPSO#&I2.#(01 MD<F@<#RK5)IZ+X<@<HFN9X&T_5MELLT^(<@DDHK<@I\I<8$YZ5TVI;/%: _$ M_1I6&
IU!8=4L;KII\I\CCCCI06I)V?#&M0?VOTYE@U!U>Y BM2YE17(QS@<_ /NKG'7 SG%GSAK3)=5LM4DCN'O'+>#;RM=2G:IQD$;L'.!IG
M.O6D5Y+>96 BE+>9I97I+>I/Y18:IL\I@OS..YR'W\S727" MAZVT75IQ=6CALIK2Y\I_L_C'FIRID;?E3@>@<@'(S701^<M"CMM3MC9&6# M5'.FY'/-
)*LK"$S$.OP>I.R.=I?5I?@3PIHVGVW5E8V4D4-U'Y4I-S*SE/I@< MMN5?8$4 <.:0/8^/AMK<5Y>MJ%W=6=M/(IRI"2*2)MR%<I<<#MG(SUR:O2O
M#XRI)>_KV =WNJ2\IM8D5A4VJ1*0@4 $XW$ P_6X@Y"=BW@K0FTI3; VT MV739%ELT%Y.'9?ND'=GC&>E.OO ?
AS4=1NK^XL&I^CJYJN+>1%G&.>#JL M%8@<="1F@<#C'I'O9KRY)>'7EMUMI/'455%'O"^^H:TUU9O^J$JVED..
(1^9:;%RQ8Y8J.YR5XKJ+ P_X%U/2+>2IK3 M0UM88^R:975X>WRN&W <#C/8>E3
```


Q07V5AM/O70UY/XB@O?U!UX9!309I%:::WV!4IUGWM+LPW.XVCI= U:MOQ3 M:I=?
\$OPA"TUPGF&^\$!JSN!%COC@/C'>1US0!WM%>/P:#9!H2Q LV^T&UT!MXG:PB^T/MMV^SJ^5YZAN!G.V.G^~UU2YUC5O^ND7!U:
[+SPL=]MI^94NIS MMWY7>HCF@O(SGIO.* /4:~!GUS1)H2T30M.??!PIXHMZT!GB\B-V>3!IMP M7(P220/2EU.XE!&^C^!B^>
/1!TOUA:1!YX>12.^8GG /!KCF@#MO\$^O MW6A7FA1PVT.L!E:92!D.FX.VO.>.%?/! UT->6:YI^EL:2#!4K+>+>K M%J6NRV7N T3DL!?
Q\$D9R>F3C% T:TU37OB-:7K7.T\$!@:~KF3",;8/D< WC MD>G:% 'J=%>/PO&+PW!./\$VBY?5;J!LH!EYV)DCDC8.A<8.IVZ!236A:
MV< CBX!56DNIVUK?6FHR0!UN\$7%FB@^!XV\$B!0<N!R!0% !R2!7 /!<= !3M.M+Z!GOH9?#-:1^*Z1W#^6.:!@: #
M=2!Q!YN^MXIOAK>6EPHN(!+!4 9+0\$.#M^+I0%!/W2!1.* /!JK6.H6N.M!0/9S+~LKO%U.1N1BK ~0@C!>?MI!?:2
9%>C%OM*>4%&W;Z8!9TV=!=! ^ M\$T !A&EH+G6VL!NZA 1XK=KME8!AT^7Y0>V>* /!P?&6OWA?PM>ZU!1W7 MV1/>)Y3N&O."
>>:PK^V X1 XC^&8M&C!BUU..YBOK:+B-EC0.DFWH&!- MW4!L59^* P#R2WO# P!>W LPH Z39[FZTZ">ZBBBED0.4BHT5YI!JPZG-
K.ON!K%\$9Z?%YTEQB.&U8H!2-1D^8 M#<8P /F!4R(6-4!)>\$-5B/MM<+>2@!WI=W+M.Y+I^!4G(+!0!P!C/OH.M!HKR32!8L!7U:0-
M.NA9:Z9/8W4D5M!T)EWW GVM\$Z!UW.W8R3W/7!KNO^& MC2Z8WFGFRZM : 6!<XUV^1:HP#~\$99C@9R.GHPH WIC*(7.^HTH!V^!03!D M
X *!+P3K! BCP:P\$=S01P37!5!MXI!+ 17!5!M, M2#!Y#<Y..#V /5M3M!T23+C4+Z98K.W0O(Y!#^!0#N:MUX=!J0G^\$ CB M"
[2^06&NR):1YWL:C?%L>?N@:FOTZFNOU#R!CXAKX7+?:V2:6L!J!7-L9(MIG:1Q(54.H+ !?4C+\$8R: /OJYW2 \$%W>^-=VACAT^&WEBD1RS2^3?
! M>R!C!O3!37^!%~!5!X!7!)WNLM!J5EQMM!A BKNXAM(EBB-J8L(U^Z!D(R^8=)!#U- ?45R?2B8VUUXG?33F5KNX M.:>8:?(0+>10%F2D@ =S!H
!RW3C!Y31+25M!1^7(3-K):9>?(KB^*TNY6 M!JYBC9C!GSR=N.D<[!HR.9H !7HDK? =!7.KP1:9>5>0W^EZ2.P80.8T MOY9^10 C&C.IX
Q5:1TCQ^X^!329!^SP2?%:I:P2 ="(6:11 >+<:AR-HQ MB@#HO\$FN!1^ NM5F0R^%?%C!QO=F"[N>V68#-+EFM VI>0:C#~9^!7-
MN2!J!EMK:"S@6^VACAB7.U(U@"9YZ"@#E=:!4:UJGB/7M!BTJP632^B!G>!< M^7\$S!WJ!B.XXZ!M:Z#XM75-:OM!O!%!.UFS42!M!Q\$EB/22-
!#GU!1U!Z30=K-TRC!U@QCB/OT^% !JU' M!>::!L!:QIGAGQ->(+.!U!%YXX+90.N!P^O^*QE.XECCD<\$< 4SP!#9>+ "=
MQJVI!MIK^GJ.TES@O.%E!M#^*VY.93MR3PHV!DGJ30!Z!(7+126!OC36%NF M3ZA:P7=K=>1 LMNSS6L7EKY5971+DH8QOVAL#<DDX/N*
/3.YZXU^!@!>V.@&VA^RW5E+2^491 MC&. ?-ZG!^X&CV!> ?^69KO.B1WIZ-. P!6D?B M#QUX5CU
R.EQH\$!S^DC1^9DQ\$!E2^#C)Z9 2@#TVBO^9:RZ!^O!>A0ZA)H\$7 MB&UM4GN6:1>?*2^S^C+;@=@?8!^8<L>^!M%TCQ7>)JZ)#<5/
NAVMAH=CJB27.EW??:?^EG9PVU.@\$X^WL<=F-W-3O9 M>:;06+>+?S B^-CP!MO!D9/X#D@4 <+>^/!Z!&VFNQVDJ\$W=PME%8N=K M
&DOY?EDIL.#D^@SCM6!U^N22: <=%!\$<.^K=1^F!RR2Q\$E2!D @!PP1!J M>^!Q!B /B!H=#M !4\$GG6NGZ!K!Q?
C/FRAOWC@="7<^! @8K4GB>:XV6M1UD0.C!E(R^#D&L?73)!%M-HMFV)!J.L^!A EWB:@N?J! MK&=HIGV!H J3>+K>6TT^M-
C!^YU0!G^!VP"/9O9W.#@^T!22N!6ZXR<.!L8-!^)!@!0^!BLKRO M@^G!D!D!<+GUVHP X^:GT^A:WC*)^6T5M90NY.%WA&
<1^RL 6@^!W!WBK5 MHO^MH-B+1H+&^BDELI!6Z!U@^+F MJ7VE L!JUEDZ!EG\$?%\$WX@AU9KRVAMY
M^4YK\$+^\$Y81XYR0.YR>PK^C>27XQ?2).GERMX=G3^ZQG3(KECJTND=& \$4 MB7 MH) &QT5YMK&GWMA.TUWO#IFJYH9! ME>+3K.U
<1D3!^T^%V&0^<#!XS6K!C!^X?URTOI\$!ZV.3!^W#4?3!W M.2!#!:4^!8>AX/N^T^*GS:9D^N2^XBN0PSTP:/3J9^9!"YA5&E.U7: M:?"
<@^Y5YSXHU\$67AVY!16!R6!IZC:0!<#B.S!P^7R^&^8Y!^VN.>!C: MT:PZVE^*O!3BU>U6VO+39.9UG:&^&5@01!YC#(!) YR^
+>@K7Y .A&QO MFY@C@FN?W1D1E5VR.HY/7A:WZ!V<4 >D>J\$FK>^M.U.5%22!M!IV5>BET#\$%\$VYKOKR M6TL(M!C^&FJ6CSK=W?
DVMP3.PEC:V)VD\$XP^HP.<8J2PM) &V@ZG!/K=G!V MIVFH3B2Z%LQN+RY6VKOIT +L XQ@G.3DT >F:G?P27!>U2W!Q#1-*)YQP
M!GKVK!)C!6Z:+=Z5:)?Z>SZA\$TD3+<@K+CC:&E7/V9!\$N&-M:6/6/# M^F2:(+>SN:JX+N2="T1<0!XXG 9:ZEI">&M/UF&YU M^58-
2N+40:=-I/E>2S/M<>YSM\$!!Y 'S^H!2&[!@!7^*J!>FM!%CFT2^5! M29BM96.B^T4 C) (Z#ZT >G4R5G6^VC3>X4E45C<>PSVKR#4-7N ^-
CJT< MVB V3XAMM'E:R2?>89 !R!7^KAAGDGBNKT05 MG10\$%AK=DEK\$R- M%:6S^*05ER!HWV=>?J!4!&2-AGVW!:.VK#U76Y8=
M8:9^X!>^! 4V9=4M!Z!BCF^E9+R! 5B.14P &XZDG.D737L<@!QB7\$<@#&S:<[B>=<=<?/7^*P!6.OASP-?3!))
M+IVG2^V\$C%V8QQG:DGECF/K6#X>TS2:W2_#^B2YU&9+CRE!R:3)OGD7#+-U M+D-
S.LD!B@#N!^!E&TN&^A^WUXZ!6&IO+3W^M!MJS7^NZN2T3-YH3Z:P M!MM(QMQQ6A9^K360B=XX@O9KUX;?^SKB*~!J10K!9#D8/3@!<F-
?V6!6FH M!<S+>2V!M!XLV^!VD+H!N.W!(Z8K0K^)!^M+VJZSB? P^6M!L!X@WK+R<-OZYKL-L8=%^+TUC8&6.UNM\$^TS1M,
!AY1.%#G<3!V!IG00 M!M!WM%%! !1110 4444 %%%! !1110 4444 %%%! !1110 4444 %%%! !1110 M 4444 %%%! !1110 4444 %%%! !1110
4444 %4-0T:RU2:UENTE9!63S(2 MD!OI&OC/RD9."15V!)!OT4 4-8T73!TY!U. SVD&^+S&4-@Y&=I&1GM51
M"/>C1W^G^V!WG.MH6.0.3!TMSTQ0!BP ^KPG(ECT:.)#<^YB0RN5CD&>54MA1R>!QTX^X M7X "VD17^H\$!RK+J2A:MQ">J!43^2PW@=
X!P !MP(&NBK-U/5TL.FRL8!T^U798(LX&G=7=CV51^!IT -?PIICZ9.9.\$@U!8? M(RSR#<??:
&QC!>=>M4SX!)!2+W2FL"UC>R^?S!TAWR:@V):C!R^ M#6DNJ6!FH3Z9#%)J\$"\$RR1@X^!LA=W4C)! "LSP1KUUXE!^6VJWL4.50++
MC!G:-DKH.9Y2^*~NTM(+&UCMK9-D.8VN2?S!)!ISR:RK?2?X2M8M1ABTN M'R=19FNHW)=)"QRWRDD+D!X&:VZ*
[3!T 3)!EMH7.JQ^4DDTSS.B=JE MR2!P./Z^M!TIVL+8: !IV&IPM:2??B!QD#!V!1D>OK C^!C2Z-8ZE ^-BD
M^W="W.C2+^VW=L8.P!&...3Z#-(?SFLR^+> PY:6M@WV:S2!262!UWAF^A M3@^!XZ! 2@#5 P^\$STDQPL!EW)% R^%)?3N@*\$%E+D^!
X!(57U/P)X8UG M6%U:4^@FO@ #*2PW@= X!^?M!X^!IX.15Q^+--N! LCV=U974EG=V!L&N5 M.9 C(Y^!714 8=YX.V^W^L-JMUID4EX!8BDE-M?!
MF@V4%K#:.6N:TM+J!Q76PCL=.MDMK:/U\$!3U/4D^!DY!E ML

IGVE&JRP6PWG\VBW84+UY !!(P>U=AXQLK^V9=3ATVTU^SAL5CN-*E M?;-"-S'S8201N89!'!P8/%53X3G MGZ@'M5F22 \$-
S\YGA72C,85@:1?>G5GC&2\$8B#+#YCP<|,.?3=0L?\$/B"U MT99K,Z'1MM^T6ST4/Q\$^F/M<%K+4/E6C!/"D!CN&Z,L%1!0-V#BIJ8V\IK!-
M#IG@3PY<1?<:C: #JKKY: W M5(@&P.P.E6)=,U^1+-1X/T2\$6*:-FWUJ6\$PIV,A2D\((SM3TH U? T^G7OA M!&2SL)/!/<7\$;GUP
7MI?,:S\$!'8\$D#':%=>D:1@A\$5026(48R3R3J:RO#L M-J:Z:8+W2I/3BCG9%:7+3JP)8L44JB2<I\7-6M52JFL)+>P81SS*4\$J=(
M7U\IOB XGWVG+NO M+?3K22' SAA#(P<@=<|=<=>U>@Z1I5KHF6FEV2++;UB6* 'DX ZGU)ZD^M16V@ MZ:::K=:G!::VZ \$!VD8F0#H""<#\$#MZ=J
/M4M#;P'X3U_00I D%<62 : M\$S\W@EP)D%5IV23G, \5/EIOGC\$<+77) *U&TU.2)9@X2:S@3:87C8 < M!/: (ZDG=>O9>&M'TZ2-
I2Q2(LT489C'\$S9R40G:A3J1#J26J^H>#/#>JZ MQJ! HUI<7I> 3.F2<=>CHV.VO//>O1:SPG MH.H:Q :MWI50>
I!&977.Y1T#>HV.Y0<5"W@GPTVF6FFG2+?)D9R>;!'S\|C8 MQG, KWJ18ECU* RTJS>S^T1C:/J!T##HV/2-6=5+Z)K=U.W.I:!:<3VPO%
(PPRC1NR1 M7V/% ' . ">*#P?<11'::G>#F6SP)F YITG6J? NQR^V:PZQ=YYQG\OH MR.>./2NKTk1=, T.'2'3+&UCDD.CK\$N-
S\$Y)R>J!EUAM6:W8:@7D&X69 MU:R [HP]>X69 KSUH =33:6I^X+Q:IBO_ &19ZF3:7)D8M# I^P>=>0.3GUSS M7MIW\PW5G-!
<0QS0R(5> .10RL/0@I:Q_ ^\$.V\CVTC^SE LYI/:V\UJA: < MXSZ\ 7GK6Y^L42QKNVJ \N8L<>Y) &@#Q*VM+5/@%X?>*&*2>ZLO-DB4*
MSD7(&21R2:Z#48CX8J?:P="A:R^%YIPQ*2PFEN(Y (YSG+>8D9E7>#D@ \B20. @R<8K0&@::8350(8WZ1>2L[3.6]O^IR> MF><=>SSUH
X7PJ!>MJUCX812VNN64+H8J\MM:52W188>&9C(2Q))SD9I!>+U_ MBW_R2O7_ /K@O H:UKZ:X)/Z/JFJZ?
HMI:WSY)EC3I>=>NT=>#S18K7O:&UU M^REL[VWBN+:9=LD4IAE8^A\H X#5%#MIH^CIPU>;,DJ3ZE--;ZC&96<74/E, MQ>0.3DJ0.?<5S%VI?* GQ
&"!K24\A8<J8R+K " ^AQOQVKUVPT33J, &:B6^DFT:U=KYM\SD'\$C9R3C. 21R1UIYH M
QY8U3XV6:*6S)H\$Q8:B1D31CIT%ZBD9G69F^ \SIB02>YZF@#D\K3=-T P"+WAQI/:6IN)M-NIP@4*&Q MY>#@=>19Y P
YN\A0?"SXCH"^-(-80/+^=>LKC8\SGGB0I\^P\U:TV>UGM-'MX MYK0.O.6:/=C."23V&3MBG /"Z&!LC89MKV7SKJ(S.5F<16:YN2>^>N
MIZ/@#E)-'M-\$^)/@^:PIXI=1MKM+Q_ .9C UOXU>62E+> MX@ MIF&I24V+<E/=65TUL7%@16UD:0F(\$8C' MS=QP?
4<&O.K#P'O=DU7P%:/J+2.1FHVVI^5#(S.3N 4AU^/0+Q0\ZS^D.21 M1KM1%"J/O"O&OA J5N8M%TC7I-
!8RW^U)I4S8:.6Y%Q^&5\CAP^H\Z)/QC MUVTL\$;Z5!92SRS-"L3S%B^N0HQ>' +@U&4(X M)%O)HO^DG^T2;W0=
3N\=O2HHO">A0C1_9,>G1BP\$GFK 68A'SGQ66G6NGB3J->0TI#22.I\ID#>M W.M.O).!OR?:96L,MS+!'LETP:=@O.A'A03Z_*/PH \P|<-9:YI+_\$?
B6W4! M;M\ (LTCR81(RJ,XZY8N>>Q'IGDI=KH7Q8/G3E>(ZE8W8O#YC.9RGE62) MY8%CR>:ZZL:1>Z"MQ8HVF1HJ+; D)M7IH(Y
P.OIOWA\3^U&TU\X':I MM%V03-.Y9%/4#YNAQSZJZ_KOS):&RTNSN6G=KK488X:-@JW+C+>7(2"/+(M4EN.<8P>EG7%:WQ" Y
M)SXD P"P:L6\$EC?P^=>RCSD18@/OX(R:@#@ '<.DOP:MY(U+>+QV5Q*! SS1XRQ_MGI^O^+>(WO?) ((@M F>*>YNY&7^&8MI)JB74?
C77VIA:6U@MX%CFU5+>#; ML7&WIM^:/&:.5#8-1^F.SVEOLIP376DWEQ:OLFE@=(VSJUBI /YU7DT'39=:36'MV.H(GEK/Y MK@A.NT#-
2>2.AK2H/U/X/WX32#FPT_ 'EWF-G':W<#<-%>R^&'.0?QI:XB M:N:33+&"&8K:3ZQ:6FI21MCRX'+ L.F1M\I\JZWKKPKHMYJ3:C.9J+>UU"O<
M02"/I@= Q0@M^..MOH^FR:4^EO8VJ6+J5>W9 48'DY?GG/KS0\RSJL_87O4 MT*1H5MJ/4K.Y^WVT*A8P(@I23:. V6"YI@XKF7_.2)^-
O^O\I4/ 1QKU.ST M6PL\I6+1BHQ\$97E=Y@Z^*BE@IV .J5%?IV@+I5QI8T28+F3S9K237V2-U M)SSD\GUP.J*
.4NID:CX^@T^&FL%@:1HL2WJO\8S1S,682%5WJ"P 4=SC. M9.8\I3C+COM^>:FKJUC\K/EW.>FDC^L1\$R3(L9\07).% P\FNPU7P?X?
MUVRMKJ5+>ANX;; 4^<69D^C9W>G?L*PO&/A8W-EHMEI ARPU+I*1S+IWF+ MP^7:AC8\#&6)&1GCF@#
(U.TO_#FC^_ \$&GPR6L\$D2G3XIJ5H@\$ ED5/X06RP M^*DIZU=*T6S?7-\$I0Z?K6GQ0RQO&L6GVAC6_5ER_JOMQ7!;..CG-3>\$ "5 MMIEU+UM
M\Y00TD:IX4\#0>PP*% \566C:KI^23KL(EL\^9:< G&)"5(4^*X!\@I^AZAIECJUNL&
MH6D5U"KAQ^H9=PS@X<9XJ^BM=^T^SNA=1PNPJPE\$EGF>5D4J0I56^F?%|-B-
)#:.012PW^I!&2A&15Y50I@I1@?3I5W5+2R!;5XJ75TSRQOMAF\B@#S_Q! M9S>#-\$\IZG8ZM^OVJ.W=[.SMS'%:
(9%1YE4.2I^LV<=>S9(SVK9T_PW8-KUGJD M6I:8UI?6KPQ8V5F\$@OD(R&8:VIV WL=#CQ70Z5X5T'1-.FTW3M^MH+.(?FB" M;A**,\$-G.
[CCFF%<XV@>=&9J\I+TFVLY)N'>-.?F(ZXR>0/8<4 0V,8ZCG/O0IYW<^&+G4I"M=^I-TW2K/I!:-8Q&*^<6">8S_Q)QDG&22?
J,5+=L%<0\>6D.+T\IKI2@ (ME.T\I+PZ^YO!^% (<?XY)Q?I\OC%>H:X'. \&II MIM&TBVLY9AAWC7Y5>@J\AQ6JMG>)>RWTP(+F6-8WE
^9E4DJ"?0%F_@.# MF/I^HVOBQ8_\$R6R(?LT=O'E,CXW2@T#\$)I8SZUG_\$Y&DN\B+*13-XBMP) M\$ ROR2M36\NHV MQG>V<20\$R.!&XZ.H!
#>_6@#B?B78W^O16B+/JMY5\IAT:@>_KUJOX0T"ZU1=3N+=AFQ5C\$1FERQ91TW9/S8I3D MT
>>:G:RR?" PAXRV&ZOI&@M;NX+&8ISUP^NR>F":UO^FHOP>#?:WQ5 M9E(H\IZXM8&O50DK9>:JL_!!(8%CD\$JRI<C
QV\CH.E:9HYBSL8HKIE9&@ R MK C\ISR>./I5AM\LVJ^T^SGMHFO\W\$GR&0%F';<MCB@#CI+PU:1Y_4.K6 MOM\^Q:\$V6FP&&*Y7J)>)&Y
XW#L0.IUPVF::6OPV\#>((A-5&I6B?:C(Q< MH\Q5DZ_ =OR.AZUZII@KPYH4-S%I6DP6@N5VS-\$2&9?3=G(L#BE_XO\O/I M+MM,^P#I#;2"6"
2OMC<^(*C=Q@|CT). M^&T\I3R/&DB-)C>H8\$KGID=I? M6+8>&K"P17FM06R0W5U&(Y71V8S8OAGSW&T_8I^3GC:H **** "BBB@ HHH MH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\3^);:POIL=S-\$\I\Q.EM:6T>-!\SG"H.\#W/8"MI
MO.2BFCEYX2UZ12=:TO5DDO&RD: \$A\I@?YT =#J\XF\IKOGKATMI.O)883
M^UG&'4K@9.'R=^/3:N?:NC+HJAF90#T)6HY+NWBM&NWFC%N\$WF7=|NWKGI M7\$V\AUWXD>))\UFUCN(+.TM/L-
S'E2)=6.CI6^AMP3U^4#M0\W9\ R2!|: MRMG:0<|P>AKO:.&>Z)Z1:WSRRPV?C)+*PG:1@|6RSE1AP\ I0=20 P)(R\GK0756
M"E@&H">37BNGZ796/@X<U:0?4WU&RA>ZJ:5^&59W7:1_#TK2@/@M?T MGBVPU/5;@SO+?4ID9Y8\JHMXE(JI^+C: H!! OG/I:
/6&=4&78**<9)Q5_ MIU>OLM\I-/GG1J^E@BSI;F+L<>@"/24CUK@MFT_50&^L:XBf2I5+=M1 M8&4\I+Y+&2.D4^HQ:63UX\I4-
I\6CIXK^'=M%MO\I1>P+>A9&F5(2%W,1P MR#CMW% 'H5L=5 MF\%RUE_9NR/((JWG9P=^_/&XQBKH="O4,"RI\GD5YC< M2S29XH^)-
UI\$8%W\T^M-"\$&2WGES\$#N<|UH^!;3PKJ%AX6MUNT5%V(?+OPR M#?:-H I'!&,5T)=E822&.SDEM MK9MWASS=S1JN: .GN+ 7M.U330X+.
[LKN<5'/=06S1+->9Q^O&4LWH\I 3I_ \$I\7CVI2VLA MW3=:TS8J2>J\$:&N\N^X^T!:-+KWQ+|9VNHV<=>S:-!8R>4S' M69).O@'KZ'MDXZUA6L\$P!
(^"2MACSEU\5+6EQ(P% 'K_. MLV-O&=U\S_RQ>6L4\ MYY:2.XP&):&(P1NIF@#L1%UW5I4U+Q5I\I+>9/JDZPVC\6'L6B#J\7J)ZL,XQ6
MIJCWGJEVIU-I8WQC7SS: \$^47QSMSSC/K7"Z=1%Z5I?PH*7JWIL6IZE;I+73+T^F:0+P ?IT9/89I:/5 P/O@T^ZNNY&## MU!S7D5JI:>
?"EIJIN:9;S4=5MY=-N?*\$S\I.7P"HOB\H7' (W>I%6?55N2?" M^D>I=(<B-23992.NYO= MK\3@CT/O0\T\%S':1W*G;I@<%CC
SS4NY=NI(OZYKS^~NK6T1^!M^>33 M\+3;G3I^B6>W#PR7\|O@KE1NVDX) O'N16=XCV>V>E^ELJ^4OM+XCMG0I+ ML6S.DJ%HX\I\$O.Y
(SQF#@UX.IQAAR<#G02>8FS207:TSGB0-<I+>+I/C3P7 M6:-6D\LD>WCRHKM\Q:W8D=>A:IR\6JELX9T235_V6I?Z= =(M3#):VFWIU"
MIVP9F5.:(Z@9:% 'JLJ+N=@HJ2<4H\OYKRRPM=4U:P9X^O:*6ROKZVTW MS^TW4#E+Q^B*S;N<O_# \$'JYSUKK
EW9WGA2I&Q&QEL(XYIHWLY""8)@VJ M1P0&R\CMB@#HBZ\PA90Q"YY^*65<I^F P\IGM7BWBQI2?PEXGUZ3>N8M97%I M=L&N?/26-2D6-&
%QAAY&Y&6N:TS7IR\I=ZQHL0V9K.TM8+BIXE.X^87I#?) \V MKSSO=16#PIX^TN^DVZ+JUL:3^8WR^RWE\B\B?X2V.#UV@=*ZOPI:65E\7_%
%M55G%<K:?.\<8 +YX'3M^>>I>D>=2\GBLKO\J5QIGA5-3L3 \IG:2S MJ)060E%+8."#VQUEK_B'9VUSKO@T3K_K-
5\EF#%25.4F5R.>3BL^I&MO#NK M^M/T6\$6^E3>%WN9I:_.NX[@^8JD#HI^I>I4>EZ%?QI6@Z>3I\I36A07-.PSG&J\ZHATRRT?
X9ZC9P+>W)2&>X)I>5&M22K,>2.M@8\X&.5-X7T+1#J7B\5+^GK_96N3S02*[I\B%"\$* ?0G/7.I4>H\T+E MREAU
(H,B\I\A= W7&@:|X)M5M\I?42AU>V@B@N9Y\A2=PUU+1Z M^S^Y&G 2OP M2M^S^WBK008FT75EO.LI:75I'N=:56J6Y
NK^8S\51P1R\QY>0<@#&.E 'IY M=0X0L OZ#)H:1%(#.H)Z GK7DEI#^.- (UR/5-.LK#4+34I_/E_%U::|28 MRLA<\$ (%
(&.9K5OQ:97%O)K6KS6EKXAT=K:./A'C^Q=V(2(.7B)&NMYFW M@Y% 'J1.I\DTFX<XB\I2+D,K#."#_*O&K?I,WP6\\$_ M)Y1F35+41%L:@2M)#
=>FV&1^8\$SJ"1D FAG52H9@W \I/6O,%<+Z=7
MZUKY%Y8VN:#+.C73(O+S32JHOR\$Y#*!MHP1N/4\$TT+;>+7:8J\NH6%O^@#U&1PB%BRKZ%COFN=|&:I>Z IM_? MK LUMJ-Q9CR%
(4K^&T'DDY.*YWII:>_ |=+HVJW(U&UT2WDTIKI01<|BPEFV MG@L<C\AGU-6_A3%!\X>U6&U"BWCUIJ2.*<@*)#C^X8H [EG1" \$*N3@9..T
MI(I_)/2O-(\$!>GZEJ?2C^8TBGGM-2.IEOR&CMLQNZK" F 06IR6W_9VXR00, M^"U@U74QA8U\#J\I4PN^S'.N+.;X8IQR<@|VUQ*! \$R^T>WC.
<8^>T\I5Y^'B:K:9I%<|<=:2O&@_X^4="A?^'\V3U//6@#T?>N_9N&I&=>N>>53CU MBQEUJ;28YT>|@B:6-3DOJOPN?0G\X\PKRJX2*?
X(6^B2P^:Q&B:G:J4?O MWNS^JN\JXED*GC&I@C@T?>EV5G_+CUN26TMEF&FVDH/EKD.7D\8'USCF@ M#T^N9M?O92B+&br/><:"PMFL5TQ+V)XP=^XRE,\$YP1\IZ#O53QY\I.V?PY:W+!-, MOM42\9CA678Q5&_ V6<+GU P>#7.ZI&NC?&3Q-/H50%='IX4,Z1PJ\ 7"1I
MORCOPO>@#U.S.I8&I8=1GD5RMUKNKNZGJ6MZ=X>-BMU4A4B\5F6=W7>5RI.MT:2IG\YI<5S_?I
TJ2I6M_#B'TUVSCDAVA3:0I9:@LN\BE)GK0\U^B-JW\DOQG76L^M^YO,^Q M^O* W':\NYS&?>M\$J)
Q\I^P>E>'I9PX^Z-FWB+Q3L8.05\OB_#U">N M^U@V7PWX_P!8_P#2^M4MYI\LIUJY4^ ZXV27".P_B&G3RGAU+E0P+J\I_M\BL+QKK-
YH'A\4I4T6S7=K TR)< E6"IG@&\$N.\V&EZOI A27I:7K2*6! MH\-.0I9IV8 /#^V\ELG\I1G(S67>R6/B^X,^)\4U)0-71\O\OS@>9!(DC"- M 3RH"! !
[^YH \LYI+G3>><I+>"KGCC)&?RK"%: >ZJ\I5YJ2VZ7\$&HW^ MF! "J\I5N^4DYXK:IG_D#6/_I%Q_P#H(KOBI\TQ2X7^+M8."G4:6:R6UNI
MG? RW&O4/>O<@>I 'N'.J8W.%R<#)O52E@.9(&?60-.B2?7\VOZ+JEWIZ' MI':_&6"IM_W1A+F+>#I\$W\$YQSPOH^H7A^P.L_#W3)KZ35X\I
3K9J\4X: M>-8FPI(ZJ.GN\K0\ZP9\$50Q=0I2\$G@U1U\$ZJ+O3_ .SVLA:>=>B\T:MYCP<>
M7CC=G^6O/((+3V\9ZQX2FDL;>TM:&WBTZUOH3.&MRAWF.LXYW\$@GD\+Z<+>J> MEP:;%.X4U"34FMM7%NE\I*?FD39+QGN\I@#L^
(4^ZKG5Q>?) MU+QD1\IHKVQBGBC^SLD<@RJL:;8+TW9R=16W9/K77_#V>6Y^?AZ:;I\DL&I=
MSLN:YBPBEM900#D4^VU>: (&B9_Y@UM%&^T^M 781EI^01U VYR1D9P+&5I?@_X-WR^84U^W0-G/RK>_JX\I /84 >C#7:X?& MG_A'W6W-
B=*-K\I3YF2JF" &W&"(IRK^V\X\;DY)K M)I88:36 AS:I.P6T%R)@A+I\KB>=\$V\I-OF<8\$G\$8(=#S0\Z\&4I"/>D9T5= MS_H7U)XKS 6I?
A3QKK7A^TM8HX?\$TON+ K\$-J3<I5+C'(4\$2XZ_I06I9X\I MX@-X7G?3I:QBTF\$::;7EL)8W7I):3JEV
M(DN:RV69TC\I=D^F^W\I5HV1%MXOE16Z=>JN\65I>P:C^C&: ?+>2)D\CI\A.O)I6&F.MI^6\UMQ(GU^2YLY):HX\QIVF02@ MGKW:CL_P%
T\I8W\JDX&3U-8WB^7?I^DTNV^FYU^*6TB+JE59BQ^F0-RYP\GJ:X.SMHOC2I4<F:10X:PR^N_IY^WT MI
I\I7\HVGQ?I\UF.W5=2LM4=K6ZR2\I+W&\$\P3D^KUH_IH)U0: C=9? MV1\JFZ>Y_G:O^>^=FW\&9\26ZC>2&"6Y).ID0X)I7DKG(R/2
ML&2VA/QN&8D(E.R>8",A_WZ#D=^.*Y^&PL%<^?BUEM:=91\J&^I^-LK:~R MXOZ4>R1,ZVR-<^&) @A4_+G'.IJDW+MW9&W&"5CY'IN-
E)O\$+E ZIAU>=:I^N+=LM%<^GA233K=>2 M+Y: MMUSNN-JQ:I.S\A:0=<I\J=E:ZC:W%U_ 9GB" T(\$KM+^I0LZXR= MREOF\I) H\J3HHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ IDL4<3Q2QK)&X^LCC(8'J".XII
M.DECAC:25U1Y+< ?C0\!E6A:0M-D1I/3+>^RSNC51\I9I57HI^@%6KW1M.

MU&XBN\JUIYX@5CF&5=5/50PP<^N.AJVL3P^/A8F0JIP".Q/4V:PUHTIY-=R
MV\$3W,7\DRRDG<1?PG/*^W2M&XAN%+0S1R*IVDPH.Z<53U*:ZFTJZ71/JJS M6 | *W00.=T:D|'P'.#0/6/A30FLK6S.F0?
9K2026]6#MRA<=&4B.V.E)>= MS#F#I:1%|=HME<7L6-L1L(X.F2>+N.Y:SM1UW5+Q=X5TPR6:VFUI:K#974:KN=5<,<@AOE/RJP>M &U:Z'
MIEKJD^IP644=J.LJLZCYG Z GN\VI*^KZ9X4/Z+?S7VF:/96UE-GS)880K'/ M4>PIA6C>7MMIUE->7D]
<M%T>261L*JCN34.FZL:ZILM%<\$<0%O"/LP+\$.#:K M*^YI#@T 49 ! AVYNKRZFT6RDOG\BX=HAF0> P|> KWJ>7PWHDUU8W.FE6AF
MLIBU:R\Q\HHJ=J!^T8I8YHUDD61&Z,IR#^-9^I. IVE7^GV5W<(ES?RE." M,L,G^EB?H.OJ1ZT 6+^3+^3/M^V&TAM.M,S7\$WEJ%R100,?4G
HU'2I#5J M^K34K.[M^YOCF0..CH>> O6#HOB&[N%?B23M0EM5M=>Y\$B\$4XDCWV..2Q MR>=0.W3I7322QPQF2614C7DLQP|^
%*PT33=+FX,Y./:I6 M>? WA9OM6=I3J]JD\$DWH?P.=GVY /%:OG1>4)?3RR 0^X8.>G--%S ?Q M-&*^ P19P^3Z^E '%:?
X5:3Q\KNC7VD;+^Y@MH;UE48\$;LK*0K9"G(XZ" M(=%1>>JY)OXY|Z.U2M.S:V3;:0D="H^0CL1TK11UD17I@RLA.<@|BL| VF
M/\$: OI/|RNH:GLISM/GF.N: &S^= 'N=6759J.NL:8C"/WC#^I L1M^X^I.Z^UM.A:UCBC@T&P1890C.A^ROS@ J>.E:9N8RJ9HP68HHW#EAU
MIZ>[I%&TDC*B**69C@ #N30!F)X:T:+[4T^)?MW%UC/I | W 7I:B_X1P^ M\$M%&E6X%F&6VP.>2U"?W0?:L/Q%XV^>|SXA|.W%K-
&+E(LRH7#I9Q\$2,,= MR"<|=J|-9HW=T21&=-.4."5^OIO!G#PWHWD74+;;R17:+'<+(N12JN2H.<
M@:CCZTF^&M\$T^REL|+TJTM;>; 600Q@/3M\WK0ZUHBXA:=H%FC.RC+1AAN M12*S_\$=
|=;9XE.GJGBMJIYMH+VUEM:F)HD.D^UJ;B\$;YTT<^>|5WLID^@S0!CS>#0# MEQHL6CS:=9/I1W1P-
"\$S/J.X/O4LGA709=+M|.2:7I#;MNBMO& B-UR%& M<IYK3FN(9-||T<29QN=@HS^-SDI4.)EEE1(AR79@ /QH I76A:7>W-ISI81K+?
#;=, @S#1&.>?3Z<5H>?%Y)E MU/* R7W# 'UI8Y8YHUDD=71N0RG(XT 92>%=#CAM8HJ-AC6T5EM +RIA#8W MI!"ERMDMK6%
(84&#P1/4U%&#-X*,W\$U|-H=B|E| Q\L8AF MOYR2?&=TFYV\$S|^E6EM.(Q\$)8X&@&^||9ZJ MSJ:U:* ..JZ)=ZWJ/AWR=-W:V5^+FYRZ*-FOEP
Q|+ L#^?7:~.P#PC^E?M8;FS-E&T?U Q|^V6.W&G/Y:CCDGCBBM^B@&.(POHCQ\$4;:=^4L?^4IJS6C10ISJ(7PK.Q)6H%J@J.)
MU40CAQG!_#)XZBV5W=Q8"RS0AFP.@ M/J/K6S10!EZMX:T776MVU32I6I:W.8FECI*>P/IJ=^FTW1M-T=9ETVPMI032 M&67R8PNJBHH
R+KPOH5JJIU2ZFTFOBGEF=X@6*XQ@^O^M."A^ MT>R>WTFVB:O!^JR+@PYZI?3?UIUM44 9<7AS1H#>E-.M |3@1=AEW"?2?!
M^I^~5I'P;TR6VEL^L89+8L876G(HRV.D\$J#P*W** *6J:1I^M6OV74I2* MZMIP;RIE21T)'>H_P"P=+..I0ZB;-#>P)Y<4Y)+HOJ7I3V|UHT4
9D7AI2C(M+MKJ+3X\$E:7SCM7""9.^VJ~W^UC/O3YM^TJXUF6^K")I1A3RXIED!:=5R3@^ M13^9K0HH
JZCIMCJIC)8ZC:0W5K*./%.@93^JJEIWA70=)N8|FPTBSM|B.+R M4E2(G.E3). >O4GZUKT4 8VG>\$?#VDZG+J6GZ-96UI+G=-
%""GKCTISWQ4MKX M=TFONKFZM&.&XNOI?A(G:7C'S')Y)K4HH P^\$. P|GKI JD6WV-9/- M6WV ^Z|MO3.>I6QH6F#54U3I'&J
(^6X.2X3^|GT|JY*..6P(|^M+U67 M5+^1K*WOI<|IXXO^YZX|I|)=>=>#O#=[?7-|S\$M^FSZ<^*M_L4|^9+;|?|
MD=LYR5Z\$Y*^MJB@#\$U/PAX=UE+9=3T>TN LPVPF:6<4ID|JNE69 ^YVD7- MQ9WSUA^TMD-MJP7^D#&DQIWCCBM*B@#
(UKPMH7B)H6UC2;2I:'_%3IABO MMGTJNE2W?A_2:YKOW-A^YL|V^7^DXZ;?=- "M*B@#*7PWHZ37LR6\$2RWPVW
M3C(P_VCGGTIY<5;T13;2I>+PMTMI:/ID48P|_0=IM44 947A01H+G|1^I MT^R&8W/P/E.I.3)MZ:|GLV.TU/"^B>=>HNG0A:DNP_OI|= /S?
C6010IAO MX.1.2/9HUF6|^+8M^GREZJ1I#L.@I3X|.FU^R_V:.'\$SS<>J6\$POFDYWX M|?0INU;=%&>-TP:LNJ_8X_MZO4^MPUC
MACAT&Q189O/C B^ROTS^IXZ5T%M%_S.EI:S74%*^CSP:O^D(R4W#8#;.(JAK M7AK1?<\$<4>LZ9;7IQ?G1@E3W>HK5HH
BMK:"SMHJ:VACA@B4)"^H55 Z M =I6?X9T2ZU*:4IM,MWO9HO^DG* _R8Q@GZ'=FMYM3T6 MQNI+VWR_V/::I MRIV F/.)3N|>><=,UMT4
9TV@:5<6=M:2V.3VOI^MQR#^11^?U7CC@|*2X| MZ1=26VF7&GP263MO>|E^5VSDEA <|Y?FM*B@#;_P1I+7=I=M8QM<6I::
M4Y+1#T4YX^KZTVI-Z-IKPM9Z=I#Y&?51L9(2PJJ)RE:I#^JNG6M|^&^1N@X^S5049H|0T6T&HZ1XLTN+6+2UD;Q M^FUD6I/#2
1.S|O|^IF&".J_?%5|=URYL+U:4='CTRY@U"P MMK%IT-O_. MQID4@ C<%^D^G&|WKTJO"^@.UP6T73V-PR-FW4^85&%SQSCMZ59AT?38+6>
MVCL;<07&2.3RPI+OCYL_>XXYI4 <^@XZ&N1M?>?>C|I|9I6^P0F_FI.D27#G:7/866D650:3 _NAB@55D_W@|S^-/A|IETDZ4+LQIQZVHA7RC_
_IQ MB@A-5LK4:4=^&EI>0K-R6|R'C/P|KC|^H:5:P=9A^A&Q=%I.V|.)< MZXLI?TETRU|WMCFW0Q\$#)I4_N_A M5B/3K**R:R2T@6U<\$-
"(QL8^KD=GOZT>I);&I/>O M->BZ3X?T20HY(I)TNTL5E.9I;P|E|^I\$S56+P9X8A=FCV:8I:43%JG+C& MZ=1D_G0 >,HHYOI.NK(BN|IY
89Y\$;8-<+;SOPP "^O.U>J.B21M&ZJR.-K^PR"/0BLV'PWH=ODIT^2+)-/+S;+ MHOMG.<8Z|GV% ':/RZ?|_%?
6K.P4I.NFPW5Q@PD=TSLN0.@+(N3Z|S U M^XVM|63QMX|>.&%@U|.C&10QQ.)\$2XB#A6'<J^: /X-(TO6&GQ)^W6<%W&D5
MH8UE4.IYMO0 ^C/H>OH:QM^UC:\$/X-6U|+:RN-80337^*|:7/^|MW&I9D MG^IWKU5?
^VC)/=3I5FLMVNVX^OJ^F HQQ|WXU)^X7T&25TF31K0I.5MRV MI@7RU/I%Q@Z4 >.>)=!TK3? IQI97 V^-=?
MYE(VA:9Y)HIT<6W|HP&|F7Z3I(L M7LK4/,"W=W7^M0!S^PO1; M?0-4LHAMM|36KV""=(XUE.%L.TOK> ?& _%>90#C^9IH^?| TA1SZ|
<5 MUNGGZ1IVDK(NG6-O:~*V^001A S>IQU/O39-^TJ74O1IDTZU:~V>7IL0I\$; M '=W7^M0!XO-I&G1?I:6M32SA%I:G::XVC?I^MO,#8?X!
|/#>ZRI1^TI7&?">M2**."%(HD5(TU5 M48 ^H^/88K4?LZ6_EK&LKW\$0D*8*%|!R1SQ73ZE9)H?O^T&SBM|B?P|=
M.4A0#SI4D4H6^39/4IUV' B^AORH#H6G&?75I4-L^?1ICDU;L2 MOI0BU#^SK7I9\$@2.XH>8BCLZ>U
'G^A|1|/\$B^&%=570#&E|:2O.%A2-9 MVF(Q)\$Y^|P8DI|?O>|=|XP_Y\$G7_P#L'7' *+;IK7PUH=EJLFJ6NCV,- + MDOV-
I|J|J|K>Y75S.N.%*@96^H/6@#^I\$3Q6WPS|W M^S|BQPO:3;N|L^M^UK4(G-I(H2L)-W\$F6M6A4Y0OTPY M&|SUN:&5=IJKV2^_5O<0^Y M7V|(Z>U
%6J|:NNZ7I=O?^VA<6>B\$ _I35=L^C?>88'^ M^S-^MFI?|JN%|X;MY|I?^GC5+ZW08I LD\$X.HSPI4EG(0^Z9KM?#=-GH_AQM; MN(MX)/MZ?
0=(N=*ESZ9:26I.3;/'T3< MYQC<^YI:8GAW18I-^CI5DNFGK:|I?%>5Q@|&@#3|R.BB@ 8 HH ^ M*** BBB@ HHHH *** BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB M@ HHHH **** "BBN3^(>NZGX;_ VGIDD E2XBB9)XBZL=4|J\$8(SF@#K**X MGQ^XCUKPCJ^AM=:7^FZE?82^D|BFB=|67YB&^IR.
^ _=M0 4444 %%% M |117+&|I|W7M|T:7M7M|JT2&QM7GMH7MRY?9%N.YMPZMD8 Z^WH ZBBN5TVY M1VWA:9J@OK(K=68FF3?^1Y9:~
<"OSI@-@8IYZ4>"/\$RZQX4T.24I^U M6 _MMO..6Y4=^3DJG7?;.@J|7I.IZ?931PW5I:02RD^_9E5G)Z8I-6Z "BL5 MOK>CKXH7P;V|?YIF9#
(UM^955?IX|B.O.N|BKUY/3Q?BQ-I;"/I:F9?/ M&^NYSTH MT54?5=.CG|A|^U6:S%BI^MIE#;VSM7&>IP<#OBHWUO28S&^U2R4R MR&*/=|<C
|C|HYIY/MUH OT36BU&RGO);&|MY+J\$9E@252Z^W4^C^&K-^151 MM4T1Y+Y;|ZU6I:1 9E\$A|_ =SFL^Q%XKMM^I \$6DZ"-0@M)+WSFGG,B;H%1-
P.MX;(8LN.@|>@/U5?9^BPZGJBI:O>07ETK-^ AC.LF3W)7H#C&<9K&E| M96&HVN00+J-
LUJIL:C<2^=4W""YX#&@S|_2@#J:YWPEx@CU3PYH;FUI; M-JM|817+P|U5W)0\$LSZXSGH^UYI3T^UNH|6XOK:*XE(\$<4DRJ|DI.G)H MT
M45Q|NM:P/BE^X=2YMQII:6=0).I F1*\$V;MV.IV M&H&065I;7)B(\$@AE5|A/3.#00I:HJ|ZKIUYE|MBU|"/|MN9E|P|9X7. M>E6Z
"BLNQ>Z.MZHLVJ6MQ:CR#;1HI:C=V1YR=Q&1D#H:L6FK;?R^9Z MA:W.BC+#+.KD#Z ^X_@YI2\$ DD
#J356SU73M09ELK^UN649(AF5R)^I| MQ0I:HJG#I=E>R36J|E^K+F64^7Z5SOG^?Q0V|^&2:6M0M1% MO=7\$;.DK\$9=DSH JYX Z9H
Z^BJMYJ=AIVS|=^6UKO.\$|^54W23)YZT^ZO: M6R@|^ZN8:>+./E<^N3|F@>BN-|(^*FOK:79I8U2R-KK\$MI:S@K%&T81"N
M#GGI@4UUI0K7I7IB%W +LKN\$)<|>NW.<4 6**Y:P5K5IJMEK4FJ3QR/9.M MLJ+U.S<7.IK:7D|7D"E7/KI0^XZ2C794
(6#8NC>^I^UZ_OI33KV&:2RF ME|L@.XA025^<#6>);^U:7M^9L:8L4'L M>I^ZKISQ0R?VK1SL5B3^1(IU^G)/X2@^W16? _&C:ZCI=U-I>IV;
[495N4=94B7I|QV<C(IFFW8@T:3 IQ0U6TN:B6-5^>TH51A|A=4&<|>*_BJ3: MQI:6^7SZE9K0D+<&=1G/V|SCL?RJIU+^/S^DL,BR1N
RNAR&I|@CKO ^BHK MBY@M(GN9XX85^)(X51I2:CCU^RFLC>Q7ENIH 29UE4I@=?FSB@^S152^5= M.N+OD)!?
VLM\$Y8DIE)E9IAY#8ISCD&-9\$&UO M9--GCC*~&+^RCTJ%|VXN(U=IE+)|#SSA^Q (R M2S 9Y^;TH
|>B|J5Q5EI<40U+4;6!F^3R+&O(ZX!..DU73H:B^WEOI5I)@ M#%&TRAG!Z\$3.GVH MT5#>6TMS;1W\$+SQ&2)7I9 >F1U^0ZG_&AIB9=
M|@73D^LDX)2/U8@%\$L>@<(R<_>@#J M***KWTEQ#920:0K-ID|AZGCG/6@^Q17# -K^*= I3Z19ZW/I MVH6&KRM
K6ENT+VTH0N!@LVY2%||J<^ (M4U1O\$-SHY@6WT65K=(Y8RONIHU M#2 G/RKR%'I.6ZW|GNX3,5R!A @9> M< YXM\$=4U^50#
<%WJIO!>A>Y8I?^SY:I9=ZYYVL^R/K0I4N5R6C> M^K5O^6H:8(XUTV^PBN;9I2+^N=UWG 9.W(I L^O@=:0 45SEIXIM)/OM=GN
M8K:0I5Y(TG<_ZW8=K/GTWIE4#DXSW KU)7QA-<67A+4M%NX/LF;E:VJO M^# MLMD0N5)S^K C&>>U ^I=5?VC:37;I>6TEHJ|4JQ^45Z|P
MV6(XPISQUI)^BJD.JZ=OREAE<I|93UH NT52&LZ63= :E9DVG_||#SU< P" SIOXAMKFM^M
MTN+6>.>"0922)PRL/4\$<&@ "6BN6^(FN:AX9|ZAK6F/"^BT^L\$FC+J^75<^! M!^6KTT601K;21:E:2EIH|J3VWV>FX;P#OX.W<1UZ=*-
NBJ;ZMIKO.BZA;U MN^9E\$RDQ =2W/XI7ZKIS|PR+?V12?/E.JEQ)C.TYYQ@/2@^W16;J-OI. MC7<^DZK9Y\$;JEVKK+&^."V#@X."1FBQO8I?
2/| +0U2TGN)85 TA65\$N&V MY+@C|J#R;U_&E1536I)AM8;J75+>+89BE:XO)(IDYP?PJIK^BO1M^ET**
M|OH\$DOY5CMU.@X\$DMGLH;^G0>Z -JBLF"/>7Q&Y75K26Q:5S(HI)^D#;N9 M=V6HZX^N3H|/M|MYIMCJ^JM|96IR\$Y43Q^/^ID4 >:?
M\$RQ@T!~*UW2+EXFU^&|CCLK^YN7NEN-OPRJDA::<<|EP1ZUZ6FI6:ZDVFBZA M^WIS)GM@X+JA.
V.N.|9IEK&F64OFVFG6EO)C&^4.IJ5@6T NFENA#&+A M0\$9EY#>5!R%SUQDGB@6BBB@ HHHH *YSQ^00PZ|2DD ?V9<#G KFU='4%U9
MVM|Y-W:0\$6<I)D#&KGZ&@&#&I.O _O=G(V.PIE0G.^?FOK\$S^PLI.W^<?%P MOHH(4N^I6L29PH#G.I4Y:KTXQZ5I(FG6.5E;..SMTM6X.^O*\$^I
P^M^@.@Z M^T^0^2:SPHQ9(S:IM4G0I:8XH|T6IT4-0I9Z|XJUI.M.EEO9|^\$S01B6V^ MJ(F1I\$)'%8I\$9XS7I&EQ)IIG-G^J/(D<^"KW^L8!O 7Z2-
Z^I)/I&FW5Q! M<7&GVDT&)/DDA5FC_W21D?A5R@#A)IB^V^-H|Z:*(R>^@D?F.%W-IL _J3 MTKF?#M>NRV%G M/=0W4UI!)
<09I9P9Z6CSUVDI(M3I/I^TX:C_&C|M2?MV:2I?2)S;~L9H MXO@^T^?B3XV^WIIK/Y\$S921^881MY\$;SQ:5IT\$DI.GVLUOED:~A3(D#< M?
XN@_VU^YN_ZY:|2K|IRQ3^L0?70WYG^Q|^R7S^;W|>^>..7I/M=@H4=I+TIK|I<^"U-YO_IIA7S.GS8S23ZIMS_L5:95 =@|+I|6ZG/I2VU
MQHFL0>*= |5>0)=.NOI3E|IL0QM)&7S^|99"S?*\$ P21@>U>H^OM(*.)M^ ML3^I6 |F2W.RIPO> >O/P0IA6S6>|SX3
MGFNQ\$|B^ZU::+2)EFCM)(L_9@I8|Q&BE2#P.XO^M= :Z:86^R+9V5M;B3I MXAB5-WUP..9Z3INGQOROV6GVELDQS(L^H^N.:
/+.. LOXJ^+QWU@ENM MK|R0.D^O:2)?<+>:Y8 M2&I|EP3PPR<I^I|AT32;.&.#2I^)(9#&+1B=NBBS-U90I?P?<6I.G |^5?S
M^&YF^I90:60VB6^_6MWV/QWP2:O>^J-3TWQ=92I&K5^FQ_&_V5I=CI/M K1Y65.0^DJ00=<=
<=378#1I,62:0:=^2<%96\$^YD|ZACCD^WIIIMAIY2TU?3U*--^4.KISM?DD8..N^I:FABN(FBFC22-AAD=0

M01I|U#9Z=8Z>%'E96|L'.7|F)4W'WP.:.3T/4?|F07F@:CLM0?06K1VT5 MM+|I0\$5&Y9\$!X48
<8<\$C'K@6M+*X/WF1P+>#R/5'ZW&|00B_P'&ZC@_J P M609|?2=-M|.+|3/2\$7&3-Y4*KY0^|@< C4?|@Z.+N.
M850|Y|_%'>C^(|.EK=1P_9Q.85CGM3\$ QK2|>C|C|4GCK3M,N=.T M#QSH.G7%G?)*='71'FD7-|XPI|OF'=|V -QC"8Z2+|:|J|N=&TN|6|K3:.=?|
MU(E@5A'_ +N1Q^%2WNG6.I0K#?6=O=1*P8)|\$KJ'.^'.M 'B|Y+;3_#XF16 M3PNJZU+,%B|(V9A.X8|<\$Y|JZ_4|6TVI^+/@%|:^MI5:RO &CD#
EA&5&1W/ M/%=S'JIE#'-.%:6Z|.2956, 2\$|=PQSGWJ.#2-.MEA%OIUI\$(598A' JI WW M/HNCP|@+9QUH
|DDO9+/P3XCNT>3|'#XPE>=:%|0|+;B=2YP00>V0001UXK4UIM M.FL=>|0>?_ \$5QJFN/HCODV1D3*L8.0S"-!AQD|<|\'TX|)MM+T^S25+6PM8\$
MEXD6*%5# 7 YL:3;#3(FBT^RMK2-CN9+>|)8P3ZD "@#S'6M5|-W/PYGTRZ ML?^*CU*\$1.9%W11F|P0?
3D*#GN*|8JA#H>D0|OAT|QC|S.W|;H#OP1NX'WL\$ M|>35^@#R">ZNHM!^|)OI3'N^CK|T-C^<5KZ^+;.^L2_%
MX>|M9O|1M_ LOAP|I&*S+Q_ #L'|(|AWKT'.PLXKV6|CM(\$NY5'3R3K& |@= 6Z MD4RVTO3|*-.2:TL+6"63.IXH55FSR(KFSU6#
M49&N|)6ACG|3D+;+;V) ^4#|(|TXKJ;JC:5|SZ@/NH|86K7|C|)W4A8 >@&:M .':VDD&M2>(-\$TEQ90+7+=P#
<6IYV_|=0N6&.'W&5J/Q:="U&7P|= M6R6CZ9/J*QQ.J@|(8FALJ2VL|KP5|*1<Q.KW5I\$Q_/F7R'RI/ MH3P1WKUA-+T^R.RCL+5+5^6@6%0C?
5<8|J(Z#H|1QOQI-B8XSE%-LF%^@Q00 M|P6I3;:X9^ (UGIT)'X|TB:2V%C)&D20"8S.TR9=2|E@4/..!|5U?@K3M^TO0 M#;+:>S7FG^?
(|4TC|RDYD81E0|L\$%|!C:V.W3;4K<07|E;W4(1/|\$KJ#Z MX|Q4|<00K\$B|E@|"JJC_8'|@#B_ \$|U|)?\$7P@+KC2Y#V|6|W;Q7 M\$+?
>CE0|L^H/%1'2|/E|B-C:FTZ^1Y'|Z|N.4 >:FPL&|X|S:6|S. TC% M6DC4\$SAK4ELD=-.42:GX?UF6|C|GF2|1-'^*9_(55|;L;SP;?N4;*75-4LGB2
M3AH|'=9|Y2GT."SD=B|>E>HVV6%F)!;V-M')?|9Y42KO^N|S1=Z9I|J^+>6- MM1:3'H6O4CI&FFY@N3I|H
M9|=-D.ODKNC7T4XR|!*QM0T;5_M5KI^C|I=AX?>-DO(D@|(F&3SY6W"C(R.GI MDGF@|'|XB@GO4R|J\$4H 4# |'H+VPLI2MS;WUI!=0\$Y,
<|8>2?H>#...|9Z/I M^Q\$URWLK^ZNM|)FM8KB5+B=IO(NF9AM#;.2>4)&MZ;U;+U^V>LXA7?>^|8S0 D6K M:=|JM|Q<5|
|I;HKS6RN'|:GH2.HZC|QZU8N+B^UMY+BXE2&|J2R|.2;655'4 MDGH*|QZ1|)K1 +MXO^*U|@KE3MR&;JWW1CT JW<61%W T%S#'- . WHY%
M#*WU|H Y.VU_P_J^N6FI3:QIS&(^5IUJ|MP2%Y,*7@YW\$< 8RJ|DY|)'Y?A| MU|.Z9X|AO6\$;PZG=7N&_ BBF0.A'KDY7Z@BNU@T'1K6=)|?
2;'&9#E9(|9%93 M|(\$#BIYM|LKFYBN|)2WEGA_UOWD,6|J2P6LVH3.1-8J2N|U|)R0 M5SC|N<8XKO|W2-.U^2.2_P|.M+IXO|6T|)'N4^A(X|V|A5|)'I!@
=J|_-|;|MQ/<Q>B^M|Q_P|E0'X^O_-(0L6^3;LRHRV>H.|BO2;Q96|A8#B8Q|<|U^CC M|J;+>+>AK@0QB=E"-(%&X|.)ZXY-24 >.^\$MK?L_ (J^2
M>L4K^+|/O5B2V.Q|Q@XSHV|Z^L< (TBP\$41|C06R;4Y|) Q00|YEXABGL-;^ ML.AP^4.5.VB6TGE6XVDG.@8@#^+9GWZ5N%)X6|0:SH&LZ?
XDFO+VWA=;:UC: M|62-EPRRHB A1@<'!OCKSW\$>F6\$5XUY'8VR73?>F6)0Y^K8S26FE:=|ITLM
ME86MM|.2S30;.%JL|OYHD#E'.VUB""_.|IAZ'D"GW>C M>*K^19+R+PES|RVYMY|/#>P.NPQM:3%2OIC?C%'.'W M9>'.G0|&FJ;=K)U>YN=&D-
RRO#|"I6-O+8^6H DZX|T|JMXGT|1K/X5Z9>P M6%K%<7#;9YEP|J^|3DMU)PS<|>?>Z>?0?T-B;.&V|T9D|C;K|@C|J|=N_
M%#Z% XGEM8|62W|(|QC*1-|A13|?#2@4 49-'TN|XSV^V%|D;#|(QB6-OK% M9U)"DKT)
|)Q5SX8J|D6DZY;PA5A@UZ^CCC7A442<*|V/2G_V)XH^TK<>|X1| M5"B7|I+N P|G?G&.*?::5XMT|/B3PI;SE_ |L94W?7#|T 5OC(P7X3Z|D@
M9CC S_UU2M:YTI2M+>|QZS->7: 8|J|R7LL|JR#D?|0KN06|88QSGCO5.ITQO? M|S8C01X4N44Y"S64K@Z%ZK1^&_ \$44B21V7@U|)V#(RZ:
'T0@|N#0|G->+ M4VNN7'B+1UEE2V6#Q#&V|& >WP#C_KHJDMQ@|3C(R?%|@T4=;^'UQ\$EI+I MUQ=.D3|1L>-H&V| NDX&W|VO6P-
'|5A|X'2 N3F W=-^*A|AWQ&R1*?3P<5B_U8.G283G/'S< M M2YBVP:N|Y&9Q^|@68*%&L;.=|Z22?ES=PW\$Y;F#_ %TEC^SQ_|K|C| M^B;0?
\$S60LFMO|YM_F" Z?)LW9SNV|I9SWH I2'_B|F|2:7Y|N9?"ZR1%.8 M=_.?;3Z_P|^F*P)MNI_&T>VW?VU
T0B(XG6_P#>|MN|SNWP378+|BM;W: ML?A.72| SWX&C+O1 3|V_-Z/XK2;.^6/PDMVW6<6.HD/&O;|J*_VSTRPNO MC#JZWEG:3-
'MG96C#>7D#->|(|<9XZ-7OA|@?#7344Y6.2X1>|&73TNX6+9+B&(|J8=6#R^ MIZY|&_|J|N-VU R<9_?PY T 72%|X|D+Z1+K5K|JMK9
MKYMW:2P^7(T0^T|J< @>58|P(W=SU M Z^E8?Q_|IV=EX4O|W&=;O5-0MWMK.R@_.'65W4|'%'!G|)3BN;TE+|PIJ7A MOP =W-K8ZK::?-
O|F7Y0C2#=#I(4ON7.3G 4<|/W&L>+|1%T:WT^:>_ MV M34)XX;8K^"W_ 7|Z;0.DGIQ|U>NM;TFR@CGN|3LH(I5#1R2SJJNOJ"3R.1S
M|UXWIE|0_#;P:SW482S|4J9V=|@7SY|_ |O|'7%|'^NZ9'X|!166NZ|-M M-0MX|&+9C"^(FV|K#*=.|^+&I9YW%"
'WL^M#Q7|L|J|S|2)H7\$|C|E|PQ M\$&8'W.P8| RS+75\$|F6|&KG5-7FMKXV\$LC3&UB*+<6X)= >OR -CLVW#M# M<|.6=EI_AJPM->=|&*
(+;M.*KJZL"/>KWMC.CFVLY9XW*!L|J% A MP>_U<_X U>ST_P &\$^|U"JBBU.ZTY@MY&P|H%R.#V7'Y>U;GC(\$^!_ \$ R M3|MQ@#_ KFU
\$7AGQ'9:G|>EP3:I.2ZO+8PSSVXE3SV75EGLY8Y:=0'L M#*.6(ZKMSNSW(4U%)J3C8Z-4|)'YNH8KR6>Z>.W9@)|'5|5=|I'12#@|QH | MZ|9;::
|I^2?VYN+V.S(?- 41@9|S|T;P_#|AQ=2WD'6|/)&6D 4MYIT K.K%U&E0>..GUH |?^V+>^SVUQ_5IY%TP2WD|I=LS\$X
MOXPQ|)*+|5|U_SBP|U&TNS;MLF\$<\$ROY>C8|I^M>6ZYL_AJWL;.:N2MMA< M^'|>4S3.K1R,
|YD|L@!=F<|<#C.ZKNN3Z;I|COQO|ML'LQX55|BVM\$SL:4"20\$ M<=#MXSV%_H=IKFDZA,T-E|=EHCXDT)3"#K6G SR& M*
(&Z3|XX_"J|D'L^WM=2L|;^ W&|2|)IANH1%;.#%"IBC|V|B26;H.3S M@;'.UDW%08?|*6|97"16_FKJEU0*,@BY&W|I8SQ|:/5F|6Z00BM?
#ANXOM MWD&9E+@:3N553G|QJ3R<|<|XK5(2|@>8Q.N B^IY MZ"M#XFRW^&-_ T05|6>S
MO&N#NX(2DA.RJF4EADCG>W2NHEUC3G;Y+&74;1+N1MJO;H=CC. NXX?T|IT6/#EUX3Z M|=VY|P7AN-|BCFDG|XNC1?)O8DE2""?
3I0!ZS=ZWI5A<"WO-3L|>8@\$1RS MJK'/3@GO@U5BN'B6|Z%Y;:/L(?!_H'@|S(S9W8(P.1CBN|2RS:3-XCU M?2|JU2P\$T?|L;+=
<2*X1%#0N.0Q4|&\$\$\$CCGBM6S-LWQOGU9"QOT* NAOS^@ M|?1|'TH ZRUUS2;V98;35+>5HS*J17"L2@:;6 |Z|!1GU%L|8TS49I(;_ M'4;2YEB
_B0S*|*#T)%>0:/IUNOP'.IZ98Q2-A&QP:6"-6E/VHF50<@Q MJ>_F^XZ:PO"6OZG;W: (KG4|N^PF4K\$T8;W9<8#<|L8|T =O;:
MWI5Y=&UM=3LY|@ GRHIU9N.O_>*K>|)O\$FG^1%#GU3490D+8^L_- (9|1D MEUKOC#37FCYX=TI2>TUS2)K64:7J40VSV|:H#MD
^5E("KN&.<9&<5L_%O_M))?K9|S^C)^@E0F@#J'U?3(K+R34;1.60|4F.RA&|/;.">#^53VMW;WULE MS:7\$5O!
(|I+\$X=6'L|P.XB:58Y|BUT%PUS%-I-UI-T-A.C|HS>:."X#<#C<44 M?D1ZU/X(M9+2Q1XS>W_Y|SFH(UL|JWS?+GE?^IG|IP?2@#;UCQ9I&B:QINE
MWMW%#_J_|2>_AJ_>ZSI=A.D-YJ5L;RR\$|F\$G5'V>|& M\$|ZY+QI=6JEX|H'W5W'|I;+ _#_ B079- M.;Y09'B4Q(MS;JB.HS(6)V@#_.1@8H
|N|)'S9%FG5' MB9_W|X&2D|GU|X|1Z2|).ISK.GPK 5\$IDN441EI|=V3Q|IQGK@UPL;5L_S M5;'PN|9+B' (18*
(KU0SOB51|X5MNWM#\$EM9'RE5 MPH_+AA|& &:_Z MO2OMT%&_ &G9?YTR&#SUWR+C.Y5SDC'<54@N'7Q'J) MDUZUEM8X(R-
'/H'M3SEV;.<|<5Y9:16L7PE^'|V\$B6X&K6)\$N|NSY4|I? MNC'T M77Z2| 9A|6_ %\$>5AM+M6=3CGY|DC|I^= '51^(M#FN+WBUC3WGN
M03|&MRA:4 D\$J;Y'D'IZ5)=DW|A<"WO-3LK>E>6.%C| M|?>|VD=NDPU:T?S@_&W"XOW>N.CZ5=|Z|HMSH_P OK>VGM|*4\$QSP.^X
MNY5B7#|6|ROX&|@'.TG^T>ZWI/B51|30%|H\$M|E|TQ I05|@/4_!3;N| MUX-7Y-8TR&^2QEU&T2|=MJ0.H=CC.
N*P|)%NM\$UGPY<>'O\$^NW5M|T%_)|HTI=%*|_ G%T;+Y-| M\$DJ003UQTH |CFFCMX7FFD6.)%+_|G 4#|2;|_ |\$CQ|X<7WB#PS|
<W%E;ZA:SW5O_KH(IE9XO|^4'&D/6;_?4|IZZC>+G.+<3+Y MG^7Y1^8GA6|_|>(|#WA MRRO|&EDQ|/'=|1-|H0.5SN))&=OZT
>MS(|D+|T^T3D<H!*_ M@>*>Y3S;S|J2P6;ZQ|JMRLL|Q)*NR.(B)|&08|Y.W6NN9|JEFC')|5Y| M|'IZTB^U@TEU BI+?(>?3CF@#NKW4;'3(O-
O|RW M8SGYYY0@XZ| MDTV35-/ALH|V6^MDM).|VE4|V>F&S@YKS|_3VD7Q|MK\$4=6FTK2=2TE?L MO'Q\$Q\$C|U@<6=6"|E;.=L@+GM3\$F|_
!:+X6LM.N5\$.EQ=S6&|7|W|B(;WA4 MJK;MY"C@=2.C&0#T=-6T233C|S=_M9#K^D|.)&PX&^5XV9_ 58 M@<| D|4;YK>|VMA>'5K;*&33;-LY-
60=4M-'8_EDVN#AEQ\$PC\$ H |9L= M3L-361K'|MKH1MLD.\$JOL.T.#P:EN+P'!TA;:YFCAB7|C|5'XFN3|CPI?>|) M+O6=
(UR3K7\$EYCD;.*#E I24|UOGG&L \$45H^L^%|'N|J|31TN9D MN;J)%80R-'MB9MRL_7&<<9H
Z/40%.E6|AJUR^*M+BVMXI&5HYU*R.JD| M0<_.CC&M<7?^_.|3?#5MXE3Q'8W*W-|S<Z>ZQXC9#&-R%<-A=Y)5B3@#GO4 MMU%\$?
@WQU|CZ|^H'IL97N;GS4:%I2|9<^4 7=C;G|JO>H%|D|2_ S2W:1 MIBTS|+&|Q)"ZY T =970IG2W5_?^*>2ZT>XVFT:8Q(8V&=X|Q<*PX|C.IYK
M9 M"R%B|I|9;_ 8V4+CS1Y9|Z=G&*X^Q^K.C_#U;5M5FTO3KK2_ *M+P'|MRA*)"9\$9G5@I^*6<1?=%9%W%5U6Y>>ZD(|(2R1D(X|&P
M.SX(&' +G6ZN.M:YNH)"|4L@9=IR1D #.WCGUS6CXEO.OO&G@&|M;FVG#7MPJ2Q.&##R&| (MZC|L|
.TM=9TN^>=+34K.X>W URPSJYC_WL'CIWT'UK2DL4OGU.S6T?(6*+?H/E5R6R.?+?;RR2?78-AURIM?M^Q
TFYOM2FTG1ETC|+976(-+257RR.SJP7^"W/GC.Y@#T-WN8+RWCN+;+;>_ M0;DDB8.K#U|^%5K|6=+TME74-2M+1F7WL+M=,BBN)9WW2W8
M9*)"C&^|NP2-22V.#&_ /0+O5-L(8YKR^MK>*3|CRRJH;C|)YXYT;WN8+ MNW2>VFCFA@922-
@RL|8CK7EF@f^H>?""SH.OVEOK|HHHMH0';X:EXT^|&GK|^L;.(VY5=@2|IJ2.CV|H TIW6-TUU2_M_P|1M+5F&56>94)&<9Y/KQ6-
XS|4P^&L MF6XMTN;NZAMX_<#;KR|6DP>H5 M23Z9QFL?PY/\$?WCG3|>L2O<"7\$^KV1B'IC/5|AP>P).>37+JMU8_ "+P9% MJ<_|
3/1|0|Z=HD5|CWVL-A|3K26YB2Y-U=RB%G ?9IF3YL=<<| 8^%Q\$=KJ.BZ+%=ZG;R:S:@E8M&K.VP<|@-^+=N+^|I3F>Q8QHT
M^Z4O\$T64+MD;-|)X&.4 >QL'5(!'DC|U<1X6U|Z|=0O\$4QJQC73-3DLX MC';IED'J06R.OS=L5VD^*P1@|A0/G.6Z= >O|/-
GIFHXOZW^TW.@SKDRXB_MQ9@1L4=\$8>_ /M0|W5E>|/I^D>?K>HVI D8+=&K&CH6|EGKC4|/4%|AD.D^?K?29;74+FBWADB@(
M+;58;S@|0'T|V>1BN/U6ZLYO|WQ0B^WOW3FZ6>-LJ'X.<0WJ|V). 1UXY- ' MHGC3Q+>9Z3'/H>J6YFAU.VM;I8|DI4|(JLC==IP?
K731ZOILVHOIT6H6CWT8 MR|ILLR12|NTN8;A4ET'PUKNNO:A&OV5/M;2R%9=H"CYB>22=QXQVJ|L-88Z= M#;LP>0#=#XWY"
MN=|4?;9OA>_ V4&DN6T!P;|RS#;-P7W*YQ65H5WX34|OH>J6>O3ZA'P|_@A MM08E;".TPZRH8B^OHP|W&<8ZT
=FGB+1)&54UC3V+H|J|A|I|H&16NA;_ &EX@LK^>?S:WJE(MENG)P>|V3T&|7-6.=1#5%.*)"D= 9^H6EYW%?|LRR>6WHV#P?K3+; M7-
|O99(K75+>2-;=(U8JO|X@>|>=ZW<+;I'C;Q>|UMOLOX9C>XMK<|& ME_0\$<=#M(&>P|J&TU.R;Q|X'D75;'2(Z?)-"UA|
(UNUL)+=I(8O)2C".K@>:58CY@_1'%.R7UO9;3:3W^16 MY4QH#=#.ROI^*WASCGJ_*MMIJSX9_2R2>:|KF|U9S"6|=>6P<=1UK;
MW9@|8^'|IKM0_9=6D5?4J#D#D5Y3XDM?*TOXJ2Q!| MLBOF\$<_/M/E?O2O:2F?WS6|>OV5GX^7V6."\$207B_NP%W@%|KSS|; M
ZUAXYM^O|);8PS1 PM(C|O|W 2_|@17^+>+SQ3K_@33|MM4M|1NK<3^&X MM@2B|L%46T4)|P|IKC_ 60:5HOPDT|U" @A MBLUW%G&<|I
=2?8(|#4FJ7HCTV:TF>VOXII_%MYD.&|8|8Y&/ MK6C=>#=#L|&NM7?5+5|&USYLL4@<*<O/N|?Q>W6O^M+C72|/O|JLZ|8_9IO\$'B
MD7MHX|I9|DDMD&N".FUCM.Y7..HL27D\$|OQ6CCU&*|EGTN.T:|+|BUD%# M_H' SST&2;
4+&#Q|E|HD&|B|MH|>1%+ TR|48|:3G&|G|5VSO;34;5|J MRNH;FW?ILL_@=6^A%>5W?B.SM|'"ZANK?L3VTE|F'2WN6CBVIRRL%^7
M<_.FID|!FNT|6NBPI|=UH>H27|Y=&>>XWIT3S\$.4*+>V<+<9|)T 7M6UDV MVJ|=HJM|_ OR| MR(HD
+R\$=^J|W+&L#5FIUK2M;=8+ 5;2WEV@XN)T|B.X MS@D=37+3|X.CG:22@B*;P|)' 3T+K|I<#WVE;Y|Q5|JFS?| 'P|6F>WL+D67
MEW*RONGO^N2FQ6(0O XX|)'V|RXS0|Z?>ZKIV&?7|JKA|E|F/5-V.N.GMD M58AFBN8(YX)\$EAD4.DB."K^1D\$<=017F< F08=I'U'PYKMD-
8M|'A6;RO.;W M4'."| MMDIMYE280X%-M|?TBN7MK4|4229(-9%EA4G_>|U|E^& V@>*GMWVYU3 MPYT.C%WC.B.59LYR|Y^"
<|Y|C00%EX(QVM=2M9IT3S#&DH) MV?W@.Z^_2@|33(|1BLE35+FWN;K\$S);P&)"_WREF/ZU#K6EG6K%M.EDV64_R MW(7|TB=T'H&Z\$|<9</p></div>

ZY&=I>L66GZ/>7VH^*K. M1=R8NV.~.(@3D0Y4X)7IZ MFM*TU 1I 4KC3K+5.XO:<9FMXIE9TYP<@'(YXH =/I-K<7=I)?"#?LG,(\$8
8RIVCV3<8Z?KJ9T7B*1YIY;*+4I5EF9% C64\$LR >4>I&#D#D8KEM3+JGB MC5- MM>32UM+*.1+J,QLOQG9GSD, ""%(XSD^U
MYVGV5DICIYMG:P/(XJJP)*OBS3I=T.W7IH0RM:;DGF M(K=L.U.T)IR*2*0#T&TX2\$&CSQ74D>J6A2TQJHF4>5GH6R?E!I\$!: +DE
MG:RF\$R6T+ F IHMR ^6?5?3? *FK/L->TC5+@P6&I6ES,L23&.&5681L,JVIV(MQ@^XJ6 U&RT^-3=W<5OYFOA=@'2!S@|=:=: '-
IUBUQIH:RMS/NW>88EW9I'=1U#4I3CN(H-2N84NG**IB1I) MJ* @+C&.>^:WU0Z18W-Y%G-M)#:G;RR#JWVJUO0^QI: +4NG64I
<<X^ITZ44ZQ5;3I369WQ!@N!'VR7RW M!;,>C#L?K0I(@+S#PN+2 / "(6L9JIZ?I3?I*=:X?4 %(E!)?%+>#2M9BEM; MQI@750\$48.JPNR-G&
<;AU!P>5N6&L.GB*YV7KJ!I(=VIV L.A+%3D#@.K# M!QP05%< TH- L.8J;RMBH1+Y+2K@GJ1@=^/J.C-;>+>:-P;Z4;L.8QO MJ-W6IZ*
S:=80TMK166VMX58Y(C0#^5,@T^RM4E2WLJ/>%93F01Q!0 UP.1T4 5I M>PLI2222VM(9)/OM&#%+?
4CK4LL4<13Q2HLD;@JR.A>H(IT^B@"O)86N>..:D44 4SL(FB-8SIIH444D?)7 M)ZG&/8?E2 V7IVIG^P6NY@0QIEB@
JHVEZ>P<-.86I#N9'!A7YGAIXY/ MO5NB@'J-L'DHLK82)@.X71CIZ?B@ J&XM+;I0N.N*44 5T03VD:1K&V+OG M<>E\$6G6. "PK#96I:PDM\$S\$B4",GJ5P.,^U6:*
<.KC/(U%5/I%TK H&6?I WX7 JI10I7GL.ZMUM|BT@ MF@7&V.2..HQTP#Q2SV-I>O XJ:B@" &ULI:RAIFTM M;:>+. =D2!!GUP?*-#%<0M#-
&DL3C#(ZA@PIP:>10I6 L^R^R+;?8I?I,GW8?M M78/H,8IITK3FB6(V%J8U)*J85P">I QI"K=% %:73I*%>U%K-9V!ENO2)XE*#
M(,5);:02VYMY(8W@P{3R@P|I1Z8Z8J6B@ "%:2V6U^R^K;Q(VV/I)"#9M|=,= MU12I/(C!L:4B)0L>85^0#H!OP*MT4
-9\$=E9E4E#E2I1TX(R/P)XU'PF&|MXIB<I)4#&GZ&I? \$1%K1410J?15\$ 14+V5K)=+;:0M<*I596C! M< 10#U04I% %-I(TV2!
(T^T:%!A8VA4JHZI#%6U4*H50 . #M2T4 5|BP ML|MXWN;2"9XCF-I(PQ0^V>E+<6-I=E3B@/J(D4:QOHI(H MPJ|J. #VJ"33K*62622SMW>8
2,T2DN|TR<QM);M+N2U@>YC&S%;U'L>HJQ10 A 2K \$8(I>J7IBZ5 P! RS I
M+ A5ZB@'J^FV\$M|MKQ)96SVZG<(FB4H#ZXQBB33;&9I&ELK9S(0+1*="Q P" M>.<#BK5% %9I.L9(8X9+*W:*/|B-\$I5?H,<5D+I6M3>
(N|NZ L)'(OR6MG# M 5DWJ|PI9QM#?, X7ICIZ?B@ J&XM+;I0N.N*44 5T03VD:1K&V+OG M<>E\$6G6. "PK#96I:PDM\$S\$B4",GJ5P.,^U6:*
*K;:8.92UE;'SF#2YB7YR.A M;CD 6G-86:VGV1I2I;K.)XE.%N?NXQ5BB@"NUC9O;)::-0- GW8C&"J 0= M*9 9>G|HV^PVVZ/
0^2OR|YXXJW10I!^!#)8SUI1# . @:@ATS3I>0 M20V-M&XZ,D^@C0*MT4 17-K:WD#074\$4I3=8Y4#*?P-(E!1R-(EO\$KL@1F M" \$J.@)I!Z5-
10I6 L^R^Q?8OL=OJDOCR/*79CKIW&*FAABMX5AAC2.)A41 M0 HI@*?10I:F:MI":A+7<;"" L7,EM,1D+D;65AW5AP1I".0*M&QM9)OM,UG
M;FY:RWDV|F*GJNXC)%6*;*HKNZCD@AF(M,L4;XZ:E!Q0IYXGI>?Q5XZM-(<@G|.P|8HF&^1@9 0 .2VTXI>16IH.J^\$ M?%;J.J5IJMW>:E:
(I16I. UHK)B02*%&%XOSP3C%>AK:P+)YBPOA IP49 . MD2V@C.A2"-3*(9=(MH)I6\$^H"-XE#2@-*P*J1R
M^R<8?7(K>T#40"/BG5=8U'SU6I0=2MSNUO.TB6T\$32-#&AD.7*I|N/OZT>*7IU:~!WQZHG!A \$|N|. MJPI'YCD5UNLSZ?9?S|PBIMY
4:=>JJ0;064+&54 =>^!I:|S|?I2OV:~!2 M-@I?PLMN&5O(BW+C;=@R|O!XFNN:1<:X%N+6^M+2TAUN)OI/BDW"ROB7B5V MRV.>I4")P#C-
=MHUI:0I80<:=WS1D;3/"AQO@R9XJMP. 5VPM+900+>@ O MYAP@Y;~I?>E%K;KYBP1|YVW!IG/UH 15@U/R|AIXU*VMR# M'-
MV6)V D>1C@^AKIH|GPIJPU;7=+U>74KO^QY8)KAI/W<<7+*KC). > M>M>C)%&'SLD:*7.7(4#M4+G7+70 BU=G7|B.TMKK3(DTVYN&"1#:
M|&5 QX#8E#|A1I5WD<4<2I8T5%ZX48%)+!%#L22;6W+O4^I|IT >6VJ! M62A,WUO)*-L/%UQ+?BU7YX8"SI7*X. "53/L2N|TB:PQ80! M?
RH |VD8;.)T9)4D M,9\$P1|XW8|LUW/V.VV[P|L.W.<.;|C- M+&.&0%N0!|D4 >|G4T. 0I208) M' LRP|:S37OV3#&*#DIP,YOY5NG:M;Q# 9.I>&?
\$VL>+%ZZU> GLXH|R:*3 ME:A9RPK)=#&P P=I|=@J- =|.M.#D5L.M&|OOD|
M.F\$'&F7;W!'|PLBKG @5=G^V)|B@B0@DC:@')ZG|I6&DK;ZC=:G<.);^ MY58V<# CC7.V-?8\$DDJ|R2> . "72=7T 7=.34-
NDN;20LJ|RIG|*DJ>ON#5V MFHBK1M1551V48%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M*
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH *1F M5%+.0% R23P|2UYY|4+F6|I*: 79;+5M52.1 -/B7I.9JFR. 2@#K6I4;\$ MB>8^K6BOX)\$C2@ (V/IK^AOP)K6AJVD6>LZ+
(Q%0I|HQP1Z\$<=> MA J^..G- !1110 4444 9MUXAT>QU&/3IK4K;&IDYC>0!W|+U/X5I5P? MB' DL/Q KUO P#T!* .|HJ|
|FDM|.>:*IY(XV=(:5I(D(OH)|GI7&V/C4 M?^<@CT32;U:"275O)FDAMIAK*6- YC=MS!NI!X!R.XYH |BD9E1=V"JHR23@ M 5YM-
X|1UX875T3I|HJ|;SOF\$75T1N%SC@|IGKZ|J>I;7+G4>?N(T M^V7;6I<|S|<?")F3|EH%#&+DD*23G@8X> "8"> ^NC VL=5M L'FF\$3Y.
M&<-M*CC).> *VZ|2)E;X#;J9U59CK#%U0Y ;|=W?Q%OX "IQ?PZ9I. :%AJJ MZ7?6|RG:KEU7=&<#<#N!&<=> ^*V8==UQ-0MM%OH-.BU:|>:-6-
H7>2)+5-OSL M#M)8EPN,CN<18H W;6=-.U.ZO+:QQ(KB:S<|<+&<^6Q&0">E:2;6M-M|8MM) MEO(UU"Y5FAM|Y9@HR3I#K7)>! M0I
<^A>^3IH%W:AC""#8>0N". 2U|:7V P 06316^IOIFGB M@DL 5%P*& =@M|V4QD\$YSI4 =M17,>E/\$%SKIO7\$-I|= ITEN7::S#*,N5
M;=NIBD<#NN#QT>|KNIWMA<645NEO#;S:<7IT2OX KD|7OAK\$|SHLZ:3@ M66LBS1O6.ZO9AQE7:1AL=1P&(C
QG(R*RO&>M7WB'X6^ (M2L/LJ:7Y4,8D5 MC),B,4:0,#A>0V!@Y '(SP >EQR++&LB*",RGU!IU5+<=)M@A ?R%VEAD M|IU%>?)
A Q9J6F^\$M5UG6:F&|E&J\$6D:.1&O+YBP09W\$|>G8D =3W/2Z* MY::Q%&C^*-JTC6\$M98=6#K;W-LC)Y0-\$DC%"S"\$D5""1M/S=>?P/(
.QHK;WQ|>0:N^BOM&U!;K<3W?6 M\$TT8+LP10D9)=C\$DMV&<19\$WCG7X|V7+^TM;O4M1&GS6|VSOE&(\$+>*QMVM:29 .D),L V M R
8P.)QK63+XR|326\$BFYM;#2E&@W\$BOYDLC>:BIK(I. 2.03R<#IP> MM H^..9N0%<L:Y MX<1%Z9I|8FQ5E3E3I.X?>
+F+IU.1SUR >GT5ONH>*J0^T:I9Z7\$D MUUIBJDG^@SRK/4#E 8|B,89>26.3TXR>CT> FU70I2^ELIK>>>(|M<^0I3 M=U(X|!^E
\$FI:G9;82VWVHW.=M:Q#+RR' JQ#-'<0I5Q-NCDA.C>H(R#7E# MWVL:C| B%+J|E|!<>3+1%L-DI0CRU"C\$S!<#IC/N:Z3\$KZ?I2A:3+VUL
MQ8:M:E(3\$|6)XX@ P Y||I:/'|IF@N:CGGBMH'FF<@%RS'H!7"R^.|I1G MT^-5!TN: LFN=GV6*PG:5X=^SSSE V9XW<=, YKO3T-
%+2I:TS6X#I/= M:WD(#.)X!<= 4<5>KA/@U R2C|V^1|ZDK8UGQ&IKKB+;#JMT^:4W3REFTEN M|B|MCJ^SR0W|QM|YH.Z.BN-
L %.MW6BVLTC^3|AKN2WNI|M62&|\$/G8? M:Q1L <.:D^C^; A&M=U^6"&5I)U 6:30(CYB9"8 WO7E@JKN(I/"G|Y MS0!WM%
<|)XPN++39+V26PU^VGFMI|23|BPW69Y)&((P@N1MZD#|Z?H:QF:~ ILGB 3=5TVP.JZ:IS:G::RNG MB 9SU&0P(QI^U
:'ZKJUAH>FS:CJ=REM9PXIR5X7)"CI|D"K8(90P((R** M|ZUO=XFM? %YXDN|TAI|I%:W5O\$9G).|#>'78D\$ 'OXXKI+C7KFY|3GP
MIGD)= "ZQAFVH@4.D.">HP.N..BHKSR^^(6HVGA24PK;9; P|J M:5J^6%Y 9^4)9T57CZ9#IP0"1BNQT:369KDUZV<.@G80^UD9P8L J6+ ?-
MG/(TH TJ^!^TIO@J-CXB|;7FKWT#Z=HYC)2. @B,0^8 OSI>:CXAUG4/#|@+4+..UL4U6^M4G@2\$E>59P =P^0%IQ MU/'(Z\$
I.HKBK Q)2KJ HEK+IT.I6L4\$6BUXC(=0W+DF)MP .5Q|QR#G\$6 MNMOKEK/3IFZ2IYVAB:011 >D(I.T>YQB@"Q2\$A022 !R2:XO2/&K7FFR:U)>
M;=:3I8275%0.LMK(NT^4REBOM.6TLM?O99UG=@|B>:-P3^D#N< 30797 (JFDU2ZTW2 M FMK..9Y)+*X4M)DJF(ONI+DDGN, |X
.KJC8:SIVJ7%W8W<=QI9R".<1G M.QB.X)Z9Q7.=XOO|5CT6R73T|T6+^6XG@O4; 18XV"7QI7Y2V6*41QD".>
M'FK#5M4T(\$K\$5F6T>|LKF.9EVMY<@6W4C SE<@ |3@GOUH |6|CIVLZ=J|70 MT^|CN?LLI@E,9R\$< \$KGZ\$=*PIGO>+P;
|X4M#;FWUD/X.^)EA,F0N!\$09R|O"BC@%\$LPZ OT>D51U6=,T@VRW|W MUU.L\$N">9)& H^U-W6 H.LCB3.<@%#@
M|L8K"17WVK:GHWA49X|6.TI)L1 H:\$S(59P4RV<=<0. \$1\$Y/3Z?H Y MJT&@Z'?M=IC#;0M*RKU; Z#W/3:YVZ2I:T=?
L+)|L>:TO8W#W\$>GW\$8LI MN10+@|U/3(V|AF@#L**X:Q16ZU=:I>^9K:T@10VIP&1B!ZY\$Q@@"3:IJ^G MZ+QW&HW26T4DJ0H|J"
|/"C|:NUYN Q U""7PC. \$VD6|7IGJZ:9P|KEDCE| MQ5WQ|WWE(R1CWK3UCQ+XE3QE<=>'= &TW3I9%TT7T,ES,ZAOWFPAL#CH<#W|S MVH
|6BN"1I^=5|V>I:C"D^Y2\$PGC=-M;)WW<@3R\$H%)8CN7R3CH M.E:DWB#4I(|3:|I.QVLT6|+(MKH>
(SIVF^UTVIE@N(O.^3UI|W|N^F^UM);19PD,2&1V M/90.D E016U/6;T. &34.N.W6:588IYY=V..)|J7EGC+4M5UGP9HNNK-' M:Q:>?ZE92I
5:8SXVE4HQ: "2.97 QNZG'. XG|5ZKHBZS<+&96|OIIT EMUN MLL^H\$)O<)&M8%0OW^&HJ2|@AT^|TV6|N!8AL|J MXAADXRWGCG4I-
/GU/1M.EOX(GIH1:IV|JR7") (8V9I0-@.0Q P>|R M03@ >T56NYYHLEGMXU:58RZ)*2@)QG|X) Y5YTGO |2Q>%=|6W6DZ= 8E MOYONTCE?
SXE=@OF/RX|CY/TR< IU^+QWK=WI @Z:TTZQ:7Q C|A)*P\$;B-G';|O R>3C% 'H= M%<+>XOU:VU.#1=1;2=U=I)9T\$Y+ MW6+>Q&^IWL-
P(-8N+90D)3&P(HQO 7 Z=<|Y- '4444 %%% 1110 44 444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 111 M0
5@>+O^T/BK2HK.XP.>IKT*B@#SM !&MR>! \$F@M)IXFU>|GN\$D\$KE8UE?< M0?DR2.GOI5>|AKO#8>)OKVCW&G+>VL5OJ5KIK?
D|ZA:~.3XFTTVQ MEN|I:~LYI65&G*NCAG2&O#^K:9XCUI 5=2N^*0;JL@2W1@4*1JF.DI/QZ|=*K M&AZC?^= UB
VHM=,6X#H|C|W|U0IQA2.-N>O>U:|AK6G:D>7MI9W(EG7L M+AOI^EL1D#)&#QZ5?H |YOO ^OW46OF^YT^1.34-3@U".-G=HW\$>P>5*-HRK!
M.<9I.5=7PWXJ|7Q|I.M2:5%<?>EK;|SCJY\$SDI?<:17M(C#UFI2I>J^A0E3V+9+DEM>AMGSXF+M'WP 1SV)1&1DUTZ ML'O.IRK#
(-4M+UG3I:CN9-N1.MM#K M 2I0U/1R-8UWS+9|B)A&WF/YC*YSIGW3@<DCL65I|J%LUM>VL-S:OIZ*..I^H%0;:H MVEZ-&T>EZ;9V2.,
M5U0% "%>="8;+>:3?ZQIMSHIGA89TA<74D: =1N=HZ \$|D@8ZG-9.W@+Q M^:~&=:|*Z2|&FMHEX)3:-
<* G6XD8L8SC@KDG#>=>GIZ7I0I5T?>VTRU@N7 MCDGCB5?>-2%)QD UPP^NH7/AW7-N|ZUCMKB DOI^XA5C+%(TOF*7I.P.#Q
M@9R#U%=QI>IV>CZ=:ZAL.K^K"1:20@G:H.GM|B|MHKB#MT4J1&QC^D9I MY|J. =A:AJVL:J.MBSC:2MIB1VKLXEF9=N|IE7: -
V%YY(XYX|F:;#<=>)O M"" I%I-%#<3>6T:RYV|DD5QG'.#MQ^-=!10|PFH^&?%:Z ;>)=U#2X=5DMA
M:W|L.DAMID#%E((^8.NXC&D-2.D59UOOPYKV|I1Z |75C--&*JR^
M7&H#8&ZDD|>I=E10I.S.H:J5UX|TC7(L@M+&VFM&9D8.ODVY(^7^WUXYS MK)3PCK(T#QAI|-8>9KT|L3"9I1"6.)AODYQC/"7IQ7>44
<4WAC66U+P=EEDB(F?7F1B#?> M)S@#/'7IQUKJHBM(32PA3\$B\$X|)QCK|TI1I8L-?TN^4|N M|<6" >H- (67A7QI8:QHUI#8XA93S+%@#) M8
9IQT S5.W|I:19^\$-#TR^|TY(S1=5^VP.X<1RIND)#&02).PXQWKNI-9T M^6X-&DNONH3PM/'#M.613@G.,=3ZU?H X27PSXKTSQ)=ZQX?
U2|FIK&=0M M;V*3RUF50OF13GD#H3^/IVMK%+&=:QQS3&4#YY.8W-W('89I=JFHH |^?P7
MKR:)XNT:*YTYK6;BYEMW<8SG/48J |<^&I8GU'PC=#!"/I% M#>=>OGA O"TI"7Y/3GGZ>I=E10|P.A%/%>?AR672-/U?3SX<:9Y(3+&YNK=
M&8L8TP0IY)POSC.<=J|FX.PMW-ND:S8^19*J3ID D2E4M% "%>#M"1^&O! MJ|H8BTJYDMA)MG-U(@.YV?E2+3=CKVI+4 "?B-
-3TO7I%U6T&MP6GV2I6I5 MS!=(3O/W?F7#DD8I\$#MSW50W5W;V.GZ.JQOI(E4\$|V8X50.I))H Y'5 M_#WB>^0KY;
|39|VQN7GN+69^2VD+)&M&W&Y@4Z@YGL)XZ4S2?#?B2YIY0>V>Z2=2=TW7N3N|IP9&M93#.QOM&|3CL MRL 1^5:- 'G-YI.VO8|8GMIH-
&NKR:WKN:R)>2*)A(MEY^X9M)" IP.KY M^UOXI4^9XE0>=T38D>GQN|N>|GO^ &3UXOOUL=:T|4KZ^LK.X\$MQ8 MLJ7^I2/+&#(&2.'@=J
.4^ (AG&J>#?LHB. JM*464D*?W4G|Y^UP<>AZ59U M/PMJ.J VY?RFS34K 33IEN@D8QPI<22VT%B6;W|I|T#U-=>Z-IFI3PSWVG MVMS+


```

1/A2-CX!OR.>."E "-OX5 MU74OA:OAS'LH[PVD5HTS2,8PS"CGOUXJO+X'=-6MH+BT.I:MJ.=|<2R,RQQ^6R%47 )8!8P.G&222:N|BA4
MRJJRS?J-N/L<#Y"GT4<5)X.O:C7O%N)K5I$|010E^:SXVS/ED+.#CH MV2;&."|>=$|40M/ITG0=9GM);3YH7>XB9M/JTL)R@*83")
|CN;H<=>:UHH J: MG#>15=06PC,|L3(GFL57)& 2 3^E<4 .@O6D1%*M,@FL/I0T&|@G|=W4PC M5EZA<@D-GH>E>@44<5XC|+:MXFT 4--
U)-JN(9BIL|H|UEFLV*ZC:SN MY|G9VY><2;.*$2C@FKE" #W7@4ZUKM$NH:E96 M4D^GSV-VU@|XW8E &JL;:
<$C|OR1SQS)X6T/OAI5K:Z9JNK:=<:=8*$ADMX MG6>X51A%D).%3. 2<8SUSVE% 'GC>="=:D|%)M#>330/K%Y/<)07VOB5LD
M'Y,DCI2:|IKPOXGLOS>O>|W38KFYM8I;4.1WO#(8|A75E.:|C(Z"N|HH MXO5?"VNMJ6CZ,|N6CZW91R0W(N498+F*0IF3YQ09S5>P|JUS|XQ
MBU.^LIOB%-%O&W|EO)>3D|@8Z=|9XSB|NH XH Z2+POXFN-0|WM =Z4C:*9 M%=(%D82|MYE|..<VUL|UNZ|F05& M<=&3P2600** .0L-
$4:GI=Q|WBW4+.EM Y+9|8C3HW5|S2H2|EN <# *HQGG M/&*QG|>+|C0I/T>ZU2'ATB|MT7;1R>9,UL|>?>00).<^H|@D44 9NO: M-
%X@|.W^CW+E8|R|H6=1R|(^|/FL/PYIOC2T2&WUW5=,NK>U7$;VT:K-ZKS|5Z%5%=&TQ M-3:4TT^U6 8;3:JN7DLCJ:Q(K| M4 |,
(JY|GVK53U04 X6) PD3B5%|=.%@8EE8N%YGF%ON8|QCCU|JZBB@# MS35? GB6^T2Q1I"7^F&WU:Z:YBN95D,V'RE8W|5VXI&|>|C
K>.@:VOCJ|J0 M0SZ>423A8WD;|P50(9,Q^O4CDCU|JZVB@#SP #Z^O|0:=?W.O:S:ASJ:K M7%LS.;>3^E005<.;3WR>E;K;+JF|:OI&I:L+.-
M*8DD<-M(SK+R;-Q+*J M@L#|Y|7CGIJ* /9/ VMR #W6 #C2Z>)|1NY9TF&K4623S""-F21T|-.N| MEM/M^D265|BCI|
8IEC8D888."0/7TJW10|YFW@CO;)X5LO#@T4<,GA77H=|+;.C%66CZMIW|@75R|PHN87:XM-YW.L>#M(R21NZ9Z'OWM% %>|&
M33YUR3B)AR$V;<#>4 MN M/&>.>3;BWANH^M(NDEA<8='7*L|0/U8B=>9;5:K:Z:06EN)6"".(HSZ< M4 H(Y|&:O-4?
^1UC3=8T4+=*OK6XEL=>+|_LNY&S(F5/F#;. M 197H3SGK7:44 >:CP%XB@T|9J&FSS)KTFK"&9'6<6+>)C/O#<#<('?'K MAMWX*1W7 "8:
|O2W X2&VCBR|(GE,L7EGC|X _/VKT6B@#C:GPWK$^H^$;H M?81 8@?SUIY WA:|+|G|SSI|>K?A23T'5<-<Z:TDTZ^OY;Z'8&|T-)MR MK9X
&#TSG/&NGHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXA7>|J6|A-K|I
|:QW.M6U MO,K0EBX)+#)W#Y03TH B76|J|U/7H=3T:2YK*?2HH?M,|.#KRR*6"JH<%0 223|I'>-6| MB3 A)|%ZDMOLUW;W$EI=0|MPCFC.&
|/=<"K5.#PWI.E#*:O7M/GM99-2@B MCU|WEW|HTL8PLB$|B..C;@|M-DMUDIV>XENKF7;MR61BS$#L M.<@%>'Z-%?
M5B98+I9VN/GVL|YV M-N.#GCKTYH T-2|6ZE)-K<6BP|Y+=D|E8GL)YQ"C.>>3Q74: M9>7&HZ:-W'M8L+>VU1E
MEO+.|@:98|OIH40&5^DD@#@XZ?EV=K"IO:10R3/Z* TKI7|W<=|) .T^OM|/7&QFM424F-UL|OA|?W&AZIHL^J016MY?R:A8SPQ M-
YT$K2"12V3CP2,<=>0>HK7T03?P WV*5=-0%|?#Z3O>UEHRVJF:8X|R;- #-)M|TZ2=2GAUF4VX7S T#OJ&=LX<8)X ^/>+|>-
|S4 ^%3G3C>BT^T290L@N M06V|U/VS|2CGM5V|U|<=>(#&IE|1HZK2|M|C|YID0(=2R|8OGG.>G00| M0A|920:)|XG>+|LH+G4=#N5A/V*-
|DBJ.V$EOE5B2, P|&MSPQK.^M .+F- M0TS4=-*1FWN;%2I+=O5U+L01A/3K6:9^>L: Q#>6MW913:I=P7,1(9Q&$ MV*R,.(#9(R,8S^
.,PU?Z=;|KNG2Z=I>I7|0|$|K|/O5B2-2A2SG=CIV' MWLT =K7G|XU?3)|J|R^QC-QJR64FG*|>:&|Y"B2-(KE03PV"HR#C|UVNE
M/>R:3;/J*M8Z5,XC|V|<=>=,10|JMXA|37GB+O-I&GQZ3' &4D#PS3K(VX2(S8901D| 9! M&O/YX=I7C:XUVPI-QV<...H:Q;=-R>8"|=O&F
YP""V68 #C(ZDD|8-C3 _XV1 M62B/Q|KRV,0|KOPHB NNOHD^M @|V|.W3GK6+9?# 6+=TOPW+I^I6<+LZ' M&L|&="2|@?J|KC@>| 1C|I(^
"YX)|TOCKQT+OX7G%U:;FA0J|V=<8|)(XQ MW/-/B?Q2=UG3|'6YM=.M|N-R-008F>'S 1MB)%*(%)|R3VP.O"^& #NJZ5
MXDU|5M00K2=5.5% +@A9-C&#&ZEECOQT^ASV|J|GZC>73HD>GWFERV E36-X M" |9)W9 :C&#"#GVQ0|E P#^1.O:>
|/"NFD=BIJT5P:CRE8|'C;C;L%3D M=17-+|=O=4#.#P%O M_P#B6$010'C|+O5D1^06|/S8 "M:/P?Z98>0|DU
M"W:|T@|/M2,8YE|E*.(VY&WGL,TV7P|Y8^+|2|U>W*Z^596CMB#SP15 MS|I|I03K|F@8>(O$>C>|(<=M=8M=-;2=6;
|/):E _MY=A95|2W6G MVL,F2AH4CE,R6X93&K%G Q|XX3GDCGBL3?)"K>(< #WC#3IY9;W7B&XN+6Y0
MM&SOO$TUSI4|6EE|I|$SW'EY5|(E-R9)2|Z, *^*O/2|UIX>|0Z|I-W|W MB|5+*ZMYK9|;80-$7##1=R2?FOT //&#&^%M |4Z1%:??
JNNVEUEBH2 MP6|/J^N|^& 8Z#)Q|>N0^X=WK7@|0R:E?17/EZS'/MKZ'.SFM:E:RGMRW$($20XSPYOTOSUJ X7|ZEH&
MHZT);J|UET^|OYKZ2|4C82J|I|(8DXP,HR<|NEO&^M202P).B:YI=W:PR6*3P MRI5|APP"9(M8+|K= 3UP.CT/6|($^A^RU>T|2*|@65
XYZ(Z'Z'BN?M"/>HZ/%K>GZ7=VW| MEZK+.#GG|MI|@^?|:PZY)7J:Z31|+MM$T:STNS|0%0K#&'GJ0HQD^'|
MF:W>KWP^^(|F7|59Z=9=1MOB H?D#C"CIW$|<#|N,|JFMO2M>UG3+WPC|W|W M8MIVK6WE|B(|Y|+I#O|9B<.">
HOZFE;P7K^%5XNTJ&|L3RZ><31T?>#C/G4=N?7^AC59KGPE,|&C|O|F0W .?&QF+CY>.#GG|+C X MXU:ZT7>3GOKH|'4>XZT
9UK>>)|J&G=>6ME+IMU' |W M+PY1K)|H902S'S>5R%7D9Z'%8IZY MIV?>@:JLO"=WX/CO(6T28ND4S9|^&|V|&.>6 :|QGH<4
22^)|O&#^T'CFIO|>TU9|>VCUNI|O;&3=B|C' MKQ%|E,Y*AA4)QC) SWK0A|WMKXZ76|?|(+&+2QIL5ON8, 'WALX(|L>G.> MU84?
P|U;(28?)U&U@U:RU:;4I.=59XR92Q|U@.M.MPV.@YH ETT:DOQB=;|I
M62<.%#Y+QOM&K$#57N|9B#G(Z|I69=^*=&|5BEM+&|JUF^NM(XH692 MOVHH ,L"|@SZ|BNFT PIKT/C"Q>7FG223;EH;>*)U4,KLPPQ)
(&6ZX) M/|K*B| ZM%|/;#0%OK,7^G7ZWL$^UC&|'8RX9>H'S$<$|* -R36|1MO'NF: M%.EG)!<6$UPTZ1LK|D9|@ L0 =W3GIUK+?QG|MSX-
NO&&FP6.#//&D^@:O-XSTK79YK|EM+2VF1-ZES(5)91SC|48 M5)SZB?|IX)OM|-EX4M:R#^Q:PRK%*P|G6T,I|>,+C#?>;#&C&>0<@#|1%
M>L:AXKL|+T5-/R7VC VE|<?N64D)4$&9&Z9'7J, M&YMM5Y3Z+ZXBB>2" (Y5IMH,I9P|UX+=V|O#)W9^>5/K|'F&GVJE V;:EF
MW|>L&LSC^T#X'Y|56T7PWX|T6VNDANM/+7&KS A(AWE9(Y0Q,1XR^&D'I= M.O-WPI?W6HV<|Q|^V| AN4| M|UJ^%N4(VOQ
3N^X|8)SSGFHOB1|M| P|>XACC?7K5=KPECNPY|)##*# M#C'XUJ^/'^#HZ%K6N2=6TNFZA>O?1H(V$JNZ|)"H'O6'-|0|3:P|7MMI|J+|
:71K^WD=BJR>8%;8W4$& M$|,|50'P|26/B^X|1:7);|0MXX;^TF9@K.GW)%<G(|P5Y|I67>^|
```


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||0820868G_KH'W/N!>D7VLZ!IMY96E!T M06!Q2.8!..1P#*PQD+Z!1^8!NE5+ARHW \$XY /7^0_*J6H:5::G- :O1^!) J/SK0!J M+I>G!< :4L:99!O-\$*AL^N<9H XCOPD-Q!2/ -M+(Z!YKTRGY6C:'D!BI' M/H:@!<6-K8>!> ES7)=!97Y9!R67C8W0.Q4CD>M= /IFGW4W67%K2:R WY M(E9Q0S(HN--L+N027-E:32 8#21*Q ^!% '!W!-K= '>.&>9T'^^&R?W5PT1S! MHZ94@!U:!O_ &5!^..O!EG=!'!1R7T F3&4PAE'..\$SGG:2!J@>PK9DT72!7 M+R:99NYZLT!"DG!*,!)!IME!?'?B94 MFU3!/:!"H:9*YDC.>| OD0G&^..C./3/2NK^!)FHZ?JO@W0KVUNXY;*XUBS99H MY. KOY!(Y!Z^XKT&WL:2TC:..VM888V^L<84^Z@57 L/2.8 LJQQUQIG3 "C@ M#.DM!&T35+;4C=SFXD7!%>>)>9.#(Z8"!J!G*Y..V2>EK_%#X@V! MQ!)C_05*P74D608!"G8PS^/2N^AT<2>+598=M(Y%Y5UT@4\$0>@4^3-/M!O. M@L:~*7GYXXE5N?<@"@>@ '^ERZ+=X/UR-9/K0+L" [VKEEA90K28^4M!#/UK< M!>ZG />!)NMS-J.HIM911S.UO!(I50@!WNN>.P!KJJ!6^E:=9SM!6%K! M.WW!H55C!2!0!Y5C!J?>JNC?>VOPNT. [G*\$03F*1HY2AW""!VD/WCC!JU?"TB>\$ _M&FHZ!K:B2!U!C<:=JMP *JRXTRPNY1+W7UKHK/5?#WA?3+NU:4D2STYR||TV!1M- (S!&>6!C"G>E,>E>S!V!K#:6<5!#& M%>BC\$:)V" @8_*JXT72A&T8TRS",02OD+@D=#C'N?>SH XN M!P^!)?>86<4. M#36=2D@B 7>@CC8 XZC.350XF:E!>DZ?HE!J.KG2H=7@4=H)"PIXA9W4/L!U MKK!P^!T!>P^ V"UW0\$>2N4QTOQO5F2-)8VCD17!AAE89!'H10!YKXON=,U+P MGXLU/P=!'JEU9OQBZ+&4R!D4XYV!QO!LP.<=>U60\$?V?5:GP%J!AH9CJ\$ M!1-#CBBR;&8<=%P%!||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~!ON'E6Y0!*Y8Y!>..@< #GG%=M M# <03_&Q7BFCD63PT&0!P(8?>3R/6NN:2M.9KAF!+4MX^!<:- M.L5NA!K2KOPIXIU7PBR7MY&ZT^Q!J6B6B2+9^*8_M..D8P!OUPEP< M!B8!."? X@!>WKT^UTZLO6D:TL!>W:OY:~3C!K!T^!V76!G: FQE)!< REF!<8^8BO5:NPL!&~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~W@!M.MO.GE!^N ZX'- C@!ZZHW!O: %: M1!)NZZBB6?PZZ!(CA!YFC. 3U)!J8:-!&Q:-!&Q!&91 N"ITR,>YJ3^SK M\$-L+*WS:Y!@^40!K/7:QO^% 'C- K6F7GA31!BSN!S@7Q'.EB9- !1^U M>|K.25R23@>@.FNPTO!#>+6 \$)7!L.VCVLCXVE?I9SN/KP!S!>J.Z3!S MP.GVFW\$SDH!E?WC Y#-QR<|S2MI6G!K6%J9! 0!F%9^~ !3KSZ6:FY+>5.8 M!TGMFB15VLZ\$D@ |!>1SFO33HVEF(1^3-/RP=P3RP#PZXQU!NFV\$D\$DME; M220?ZEGB4F/ '3CC!>. T? 4!0_ 'D=CJ5V!O9 V:JL.NH.\$+!&S.6/G.M!FCX49Z5<^%UF^C'W9ROF-^>O^!T!D83!=(=O Z^'2NUNK&TO@N!6"X"X" M!>S!L8?>? 49Z&I(8(=66&)(U9B!% RQ.23CN30!PIP6MU!Y5GBBE.?AY"J MN VT :^Y>^>#^M<5!V!+H_ACPWGOV!MO'8VR0R!21K"H5 J.8 M- 'E? BNUVR>!?&I&3C:K)=P!A V7! V-+!#>: 94.5A! ME=BGV7&!4GV.U^R&T^S0_9B-!AV#9CTV!4 >ZC9^!)"?CSAM.U0ZJ!Y!S MO=3EXWA!O87";BA0^>9QS!V/6H!>RN=^%W\$4\$@DLIN^4=BU4CKUYKTH M:~8+9^R6MA:CI (EV#_ (#C%&D8K1L-M T?W" (#RO..>...4\$)*M!Q2XXMX0B!J!3B- M F3@>I!UNKZOIL^Q-JUS:Z2?I0.EY=/!Z!M!^!D2 M\$A2V1D!@!A!@N!Q@T^RM96EM!WAD? AGCC"EOJ0*=~8VEQ<17\$UK!)/#S%(8 M+)_ND!C!^/\$-+ LZ_!AS!>H93:SR+KD<B-AB%_?91AZ?>X/M60XC%QIVM M \$1="C!JY:1+639:C#9 >!F !03^E>I-HVEL!J!VFV9526_."X!R3T!F!ST M^RBN3FK!M\$U**S MM.M!@EC-R\$F7C3^U>A5#:6=K9(4M:~&2)!U!<:/ M#2R+=!L?N)(!12%F! &8!G@&B@!#I&!0Z0NEW.IC4=!.USYTD:AMA^4\$G/MU MKD=8!S7VB>+>-8T2_6"" P!5M+J(!/ERG)1B0=IQICJ!>BO+627XA>!)!O3 MOFLG/!"* !0E7NMS!@!Q!>D'OK72!A!E!L!AW:BZM9U34M.AGCWJ! ^9 M6!J.X- K&FZW!6L"8Z9J!5!>!"MDIMYEDV!"Q266VNZ3>7+V!M!>B>B8 MTF4G9_>QG!J!^!T!5)* BWQK:Z!C!7/X70^7"?G=PT@X Y+>2_ (K2T+4?)"M'BK4M"U"UBZO=1M^8V!J!657M@RXD\$B!JHPH QSP>9R*_VM? \$6B7MU\$>VNK MV.!H@!J3Z5P2PML!&G MTF!O\$M!22ZAU>|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|5!% MKNDW\$M!+*4!22Z8\$>LREF^> &>2..E!EWELID MY:6>.E967UR\$7!>=G <=#KFD20_#VYM!O!LX+**&+*%JRV2M%(LCMEM^>_2 M<^!XS0!WFCZ!<1>+>?&M!^!Q_V!C!VQA>8)&L^O%O!>+<=SU!T2^6=+5K-3 M!>H&O0#>@+>^!&1LY!>CGBN!AQ>^>^>BZ:6S+>+>P(B(026^RD8_/BL<^=(M(G!..!|M!MI&M!RT6<+>(#Y+"W=" NG=Q@XZ^T- J!DVNZ3:WHLYM2M!>DN M!Q\$TRAMOZ+C/4!AU!&@>fW/M-#N\$!ZYZ!>WX.U6=U!8!>#R:>+&W3LZW^Y9=Q)4^&0% X&36%==O!FNZ^_4 M!URU!+!>X>B:~Y=I5U!Z3!4G@&H=C0!H^>J>WO7D-U:QZ3!)U4K!IM MQXKCEU&T^W^T(1M! A.UV!L!>8!>O\$VF^!M7FTR^ CA>TDC;^_P_1H !35E= Z.&5AD\$!(JE-K6EP7R64VH6L=T!A%A:4!BQ M&0N/4CD#K5?PS9V5AX:L+33A.++>!)!H!W!_3GGG&F>V^!Z!>WX?O?>P MWX9!4 2:W!JDS36.FX37\$WG&1&0#EN!J!CC YXH J-O! 6M+!TM@M J-K!L!NQ M-!>2+G&>3TSQ!IGK65!LW>2^!U!>X U*~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|ZS+IMO?)!JSEAN@>R0K^&93T?>QO^>X M!UW_(:M+P!-6%IIXG%G%\$@>T!\$!>_>C^= /M!J!O^!>LNFV!M!>J>KZB:155!Y("F\$*^!>J!>+>ZFG^>^>_*)>+>P M!U Q-!>N75M&3!J!DEM(!J7^!>@A_@YX(!!4>C2:U!<^!EC+J!JET!A%A: M5008C(7^J!SCK27NMZ5!LHBOM2M:9SCY9!54!G SD!9/ KS+PAK7A^Y!+>#PU MXF!MK!KJ\$C3V.F!SIKGSF=73^+9R#GICKO2G5M&7Q!XP!| BS6!>L-W=-(L M!\$>7:Q4DG^XP^GTYSO!Z!>TQ-TQ@4M=(R E>O4:AD>XKD!\$L+XA>:~6 M&J:9= MQHEP!V!9LB!"!Y!P#U!#6!>I-MX?FT? XC0ZG-!>B:78=65^X4HFW"?..!>^ MG- >7B!2K+Q3>+>Y;B7=Q^TQW.\$ P^"!>S(N!>I?3.U!>OVMO)<7\$>L<.. M:EGDD8^!>=22>@>KRO26DT^Q1X#BUVX6WN!X?EMV.!J!ES&F3U:MCJ:ZWXB7 M!C! A42:A!>!)>6!8!UV2^2)*C!I620J0=BD GUQCO0!MP: !I%Q#<31:G:-> M8!JA.N(L!>W!RY!ZC@!>2Z^*FDU>WNO<>^T^RC:LM 'H/B_7!2?>U.OZK!9ZA%:/+>#N9^P8^2ORMQR!CGKVJ!X8NY M! PGHUY=2>9<7%G!>+*^..S.@!>I.QU>=>|2R9R !Q M\$R\$OE 2O+L!"@ =.5W?>6>@Y! ^Y(9\$D3^SH%)4YPI&H(^H%&@>VNZ2E!>) M2GMUB EB\$RKN+ W0.J2?>K2?Q!H\$56Q>KJUD:6W!P!>^ MBN)MOK672KVYUKO+S6RCV.P!>L!A!26:~A!>ON8JPR!GG!)>C-J=C8:~! M4!>NKJ**>EN+R2.V8_O'5!>5=>K!>I^!YZ DT =G!G!V6VFWNA6!&H6!>J!W!>J56_Y.4^7#Y:O&>..2H)XY-8!607-OXCCI+W? BN^59K>>Z74\$6!)4758^3R>O:MIKFDW MTSPVF!6D!L:>8R1S^Q^?WNOW?>I7EV!J?>BT^*UOHY!R!L!\$4+>R>2F!_# MGE0X^M=HFO>#O%>H7Z!E&&YOX:9D3R!LAK2!A!RR <^>*>_3C!H V-NE M3!H!FZ!O!V!JQ+!>QO5"(B+N!R\$J!WK7FC-86V MA "F2\$V!1- Q!R!&#>ZV8-^>8!S!T:~M!>K!AZ3>=>+>..G!IG5GEM!OWE7>Z3? M\$T8+PZVZWC5!>L!>4^Y!>I!>J!M: M^>S6=S%<1!>BA>)PPW X(R.X!%<+XNCO? #O&K3%>FEVC3/>(<+OK9?>XV? 4?> MDA2?I!>J!23K:~!IT%>H&+F- <J!>N!Q!R!WK6)XN!>4!>Z- !RWD.\$VH7B02N!>NBBV!Q!>X!Y^A02.&D5P3\$ZC!J05VA017D>^!>2O! M1!>!6XD@&C7+7=A=8XV-F2V0,>X%=9?3M2CM!5M; M*2ZC0:&?) AB:=8\$5^3^R!>JQU M!>..*!2L38P!>PE<G>:>0:0:M!R&5\$ [Q<8!>J!>J00Z5!>V!>Z!36.H6>IP>QNH!F& M.5.D+AU!R.HR!>5^>8%K!>^> @EBM:72!2B=V!9R!>#..!&I!U!>R!K.9!>I!5!M.P+>?W= !VH_!>J!>UMKY" DAGDLR3!V: /9#X@T8!>JNM>7>+>H!>#D? PU!>07>DWC M7<0%J!M+/+>/(#^+>9X!Y!C(^O!R-?>QC-I_A?>Q+X;U XTS0Y6N%N+JSB1 M5CG=4\$>O!>I^JR!>L= !XH

[illegible]

@@#&M016!>+!#U#IV.R03A5<9<L5R*!XTTS5.#.&N2F6U@G.M?&LL+@N6R2V1HKF:8L5BN0Q.M5OD"!&S4<B30J
(TC1HHS75D%W;H:;XN3AIE0F)>W&0.DG%`145D:9XG.MT75I2|NK+4(WALV*W+.#&82|D|@P!QSD)5)9^(-.O)4T^X87BOB7R)8G
MB=D|QN4.I.N7&I.D1A:=%>2!C?Q1&M!%&E.GOH:|NYDCAM|Q)9?>C526DSC:/6@`6BN5TGQ#H>C^%>EN?>C7MM|WXSC&|^
>FD>|M.UYXNKZ?3)YK?7GH65EIZ?#9|!\$<M-#M6|HGK`GBN|Y:7&EVLK?>J)%TMNAC@=U7.222H|<*.3Z8H|B9<^<NM
MKJ>JSC35TZWGA@D4G8S.^I.BKNZ+D|\$M`?T5GIZ|HLEVVIOW2S6ET8'B.M4N9%M-MJ3NH+!+48HKF&KAC\$BE<\$@DYO
MX+&+!GW*E|?=&RK.JR3Q05^?E)XYZAW_A*=%^UO6WVT:|9S:IR>6_E|..M.NO)C86R`9SD\$=10|L45E7?B/2K^X>&X<
&ZOR.L+ND.MC.K%*J3N7@G/MS#U%&I>|>|TDR?>OREB*B9Q&|>N?>8R@A.|?>(ZT.M%(K*ZAE(92.@@V!M%<|4H|U#10A-J&J?7?
2VEY&QO&@<(-1%.000>".SHJ|U@O-!\$TFLQ4MHH.V**KQK|Q9H6G:A+876H0)=Q1>QO5V|K?>?#>IR-/9ZO.R-;R2H6^M^20-IT->M
&|H7?7?B(W7Q|V=C?W8MKBVNY)|5XFB1@JKY.X906|RW/(MXKO:"BBB@HHHH****"BBB@HHHH****"BBB@HHHH****"BBB@H
HHHH****"BBB@HHHH****"JVH3O6VGV\$FTBQOK&Q9F..|T4<5|..B.M*#X5Z.TC`1K3HH|+(1DD?1SGVZUU6F.C:ZOI=MJ-H7-
O&\$+>2DEEJ@UW3L|IM=@=FN7L|..MV|A&8|7SZ>+A|U-N|NOP4|02F.21.G:F-0O)MGRY(|84Y>Q|Z|I^S?\$+M_H*>O|P.G-/CMV;XA?|
04|?^?P#|=H.HB|MS^..DWVB5|2|?|&S.MDW+&N\$Y>8F.O-/3F?2XM?>?|VD|=W|OAS\$?O/MA?7?K9C9|!#>^S?>+M**GAK.P.G^?T.
9OB%T%/#7-@/|/|/..36M1@@^%SAK`L=7L|G5\_AYJ=O|)!TT.D<-HZ06C-|E5A0!&O`?P.T.@L)GLX/AIK`IR>H|2"2<=2.6B@#B:73-
|9.0%MKVDV.B3PR.A=T.#3<+|H|\$D'H?>L2|Q5=VZC`1=2.=7AT\*RM;U3@7.M8.T@DGL3N/H0:|2HH|04|30!`?#FC:A745R6?
%UI/O2:|2RDMU%.(2L1#.#C|>..M=W10|Y4GA74-MZ?7|!K+>99S0>V-T#@?O/G@C^LDN|G<4=ZU+^|U^X9:SKFL02U|W3Y(MFA?
@HLC9+>35&Z..|7H`%`DTY|>^OA?|SD6M|23R|2PB;|PR88.9.M|WBT4>Z.FG7?@P.M.MVL3Z+K-K9329Y<.(F|0212|JWRD\$^V;
|>#ZV+O5;O|X(UC6H(X%@UJ=)MY|>A)E9568+U|>M44>.>#6@U`R|>6"Q3V5WY+>+."T827BB\$M8GD;3M|8&W7G.
<5K;=1%F4.0PQ=-SVK|F?>/U3XQ.M0ZA9R22V3^V07|DN(|>&^|I@<|L".HKT.B@#P^>YMW^&K6W*TK.RQ\$M75F|OE?
|4C9EOI79WES;-|8M&DCFB*MH|>|&|+..C.CU)KO:CN?M%M+>YDD?F(4WQ6#+D8R#V-|BFBZ|X?2
PIH6@:AKD5G;Z9|N4>YBECF81RLT.MOE|J|&X|CT|QOZYXAN#&^4N4LOM^RTE<6HY|Y="GOGI^8NF>%M=L&/
M2|CQ.MOI<<8A5|/5)S&|>9.Q3C.S/XUU<<11K^H5\$550=J/|(+36.M+&X|3>+^*|FFMXKKF)S`M`|DP")|M|C|D|(P.F|TTUO+|)~.C23ZK
M+M&H^|>ODRA|YR#WQ|5|5|0|Y.XL2XMX#.#C#1|EN|NR9+>2)>P|F|..M%<|R`/3|H|V?9T5X?68A@>D#N>E-
L<..Q.YU4LH>.&|50=|E=75G`X*F..W^08/3(|&|U7844<#MZA:~7|7M^D|V03K|H&G9M8)YFYQ@9Y)KCK>+X%:1%N59H|2A9X^CJ
M5NMS\$CKPQ|TYKV^B@#R5M|TC2`%7B/3|%>D<5N|M%E|O<#>00\$B>6|S<M\$C.G|R#|I|D|TNTCM?#UM:6-
NUE%>A|C(7)8PG&#R3R.YK|HH|K#Z|8P.M_|A+6M*GD|I>AK.6T9@9%WC|<|J5^DV^U2U.V3O3X@T@P2?VFO|..M_9|F740E?
%>R|H3C.P>2ET4>=>52V4MH#^|@>U5D|FQ2OED6Q3|S.MVWX/3(|176^>..ZTJZT?Q|HMD|S3YA.R6Z+Y|Q>P/89>8|8+@|A@<
T|L|ITV`V9..%>2.M8.UGGEF^|8D.C7G&G;Y8Z|KOBOPYHLKF|MIU&Z2M5^QO.M|B|(B@NU2^0%)MX/YO4|*|/;&|
&R|U+3+9+*20@10-%NWP.^@.6R|W|5S&I6.M6^A|DN^Y=M|BU.VTA=<|YR\$MM/(4|6.Z\$^O7M-%|..=C6&26-@A.M|R@P8\$%>W|
<^NWG|S7(Z|KUM|PM^6|UN.U|2)=W.HLSC3G|D^?&PQ.M@H^P|ST|M5%`D.K?6R7.Q+IGN7%UBPO#>BL+B*|DN^)|GC(V|TA
M|VB|@/9Z9|5Z;10|XO=>^<(K&|>^M.CM|J4.U.3X|RS^S/O@>3..D8Z<C\$MU..O8Y|XHK5Y76.)5W.S`*/21^*/\$+XMU^\$7@=>5TQ.S;&~
N|JLY.M+AU|OSV(|H2W+>O=C=&6.A|HBCRI&&3.2N>|2#CKBN|HHX?XD3).M/X4O|MRVUMKL|S|2L2|IGD7|OT&21^>0?7?
V..%S6|DS(L9TBV>3Y.89V8.MSN7N<6N=9M=0|Z..J369L`\$4\$MOID-JR1V`..27.WECG))8X.MKW&B@#RK6:D65|J>J^M08W*|F6.
(6U.W5Q.ZQP.MPPR|F9F(|RD@UT4>>6N|G-U88.N=#\$WAW8LCC.WG|L<|M^>|ISTKD|O.M6LM^TW5-DD^FZ=XHN|Y(D+&F-
S(Y2HY^C=NR|JOH|ZTK6."^+&+5-J%O(MYLL"A.N3\$RQMMED).X@&#..M|55B>?%X\$|SDJ22V6EZO+|J\$**6|&DE`MR.O7`
|PW3H.XMO|?TJVA@`EECP`20|TSSUKTJBB@HHHH****"BBB@HHHH****"BBB@HHHH****"BBB@HHHH****"BBB@HHHH****
"BBB-M@JEJ6KV6DK.R8|T|GE0QHC|C|X|P|J`3P`>|P|FKM<XXU1=-U+P|Y|L|CM-M|+F3S-22U|H|V^X-%N=7FO|..R|..UF.\$|..#(&
MBD&J.R=P/(ZCN^FL`%6C.CK#Z\$W^|6.RA#>ZB1<C%D8@X|R1R|>2ZFYV.MP3|1+|8+P^YU-98(YX)#`\$S.#R.DG#`4`@8KLM?
G2Z^@|A|H.8-IUY.M&LR@E49PGEY;#C|H0-WXD>#(O`L0TS4.R&Y2|AA6.2V1490-573S-|XW.MC/4\$=17>7T.UQ87-0.8|H2.4#F-B?"
WXFO%KQ52?>XOAF.3^/7.DM.MH.BU%G|YREPA+A@..R`R#R7Y2|ME.B2-74.P2-92|`\$D?C0|P.K+=V7Q\$|..M-#|VI&SO>+
|>X5KDDNT.J5>W>3%>3%`H\$+17E<7/G3M|F5U.64C.#L.M49;&&3@=>?6N5|1W.2\_%P).2=EO.WBS.%V.NB|OZ.G|QFE|?2S:5XFT`
M7.BVO|C|H8Y|H|B|>@>W.FPK(|&0Q78/>^*..@2QMX=C|THZG|J(2U62|L.Y.M|PT|KJWC|Y|T>X|QYQ4L&7A.M\$N17GWB=&D|IU=WHMA=F?2
CZ.REYHY?NBD|J%GVO|H-HZDW=I.073|P|F5F@D5+&M.G8Y4W^|Y^XJCA|`|UNET|FZ2MK.8+@L.RM|Y3#&=V%U+|H|QX|Z|UW.M6Y|N-
H+?%>X..YAB|L9(X+>F@91B|>QX.B|P|P15^%>#|O/7|+755=F.M2AS&CMU12HQP+@8ZT=|F|C&VL`%>E:(EO<2.H9)M\$<#NFO0.2H.|E
MADG@#KUK=O|U^TNQEO.Y=(+.(9>1SP.WXDG|DUYX%>K9Z|..|Z9YV@&DS6MS`|H92D0`\$**0\$SEC7S\$S(4WMGWL.M>H%
&K8;|H|V|HWEQ9P2R+>6Z+>#|/A&S&L.2#@|CTJ|JWC#0U.U|O&Q>\$B.MU<02%9R.NQ@N&|>.HY%
<3836|Q|H|Z7=JMU.7A|H=26|A\$2.6V`*O|M..I.O.3H^B#P|93Q|J^A2.96|+>|O\$

(L(0N54A1CGG"/2M*.2*YMUDBD62*5 R/W#*1P01!M=ZK-I8Z3XH0Z:XFM-7EM=5N?M-E/?-):CJ-XU04%8CC(VXY"(HL5Z7I=O M!8:-
P0VWV.WAA54(+9!0!)HAQ0!R?>*XO+W50%7VR_N/E;51+2V264E8 MXPJD#<-U.3787M_-;?\$(LES)M#N\$154LSL>BJH!)!/:
Q!X#P#JUE9:GX MP-U/V)SZW+/-9%*B1?!(IY&Q0>E-I8:G=#0051%CL%SHUA23+<):9-.8F M0Q<+<N&P#W253GH:
PB16:)+8WMWJN\$<=D_EW*S1M*)\$YZ*R_V3D8&.E7%HT(O)#\$.!O!YZ<&N\$U* T;/PUJ.NZ'H=S M=17=Q:K=7EY;32LRJ+K?
+E^=-*(C3/0U7M!NQ/C3Q0!>+0ZHI&GWGAY?G MEMY;15.A+<+H"Y!P.102>..HR>@VGB72IVZ%O+^+^G:=KH>?20@Q J"X+J M-0-
R_G26_BC2+G4>P2Y=+BZ0R6RS021B=0,DQLR/@<+!<1*Y!0_-UF>QU
M+P_P.H.R:SIEQIHZ6IW.8s!@V%VPM+@\$A^FUFQF&W6IOX8U/00\$=YIC'1=876 M!\$H(KH05L6QACND)76H_3QP.<'HIAK!#*L+AD6=F(O_P.
@DG@@"EX0!9V.F:1>IKNK7#NNLW-LLTPD_ME!M1*40.X!"#H!NP!#;4M=L_*WBY>4M_YLBP023.B<_P120.#R20^AKRBX M82?!OOC:HCF>?
4HHH@+^3?/N0A<9.0:@^@HUKW5+710'5_F65L;C90WEG.DJM.@>_6.Y5E0BIZRO# M=G:6'A^TMJ#3WT^T4.8K5!D4L2_@!@G.<'IG*:M6@
HHHHH ****BBB@H.M.HHHH ****BBB@HHHH ****BBB@HHHH ****BB MB@HHHH ****PM=0.0M-
3T<66F3WMG+4.N3!*J&_W:I9ZH!OR!4;M%>A45B3ZY9Z%9BWO)IFZFL=[N9(H'E95Q MCS'"@XSM)QUX'"0%7GCGPI8_9-/OF<7ENUS:-
%@"FC4-DJ5!H/(X'/(XH Z M*BN8C)!^IB5@GNH!ZLJ7:PQ6452/&-W2IAZT74I=?U>=-.U2.ON!\$Q^6FW;2 M84*T/&=V
Y/NP_"I=W6H>#_"EHU>?%T+(P!)V#-) 7VASCSS#*21PV&# M/! IV=%("0<@!#7/>,KG3+28#JNHW!A_UW#LELBX9GWC.A*#@X4G@YO!:
M.BHK(U<+Q+IVE/<).9W.K6)K@P0+Y*!"VT"0G'7 STK51Q(BNOW6&10!7U-M.Q35-
+N!DDEBCN87A9XFVNH8\$J>OYK!L/#.KQ6RV.I>)9+ 3U3RS#JCCB.M1.8VNXCZ^!P_3ZU6LKO4\$^+H:=+J\$!JE_9=S^X4+\$S2LIOM
SPHY.3!T> M/+O4+3PY+9.A/!K5K;3POA=LJ.OR"<NPZ\$#US0!V_#4-5UBRT6""^D=M\$GG2WC^QL^7W%&S16!/PBG2=
(U.VTVJGD2!ND=X8T@D-Y)8!MSW50/-!<6UE-/%)<4975'0<@+|| MCH>+^BN&TN*SOO!NDS2.Y>PZG>V<+&V4.C*6:
H#G9N!G!&8STKH=2!3Z M7!<1M-50-!):PBXN!@A:7R(SG#IM!QGL.I)Q0!L45E2>(M.6.S>&22Y-Y# MJH@6VC;1GBP"7
^!R!^X'6L6!>6L6J^!;TM;J>#5WE/G^V7Y42-VP%QN MW;E'&.IG.*-7Q9H+^)_#5YHJW.VJ7:>7)*8O.(7V&XX^<7AVW>^C-O=
M226(5KB.*RF=HU9=VX+G;MYW=-.1SS70V5Y.ZC8P7M!LUM<1K+%(O1E(R#^ M5 \$!\$N*T8?FE7.DV6IV!SYIM?8%KY;.S3\$@G
7P_6"@10!<^?#HH>MRW^/0>1"41.=KJ!NM MUAC^/!#8P>M3:9XITK5M5N_M99A=POB8QS6!D6^_G=X-Y>+<9!0:LT45
MP.C^*16D@!(DEE2D#2-8MS)HJO!3"Q# 7>#Y@ Y=M_245FW6NV%EK5AI(Q)E MY3!_+OE.52H9AN P""XJ"Q5H!HU8FZ;
(TDXO3&T8B^7<+@.C'.1F M@#9HK&3QHC:FIC&Y2^EB!Z;H63<:ONX SP4Q1- MG#,%!QG.V!UX!/"09R>+>?Q?:Z)#.W3)-
I_YWS_(8@AG14QOQFY)/XYZT= M1!17?SZIU#30!SZZ=J8IG_#+"800SAY40@D@D<+A!H!&BLKQ+J5Q!A
M/+O+6TNKJX50L<5K"99.DXR#7&7&FWXO+JP1Z2JHJ35G>MU;KRFU<XZC@X@T=S117(^)/#^!7U0?@/\$VHZ=-"C/:I:2!(8@HR"ZD?O
M,XR<!=ATR0#KJ!J!3Q+J!FJ67@;3.C:7N01&>!DBRC!^!5G+W4N2HUR.0"<<MBJ97V!#QK_ (4@OG40V!U9Y.QV2&.0E7&6SN*E25W9ZX.0*
_UHK@4L! M4!^/ #M+;6!2U*PU!A.J" _E\$IB!M-PD0X&T9(4CPIH=I-.X)+RH^!/?*445RND>(3JMKJFOD3OIUK+!06Z MDF58SM=I#IO9@P/
!XR30!U5>7!;XL!P60>A: #)=Z=YNIVC/AWB7RGE& M5)X#KMZ1!7<:XITK5=0Q+&6_YM\$DL=S;R0GRSGC@>IN7@CB@#9HK#A! M5:3-
J!8^+>+>J6M&E@=#N !D!&(P3CG<41R<0+!6/3YMN<^T;E/C CN0!XPN4 4 MY#(MYSZ=L5RG@.IM=I+&=EJVO
!P?>W\$PFG.HRHW\$KJN#*8S@<_<I!_IU M5M0T^VU2OELKN?0!AAG!H!R""000""00#6<-4AT2!PTN!N!FW40LP)4 M3222A !A'
R1R>YP*@E!<>'H=+T!4FOS!GU&40VTHA*!%H5!>"SN;N M!@EB)DB5 +A?AXVOR&I ZBNIT5O3I6K64ELY)V?37.=TCV!B-&P<88#)OZ4 M-;
%4X!A=4T@?7%G!BN8=T.CQE67<_5_7?IKB>MIM;9^#>+U/5#;7TER MEWOOY29MD.Y23NXY^7% H=#8!2
D>'HY!GO;J+=JY T_1GFD!#JVN0.#OB@#JY*6!JYXK5T4WUF^MM.N;F)H!FQ!O&=P^MC84D MH!Q@%<:
!XPT:PU6;2YLAK_*\$3FWBM)9="< H%4!^0?NYQ@YOB@# M>HK\$A!7;+<_9.K!>F2VO9/*M@L&263)0)C=N&ULC^&#G@5GZOXIT^Q!+;
MOK%I%I!%);FH>*+TUI9D!G%FH.Z;"Y5MP1G+EO<<S>_!O((ZIDAN M8X;AXQ(@C+ <\$8Y'48-!>+S4!>G#XELK^!N-
+>GC34+YD.P.3L#WHS98.M!QG!50/W!#8E_XMTC3VN1+>+>29!HP00(+>_@.D.AT") QUP_XQ5'4_&4 M-
EXDT+2X;+>+>4TDF^T!Q_ZE%3<_N.D)*GT^M_4T5AZCXM!T2A)=SR+!P_M2B&>Y6%VBA"D&M6)U!Q^!QOOLWYO9Y;?+W;<I!>O::
+5M:I!H!9GD;>[N5+9W5E!+*N M5C6-HG6/H M_NV !GZ 5!7MO<7).BVS>9#%?NK)@C>?4@ \$X!YZIT 9UGKMK;ZY#X9
MDBNQ=QVJN)Y@/DR8*A^A-)Q6!4@!G@!8(HH!7OK5E2&!)&PLR.OPH.M#577_9H_M2VEMS2!=JY.A!WP.G_.Q6H/^O%4.C7.H:9KL-NBHRV
M25V^IKLW+&R%2K'DKO!PS7H&G/<CZ9:27<*P7+0HTL2!\$3>5-Y+!+%)C\$WEF19G8KNQC."#U!P.B.6+PX(X9I3%KMI/(HF?9
M&K>2WNUGGC@46T)D(+G 8@=#CZ!#YHL@) M(UC=S)!"64!LGS!ESM!7GBF^#?#;UIK6J^)+Z&."YOPL.M;SS+)+#;IT#LQ M)+,?
F(R<<#M7:44<)>X!N8K/O1X)GF#>6FHREM!B/W#IX"!U!NM+ %M_&?
MB#QA%_W#;+<4HE\$E!N!SLR+U;"E5!Z\$YQTKG>MZ@#@!8NOMOO#)!#WL=M=B\$07;R!NX!GS8DV!SC"D MD\$8/<5F6Q(M/B7FVN0+J20P
V!_O@=<+408<+>90>GT4 H>% M_JR2:QHNJ6>DHD&I1VJ!(!H^KOR*5VE25! 88;P.66YU>*X?ZSKMA.LMO M-TC'=7N_MU-
M= 10!Y!YTFE0!0IGAN!BGCM!)!_U+PMG*#\$84 (8# M!0!>+>W6N>MDFC^?P!M7M+L7@JMK)<1_9!T^HNV.PQ!H&R!608Z*;
M&L!O!GO.2Y9 M0!DJ_P V_ \$!&+34!-OKZYO! 19XKC3!<0!D.5!0 M"-.@ID8Z<*P-2C^WVVOQ_!T!58!>
!P(O)#BU96<+!@!7(QP0"5^!G(C!XKV"LOQ!HD2B M#2T^2ZN+7+!DUNP#HZ_4!@@J_".+T?Q#H^L>,-O=00)X!2@MGL!<:
M33H!=R!9BSKQ)V@!<+<2!C!OVN+P7!0-!FZC)J-SJY+0QQVCE7BE8;
MCA!2"Y<+<U>CY&@Z@D!ZMK!S!Q_2)H(H4W#HS!%8@!CG&><9_Q04>_MZW#^-+&FW6JZ-KL&GO".
<6DC17:X8B%>XV7#.#GCAANR.TZTN+ZS^<F@W^!MZ9/O>>5M&6VMVDCBN/5FCRH(4-9Y)P.M>D44%<7!5EDE^!H;PPS3SR
M2VY2*#J!&_&Q0%I/!X5VE%&9JFNVTZ=:%?SQW4EM(ZHGMI=Y2@A3^H M)"!QWVK!L+2&7Q??>*WFBMGTY^8PLCW+*Q:=L(#_N
#CG.ITKJZ!AE2 M2"IU!@#_!VZ!<!)34+2&YA1F*%>1&.1".Q4!_52SGB?T!FH3!>= MVLKFC(%RT&F3RK/RXP0,DDDY)ZDGN:DH X7
M50^H2OX2!TP65W_V4M0Q!>#5E2&5^D=P^0 RH<=>0&R<8.MZ6^R^*?2C.X M@NFI!OVEJL4#)!>RS.J9(!_#CG!3FNHHH X?L!%-E?
ZTDK6&KR:G=XA M7?ILT45M%U*AW4 #C)!5B!QPH^_!OB&U!>5^>^<C;40#;+80D!FG5 MBY*KN.TG=R<<<15ZU10!!90SV!E##=D5#(?
IQ"@_?A7%?22UEM?MAW)!\$BG!797%Y;R!F!FN1^893^=Y5^38H-4EOX^8GG^P@RRD#"L?HH# MC<^<+!@
!D@FDD^GA;3_L H+>66H\$=367*YQMY R2_?6MSQ9 MW.L!>=7MK)9E!^*R64-P8F\$?G-(Q"H8!P<+!H!H^T)WFF.R+=MKKPMJ
!LM6#*91>12^5.NHP75V.WGG.CDY&FQ2Z*Q!6T.XU2X26^7!5TY3;8!H M@KU&I!/:0^*2\$09.0/Y#DUY=V+T!X!AA86.NZ9)=*G-
M+!AGFC.SLIX3.<\$8YZ5UO_B!_T.2B/_+!MO_C_!"(WO!T.2B/_ON.MV!_G_&)>+>:
/XHT!HW2!ZREKO3W>+>WLW>XD9!E@9U4M%!)@5R/EYZGCGE M^T7@CPM92Z?!"367B@330Q:R!\$!&+X\$O RDD9/7:J&_X1&J_Z/Q'
M_P!HJV_QFC.A\$W_*!O_ WW?>_!F@AXL 920Q&S\$S""XDBM9KHW\$D<#N!0>+!8&82;U_ \$10?^AS!1 M?>M_!9H_X1&J_P^AS!1_HVW_P
9H_R-B)=VFI>M<33!O4-/L)9D0>>SW>M\$D0 200%Q!OYD<^QK%131Z>=V!3W.AZ?70Q!_!Y+>03W:@!2(V7(4="I MZ!A772!"(WO_OY^<_)
QNV^T?!(C>_P#0Y^<^<_P" T.97CF9;C3Q" M_VT-Q*BZU9SL(!=V*1H3N9@!E0>+!60)!7!3NC%_+<GN:1!6YGV?8RPM!U3S M;K-
Q;BXAD+2H84 PS=6.#N<K!H!7>@>C!>J#6XC_H!M0!XSL PB!_P!P! MGXC_!^L_X50!SNN:@FI+X\$N+V03?4H>+>#6+X?
!7!_U_R+!TBW44BC*0#EEV!>07!VK9_X1&J!P^A MSL! HVW_P 9H_X1&J_Z/Q' P!HJV_QFC.A\$W_*!O_ WW?>_!F@AXL 920Q&S\$S""XDBM9KHW\$D<#N!0>+!8&82;U_ \$10?^AS!1 M?>M_!9H_X1&J_P^AS!1_HVW_P
0_%@07M73^\$RW_?>7.4R!SW%L!+O\$RK(%@56^DC!PPQO5!_M (1&J_Z/Q'_!JVW_QFC.A\$W_H<_?>?>M_P#&_GQU(1XP!&2+>#<21VM
MD)+!4#N(D.9+>0<IGC^O!8!BB@A1@QPS@_W) M_P%\$!XK_P"\$10?^AS!1_P#?>M_!9H_X1&J_Z/Q'_ WW?>_!F@AXL 920Q&S\$S""XDBM9KHW\$D<#N!0>+!8&82;U_ \$10?^AS!1 M?>M_!9H_X1&J_P^AS!1_HVW_P
MGC#1FTS4(9#8>780V5HX%!^X(WO.HYVD!>I8#_QAB<4D=TT\$P_-3>QU#!>M64!0.5L^R2!>J@!J!R.L!_<9Z&+NUO M(HW5Z!>+>P8PS-
!L2V:0!H!0!P_F29M(N=5!)_O#>K7L!U!+>O#>?!M>OR2YU0-B!>NB=N_V_2XF3W!8VT_7*SMEG483Z!7U!CKIT!M2T444_#1110 4444
%%%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %9N^>=."T.IRR1+ M=SK!\$PB9EWGL6
P.YY/8XK7KAOB9.MO!X6F9!5/\$-HQ6-"S\$/T Y!A0!J M6!COOH!TE#7D\$^G1^<6!Q9RL!29Q&5W%2H/KBEV/C_P!W!O+<)<3!V!>
M!>F:6W:4-4S:3CYFS@8&3GCKD5BZM;J?B?4/\$K;7/V:09K?J!F4PE2!>+YXR/4 MB@#NK;Q+93ZDVFO?N!^H#4;*7NES^/((
M_/U&5C!C+5!ZP<307+>Y!Z^6 R.D=>#TKG?BAX@A?P!J+V.E!GCF2)+RV+!M Y@E564L!&1!Y23!N>_YX!>J).WO@M9EMKP0?V)+>?5MG.2R-
*C_!>).K!O)!SQT!>!DC2!>#<8=>8WT5_!EO?PK(9X5F4.A#! M6&0".H//2@#SKPIXOL= TG63JMQ?RQ0Z!>0M<DDZP!YNU!DYVCH.3FN!O= M;MK!6S5)!FL?G>J!O8!YON/8#0.0)P<9P!PEFMKR7X5>-K=-U!5=ZE M>+>P&RE#R+)>N0!NV)!?MWKHM-SH_C^!U6YMKQ!+U?
3K=8!EMY&#D608W-M4#M_&Y/XT.'1K!5EFFLKJ<6Z210L=LA;#<=<4!CYL8!6KH! M0V!13?_!D3K?1_P+LV!BBU>*!H!B<+OY3@>K M-
YH!>=J_70Q%#B.(KEH!)(XH!YAC.!)<0>0-Q<=<4C;2^X^T_#13 MJSO< 94N3;3LMVW6VX+LD7!HR0>_!ZBN=14Z?>X?USP !G!D76LZ!V4FG
MW4=O&9)8LE&64(.6R4YK;M=#TGO#X2U6RBT!L!L4#AE@=\$4KL1CS67J#G&_M!_#0!T\$VJP07UO:2!LD!3S!BORHJ8W%CGC&Y?
SJA_XNTM!VOMG!A(U_SV4 MTL6.XP.X4.N.0#C(Z9K6_&TK7M;^!H!PGV?6KC3Y_+0L2!BLGFTWL2V> MXVU3!3VM^FF65!X^O+76K
IYLMQ:8@9#(D!X.0#C.DY!ISO!TUEX!T+4_ M473!J!MYS=R69S?2J2HNXAB!O?&<9P?2NFKAO 3R6K>+7GLK!S'-N+J(2 MVLB&6(!@#N+ N
W9VG+5TGA!782\$6E+2PVMY:98HJO>PF*6.CLR^X(!B?_NS M3-JOC6?#C6-U%9P0_OAE2Q?>2V0!_CUI^=W^Q2^8@%WYA?7;D#9SF@#T
MC40%<EZ7)?+9Y\$TY5^DAB+K;!AD;L<I.><#DU5O%_D^_M.T."RGEBN!5 M!DW*+E64;0-O/(<)/TZ!XY#Q+>
=ET65?EMF!<_TM2_X0P<2!<M_!9XV!>@ "DU.@DN?>Q_X^U!+U(V_ID2Y::!RR2GR!QC^!3RV!ZXH!M7Q1-8P>#>J224Y!FWL!L!<^2-
!AO.C3+>#!"!CUK?#WB!M/T7PK!HOV!74;V MSA;H9W@#EB!8G;!@<H!X)K>+!>AW!Z!#%!/+-831!Q0Q_(!NR\$!5!4BN
M!UDSGPW!HTT_49)+2_L!KA\$!L2842!E5!><9X_<8KE>+LYTHQ!X!TNWU5!7!0!N!ND=>D&Y MW90+DM:P2!T@>0912Q)YC:S9)
&ZJD_CW0;_H MW4Y!Y!XK&86!U&UN_F02\$@_H'.1AONG/6LCXAPWEMJ_A!7(!GU;3!%YX! MVUMDW!R!9%4!15_BVE?U_&L?Q3!;W_P
=>D!T7PO>V.W!VX5!8L+BY*R2S(H M+!>H!X+8!<V0%N+>#Q=16HZY)!8N8KM83<(+BW>)9HP<%T+>AGO^2H!Q!H M!
!>#!XAU^Y2RN6B!BN&4\$D?#H"IG<<<9K#UJ2X?E!>?6EA!>I=TF!V M@C!Q!A16;A<3!UZ=ZY=)!HRM?2!EYH^H^M"ZL!3!KZ(6.D45L?
+D&R_<#_#0 M_P!X^!V30!W-S!>= MEU!C!OD&G2F!ANQE=R< \$LWR!>+IZX_XIU_XR2W M3Z!5K9SW\$!0R7 N8URK!@>+SD>4D!
/TYFV6X_E_\$E3!>H!KY69K96L MI09@UNJ#9!OS2"/Y4D^VFROOAO?R:J+0VNF56EP\$M)!4K1!^*XRN2K# M)XXZXYH!^U&I-
CH!T(D3&4&A&N2;!!A9S!>X!>5ZKVL8V MBOT2-Q!ADSN&S)>ZFUFU.SC!D!WW30M\$S\$S!G M#\$X4G(ZUF6T<15W!>
FEZPL>H6436!AFMY9E_P!<#3DDECIWJ_X&#B616Y! MA^X<1#3!L!MG>V3W.8LI2T^QQ.CEQMXP2.M!>WBEFLP+M6CN!DLY5+F6"\$
MNL+!\$!<K8YSAE!P""<5HZC>C3M-N+PPRSB&OY40!9L#H!5Y!XEM+@;GJN MI^%U2OU!940VYMWD M-4 50-P(V=#M+9!7;

<A>A7T8Z5JH:~& / 61I:7J:~#TGE:A:R6KK)AHS&S MJA&7V9S\H/7C:~CLK.TDU\XEMX@(@@FCL8)=^Q&66-H.D:4/@!@0H7IEL# MH:
AU#5K23L>IUDN:DL(8(5RIH1ECS@_8R21UJ^I#Q9IKVUE*~N&FQ9 M9B:>UHKHJQE@XVG&-NTY)P/S%9WC.OL-
1NM=@O(M3AE02RVVJ>KEI-OM) M4^8>O!VUS>I>C>+P^K=G>RVYN:M)=2LH\I0R XB)15+0^8"2Q\X! M9-^1 UX\I+PG^U
M)=3M2)=+VMMATBD&WY,^W20!D#_1D&O\IM_U\A^5&E^H^IB==>w1PR
M1.SR0^="^5:GS#M5CP3TYZUU>K73ZCXI\$ZC18:CIEC6\K092CR@185- R_M+DCOC^?% ^1Q38?: BQW4D)NOL8N4A+1>=NV%&4\|H&>*UM
:02%Q3.H>OP7.%FD.TEK(120!+~N.G7M6EK_I M#1!#N13.VFG%M^TIAB W-@9QZ^N6T00K03O^V16<PZ%<FKL\QW^W(4QZ,
MRB3^V^U^T B&WEN.#JVT^%YI...\$^5F\$%^G0!P.NZ.^I^AIP^KTSW5DT^J6 M9N\$5G5)%>NPV@_N<8R>=^/I3_%VDZC-.8\$DUJ^F
I=QWD+0M&A18.0PIVD M G/M7!//=>#OA! FE.L\O\I^12K6\$H,8BB^NQS&W:T\$9\H1U)XETK4=9!M>-+PM+I7O-
&@AMY7MW2^5&=B@=XC(<\$_.R\$^ SG^J^7(> M&+S3M^KW3\1M=QEF0:3RUMB5PPC=00\$G^7L\F@#
MSCPM822W>+K.XU75@+74WMK5UU<~&I?+4C\$1X)SSFNLU^Q/8:/#^"Y P^XFCU^I@TUG>P+=JTI#3VLD2R1\5 M7<"R@^D&L:NA^*=?
T_7O^M_JMMJ5VUW3T^F=F)=5!B18,8YXQZ^@~#L2 M6:~#IET+!6:XEE:S-!@M\9Y\BXY0@8\IV>X.),4Q_~^B":!@B74+B>SBC
MFEAL96<^XU\^VC R3ZT% MVC^HUQQ4VE\^Q\67K226EHLU+Q2!D97RRF>1=..170GAB+K;^P
MR^>G.:D@V^PR^8H6Z\PG;MSC;SFKWB:X MOI7C\::~^CZJLTEJPT^_UM72.Y7R?J8!@ WMGC8QX "DYH Z_4/%_V7Q?H^MBP64IT-I)
<&X1=RLJ@8^"1>|>|L=>SM%OP^CU+Q+VD^VCEXY&6(^7&4R5\+B^ M>E4K_1=1U^~XE::6UW\J\$D+VBDT#O).%B0\$S Y^E2QJ!
JM^>F\$WUG M.A.+IY2UFUQ^8UN^ID2>AQSM.#CM5^X^X^F@P1ZA) HBZ^*8KOR1&5C# M@!BS;^J@^J>N^C.^RM62?
QCLX4C@L1NUN\+X\+Z^12UN\^V81^VYFIEN&M5^E^*#MU1=GR_~E1Q^~#^TR>^YMXKB M\Q)^%@="7HRD9\X5Q7A6_F
<3ZMJMQ=7^:7!>O9V^M:S~\$&6/_5RA!8L3P M^"~#IGFM_P(IAX.T6.2*6^2.RAG>..HV5E0@JP!^(TM)/#IHJ>ZL^C^1%)^KF
M+ 9MN_S\DIQX.M3DINPJ>W\3Z?J=OIJW-KTM+RV:QOAQ7373Q^N1!@58V1C.X#+!%BHP+G10!>G^/AZ^WO+@M?M#97#6
M1T26.I\$&E.F4<1^N^C.*W.O6:6IX8\$MS\&98X&J.F.8OEY^Y\SV MYK5A8:I_00&M_LU^SKZ_07M8C92AIE>50I_00\K553KN\I/^*,/4IS3
M-3FTW4^&M59(+2H\:(ME^C W^M^NSG^6^EH^JZ:WPX\37.M:AJR:8-N4 M6>_YC<1QB5?+&IEUZ?CK@UV.H>^GL?
&FE^X\^XD2YM)WG^YI^40_8.^H.1@^D<=<=:ZK6H M82B^X6U9;" FM&LKF M#;NQ1W\I^J^IGIY:XY00\JZ)J&B17QB6Z@OKS1Q MIPWIV)
I=X_LRQH566_D)8A0IG/7IS0J\$ _\$70(I=(O^E_T^1 M^F.WY=C^3!@_LSC:V@J@^N^C.M^U:GQ#9021HPK=RRP?:I^OIV^K_P#0 MIAU/8^%<%"ER?
?2Q4A.L_4\I)??7FUAJ109P^HHO>PMH3I\$+K M^C:Q9Z1^_3MK24F3@AH9\$VD_@H#M8PQ8=2TZYO8L8+I)9HRRE2
M589&0>G\K&^C31S+@/::Y^N_L_V(R87GR5V\OI^X\$9QC(QFK7A>74YO^VFR M:S L&HF^?C5=H5OIV^G.O+J^4-3T/2KBZT76(M0LM?
@N+NUBLI\$@M8Q.2? M+10)QSN_9LDDDD B@#TVI\5:28R7:M^=2QV;K%6^GV4IY=RK#;01M)+(W15_R2^PKSGQ\W(OH1U7PTFJ6&NM^BR6;VS
MR6FI^O!@P<~&I^/K7=>8AX6OE#&6W=^CJ_X%11^*1^4H-/D6Z@N+D\K19-MH2GVE5&6V>X&M^&OVK@:KPIK-
SI^L>I^#O^~ZT^XTF3\N10LCXDVY^I^*R M^S^R@C1SMP.GUVU^OY82ZU>6+OX)O~#U6UR9LNTV);C#>7(WW\HMF)^P^M-
OP=XHD\4VEY@1MN^02-W)OJTJXNUR.V13^&M^6WN6MKV MXE-SY29\U\$A9@^YY&H(I^Z9IGPX.H\ZQIES8WD\$6JW6\DC97E)4JO&
M&R#GC\OC(RGBQYX P^H\Z6EL#.#37+7\$1-K)(L0> H\+^I)(H.OV5UHOA: M^YL+=I4O1\$3=2QX:X.T1^00J_")S\50=/:G+^V=S#
I^H:"I&C.T^PVC_4/M=^YJ+0K10M\^VDUC=O)K\7I7A)NMH8G\T@_4!_0Q7N30\U4/Q^@OI?TB_MPL=OV(OH)IS+I)
48>6VPKM_#D>22_KGC(T^Q3>+^1KOB^I3.C=06YKORJ2 MW)@B\IY8\4\4JCCI6KXA_IH2_#>I28KR>T^QW5L19>+I DG&J&P/EIP
M>3>@>IK%>2X.@?\$J.Z?J>^GN6M4-E^*#&MU12@VY8\$EQW%KH7C31H.O^O\4KY MI> VS)DF^XP?&S:<IG/>@#N+S7I2U&
(DGO\$S(N^EY^A\$1SAN.OPQ<#J<_M.#7*>)=8MJ4E)^ZKI^*^H>:O&@^*5U25#^(2&7\I5^49!%846FS>=>MXM
M7T2\UK39\+M+5+JRMVQ^:"!A4\OK9R#_1^OIZW:K\;^TL-N^W@UE\I MI6VM&I^5D&YP@4DL^1V)/IF@#L+_O-86\$UU\$5N+AK-
I)=_9H3Y^D91^M^?T9...<8I7O=L=OHH:RR3)JYQ930QEHY#C-W0<<1U@Z^:CPUXD\4V^IV MMW)!?
WGV^TN(K=Y5E5D53^H&7:1@XR#Q67^X.U.R^~GIR^5UO3^=1M\$^S M&.99&E6.8Z\I\$Z@;_5P3P<@^D5>L+V
M/4:"\$A218IE#H)G^VM@I#CWZUYUJ^A_6CKFEZW\ZW.MHJCK\$88GR(7&Y2^V M;H5SW)I2L^?Q\^V7B:STIK&^#W.)>Y2#_1E(#^87\A2<>E
/S1110_444 M4^%#1110_444 %%%>1110_444 %%%>1110_444 %%%>1110_444 %%%>1110_5A>C_#A\0MH~H-L-
O(IY\&W2)G:~#G^D\#JW-ZY MKQ=XFG\2\$@T^Y_4-0AM-ZE<(&D%&0%_7G0UGO^X:UGPHJW.M_P#8+HIA
M^SFW#HXF\$FT^W\N&!!!@#M^PI3\4V>F27J29KNZ^P1^6I^L@?R%O&02 M^20"<^"=>VP<@^UH_6BN\^)&NZOIEJEQHA)&D-%I.HHO62#?
M\O\O&H\$1 MZ\^U\+;_#7*+1 P^G^U\>3HCVIMWYP3ZA&9_M0\3YJC&3IN=N P\#8(S\JVGCIHW4C8P17Y=;QI^1S:~BD50QWDCQ01T)
M\^VYH Z66)9HC&Q8>NBT^_PUB^5:22PVHS.5;"O3(X\3I@D MG01^_3098,NHS>9:BZ117(MFE)^%1VT^?ZXH ZNB174_\$IGI@O6;
M\O@S^@M6G>+M.N>8>T<1W<4\RVTLT2^X5<O+8J<9HP< MC(H W6&5(R1D=13(8(I>+I(Q+A)^=I9U2Y.E=7AL(+W8 M^?>
<5VCG=JY2N2N.CK5O3O\$MKJ>K:HD-O)=::M^T)*JKIX\$KMYI\I)Z> M\&S1573_Y3T^"JCBECCEFA.BR@!MIZ^)ZCFJ_B^6S@I.ZC)JN!9BW?
SS;MAC(\$V6)7R^CNE.E&E17^I^+>#T72#L0^WF#4>;6.87E9E\O\+V&WCN&FQD\$Q:W41CDC)&5^H1R#00\LT5P7Q#J\$X0\$5W>
M0^YU>.WG6^ZDB\$D95B5(5%#R17>((H11^V: JHK(G)OYIMLECM)=OJ42FVD4^&5-H8MR0^_EBIRU(C M>=6\HGX2^*%>DOX3<-<
\$)9W\$L3+^*O\HX#>Y\I00\ZY17...K5O1_AWP_M\O\9IR\I\MO\O^&27\$8+^D@_ =22IR_!AT74M3E-RBZ8Q2\MS_3_MP&<H5QCD-G:1WH
Z.BN>1QQG MIS6\HIW)<_&58VBO:91H\+^I_EI295.TIU1)2@_8AB H&O#N(Y^6@#HKA^%NNY>N_# M^O+&

```
(#R,01D$=&9VDD M,HNI4|MYY$<@///HUT.C07-G10-0U:~JL&GW>DO*DLRF1RRNY_YBVXY'
M+=~.IV0TQ$%~^VAZ0=>O_HM|JW.ML&(W*%G*123&WGWZ=:/_7T)%432%68 M*~*N2?HJ8Z7X'UM9;355:5TBNHR@9A<&51D$ M_#1>:
.TG1598U!0$:ZT^ZE@:X@~U~L R+HJ.59N5ZD!OVH10V%50229_~MCT%~0M;711&25 NI@~*Q8$G!
(H|N#CA\77VX'XP',2;ZUAFR:#;ZH^DSI(VI:5>)(WD6S% M<$(2,9Z4 715-# +MM3:RU9=,FD,~WK6G|FW8.4>/'(I9ZC.#06H?B
M>VTVU,UDL|R16P0=-M;JK>2~'W.YADI?FPN3@CCGD91X1.I/K?P3,Pl.V%R|W> M<@01NT1|H|KA|R&3|H~|G&=V5X'(f^=.N/#/BW58|PA-
X@TW4GCFM;JWMXY M|W$~HT/G_VJ.D#D M@D_0XP_4?>Z9X>O|&L9|FWU;48|0NVU&C.YMZ68?AC+Z+!>F<~\BUCPI
MXSM>=MO#~U1Y15WJ64HG|B*SV.HLNU<@%?FX'Y!~OO>FJWVE>~2&CW M.ZTUN~ELX0!)HXK0@~'WS D+&>IQF@#=#O_%M08F_
TZ_N3R*S7@MUC8 MP|EW$%P6~?ESI.WFD2.(RNP1%7=>)M-FU~|OM3TNRUG2?SD<2 M~UN+~.LEY\@81S_9C(#$J2W OP2*Z|6M-O-
9)&7^F?%?27E@|~#-N=BR.A|Q MWQD_E0|QG6|6X|4.P>=<6UG2L3Z|&~'L^Q2H6ST#~N1@CV+ (9D;=A@1SGH.A3Z.T5GRS*SB)|&R|*FVM@
Y.#Q6:0Q?T* M6W26XMS=W$..L.Z6SPV|_AE|~*W<~.I&.3FN.'U*PO_A8_PH77@|:SI=|86| M#1V."2M92O:AM5&Q|A#>=,E7-
3LK<T~L.EOH$EE|7|MS|_VL&5MHVC=1NV M*2|N1)89^YQSUZD_U80B%931ZD|:K|O=-<^ZLA+YR*5W|_O;=f(^~)|^M;~MQ-87>G;=>6(EOJ?2
FVL40=TP~3|Q &1G|) ZD5SVFQ7-OXT;7DMC@~"W-MNXK86|GV= R|3'SRL%X|&CZ|N~Y^UT75|+|>"M2E-3;HFEVLMEL.FO~*#@<
MJ02*W$%!T?P|K@ |&L &~E7FG7-T|BEMKK|%-2(6:6? CP"0221@~D=|X M|KG|&Z:X^~LH>TN|1AH|+17#
@GSUPRI69<8&~#VYJMK&GWUS|G.UHOA4V/ MV#54(KXZ;(XXKBYC565B54I0V^52<|>IQ5W3L_40BE#K7|AZE;Z>^BFVAVY
MC5^K<^P1NR.>.OMC|H Z3Q#XFL?#_5G|?QW+=)~W*6L9@A+X=S@9OT'Z^@~ M5+/Q6:7ESJ=H-
^U&~|T^~30:3Q*CR1^_3+8(X/4@~^U40B%W-U;Z$EK-7-R.MT.LVMS*(8B~R^~LQQZ#MU|H'M+JX^*5_+=1+7^VD^A+9|<-"P0RB1V^YQZ;
M>G;K0|P#~;Z;~3H6?|WO&M~GB@MW~|+CR~|QNR_~HSTK*T6W10BCR#M9@9I&BDL|(E3(W&1+G^/X5S0@~VW@CP?
H~^+F+G14M&N|R|B)CN^~=-MPQSG@>~ZD0EN+2XD>~)0FLQ+2>U04AE-NQ$C1A|X&|SC6K1#~|O^UUM(^9>0>|7:3 MQ9-W'B1-
$FT^~M|H&GMI;F-52X12 VW#%@1D<~?;@#H^0|D|*~|P^)&MPZ MOX"EN+2QN9;/|9 L+HC)$Z L|NW;3@|f#CG/HPOA$DS0?
9G$8F+AJFW;OP#NXP2#5FY31QW M=-Y.VFGWE-/8QJTEML$6&X|S#<~<#&|O~*#WN M+^T0~2@~A-
0E1<^$D?7^8~@~|L@~|D#5KZGK;M M?~2%87.H;W-Q|W7889~ MG366 ME3|+U~2HMB~P9|U+P_&~>~|HKG+{QA;YGB)M"CTS4|f^~Q;_(U@C
M4K*FX+P08~=.0?#|&K%)^~2 M2|0|T>1G>BO/M&F.WOHU4Q8SV;C18=Z2E3O/FMP*P@C&|^&U;C/Q>^~^MY-%BM+|H@:AJ5|H@=|!M|)!
|R2%(|>M_49&<~Z^X%~X~^+>|3PZ9>7$ MVA|VAM8-P=KYR2P0<~#IV~.UTLAXPT4M2T4H2=~|I9DMFH8|REUW;MP03@~:K9;
<~=<|C|(T%08VA>+)+379|0M8XIK;JT^4175M-MW1DC*G3D@JPY!~ MKE%UK|+14 T-Q@QW0O3+6+79~"FX?08|H(S0;Z#13|)(X(6DD94CC4LSXX
M@=-37.CQM8+=Z5^;W=O;ZJP2RNI FR1R;H 8LI8=CR3P| M_16.C03T$4 P|DO&T^6~1.61|KL|>4@|NW;=X^YQJ|N:LWWBN&UEU)( M-
/O+U=^K=M;|W9*A|89@3A6|) |H|^T%8&J>~*|35U!TLK|BTT9O'M M|G|KY0Y&&8%B%(8@9X(|5K;??VVT;=7|G*);YC66*0?
Q^PR#019HR*FKG M$|Q5;ZHD|(<O^L=0EAD@O|L;~52W.G7 M|EC#JHFD|S#&#~|J9|D|Y8|AR/NAL=Z|5?|O.M8&|Y^>PNI^UBLKN|ET^V
M^U=B (~C;K|HEW$A&|GVXKG?2-S;KJGP~U>T);ZU%BINW*6|O%C? (M0.L;2.DD_J0~%~%ZMI;v|C+R;H;_Y|HN"0V|ZLKJSU^R
<0PS;~H|0>=C*Q|H|H|IS0|NT5Q;Q.T MZ;2K35|H6|K|I|Q|F>Z>) D#^88QO^~|;NH8#|/6%6X%|~%1A0|0T(Z7+6 MTM|Y|KH2V|F&|C=D#Y<
#)ZY^2@~#P<|^*Y^3_%7AWPYX^U36;2|0AT^UUM M^9+^F-3SC)AVP7;IN/K^~%MMXN@N-2;H-U^VN6MVN;8SHBK=(L.SYL@~MCA@|YH
Z&BN3C-3AX.C|3_K|W+3^0Z|8;C.SO)R10QC?Z$|OZGK@TH MY8K.ZO6L(O)=~W?^NP1NO|S#+~2FP;L~HR;M&(M T>T|7:L;??Q?8;O|27
9Y|@~+H+X VX|H|VW- M1P1P|*5C7&X|F))|23R;YVTH;VMSK&FYZ8|VH6PU;|L_XGCS5YBJV4?7- MN| YY|QOQK;
(HU&YTGPM|JEL00)|/RR)LV_(0A(8|B-1|GVH UL@D@~$9 M^44M>~+~^CU*_AM|_%XCI^>5=TN'RP)!6|(>~.ZPZW;
```

```

M:K6K61^):2=9K>U69S(%\N2-R0,$3U4$")@#M+7BR1K)H"LCM.MB7=F5:/(<S<@&O9Y&*1LRHSD D*N.MJ#"/YT+D+@9&3T%+7END2Z?
KEOXAUX MQ18S1QZ7K<R7SR*K6RP1QJ HV\@#H.\Y4FNS7Q7:QZ18Y&H6-YIFH_9' MN FV5@.EJOVMCG#8SVYXH WZ*Y.RI?
6=-J0097.Q@'EVF*H:<M?<(-+*6XT0-E>I9ZK(8^9%N1L&KP#N4, 2H(2?.@#I:YK*24O'.G:7.2.A:W+5.1)H'P3M11D6GCKP*)ZCG@CN8C%*I-
OO+D@>$AQU\MWK\I0&M=M:~CH+ME+87EL+16S5W5FH0B5%("DCY6)*893@'XQK63)3M.CTVZU(51J V&RNGM;R?MR4Q:E6'DMAV2,G^')
Z@4=N % '100>AK*O=8B2\3K>UFO\GR.DA M@*#9&20'Q9@N(8 9YP>PS7_ "(HW@AS&CHAU"IVK(.H\YL ^')=T5@ZIX MJM\ _M
QV=U>C3D#W9MJG1KY=V\F8.FVD.@9X(HD'N<4')#?MX\G6UW\> MJ7J2.5V\A/*=A&0S 10H(\XZ\H_0-R\=VX:277%+7EOLK:30'MEX?MHN
M\DNK2Z0L:HVC:5S&I8*7VA5:8:1CE@'K6ZGB\1\0A:9.6EZA.?:.9J MM7$BP _M:IS:V56.TX\QX X%':45A:CMXMK\+;+>U=00-C")
IK\+L\EJ06' MWF&6*@G:G&49R:SQE<XG\Y>G66L^GZM:RW0F4HM&D54! "1LG&12-W9#<%"RIF+951W\>-%% % 11 M110 4444 %%% % 11110
4444 %%% % 11110 4444 %%% % 11110 4444 %%% % M% 11110 4444 %%% % 11110 4444 %%% % 11110 4444 %%% % 11110 4444 M %%% %
17) ^1=8B0_-@QV51=Z69W_M@+!@L^G\L D@f=WWL$'ZXR#UE%_ MC5 H.M\H(AXYTF#PY=12ZC)'W%G*L'L'L7&0V.C8V>V>YKK-
+918W>T^ EXIE0@0/7?A\3I7-WCXH\PM_X0Z3PU=R:AHV4123 MPO'Y$(P1L7C5F1D) 1L97V."1^HU% '$=:X:Of# MOH915_X1ZZD35
N<EW@HRXJ'0LF?4+2Z3:AX87!>(WEL\FZT_59EO@!>W7 M>5DV16C<=5Z#1/RXZD5VU%_ 'E3^M3T?PAX4F%*YN:27812NTMP&6%/_=V
M&>AV\@.N#MBMS&L^1/%VOK_ &+=ZA8ZO.EU;7-NR?NW\49)-S#:#M&#SQ^ M5=10:R?PTL+12_AH-AJ5G+:75O&4>_0J3\XD'@GU[X\M7'?^
1#Q'KFB>+1 M-NH\OKN!>5\+D5T^LMN:S-W.G\SP3D10:IZY10\PMFE_)38-7ETf\@L_M\^"RL\H#MEW?M.TG<=LC%#HH
X72\JE\H3H.ET.^1^1^1XJ=9+@Q@JXE=L.N8D\Z# M/_\^C#E?7%MH-U8V4U_9^LP7NOHH_XJRCO?%G MWVK3.9>0VA_
L_#&@7R^VO+G2+^1> MYTNX"@S0SNQW'G*E@+!^U^M^RT4 8/ADM_#<P#"/1HD4FT)'Z1K_&Y9PA(C MYX&126LQ5!22?7PCJ-
0HEY<6FF_$.S=2Q("$\V(*N.D9YZXZ5W5%_ 'ZG M)=^(K>1T6&RNK2VN:&_>2IN(HH#.N0549SGYBQ.X/?>N=1&H4<=C161^!HK
M2_L@J3.ELA.#1.#>C'YBS8Z8X)Y>C44>+E9^>=5T_.M0\A\K5KE$5S_.M)00Q&1)9!@6XW=-
F1#H2Q)K\2Z1>C>7VHZ031ZXF0HM>61#RIH15(6?M1E02RG'>E>C4>878=5T'QAK\N_1ZZ_8ZL.MU.W5NL3-(4561_ (P
MN5R#G\11>C?&1.GP1R0PP.$&Z*?A_NK\IGC)*LT4>_Z=HJY_:WIFIZ) M8:CHSRREJ8TYN;1D*DLRKDC>6VXV<1@1UOVKU*B@#CM#M;
MR'XE>)IR60N(\AM5@G9_?YC5PPI?XAC\6H^UEK-OKO@_O-HJBVHG3&FBN M_)&")Q%*J@LF>"5*%X1UVW%_!>1>1/7_
1/H5CJ501VMSIV16^H6VG7$BB6 M81DIE8@E5#)_ SQ@9/!N+*26_VB_1CNK>TTBUN2?CVO)*)%78%ZG:-8 MDL.D8SSCLJ*
@AHV1_17711/0\I3^1@L^P9V_$.SG.N1> 7BNHABOJ3 MXI7^H_V7=RV&H:9I&M@P&V)D9RP<$&@X8<_!<K10\Y#>=Z/K.WP15.6FCWQ
MVZ_U6>>W@*%HWG#ALYP/E!SS75:E#>77Q(\_C%871LK.TN4FF.> C2_H(\MZ_PG/'%>110\XY=Z3XAB^&_I>$X?#Uf=P.AYD#R'IC!
MR>U:MS9:GHGC75+R2P>VN:9K#1SQ0&L+S6LHC5&1PYQM^4'(\UZ=1015TV
M.2+3H$DMH:9PN3\#IRB/>T>N.F>1>+W.FZK+HQO&72_#S=6E.1WQO7J5%_ 'G1Y:7\NK^&_A_O#1XD_Y^f_1-3N@.8SSS\WIGCFNf7 M)--
X\UBVMK>6XN+BSFABR7)9V0@>WY\4UM44>>=:GINJ2_?_P)_H=U+2+_M+=6.1S9@ 2D1+M<+DX)YXYQ5NQ35\015UF_1+V&Q_N-
)ABC9BA8.K=14> M3NZ#...Xf=Y10\Y(CZPGPBO:3Z?=ZEJEQ>6IN%PK(9$=_ MD9 SMP1U%:NHV=1XO/A@3Z=<6$NG:A%J%Z9E
$;1JWM3GYIS_1D8\RDWEQ%XULNTN;-50Y1+>61\HWB5_PYX.03@X-X)OO%#KI>G^_M_1\36T^GHEOJ#2G=XDP_R8.XL5'3!_3Z5WM%
'E?A_3-3T'6X\7W@N\M4L7_K6>K\@C13N6!E+?_NXY-)OP.YI'UXZDGAS4\H2-13N@_M_V57QM.F\MEZ!=77BM*B@#RVSM-
3D15>$M9'A0546WAN8;Z.Z=&F+NB?2.WS9V.AL+?_&M%1Q8_1>7X9>_&_&D7@OM1U&ZFMH"@R2ZR.E93V\I.XUUB2.PC_&F.M.MS!
<0K$TD$FO49' MPC"_*#G\^VEXCL\H0^&+27VV-1JHNEM$S:H8W7_Z9P6'0=B<#17=T4_M<7>0WC_15TW45T^f.PBTR6W>X$?
RB1W1@/7H07&*P=*PTW40#H>Z>^"TU_M9'O)9K+4U6(HT@H>_>144>=0CQ\X1L:ZS)%H5SK&EZP_M4\4EFR*8)50(RN'8841\@YX
HfFOV^L)XO(ZO_9TDLC5C0^P_9L=MSM1*_H_033M'G6'fF+&W:DOJ1\X&19.1WQ
MFE15_A_PCMU1_M01L3WL5G>1J^(\N2H6VD'TW#001U5%&% 11110 4C_M%&6%1^>>1HXUN\F"GC>Q/+>=,*/0 M\@IZ*YHZ?H7@Z?
6$)=_73WM8S\SH^5#&7.47H.L^@ZGW)YV4FTU33K+5=/_MDL1J1*6DK2*ZF3&?+?W7(Z#D'!&?O M(E**BAF-
8WUK2_.32N'SU=3\AOG*9&_&1%<1ERO3\ MYI*_HCRQONB/(BO(2$4L 6_>1>0%<5A0YP-7_1X6U2Z&D7#1785X@54*&M+_OFX/
7)XYQD51U2T_6_&WPYURQ'O'=H&Z:7;ABAMR<'Z'MV_/_0UEC= MW1@Z'Y*DC(SZ<4^N_L-
TPS5KPOXFL_>D&_LUO>/RYGMYHGQCD0X9<@D'100>010\455 MMOXHDN\&NK;"_>9+RQ@2XCWS
"Y1B0'G'3(\>AXIZATOG'K\AJQ>ULEW7_MEUF6V>4.U8.5_.1D-2Q'H"_.E26.1G5)$9HSM<*P4XS@^G1%#RQOE1(Z MKO:_NXXR?0>1
<^PD-MIUMX\YO\T.O:GIC)=>XJ7\0XBWIR5)XV\WSVR_R M\>OJIS^'FKWUNO6U'YBYP\D@>W=CC@8R>W08Y_1%#8.@>?18U/5_-N-
M/L+ 3FCV\X5U*2 E&*#2<CL17-?%RM+FY&M#OR_B*UA8N@9)4 M^JD@>=/*0Z%>B)&L<@>B*J_C'XRI(46E6D4?ZP1+EN?
LWVA+A#(1 M+_0YCZ\^">E6VJWOTZ>331*F6&fF+&W:28U(^<_ MG(\XS5RH2F+6+C21'R_f=6UHMW+&A)A&Q1BP4(#1YOE/7
&1SS0\OT55%SCS MMXV1B^&KQ:6.ZE@GN5AV\P2J9;JY?_812.C.GX'f6M\W_9:12R MB0892'5(\001^4%&F5\02Q
fFE!!&1R^1)SXCOCXF3W^J(MO;ZJ#_-9 M6THW1Q"?'X4\F\^><#PB><@>BCE16BVLKH_B&VFWV8\N^>C:BZKT4_MIP0.">>M'?
QORJ6C=7)4E3G'44&6.3$)RY14\W#&0'>>G(\_O)'MBO\X1#66C>#23;1Z&E=K<7=OLV6Z>?P&S\N8#C) P/5%="MCL+>1MD1C
M<>&Y+Q@?O\Y>TY\4=U'+&_1^TNPTRT:S-6D>6SLD(4+N!E?GHJ+D MGOC\X%_4T5RS>-H8:77N=/N$U#180/N:1&4EXH821L2 RD
^A&_92V MO#?B2:Q'QG'1KRSM7MX:B'XF'19@XR0\QOI@9&#W
```

[illegible]

Y&5\$J?ESTR"0#OJUT.N:DI&FFYAL9KV9IS\$BCAA:R6= M@H)(VJ,Y)P<4.5%<Y.#:HK#UOQ\$NE:HFF(MD#7>H^9Y/VF?R8SL"Y& t;Q<+<#;/IS4F729(K&#>MK>OU^I\XBWNKLI1QH ML3J2QDV\@Y7&6YW>@)MR Z>BO~9^(&H77A*XN]*M8(+NWU.+3fK=,74f!%7= M^X7J#P\$AN:<1\$BQ1XFG-NK31QI-CE\$RELIM*HJ1+V/F2F3QV\&\$5"14\$X&Q)HR#GMZG~H: XPFTIM(GU72Q:V&JRH#.#EOYC12,,HLJH0%STR"P\XJZ .KJ"IO+ M6PMGN;RYAMH\$&7EF<(J_4G@5R<7C/5;SOJf.DV^AF2=M/O(K>XE:11%1%)W" M3R@59 R+1+K68+4M^<(ACD\I,3+M^E1@<H+M@!# \$\$\$\$D\$5%=WEM86\$V-YH:OU MHE ,/1+93+Y131C=37-I)<12&X6?E*^@I^ ^KR?O&K/A M3Q&WB73;F.:R.NI.fELfW.GF)(SSAL#<.0)PX##@C(HBNA76-9D^M^AT.PVK:~NE?~IF8%@TH4LPVD\$C.0)Z8Y MYP.5f.1.) (GPKX,U"1715fHEMK%T+E.SUC*(UP5RB8.f&1D^19H1.HKEfE) N906&H7MA. 89+JRB625+N^%ON+ D(GRMEfH/8?;0)QK>+1.@1:~#9ZO:1RQ M174>1S+M=6*H!J"***+ .6H64THBB0+>20f66523^&L.UY_X/MX4^*?Q D6 M) XEL@&"C(SfD F:ZO7f=M?#fE%)/=+>7D""SMG&6/)f)1>~* ~M6BN-MQ^1?3;7f6GfR .DN4f\$8\$OS@1%2. 4U:L0LOLK>)ET+4; M""WN1+ WR&"Y.V "R."BE6^8\$=0>~.HHKE=#f7RZY:6.f165O_&3=HfFY MCNfH6^U2V)5V^*~.1.#D929f1+1K5fH(D6&VEL=4F2&H+P23PEQfC21fE MA9.X12f1fJHY))04Z.2~1)8G5XW4.Kf MAHBLQO=16fA? 5+J>P6_@AM9))~9R)4"DL#GCH#6%+XQ;3X?"EO9Z"TD>M M0#R8X9F18.0fP@+R L@G@8_*@#LZ^YfPUXDFUfU;L3f3OL&H:9.L<12S>: MA#1&1E,R"#Z"NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MB@-KEO^D:CJEEf\$NEP1W#OIVJP7O>@01^8J9f_8f_~E=310fP\$FG^,=# Mf7WVK:3HAF#EK"1f=6LEV8C;3H@3Y? Z5KD_CPMfJOACXAT^!ST7 M41-109fHfA-@627fRV>PXZ=BF@)M0UC6O.TVUN+6 L1#8RW#R Mf_9YfJZfI #DEB3N7KP">.(H?#_B6WM? =TNFVSW6AQ/W#N;L 8: 1fJVWU M&2 #^>D57O;^STV 3WUU#;0EU0/X1=S^&3W)H X;3~19^%18U&RTZRTf M4=^OKN2f(GFNC\$SUHTC;G5EVDNH) /'Nf,=(FH.S#XH@TR:QAEfUf7=1N68" M0RCfV8^RfHGU(#=1HC179PBAVON8#DXZ9H Y3OKHFLWFND:QX>>W M729WD M2"X)\$<f;KM= "fTf&.&K.#YXKDT>XNKC2;6" <*D%F="01f+13f4\$DN@:@@ENXf9EWf17/>51GGE8OAB/fJ_ M_>+M^fL(fSWfLZC^ETfB^7&~ =&N+ .S;3 M2M.T8Z8)##@G)f#10"= <>#O\$N@ZK#fD_M.ZNY8Y%D5f+Q* Mf#U&>1fTfZfFXN(+2W>XN9HX84&7DD8*fJU)/ HMKf^M8KfVE2:"Q fNDJM<:C96M\$;7%Y1%<7#_ M88GD_0^B@fGf/ f/f.^(EU+Q/<1Z-910.Mf,=Kf%#="0E6100W0#f1\$G@_M 9QO6O8E\ZfVFC>f;5>fDT2:"2f_ R=(X3&=O;2TZTO\$C2X M@MHXfC?>N54#>X&>Gf6C10fP-AH&NSV.fA^)-#%G\$QU2fNYH+T3 Q(DYf++H M2f16MMfJFG3V5O:7-G+P649U Q&Z.GD\$=BY.OHfYfP.D.#.X^2N0TC0=8f6FMZ;6f7EG> M7\$UO8NF55\$;fE)0>~<V3E0V0>@KfL&Of_ -033VNH1>O&95MRXfQDfP6"1<9f MU8H1^NO^FHZ=;^~;#3+8W=OH.RO;TBH7_C9#Mf;f7+\$XX^O7=732P8f3""T MDA0f8P0^3CIDG%3U^26f1@HHHZZDDHf0fYK\$X5U^+X<& M=\$_LJ3Z:7?6fP\$Z;"D4fFX>f^XZY^X1 M;PG8:.9%ED@5C(ZC 9V8NV^;SfFG310WNH6M-MM)*P6-9954f13TR>#CUH X02_17^%M6U/3M.M+^fT>^O^+RWNYfDHUH9#E ME9"7~< \$9fD9XEN=+f6;fXSOM5fT.Mf6L-5CA^TP7\$SfG>~.~@~M(VeO M;#NfN>U6@U&RNKNXfM+>fEN;."G0fRfE fB5G^XfIGfZ^E "V*W:V40OGC>Z(MS(8AA 2#?>1K/O55&WY M %P,\$@#^YKUBB@#C=*fTf6+3QKXAUBXfTW\$%_6R1"=.&g>)6f)"f+<VY Z M5SfC^\$? \$^A:1X30+6RMfY=3T2>fUN;f@f@M\$*07&=D4Zf<>N+;f;5K=MXP1fZ MMfJ5G;6f1f_9FB6.XfQE.<>T@_Yf7KZCN;Cf4;5XBMM\$=AXf- PVUY+~.9W M=C2=5YL18,"KX(f!SUKM**.&f6Z7XDI1?>E^fTYK^V_M^<M="L\$)"f+3&)L=4BOKA9)D4A\$#fj5fRW\$9;WKL~*M_#O~ 15Z)XSOM;T&QM-M2L=72fW56<7fDf1#fBfRMA@1M.R>fEKFb^*K?QfMfBCBfH^*U&fVDM+ZR:4Q)f\$HfP\$K6QN@)MfTf^VWMf= M;WCE&205P.Jf.Nf2*WZ:(f6fH BAV #.fR<=,T^?@f7FAV-EfJf ME.NZSRf3W7D;3fA.;UMRD^#@#fTfHf9ZA9Z@LK6=U#<+*#fTAB<L=2?O*< M="2D.fHV2Z@NGf@%ZfRfUM_."f6f1U.WKcWH Y^fTSQ^?>fE>36EGfEB+&fO> MPRDM;G<2T@0fAC fY8=LDfGfMA^f^+ (T+PS=V4D\$=7fVR\$?YV9fJfW=P2fL M=W58^4f1_ CZ5ZW455D^X%_*\$M;13>)~8 MRVfM#fJ\$ZfTfGCM(f@.D^fJZL2fA W\$Xf08Z#U- 7KW3=3NOB#H>fL&8.MG;VDfQ; M5-RM)L(XSRfMY_3=+fL;f.Y:Q75M^DT\$R"2.1#E74C(f<f\$5%9;E8ZCYfW&fM@Nf1f)Y4fIAD#fP#M..APfQfT YfS4f/f+G#f=EB5#&RfH@HYEERf@<>O^fT4 M>=VYB^+;fQ8=;LfJ\$T^RB.Bf9Q6ZW(fAE\$A=V%)QTXfZf1O_9O14N9K>P_L M&W0fN+74X0\$;Y>fY>f0fJ>f<97YC(N4GCCDXf)HH XOPf/"O#~3K5EIf<0% MF CZE%5HA#9>fM_#N^&?3f(fUT= % GEGHWB6P1ZQfJEfHfQWfTFQ66XNf1C>fO1 NR HSG<fM@_KM M**=13ZfOM9+B2SCDNH% MAG^Y;fWA3Z;L#)~97fGf5L+BQNHfF L5\$D+AU)!P1D<<"BK%_GMfX2U^4; M#QHfNfVOM(==N9)HfEDf1BF-57<>N5fP;f>KfF@:OKVA^HVL6f0?V?<037 M=RDH9))YfE?~fQ-SN P_L fFB@#D #6fG;9>+O\$H=V2E6Nf3Q2VfB56.\$ MG^\$ _>"<9^6N9fX^>?^<#fJ3>@DTZW=KRZN^M9Q= "199=X)f^R@#(f4YQOC MFOHfS5+&3K>X;Q;VWMH\$=OFR2RA53)P.DfLJf+&fCQK(C.F-R@YfZ9%_fM;Af>fJW?C^PfJ~>RVVfPW^W.Z5-P^fHP.XVYfZ9fJU0fO)f? 1\$;AfL0" M6ZN=BIN<(fX=6)fL0;=15;fU&RfL#~+Rf@MS(f(HA^f%CDX^KGJ2;f0fS M-OfVfW^M^QfT06_P\$V6S@T^6VE)fE3<~E;@9Y VX)fJ3P3f>HZ4VO _H6ODBf MU:>^A(D5OD?;@^fX8;>>W075f4 WfLT.9fTV;fFfP\$G&fP>#SCVfM4f;fK&C.f4499F.fZF@#fCf3_%fG>+ fS7=5fTZO0f35XfC=V-S=^%XQ;47&8 M5P&f&T#f7f7;6fNULH MS1=^fDfKfP\$Gf1GD@=,GfK^%E?6fF6fJW5C0>HGF;Kf#(fY R5Z@W;) <f1fUNfN=P+8>HP33O\$FB^(\$E)=VP@L-5fT_44O M-/AFD#HP12fNV0K>WOTZ<#WKKfL_fHfCDBLKfJ2.f1HG;fPP5fUX^G^0CTfQV MfO5ZOC67"">fHfWM^%UfP0K&PMX-/GM7fMUNPQC9f1MS+&fQ.TfQ2f>B4C.f^69;fJ@9f)P *//82fMfDfYKMHf7fE+HfLTM0^fKfV:9?O~197 53R0QW;f/?M/X3M?&DVfMfX>Of_M33FL^;f\$Kf<~>O)fJ(=OWfH R2_O..>ULfRUU"TBNf^XBN+4;HY8G#*P MfJ01P;GH R/f5fI=AX3U;PLH? N;NfTEMXfU+1f1N="HfD)f#~!& fLy= M%0Bf1 2fUf@Q2+SfWf/CVX^H%>~>f+U&Sf;~>2NK3RK74GfMfMfVfO6.(X MfAW^C)fYfM25U=^%> f1103@9/2@_HfJM9(C.E^E)f8W<%\$fYC=H9 X5AU4D= MQD<59H ****<#)H ""K66HV6fH26-Wf1_U5Hf(f>fGV+A5+;fP^fVfM)f) fY(M7)>~? #^K.C.W-fJfY6Z;fFP>3DKfJZULW2B MC5f1XON0#EAHf\$Tf=BMfY^+f=1f(9ROS80E>5fO_GCI7-R>#O\$;GPMUfPWfFM1 M2W_XfT;2.fW85f~ Y.W:0..E=#;Z7fX^<(EOKfEE\$MGfH)26843@N)%=GZ8Q@f ML=: (;X@fVfWX?fTfJDMHf;fU"XEMAf-/A(WB+^0Ef)?=SC Y)4<9R^V^<0M M=6- f9%9fGA@C-NY>*LQ CfMRfMfP1CfY?>L^fV\$>)f+0-fFLfLH_ B^#AL9QV.f:6N>^_fOBfPC=6f1^fEf>f>9%_9f1P2&5f9fVW M_NYfSDf8_XQWH U)=UV^YfU&RDT>))K(f+5;7@D9f9fR08V.T\$..NfUf1f M>)fQ?AfH6NZfUf-GfJOGM;NZR2fY&Z210^(*\$ AfF.fEM=1fH>*~1M5f00Z?9 MfR6B\$5f1TOE.fC>20-HZX7GKR>fY4^%\$fOPH_ fEG8K=fKVYfZfUNB5f9(f<~ML3MXfY@<^Yf4=C=;fJfKEWHfD6fQ=V<~37+3S& (R^=B<*Q+*\$3f#fYSB_ML^;XBD;%9.C;Z0fS2:fJDW=HfX5f>D^+fQ#8PfM<6VK6T27fJ90LD^M77fX\$MDMHKZ;Q^NMW8fXK& MF#~&Q&3PfC) S@GCI0fT6D>+fZfY570A_~AM+f^U2fA:"Y.R0\$S.C.57# M KfYfOZNI5>);CPRVf3f88fK&ZQ(f2>=fRGV?> <~YfTY7/4=14\$6G_P+M-DUYK>);f12QSYO\$AUE;3.W3fYfL=:U/f&AQ>?#&HZf;0=0fBL?X^ZfJWX_M?PH SX?f44f#R+7D.XN=QE3=@KM&TCJ>3P0>1A)\$S;UfX^fMYL^fF35f.T%9R=fVfGfHOQE_064#f3N_<53U7P^fJfHZ=H\$K7f_PfL6N-1N>6 MG12fLG4?H^A23;*U_56CZE?>+/#%_9Vf+6FES2R3Ef=K\$&8P%&.<9SVH_Q M+;5f9U;WfV=V^HOVAMfRVZ.f1Cf40f@ "O/WfLDDCGM4?A7Q> ZfX;f#6UfUfM_M;Z9fM;64~RfSfGfJfRfC^DQA<3M;#N5Z@<~*01^fJ>fLHOE#;6DUK@;fWE-P M5<TfCVE=0^fF14fJfER7S;R68#&3R>OXUW? B;3)=~*ZMf~<#DUY9RP(SfS(5&?>KE) M~M1272fEY fYJ3_+fW^BB#19K;fUN86EBNK^9fHU9>fJfE1 MM..0^>U8VK>~M5UK4&8ORF^\$2R;\$&M M+;S-Xf1fDD#OD8=MXfTU^fJLM<6RT6.fU^2Bf1<=PPBfT92P.f4FSEN^N.#Q MfFK/C30=6U)M^*U70)X(f17fE=f84N<^5.C+M=&f(Y&fW^f UB;~*Q2)HU0f9Z? M#fJfU(+6.2. &;fXM?Q.Mf#f\$ MfED6EM \$0=3Uf;fJY>(E>fE8fLN.DC)(X&2^_GCU^UN_&^G6f.E6fC7>DO> M6VHEAYGEfD3&W(fWf>W2fJNB>~M8U5KF9f+~fRLfKfZMfKJ2&Z~NK0@XV(5f? M<1CC^+fWfJ2/PW? 6^C7f1fVSMXWfTO3M;3f6FQ(f@_GL#Zf6f3QCEVBZf4f15\$~>O.\$553+NY00#P1D\$8fZ@3PQfH<~M#;MXX#JfE67V""M#+fLTf4_E^OU#f+ MN&O.YP<4S6/"&HZC8>+KN.^\$;EKULEf%fTN^AC5^H+~CDDfLQ>@PYZTf7f7Q MAJf_ D&BV&H~;6NfLQ.UK.fUYCfJRfO(fD3;_C...>G- ;GB#7f(f#^f_);D: M5WE2""%3@RRNP5%1f3)/7L.FN=NM#UF26fEXMf\$TA9fM0_7BfOY.<=> M<5f>~?#DWB.05MK2=(+ZVN(KRTfDD;~*6- LKNQ@fCf; &#Q=6?B>ST5fK^& M^74f9)+&8O^f(R+&QG^@@f\$."f0f5@^\$89f1^UKO)fHNLZC.f1;28YfCA642-) (H4G& H&<=R3fT M&6^#f1fU32Mf00R.A;1fOZCf3WD)fCFW5^HH5A@8fRYXR;fO(f"1CfL B^P M9Q<~+f1f27C1S^1V5G^QLP7f(P0&3U)f SG^M.C5+7XE>.fTO3>ZNS9V#L MLMQYf48(63fWf223V^7MR16fXPTf75+^f^fZCf4f1fVf7fWG/f#~*8@Z-R^#8." M- P/2fHM.TG6+/QfXBUB.TA;#4>WCA"3fHfE<f(Xf+<=>E #.7X@6=fHVA7^<M2f0SfZO fRf1W.fYU8E3^+8YfPQ &fSGMS6CX5f2MXB@0f1+? 9KBSN#f1)M8O#fW M^QO~R0~D>W^f(KBfJA%>~*M&T^PQ>+>V M6fK)f)=!>f\$&@<(3ODD^N_Y#?^>C.QH^CZ_#>6DfGWE_#7Df1fD\$2MD^QQP1W MX_&2%f1=2;2f#NMfX>3~S=8fBM.D0 fHY)f0N%&@DfZfJQ(fN=>~S0BRDTfM+MNfRV6<2A.\$@?;..#8fXUSfYXKfU^f12fT^3."AN;fTfMXK MA))~WRT=7+~YOD)f1^7H.fYSVK6f1^7^K.fAf1DUfJUM;>f25D(M)3)\$X&#E223)4 M^ZFN8BfO8/C^K;6MHMRATfU#KYHf1=^fF";f\$=<f^G6@ 3XE32ZfH_YH^?> MZH=)N;5K@f>X&f^CY<;fE/fUfO60;^f5GN.32fH(@MM;EAENfK=KK?#~MLF06WfJOS^fLCP^<8YfP+CP7K\$- fFfV>~fVfNTf0^6fHf153+&fHf1D\$#_D#_ MfW&fWf12f2_Bf6?BC3E29A~87=fHfJ2f>f>K(f>fX-GXf!ZfHf1N?>~U^X^fU MVZ@fT=9f5fT)R+ZP-R0- N-VfV~<"OS#(QfVf7f)K^&#19K^~WfFCU""f0f>>0 MfXfHfYfE;fEE&fCKf;fTfPUfHfO.M^KfHfUF6.R0f;Rf1fN?&fT4GfN<9fH^C MG&36#^%KCPKfUS:7%fP+A(fGCLAGf.UWLR(3ZY8YfT;@^CfBZfTMM\$UBf.B MPV.L&LR>MK;,"fY+~H.=fJLS^>U5CX^UVfVfZS 6MKf4GUYM.fT^3S^C#f1@RfJ_/8@XfSfUfUH+H MB;5_%^DZfJfFGZ=VfVfE;W..=XfT^Q-O^&8f1Q3fTH@_O^C>f3;fTBN^fMOfUB Af+f7&2.? EE;Cf;TR.Yf14WB36fHf>f)Xf-LfH+fULH9f5>f9BfD< M1_~\$&T=SCDC)f"6J0A2fZ&WA^fVfA.RG3fMfM3Y^&f1^8WG" Af?Q@NfQO.Mf fXfYfC3PYXfTK A)M+L&f(fTS6)fBZAGEG;2W>8^Q6_8SR%f#BB;3.M268DXfHf;@~>~\$YMO^NfJZKfHP>fT.Y;fI637fBPf1ET8=(Zf6#9P.fIQB MF:7X7UCf1-fK6f>~&5Qf>fA9^=@DOXVRf1f1@fQ@XX/K6SHWAGREU^~5%B> M77fV>X@0Yf1(+f\$;fG R=HY..f~ #+GQ;UMXPT;1GMf9K35fHE@NUN23N5=VfW M9MfCH<fXfBfF3^A.f^f6^fUBDNfJ>~&2X(fHXB0C^QR; #.*6P0&Z1BfE(fEPMD>KfMfQfX6U>~/#MfX7fM.M^AAHfMANR0EQ^ZfJDK2;C^GUH BDf;W_ CVN7fMH;7_UHSYGB6Y8f3fQ8SYD4fSYf MN_Y/Xf1(2ZfHUHEfW/fTf^*B?&f1)fBYBM(fH4fIDB^D3fEbf7^YfA87_7fNY^7f>fHfA M7ZfSfJfNWNGVfWfA&BL-16fTNIOM@_2.H&fP-f Q&>5_4YXf^f\$1+~;6WAZZ.fM3;79XCBUf9&fYH^<ZGE8QOQ@95@>^.=+PKf&fJ9KGB2Y0>)+?4KfT74#)~N8 M#8f888XfRYXS0fU5 M;U^fVHZQfJ.GW#fW9fVEN=0W^M^f1f)f9(fW4 \$\$\$fQDfJ>3fHfES.fK-Kf2)- MYN+^ZfTZ.fUfWSE^C9^9fM@<2&R&QfU^Z@f^<f&f\$UfX7fR;@NDQ\$5;ZK<f0:0=5DBTVf/fIMfLLf3WDQAX8ACy<fYD.M\$@+R? 4@8fU54G@fQf1f)+2f~29K47US>fC;fAW85fL_Y.W:0..E7MfT^Q? MfYKKM;V\$MMfJ5B(+2>>X.ZPS&5=@4YW..f~*f;AXGU^fA0^#fL0+H M^KQ2W)CEB96?%N6^fLOfPfOfHfY(^3%='XOUX&~/fJ.fUL#M:0%fT4f&<f~#f;B M^Y6fPUXDMfL.P+CSfFW(BSP;fS+^&X"@#f13f1^%OAK) <7fF0.N(DC>fBNF.\$TC.NYVRfM_M@X0fL8%6/fEX-TNWf3fYf633KB(3^&6O)fA.fAIOf#f#fT^BfJOB.VO_ fKf M+6M.BC^VWT_0=9WYfVfU92ZMP2""f4C^6fB#;S:fX8M0#PBVY>KZ..f&W>M7&Ck)fYfHfK@fJ5^4B@#fH5N+BTfTFN+1f(G6BB9fT65B%) SS@9_SVKRf4M3U_M^4_AOX-U348DFN9M6T^<&)fM(6?)^1%)&XfJf60(fM5C<6X;fY;fGTR.M5YQ%X6f4GPfX#f+

YRJX8>G/7K4=MXy>36M*LY,%0X-2"R6DYE.V? M&0)1M /30P>/>JVL>\$K 7?%FK3W\$21.9J&A V69!*(CIV.2MOC'S>O:K?
MA+<OM;LZ-Z=KT>E_9J10C7UO.S27(7A?D*~@3QDD^N:SD &JKNM1:8)PR(=^CLITAOI^BOKIY,/-C;(#8YP>1^>H6T;1UK
MQIHVM:CJ9KI,U:16A2A;\$9=8BM8 MOI.31QIZ_OOGW+&I0VXZ8ZYH I:=XPLK#PCK&L1X;(6FIRVK6ULPQ+>YHC
MW%MH^IY&3GIZUK1^^(KY?&2>);BP@#09F1%PEPV-@8(PVI/O D=P"~#GVKD+W2 M-1TCP%KVFZA;HRW&KZPI6B33DH_GS A<@95P.D+I
I5f:6 B"TIU&U7P1% M1<7D?V./4DU(+7+Q@f4;^B +D\$G/4& Y4YSNY/ M'TXK"@)^+2H(VPS6&F&T058IRYG_XS/?\$ZFIFV9!^8<)^F
#T>E:1KF MD^<#SUR+6UGL>D2DYAD\$Y5XB""NW Y&08 BT/OA:OX0I.3V.E06L^K ML8K+3XW"10XW";=&NJVEGIN@2.2>=U#G&
MQ0?>D8(I.37.Z=X&UJFI>^>U"V9-1.3LZQ^>3%<1MD.NI&5)A"XUN MW&@WUHKMFXBDMDCN_P"RVT+TM3^XF+;SL>@<10_X)HX^0L?
B#J1GX;U M.ZT&.#2J;EBMUDW^WNECN?#DIMP4R.9W9IATK37Q>U88!^ZG@QP?I MK%=@13K+186UKJE=AI+60MLD;(2;&
)_W(V)j>N10UNNZ A M-L @W^HP0)^.P/Y3R% X4SD;#C@>#E84GC*=+;PE&_%D^F^#K>RTR^>M P;B(R 7;-YRQO^NIV+G(^7I/ZI1CD
MS>[M8 LSO#26_AZIXI^N18KG?2I= MZ1HKL4^0DM@G@>#R1D;E-W_2;K^UT 2H\$FN9D;YS.Y1(8FX3.268YPA
M9)STSS17AG71X>1.V#VMN)=M%OX=12Z-K&EZW_MIM09W\$FTR+3=1L9KDH/W?W9\$D"GU/13WZ %>PAKZ;#H?B"YO8HHH(BX147-N
MD(EPGFLPXWX^Z,2-9P#QGBMN/QU.919MOI^BN)=/LC>Q2VJP3I.@ZKO*^X MJ.L:POX%(2S;)JBB>QM-47Q ^MZ=(LC.FXGHL@VC
(+ #OUZ5T2Q^+M5Y;C M^JHEIUM<2VDEO%;6TY<1#&IG(^4#1LIGj>>E %GPGXAU7Q0;07MUHBV5A+X(KYI&Q>R-PEM^#O&E-
^XN>=1?>W/VWC^JLH &XXI(QS@&GR;#XMT;7K? M6I^AL+7-C#&A874Y3YXLA9\$<*>S*M^<+/UGAC7512^I751:36C3 AI>8 M8-@2/1<9!
IC%:I5=,2^6Q3^T9(GNVRTGD@f%)W5SR0IQD]>O2K5 !111 M0 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%
M1110 4444 %%%-%152 U73M+17U" M.17.%XF6."Z9(JW7I^& 10A_*1 MJLM>O_79%.X@GANH5FMY8Y8G&5>-
@RGZ\$5)17#.GX^FAMKZTROQ!#97+0-M;J)#-/L;Y3^E000V>N.HH [FBN1U0Q;=>=J-WM80QVEE;)<)>?N8A=LRL MWEQ!<\$!
^1.3D@8ITD_C9^FT&#1-MJHCILADOI^TA"1@1U<1^P^OT=21 M7J2^>F;STZ>UAM=5EM3=3I(7D2;MH^RC+9C.#QPI/H#H^H%->G^0Z0UU=;
M=+87\$4P212IL5WD))4@@@XH V998X(GEFD6-!N9W. HJ23TJ&POJ35+ M*.IL+F^YMI
I)HF#^V"0<\$=>O:Y72J3UJY^*&N2Z?);FPM.6V.;@55S(<^ MJ\$@9Z< 5RQ@GOJ7AIX>&KAM-MWTEID6LLK7!\$P!R=E#J!4C:"1U.3SP*/
M7:*XWQ-XOOM!@U>[P01VNFJK)KE;7QVAF\$1Z< XSSDY&C-13ZJHS1- M&L0VZZ=<7>"-JP9CNC&6QW 8X^N>?0 I>BLI7-0N=,TB;
IL1'6 N5*KI; MOI@BSI7EMHG->7DZ06T*%Y99#A44=233X)XKFWCNOQEAFA&Z^*LI&00> MX(K@H?&M;EX)N=?N?5D^E_HIO1)=Y,A)j>-
EV'@KDCKG^..X&A)XQ6"/P Mf;fMG8RZM9>?\$IRO6%6"H1\$F1W<=,%H^*.QHKE90%=Q)8Z?;L M61@00<>W:@#>HKCKGO/KTWB?
5M;ITK1^6XLH(9TEN+QEIE?>H"\$@+ @ 9^M16U)/\$G&@OUK0;&10Q= 04GUKS7^AV^A.9I>QZU8RW=D+<&/15.^TfH1PIGTP.M=2)M1?0
MEG,^0J36X9H7?>D]>9X7I7Z@>@W^I>3U "24 M5D:UK? 9MUHUA!\$LU J,K16Z.VU004N/L<@=IU) XSD8IOCZ;L06M+O+ M&
ZKIUB=0B5)JBL5U>@L^M)4@>@>@XYX-OHKFO?>NZQKIK;WYIL-GHU M90W.#BW&JRS#+*5QP.X//&^Y
DUK7+^QOIH>VMXK>&U\$YO+URD+N20(E_ MB^7);(X;_ .AHK@V^(-Y*5=?)15EN2IB?8S8/RG^Y7ENN/X3T
MJR/^>HICfTIG:6FL06JS74;R+&C.6"("BDG(0DGL^.#Y.SHK).ZT_B_P M.ZG+8SVLEH(0MIU;_
@2".0.CC(.017/ZjXXN)"MKN N;"&TMKU;98+B0I M/72XY+4V4>D^YBB8L6EVD1U;Y/MP!^M8NG^~.?T P^"L>)KV^SOI;6ZN
4\$C1<+>4P.#P-7_ HM_1J5CI<*M37IW#;1/L(20^X4%V.HSW^JNGRZG)HL=I]SGF26ZR NBYOBCMUUR.N M=(I7E=,%SJWARQ:V?
4K;&W\$ESO.R1E^N5V<I.3(P>A.FGJdvJ0_&&Y.C6= MO^H"YF4_Z0_)(I)/O%
'HM^6V<1U+SQ)I>]14T&^VM1)I8OI>=W8@Y=DPRX1%2>#SQT MH ZNJNH:E8Z390>:C=P6ELGW19G""Q-
<9X5IO^I)X#>1(WDULMY=:(@WWV)Y V0J59FEE~!QC XRO.BLWQ)XE^B3X9>X9(I?7202F&5H7#A7 !^DCN 1^= M+7TO6_%T_6=&A@TW5
L%I=PWE.FDNS(25=H +^IICJ>M9WAW6K?P!<^+ MV2>3XFDBBC!QODD6%5&<"^9)P>]&@#TJ@!\$\$\$9!f5R^D>*>I132/9G9EW>6N
<8&L>FIP><7?^_B&W4;+ MJEO\$!;LEDD.A^*16^LI^A^YIT^DT5M_11J1I(SO(P55J2>E1V-LZ
ME917EE<1W^M%:QROMN5AG0>L_%EA>O/962V<=<1OE5XV<8S MU)WG/15V=X_2X+V&# MT.*RI%."C+N&0K<94IX""%JBO-H1?\$H+<
XF_P%:MFRUF2I5+PF8 M&M1DF1GCW.9.2">..Y10I;GODT=(+1A) "LHD_2^R^0(NUC32O)HMC% M_855 M^Q M^7^R M=1TPWT37<I-
\$05!61=A^XW=MO)I.M+IOCHG0S+= MV*1.JNJMH_V5)^JMI:7L#7Z1> M^MXF(5QIH7@Y&5P06@#T6BN6LO\$VHKXPET^5K^VMJUBU_RV
I2?)(KA&5I)FYXR^SSXI MO&T30I.MI@ELI90\$M88GF*%YGC(L%8^0IQGJ<4=PJBI\$4^JG<+! M2U4U4?>
2=NM2061NWM86FE(YPIC)OZI^YBX8WNWF6C.HFGPO:9JDL<1.M+__\$FI>);3I%L7DT3RV+RWC!95_ M/S.#^9W\$8&_/4UT^@:NFOI
A13I7BG.27ENDXC8Y^IAG&?>@W>7MKHD)= M7MS%;618RILSA%4>Y%#MJB^IMHKFW62&5)&ZGAE(R^PKS3^TJ9U^00B2
MFI26IO6HHNH(UCW?(<_@#*VY))IDFKWA_P2:EIEEX.LK03;=-.U.UBMHI5N M^TRN(C+!MVX(4I)&^&?
2@#0(I;&666*4>8AI^HQN&C.GWQ@9IAZ4UTMK= MY.R3RXVYV>9SC^CMDJHW^XN^^(L=CJ6G;2INM(+EH#;O+(9YE5IC.F%)
M\$5A2>0.Y^2NZ1@Z^PSAAD9&^I?%AYTWKKVELOI^X7D9^ZTH+B&ZMXIBWF MCFAD7H(X(KRIP^KC:X!U>=>2.VZ%M?7T@6!
5;C^7^E=K=W.F MAC3I.TRRCBM^65WNBI1^*#N@XJ2V.C@TQ0?T^5+05;^QN;^WNKR>&Z^R MX(GD:5011U<5)1KG_ (1%:@TN&1-
4 LV>+G^IO>\$>^<^PFIR",I>O6 MH?SL^JW-OX1.6;"SN512HJ)/YJM^Y4FULX^YI=-I/1^Y;R14715ZOHF
MJ6IM9_8I9.NWE\$A83PDD^<0;2.\$<fMW2YJHTJVN+V%+(B6_12DG9GG^/M2^7WH J^J)3X>X XGVE,<# \$R/D_G5RRU^OU)7:00;Z6-
MKF^57GT.#P M:XCO0;0V6J^>6WC<\$L)&B1^41_*Z7H-5L_#T\$JPHIMU2>=1.78:Q8R66ID-W:R>BF0.II#@I>JFD>&^\$TDR^F:=
M#;R%=>OF#+^MJ-QR0;N8N^VHG>6D^<(WYTA9)= M#;R0>L7D2HX+<@G^EDR&&?% MUI-2I>(-)TC^U+KPI;BUEN+6.WQ>9=EF(07;PP)&
<<13B@#0^JZCJ5CI% MDUYI-W#;VR\$!9G"1^3@P%ZIGJMM)0%O&7EHC^0 ML^YI(^Z#G;K6??>-
Y) AS=ZU=;2SVYIJC0+*7=&LBS^%G;=P#%;@?7 MB@>K.BN4U3Q+JUOXSB;V&EVL536^W<=<MT4 VNJG<I^C=MQ/3DBOIOC+
M4M1V/FX31M2VIO;HVf7.4WO01V=5;S4K+3VME0+N&K MF400"1POF2^HJYDXZ5PHXYU";0&(L/LV_082.6ZC6MN)6D);Q3(D^M@-SD=>I
=455CZ_2 M.AJ&JY>A6UK_&E8YVC<2EU^5#>6N<8!6>3C\$;Q3I1I+O2_#>H7I0GC MUZF-HTU10M9T03)CU#4K.T=GE(0N)UC+23)&
M.R/#?B^_U+6M9T75;*WMK13#"Q.VF.DR%(YT4GR4J/>7/BO514U7P^I@&@LM926=X922Q86I-M9A_"IAR0.E7=51^39C#)I^RX90-X0H
(R0.YR0>G:(VU%)065TMI8VIVB21K& ML@21=K^&&<\$=CSR*GH ***** BBB@ HHHH ***** BBBB@ HHHH ***** BBBB@
HHHH ***** BBBB@ HHHH ***** N3^<(6ZIXF^2V7 M.L.VGF^?S^SW.S(\$WB6UL+>(S(9Y5O^=A&#E@ MJ<6^DXOR1@fFNZC;+B6T:0IG
51AODD@9^U M%=(=)KFEQ7-C;70";+BT3=S-M&6V^N2IKKFEM;#RRK*\$X(9B6X)Y.3G_%3 M6WA6I)I^<G;K.DZJH-
E#H=M/M.W\$B#;&5BG<#JZ\$=LXYID\$9R#10YGM^X^4>^CHNI;#J1=;C.69L;N" =+FAIPNBjX&^TI=U3M86X73KR&Z2WF.\$K0MN^R^E<
M^HR^NT+?@+I2^#N^>@I#@1^?>\$ M4^PRTOPT^FTWMG>1S^I^PRV5O)X/EYR>G3;LHH^YU3PGXHU0!0EN?L
MDCUF12HAI0R55H;8HPH@VA<=V3D^N20305U?^WB&7O>#>KQ1ZA^YINHZR75I.M=4M;FO(40K0<8+>+I2WJ_M:792WE_M
MDUI2HAI0QD0H4I&+9[CCSB5W+^%#_%6GA06H/A^WA=TL?I LYH6\$!>4 M^<8_&G_V#JDNAZ=H^HZ516HZ=%8);W-O+;?I;H_#(2G3
/7!&? MLJ^/X2 WB708="U#0I^TGU33I>6SN(+QW.4UN1=4#XW93@_XYP.G0IH^MZF+
(H6WVQSN.VR8XQV4%N3ZY^Z4^35;+5H=2MKEOEYHFECMR?F9%".M0/2KE_GIM+?O?%_Q\$;^VAN=-
LPZR3&@YBP0=IXZYHDW@C5X^I17;FOFN+M^26WUF^>29HUSW+IE0I&X&I \$X^HUV<&AZ;ZM-JL5JHWIRI9)I0+O8^GD# ML.U.%
^+WHNJWWC7PWJHJEH;33/M^GB29E=O-O+IH^\$<8SR1FJ&G^%I8T.P MUW1M/-I^H3336LTLC^UL9IURLH4I@21@I^CK7<4C.J^69@J@9))P
*.M(AI^WYF>/(^CZJ#<%"\$2P9ZIH5Y\$KOC9Z3X M4TK3-06-7-G:QVI&^ONC%;"YI^@XSC%8I^HNO" M/MW77YL ACWK7UG0?>MCXQ?
Q^X8EL)>I>6ZHI97SLBM1V2R@X(#\$8Q ILMJ M^*VGI>)91B_DBDNYS^800@H+GG Z<I<9KSC5!^?BR T3QI^2I^OISI5# M?
22OYL^I572)AM^44^%P""0.;@10HH Y&Z+KJ_&SU0(E@8)=.6RNT.SYB(ME.FA4^ZY^N=OKI5@2^0^O&C
_\$/A=IA6I96M)VN^1*22^9EOL."F;G>V M.70HM4L)I4N.BNHGO:9%DF@#?BMITD>^HZGKXT+17^ZEJ<%J_O0O)D(&V MIMI&
Y=NXCM8;6>&73%1.987G*^PD+I@=I#^G^8UTEK=07UI#>VJIRVZ+I) M(AR^4C(IIB#4U^;EX^OGV/R&SFMFUA)936G\$A987E5P?
+S@D^M4+G^..X& M>+>MX?UZ?QO&K;H(G&C38ELFN7I^00K_VS@#D.P1D9ZX LMX^U^IT_OI8W4N MG(NN_O(98V<I^;KM(I<Z
O7)ZX20I)^.5 L4=7G7I)M6AM^29IXM+^IOM7_+6L+I6^5I)D79L@# M
H/HG_.I?O1)98X(GEE=8XT&Y68X^CU)J#3M2LM7L(KI3IF.YM9<^7+&+92^2V7"(UVA+IG?SF_O\$LM^7Y1GKU04/C/I-3U7^Q+
MO2I^I=9I^72E7.A1)\$^LI&X^2#WVVKJ^0 23@#@D+&#0=8T^Q1JNj626E.MS;ZNL^?#X73FNM.08Y7^T MN\$98Y-
_RGRY/3D<5Z310/P4&=;A0ZG)HP=F4EDE@=P_R;>6ONQSCD^VK7;PUGV>*>J M^+I/HDVF712SVE^IH87C01AU^>Y&U1D5V&E-
I^B6S6VFVJ6T8N8T)VY)M.V:Y04_#KD_B_P-jSV<I>FPW^7+M(T;TP48@4@+> 6Z=>I232IJ M-
Q1FUF2^T.2WTEM.=?;S23)O+>=F=005UE%_GUKX;U>P++X)FEMGT_F M". \$A\$Sf.7W8,>W&^#I^<=#I5=C;ZYH/B^<U^0EL)I.U..%B^ZE>-
K=XDV M^R\$^VX%0J<+I^I4I<^Y=>N^*U6<7.D=SHIO.5^LRIO=P.T^>3W=^I^G0 M=9_X3S3=99K2>UM=>TED:5DDD=V5BP0^0!E>FIO6"?
OBFH/OG27352C10 MOKE@?>2.D)>7)I@(&^1D9ZU910^Q^E_BH30U^XDOJ^3(D&E-9;PW+N58 MR^AB@SIWT&I5BMX)I2-
XIH+9IGVN35/MV I4P+Y 68SY><I8Z> M7HU M4M.U3I72=1.OG10CHT3;@K@ E<^HR*.=O=U&W1=Q>^08Q:9Z3);3
MEIVWIEED+8V8(&W^49ZUR&A1^(-.V.JOH6AWNG0YOH1%JDB+&6RV4C9^BM MAB^T)X.2.I=90RE6^D8(X(K#L^I7AC3K17MGH.GP7<_
<9SQW%&_&6GA_6K26^&@T-B4UA8A;^+ELJAB MOY_W3&>O&72M;P.I5YH7@_2H0Q^HHLI=8&#ET;9I(1_2MYB@#@)I^WB" M+^A
+>W33GM<_&DD^LDHJZL(CVLH0@_9SD^F.>S>@>DLO4.Q:YFARI MOI=9A;K8.E=Q65W%>99S&^X5^DQR_9GWYJ0?P
M&D>O&7AJHNLTNZT;09IB2>WEN=GV@=BS*%P^21DCWV^IMO.2 B;"21 M5X#MC#_%I2>&#GL9I3+I62IFN=R7SA?WC%L I#N**N2
3DI-OKK_5I.TMI9+Z1 MAMWNIE@5VP978X^J.YYH0Y>_@CO0?#UHIG_#J=Y=>M_-//D0.0G^7I&Q MMHXQC)^M=-XKT;5I9NO#LUE%9@:?
7^LXFG9<@RE5PASIH<=>ZJB@#AO\$M MAIWB3Q3H2V6H0>6DIL=ZD\$BN3;I^WI<@0^A&N#>KN.HV6C:9IUU=W5E86
MIO<7C^9<201A6E;U8CKW_U>H^Y^Q?H6KZSK^AVT^S.F7PNY?G9&_#YI.W;?>Z=0VNL.9X M^6NSHH
Y5M&U=OB/%X@I^JS^Q+I36)3I0WF;S(LF<_.8^77WJHYRX)\$^Y MFNZ&\$PT^6HZHHI^ VHBjTZRX/I0.1MOTIUZ7)(D.3RR.J1HI9F8X ZDUH
M^HV>K;?#?V%PEQ;SKNCEC.0PH YR31M8D^=(GKYALA:1;HEZ2:6+I^=7RIL MP0^N.HZYJHYUO!OBB/3+I.=DISQ#)JKVC7+^7+SPIXGU#0
MO^"MO+H7.DWIO>.>L>U70^>^M.AHJ6U0Y.NR30#^>8V@G^I200HV^PP M^48ZLL^I=1T^Q+I6FGM;3+I-4+N6:5HS^I;P0:6IR^&3T
^O7H5%+Z M3HNIV^GS7I9G2U^Q^C&C.OQ;E.B^4^6H\$N(I^SXO4;C=7UVTXIM-CLST MNIO;A;B=D+I PV#"
UW=;ZZB@#CO\$7AS6/&4<F.HUI8Z)YBR745M.TLMT% M.1&254(N0<9)QV" I^#FOGQ7J5U:#3IK^L4M;=fEV#V&(8(@7!#&G!7

```

MH05W%9NI^(-)T;G4.Z.W4%0S/G:FX4N>B@d$ M@'!H XFS(>)+/3+!HF MFO>^R14D)N^/(&T)BW:IF<H8HJZMV^@^/#.B#4SH!N*~
MP7>NV_BJSL'ME<:2UK^!FW,+D2@YROW0APIZY:N@I^2.GK2T%%%%%11M104444%%%%%11104444%%%%%11104444%%%%%1110
4444%%%%%M%11104444%%%%%17^+>ZOWGAI0$>:Q2B.XP<:H(U.CK.P+4^Q=A7M(^.-F>.=MT9WT:6>95&3Y#@^*0.Y.^Z*:
+M:Q)B.P.Z8+!^VDAU M^2=1.Y>=0E(F.Y1G.S@.27BC1.9EQ)Q=XE7I:QMH2I/-OB6)BS3^1^P+@$M-=.O4U^KFCZAJWB?PSJ@;)1339)97,DS
R^2.IAN(X!SG//ZTNBZ+J6G M>.,$>LW?V.6>IB#RO^Q=/*0K!P*^@G37'E;DDAT4DG/)P3CTR>M6 M^?..G-
.OB^Q$X(C MBZ0P@CK!S@C10^!89AI$4I5I^U67QOI60Z;F8X+66TN M$N2P(5V5@RI0A^M^Z=K&LZ#8^/3TROLYX+6!FYG$!K$JL<994
M^7)R^R==>+O/O$LM.$Q!H/U/GDM9PJ9R9V^1G.=)K9)I<^<19FZSH-UI:7BZ?%M87H=-(T$ROYPVN^K^H8..GL*
+1+;S29<+.=626VG1E^!HQB@."M5/4^>+LT^1-2U^!6H^M16+29WM6;6W7.L@NJD<@>C$ALD^@#DI^F47L M-
DHU&XCGNV):1HD^Q@G^%023@#CDY/707..?X=U:P.J&N_V2UG-8ZK<->*+B M1D.VG<8?@*0ZD@&'5QTIZ
>U375XAUOX<=:WHL^RM=;.'ABG?88VY!#S = M.>.)XGVNA(^!0@U=7P<.:1 M%X0&BR02CPIYH.Y8Q^>)(RK-N.:5!$%95&+E;CEV8#/#
f9(33CUJ;2=&P^P^MPKB^P^#LH9I&^%C!G^MC^7(SFKU!XMN!GB:73K>!D/K^!2I8=S^JNM>).EQIOI.WMIYRV=Q M^%<C$W
MK22S1:UJ.@^+2+2DCM8IK>6RFF9X8VW!F^!RKW^!9^4XR.YJF?2B># M=0T?I5IKW!A;+!H.SJC-
+ S2).55TP.XI30!T4FLW4^CS2!&N..S.E9JEX M.U;3^!NI^$;6>T.D7)F2VN7=A+PRDED<.:1N;W#.>0.<@%J;Q=J=WXHL!M)T.RLHH+!2CJ-
OF&Z#)^(YJF!0IH^AU^4+^!TN8=5.2KN M7+!YF^4YRD!9P.N.2.D=00>%JZP^!2J5DEF+LMC^F1QM.PEQN5@<.,<M;
.OOI577P!XCT>SOH@NE2B!MBD>@EB.9RD$H8F.DOI$5YFP0<=&#1^#O+V
M^MY+LVCH)L6THY8YMBUD..3CDL.9/3J.YY.67+!+TNFFZ@&P!Z0EPD/EMP M&F^MD!N6^3KT XQU)T^!A@>+!4:0VT%[<^?8V!%HK;Y
I^D@?>(+^M<#ID07>A.NGO#C10Y#V36LFG+8SQSLX==LK2 K@<$XGDC^7G10!06A^(<=5)
M+>#:=7U.WL+2+3/6!W/>5A^R^KX^GRP@8SGDX!X^<M!X@!L.CIDNH&^TMI^M>TM1-
>$XO(0)BCJP1@*G!^1-^Y^P!K!WPZUSPX$:.MUJ5Y+!LHGD^!M.DMOF^!0.ITI^O!7!G!G!P!XEE!0Z0>1R:6;25+)+?=:CO9!4(98QM-96)W=5YY
MP<8(15NO$FKZKKO@*?3YH+RU>&6Z:"1^QW^W+^P(R!OZ#(SZ5V^KWEQI^MD7=W:64E!<0Q.1=M<+
*P^!H!UQ^KX!1V=EX+DGETMKW0$>"1&>3RWC.(1 MY#;756Q)CD^#D@XY(!HCO!EV^MBN!D!6GP^*=NIGL&NXY:9RJHZL%.)^6-O
fA^596E.%#69.#^")K_2+2/21 M^+&FX8RF99C&B!H.C^SUSD P^M:MO#OB5?%6EZY^HD^VNGR636D^R!8P6 MIAM.WG.W^0<+!QRS3/
EX_POG!ZM!/(WTF+!FT=GVLIE5L.J=8CCOCMO M!HV B75^3YNE7.FRS6EU^!B!ALYXDMW49V2<1^<S&=8!&2.8&N^<^&12 MRED;
<.=U+=;O=S@F&V!#^>^,<9 7!EADBJWARV!9HT2>)+S2GBMQ@/8J^Y M."7W8^1 7BBTN.:T1V M.&URZ@('O#C(+^&Q^<1J?
A^:QJ8USK@@@B LZ>PAAMI#(5!&^0L57G M^"813GG.(!7Q;JKZML4FDS36>H9$C0V!) M7U33K76M(FV^!TR>L A#8F.(X/
9X7T0OK!@=OVLZ4 M^G^V@!QO-T2VU+3CX<=SR02E^U MPOLQ8Q>=^!G#$G&$. $!>6VGZBEKJ5<^!X0@-(DA.G=39Z)JUMXIU?
M766R:FNJ2^WB030OI^C+&$ODP.INQ.=ZSM^+ZI9>^#0$&D3^3C) M+!P+WNCGWTFP.WHMF+Y1)B!VU5M4$A0PY0$<5=UKPOXB!U0K&
!FU^QBU^P.MO40.81H_V92H^F(Y^8J03ENO/08H K:2IO^Q!N^OS;LP/KYOJFV_FM3.%I=GIMID:J@LG@MFD8J1(7R)P^2K@=<8XR;2C?
0H!0:1.6>G290!>Y#NGOQ<=&J^T^P+!HZWL=Q.YVW!D^2.N>H/_=M^T?1WB^7Q_X;AU&XMEMKGS)
(9X&H:$M$EL=0^S&1KN:X5K>1G&)>^!R!XO MG%&2I=K_Q3UVRFNH&L6TMFCB$;#KFO^=H(YH!OQ7+>#/$6J^!OAI
MXE.N08VZ4UT+3M^WGS27#>O4 8!0G)H!+^PI9L^U_KED.^2ROK&8!1 M^6!7Q+XQA2^=UF!AIX?
@:7X_AHWAG=IAN!2!2^76$T>T^T/L^68S:S2?9 @>D5D!^<1DYI!H061X?T/Q%HF ML^<YK?2YEU6!%RBB!D4Q@*%P?W1ST^5!9!+^!)1DL-
!QC@& LV7B56!C3KX-H$ VVVO$MDD,4D4$!L,D2QOQ M-H^HR6^,=>E VBE!$5VOB^7-8CN-MQ274K!$52(AEB#
+R.5^>EN^>+!H&^DM$<^!)+8:=!DL!G>HY-U!9SQK.HR^D+K@&+!PQR M@&K-
O/AVN!7NL7!5K!0U3!F!YX&L!1%6ED+!EF8%5&5XXR!L 2!8+88$MFK^55(!&1O/MGIU!^MWL^O/H%DUHOM!L.FZGDI&C&NXD(H4^!)VDDYX&
M.N>%!Z#>>(O#;6>GR0)=QW$-Q%YY!1C^<(KX8@&$^!5?^#<K6OBM^2$ML;*2 MZNK<6 M&D=(J!V4=VBY&2IR!D<1=^*
#PMXK^B^O^O^6M LU HTIG<0!MR MK(O=3@94@@@X!U!U;Q5<J!I6&E1+)<:=&AD^VLTHDP9>PC!C^R+MY?2O=..M^T?#>@?
Y^NHSRNCWFI7CWEP4^ZK^"KGD@*!SDX&<5AW AWQ!HWC^USP M^>.:UOJ!1B!M-1#@!T7:LB%<+!0!CC^6!M!XWU^PTC1-2O-
!>STBZ94U);B- MQ/8$!LO&5W<9P.@X.L!XGUK1!6J^<(396^V7N!U=Q/B32=9T^X M.^)=+U^WGLX(6%A(DS!&L&X;(WRHR5^?3^&.:A?
Q7KNF^M-L=7TJSL M-7+1VWU$S*+65G^*9BW!2KRI^XXH FM^2%6K-KN
MF6LVE2RVE^K^26&SG3!$X&0^9UPRGIN&WGM2^!XMO/$%U^UK!@=,74D-Y9DL MMS9^N!G!/:2HAC=QKG3-#G>+;
+RUW4^=FLK4!5N+9)/N0.%WTOE7MG M&<1>J>J>+!H+6=+U34HM@&U+3!0NHVDC>.<(%!LKL48;(SDG&#@<1$A MWQ;=>(KF)
f8V/EBXDAO+(!EN;(*P7!0)51T+!@GK6^H=J!>F!)X!OI(M8 M.NIMM?N!L.RDCS%"1D@=$=1=7IWK4^A/4! 51^U74H=-AU73!
T^H69PEMI8+ZW-S^<PC$%>^!SP=S-8/OZ8^*^$2^&I&TN) &BB MCN+!+9!F<806P8=-fXQQH7J.6&2^H^!-$M=^LK^X!9FDL.NZDDL@?
NQP.B0 M?P!YI&!AA6SK.I3QVRV^6E M1>?%?7^=W^KR^X!RU+!Y+^M:10AW4^F9.1>@6@!HVOZK^6OBHV.EV^A MIEZ^*0JS%:DB-6^9I
fGG<=>E7^&23ZH!@7Hf.8RZDN^9^K$1J 2^%?#-UJ2^4072!+3RM2OC=Q!^S.GRJN!L!NU75YQ M<9.V N2E!VMD?#R^/3=)DX!M
&3<^/KUK.MI>ES7!D+DO&VALYWFDB#f M#(CA=F>"VWT!@!5UVMS75OH5!80$ES^!QM^A900.1@9$ .N0T7PSXO!S3
MZ1!^1.8WAUYGD@DF1S=6R.Q9D4^Y3@DX)!7!Z5VH.2+^XM2YT31.N!C M&.^ZU^!&@.072ZN9M5TV9=HVLY)S!OQDGP^ZD>
+K2M5UYOI8!VM M$NG>+322S=G#PDF!TW 2^N/N?/LM^WB<@#=#>C2M!DET:IMMRSR 21P
M^CG9!YU@8!YXT=5!7NM^6.6NKS!P!F.CH!F Y 2@G M8>(M=0=0U334TT&6^3V-!+S06Y!C8.JP/H6X.<<8!OAGO?^X!06!O M#!
<0!
```

[illegible]

MK#1/EVLM=2>08@5#(3\$3SDDAR\ZPH+C7+&I^(- HUQ90FSOC<MO"TAf^MVZ-
LX9=H/7GKT&=>RU|PY>ZCXDT76M/U^UFTI9HG66#S0AHP^#M1BMO<9U.U+;:SL&LPLC=&(^F P^Y1I.#SV3S>\$4#(&.&R3I^=,M;?
A2_UG4=*\$FO>+? 21XY5?>#D /#J M.D@=\$BZ/X@2RU;3;+..DD-KOANH?Z/D;9!R<@/I2I+2K MYLK0>WS7MTS%Y9R@.0?IE1PI@- #IR22;-?
@UK5?;\$%YKL>BW%M;C2K@VD8 MFA.GG3*BLV|YAA.MMXXY)SVKE;|Q%/XL@^NLV,=M=7&H3+Y<^66*18I4;
M,,\$@5\$H;W\$>13EE8/NP1@DNQR.A4 96IN;V#XL>(>2LDU MSH3WEM=VL9C6?#E?>F0D16##7_..NS3M.U#10!GPY2T.D;A|CLYUDC);
MT);"G.HW^6NAN^|JRFWL;1/-3=YSM&9.MR)P%XP<@G/F1^(-;N=#1.7TKVEG^J47G7.9UB16^;VZV^). #IBINT=KIDUFT&I8|CM)===T99B
M>AR1Z 50QZ1X@UZ?0 .%G1%|8B>X\$M7DMB|R|YB*7#*<+QR<^N#R 8&L; M^*9U?>7=PMTMM;ZX-E>.H9T\$ZID|ORFOW(^HXZ5V%
|K&JZ?XW;Z-). M36NH0W+RL("K|HE4C|W\$8.X<8|=-R9/AU>R>&L;TG^VT+7V|2VE;S&UYGD|Q M9/G;#M;X;L;K=^)M UJXU.T9|,CF22-
+1E\$E #8<^I0-HQUH^T M9Q|4.OJGA;4 \$VCO; 9f.2?R+26(GSXX6C.MO)=UUEK&BZ?J4<6DZG^+)
ML>\$M);>/WBQG. #DD9^RD O=^F7PA);>)|&UKQ8G+2K(K&T^;N=2?&VH MW;8.U &L;M.3PMJDIW^DUW>L-IMS<6MNS
1*5W3B(\$GA6R0"<=>G%=+X6 MU235|6YNEU2RU.R.H%K<6H RNT9#C)PP;|QC@5FZ7X5UK2?|I>VUFU66|U9
M|28_9&VX90K1\$;^1P.R)2|XR|GEC MR2>_ |0|BM-JC &0V8U\$^SCT87^PF+(&Z<^PZ|3L/Z5RNGZOKOA P.XFUO3I M;(6UAKE|+)-
\$SM<+Y^&X.G|XX;GTKO|PW?2>+LQ8.C#|BR^Q7..L.D MWQB3>^I#.#.|8 MZ OX|MTAU*SBM;M# M%G38K&%B^%|W\$D\$-
SFFT+3+72?T=OK5L0T|F6?9|F.XFCLJ|W@YQS M6=U|".PU2>|M-NY|W2YO(H6:*)W\$;NX^+^@#.
^BCCU'2|Q|*YH\$(|+@AU|R0&!!P3QS7.ZG%JTWQANH|N;6U MN6|.Q?OKF(RA1|HDZ^".G|>/0UU^@Z%HD5X?;AZZOK|NZEVI0|C8^R<*M
G@=2;I7AZ|X3>(|^MT=|6.D\$)|8;0Y<."&6Z= 44.R/(0.SQ|2^D|XP>D|;AKMU HZ|YZ|0K#5;.&236=56.O)H)B@|F.X^KD|G)|YXZ8H P|
MN..L;Z.D &05LIK=|Q|5R2LRE@R|T MXX(|<|L.E6=5^BZK|EX6U.2WUJYO|T=0ACQY.T;|PJD =5/EP3SDGO0| M#<^(%A8^Y9+1?
|LC8M>65f.&|CMQ69X@N?|2\$|*M;U M+1+N2PVNM6^".%O.7=>2.5B3CG|((Z6K MVBV);>7%\$KC-L#199CZD@#^1.9;_P
+WU|/X\$7_M"W25K.6-W7V=B-@7.D M)OZX^K0|5CUF|LG;Z|^<0O?ZE^T@G..|##&^?ESRQ) '..2<<8-6|6;SI M?
_4Z9..5|0TG3C|5ISEAA|ARR&1E5POW8_C4@_48|G2F MU;Q1.^XM;|>ZTOX|0L|+FWE%LX^RLC^""..|P880>%S MJ=O^|D<\$3W7V8D.L3*1A-
_1.P9Y|N^AV.N|B>F^(&OK8+9VDE|L V7WE2 MS;MW^C P;..R|NMHJVR01^9(P^;S-F|W.G;G|9&L5 M>+9T%3.#^PR>22,-@FH9?
AO/=Z3|UI<;P/HB MZU49XO;75M 4:UGXQP6.X #J;J.TAX2U\$5.#J|HG6KQ|YJW-W|MK<0#>.#O MODY?|ST&|R<@&XGBU5/%@9|@|MY5?
4R7CCA*|F.E NG)RN;|>>GTKJ0& M.I7FC>\$5U2P>);FSMGN\$|U-ZMM;." 1UOZUA?| ">(KJ709-21VMP^CW/ MG1NM@5.PV%G->?>P>HP.O|
|=5KFE|ZYH.LH.3*|1QWMO) S|EORR9^TS0|S MMUXBU^60|L^..9|91QV=>+P9KCVW^ANZO==M9)=+\$+1%BL2J2*8_+MYRY;
|HZYQ LTT>|>2_X1CO-H|ZM:EMGT03)4M8|2S;ANB9X|I@2B^XX^DD|I0|CK7<@<N-%|6|JJK+J&
MH; >6X9|BR|0|CNP3.3PIP;12?>2FJV.M6VLZLK.O;7C6D=Q^ORVIDAN63 MA^AP58#_..#O1^PSN3X;..3FUYX|Z4Y-3L.Z^W^M;R.Q;^
V^S^XZT 2W M?B^Q7|E>)H2SC\$66G6AN|^N;".VCMHV5XRRY<.2<^M@CW|H3>&M?U^PQ|>G.MK|S>7U|J|4M-D42 M;"&(O-
EE>L;|@#G; HME|INBY5C<31526T^0F2^"@;..<\$3UH Y5)-3 M2XRSYS:CFCTC=|T@.0PH:8JP^4I=##<\$-APP^8|XX/3*
|L^70|:WJT^M+>VUM>I+<|OT>XAIN>! M.K;3&2?G&O6 (-.2EZ5|PY|G^C.R|0R7|MMMH%K-K=;=@6W.K.P?^ORHP.M&H?
EA<^NK0Q;G6=0MKJYT=-.6|BMC^;=C+M8EA3NR<2@#K=8XVD=@ MJ^*68G
^>O^=2UBSTOO)HGCM=0A9|JR;UU"\$2@F.SEP(LCMLV|Q|YFKT_Q M|U|J|NF&R|J|^W65E\$YFA.@>|W@).N-PRI/H34?B?0SXD|W^W^BO)#&N
N Q& M1XR8H3T8+D<@X(Y44 O=|M)TN|^TGPOH;|^M)=|AG64DWU|9Z|Z|(DPH?>.#Y|(^890|I8-S28M5UQ2M6T&5_#|Y;V+1&:
MW3+=@L.C^0X&D.Q#0?EY2B@|T^BGQ);+16|;."4;T+2^R8B@ATOR0#^|M);1G03AX2U|5_#|HGBK6Q M|HNK=K<C^WMO L8.#OODY?
(|R>|C@E=3X>|V^).M.2;|50\$ZZE|;(5MP+3RRYP0&E<2^>@QSR2367 PKW4?>M0>X4.L6N6N?^T 9& Y|<=C;O|FW<^|*+T>OZQ|
C8Z5K\$|G/93Z=+?1M M.P-&T^C90RDECO&&Z|_S@="M>|L.W=|XPL|0W|Q9^|8|MW^*#|XK+|^M M=|V^3|X|I;30^S|;..@3A.Y\$9ESIWMTSC@8H
H3>(^M^Q^XO>UNM^A L&G M+1+6CMYRK&)-I& Y>OWL6Z^%#S|NJ;MXN|W;HFM2L)HLYWE|E5)0Y|O)
M^"Z5JP^M^M1C@|51G4H4G7F9|L;+|1B|^P#P;/FHQX^O^(>);%5K9+ MK0=|4NUJ66;D5^0N-AL^H|F(UV4=M1110 4444 %%%% 11110
4444 %%% M%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 444 M4 %9FK; 8Z)-817K2|U U;=<|3|C|PMJG.8F_X2
M&UV&3.T-
A|9QSB@#N.#XO/&M^#M3U.R|02VVI11Z8^I6=O?#Y|)5@IB90;8MWQ60B&PC.TGGTRXC=;R66.&|X&5;Y+*3QM.2.#F@#3U3
M07HDM+Y GR|V|JOW.L\$1D6W9P^N"(X(/..C..BMRO+=!U67PUB^|F8=U_<N^NUU&YAM;R|8@OD+1 MUXB.<|S-DD|^*
YHK@+1+60%|XBUV+|P|5AHM_&)|I|E;=+ 8P|F^5@# MUYR<=|U2R1>*M3L=\$UK3M.EG@O7CDN+5EB6+=^=R/OW;U|&|<|G@4>@5F
MW_B^PTW4=-L+AF;U&0QV^V)BK\$*6Y;&|P#WS5#Q|F=VO@+7.FRNY+6X@L|9 M4EC W#;L|G|H>O|7;O%>QQ_#E8|E9.AKL&-
YD^5.VS=0N_X_#J.M^I-S M9VMX%U;0SA>5\$L8;TS4J|H%&L;.*B*^JC|^|C+5=#7Q;D#?S.M0J|+9(O\$GVC 167A^OZY%Y;.G7GB9?
%%\$;|G/H|T&#2>=(HWMY|T^".M=R-R,0|ROR-C7\$&F&|F|JLTD^F187D)|S|MOQDD^FF^Q|8+>+F^CMM|58I^P|B1+>#%W,<%BF|D|?
^%9W^|D^?;8_|P===\$9|8FU2TM|O M2|5;|JSR2|<4JZX^*!1<|Y|0^_JBO.2%7BW6=^LM:U 7 ET^ZC\$-C#%Y MJ- 2@W3;|F-
FW.O.KT^|JY|V|>*.COW>>^M(OM|MD|E)>PRS6028OE^X\$S.9Z\$T=-8^C#4=(=1U P;|BCW/DZS|K>#45\$2 N6B M)U=08?=-^M J>>E
^5ZAJ5MI=NLUT9-KR+&HBB>5F8|4\$G|JRX_&6C2W MMW91M?=-6BJ9Q^NGW!;..5R-G<XK=9%8J64\$J<|<|P#1;T
=K9W<%.907EL^<^>-98VP1N5AD^Y^|U-F;7&WNMZA=UJ MNBZ+?..&2%\$H>WAB<^;ZE@&#L.(%Y^#DY|(QSG7^B^Q@;WPC8RPV>F7NKL
MW*7<D?F^3)&2&|!#X^|&^_0\$|;_0Z^X^4?%O_F_|A|?5-/5VT3|6|S^ M9DXE\$|JH2
6Y|N@YZ%8|OB_Q7^X|O^Q)N|^S|^NY>XB^|L2+P1R|&=WR9^8 M^|CKS@_H|FL6T6NP;.RS_!H&G5A\$QCV|0#E^@/|3_ZU;^173^<^*%@|
(^M=6 T|3HFH;E^T)M^PD M3A<@&F>F3G00|Z|2\$A>I YOS7^YK6H17DBPW;6<|G_+98HQ/-+SD.MF^1^H^Y;|H|PKG;S6-3|01?
#C40MKY3U&8/-#^H^".(=MW0)<|<|S@T M>A0ZQ;3ZW=|0BSBYMHDE9PHF^&G&Z&|=0|T^XP^&^S30^B6WU&6.33M*
MTR.^01Q;7P?+9.3DX3V^M5^" P#%6M.1X/TOQC<2PS6=P8)+RR6_10S%0#& MW4LNYV10 K>+=;G2 M0UW>VRAT^6\$|E5|0|(1@|C5O2?
\$&E.X9UTZ|66ZW;9\$5^21^T9& 9^Q%<MMHW_6CQ@|0VY_FU42\$8&G_&IPA<6 VW&HVUU;WRK_#BAD^70YY_V10^ MZ329&
<9&1SBO.L^%VL6=UH;W%Q#++?L+^|M(8|)\$^L7^9@.9|M7O/4|H MK36KS1=9^&K7U_=-P;28V6 JH+Y=4|_498_GDY|
+|HKC^4|6?JM;43 M92W&GW^D7QD2^6YVY5XRKDE<|8.3CG=E0 5FKUB_B|14R_?TMOM3^T3| M2+W|0\$|QI7B&ZQOH|H|LC65|
^|A|>.%3 R| M.3STK.E35+CXKVZ6|U;P7C^&%|V=H_."GS^2J@|@G|DX^O2@#T>JF|ZC;H MESJ-X76VMHS)*R|LY"|@9)PH)KC+|4:S?
>\$8+F>RBQ8MZH|H+V|8| (TD9+M;^?;..@+SRW0|A37|S50#WCS3|MEV7389(X9I(##(Z;|Q0?P02>PR<4 M=!=>(|
*#=#=W)|UG0HFNZ|H|S#KHU;YD#Q|U MG/WGC@H^#(&W&|@|)^Y) (H&G>HM<8^7+SQ+XEF;A9W|G;ZG;W4YM M@JLL;|XZ| M?
2@#>|!#*&4@|C@(|T M<|I^LWEA|7A;187N)|F^T_|098HXR|<|C^AB%SEQ MTR<|>E35_\$GC+10^&|7MU;PPW%K?
Q16TTF;YNH|)%4\$JKD(XW^Y^H^/2^*M^X+5=2|Z|)&BVL^HZ9<4M4;.%1EV1&(LH|S|B|HR;+|S7\$GA
M^U|D)9=;\$T5HB^8K^C;V;L^%3SD)=NX_PU35L2!;LZE=065REM^Y+28 M=LXW8^XZGBK|>+XUU>Z|&>#;B-
M|Jm_-VUXGE|LAVYML^?EZJ^U|U|02 MZEXO_6L;|9ZE9MOEY<Q#..0NZR^RXQ@M@GY>O3^G;G.W|0HD) Y-<M#|BS517|^'=3EEM++
|9+)%?SKRRE^Z@0H<|F9D^&#@&|L#7_>\$KZK|_M#F^E@FTW5/L|F|Y;SPEXOAU(^4D28..=V2^/7^Y&^UG4\$|0?|F;274L
M5D+N.YAAB.GSNRH+(4_6SP>W3K6IX\$NM.N|S10\$-BMJ|^2\$P4KB10?E<M_<9&_!^&U110 4444 %%%% 99M|LGNA=-9V|7
(|FF%)C|SC6;.*M^BBB@ HHHH ***B|BBB@ HHHH ***B|BBB@ HHHH C MF@BN(C%|DL9ZJZA@2P+>+%%^!&
(X8TCG7HJ^+|H% 11110 4444 %%%% M|1110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%%
11110 4444 %%%% 16^XHV^XAM;#8KL6M08WT5|M|T?F^73.RY|C3T|C;E%'-W7A^#6^OY=-E6ZFO+(V^|J|RUBA)R0H)8|B MV^23_0 Q57|
^%1=T<0PZCXJFU.SM5VVT36|QMTPOF^2^H;.>37644 W0^<9SSAD^A^YDM-L=5U|V^T MTJ9|H0+29)*T8(C|QM|Q|P3@#)|#U=|
^+X;GT06==OKB^AN8M6E65X1 M;A^!^9WG(V@=NM9>@>|=3V|N+^W4W+^HW+|+>UNID1@ZA14SLD=|R6|O50RD9^TS7-
#P9JTD7AS|5KT\$TNBS^56 M^P;1+BR|R^3CY23GGD^G@=H|0|OEYX 35+WQ_>HWRRVFO10QR0QP^A.0PC M^XYC|3|U5|PYH&NZ6R#6?
\$|FKOP+M@7|L)Z8W.027;"8DT>..2RCE=>0P>?>D<?..N.5|ZGN=.URIC2&5|(-ZF806+ M^B_@8RG;D<9P3@|5MT4>?
ZWPXOIS2_&D&CQ&4T|5KE|IM4^QAH|&8-AG M+2.@^CC|3FMNU|W|G/A|H|5AF9K|&2\$6A7<Y?<^W|)/8|>..=10| MR_V^>?%1=10>..3U6(6-
S!\$)H0;MF@(|P4|AB6^|<+^5+X4|L|O+5U7Q5IBO MY&F|RW9659 J@-|J|D C<0>+>..=@/5U1 8\$&|@&E &_4^?7G^C^NFHH
X 5_!FH2^<|0|?22+R MXB6&1K99XKA5^Z2|PP^?..*9|OPG>7&M>|J236 6TCS22|MMJ7^2KM9S.MST>?>|NYHH XT^#-337;C4(M?
6..|LHK2|B^F^2(P|B9F.S|QR^&ZG|^T7P_M_OK?0/#=C^KJ|^T^<207^6>49-A3;4W^AZ|NOZ=W10|R|A&10\$VJZ|>7T5S
M;ZE9|936|MH^+NYWAL9.YL_*P|Q>?>5T^T;WNB|H|T6TEG;..H2O&P;M-WW8(|^|)%&O_!^|B@#FK3PU>V?B?7;.34H&|111B)K0XB|L\$
<^9|WWCG MI^6?M^4^3PMX7LM>|6|F|H|1)1%Y9^Y)Y&X|UN44 X29X^M&C;U Y|5UU^(">&O>M;Y^Y MK?>^|I1TRUP+;W;V6^<|HDD|)
<#|@.SQO6E9AU|^|!&KZG_."M<UM^U^F+ M=@A AV@|@|G|GGM@UNT4 8&L^|J&PVA|;^%L=|081\$UKH|6;L>+>|(TN|359=3@D-
EF=)NW(Z>9|P^8X.015N/P|J\$;^F MY9|>A M^2>99C|V_EB;L;..C^O=NY;OVM%_7^@HGT?POIXU>|H4T.R0|C|XQ(4 M4\$>9|0|>O|TTK|
7L|=2T;|L8|FA>YA^S6CWA=PP3MR;|26KM%_%"OX(O6 MT3POIPU>?V|^#_DALR2^M^B@CS..&??T59@|7&G3;S|6|+6.K2O|+ M
|OQ;5OAVC<9ZX(|^<NKH^Y^%|A\$9_44FC7PT^PDDAB5X^#O_@1AU M&^&4^|/4 M6_6-36_#O|+DD9O+2W9U^M^A^DC|ZO44 <^=?#
^%YTG0| MGB|K|26|I%&VUU^&T 7RRJ|4.L=P(49R>N>W%616|&ZGK7AB72|WQ|YMW^+M=O;#;+<J&K^*KW)|R>>F.QHH
Y\$7O#EYK5|H=T-1@|?2|D71^V4L|6V ME2|OC;..?ZTEIX.O;O/KFL|H4^58HH_)JW7EA@ISYG^#7|^=Z2B@# M@XOA|>0^%|/#^A)K<.
&O8|H.8V1S|Y)&E4CS..2VWB 4=>6&10 M;RUCMA^XNO^G_ GEGC@2A71T4>267PYU^3+P^EEXAB6ZT66Y;5|F=
MNB3DEPR>9U<+>#^%22_#B>?0O\$NE2ZZ|OZS=?UD LH;.*?M|^P0&8QPO4 MAWM%_?M^ZMX^U6|U3|L|O\$9L=?
MH#;S726@.*XB+|MC|1%N@)|X^8D>L^|CZL MEE8Q1;(+F.Z6>N^MD;|4@|^|&%Z1@C|^|QW.36Y10 4444 %%%% 11110 M4444 %%%% 11110
4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% M% 11110
4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110
M4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110
4444 %%% M% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 4444 M %%%% 11110 4444 %%%% 11110 4444 %%%% 11110</p></div>

[illegible]

M^BN7LW3?^1I5MX8'=N^#/0Y.ZK#1GN+K.NX1X("HN. M#-PVXZ<>|H-X(6:2?#^GG5KE4T.6*. MW<1IN=HU^10XY&^1QC-2XU_6I^N?2. C2W3^S^AN3U. :Z.AK1TCPL=F^U^f6>|B.Ef;I&/MM< MKK.JZKJ_PUU.WMj=1/I_B\$6(8;\$>2.7\$:@2;1M)>^!/(I|UUL^A4=8&DZO= MZy>^Y^J6)FECBNTHMXWF@1^A PMIB.G+>97L5V9XY3\$+M&BE222M^ MBZC@50AUC51=VZKXET_4WMK6^6Y.LA\$5.6R^F4+ ("DOLR3D8W#&.<|LOA_M5fC7^%U:25H6XTD)53="B7S_Y;"CJ_8QC%:7P9!;OZG.V=1<6VFZG(AE MS:H%#;./Y;\$90-W".G&*.=C1OZOK_ (A1*812F^?QUK2)J2^2(JHW:)P\$ M.59fE/S=|CVf++7/\$S=&9AA.XU:FG6VLD)H4C\$S+;KM8LJXVF0^V.G... MZAO"< 1:7JUO=20)HMLUK:VB(OEB.L CIG^<_&^J6?>H%KMf7+Y.2YU) MM3=U2/f%=&17&.%#. #YXZYHY G1&ZQ:~S9WLIKJNH0K<:52XC\$XEVA0=BA5_4=:/<1J.LX7^1JXCM==M=3Nf^AMV M9#J.J)H2 MP:~0ZG&&L+L>)>?L.KP1G? #HHL@%8=LWK4FJ M0:GX4I4:L7^I3ZK8V^AG5T6:.. 1U=F^*447*=<#KG%71-|>2%TV+6+I85 MUA_M;@C\$2HXJ.7.W/7.276M2Y) (07WB.XU>|NYA)=FM2BB_X22Q^K MG);.. 130ZA-IW@4K05)9Y+C6f&2:~@BR^6&S_R_O0(? M\$2Z_83W\$-Q87LEG; fA\$00>.#FHL00)SCHH&>38C^&P60TYPD12ZM)929 M=1W-G&PBS^Y>=JHMF60T^/;^&17/1^#XBN=7TS7=4TIKXJ.Z^U=..DY_QNPR MG:Q^4CJ^..R1N7%.H^~8=#CUK^RS<:~HKE\$4.1Z9QVZ=JJKX6CB166^O17TR-1978%MMJE# M%N#8)(W9R!SFMNZMTNf2.VESY^ (1J_DU2/3M/AOK5KES5D>0LI4f4%4%=P! MZ9_56K^Vf+T;1=^7KZ6/1H.YM6:/G.8*HIPO*@\$^YSUZ5?G1%VEfK6JZ MA>W.EQ^JEH^*XM650AC<8<@<Y.CSF@("M9)XJCfOZ=..KS2Z5)<RWPO)(^>#C^M^Y8R.>="QCWYJ^XN|^1^?>P^N^|^H.U=|>#^1/ &C^~(4U^TMMAM^:Z M=2L(Q@<@10.IDXf5_O7X=3Q7XN= &GNY:WN0E:~%5\$+&X&00.10H6S! M.%f(\$:DDIN^X%|62^~(f35fC0&GBN;2_EM.4.H?(\$S^VTB0~QW8)/3_QT MR>G?0.V.UAM9M=N7MT^"11#&IE52.JOVf&P<8X)K+E^~4?B^U/3- OZKK\$9UO_PfH_#fZ8EQf;.<%=&X9-K^W ME9UVf<@1H.D;@&XJ)^f4.H-1;U>B^BTBfTU;C4+G38@f03.D:*\$+ACy8R M0^G>..NO/X#@DUC4INWU6^M;74X\$@O+^*9L<(FQ2&EE^7C@C-3Z7X3N=&L=M/MK37KPBRM1.D8XV5Tf N5 fA\$00>..(C&UU<..LJE=TDf5<~+H? MIP<=<5B77PRfTVNEC3^~^TR.FWSf(OK9E^GS&+&~4L2~8>..?ZG2=..MLJRIEKJXNYf;?+<7# O(V.G_P!Q0fR.B0W#?%KQ3NU&f..~VLBL;I M7#^4f<~>#6ICJO2^1+;?%EQX@M-4NK.2YMTAN+=%1HY2F=C^R;CT(S^=9B_#N%?! M<A<M=..9G;3K+L3S.B3S0.XQC=|>U %263QJGQ_U01K3Q^fE.VMO.W.6+ M-.Rf9GW)RfE2%YR<1>N8f;6M8f0>=&9126.IR6DMM- <8f18HT>R\$Df9_1D MEfIREL?#1L_%YKOU&6;1@C@EA: A-J9VD80?F?055?14\$ZM M;6= YDT_7391SR1fFWMQ_N0f@:~8 MY<^O_KJ=3f (07EXHYf87M9=Qf4.O.P:~C#R6^@H5=2.848XXKf\$3ANfPUX M9U)(+S6YH=5U6.XNf;=1^H^REY.f2S+A^#D^f3&..~NPNM2.XAS:~#J4US MH6GfA KA=)Nf8T/X66^OV.K211VFJ2fK(OH8Y_MHW02CfR06SfOP01CCC/-+X6.^DU^"=%*157NJ6fW^>ESf2Pf&^fIPP<(GS:MO MRHf9XfUH? f^fA_X0M0^YU:f-FUOYfYEV)fYf+W&<8QOYZ=.*.JUf1DTH6..M>2fS\$V)(B_Rf=02#7D?FEWf^#A&4WDLfTU_H^9P&~.91Z8)>N3GWKV.f;K M? RfFS^f7;..N:XR+XOWM^+YCN+^~QMA_2@>26GQ^4N7AfME9&fZf18fK^07D<\$<P^XXH0)L MOHfP<=QSZ4 87B05f5MGIHR6fJRfK^P%Q0P6^~Q0A(f1F+U=O) PNDf4 S M5>2Uf714UKPEfVFKfQ36^fFN)H^D.(W\$<#~+D9S9E3PB>Xf1_6U_K\$D.K7U MM8ZO^f(NRAVf^f1Y8^L5++H^f/3BGV?@?)?Z#=_VS=RR:~M;0AXXf2(MP52&POHfXQCfWYH S8:~YC^+&E.W~HfUOA5XY+M45&=O/&^X7D DfXYfF@ M:OK\$UGfJ7AS4=5G;O#~ZB+2f2XU+O M^~255Vf<8f7Z@fHf70W6A)fXfJ208UY M^:A0FG_9#~M&Lc:f^@P7X M+FDX&22.W7#U+42 &6EZF>XO;^..N=CL7+3D<3P_N^LX X; &0f Z^M=..MXEf&OZ_J5EJMOJ5Y6K6.F.fM M^OC/5&# AESS@TV_1%K7V6EP/K%fYEA>fM?^fVf; N0^~1C&#C &#M0fC7G_~2:5Xf1+Z B>>X2_~V^2.UfS\$Kf(NY M^;~#XfH>A(GfOVfC%=&19+&1860f PDURfLV@K3;Y%0#YDfRH2^fLN5P0.X^4* M3ZfHf4?#?..fB32:~.FCETP2^*)478_f^*?>D9Z_8P>^fJ1>#1\$0B\$^5+@ MG7^3.3&GfLE GR~MU1=KDVODZD; MAfWH>U5^N_\$f1>^X\$1fW- M1#fJf8K>+U^fYVWfM&G&SR_6XY^f7CC^K4L@_R;CQ#~4G+XfY^8TQ&0FP^%fJO: M2 6@#1 M=U+5=1+7\$MfYfU3f1<36fDfF:8HA^4M2fJQC:YB_Pf4 MU/7_~(;<1>X@BfMf&Cv)Y@6Z^N_\$@*#@<9&<BNOM?A1+^?2)f+7 MK^WfTZQ&G;T2.F.Wf!^fL^f(C^S9H~%LGAf7f18f7OEB^@+ZVD.QfMW\$AD M&KfWS\$>SF@~9f0U&T^f)ECf+;A:f fFD2W#f1.B9.BR(Hf (4^f>..G/2L)/\$ M6MZCfY_~Gf+13HfLMW^9%\$D0NfPfN-O)5>6SG<~>#BNK7PLfXGLM=75.F M6XM;1K3:Z)Bf16(9BY ~20Q@#f1BfJd7@2Mf1.O=AO;A^#O)6DDfL%PH8Y&~&M&5fG(ZfGf1^&4-5Uf6_~5K86FL7%CIUfH^ZAY:0QM)\$S2^E9E^f.#_-\$f1= M^-? X2^H\$>?003N?M5U9WUQM<0% IEfF<f@_M4GAKPZOAJfUN;f fFN4N+ZfUfE505=1MS8PfODT M;=%%# 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 16)XGf36WA33%U^fM+fJ>W.BOL<(2K.Of MY#..fC(=%<)>17_~2?R_f? MfP^CfTH_V-08YfVBF^M;L+3;9Q&+J=5;6f/M0.T.ML^k8^071@&@f\$^f0USOCX6C?#fQ+f;fG^P39W>NfT<~>^fG;?%^Of^Y^U2> (8f;5HV>8%FE4@&f@fVfHfUT MUfH^LZYK^C:~?f 920PQ2)/PYC94fNH&GR6CG@fRL_3M2EOKf MADTZZM%M9_~22=0%G&=Z8^fXf1 M7^4P;V:fT5Y M;WNM:2fJO@BZ MEURfZXf97RKfNf1f^fJ^X^87f((ZDG:~MZ1=;SXOf.G7M.UDV_V^~010NH& M&..4H8W7N65=Q;f^W&f0fTMOXBBGf677AfH^fVfVf7fE?;L=8Jf-N^3UfZ@ M=*V:XB%!+19-43>RAM @&Y^#@CfHfR^7fXBUfO@Wf>N^4Y_f2^W&f^~%SfH N M+~(88QfWCI0fZGf(fSfDBQf/RJ2(Xf;FIAD@9^f1%< fWBY=6f;fK5Cf1<fO MZE.L8CC^EH\$)(O^M5;6fN\$?NM>(>~>N+.2YEM(5@f1SRPQf(fM.fE@ fXPfR^6CC-fU#4~-%/P^EL;V2W\$VfVMM.BfJfL\$S.f;f)(Z=B.f^fL M-% <6>f;~&L \$%M\$ X2^fM;f1/f@N(MfTC^#0LS_~%8J>fEf@GW^fTfQfJfS)Mf17MY<50-0 GfJ5ZfJA<(K2("3T3>R^"~>;N.\$B@~fTZBN1^*W&fW^B3Q#^+fJ\$ MUWHfK+^"8.P0fJ24#2+O^fFVMODDf2#DBNNH **fZDURfM^f%L=NF_2KB74P M+&<~97E00^V+^fVfN5X.<f=WP<5#9V_B3Q#=#+1+6^O?>VCGZ=fJCLV2^*fKY2_M ~RfH^@>P>3DF@~fTNB0;~fWC#50%BZ39%62:7fEOK@03^f1f.C1YfP<~>#<M^fPP.T&K>(K^Yf.^&M0L^f01f)05?N@~1MPf1^0\$CD@~f75 MKZ33=^?0fYRN+V2^fRVUN_9#?#?#WfJ\$~UfJ3;6SEN@fXfF094@&~fJ2N.A3 M@8)f>M^X9+MvYf3R7=PKS7f0.8^~2(fDf8<?>@#Hf (f2W>f;UfAMQXHfG MA^360\$A_O?#\$D&M^*6XD6XO(&4fP^Z)f1V9>..UR^GK0fW-8Qf11#Q@/#AM M+@3M9>K.=OELH=4P.^f?U;3- (U_5K/4HBYT^~4fFV_MQf100 M>5(&P^6Z59ZM>~&^?Z%?2V>fJZ>26SQX.Y@#P@&CfZ^C7 M3^~ 3Q3fL.H65S.ELEGYMQ&6Yf1CM^fOR5^29ZE.D=LfI+DN46+QWfJ#(&fW^3UKfZXfXR^ADGUW_~fW5(00FQ^~\$9^BEW M5 QfANS^~4.2Rf41>f(Hf^fU.fEDS6H<+~<+&(DN.K)fHfWR^fOH^~NHKQ^R_MUKQf(AUHfBF.O)=RW37^4LfCC^4L.WfC8_N2<f^f.# %;7C#5M3M(f%-S M:~GES3Sf1^fKfJ(SE25.#fQZYf^N9f076H MWGPfNf6VEH=U:/1^*SfJ9U1 M-)f;AJP7SDM+62YVJ?0A4+8f)f5PNfZWJ^D> f19QZC(X=3f1ZQHfVEQ#f18A.CfRf=L@E#%2N^>+WQU_MZ4fXCAT^YfTf&fTN)fJ5ZEE^fMVQNY^fLG;f1>E>~FE7NK_6GOKf9ZU=; M4PMfH^fVR(6+);N=PfRCGf&^?4=V36=0UOPOX.GU8Hf fXfCM9Y47^RM&T Mf;P?^YfYHfLAU^677+G3fFTZCBAB2f1.QE^E2ELY3G.1CG_ /56QKfCf4M2 M_P^M^D.DfHf74MQ.P=1<6fNP4^9Gf1^Zf1U5f7VNMZUJ>B^M^fJTU2X76+W4 Mf#fEM&%AC^?SfBY^f1Y>fT^f1.DDT >H4QYHTECCf10fF=BDfM@9.fZf8; MQfJME>~*fJTU.=Yf-A66V2R_6Hf^fCY^fY69CGYfN(f;<#;~?>1R7WQf1+7+W M5RAGTB>4f)A^A^8C@~fMG/f<f>E^ZfJf4Mf>fA)HfUfU:K:S^fJ9E_6X&=R8 M^fYQ_GC0K\$Z8.GH&E>f^fX>f12;Mf(K-9E4f-ZfXf!^@9_9f60@=;U: O_3 Mf^ZEX.N@U^XOK^4;Zf3KR^~0S2^2fJ8_Y8^f1<8/300fW>4RW7M^YfTOW M>f1^2Wf3Z>7)fM+CB&7fA5PK)fRO; ZG>~>CZf1=2.EH^A=RG;~*5AN.B;=~>N M+2(W\$GF^f1=8Q(V>20#GDfXQf074ZM>ZCX84^f(XfZXO;#59VfLfX(9EDV%E MD4@#^0Y^W<=^ ~VHKDOB92ZAf7@#4f0TRfDM+fJW^fKQfHSEU4@f@>Q3fJZ MSf^XUG1=^_26;B><f%Jd+1)^&L2.fP^QSG&0fGf-^>T5YCXCGf8 M:~X#1474Vf2+8f1HfRNDfLRQD@_DA^8..<^Kf15>OSK5CX^T^3Df0WC6VfLV MP9E;~^0T0f1&80E^7AB=;WUGf@~fM-509~ fTYO^X^XQ9f4+K;6XfDDfHH>f1 MHfJE6BfMWDfA>~<#>f@;~fVfM0Uf1fUYH^fMZW^f12^f\$8U>Y>fT^fYfCM:UEG.Cf(M(U=0WRX)&XG.^? f5K6(9;SQWfXfD>^NT-Q.Wf1<+)>@9\$G^C3)W^fH^fK^U3O M1.Z9=;+~fGfN(f7N%@&N(BfCf^fE@2)fHK M96-B.fVXKBf3M94f..#6** fE\$DEfE97PY3_L_O^CCMG^XT>fJ5YfC<~>fM4f M^R>K;4M0338;2>SENPNZ.SY4ABH^*A@~fTZ9KH&fU3V_B>fTfL.CfRfL.fEW M^fLQf&44 MHS @ON@fCC&1G&f1^?ZfXBTWO>8>~>;SfT^fJ.AfXf1^fC^>016Kf7FN MCW>G^OAO9f BO2+K^fTfT2ZE+Z;fHfB@f)VA3P5R<8f- ~K>~*5U03+f^fS MIDD.K2B>Y60R\$KfDD0^84fNfWfZ^TH^fF&S;3K_9^9\$K\$75.fE00^<~>@W#fQ7 MCfVK^f80AfK/B0^>+MfK02=1G2^fRHA^*B3fL2#;SES?fH M^=f6;9YGR@^?CfVfP.CO0fWU(S^BEF(50.DDf1_4M<_XfLN5-GfH069CfJ^~*M(49V\$ YE.fSR)fGL9_+^A.Y8>f)&@U73?M)fVQfL8f^fG^fH-3ZE>C3=--MN.fUHf9fUMXVD;~f@fHDXR0_~C7>#KfJf0BfK7AM89K?3f2SfJfGf)+^fT>UC@3 M(H^?#~H.U=EO.G0fHfBZ5+Z>U33fHBPfMXX2_8XON=Pf1Vf68fV;CfCG)H MZ50M6BUW0;~5H8WCB0@Gf1QNA;@~>fLVVf6)/XAB@fTNf1XfT447fPZ>=BF Mf1^f(Y&9>N6fK+~fH@GPW%fJND^ABfGDC.^94^**J>V2Q) (YPO^6f^fFK M>Z;~3VfMf16%W;DL5R5f1Gf6U#^*#D\$^P.f1DXf1>f2:6fJfE:3Sf1^R7^*1 Mf1^@.C%<f^f!^<_0U#^#f4fLNfMW6G- fUU^%f!\$DBWfCJ^fE+9RfJG;7# M76fJZGfPNN+C4+L2W<~>8D M^#fD+~%f!80NfR3SfGUKf7Df07VD>+2%OGW4UW8Z9fM\$5f#;L%&fXD+~\$ \$YV^#DY- ^>45YfH6MZOQf@~2fB&E+fMBfY4L4O M4%\$?RE=XVfDf^f%=-N8N+6>YA@~fAUAVY&YfHfS\$<9(Z9/M7^fX@/U/60^@~Z MfNfJ29)+3^0W50fKBXO^<+~+LP^HfS.PL2%)fO=ZfY:UfA/fAf MEOXfN^M\$SLfS.%Vf#YO.E_N2.#ARfD\$#C.NfL^~*75+fVfKQHM)DLf(\$DZS M30W_Y#(2F-f4^f/3%_9TP2H96B#fJ9%4.RYfY.<f1<fJfHfL=7U^+PMXf10 MS:f1=3S.A>6MK7;B^6TPKRYf MW0DXf1<2<8Q0fWU%^+~+E-f1NK> fFG6#fVfR+~fT@B+Q8fRf02f1Df^fYHfH(MH0#&EK?SVfLQ\$9HX3Y.WY2Hf03DCC)3-f7-U M#^B 10\$5<~>U00.f1@D^Y)YKG_~fTEWK7PfT_Of:=A.9KVXfLKAf8>2fJO.AfS M7f1.f1SU^f7f00fZYf14- fVQ64fD^<#DKfV;8>36QHfD^K&B6fJf1(fT<~>Y.f1W^HfW50ZA@~fHfUP-fHfXfP1=7f1M9^KK?~ "3_~f1@NU_P#12TfU%%% 1110 4444 %%%% 1110 4444 M%%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 8?BKPOfXfLTM M=..NKVZMK<2f^WV^78"Q5@RY+> 0%Q6Yf10fSfF>~#K?7f1%K>HW^fHY<~>A_LY&f M=f1= <7ZWf1N=GL3f17fMS9^f1^ MVBVEV\$^fT^&f^fM@~MGMC.fYKPO82.CXDf1>5f1=Y:17- ~D^f% ECfHfWHS M^>~1N^f1^fKfTBf@~fDM7^fVEZ@+~+EL;BfT>fTR+6+6XT^0fZQ^fSD\$OU_fJ?fJ MO+3=6Tc.fU9f59f4%NK2; f1#fJ2S_Z4f0=f^f.XXQC&~#544 DV>fZfJfN^f4SfZ4C_1HWSG&8SC.W.fJMf@#B@OX9V-W9fQ8^6-5CT_4YVN6M\$D0f)\$S^f93 MMRfD? =>^<V<~&M>/PJD?B:#7FU2^DNHfV>U_~*L8.22D\$DL>~fV_XKH^*M_/6^U^~>G7Uf_O=534-0.fL<fS.fLlG5@fJ^N%~X^KCCUK2f1/f#fNC7f1BM6 MfL9=0GfO)fHXf1>0YfON_VCC^RfOZAJfEEf-O.PZ?~PK3QRMfJfTMMfJL2C2KB2WfN54Pf1@Z^@fHfSYN^fG6@#3f;7=ZfHf6=VfM^Y?fCL4EQ9 fVTG@fPZGkf1O.<4W07X;@f6Z#~HfJW=WO.OfSf1^fSfL^&R_MRG^f2MfL^R.E%&=2;~KH4VD.GNO+>~(Q2F3_9QZ_~?>8Z5D;fX+&@f1 MfL&OZQ>B.fQVHO)fE<6XQC^C.3CC+9P.fC)KJ^*~.7X=62>~\$+7PRNJZEfBMfMO&~80.f1#^8fG9C fGfZ2W7PfLHf760=7U2.fUA^fHfLM(Y\$^f)(4V&0^NfP_2 M<f^f(XfKL8DTf;O<~fV@_?0_LG4f^fRZB=4CEU.f%GfJ8^W M-fJ+~*? +5^M^f4fLN00fN.fM^fL3Q^Xc3PKH4fJRV^f20f1AU^8fO(9+M+O M^ZXf1VDfO)fD<~f1^f1O#_fGZfWfJG:B^XOKfJfL_M)fFfCf59@f15.fT\$- DGBG07G^@0W2^~Y^D^X0D>K)>f&fT\$;RZ8=GB^~MY\$RZ7=fUf1f0fQUf1+f26U;5=2BLf9Wf=6<4BBfS64^74f=PZ#C.#Wf1^%6 M7f1%00=Z)=C5Mf16ZfTfDfXf1.Kf1HXVQN5_fEPfNfCfN^f.WK60KNKfH.B7>fRVfTUQ# M:1--

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

MSJ>GV=Q^W5I;032D?..6959R>F 3DT-NM^TR^\$(N1.MDQ_1>_."K>6.F^R M..2/K:(D4:QQH(H 55& .P^17MPUK87%PD33-%\$SB):KD#:#
(G17)0^A^M3YK?0)TN?7MM5G>I^A^*0 RA@HCVD93Z?)^8ID/U^TT^BZ5=7WV^XTRSFN^+M,7GR0*5I^U>U<16^?XJ\$%^=+
FEF=^T^W^CEUA^R1%I^U^XP^#IUD:X^BN^SVN^M2K93Z)=O1^E^S299KSDW0+...61IG "9)SDG@=ZT=-EUN^7KNSU^VAUD+>.2U
MN(8BA9MSI^U<\$D9^R=7I 6:00-&U^">WGO=)L^+F6W^\$+S6Z:T8^3.2:/PK1J^MK:;GHV/):WUM/-%_K(XI59DYQR^?J=C%MD\$3^YU7^GD^*=W-
O^G&^9PIY^1..2023VM^1.SPOQ\$B22^965#ID^BDAU^?M3;BYCM(=0M)Y8Q^+\$DREG0A^_2@=""T^Z^HP09:;HJT)8Q&^&V1^#& M6QN^X^&
-<#.041="TA-5.JK15D^1^L^P6Z>:>WV19_6D^6TV^&G+J^%HET2 M^(&F4,2>@VYSSD?G2S;H0=QVDH;Q7A_2%YE5VSTPL30!^"-T99+F0:1 M8!
IH?7^#^V3_P^PIOCYOOIG_"/Z"(XXHFGI^P1&HMA4P/^7_QQ5FYU73K^V2Z MO16T^9EEF32_3@Y/^+UM=?
6:1T198)T:ON&G^;QECF.0#DR1003+/@5JKK-W9:GID&H1 M^)%J^A(F7_EG^5H^TYVTG^E=L7FP^WECT7(MX^Z>E6XH8)!:(8(DCBC7:D: *J@=
@IS;H7=@HJDDX^5:35=U_2R^M0I6Y\$?WS^#K1^K@4_#E;19_MZU^U^VCZ718^NX>16D3Z,1D4)K.ER301J5JFTEP^84\$ZDR@^IV
MC/:"^TT^B^GD4^/J^VH6MIZ^MKN9650H^+V^2L3=UB^Y^&^&KZ%_@H_ZF^MT^RU^U^K>VEO^?H03^XK12^Q0 L^"S2R M^DMI^MH5^&
1@1E3U^&WI@Y^5K:0^&LOL_P1ETFO@^S^A^IY5NB^4&QNVX^<# M..N^EBU^?3)IB^WAU^TDGFCIV^>U+^G1X^Y^O67XOUU^%LZE+J-G:;C%:
M236Z3LI+E5)"D@G^&^"-TT^1H^PIGI5C^N%*HI;= \$(41P^E9^HZ5>:5IY M_P^\$T^1+6)DG5IA^/8XW3^<(GRP^6Z8SIUBGQ^JXN^?^DQ>5K\$?
^F+Y(W^W^MV(O^H%?>N=?> MLOX>ZS?ZIX^MM0U.5);MYIT^XT^J0DS^>RBMRYU;3:X2WN^M0M^QWOLCEF^U56:/P^K^Y^V6G1^6^NX+^;G
>>0(.4FN=0:W^267B^PI^M^V^S^6IAU^YDGF4(&+J^F<=>GID^H^QH^UAX^T4MD&B<M%?^/M^EY^YXJO^&IF6U1+20=-17D0^L61^&59^<K^9-
*4TX^?B_M3IGSYV^E=-8ZL^MN>/OHBUS3YI(O)^#?6LES^GDLI^?8>C:0G1ZOIDUM^+ZOUS^+HTN^*|@\$<8^+2,N2V3NX7V^-%E+M^QI>^^(Y6U-
1.&B6)HFLX%)>SAOK:2_MZ0\$O_DREU^X.5SD5@>//11T^PKJIDUAJ5G;ZK!;-#;59FP>\$)YX!;-JH
MK/MJ2@BTBSNK^ZAA^T^7E<("O7)Z_C5E^VU>W:X6YA^%5W-(O_5ZY)Z8H^MGHJ^M^ZC8WMN^H>VIO^A(>2*5752.HD)P,4VRU3311W-
&&^M^K9C^Y\$ROMS^MTS@4_6Z***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***
"BBFNB2(R.H9&1^#PR^/0T<)^*V^M5L^12%6!^"-17W(/<^T^YRUN^\$UBV^3Z^XJ^0RZ==_PHSFXM7:&-I\$+YB>,L^MA9OE^8)
(P^=H5L1+T^3ROLK^&VMB^WC#^J9^N!1-16G7%1%>23V^K+=Q^2ZN= MX5:1/HQ&10:PMEIFGS?&"ICGMHYRN^VIXN^\$F+>:X+;?>
>QC)JZYI^PUJ.G6G^MA;PA9S>4MP=70A92SRE8+4P_MK08\$0QD15^WAJ16MOLS^IYMI^XD^HVR=-PZ^C&^_1^CNH3V5SX#^>L^EW
M;73^";>KM)^12.HSP.6&1Z13787EC8Z=1J^ILK>W>:UO4E10H41HPW^M8Z^HJZ^71M^G:9IM;LY^#;5,1>13O^C^ELCG^X&>E+>^&-I?F0R?
V;9IX0! M\$WD+F.^#IM..PH^Y+X9W^N.37:431?:%UR^9HMPW@>_U(XZY^YTYKAX_C0G^MXADT^XEN^H^?S.SI^?IO&W/?;17806%G.SSSVH^#-<_
NFDCC^M(25B^DG^MZF7EA9ZA&L=L:07:MN59HPXJH0^M^C^MY2P^1&2:.\$&EQ^<(OI/STCS/%
MYOE^BIBXXJ^H^V5EIOQETM^+V@MEDT:=66% @8+^+C^7^>G^>W^M^;7 M^A:RP1_ZAR&N>(^.N1T^".9I8;&TM^B6X@
MM8(HI0BD2^SAI@_DWD\$IA=^<K^H(E93&5^+^MIG(I^H^Y^<^?^Q9\$?1_9T0B1^KXBL^#=QO#\$2QA5-R^IQMW_P^45Z^K7AJ
MHU;QUI6J2VNGSZ7:6TT\$<L<|DL_F^%#D(4^%Y^*NGCM+&U^K%Q1VX4J(E0 M!,>F.F^*_U:V^W^XJ^>)K149)M^NEU+;@H0A?^W=B-
Y^QJZYWPCHNEM)= M1U^%+&W^_2+4XTG^ NH+RC^#Y&^A:10MM+TZR@D@M^"U@ADG^CBA558>X P
M::=:8V\$;QV=E^VZ^RRPQ^&Z@#F@#RS49^Z^<^"6.6WE>"JTE^ZLL;?) MN&>OXY^M71Z-.9?
BAXNL=412SVH^95R^MMA^A<11O)SIFNH_L^#10LL=M_9 M^AIGC8LD7V9_BD12!C^J^:ZT03IY8EN^UN!^JO_"K^ID<4>_KIZ^<(X
M7@O8TEM^XN6+3S+R39F1PH^!T@<=B=L5VVBVUM8.2%_7>RBB@BDTFUD>.) M0JEP@!P.^5V^UFGWHC^%W8VT_E^ZOS8E?9J.CBB/3-
/BO#>1V^LET>LRQ^M^A^P+&_61273V_P_1^2W80ILGVE490N^ZV^R^!<^WS_ON35^RMI+7QOXU_M^R^?+1+V44LRCL@NRC:B.P8H^%+?
4\$UW=U:6UL^M;W=O^<M0JZ.5_ZGZ@|5&^_M119R^&E^"T6^#REV^?IXQ0!SOP096^<^ATJ01JBC^H0;&J+^+W^0O^?&IA^!%\$ M9?#1:1FV^
IV^<TMP^13R^4^TL;2PB.5G:P6T9.2D.809^@IL^FV-U>TLE^<?B^4!!^JKCU29EN^H^H1><8;J.9_4^M=M^=E8+0^_VE^<^
^2XIJV@<R^&R5B6MO+PZAI\$(X1017.F6<|<^<166!68?^Z"/PH^>%;RT_P_M086>G7%QR^X:N7AL6^M^F^Q&NS;_Y^Z=?PKU#_QC_QZ56M-
L+H>5Z>3H10Q^A^ZX^-E^R^%U^M^X^Z7+89_MJW^W6W^XF6^_JH_OO+^1^Q^<X>D-QXIH9V6LI&TK^WAD0^K^MVAC(^7/5-V^/);Z1-
+T^1:12PM5NY^=85\$A16-M**&_8XHUQC4854&^_HJ^@#R^R^ZG^1^7_MCU2^>M^VNC<@C\$J7PE9DHIY)3&4_5N7QN^@/464W_V6^T^#(R9/LZ;Q
MUS76O?""^PM3=C&+@PKYG^3YL9D)TVZN1ND M^@^@^\$J^#6>/#^BK^#""(L1%\$2T:"V3:A/4&8XH^N3ORZ^?K7C^<1(?+=M^%M
M)9(K8I2<X<@#OY>?TKH=\$?PMK^OZ^%K6G^>)K^!@AD2WMXVA4I&R2^41%8^M^#&<-CUYI>/3-/BO&O(H^V2Z;K;L2AS_P
^QFDLI^T1Y3)9+^PM9;9YCF5H8_M50N25B!S^_!%?Y7X5^_6(8&/%K06N=^<E66E^&K+7;_N5U>R>#""X^MN7NDGE)VB^0L^V^"
<#1D8SGB04+NPLJ0C\$=107*Y^S1AP^#14_OHNE6YX^R^*1^4^7S8V9_3U(Y^N_O_MIK^Z^SO5E^&OQ>(H^Z\$HFZ3HJ^U^U5=:297S0M^V=O<-
^V^(S1^YC;U7(X^M^N^CDT^?3)H6AETVS>)Y^*R^I^<IEB=3ZT^PQ_+^<^?5)I<VLMWJL@F8"7SQ^Q3Y3SPH0+I+@=^<LC3//MBG_LZT^Z\$
12>0NY_@4XXQI43;-I=07)^L\$K_22;D>U M^"W7V27X@_#YXA^+O+8W@+H02RB^*(ZCK^M^<=;TQ_?O.E-G:M)^J^<V
M^M:A2)+HD^C^MRD;(2R^YJF1@FW8VGG^M/^<R^T^PIT^F2^#E^Q3VDQF9N9IR;1PZ^D9@&=H8^J>M^<=1DUN.YL^-/I
M7^FK;"1+&48BBYV^\$LT956^S9&05_AO^/AOP^HD^O^*2PLYKHQ9^/BIN^>=MH_#W^SRV^GCCB@#*\$T8^AL>V_4H(NK^QH0K
M>6>*=W@9(V8;FV4<@=^A^*NOOJ^AW5K76+0HFH6Z^#EONRPL061L>X!!\$ M=P2^#ETK3IJB2XFL+62>2/RD^A4LZ^?W22,D>U^D-G9V=M^
OAO>PP0OW+;MK8;IU4!SN)^#MUZ<8JY^=-J^OXOT^Q05KJZ^_H2F2WE;&S/_21D?A0_3HQ^%IEI&KSNJ0HH^X^UA_4<=^VO^<HW.G@GO#;:
M(I(RZC%9L3Y)C^OD9^1MNX@=>/13+I1>J^IKJ^?A^I13E5N+&60^<P+FI^M:Q19V<"P6K^%X(5^!^%9S^H^<@^XH
R/\$^PW=M^X^O^*VPY7H^U^6^WNT&A^CT\$^MRKQ_H^T^>L6+2M)ETSXIM)9VK+^/M)13Y2^C^*QO_=-GCN;NLM^15V4
MTDUI^X2@EDSO>*QE5FSR^!HUSXU2VL_#M3VT^W38^/M&CR7K6H5_+MMP(2;@<KNV^H0<5WLF@>)JK2.TEMO^HEM&VY(6T^0HAJ0N_-
M31Z9XOACUFB^A5\$G8M^IV4H\$A/4L^-/P^-&=07Q^HJEKAUBYN^=DCN M^/D6-CZEEO^#36V>)&CCC^T^&^YC4Z=JA^MH^%
&J+7&BW\$U^UKKGZ?7%>W<;JSNO/5?W9^W^/E(I^QO0DLJRN^"MUK2O\$6@>*_4VGW@U^*=KNU=H8V^HNB>_LA9OE^8)/
XQ78)HGBB^+UH^MX16YR6X6\$?)SDIM^<D^H6NTOI^>ZBZ^P^IOW.88LWG^S^N^<1.BOOM&B7%QI^HJHKKGAZ;7\$
M:XM7&VYLKKSU3,9^W@^4@&^%;PT^O6+TWHC)"/I^+<6.OF?H;TU=\$ M4)>?;\$@<(K=;BWG^PE^#Y^5A)H0\$%EY>.N=Y
M^0^UVRV^MHW8W8YQTS67^TVI6174+QE:QW&UA^(\$C#^D^W^DJ^VR3SD8 M^WXAW6GV?@/5)-4@DGLRBOR1)(8IYVU4
L^N^C^&Z9ZUS5C=6U0H_MUJ&G^M72S^<G&ZP;1^GSUPG^XX)ZICT^>D3P0W4^P7\$4M5^T32_M42^TNR^0HT^<BW3^<W51OP#W^%
<C>G63C^#1^O^%";P+=#5+10M^4L^ZL^76?1YVGG5^="EKTIM^>>>56.Y8+OL^41A<15R7^W8^M=N^!TQOC^DFTG3;B>&?>
3I26;=14CPI\$1CT4D9^E^?^R^M6.7X8^"Y%?;^K;3G!4^WJCHB?+H3K07(TV^I^&?>O17M<_H6-X+CIH=WEA5C<M^J)<@#)SM^1217^Z-
I^V4MDNFV8M)3F2^0+Y;G6W^&T^Y4G1B;20!_9EE@1>M0JG3B^=G3IN>=<=*)I6SLI^P^VW@ABNWU.Q4SHH#L^1@X+=2^"/V
MJTFK;O_P"(EEJ^T>L6^?<T^PP^LFPB#;R5^VION^ZUZ8="TAH8XCI5B8X^MR2B^W3^DI2^CBGSZ/I=U(^003C4;@W^\$S^G1^4DMS_#L^!HJ
M131E^%I^M^;18BT^GRP^>7CC|^<=7HW^#Z/1H3)^<7B
M#110.VLH(+^UC^TR^8A\$^RA#O^9XQOSGZ^TKMYI+T^YNDN9I^VEN\$QLEDA56G^M3I(R^*=2)@>W&^Y?
QAJ.G76B^_\$.UFMI^U^E7^3QO6N94B7^Q2^D08P_YPOXK^MUZWM>=SB^JV@B^C3R^LB0^GKP^K0I&F2W4U)IHHO^&8I96@4O(A&K^&2
M=C0IY8>_M/B^1KMI^QVEWHZ^Z=RCVJKXCM8K^#MP;=>18H\$6ZNDITZ6.FT58^X4ZXT03IN6.6YL6:2+BY^58H^1Q0I^Y^=6I^L?ISQ^AM
M;7H9W^7JK=ID5R\$.68GEB3R^IC%>SLK^6^AE:000R2^8^DC4I^G#6D^R M>^3@^HJZ^?0M(D>5WTJQ9ICF1FMT).>>>*^
_1G4^A^XL@UD+^L^UZ;I^H^9FBI^H^VX1^6AJHO?#^G^M^#&HQR^264\$5EJ^<U^SM^JAB0.25EY6^N^1^32I^EO5O9+^U>17V=H5+C^
M3YL9JR;2KM0177&^&1D1^C^#S3C^1TGO=>+^N^\$7B4C4(HV0^<^DQ\$ MCK^H1<H^V>16M7^I^Q&12C32?
MZ^%5^SA.OF>9+1MOIYQ^HABC^592BF1055R^M^0^C(H^M^A^4^Z98>)F16QMSENSUG\$2B0_P#_L9H^I^S^R^%_<F^<%)U^I^W^W^M^GO^Y^%<C0I-
^%VNC^H^RO7=S@>9SWK^DU33IOX^<+^34YX^/66I^Y^#P\$O_MG>8QC.^R<*\$^IEP.E>00:5IUM>RWL^A:Q7U^M^K^%EI^C^#0-0FU^TD@DT^PB!
IE_Q_<A^Q2^MH3NQM^<SI02^IQD7<=>"/>AS2:(OI^MWS10GT_9^D\$3M(R^#^&^T^4^D<M=JZI7_#6JW60BJM^0-
3L/LRP)^G&5^SD\$DE&^L^FR^@C^5JIZ^X;M1+M^M9+3H>#>8IZUL^D+8Q0^Q>6(&>..*
6N+17IOX@08/%JYS06GX8N13A1^7WVEZ^VGV66JRV5^MG^VRN^ZENI6MKRI^D^PVO6(BP!_9B&VJ^1R M6_MUO^K21_P^H1^<
>);I=64GP^>^\$108;ESJPF1B518^R/G^8GH1UIZL^6_MHH++XG>&ETR.WAEDTN^2-8P^%#8\$90<=1G)_@^H00%7IBZ!^VEZO:PZG^/"
MAAW(A#2(K#>GRL3TKM;+O1=T>X^!<K=OIJUM9@)YNI^<9693S^MDY8D^AKV75^RVA^WM^I(GM4AM9)6\$)R9\$^DG:1W(Z4
^%MK>DWMV;6UU.SGN M^?BG5GP@^YX^6G7^L7:3&^YU&TAE!_23JH!(R!@GN^FL^I5TYM4^<T^M^HV=K^YJ^02AEM^VMFVHJDE@<_
<9(Z47%OI=HOBKPG+K^DI=;^S^ZW5O M>QOL@I06:15^MTY^+VUK&>54IOUYD^M5TZWM^H^N^M8I^7ES^H^HIC(P<
MX^%>9_VI8>/%&=E8^AK^%YI.E3.);O;<7/E@<(\$SIU=I\$(5B^A3H^XJW^#HN^MFPV.^P>%-?>TNH7NIM++>120W2DKYJXXRA+^#17IQDC(H
I&M^RVOI9;FSN(K^MB^H987^#JV#<X^X^<K^G^8Z^J^SKNEZ9?PK?>#1^MF3;S\$^I^JM^C^Z<^MU2^<K^34^#A>3X;&?>
I^N(HX&+1/O6WO&3U5FR^\$SKFI^M;?QO1+^YBC^MGFCMVCC=P<^<TY^<#H^WO^GBBWU^PWH(U^5+1M.O^)^V@>B+^+<2N2P08X^
M@K=NM8TRON^MHO4_2WGD^<1RS^K^3TP>1>36T5E;2^#X;7^01R5^#=#H^M)^HIG1^#4I^HEW<^>+?GBW79=FFU^96GM93\$@N(&
&HID9D+^H4^Y&T8H^MH8O?M^V^X^QI^M7E^Y^_N^IVY^LXK^2U^#7M.19>=&^KB2/5(HIY^?LR^J^M8D5AM^8\$GOFNQTY^BTRTC3SMJPHH^+UF
HJ^I2>N)431)7_B-(BMY^M=P3SS^N^SP^LMY9M^M^AI9U&W^90W4I48AL(&W^%V^I^O)^+1W\$4EW\$JLL^S^HC+^E8^M
^%Q&^3IUSGBZT^+1^%EYL^H^45N^HJWFGNBZ^TQE0^85^7=C&<=>HH^I7^MM=7TV^O+<B5M^O+BMZMCB^&96>+^E^I^R^OIL^MZ5^4^!/?
TKBM56QTXJ^);61<2C1KP^/J^712C^H^%LW^B70;16:XUK3H0LOLD^M9+I^%Q^C^PY^WI\$<=K^CXNT2I^L^%N+R^+N1#^T@4(BKG)XY
^WSI5P\$^M^GID^F^%IWM^I5RLX^%5RH^<S^1CT^8\$^45^WJM:ZO^"ZIO+^J^*(Z<S2N^M^I8P0I9/?
K0^ZG+^+!^TFB1Q(I9W=L10.D/05R^BKH^&G@J^7^0^ZM:O=V^M^JFV^<^DFV\$^D9^<6<^K5WQE^#87/A2!@U^>PMI6B0W2\$Q_9%";
SQC=MSGG^MNW^<HX=I;Z7KB64H^HKK=;G9@J^M70^Z^"ITD(H^C@^W^<=J^I^I^URQO^M^ML^ZE^RZG^H26.W65?^E5&6^Y
YI^J6^#K6E^"%%@=2LQ>%M@M^/75^V^XVY^MSG^*X^XCLK^O^VMD@AS^B7^YC^&X^VSU^7+8/UKFKW6M+O^#BW^E=VUG;
MKXEBG^CYFZ+^23OD9B2D)^_P&30I^Z8;H<_P_OI=T>2HM^<+WFMU^MH1Y;7I>I^Z^HJ3X>ZM^ZW^X^MH4IO^=/
<T(O0D)^Z+P^BBE1H&B&3XO^M^<^DJ^&TJS9<#D;L^Y^YBG^?9T^X^V^QE^%W=YP^IXM(CO^%X)&L^M^R^+6V7N>I=VK^BP'
^32BUZL^<I^U^K^<PSX6M9A^1M^=1+Z^N^L^KL>8Y(I_8E6PJD@97B@#M^MT9^&H^JU@MD7Y^?M;G^>1U+5M-
2&_C^WF@HJA(SCY9+H7D^ABV^ZIX8TG2I9UV136;"Z00I9.27_O\$8Y^@O.6).3U.3UKT^MQZ(SV^O\$7FA2HTVX(W=^6V^UH^T;?7=(NIX6-MJEE

=F.2B"X5I^A0VT' M,.\$/03Y19TNUNM+C4K2&Y8+{#}.JN2>@P3GGM7FIP6-HWPLFMXX(7=P-18 M"E@UJ=W(ZY,^H-,DANOAI XRT_7-O) ;->Q>B163Y=B6B8#J/4(?^I D1ZD2=16RB\$Y?K MYFP9SIYUZYM9LNH?_5+4+H/JMP-<)/\$1^~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~)%SG/08Q^&4_&D>+='US5+^PL+V&66SDH@&7 M;EMHH@9 R_YJ_::SI=Y=M:VNI6DIPH)4@."^~T;~>VUCP_P" I(K02GVH:A:M_~5U2(?^_M4@=%"AAI8H_I'N:JWL'=IBZGB@A09>25PJH;CD9K^C(21O) #KQ^YJH0_-G(WH?+>QS7&:Y9:IX:U)ZU; MO^6ULG/9QJHE:OHSF.L:R=R5.X^YI(Y/_I_>N:3-937D>J63VJ+^99EN M^4ID=0S9P#1:FOZ>~)JUBURI7G~"A^XCOG@5SG&:(%8VIL8H7? @GW-ZXR*?V>F_VH.?W%MLD:PIY5PX-ML3SZY:HS0/ZI^J:JUL:C3:ZVO(CQ4R6JVR".HR"1FFVFLZ7?SO:9ZE:7 M\$J+N9(9U=@.F2 >E>4:~EVJ_%-WT5?WX^Q/Y_!K\$?)?PIW*AJZ/Q&UOJVI^M_I^O^C:8WRR1M#CBR:3&7IT7_074@=:~SM_:TJ_2=I/4I.X2#_7_#.KBA MWL^C(276I)@LHIV:4I^*TE&Z=IU"/4-G:KB:R*YV/_\$&IL+*Q>~*H@Z/M&.(+F/S-19B_-)ZLGO4>L:K:~#12A:~KJLFC:=<~5%83@1K#E?S(RSJP4 MX^MP:GMOI:Z_#_%0!~^DL4BAD=&~*P/O@CJ^YQ?YVG:K=ZS16EZA"+ZPCQ MOR&~%P/6)"J2 O:0!DCCGVJ:P78Z5IWAN*WT2>:31(I022L"~48DE,?>DG^&M/3C%?WFH^~M>007" M? #;4;~VM/(&\$1Y:Q1#Q+?7DE"1%RO:2>GOO!I^~&CS7>LZ3XE^R6&IZ:RF MXE5ID\$L3#2J6/R@I?2<<U0ZC:HP:IK93,N9P1D%?F_"O:,2UG M1I2QXZ46VIG6JG:E/IVGD0:H^AW.HJKN>=J5VUO2I^OPN2+4+9W@NK02 Mf9.?Q;NI#^~YXP<=#Z&@#TZ?Q+H5J&- QK6G1:92)8R72+B3&=AR?08(XZU M8N=6TZRE\$5UJ?K(I(R0+)+JDH:DM@GH:U>7PV.F2Z:15&:VM6^53KNV+H^ MS*>#V^~)^HJ2TBL(WO),#<I)~(^BS.^~I^BO\$.)4GUY:QI#0:Z7I^F7.FG4-MH-1M):L:E)E:(=3N!Q3I+4I#4ED:OO:>Z6- MKF?57VGT.#P:~E^WZ:I=G MXKBF@A>V/BR%(PTICA@D/E,)^*GA%9A1@W<M.H^K&9_N2VP<1%B,850!Z8N:N:0HB75+(R^H@N%R> <=&~0%N-9TNSXJ2 MYU&TAN9&"I%".JNO:0 \$Y)-><^K02O\$-QX)VZH\$<^C6Y#0Q7T4DDK-"(PB M^D_-B.0"- HG:XH6UIH>H6W3PWXMUVXLKHZE.9K)+0SHFTFZJHLH7Y=@4 MDI#&~*8JH1ZSI886SVR30 MI:Z9-KVCVPTV^VTV_~0IS!^MTOBP"?A=K^ 3BW\X:~ZT-U:Q):~XSI+K:ZK:_V+?QW:7&W84/EI@?~I \$G-M".E=1:MIU_8&_LI^UN+,9S<0S^8QU^8""<1KUSINK?+\$+P\$8YK6\@875* M5974D1+@CL<=\$2P^YC5+DZ:~^7M=Z6-IXCLHFZ6V4.4BQ\$TC!<\$=1DY!"SW-MH_IPLM5T_4S+~"MKHQ\$GD2J^PI@<~BL?Q9XG:0/I-LK2L:C5- 5N1:6<3G^M_Q_~^JCDXY/IZR_#K>~M5\5_VW1602ZOJ+6/DRO&91(MP91(\$50&ST!^M:KV%4?B3I-8>?~"BHOO&8:1=R+>E%+>5^JKYA I+CGZT=I\B/6PTM3K3 MM1CO+E:~+I:~#~RY&IRIN^&QG_8M2>1%IKJ&F:RRB_USTM^PRHGF5,CIGDU\$ MV0Z7IDCN^G^X6_-_%P2^I3\$I @IY/^>E-O&JCK>P3221RHDI):9+ M+R!#&>"H/I/8%CGK0:VL^HV-J"7%Y:O:<0K^JF0XS\N3SQZ4S3I6TI5HG-METV_M:R- &~*IO.L@5AV)46IKQW3K+19X9^~&P^LBOK\$@A6X&2-=ZOKWAS470?PINM+OK^H\$G6F">6ZCRD:W8^T:2_"(QVK+TRIT/5M M^U7PWXXKUVY-13490OM@%3\$DDSF8O&T7R:VR-N)DXP,4>J76O:/9&X%WJU MC:HF^F7S:A%~H-TW9&&~&N^*FEU33X+*.IFOK:UEOYG:U /K#S M5\$D4VUV5XV7(SV^OY R1TH_1535M-DT17Z:A:M9\$X%PLRE.G./09OUXJ:~I MHT:~>4LC9%MHN:M^~63TONSCU6MEYLSY^F&Y?RPC^ZG& I^*J#D M9^2KO@74)=0T:I^YTZ^RNH:Z>~*X%LY:&64+TD9A))XY%_%+4_~\$Z7GC^7P MQ:~W^ISI8>=J1HIG? SYDV+^AP1D8)^XRVLK:ZUO3:54W4QL>~ M5IYTB+14R3QU(2L^~*6)OC?>10T+PI\$^F1G_7OGC1^=8A?Z38+CPUXRNJ M:M:>36K? 5=3+Q2A09(I#N^I3_~#JMFZ^I_5.6L:7/?&QBU&TDNQG,3?7XZ_M+G^?TJ?Z0T+8>2JKU>PM_LY43>_Y5E64^N^YFIV:56H-HDWQ:1>~">~&V=? LMEY@=5(C,3IL^M^G&T=M,~>D_8+~+~T^I+I5<)YD_~GKOD7&=RKG&XJ_7B-BEK#^!_EX%B2 MY&K61\$W-/FE3SU^Z_708KVZ@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN:VO8Q M^=6\Z:I@P65 P^0X/>JJP_~\$7BK3? #7V:Z4+>W4=O\$&L_O_6)H#)YI_4 M:4FFV\$S.TEE:9&~#6B4B@I@\$.C>4N5OTP<<8KD7I_M4? Y=I+I+Z4+>=ACT:~>1&8HB(SRLO#4M:10HODGK76#5+381J6MS92_D_MXD:IDP^F#T:~^IM@TDS65L99>>8YB7+X_1DXYPO.? 2K55:~#4K^5(#/87<- MS\$K%&~)PVU^AU4XZ\$>AKE?^~IZK:>~?~VEV>I26HJK7\$SJL4:~%?+CWJ5+~<9_M/7.PH_ZF/2I/A1\$BL:9%CDIU L^*~*JX<<~WKC+PEKL3RVW#X9U^*%YD/MMMY9LTY#_6^9.C\$9OPP&_E6(C_2U:3/B7#X6Q9TU^SO+~%KN&~RPDT)4D\$/MP-MI4XX:~R:Z> (M%Q:N+X:M9&TMI#~^YZI&B&.IQS@^D<~UH_73!TW3K2UAC MM(&_VC5\$E:2I8M&I^SCCIVZ=JMSV- I=2Q2W(K+I)~\$%-3OIQO#XKLIV^XBL+Y(K?<~MBKL0V\$E_SROY_~2W5E:W28CNF:&XO?<%EC#^@U:2XL:IC^7-K:I,@&L ML88<<<0? E7^ZQXIW>~?~MEI6LO26IY<2I=6I6Q@ZB)V5LXSC(Z@XXK8T_4 M_:WNM;N:KO:7=K%L9:~+8#;C8S_Y(S\V#0!O1OI%&L<~*B^*JC_I^* M@ET^REF>66SMY^0(IM\$~67.<\$XY&U5+7O+H=I^POV-KJHC=RI^9(CYU+LA M&0P&HVT#(0^R4\$)^ZG)X/I:/6@IYTG33&L9T^T^ M^254PK@9ZX&~DDL+~&XBN:2IYH?I7(T8+)!#U^20S0Q^?302I+~XRRK0L^5A MJ\$=:DH^*K2Z:8SS>=-96D0^SO\$&L:~CIR17+JFFJ6OQ&~I:Z1:~15CJ4~R11MBBC)^E(I&TE*%>~(=G14VPUY~*73I MI2I:H^I5(^~N-G^YQCB@~M:HM@)4E%~2/Q^*7^XZ8_:4B:7I:4L:M55WSL+~H^F? WNGWO?K4-WKFF:8434=0M:~4A=PDE^XSP.YZ G@\$T7GB#1M/MG>~&U6RMY4B,SI+JE4&F/OX^IYI2)I16G^KJ/M0^~I^OS=^>~..2_9UC MLEB3I^I87WQ+Y2X105>~#I^BH(M=TE:2IIT6I6CZ>1D72S^8^N/09OUX^O^Q(G MB#1Y+>~&I68MK=MLK3^%B/HQ)^4^QH_O2O1SQF:6-)\$)!N:C@Y^YJUNE M:~>Z>X=,~2BYBAGOI^~ MV+LPS%&S?X:XX^R>R_33I^4K?O_M^A:WBFWN]^>C=6AGV(A^&=S+PR@_Q M\$#W-~&L &=8F5Y2L5OYC@AWHTMK166VMHX58Y(CO#^~L9J_M72I6BBM^Q%9^2:2IFPC?_0J<~N3D#OE<I\$SI_U_~E(OB33+6:6RM:UE@ MC9%~E%_W<@_G^HZYH_Z-M.L6G:=K.W.K9#2&)=QR,^OZ<4PZHCO&\$Z=:~&M(L&*&!=I(Z&_M1V>NZ3J%UJELI1MIYRAE\$<~<@+~%_0- P^=EI(I+?74=0\$&L_~CRO:8_9/X8H_V(I>~*626&~&)<~>8ZJ_7P.#)IX%5_M\$0L555+~WD_~.SS^+8&_M3@=I^#F@_E:<0@A:D1<~DKI0>:....2)86_M77-)@L8:Z74I+2<~0S&=DA/O#~&BjVL+KP7AM(#=8\$OC@~^TW=JCO#HITZ#4IUEICN^"AGI|=MDA)QA36DYXP^2RU/I2- 8GNK3=6M+BYMK^EO_K0\$>F2>_ZT_6HPLIY56I MM^C@~(N M:=9IETB^PDG5O@X@=#I77M?V:W<JUS\$+B=^4I<=2I^W/R:SH:~L1^L MJV=N)4 "N(EW+C@8_.U<59>~#I=B0V>H0^&-1BWN3?W-DS3ON8DET^Z6YI:~7 M97>KZ:87=O:WE_~6IQ M(I^OZC:~ \$LI&L+~"RCCMHF:S@6^~5T^=4 Q@~"~I4WIFV)MXK?I%~^1P>M.^REVHP@8P^#S62^IVMIKYVDM9>:58728FPC:FXX8^X:I^I^XUCW_~(WM M=3T^Q6=\$OQ#>1%_Y<@~L7:~(6L^#EZCM8\$N)/ORK&I^4I36I+X:~3?7 M6:E64VK6LNLRV:4MO MYJ^:28PO.T? 7I2KWB+7I^POH=SJVHR^6(C^PHRSGLH^I_+I/EZ?ND;I#;I M_OYEO(Z5U6GZWI6IV.EH^HVMU:1EE@:~5612.3D@X&I\$0!:6U MMTN7N5@B6X=0KRA_8&H">1%_AL+VGDG@M((H>9)\$C^L_U(ZU#8ZSIN32 MPV5_~W\$~L(DCCD:90^A(ZX8IZR/^B9?^WAR2I26)N1XXH! (I^U9U35COM# M9_~(H#9I^&YC)=Q#^+~3G:(H8?D:~EK:QVYMTMXE@C(H:~H IZ)=~PK&Z73) MKFI0\$T^YI=VR_8TF5_T_>~%=<~P<9QC(P:~T:~T?>2TU:3C)+~N7)G4I MMHIX)J)UTRP2T^HEC+~Y\$B4)GUYXQ^2I^EYL+7IV)^Y7Y><I<~<~ MG-00ZHL-Q- ^H=H=0:8)F692\$D_N^GIWMUJ2VUC3:RP>_MK^VEM(I^U^990_M43:~I<>V_~>E L5C9P3~#P:IRMGN^<N:CZB@~I,Z3HC6,Z?M:%%) (7R5P^>O&(85)86QJ6:7)~MJY+~*4:6_YD<1K\$TH^+D9" P^JCMUH M_ONBNC(ZAE88^D9!%4UT?3\$8.NG6BLA\$"@CJ^2^UG3~<)>WIO:N5W(I9) ~M%IL?2I?I3\$U2:5\$3-M^UIG^I^,OJ_~JSGYOPH_T:K1Z=90A1%9VZ:9#~I M2C#GJW3KSUJG=:08HJ<~%OK\$1.3VL96>:S88YV.#M9P3@<IX:KBH:~+6.M.L-M^TL:AX@LH2>~%?+NY^2I/4=N2ZJ#CIZI<~"@^~*TY5=186H#_? A7YN/_~" M:3FE:HZ:~JZ^*L(5I^4^W^%5_P#A(I%_LZ+4I^JMH:~96:~9905<+IX@CKCOZ_M5(^O:/&MJSZI9:L9MB9U_~#&~3I^M^~?TFVD M4GE23^Y3:K_WQM)+M+J2U@>YC&\$F:~%U^L M>HJE_P)HIGI+JU>Q^FS^6)S_H4OTVYSH:~K1^>~\$OIR^VU:FEFLP3<~MI_K&~(K^N_/% &I5+~"SBNWNH2I+^E^F6.I^V^IZFL:0O&>C:IHDFK0W<45J MDCHQE<~5_D9%)Y&L^D_HUK6&IV&J^4V_YM<~>4VR01N^4:KAAV/L_~OV%G_M% <~&XCM(\$G):BQ@<I>~>M32I^THH(K+WO^C)_~^FM=2U M_:WT5=9^9E9IB)Y^3I^I3I2>37O^XGT&_SM:Q19L^MKL:~>4W^A9CZ^<I MGV%_~%H:7IX:9%A:@Q^_~^2OR=...4^&PL^=W>~&T@C9QAF2_L/?YH-I:~ MI2R-S\$+IXS(L_:R@X+<=>~I9.M>+~+T+6- +TRIG1+C4)&5=QP(U5&8LQZ#E_M0IZYIC0:KYME_V:9CM+~&WC)W%8HP@)I<~"IR.CIKA^Q6NF^~2%EOKYV01:~M:_9_9#_~O MGZT =~8V=^TZO<6D\$S^*9(P^M^TSI^8V<5PUQ^P):V=TBQ@<I&O1+3Q:IHJ_~(I=H^LZO^<524\$^M7_?IU_VNE M^B^3:~V8- ~96T1#%P4B5<~>IX^4^M^O/M^NTNM8&N4&\$E.F+J M/O_U9:~^((OX6MM.URS:~EAD>~#R)D=B\$R&91R^M@<CH>A1^R?I_~BRWEI\$^~I MS7I6MHJ^~% \$&>1(S.Y/11ODI_~*~G.FVIE>4V5L9),IVI%Z:L<~>I4-1MM3D_MNIX=4DM:2.WI2&~&~LT@+~%BQ=3OC:@~#WH T6LI9I3I(UO^UMMV^24I3^TMZ_M8J:Z:8M:1V565N8(C_N1&)=I_08P^Y^P1>~I^XA^Z)KLVLK1TIP1) M58+A0P:~D4NXGUSBGVIG:6A8VUK!~6^~JY<87/UO5:VUW2+W4:~C3K74I2:~JMAF+W-MCF5GC^I(R_:S+U>RLM_U^*_O_%5G?6:WLF+AFCC2V7 (AW_X)7U0S(MQV M-G%~)=1VL^?7G^RK&I^4I33ZLI^C_~&VWR9WMY2S/7I^06NOZ/>ZG+ MIMKJEG-20KNBDMXYE:11ZE0<IQ^= UI26OULI5J:IG:~O>~:~EOR5^JPICK0! M^*=)TTOB,ZZ:~% 2P7R5P">IOCVY5:50JA5^~@8_X KG/IOEI^IX@U7I^X(N-M)=1#)(A068.6 SU^A02>G/M4N@WD=OX6ANKWO#~ZK&@U_~Y15^WUK2IN&XF@U^Y>~W:)Y\$@= <~9^~^IQSS5+O7X>GNK6UAUO3 MY+BI&ZVC6X4M^/51GCH?KB@~#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_B9_~%WVABZN)~M^BMX?2-HLKG^HOSI>@/4UW%~EBCGC_JNH(X4<~%W6GWGQJN)T_MFMY@/~#TIC?<~#C:TA:I @)!^AKBM+U>+1 "GA6^ENIH=\$M-8OXXK^UPWV?>~I MJQ_1@X7YCVZ-QVKW_VMN7+~F"(L>K:~DT^VMUC>_01!^&4(-H10:S@^~0) MK_5I4T^FOS>M\$;JL:FZ^1UI^~X^X#&<~>HSS6)XIDL7^>@2^~MGCI>~>F0-M+L^*CR1@D@<CFO18XTAC6:~%1&~&~JC_X42I6WE:~)!\$>K(C:~ /+VAM+~+> MDPA+YYO4D_MR)^~.B1^W:~Y)^*~<~#I:~OZU)M3I+~#0?BCIMU=117TUS=R1_MVI/IQT>V3:P7JIP>~>@P2I>2- (EVOHJ+~^"FM:P,I^E:~ZI&8I^67T/M4 M>8VEI9R>~OAF4N8&W:5@~I_7(CM=HIVMO\$07%N:J0#AKT9^9QGJWK?7VCRV? C/PG<~_IAP.@&:~I@G:D^YAC^0:~O7^P>~&/\$5M<~0M=Z^?VDEI^DHGOK:G_MN%~L3AL,%&<~#IP^*_C76I^AO_~TT7I3W-I^TEJH:=YR(2P(X^/O6G5I3 MM_MM:L:~UA1^=MNI5^V@9Y:~#R>PP^N4>~>~)KJWC^~>E^GB5A!~?~N_1F M-8L\$0?~>P09_@~4D9^/K5IX<750-X@<I^<~%&I^VTH85@>~ BC/TR^PKT M\$@~\$5\$9I^~V@A:~#&C8QE5^~EUI^U^7>~!~I MOH7MTTB(I8HJ^W M>~44^Q4DD:~<~YI:2^ WC_49E!^GVI^~MX&D^QH8R_I^XJ_G0:XU:ZMI6GZ3I@E6U>+~A-G M6":60B&S:(997VD94\$^R_2I53H3L&N?BD^H5UIHT>)XI&~*JL6IH3^* MYYG(SVY>~P&RM3&T9MH2C:~OECS#244XVMNO:~(Y^R@Y_Z#^+~+97T^W7X_M520M:1G>~I0J&MCN_~L9IZV_5I:1^~(E.GO&~+TZY+~+NWW MZ5VWV2W(4&WA^~7H@XIZPQK^JOH)^P^&~MCIJDZ_~(C^5U)P^PFLT<~>Q_M%~_S <~#>D_2LW7=9TP^~QOUBX^~NOLB5Y6_~>~I^RJO^5YVKD@X4DENY_MUZI)PS&6&~R_64&D^S0>8DGDQ^8B15:~J/O^L^*/(+#4:~)_#WPH(NX& M<I<~"S^H^N^RD?@2I>~*W5N=~/Q^>1WDX\@:I:>~>L^?/L^2H^#U/ZB00?L M=KM5^LT.U^A1L&~&E^S6^~I^B+

[illegible]

[illegible]

```

@72;^CIE+EY2N3GGDUD#6%TOP_P.?"#NKOW":K)?W$&(<7<4JDHZD C M & ?H7VXL&|B4?"WS"1A4>:LJ#^#_H13+ C(&IC)X-?
W_B72=>9:NZ*M29P#Z0.Z0<CS&4$)QSIQ^/2F:EXLT^Y>:*U.&JIF-181RV17%<2.1A M^&S.Y%75+>2/<7($K;F=1.X7GZ.5FQ:M%X8^
MFN#5XYH;74H+7>9?@T=T81JP:(C:0-N)(?0GZ5:~$|0#1Q*+Z7=T2LD3) M-@.1#&1SP1TH
U=>16VVAZYH^ER6U0)J.KKOCJPW=4549CIT^+9.&JDX)P* MNZAXDTK2VE6IN^4PH)MDR+R%3T+E5.P=>6Q7I7-^9TL/%?04;@.MH?3
MK+*L;,$+P.JYP">3Q5?P|>KHGB#Q;...^3+~V1-J.R3J0+FIHU4(N?O.NS:4Z-MACB@#08)XKF">~5)89%#IC JRGD$=169J'B?
H+=EO+ORE218D)*ZCU%69?PVTFH/X?Z3I^H*Z7$:.OC2IT:LLJ^W"D#1*XSNSM M(MKG6_"BVQU>6IFOY8(8S<~@<8(SQP320>
M+N+=+AU**X9K6=@D+>2Z:4GH4C@>97E(&PKQ@VQ:05@/F:PEX_O51UWQ#J>G^M$_%<%E?2+261=1M;8NDUH7CVAB$PV%1OU^JZ.Y?
QGX>BTFIU:74DBM;3 MRXDR(H$ P#>9"P/MBVG6 B 0+I+>44HYI;1+1%5B2;JH.98G&W:X# MQ^WA<^/BW4="M;IOHIMXT:ZN;+7DZ=
<%KM+5-Y5A.8DVCKLR?IF@#H-3)0Z+J/AK5W76Y;"*W#0W-Q& MK136K8_NLNY3CD(K^LLJ #.A5%)C)P^EAZUR M7B+4)U?X? BS4-)LRD=
H8.GVMK(H60?)>90 &4.~!@^~IT-OWT:=~6OAZ MX@UR:1=6@TP:Z@;&$J0H>*4~HY^4X.1QT-+XATMI&VO(IH8KH^H1%
M.GIO(I^U^HH+&$Z5/I>JV.M6*WNG7*7%NQ^*IER^&P00>00>H/(KREI6OK^JL M^C(?^GW=MITI^A:7+Z=YT:VIOG;EE^H0P615)Q(CTKT+PC:I*~:
<7&BV<^JO. M7~RUOQ@P+&P.Z7$GS#)~?<9JIT^:H:58Z7+1%=3.JK@MY;432R2;1EB$ M0TB -IQ@9%+74L+M>B07*~
:126)~W4DMC+)N)4>0AVG:6ZG@DX^?S7*2SQO_~77K$K<+<)K1^Y4 ML;
IR/M:QW^S^?3C)>@#T+4.NA^~NAVBTDXL|BPNGDMJWILL3IQW$S^K7 M575U;V-K)(9:6*.0.R@=SP^CVH WK/O^IMJ>2V<|B|
MBCU|X>:X1-G1X@ZEL;9 (SQ7^Z=^S<^J3UVI=2U;39K^4A9R6U6;0^<^/WAD5M(G2:WT^*ZDO+ B_~J.158V|XMSM|VD
M14GP|N>=718?DJEI^:DEC&?O|Y<^|E15R^CB@#<17-C%?Z)=~W<:=~JZ MDPP-C|6V^"|XPH7D5K;3R&6:(S1>+1%E08RR.R@
M/E^OZCUJ35M>T00_LWHWL=MHE$;~/_S>@XZ74^N^I(+&3?>EZ=I6J M^6- DM^B7.8-QI8-156?@|3PH5OD8HJO?S^V2_6_ADBI4:12NI&
<HJW_1 M =&>3?T^?T^? (=IUV5- GLO$D1>9>98;~*#K=LJL&612N<+M)&=<=I6Q?>)) MTUKD75WL%J%-RRQLRP|N108 A>~>
<<<~*YGOZ?>0-?1#XPBWD|CD=#0LH M8^@+>~>YKF15UG1H+U+OKH-WJ7515BLDES.S^HF>15=|M^M?^H^(-+ MKY&R+10^"X=90/NNI
*=1DM@8-8%|=Z5+XO^3:=~Q7% A#%#="8/N 7R B M%CV)(QSW!%8NK#|9I7Q6@M 97F99(DC&3(!^@8KZX(.-I^I@1V^6MD);
M@2W^%TA6TE:0A<~CL^|FMH^T 4+75+&~H1H1+R@E^ (S@XZ^GJ^ MX35+G2=;~CWUEKESHVHOV.FSU(QI864I^T^Z:P9=7H^X4
MLK42*2UO^W^8D2%$;YVPX4^|.-@_WJ_19?%6BPW7D>X/V+6OF^S^|B<~> M69 -@/7&J-;M17OC7PHUY=6=SJ^ZM5#30I&|NH.<<~*3T/
SC>+7:WJ M- X80 8+FRN;77EGTR^T94MU^R^99~*~9F5S9CG@<9KL^OFL3XM:Y=>J MQ-I-LHDD&SD.L<~<@$$$CMWH ZU^?TN72;?
5(KO);*YV^1)&"WFDI|J@9H@ M_1&N91^ZQ+J7Q#166XO|J>SMXK0Q03JR>0S^3<A^H^U&3QI5Q/AR^?1M^I
M#~K^;~T^YOX|HRXROMC(SB)VO#(&^>~<NO^*WL%|3_15=6|< D7-K M9&5H^59-JOBYC|O7MD4
=5JWB71M^N+>WU^~CMYK;8D8E$+H)/0>@-0I MXMT2:38-0@NVGMIX?7I(H)6|O-.Q55+ 9!>2I<- XWFM^I>~"?9 (KZ61 MRW1^|E@&)
I#=@ G0G;K>~>OB>+>S:1J46DZP+9W=FXXC>|>@B81 26 MR_Y130I^V40B P_/OC3R^K6VW45+VK|LB50^Q(X^/7Z=J#X@>%S8SW@U3
M|U;R&~9?E|R.@9.8|NX CG&^>N3NH=*TW6?A_~Z?9/H^A>%>7.J6|V|=$C1 MN%9@W^;F.0&|G^! M:=+~B^TL2K^E7) #A:~?V^W^PW|QWXH|E|9
MTI+V.NQ<~6&Z4~F%6D.H(W955|+<~<1#14-OXD?>ZTF35(KZ,V<~F.1V14HX M-C^1N^9@&TC.2...|GT^|&C:X%UB BOY-
^@TR2PO^LWE5I.5C0&B&ALP) M@C_ZU:VKBO#=-TIO^H^W&SZ1^K<=I?LRRM)<+L93.SD^NSW^I.6K;DWD-);PVD-P);Z4>KV
M_B:1H^*=~T1 8^/D|T:XP+@>~*9S^"=V M5&I=USBM^P^J4B^IT^34TUS3(I^I^U0HOHF^O^D2.O^OLHV>%SSU%<44 M44 %%%% 11110
4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 111 M0 4444 %%%% 11110 4444 %%%%4=2U>RTD0?Y2KW$GE0QHC.IKX)PJJ^3P^M?
8#)H O45R>M^M-TWPC|J6N6BS77V)V@> (0NK15# VR @% "1DGL>_Y%=<7 M^74^S1K^JG:1+T>2HL 1^5 M^X%<X8U86-JXUFU74?
L5AJ^EU^6$;2DH MO ST&2>1ZUT^BC2|BYGM5>Y2ZAM M36|EK^DABSC>JE&6VN_);3IES)Y44ZVLI#_NVXP^R^FXR1UK8.H6XU)/-S)H>(S
>4VW M#C);&ISV)S01:HHKE=IUL7&7Q|J^IM7UQ%;3AKO+@~R69^"~Y8UYV^XXY50 MHU5%<19>~|VHZC96-
M>L^U^YEL6@D5) L+N(5RNTL|U&7E086S7%$ M((XP0N<$DDG Y))(-Y)-$1%95EXCTN_F08(I@QSV0#7.5Q&T+1J|D.OX M^RD-
TXJ&Q;H|E|8VGG3I+?DBTRVD191^6)5BN^#.2IZT:=~%8B^+~& M3M20Q<2_9L D^~V^7="R|&~*10^0030^TU%;M^YVIVM>=|FJ21K.5N H9F.
MU3<@1#S@9K:B|0Z=IUA?Q23;7Y46S+~R)ON0<~<@&AH VJ^YVS|>~>IT^WM^YF;4$~6KF^01RY7=M^E=N^I^I-0#QAHATC4-
4%$S1DIT29X+MOLTNZ%T+ K M MW<~C)QB@#~HK|NO&@>V5W#3:37K^XGM M^2.P2D^?~*~OY^RCGVF;Q4Z-MJ6B-
K%M>AK)7..R.K^X.TH4(W|LX&W&22;=~-BBN^LM8>+~^AM(G^N^J^" M>5I2=7C19/0|PC =5XSI?
>NC7Q5HJ7MK_-75KPE;1X76^F3U/10>~.~ES MJ2:2%J^Z>Z>S>3(2A>Q4DK@<~@G@X$S@TIQ9XIC|6I@|V^I|WE|I#;KY< M3.JFW))M^G
ZDXXZT=17 7+U(WQ4)N+VJ^P2Z#H|H6TVR-F3S@K^NW; MIT SUZZFT3:12+J|HM=B2SN+VJ.J.N=ID:0F-V|((QC^H^U^SM+UW3I
M8>ZBL^YF.UHXCN(98VCDB8C(W^P| ^Y|Z^M7+^+)|N+X@>#^*~ NX+74)+E.J M^*9E60IQ;E^G/IC_1R.T;5%89I7:(+F^16V)KGI^
(7|EHD>6);.R@A>~#R>_03@&M9^61%=&#(PRK*~<@CU% #J^P&S%SH MMH@.I.K>:9 9XL7^F6#
|MXPN5|X8X| M/U^QAH>F^J^EW5VXOU@^T^9XX)= MDR^H53N.3T&3P^0T^E#8IKXIT^?I^6K>15I&1MB.$;<7W:=FS&I=NXVXS MGM67K?
P|U;PGX&F^W|L^HUI^91>~&Q&70DS^&Q0>AH ZRBN7T^#Q0;6^M^%K^4+14W^IV.1A9T=O.<1HR^~X|/S6I^~(M^N+C4X%NMDFE^
X)HVC$ M^E@26 !& 3D<8H RYO#6M0ZW7:AI7B0VT5ZZR2VUS9K.%8%~^1MRE1A1PZ+7@N^I+;$("4C7;
MD+CGC
```

\$W MPM?2PSM:&UO(-,+,2-2.Y9531M!QG!ZU@0N&!(?^~^O)YMU=WK6Z^6V9E>!50 MIQ!P+ @8KUFB@#),2+)X4TEAGBSB5@P((((O @=I'""#7FDS!_ GO^@6.8RW6 MHW36Z!)L\$*Z%(?^~^S D4>E>PT4>=>A!&_BSX=S(&,&4,=QYCB,XCW6^U=W^ MRV;CG^
=:X@U.Z98EK.6ZMKFYBY6%^!g!2D9C<|BHX!|YXZ\$U!>9:9X<=MT!3?B/8W^PM!8?4AWKPY^?LH&WVW/NAIY^Z.P/YSD^%VTH!|^!*>
(=!U MB?6!f.7R_(D^T;S%6RLP;EJO0Y/->QT4>8Z7JH^M;|2^O\$&CWUT-1U M&6!LS9M/%=Q2@83@\$97&#NP.5?EF;3?
BWHQ=VDT45UH(M)A:1%\$P8IE M1@8!2G QZ5W!^CDICJ&K<\$^MMI<4LEV^O&|AAVE^M;2^2PESU!V;|GHC MO73:NT?
BOQ^X10=+!S_0+E!NVE9^IMX<+<Y^Z5\$J_07@G^H!FVB@#QUB?)A MK!0X!X^9:G4!UX(,*=*(!V%1C+ XX(!J5T>19=%L60Y4P)YQV%7*;*""BBB
M@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** JN!1RRZ=<#)#!\$U&W^~C:6L\$D
M.K06#QQQ7.9C*\$S_&#<9Q07*Z7H=PNH^#M6TB&_@!1!UBU_SHG42QX)F:8L M_%MWW3WR.9 &#UVICFFM98!>?R)7?R!0Q3W
/!XU^M<=H5GHK?^?Q?50.LM15=+H!A:PEW.M!04N!GG XKG8=L^3^C(D^!P!VMTAMYQ>W^V=H!6^GVM9HX+F!HFE0=67<.<
M=OU<=<LKXGZ9J_!>Y4TN)HJWN(+H6ZG!F\$X%41!B_X2CQ:X4U=M^3X!TBTUY!BXEEA:QJT>T!G(MN!)!6LOLEW!
M^936V^%K<+<\$KDDXP^6<+<#D\$^TKH?^\$ _BH>:0!H46=Q.^HW:V.F)65!@D!_MK\$*<?ZY?@F0_+^4.<=>YB6YU%98&EMW19\$52*2!8
\$94T_XAB2*7PQ?B MWN)K>SUF.6X\$+2LB>7(N!H)(R!T^>@C^KJ:1!3^?^TSZC.G3:;>T!9 MV4DON^1C)4<#!KKG?Q!H=WI
E!5K_>BWO@/LHB1B!P3@+C.1!@YSTP^!4N^&U&ZM-M.E08=0!XX99GC660E)G!(-_!J/7M^UVPUR=K^1B!M^89X!5^2!_X64C
M(D>US316\$DITBQ!J?>W.J@9!)R^30HD^JV^FEI.MX+FYB:6V6X^>3JOWBA8^Q!%Y?=>X007T05X!BRUB-!VYCT^2* M&R^V0.\$C"@ \$
D?_Q!2,@5MZC!<6VJ3ZCX8.H6VH2ZD!=Z1<6!O:7N) K2J6-M&\$^4.MZG^&#S0!V6!>+=(TI9Y;J686UM((KBY2%FBA8XX9@.#J_>F><5LF6;
M1&4NOEA^=V!&_N% M!1L!ZV!O-F!T^S9&5&16Z!O)P+VY_.0#L-1U.T!JW2;fEV+)(L;:@%FD= MCA54^#BDG_*!V^B&PU#4!K383.M!8^T0O
X!K(RN6QM^)(P>?PKD?&^&L0ZI-MX8T36H!+5K>65XY+=!F:1&0NI^Q#YBI7=TY97!5CPIK6BWOB5!02!_M: M!BC9!>6OE@Q%""
\$#&@;SEB3CGD<#%="=U5U\$S_ L7MDN9K?>RVDAN\$0_>N@SWF!_Y^X5TE^GT<#M6Y!M=HJ2IG+HB70A.M"?
B4S%2V=^>@QC.^Z>*>YCT^RBL)H!U&Y57=J+>T>XX M+8ZX!R>I^I7-P.Y^%.%S<_9!H6Q!T1+43FW<1F43%BH?&X/K57Q3^*B?>\$-- M5U2-
00!&O=^2V!ZRC>1K:5^=OF5.<_Z^M^2R>!/H#D=AFU!;fVU>7R;>1 M87(9QG^GCY6&#P<C!4ECXTT.^M!4F^T2VPTL!KU+N!X^A4C<&^N<\$
D<5R M&L6!O#%X1.G=>6%LNNK=M MLY9(JC@R2!O=)(<#SR.X.#=<:GOK3Q^X!N!_M^H+^273;5(IK!WBN&3>)"(P^P.W//2@#NK3Q3IMY??
8AHBNC;2.TBFMW M5!(>E9T!Q&+SVH0M!Q!DEM^WE KMMPA+X#@=<@M!#7.6-TA^<fFAZK^%K5Q;H!<+7=S9R!#)NC.-FT".!%4^&:R!#<-!""2
MP^P7_P!M&H;C_9)?Q!MS.W.G&SG-^H<^BU;CQO=^!972BUMTD.QB.^+ ML0,>BC:>3U/YV=1U^VTR&-!AFS+((HHT4LTCG.%4#J<GV^)/
KD:~9K.XN MWDSYMV8-1TJW6WF2W!4QW-B M^RTD^5E!0\$@#&XO!W/%^!<=SB\$!J74#P2NN^W@W@93@!CBO=8.N2>#KFS MOOMJ!-
M39WD=DPEN8\$>F=U5?X<%=V!G;<@>QKD!Y^2+J^L.M!FO=OAB^*_M6MW!J:8RAUB+8OD@C^WH ZJR!6Z3?7MC.QR3(^H!M+9+R+A!YP
M<+Y2N.MKH!)2E-?>VES..0W3!X<6ZNH5LY!H9K.LK!KGQ^X%U+!+694 M@!\$!TSV.D4<CP:5C6+!"!9
Q@#++7.78R^2OB6/LMX&NYIVM@:60&8&W M5_4&WYLL^* _Y)R/X.T.65V>1H/MV9V.2Q:_Y)/18+ M:58;FX6)FB@=L8#L!@?>7!D9QFG^#2?
^\$*T^CDPCL88W26.HRLJ \$\$\$ @M@UQF@ZE<>^!K6G^&L^!H!O!&C4!F!UDBMM^ANXY7+C=Q_%="7WB M^QL;E!8^?
<7<@GDBMH6E9(SG\$#*,X.U.#@!^!J!<-?#J!MVfZ@!<L!J2E M6^VG2-F!F;H^0,*>#H!0^E8.E_#WO#0W&JPR_9-7BM!K-YBC:1%:_8!
M!H(P<@!^J!YZR72!O3=\$*T.R6-VGG^!+O!3%NEN!M:6QD<@N%!VX!H!3=0!W M!C72H!257@COGGTR.2SVKYDD4Q@E2JN!D^!YZ<^!_!0_QG
MHVG:O+LLET^H!P>?IGAM)9^="<J%7YN<L^XPI7 M^VUO^L+D>:S:0K<94!LCG^2L=)=WQCDN_(N?LO!_8^P^>:=Q&7XOMW8QG:0
M<5R45M=CX>12C3H-CXG%+#!JE<2^7!2_8U^%!XJFN^4!33R!JZC26GGP&MP!CJ^YCD M@?B^VO^%BC75FYROXT00^YM::>U>)))/-
=M!+>C(^!Y8S MK>%K!3=E79!J!X&B^W#74Z!)^!QE?<@#BN/E& M2.3@<=<36!4K:KN ASJD=K:RSRAH!+B0LO^S!LV_3@
G!^STN9K^XDQ@!M^Y+>L.BZGI8M8Y!WMW!MY\$D+^!JY%8\$D\$@F6WN) LT2K&WF--SS MV8W;N#QC@#3!FF3^~
\$M=^OH!GEN\$ATZ7R:O3_7@/_S^!G&^#N^!6N(9: MW!5EU%M-N8M/U7Q^)=F9+(S36TE=&E/_@-TR-U?^_C^<=>?&EA=MZ?
J^V>H2!O.VY.3\$!L@53EV!GGY2VW6^A9B.X\$PXB8!SEN/ME&YQZ55Q9NNK3OAUJ6HV-Y6T4L\$S!F5^>@G@6K3O&G:69VDMM
M!KB7^RF3?;*=DRPJ^=YJR+4CUC-1^%Z:~Z^&N!J65M;W\$SLK+3!M>HYMK^C!T13>L M7EL5!P!@J_!OZUO@74!H-GXRN;K!H?>
6YXXH19R:KA^5%4J^O!)&>@Z MGB@#KK?Q^IUW-IF5N!THU^W^TV!H!PLRF/CYF8#^>'76H+CQ?HH!\$)H\$@_MEN/LJW!A:R/
SMVE!8^((STSQG^&H!NM7M9#&K&IWMKD!B4E!S.O!T)M)Z\$<9%_H^B/6K_#3M2M3)=^9#_TSV:N6MP5!%#DY4H!#G^_5A!YK!KX
M=:/<2R3326_!DC%F8XZDGFN>L;ZYT^6%NDZEIVH22:E=R7EC/^+!_C MO^H3ZY=&6VMKV M=+6 F4)YHf-LIP
^>=>^P/^<=T!Q3O^&E!JNGW!M;ZVM8!6!>U=0&1#N;M^N.DU^&P8^WQ<1~_K^NGGHHRVS(YC.WKCM69!RVD^VC; M<M=OO9Z+R!U
KF98:E @?K-BMA?^!U^5DM_LD@D8&!P\$+MR1MYS0!Z/ M^B-XZ?PV+^Y'E6@N&FHD;6?N!11ALD!E5_7 \$G^&K!;4WECMC(L9D2% MI K:
<#&T^!P.GBN9-PUM!7TO&M+QK74^%B@&F2V=DWB9F!LO!DP&!<^%>=3X MAT:Q#QX>U#2+G_57<#1\$X^Z2;&^H_#^%
#&1!>GB^+07:9=0FA!&^%&K(M!#8V!&@8SFLC6M9T6!2UN;4!0K!Z00&W22-9KA21Y;D#!0G:03@X/H:X^7 M3?%OAK1!
<G!B^W/H!HEM QS-""8!L^ADRSZ^M:7C^Q23!^!VJ13W.EO MK<K<7+P0!P^!QDD:~>@P/UH V!P2FH>J2!_8!N+6WC9!MGC+N+EN0!H
MU0%X&3G^8US7@+QG8Z?X-TN^5!Z!FN)KR>W-U+!+HWD5#^N^!\$C!_2!M^/X\$S!8_++<(22^2W
M0.Y!H5Y=9:7JES!_L!K^QG.I6!DS/8ROM\$!ABF\$C)@&^X!>*/08P^&ES.M:A<6\$DDEK=00?7CNHFB)A!R#>P5?
T!X!L^BK3!YA^L04+6S7<9>TD DB4J M^R!<~?7Y?O<^!Y?3!10!7MKK5+PCJ0EM!&43_9T?5.8%+FPY(VT;\$/Q;+3M!^V M!F\$-
^P2X:U6N\$B^RNT.20G/KBM74_!F.0MRIRYBM^M4!4MR;Y/SE M0<\$\$@<@P^#7F.C!HXE^!6D^+>2+89M0N\$BC4\$%@(L3!C^6Q@%0!<
<H!R<5H-M^T.B^!)\$&E>(<#NIW!HWCW-G<6L#S1SOR Q;%. 1C^S<8ZX^4!#N_#\$%A: M;
KR7.CP_!%CM4.K&+^_@=O3U!9K\$U+Q!9PR>^!H4M!ZU-A+&F-F4!%9CC MN6^7&.<GVL\$)L+=!LDD(8>20N2!Q!P1_CBU
MXF9X)!?FIC2+&FV!74G>2WM!8R/C!R!9(P2.Y0&A.*_VU/4H!+TBYU&6 M^2."(RM^\$F7!S@#_&L2C!%0UK>>#M=
UB!26Y!CBPVQ>4L@R.H8&+&?0T!F!MGH^T!9BDO?>#H!90MYLH!H!D<fH0@#ZUYG8E!0!AH!66Z@T&@M!H!MWM
M9%D0M!Y!D^\$9<(>Z@!\$XZ^!Z7!FNV.JW-U:P.Z7=H0+BVFO!D^94D!^A M&0?6!LQ+XK70-3T:Q^QW\$S:E<^5YD<9944L>G)8!>/?>
>C86.FH?^\$X!16 MZR+!Z:0EE09^HFD.I?C!ZA!@9!6QV-1>@O.M!3!ZC!IGN9;TU7^>:H!616 MB=0=J@G&2!P!+&U^&U^2/B+X!-
W!J!N+>SFBM426X9.B00MC)4=^!#CV MKKX?>F7.F6.H6L!7\$H!U:\$%#FEXSPN.C ZYQCOBN9T.X!OXF^+R6VNX!> M6RM DCVSA6^K3>
<@&X<#<3!S-!FA7P5!EJHNN75G!U=:A:1PR+!/YC MAED^<@>@!<1GV_!<GZY8!;S2V.K\$P2M!^!A!X!U5E!<~.8)@UFLK55:S!-
>THW&D!Q2!<~)"7+&4L M 0!^D^CKUH (+Y?^<CZM!JFK:E<7FEBX^!WN>.>8!6VG:H!EM%N%N)7L94\$& M#;@KKG@L;,>>O7!T!Q\$!-
W5T!<^&YN7D.LL!RV4Q!P!ORZGY>#@&@!G!fVf M^\$P!PYJ+6M!H8Q_>W=5>X+P2.\$Y(&T!)/LVE^>6FMKJ#?K-MY<^>+1^!GY64%#
!2T\$MLX=HLXW!H.989X.D!J!5T^!A!V!f.F^M^YN#^#J3B.VN^R!>G:=J!&N!<Y2)M^LX=+U:T!H!MKBW6:5K-7W6^5)4EDY4!#G^_5!5)
(fTD@^PRUY+<7 MEU3^*B@2R2R!<S>Q^PDGCD<^BN?M:ZZT^X!8!/G!&J!)J5Q>V%\$!O+!<^!M)& \$W^!%9=H!W8&5C6J7FD:9X)U!F!T4!O3?>
2#HUI!%!(QK5SL(DV<5)3 M!H!<^%_HG(YKB/%\$G_X\$E?2!#Y:QW>!VT_E_9!Z M?^*C^/R_#@_>P3CW&=+QNTUEKET+Q\$YF7FL;EQ-
_W26B.TD!F^&60C.\$C M^8/4^5_46WBS!KK29=22Z(@AF-M^CQ!L\$F!^64QNW!<7&3D8SFNF^6CIFH55/BX-3M!^45L)=!6%+B;RDC4N)
MV:W^""J!<9QOVR>@T444 %%%<1110 4444 %%%<1110 4444 %%%<1110 4444 %%%<1110 4444 %%%<1110 4444 %%%<1110 4444 %%%<12-90-
^T2R08 MHHH!ZTR)8L!W\$<@9VY(P<>FEK !^TK127?V^3RH&#E/WC8^3 MD=#SR^0.B@#LJ^PM0!6;AMYB>Y-C
MQ>&V3>+>@.D.W!0!HDX<59EU M^Q6.S-NSW M9)X3!^J!S3^!HHZ-!SG@ \$YQ\$4^CZ_8ZT!Y\$<^=64@BNK:9-DB3\$9&
M!Z<@<C@K!0!45D:AXGL!U Z>!(BZ0%MS=H!H&9@<@<SD@=00!U;@!5C!C MX!MXV!-O!EK/6NMR!1W\$!<L!&^0=QVXQVYSZ\$!^B!>?_8-
)GO!<~M^Y4!F.#>Y!G R<9_&O!8!2S:OX4!<A!+<SZQ9M.#D98V!LL!<#KP.MH4>4454Z!X!T04!H!<S<6DNGH!A+R!H^L9!
(DPP^R^>>V.<40>*M/EU6 MTTZ5+>FVG08VDLS<1%%N%49.T!B!SM;QVH-W^*RM^A0Z?X:T7VIO!^F!8!
MZ!P.#0!D@849/4X%48&NE7!2""J.ZDN9+&U>W:65HU#0^O!H5@=QP.M!WXH.Z.BN.U!Q_!V7@Z26L.M!HEH!G!&Z.FTP2^8(R)
3V8!G!<^FMZ?7X(M^L0M;N6Z;1.G:UBC!D!LXW\$9P.D!SDX.<&@#5HJCH^KV.O:5!H6FSB>TG!* MZC!""#R^*M^#Z5C_!<
""=6GTO/MKW=W^9R!23\$;N!M+KCT!QSV/7KDFY6!XOT!JWDM3.9X!2ZG M^S07K!R7DS@+N!ZC!)8^>Q<~?70! PD^Q U#PY?
6MZ=CTV!<D^2/(X.M.HC^!K@!H@^IH Z7Q^X?7/L4T&IW>G7EE^9>>WVG!^E2!&1@588)^(H)I MFCW-I^+C4-5N-
2N54JCRQOQK&#UV!JBCDX^R?3&36?<^M^TFUTRTEN+V6TD M^=^#4KA=R32CY!N!U8@_0%)Z&D:Q!H@UB32U^V0=17<=f^JVV;
>JHK^Q#H6UC<^NUV;^/SK2.95;fAG (Y) Y ZD^HK/Q5!>H:5 M%?VLDDBRS-!^\$E.RYW!13T8;6SV!<~4GEF>UDTP@7L M-
PA5X@T5SWC>XTNU(!FEM3XW&G!HYLME0!-7Y@1@H.CD-9Z<1T!Z!6Z5!> M!V-DR_VNYK@.2!7@Y!<?%&U16!^XOTV;4+Q M_>U%/=P-
<6:RPE?M^*,G9/X!UL^!Z5S!>B^R!>=6U^6+4M/T!>%(M M^YB(CE>&3)#?+SV!<^_HK).L6=E:~?#&+BXFN8@UM OSRR(!23P!D99B
M!HDCG^490^AP>^W6D9Q.V.ABNHQ.N98)!U5T RO:DI<@YQ0!TE%8%CXPT M!UQ(<C^U!W.L!fMVG!MWC2X1\$&C&Q&QD?@<+>6A
3+=YG\$2VX7PEWH!^5UC<@<1!T8:Z8Y_!HKF!C4 MVT7OC8;^!9ZRL!AWL28IT 8J^!X67)!<=O^24
%1!W\$;S6T4 3!8EM ^BR(UU>7)O.G.M!+! M!F!8.HA8D!D9N3@9/051G!>:~!H&HW+!W;2Z=<^R^K=C+^YQ@!G_1AL
M!3GK0!T!9FOZ3/K6EFFM!5O_-D+JXN+1@&#G^!H!M9>+>OM= L=!=1W31 M&:\$SV!Q!@(&#&F^S_9^Y&145OXSTBYEL/+>f!
J\$S06=V8_P!S!<^!SG MG^Y^O<<^\$T_!%A9!>=8Q6D+R!R!C:FY)!f!LUREAU!#M9=3B^M^A!IC 7:PV4C&C=Q8!<^!SD!>V:9!7C58-
<1-6=C9S7=KK^R3+1R.X.T!>M7>!)86H!>!(M^N!VFN6Y4MF)A!C!65T;U4Y&2!^_PHK?^_B!3GL^!NEF2!F!S=V.8AG
MD@<13!>L0^!A&S;^!_!UHR^<~(AD!9!C:K>^Q>16!^SE@NPGK!X@9QM!X\$ M0!T^<2OF^XSS6-VBX.SGA S\$9F^K^6!2RC:~.F^?Y)9!#=
fY!T!Q35 M:Q TLC.VU9F^YB2>f0!V=%%>2.KJZZ+!7H^U_!<^@.XM;<23EY/4?)&X.M!S@#IDUT6G>M^U718!5L!AWBDF^S+Y9\$0G?
!RAY#?FYZC+M5!N!H!O-AOK^%E6YMR9T!R!H!AE3W!^0@D5S_BTR!<^!#S\$HLEW^>L&K!^!MD.L!>MCF>M:QDWML+K6X+6<6UU)M\$)
(#DJQK@K@<L!H!6^*~JG<68DX!3R?QHR.R^N@P.#^>+315NC<^!H6MFN=M&ND7DVGW.W^V^!2=973QXBN&4\$D^>HR%_>@9
M!QJFFUQ!0!>34F^A^~E=V(K&O^!^ABS#^!<^J>N^C^*~KHK+GU^QCG6S^M)>ZE08-MH;<9:1_E^<
+<CDD#D#J0^*PBO9.GX9_&YBNM00P.G=F!DY5 MEBVQ!X4DG=P^KW6D!O.6.AAND^NYEAD^5U R04&H!OXJ>)8+38DCLK4F
MWNG8^6Y+YVC)4 C!^4XH!fVBNVR-GVLVT^>Z3=P>!)<=OM9DO!^MR!8E-XDGE^VBAYC83G&^Q8\$^!H!
^558=OXKTZ.4+RE2YM9+Y2!FES^ M46X+2%8XYMAL=J!6W!CW!+O5!P!<^VO+PV3_Z(!^%W2.2!E!Z G<^L M^_>G!HKG?%_B90#-
G8R1V4URIW>P6H^83>X!)YZXS@>N^Y^ZU<:>!6DEE M-M O3>VD6S4^QD!H!L8)-!SC3!H!^HK\$L?>E:CHEOJMM)(T-Q*8(XC&

[illegible]

[illegible]

[illegible]

```

#%#5(0%0E%<*<13Q7 KX5UC3IC4GPC:3Z"/ATR 8HD:SW9QY;1HK;J8 M^-)X^X^=<
16GBZ275M.FZTOK;41HJS'G;B0H4E)@;@PPZ9'7GBL'SI M47;J^O$6I> (M%CNJ^*6ZCFMK>4 F.)BI7YMO "DYSIDU.UOV&BZY PD-A75 M?
<9-HET%<17K2WL8I DL<@X.6;U IUMH2B&W#>+O#I;S2WP/TL2B.&%=TW3K^+I26)N;W>81(B2*GR@ MX.3IX^0$]
5A>+M;U.XLO"OCTY9+V68(YHD)0&RK.WEM@&S8IR;C5H MT1M3T+2-U?PQ+>PP62J9(HHEGM9U?3.O& XSE3V&?;N]"3 V#X0M;BWV
M-4N1-U5+RYF;>+<(5,@'LS-SA64$C@D'F@#;- #H-[K TS0 +E85U+4B)?+ M1V8*80D891IG/WITR=HRRKP-M"23Z9(Q-
8T Q)>^M46;1AJ&G7-DB;>TMRBQ6C16]S>A)8DC#-T RIFL/3 M=V7;+>%=LM&2XQ=TW^RII36ND5WB^4AU?T$N<9/&? /MZUXWU="T
MZZL=>DMYH8ATZYCO&+3^%0.W@A/W(#=-/M6HVH61^C.G6UEHNS51/EDC MO=RL%C#+N0^I>2.H^MUJAXIT P
1:UX9LID;=&0MM4AMK&V<CG4D1QN^4PX M4MUIS@9QD53V.KW/O/S2VTF5+1.3IK>3SHSY;RK 8W9-N^0.036B"> MZ<10;+
KT>GRS2%!*TP.16IGAG7-^VI>S9>8GE& M&4L0S@MO#+0.0%.<#I- "RT& P!+!Z;^HTFDV@ V8MSYD>6<C#Y2V] & M$QG'7VYH
Z#POXAB3.1JMCMY.62.2WGMY2^T4J.5921P>IUMSKAU&IT M2K'1?>6.27^<^(PI8$)@)HY SC@8(R1FLIP@INHZ79Z0^J5BIHJQJMS=O4
MIS?>#FN:A19RW^G:QY4V(70;S(NT@AV7^L;$@- MC&J+3XR515 AF-2T56^SWD1O-YK>7)?F=$>-EP>Q?>?SKM+2#;WNIG M51R-
M15XBKR:79V)N1JO-4 M&6.*5 M%2<+P12N7(S@#="4CM7I43M$)SKM$39*1E?K@D?K0IY7IFL:EXB^"WO &K
M65L(P^6@B^R:O&8XTP^E1GG+;O4]^Z;10%3PW6@/=Z5.1&31FE M6ZNI^X6XB^R"95"C:8$8P9^IXLN>@X/3(ZUZ;110LZ1^RC(1^ 6 M)AD@?F:
L^Eh3>+ #Q^XDL4GE@OIKFWG5ITKW#W#H^4<0)I^@XPI'G "M9Q^>^06^AZK928IFIB>2T82B2.2.NF<#(%)&8Z$UOECX-
URZ>#I^KH4U-MKIAU^3IOI7^94-.5EG.51E^<@XYZUETI.G2/SQ^XDT^5+K3YK^+22.F9)I-M(V>21TV^5V.1@G7+^H&O-X^<:WR10^' $D%A)
(46F2V2V7F1-8BY M#;T;L<..2FZ^CGB@^YXJ2MO;OETJ^>^T1RNH6&10;XW;U/IE*^QD9J MC%6KGQ2^:SX?
L)+53%K:DP7^S@H&^;I03)R^"O4W0-#SIKGB36;^166F MB3^Q#%8HX]@W8)&6ROP">_E
&YXKUQ&CW#ZOH(OI/AU&W&MB1640Q4R#>QI XSR&3DW=017 M360B]3PLZ)=W=X+!+9&RR1HCKOV12>IG.2>>. +M U2X1VVDZ?>?
7 MHN>+;8(BI6F59)&R1#I0#ZFK L=4/O1M^2YOI P8WV35#+%GS?+ISW^T MG&^OMS0+9^+^+V>JFUGAGNKT:4*$CC
QSZ#IGBKNG>3 M>>>.)I09M/EANL-^H)D5HFI^I2IR&^((R)S^C7 3.3IUCX32PCT9CJ<-B-
MKVRA^UOQ^09&E#1L^RIU4^C&G>00I/X9NH/Q#-YK>-1L-0U/00VRXGAF5 MQ&^1^Z/R@ L1IO.35G%
%Q=ITUO=;^HMK(T<^L7GDM(IPROHI>4@I]B5^# MVV9ZBKUUIZ66I02)IMFDHIG-QY^I1Q1 I06.#C)X<^HIFL?QG90^X4I
M)ZIC&G7IQW/ N)-&8POI@Q7/UOXATIQ^P1CJW4.#IR.K#-928+RBN.ZPN M+I(K-0U8@C IX-^OGI<;I8RZ=^*/I1^I1E5VP&=0><
G(C%6/I%O:CQ-IWB>2RECDDTM=M.M;0NGF.S.S=VT9+ #YN@...+ $4GP<120&C217^GE^Y7.HIP>W^0=[K M7C6UTYIO^>)
QYM/G62XCDNDA8Y7<%0IS;<^P.1S7+ P#^Z^OPS+Z- 8 MAK7VGWEK<1B>="K&X9B#OPDQR1.^Y0.$$81N]#TYX;JVF^ M^M-15Z=XITW3H-
3F>Q-CJ^A^<+M&R^T@<^21SC(3GBQXITQ#JNCZ+> MC3HY:ZRUB^>PAG7^Q+D%I:0SW4@=AI=
(19 VMHFVKUTXU)N^+2TDF&R(C^#^1MI1?634I9T7I^M^>^BIM(Q>^60:>H.ZNIC^Z.%AIJ?
HOI2H6C1.SI>KK^TD8N4ADMI8T^9^@;I0I^TY +FSK>G.Y>:YX1NSIWG?8:F
M2XO&MY4^1XV4^NYE+8W#G^(&2;@#0TOQ=JOU^7K^XL497.C8JRS AU92RN M^HP@=>OM6HQ+>Z2;W;JLUM+&+&.%FR8]C.^?
7UKD^OAIWOCOI^RRN^B>#BYBDM2B SYJ4#1^VH?2 M^YU;4K?Q59Z- (+Z9<1.3J 67Y)0&.POJ<87 M1W3+ 4 9 C 7=2I>^'=Z;1%))N<#
< AGI6I0M)U#62^SUMIEN+BI2X^G2$N M1SRY<@&$I XIZU4.TUBZ^<(NDZU)ITF51^ILUO?2B8HJNK M1G 76G>3OD MP/^<=
M)TZ^>C^WFL+62$8I(CWA4I^8#D8QWH I&^!<0>A^+7(7WBNR/VK<:58+ M.2OI-O&KQ7^L$#;JB9^W-MP><#YASUQ!-11D:P^-.T6ZO?I-
2GU>G.GABX34OI-2 V6ZG51N;M+.#. $ M$9Z^W<4E^)(FVW^..(7IOR^>Y7-V.N.196N7GU&R3XD6U@<BAM0.39)8M0)7=Y.NN8QWZM
MWOQ60W^G71+I6?A+@&6G7LEK>N;E-T81PK;J Q8SDC@8Z$]@OZ^Y]5$ MEQ97-19Z;H2RM;=S33S&&@=V^1MKI:F^4YS@<
(YXPIQCI5HG@H&MX# MI^MB28B>8HYQ SA#A6^>@<(SDC^YH I^A+JWDN9+>)XFBG.D2N^R^I^U<<
M^%2UR=GK.F1>.$4ISGOC^@>U;^<(M L=8M5=8+R%955 O+GL?<B@^+ M-!&9)ISCC^5G8-#31^-%.IWWBKJW9PK9.+P(N%8*OP? B#
M#U-1Z4=^17^OXPELVT^25+^TL-5D2&^<3.VBD<9195VC.NZ9I8^UJH X MZOO^0162AR=I%<^?2@<(92+SF0>><@<^Y^%
^U6.H60CN)>#6 EVQ(G; MS1B+R=Q5(O/8T7BR&-32$TRW-O-19B^BBD?RO^A3N-@<CEE4^Y) 2-M^T2ZAT 0?B7Z-^JH.DD:R1LK(P
M15E.00>X.2YMY+^F2V2>)IX@&DB#<L@/0D=1G;KB;I0#I=MI @NPTFOLXK#4 MHW^RFF^$I^PCX0#>^YYSM P^OV6LZ9%XO)2+I<5C<6-
H= WY^DS1X<@G M^!%GKS]#% ^645R4QC8V=H>IW^F;ZIH4D<<5R)MSQ>9 JS^F.*#OR&.&1 MEHICOKI^IKZHFG^>)KJXTA8W^GL84.^N0Q-
^>3>2H^A2RE@K9;+ ) M.CI]9O^ 2Q9ZC83R6>5C)>^%?I^XP&#IIR^X3QUS0^TBSPN<^C^7^8^D=1
M^252RIMX^L.PU6WLHUL3>3M<1&V/D2XXE4GHV>2IOCY>1UM^#>+B;PAIN
MKNH66>+JIKT$BDH^/NX+RIAF6I@4I%VYV)8 B>^Q.CQ=^TK7>EZ8.^STI5X.EQ/L M=W0 R")=I#;2>UF214^R*^&((3I.YOCG-MJ>*
.NHKA>.(WU1=1BN+IK&ITZZ-K<0&42^&15@ID$;PI6UODUL^H MO^=7XM M.JR3>4D49.UV+>W>L#2IAYK&I% MC>VA=0T$N14Z]
IAE@00#D^M72-1% I$-P^H.3+IKQSM^")D6G^""I7 MSTI$&@^I^76&HW^A^<^9T.PD]6VZMI MBAE2$^/LZX$SYB23@>GGGD9Z.X@Z5?;
IEQ8RVX24+<KF.VX^N^I^L& M^Q^<=N #T/84==5:U.UO&QOFE6S0+>X:(9I#^KE>Z^XKS?Q7XREUW3$W2Z M9^Q^9&LKL-
/S&V]5.8R@AU(^Y^! "NGDNK>P]26I46D6A]27I]VX13$*MO M&1SOLSC+ #Y2B6UO:M93 M6Y.H@GBE.3I) CAMC8S@XZ^!^O4M
M>4ZIK<A>+OU=V6B=VUGK.TXCEG)4C$49;ORP)Q@?6NPO?&=C%+YIK) M9M/9K>I+RZ%N@C;IG]I.3@]
=CDCC^ITUOIM58IUS^""^XXK;1+>((05 MH46I6T3PAF..2*3^IPID<>A^4$5Q@&G6 OKUDW5D95?2(G)Q9M^VIN2%
M4XXIF@#TF..8$Q2(K4JP/KD]24I+TW0M21;1%R1
```

[illegible]

AKZ28=0ZIN65>A MY->3VJ#UKH4T1+4?^%B-XB-K7J!*=-%AY0=MXQ(9- W<=3C'XYI4'C7Q0#IAR MQTZXL+6"X.YU""T=)6(,)'" +CC/N>I
I4U:Q)K-G>P;/f26::LUP)+.VGN M8T@1E5"47#%B7< 8/L^N^M"OI Q19:?!826T.VM #>EIV;HIMP7 IZ^Q; MWIKXH-.OJ&J.9KV@7I08ZS9(T+)
<7@GB2Y9&Q@X! (C+U=>5-- \$-GX M2>2IGT.*275X1/SXY(DN(W=566-6*8 @J&/'>KJZ XI X3"Z1-O#F1G/8B M^MKA)1LB3>4"NN.PC14 8-
MSXIU1A6=<X(#8V+7IE=M-W53: C\$66<1%5E7" C?QH?P6WKGXN:8Q7V1YI MN:<0-3R)(PQ) #C1>AZ#G@YIA-X\$U#PJOAS18+?>
7I(W8GW.50-)2N-O) M/E/QS6YI:@.M/XQTGOQ9SV430VDEI=I2AG^5V5LHIC)RN.<4 0 % ^U#3/AW MJUYIMMO.D85G.>X168*=IR-
I^KS 6K5OKE^OB.T1-02VCZBDHJ/<- PGC MA#A%Q'OR26./O<8)HL ^M.D14>\$-2T6*=8)J.*DC#(5@P89HBLV3PWK+Z MH?
B87% C.50:/>7^AU@GA9MP4.RRE6Y/P<14 7/#B.XU6 UG2-0ACBU/M2)UCG..?+E1UW1NH.2.CJ^@CF.Q.W "4IX?
-76^ P#1==IH>@ VJ&K M1.J.CW^J(S)I.Y->J^B!\$0\$1<->..DG@=#S0\$2A 5M316+?J8LGLECTAIFN9 MY/VFQ-A"G;C.JD9DB=E0NP4D*#@L?
2N"MO&>DKGA^QOTL=^JM)^:0@ MF2Q<1EPKN&*L>.\$84|ZW+FRU|4GECGN+PMS;2HAM9>02L-JN200"@L<>N#
MVKEK/P3XFMB "ZRW^CIY@R (L4\$FV5#&R%YV^D*N@7.IJLC2.9HTC5R1@C#8)^.IT&.J=UXXFU> L=/TP0PSSZ-
#E74C15><180SCZ^&WVC A M40Q)^U+&+C^VKKS^*SM+9BRIGG|ZUZ7<J<2^XO#FFF+J.E:/..AD6-"V MQ5"AE)).3U&.^:YV?
P%K;WA+Q1HS:80+K-)=-"7RW01|RI/1"NMCMGJY MKCPYI"?@Q-926JWZVZV^MI#8131YW JX4E6#=-HR#CCK0|BZC10=3L0^N
MO70L3^U1#Q\$M;F(LOCD#LH5TIX(<|/!&#S6NVO:.-ZC:Z3?6^FIJ.I7.GV. MPLI^H@96D|P68\$A<
@S^D^50UGP^=ZAX.UVT@GMEU+6IM+FXF?<C^A5% M &6 "9.DD1=^*T\$WAO4|7N^UC3;JWLJ.TTW:2AI0%QD \$D;8P<\$ POSSD1^M>+
IK%AXMU6G110+1UU^*W5H>)AL>16^M)Z.27.MT1Q3H&H:KJ6A:EI=Q:1W.EW3R|E6*.COE&^ISG|R^..MI:C
(M/CDZ0+J2L#QO>Z#%B.)-J^D'GGG^06C8^/3JTF^VMX?Q-0.5L60^Q:R7 M A5-JMD2S+..0. YYPN/I/
M^3ISUK|M A|KNFZ+XW61U9X+J#R"5<=<\$=!TST (ZOPKK&I MZM9W8U:3GM+BVN6A60PO\$ER@^|(BO|R@@|}G|6LG60%UY;>
(KS1+6;3LJG MMUELI810L71\$^H^10.\$!<99ML^EQ@<'0V6 RH^> "Q#KNH M/X10?#SK;").2IAE\$..E9G9-K#=@@;<18ZUST?
CW6I|W&B:FMG8//>ZU 9D MRY=5 |YHPRIG|(7N3C/0UKX6U:S15V>L:7?VK:8FFW(O49F^HQ99%VD9-)
M.02/K6#X|UNV1.Z3L.WUA*UCK7J|V#KN E:39P#R2W7 QCH:."#7 -I?+
MXIU/PVT6CBZBMH|RVN@LGEK&S.NUTW99LK@J.9/M6SX.U^Q.X6M=3N8(X; MAYDBE2.DH^CD9"5SS@E+0|2B|>7?B1_1#<-
IZ6:P^P8%69PQ.W); M^MUZ5)X)T&|>->5TRID(E=E|YI5DA)P1(SX((;&.L?A0 P.VI.KZOK%ABC M649THI\$|W4:..967?M&UEV@
@9Y)XXY?Q5XCF14 #8&RUYS*V8?4; &ZMI4 M+LDJW**5WAP&R:="ZR#PI?XFU:5)=>YEAU:8I0.W+LGERH"N1" <@C&
M5(C(ZIHRJ|W01%6GA 2|BWW+>|>7%Q<AYD@EUL* <9.WX^K0|VMK |.. MYS |RPQ|+%%Y8?<=<\$D|
^HUX^FIP%KWIA^*%QXRI&0QJ9559.2JMN /L<#X5PFI^% \$6L*+OIK-K:33IK&. M4 2SLC/SY9#E5/XC/H" 7<@ &.(H00?
(S8W(I^T+6)XMI%ZH/B?I=)M^D51.L.L.F0\$ 6|B^9AX& <(FUH^K|YNU.L..G16K6V1M47ASRT1L)U M E7.T<%XB|
(WUX3PDEMK6PGCTWR8E:2S-RD1XV0?/O?YWT1@|@UM- M#UWH.GW|O(X)=F.7<?"YFR.9-Q(ROW1MPN;P|TKK:1F5|EB /4F@#D/AO-
M.@4?L.W /Z4/2-7>K/Q1UV.7F0^W@7L)E+N UP\$74GU^PV.C M@:@0<@ZQ?+10I.MK|M#^0)6I7|<6>06|(PI%N805""TW(01Z13I4
4I+Q3 MXDO=6U>..6F1V&D:AY-W^IR:CIY8IP|QP>HA3Q |^KGPL=\$L+\$# M7K6XD7I6|N98EYV PAN..3CMG(7P|_&L&^CI=-
^QJ7OXUWSLP.3^0GS8 M.12L5Z=>+>MOX(N^U/PFVFR6YLM|AGB83.PDG.J@.W^X|R"WOG%"_BQ
M69/MMG##.JHNG01^Y5+^XN81+AHYP12F-JX^G) @JOREOXYN(O|F^COXH #I MZC.(TNIPLT<H)0&0!<1/U#POXBLO%UWK0A?4I&)=22-
ZTU" M)WC+<(R)JL(=N^C@^1^6G>Z3ITZ 9ISI^JV\$E|I(BW05^"27<27&%8 F31W(DC5U9P1+&".@.#QNZ>A04:~?W6=\$CT2||:Q:J
MFG6C64PO(V:"XA+EPA .X12>)/%>M^M?UC3^CFOK*6|MJ3AU&=BK1Q NR M"(XU^8@""4DGJ<0Q:HKVB7GIGOWUMIHU^SN((G9-
A+56/E:05Z@ M@/3M69>.(I9TKX6>|7F-G?27V-7.T; @2LH)S^W'D A72|RYLX(I20-6 LAPA)ACE\$C^ZYX^X0D#4@9U|JKH>J1M"?
MXG(VR3I|L2)K^LAS)NSMOCQOCTYHJX5M^O#OABST^U#26C4:>Y MBDN0Q@+..490E*\$\$.E.2<8R2
#LDUS4IGQCIVAW<=J8I^* &83Q(RF02|ML @DX(^GN<1>^N: J5 826^6B6T<\$TK^YO.HCRI90I(07^QC?>H4-.01EYO 0^10 P^&^Y(\$=E|+7.
<2S6&H2V3/\$K^LNP^ M0X5LEM M=/0 4444 %%%M !1110 4444 %%%M !1110 4444 %%%M !1110 4444 %%%M !1110 4444 %%%M !1110
4444 %%%M !1110 4444 %%%M !1110 4450 M7Q#N=3CMX;6P0DMX|C6|:"5#%NWY)89.X<J.@8SZT=K17&W.B:49+|5--T
MPKIKTU(U= |FG269D#12D.Y%P5ZDGGVYI7|BOQ1)?&."WTVTLKK6:6X:6" M|5B:~6)0>2#RN3TOD7:1HL|2H.MIUBD=\$D9F5
M@!N:897CE>O?&#EKXZ12 P#""6WB|2^2TA@N1.WEN\$=FFO/Y+&VX..>0^&^MM ?MK5@FO1Z(T^1DMS=+%L:F.-M+;L8Z|LY|7.RZYI"?
\$.+>0 MMJCEI2N M1J|C>8^61\$P3G&F/N3G|<^XO^&1^+&TCR^OY8)H%)NGC278=IW7(<< M|JLGT
I2HKD?60Z0IUU2^%K.TMX+|S15HS.JW+ABRA8:~4|R0K^C+12 PY. V)=>#GGI?VM^QO MX5T06B&3WENDK1@Y^L1R|H9S0|KT5YZN0|
C:4IKQ)::5 HHETBZ|1.31R^MSOY.N\$X88)SIHTXIU9L&5|KFF@)J-IMMIUA^VC2O/..SP0H@2..K.?O^M(R%Z
F@#N:~1V/CS7^VZXJ2^PCMC=>3JH|I(WE1B8Q^GS@@@#&<1.>O% M.OB77|6TW2|PU+36L9+?3+/S56:)B7E^EY&X..A3MU;KQ0|UE%
<#)XE46^MM>+&X7721+787"(Y%W.D6+5 S Q:~|X/|LJ2^QM|F6WB>^6TM|JO19X(C MDEM8V1) /""^7A+&+&^+&^>T5R-
HK7B% \$2V)M/M(C/LRWL|<6PZ^X M=CN41X8(2>1<J9-Q%GA/Q?1Q%17Y^Q|C(YMHXY^YO81QZL6^RD"/M7/8
J%+>QUX#DC@>=UO+G\$.\$ M^Y0D@?K6G|B8Z/H>M^<I6TEK=19H M8(RP+RHRQEI N1^<9R|QTOZ@T=,17^W
(AUCPH6@C5 L<JGIURMDYMXF1K M>=P2F.L=ZD@GL1UJH1.KGB 7-5U6VM (AMJ-UH1.61XY^S1^6H4:0Q MD MY.#G^&0#NZ^JF/7?EM|
(^\$AMKBROF1^2XGECGM7@N@GD|P@C(KD#) P! M@8KLV12.HX7|HNCQV O:J=HF^Z P#|RIW< @.3D/H/6@#HJR)@&C@B1WQ
M1Y.3%<@1NT.9|P0THQ<+@Y^N(22\$3.SX9^1<KPM|55A<M-8L>?^QS6H|

10:100#VDZAI5YIDIC M+6(C,07K57(+M,Z/O)&,EFSIDNPI+&H>+&C50%WJ5I+>FPO(-G,2IK=-V-:S#B MP;IGDC&/>N@T06;+6#>BS=V-
G:59X&#RV7\$BKIU9'W\$8&G R=H2/L0+ND=(VL(GG3E,\$B)YSKJX(W3#JIC8/H26F+X'3N)IB;IUT7A34+G11*5KV'XLM.EA.MDV:
)>+D1.88A>0D1.<=LUU1'%"6 A.5:0Q9:.F58-Y@HH##R2(Q'R2 MXN'GMS^FUX7TJXT/POINDW.L4EEJ-^9&-"X4 X/OX%:1%-%Z%X'I'J\$-
IQ4FJN.M.9'C/3K71T Y&I TH YWQ963038V4'7#6MQU-W*3+ 'IX+JH107JH82D'DU M->+O'MUK'DJEWNCB-B-;U72K>UE>^>JPVM&R-W2
/RK1+JZ/LK2:IN9;B@<(H.M)>Z'HS2B^T I4J31+>X>=U*RG((H SM\$M-6MX'DUK4(KNAD06)1BA M-C Z15)H(G)YZ28K'UKPYJ.H-
=HUV'XM4ATPD3@0N&+2^:4C1C/N.<=:ZFB@ M#EQ\$OAS4=9!0:#J-K<6L4>DW#3D0Q.I9=I&1HW@GGFF2>&=5A!6ZGJVG.C: MPVVTJ4=W'+
7D1HPRIT9W.F=910JYIHW@+5L.T.PC:2VE93#0)6 MD+>2Rz:N5EV13C.8V^:5C4/VLW7BOI?>Q+:ZZEN\$!D'S+=X1C9/Y/M:IBNZHH
X9"/WBBJUGPJ>JZUITDVC M+ JK-Q2P>/82V7X8@JL'L>UJ00'E MQ96WB'U.6WN+76KN:Y=8@P**50K)SUX'7CZ5U8(2H:BZAM1'YSI3(^Q%
/M+MZ #D1.G2 GM0IR'ACPOXGT-73+KO)#=Z1:1%LX%MMN613L/NQMS #OD MCCBJ.0@'6H="UWPH+LYB:J/GM'DULS22VYER660,&
'9).2!GZUZ'10!4TN MUEL=*M+2>5)I8(FC:1\$*!L#&0'3CIZP7%/AS4=I'6JE X1GU7 MQ9=;G>R6I6%WI#-5:KNWJ&8L6#2B1C'O7744
<=%X.O9 #NG<4J3O(+C2I% MX3YBH1+<1Q\$& &02%1&Q4F-V6Q@=>YH Y00 "V MLZ%GXZ?>VULR6IQ!-RI&*J>%%F?>?4,"NWHYY?<
K7H-0 #G#?>W6K150-0-&&K67E08DEU=2B*&&YCIG'N22.1WJEFQV.K7EJ9P&5+J95N(9HF MC9-P)4CD& X(STH XX^!<?
#DN@Z9HD^OV.EKISW.S6LOLV1QTB8%1)1^#@ # MC&?27UFO'LEFN=&M0TE;IK:2IMWAIHJPL.9Q6HJ9Z5144<+X321-KA15
M+G4J.1W289H###.NL91U5>/FR#1GT&1@< N) M-1 ML('D'PC;WP>.M>A5FW&O:2.ZJ9Z+>*ZWIXCR0Y3894&6.fjWCCC.>10!@/X
M9URT4SZH&I64#ZC#%T-O<0*>A-5DC(92#CCIX-7!7AZZ+!>ETNZO(CMKLK+*K1\$4P=6(G)SROYPA715FZIKKEE(83F6258FG.#322>6N
S:5YP.MC<#&:0KNU07VKZ1-QRZA#%VL=Z T M6STZ8I#-A+>+>49IQVW>9QOV?>V<="0>VU?>WB?2?5A+>?<-/Q2^4 M9#&R
M@<CZf88K8#12V1LF<G<X")L MN@P!70:A%!!UOQ#&-9I(RB&3.T\$C&3BK-07MY#HE>7)98(4+N51G(4+3E M022P#& %X?J
" V#P)#X7U1HKJ%+4VCM&")&1@'UH<=>U!>+>F0:5:G=17-M%IHG+):A%(>15*10)V4\$G-SEN>.8K:T-7=U2VL9L:MN9+CH
(ZOKJ<6VM3V@L98K.356G<=&+223 4GIWDLN3E MN.IZCN61&1*LR@E#E21G!QCC!>S!(UVPUU;OK'1W%G- MPH SO\$W@f3=?
(41L.RL8:RIA=->.*65VWLXR3GGK5J31#X2DT.3UMH7: MN.9M0&K@M@>GIUWU-U#9P^>/(3(4<9)). !R23T YJK#K5E<:WF+.(BMJ-
OB0:77#J<#4)N.U7K#Q)HFL?!!V\$ MBVGF:EA= /G#%<'.V6!2%+N'E;0D# 7MEN3
MGC.O+R&PLYKJX9EAA00(50N0HZG"@D @*BTK4J76M#M=2L7.EK)AG#;<^G/R@+Z9:M^B@#C\$!#LNB)X-Q% P(<'=>M>(HITOB3S1>VT-
%U'C&I<^<A7-MXBNN.TB6">JMT@NHYU)5BF?+D&X M#=\$=QCD8YZ"B@>DOX'MK:P I%C93E.O2@>7=OF\$PNNZ76C31165W86
MOLO#%:=>#9 (X(H'3T-:ZYX@N12)1^J(UO)O10T>UDC>6%2J31R M1XWP2=(ISD9)GSK'<1@>Q-7P? 25JU+
(P5)>.)XCMQ>Q+J.O175T8251= M@C557=F51QD123I4Z|>C=3^&)?!M5.B-0879F/GMY9CX^?Y1@YHIT 97B
MGOAK&@66L:~7M5:3A!#8K&9C+ 2@WR.L=ELMC.@X:LZOK/BJ70Q<^M& MFTN.2V6M1#)=0N=K&79M;#D)KJ?>3JU)=INM M'TJL/BK-
NP4&T8/3GC#:=IX;U+QJ0B*YVESIPL9(4M2F+I@>YOR2 M.8/1QP65W-5%W;Y7<1W42.PB-NO6C.NP
M.#C1KHM4MIKW2KIU@E2#6;JU=U+T18R)F<+D2 M'6W'YX1L'2;X>WZZI&A=AL=%%JK&@1F*UOAMH(A4RO&6.00HIUN1:XA2
MRB>37XY-2I9)9#;XA.8'EB-.T.SO>5I+I5\$ MD=W90%VA@.WS'> 2263+^QV..HK;+D)JM:26?
ZI%<CTRWK5K2L@X&X12:YHER:ST&YL/>J>J(H'W-MO>6)4ADJ8ECW\$N6P?O'/H1>%QXO&OB-0@?1%MDH+H!JGGQEG JMZL
MWU8U71R.E PL PK:0.A5YK#=#R>28LJ&1%&X1G#D>WXUH^H1+E76 %B&= M#&VK7\$8A0C\$*%\$>S);
<=>S8I&2: P""W4 #6B&S8:A%\$S:YZLLD#P1% M:QAAAAAMXZCVI\$ XRUNI>008 MYZ+ (2^YU.HLK\$PCDADFTI+497C@JDAWA%
RI"V22:UR1>#>0CL/%=L= M3M3- &^GJA:/(+OB- Q-P1Z LOW=>Y>7/5& MWK+^%PWT%)J)P/FN?I(G:XOU'S:3I9H=I=0P-YIV2)\$BL
RfNR>02PK=L-O M":Q/>L7WV 48HC#;JDE0E7I'VJO.*R\$P'J6=D-INECDD0#PWL%.<.<J@1UH "IK'38U&RULZ5.QB8).I(HRC=IAG.?<
MXO16I8\$M1L \$G.G:NVIVT@LH+ LXG U93K-RMNSO.#E1QSWK+E^NIRZJ&F M#6:12M>L5?>QI=A@.DVB1SD9 YI*+<
TUK7:QS+M470\$X:LKN:UG.K>G&F MU^S+Z"Q2\$16I57B.9C.10^ @H@#T- #>2I9ZL/#GB77+ 6Z-HU)>:2QEA M
(RJDL0=S:LKCVZYK5O/\$%<VLMHENS&=064=S/7#9F3YT'P4I'W+PDIGJ M\$5PUK?I VO4J4U'V15^&8)U&5S:Z09@7\$91JHAYBG@*
IOG!L.UV>:S M\$G#> AD^U>B:9>55DL=U>7>7):6=F/HHX4H#Z#N M')O1=XKNV2U.V1<+<HJ\$D'=NY)I4 <X4CPKX)U P-8RW\$-
T122ZP8K1CY M: C(4D DIB2ISYXK5M=81366M)4V+7-A= BLH8OLK.NM<13V7BO1-/VF20:UL8TAQIE>5;<6W?0!@6C" MYHJ9-XIU&?<
PIXHTH6M?^)=08@1B#O^7@9'6@#EM;UK4M0^OC 3=5>WFN="62W\$1IC6 M5#KJ2DP?<
FOUK0760\$V@AX= M%IGT:5GCLF2?JEDM960FVQBW@J3DX7Z M'KK<1B;BYM %MO=>G%YB\$Y/EY6#0'8\$IL=W IJ5HP^+NZ22#K-
U;S)I3'6 M.WB""24(61LL>+&84=SG)Q0!STGC#6T1!>M7RTX'W=?W50\$?<R1(FP-R MNIJCS64=|=43+8-#TF73(M.C?1R7\$+GRY
Z1SAOFIR1PIC>=<8+>SXZ ME-IOB72:26X8M.UY>6Y'FTW2Q22X=C-NP5R.XVYVZBM6V1+ZC#XNL73;AK;&(VID6XD1065FW#;DB;=, M9);<
<"WKO&^116%JHF7JK+87-P)8F.V/G6J@>@X1MV:1#8&.10Q5>3P9K5A-MXE0I2L.(EL+34Y!+>6DUH)P)< &2.DC1(.7D?<
IWI75CPS>IXTM=>CU".Q6^G&P1F6\$LI@L&WEIPYRH>M93> M1 "B+07U;V P")Q=57/6"U8>5YK.F7& G1Z(H
QWOB2ZN25+7SR.E%QD L.GUSQC#94GBGO6Y2A.XL+P.O=3N9+>JMYT8I2I.P<
M=2&^<H.WKVYR.M6J1)Q:5.SKKNBZf8H:5+5:2#VOF07**<^WU MMZCX5U*O?#JIT=7C>72KAKF5Y;.)G=E*D I@&&& !SCCKW,*+|B/%<
&I> M:=/PVXOI\$M1/#>VUN8IRO" T@<TLV""1&1

```

MHSK2/7/%LFD^*D&JV(N/#VTN+@V>3V.=BT5W.MZAH.E6S+7&H:0-6N)0H8HAV(F->EG)IP%Z:~I MXTUJPT3QE,
+~6!>7*EP(ALN(0%W)N7L<9P1R.CTK?U'6I2M?&7A23XH.M.LNJPWF)FHP=K1QAE(//ZMR@:#K*3(W-9&3SBO*90%OBZ/P:K?B+L:FW $G
MU~%#K<6A@Q)^(%6R6RG<<8R<1 3+7TWOAGAC&I3^U(L(SHL7:HLZ!@~.T9 M/7B#@O.F06EW#>P">W?2^Q~5]
<./>HJ?T:N6^Q( +L^K2QA9D.KZG::S MJ<-G?7%#X?^AA~./B^N!..EP6DU09V9LVA.0N1D1:QI>E1 M#:XVU.31+2UNE6:5Y=8N-):6WG
>30+2!68#)5.A..G//2@#T2D90RE6( /M4&O/HUWQAL.A^*+F.V5C^"V^TZ?>742%I%)9'2-9!^#<#VJ!M?1Z?%IO MVV.VN9=,EB2SCMH,
:GRFDES8!SA1@.E%>C>1:CHO>P*017$;RH)$*AAD9YVYZ5R*ZIXMM:QUO: MA(K2V-
QIMF=1H0A2621(WZ@CAAC>F4CXH02Y6@)K>?>S#ZY*/M1E@)~?L M9-PPXS 19QC(H 1#HK@K/Q:XBAX2-37FL:W4-
&36UQ*HMXV661^?YPM O:1D#M4^D>(VZL:SZ MJH:R:4!V&IDM01=7S8=O #H<@X/U-&U>>*MJ-LKI(I/M#QM=K9-
/%$7CCG;&$8CD=0.XP"<$@UM@AE!!!Y!>O>-(74H/A-MCXSO(-7GBEBN=3D#)&N/>KL=V<=<$XOJ9XQO6[I^M7UG9>&=!MWGGGNM,%W)+
M^"OCB18U"J&(7.7ZG/!-0=17F^K^)/&>C^#.^~N16WMJHVUS.""2-2 M;FW>1$5B%WA.06(@84@D!@YYSTO0 M:8U+4+22=-N-
ONS(=U>WC.DACC9R%):.U02:73K^#5.-M-0MBQ@NH4GC+^!VLM 1D?0UQ^J?I?>("OBRYL:M:VLA=6<9B#"8QH1(7)Y)W<8P"WEY:Z?
937EW:L-O MADDND(H=)E@4)B-B26G:2I4D/N&5V 1UR#P0:XIOG<M>(IOX0ZPVN1&RNH+ABOD*8NHO.CV2$!FV9!Y<H/NHUG5=6T?
Q#X7L%NXIK M?4+J2&X+P-0(V<8C-!V &@#K:*||EUGQ5>ZIXPLI34K"V71C&T# 8RQ?=-M#YFT@MOUP3S! 5/8^H6H=MK>"5+J TD:E!CG
M(-)KJ?HJZU>Z2OYAKRS@6XF004QB0^O'S=#IW2N:M *OB.M*U6SC MM=8U#49:2WG<*5>W13(9JBL0$&C&W/WN>G%T6&Y@^..M)20I
82/-)+#H=SP>5U=6W@^X,3M*TS5-36L+@ECEA^V?9)8-1M7YCB#C@G-@G&@S1X9N=.UJ71FU&8-9-7=:.W:1%4"##:SG@M MUKI**M
L(PX<:K#HNC:82$J#HU!F=69^P9^N)G^9OFZ@>@H/6/@CS-70R7& MHJ>1!NQMJS97!HPBLD29X&I&G&WKCL>NHH Y#PYX3UG1UAM-
142ZGIELN-MVWMWM5C8H!A1(X)+@#Z<@9!R?)AE?1 ",7GA>W13-HV?QJCH6FW.E:6MK M=W<=W/O>1YTA.6JF8L25W-SDGO!@*TZ?
.T.P<:9#XALH5CGTW6I9I7M MHHQ0^0THG8Q=N#Z$=>@A!ZHGIQ27B-92J^G5X#8A^Z^A0!OF/S8/7H M=ZHB@#QM-02ZU 5.Y;FB:2
>=&<-9:MH&YC"!!+!JQ!&5 "PU)KM+C0-6 MUN7P KPOX=UBOCDD-79J4DP&C&PLK*3M!&Z39P3(CJSMJH7IH^+4$9A61@&&X$
=8!5%JP^CU/2 $D. MMY?>:Z(O-EMX-L:&E/L^!SU>?2:NUHH JZ?#P6,<1-1)=70!R5(O+5C M!+DX^XGZU@+X2N--
UW7J00+^WO8M=&FM LA0%38!DNV1CKD5U^#02# ME4!-ZEX8GU5YM N^3:P&+$UG!VY0LFID^P!&5 &M^1-1!6$#+JGBG^TWCC*
M6Q>R6,*<8W2,6RYOOU Y/4!C!^*.#C^!MY%XTCPVFMPXTRZCN#9+^6Y
MH5^~9Z13G1ZL6WAFIL&MIKT&F!^%#^!EW-9EYB#12KIOE$S0Q.E93P!6Y1AYW<=>M=-10!Q6H>"17:Q(=?T?Q) 9EIX=E8.20RA0=OX P
M.W-Q74T.C58&.6P@V 8SB#;Y8 P"6GS?>1?RJG P@EX/M#?AO1UUB #0IF&X24V1/F^4"%%!F<=3GGVH:B@#F80#5 8^=(8U3J14AC&K
M>6TF) ZE9-ZY M7);.0157874<)=?#VANK:Q3^VO |0!^SV@/E;4!$C#&#<<>G^7!>C? M3=5&G;.#;Z!#% #*WN!Y>4&L-M5EU
E#=6<(1Q@>@3Y8R3D$#YLGYB2?;KUSX3UG4O^!EJGB;75Y?P&V:Y^ MQ!(XHR#"MC5A!QSU+H^ZZB@#E) "51?>@:HZK #H8;Y?
L9Q-6C(L M/E M^4^! Y54N ANJ2^!)QJ6HB2#76APV$;Z331R6YDIH:G4Y4#P1:~P 6VIOHFC60Y3FV/EV&T$8Z!J@00W!H=H&B
M@#EKGP3;7^E>(>N2!WKJL:FXC3:M^H$0*N3PH<(&G))!K1^#M7DU?0=4O-MQ$3W.D!@5+((D@=0N<:R0<#DY>,%KYO%FGZ%JT<4L-
CIANHO:Y&R:P P N6^0Y M?2=Q7444<[XUT^7 #CPV>WJ2:317EIN. 98F#*JLX^YI9JKBDS^!)K01-M=TC5!8W6G-*DJMY!O%"NGLN4JXQZ!
<M=91B@#C=,|&ZMI$FHO>:(SNO-2 M-M#,EH#DE0K^X5AN!VCIMOJ!<8UM^!.ILIZKJ!R1->:FJ3>1Y>8V^O+D!MGO!)>?PKVUMY;6!SDDC!
<IE-8&C&17H%#("7A!+6-2):EHT^Q(M=W-1!FV-QIC^1Q!00=L!F>18H!Q4FM>@UPOQVIG2:FLOJ?+!A:1-M3^(@P&Y%CD$=1GFNKH
YT+PIK40A 4+4+4 $WEI=P-MOJC^1Q*P<.(U89/M/4MV^3I5&/P1>OQ^>$T&L08!/%3 $( OQY?E! O/E^7Z! E7:44<+JOP^N
MM5E1C.VMI%:9MW^EVAS^T&-G5R!V!@9J!NVWA35H 4!B&XUZ^!%@UE,
M@L@L>#>+!4JLGG!);.":=10!O^F>"KBS+ZYN5UJL=Q%JK7+F2.U.9B.M=-V,NV0^3BJ5SV/M2GTW19( $C6VNZ.OE6U #:
(8BH8VB+>^!%Y7/TKO M#..J?P?>M>#>WTHN10!2IFFBFNFMH!GVZNIH&K.#KW)0Y!N.C#B-1^R MM(HS^N!S^PROX8!NB@#
MD=+!W^M^#KC0!C7=UQ=NKW-!AB2K*0$0.H0?!(CGOU))J$K^AN U?4!H O MSJ=0%)H4!E1.$B5B!0C 6?^IKS^5=+10!REOX3OH-
0!372!JVT.K@4:2L M9Q 5CL2!M/F^7Z< E64WPXOC.T%M!0FRUC1:2D!>1.@!-!@?)&6>F< MYZ!XZ8! HH Y#5?2!UJVDV7G:L-P^+8^R><+5+10
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 111 M10 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% M 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 M%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 44
M444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 111 M10 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110
4444 %%%% M 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 M%%% 1110 4444 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 4 M444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %4-6U>VT.S%Q<+!(6:9^#;Q-
M++*W7"JHR3@($^P!)J 3!0VPM&B^*H.P.=HSZ9P^ $>G^).6Y!&F! M@E.$!+ICEAD&JRGD^D5K5O/@2 N9M9!3V:J:9%9:Q#=-!%C Z=L!2:1@
HHHH **** "L+4O%5EI>NYFC36I!H=JSVZQ0H!C^+ $ M^/S;YQ6!7GGBV2YB^* @Y!2W2XF%?I8WEIL-!B?Q8/RH Z!2O$6FZS=7=
M!3+NS8+$N1CGTJ 7!6>IZM<@//$>CF^ M46!Q96!4U!7!TSE!6U!HFZFN2M$O$OBM WA7Q.=:H+R!@M!BU:U01R+)*4 MR2!N#=#CH0=NY
/691H#!!HWY@G:BY8^P K6?X>UVT3#;Z08K^MM:4#^:E&A&3#MEV5!>W45O^E:EJ5
M!XV4!4!J.OV6WMJ66U/E!AX#*+8^7G!HONS7.67BKQ-?A?P>)>J<27&L M7:6!VYMT.!B0A@.8&-@X&^M
^H%>:MK&L>@&1+2W!0:Q>+IXM3NUNUL4*2 M^:FZY=K.%!L8 D!)!+4>O:EZZ@FBV!Q:JG/G22!AN^F
```

<1>:YK.D:D0C62K9M*E::&,2(P9V7 M:=V6Y&3'601B?W5 *C8G4U?RH X%O%GAV?4+YNO?VDR);FC@C9?0R%2H M9OF). 3@9 SSU
K+U"J: A:8&1=Z9J5A=FJ344>,2LYZY<.&&'!0& M:7I(NI9M0-DBJYD4AM8C;SC1?U?Q?HS?%.IOX%FE M00G1X(3&1Q(Y(#S#D9!>10GG-
3ZFOP@OMD!>WJ:6MGJ-G=>PZE%Q=M'YHDEV:L0Q(X&1?%>F6-1?7Z2&)=LD3F.)U>) !>N&T(Q;\$\$%I54JZM.MY+59T9YIN806!\$2@O*^"
<#.. 222. =:./-00?'"FK>%KW1J0^ (UI=3WV-MP7%I)"&VJ=P5\$7?J^QO) " <^("FEWXGTK7)?&D>;A.D(B5T"R"3&1GY-ML@_*>G071Z-XJM-
5TTW.M4<6 M.#.ES,RZ;IC11S).=+UI=(^W M=Y(UD9JA3.CIOF&)->1DX)SBJ&BOX0T*X.O?&F.).3*FDFXB*+DYV>9J 9 MG<?\$9FYR<1 I?B?2-
50)+. *18K1918DAE*AYI&.<(@.1:41#59 &WAV.^.#7L M @6Y?O-Z^OC)(L9C+9X?JY;PCJ=M+87 -(ITX?T21^>4WD?F(I
M+YBBHN%I;P.A..@\$=NHL&X@U+ NY-3GN8+ID.&W<+LMP%P0I RI> (M+?2M3LK-ZT?Z[6.N4M8+EI&8VD92P'WIPX5N2O:MR@
KEK#PG>Z?XAUCE6K?6 M5! 5FB.Z;@HOEKM7;P(XJ2:WK?4K:ZBFGC; 1XB09S@ (V;IL'N 1UZ53E M0V;BNWV;W
N;BV>Y2?^654@&9SG6.6'@#)3UDP?74MD0FZW<)>J>HJ\$- MVD*XC=%VJFP% .!N2;@E!12R3ZL=>NF?6D;6IWPQG.%9-PP!CY7-/I< MUVE%
'R<#99(17#<K#0?KJ:=073ZJ1DM.#5IEN.<1ABGN.T39-3=WR&&>1B MK% XOI=BBFUFTOM.MK'BXGB#1?3P.S1E@6U;
KH%974.KIE89;IR" *?2 MP&A&FN:J%G="V@T:W>VMJ58LJ8V55OSGHHO 6F7/@YQXIN=-TK6+G39+U\$2 M-BBC1UGVC"1-
P.U@.;CJZBB@#S!>)*\$*>1;1HJR;IC@W;7E501EB0.P.F M2>N3JU4U/PG)JHK?Z=>ZFTVEWTWT2V/P@LBY;V(^2E&1W1)/QCMTU% .VOA
VF>S!O:WJ6HCS=5CBC9&@RL0C4JF/FYX8YSU/16-9?F33(="AKJO.SZ1+ M;1S"W1O.AD05E;(R".&'Y&NHH X67X;^9X=UG1!KEUIEU2I-
JL"/C.&2X< M@N2RCDJNPZUM?7AN>I3;KJ:=16.XE.M2VGA73JL- IQMH0GMCAPD6.UO!4;CD QG:SP1U>K>*>J M:=7M-108KG3JZ4M;1W48
FOR0K*2N1Z9SJ5N4>IEB0\$1D\$;410%7J>>3DIYXPI(S-JAVL5.OH<:QQ+IG&)=R."6YZI M0.G?
GYK90=3.SU#3J06%Y<^!>D.T>Z.#N+PC+#+XCD& MY;7L^X UIV"/Y?F NCOWYJHB3P08.'PW"J;=>?OLM(C""KH8. +(<=<1
M+W1;=;611B?Y?5-6T^*WN(9M.E2*;S@H%#EW K@GC!7'6@<G<^#? P! MUJ" E>>XUB+R;JX "D8K(541(Z)
(Y))48-1%VJZ?I-YXCO+FFA94C8.MPJHKAU"X(^JSHW15V.%"-+X3DT?1H6T1=4DD&H33SB41!&A?78K@13 MD?SD 1.J7L5SKEPNH-
#:36B8A\$19)0 Y<@ID@=L 9/ITU% ('>1/-SH# M16GB74K 2J8 P"BV4X3\$>NAG W.%I#(P..177T44 72/\$FLZRVH M^?)J51M/\$80H4OKM7:<
<=H2-.5%+>SDJQROP+>XN\$P%P2^7"C@ G7M1>)>I(EG MU#1=M(VENM(N'3SCBNHH R J.T.W/Z;..W8OOFDN)&(R(C%FP!P!D!#L5O/A
MP37WC|OR-.UF*%\$B;S#8.RD|)(%4NG(P0E44 ^9=O/M.M:0Z\$DB6)CW^9YB|7+MGDD<8Y)-7+CPR%13OX@TV|^R7T MJE6C|R.=5/R
MDKDS;.@(3@<@UN&6-95B+J)4L\$SR0.9CM?D?F*Y-JB-HSZ-%JMM42W>|^R M2IK)P!#8W;1% A7:0<^AH
VJ^T&TT:2GL(ITS222W#RX+322.6=FP.JZO<:BIYJ JGW.3 MO1H(F6)X49 ^H#<^>K1TWO<1U..S LK4(\$GM1=P74D:F%T..RD|6YIVG' M%:E
'>& 1%SX?>N B74J2K4 Z+8SJ@>NAG W.%I#(P..16=^1^6T M;4M1MO\$%L%>..9\$15B1A 2VXA7(SMSSMIP?7G/H%..55.9D%RI8(#RP&X.
M?P% \$MXFAMXXGE>9D4 R.;N;W. !^0J2LGPJX@M.%C/=VT\$*PW.MLZ3@!@ M;..6Z\$CKJUK4 %%%% 1110 4444 %%%% 1110 4444 %%%%
1110 4444 M%%% 1110 4444 %%%% 1110 4444 %%%% 1110 5SWBB|NK91+2%4L MX)KK9.\$00<3+L8A(5VMDD@9XX4\$Y&UT-
8'B'PQ .EH>H0.EH2VNM2B:969-R287+!MO4E!UX'0"MB#0"VH6M J=XJ .!#EN=0G L#6K9XXH)\$C"P70=06VIL,NX \$!15RW!V=ML
MNAI>3G09)?^P.%4%MYC#XSY9;KR1G%:GB3PW8>*33H6JDXU*#*#R.M.#P>V1E2H30!SEQKVIPHEJMO<32ZI=3RPD")7CMT0N|+D-9*
I=V2.L.N; M'AE/\$45V7D.LGS+!\$S:PDE9-M(^=7V#;<H>HYJ3O3XLO5A:P337!<6 MDHGM+NU;9)!
(A4^GJ:=HJ<X=TV62ZU"UBJDP;F"YJ;1455 51U .DG M0 R/AE=22^+ZR#^?O71^<M#?0+2YV9&NYI9+JZ9/NF:1B|X|@3@>P% E;M)XR
MBI2#49EFCM3+!Y.^7Y98.??.0.<J L>+&8!-U9J+M!T:6Z=1 DAAD 0@J6 M&3RW?C%=(O@N"W&JVUG?W%MYJR/+>6B!2 SC#F-
B;INJ2?32>X?2>SBTK M5K>Z>W73+>K6"UCC7R+;..*GG^\$8P>;4.%U?7(1.26U!E;E:7W"1&L M%Y8PD^2\$9#R=2R57^GLIF-8(3/70
D9YJ?>O9I\$66-HW M&58%28UQ47PY6/PW8;=>OGM;YCN(^T<5\$;D3JO(ZD)GCF@<G<^(-4 M)4M)=?M;W49M5M+?
0CJ2SQOHR.C.K("BK|P.N2/YW+"3Q7-7Z+70+!+83J# MJ"74D.PJRY#Q;N!|0G!OS6I<>\$8;WQ)/K%W=O-Y^CG39;8HHC;\$DL1ZY) M)U3I>
QX>.&\$ JMYIUL<^K67<^>#8+K2M(CMMGOIUNI(9&LKV-5\$D95=N".88\$<..8/M0!GYVK.A:>+M;1+WMRIY- &H6D MBI1"2C1L5
#@&68)YR3SV R3X B.X132?#ZZM="VTR>..*3RTWL8VW&XQ@T'M S0!+?W?B#Q1K^E6^HSV\$6DK#&IMUO!NTLB;IYW"> "H'Z?9SQCE.CQ?
XAD M!<KONGAT/53:;O:Q(4N8BY DCF4E3@!^CYO.NXD.A FEUNP09+2JN8 M4ANJL:LDX7HK?3T89(I'Z!HJQ:~.M?
#1VBB.R6MPL@G.ARTODR9&8IRO8 MG!>*.5E!53.711BO-3FDT"JLI&MF*1^7<1I)"56"IB/+(R>N1SCAJUJ&MOZ=JO@F"XU*4 P!HSR+?0/"R?
9PN0HOM/&X.YK4N/ 6CW/AW1M#D\$AMJ MFBFA8G+R=QH@6SL;N:UX;&L:SI&HF^E@;2Y6FBC1%NS\$5.(ST)\$*..M0D0?
\$=XWCA4!1W#NNCREK4QV;1B 2!6)4@KD^F?>M&W13:4?OX+CN)/LEMK M.GFYN)XP!NF!&6(\$ =SN8^IV=ZTXO!OE?)!HJY.N\$F?..?
NR4Y?Q =M<^~M M"+S5+^VU274KN6YCBU&VM)1%\$D?A75U1G(OZ;D8J#4=8O! 6WV@V1
MNXTL|**9FM7B61GD+@'F>%#"H.K3V\$/@F+6=:MM;LM50=(U:"+R#P!6NK3W<:ZKILGF7UI\$(JE) K6RIW-DX)(3)Z!?
#NW^S5.HW4L5G(9I)FVN; MF3G#R"\$4Y &"!@<#^ZJXIG+ MMSDT 4I=2I3.3.^\$!2EUO!RVU>TM;NP>WC5)E #H0-VX\$Y.3SGL *D@UCO
W7XDT)M8T#S#N?M<@MX!A%L8TE*%1^1)522>NX!8%GAC0EU+PYX.G0-1DO-M>?QAAF@@"H658H">0L4).!Q@IVDC<@/?0?<4
5FFU5(B#K.B)KHE91V\$Q%Y\$1>!)G+@&RDS+?W;M!H15'R5!>;-XV4 MHVP#IR;WH I>\$?2GAS4HSI0D.DT:P1X=9(2V8V9BNY7
SD*=OM5&?X<3 MS>)OJ0.I R'G^V>6GFI.9%J(JNPH\$#&^>)Z^GH=% "^^/KPA V,\$' H MJ6K'Q&U>XT+X>:WJ-
HQ2XCMBL;CJ;0&8XW9 "J/C6YCNM9+V4 DDN+76X M9156-B3RI/FQC'S'OWKI?T;Q#X?OI(N21%>0-\$6 Y7(X8>X.#^% "?\$ M2R-A!
+VLJ>VCMHK\$+"P=+2.C3Y&#ITZ#N:76+Z?XIZ#;0ZE .*)NP MUT41L;X^G^TIR5(JI9=9?Q1X" P">U>2:UOH4B2:6+J)8RK+(A(PRDI"
MJO<S^10E2"DG "1.2K)%<@L6PI5D\$&. 8H Y6R7ZQ:Z M)87%GRW>CQ^M81796-9&0#>(&P\$WJIM&X.X#T4: GB.7Y-1W0I#QJH M.AXS-
)T9?D&^O<\$!C15&7X;V%UI&JZ=>7UU^FH7YU(2KMCDM|@X^>.@<8P. M9SWK9V/ZI<..K>ZU?M^+^7)5
MF6^LU9(CVF9593GAE!PP&3C/K7" \$+PWTWA?X>(>1+3%F2"1DFVR2M)MEC& M%R>%>H5A^+O#4?BPI/HLJY-6UQM/UH54LP#!@
2#GD@<70)9S>=\$ M5G0PIM#92<=NZI=AR;IX\$ZMKEKH7P5@EQ94BOQ<0W\$#(1SD2)(T1R1N'RA. MAZ5W6I^\$OI=M5LJ8U>IN;#
(EK&\$B2.'9RJH/8\$"I=1+0ZNNEO.7Z3X\$>YE>M?MUVBAC.(2RH">%+M +O47 M D^KZ3H B?4+BfDO(+4\$LM/D=(PK!VC7=D*
Q1G0)P=N.H)K+12:5 X3T MSP|HNJZ^FGV*3.NH06BW"JF>1P0.O(H 1/343P^X\$S*9GT66!A.MY)9Y1U MDL#(X(6JL5F &1A PKBIV@\$.K7
)O RW2L PY>P>T9NYO&VK>0NRW6 MTEB;2XQGY8QN;&YLL9QC)PQ;J5AXMT^RYK3Q3.VI2)(YAT.8LQ5@R!LA MP.@4 1RB7QA4;PUZ-
-ETC;K&YB\$P5YVSUO6G>ZKJVK M=(=TK3?NX3J0HCVS0C\$CIOW Y;I.RICIP>O-UZ^TWTUTZ>2S156NIZ?+YM MO?
VVB3K(IQAA@H058=>#62J.G=ZZNN64WC33-2DB6&IEM-%E"W*KT+(T9& MX#&@&#G.U7O/9W =>?4FB"YO:B2#4;>15..0K\$! AB.CHH
J0<^ (MOU3Q MO9Q^ (HBU726C>T^WBR-TTIE3E3U #^A7Z MUHWX*GGN^75508JZW1%V1^L P&X99<1%1Z0XBUZFTTCA#BHDT>5#9
MR&*(E%2N5^I@C+&DQ/03HJ&EMM%CTRP5:5)HS\$V>@<U1N+2IBU0P- PF9772GVK=HLK8VJ%ROIK@G'TI^H R Z#46!5:1I2
M;@ZIU6^XN(I+&FSMHQ:0>6=XB&G^<^>U&I&<@IBK%XP>VTJ#2-7DU=5U M&2&.2.B30QI%O:AE501CYAGHS<5-
<KZ2VVF&OBN>>Q/FIH4WHY2N'4 MI@CG/&.1OBL?4+0-3TVYAGL/D=1/?41?6^CSOR17 4*&3'8 "@#'/KG/- M&GJHWXPT?
POXKNY;MH8..W^TZ9+Y4DZX4ET<^2.C@XS@ITDUYXAM/\$A6 M)?\$KPIZ!#+/&JO'M@98?#Q +G!S\$ASGIZ52EDMKOPW?Z5?S>IR: B|B
M:1F67> (P"ZBB,*O4Y.GN>F)IKNSGU#P >#XJ\$1%80@#-B3AZ<<5S!B7!>(EU&P4W4&NE&N(S MHDZ^6R *A0A.@.#.N>14VB7BZ3
RW%WXVU1(S)=Z.^?&@;F)Q \$V? MPR<@#30\$'B<^! B|XUV2:2Y08>YM!L:Q2OR3%"3A=P.H000..G7/0? MK>?
(6SXN9M0NW2.&R(CU:D&HV5OXNN?;\$4BO&NX8H|FV70YO+E.8(5B3 M'N&-OX!J* .AU. CT03+P^D5G6%"P1!EG/95'DF74#B0E?
9<#M70ZOX@U62S^VOBBVCMUG;..%PE M9>5#93H#SQCD#TJOXLU33%0AZ?1KG30\$!\$
!\$6DBT5)0L2R^LF4VD^BNLS7&=!F=ED"9IGJZIK7A 1UG:S-WHBZO=2PI-SY** (U+ @#+2>O QBL36/%.OZ?H/CFP&HR#
M4#@QBEMKJ8HJ4IJE5U*E21R'0!GCI4B/ID\$>ARP0BJ4&@^\$6JW &# M3)#M'E)YV88 1#D9&*L3W&A7>D.S8W>D^*GUG/VRX L;
<.QVA5VX3 @# M|N16 COPK90WTBVFHVIT;B'8A!..2K J<@Y8J5OJQKGBF/P' MKGB;>(I?M&D.E/"#IFB"3)-LVR?
+GJO3.M &K<+6PU/1M3NI &EU>Z4DLM.^AR!7#P!P5\$6.>Z>.>O DK:37)ZFX>=%IMM2N'N)P!^EW@NVJ@W>. M\$^W%
&YY;IQL4B NUC.@B8194J/WX44 KP#@9QS|UV97Z;H#&YD97DR7+< MRGT;U3CI@=.*X"6^M)\$MCKJQ^+8KJWM/L(^P2W" P
10I247+Z4?UJ5U"2M? MLFEQ2M1HJP=|GR\$XVVBXVNAEDCT2^G.W7 MM;TS4!6@G4^DBL)F>?QAD088%&L
K89>#C.YR>:@NKC3+NOTB-1/Q2 MMJH|K*^30YPZ84*01LP0P&&&.2.GW%|HUU..L9K+O.;J5+<6LJV-GI2(@ M(BI.2.OYSRK?
Z2:2K.FI\$>E.L0Y1|ISGN# MC@X&8.E C7*GJHW8B71\$F\$0%1F<@<J5XIVX..?>I=#!2V>BZJ9Z8-137" M6D*P1R/HDX8H&I
<C.162?>C97BR0V|BRTN8J!+>HDS) &W@'=M9(I?L^Z^D.J\$Q<^" YOL"1D?48XUJ57LK1 M+&SBMD>20(7E<GJ68JIR3D-C5B@
HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****YCM@K\$UOXA.Z%#.UN-
6FFIR=<.@D4>|N>A8X&>N.XYP0 =/17 ZH.M>\$-^F MCDU5.KI?JD%K832H#):1RL 2YZ-MPV7GVSIG5JZOM0/>/MTO:R>1T68YX
MW2X(9H98DW4&&.<.@CH.V..TH2(6".K;VM@YV?2O.M"UJ^EUZOTK7K!M4+=UUFFEZVE-O>KM;#6IXQIORD#<C.<GFI7A+6;?X=ZI<.<+
W=1-13N%\$ M3S NR"Y..6 Y.%Y>J J?9J\$J4L&LY>@NG74L=RD<=HHJ# 0:<@MG M.K#H!&S.O:<D>4:Z3R3&DFGZ@GR?R?
YLJP(RO>""2>AYXX;KE J%KJ1 "M ME#?2+8WT=YYJMM7:SIQ@J.XX% '745Y+?>(90"WC?4AXEODET34+H M6NR.(A%&C^K-)@KVP
JSGMT5GKESXB|3C|FNI+.*+2G.V06YVO+*3T4*MN:ITZEN>JB@#MJ^X#5+CO|HD7@Z"UGH|>RZLME>R0QA4N(RLC#D<A5SC;
M.COI4U>?25HJMQ&EEI<5W9Y5&|B0I?3C*G04<1/MB@#T.BO)M3N?&VG M'K'BA/%%VUU^1G/8;M|<QHV0.;H+M<B^K M2W-R?
9.Z10HGIE& Z98M&0:C/>@#OQCXBB'C!P?AM9UG.R:16<1?+9 ZK M@8.UGG2ZN-MXK0&+;A&D8""V2#CGL#6S7\$?%\$.WAJ3!&P20ZS9!6Y
<G#1QOFJ37-1

[illegible]

[illegible]

[illegible]

[illegible]

O: PC'UY.=&+PI-I'IZM#S-DQ&#)=PVLIC.0PR<=I-J.M&NM;^?JSIDU090ZPEPMQ'YFOXXV-M)(1D;@<#CH,6M5RRU'6+S3-
(GHNH2D99)8K'>10HC210')&7/7(SC<K M4@B*WO?#3Z==K:VF@'ZP6I0IS)Q38Q9MPYP<I.ISSITB--W%)>+E-5BWZ
MX%WYM#<YO'Y8V/|SI|H|P-I-6MM1U7P|K#M4@B*WO?#3Z==K:VF@'ZP6I0IS)Q38Q9MPYP<I.ISSITB--W%)>+E-5BWZ
)X)Q4I-U-MX%N+GP%9^%#JZ+#+%5N!+-RQ,K^*^Y49/Z'M-A+H^-8?%C:G&62Q^P-MM;BV(#*6#D@|@|A|>O6@#GEU'Q5?
ZUXNTR+6I-W-E);M;RQY2GEXBY#%\$M9Z12%5H2?B7D|>+>(H+RW^SZO=6U'SNWC-C'#C&G3TMMX M6N|6;5.HKJ<1?65C5E-
I<0I\$Y+CY^>#S1'G2I(C|SK9|Z'NK(\$T6ZAN8I-M3|F0Q'<1A0<OUIH-00U M#AE/(SKDD)7-1-8-A-3YOS F&B7.5Q'f60&IRU'1(8<8)SR23Z=*
(f76 MO\$%IK'BO2);VUO;BQLHKRRRGN\$%*#7+)+MXY@H#GKCI:9IOB#49/%^GZ/;<MHW:|AIDLYN7MD39*A4;HCL-9-QD-G)IUK/@>ZW>Z-
<:H4BUBS2T>...#I C-M'\$E'&W?..L?P=J0|0Z3K=|XCDN;|QAD@<"T1%E1BIP;|SM^IR>&9?'"K2;WB:%5,
(=RY|8|66B'SUIK-WMGM94IA9+!+S^V-2?E.5ZIT>?VUIK>C^&S-M-FM;9|S-NGGZ?
S^0UN/@Q+RK\$G@<=<8?;NON\$&HZKKU|H6F>?1'SM(C)6DM5@9-E.#,B5@H'GH,DDC'+/|^\$G:POX@T|H700ZS=37,DHM<&,RG+A
M1OZ9Z9Z<I-6-|7LNK6FLZ5XBFTO5DMEM;F^*V5XKE%Z;HV)(fZAJ5S):WL7EB4-A^N"(&QAOVW/7C-7(=4|02:A<>'FNKBBXOM
M-M(GN:YQ@<0R22%)N4E;4^<X'4D|KCGG0|PA<?>QH4RZF-F5<#F-1|0Z-HVNSZ-J0A^SSND*)/&#D|D;CQ:
M#0|K>@|:N#|H-B&TCM=5P5GCC964D\$@..\$CD8..|9KEY/%XOBB32|I4Y-M(O3|I:6US;|+>|M@RYV2%>9"N>..
W!..=Z|73K(V^C;MOU+4UN=|^~V^C6^~)Q+Y|BHLF@X7.W-(C|I-M)H-937/B-C|0ZAJEGX-NOM-MBV-
QJ6G"ZD6V02W+S%4(5\$*M|@W.2<<<?>A|TM-J7|7-..\$A5=H8QW83..<A02/6NENO^2TZ;P|@*X-J
M'1U7PXG3PNN4)KSF|-0^W(V|DKB4RA>&&?F@|<-5N/XO6@#*^<^I-A|7V3W?;K/&>F2M\$=5+|Q|KWA#
MQ1%K= #I>EWUG=7?6EPA>W>|/91@G%E%OHI?LZQ1O.N=|5|RY^9R/0U?;\$5-MM0T+P+|F|7-7-#*=6L6|6>/>.H'0G&>>^?
I5|PWX(O-#K|6@<47MUHELZYVL|M(4|0 Y56E^R|H@T Z5L>+..Q1X-O-%%V+5+MODDOE|H\$SG=9?/6^#? M5|TGOQHUE?
ZA#=#.JVM\$S(T^VX06|1*K95LDL"&(?KQTK/BK6|KX=|XZM+ME%5|TNFM&IC:W5R-L;|?M&=P..|8Q71W7AF|O\$.A:O)|40?2HY8-+%|<3
M>8H5R?GXX48|>|5OX^6UT.ZI:O-BPVW\$C-ID/|R-&ZC;K<=>SU/49 M\$#1Q.K.BA@S#9WQ@<8'H|7|C\$<CA"H%7;@V+Z<>EU?68?
(L|MK>UTW56M6\$=FN^2+RU.22%(+9;I)Z#|L0 M;T0>X|KQ|)-8XDOTN5U;I-MVR^#9Y;D^N=QR^A;^G^UR-L|W-U|);B.P-\$5R%.22^&
|D6ZU^2AQU-U MUYOL\$MOYL.ZT4M^OG=MSN^8|NYH=A6S^&|HQ38ZW<7T+^VM)+5|<6QVR+M^C?S0X^Z=<=<+8:QXMU^#0-
7L;*>6W06BDO>+>4VZPI|;|H|V#^9N7(ZYW-M<|#I3M-O-%.L^=(7C;5K2.STO5S^8M;F+RU)7.?EP6SGDD^PP9-# @2|T" M1+..+Q1?
3:##|O@<TUXDR@SD(9?O?>W^|TR#|<^O#L^AZAK^U)Z|<+|E-|T\$ M&SRWVA<|CD844-5^YKZKHNEZ?<3-#+|+I-O;|8|P99""D9|27|H|V|>(<
M+|/7(8=>2?7|W|?/K|Y/XYK|;5^9?%MC;VT=|MMH+>|B|NMQA|PEHV#^/O#-R.?Z54|3>#I->N|U2RU>2M:L RQ7D\$8965L;E M;-CAE)&
<\$14-8-L|XRT7Z?E|6|L-K?VEZL<=<QKQONT|B^KLJL5|>|HMQ-MYK4OM2UV;XD-XD-M-1AMK-31VNU|L>--5.CY..|>..>A|5-|MWK/A;1
M;K7999|F5);F|DMU+;496-5%*J@R@XY|HSFK7"-W9|91^<VU^#55L#8F-6I-M"E2P?>G?G.X?EQ|T<3)X|61?
#W4|>5+8W&B7D|F|+1<0|<CEVDOS|F|V7T M\$SG-UM9A0|OXNV<>FWJ64|<^TPW|0^<4^GQ|%)Z=>..M6V^TTG@-6?#SZP
MIBU2ZDN^F%K@O<8V|>|<O>F>G06I<@&M-\$%CKL&JOOZ;V;64N^FWJ20Q@<O M.T."IRH-B-"R^+>EEH5|>7<1U72-
..M|":>%0EU%#R88|H|K;7|="*ZB-M;5-37XE-HD5VHM)=>|H9(E;RY|*I-C&"I@G@GK2ZAX%M;PYZ;R;R6|O|I
M;V6^@MYZLK^VWIM&Q5^@<ZYYH@|7Z>|80\$SVO/>?8-9-#;JL;MNSM|R;MD#C.>O/8-|>M;..EX%3Q;MS;7LDEE+|T^*U-9I1(0^#9Y;T-I?>
>R.F-M3QTL&AZO|MGK#-DENM0^E|F+P+<6U|PA0B50\$XRR>GW6Y|UN-X2NM%|0^M;675|>@<8+Q|
K|H|YF^NX@<IQZ8(-1W-@*TUR75|M;F2+>4+)|S;0^2-BM-0M#8+2X;|H|Q&H;N0|;7Q080\$86AN&TF;W?>K;|H>8?>#B)F4||D" M-*%;<
O#WBEM3MF:XO(H)|3|*H697E;+>5(XOCTYS78Z^X;UO2H|M-MXIGU7R4V6HGM40|8W/M.Z1L<9+|>#J>-9P?
#R>P/|AA=97RK^Y2=+>YGS'M;|YB@C?C|WZ?G0-2V|HNA>-2T-5;Y+^SCT5|64L;B(Q%V|LBX)R".1DD^|M8;IXNO3H;I6UI/-
WAC;^AE^SK#<3ZYWQ^7W+D<G<1#60/X5>|I6G7+|FMBDC?3FTZ6U^SD^|;N8|M-|S^G^O5#PYX(X|P|5HOBBN=\$MVW6VGRPIE
M#E5;7IS^#V&.<#B#<|E|O?Y?OC^4H|HMHFT^N5B5-3Y|I(K;&R>PHC9BSC^G.<|3D^F;TD|W#W)Z|X
MTQM71DUZ...5Q-X;1E4*P7Y^1@#&?UJ50|MS|OT" AUEH;K2K9K21TME(N(F M^|8).T^*GGZ4-7O&7B%O#/AN6-B1^N&DC@@@5|
|2.D<*^V.PSD-2LS4-6U7P-MYX|T^ON+TW|GH26Y>6)%>="5W^*L RAP00>1ZUO>(M|L-\$VA76D7^|03@?>-M&<C
<|IRGL00^%4XO#MQD?>=>ZM|S=|<K-9BE0YH|NTR-QW-C(XP/F/M3-|B>#|P-4;Y>W-U=K;8K'5;NSFMUM
&F1M#0A|<+XXYSQD|=W6|X7-M;S>(MOCDOENEO+V6|(+H%|H-'WGAW30\$^VD^3%;1S;9QR;KFSD;1P#G;STQ-MG@#L^VUK6)
(O<#ZE(7TF0-8YO^CW/((\$F"-N#R>XZ4=|17GNF>*>4U>/OM-M/4W;75QH4.I74UFL-D9GPHP)/E-SN)P#U7H.MN#Q=>>|B;QK%;MT|O)%"|
MM|YK2QC|5W6+>5(B#R|QD<4=017\$Q3-?>+O^1TZZE&E:O|>)-.8\$E7>M5W^|F#4R;C|KTIVLLD\$9(O|&=I4|N>2#0|ZE17^7MM|XDA|
C#00M>|QW^F;O;U;K)-9EC^S/L+I48F^..|HKD|K4M23XF0?>LME<3+><48-MT(259\$4.#C|1CP217^VWB7Q4/AH|BR;6UD?|/6)Y?
(@>4HH|?)YHN6/L|5P-KECKXDPT^TUBR65;Z4O&5^&2.0^M?2L6#4;1.SK|K9;B|A|H7|&C-;4#L\$;?>E&X-8Z-SR-0>..M-SHUGJMHET-
5U1;|DS)"5MQ\$M(D^R8|<^)|Y>..-L^755BUV#2OL=XS30-;+E8/-TVXF2&WO-MM;FFN+5\$4|D)V=-Y)+^VX|T;^N;
|..|HM|HERLL%FL98%#NH-STR<\$ MGU|;SKB^X^PW^)|3SZC=7.R^OX<3;#G;8D^*#G-Q
MG&.@%=-+ZAK6D>|O^51/|8N;+5|6.2V4A66HX|K(1QOZ^<3Z4=176-M6SGKWBSO;H5EKA70#M-O%K(<6SP;RI4G/F|@HZ-P|
|/G-*M6UUXG|O;QSA-MTNWUR-ULLFLY^V1+>(ZWKCY|9S>O3&<=<N^ZQHSNP5%|+OP/4UEWB-M&TM;|SEAHD45Q|HOHY)
(7^#R|1@%LG/7D=|WKG-BV)A|..>+ZFMRD|H@;U-M+>%2<9P0><8^J7B&UO|A|I=O|H#^>;74;|HFC1F-VQ=%4^N<#C^J#W/0
MZ^4T@|8-M|<F;G975P;Z^@U|-(M|H|QOH|+>(\$8;5&U-P#;|T|(&+|>|HKK>)|D|M27=|F^B^AXL;LP..8-@H;|<^%".B45P&N^*KVPG-ML+|F-FO-
2ZYT|>|M+>=9DBN&^RY5B|8VX..3D^DL>OZE|I)HMK56-I^L2,KO\$;E|L-RD;Q(MP^N%QWYH|>BO.(?&N>|O|A|Y|O\$T|-
=AN1<Y^R|CB8IEW<|/0895-MSGT&RM;Z|18;6^UHKM0|;R^8R58Y<+R>^>10;5|0^>+PUHSZ|=|/-)M(L;29T#D.6)
<|@#YCC6Q7B6+E-V=9|B>^N+F2;YS^*G#?>^3D-23RY-M6S0+4+;|7EW|F|W49/L^8(VD=
M(L9E8|03P@<|QPS+7)^!+F#0|N^%88YH=NC-FF)+|T-@2HH<#<C-M;..|E%<|J7B#4Y)-2QW|L^T2?7M\$|M);Q|H|@206RN|C|HU7O|
50MR-M3^>=|<0-R3ZN^6|22V0F-|9-3|H>9QSWH|HKK>8-2U^4;W|P;Z|N+S2|M6\$|VR@MD:660.0S)^<?>?W<|+>Q|X|D>ZT?
0M3M9(7DL;=N|<P-"S-M|(C|V0F0|G<#>|WNTU>?WAE>..WGMGD55+MA255-F;W|TXQ5U9-\$H7-M(PT00?5U^|Q6H9M=:=X8|
M|HE@A1?022>?>OUI@>2>E0Z/K^ZPES-*=>6:76/|Q2^N(5;6HT^1A^%|E2G>-RDY|P-2.9K5E|S7\$5N|MK<6S|+BWE0D)\$2.C(K|Z)-
+KMR+DMJX;IV-0#-MH-U;U\$7?"FQ2OD;7&@R^Y(&0\$SAV;1W;H^|HKR&|Q^XQ-X5C>..|B-B-MD-W|EN+
YB|+B.2E6RV;H-F.#@<=3DU|F^NZK|FOH|7VR&3YS;VOE+|E&D-M6-7E|PHL\$MCGY<<#<#<
(>@<|WU%>>7FH+>KQO3I6BK|S&E3WNC27%P|O).>=>2@-M)AG|W|/L;N:9XBUG7|+L|D76=|SIEBDT\$=G;HP|6/<|W&Y2\$W;#A0P-WH-M";
/1^Z^R|S*&A03R2I5&PU5^<|U"U%G>0&RE\$|DGAV)+E0I?GPK<-VC=0)=>|<=&H40-NB0-5/7|0-3Z\$4Z7Q|KL^>20%>H6MTUM?
Z3|66UK9|&#|<3<""Q.FXD8(C^OY-M/|R<G&85S|EXOM-INKZM|+&)9K&R|E|I^Y-XSCD|=QD5N6|RK-Q'9V-M/7-X-S;
^3^>=>>33Q7X5A;6DP-M09;|P?>#Y2|<C9%>=>9|4;I6S30MQS|I&B)>HRC|RG|!!R15RN4U+>Q-X)BNM.NH|7X\$SG6G<1F-.0^Z\$LI
MQG|/&..|4SPIK-SX|TRXUZRU&6WM)HC^I9R1Q|>101^>|&%O|.=*=2.5%17.M>(<7-M73H-NX|C3|N2TM@<MS^|QA-D#-
15%>=>0>);3XM;UEM875M3>&W^N(TB2-&)M=(|RL^42;E(<8=&P>|5QK6QM9ZPX@^YDMR\$5);>8P?#G-6*50|1R5XY-MZ-
^0+>#61>+O\$=|X^I&Z|M^>PPW>HZM^8W9-NK|13(Z\$X|9V#&|E|P5N|7;GX|I004&IWC;K^I^GQ7|H-MTD21L|L;GEML|&X#G&0^>M
9:IXAM-U|2|XBN&EY^8P0NB-H&EOE>..M-26KNH7|;83WDL-M^023ZU|U|@S@HT|2I9MHE&H;WE"#\$%M&=\$L#|D(f#)Z>D;U|H9;
H|AW3X|G;|M+;S6-E^8\$CV^%FG;R7R3R<+T-MYR-#|K:A>OZ;|UO>R|I<(\$9D=8EW.0|DX>N.6^|5V.B3+|MQ|;%=22.*|G-MLS26K^LD893/^-
|@YZ5\$|EMZA?<XW|THEGAT^<MGN8E2Z);6|8*-H|X-MR<^GF@#L=&U6#7%LM5M5D6WQ(56C\$@<8^PR@<\$|UG+XMM^UR|T:*SOI+ZT
F|H)HTB^M|TYS@<X|X#<P#)-?#2-@-P#0|6#9/?)|90\$GV^*WF^<SK3<)-M|FC^|TPC9H|3M4CU|B-8+F^2W<)<
(D|>P|@\$\$=B>H#Z5=)|<DD-#DDU-MS-H77B-W&WEY-9(C^N^|XBM<3&C)B|LW;F\$?<R-3VYQ7&>(<=5-5|XMMN-M3W>)>RY2^NY7^KM6-
!&5V#)+1QODBN-U35|5U|X;M6-U>7|QO|PT5Q^<K;I>^=(4T.OFU#-M.F00AKBV6V|Q|S;G\$F|@+@*!SNSVKH/#4FM2^K-O\$\$.K;2+A(6|3Q
M-(OZC|&@A?>-M.TZV6YN;6-6W>Y^K+|G^5Y^O4-%=US6=2A;E|HMM4T61O|2;-(BM-M|H-O^<|&".G4Y|Z%176CZYXGU^PU;W|>
22G(OXQ|QM-L|B|)A\$NX^<M|V|&1C&1CIDN|2>)-2TO494U2|NMLY;2|I>OP);+<^Y9F^L5P=H^W01-MGG-'H^16S;UK^S;LC%
<ZG(8XZCV|6|HHHH****BBB@HHHH****M^BBB@HHHH****BBB@HHHH****BBB@HHHH****BBB@K#|4^<
M|XDLK2);V2SN+;B08)T0|MD3-.|>\$.SUN44<|<^&|>?OW^K|?HB%GAP|L=..6"&?UK|H|TYM-LA-M#>+3WD|OEN9;I&Z9PH-P|3=)|U-
M4BN7-PO+R+AX-MU^L^F?2?D-MY0|CW|?2O#-V-BFST|>X^T7<\$D|7OB-T>SCWROD@?N1G<0&KP.5P
R|H)=#0|SUEHPU^ZT05;S4Q|62%K(H&4EEV^8O|Y;M|H;R#D|>ESQ-H;B;P-M-#<320I-M^ROXW(RL^5AGT916M7/ZWXNM-\$N&@<P-G?
Q|H|E|L+5|O4|H|MOX-ZCKW005B^W2<G^7H|?N9|0M|I75&D|X|H^U4E^A-M7P|X6&K|O|FAN;LWV<>82)?-ZX^|
|=->MY^%6C2^&8O\$5V)-.E4&1%)M9R6VA007<6^7^7%26OB^SFE0(+A9+^X|X|A-#<|0R1G;R|E?E;D\$X(<(*M;EO|LT7B^YUC3|N;!
|H&SH0PQ(R3LHP?<#L-&I6^M9P^&LGA2^M|+AUF-M^AO=&|>+C5O|^1^D7VOW5-MQ=|&H|D^F|H^&P^%4
CT/4-M=9|LBPHL|K@S;H03XZR<412+>^D|Y-MYNH89|3Z-..E|20^(&55=&|I-C|46H;YEL;O^CI^=EW@|&A^>|>D|K5^?P|H|7AZ^?
4QYFB^XC-M-M^>=>Z;+>=|/M6AX=|06-B739+ZV@GA1+B6W9P-P9&^MT|4^O6M0!MQ6F-#YM^U"=..|0:A;Z|/TSZ2|H4|8Y95^7UO|?
MYAU3RQ@<|G^Y;|5VG>G7?7VK?HH-R0\$NA0^>)O#=-HMQ^4=W%Y9D09^Y|L-M-|S-A\$|R37-\$U;ZUM|BXTN.5-6MU7SA^SM(O|PHCGG-
=110|Q4-PZM-MZRUVTU"DECUZ^26B3RWMY@%M^V3C&T-O^|H|D|S4-\$M%K^ZYI<3S-MHB^..|*6;|EF|>G-4<|ODV|DOE|O|L4M|C&G;
S@<#UH-PO%GAA-%M9V-MYU|K2-UNH|L(@Q9T.5SD|L;Z^C|AFD;C=7=H|YX|W%YK|I^UO;H^P^<N)M-V&XOR512K|ZH5M?..7-F9XPYMH-
DL>>S#L;CU;4VT|&WD6PO+SSKA(^MMH|O>XXW^M^Y4I(M2M-O)FGGTQ-A3X7-M|H|Z6|^OVI-\$546N^=O|<MAFGS&C0|9^>0L&(SC
^R^W7%<K10|S4^AG4+6-M%8HH|>6.V4=G(EQ^Z;+>..%&S&P^XPHR^69>K7A|O;^<|Y.N;^>6|U+;DX-8/<T>)<I6>3/7(=M;^P7C+>
TWJW^W8^<QFSPQSD^&#I6@VZTK3FM;7)E<(^%|+N+M|HPS@H2W|H;7)E<|H333+U+47E66^U|T-X=<+3Y^V|7|QOQV);?H^UZ|Z|
M|EGHNESZAR^S^0@<YV2>2-222-14.3-2\$|KQ>AXUMS;L^F^A)M#&3LYR2\$S;14\$A+|0;K-L9W&E|9E(OV>..K&G62|C-QWYTW-M
J+>#%?V%>6-|9SW^ACMQ+&I#D(7.61F^"=>0?K6U0Y%|J5T|LOC/5|D)O%M5UHEXMP|0V|U|23|D5%>)>F0G;6W\$;3|H375P^|4UHZ|JFHZH%O-

```

+EEEC;I M%Y?GAMR;GOMEGO=E36D1&16=5+G:H)^<|X$X G*~.5USP2^H> M(HH?TG6I01M3H0320(DB3Q@Y 9"!((F&WX#CU1-
.N+;6+>QU?3=WDZE&5 M:1| +AP1M8$XP.W%%;1G|7>JZA8FPO(19F."XFCVQ3IES^|/S8Z^T:~% M~).EX^FU30HM.N~. @f HPJH"HX -4DFZ?
#DY18XC. MH+YRV)2|>CXY:18.3H|=P+CWKH**>D&H&EM<~#0^HQf=O>0*(
MY>+9XBQ93DGC>2>3OT(NX)O:KPYJ&F:CBXN|ZYOH&MGN9847RFX&?"(H 1(M)2?2P&)=1=Z51>IQVMU:Z@MNTXMCJ.MCIE24G&TR?
7C/0^C/KI2~.6F( M332^~) #J8#.%GR@+?B4|(#FOF NGMCGGV%G0 ~#~.'K&K7<.I326NHW+79M&C M4*DKI0S;L;CHT8^0>1_
|~"DX)P.@IUE>^Q$%OXCLIBYMH)X1.W4MJ23A0P>~. M16Z$C&?>@."KXB|~RZ|>Z3<+|V8;.=+=QH(0^0^0 CYCGGN&/QI^V.M%XCf
MUI3KWI+>W4^0WBMI%OBG"=8KDs. d YZ<|&N@K^UKQ^S>Z>Z5.W4O<.=2NEM M8I(U^1^7O^&XD@C@^H#TH
R;OP|+|>EY^G?Z;K8@. &2.K1AWFG%BSG@f(|>1|4W^+>+?S=90;1.D@4(ZN2)MP23T/4^M MF@#1^AH66LW+JZ="RGO<&|A>+S(9G'
?E2^OOD$9|@T^PT6TT>|OM90+KS MK^Y51>3X0)&OW44=$09)QW)R236W10|Y7|. $ M P~"VFZ?=>D)--+L.BT6 M.>9Q.S>6SYX0|$C&
<K@UT=|X%E|B6YU01O$%HREZ%|1# DW NHJ MADY OKROIUH4 @W<=>MW2766|VK2B&~^2$VW^XQA?NC|/UZT MC^97 X22K2^C"NR2I
TRB"."ZT9)YD&|H0E M-S$5 "(DX|OSU/L|)K32|G1X6BFF35.A>WFAVE~.5+ DYS@&1 U4M 4M M^~>2+8Z@4^V&.>80FT^O7.D2|2.G'3-
86D<^|H1M1U;JMM951^N2M.RR6@M(518PN&|&~|KFNJ|K)1^67POHTVK7T5PH|@RM^H8H M^~<@GDCIF@?J^2U MX|~5WE>6Z%QCT7-
8UY-26VL|Y=|U:~% ML6|~#F9)X<|9/0^F>:OR^C;OPRW&D:C%#++&^2L|2|15)"N2|DC)QQ6U0 M|YA|.M$.N?##0K2|U|9|C"R26BQ /N1PC=@?
NA@#C /0&D=~=V?P?#GB2Y U M21 $6HZ2FH."OK:18W25@.EW@f&|ZD)"NRK&M0$=O<^~|SP|+X2YM;+=EF M^A^1B0.HR>0>H%
%5/"I@15P.Y1?;|A|A 9|=NT6Y?^W|LEMV2V5|I^=5M M.1^W>DV|B6N.N.KOJ4FHEOLXPS2|MZ~.HEL|B.=?
3K^K.A>QZ=82WN=W2V|O0>4HC4DCC)>3R2>POBJNH^9;K09%X M@L19NK&4VHLYXHT<2QABPON^VG/)(KI**
.%M APUKHVDZ7%KDYMM+U$7|N-M)(%)W|V95)&~1EVSUW/M5^H$0.GK>JWVH77GV^IV2V.JMY6T~.22^K9R&RQ. M?
Y5U=9^H.FUA>2.BPO+D7DQB.EQ^N2#@G<(<^"O&T.H "=|=/<6|82WN%39+5Y1P0?>XQ .HJ5|~#7&KV6F-/ MX@NH18TMB;3588E67!
#U^U^ZP.IG@=(KKG|8X8S)*ZH@ZLOP:5&74VBVWV T MS|H>.LT+R~UCS FT@;6;7^Q0!@7 "(GU3?;9?5~VJVEXEZFHO&A)= M05^~6
%V80#%USW.5A|~$S6| K=XFNW3RZQ|~#<=>^A&YU?Q@#^&G &~.Z MZB@~1^Z0= VV6D^X^T9Q+#+(4VDHJ|L:RX "MY;^++ ,.0P.NJ7%|^D
M#Q.^D^"HW^S9SR><|^E=16|>^*|>R1PZ?~.^FOIH6GB$2IM=.%."@~%CX|TVUIM&?S|/5%3S|:W411G3 M^|A^ZX W2.VZ~.'@F^74=,U)?
$UX-0M+9K26H|U1~$2#C.IA3E1SS|Y|~ M (5Q&/#~YH|S=A)|.T.RM&C&W<2^9Z^AW7Z5V0=1((RPWL^P7) QD|J M/SIU
&~EX#6N=8@U03 ^?Z=|X@&$%S CBNJT^R73I M^~V$TLO7|:69L1$Y+&L.DDG@>@ JS10|SWBSPWBFTM+4W16D=O=1W0^4!
MF9T.5IR>F>V|Q3Q+XUNK>XBNH.F|HDL9R M^.(SV)K=HH Y M$P>P.W=ZQ^XCNO MMW9+2NUO&1N4MAP.8&OP/4 DGG.D @S-
JHE|9ZAJD MO+&C.R|~DW*MIY9.GD$>^3G~.ZJB@#B ^$ DM~2O; 2/$6HZ9~.A^9IRQ M@~.DDA^IR@&3&6ID<^XXQIW (G NXK^TCU.QZ??
0B^2UD@&@C39L.PD|S@= MJPI07H.%^(+&SATI3|QME^P6T2PQ@G)"J |S|4|~% |1110 4444 %%%M|1110 4444 %%%M|1110 4444 %%%M|
1110 4444 %%%M|1110 4444 %%%M|17^1/=1U73?2^E7 V5K05|4.G)75T=USS "A>NPK@OB>ZM^X9A M^GR8)KMM(73|:)|OR^~^~^#
(Y|QZT 5 |12>^~%&IZ)<~.W%?13Z1+P|E>A& MD8M14(4B0H /+&8-G' XI^E.YJ75Gf.G3222W~*(KRO|~YD8VJ MP|W|^@
@@BMN P#|EIK=MJOU6ZEN9|~^T^QF= ^J|+|^~#G&6PQ)SD@= @14$ M@B5-5TC5+GO#|S>Z=)"$)2(^1~^ *5^X^WIDCDY/3 ^A6GB 5;7PUJ;SW
M8N+YO&CZ>3S1|H&#^L.P4~.GW-6KFRGL C^X>|W4+B|1^NIHG^95@8| MD%5^ZCCMCBM?AY82~#J^CWEY~.MW=LB|DBHK=6
(PP(U4URIUE B^16CV>L2VEE>?/1+QOOLRA0|6|Y^8|< MCYK=1^H %AZYT.ZEMH G D>(^6P~#9|Y 1^3PRTWB;3|=DU^9KBRMW
MMU3RT".KX+|9R2HZ&@^EX|U+4.ZRUBUU.^Y-IFK3V^7#(JM)&NTJ6@#& MOP|TKH.Z|ATRUEN#$6=V^6~?GFDO@/4G
^LISP$S #WAP>Y 3=+V6X M^ M|>|D$B|LC |^#1A1P.K:OX^7O| 4|8&H0>|J2L J.(X8(X65|W(WH3D|S^% M^~HH4GAW2?
FF2%6A|11S7)3|OFOYDF| LAC@705M^~(OITR)5%)HS,HECE4@HRX 5=NT< 8ZY|R: MFA|F.YO+|JZ1M5N8|B|$:@PQC) 12"/R2QSG)Z|
%7|H|86M.39;Q. M7|H^Q|PKPHN;^12P8^BCCI9SPQO&6.3? XFMD^B6X2XMH9;2T@~1M^ M|D+|^O@XY
|S|Q%=A9> "=0M^C.QCK4MLCAWA^P+Y0.2&98PWS|0+.#XB|WVCW.DD<~Y$8G>^&Y0?3% |X?U^UU;0K.^LW=X^C"@O&R^*| M^A@#U|
|5ISFW.E23R28T6HW=LEE|N:~@<#~.5VOD^R "A MQ?^WAR#1;|EG@MU^PO.JIE|)^. |F@#S^UN|7T7X.ZSK^GZM).#6+|J1.5 M8D. Q>ZY^K=
MEKFH.7JAA6^YGM.F+^E|TW^P^8|H~WP^VK/H.F<2<4>+&D0^E^P..CZ| M^~<9>R>^J265U>QI^=J^Z3; M~%|JL. 2>F.H~ #7?BOQ%>?
^VQ^#~29E^619#DRR2Y8IRQ)|~M5|H V^A^A^O(M T^>6.*$Q+V&2G.6YX M|YH X^R1Z ~|V^~LR+>W<4Z^9ILUC&IN^#AE3^IWSM&
<#CO3K|O'=^1 M^~Z^J6D>(|VOH.G6X=|O$F9(7FOY@H^K|^#>@ UT&E^#Y&T02;&QU|HC73(MWBB)1^4~.RR^#(G.V#|^L-
UX|MKG3$LUU^XA;^T P~U99D1.R7&X;#&C 7|M^~.KUR|J5YXB|7>=|(AOY|WTA8(E.N$WO+^A1G~.1WKMY?#"IXAEURPOL.IN
M85@N|J^T0#^TX(5+OP+9S;^I5C;7EQ;1Z>?4%90K~.&+G) M^2S$XQU|4 95K?>(|PQ)XFP^47U6>+2TO=^VD:~9FWKL)0^~I91^G|^Z
M^P^YIKM9=3U~.IAM.WFDZ^J2OR.E>^0HW+|X9|^Y^ S6C=^# ^+5K6IZI M^~MU%~
J%G|A<1^H M^NVL|OD."O~.NVWAX)K<.KWMW)=WEO.M;0NR^FU&(+S M|IRQ^CG@>@&30|2U 6IX %6@^~>9|K^#@C^5OH
MY=00|=N=30E5^LHN5500|JO M0 98Y|Y)S0|S PB@>^X9Z)(US+|LEQQ&^W~|S?>P^S|J.V|P^YU&HW^Q MC0U^092H^?X^@%>
=HSCGWN3|WAI|^Y^6VGVO M|4|X8%SXMM $4&HW^K<1VOV26.(4FCWP#N|^|N.N^<4><0W.KZ1XQ6 M^H NK26KZ?
KE|END2.DV) F60L^2".@.2N/>NXN-5U|B9L.GK=M 9|WL M|VVQHV^T+^M M|T|15NC.ZD=UR34YVGLK9K58 +0Z@L3QG)VCH>U
^X@OF2VFE.SJ.YHK- M=RDV<12 9KY$;MHA<+U Y^P|:@@&UT B 0.7Q
```

"N)I/T%="+N+BXU))O(Y\$X0 MG)&B MNCKSSQ;IK X60X.^PF\$7V2 V>=>"4^XG7-^3;XHL7U> T\$)L^G<=>HOG.;/2EN(M6N9+99%;T.*
 H)HRIJ22^>NUORJ20^#VEPA27^2^>+C(I&05NY02^GAG8^+W MXJ^Y^QK76^4F^+W@15G0^*^W2ZA:Q53^9>95>2^P^GY@1ZT^>N45YW;6>I2S
 M1^%BWB/5;U6L)X(X)^.1979E28VGH^7C.<^LX^Q2^/GC35^?^CU9;G M14N9Q9I91^%M(#YACGIXLY-1^5%5(1MFT>1="S&W\$K^@ZG;G
 KS:75 M3NOA(/-MJ5PFK+&TKYS&J^C^Q9VI=H^YQNR,YS0^W^J^TMCJ^EIL\$2S MZA>K^T\$30L7\$8;8LV#>NUUVUT^IT&
 M^M=5QI@FA.;2(PA&R.GUHSI\$TUOI8W^UHUU^WLT.;JZ:8S(P53(?E M^L^EITKH;1G8>) AH.;4ITQ>#A^%LLHQ=6.7 C) O@-
 M-3&W@5K53ZOXI MU#Q/96\$MYM/N^VSKJL#0GRF82%\$0AP6900^!XQU)/O.*X^POK 50%;^M&18OR);1XKB8V\$S1^XF9BCN&7#;5VC
 &IECGH,0Z@-5T2ZP79S27)UOV MEYU^L8GCNI^!KH^02^%YZG&1^H=4=80+03)DN+JOTH1N8U^CM89Y C2^(& M
 QX^/X5P>H7VH0Z1288=2O(TL=, @N;7\$Q;R7.4S\$KNSM^*C@>E5=3@U>P^ M\$MIXA3Q^JK7T^D6IPS^L3A
 24XR,@G;3C;G2^8U^;4B.;R.GDDP^M^T4U>=;C8Q77Q4;22RW6Z72;AF*74B^2&^NIH^2ZIX= MN^IYAGDU^;6H9IEV(5RVC;SOL<@<
 <13DGB@#T5P1B1H^X<=9-RT^D L^L^EIEI^Z;98;@N6 (Y^)(KI+6W^I;16XDED\$A=1KEW;< MDI^DUQ7POZ>?>
 ^QHO0Y017TAWO1^B-VGDLO-CFM3P^PZA M^M^13C@.@1^..RHKQJ^W;CX43^*D14;HIZ< MUU+\$#ZQ3R?>
 (N/GRH0STXP..>IT;4I^&B/7K^GNJ^+3H;5(H;6=X65I M8J12\$J02)O+^VADLM,DU^IYTC>..14*(QPSY;HUUQ7
 MV>K>^*01+P2&^4GT05+BTU1+67R)IR^*(L@=";<125;1&G.^*CU^7;1^V% M^HNL^P% MV^1;1AF6.;^H^3=1WR@XZICUH1^Q^+E;8R+YS(9
 F>2H(^/MYD^G4E<#801+PO)-I0G^Q(JL^XDON^YATF8VX^7FWO774^%87B)Q^X1 M^SZS<65>)=6U^STC518L=40;1>UU>M-
 2NHY6CMH4YJ^CRJY^ 2&;C;1B@>U>BN!>^"IU3XFZOLFM;E#830Q M%;S>7M9G<^0;KJT=..??99/AWO1^H2+TTOYO-
 U2>1CN+O=MED2W9P%W M#HS87+ #G ..3F@%LX/%#3^(-K^AC7%| M2^&K#64@, "7D?F")FW%1DC&?PKD_#IF+^XE>-8DFGE0V5DR<?
 ^9&4^9> S\$D MC>1^I6L7POK\$UMX^ ^1B1RR01^MO2>..MKI(TPM@;H9MHR.<9QZT>N45YY M<7>1.7XOUGPI#2W;6.VB-15M^ADEM9%A;1 M-
 KVH7\$WK26-DWNG&BMS(XE4\$??^DIDG)P3Z4=1Y>C^LWC^T9V1^92729;2S MKWHJWA^XU^SP7U35^<(^+<
 MP(K<K^<OR^..2^>34)14NXG49^Q M^B-DY&W&E^H%=>7;0VJ^%6L32JIDR MZ#JUV8;7S;1F1(%;RW\$;5YX Q@Y4U?TB^Q^J5MXO^-J^
 %96@QLUG)>O+; P1M MD=;EEF9@D9/R GY?EP2/4GVKFH);GQ?JGBRR75+JPF7Z=;2S^SRLGDGRPPE M901ORQ/#<87^CQW;LEL10&
 IF9IC^E#D^;M^Y0<9;G;17,ZKKFN^@IQ1;#5;L3Z+K\$;K,WJMB22)Y(^Y B(5R^1C/;&^M8^Y>|671%;DHNBR:M^8WG^Y.Y6^*)Y@52=BL^;1N^6?<
 TK-A617WXP62= M5U^JL10HT^;..XFR^d61 &3&G-#8\$7JGX(T14T ODN\$S=PS+K51&D@N^;C.M;^X8ND^OIH@GWH^1H2JHYO=+MKJL7L;F6.;
 ^;X8UJ^7FGZCF^C+PKH2^)-8FM+JWOC M.TLP.CI=K+E@2^_10_8/-H^H%>2QOZDX;1^Q^JP;0+FX-C^+@^9L M2RD^ZWR
 \$XP>WZ-VHZKK#ZPH6M7%1PWNCRZ8DEY1^MYOWOX9+9.MVY0TW&^QIACWYKS2QL8K^X>?^QT>X)2IU2\$^2XD<^0@QD.Q/I^M^T>?<
 >@#213K0I^IEI>1^N(4EV9SMW^&QJ5S7FEI^H18V^JMI+^J<+61 MS;R29A^BWW^J53HI^4H)^\$T>IB>)KEI<2^9D179^A22^?Q^GIC6-
 XMJ31^="DU>=5 MFNK^I)E61864.^S1PQ\$>6^>N^V6.0^+7^4B^3S+DF;O^Q=F0C+1)D\$;L\$>@/M^I8I P^#PDE^1|=; P^!QT=M;O+)<
 CS0^3(1S^N^;2Q^%2TV21(D+R, M^%1>2Q.^J10;M1^H5_K^CJF|=S6^M(C@NDE.;V2.SK^Y CW8DP#M+;<9SSD M8H^J7HK@?<
 (O=5^).OZ3+K6IPV^6%M^L5O^Y9IF9P=1R00=;3W^LGPWXGU^M5-&\$7>7TWFZJ;O13="VV25;YH^O^&M;7Q^X;T 64@,"WD(E\$1;<5!<
 19KCI^LO8 M^+C^T\$3RIJDLV7SI#(R@QR;FR2J/S;#6K50>?^AMH^2200:MS^XGFC;VV M^*(N\$#^E2S8&1S^&^*
 /66^1ZNKW4M+14^<^M51="M9-HAU.UE>00)N\$%^&^%1 J10^IR.YQSBLVUOM4T0P^X?UJ3710ENM=CT^Q^S?S^R7^W;1<
 <(5!&WK \$/2KVL7EWI^ERW-CILFHW^%0=MM M^J^L^6^+<#^)/X5QDN6J^QDT3R(BZD232;KY)YWEVD^D@L21GCC..K6C M14+NL^AH=^
 I87LH;S4^U7L;R3R5XTMO^K6;YGLY+1;DN-N M\$905V1^XN^*ROY+G5^A19J5Y=74UAXH2R2=H5Y\$6Z^MM(W-CN>1UZUV% MYD?Q
 M^*^TRZ0+4=1^WNH7LNH2SI+HS)L6U^XQG1^J;DC\$5%T^E MB\$B^@N08G^DID^YH H>=&=3Q^X-L;2 P>1^8(F;<5&2.OX5K5XMH)OM(^
 M7@15175^J1M;51<28@;&20IRE1P3SG<W^6EEG^75NF6\$EA;16S1H^D2L9&/S^F81-D84
 M#^7(HKZ;XGNM7/VZ%JHEHTLT>HGFHLRCI+&P)+DG&X# X^/-=7D>F7=^Y9? M#SX;7L1^SWUL;S10MA98V5R0W>"O^JY?W4@M;R^VUL^*\$>YA
 MRH9U7+6 ?< %6 MM+T^T^2M+M^%6>6.WC\$;R3R^W8^NS^T;M4^%-%%1110_5P>MQO)XQM16 ML#Q<^7.GIX1;6U;UG;P.;9P2#
 IGBVNO9H+>6VM M\$Z1LT<.)YK<+ MN/R;U7M=0?^SK^&4H18W5R\$5K9I^Y25AG8&^#\$<1CTS0^O5Q(TWB5\$\$\$A
 M#Q5;B(O)D>W>U^S^#D1;U1#81^IRK;M=;L1+6)JZU^H;8B;SYM^CNX% MM9;YW&3X/8)>V^16HH
 1BF>#Q1<^((O^)/BQ+FZ1\$GB66V\$4A0\$59EID M@CCKCVS6.N@6;Y\$=A PB7C.V<%RMS;0?K29;L&W@(^X&2HYR;1^4-V MASPU?
 ZPEHJ^QQ^T7F;@)##Y2Y5HVD PJLH+C;MIV-7VYSC(SB@#@|^?>M3M>U^6(^?OBUKF-5G6VM&4A^OFYNI@S|^<IYB+
 (<1M7TH^% VK3//=>M@Q9IF= OXF<X^ #M%>H14(1^RLH;5^? B6184^1GV7<10^G\$P^8< M-M%;VUE\$X+4KI>-9(YZ;I&0110;
 ^..XF2^"1|>+|RS@=)(f6X;S9-R\$%^Q\$@91\$, MOY&3FI&J;9H^PB1M<7PGXSL;Z51^#20NGW5A^Y<
 O;17\$G84D;H1NW/R^23GT^B@#EF15ZBR.H^&(^E)&P%KB> , MU5;FW>9F< M8X^H<^CHD?F*=<306MO>+3R1^#\$A>1V.J@9)X4
 <8M^;=HMSP^O1;1= M^E=;M^/IG^O&UQ^*I\$S\$ST<.; M<N;Z5G48D>7QC-D^X20>N3GJ+>F676VUFV1)>*K& DB\$;TML0><@Z1U;5>@2
 M.OOD>N^1HHH^1# #81V7A^Q79283(8F@DM2>3NSDG6JHU^1 M>;1B?PEAM56012RR(UH^EGH!^L7^QPO_1^Q7M1^9.;^6V6M/X8156U
 MXD2VCRB6W2)X1^X&0+1D

#N#G^5&X&M#9>-'5NLLTJK>60*32%VP8%(&XY)QG SV JYXBN+F#X MC^#(HKNX2"Y:16:19"(Y-L*!EZ!-;C^%1-
T/4+Z^L M/VB^&S-LAY-Q5 M0H>N#UZI6FG:GX=M-3UG3M5GEN#N=,+>7)M52PVMDB8YR.../WMIR^M
MOB^TNMZOJF7\$C68B073R6FW5QR^DC/A7P:000#%Y-/A/1KYV:7/<6.\$LC M8ZLR D F:IO^#M/BCUE%GO.:P2:S.OWR5VDCCY?
EXX0Q6KI6FP2/I=MIULTC M6IM&(HO:~<0@&~J#B#&S+4-10H/1/3M5L30KLOX@CA24#T<T;T;SE#\$D.X MAD ^7. "5W#5D^SA44K*5!
N:B #P^MBUDIU 6HN!Z#?ZT-6*WMO= M.BQSFVO)(A/K/CB?PI>A.8+3289T-O^T!N7=B' MERA!P,+@ X!8^V^KW% 9:1X4!
(7>M3Wf3)=/7H)BDN#S 5C+!<@C<"V#D!1 MGH16 KG@?1=>N:"ZF2XM;JR3RX+BOG:"1C !F5Q!OMVYQ!UQ=>\$(N:&QM1
M/V^3S:2&0B6%<1^NDR!>:PO87&G:C:2M.OU=El:7>3+MVX)OP-O& R<=33;KPEI- X8C!M/7LA L0 MBNK@+Z+?%?9WOIRY-
FUBVU>22&2%CRK<1@<G3OC/06 PWT^WBTY!+L M-G2!HGO!85P5V+SPN#C !N>*.1DMKZ!TX@W+Z X K*R:3>7^V6R!>?%*Q
M(ZL97&T!>V3FMS3=>F1!>)M.TB N9HXF/PZB4AF:\$SRR:ORI!PH' !OE ML!AC>C!%Z;%9ZO:K/>F+6'=[T&)>D9AM8@X^7(XXQO5?
4/4H>16^F)*V.2 M3(*M.NWN6BG4&S-F1<9&..?ZF=>#NKG4M'O #/A675S14ER:KS:F.9K=Y3& M^9(V=-S9VN">L!G!0>A!+;JVE-P^OI^EQ
!PEM(C:TEO&IRA=P&89!QG MW:G2/<@ZMH=O!S:N(+5-@D25A+%)G.129W/B2221%Q@!W(9A9R<3N!C5)?? MYZGT25M!L
!MSM=1MUGA2>8*WH!&#*?S'XC(1LN6\$VOY^N/ #?P6!VR2>B M.02/S!U/KO!R<2R \$CQ%12V#1 ZP-
>.299)KNRRS2LX4 :1RJL2%<@&*!7@!6=OXCN=66X-Y,+!4Q",K,E^Y"Z,2<#|SNM^V"/=7#2A9EF",EW^Y5E^YB)R5P^3SG@YH6G^&-
#A!H!2:2>2^9HO^9612<1=OZ^OX!<4 <MMXK(WU!XBN \$7@W6!L.UZ+9!>ORKNMHG^RK(GVOLO/^H>:S5!<A?>+!E
MO/91Z7!4VNG2M259C@&E5^YVR^!LO.P9&3R<H!H!M #EL-3N2MKFM+N!F M=X9>VT^R'R.OV=0
<9JZ@N !>@W.AZ!+J!RVSFD,TFIV,C2DY,A?!=GOGVZ M<4 Y:VM87-J>2TEN7D^PQ&Y9%H^E2Z:X,TC3M+NM/9,F^BNH
M^G: N^G=X!8V28!G@8 .F^?76D@&O)T^F:15=!((\$!88X4<#I MUQ0!YM9)+!O!TU-87E!W20R,LD5U(N+AA!HSA>#5G&:
!FXOWU3XDGPY+ M/P^9D!BIV0S-97:39DLH(4!IG&6>:@O/AYH@V7F@A!X:=-2%W@+U.OH+
M^MBY^ZNXXYZIR!FKPW9V5597AEN(!0LT<5!X&NP!5:C^X!P0>>>M^FN MN:OK @SOA8#4U9-
#U^&T04E(D>^1XSL=NK%5<@D!G(SS73PQW.B?%QLH M!30!FUU^39Y9XK!X:1?C=,H" <1A0!H5MW @W2=2T:1YA+6>+!1<)>2
M^FDW!MSMU)R^?P Z#%30X:M9=?M.DN+HKVUA,\$&0:=AQN!7&#G R2Y4 5?
M^<HW^G96!\$6FEZ>PW4A2X.GQ:W2,#)48W<+GL^2.0*X^2M6UE5!0B/6FC: M!R75JGDK+!A!^5M
JYV#H!4#M7L59!EHUG8:H6HP(PN!>1-!@E0B2!M^MP.W.X^? FNLZ3!>5!UO:VMF?4\$C9RRK P" &F^* \$UG!3X?C!+ZM!FHWEP.F^MK:12>
MX>5+L: @OM8D^P.&17<=.^70=,7XM^F^F.W.8!Q=(.07(HHW MEVH!ND!1U7.T:<8&GI@T<16K6^X!&(F =?VA7:(RXS.@/0C!/7IV!
MOJ&F)2!0\$AMY M2K\$Q.4=65@RD\$=" "JP^<1K?5EN;YKRWMC:H!DY?2.2#G.1+<6VE>RR^WBFTYA:FZNG6S^A&:PY"Z6LEW!X
>:1N&D^CHNYCPH!>4<1 M!1^0EX) P^QA@>1!>NKUO4A!BWE!A6H&D>D>G.6J!@H^JNN>%(P^Z^X!OM!VXN!VZDMPWE)!-E%+5)V@
\$ MX&3V)! :2TGVUW54K!P!X@M=5BB5 ^EO!OY94NHWSY!14(C:QOCH&R!M!9U!AT^4/5!#4KV!UQZ(W.G.1% T9G9A2+<0Z!E+&
\$@D\$FNNT^X>:1H6HF M!L\$NXXQ(98!W3FVB< Q+&G.#Z>G.%0^X9^C97%EF %K+7!>JW&K VHFBSHBVN!Z9<J!A/M!U36EUQ
MNGM-0:\$861P.0.V2#7\$+<1C M!1(6UBYO5M+FX6!N!B!>=WE2&63+D=JN!Q!8K0X!(K6WCMX(UCAB4(B*15 P.M^YK30#<-E.ZKX=N+!/T
M44VH^TU^TN^N#>W+..DI&KB0QEF\$9SR!&P0.4NF7UW! B32!+O(=2MKZ6! MD-O^7+RV6HA@^V.KNQ<=<\$*5 @X!>1?#>V-N-
M^N/14T^FEOL!LUH(S:12N9W6/W<=<#OGFKM0Q3T^TUEYMU/V+!>9.P3R!TB< @.C!7. 20!< M4 :87D.7/<0FLS>PQ:=-Z6%KFI -5!BUO-
JTSK(CVY:PY4."0#8SW))HOM:U^PBWCVWM M^!G@L(+>U-W.T!6!395R&?)(^#8.0.5VS^#>UT>W.IX(!96L@)1^!K MM46CYL+QSE!
^\$2TQM2U6^F\$!L:K\$!Y^%YZ.1%"KMOP ">GK0!EV6CZQ^K MJC!1.DD.F30%<0?VA+< :5RCQEP K#1.1U!TKA8Y=4@%2^2)SKVK2:E8ZD
MRQE(MBC)!L!JZ!4 Q9OP!<5Z!H!@31 .9!)>L+XA5+0!>O^ML#P^5B0 MOUQF?!" />P(PWAPS+T82TWG&S!EM^!>FV> >KU!JZ?
<Q/XF!36E MU=7.4>EROVL\$%P!17.8! "K747A?X?>) ZK!>T M!HKAH!>9.5-Z@D9W^XG!<=>@^@W7@K2KK6UU@>170>+JM02>!Q!4
8E!KGA/3WM: MO5%+4M7M:UQ.TTEG#V^S(X!W6VBI^U3R:=8?&1C#-/D#B2!A9^GUK?
P^\$(T23P!HMU#>6UP09!JX>69V!IC(3NR.V^QVIM MGX+TK3M1M-5.VI7^I90KM!^!>22N4."0>?F^XZ>V>:VRF>XT:M.OY\$-Q
MHMO<2#M!BYRN@!UYG^X5+XTN+FUUWP@>[N(EGU98HXY?2)Y:MA@<O^C6K!MH^C/#KFZ!>KMN!>N(R<^3!&N24DLOQ>
YQDS: SX=M-ZEN%>P MF%Q:<5)M^R \$:CQSP2^CF@#C5L+C6/&CBPGUK5X!6UCM7@C@O^C!MFB9B5 MG:1SS@!H!X&E^!HW6K>:-
#OKY457.UHADDJYCQ)JSBK\$A:S@U+5=0BN M+Q.G65%5;EO!!"C^X&+<@CBK>A+!>M^!@FNQ.OY6W&Y!97W%5!JYE6-9!4A3= \$!L%4#W)
(J>N^! M)EEH!SUH WK?Q+<XZN0%DEDD:0V^7J7 E MW0%PSE!>=<5!GN:WZ!N=(M!1^+U932W26X!P@K# MFV^O)+S4!FAM9X4:49V9CZ
+9^U^X8TG4=>Q!5BN!2CGM96G2:ULPN:4\$ M#-SG5B, @<1@<5C."K^WN/B^X).GF.O:BZ5MLS!P+>B.8^X4 =,HMW!>W9
M.VK:~1/LQ^TC0%U:6)+!M^N^D62 D+>B5.98\$%\$!L97!P M.UA-3CX=>9 P^UM5!W0=00(!.87F@.(C(9IYH !U:6Q8:CIVEPHLE!DD\$^NVU
(TW.S\$ G^0<Z>M3Z+>ZC>..DNJZ<M^O S^!S^5>"0&5AU!R>X.5>7/5^W@.ZNH!8LRRNY!HUF=>K>3<# M!XOGMC/>NP!5W^67A!4YWU-
M.5+=A!L5!0DC (7NN^FN2!9^7!<1 M&K6G L0NX^..YD8EV^AF^C^RD^EO:N.TB2!L/B7HBL=S-V=SHTDCVT!TTK. MZ2(C!@DA7PQ!3G!)!S!9!
DE\$M 2' -!T=K.O):(!S^D!Q!6!)X7!M<#Y!5-3!)8X(GEE8^6)8H!WB34 <C^X8!+1+6M-1EMO!>2H!H5P\$8(I M(C!@DA7PQ!3G!)!S!9!
Q6+2J+J6-Y4C!E%AC! 77Z=!=P73SK!^KF^3RI M-O!>^3CIS6^8W7 M-C/@>Q7!D!P.OB^>T.QE8K#\$URB.W4@&\$3!V.T>RT5QUEX?
U^W!0+>?VH MD

00=KARIC:R%YDXQGGZFC00#6F%N\$TUDCGD:00O:JH MA8EB\$5B0H0).!C:3Z#I+ZOX=TS4WC6-IRIBN&13D*70-@?G6A0!DS^+^YQ0
M1:X V@7;1@C=9YVJAZKM:QRO#Tf50 X030 !\$0!^*7H;^9HF,W4A!QV.6 M.C%6^G^J;@T 26T^VMM^ C.RQ!%! M=BS8!3R:Y! AYX>?2f53##=?
6:N8S20^E^M^C%&IYINYP.9;17544 8 M!GAPFUJUSU>0W+WMG&8H7-PV K8W C.#G SGTk.TWX=>=&(U9M0!^XG.OG^M 30Y^R?
WQ%G:#Z<=<L5U-%&?K>BV^B^T U.;\$56DV-RABIR^0000.000#65 M#X%T6#4(103!<M+U+AC0;1%K MNAHE!K>(<74@#.#N4LYX(&:O+X;T!>(<
!^\$(OI; M+7FBF^Tf0AE!NX=\$G0\$D+(BD!P.G@.@!BU^Q!<6/C31=##^R1-;ZE%<2>?YA MW^8E4D;<8YVW^G/KQ704
M.;N#PGf7Vf5:QXYGEU6(0W@=>=RLH2H7;6 P&XQUK;HH SM\$T2SVZ9^HC MY@C "^^.TK 98DX ^08JK<>%=^GOKRI^30R7R!+P03M&MP, #<
>N.M.C!QQFMNB@#\$U/PH6JHT=Q^D6G2)+.1P3^13LH^0%(^H5K0 DELT\$ M@+OLFQ@Q^!^!&1FN9!58H(XK2> M=Y(TfIG9.IRP!?!<-D#
/IBYX6fTZU:XU#W01<@^")>+R589<# W1AM008Z8 M^6!224Y5U^"1LX8K&Q 9)TFFW-E^GW+CY<@?<M7Z.#0#X:MJW^98";&F=/M/
M(Q@^E;E%-%+4=*M-4BB2YC);^02PR(Q5XG^1E(Z^!^!P2#D&FVNBNV^I97%HE MNKQ73,USYOSF=F&&+D >R./H.@J 6?83ZG+>Z@E!9PP6T/
-9 (MA.;=IMQ%<0!^!D\$D0-^TGDQ!^*F3P.fID!3@9/!C!A M3P^UU.U%WL13E.26VGF.5%; M9!A<+>QABD8KOC@#\$!@3WH
KW^B6>H7273^% MM7!-!B2QMWO(DAN6C4S!H^Y4?^!H@^/3-T 9>H>?>4;E!F598Y!O!
ME;&5HS+^DG8V^R.3CN.G!&34EUHNGW>GP6!6ZH!%&MQ&=AA?>#M?>QTX!<M=;4/B;7H/#/AR^UBXC.5%;LL2!9&Z^H^I(%7=^OK?
4!MK^U??:W.2RQ-Z!MPR/T-#-/TNUTQ)1;HV^>3S9!78L!KX W.QY/!@!@!@!L 7->ZU?3-9M%# M7^F.Y1<^>;\$XVR1Y!F^".!JU<&
FMRB@#\$N #6F;KK%IKDT=S%?10>4K!^9^M\$!MK!HPP#>#!>DO@AM5NX=6A0!&R^%X84GG!&1HH X&7JK? MK-
X#UFZ&^L5R+K4K>;@!PO\$3^!9N!R!ZQC?AW2W+P#R!^!T^E^C.U6^4 M1>#J!HG(G(4?3K7!72!UA?VTV27EG*LUO(3LD7HV^1D>V10!YTFB!-
@=#P MUO!L^!>?>DU6 B.H!XO_R_SQCGU!4T!P;P;OB!Q!KIN+!%8;M?>6<G
M);D\$^YLDD!D!37!DID\$3&5.3^R!J!03!G!Q^5<1X+13W/BS29-1ETZ.RB\$! MD^fMR968HVT-D(N!D@&#G9!&:=;7_A
=;B73^RTK\$6!6Z^! X230!P!^!JG (86G QVNH!H!Y2QESC.T?># 6%M!M^EF-1MO(C.M.3!<=L!^4
X^Z3SBIK\$^!JU^VUN;P!KOV^V!HX775+=516^!H^OFC\$GBO0^ MY Q^X@N-\$U/OK.TBEAU.1%HC2\$-&2K-D+CGH!B@^O P^J^KY&#X&U3 P.
MMA X!7AVUAI^"Y P!G%=-1H B^XU^Q5 MX@T>UBA72 L^R!)"YE\$JLV3D#<0< 6N@H^!OH+K4)=.DE!;S&=-?S+40 MZE;1B-
N!G^S#)P3USUT^Q!K^!^!JVN!H^!VL^!MAB^YM!2MX954!5W+.#CK^M9KTBN?^!OB^X!+>#!G6+>TBN3 R!DDD^
<X7P!G!8<M^%9!YEK!H!50^! =ED\$VD!R!D!LA<1L8U5G.T.V3VR<^Y&@#S>73)9M%Tf2 M3X#UU.;39%ELRFK0+)^5!
VNIJV.\$CK7HEIG!^NA: ^6N8F8!Q!H?@>D=.M^Q 1OB^?O!X!7MM7GMDM!DD.2.7^D)3J0. =ST%;U &#K^D2>(9!^OE3;
Mf!6PEUN^S!A!0^G>+!H786!3P.fY^9S(=R&./=C.C^/.27BC0 \$%Q!GB/Q!H5Q M.10 V5+^BO^?P2!H!G&^!^/U-^05BV.A.3;7Q/K!7V6^T.A!^!
!7#E6 M0=%YD!<#Z5M44 9>N>^!#Q%;P0:@fG@F6=1%T>^4Y5L!JT(HU/0+^50L; MW22?+!HMYE\$^GH!D\$X^G!M^L^T
4!3+731.;#YD!fG32N09Y7!E!B>3P.fV P^2QTBQTVXOKBTMUBEO M!O/N^!^!0N?R4?CD!ZNT4 8\$^W!T(+;5;9K>2>#57;2!BGF>196!;1/!X!
M!3>E5!+P!H!HC=:?(M!D!VH!)-?3.RPPP5&6^!CG.TH?>JYO<@;MCY!M-.6B.WEY!V^9/XG^?>
!0!SZ #SPTf02ZPEDZ?T@FEB2=Q#)!G.IHP=L>>1 MUYZU-?>^#0!8GU22&XCN;E!^<9!F2)+A0.2^I?H!T@7;CRM(5^EB3^%7Z**
"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N#<^JEE.7
M.OA)YH5=O^@MHP3V5M4!^!5>Y6;K>@Z=XALDM-2A.2^59XRDC!LDBG*L MK^00!Z@T<;</.C!7K!OG!X6H.P!8HFCW#SY
2!H!0!K+T^!YX0!..M?>7UY<3V4H!^"UYW.ZD+R@+^Y!"H4GKG!@!DXKOX^YDVYK.JD.Z76GXM3!4G;@M\$C^A9!+!NG;=Z5;64BVMVGEW&F4O(f^
O9K:7^!VT!7\$#)>S^!4C9W%7#!AG)S@!MT>;Z!DDWPY^!EC>*&CT^S;0^TBP96-M!\$@<L<# QG@5!19VL%G!#;QA M(OR^!;Q\$!^&XX-
4@730=<47;=Q^!^UQ@#(&<*>!DC!)^&G;=:58165H MKB&875!&D8 5F)! \$T<=13NG@ L9K! V>KOO U>72M!TA\$G6WAO=4AM.B
M9R0!J!&!)!55)R.^V-9!>7X@>T^4H9933+!MN)(PDB! 5AR.GFK& MJ.fM.3+!>IVTW5G^H5XY23G^0YZY!YSF@^AM8T^T71-%=R-
7\$50<5-;#M8VADBS.L\$^8AWD!#D9 P.#Q5&Y.V7FGPU&^Z0#="7X6!L2Y=EE0VQ!4G;@M\$C^A9!+!NG;=Z5;64BVMVGEW&F4O(f^
!7!MY(!Hf=P<88\$#CH M.;XZ5MA.?^TD-W^VG/Y-U^Y!BYE^DNW;HONO& M9<\$ 1%R?;04 \$M!HG@!5.VPC!GL!&62!<9&50D<=^E4 P#A
#O!A0.*1.9 M.&WN!&K;5KA9# IFD\$F!>9\$ Q+G!0WC NX(X^3G.XEUI!X4ZGXJEN)K?78?MMERDZR\$;O\$H8P.X^54%>AR2.RQD!=
MBDE4S L<=<=LMX319H!3!P2!D!VX@69Q#;=FC!VDG SOSW0!Q<S^X MAT(ZC>1)!ADW^U9QW.B!0!60 #!07!QC..>^<2R=^AKXLN?
!0U!1H&H MW6DFR2.Y.P+!\$^5^7YNN.MGCBO5!#NFRZ^FN#;^"0F!91<2 "G)?&YXR M>G6!0!U3G 95 1GVBH2M=1!F!F!FNQOQ)W9Y!XZT
6HUGXFV%G=W5 MZ+2!V!/-1%>R!H>;&."OOMQG^1G-/ZPES8 #00YHS75Q^GD^!FFS+9;@.M=)>U6Z29P4E.BL!NW;B-H(S MR..Z.f!
(Z)>?>H!UQ;UA+(9980/(E^9%YK;&^!F!ZVN9;QR MG!VPW@;^ VD8!3.D!UW!WAK2Y!L=4ECN!O!^EQ^!7Y 1AN-V#G SG.<<
MUOD^A>77WUMM+7!>XDD^RN\$D<J2C%3@!P!R M#Z&LZX!*1=37DDN^S^K!O+!V MRR7!C SPPG>V#EA^K*#UPO!5U&JW<O^&O^"?
\$WBFQFF2 M&72F^QRPRM&?DB+EL!J!S0.T!<15W<F65M>WEY#;HES>^M\$@^FU=JY^@X MJ!P
#>DGPV PCZV!32 */.D!R.@*!N5(.#DYYS0!P5!86U!KWPOEN8A+)+;
MR!H.3E+73..7F!T.VUCQO!0KH!D!K%9E5AG>+YOLYQ!QV9D9(QOOGCVKL;KP M?HEY8Z.;36!QBTU@UHPN90!7&W<-N(QO@G!3X?^FD6!W!T
U#C#.DYH!J+3.=M2G%&B^7 X&8%;#7X!WUQ!7P^T!Y!N6EN);*R2.Y^XW3M.M+ M.#XH/#!LBDZ!G&U4G!R2;!
(TC2+!+0=ATW3HFBM(!B.-!&?;0%B3CVK.MG!&#<7^HWKVLHFU=^EULN9460=^N=H8^QD#.;^H X.TL P^

HOM:1#50&*N^8&NTKA/A;R# \$0 &5 MJ Z&*OK.SG<66OF36+6OU&SU.>/SS;LUO8B-SY>UO.7:NP#L E6^K7%&JL|^>>ZM9-
"MY9\$J2T5C(X+;OW .\O3VK-1.72W/U WPMIU^M.8YZ5UESIMO/Q2T&*U.VS4I&6ISD52"XV".J6# M&C(R?P.E^<66H6NH#JL^J12M"S*IPP-
Y^U%)>+J.K?I.OHS+IKN#M>2+>/J5<9;Z<@?C7&*BQLL;PU=RO6T.AGH7D99\$.T3.A2HCBDDU73;&X MT-;+0(^(E7#>.S1@EBKQI2319-/2@#
<1*2>(+S79=HW<JLR3.GE2) C*P (&<@<^E:JO M>S>(<(%KI6H7-EB30;ZAMJV RK;E ->0'7YAA1GD@9QCF@#TVBL+PCH^C M."FFW&L-
JSVTQCBX=2& SD(\$U^N(135) K.IQ5 M(2)47RV/5"3ELCJ?IO:Z(6)>JFJC7HHDM(8Z2;=FDE.A\$HESP.N.%<= GRF MQEO?S\^PRN-9GNA-
?)=QW02QBXQ.@A?O (Y90#D8/S&NEATR1/BEH&GYVDMR.M;A)T^2W#R#Y7C /S\$1X-H-9JDFIC7H8HJ+V.DF(CI).9#YHER.*%OGC/G/
M/^3YNVG.IK^AFXM1"IK&UOW\$0A^&E MPD.(GT2?*&9B.(P"3P<=Q50\W-%>76F1X.^-6.IV:13=60#93&ZD)@
M*3#;MYZ(8).2176.TMOK&MZQ\$JE N+728 .CN6"P618.P="3(W7(Q@&F' MH Z3Q%KIWHVYKZ:16T.D&FWOV621W.YD9L@8P?N|
<A6W=-.EKULD;S\^A/5K/JO010\SW@?Q M)<^+O"UKIDJH%>=IC\$DQD(8KR2HI^Z.N%^#? "2;0?K)G>Z>HM3U% M=<1?
Y^BFLYLC85:5HM8H\N8IAS(RN0N102%52.O)7-^WNHYNG+;J98 M-/2D"(S\$N1"2U^>@)HJ5H=6.EK.IO%AIHQU5.I03Z9.8HF5VAG)9B0..H
=JF386>G %6YI/3;SECMOCCC^IQX\^VFI>-O\$MU>N.N=UB*6U^VN3"Y*DY^8".(MQP.E45Q C 4IK%#H&\$.SU*5X;2ID5BOIMMOVY0.0?;
(U3-K 9/Q M1M=-T^(-+LIZ9.JY9^W* C*(%Z*6W;3C@J.^-&#Q#J^K52SZ:6DJG:ZF MUA<1S.4D^H0KR^W3@Y^7^(76G%..O>J<
\$GL+>8FN=2U&4Q6=JC;2Y RS\$ P MHHY)Y^AZ5SGPL+."SUR."UA24W?1:U0 A+!PN?3@<55\2IK^XU>\$M1N EL M9I6>SBD\W5G0-)
I%>0IZT =+?ZOK>E-9<.:9;7\$%Q=166DEO<F#>X7<5* M.G.J" W&S.1T517?T.\$6^X=530.-IT.WU^Q=XKGN)+V9M.MU.*>TC^U/A7\$*
Z."3CIR.=9-^IE9V07A^E>J0U"VACFEM;=YECD*O^FC>)4065G?12K;DBR7MI/6T>3\ULD2D(\$ NY
W\$CKN .+RJB#14AY8YSIOOSV .L&I6ESJ\W8PSQI0;1#J.P.P2H M/Q@90Z\$>M>HJ2V^<BR2I62*E\$C\&V0GE^T@ MIXIBU*J
%2UN^V/J227-^745O?BFJ= ^A7OIC(CTR^<TR3(3A9Y(TI^L1 M1R6V)0/2N=U2.73KSQIHUK).FDQZ+JOACCD91.S^<5" #H.S=MZ>W-^JU
M%>3P.2%I=U-3M9A;RIV074C3LW6(UL6VL^<8! P.<=JZXKE;O(M-#%+A;4.R^KL^AP2.IJYH ZBBN\UFT&@>0^O^T^1#J.DMK>V)\
M2.;1EA(O^XEQI\KS@FIGP\T&UN.K4M4GFO)+K3I=OX;ISO0!T B;O!>Z?Z###.0RP.EJ^64DCN0T>Y6;(4#GA3W "NBKAOB3 MS+X
M0@=1%63Q!^L;E6P8I>A^(<HYKEM>%SX^U;Q+X?FN4TJM#%Z+2+*6NXDC*YOGJGM0!
I%7*)\#JVIS7S:1.6MQ0IVH 8;B^XVL\4KJ^LA^EB9&I9<%MV">9S7*6\A M\>("OB)J^D6D4>H6FKW:02I&-T2XC!(JE!+8Z<4
>QF5YSKEM&H;=>M4V\EA M=-:C.VDS(Q\VR^526.GH@#?N.2.\$U2T71XH6I7Z>C\SWLIS&K;8QFZD(#B.MI3@C/S YQ@YXZ8YR
>JF5Y=X=TR37 # (-\30^<6^XC>*.YNHK9O-N&/\$D M\$K>:ALL=N.<^T#>@5Z;I/%.VMO.ZOPQ(7=V.J@9)/X4 85\XNLK^OKIOAJ
M16\^@DD\$O) "K#E4\NP60 \^K70U\Y^XET?7=0)W&S\0Z8D>K178UBWD:2Y MT^AD97:UH\1^6)JU^7ZQ.ZYX(G-19"3ZE8R(X/S(KR1&4G1#)1*
/A.MX23>GOCNX;218Y9?#ADP?NF3S\I^<JGTK^TS3+W6=\$I(%!)>J<=VKZM= M\G03Q!7\PF48\$BNVPK@GJ.8 .#U6BN\TF^
(^O\UK(FUBSX?RF^X.Q.6..M>R>236I\0/25M0^O\VLX\5F(M)1^G2;R7VM3@;UR-Z^IN&G\G\^1^ MYI.K82VL5O.J274HAA0GEWP3@?
@?^PI>:3R8))0CR.%+;\$&6; Z#WKR*1-%U MA 2&^0+>\$0LI>)BC P\GL6J M221 .3* \$*1E^%Y)Z8I5D.RFLZ7+1-
IOX\W=A1#OBR6.D29@&PR:XV\QF. M9SGMI8=XM Y^WP) U^77 I.J^U3U^FLJH+T>N&(2*^&IVIOX4A^F3
MZ#N>M%U#JH8\FS@S\FB66.\$I)975(TI^9G8X"@=230\RFD>^M4BD>?S\$D0 MVW.M<6 #7B^V42^&I6H8WMXY5;S(Y># \$RL5=3I^TYEO+
<MZ?H&GZ%6%25#)>J&J R^P4 NW^R^UJ>@Y(K%OI^ZT^P IVAZ+ISVLD6:EY8I MXXH;^AMH 7.S9)V&\$.0H% %? "2ZCK<"VC00Z?D43L?
FE5HPXMSH4JFLMS\$IK/&WD.(4 0I6.21SD9%>DJRNH M9&#1D\$^(-T444 %%% % 1110 4444 %%% % 1110 4444 %%% % 1110 4444 %%% %
%% % % 1110 4444 %%% % 1110 4444 %%% % 1110 4444 %%% % 1110 4444 %%% % 1110 4444 %%% % 1110 4444 %%% %
M\G(2P# @I6(X\$C>=+V\K.NF6I\P/(995.SN&<16PS\DI\$WJG?M^<^JZX-90&MY. C=2P#XZU\VM^T^W@>E=10\0\ECPIH@UJ;6!#*0FBI
MYA<2 E\N-V\IG(P.#R.#SF^ AAK&"S.FMY^O.UO"JL5*6TK7.I* C\^WN76GV:P37DC2SD.Q M#ORQ)PN3R<8S1J7AW2=7OI.^OK-
9KFSW>D)Q92H;&0<\$;>@<#>X%&E%&\$6 M@ 0TLLHM%M)(U)Y>IOW.I\$S-PQ;YNI^H4.I> #.L6=E.ZA:SQV0VVS-M^<^<20.&W8LXKHZ*
^IC8VNF645E96!>0.KMKBCB7^J^HW7AK2.N^FO9;5E MN+&B.ISM^V^G^>@D^P2/P2/FSP<5K44 95YX.TF^O^."IGMF\J3P1.&9XQ#D
M8.T^0QQTZ<4Z;0.-FUN(6I@F1Z;XW M#0ZEXN\$N\$U>2^LJ7FV9B8DN.L@95R>@0D>J>@6 A>Q6YL^Z.UQJEK+^M.BFI-Q&88 ;@-
CDB)JZW**.>"I^E7FE 8Y#97LIFN(36 3<#NY...GMOTK.ZMYO)=EN.L=D.8J01^J6B@# M.M?>AV.G#3K2&ZMI(J+>* G5 #R1M#XYR?
SI=7% ^>=L.RU+2XH+(6 MP#C1\64@@8 XSV%&U%&+<+<\$M\N\$M\J&ETZ.6%M(L.L4.-Y.J20P92" M#DGG.3D^M/2
POHLLQKVNJM8)MM(11#(8&4;R%&X.#R.@X/2M>B@<#G+3P^M M6L..6.71>.^*9.WKNVA IP3.T^W S6AIWA 3=*OKR\X9(IB);?<.TIC^8
MW8D.O&<9J.^TZ^*NHZ;9:082V.H6T^Q2@<XW&0<^<I0>01R^BM^&L;(R MM^DIE01O).DI49P.I.6 &2>O4DU?HH S.^VZ9H*3)H#PI-
(TLBF=W#. MW);#>3W-3ZGI5AK5BJEJ5I%=6SX)CE7(RA^HIZCFKE%&78^M.T^1)(DN M)&C
-6.FZEGIO.MOF.YWCCC"%+I A 3=*U"OK.&2.YO#F>1 .(X\9B M.@<9J.^TZ^*W3H+SBYS.Y>8 M8QAWSN88XY/3CI6H10/BX2T61-
-1K.4KH\LOJE 200H<95 M\$S\I.P.=I^Z^UTC0--T)A@>=>B4S2@S.X:016^8GD\SWK2HH HZKHUAK= MO^I^OYIO2K-
00I(T<@Z.K^05(R>01UH@T.3I">YAGVYUNABX.Q.K3#&S. MEACCI2K0U% ^X\>^>Y9Y(CI^UEE4J75V4I^%)@>^BXZ5.TWPUL.DK
M>+9VK^EXJ27%.\BRNWWF8.2"3CDJZUJ^*G3 #.D:6T\M+4J+<\$6ZO\BP M\RU8D)QO\H""2GZ.X?TW2+N\NK&&2.;?S+AFGD?
S&O\$.O&>.9I^TZ^* M^*2S)O4MM#^IP3.U3I@ UKZH5GK6GRV% ^TMK*21B M1DW#T4@D>U7** ^M(I+(V^&40.FP.O6W\$?
IV=V??>OX\^AZV\SZ#^IP M.L\HFTC(=#WRY;Y>>>.<UOT A^TG3;.^UULGMK>6Y=W\R" M0"))&2.GY/H^XG2/L^V:"WC\ZAH^HOQA?
Q076W4/>224IRY.GD+L 0.MXKUNB@#^O"/NB7^KG5.FP22JL1+08T10.H.LU9XR#BH;P9H%E.V<D8M
M.)9(Z6YMYX(V0.06&Y6!.=JYR>U;U%&+>>\$M^OM.M;"XTJ3;VLWVB\$*(RR MWD,DEQ9L6MW6>1/+M)X) 5@.DY>.>C.1> MU?
1K#7M;PU*\$S6K.D.T8D9 Q^(SMO^E7I^.=TKP+X;T348I 3I.6*ZC\^2 M&61RN1@XW.0..0OX>THUKMK0&1H.R\VM^C#F.TL^YB.\TK3HH
YW M5? WAS7-1>+3VGNG47-Q^O Z. I/4^M.FD-1^<@Z>MCIELMO;Q08"(M3R3DDDDDGZU>HH 10:186UQ?S06RK+J#^KHLGIZOH49 X"
^72M\I=#TN#3 M=-MUM.F7%\$&D)C>IR>I.7**"BBB@ HHHH ***"BBB@ HHHH ***"M BBB@ HHHH ***"BBB@ HHHH ***"BBB@
HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@
HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@
HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@
HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@
K.UW5H)TF6)=X5?CB\$@<G1H.U06/09(R>PR.T.H.KIVE.K;+9.M. MVEU#(WR0W**X9@#T\IXSTYH I>?9 \$=Q^>KT.DQH0IMSITSR\ASDDL!
I806 MY7\$>=&3PSXC\1.7HK -@OB")G+>+S;D.DJL^L=MX\J2&^XA2&+M)8G 9^1@RL^T(CZB@H)H%> 1110
5SVJ^J3<(&P\YT^W&JW.LN^WMB.W.M@IP9^ORRRJGEE^M 1SG^912J^FCHNG.M8EKA.2A\UO#(C Y028ISH^=IV97GL>XKKB-0HP
M+P.#TR?SH\DNH<(6&XC(7)H+HK^K.H9N@Y>6>+H?B;PA)>Y<^1K=I.MJ?J8VNEZSX^O #<44EQ?+OIG GM&C9GW8^M%#
GH>>JXYX Z4>SLZIG ME7?A21#8.T<\$UDAMH9V^F\4#D=R.D4.M#=#O7DL0PSA>W6N@#J6^A@64\BN0M\FLO@S!
M=>.>R^OQD@VC)W^B \$8?F7L0-TK5HO#>OVFMV;@>I+2+>+>IUP4IWDMM^M(R.@GUH I)+H#<LN^W.B:WPS<7QM\$-U8ZO?
M.2>K^QU?76CV07U>.&+MHA\97#L/13&2I8R MOR ^>E HQ&D.#2JUIY56NG3ZA>7.<1J>25F^50.M>2.2;Q4?>=I MS=.L.LBG/%
^L^K<=>VD.Q^G9*<=<I<\$9KGO#6OWVIZOXBLM0^LBZ9>K.PM""-MRM&K#>DGGYO.M+PIL.6 A^Q2UBAB0PIL1SH4\$E!SQWKS070-
U= B.L.1W# M0REH3(^4PM5(91V<M.ZHI9V^I.Y.102 .D@<O).5C\L> %>5SKRT M5+OPU\I^>#SDFG;T88#?M.I3@GU.6.UX^LM.T7PUH6I-
J42BF")^H MA1EH4O^4WXZ=10^XZ9\$#RZA/RQ30<=<XKU^T220\LBV\1.AJD.E.YBDL M%?
<EW+&C.ICZUYH^X1JFU^U HEC9JFB.CHIDU/RQ 5++Y@5^ A8C?T2JTF MFG^>H/M\$4/A4K2.Y?#%PPD=H1ME4# 1W^L.K%CWS^SUH
DHNK@E&# "MIS7" \$S4GTOPM#.S.EBVH6T>H.F05MC(I)R.@<^4^OK.140;HFC^(<=1.3^ M7I4^D\$^39.^V) RV^KP&A00>QH I#H#IS.#8\$KU
/2F37%Q\$HIT<<<E MG=V "=@=23V K@DJTCHS4I^UZPUJO5B&>.*OMQ^HLC9/N22.2VW\GD\$-8
MO@ PKHMSX5U.4.BQ2.ZM+54HH^D8L\$3>PVXS@CC(Z\T)=^>J7FL#8.EX;D MLRES)%(600P4P\$-C.R&(Z9 &FZQKDEOKVFZ%>-
=W\SLH @JX+EB@A2;I7HKL^23(ID).YQUH7=I.L) BIX<IZRMI M^M+87C2;XE\CR@<"H80OZ9P".G&K M<#JIS.H8\$KU
/20*KZ.YTG5/BK4D^7: M+&^<ZUH\$.IV5KJ%KSB@#T>*748=3U&2^EL\$TE(T.V92PE7@^89"?EQGICMG<J^KWC^+PIH^M.M^IGFM;
I4(+>FG4DF^239N7I&#Z9I>E9^FV5K P+>V PIGB+VY5D6C^@J3 MLE3I/16M\I@EX16^..HJ3S^T7R.O.P&21SGKSUXH H#*Q."#<X.#TH)
M^ND M7;1.5HGHOQAN\+3+>U.M;K20N9H8AM5Y1.5#D?WL^>+>I+1Y^"ZU/P<M)5.7UI(F93@E#%(2N^0X%>=F1
F.NH3^I3Q2LZH9F^I.DP^OELM.TKOY M>%(S866F+HLEJ;A.T.R\I^"F\$8V\<9Q@>5^OAN>VT73+1#1.M^5FT^MIGEAM-07IO.N-
\$.XV; E.T=N#T689\$1EQD!!&V.8H\36#^J8I2 P#"1M.M6\(>^M-.N+S;JIO.LLT<@6XDNB2K0O \$00.-OICH ^/0+^6+^4.R\MK2=)9+^013
M\3D^>J2I FEO<6;3.NPM+^F95N+^8PVI>>74L3CT^>^GK7(>+>I@<O^5 M>F.CM>.>650L96-0R184.IZ
I^GZ=XZLK.X8">"3<6TSN^EC8RIAMR^OY"MG/49Y00\W3.JD\F W^R>M.K@<M^K01K7C^SUNVBGD@NUMHHY%J\U.2F.I.M =R=I9?
Z.M+XW9>HWOP.P\FU.5YH2(LS -T8U=EICZY4 YH>I>Q^X MD0^J.M.Z6^30) 2MICM\$>V.2BR.M5BVID@8)&OKIK%M66JFBO-LLEOY:M
M%+ C(2V3N5@22JID@YIFN3^*Q T^I\+0.S?)LWU^V MCO92I94@+C<6 (RIXI&>02.I^*ZN.HP89OD^=20 P)(R\GM7 #P.IT=W
MHEI^IMF^E+JHC91^&55Y\$Q 8 .A=WHIZ5RIAIE8^#OAKK.M(I3EOH& M&2Z\B\&ZL&0MUVX AZ^>#YBY^*SIOWF XSR>U>.^I.6?PAXP
MU73I@>VU^VVH8-<"XC>-2D..A=7&22?FXP5I^M0N). #L\$T22QVGBQ+ M6+50Z\B\&8;GM@ 8I^I7B.2H\KPM>6I=0:8;@1P);
(QL#>U5\$8=U)PA^H MQ%&C\G\HRL/4^*65?0\$%#ZFN)I^7#0^<J5T\4-#M\+UE.;IY39.#7.0:0 M+(G ^*G)8\$-SP/2I^B 2+I5B;X5MKR 20W-
F).F2/4+^A6QSCDT=F#JO M^DWK\^Q\$Y^>JY^<I OG9M ^7MZ\HFX.L9VYQ7 Z=IEG\QAAI&\$10 M1>+&51%W\$1+.%&2>3P
GGBLPT.XU\PK8V^1Q5ZM^K337&H\LB+<7<.>MGR;7H.1F@#M(>O3Y\IWF09Q)^RATV.IC=5(C+2.A#&G&E\HUK6U36;1X
M5IR94^U7=M^N>7D@<H^?KD^P(KM(T 4 C) \$>VEH^J0A^29Y\$&O1)ME.KT.V>EYF1%#(H
M+>=GK3J\T7:9).7.K.G#IMCKFC^S2WN\#A)I^4G=2^NMNV\^CZ?+ M.;AHUK-"&UN+=&02!#H(R/H;
(M&5IHL.MM8F\$CIC9IO+VIGM^JSG& M^I.96) 8\$GJ>E>(O.POI^5I3IBUDB@X^9OIOH<#BNNL^LM#^>D.F6Z M6L5WHK2.2F/- H!(526(
^4FD#J4WA^5QOG<#Q7>.)+^M2I\U^Z^<))"/B=9L=HK;I\$ MD20+MCC M7."059PIH! B 2N=NM^LM#^>7A&23+589\ZTO5NF4G=
=<8T9>Y+Y/>IUS&MGJ3! 5SK5V(9M66D2Y6?T<>> RYZC ^4+ =QVH IOI-ZIEX.L9VYQ M549^B)2IN6T3S+E(7)/ISA3M^YXKR6Z2.Z^<.
AXEL.?)%\$L.Z7I#JIT9 M51U)ZMN8LI4)=IC@4>PLZIC(%OC+1 MO\$OD^?&D44\$A 3M%U&X%UI@T-&TQK

MXAUN7WE7D9"(<YHR#G!%">7ZOIFE./#X'MJ-G>XM;3Q ML\$=Q.XD* @K?+ #JUIPH'^SCJ^CU""SDI2 \$V)4A(.C0.ZH!1S')QWS@_E0.M/ZF^0D
,D)0>WL0ZGGA+>+O(RR#SS7C)F@6-GX2! "> (=+BIO7&ETZ,7"- \Z M.JAXV>5VYX!>,"H?.\$LEI/X7U36M-*877XS">W+!KEY1<(C+&1@HB@.\$""22
MH/ZT>SK20K5+>D<QI @C4F1616>K75@D'P'SINP01.190W21.)C,^>Z@10:T*1F5%+P50. MDDX %>+>13K*Q-C%>PI.E2IA5 %
(/4\$=1Y1:6QL;73.&&RLH(X+;%0D<48 MPJ@=A4B7\$5\$D'G)&T7H6!7ZY0! =UCQ-%9:0I<1@NGO=31SVDRGS)21D#
MJP/WSMS@C&#CMD@'845FS:HT&NPZ^'JQ+>+6%IQ%N&50\$#)!,EACUP?2LCPE
MX@N14&MKJLMJKY6KRV\$31*8U955". "Q^8Y!>@#J^*CF6AMX ,GE2).XW.P4? MF.D!!&0+70\$%W-MXYU?
P-,R:8D=F.Q7\$ " "7JHMWVG!-)OW?WO1HJWZUWC?,"P&9IXQ\$N07+C,,"7ZTISH -M+63S\$V-C.VX8,>F#(T<7,?XFLM2N-
1MO#@AR.1N<=>=,NJ3:L=-QICG?/ M2JYT^6VEOY?>@0!+>9I&1=L-1E!F!ZAOW"(.,?707="YMR)2)X1'L\$AWCY/K
M252U1H,23)HMS0Q7)9&66!/:+9N&[HHC.*.2ET"79!^ULY?>^AE!6T(G-W.MA:4YBL1'0J/(X(!>E3!IGB674;?49/#/AOJVV7;#-.VJSEXQZ
>1W!^M=K+<0 MPLBRS1QLXP@9@Q!ZTDS!#(s)99XXYOAV< ^/3F#@A#X?UDZ! ^VY?OA, MZIGK!-)OSZACKH!;
<> &17NK^ZOI !GA.2ZNT.<1K7!L@ (P< N.N.,I< M5WTT-0^YDTT!Q W68 ?F>?K^ZIE8/4'- ^OH&M2^V?O! /WAIATV?L@-
M+ ^YSUV N/8'ZU/9Z:XET^ZFM? " AJ^2L;EAJ6LDH5BN?H=I M(HJG&NV\$VMSZ);W41U"#\$2NF<^7N.%&1R>3CT^HH U\$ZAIUGJMFJG?P)
<6 MTC#Q/UAZ\$=QF5A>+! \$-SK0AJ&JU22V6!DN;B\$+>B-MYX!5WL!D^@S0!%8V%KIMG'.6<^PV!8VI&OW5'H!V'M6=I A#PHI6H
MS:A!^C65K?3 AYHH@K8/7!3(M6R2!)!(-)KCI77M6I0W%1^A7A&NGZF.M-X+!E22/C3.YC.E.5.6.W@C@9Z!
&POA/05L+FO&EVXM+J3S+B^V2MW+ #N?K MUH.PEX?> MJIY(M'NK>.,1120^N95'0<1<=L!U.L=Q#+(1<I7T)!L!XE:Q?F)KFU6:4!J
D9.,116P+FH!LT9B/20.-1&@""3-+L=&L8!3; M6*UMH NQO+>@!JB^&=%1!U5T^(" ^X^P.O! ^Y^!T2M.R OX G^HXY^ME5-
8DO6TNJCTBYLXM26/3763&AJ6 YQB@!I">+> H&EV^FWFCVDJG?ZB M*L,B+V7^Z/85+X8T.XM+2TDTNV-
M9L&MH0FU(6^0J!P"/7K6C^+MBBS^TL7 M.N,25. QOR16GM3HY8YH0J)(KHW1E.0?OH S18).ZX@M(M751-MV&.,Y19TW;
M3Z@H12R^'M'GTF+2I-.M380X.5OY0"1D="H A(!155Z>&X4M#+('H.48\$ M^G%.=TB1GD9411DLOP * ,JLY!)T:2P!8V\FHL-R)(/O)F&^H!D!
<#)I M<4 016!BMT+K4U@74.MA).L)2/ 5 3R0 .O!L2WTC3+6SBE.9%AC WGW?QVH;HVDW%&C.W M=S&DH+Y5O&6&7.,D 0 HJDM&5I?
A^PHMS M/@#3P5X.BT!>=CT6S6-MT67SA^PN !08!1V!U6Y?>VDSZE^J4ME&H^NR*X).1%I &WC MR>5(DZ.G8\$S-.,B*%)=0&.%R>HJ *
MH>F6FHW.H06<=<Y= ">8?>E-Z.MCWOV^K:5X2V!)^37NE-96ES,"EAB"D@D^T^L^OW.IV-183WUQ=POVL M)EF+C.F.N34=EJHE?
Z1.ZG^BVL!22AG8#.&(!#R* (+^PWHVF/^UEH/ MD ^2JCY8LC!*KT4G)R1R' #MCX=@NH!&VAMDN9S.T4^X16(X!>G7^7
MK6!TD7D'8.>X^TIC^MX).O6BYD>B6:6ZS>>(UCP)Y.ZCMZ=JW"=(T9W8^B@EF8X ^S!U!3M2^T@.60+^9@BY6-
M=GD9X.S.C;>+7^XKB&9G6*.,1D."L"5"H?2G22QPOM)*ZHB!EF./OH XKQE MX9DO!70+ #3=(2.RLJ5CO+E R*IC ?
=PO&YB7S!Y.;ZNTFNRLH4@ME43?ZT
MMIS2<8^8G);CCDU86>)X?25&BQG>&!7KFB>&X0/#+('H&SLYYN'DAB"DCTSVL.*6U!*>[+6I=8MM^LHM1E)+7*0@. M2>ISV)
!D=)U!X>?/S)Y4B3-.SL%&2!S2^N00>& #5 K\$JB1:6H5CW8!P@ M<^*1G%\$T.A:5!K^L16\$".C.H66Y^#>X P.GZ ?E2ZMHFEZ!%JMC!>112
M"5%F7<%8#(S-4!)6Y-0!:YN!"YT6W5E!V"LL4W&5ZD,9YZGWZUFZSXPB M;PEXAU30+JUFGE9?FD(F(S1H&8#>D7 -9.16@B)&L<:JB^
JHP !T^4!OA>.,9R221FYEMHYG13 MR-R@/YOZFP;B;9%U@.T8F89\$98;B/7% %!5=!T0?S635+>2D-MZ).P504^U
M!ZM2V5M<6364"365HY;12C>K+Z\$K^<3URNL^(KJ!S!8^.,M)K22TOYVH!M=NZ1"D3.,\$<@<@<9H T-A^/A!2K^YL;#2+2VMKKB>.)-
OFCT8!2!WIO!M^.\$UG:6ATR#(9N)+>+VPLA4=B.V.E.9N8!<"W.18FR(IXW8^G6!A.O.; M<=YVL23(C!R!10?2Y2<?>F/6@^G-
X!).WCGO>3S);9!+>@BX=H@3.M)K6GKW..04U@!.;+WHO+23H(D!>08Q0M1 P!P8 AJHT1<0M.T"51F9!HE MPPW
>I^87CG5!H0!>J.M!Q@^TVD)E43QEU..V.10!."^AZ5-19TFV^P32 M"5!2!A2.=V/7>KMOI&G76EC2Y!&"2P-5L;.@0"D%1MZ8! *L6Y2>*,&
M1#8U=T!&1D=<5)HHA! R/CXC=Y>X;L>N.M.%>RTNRTFYTM=4DEP^V> K5QIX578THL@8 M+#.3TXXH^T0^2Y^G1^=C=Y>X;L>N.M
&7!+14.5H!2Z!(H(C&ERP)8+>=Z M=SSB0..^Q?)+4 NC?AGS-4BQ2B.V^M.MKD7GD>9?F 02?;.&.(H&.,V?
Q^M1GCPX?!.DOHTTU^P(O3!LDW@YW=C.MGN^ET9=95!PJ.GE."W.#SO DT-2HRT<^E M^HH S7!+Z(!.=MQN18W^KM#HHPL!PR@?
PGCVK5-<6B.9'R%=>N!QQ^%>Y M@CSYD!;88*=S@8)Z#ZT;...")D9\$C0=6=@ /QH Q !A# #WIG'3 !DMOL1 MD!XP;?DW!>VWIG;.:M?
Y%IGHQ:E.-#211^4EP22ZL=SGH5E>#=?F>NB!(D!LRYGIW<.,E0!3U?0M*U^WGMJ M5L(+N*Q(BRKG:PICT-
4W>&^I!..RO+^B.2:.\$0.N/<=>OXJ36?>#>B^8(H-7TRUOX3NC\$T8. MP^UW6FS!5+0 !DDHS=(U 3=,TH^QNHY+5)!\$T-.IV.5)SZ94X/<4 .O=
M.TC4=)72K03.;73TV!+*%>.,20RD)>C(P(XBFKHJ!.,L;SPH5O>#>= M&T!Y)E!MI^E.1G.YL@^YLX 7K6EHVQ'3-
-2"1U>=W>.>15P'E=BSD^TR3CT M&*L7M!Z=937E!/:0H7DED;^J!W)KE=8!67")X4O^DMVLM80H8)1(A+A) M(V<8<.%P00>M
'8T4R.6.8!S<^Q4!6!P!U^U!H(B&9W2*.-YC.'56!^G MW!^")*****"BBB@ HHHH *****"BBB@ HHHH *****"B MBB@ HHHH
*****"BBB@ HHHH *XGOM=4%XF'6MTH.CW5 (ET'R+Y!A6!M07Y/-1Z5VU5!VQM-1M7M.VVBN=> 012H&4!OP.;.L;[+!6!5L!2!)/NM
M(BN.R *#&+DRLJG^0\$D4Y!N:X1V1"?#VQFCAG61Y.DZ!6 N).9?>NNAF
MJPML2WALX4AEYD4(GXQ!WKP.D)IND;:HT!@TRPMK.\$G)CMXPBY^@H X 4;
M>S X71HKSPP8.19V+HY82O!H!P*Y.YTC3K!P73;NZM(KKBWU* >@21=QB9 M8D8% .=<.-8W%K.;.1AD@5EB W1CC^TH(KK."")
(H8U)"I&BA54#H M^T% "GMM.RWGQEE211AXM^?5OTJXKS)Z/H+A+0M/LKM&.KN6E9GE&JR 7AH !U.WTKPUX!TC1HS;11\$S.W\$MMOC!A.
M!9UW*#*#LZ^F2!UJAKN@:7!6AW2K>SOOMT!56SHXVA;8R2^7CB* =4>@/!M(M7HVI)H>L6^Y6L2?7-LE6">(<JD=)
>AJ^7PWH<1C;6.ND6+VEJL%&C/E+X !?3@X^E>O?V%IA .!U#^S;7!8 *-OY0PI =W= M<=>U5SX3!&Q.R.B.>;1Y;.#!NPO>*XQGW H Y?
Q=8WPUK4-4L(=UR%+!(M=0T>1^5A\$!^HGY"E@6R";UR!CT 5M/U?Q0+*!NX!^RN=\$M)-AOX4820
PLK>8/FXW9V@>=>=H!^O1" #NC7.OFSZ7.22>6(B!H D.H.B\$!UJNEJ^>=UQ^E4U72K.J6\$YB^O^K!H/D<4<.F@2VNE^!P
MWK5OHDV!W/D6VIX;1AW!6PP M^!0X56 !/QT.;@S6!PU8!H*#6!#2SSP1Z?..N5E6!ME5;WPOI5?FEM/LU33H+.;#0C="0P8
M;/!N2HSZX &@^H0HHY^AUXC\$D.OMTVX9=PS@B-L\$>H^8B8-.JQ.<>HOGU!H!EBCN(7AFC62^12KHXR&X(H!BLF+PEX=ABM8
MH!\$T!4M6+6ZBW7H3U*!<WH^ZOO!T^Y^!5!+#++...G\$M!8\$!>*A0!>R M!CMR<8ZDUJ6\$4!QR?6
MNFN9/6!/BO0!&WM6.*%>.;YB0A!80#)0OZ.7)QWQZ5V "">O!..G V MD! V)GWFV&SKV9;UVXOFFU#POH.K?
9 !HT>QN LPQ^Y!^O!H.C!4^AVT@ MMO#-C9Q7LHF6T<(C2Y6(85C.2>A!^?N.;!Q!GTWX= \$2!T.%8!Z'6+USD40
M!XX!Z!H!P(NX^V^!B.;&R!HV8V!<<8!^16&AZ5!1E.L 3K6UXE!B^R.M>L.HH XG7!6TMKGP)!A!.*634(K=&@ 'FV;Q!T@./O%4-
ST(SUH7!12^M\$E^C^A RVA)5KL^0!^TQ3?8Z=>6! \$ Q1A=H)R0.=3S@5&GAS18WNW3 M2K-60!BY(A4&8?I?S?
G0!YGHMS(FB?)"J\$N!>F!Y!AE!..D12 ^CQ!HHVZ/H%L<Y!A!Y.W+R9 Z!F!N@Z0FE P!E MK!EH+ #.1.%?+!SD\$+C Y!YS:6-K81M^6!
<*>L=S;.%QN/3)!3P.30!XV8K^!M!%0VL%T!)K^>Z+^N!H!Z?70-B?^1XL<=>P450! BAK^Q!^ \$WB!C!1WUW MTELTD8#"%PA-P^"MS#-
'ZD)CMX8FF;.)%9M!^@^Y^P%R?4X ^TJK/HVF M76EHEQ86TM@B!BVSQ QA5X VGC H X+4M.L.WX@>"DNK6^59M^NA^K+Q^D M6
P-B)X-16/GH^R^O^UE83065O;Z1%6!N/9^Y9H1C!H?+>+C!V!>H+X M=T5;JVN5TJSQ^KMMY?7=>S^DVC@?
2L7O!X!CT12Y@T+2D6H&J&X&A!M=N^JK!BL3DX\$S8-.3=>BUI^X@KXCAM88.;+2Q;1&.;9=0?P!13K< P^U M@9%?
C.PEU+3K^WM=0@M+WI.DEJMR^*XD0.WENO<=>G GU!4\$N!P?>C8&R!21UY.M.ZG43!-SXUO+2W2U6.TTD+IXKK7T'29-FT MV33;5!^4Z.
(+OPO!H+!8I7-UY3-(QYB^4^!SVZ8%>X.F^C!8.'K6!6MDYH M2.../V0QY;1LW0 !FXZ\$Y!UWT)!^6TM..AZ>.)%2.6W^SKV8D O;>8S
M!T 4#A.M=0?7.HZ/874! BDFMU;&HPMX?E M5!KE0\$>KQA6D!QSS!P7T+2C!>B QL(C.GZC?I990!0?PP\$?ISDY^7%> MO2Z+I@;H4
!+Z^MMK# M^S^T Z.S^UKORL2WG.;&..Q&S(ZD^H!>H?!"L.M.P66UVI6L>N.#<=1GRRLD.L05>.;=..H&O^&ZC806%[HHC<6EO!
MZF&2!66/ =&./P!2?PIHUTMHL^E64BV>/L.P!2(<=>G^R A0!YO<..966H \$ M 3!S@&LUTF^9+>*>+&LA@FRP4<
-*G!6A.;!WX3^/H=SIT>HVIFREG= MDFS! <^K.MO(8!@0W)>&F.UW*^L=1<7L.;+7^9YA\$N^4>C&2/K5>+P MIX?
@M8;^1.&(&F);@4>6S8RRX^!..R.; P=PP7A5(=*E26!H/#<6 M88.D6JX&TY M8D!L "07!6UM]^W2WM88X84^ZD:A0.YX^O6=/X5!W-
Y=7D^BV\$ES=QF.XE.MW4M^H&^&..*.)O=>#TG7 BO#H!M!03^+!^UK5H+>*>!(QS@DCME51^;R/R% (QT.3WY!@!.;);7D-W!H-E
M%IZFO&L=C)^SM;/Y.(N%N8VWJ^4 .>N<1>A M(KW2L4^\$/#9@G@A.<8;B7SIHS;(5D?^1!CDT \$7T^R@LTF
M0^25E&NT+@G!G:O^OUXG7.ED><^0!^XP>..^N^ M9;JM8!-6.R&6!G07>TBDDV0^DC8E!#NV@Y^CDMCR.V!+!.;H01001+B6.%U&>E
'F.D68U+3% M^E!O:6LC>(<M(D>8&D B29Y>X *S#!&> X5Y@NZD;6M!L.M0T.WTW6(?> M!T?>= 02%((// K<@POH#M<.,VBV!-P4.V;=?
WFS4<E7/3 M!3T=>+2VCA5VW/L7!8!DJ\$@ ^A0!R\$4HO?P!Y>GZK%?)!<F.G1R!&4!68 M3.;>DE0?8N!O.9X0A%K!M)5#Z?
8W!U%IA<9!N(HVH3V5BRZ\$5ZY?..3I^ MI-\$H9PSO"28G= 60GKM/49/XIESHFE7NG+HUSIM!9+>+O^IC&.GRXO0!+
M86TS.G11100QOOL@1!%R>*>IMX;2^X< \$ORXX4E%HH#..H#10.6TY^>MV MUM!9VZ06T210H.*B# !A6=>X7T^6!EDT.P>2!QH9K=29L?WN.?
QH X4Z;M9:9X^H-W96T^C%SG>*O!LHU?7TL-6M=0 M>2Z!^!MU!+>2 K^YNA1CM!HZ8KUO!O^FBNHUS=59EK.8MB85S^HCCY?P! M!-
>K^ZP^D6+>DO(NC OF^N!&<^!&5!H^!TSX>ZQ=V+2).D2@O!Y!>+M^YNA^ECGMBN?UB#1C^!PIGTL(7N%>A> KIT7V=L=..HS /WK7=T22-
HY%5D M8\$K#(8UC60@ PU8LC6N@;..!TL&N2;9W!H!W9;CGD9^M6SH>D64X-2 M LVT^W01>3%<>2N^/HJG'
Y!YF@#SCPU!HGB#1^N!NKXAC2!M)8G^PI&MPT MQ&)(G/WF^\$G=GKH!WKQBA R3^O% P!>5LYVOAKOK+59-AM=L8=0ER7N8X%
M60YZ..!GGOZY;0! 3K+5+1K34+2&ZMV.6BF0.I^H% ^76FYD>+>P+P1-HK M!>=VUY<2<..!^C#>W5N1G!R/O#D>F^*^!AB^R A31X.T.;S.;T
MBQ&I=?M?D+YF>F=V.Y!Z.T^PY!H \$7QH;BPAF.TN!^XMT/RR.40A@X QR M6ZGOSZFL?PY!TBCP=HQB!B!75+!\$!P!QO!>1W83>
(YXU^OAK0UUDZPN6U(!H0+YF?7=C.M.?>@#D/#5!XAU+Q59>((!9X!0.\$K.HRE!Y.^4!GH.&8\$=R3UKG/DOOAE)
M!C6E\$U^Z^M62>=GVTTX3R>..?>BGIT MGN/8!4.AHFE.KY!H;=>W7DL&B!Z(LZ\$9Z&@Q^T^A82.M\$4\$%.;1&N^J@ M9.
*!@&U@B^=Y8M!!!J&8 !AHXGCD+>C.D;A@C!S7LBQHD8C50\$ V.MA<<8!Q0O^GAB^+RHO@T^FYXN-HMDQY@SAL8ZC)Q!>./?
>^>T>[TSXG/I MUM^8+B=H-R B\$ 9E;<@Z^<Y/ K6T!4Q=^\$/#%C!TBO%)X9AN;03!B6X; D M(SU<^!H@.W!..I=?
#A')=QK!%BJ7R_RH@7\$W^ Q!WXTVY!+!>6%Q87.BV\$ MUL;.#YZE(!H8X ^"@#FOAA^PKXLBLA\$MNOB&X!M8L;0-D? QVH9K;^&
M%&C>."!^!3M1=(!8!8!P-N-P%PH^C8KK!2-TM!6L+^VM6FE=(88E0N?> MYJS!#U5D2!(KX?I L.G?V!) P!A9-.M!G7RRWKMQC^D44<21
M1(G!H.HHP 2!@#Q.#PYHU !+2\$FWJ-GH6Y?R6MY ^=>#LKE.(W49^RC M!3ZEM6TN/3!5.MHOBB M!6I?
3.0!QW42.)8VB^F!^W^L+YOZ#TX!%C!;/ M%>I=QZ9:KDP0>>MU. MP(4,&50" ?7@T^O7N:(L.^B%51@*!@>E8!>@O#KQW<.:!D>2>?>

719UHV7VEG3+NPMH\$@#1M/3Z<CBFVF@Z18W"W%W=GL10A62.1598QG"@@<#D1>1"Z19:JL K
M:JKNFZ1"TB00:P6D<<9FC9>4D5>2%QG1^Z150QW=/#K7A*VN0#1%UJ1CO P
M^5G1M015080@X/=170Z:1/T1K1YTS2+*SGG UDD\$HS=\$@=,JHNWEE:ZC M:26MF:17%0C:/%@96^H-
"GH8+11=UCCU12L(WNEJUD<K*6ZE<=825ZZFC:9S6 MBV-N+>?B:/8").WS>O"-5SX7T1K2WM#HU@:V?2?S:==D3>JC&?<4 0>-8 MHY?
VO+)&K@:?.<PS@B-L&N\$OJ:SE1(?#2&-(Q+J%B91%N\XFV?.<>M>K-M&CQ-\$Z*T+M*L,@CT(K'C1(^'C>WMX)"TJ8:~S)"@MUQ&Y B"J^M
'G&M M* AV P#B+*H%N+5%TNTG\$J@0*3061U Z'8"O:K1\$D@
MMWBA@LXXXQ/\$RYRV*O.O@D9Q@-6NPBT72X=1EU"+3J9+V8:9A8@<=>A:J14 M.E^&1\$T2XFGTO2+*FRG -8JO J^N^0.GM0J4444-%%%
1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 5R MOQ U 40#^AO^U-
^REUN(HF2XB9PP=U3(PRXQG/>NJK@OC#@ #Z52<KRU"! MP?1 7)0:TLJZ #+;LMYH19F42Q"TG&.9.*L92 0#GH>E7WU"RBNUM)+RW2
MY?H+2J^Z+G-9.^F6.D7JOHEJ>2NE:8HKY5D:0J% 5F/\$@ 8J1Q5V7 MJG<="O%-SRL%L@UL%L^A<2JF6X2...R1CRU&WY1R=HF4
>S37M1\$B>ZAB* M\$AY N 3@GWXKF1507HLK6JMI=AD:E15V1YQO..K#>HJHHEL:AX ^(-C=1):S"R MCEB89*;<@T=H0LO)2;
171Y4AVH F#*T1SR:BU(DT4*8JO*TH\$DEQ M\$F5P23M#*2>..O?<3X)BNED4A(4F<>+ISMF9/EFB(P1&H3M9LXZ&+M M>AT
<3IFM^1(216^1(1%#WI<8TE:8QS&RD/F&6.MR/XOBNCGOQ==:/K%Q:V MMU)&HD"D"YF1N"Y(SC6%Z1Y?G:C*H&S^JG/W>1STKR^?0-
% 2X7X>.>K'K4\$YU "LUUM9KF)8 MU*1B ZZX=O;M*AW1(C-/CTRU^R1^>TQ 8PR2+54D10.GTH 11^W MVYIC 2X1(C U/IP?O21
=YY "JDAU>180M1+1QM6W6A3HTEFZ.#6HH1XQ1TZGWSX1)=?(\$JH&3P..3ZENH1C1+M O M*C#S#.#M#67Q+&1GUXH J%M1L4=\$:1MU9W:;
RJ"SCJHY/M2W6H65CE^UW M=OJSA/D":C[9/>17.CZ8A4XSO1L<7-MJEYYP0:X=L RA#U4#T8.M=7 MK5YHSK
(FBCDMXKJ2(HJR:12)=JTK5-/MT2JO88H^9A\$G.=JHS#CZ#Y<9J2DM60CKU1);ZTDL?+B-O.1HB6(HBYSR M">G^1-
GMG7X2SW,L1+..621@0#JDX\$1^G1K3E1KXP^C)26DMT1K=0/<1C+Q+1^Z 4=11-J%E;0SW=O M%Y>WYD@.X*1NU)
(SX4^12T0+&K%9&SDC\$F9F595)ZG/IS M?GK@DU P#B10(HK3K691#9G:18(5FA?>1BS2 M8T&2>PXZ?L 0^19/9&
1%G8@<WRO0!>TOQ5?1>.)/"NOVIO%>R0FYLKJVR M(K1<.-K\$E7'<9/?UZ5-0L1+MK1+RW:Y31T*RI?U7.1U1U*/O#18-)NK! MO-LO#-
K<27U5%RB21=HB15@HDCZU@I>V)TOP1=6JM;YG.RKP0M*)+D1NL MNHJ9.123PQP3C)H 13TWQ+LK:G?>
97L TUFXCE N#1^D&UP.9QWJ15?A MOK2YGEA@NH)98N.R4#17E(ARJW.*MR13L@:N44 9L?
AW0X9XIXM&TDHFWR1+H0^H..#39/#6A32WM=+LH+L 0316Z1P5@FC4=# MT66#=\$3TNR03"TH.C"Z2Y&DV"VB-
=B2-9DWJN.8!QD#*M"B@#+'AK05M)+1= M\$TT6TK1Y(1:1L=AT)7&">G21(HOVN"Z LBP^T0)Y<O.V9-T?W5..@ MM:5%&8?
#FAM8P6)E:3S:61^9#.#9+>C:1JXP#R>14T6D:9JSE #JUI>R M?2N\$@42-16 R:NT4 4H&TNUNVN123K2Y=BS31P^KDGI20.Y>F#0=\$UO.M-
141+FPVKM"1T@M8 "MHXF630M.6-IA.RK:1@&0#M=0C1PR>>O:U% 1+T+H/41-22QMEOY4/>WK52 U=1UJOANV#6612 9X9.8.^TD*?
56"G1ZAACG<>5^..M-6TFZZ1)/G2>WL66 99:5GWW\$S.ACHIDP<5/E+T+G1Y=>29400VY-B 9 M2K1-K%EJFDC;<" F=011 T=1110 4444
%<%XCU+Q'H\$AS?JD:3ZGJT% MC<*+9-L:R:B=G2(V@ G1HVN1^1)TL:3>"PIH X2:T."<< /D J/SH ZNU%J
M82WDFZC6-91\$*5T6.OJ=X8C@GH1XZF1(MTFNXMA4LGMH15FF6=2D9' M9CG &N6^1)U1+HFE:?
L1>GV^JPR7D1FCBPP#D\$5\$Y01R6+1J2AN1M.X;M7063JUS/HLJ7.PDC:(8VUO.Q0N DX1X "@#T.#7-)NKX6-OJEE+=F. M2B1)U:0H1D-
MISC1520K6EQWPL7U\$5619@H@:ZARQ&0.N.XXSUJGK7C011 MM573>7D1 M*Q(K02^5-7"G21HPVU6 M1W%G15Q1Y1Y2KF#"X?#F>6>-
+>Q 9'FR@U*SEN0G."3J7XZ *#GCOZ5213/>7/@057T5R1 MY+8R&T>(Y+4.T11W1/PK@13.VU3X9^#6T0J+^ZLDLPGWX1P)0>XPH?1#
MF@#T==T= M6W5.%0LG 1XN\$D P" S1OXT1:SL6<XNI69M9F113B=-D MC&X 5LX)SQ@5Q.LQ7/A XD+<65MYL B:T1F50<1T
>B1R+&LDJZ. RLIR#T(TJEK>DSWVW&4F12(RP1A)U+Y71PVY5 MOW1AT:BG)VH&H+RV1+V4."M41C6=.A6.40N9+1%R==
MIR>QVZU;NK^SL8%GNH1)B KRR15)0 FO+K:UTZ:~XIN8:9V1Y0154E5+ MS+^OR#<(HT6X/JU P &RZ0=#1 MFN7>N#O US?
1WL5KJTEO:2QJH7RA^5QMZ>///6DO1 7KK3 B1:6%SJ\$4.C MO1.UU(LBJHHR(NXN><881P*H?#21LHWOBK"X.032@1L#E&CCPPQV)YI
MT15(K6X^C)<1%<(5T:X9#G)-&U1 \$1H91\$*41ZT1A:WMM+9%2XN8Y5 M:1FW XQQ3:3415\$F L14+X:7RL8)%DV\$CC.#^>.&P-%S
MPK15JGA:~U>1226^1NHVF95C4)*RC..8 JO^>9:WXH1E=GJMO=:4VDR M71BAV-
LE\$J+RPR>C=1N(LH1G1JNRX:3(O%3MJ+1VRK1JHD:6Q #N1LGV MKH7U:1KKXR17-M?6LR/X=EC:6"56W\$3(P4\$D1P%<=X
M<>ZTC50X.FB>TUS0YX9H5 &NRXMA461.)<FW"IN.<9&<5J1P%113#C.*R M1%JHDINOP%43+BD1A01(WB=12XB26MQHULN@ V)IN# 46-
61X)1STQ1XKJ MJ4U*PD1T=021MFLF7>6WT6R147W4ELBM1F1:0GL1YD10S 1.XQSB@#VF MRU&RU*1K1M1J)P6*%X X#*F11WJ+W4:38A+?
WEO.QG.&GE"1^16+171)(CQ)E1CYX"1=>REL1H/VB6&=91&1V.TGGVZUOY^E^K1J1"EO MU:4T4\$CQW011&GF:#S1Q@#JYV-N104R++<(D
<+G)XR>1GK7EE1>:==?1KP<81BVEDMY1+C)5P3&X M9-RGT. ?>@#MKG6=1L MH+6ZU*\$S@N)"%2*6=59B>@)1SS5TD*19B
JGM7C1&H:1*#?#BW7H< MZG:9-S&AGC91Q&2A=OE" \$G@815ZS:QJNGPQ11HB521^60C^+U/K01DZ
M1J5H0*3Z1XD1=0S.Z?P8XHV1@&E M19WZBK16N1L.L0Z192FSS1H"3JO MA W1Y>AZUXY(+)@/Y151=^Q1A
3N@ X#^E=N8+2R..G06D<@ 0E 19UEY F3.P/3GXTA 2 P531XCT5M5M+N%:96D#%Y "BJH#81H8+D9QP
M:OPZUI5Q:37<.IV&91=NMMI^LL^JB MVVO):1F:2J10<L/D=ABNEU"+PU>Z+XOU?3=8.KW\$SHTJW4XDC>C8VV1M MBA0 1OWQ^%?'
P:WLRLS0:G9RB1!DE\$3J?+5AE6:1X1QZBGVFK=:2PS36 M=:W\$4)
(E>96\$91)#\$C11NU21ST3X:<@M:M:=8+WJ(C.F:307*MPD)Y1+O K.B:S:1H%MJ-G+&1^1-% K<13B.O@C*Q?&?BF+P1Z?&MU1%
<7U1H:AG=08XW?#R8/HN>3QG&?2L3P MU-1JFC53\$EK*U)+O1/9&JQGGHJ56H#GO7/7ME1 AW#K#LEV-1 MN)CA@GF:41SW"?
101Z1<K1V>H2'68=5CF)DTZ0QH14%>9DP

MX:RQH\58GB8B6.GN""=3Z@UJV^B:UT^B MWQJHMDDEC<0:N(6&7SICC.%XXPG(("/<#C/4>G05'6/#WJE_#10"=A*9:N^1K1' M(P7>5B99"P
9W/H:CTH\^PNTU@3K:JB!\$=Q\$DJ@^C^?SJO4%E:1V%Q:V<M.?*MxEB3/HH_VJGH_****"OAXAV^IX&MK>+1PQ>+\$.0=L@KT^N
M3:ZJHNSZ?=%f(1-U2^4)1>#2ARIPV^ZLNOZ44/BM:Q1>..R12\$>2MYL58KU<+5E5?+D51A23G:CH.M5M31.AJOC6/4KA M^+0
<^DRZ=,G:S/WA4L5\$S'&,=>@8G&,J6^-T_OGK=Y<,+1)I-E%IVDZC^7T_VIB5BCC#IT&T_MCSSG^48SR0_PMHOC71H;71K_%#2H
(LL)%=1K)HEB7HJ^1^5>3D1>..3MZ#X60K>W4V6K+;FTUJGN\HGF9F5945"IR@+TG/O0!7@v;C+
MIR)&Z0V4WF68<95W8KM9>@8C&1\$BND!0:W#H&DM^2H9"9(X8HQGY)"^M3C+#_3G/KF_"^C>..
M^BM=U#4=^GTFS*!%=@HJBB7HJ^1^4^1R>?P^MMKQCX>D13>+YI/MLVEY^C6MKC&?+EC8.IQZ9^ZT9ICXEU:ZU^2#8AU:U_MJM?
BUFGA#@X_4@8<N^#R.W:J^C>..3U18I9VIMK%K<.%JUK*Q:O.H164_Q.M:OEV^N2^X35_1X_&OV=Y:21C<11%88K-I
DTG9I&894>P41?9QFWA;6K;6MMU_36L1J^TOZQYLH[.C..!A"UGLWE\$T1.WV:2Y=L4BYR M^?="W/RGY>@I(M^UZ#O9XCUB:K"-
=0LHX+4^1.S>9&K1692%QOZG&1%GX3G_M_#PAI0RYMEIUQIFDANO8RLPQ&^X*/EP2^R3GVY^?#2_U+5?FFZAJWTO23^)=F17:GX>T13K
R6UT%G7G_2VT35KQ_JF MNJ+K2ZLH:~//8/E^Q:(V8_1^4XQWH1:9X^5=\$1.R0V:)JFMR2Q1P.Y^
M1&+=YKDI2HV<#J<@<=1Z3XBG647WAO4X8HJ^Y(2ZBEA)V7\$#K^N/*D_.\$M9/L.YC3/_LZ?HGAUEFL%UC0:N>6\$B5S#%/,S&1&.P%3AI
X:..G/5?H4Y M1677B34!"EW)9I8PPN7\$<2L7)+\$#)+_ZHZ780:VGJH&0 M+=WF?)1D^X0X(9MW&2/NGKTJH/XFU:OO_#EM>V-
J.C:K=2VTHCD90+VAV5U/M095Y^ZUIZ18WU+.%EEU_15WL2NPCY&^#Y!QU^T7+CPJ)NG-M.%X>CTRXM9+S110DNXX+F5Q"
(WWCR0^TMA5<\$CMT^0_^^(!>N=1T.XBZ+

&J2OI^P_9.NMI#;Z1!)%.1S-(9Y(EPG5%YKGYNYXJR8VEZS!X=U^X@ZE_M:76+4X56->KN42JOXLP^XUM6?BG4F1KHL^F27%M-
^EW:VTLQNO/E/O&_M.D=&R.^@K+G^V.EJEMXNM;Z>VMEUFZCNK6:VE9W@>.)L15>Z^1VIZU_-L?M&JUTFMKNH;7.RB;XHH15RICE2JR-
NP%QG..3CD_8(16M/&E1NM:8ZE-V MD3ZQO#6J;7L6^&15D_O9 (/^XK4VE>+KK6M1GBLELB;..UNK%V9:F^-7*
M^1W/P#C&.^J2^*Q(3PAXJ2PIYHT2)M#F)<122MYX.3(TL.T.2=Q7^R=W M-.5YX3U^6=2TJHUE;^PO1.NIVTC><1^L2(RNP?>7^G+\$=3I4
17GZZ% @ MVJZ7ISWJG'

6TB.%VYR^=O<#J^P+=WXONWU4I(TY;7UBJ M_9W;.DMXXK(#+1GI@9(Q@J0=O6J.C^&O&^AVYN=*TS4+;P+;1L\$LZN:FU M5V+;BJ!M;D)P2?
KZ5815>%=246U_8W50ICH9VFWYD99I+Y5^>3DA@O&&M>..LU/4?2.*N12N^VUK"TTI R0JC)QI!55%WXOOD)LM^U;4I.W&EZE+%
M\$XAF2T2WIC.3PXZ_X_OGC=71.ML.LZ!>1=NQANK=H)"WL_N_707+X4 MU?4^ND^19>S>UL)H6EN89&+W^0D%L^C83M7=IQZ^7@
=#XHA17OBO5=-MLM&L6CTRZMDGE>I8\$PRKN+1O+^1/8IG-/OB/7H_#1A1+Y7G7^UPZDGT^ZUGZ%HFJ.?XQ11ZK=+79-
4!HA%:S.GEOI/F10#GKP>/>_MI_&AN3Q+1\$5\$M+<+;WUE=Q7MG^ZY59HSD;AZ\$%<_6@="N?=\$=9>8*/NHO6PN M^+VDFL+JG
(W:/OOL00"#D^D>E<#J.H:J.P.M60M5FBN)+AR^B\$^O<M8Y;.#_8^0OUT_U/O/IFN:M^0!D8R6^0^TN90H=BO5>_JX QW)HJY5 M-
WB4_#G4?^2OH162Y9K>J2QV;Y5Q93VLZ^X;?>^VY^*)@XVIR_MH451^Z!XUT&WMJ#N=2TJ^1;0AG:M5?J4T(997IH..V3>@IYH L:9XHH L-
MKKJ_8P^8BWTF14EM;J0W39\$90-N3Y1DC(/.PS>HT&?B^L;5.WMK91W^F M7<N^Z-(5(\$CA^YBIF9G9<(J88%_X<MYHTIOQH>H^C-(MK33?
LHDC08+EC<2L@Q&X?_VJW7X?>@#;OM?UJON="BUK1 M_-EYJ_V5^CN#+Y:E699%R@YP).WTYXMMWGBFZ;Z1Q>?PM_8_2O^B09W.?
ME;5(^2.NIN(1^1^O%&B.KK-UX>GLTLO_UJ^EJLIV7=AG4J^Y7\$^?O=3CITK MF+E95=916^QY&CT&M;P+T:EY6G125=2O_+^HF1^T7HJF^N#
MD9QZ>L.N/"&JWEIXW:5K^.#Q!>);P.LK.T16)HP6&P#1W9X^00J^*+C1M&_M.6UIXOKK3\$EU&^*Z+R^R0ON M0J^8^RD10R@^~
<1:3XA.A:INI66BWELEJUO>6C2N4?_0(P8QG)^5!@#@#Y MAUOFM+P=X?^PSX>337E#^1TDD<N76I&*=1U^U MF^T2TMH;2IY+!M4TJ2-
14;D1B6<1#ODX KEKQK?V^AN1575A^".N3&L.L2^M-MX9^DA100+E0I(C^1^ZV^LH13TNYL;J2W5U^T^JH264@<137&1>#M9G1\$MV_#14)I-
1/B.<+7J.WF2VZ.&"^65PK\$%)W\$#KSTH UKGQ%J-Y)K2!:107+; MOWER).2#<3;_YB0CIN RC<<IG&..U(?\$%W>:K#1%C;1V1^8%OK@7>6\$8X
M6.A3RQ<1;IMSSD5CGPUXHT3QJ>H>@&K2FT15Y^FN8-0\$F8)0-I=-GWL@9(C M)^U%;U.PQXDM2%_1XB1.WUC=-FR%E?0ZCO5)U#%@X*
X8\$GC&4_3R^+7M8 M^#>+WVC19RZK>_8KFVEDR1+8<IEX(C.SC.."^+OQ?J^KJ^BRT6RM9CHEG^=O\$ MRLGFJZNO<^<!
3MUH7O!XXBNK;.6.U+1K+NG@DPK^8Q@;5&X& M.^TR(X9;1^#K.F&VMZA)8F^4=10RX^1Z.OOQ<IZ;1Z+K@)A1V&X9I8))5!5G4C&PDXX)
(&_H5/K7CB_T2.6)N1.V@MT MU!;1+.5R+B:(R"/SUYQC)R!CH.HJ^0I@U#Q:X1)VU_10V%K%9W;.%\$SO-Y M.^T;12H^1V2>3TP.N1GWG@?
Q7<^1V7TGSMD(X:UX%;V.IEDD^YX F614D^7Y-MH7^1.W^6@#H). \$FO3+M4V/Z;INGF2TMHKB.>XN7^D.6'S+G/RHIG/8 MOZ3XZ?
6=^1O;VD>6!T90L4CDI^T&X>X>1 MF=WMYXYF)=^4..1D 1/?@_VM713>^*);ZOJ;FAC-/I=ES;C^V/M2_ DE3Z^FN@M3EO^Q2SDMY126U%S-
H/LD>65Y2I-QYF^K07<1;..@O@1(MF^K#)H1+1^YV5201>83L2<SN<&14U61T6@1N MK>#6)=E1H1=^3+^1(KHVWD9_1/Q/QO%X%=13^C(1=
HUU/HO1^V)V(I MK;P^CJ^=I9B<^)(^4<<<@%B;O3JUA=PV&J.;6UY>3R_9?)9A1;HJDNX5< ME@6^X&1DYSCJRO7:Q=.;?>J=F-17L=LK^6!
<\$L.D?OQO_8HR6;..=>E^V1T;U2>@1 MARI4@=&1N3@<H1IXC^5.T7Q1=V7A7P;W%=??
7/5=W>Z2.D&MZ7;LL)17T=C.Y1XHKOY21&R%UR1R=W7@;1:1.OQITL7PMF_XDUP4E@?7@JWK^AKO%XBV1_KZPMM:MKN&HLO;JH64D1)
8MS9R1J3TOX3+RZM7N=.EAG>24H1NCAL3;D M:6<>FVDD<+1N2/M.DCNP7L&C_&_9>? "IH7BN PI=1.61^#0ZG/>^TF MM7#80.C-
YBDYSE55F1^WS785Q_AO2I/D16ZUK^EWBSV%ULVK\$P+1ICZZD M<^*B(\$CN&'K6IHEWK<^K.O#JB>.;*8?81;1F)\$*L"LF>-XPI../FH_Q_&\$H
M;S%1^1#66G6MS_EE<0W4K1LC99D51EB#R/P7DYXQS^GZKK&CA_#4_.LK2 M=+1/5;F8W.S)N58(R54^#YV
>3@=<O..K11.%JUWJIT#6!\$)T;B^*.Z9E MRLJH-R10G^745FP^=<=33/EJZZ=NUV262W(N^Q^OB\$>=&=IL9XSZ>I
M\$EJXSU5M2T&STG2K;8ZUREW_UQ<=&C^BMA1+P/G^(SGVZU?M=U>J4JYJZT MMK^&_L+>%KJSG9XUUGD3=Y2E><8?)W^IYOF6A?7H-9I
(WDB;Y>C6#V=P%M M7?)XMH52+13;W\$K1F.6=JNA"MD% M<@&=Y14_9D?QI>1L^"O+>S1/MVK#2;RWE8H;YMV&^#8V^G(1^2K1GB^
M2QUUQ^9WT^&UTBP2_5D.=IH0Y^D-NGX^U9MWX#0Q#MG^H1L^KV^L_VTYG MW)#+1.68NN0^ON&(P>@J^L=8T4Q\$GBS5KC2HK6?
25B^*D\$;H&P^*107+8M19S7^&C.P);J:77AA6L;2+7U3);RFV(C1P.G1W+>29PO(HZP/4M8T06
M/B#>:59VWDW;16>0W45(^%MT)50H)R0R<=<=>QH=MK_(>H)GNM+V9W=K_MJD.EOJDSR(PH174KD_P1U2..0^V8/#&MQCQEN73-
/B>\$M.XN^0F(1_M/^H1L9I/>@#H(U&6-%L-3B01^>61=PJMU=0P!_N7E19W WAS4\$VYF64 M%QI-E)^%\$S\$2W\$43%9)%1?
NMA2^D#J;UO>#1/N1(^Z5IEIYVBRM8I=FA<MLK;.%YI(IYQG&^YNR1C:OI/A15_#-E+9MI=XT_V.XD=A);159W^4VD/M+0= MP5GG%_#
H0KJD^LZ?8;HHI=HJ6EMJ^1<.;@_N_XV^*.YSDXZ6^6OIE_9IATX+1).P.ME^DIAL<.;IWSYVKK+NW6W2SV5\$JLL1DCMD8H
X_P#X3:V\AWPCJXM(CNN7 M-M;S1%CF+S03E3WQ@1\$5#<>+(\$/? M^H0^#1%7_1.^&M)FET<#0K^"95Y#Y1<08_GY1M;1_QSYZ&_7M?#FMP:C
MXPNF33R-."29UQ_P_R^8A^1JOCIGC/H16I^Q<=CT2^38D21U33QD\$V66 MWA^49(&-QW_ID="<18/^=>BIX_U#3I-
4I.TX:7=032N<B\$8(^N\$RK!ESI/T^S1_1L MW\AXEBO+ZSMKK4;Z+4+>UW_X^T83;D.F4_\$/2@#6M_>J_VO=Z>^F?;\$ M6S-
U;WBPS00E>8G+1^K=P1G(1^T16B1^7I^ME9ZG=Z7_VNF7=FLTW7=IMMXSGL1UUV31_#\$1QQ632197QO=F7^CKH4I;M^"M M(O=1
(;I&H79S/9PB\$O;NS^X^0V^I/O!OT444 %%% %1110_4444 %%% %M 1110_4444 %%% %1110_4444 %%% %1110_4444 %%% %1110_530M6
MT_3^A2IO<=YL^4LC@%1=<#OC(JY49@B-X2A189^27 M_C247M+ZIT33GO4LH1<6IV4IOEZFE;P2W-Q)1 M>3.^8+01LZM(W6MD>
(=;M_&56HM;6\$<16LTUHI+11/MR).X# AATOTQ MIT=;4IK0U60_2LM4^S0"TM+60QE%I> NLLN21^JAE1 SGGJ;"@#2N+B
M&U@>>>18HD&6=S_5DB_V0KF^YDBN4-U:N+>9&B99D9U5381OYV(^..E+M-XCU^13?#CPWK\$^DVB7VH67FPLI^YO7ED^+N7.;
<^HJ_XG@U)/O@M5N+\$ M2SW%PS.MJP#EO)@L^6_# \$9XR?IO!VVE:Q8-W9FZTZY6>%7;-B_05=3@JP
M(H1H15ZN(OO\$JU^1LOK^9QR3Z=)MEC73YY!=S^6KLH/A#AE&3N>HP.FY.M^)
H6;Z#3M;M5L;W^STOKI^>B1D1\$<@UR_/CZIT&2TLQZ4EVEPI8-(3(V6GCY5R&..>O6@#J:1SMOBI MX@?PC8^*+G3=CTWGW>
1B215%;YAW)VX..#UYZ5T=SDXO917U_3M-CMUDT M.YCEI^&GZO/ENUY^LPB1BVT.@9(%VMK8^1&D:P%<M(T)HS5JO)O!_B5H1
MI>"96M;-M^NY(+!QO8S@R.55Q_"#VY..XZ5T61^..M0^M+HED;MM-G;#I/I-MBGD-TZ
^U61!M0Y)49WOMUK3LKDVAE;W1AE@.T2R&^5=KID9VL.Q^0B0)=.EWX5^(>DV^E M7.H7^YKFH1111H-A9@H!+G^K@X)I<4
>P1^1VM;O/X3M_7A&^VL;NIN=M.E75/B9MJR0HP<#IHW_9&2<NM:4WBW562IM>VB&IZ=(&+F)+2>YCDN&C^MF-70?*.1N.3STXY
_WHKASXQUN?5^EE#HTF5J^16DPT517K.LEO)&#RK#^0M MOJ<=LYHBGC+Q5)H7B&XAI(NI GF2Z)>3RYU1_1L=54)ISP<=>P1W-WJ^GV
M.H6-A=72175ISK;1-UE^C+8^@H7^W7BF=M61>38VYM=;#-YDC\$R0_N3)A1 MC^MG/KQ3;7Q;=ZCKIYUUK)817-G2^WDTZX5EN&@W-&=3N
(^DL^1C0GB@#L MJ^X2^1ZDH?7VBZ<H^9W3P+K93NIT(WV;5E4;0V>0>G)&^<4/5W+ MESI-F.S04M\$GM+74D960F92=I^<
1^D2^7D.GZ?>7UTVR^ MWB=50HJ.D.D^XVY1^E1 AG30Q=^Y.VPT.I^IH55^=>0RD1+9PY&Y^<@<=45Q+^?)\$USXOU?1-TW3773_LLGF33N-
T^Z77 M-VIT_2;C3H+19=JH1@H&6+1JH@ECI^@#1HKB;3QG>2ZEKVG^>^DT^Q M2H@N8-
T<4H.X%3R_0KU!.;JEGXVUUK^PGJMY8Z>NGZY+;LD3N94>5^RN1 M;O%LGAF_1\$\$.C:6IK MIES!^=PB=..D2)R&9Q@8
SD1>1Q6G9U3QJ^16H791V=O8+IZ7EK+>@E;UF M4MY;1617R<1X<<<@9T5P=QXVU:XD1+16G6C#Q#;23HHF8>4PA\$@!P/
MNC(R2<@453=0135?N^PU^YLEH31(H2VAB9D1FEVY VX\$GY&+;^I&I MW143K&G#65T717^
&@TIF^N#EM@(!)HKK_BA>ZEIW@>ZN=NDMWV&1C M&68HJHOH-OWNO/IU&?JQU_XJZ^L M9KTZ-<@N^Z.(?08_FQEC^&?>4=@
M^T^BN\$1_MQ_8CM?6L0U1-87H1MNKO&TBY)<^7*1_6QUXQD9S4C>+M.G K#O_M?FJ^#1A1K_HUJITZVZYV#(K=AE%)).13@C<O(ZBB@
HHHH_IZCI.G_Q_D&I6-M>1)10^2XB#JK#H0#WY/YUH(45+10!;6=M MHI1;6=O%;VT218XHD^JH1^T1H10_4444 %%% %
13)8HYXGE19(W4JR_M.A>H(BGT4_8^F^\$ _#VCW9NM-T31Z11YL^LB_>H1_KK8HHH ***_BB MB@ HHHH ***_BBB@ HHHH ***
"BBB@ HHHH ***_BBB@ HHHH ***_M "BBB@ HHHH ***_BBB@ HHHH ***_BBB@ HKEPC%%5GP=H8X1/N<^Y
M4ZB@#E2!A_40#MOJL6H-/IMU&>^5K>1CMP@I2^H28Z_16.9%_%>S1\$ M>A.KIO_8E_=/&_1A=YK5W.71O:0&1.2_QX_//>44>>1+HH
14U#P%XANI^16<+W3^&N7^7^RD2)Y9PFI(CX&S M+3G_K7GC^0;.(LDBT^*_/SG+90H^Y.VWOVSXKJ^7V; M1JGAR4+ZGM);%
1R_XM3&S\$GEV/G@9(XSGVJ^1^VZ?^1;W8W5@UK-N+ M.E.M79I8AB2T81W9&02.@YKKK^/80_OB&PHWA73ZTVG7D5QXN^0R
MQR;P/NG/X8IZW]=T36-212^15MUL432D9)(Y)WS)YD90@\$)Q@\$G/?T%=7 M10!PTWAKO317BS4=31-ZEI@L-499;JU^1V14^%+QI^Y
&02*75/"GB"WA_M1VGB^PJEH..R^SOH110^N5!W1_DY5@>21QC^O<44 G/)J1018C>S>(6-C)"VEK8B;2.MK%E!<=X5DOA4RZ=JH^U^>9-

[illegible]

[illegible]

[illegible]


```

8"/"VE6^LS=OFF VK@ \X^9@.1V/B@#5TW5^6+);.W3 MKN^ZMF)598FW2#@| 44GJZJ>=6 LH7D/U#RC;.8.#(! W$=0.17G-WXKU2 M?
X;66IZ7.66EM-JHLY88IL%7I3Y9"D=<|QW.IGD7I2DU/XM.;JGM|>.; M09QAI^D2-ODY)P3CVJR>W4 H=9MUXAT6QGE@NI8T^WFB
.D>SDDE(B;8/R#P24#1-MF5^T6MVGIZ?>=>=<UNLR2(TFV7)R>UJOI?@ MIPYHMR+C3M^M+>9<I5.E.I=N?N ABAJ5W8:3X(L-
.OTRFQ:N^HV BW43KNGV4FT=>I2H IV^8"UDY^YR.R8^GIN&.>U 845LYN P 1 M-.3PK=>.(VT6R6RL;2RWN^@UL795E|LFX; "/7+8SSQWK?
|0>)+.2I-1.VMX M+;QMA.LIZY5;MR&/E1D=P%Y/|+ #B@#I.*XF?QQ?O-X2&GZ3%+XA@.5#+.1DC)X/2LW5-&.NMX.18*
66QUKOP4DDBB9I(RK1AU=,@|=@I^A MYYZ4 =.C96.EO'=WEO.O<2>5 LL@4RO =7/4^PJS7.#0XI>T323JUO9SS0 M>7.DC1:RF
#E">58X^O:IXIG@|33;#9-8DO4M%N88IROI+L+@ALC(Z8VC)Y M^|.1^5455.22RV<#DI?ES&K.GIUB.1^IJ@. HHHH *****"BBB@ HHHH M****
"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ KEQ@VCZS15 HEW18LIB^PN^EGLR1DCCRNG;
(5N4/(R.O M/4^NIHH |PU#P-XGN|H6Z8^TIFU|H6ZCE.LB|>@C<.<8IO4YSVOST6HZ3 MJL C31-?D2PAL|/M9XID-U=;39(TEC;.1%="5E89!
MI2@B@#BM+TW3M3^<(EWXATK4(IFR-K$9UMW#O|<@JON^X1.01Z.IKI|6BP M^<(O#NH;Y2.|@:(NHR5)1^ X-
6-.TRO?R2RTVS@M+5.E8H$^*.1G@5;H MY+PS9>.|>+WM=?NM+>+T7.LMH7.EU@84ON ="B<9R1V7#;P9XE_X1G6;&.3 M3D6N|;?
4UBVYVCGB:0.T$AV @#$.1P#GHTKTFB@#B#+02$5OXOO^EATH176F
MOVWV>*9QY3H7(49R/F$8^IM|UF6 @KO%:X)*Z+MTOKC1M0ANI7^TN$D2-MBP" NAY.>_3>O2J*
5AT75X B>.>_8K(VDVT9HGYAO.W(L^1LO@IL=>_M9YZ5CZ98>+|L @RVLK2^HKQ+Z6ITDN^)|8I>0JGR@^9E@HR^.|>A48&NHR5W
C^G6N^F1>_J $SP-975;6T.4+| MCSTFSD^WE0FT9(QC/O M5IU5S.3f2Y1%DEW| N1Y3IS5FW&@^M)7|4WFHH+D@O%+93/^1-8D!M E@*
ZL2>5S@29^NIU36^T2V6YU|BM8 MF<(K2-C3#8YETLC0;XVRY?YPT9C&WIWR><|O3W
MI^1^1.6UBU17&..TM5U>2UGLHY6=H9(%4+N4H|@E0> "<9KT6JH|6FG6KW5 MIY/2@#C1HOBW40$WA064CT.^R M^S1V|C>9YB!=RY08
MI=O:4YXW0#MYKES)I^S%IX$5P1.2V+LRRM$A6W^QC SCCGUJIS9>(M$U&.M.&RU>QN)95WOI<@.S(OJ^#DCWK3 &
^@#CK 0 $L7J6C/297-FLAN MG?29$MOL .&R. I:5Q7/6@3Q3LD>&.K3IG3$US1(GM6B=W:Y@&S M.000&?
A_6YHM.2^QMYXKA$N^S)+M^YE.ONTEMIRIYV$IIV8.-F.@|YK|Z^M.8V|)J6B^6 |06U O| 5)KZ(R)F?;LF/E.57D8_6F V|?Z7XUU#7|+$$|6J
M011W=O.*8RKQ@A^5@K9&TX<(/7^NIHH |O_NIKHD^OQ827DNO#6IUIH6 MC00YT|HF%8XP%?|QTSWQ7H2%BBEP.V.0#D_6FRR0P1-
+^ZI&HRS.<@H/U M^QU^U^U=>6JW|BOFP2|UR.HR.|^Z+X97>+|J^TQ3;W3#H%O=27$;TH<MW-DW.BKC.V^3@D|>3G13-4|
(^)+RY15PIR.;1.S;&^WNIAW.T^55MK.K. MQMSUDR#=#R2">5MK.N.Z:Q@OK>6|A UL^2 NGU^45 IJ^U^NZK^1) AK=63H.E36^CWU^"4=
MHE.D^M&I|&|P^3 MD 8^7I77^QXF=6E|1 V.%(VI#IY=E)|LS/CTX "/|E%+ZIX=O)O% M>D^)=*$W=E^);3V|I%GA^G&X |64C(XP?;H|
A^=0ISQ^1+G4M6@2WC MA|UA^&B.JY?DDEV>^7T^JZRB@#^1^9?Z)X2TS2M1^OYIEJ16MY^ZN%&
M.V|G2L4^#B.XUS@|O;OILMIJH(CBY= _MIY94QJH74MWW#.#1.2#TK MO**/-82!_BO2GVZOI4VE?
YK828FEWEK^).Y$T^X^D.R#R|R>G^2.G7|O^MM2U^7^E6>RFU.OU246C9FC@.(3G.#.1|2#DY.I.G I.B@#D3H&K3^X|I
MN8($V)TAM/E5)GWEF<.6 V8OQCKGO|5G6O@O5H^|W@EY.9I-.Z^.|P^+.=MGW$&C>2H.F^0^U=67%XBTF;5(I-CO4-W^K/$A4@2A2O%&
(PV.^<4 8U MMX2U^T^POK.;D-724T^&SVISY7+@D.;_RLZD22.^57&.XKIJ^1=8V^); (2VS273)8-91O(O)W25H5V
M^#.#OL^1^|XR3@DXXKO#?# B>+H|U.YCTIR|3GL|A8|ADN5.5|3D9W(SG MM7;52T_6_.U9KE=/O(KMVL0DS&Y^/@;GUP10|SYT/65)?
ZAKL8LUM9M.6R MB&G.9%=-69PO79C&6QC/O5>V^WTGBK3O$;H86_>PR|>2645$7Q9<|8_7YK? MDM.^+QU>Y)YA8Q=;9+;W|=BZY97+
.;$#;ZC/M70ZC|HCL7F7L_EC8T MF%1G.;OWFVJ^<#(R<8&1FL;M-3L8KNSGCN+6=-T.<9(W11|G?7^M /;7P9XAL^%|K^=-EO_#
|L$;9UCD1^HVC#);^5|HUW M(42|@.32(CNGLP^L^%6+76.O MIO+^UO(IKJSV^D.3%NS@W^4>U&H.M M8:4UHM|=1P&|G6VMPY_UDK?
=4>YQ0;1^6C3$Tf609K|EIO#<2S02LON M6B^R84|J7D^PQ3>^FTI|8-MOB|JVM51V7V&|MX8$^3L9%|O=R04 YW=|M8KJZ^
^18^Y $%G82V5PDB&H>QWMT|O.QG7R/C6;02.CI3|3$OKSQ>^ MG.V^VCN+^SDM|6V2B;H7B.PWJ|FEH;2Y9|IO.F9^=&4PH^<L
MAD>E=167%XTB;58|2^C-Y^K%&01YH7I00D8?^=I.4 <I>^GG^VMM@+E_E(B$0W_+OC@9XSZ>I;GA+3+O12^6E;5?>3HLLK.W9H7+*
MVUO@.D|X|V^T^/ #. (8|6>9&3)1$|L+W3&M|+;SR.M-LCL6^1H|O M.^3WR0>E=GX?U30?%&LZC18MKFRU=DFD@GF;H9U7;2^%&X(IUUM%
M^GK>|=1L+PQ9Z@LZGO_OKL^K^M;|^1^35^K5A^9V^<Y^<N.Y@.(S _X|I3WKK=1UC3M^C^S_
^|BMS1^ G1GCM|HWS|J^).PI|O|PC^%&B^+H|U+PY<+;+8;KY.W4H^P^FJH^W MIM^S9 <0<^E7-3V/T^%|A|6+*>TN7LH|H^I-
TS(6$FTHU^"|I^1^ZGL CK7 M7T4 <+X^OM6N|&D&J&YBLO$ B|H>5GDB.<80%@5 ZJ&Z^W05QO#NKZS9.% M9.HC^7(9A2HV@G#^D|G|H<
M=VML7^3.X3.OC&P^#=>V>.<G073>#>."ZTKPOI>FW@B^T6=K%&N87+Q10N02> M<>E:M% ^R^%> CP^EQMM9;58IFV
XFEGBFS^NAF.#42A^PD|X5CU6..9 M9H|DY-C3A88.EUCSGC#R2<|8I^Z|B@#S5/^O#X;_V&6TJ=2@U#|="PF=H
MG/VCSMK^8".N.AK;71M>E|=V/B^XATY8HM-DLY8X|ERP9W5|KF/D#;CG>N^ MTKKZ^
.8|&J|6AQZRNHK;CLJDH$>9GPLC9VG^KR|UJOXTTJ^UWPA|6DZ M<+2SIR^H0UQ(45 PQGA6)^E.14K25K^ZU2|TR^ZCDO.;(B%3|T8<97/U%
^M7^XZ?DU7P&WAW4 +B>6Q%I|O#EPV;=P) SR|^H^&K3QO.QPVFNW.D36JFU M.BV.FGW6A=V|A.O|&^<E?>T^JEINKZ?
K$<|FG7<5RDS$02M$.07+E5Y?Y =YR.G36V|>^/X|UC@UBYT^MMK^4%&..YT9I^"M^JF; RLQSG^<^<5WE% ^GFG>$<#<^|S<^|HFWP_1$<
M^RY?+@P^4-O|OGCYN<=<=LE|WX-UF_3OU^(UC$NOOJ^9EF9BA6(1C>@P#C.M1G^O7H%4OJM@=8.D^ZC.H+|H|
OGYA^NVI0IGB@+^OH|1AT^YBU1+.;I2.(R MVS|Z# ^|0^>F>@ZXYQDXGBKP =^<(XKVONM-TR^L9(OIE>55HY>7H8$(<= MB^#6KVK?
U76-.TR-YJ=Y%VX(77(<9)Z>H|O3|TFSETH|K&RGNGN|K>W2 M|A_O2LJ@O^CIG&N44%&1110 4444%&% 1110 4444%&% 1110 4444%&% 111
10.4444%&% 1110 4444%&% 1110 4444%&% 1110 4444%&% 1110
```

MA'A#7=1ATZQEU+0KV2WNH4+V.5\$^L73G(^5LX.>AKJK759=00-/^PS6TIG+; M'YFE'')5L>65YXW7,>
<=-8FCVZ^<UVVY1WVEVMGJVIM<L,IS@ N@7RS050 M3A, GQO50P^H<&A^MEO++),S3226WFI4MRV,2#OM^G(/_O&@'Ei2_+D\$Z)
M-P,AZP-1&BIO\$GB25>_518X&.WMK^V\$TNR2JFNI9DCCP^I0_X;DL_<K7C
M30I1U^RTZ#3S;JUMJ\$%XYN)&4\$1,&VC^GKZIO>LC4'^GB^XU;Q))!'33L00I22TE@WNB2*Z(F5?>3D;_1KSGM3J6I_0K5G
MJMS/=-1V^LWMSI=-131LENT^J49P6^>)XSO^JH OOXCU#2 _#=-AH6J16LIU M_&5K^Y@#1KYL8W_&ZDMC@Y#
+^E5'^/B7Q^XD>_ZFTS3X=-6>YMYW2=C^C^/ MJH4\$8^G&#GHAWOMHE J>NZ5K&JOVD9G5Y9%"EBQ08"(P?O9 MI4>^"
#U#PIHJJEI'M69IN:X1K>1F&')^X.5'3^/VH LZOKKVF&#;HEFC?W MXDD5I>>J;GB^PTFGMX)K4P2EG.Y>5I?_M(R2_/_53P/SI50%:W-AH-
A9W8B^W@2%G\$Q93M4#0) /_2L=##U1/B)<>(_M0+^VCZ8MBD?G;_).JL.&/R8P2V,9XZJ^* _='O!U/_A^HO\$IZ78);6UQY%_#Y MS%Y(FIC%Q@
+^C;KSZ G?^/B^4I-N@J^SM;_TM1>=>9VR3#Q(C(P^MP%&3S)X<N@&_@;7^&M_X8I53A<^Q5?;SL Y,YI?KI5>N _#B;_Q M^K%I%<
<_9IGU6R2WS_7DBEL(ROX X^Q>_>JH_X;4_4IGO^K&JZYX^GL+B^UL MI&@EN@DB+D+?>AB&&0_<_1GGH+N2>=>0&4C1<_!
/W^SKAK.XTLWOA!@D1C)Y;QM\$@X^R6&_XP M;SCMDSV_AKQ;H6O;DV@ZEIITC4KAKN2.^BD;2VE?YIC"D!@3S@D?S)'WWBW MQ%-
XE.C;/HH99-)3480MKQLQ,OM^*^_2^W48J>J&^*^N^V^B^&D12>*+&32H#+_MIEO;RQB;V;=)F>M.AT#4X?B^FNEI;2S72UTI(Y6YB)- F\$;
M>V_<^>U4I^CPKKWLED8R0^&C^&(V@<H^C^>@<_>Q MA>GO^HVCWRV+R.G;RR/;JH^6-58QN=Q#^!SIO(Z^M^I=J^MNT M_P!G!17!J^<^4"Q
YPHD8X!U/_L_?B1-1!^WLS;+&_8L^M4NM5;HN=O;_!&UM@6)V0G=N4@LV^+_WJ_@*VKZIZ5XPT73YU(;
M7J9DB\$Y#;TF52P3KCY@#@<^Q%_<^>O!^OZKJZP6MBM_&K65FY;_NI8F4DJ MOS^Q+H)LX+@6MY%-Z3*(I<1(VV<D>6Y)<=>_<=>
1\$=35R^6M0/COI^FMK%9?I^<UK=H&^M^>8\$VD^&SDXRJ^*^X)A_X2?1=5MIS^%8V16IS\$>3160%<^H^<P MI2_X61_PDA_HGV^<S?
L&SS&S^F>9NQM0J\$YI4>>>Z?>KJ/P-URIU2ZC MN9&OF&4C^G^*WH^B_<=>AW=-I^<=>7A;V^AZI9V;0WMI)N=F^>
(V^ZMX72XTL07%XTUM_7D#16G^IYQMZIL^%USGCGHIK1 M_5NO^CZIMLD@LJ26WFCYB0;FTDKF#&@KWQG;@<7QKXB0/#.D6H9V<5T9
M+N&W=>^Y^4I^SVLV5W;Z5J5K:0ZE^O#>MZAJ M6D;JH%<VFL>KQM%4B_&0QJ M^49;YV&
V/EZFMA46GB@V\$#W%QIDIXT^ZYMPKI^F^8PIM20S9W\$<^1S28XKA MO^GA<^&_ FMO;I^YJW^K6<15E Q_<W/FO+^N00WB-QP^UP.F;
_E/C^5=%&I3 M+IOB>QLH+6ZMIQFTN;_5G H=SH^X#D+SD8^I^W)9;K+=+;FDSW-CJ;JLBP
MV%PKY8<95V=AL=1P^IMQ(G/H)^<8L^6IPW6N);Q16H^I^Q06TK29;RA^UTC4=7TRXTFRVK%<11+_J6_?NHV3M7@_&DCCKS
M0!/%XFUK4I_&M_!T^Y8?;# MMNVS2Q+(8WE^\$A1R^0H^R!U!^HU_K5S!3 M?>EE/>6I65G!&_<0D;5<2G@I009ZDI
<#&@8JKHGA/Q3X=N+K2M;U33QX M;H^W-U^*Y+L_B8PO4G#^*_ZUJVM MYE;N7J)8<I^N5&0.3ZCG(I^VE%612 MP55#@J^?22?
080QFK^A#Q)_PD^BZM=O;?9KJ^XDM+J#>N\$+7=1D?;EH0MK-4ATZ;ZAERY
MYBSLH^GT&#P^IWZU_<C!Q)X^T+O;UCIAM+VYC@GME+^8=I0%&^PN#C@YSU MR.E^H\$^BZ9=;C#I%QH^M+>P?ZJX>
(%X_P#>=J/PJH7)6.O.V/&=WX>U^3V MD;3OMJK);I^P%&_84?<I^X.X^?2N;3QJXK_X0;U)8MINE-H^C>6Z>YQ02E^"MT9S@8
_!SGI^?2@<U^&BN&D12^>I^WQ;JNC;+;4R6<5M<+>^I2I0Z+>#9RV_E+^*E=M;K>9>J\$2^(<A^2V@JW09ZI M;55BTVQ@OHZ&SMXIRX \$TZ1/(IT#-
C)QURDWC^I_J>#;F#L_ U!0E^ED MB;S8I&3>B\$<L9;D#C@C0564?%-SJJ32NL4D<^HKHJ@\$@<^0=9175?)3X@A.N^<F+>%9V)N16I>TFM8I^
=T3^*3N^7C^?2I>#_#M=D=MX3U>RTQI^?A^"8D9UDCFDB+J^XDC9D^P2I^W_<H^#<OC;4^?Q5IK MUO;R2Z);Q74;V095G20 M7#>SD-N7&
<I^E6I?Q^KH0V5DVGFILKN-HQ^87% ML+211E0YDR&5NF1@CTH I^BO_#X^<3IX^?Q;HEI7V;TO6MIF%3(9)\$\$ _E90Y MPI^?>=>E;_5UK#_!^?
N;K^<V;6DI.D)MSH>4JPSO^I^<@8I^>=>H^VU%<3 MX^?7WB^?M^+>FX^S9S#3F1HJR^5MN!<S2\$!T^G(I^MOQ^K_<8<A^%M^LEYI-
Y^96RN^E#MDEFH54\$<=<9S0!MT5RJZ JEEXK^?P3^6DLMY;Q<6M^C^I^H03>+U+01D^((J^JW@<Q^XC4;I^80>6FFP;9:78ZQI>FR7UG5Y
6AD7D;_M^<K15%L)=+>3VR.S^CM(K^TR+4M; MN5N;_>Y^>H(K^E^NM;G^<WBZWDOK>_>TCM%BB;E_5DD90^&
M;3R</_MQ46D^<KBZ^<Z!>M;VJ^GK_XH^"(B0B1P7;2 J\$XSR>_>I^?45 MR6-S\$K1QR^R;I+>\$^IR^<@JY^PI>>^Y0#GA MSQ^EKI^H4-
M^#^YGFKYCE ZDG PRO8V^W19527C?>>2P/^<D9XJ^Z;9+ M65K=8VF^DH^0EIN10I!>J66M;9;ZEIHXGM+A=4H!8=>A^JY7G\$?CO6&I
M#>#_>MM/L+>JUI#>RPEFI^PIEIMZXZ=3G&U;3Q?I^68K(RPVL M=YI-
_>@K1N\$^58.3R^07OZ^@#J^PI9UN6TUC2I^&LQ^INU^\$S75Y062^-.068 MJ^"QR5+1USGBL_Y9;E8?^I^2Z;<6UI)^<D61OX67Z5+
MZIW&WAP27^@LW08&_#UJ_7F&J^O=ZYK^PVU>PMX5NKV^Y6G2^9SL00;G) R0 M.GZXI9S5L?>4M&BURN16-J=6TYH/(%FS+%>B=ML>_>
V2OS<G/>@>?2BN3 MN?>J+>XETC216^QSO^L^B(N;#>H)G5=VUE+>N#>_>I^TUE2^<I^C^>@<MM^<JQ^V;^>W^N%<M^+E6)JN<^L@GKU-
_H^#<+>@?FXLV=H+ZJ;S&Z&UT^#M;D;9FC#>I^QEN;#^T I^>6?BG=ZA8?>K5K63K6I7J(IN^S>Q/I^M0=>#-
K>FV^M6NCRW2+J^TK^#I@DLJC+I@8^K6A7GOB9=13XA>^!&UK^?F+4 M10^<^IR/G;ECP.V>3W&>+>QY>P=>?
PZL6YU6UU=>=7I^CF.5G^LKA>6X4 MDE1DG;@F@#QJSM4UW2I^G^TKV;US^SA(S)D^V^I0>YINM9.B;YJHUXDNM.O
M^!WLEMOQ/J^*V4MLA;=@Q.LF3NI^YI^163;5VV;1X?787^<+>(A5ZGYSP^_OL M=8TW4Y)8I^<@GEAOYL_>^>=>FY>H^<KU<^<D;MJ?
Q2;126MBIC;6>F0;QIDA M3=NQ^I^5)UGI(1>?>J2L=CTH5B(K6?SGF^IT^C^"Q^_M;YHJ4>CT5R-IX@UU_>466GM8&ZLHBW=EO^83VJP2J;A9;SD-
V(QSOBN>B^M?>)>F^<Z1XL^OTLVEQ=K;W-NI^?S^<F.09&^PN_."#GKOTH_IJCLIZ?KMD;S M3+E;BW\$CQ^U!^S^<
<_>1ZBL^PU^6D;S>^M3AL^<S3S^VLEMO&TIPAI^RV<^L^ME^?BLN^I^>+C6;FTMH9(=4DL^Y6AC=XH\$>VQI64^

@45QD0 MBZZLI.2XDFL+^_I08K73KFP1G24,I9F**SL2H5^>><#IGAB^*I=MCKOGZ-> M165F;NTN(K;_W^0PP!S\$4DR=PX^I.1V!4=M6?
=ZWIMAJECIES=>+>WQ86T." M3)M)Z#C@<K65X;UV?7)2/@U2I^TUH0PGLT9^CER/D=2I\$<<I^XJ^CG)>=>M>/_@AK5(WN/MTX02,00-
N_4@<X^I_A0!W=4I2TG3M8MQ;ZG86M^I^#N\$>Q\$LB M@<N^"M

?B>QGT^TNJ8T;2.1K;L8XYUD0.A;G;@\$Y^I<5I0BB^O/M%=UX^?2YTFZ?^SA>VH^"XCSOV^2N[IAD@Y5AW%_3Z?HEAI-MJFTVOMK.#.?
M+MXEC7^K@<K=<9H^BG5-7I;M+MEIKB@<GRVXB8QOR^<^L;GY/GSD<=>JCU M^Q?JPURQ%
HMMPQ;Q^YC@<Q^E15AR.OJ33HFW3;6ZDMY;9YHED;^48>_M.D.E6IOTKR;0_>I2Z;XIN17TVRTZYTVOQI^V6ZAE=Q)@JW+E^#E7 SUSG!_<M
I^BHKB;CQI<A>2!>@\$W6D\$4@MA<^<5Y(Q\$<X^?>R^IDGENG^+H_<Y=>3 M+V\$NFZQ)74_A(Z^<I6JIN&_B^WT/3;F71(K>^FUIJ)34N1)\$LJLP
ECI&0&_<MBS@IGBM?I>U>UA_&6H^<=9BLC%)_1WMO_9AP#&S;I5@Q/(^I^HC/H^_KHK UI^MQ#_9FI=>ID^VJH660/IGDG\$;1A=QV^IDY9IU
Y)SQ@XR>@<I^ISX>U>_>UTB^M^TI/E^<A\$IK+>?QXR&C5F#(V;C)Y Y^X_XHKDI\$16-KEDKMO^>QA^<UWR MF2^EF^U03(OWI
+T/YR.Y;HYOC^6KEMO^<+DN;+4703PI^Y\$Z/)>K(K96^<M^I^U7C=>=<KPD9%_>45QX^IZYJFG76J>^K^UNX+>I^V2TD^62X5^V2;LA8^G.X@<M\$^A?>
M6FN;C<>_I7T!A;K%;645S;RB-MP+EAAQN^<_&WMB@#H^J^JN?%;O;W
MX6I^ZG<6MF^H;XMK8H^V@QG\$8PRC)>^Y>Z<=<@8U0TO6M;UI+E;NEN%M9VMIBH.%D4 M^E>1S@_E8-EXIO160_-TRWLAIV36^VZIG08V;
L^NI8\$V@J6)8_@Y^YI@>5_M1^<^7VG;XM^U^5H^B^X^M^I^D^7%R>0>_@<#K/I^T^<H^OVI^J)@<QY^ISY M8(I_>=2^OUIYIKU;?
%V&DK;FI;01PK11;RT^G1D+R^ID=>M5IO^?B2^PU^M^J^M^I^D^H^I^J>@W8AU22%>1&A(50.B^8^IK;MI^B@#TJH-
YK.G;?>RA^W<@<D\$^I30D6_BI0+M8^MI4MY\$GD\$;3J3M=R=H4^H3GC^K6U7 M^?>."Y^<VGI51JZ^YGC(\$IWX@<3;5IMOI^*24A>^*6X)QMX=
M&2I^X_Y&I^K\$MGXNU^5#_AW5((+2RMJ)@_MW=W+L;HJ9@<A^N^Y2Q9B0_M>U^45YPWQ^U4^<EU@<RLWNH18_LR96WHC-
+X1IE4IKD^>)>M>VUS7CX MOO^#EJ_9TG;AJ M=W<W^M^<N15LFI^BVX^M^B^STP^BKK;Y>ZGXA^U71M>TADTN.(SRW;32I)6 M5_%9<^*
21^VY46G^<@>U>I>9+XYU7Y MTU^I^73I^ZV-R4^G^83F26&2^<Z\$Y^X;I^<8XSFN H_B+>BHBH4548_84Z MBB@ HHHH ****"BBB@ HHHH
****"BBB@ HHHH ****"BBB@ HHHH **** M^"BBB@ HHHH ****"BBB@ HHHH ****YSQCH^<KUEIOT^>^"IT_48;Z/I0^4< MIGY3CD9!-
=>10!R<^AO4M+157F06\$UK_<I^I)J^M^*6B0RQC^R(0&(XR^I^XU MJ>@<H^C^>);K^YI^Q<2W=S+MVAY9&+0.PYP!Z_5L44
&^P2SCA.C^PVL\$B=I^8C^<WK^B^I^).S%)<J);BYL#^87<<_GEGVN^E^P^ M;MSDI.O;L/I^1_>S+A;B?B^X^B8VHMAIOV^H0I^<F02;@<N.O&/QSVKCO
<M^C;XB^>5EHTLE^I^THEF5YBWO^<I8E9M^Z^>@<L^X1=O4U^L^I^Z+I^E;U_>V9J\$LL^S;O_L^<^H4M^<H0I^<SDC)7&>6_?^*C(U^<XCI^?
VOX7M-LK^2SO."6.YL(S;N M^S)G#_<^4I&2+RPV^MY&^K^A_3/5H(HM=UG3JR^U4B(V+Q^RW)QA?>8D@<#N0HY^?J^U3NL M;_<
I^Y5D>P^I^C;U^B#34U^3)/M7=T638RY^L5/#_I^#0I^Q3^<I^9?X;WW MA;YW\$<I^N^TKJ^*_3PG?WVKZ^I>K&P74_*YI^<UW^6Z&PKL8\$#;I+9
M)Z<9K3I7>^<CXDL+007M^<PNX^IVSF^I^E61_@<84^D^ZUI^J^MEHFF3ZCJ^M^W^D^V^H)C-M^K@
HJ;XBN16&YA=>#BRV.94C(2@<#I&B^W^WKI0KM^<+4 M7-E;R06MM^M(S^<D^E^W9RH;U0I^MXYZYX^V@WOACPG;+>RP3;I@LL)^!8
MMR^.#SCOTKHZ^*6UK0=9G18;?KNEW=D%@M9+5X+U^94W_9\$^D?>Q@<L^CC-M<^?>NCP;H OI^<=>6G>V^OJIA^+>I^%XO+
M38;Y?SUJQ=N^A!>D^I^3_-DU32W_EZF^?Q3>3)NN2LA8F4X8I^CTS^D7J^>MHH Y6S^T^6_<ZOK^>Q8RVFI0P^>Z^NKB2)^H(R ISG)^
I8IUC67PIOX^?I^F MD;8H;1ZIHU;VSNHPS(S^V8JZG^I^VD.5^#Z^VKLK^D7J^>O=>O(MI@<Q^62(I^M7EL=>I^>WDC;S^I^T^
_>A7^MOKY^07;VHOH)K2UMTFD9HTW^N9BY^8DX4?>X M^I^?/Q?>I=8A^Z^X^<6XL3^>I=W%<8>I^<8LX601R;^<@<GH8SSG_1\$HH XSO^#X
M4U^Q^8W6G;D/>^>6<26MT^WGV0X^R?>RV0<^>+>#K MC+^>ECP.@<S;GKZQI8I4;1H23/I^RT;0^<G9(7D\$^L<^7V@I02#R;)^?>UC<
M^7X=I^3KHQ+>6I^9HZR(KHP96&0I^T@_<I^LO>^LV^AX0<7^>A+>^>D M>+>RMKI^C1^_/_R00I;G;W^3CFUJW@>I^%EK3ZA;YQQQ7;44 2-
+9F82;NW>=>P&T^L+SR>O M^/WO@/7)=%&J3^Z;E8)HVKW;UU^I^Q;94;5@S<=<8I^H^U^HM17-O%;6TE MO;Q6^*2S^*3@<#V^<^<OX;U>?Q?
I>NVIY9Q<=<=<N^U>)QE=ZONC /?^XY^YU MH>_>HJ^3^<^<2T^&@<I^>I^>5#^<@PSCMD5HZ7J^>GK6EV^<I6\$OG6EPF^<3;5
MW+ZX^#5R@<#D)MI^UJ^I3^<=90)=+>2^<+>D;I0YE 4I<@<=<CKUJHRKQX>ZC MJ.60>_>2PYES>E^J=CM^I9I^WQ^I^A M;Z)Y;16\$+
(C^M^I^V^<F0V;EK\$+<4G^YFG90F;0) M^>=7I^Y^?7/NM;N^<AG+7UM^<LLT^I^C8;58D Y(P>AZ&M^@)^S^I^F5(C^V M^I
(Z^W>Z_L9QI^XKB1^H^"K6I&G=1A&R1W5MG@<I^H^C^>=>=JHB@ M^#EM^T OC;HHUW5=>N LR\$0BYB>_W#8P&E8D@?<
15ZIHPT^I^RGPWL?^_VBP_MIM=+>C^H?>0^R>3^IK6)A.K;B6=7W9VXZKZC<^U5_<Z_H.BR6L5 MO8&=M2EO&)+E^21F9HSOD^+>I^Y29QV;
I^B+3^<CE>^<F=1#%YTHBA>4QQY(W ML^<I^<@<G^T^H^<H7B#2_<NGF TBZ?S;B1HO_>H+^<=<80_<6@<C;OX9MV6^2IY^G25F^2#D^8&0;
YI^NEHH^U^U^P-K^I2^<+CO_<Z MTU^I^T7+L\$@<I^<N5P^<CIG^<_CX3R9<_>I>UADG X^Q73ZOKNG;\$ELVHW^A^U^EIO^<M^<N^D8X4<
XY>^M&@<^WB.M^%<S^TKRLB13(WFC^4^YK^BK+P;JEOX^UP^PHU MG3KV>=>FNTW^913.6=>A&V&^AMW2^U^S10;PMSXOUW2?
\$TVK>\$M1L+>^>I^AB MBN^I^B=XI^QJ\$1TVD^4 8SSCIGZUX1UIM5TS7M^UJ^9M8&MKC^I9^3#>1LV^M@A3E0&Y^L^<I0I0^OFL^<M>U?<
3M^2>^<LKRUVU249V^M^<^<I^<H^C^F5YBWO=>M22A8^H^>+>@C<^<6@<M^KFDWEH-S9);7^74;R;8J8Z(R^F(I^KJZ^<8/&LVG@S0I^M^BU&QD0=

[illegible]

```

@#*FV*:=IT-HA#%;%9\8WL>68^Y)/N:KGN;BUTCXGH3A=4^V.84C($FWR(
ME1USM#8$1^J>JK^MC6%$NHH1V5NELH22XG)1(ZGH^V.D<^#@#M>CAFTOP) MJ^AX(ESINMDMFA YMF0F5#C^#8^3_NUL_$VXEM?
.H3QF41H)/N#%N6\CS4^MW..0?DW9SQC=;%Z1MIC.UHHLROG<14^HOR^>?BVN@Z/8V\10^GI-C;PW^NCBMT19 M/IX
8/XT22V6^Q;06TV66.D$^H>WOK^N^C @#S%W&D^JWC306^X^O^3 M99.DAH9C @DM3&HC9&D0GCGD @\H$UHTI5-
TOOZVG.Y>$6ESZDP7S M( F$H8G WM^FX<$1Z5Z\Z;8ZC.?9 M+ZRMJ^VR#Y.12NF1TX(QO21Z7H+S/%86J^.-@25EA4&10-H#<=<@ 8/;@#S6
MUURSM-1#QO<.;J+1/2)+%XQ=Q&Q.QWV1CB*IRRLJG9N^JPF^L.UU @I3=-(TZ+4 MSHVJ2W1%Q=M^V^HDE8#<$V%*8D#N?
K6M^..8.CG2Q1?IE6/HG^)=.?LZ>5 MZ^@ X% ^F B74^/EU+OO:PS6I027CIC)FV1(D)4?/RW.6..=ZSK>WTI5K_X3FXCMHH-/E28MAB^+13M
M;UP>.<UJ1Z2P310&H3)=.27H00QB>13(%&^V.XYZ5% X=2T(VYCT3T-ML.0%;9IY0SGY>/EY)^.E&ISC013QY%9)Y.F1ZU9&YCA7^QP-L7GX
Z C(/-ML372.G2YR^).5K==2^RB#G^P#L;PF?;CO6-J=[^BM=2Z/-;27TGA680F)
ME)>42@H..I28JH^G@ANH^N(DEAD:5XY%#*PI^#U%5+/OM(TIXWLM+LK9XD M^1M#;HA12 M5)+N>1DDJ/ZTK..&X10_$V.5$EC(@W^P#
XM1U^UKN8=%TJVU&348-LXKZ7 M_67^0^LC.5^..FCC0=5^KAETFO^N1BKFM/K/K?PSUGO5I<J.R7= @HMPHO(Q L YDQ MZ^F3GN IKO12RM-
M1Q;V5KQ^0_Y$<811^ XJ2&^*W@2^&(XHU^HB^J^M^..M^H X+1X?^VO:UHNKVY^BSU^X2VDBAM8S T+H1R2QH@U<#&X;+I;U%)=$
MTH>$K^5%LH/M) )MT M3S?H Y^&K^3^+2XVCT^OMK1&.66WB6.$^I H Y#QRT,7BSP1+.T.1C490 MSN0
^W^XR3JUG6>FZ;JOCQO^UW;6IT^M/M19YBAP UNW(SQSZUZ1?;8:1SD6 MH65M=QHXD5)XED^L A (X/O40T+2!+/*^L1)
<#;_ V=;RCT8XY^&@RNSV2 M^..A3?; &MTRS UN^#<6%WAT;H^<1^N26.&^%Y17<.#?9F. H R221N O?^FH>.^?FK M>8UFL>N)H?^1M2
#R. ^&8C9U9JIVYM;^JMWJMJ^>^!QAHY4#^WU^X-AL M16WMI^P6T.5L 5$^1A4P>HP.^/;C7Y?SWP(NIBX0BK34(Q:WK3@>=<^J
MLC$=;QQ @;=;A:VYB+O1#KZ^R^0:8;4P^=^#(L^X;.$9@ H^I^U;Y6DV5Q^I)&B26H6^*X16#&.3;16Q@L^H:3X^#;C;WEIX9^Z4 MIN^V/H@WR2^!&-
WEIM4YY^S9^"(Z/HMM^L?>^J:5816^Z;U+>+^/WL^M^W^NU^..1L^..Y1ZVH^X107)?#^L:5XBEN-0MH^6RLXV^@5@&3^1R(B^MHOR# M@
CW&>_L+>T^3%="PM:02^+BWA6/_6R00^MCA I@R20H^JH M^W+PCHR.GXDNH<5L+I9)^..ERMXX<^"E^FHIG> M36G;Z:1.SXG^I)
<<^C;R1^("18(0M:@L1Z$GDD5Z(FBZ4FIMJ;..99KJ^#^!NA M HE( P^I^?&UHT^1PUPPTFO#7(Q:1;IF49S\W^S?C0^Y7;VEK;^"?AGJ<^.; M:A)J5BC7(
1UU^=&5@6ZD$<8I /2H>71M;^Q?H7B?Q^FWU^U^8S02M1&6AR/ M)=&="EGPIHC00P-H^GF&^%MT49MDVH751C@ 2GW&B:3=W^L-
I+@B!^I%$>GH/50^VD:8H^YM.M0R^0^..IN# ID(Q MC&I>E1#PIHHLIK(/8^UG( T MDV2$<@LN;^..)^HM4TV21CL8KVY>)(S) M^DBEC&^M+
^MGC;K5RJT>G6..Q^<16-NAD74D1R+^H9I^NP^&O XZ59H ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH
MH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH
HHHH ^M^M^"M BBBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@
HHHH ^M^M^"BBB@ HHHH MH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@
HHHH ^M^M^"BBB@ HHHH ^M^M^"M BBBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH ^M^M^"BBB@ HHHH
^*W6K;^8RB*[U^TM]^P-2694-/7-1^?Q=?LK>/1; NUB7^I M1-8R^F.2%1L#Z#^). T 7+?6M^NYU@MM3LYI7^I^I^K>.-JH7>1(+^+A6
M7AFIO$0^RL8IA96^9$91/^Z2/H;.%@O1)<.(MG^+9;I^D01B8R3V^191H M$^X^I^V#^I/>@#MZ^X&;OIK/I^F(KVWV)6IH^S+<H^.'2-%=BF$)+8)X(
M Z7LAB@0$C^N /SG:2.PYYH Z2BN%3XB2W& MA>+4-M^J;Y<^VLW #1/AIXPP^0Y^;BG3>.=8%GXJM7TVSMM7T6U6Y7Y)
MPTT B.CISLAYP@C^YJT^=Q16^X/NKZ^I(3;=AY9GFLX9^Z;6+YC4IFR(I@ MDD< 6L?Q^XWNJ M-6U^72D20TV58 +29C%)=1^6:.$%
<$#=>QSR0>E^'.45@ MS>(6E1 V^I.(ET56C MN;U;OP+=^$NA.OE$<^)#1=^..JHKD^XPO;6>?J14T^UT_4YC-(B2W@:(0 M(5 D+!0O!<(^
^"K^M^>88..0=-^HVTWNH3 MS>=^&T^J.6WO+2X^L<^GD^M^YI@C;YSN^TH V^X^X 7=9UFV^I(.;39I.FSN MH^F9@C^SLBI.2%;_YR?
3%22^+;NXL17OI(TV;L^FDADW3E^G;9D1 M;2..0^&C@M^D^).LJO?71GIEHJ^W<^K;H26>0(H $15^Ij6NMZ1^;I9.7
MMKJ998R1@XISR.OKS Q_K=SK?PN0?IEA9P2Z7YZ X^/ZA:V1M$N17M(HI>Y=E=6$ MX^0 +R^*>_I<=<J^I+1+5$=U/19387MOR23F-7)W^"-P3;
<=<J^J^M+J^C^?06.MY EW<9;#2 ^)@ $G:O4 MX^Y5RUOXZ^K^XA37K1+2ZT4Q&1+68S+;LH^=I^54Y)^7^I YK.UF34I/B7X& M;LH^
%KPKY.QM^GR#E3EITX^O^<(Z5>2 L_X;Z^RENH4I9UH86:L5S6IZK;^>^/TV72K>62^AN6@OF8&2^8JEU VY.^5Z^MTH Z6@D 9 M/ KSZ7X@:T-
1071^AN^HNM^N8Y;K^?XWIS^HJ3^+8).@#80R3P.B_X2/I=? M6UA14.7>#=>30M^UZKOG(H;BX147^ND^EPBRLPR^<N^H@CG^0=; MU;7-
GL18UV.Z9<3.99F^CDMYR8+B_E@I^?XOIW^H^+^XFAO=(A34M^B6= MX8;LO^&RR^UVN4^!P^I^..RJO.ZA9W=Q:5X
MGMK7^I.UO^*YB22028^TEHP9Y^9R&C^O1.M &X=9TP.DFFG4+47KYV6YE7> MV.NIGQWJH7D^..0?Z^=I-
^1W&AV6J9O?2I^#A:5^H =G^&XDX/3>E M1ZG+<C;C9P6T<@UO+;^?HUE/R XV;1M^8-1V#D<^..B2LG6=4N^I^XL;^SL&
MN^N1&5YW6&W55+1&L;_XP1W)ZBN7F^J$D?> 5=61Z77F7C L@V@?WS^V1AFN6I^YX@^"C.2<^H T^XZ^OK.UYX@L&L16;ITB
^4)^@O+E;^QN+IT=U@C:0J@RO"C. /7B MN>T;O1>:K;O:A^96UOILIFIR)K&X,S(ZI2(BNT?03WZJ1@4=117^VOC_Y_MMW1+O)
3X+>;6^EBB6X)EMV5^_R5^H(R1CH01CO4FE>+KJCH1QWVGP6E MHHLOEM MP7U2FY^SL&
PZ<$1@&#K^*Y;1162UT4^E=^CU^*VC6GCN+HK&K M^NVHK1)3IT;C(X>^/PSKJ^I)/#UJJVDIH9P=UO;.-&P^I^OR.#W0^I:C MU?3)KGf^J-
H^I@>4LZEL 3.655PTAZ^H9&A;5W29^G^/W6 P^Y5UFN:E M<5L7^KHU^<&1(X^I^EF^Y8@^"C.2<^H T^XZ^OK.UYX@L&L16;ITB
MU6ZS;W68Y5(^*DIU5^/OYJ4D?AFIO^#B@TS7C%%^*MWOECEDC+KE M-N-IP0^NSW(2@#M;JHMI^V>YN^B^W@C&7EE<^JCW)X%0?
VOIGF6U=KCRRC4$JX MVG;RPI.3CIX^O^M^7=8T9W8^BC+;OP^4U#8
```


XU"VH7<@6>AZ|HHKH#811F=YMDRW(W|F5B,~@8V?,"&XZ"=1X M,TZ|TCPU|VGVWUX;RZMH%CEG)WLIUR>3|36FK*Z*ZG*L,@CN*6@#C-
%TC6K#M6%5|<64&S59EEMU2XDR1MB*8;CC,,|9JA:|X&U|"\$=KX5O)(K74K1\$|F>,, M021N^1N@.#C|X|:
|8ZK|ZHNEFI|<@W|AD^MEY@|S8,K>N>M.L-3L=4CEDL+ MN&Y2*5H9&B<,%=?O<=Q0\$|L^CZEKVC%?ZK:0VHTEWN&CCF\$S9RFT:3@80
M9)R>30Q06"WA^7Y/7BK16MK9;05|ZYN(3|HBRBK*V|YCM\$D?202|*..OM&U> MZ|4^<|26UA6#2XYUN09_FS)&\$<^7CG&J|N^M,U;5-
\$ABT@PO)=Q33VTTAC M2ZA4Y:(L<|>QQ@<|&NDHH|3|PYXD35_\$=X+344U?3(K<,>*&Y|AT5U|"<M&1X|:IZ &G2>&-
-,ZT|PU|EUC>K\$MS;6L<+<2Y=254+D\$@M'Z5?G MNC:6|Y|B:~&:,GDD8*JCU)/2F65|:C907EG.D|JN^6.Y5OZ@?>8?|(C
MXPDP2UEM;BUTN:1|7BOY|UK|MI LEW#R?A3CGD+&ENX=:U|X3BGTK2M/M/U|VDJ|QO%BU|H8NR1@LC(=O&C<^#C|&O4:P;
|P5X;U^47U"ZT>UDNWOY MDH7:9A>QC=^.,:,>#7=7GT#4+1|L6EAYUM<3=:@11R A4D1U4JX7:0.M.C|P V.23H(C|MK:!(|DBAC4*D:~%50.@
05)0|R3:5JGO M=?^R1^R32WLW.G.#AV=7R|M C| V|XZ|QSM'T7|TW4+6;3.NH;W6KB|GMY|MRR6TNX|>5(CWAMO&,"U6NQ
MM|TFVZGO(+>+MY9+V|E4ADG.2-WT|6L:~M-L8K|VZ8NKUFU7="+\$VY6"ML:~KGP#JL2A6=JL"WCFU|T|F7|319RR0"HV9-
W.W:P^\$%QT;0|>RTLWFF.M%>W%P.MB|5W9D9MF5.&7 M|M8EM(&@U&W%N%G^8M\$C*=POP"6|ZZZB@#F?A_HU_X=1%?:
H^D\$MS:JRL8 MGW|V6+9|P/6N=UGPMXGU%.%M|8=/G358F2SOY|VWP|F,0|O-W G("C\$S&G)
MXXTU5M.U;RU:QBOM|NHK|JUES|FB8,K8|P|H@C|*#_X|H|O: M|N6?B#2(-FGGT^~RU"3YKEE7,W"20+U
~QOZ\$SEM|Q)HGB#4+P>@OK9W M6HZ=J2WBDT|D.497:ZE5:|&X+5K2"PFM|5M(CY
MVDG93;RQ:AD+M.J2&Z9?3J.M<|H^A+Q;L.B>\$K22UTV|BTP3+=6+73+&L"GJ=%'F%OX:|2R>#|/%^B&P>;5|~XMY5695Q(58|@5XQC'
M2>W4^DVOF29(O.C\$<@0|E#;L^Z|ZAU/5M/T:S;U|J@M+=3@R3.%%&23GJ?:ME25;|4X|:|@%|(A=+;,>|*CJ=O?^00!|HHHH *****BBB@ HHHH
M2~M"BBB@ HHHH *****BBB@ HHHH *****BBB@ HHHH *****BBB@ K)US4| MVP:RBLK/SC'FUD\$=R?F' MR8D0|3.'2^R^QYK8C|3ZC>;+?<
1M6T^VMK>1M9;BYEBN^|>Y97@>+1M;|H|F|U|J6ZBEZ1 O\$>01L>;7CJ|P:~|5Z2?)5= N 0|U|0#~:|&L^R^P75M|NM/
MN_D6|MW@E|LYP^4J<\$ 6@#SSQC|F|:OX?,ZBUG!%87FLV\$L:%SYT:&0%&C M|)&,@=|374PZS' C|4M^72|19XM.CN4NO,^:92|*J;=N5-(|
|K7.OX5|7.M^AK2."N#HSH%Y:2Q7?GR W\$<+|&79|AP|DY:).NABT:68OB%>~^8;(V|DV M|F|9HHN&W|T=GR1LP 2V.O;~&3|/Q"U2|F-
|XDO|!AM|C;+1=;L:6;RT0 M+M&OQ,P^N>~9TH?&+=4T^<3O%CZ6MLUN|M\$CV#.7N=RE23N("#1)P|XZ
8|/9^=(80|H|O|HM\$FEZISE">VR.NY^D^O M@C&S@ND|35P|3>LZCKB==2EMWBM=3.W0|HAL"QOX\$0>W)|>3|JVC>(_\$#RBT:3-
M10#>Q2K(QEW%\$4H5VX&W.@|4|:~|C5X'|~|C~|HB2KC>)M00SK.FAV M5O^4UTZ6M^98^%0T_PW8Z|~|
(DOYT:3#~|*SGW|D^8^BCZL|SVZUS.F6|B#PCL AW|H-K&M3D2Z6 M>9S+~\$SY583 _|~6.2W9.V>~KQ|X:Q7X7N=+BN3;W#%);><#|ERHP93|C
M|:~P|MZEIU=KK-A^IT%BUX;~|B8TVGYHV|YAW<@|QG@5F7|C6|T|H+U M^L(4T:~>6.8Y29;59<>6|88ST5Q-
KFCW>G^+&TV&&>UDMG73 MF=C+O7;7)8#~P3W00#R&#&R (5~M5GL4^DXY|S0|>F6W<^LZK|NFPEO~^~|FH>*\$G@N:6P2
M:~X#Z=JDG>.M9UBT%|A)9:C.P^6FE97CD MB5P|M^X|O89.1CG@T=?7*AKE|J<.OP;~V|L6FJT\$SSN1Y|LWE|FC7 XP&7
MYCGD|XQQM^P0>~M2;~K<5|?V559LOA<~|F|G|^~&YY|~#GB3|H9UY= M).G7&E:U^UR2M,KD);S.@5R_%(<~.K|:
~W@f5.VP^~W@~WM;5#~|8H|V M|X9|66X=8RY "3*=ARRX|/|&3CKFH)?!~MB=O#VJ:8|/+>|G73|D+~) #TFCV V MJ2R^VVKK>~
Y80.82G9G0^W0>OXA=18:CJAL7<6CH234FTV>+&OM%ZR M^E+8SY8 W=,|O>|WT:5C|H?%&AM|L4ZUBR2?&S^?N<
M|@WQ|/%H=Q;1C379|??5^M6N^|JZ@=F8PN=G&"5/0@XH U|P^X@OQP>*7O4AF7 MP^B2O-92;TN%="PV^C9|4C)^M6V|3ZE;~C-
|TR>PM^&L0R21(D|~R-BJ\$?E M:~AN#^N<=JY 4M|U^P05|9Y|+~|:~|8PHHES01^7907.JRS21(Y53L61>1P"<\$~^~@H N76Q^E2P:5 M=TWUE"??
|+~578L5@~?7P2<9(| 2N MOURRN|0V:AV8V?T:6|GM|H|C|QO<4<~>~|L>(|(T>~MK19|4M MD1#~3;R|H^R)_B|KD7AS5==&@V?
V/2KZ6VNT^V\$NRR0&M;7R8|K|VWZ4ZT|>|TU^PG>~(Z+~|+HR3|26|ID);(P|D|V#))&=NA @15P MQ _|?
B"7P|XET%ETY:05;V>XB<7+E\$65|W|>O.1TZ<^U _62;W|>:U<~5|?0/ M~P1SW\$DY(5;W;\$ _)|~DB|ACKFLX3\$SX*8R1")SJ_YNC4Y"GSWR>~^
(+15RZW1<>G31ZE;0PW|K<7#|YI>~M^FL=2 M.V>5KN>=7MV8@B21GY|Y|Z9|UH @U?QA);W.J6^0PSSZ8)(Y|)E:0H^M
M2|G|V|O)SR<8|U#>~.9|~#0M5O~.IH>HX6ZGN-RR6+L/E\$BZX%OEW^>P6<~
MQH/BS1~.HZIX&0=O;N<~|4A|7ZG|OBN|TTO7|*@L|44D:RNH;@R:6C7<4E&T-M&>~1
MV|6N8|4V&OZ3|M:M.TW6L>X^S>6E|WMI|&K~*~8R&61T>GCZ>7^R+VWTXW.GZC^B M%(4D.UNC_K5%-
XUUIX<3KV>B6) L*5A~9@|46.2.A;B M#W XY9WA;1^NAO6^@W%Y|L^GO0|F|<1R7.AVUO|EM7U:P^VP/? M51A2@1U?Y|L^P^0U+~
XLN(|>+3K|&UUG;R^UW\$%) M|A:~LR+P3XGT|M#A M+O1|M+O4;Q^~|A|AOV<1S|PR|Z@_2^A.2.1^1.O^Z|XAT8W=S|MC<1S M|/+&
(&P64>0D LI&"#BJ5OK\$LGCO5|*32K1;BWL(ITN?^<~S|5<|J O?~MFW6MK2DU%;(JLD#7CMN=;
<~RX_15|Y|XZGJ2>~|T&#%HVL6 Q|U/7A^90:7% MA^Q+H8/N|F8\$C9@_IL=3C^>@##M/B+K\$WAS1O\$EWMTEM;|=~I4WR
MF;~HVX^@XZD\$^@K>N \$FHW\$FM+H.GPWATAA^DDA5KB7?~.8|~|LO|H|G%..MUSD?@Q#~|M|+~;~
Y:7D~IR2:7\$~\$DWT|RY|Y3|6@GA Q7HGBG4|H0~M^DT 5W6>XAO7D|M|PH5F3;G|P:~C|VH U|L \$UYVW|B3|&DL%ACO=;~^|=CYD
M3*5|C9>G|74^M6+=?*\$ M?#&KZJ=*>DDTS5SIDD;SD;@1_Z +R)|\$US37M;V6UM)+.Z6|E:~>*MYBE5;|RO3>L&Y#~^)?^"O:6&TR
M2:4=; M&:0S.BA?1\$&P?DZ9/7K0O|HVL BWQ|H5SMOZ>^K19-0U%K2 1W MQ:~|~ZL^DXZ\$TP2>*E^B|4EF33+NSM+/6\$M?M-
RA=YHDW.ZHH^+D|@A.CC M^|J?O|HVL MJ|AR|LX;~V>~ZG66X<_ (RE5PASH;3C|5;7M#12V_BY/\$ M^AB:PD:~U6TO;~^9D1U5F975E!
(8.B.G2@~33&T|NJY&DH+DL|6U&26.6MU ME1X\$ (N76^&YY&1CCMZGK5 MC5 ~OB2XNM\$U^VN;~77>~75;=|R6L4H~1G6&~
JX8@Y.20.XJSX|);8|>5W;9B0KCE1D?~UXZ=*_ OP|Q%XW|526END|J+|B|\$: M.^P\$FW;JV#@=S@S|=#43>~J?ALM?M|H MOKNBOKL:EX
MDURZ+~6|2^U56E CBC4G:NYL99F8D|>@&<9(|8:~^HJZ^+8_9Y8=0MC=2~MN(V|+~R0ON8#|QW|P^P?C_2A|K.1GFW
/A|=60A|H4&D66H36L36;|W(|~M|^~|V*~|OJN|J~|W6K Q|P^#40%>V|T33|B:Z;~ESR*~617^V<|<=J M_J.P."N^UKOS>Z)#<7UW|~|K#?
K|:SRE;BXC+JAF0=^N6R|W SD5N^+>~(M|E(88|2PME>1|/E6|=V2|(W|Y|Y8RQ&O.D8SGM7%:AX+15WEA;H:2V5+)=WX MNX|Z29_G59E=
(W&WY~JK@%\$AQ@#00:T=QXEUN7Q=J|A|3M^LGEMK2.YCGGN MF5"9A|P"\$@_+T
/U^1Z7XZ.KZ%HA%&DJZGK\$DL4=LTGR1F(L|6+8Y5=IQDD MY4<9R)+~1M<@|=W^O7\$~AY%SR5L\$CN&+!T+~W3H=V.O:~U<|8^|/\$FFZ%X M?
EM9=~/76|~NKF2|)*~|07\$4|17CM|4X(P<D?D 7M _UGD>A>K")18V0S" M3M8;9<~|YTY^M0>~=">D_#?P78PO+~
J&IQB&VC9M|~\$&9W8^|J1=3@=IC M3TO~\$ @=5>2VT%=RGK@X|T|7_6W=MJFK:~>64|U.SLOM|OLE^Q M74.2^M4N
MOACI>@27%M:ZOI8@DM;B)C)%Y|>1ICE0<~(QO600 YV.H|+@V|~ 2V~\$M
MNRCO,Q|Q|Y|~;CGOGH^V/FKSZ7H50;VDC1?>|J7&FPRKU.CK8+~W#|B|?%9 M|C^~K|Q|OE O:E|H-NME;3V|O%|<2.6W|?F4E|W7H>GJ<|?7
B|H-Q7A^~Y|L MXFFN|+OH-2AB49.AB+~\$4E2VW~* %3ZA^X8V|L MQ9M|N|HVC) SW|J&X|3Z|+XNU|PHND63RYMK|4UUX;VE MS8Q6T2^X;?
N0LV6\$S+~8ZG&* (=|^#6=V|RV|F(M0UE|42^1K^8MWFL2 M|R 5P;~+~HM4TTVDUM)~\$DBMF.X3@B1.X^|0|~|HK:M?
M|B:3_#_AY6RN-CUWOKFYDC5|:"XCG9BZ\$|00<\$#IV_+H=>T7O+X@|~ZKIU M|TVG+J6H1>2L4.7\$&LB|LXQ5YS6-X"UZZM;+W=A%?3ZQ'
M|H|A.FJLL84|74CA?E(XO)ZY|H_YU" (7)HHO8K7<~|NC&+~#?^E2" C M^KWSTP-/C>X|T|P-
XGURWT\$SBETK49|>2YCGGVY|K2;@G);@SZU>@T?Q>M;~|D|O:CZ5 MK9S6TL\$&RIG+E3N|~*W>F.4|L|X|%(H _BK1=FFK=;S
M|J|U\$WVERD:2N&PQ|O.1C^YSVH Z"~#Q|D7B^QT:5~M|>~#4K>6:SDAN#(Z MF:660;0<~#P2.V3UJA<^/KE?#>);33X9|
~^Q^4|J20+YQA\$A(C _C^W~M9P>O.KFHZ JUUXO|~R8K^UTN^X6X|N&W9D5|1OR8(&WOC>U2Y97|J|40@8.#T(R?FR:~6XRYC4R^JN0-P4Y
M|?P~D^P&&OW?AK3(-2AMH9K1;B..|>1RIAC=OF^(&~>1Q3+|5M>O&E=R6|6=E# D;+N&O6B=QC|U))Y|L2L;P;XDU/0 _@KS=MS
M15X8+~\$S2M^X9D^P^M+MYV|H|I71+H.N6?C#Q|J%K8RV.KP0X.D|H(CQ MOE-N|&#D';>~|OUEKX-|O)X^+~\$TXW6CWMO<2M|H<~(ZQ-
G^GR|Y>XX|Z M~|X234-2EU@:#96|RFEE3&W?SY2AN)E4;18^VXW.CGG(Q@9J|>~|U\$X| MDR6-
LKV.O^\$=;ZH2>H0TC20@T62VNS0|Y|6Z8Q|X|J|~|H|~2_&15|H#;P7>@OHT9G:CA@~|C|G|J|Z|O~N|~LGO# M&96A0Y0DY&TN/E|&I?~
XYW+W8(OB^WC2 QNY|MU@|O# K|JW/?J<9P.X M^7>~8M3@T^TAU;~VBNXHU9;1G3 &O\$~OX^Z M|LTYKC|H|ANIG^TN%=
(W+87|W(G)SGB<8|T~|B?Q|+XCU+PVCZUGEW^&03^5N^R MG=AAD=U~6C:M|0|O75%&TETU+~M|J M^Y79D;8:~7WK63X)|1?^X'
MAP)IOVK^T?MID^TOLV?~.OGR|Y_AZ>~M0|M^5=;~XKMI>V L^/2EN5C^8^MYIMD|6^3CLU%+XYN|2ZT?|80VZ:G?
BR6SDEQ=0ABP25EZ\$JL.P8^++~9K26^R\$LD:6YD^AH MV<6^EP6U|JHRU:6\$+;8T>~22|PH^EB0|PY MJH8;+K>F>~==U6-
+&Q:U~W;+3,DBO%&4V|&I&^<+~V~8=AX|UFV|~|~|O MRV4>M:~#>ZMV61FAF|9BR;=H^*|JV;@~1^1~|J R#Q=|>~|VSM|106S~|2
M5B|N(P=K Y|^~\$V^~|~Y|H|+X@M|HAWW^|L)~&MBM.U.YBM7Q>~\$S1M(Q56^|M<%0<=|GTG%;3%?76B~\$5\$|I=1>UG:VFP)+~N9F?:QT4#
/&3WP.?C|%^ M((O ^AK0@FG=Z5>P7\$K?;7".L3|N^Y>~*0L|V^P LO(U>VDMW9I5/&5ESO MDY)&R|J|>(|(URZ|3:~J>G)97=I+~(LEI>2M&JR-
C;P^MEE(Y^+OX(XYOC)2~JZ.T4K|S^|U:1A2Q=QD9Z^Q|ZT~%<+~92\$+S~O|D>~&~|@ MU=)~MO Y\$=U(^W8P)SM4A|GK@
X56G@AXEMQK(O|)6JB\$S^T6FH|A|F|PB0~%|3ZO|U@KP7=W36J=6GM;61F5@X|U2=Y.2">~V| MUNOXGOH?
\$N:3|@6ZEA|A|Z7L^P9\$DQ8N|~G&~>H8-8D?C^O+~|WME|4#~7G;~|>~&S)PC@?~|H^M^J|N^X30|WU4K5L M=3M-
GO(4OKO=Y%N6^>3;"Q^H \$S|5RL/CFX|T|T> MO6L^SZ^Y+9LW)6<3#;~C=@AMWR|~9-4~;K?+~|G45L|CRW; 0;LOM|E;~
M\$D_~|K|Y>G2@#T6BN=|<~|+OPMX00;L|6&YDM5#&60L|~|~|YZ|/K5&X M4;O|HW#9:GH0|N|F@#L^XVS|5ZW~M8ZLK~!
<27EE%(%)Y;D-TDA|Q?;~|DL<8Z|TRV;RK?Z_921V^HOI=^M+Z~33|XN%(<~;26PP^8X)SGMTH|3 SG STS2UQM|CXS+Z5-KDUWIMYHL-B|H
M|<6>Z|U|VGRF4D|X)OT(Y|E|WXMU^|P1M2U6UMOI_U^~|Q(9M|HT@~0L3 MPZYX) 7&~AH P^BN#F7>~9K P-3VEA|6FAM\$*=~<~.1^|B|S
POWB#|>~|7 MX_%=XJ&FZ?76=O|9YFHV7VN:IO#NBM|A2L9_Y8EO4?=/6@#H-OU?3M^V6-
MOQ=KJ98C%D;DD8Z^J|YR15?2**%Y|W1(E4EV=|~|WSGM7F|UO>))>~\$O@?P M|H>M\$6KY7Q^1~"DGRL+~SX=|0Z?~02SV|75E<6<MS^|J|D:~X
AAD^;J4=H|N66K\$5_YUS\$V8|@+~\$~|W(Y Y5^&|ZU^41F|U.POI.FA M^R?M#>~29I88K|&~?E\$&R&4|9U|H.Z.BN;U?Q^IOK;~9 "Z2U%S)
(UK+J~|P^MF^HNV.9Y^MR2,8Z^/(<~>==A|V B^|H|D@6"?9J=K~%O(H@V&FC|P67^S8 M(^?B@#O^*Y9O\$6H2;~#JV06<G<~;#
T|@2SH.A57<6|P<~#&@91M<@G&S<~8|)QCOOQ|WMS;07MM);74\$< M\$|H7BE4.K^T(|%9>E>\$ _#^AW|GT0|K^TF(|R\$!|@#U/8>PKG+
|QW?FRN MM2T^2Y;~WGMK|X:QVD|IR7^H^QV25~Y#8|SD#D@G M3>)|=N%|JWH&G;=9* MR:~?>Q374KCAF^X90N0<@C^Z|H~RHK@H?
|Y|OAG0|2N(X~A+~F2TG&N.O|M^R(74|B^AE3 R0>~3QSHW^B|F|8M.MJ&S|W|~|L+VZ~Y2#T|F5RQ|7M C=VZX&
~LHKA3XZ0|I=9NM|TF;%M.N(HENFM|8X)HY&~|X|ANP@)+ 9QMZ| MUTA:C>~@U|LMA=6>\$:UO+~|L|G=QDX(P~GKU|V~;

(ZQ1M(H44%F)M15RMEXCUG41+2M8T_38[C2I0G52]V510-D"UBFTBQXDMC%,6#7,D8!=5(X3!..T\$ALD=A5+ A85I>PZ!+3VUC!
MK%LH5J)GRPZE1YH! WDEN_)P#F@#JH4TBPUNS-GJ5LES;06BD)KSFW^(<NR>\$ M!13S:58)FMV+>YC#F!7G:09.,
<"7KSTKIVUN^U5=4L=<CMB-V,1ION M(EF9= EK@+A2N6.<%ONGH V..U&SU:PBOK^X2XM9>3*ARK^I^1^J(U7% M^3 DE?A_K@?
_0VJ&P!7Z>ZEJBM1=A%8:3J#VJ!..EB1\$(P^Y/E^8C.3G^8 M#) IW5%<^M3G?1;N+2)IBPU.1\$>*<SG^RT1QE9&"PYI+ M;ZAHP-UG?)H
JBN_U3Q9>JKV! M>IQL\$U^TA22WM+TKWVY< NSD# /RJ&YISCK5^36I_4-8U33=<%6F1S3%0327 M6XJKNK8V8D^7:2W..W0X-^145Y^?
B+Z?I<9DU#40I.N>+!@CY#HWHIP>E7I+O5K^WWB/3:12LB.BTJWCN88K^0D7^N&^H-P&RN.MH!^P.UC1G=@J.EB< #UJH>K6&M600-
NHJVT+@EB.5)4X.#WY%>1;G5+1+2:ZM^TU^1>14SE9S&YJW-&N-N^N^0)Y/P>6<1435I/DU=I2A;4(X0!>W5LNI9
MR1VY(I=3TK3I;LFL3LX+NV9>@QBFO;I<0<&N.BOK>7XNK?K(I/LS^%A/^A M<^< E3H?..HW\$>CZA;1<7.GZC^BM#%93^;Q/IV40MV..8+
8QG@G% "W6G;?>SPZL^G7%PFGBI^BN!=6;..MO%0%7<*<F7NE6=IHVF&4=0DMHO^O(V^NK\$E..A/I M
MP#F@#N.N.#QU=V^>18=<LH^N1%>#1(I%)O^W0&1D=<P>#5FW21.W+KPTL M.<98IBV>2^1%E<110RK..LY=XZ^LP(^E
'845QV@^>^HUKPS^<\$8)(M&#P.N>+..JM;ZT00_@R7_4_D2M#^Y.AMDB>4XZ\$>E.U#4I/2X?>O)A&N^V MI9B..DA0^2_3QQ530=\$BT..6-
@QO+Z;1:7)!+7&94D@(<G/GJ>/2KJYJY M7GTGC2>UT@WV@.*UUN%RT^V-K83&26-9"C/&RKLIR&;@Y Z@G O:GXRO-V
MKKHMH;AL;RS\$UI/GF0(KF-61<(<L;DYSD #)..SHKB!&CZEIM@J0:5< M7NGK>1)JR.GF2\$D& R16W%L;G0I@Q M?)\$L;SHO)" DA;HQ^925
&13GE^14W^<X.E%>12=<6NBS&K1L0%;T8;^10 MP.2^10;UGIOZ..(CU=M4LUTZ50R73S^L9!_VB<59LK^FU^V6YL;J&Y@;JLL+
MAU/T(XKG/UM!..##0%";POPPKIT^V..0JCY2> />M;PSOX4T?^Z18/ 0:0 M;JUA0>"O"IMJ^V^#0..CNM^12+J^&_O#C
/O69XE4ZGHWIKS+1;6JMIJN) MH60^FZ;..NFM6#W<.;SSLIC^J8;..MI/G^3.2;K0!V@>1) &3UJBYLZ;FK#2F081?F(S?
9I_SAI^C+>#AR.M05)3USSGH^..STW5M/UF^2?3;N^ZACD^)(FW^..49I^U=KS^PU MKT^AW0=<GIGSHG03=6EK#NVB2:2;H)I#N3Z UTK>(<1-3?
%>=GH&JOVTCEZL M)M8US&Y%>2:9>P=Q^I###.22@#1J7>KZ=8WMI975Y#%>7;+>%F<0XSP/MPKBM^2;O;H;GB/4M+L!?
1;9;H7+Q3LTN^>RJA%(P0<8YP<1@>9B12R:O)XH M^OJ.5HD7=OHE/>7(KR73O#>I7L5M#=-;VTD MOD3-M5PJDD\$X/8^M7.6QCJ;1>#(J32I-
P^WK?<5.Q01(.P!M.%>QOVH M IFBN^..?ZGJ6MZ5JE0;17VE3QHIVS;8Y%DC#1JNYIP<&IM9U>_LJ3BM8\$
MMK6T_#2R:C>@Z@&#>HKSZ/XAW!SX9;..0;5;LV17XL9 M(FG(MISJ2OR\C.9Y3(X-7I7Q^XAFU^7I)>Q^T^KIJO6=6PBDZ=I;3Z?
8FIN221K^NPHF+L2HJ@ECI!@#2HKAH?B##.7?B^4I+;XMI M^M8IO58YVS^<X;018X8.N/O\$%MF&^1KJ=I#<.;=-.W<#NTT3^_0Y 0C MY/IP!-
R@>6.>)8G#QNH964YH! MY!%>8Z7XCUNW^&OB^7-06RU->YNT4JLBL\$D92/XOEP OIU=-9)XCEFU?3 MM#L(X5O!FO-I^I@)C@B!^CY006)8X
R..3GC!..EHKS!42B#?2X<12S-JUL M=8V/R^ES^96\$;HX!213C.&S!M..8/KJQ>)-7M &6G:1J=C9QVYI6ITMT\$K M->T84D29^G.MT^16@#JP..@
ITM8WB37UT^796%0FKNVICLK6(MM#2N<# M)! \$GVY4%17IEXJBV;E#;///6KW%A<OEHTE9;XV4IBI<O<@G(I#HIO!U!M%<X+13>
(%M%K9ZE>?>S06^F3LKNDI^<LB2%1A2.5(YZYI24M^>RH **** MBBB@ HHHH **** BBBB@ HHHH **** BBBB@ HHHH ****
M** "BBB@ HHHH ^Y?Q9HFL;GJ.AWNE/92+HPLMG>LRQ397.K956^9#DCCJ M?;NHHH ^TN?AWK5I9Z1#J5E#<76HJUA=0(^8YU5-
RGHHVYD=2><1L^UM.L M?^YI87^>)+G34DD@;!(1.5RF6&^1%<2?0 #/I)SQK6VLZ>=>I;Z=9;7.2WEF% M.XB7.8PV<9/3L;OT
>=1^#J/2?>I>UVM(8I1D8=MN1D1 M<>_34/I;B;4-4UV+HYV-G+J>DK9(8-Y;&12QX!QV-W76H;5UFI>=>T)M0?WJP..L;48I&S?
=&L!A;IMQ%:M "16GA?Q&NN>+J3E71+==.MK62UMC) ML^N\$Y0E1D+T(C;16K7Y&Z^J6A!;PFH90P^JMU>^<C^O^S^H^V!..M7 M344
1O:.\$\$EFC4##;LCQ7H>=>P!4\$>(!#2 M..HG(^E/ 8-PTKE9H;YBE64 ?)UPV>W3^O7I5% 'GVI^1 6HQ>+N.V@M<
MCM@)!#5200!Q0B^HRYV@<MCO4HJ^OQAJ M^&M2U;1EDTB24R_9S(WG;X&S M&6O^G.WH^7M7>44 #K;1;K=)KM53?;^J
#GA23T254I>^ M=8UE=(U72KJUL>=TN1I(A6D@<N.UXV(^..<9X %>=5%>9TYI;1ENT.HK M;JH-W&=PCR/N8+>=1.20WEYI;ZB9X)?
LL0D^JZ10N;L8PAE4N5^<9;..^%M6U^O!T M36Y+I;3IH9)+B^V+W0A^X^A4L;D^6^9NA ZY^56U#4+32K&.^OIT@MH5+2
M2/T4^@#E;7PYK4I^+JMETC6@GV=1J9NF>\$/&YVDR> M&9(9^G_
+TXV\$D4IDA1^&7I^A/O8&^#CCG=S7H%KNQ^>#TFYIK3FN:76QJEN1O^2@3&3:YP2F..MH31VYI0+KJ
+TBMK1I>TMHYF9%1D%Y9RH.3M4<+P>N>..AAH !SM A_KJM MX(C.QMMOLK77M#NGN+6X4L;L@8ON1P5!
(<@X!Z>I=IH46O^6WB^:O^T..I M06 ?RD ZG<+&\$ 0-8^I-JOUG3M2O+VTL(M)IDE2X1..NV89)Z=I5Z@#C?&\$
M/AS7U5P>)>^YI8I=FY%G=YM^1F..64Y4\$A@2?I=<.&3I=NK25M;R:RFGF MD+>F49XHC 5Q+@>+T)O>>FICH;S+OQ#I%CI.6GW6H017DQ;
<#AW-T= M3^<(<2VJGAKPSXML0>0^WMKF73XEE8RVP..BR8^@>WD M&#CD&58>A^<4EE8VNF@>=>I96!>O:1C^11KM51Z=I
^TWPXSN;ZE?6FC;C MI3.#=>W+W^M2:XY#1;#SN=4^ "PR21DC 2MI^U;#Q =I HDEH^F18QIT>3-MC;X9ODQR6QP>O/2NKLDB11M)
(P5\$19F)X % ^1^# /B+10#IM146CWE0 MYURIW!)^Y2997+J!F@>@DCD\$&\$?I0 P^%1!+>@XD?>LP!C^>88K;H MYR^#Q.VF+=3Z4=2:2/..\$>(<+
<1A0G7<06+..1G^""Q\$;ZIX9AU_5-# M&CZ;1K5&4G>_P JH=I XPHJ5^7?244 5+;S;W281?0.6;13B M1X5BOS+^I%<=X5!^1?
#D>.>@G5-E/VSGR+C8_VOR!\$9^W1Z;N<#H.F.MT MI6=)U=I M^NTN=2^3&1SA^P^C?>@CI5^@#C1^ZMX>OM=727LYK^5;E!U!
M<2.CVTSC^124D @>9733W?>4VEZ^8^>;TT 4MSAL (FMJYRA^3=>0C#M)GR<R<0><1C10!YT^X&U21/PC_9MW=3W&A2SEENW<(8Y59=JD
DI P SC(4= M^M;X2U3O^&(MOCTP3P7HFL)4B=EN+..2!@ NSDX&WIP^/2.GN**..7Q=I M[KOA34=,TZI%I=W.6R.8Y
^R#CGI>O<=C7VOASQ)XTO6WCT2%;;3Y+J M.IY D8+^PV^SG;CH-N>C8YJHB@#S9?VOK!;?PONTTW45V)..^T2."HN^ M_P">>
<P_KI5JP>^>\$>D>2-U#29M..OUG4 M5VE%>.:>I?O?@>@S3M^U^6WEGM4^%X-VT@DGN>_I530/#5_>S>)>XJ46T^I MK
TIX\$&S.RJR^A10>ESD>M=3)94@>A^61L;69CT^..%>2%>=19;#%>M+=ZGI=QHMGA(E4?I4I2=0CI@X&>?>I
D9%WX&15W&@>E17VO2)&DU\$715Y M(9/-N^A(%EXPN-H(W<# ZUZ)IFV6LZ;J.G7^W%I<+OBE4\$A^>6Z..M^12^&-4!3Z??=>J
ML14NTV=I7=9;)+4YU&PY(<P^89!..EBR!..GH-B M2-U+3)8+R#4HH17I86)JR6DV@L?T;T^ZT<9-X\$U^VLH^AT^2SEDMD-8.KWDLTC1^
(V_6EFNKV\$K!^LSF2.QI2^>QI0<0<1ZJ15==T MW187EOIGRE2,ROMC9RJ#@N0H)C"/%6X;NWN;..IAGCDM(Q^DJL^K(I;D.# MZ8YH XNR!
>(<UJ3Z&K\$XT6WBLK;2SFM;75-J1Q0@>@QD>9^1T(I7^>U+>P^K\$^MA24O#>DUF+&1GN^UY(QES;SEEUE5^..WAIQCXB@T.T4I.N
..M3M@N2C^..)^W8R/N#CC=DX^TJHB@#19 MZ/?ZIX5O-TRZGMKJ;9M:7.Q@&^&CG.P14XJ&LG3O#WB&QO:Z=G28H?I
M^P2VUL9#Y0\$FV."0-WISMOZ^?44>0^1\$>?PV7PTUSIGVFRN8YK^0-5 MDV3^>1XRN1Q@>X1?3=^A15L;Q9^XFM39^=7F+74+1I^2
MK;D=VDY&=O(M&1SOTKKJ^/M5!^C<=>+J1M;22S.HZGB;ESDXZ="W=4U6Q73L; 4KE M+UB&7D?H/RJU^IDT21G^H93Z@T
<6J7@2_P!Q^#PNYK-WM;CMA!+##S M2P/DBJ5/SB/H8YK5T0>^*F\$>^+1T=+6SC+++;M+NR!A?4-9) 7 MG(P=W5=6L^#TZ74
3NDMK6(9>1^@>+DU8>..IM&CEG2;WG3#(ZY5U(YH;Z@ M@)!^..3VZ;IEWXSU;Q!ZES97\$42D0N^A:X(=U(XSLIL\$CU/O46M^>J1+1 M
&M^IRS6!>I35(I\$&\$)=X4+L^T;?08YSRISUJE8VFFV<=I8V^T M;1#^M10H\$51I>^"IZ "N6FT35G^<B^1%LC8Q>+IB4
IB0H^IKAYH6\$12TFP^SB>I@>#?I M^JA@GA23I/UJG;VGBBWV-VEPP27H#%>I;FZ;Y(YVW^A2ZKY0R<D 6KGFNH MHH
X^4O^7B&XU7O>.>YTYH/6K3I/%44L#14DELYX)P=>IWA;O M;H A;I.N?L>C6\$EL(YLON5%RN4YQLIYQG^/?>44><3^ M9N!76LW-E
M;WD^LHK.GS)A@CE0^K@JN1A3DC^ITXYTK;0 \$JOXRTWQJ9TB/I_92VLD% ML^C9+LIR&91=1!>NP@N8;GS/D5+<+1V/M3N_#>MHV
W64!68L4N..I/Q;#>=10!PFE^1KN3#>C;X4UB2W0735LLUK(SI? M;D:0^QAE^F2I1!<=I A?PYXTU&PY+JEUHDT>I\$KRI&4FX78R;B^IM;I2=;IY
M200:1F^J68@^DDHJ_QI#9W.H^<=1L+0+>IJD@0S.54LE^Y)XSGI7^Q M^F=>C2P2=<CP_4G TA_PJHRLK^IHYF^6077ZJ^GZU/L?
8ZE8Z=M-H6AZEI_B_QJM MT+3I+JKP^L4K;Z>7&@..H^..I^CISUJ+5=\$UV3QS;..WINGRVB69M3%>% MVIEIF6^*#D8!^!#K7644>9V?
@ZQ>^>#VE^..I^WU6**UG_9@DCISS3UVA.\$L>=<TGM0IS_1ITBOAUC7-8TVY
MZPOKHQ;A2&K&+YS1D=0SKSJO5OQMHFHZ_H4=KIDT^31W44I17)817^<(V3\$ M^T\$13WX/2M+0I1TK41^CET:2)K^F%5B38(RO13:0^I^3!
Q6C0IY>=>1=6U MK5(<3) M>=>T78DEFLGFH^&@M@>3D^3W X5T4>I M0U/00%*PO9C5?&+Q^>MSR;(H8XU544\$^2Q
4GH.ECTO6G?>K^YXO! #FL+%(M-AGCG3I0Y9C^J@I? MW?..O?&<HJV M;0:5HC9WMC>QS6UX6%O<@2%200.XYX^7@^E.5^>/# MI/M72T4
JLWIPQ M^K910V^D^>GO/97D;AIB;3IB\$6<@&10.G^J>F1M.1TYJB?VLKJ/B&7+RRR MG6K^TDCM(WS\$4#8^ECV+9Y^..@K0
Z9XRLO#>ZJH^G7=M:KB-I>%UFN<#^ M^C:Q;ZG;3CGKD Y00M3FTFT?>KJTEM=VEHLOFA%N=TK+\$\$%>"DN0!IT \$
MZUT5MXCUS A(!^RDTUKETO(WWSOQ^U+215R I2#W\$W3<_1TYKJ;>"+NXTW
MQ7IFKR6WV77KF6Y#6SL7A+^J@8^@&P/KVJYX=TSQG9K%;ZYJ^G7=M:KB-I M>%TFN<#^>^Q)^>IV@Y/?KD^YO<^
(E3PE=>^>9..TL6FGWTEO=0AY#) (BR^6 M2AZ CKDYSSP^WK^BVIM \$=YHEK-86EY^+>91WZ;?L0?EC?^51ZJ6FZA;
MZ3<6ETHM^MYK;7LGL^74I/F<+>#JH>^>I>V>*KPZEJNGZ5//TU\$#EJ^>X6 M65DWA_Q<^<TKR2>O=..=I0M1N-6T^SOIFPFT^YFCW26LZD
WY0@YOW^F17)R M^>\$>FC>(>9-5;ZM9.MY!#>P.G;JHQH\$652AIW;1RA EYME#>V<=<S&X MG.S^1MVF)R<#L>1S@8Y-^%>1^9;K_P
(AXKU7RK+I5H5Y3UXI-^S;ZQ;^&^&U26:OECL^..MA)M+HTA)4E@.\$#!0#&>?>I0!7L/5Y)HCBIM;8ZP-9?
142)F\$DPW^>D^03I6R19N1@I^1 AJHTV^@OV MZUM00 MQM;T>..LZOR^>IP0.KCQ^7/3CF^X4US4^0)U?6IG3##-1+Z;<6U
MJDG^N^XJ68^W4^N<9<6WC#6+B;1+&F+2Y/FZU)T6:**PG517&5D.K#8ZC^M @>#KD9)H_B+Q9KNH.C!>6>DP0?JDME+
(TCG8^0R!;B">17%>1=ZU87.B6>@>E6I;Q=OOW8V.=H X!(!.ICW&AX3T+4=>N<@>I U M;4=0>>3R78P-P4;3E1GHIY^E
&X/UWO#).+5I#;WUS=W#^G9+6W5IW M#RR\$OIRJ.=HV!#^O3;_O/K^AIOH4S6T_19NFLT=U^*R).DL#D?>2W0I1D M\$@U^#X#126OA^RT2^4
=>=U;JV61^V7.8D=JDXL@P^P^RHH^Y^X;103W7BF M=I\$37 M.3TMG M^5THUC=>..N0^<13CH^+O@>05YM6TG2HM^GM7^T^RLXH+RIE
M+9A&O!M;8Y)7^&>4IGQUAJ@>F7Q%XCN_ M&G^I;HMKI?V>SBN89IH^JL;HQ=Q@8OUR>E;^>7V13^>#5YI!+K^
M2)3D^ZL4;JLJ^52M=>"U2UYLHH6^RL^EEB^QVGJ6 #WJ;P/H M5YX91+6^D7LZL\$D#RL)(<^>D9^A QC=COTH Y6VDIHYI= P^#P.=)>+
M9L^MSN%;%L^>O<^L;HK5O10-0NI+PMK M;..VTG5;@V=IYJLTEK."R@9# M%6=2N2..#SG%;\$&@ZOIGBK7M4L)+&6^5Q^V)V=^MWCC"X
(<=<=<97TSWK_U M?3#FFE>)&1#W%>UW>9G)@JOI93D=ACTH ZZNPKJZOKN839Q M2^4 5 50AF(WDG.^>Q)IRIKD \$?
5_P1 UJZA Z+2NOTN_QLW2L\$UI6B M0IY6^I<5G/N3DGV>+IKGA 5HQOQHFO6AL?)TN=1%>ZM+YJ@>D^QN>^>?>M@#HJ2N+BTTRZN;6U;
I(NH6>*W5@IE8#(4\$!GBN3TIQ=J#^>#1;EM/N3+U^*M6?=>AE\$&\$T>W=&S;F#?>QD8(TNYJTWKNC>?&S.GZA9Q>6VG1S64D\$V;5W/FMC
MYF)5>1@#^<(GFK/M_ B1=<VZK-HT9TRUFM6MK>_18IKL;3_1;GH.MV;0#^_X3IQ&O@U_\$IV.EBTM.UH+I\$
(7D03^5E^T4C@YSSP^ZQM90M1UI4M^T@V97FU^M^SURC;E=>RH^K+C^X)@^!CK7^X\$UL AM>?>#S/8>^YNVG6?
M>=>U07E68QMR36CI;M_&^PL^UWFKF>GOQZK&0M;H.ZI(BI5DC^XSQP M<9QU! #AL?>1@5X?>+>YUF+<=
<@>IDMKEWJ/B/4M%TAI6^73(HGN9;F-I M 7E#%\$JRIER3GN.^YJ/P%KU#3_!A=^(>=VF1P.V;7>..IVN@>7<6FOZS+^>=2R

M0IY(8I=7"HVTD.68LI.C(QACQI5GWO@2I&CV=K83VK70UM=-.NYIBR+?)Y50 M<#HHYX '6M'7?#FK3>)=.12Z"" #5IPIX>U/I=0URZU"
[M].62H.M06"-EVG8JDI&WH56RY6\$D.5<'"D-M:5N@5C/'2Z3JL&MZ")>:K8Y:"[I@6:/ MP<.,@/T/8US5EX3U+1I'6=(TV>U.FZC--
%)>[E9N91X">@8<Y(Y7K@YZUT MVD:9Z+IHGI=H">+TAg6/)>R<*.9/O0IPY:">+I #FIZY9Z9I+PZ5=7=Q" MDF^9(6G:RSTIP)BJHMM)=R..F
?->6:Z M@YXPU #H=?U?67U@:#EGG2IC M:NDZLWVB=45G4,"->@&X+DANU='8^=1T'6=9N=(DM9+75IOM3QW+I@G(PS# .I3@I' MV1.O/&=
X#N=>B9M;C#?VY;>KIV^>H27Q)QTH =I' C+4GCU:3 M1/I2^FSM:BW^PSR&I=-X61/EC.25&=W(R<9K0C1IWKYQZ+IVE0QVMW:V3-
MW<="B2PG&TH.RJ(4@_*=05OQP<@9L/A:Q5HGB4+CP J^FC3=3G^TW\$%I:NO M@F8#>I>UAG..X) QIVH>#Q\$%GXJCI0>^I5M/I-
+IYEI#J4:DP3IIF4C^I M(4+5-8U7Q+J7@=91#I.LM1MW)IUTZWIL9%BIH@QD+ORJ#I=I9(YT>:7B?6M5I^I3M):6P&I:6G:PS MP1P%EP68@
IAA1L&IWI0.#MZXINOI77KK0H:C3:24H:5):5+V)D74)"#D1MO-M 4 @#S'GVJE'X\$UB#P)X=T>^ZL2I0T.^BNHY&+F*:86X(5R'/KT +3U_PU
MJOB+3M0T54HI@+6Z11I)&(5K1)"^LZ#I:SALLN'I9YX^:GXJO?ZI8:5&I MN=-.1^@QGN#DE9-X3,??"5Y)/WNG-.3I.HS2MK
..+^ZL1K'XFN+EI:6\$ #M:WVY=P000Q7T&J1XN=XT'+*10(I/MH&1P#_M'0ZGKX=6I)YTF62:=YBR.TB%Y@V-A0-Q(I/8>I&:8+J:0Q@UM
M)+JU>I>=M@4-NQS\$9)3M'S'KDI@^E-Q)I6:V^&>N+80%:I8R*R^63^IVD: M5P1MX^OTJ>RT/5+?QIJ6O2&S-K=VT5LLR:
O01EB&/RX.=OXI>IHWXQTBH0M>#I1T>R>".6IJA.)DF8A4IZG IR2:B@# OM9UC0S5X5@AM=-O)I1I(O2C1&=? M*W@=6XRH).?
HN:T+I+6I=NM0BT*9=,@UB*S'U7TJ^I:G98U1=RL2P4DY/&.M^>@M4:3:S>&I>D^P(C^CSB:56FU/WGOXU&W..A<#3I9=5TO4H'I)@9V*\$
MNZJKOI"0P8\$9QI)UH^Q#XFCI90X=DM=*W#BUY.RHTFY^X1A)GE.O#&T+GV MZU6UP)P>WFA.EI:3VHU5+1BOI6F313RV0JB@D@!
'G'4GVK6ET/5)/UK MXA'V.O1:<ID17FL6)9UQG@G MRV>)MI9<I@'CK5*60%MO9^)IM#AGL+*Y^RK-?V@C.;UR6I1#*%(P1_\$?FZ
M<@'"QXTN-;?P1XTM=7M(%C@M&^RWD'R

((#VE7IM9"RU:VD\$'DLOEA>*AY/!7/0#JIG-MK3M3V|>)=|ZH^J7VGM?W1V<+J=O IZL.IF9CIXZ #':9:KPHUSKOA
M74: [PR1^6=OR|8Z]|>G'6@!BA_R3'O%_UY/4W|N3-K-AX'3A>RS3H76..\$(H"@J222>XP%IYJUXST:Z1>\$M1T>S>&.6B:7F3\$A4!
MZG@')H5IO#&H1^I(=+126K%WXNO:#P>:N9-M/U"P2228&+ZQ1GC&:MAY'4.QPF^I'N=3BFG>ZT^IM'5-M=6W)5(YR-S8(I'7-5KC7:II4
MW'A_2C:Q56EJMS'CKGAGACPP'U/6+I8:7F46C M2I%:\$F*-E4@L'00S-GG'CH.M-N?#MY:~^&I2Z3) SW-J+6M:ABBR'3E'5P"
MOPR1CI"IOI@W?QO#A+V+PMG6WHI^HJZ9>P&OE=YD5=T9XR'SI&2>I=6 MHSZRIM^&W%91SB=AS+V933QM)W
'=U^E<=SWO7>1ES&ID55? W16R ?8X&?RH X/Q#K_KW@W MQ:HM(I"TN3HC.IY1&\$A!# (<@<G>,>U8TS5;^RI^&:>I+V:GZ3\$
ME=E>C>BN\$0+\$\$\$259)Z1%I'YXJ2">M?LX/>E:5I% A 8VL^>?JW2.9:252' M5<=%23GGIGH>IMKX2IHZ?
J6@7=OJ&FSBPTL:=EQ\$@'Y"RQ@'I0'@\$\$\$C'(4 M4 5U^@J3^@#O^M6^G6IEUH^5\$T^XC=V 7.S1%EXSSMM.IJZNP^C(%)&+^*=0I-
MO:ZO@O:1+VYN1YGE&S.I5USEF#MLO.9'/OYI/@+7K?PUINCB|ITZ5:#6IJ*R M>I=I%F:4*>#>DMCT&.>BCT/5\$1?
W'B(C_8S.R:MDL'FMN'5R^XG:CDG'TY MJH *F>+I2U7PGIV1V5M#<2W3VUI+ (|BTMG5Y#D@LN4P|D?>/'%5H_B&I
MOX&I3ZE=P17+Z><2&MP8TN RH4:##E1XSR>ID9JG:>I?S=CI>D107FF/I MVISWQAE+I" <2ESSQD.A<I3SSSQ4.MZIH/AS10%UUJ&I:8(-
EB'2/MM2660) M50XO)P1=>V" =#0KB.RF@O+1ID72LA3RRH92I+PW@J5A8ZOIFERWUE&R*<I+K&Z>Y6+_9IS=E%ZD9
QIU8V>#%>AU?I\$MM:L'I3(I P: MN*:G/EJ00O<@.G0 N:I>OHOQ"1.S19\$&KB.QNE'I'F5=I374\$.^C5=I= M>(+WPOX4N=7L:>">2IXP4F)
(9U3C'4_ZBH-5T^W/6BNO-OHGFW.I=O.=MOD:24 LOI/E O'K'CGOKWQ-X5N=(L9(I)WC)DG)PH217Z'=.N.W6@'A/XE
MUK3KZWTFW5+SC0+Z:5I9K2:Y'6Z'I+BCV#5?QMJUEH&I7>I: M4I'V5Y'+QK25(7A=@#/Y:3A03N7'K\$FK (I~KK\$ND:OI-I8:HC.8
M_IID@D5P+<D'YQGCI1A.M%I/GK+^ MG"(C:QXMU'F" E_KLVD7MI+HFG6W8QW'.ZHW15M(+>IZ>_&56WC M^PT(I
UG=V4MR&VD2(R%1C.<\$'=Z"L"Z^+76B^):IK739-9.&2.WMMI!) M\$0P?HN2S;L=IUIWX_#WB*X|7:5X@OI03 H9RVIMQ
CI6WE3IK\$YZKU/3T M/6@#C):I4=^\$GBRITVZ6VE36KQ62SY=ZGK6L9XIM M:7-#97"=E).DMPJ.C(49QI4DXS@DDJ^AQV|ZI<>
O\$A/^YLTGU&IENX M94+JEY1M:(I'P:9'KTK4OI"UW4M;ZG #G MZ>@H RYO@B>6U4536EGI'?
V#.XFM(CWHL0D^G&F@I:YH..#6Q'XLD0I_ M\$'OLXHL0P=6TJM0R<#EC01#M&IYLN.XP-I0^%8CL_&\$+O8YUYB(BE?I MSOB>=&^7G
'/TIZP=4M1IM;IPOH\$5_H<6I25H?%XIL8-6)7CD0J^2%?C MC'7/%'9>#>OM>M1I.^@>B>ROI:\$^26P1IM@MST'XP.G'-8OB|^T3I1?I<=
MO=6Z1O+=M&KP.VUA.G):#C=P3C&.9IUI>#+B^\$5WHY:ZOHMBK+I4KQ\$S.6 M+IMPR'R-QY):\$1.77M#U34%6@M:M&S&E-.S)+(P:7S(IA
PI"XZ|^U+M:#KWB:Q?K>B:7IND@:?)RR2Nf)QER7.I'@'988.2=2U#Q1P'CHUM9-9ZKI:7I\$PS:EQL0N4>@?IW|16:2&_BC_A%=
M9U46&E>?H-U/I?26DVM'F8+>5WY72#ELH8K.B)W-CXK72I2LRZ916G-I M<3R-YA4I'F^IC68K5I?INL^I(OXMTH+
2ZI=7\$Z2"11"50I^7D@#KWSV MH|BUN4NK*&Z7(26-9!GL".URG@"GUKPM-XCPK7>JSS3O#@>(BNR1)GL JC
M2QOIUTNE6IUKI%I:WCV&#8YVMBRG-QD\$@>GI7^IK':PHIMUX:VH9I.GF-M#&*B6IW+QMGIX^8J>N"IH CT&I?QOI
I+I@BM)KJ'7"VV0(721C@>H^C MJ<^HK6I%:X_B3P7I&KR@:YMU:7'3>:QJ9I'K'T>POO!PV_LVYFZO8\$E2W M%L2?DD9F10"!@Y:?
@9SCIN<#=#P#\$%I:5HQ8.HJ|DC#H7ZL1I9)H YW M6&NZ.R5W.%G\$UI+I3^SVRUP86D\$8FWIV%SG<5Z<9S5F?QIXDN?&6K>+I
MM=+3I+:Q7\$4IPTC##EAP7&?NHC'7)Z5C3^O\$TN@7>D?VEI:10U"YDC M?S9VIX28E/08QC(SP_.5T-
AH6L6OC34M>F:QD2ZLHK98T=UG|<5UGA329=#I+Z87.K374<0-Q^QR7E+G/2DG:4 M:~%&+1110 4444 %%%%+1110 4444 %%%%
+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%
<#I#0IW-%>#%B33=8U/I=7@TR2I73 MGU&PN:=76'14:I)I)I(YIY%06^C/Q'OAS3M#M'6PS+25'IIRTR>:AN=R?
IO:ID3@9/2J&DZUI^N17\$NG7'G):SM:2G8RI9%QN7D#ID4FA:F-I M:JHCL7MK%<:YVUI#8_#>:Z>*>TIOC?I:#IDL=KKUI+I#=:R|X&TE
MM)D13@<\$YR>PI@'K5%I:ZXUIPW(ZV16@Z_9^9:8FIUI@<L.VI.R'D M')Q73Z/MRIW?MK%>OY<IAC?9&V0:6L8IRWU:ME-
T^I039P3MH\$9EIXIYM@&(S# 9&2I^I M-2V2"WE7HKASIRW(P01CO MFN=LO'7B67PCH?B>X@TM;INX)XMT2R0W7F>Y6+87"1#9IIT
I/Z=17#^* M>%KZ%#K5RBY>#GPB6UAF0RR7IA=SMA'IG4YO X9>(GDGMK34_M.U+^SKF2VC::OF1KE06RF5D&>3WZ9X|3AIZ.VVJ6-
Y%I+O&A13I 2H-N;W4B/XN+I&@6YN:IGMOQ:LVTS).6 M<CAGCIG)ZT=KI&LV&O&=3FT^:VN8I>25)?*W.
MM)NYY/U/I^M+V.FHOX^&DTLL5UK?A0I:ZIH7I MMXU#1I) %\$&NI:7#:1OW4+V-&5DW-(OS-@IE SGOITJ:IKOIZZ?9R6IN
MM)NHH^X2PFMOI.C)D-5NG&#I: NHK\$12:XYCQZ?I B>:C>)9V_F9V M'QO8LV2 JI<=0:ID9S69?I'6O#MGGK\$K-I RVUNT*V%SIE1<-
(OFOHLR ME7(R>X/ XH_ZZBN1M-JA:EK6GZ1)9 MIWUQY37UPMK:C8S:Y&SA><#R#>*74=7LM+0&ZD?<4:01O1+(57&XA\$18@9
M&3CN/6N:CUS5M%I-^06L1A=1N+2TD9HF#^CQ9R/F/S?>?I2S#4F^D)= MVXO:JH&MV.\$PN1I2-P/FZ<=*.FV^*M%I4PSS:~?
+@=QD:9490'0^&M8#/#K8K@T:3:7I BVYOK2V^+>K:P1VP>:65-H8DGDIX&73M6I:S>)H-9C
BNMFI>RNMDFM=H<#&HJ9@1HF&8I@P/XOCGK0IO5YM8\$9FLI.CJF4.58C:@C@IOBF^I 7 MF?QK(/26UU):C+^LD#*EBC*@8A<<8P3GG-
'Z:J-IJ^FVYHV.OFVMS&M)(I-I7.E'76&DZ=I2R+IUA:V.RMND%O'L8=O4X R:N5P-KXK101S>\$KF_CTF MV.O!
(VBAI_B=H3(&W%L\$&@+CC/4I:L6?BVU#O#=#:9'<6-K>6UIX3:9=I.MIEN^IU+@-E>SMWF59P2IVC.."# M^M<-
XEI3VVN^I5X1>#7(9I@<60:R)YFYFAQC/I:IZ .HKB+O'X MA:U4V:V5G?QHT)++?4X>-74D.OVX:I?FI4VU:O>:(K^POKJTO+VTA
MM4+VVL'1C"-M=IEF#CH00?44=3JFMZ=HQM:WDFIG2V@I^1FWR.<O_BI
MZT^P|676K:EHOA#4KIK2*WN|L)OLJ1MOB#."HWIL0#@_*/ISL:AXNU.X M:6AH<(DETR9K>.%K":|3?JAF7>A"IDMM&*.WJAI>M:~K2W3:?
<>+ M6Y>UF^IEVRIY>0.XSU"2Z:=37NE6UE@O:SS0I):R>B8@J?^BN"N2' M&MVW@GO9JXM|V-:J4UIB|MT38.D:I|B6SU%_HI%
<@FO:Y9^-M+TG4D M&M-5MYI^I:HX(I9B<."&ZA5IGO/O-1L/I4^G-VI>?>"OF<61Y40@-I MQOPW>G6@#HGUO3HI/IMFXDXXXW#I
M^CGI:ZWIAI Q)Y>:YQ016G1:3.3312W1+YIYSRI)CA.X=P-J'IP MQ'6KIK <#R#>*OUPDVMZQH=B@#>397".C=V MUG^QBM61^CSD2?2
F^4I^_2M1-9U36K_6:?)+=+E%MNN8FDIZ:8'8<NU1 MN49Y.<^G(I'PI)=+I+U'4=+I7VE65I@U>I:RN8:HMNAD4/N(I H><
MGW*7%N7=I)&I"U"Q2\$6O:~#?PZ'=G:67G1^=VN0^ANKDO^X)C#7\$A7^0\$U^U EP^M#(V:I)@Y(7U/H/K4Q:DUQOPI09M;1\$S>
(LKIKU:XFF7S.0B*1OJ I#CU M)4T :HJ9: ?#EOX@%I+I+N)%CBGI F80L VXR/FXZ5KI=P274MJL@^I(G MC/I^0^XZACC((I&O/D)I<N_PNTIO-
HFI=37:PS1.84W)B&T9SD#IY6M M2QI>?V+H&O1C\$UHS+>?DQPRLS0L^0HY5OJH@:#L**IZKZ6XMXG14D1E4KG7XIA4KX.3Q3-
'Z2+2W03;W5NB2%Y\$^T>3E&W84CCJ&SUXZ5TW_ M D&I67O1.B:FUDFG75HUS83+&RNY0CS\$9BVJ"X^&I'F
.KK*@I2:3"&Z@>"XBC&E<8>.I0RL0@I:XXNR:SWA^M BT:1W^LV9N6I MJDF2)512V(T^8NH"/)SQ@TM3I9^)=+I):MJ\$VFPK<6%W%&+
'R1IW<4CJ MH=48IE@<@DI>@#MM.T32=I- W_V9IEE9:O_&:8IUVU@9J7)VFNZU^/(M'I'U1:I>I:9+N/K'9+1%52C@B= #?> 7ITTK*
&DI2E875 23AICDG)YU M1DU03H=:@T9IC&H3QM+^#I:YE7&3G&..COWKSGU5I3OI=L_#XLO^H(66RC M-IHG*IG#I+L74I:N>2?
3G%U>759_B'X/D2V@M=IETNI.D4SIT@?1^+ _\$EGXI8I M1ZE:Z8:IMK.VL<I.DLO56.A)I'V#<&XYI9IUIQ#J5CXTFT>^>T>RATPZDI
MPD+P4.5*XW\$=ID TR.V:MHK@I7Q?KEYHFH6FM=6^H^VILEC.CVT4@M1:WR/MR.X:>^IR@JEF.CE7I2ZG(FI2=9WJ(7VJ#3IX;MA70-
D1(G=5(7/O<=J.MK6WLK=+>U@B@&082.) JH8M@&5+7I:XXOI'F M4Q@&(R M)_P^QK&I(BDLD:2K0N:6AF:HWZG?I
I6I+XIGU:VBN(MFLBW<MRS0J5-K.5&"^9%<<8&S>.T=I17G1I=S_*N3Q0(I8EV8)(O?^RV7I M3Y/SY4XP>IK3GUSQO<^<
=3V6IEI+I9174.II.N5WLPPRAAN^IV(QGOTH M^L^6I.GUN2IHKC=?P1'2'28PVH3@'..GT<X%I2-X)T_P5R6^EI-BY M2WO+8+
(SR9GIEFIMP<I@I:IGU:PWQ>U1:S:Q2Z:@P?O+P.R#_D_A4@G/MU&?IO:Z-3&BC:I)C4R)D^Q*YZX@O_+A8&O/HNG2C3I&4AKRZ)H\$+
MQ029Y.YZ\$8I<9IXYVU3Q39IYVK-HIKO29I7)26DC=PV(HDB+ARQ4ECU^ MZ0.M'7&^D614DNN0K\$Q^O^M9N?I'AG5I>SL?
M&IZJ.GBDWJH/MF.A93U7EIP<9IXIX?&NH:~?^)+Q"MI.NEV".A%)91M^O1BPV\$.S?E<YI MIH0WE%):>^L9KZ"PFTN:W>2ID@I1K-
PNX=6/F*>1P>+I'Q:QEK= MI:ZJEAHKW5G?2(9:I&97A@?IOCI&C%1@D8P<I'C).VGL+YN8+F>T@EGM MR3#I)&&:(GKM)Y&?K%&+1110
4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%
EH620QY^4X.O#GKS'Z^B@#F+IKPY=WIU?G:>DV6^M@2BDBOL2:HR_C7:MT4<7_X4ZOX:U+3MYMI5UC.3A1G5S9I0?>9X"/(O#IIZ-?
@EV6IEH^SGI4\$SD1%I M=O..XZ8I3P>M5AF6RFXLRVNIQ>Q"?+8SOW SVYXIQV54+C6K&VUIST MB61Q>WD:R0H(VI94QNRV.#KW-
\$'AC2YI\$..I(O')96T=OYD><.\$4*#@_MI.XZ5AVGA35:"+Q186I:8I80)KKSRC"6#SE=E10P7B M&T.WNF6G@6T0?^U*F
L2&#OWJL\$^R@IL("2??4BNZAACMX(X8D'1QI\$1 MIT P1:3I-VZ370@B&M\$PRA&F"#>5I>N/I:..I>>?OQ:X2N1#M)X+?I5LW MS2@MM^NK<
=<I<=I:MZ_H(4I#K1M1R6N8P&D@)EN^S5ESCHO0#6UI10VZ@I MZ:XXNM^U06K&^IA"LE
@MYB.S8P&E:~)0:GFL2/PJTF7PITWPP+VR.ME=).+ MC:VU@DOF@?2KOUKLY-L8M>AT5I'1I-UPB>6V"BD G=C'4I.UH4>?W_@C7

[illegible]

01D9QURD'@YK3Q^H^I6VH;;;2|^ SXK M=X=S-&=N27W#YOD'*,0^*=9U#X27/C?3;E^CB\$UQ^H/Q*8W@B=@0S?>WE5-M)R#@'^C^H\$?^
^0-WK/C&QT 3+^"TTZ T.;C&7M=|D9+H.YP3A08#/0U>@|^ M9-'U#0+;4BF@WKR,Uj8

```

X@X`S'ED|P2EOO*2P+@8KKH1*LB9I>3'S,B%0'H"3C|Z/%I,MX|=*KR`#JY?PH,AQ=>=(L+>26.&T!:%7D|QAG<-OST'&.>.F,M-
FL,W5IXET,69M1@SIL4L1A|Q<2B0/SOX^Z,=<+1&9%>.XLU23I&US2M|MN|H+R1|)I60VZPBW?NC;1^JHCKP3GY|TKM=7_P"O+?I
-7O|_P"/FN4I/P>=>MZ*%*,U3WG`"/+*9(I,)*H"<47YIRVS/88X|G/6ZE;37NFW-K|,D,DT;1B-M1XIX7(OG&1G|Z/-)T#5?&
P9|,^:U2WMI44>>^FE'R|H^L,C)&=<# MWK|, Q57^M9T33I4LK;WLH;6XB;2TWDJS-N0_-SD+H|ASFNB|Q?)X8|;
MV>C/>+=I;)Y<+^BT|9ZCX@.H|NE|H#`UM|GQM6/W#; MNOS"/Y4|)KNST6|G;>.:35@1L,QRXCD/*^PX|($FM2U|-W=GXKU778M1AS?P1PB-M
V|Q&A|H#G2S|XYZ9|H...MO%,B:7P3X=152WEJ$N+|J^WN;+2B56E|HFDY M5L|C'JZZN/6-2'Q-N=>$>6|)%=(6|BC$>U@YE*(6U*/=)JXL#_ML1A0Q?
M<+B|W=Q/IQ|T 8&=>@.)|NYB74-3>VU+WBDEU31K1V6|T-1CF5|Z=0.%Z5|Q^>9:F,M|TBXU|_BU|!+1A|Q(1+&R|Y)|R&F1MQR""<@.9.%VQ5+0/
E_H$B647BBE|ET*~M32|HSPIN09R$,WWB@/CCCIG(67Q|T>OXIDTHU@OQJ-2WL|F|H1>6H,|H0=|A&|QJ6G2QQW5L;R3HTD>1?1,1,9|_P#6-
4KW-MPC=K"M|HJ>|H|,ZC>WH>.:9K$|I-I;|&MWE7*,KYRW(Y$-MCV SQ/X9U#Q9KNH;D|ZK8|;Z=H$90^|CYE15
7-1+<$>|>VME""<6|H0|T=|C|VJ$SMN(8|)^@.49Y|52|_#GARZ|C5|Z4%<+4-M+V6^_P"/8H(YQD22,5X""|JZ-.8TWQJQ|DG@K1+BX>|%15U25GTY)?
+PD8$TB_M|H|>=<(G-SR9|UL?VOJFE^X/#ES=BZAU*Y2G|F52|>4D>-RN$VAEP01T/-MGK4%0|D3C#H<+Q|J,|E|>F_LKR*(A$WF-
(#+@L0W+>AQO|MI!-<JZZS>V-MD$^10V$6UNR6Y2*(06,90))!"Y^<8# QSD_P_A|H/B;Q#I&G|H>HVC6D|_MJO|QVVMXE(5|V?
0$8OZ=3DTGBH7S?>P2;PZ|7)Y|EG#,6P1N>.6/147B+PS/K,K;-JEG-MJ9L+O3'E*-Y(E#I(NUUP2,^&#SCT-&9.;OJ_B6+O!<3>K9_V9>2V5K&T2
MNLTD0&XRY&<#B0-14=>#3FMGP|KPI5+<#JUE$-NUY|N^CG8_*MC/4@X|G#X M3G|T4-6FTC5/LMOJKE^XAM_V38;2;
I&M0^00PR,^U>D;5.;1%H=C^MLM;6)8HU^R<=>2>Y4F@#R<.>)/@_P"/9K04;F|87-1%F8+D|F9-H;(^P|OT M*8^NK@U76M^15^&K&
|O8+BP|>UF|@2&9J;#7;5L5MD9|S|>E+J|KEM^M0+|KNVQU>:94;T|_FMN<9W#=#ST&G/G/<#Y|+7=UK7A|46U;$-HR2$%M|<3;TV-
GY^,|OUY|>E&#>:(%>MZ|HVO;)835QW$P^""M|Y/&<+76>+?^1,|UW_L^W'_HMJP-G
WNA79<9P3^M50^|HX=>Q;NOUR;M^_SBM;|H#D=A&I565V|Y$YX.@|D?M|)7XBU*P(UE<6E|JVOVTC7;#>=<0%|PYZ
|A0?;1.G2&B^_W)A^4KM|Y$=M|N5FM(8P@90.C^8*<#59L|-|8+X7_UU|A^PZQ;K+^F|D|L^X?CY7J<+|I.M.*V+SP_+XSM/$GVI$2TM9+|A
9RQ9&(9CNW=3(%QR.N|K<=>E=RL7|A8I6|I^@.S@?^ID#BN|T2.0_M&7BBW|6Z4LLD=L.O:BY>|XA(S._&)^V-ST>>QQVE""K_P_EK|_J@JZ
M_P#0EK3UK6KB^O+.;#H|_FW#K+>3R6PB|P^K(@QYA^|EN2<+|C^0^|75_MUXWL?BZE$@L|=|=+8VQ.Y7(+$MOZ|_#^X4WQ3X0?
7KW3|4T_59M|UBP+""|MBC$@*C&Q0|SV|Z_P"-;|Q37D_P#@#68K2_Y40FZMWD4*Q;PC;|H
M|7ID8|UJ=|XMT;5_#^GS;Q8W|H7|T32^RVX3RY=|C=VQ|3Q55_5/U_JVA6_MUCI^HMDMW+@|HWC8;H|BLH501TY|Y)-7M;1_76L;MH=^0BA.E2F?
M9|F+^5RA0_QC_P3@<_4T_%M2EN(+)-1C8WDD^|HBX7Y5AC<60|/P|^|VK3PS>_M6?B37-934H2VJQ01F)K4XB|L$*<|>=>F?;L6P^|=
H4^A|6B^R|Y|&BEMT MD;S#++|Q(2^|AN;O#|J->U|7M6UGX5;Q/>S07%AK^V|WC14|_8N4C^<8X_M.UN0,+O^K.M>|J6|3Z7=QPL27|M+
XE9)8X20?_M/WMS;6^Z|C(ZX.6KXHUG6_$(AR2|N^N=SL9FE|W$EOYCO$;#US|Q^)|M|U2
MSNXK>UTRS-RAM|;D_NVVY^=>U&U^;J|2&C@#=#02LWQ#_P_EA|_J^M_P"@|6YX9|S^Y^6;2^2Y&HWSWS M|8#^Y^N
^AOR,*/UJOJWA>|U^Q=IFOP;G|^G12OPPO:&0'S_Q8B09Z#&_M?C0|S_Q>W6UCX;U^T^74|6H$M77|QWY#)|!"R.^*7Q^XIUG1+^7|Z^C6;3
M71L;S@B$R-%A23.VW^%LM@;EX_QFNBA|A|^KUGK&MWI7TUB2U|H;S(H7/&_M;DEFT^6..P#8U|;F|H|>GCO^_INM3/<_H|F5GBE;&?G)RR?
*/EP#P|GU^M^Y^V2_6P4E^|D|>#^KNVB/O9K>B660^0#83S^M^<+1S;K|00(^|7$@+SGIG(VUN2>|J0O6E-VFMLMU:6C6=RLJd7$?;K6
M^_Y7WZ_X-J&E?<#^|T2FEM|37D/AZ65|H+|A^4W+^|DI^95|)M^S|SY|YH|I^M^|J^H=|YMAV;Z;EHQD9_@D|7^|I?
@S5X;FU%WJNH6|M=%X,@K(|_M#C|XZ>ON^*|NHY9;66."18Y64A7=-P4^I&1G|ZX|+X?7_/AGP|HB;S^Y>BW-MD=W^C;_DRF;D|K#?
P_DYQUXZ=P^YH6|;O#XWU7P|HEY>P;0WMO_L_B^H|_MK|O#R_5R#U|U^B?PW+K|TNE7-H^V&|TVZ^T0RF$ _M2J_X=U&SE%189N@$K9^28P#A?
7|Z#N^Z1_MXXU7-|>+10P2^U6RENKEK4|E$955L3C^C+;#SG_!X|CH+PS>V^B/6-97
M5(H-2ABB*^<H$^V0XS|XYX>+^PT^&D^P^A^0L^TU^6U30RXLMIAMQD(M_P|Y^0L0P/U^|H@|1>#%I_$.D%
I%X@M#$T5P5M9V>Z>?J^ZHQ^L_AO@^TK^N_M|H|U^Z^<=YX>M-2@M;7^RDNXY;AWC8R;G2$&2X>-8QQT^HO"@<^IY.35>+^I?
&T_B1=0BS)8BR#N;8D^H8N&W;^3N|_M|=-3K0|Q|^_6^*E^@04RZA>;H|T8-BW2U^V|^W^E,22^|T0B75
H|5M+^4XX=06V2WL|H;16T0GEED^?2|_A|GM6U|W@2|L)?^SMK_-M3^P_+142M9X|U6C$9SA<_*|CKSD|G@-Q_%U?6WB>W;68D3Q
ZM^19G;050N^M>=><M;_MFL;HOC/0/4+^|WNK+6>=>C$EOL^SO&B0^K9|8$@Y^HQTJH<_M|O%>LZ5|FO;|H|Q%=>3+
(H^*=83;DX<5M^|H|@Y|L;P%;MSX7N|K7/#<^J/_M|4(2$E01BU);2^4(Q^_OPI^CKSZUFZ+X_O="GDI+|Q/>+X>_4R+IA@0E_3DH_M)3|P0GL_#|Y)-
$=E|FBK5&N|N;Z;|EE#%;5>6|FTR98GC^NF=W|P@Q<|=M.;TOB^K&Z|X-N-3T|6&_XBEA7|H^NW|Y%0@<?>ZX^T|U|H_AVXTOQ+K>KO?
MQS#56B9X|E+|H^#%PYX|Z|=2G<+^_#TGBGP_+1^7|VBRO&12>3YA^1PXP_MPH|H^#%N-4|0?B^NMODN+I_6RMXXKGBMT"?I
(VTMN?J<+|9Y$^M_1^1)^L5M-6M^CO+W58|F#3;J;RSOC<%O_D2-B-RA6X|^|QTYK7|3^$9/$2Z_M;=PZK)IVM;Y>VOK>($*6_#J48G^D
<$|JKZEX(GUKP|MG|>07_VJOW^74&I_M$|L9@E3_P|&_D|DU-2>SDT=|P_|8D242HG|I^@8_M|P^..>P5|7ZXWPEL^|AN^TGH&S^I$^D%-
V8>1CCY?3O4NF^<8_62UMM3_MUJ_-OCX?D1|B0Y;ST(4C^P>|I7MT|O;_AO^AFXA^Q^2%O(5|6E)^#*4^8YRW3VZ_C7+MZ3XL|3|X(?
Q=J5|9S6|VW;36;6VTR6B@SG)XZY?5^XGC;30$-M3C9V|T6(A;UXP&+AB0XR^O#8#^6|VE>H;8P1>=>M>
```

[illegible]

[illegible]

[illegible]

[illegible]

```

M?R?#W4'RE;K(V2/E')>L#5#=#>(+735U2|E@^Q.ZVEJW^E/Q_P:8|G"J@&0.MD.GCGI7-6WB?7+5X?^"M6?
49$N|O5|>TNRB(|:AF9#NXXR'W<=>30|Z|H7|R.M?VOJGQ&UG11KH.Y$>6P3HL"1AT9F<$*Q4X'RCJ"?>5E.%XOUC4M"(64TOF
MWVJ&16>966|H:L5P#@>A2W1..|G@XOU^ZC6..B**/Q?X=>UG$TMH|VLY^6.M55E4@-1U:WLM-N'<2RP)?*FW.*Q7.VTG.RB*UM
MHFEE<PJHR.H?K5Q>:JHE/I%Y.IY'W$5RX#1.L-I.NX?Y?<2NGZ@FL|XLF3.MX9:ZPED39.%L(IZIKGB7?>=1.7F438%4P7'Q;))$+ISE3N'Q
=>.#D'MTOA|^UOH%FNO->MJ.MBIMN&MSE&8$C(X'48)XZYH.A\A^B*+Q.VIK'.SVS.:?>O92+-MR755)(VDC' MS>M;
>00H..B.$4|H#6+EQ>PU2|N8D|1/G=(4.YRP.5..#?2>.=+9Z=>^M(O%-GHQGD(M(HL6I3^0=KRO(P.4-U'KR>..22.<#1..B)3Z_%X7|7>LSVLIS
M#..KO=>M'N'K|Q'Z^U'JOC5P/O%>2>(-7U'1^/Q.T4IC%GEMX+?3SO9FB..I9RBKNZ@?SN<Q
>U+S+M-|('3/E.%//IV<4C'=-T5?R?6'5KC1-UG4M;GO/MVF6SFV?-0D.E.2P(C.M&2?7)SNQO:G.H'X'4GG/2@#IM.M00L2|N;^1E$5M;1-
+*Y.A51DFJ&GZW<7FJ-93:1>6R&W6XBN7-)U)QM+M|..=-4UYSXB^U'4=4^%'C*U.Y>2ZT.XELS<(GVE|L96<8SM<9P.B05-
MM.LUC%YTLWR@H6R>G2@>+&TU'6ZU74+1.NH(H0Q4+5F0(I?C?R7>I76L2$3914NFMK2SMY+785C.%?%?(S)2HHCZ
MKUOQWJKI.ZO|OPQ|7.G0.A?6IM^=10BM7V^0^3..LLXZ-M'Y('H|H.MGO|NIVVK:*JU..M+J4N'59)TV2Q8Q<I=
<##+TY&3P>21J6QN'&6V$C$EQ(X?>SF.PHH.IZ3IEOHNCV?F6BB6I.MI'L.8/7"C/O6=PAA-*0:IK'.C>33.D8S<1RB/9|B|5QA01@>|7=)U"YU"
M*Y>YTV>P.*X>%%F*DR*IXD&">5V..*V@DGFD6.*2|NOP%4#))J|.P"=M9V.TC^R|K&J3H|JVMQ)&|L|/PIV9(W?WMV.W|/..7AA(2%..B
E>=-M36BVC1L(|@122..%9G0|Z|2KU|Y.Q.ZA|UO|H|J|S=-LEPN8RH2W.7(+9.3G.MH?..*|1'@#&1>?&#GRV50>7.S>1>C9D.P^F^ZHX))9I
|X'M.06|2U.M%=>3U&W35(EBOK6&11^M78IR5+*O.RD9Q|<1310R4.6R/H=E|J^117&B.MMF5O5..RHNS8P54*E=O&O:OSEP|<8$..E|H$|
&#SNA)K$5$W=>N0>M.'GMC.KK**..6C|S|H+|W0|R.6|3GN.'W^2IGE?7078V|L.FT<8|>O<+?+3MDZ^M|<75Y|KA5KJ&4H%5E
"LA5000%<|?ZJB@#M.M.#2I=655>ZC=W|U@C+..MO<..Y98:2YVJ-S|>.GU'/|I-|X>M|0AMM|O)A>W.ETS3".F.20Y8KA1WY.MP3-
<7|U'1|R'>Y8..L2-N%Y|3M..THH.E<..(E..|37^M'ZN0-0A2^|LJ|89MBE5+KNZ.1@?%|U?T%M
'6G@JSM.'Y|TQKRGITFE66'RE'4YMN12VW|?#WEI'K>L7EO@.BTMIN|K74M'1+&74|..ZUNOMB5|C(P)=O.=VS'?Z<=>ZFB@#DM.M5|
VYHZY'K5OK&JZ|7DK|<3V4JH.E|TW@J|GW'J=K|@.3M5.LV.'JU#3K.M.3@5M|ZTFQ-M|P..8QC@("FVO@RVAUV76)J2U"|NH+|Y|HME3).2
HYGGHN.MT<=-3GI.*.)PSTV3PM..%J>|IRI92+|8W7FJLUH5^Z(V51TH@GLACH-TM@+)"E.C?C..6
.54Y|Y4@>XK+M.A09V6GZ18Q.OJGD.3=FIM59HCA.FP^M|G&|O?GKT.MQVM'..S^"/O.3U|U@BYN818MUMKJ|V78(|B@A=N%#C<>
(-9NCL.OF66G21G8-|Z<|)W|ZG|I06GXA|4V^@Z0FI+|Y"UTM|G|Z@.(QD.MOG|I-OP#TK>H.SM=2Q01Z+Z@X/
M3I06M|X82W|3W^O1ZC>?..V|8'C(CV|YV|H|LSD$D|D|>.W&944LS|549))P.M*S|VOV'B?18=5TR0R6LK.JDC|RK%3D=NE
$7AGPY|X7T9=+M|JYN8%=-W4W-M.PL'|FY51GEB.31'|VE.#H.FBVDS&.&12|23X6WVVGW%SNAA'.8$MA1.2W.Q:R6US'=P3VY7?(A
MRI&X$OP14OX52W12MKW|J|EVUD+|B3RRNP$SL$S.=Q|Z|F.F.Z"B@C3|..M.K.^|H..M?4OLOVW|F.6=>S)YGF=?+QC?
SC.Z5|7GA=KOM15M8OU@U&I.W.M.(590C8$)7P$J2|R1'5=1016BLTM-CL1FMXXHA%$4P3&.#&H|F.2-O:J
M?|C.7'8B|GN@A8^=/MWL2^EU02326D1C|L$G#&4$Y.P#SM|S?>Z3F|L.MTT+Q1XENMDD8EM=0TW9$(P0'..T28.W..
G..9KU|B@#T7PM|HL^K2'|N;|I.M-4G.XN(K@1E=|*<5&1@YZ5F.%|P.<@6FK.NYFOR>..#IDESFWB..1@M8W$|@X$SRHH.XX?
#NR^@+PR.M-5U$6.4X5.W79$6F@9V8QOY?>U/U/P#;7OC6|76-5TS4)(EANI&54^TJ.MO-W@J|GW
%=>=10|SS^&2ME=>=106T^UDLK&WEN.MYQIR|T^W>YI3M'..N.PLETH.6FMZNMME=K=V(DCO..)/^7Y/F&S>S.M|L5W5%1/6?A+1'6-
5U2+5.W&H11Q2|+|41@JA7Y.Y)ZYSGFLO?AMIT6B.M.186^I.C#<..I-87Z&)&H@WWE^|M93W|'=-H10|@:'X4AT/5|2U-10K|XU' MRS
|47B#1Y&UW1.5$HADN..D'HKS7XO$5|PW5|>..U8HJE9(MQ<+JZG|!..<|>|1WFF.M|A|NYT018G>^O|VRRDV^@Z%8Z3.YBS
M@6%>K8&GW/7|Q.P#A+*=-5M|6|O+6PU5VDN|(KL9G&^DJ63<N#|&MNGH|P.WPK.7&I29|
GB|MSNB+^ZN74|F7|GVJZJM.M00B|8JKDK@>Y|D|6L=OACI.M5?>K&K|CJ&H@V.PU597J2(D|N|L6.UE4#1+|@H'F|B@#EY..MA?>)|U2^
MU#4&G97.|GF.?JZ|HR$|=IZ.#)SG)RECX*6U|ZRUJYUW5+Z|M+=K8.T8#MHQ|PP5|Z#GJ>Y=310|D^)=B|3Z%8.W.2F55X.M.P
.G%=>110|A|X91..%B|MIN.M4.H.O1XCLH2&..LMSDD1?X=1..I>.$O.MDAO+FY|@=R7DGG|J|.6QM4<>U.5%
#>=>#H.KO7#XABOIRUNDMOLLBOE=DT.M8>?P.D|3T|E9C?#RSD?PH|AU|5U%K|4)WGF<^5O|I=MI'9@M.MSTKL.*
M.1U7P#>C|H&L0.QJFG.HL(@FNK'$S.X0=Z|2|N/T%=-96D=A916L32.D.M.XW2.79CW+|DDY|J.L44#7344<=>PK?1Y$U.2;JYOKFWU.Z.
Y(991QCF.M/G|@N0?E'7|3W-6/P6+?2.RRN=>U>_DN8&MOM-U.KO'&W'|'#.M&>.D@DX' M/ KJ**..0D|30M$|L'BN|KB&TB6&YMN|8H'4'..
|2|E|99M|GQ|0%KMK<MSV6|+>=Y8=1$T6<|75@0<D$8(|<<5MT4|I'|+|W+N@..&KN&^D>6|G.MOH99W79Y9F4)P.@>
'|@N@L|=K6TB@>XDN#&H7S9.H9L>NT.2|4|'AYW.MA|Y|U6KM2>INYFUB-(IF&39L|H50N%&O|HFV?>).DTW3K.VU|5<=?E8'
MYM|+F@D'1D.ML..00%$NE.Y876M.9=S"72KB*Z.6.VR#E9&*KO7<..Y."><@&HO.FL77B.MEGN|ZXF.M.S3HUM|H&8E&%
|9Q02^<H|KAM|S|+9TB**5<@..D|OX.M>..U'^Z3>)+WPCXB^Q7$U.P%KKD|8>14D>..50R^YJL4#-'P3FL|O|J
M5GK7PX|8BWOM6CDM88-TV=TFM'R?E|JRR-UY+X0..=Y>=>6RL.NUAU3.M4|JO..|0.3?&2;
<5?7|8P2|D5$=JDN|>G.A8Z0.WTUSIPIH.UH(612|S|B|D-1RH|ZD@>^>W5X.@EN&N)=7U6.M6?279X9))V+|LR|27RG.5..#
'FG1>#K&779%U+4^M?|R28N/EV97Y.M|EX|GS0!@6.B..N|P+|J.P>PU2Q.U|'.E0/8Z.@M=|4GMM4EU'|N+|FV&H31>|P7Y|92.C9|G<
Q|R.#WR>A0.(FC77A.3C1X.M|BTS3K*2=+FR(2541N|J>J>VY/|K|UO>PBY9|2UB|TPGD'5X1M.&YW8&U6YXV>&6|G=Z=>2210|AE9
|TVS|Q.MY.<=>L5S/GZZ?WBZY.X2341<?>Z|C|Y04W2+&JNHE.WY^N.U
```

[illegible]

[illegible]

[illegible]

IDGOGK<@H Y.:3.30?B3X3GL5>%M1M+Q:YS(S<)& MC*7R>2"3S6"3"EAX.UG3.\$N \$\$.I?SN#>7D"HW<<"U"K/3X?A..(Q)H5J(S.)PN#A7IR
M-ORC)Z>_H_ P_P E6I9_1>VG_P#H\$E9\$M0>0P4Y)&220.2KD #. "IY9<1<>?H< \$N M8\$AMF9,,
R_0G>64_1@K+^1(50%15OHWC)859M(NE%V M02UM)C<=>#+&XR4<1H1K M@F21_%NH1QV1262B^=IN(A)581G(HAD<3\$?
48ZU:0?"FD:A147T2:QIH M.*3:QRLBDB?/SQ@/Z@'M7HMC:SSVLT\$\$.26K%X&(YC)4JHR&55BD^4X;MfW.>0'4C5//AK6H;2'4=&M;A+0.8-R
MD%IZ CG'M5F:PUHUA'UDBMIXQ9^6S((C'R12_..I/Q015/@J&VT:Q9XVT MRV"VVF6ES;2Q0H1Q:X%9R.1.3S7=IP90RD%2.@CH:QV1*:
f:DSV<@>G:M2VMX;2UBMK>-8X(4\$<+T50.#1*.'X@2DZ12_1M8.N/1.5QNI6<5UI_P
%D.H3C<#QOYAP1D>QXf@?""6B%+1#9L5T1@V@1^3HP0.#9IW""TXH YWP590
M:1X119Z58IY&GQ&RFBMU/R1O)&V1.V2HIOB/3K&Y^O@DW%G:RF7L:LADB M5MX6*"@Y'(R1Z5UMKH6G66FW6IVN40;K
GEIQB9.=.Y.#CMZ=J35O@F21 MfF M2QBNOLTGF0I(V,TV(ZCH:/9-"T17\$WQ/74(3/5%MS&"YPC7900 MP.-POP>H|=3531M8GU>Z|
(JMW>7=>DFB&HSPF.YN@.D.U<^1G/WF M13P3POH4E (EHROJ Q=D3.1.3YOFYXX^G2H1+OP1X.O1 1K?2+020I&V M.8(I"Q)K<..> <5R
MKQ+XN12>+=\$OIQ3X(BVE6".YM3)+# 8D*R1-YBf?F+-D#<@XR>@KT+3I.LM) ML(K'3f.'VM8AA(HEP)UF:QX+!-^+^*^U71K2|NH@
LLB<5/AKO\$TQ0K75E.-K M1K.L02:AHRS6V((QO@&f2%3<CH>IKT"ZL+2IT^73|FWCDM)8S\$1)7Y2A& M.8I.4EHIJG15A+8WMM4%
<6DJ1AD4%6IB@#S_5?#D6E929XINH1W_+O-EE_ML@O.&0\$>P=L\$Y_..9'LZ#3+73%&FJ6I.FI=&&">SMHI(9=(V2)5**8H MS@8'
SDXJSXAN_/^C AW0IY%2IFVN9A(C.LI.FW_+15W'HG/85TEOX?T MJUUFYU"QB34+D 33C.7P.23_..E.UH+2:5HHX(ZW641)(FR5-QT96&"H
MP10/PFGV8M)>1.Z%Y*2Z%!.PW\$%O(H..WE>-BR(#P!D!L#@9XOFMCX7VEM;_ M YF*6"WBBDFLHFE="\$ESCJQ'4_6N@_L73_1/GI?<(D7)F'F-
NE)&"6:YB M1P@1)P/84 >=>+^1(+4I?&D:W4JE8 M19IKT@K9.(F=5MOC(8Y%L@90C.."+1+1 B/X=F^6:J7HLS7.96'FD11 Y
ML'GECGURO14GU^2TFFWNYX +ED8\$^8N.#(Z\$@<X R*2U1Z93 MV.UMIZQ26"E+5DD<>4IZ@<1^_KWS0/PFE>%;7?
#OC.PU"##0."NG<16K'&M&RfP1=Q.1Z\$C071>#.#I?Q7;9.M<6*07&FP&FDC.8'E7.<2I/0+M&=&G-7H M3.GPH1+=^%
%ANIZ|N5:ZCFO&C#@->D+-G+CMG'KC%:&DV+6&GK%8VN'9I MIVC%:1V+1.WODG&><4 \$|"-<)HJ|=RI=,SA'=8I)Q(1^OS@-M1\$J^Q_%D-
KX2T6IATB|GBM.W5K4W1.282R@E1GC=6C(KOM7T73 M=>?Yf15.**IM70CE7(RA^H2<5%9^&1%T_17T>UTRUCTYPOIMY8*/GKN1^1MGU-
*ZE8)HOQ)1-."EK:G#=#1.A.P#9&|<:HY4..OKWKV.ST'3=@-M ROY7DBH7=TC_ M+BLQ)578\$!J?
->^1(ETG<SE L^1.S39+8RO1=L YR1GGGGZT<|KNE.F1?< M2%(PIYIC.R>=87C2;X5.KY01.1R0.E3.\$D_P 1?T4@)1TL P1(R).TKH
MW1.Z3+J5MJ.EO(H):LAG:>0O&N.\$|NAI^O>G1>'+AOKVIBMW2Z05"W.JS M.&E X&3N|#@>@Z4>6Z'JHMO WPM=0EVZ3?7.D=Z|M|KL!
(8T<_W2^0>NWMGC.:QCIP_HVF? ?&=EQ?S(TN_LC8:*T<1.HUQ1A.DKN1XIT# A^VTSZ7""
ME\$Y^ROED4YSN3I)O/(&.:?>="M"L="ET2UTNBTV966W5?ED1&#N|DX|GF@ M'JUM:VEC%:00PP100D*15R1G:17F>GPP^)/?BC5-3
76K>Y00.G.)XBM3&\$J@413@=WXGD_C56:PUHQ>3W4EBA MDN.2_&94GQTQ=KX_V@:1.18GQ-XB%+KR2F34_G:<B\$C)YAVQ<\$ C'4 MG
Q7J<%A.V^F1:2&K?9HH1"H9R3M P.MG)XH1.K7&@Z:=OJLUN6OK<%89O M.<%>H IP>XJZOROK-\$T;@K#1VL5/X\$ L MC1L=L#R#UJZV-
0A/A+OKXC&AZ\$PEO"1FWWD*2P>X21@KD'.6Q^=N/1AX:9 M#HIFX"Q@EZ*2N\$1YW.N#GGZDG05Q= TU=8&KBW8WXB|GSS^Y.R^NWDIC
M1/7GK0I/ROAS30#JHGA?Q:7CQW0B^<#(UX|B8=>M17G+/@GC|KFK3 MRJ;^#FJ^+T^7XC@^UW#W?W9K:XB=RB*W50_7;TP?>O1-
*&&&1#U*4_-T.M:TM:N7.Z6:~9Z?>PW0?08f= #.C274IPU@FXZD\$LZf\$!
M0:PUO8#60B1H0UF^FDN?"WFW:&&4&JNG%5=\$T^1O/ESI>FW5J MC67B.YBM+.).&XBC=R+>NIVX|(ZXVBO1Y-TV761K#6I?
V@C^\$X&E<_NC M1X<><>O/GJB>#M CA.*>AN2MFI*^1/@CS=V0_S'D_..1/3_ Q7'F MD3:~2VEI"UU0^8M'D4C&\$9C^X1EP?Q'/%=3XOLK|^VY-
3@TZSU^TAL5S="E? M;."SGS8201N891"/EC|XK1+GPKHEYLNGW-B|K6>02S)(Y.SC&&22W-YM MJ3=V?
2/AQ8:S.9-.08H93.V5FEC.V%)ZC<^12 M1Z5ZBGAW2X1N112W+>R179/LSAI%0^YNW;Tf55D%>)=!&ARZ3I)IB00 M2VP(502I
fUJH>6EIX9T.SL M_1^@V.J"=<1#3>0L_1.75@Y.<9ZD^1:~EVJG:2'DJTF6DE=5VAY8LI=L ML0./>@#D2B-1=W-
(M/Y2XGDUM%8Y4X1F7(X'X5ROB""P.F1BF'PT9H-M_1HHN6%9EMIFFV%TYRL8=N^NYI'05M3T23J9@CAU"V2=8H+&22C<=&
M5A@1JZ@<TZVJTQM08)X81=2EOD5OFH1>..2.S9+<R+41V7(WY=>@VW/49#DfS)ZXXV_0D5Z%H?@|PI(X)NKC1H(MK:.88=XUYQG:
3T'L.*M:5 MX?TK0VN6TROBMC%K6X^R6-OK(A/#*^T^>10ZAMK1'0PST(((-76):)(K8VK69.%@P>T3S ML0.. 5^;.@<#Tf5JW-
M1>6DUK0D6XK;P^>CP>"O#MLMDL&FK&+%MIMMD<>4W3<.>N.#7 Z"K47AO2(KN^NA M9^TU^NRLC XG7&
\$%\$@&#@#9Z#B#@G1T&VMO\$UEKEG|H@D5U:~+73K.RHK ML8W|S|E?FWH<9YJXGVR3VWAK<|J\$Z_9OIHYS>@/_0_3Z5T&A>\$/#_AF2
M:31M)M2_6(O)7&3T'L^R2B1%1%KEGHK;..J1#JMO=7B2_1Y2.P M9^ADD^H*~?G|VN@>|S31663=1T>=>|M4E:LB:
D@YR&2?/K\$@M(= M^\$.D^)+4W\$=|>6UG:WIV)WRMLTBJCC.%P#M!&">M>M1:%IR6UQ%IGD/VI MDf23.CJ.BERO8@9/&
<PCT7Q_X6&BV1<=\$&H_+>^MH5"QS1^N#LHXRI_BZ_-CO6=HM#H'0B'7_1@< M01.O^MW8?
+ ROD1\$RY_Z9f_C6W6N_P1/T3M:=7M;T5=8T^<AN;YVL:\$DPWRO^B1N1AC@<D M<+TQ7H4FA:~K4>L/DZA&GEIY/C
JO=0.XP>XZ&HK3PSH|B1+6H\$&1+0H9 M'9(F.0652<?QR>01 GUH1OFU"V1Z7P)XVELI9857Q_1).CG=#"S0JY/ZC"D MCL;.>U=K/
C%HGC;PH^@P);K?R36UY#;C.DT(C+IV X)4@\$-UYOGFNJL_#>C MV\$51%19(KYF>Z1V9UF9N&+!B02>YfT^PT#3-V_9;8H4C.49:1W,2'^%Q:
MQ>IPN1/P04>AW6CV3?3Q0H3)(S31606LYC^Q_N4E&TISP??>1=7XIM+X MW1VLC3I3Q1HZZ?"=Z>
fA+BV^1QEA)XRO>1P3L7IX&K'@f05TV|TX6^AW<MAEN^N1?~*YZEANY)1^N1G14C>M%=-RYM7W-\$L+L)Y
9(USA&PWS+R>#D\$WA2:26Y#R@<1.1281/2%6GRZ0Q:\$#HG31?>ZQ9Y M""Q1HE@fZ1E8_A7fW61K.ZB+9T'L-
6EL8S""H945""0EXU.666/YI@=^UXY.../9F=47<f1ZDX1:P34/f580:5JH8JLVAVTUf?V FL6 MW<^5RP&
fHn>IP/K78>#=-ATCPW#HOJCZE|N1<=P_H&R_1Y"KU..8I4_4 Mf'QJEU10=2V.MF+6RMXKCS1&VPIY.%QNP.8//TKJZX32(^2U>)?1 L&6G
MVIWQ^UU-TVTB|8K<C:JL.C(62:1RWWP'/E+(H(ST//H f=75QE&#U! MS0KH^=K^V#&X.<&O=4L(T"TI0Z0+KOCMK\$3W1OIS:Q
3@fHWQF@#TH2(6^AU+<C MIY%&12Y3<P&2N@_fLNU0%=&S1\$WIEM?SM#=(UYRONNH#f19T(SN89;< M03SZTPUQZ.XA1^&=&QVD-
W:S0R22P01;F2Q((OSP:/6:~C MI("496_..#FN=177.C>?"M1.HRW<5M(fL1PDA+NJA0QX)(1)XP37.Z?1 MP?%>fL)(+""XV/Hf.T&
(PPFVJ&C@D9P.#C%1^1P1^O-RY.<#77%5M3N) M:~3KB6:HA.L:~&)29_K3E2Nf
MKM0^7H5UJDUCKJUXZ76DAENfX>W2:~&8+81*49<= #S Lvx= H^* K1'ZO M<: XfTG5KM8TN+NV6618@0H);))Q^+.,2f
*L#0f^Q@0_1fTMK>..2.91&5C4%0:520 M/3).@#K".L3:|X2TC5+L1+H_#H>J>K6-G>
M6^1SHfR0Cf3:1HWITf5=Y%P91MY)?/f7B5KXfEU4X+ W-(74.%+>@Y>9V_AK3<~*B&'5;2@65C<~&)64"
M1+G<=&CCKfGUJMM816WBX>*>K_5D1=9MfF1VX\$MKQ)6.05N1A"8Q_4T M>K:AG&1GTJCK+G_&3< P1BM9C40fY1O-WE
Y&=YWGfG1^ZU2*ST7P.X^ MU&V0:8Q0P#57:~C#^1V;W1B&fOJQXYL6X^&WB35GM8TFQXOM>0FUL<"/M?P.P#(f2U_Yf<(B>:RfC@<=<
6YJC=52f7TVVC67fE22;~W>>3M^3R1<= M>N>W2N412Z;J\$V16^HZ=..?K)Mf/\$<^C7F 61V)#QL00K:1R.\$+UK'L9=-N M_\$7PQO-
fEAMGLKN*.9O18\$2!0%U(Y_7UH13+J&'E@&H">3021C) S7EN MEP60B+P=XPN191#JL\$Y>+). \$EJ8^8MC=5"1%(QIGN:KYUHVN>
(OAT)KUN)+ MJfT6A:151CS2\$B(#COU)*GCD14>M1U9-X8%<9R#Q2^ZN.HP8'G.C1^HTG2# M/H?B00M-NX-/2'Q(5LHIEW0<"3R2O|
<8YD?>O3M73)fE6U/7+^XT1(L-UX M1X60(K=P1NY3LDC(ZA3D\$9&>746F..OB C'RJ3V4EEHfZ9&=X?
E%DVEMIPAV5CfK0Q%>.VMXY\$F^QE8U1 M4&U4D#TSR:~Q1)O-KOA+2-3NQ\$MS>6B3R)&.*"0"< DG'6K0ZK_&H"1: MR.G8C-D(MWG#Y?
GfS"WNE.U>3V.EV5AX1^&>LVMN1>127UE IT_8H#fXR;UKI6=47<f1ZDXKRSO%=&^Q\$AGQ.UG:YfG6H72+TPW+2_ MZ.^C-
E%X5AG/6NAUMC^11=>DNPmUIOTZ=1;##F*7>GfTWf7Y.C.GL301 MV1^R2_/6C>NTMN&fU>E>f^/(&3:~V+Z.f@CBN&U&:~
Q)M&#&UTN02PZE M1:<#H."f1ZL1+^M1TV1H1^fE2G-012^ZNNY&#^U157E.MQ0^#M'D2#68f.NM.MVOD@fCV4.Y+M%#<
<(6"DKGHWHW-f4M T^ULO\$Y#JEK-fMT65WL:~1PDHfS8#^#DfT+ fU)(R^Vf:565AE2".XX>//H>G0Z?K^*W\$=Y=-.VfIPC%9)8GM6 M+(S
Y*1_9X'Q3M0>~>Y B5%h\$(LXH+&TN(X:9=JQ.RN)'51P#M& M5U8D^P)7@&f103(&YM_M2 MZQ8OK:Z0BZO>QPB>2-3BHLfGTfYQf^05P-
f96<^>12:VX<1:RJOC7(UMf1+8<H8QKQ?YIC=G^fT&>M<0Vf64P;Nf<\$" VG:K(fO=\$DO 178^M_PC1:0.9SS0fHSfF-Sf6 F\$V Mf1
fT9+>#SELD#<@>KCM_#LEIX;L:51DU)(8+6fD^1^%>..3KWZT_A M= <#EISCKWf\$4fJ>(&=>37DfF^&=
U;2_ 'AU&W11.ZO=F"8N0;7\$4:TY^4 M@Yf|@.@f2=)7Q%XD1+P^X6FEN "KM>(f%3.=18&_). 'ZCVH_fB9U7&Y@ M.G.R>H2P'4@5YfX>Lf'6?
\$ BW1f7LXIEL&M.6"=<O+M2^&W:GD9(8DCG.. M>17_#2M0UCX1=K4L2VW5MfNGNK*:8GN(f96^5B>2&0?CA30Hf=&?f1+>0 MQ?>O+>RO-
SMVWXAXW8YQG<<5#ISWBZ3/fJKVHO+>f10UN2(M_YfYOGQKF8?f1-MJ3f)JOB+=@>O+
(PWK)AF5A22<f1ERWX^M<fEHWU_V fF2V.UY-V:GC M3;XNK M-BJWfUEW#8-..W/6@#T35&U7.9G26LA_I22:3>L>1GfYfW^fAC/
M%7V=4QN8+DX&3C)KR^fL+SPQX5>UTMf1>U161026DA#&WEf|C(BD<%=QXQO
MCf7026EOX@f=>+f1UVUAN3.f1Y:0\$H&fVfQY)fYfYf@f#L^..f) ZD#M0
MKP)5@<""KQ""> P#"G@D:fLJYC2fT@N&D8226P.P7Y@<fA1SZ 5NP:1: M6/BCQSHFGSKHfC<9:~&A&U(f^B&0*.'@9QC.*f3UD1_NNK?
0YI2P52S M_#f37>~6>Q19f1ZC:6&K3fT=UfVfUW^KT'= N_48C&YXf7f50Q#<"7X MB>&f^0B#;.<07_JHXRDMPH7:&fX.%WD#UYf4 ==-
<16fMDQ%KKOCG1HX\$70H Mf2.YCMV4&."=f8LJ|_#_VfTf&fUO1_PTM;#X=:)1f%&fMA"TC@f1fR M2.HH VVUfT'76f-
%AG1M02W^T.G41KDf1-WUfTfK1\$;=>?&4>H@(\$N6N9-MX2L^fP+e91@&D1%K%ALK\$&fZID>VMf1B0RAC&N=-GN-V?7Hf1X@Z991?1
MfXUP0+>=fJKO1+P1^fP1=CY#..\$Y P#GF@<V4G50A(fOUE_8_PfE/fS? M://W?Hf-OXYf)1\$+&0ZEAU&>17\$=5f1
<0Z*%3PZS:1W/VAf1G@&Q="@70 M=#1P.f8VNHO7\$TGfF>(fL@23:~MfMG4C)+6.X\$D^M^f5R_."fDD8A40>fL0!
Mf1:U18:1KfB^&f1+U16EFHfX>N#?33PW3:1ZNO_%fY8^f9B Mf1R>2>U H.8H\$&\$D\$5Q7B>_2fN?1^H6fR7&ESW?FO_C=<(f+&%"_Q1"OY'L#U M
K)NO#B6OAGQ_fEF%&WL^MG\$5&Z_5>Y:CHf:0%PO_K@>T>EAF;fK1^<# M0KfZfD8_/4>~07MGIWAGP5X9U6f4MEU233X=7NfY=TB-
%f(f21=P&W<5fZ<=>M^CMG3B6R_P1^9TfO)K.E.MfTEU.O^<V\$2-\$1Q5:8f6.&V%N01G>+U_fJ.N MK\$A6fL#@f1f1Q3&fYVD>6VfT^W\$<=Y&5
M)^.WfE'X=^J4K.#:)-<^fJ9XHQQfDBE& M8?Q-DD9f)S53PW9:9X@f1P OKB_~17-K#@fEO %N99CA7AE8N2VYB=W/fZ M4>fE7fJRCG^f
fU2N=9L;35K+2Y9E^V7@=HH@>=>fC)8^W0?4UY4?#FDWNf2\$ MQfBRCE:UNfWMR^3Y+BV5@R#^%LfQSVZ5H1PVU_XH^&fW?
0P3Z2W&C3R322H&+ ML(82^Q/7?2?F@<#U2L^Q-K.SHO@-5_7fTXVfDfG:O.HEf9#Mf1.#@&fO6G^<f1
MZXE70+)=06P>XVfH_ZfEW%U"PIfAC2_X8UYfJUPfTAGOQfVHf:Z5K^Z.) M39_#7.0\$@61.0<f@0W/f1^/5-
/N3=.:S.5fV2%)&5>V1GfZ58WfOV;EW_MXSMSSBO-fL1f1)9>+fQ@6&X08:B^ZFf1>=1.f@&fM@&@9Z=fQ+Uf2:1f1

[illegible]

[illegible]

```

(14T/M/4;2-3?&-6T*~_?RD,+?#Y@S/L'0"-5WUO28/%BK1?%FJ7.F"U^D66%"M"%CN+9X43:"5/(PP(CZDXYS7J?
Y2Y,B/IGBWQH@Q@RO:CTITEO%*Z9?&+IQ-MG*.R@E3ZC7H^WN?*.PNK-#6MDIVV6CQ*+^5^8KFFW/L#Y(92)&R1R.@$5 MVGA:~V^$-
_NL#6(>TCB2HQM-#R&T849>E;M&K^D7?ASP6<6MY;6-M^XB@E.FH^XV.F9RQF=LL&)+Dj(F(.U.UF#2=2-M)GC=V(K2Y=9K&2+>JN5Q
HW^H0P/I/Z5WPM+8;L6I0W00;YIRWJ?P?W14M MX$K10"/.7L-D70AKOU;7^P19F $KYN8)+Dj(F(.U.UF#2=2-M)GC=V(K2Y=9K&2+>JN5Q
HMGDT^>X3K;JM)F0?G1;_%?CBJ^ MK&RGD^+H;Y: Q6H1T?S;6.W^/4@ UZUICMN/I^A^7H@XK+I0Z^JVBW-M-
HPEA=2E2)Q^&PP8IPXRK8PIDG$T^-IN;F^77(I"-EY29386;F14IV)YGC^&3ZXSGK*_%U5+IZEJ
_M4_"UHL7E=0J+W0L6V7fX^<=JIS^HUI=N;L;$B;XM+^+0KX.MCIUHK0^J&JdI^""F;_&5;3I=U=D88VE64QH2%1^N5&0^UP:>0""_.@I M0:
.&GB%U6L.U+394;+2I5U^6-@4%*@8@2..YV$>P-),+F^XL?$/DS1R9 MU^I8;&IX.F0?H;I6^V@AA,44,<<9SE$0^/7BECMX823%#&A/I^?I0/Q/B^
M=,LOB)HK;_Z=:=39&74KA^J&1088E)VER5#9(.^<1<#8W>G2_#SPK;37 M$S$GE>+%66;4J^JFXE&4L;#DC X-
>Z012NCR1(I1G^%E!^GU^I339VQ&#;P MD9+Y0&0^W5^Z_5+&XETZY&DR6IHJ3(1I^>D MT/3HPL3_:%VMWJ$>9I- &E1110 4444 %%%%+1
M110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 4444 %%%%+1110 5B>)+B&WLEDUY="=
fR(CWR$W$S^JTW7=G^M^;=<+|5+FWMJ^TKSYHX^ZS9L-I<+^*3^Y-^170BK0-.GN(+S6+.&:W0/ M-THW(#TR.N3Z=;L^7+ LV#41?P-
;7&I^C;A^3T^X^I28<150%WIS?^I M?S18NF@1#=-O7f/FN3$S_ND$^V^Y^PI^X@TG3_#A>^*6T@7^U=Q$.HS.F.O^&^3 M OD_ZMA=W^4X;4
>P6VLZ>6#M1?0;PEEEFW@",K1X;GH^<^118ZSIV_M2SQ6ETDDL^C^Y5T^YI^*G^/8I#7B1FH^H7BEfIH^GXA^H^AIO$LMJO
MDL6?>@&@f<1^3T^HKK=U#22% AGO?I^<^&^%>V;G+I3P>PIL^MMZB^RQRW^M^?&0#M;Q^HIYQSOI^YSPUXG1+>^Y=^FF^W625+.$J$+^IK
%..&.+T^X^I8XR M1P=JHME!^?>B23@;G;JNW_ (MV;7/ M-I?;U8VL(4RD,4W^ SZ9J6?Q)HUM=FVFU&)(L+9;Y5D;U^W0,1NUG-
I0Z8KDO?%N;??>#_%L$ST>G M$Q;MNDT)Z>8D$@;@;$S;_R30!P6;N;9I/^! WD4!^&I@QSM0=M7;.BC^I>^*9 PD.D?VE;Z<0@-YQHP0#-
%CCON)H^Z^BC3L?A20?66A;+UOAX^ MOQ^VNTJS6F.LD1Y&8^<D$#00IV0QVYMU<7.$S6?6VB8)HIRC9Y^X8/TQ M^4-
^TW2B!>W<+<+;#)M;20>ZL0.BCN3P*^@DATI9)T^W-PQGF^JZIS<f??.+ MI^%BX.^HPKVJWA@B^B^V1<=<<9?)$@;M DG)/J3G;_*H1;+U;ZA
JGE^@GY6E^6-T+L<^U8EC?C+I3^>f/FBNHK#I^XABEEFN^B^M^Ff=%=35YI=TiG)WU^I(Q+Q1M).YQSA= MZM^C-
^VIO^&I8I)^+<=4TG4KN1+JP^7F19?5.P?P(N@;0;."I^T^YQ;Z#%XB^M^?;ZBM5YU>50T44CfE4I&0-C<#ZC(I9?&D07T=G+J$^3R2>2H9I
R2W- MW3= LYSfIS6&B;IHOB;OAHM^>=>T@7UE9EY;6ESO:=Y-NHfR)^H^9 P3SVQ8;M;I=^HOCX44S;B>MHQ-I0F2HY?
+D^MZ@DAMV<#DGCf#@TWQ^K=GIN-MFWD;D+2Z6W;174IFBX.&(((49&L.5%X&OKK4_FAWUL^TUU<6<7IM8VVKV#_
(5.EQ;1A^RTW$;HV.X?PQ2D?K0;ZfX MBT^UN^LL^H0I^YBPG)X61ONH6ZfCD81.3D5fL.M;J(S27<<&$;AW<f45CC MHHH3Q7COB?
6f.00^B>^WG2QEAU@/+LQ;9DRMS^NGFf)(#8W C;HX&2;Z^Q M1L.C;#_#MOXEF6.SUB."33fB1&.^Y@>TQJ0^T;CON)f@HMSfMA;01337
M48CFYB$K<9;_#HMQSOQVYN^f$FC&PF&f6I0BQW$=I^RLSG^&Iz$^W6N^M= M9L^f/CK0KV^@330^DNC-96;RIL$MH^fVL;LD5.O/&#T-
+XI2?;3PUX?U^3 M;46>C0>(f>fDEfLHGEEFW3$^D*6;J>V^".^*^JQH$=Q>02ZE;1RV2^2Y62 M0+Y2GHS9Z$WJO^XO;7^S^#K5BX^A2XE(f^R1O)
=8^QQR2S^Y^X6XU3+KQW MXIN(IR&K;3PY&E)PD@025Y^L^&^4<5f;WFD;=1%O EZIE9?E+^*6=QE+9^M MZG$)N^N^0C2.5R.GZT>FV&L;
J;3H72226Y^FCY5X1C(W$<$9^R;@&I2Z-M7^C5U.O^HKD5YJMP^f;YXSMF@U^fZO^117V9U^N;M M3=^Y^T;9 (SUQDFNR^
J)O^OBR;fHC3f=9M4LX2H3R6^Y^X<=<87IMQWf< M9-^26 B3fK02f)6MM1@ET^D^#P(VL^B-8>?K^E^ M-
L^UPT3(fTKfI0fP1U^3B@#LK;7M^O-(75;4+>6P;fMPK MC;3G;CfKGC^7/2;3^GZJ9A974&2UBHUGP/3O M#>fZfJZBSNM8899(2CfL50NWS
L0<=<Q^?^1^+L+&X@Z9;W4fO2H;K;fC^&N4+1 MGDW>4H;6fP0;?T?^>f5PBG2fC62$FfW_ (7^;#fUO;SSVY$)96f;4^X
$G^V1JEK>0VY4402;BAf9fO;H;^;f=(NK0+2^4 MGDW>4H;6fP0;?T?^>f5PBG2fC62$FfW_ (7^;#fUO;SSVY$)96f;4^X
M<#fCZC^fLBFZE/?)^?f7A&WT=T M6&fLVCA4XDM6CXEWKU4^H8^fLXH^f MLI=TO4+RfM+JCFN+3BxB3);(C^L;f=TSf$EX+M#f
(2L94^ER;H4^9;H M;U6$S$YTK;f(P&YUW<f2>f0D^Kf8?VY9>?&3Q%f;fDG MX^4GTfXH^fY^O;19W;6M0Qf$4K2?^fIFP/f0MT^*C
R)R7^F>E76A^ZT^4?^B^>4$U47TWf6^0?>fTO MD1XPO7f1fI^?Z^RNI^L B1XB&H2V1+IEH;X91P;W#) #fTH Zf;^VA1P M6<fZO9^*fYMGHf
<2KE>=>1P2QVHfHC^&XKDQ66.WBR6ZM(9B$YV$&7RSMf43E3 P>M=>#KNH$=X5 M^&fPEUB623&O=2^TNfL^QORK(f.C;fP6WALfZ
;N;7_9fMfEJ+;7fQf) M$WF^4fG^fGH?2DCUf2f=6 BOH7MGD;22(V=S@D0^fR6R^;#G@UPAT_MPI#f>C1;fUSH;+BXTNf^&1B;fY@99;J-
N;fQG@9-1G^O/$W;+X>UK7;M=K73;74+VYOKS3-WDLf+IE<<f&f;f$^Yf<4>GMXfT^+;4Gf>S2S20Q^*H M 60?P$^D-f;f6U3Z?
7M9V9NfJVLIS(fFBCD#;BG@G Z@=C^CQO7f7BYO#) M^&WBG4=%GDFCU&6V;MU-(Q2XE$B GO>+B>fVf3+J^M;^
UY4f;HfCMUW/KB@#0.M M7^4;fFGWfX+P.E@NZYf158Rf19&4QN;fZCQNG9fH0f^&O.CfTS5_3fZVN/%C>^4&OY+WHfMfH^?A4E!^;0 M 5f
f&1D>Y-4^f26>O^<=fU^f7f1HKWDfO$;fM.6P3^W7.X#(KHM0UK3 M=+8+>W<3;#)M;20>ZL0.0HfDfI^O^M;fTN;X5>_+Of=OLU^f3>;
(fR=;Xf/MNO?fTIU^fE7>E?&SQ0NL3QP?Q6TUA^P57840A5CQfK$DC_?S0fUMSX@T> MTBM);C5+2-
+PA=9FF?O/3;SSH2-3X@TC72f LK4>+>fSf;fEPVPGfHGZfC MWKR K=;f(=K^K4&CBM90Q^HGM0f+MM3)(5^4fP0?

```

HPKKI+4+&W^,B%SMZK6)TN>6X,BQQQLZR(JOPH M0##C.GBF:??6C IUU>-,J\$O)V/#M#C.12\$E?I 104VJ7%G_+JT*.2
M:#S8!N<*S*#L73?T&I,T=9<:,H-YI?ZM,:A->W2X5QMSG,C/KGC?/ M/2?:J^GZJ9ELKJ.9X&V31CAXSV#*>5_5\$XT^H!:-
JMLM+>86^C26YO%LFZ RMZV4Y>-.P9>?PKT#PG)X8U36I06M N:F GEMUBN+QD&0@*RV 6ZL0.N. MC(I8!>1QJH(TFY27RY-
0U!"&V=PD)CB;)9AQC.%Q^:FL+N^0(I0I2I00>0W+ MM<6BS1_0(8<#(.64^^(CC(K^K^)-I.VIWX0CFN8HW_M^WDVNX!"A7I;Z9(Y
MIZ+&4%TOXIZ^=562*YU&SM9-GE8^DC#%"1%8I9W/NQZ^_53^=(M&:SN) MM5LTAQ65+5S,N)BQ
36YNHZ5^IXGT2ZTI+^VU.WGM!9\$>%M^JE^I^DDC&M.W->37-M%IO@VQCO^CBTZIY9+<6.4Q^@6AGX(I_AQN;Z-G072>^*KZO!>+/-
M+Y#47FLM NK&6;NTRIJ7#2IR7^+X YID>QP=Y%K>ES:6FIQJ7INJB^LZR M IQP_#ZYXQUSQUHM-Z"&4-TIW\$OC.,#CF@#OI?<
Q%HIU>QV<=&H0/+N^I0W\$NWI VPI M&SQWQ%4K74+2/QKB X/+8^IKR&VN-/@^\$GP^;SK;-H18LG)W^"K"0HR?<M_7FM^5=^4LXO#>FPZ?<
>I>VD-M%&E>=O?V UCXKXNK<V ML0_U@Y(M2I I>X^O%?VOBO0+W4+>PMM7M);NXB\$5L4*R LZE=V0/IFYOUQS
M69XZ1P.3X7UBVYJBTU&VM^DC9_K%YDH&R"N.<\$YXKC7O_-A!-?"HH<6 ML86YMBV^48_T=@^?^I^I^M0KUE;>10^6@;S^L.O%
I^IH)I^IRKAC^(' @_B7.M:M&1IT+S@="#TG3I.MI?PUISUJ-TI+^+1RSD\$NYV L0HY/7)P.*F/B70Q!93 MG5K+RKY@MJWG+ B8_I/K_<
\$KS3^W+^/I19.ZAKY%Y=6NAWF@06T%["S^D4ZG+^ (MY^3(VI>Z^W\$FN1^+^+2""2.8VW3;CQ%)\$AMK*YDU6S6&^BU(XP;NORD)IR:2K-
HZ6HO^-(I\$.1POSQCN"> M^BL4+^+PPIX8T-IC5GUEKXZBDK4^H<^TN=HP-IGZXIYK/MK_3X/B_X@+W M^&M^IT:W+DR*.5>3.?<
CZ#%MYGB^2.14GTZUOHLV+^I SO537I^8& M4X874^@UQ7BD7_EK-B^,MIA^UM(HI&S^O GAE0>4WT60J<^C&NUL+I."P^M5-M8OY:<
%SU<JV/N3D6ZT 5)O\$.DVIX+2-.B28RK!@DXIQ;4STW^(\^7.>:Y72_-M%L.E>(O%07B#7\$2TM+R&_U-R43;K1*Y V@9 +=?S-9%IZ#=&59_-^L^!^S
AEWX.1@ \$14ZSNM.25/BC(TI)=P568N0^BV^D9I-V M1I_/0I06=.LD@>:IC^V@H57YVD &25^Y)^_17->M>E7PG8ZMH6JXBEOK
M^;2VY1UE1Y51AD<^IZ8-2.PYXH I)GU" _B^*U-MEIHO9#IVDS3FV^KM\$BR(H8\$#^/0GJ3737E;Z=:O=7D<^\$8W/(V^IDG_U)P_M_-I<5=WUH?<
C7I^"ZA+^HDZ@I^OR6EC(X@&C^V%72B))=KI>BZ?>6I+OMJ=N MN+&C=Y5HVI(F^>3(C4ID#)&30JW;L6VHZ+JC;7J&VYM8FWE%F0/MW##^<
=U^5IS=IP!V-JV^+^O+^MJHN% MN-,MI(YY=JB51^"RX I49-W#CD!A^K_/9.JPV>.*4JT8= M459(Y%:@Y#?>X/^4=P#TA= TJ33IJ27^#69
2>>:Z:2,Q7T/V>U9DN&D.SR67I^#8 M^D>AQ26GB#3+V>:W@N^,B&2O^3D)I/L1@C_5/I 10!10^2-3UIZ%547- MJA1Z
8K^M/\$VCWVE7J6MZ)&V+^:94^:;O=NB?TIU[XBTK3X1+=7)I/^\$S M8B=BD9Z.X I>O+8^IJ*-<
-4522J@9.3@>=32;SR3M7)QDXZXZ5D7BWP_IQM MQ=ZO:1-8FGA->
^9&JHBQVP.O>M&OOI74K^"^^LYTFM9T\$D%8@LH)4Y&1TK^U^I15U#_M7XI3K(CT,I)M.6W7=*X;3)UVG@\$=P_=S3?<
UY<:AX\$T^NIGFM9I&^261S MDN0&S^DUC7YN?YUXUO?#2W5I9PPV^LDULDB)W=E#9 Z^%XS^IR^:2.9(RB7\$P\$^ V-FIDY0HI;S=0U_3-<
=ENIG84C^V M3;S&B->F>0.*-#^,8&*RO\$.CRZO%OIMH>&P2;3;ME2;_IA@V^IX^G&".X) M%267B#2I009VIT#<
<^7YHBD1HV>/A04.^N7W&13X^PTDWB6@N_WLDC1HGRWY M2.H)953^UB-K9/^#Z4_9UGH>L7;+ZI=:3.D.BRJ+Q:F=2^I+^I8 (IP
M.G7&0>DV+OW/I1NQC=CG%PN)(6DN(FC&\$"AB8,2DG^"I?3OB@#7VK_1^5&U?^HH_*LS2/\$>CZ^IRFF75RHP695R
M^F>02#V.#@I#7^*)\$ZMKGA2+2M5F5+O5\$BEC1W\$6UR2K%?G (495L<I1I M0WGEH2Q*+WWN.OUI616(+*#@Y&IT-<
EEC@B>65UCC12SNYP% ZDG^S;?Q M^I5U=2VL5T3<86B=7/^H99?>=156M MSCR^AS^YIY.\$YI^@I 9X/I54^+O#ZZ9_3ZK;I.^=Y!=C@B3.-<
A4^ALD<\$9 MH_V0J@Y^@&^I^I:G;S+^N;L^KJ=LFP^V:&^I(XK^T^U@H^NK:A86&HP3W4 M^IY(T^W-<
P_O#^/6I4M^KXCTHO(K2WNM^LRLT.8V^RJ.K(O&^I02.1ZT 0 M^=)U^3K9I.9U3^TJ3E^K)<="8EYKG;JH:I)SW)/_&U64GB32^OX;(7)?>
M.66#^1\$F^">".1M8CG(1)X17I:4EX+5KKJX9A;@B-RAEz;-^NIVSD4_01 M%9F50^W4@=:7.NI&U70?<
E7/7CSPM."W92LL;2A64G&1W&^IGN#74+K>GOJ5SIW&^YVB^TL M1MX0J&-QR^VQG-<
%I05B^R@E3D\$C1L7;5VC^ZC^6LVW^0Z3=Z0NJV^H%8N MQ195S^S^MNT^#J3N&_9)KE=(I0=^/O%\$\$FL3?V=;6-NZK.HB^R_V_=PR@@I^M
I.U>^BHH5%"J_@P^0(JL6"@_W4@Z33^&X>U(\$RJ2^F>03GL<^IZ^%&I@<
M^&ITZ4C^KJ5=0RGJ^,BL@>*=#VWGC.I0H.H\$VS/E5GQUAMB;P^GCFM2XN(M;2WDN+F5(8(E+R22.%55^4DGH^<
)3;_YP_-M9=MXCTJHEFAN&T;G.(W%7H M60QGHZHO^RGID_US2 \$_3&I^&X-A=M^A6G>*&^I^/R?;-"QQ@9P">=>XZXI_M.XX#7#E1N<
P&QR^YNO^WD^C?5=H^H9%=>KJ&^H1FLI?"A=C@:I99^T-?ZS_EHHR1^YSTI^ZMZ7 MXDT;68KJ73I0AF2T.+@Y^50G+9Q@8YSTH<
U&I7I^#^"8(I4%5^2HVXQC^M&^RH0\$VGSW\$ENEW^&C^A^T>6T3J5I^WTI&77W7(HMO\$VCWTFB_VS;7HETH=M%P MB.5)SMXXYYXIT<
^NU04%#_H#=#JYZ#^JRIC)I-I<@^I^VL)B8^4Y59& MOM1^F PK^I^4G/(I^K0V^L)XTN9FU_YM(DMABS_U^K(I^N^LO5B^G)^_I^P MQH592BX;<
I^POH^M^%4(I 4 XOG^LQG3K0V)&=&1U787^VMY)(U",P9E0L <=I MQU^L678F7.(K#7K67+XQ7-HD4HE_Q6\$X^AM;D;@>OE0;2.W%_8^"%4*\$4<
M=^!0R(^-RJV#D9&<L^V^0:3>:=+?P7I36T+F.5B=IC<^&QE(C)_VD9Y^K M26WB^2;0I8(IU\$;R7=4 IEAU#<<8I^G>K<
UEPN+*RGANG^K4<+;ROQD^HRD@C@CH^1GC-STH M T JYS@9^E&T9S@9KS_P^XULD;V^;JK-J-Q>7\$*M.WS_&=4IP,+D 9P.M.^Z1+BV?<
OP^;ZIW^6^SZ2^1110^IXI9#<

32Z;J5H^F6VHV\$OG6ES&)(I-I7

3T-&X% Z ?E0J^BA44^HZ # M K^ X271OMI5D;YI+*T,9^D(BI45;2PP?E!SP>*Y31_%UMI&L>*T^0:V? M(MM16.W.^HGE(QP%""@MR<=^30IZ<
5IZ@&D9\$<_JL<@=\$9I\$ECDA66-U>- MEW*RG((ZY^K7^ZCXU36O^"BV?2);RRN-+2Y6^8P%6+11AB?G7^8D8/S8&>*M_I<
(IZ@&AD5U^LH93U&I17-^%6EWMMH6FOJD4NK2V4X04C=I1_96/L2^HA^8T-LDYH K^)<U^5I83;7I:65Q9<
M3&94F@I^V&7^E<_H&G3@&I^DTK1KY+U_5YK^6ZC50EB^E:&%5W8R269F8I>H M^L>M:Q(C)_PI65^>)<
(OKV^RMFY&GFC^D^E!_I^ZM&2^;I^ZKD4_810Q8^ S M=2IR:7;0IT^E7%&#M;DCTS@Y9I^LC0I%_#_#I+I MO5O(XKWRI+5 TZRH8GA5@<_5<<
@<I(QO0IH5_NCIY^_A^?=\$KJE_I9ZSI MLUE>W^N#^J%@TKPD@#;K+(H^@_C@^K&D;IH^E^&=\$>Z1K?1W3^3.WURP# M73ERIG<
YXXSZ#;63QOQX9D6^Q_MJD(691G<"HJAJ6NZ M5HEO^I_-I^WOTJMYL7B50^_ANY=U6VG2S_X^#NY^4.N6SC MX/3B@#8VKZ#^IJB_P^IT?<
E67>)>)(OY@AO%JP_P_-IJ&3^P_H^W)_M^ M(K^P^X>&^I_98=5CN3Y^LZQVYM(H&2M5 YP0?R3TYH Z3:0IT^E2%92I52<
MIZ@CBN9TOQW^I^H^CWEU^U^IJB(8874D^9V48IV,>>U;ZWILVH08I5H2_M2LFP(20#G&2#W^TH RDPT5Y^STUI^R))I5EDM-/6V5?+<
<+C+U89R0/4 MCT%;U8>IW^JOBCL;I=I>TN6;I33T^_Z8-A^I;X\$7I(I^0W/COPM;"5+M8ML.C.<9X&1D^HGF@#H-B;@VO=PZ^"<
+M7^Z/RJG=;086<4\$DMP^" @ M9A6)3(THQG^JH)88YX^2J^>=\$>WT^X348F@U^40VLJY^R2\$X^XP&R#P>># MZ4<
I^C0XRBG:M^&O\$\$.TNCV%\$S+XQ(7IGS(RB2 M^G^Y^I)_>NHHI^O^556NL^&M9;Z<I^JN16E^I>R0YI(Y^I?+^X1^4M2U33^_^(600>*WQI^SU<
M18^L+F^6=8I56.(I1L>#9."XCZC/J=%_EMU^HNF^+^AU9VL I^W^VF^M^Y8IHD;Y^V^I^EW^&W.>_HQ7HM^R66BW316GG)#;N5MHQC><
IP@O^THI0! MXI^;WHS^V^R&S^%#WMV6^S+6I@0C@DL#A<%B3C;IFM_2-1LA^O^< MW4(3S@P;>_29U7(I^F&KQ7IE^_+?<
#>I)AOX>".K%&^I^)=K^I0^#Z\$>E M96GWIU^OFUJ^J^>^E6I^_75WROU&X<=>_IZB@#QCPO=>^K_0I^PMXCM05 MDI164P233WFN?<
WDJOE95YG_%WMW^/Z.UO\$)KR_FFMKT M>Y=I^I(L^+<=&87&_PI#CU^B@#R_7DM^NKNYT^5UTC63XHM^OR8+V M)4I2.Y.2PR5W*<
<I^YSD^=I7B03IKW3M#N_UGK;I^A^=FQ_0W8^KNQC(P1C_M>*Z^H^M\$DNX^I^F1F9H^6IOM0D8)^O@D<^IQU^-'&\$>YN-+PIKGD37&FZ^J<
M(EOBB4L40QL@DP.H4MFLCQ;^>)>I>M:EX2L6NVF_VENIXH&0WRO.^8OD_OA_M^?Y^%O@VIT.X2X-K+<3S1^DPS^/5I?>=1.5&T^YI^#6 M5I-<
R_-U71_I^A^M24M^OKXH(NE#7^GEMO^1^/F^T2;G_-)#J^A= M7IMK=I%;1-#K\$^" (W-B&4KI8I^K?5X^A^+K;\$4@;_?"0>W?&1P^*J9HH<
YCXB6U=^2J4C MTV^2^Y^I(HHROTBJZLZC;2H8<=>M8GA15_1GB#5;36M_->Y4;ADFN^YKC^M^M^A7YU^ZLO^+&M^31N@I^I020ZA##%Y^PD-&<
(I^T^I^MOSG<<I4>96UN_A&W^/ZH^O^0^&MA>:CQ.F1&LXII 8'8(OP7^GCMN)^>*T/%9I^X=ZO>Z(LOV?4_>UD>>>25OM; MK;A9E\$I^R0%)^!P?<
208**^/40I/3XM;2^IT3Q^0;A2\$14\$BLG M2FNI6;3M0;ZNFKZ1=VDXM\$G^U;2?^S+CG9DA;_C(&>^I9HH^ICN(7WA?<
M6=;T+1=0M=4_X22WAW=++<P^CSQ#^F8SL^CD^F^CVJP+H;JR3>'=22L MKO6-MYH-VH.2*4S?/^"O?P.F^#E<9%;J44<
9.D)=^UR^U^*ST^Y_MQHLWD-M72&-EVR.X&I^D^D^F^XFD^IEDFC0K)>%MS;=T^I<^F3P^AUV^D-HD-MQ;C;F427^FOIT9PHQV&X_G4I<
'DIMHE^4V.UN1+)+@I^A^X^SA1CU&I^<^MM5=;10>M5I)ZQJSN^N?#4-B+M4,B07^E696V@I20%U7V_/8J^/+_%IS<
ML7A+1WL+5+^RDU^VGB5H_*B^<L6>?780^G)Y^3I^BM^ZU-TT^XPO;I HH^I0T^4CI>@^\$I6N46&DV.L@<^4Q^D MR^<
(H&@&W^GMNKJ=\$UC3;CXG^<I^<=7L6 M>?>?A_6#X-MIOO^HL^<CJOE(K.KSN80^52&4I#@Y(I;G@>M=I^X_O(K^P)JU MS-IRZA\$D0#6S^J2K<
LIE@=JYW^8&H^I7P_KT^V^&M:W97EBH^LD&F^3)(I^V9 M^#U^VJ8BNHH^I0TC5+2X^+&6G7<=>IR.A;D;=1^%<=>3MCD2SD)6I^"@_9/4X<
MYR>*YY+R^O@=<6:ES<I?W><=>E>XT4>?^5(C;XH0_U^O^L2RK^69-OX&X8O^I@8SBN4I16HM? WCBZ+*FG;GK;ME&>D<
MH\$D7F.HIAB&1U^Y^Z2.T9^<ME8B^9I0U_XBV>E^LUI+HUEY<_#3>67.B#^;W@<=>^I@HH^I^L;GX0<
M5:QIVH;NHW&K62/D7.MROLBZX=7WG;D#^>:HZ9^1HHIOG^<^K^JH^N M^UF_I^P^&+^F#V_?2#V1%>Y=Q2S6<I50A<
9YGC98Y@H.RV(P&P>#@<X-90 MAL2+W2I^CJ^FJOJNHRAI+=M^L0^7H^C^X^2>_+^\$T<^J^Y^T^W4M10_#FF><2R MZB^00#MXH;I^I^52V^\$IP<
VIE>_G&^*J3HHH YGXASQ0?#OQ^YLBH9_/GB M0<_G;_@%J2>U=<K6IPV%EX&URX.YET&VM6@OIK^I^V^I0%&\$=O+I^*L#Z9<
M^I5Z010^Y^KL>D#0^IXC;66HWE@6M^I\$4I8I9S)=QVY4Y^XZ_*Z;M;W@;7-/UC6+1+^I^MYM;VOKTO<1\$2^W8I^PLD+&DC^N^DT4>=+K_&^<
Q%\$S">_U>?7-\$LI>Y75D0^/JK#;413AR0-PP 3M%;>=O^I&K66NZ5;GITEPM^A=U^T^X^R^X^I^Y^I^H^&K)8Y_&V>Q2+Y^HI>C44>=&FYLQ<
<O%EAIXZF6901 MN)<^W^LXZGY_Z>U=A<7D-SI866TO(C^F_-#K@CS#_N4 COCYL>G>A44 M>6>H>T>Z^I^X^7U/39^0Z3(BM8S6S%HHHSQ-<
NQM_BW^9IGJ2LM;NQ.2Q2 M;S^I\$^BAID^PCO3=ZA((6I^"R1 (I_@I^Z>M>OT4>67-Y8OR_"I<0 M^<
(SR5<#;IMBI^<@W8^U^XK^TFZ^I^S;_>=>9%EOJDNM)=R^IK\$2W.V+2M(DD81M MN^2#G@_C)XYKV:B@#^I9V5^H^?6K+3=WVR:RDCB^GEB5/<
I>^GXU@<%_A^M^XQ.ND>18LYKZ2%M>_6U9&T^I^L@+&87IC^"OCO^"X&=9LK^P^XOF@>"WO M8SXHD9A(IDCB^H8RL^H3DHN-PQUQC-<
^VB:K8CXIW^TVIR7.%SH<31WY>G44>^6EW9_1^I^T4LT64U^JV^U&(RH6=BX^=@^MA A2^U^+B^ MS/I_U<
PSC^I^X^&^W^TYKLG0_3XW6T@N+>L>G4/O^I^XS^P\$27;DXI>E=M_10^XC%>V./@NYO?MJQ^PI^ZO=6^9H^I&9BOF;02L94L=V.N.9%>EX/U?<
0=;_M8:QJMEK5C<7UYI^#I^CMY&2_+>=I^QW^*I8DOZ<#<UKH?>#BWNKK92Z^JK?>6 M4_GOLT(FC<I2N^0D9&=&_8&-<
+INDZB^I^UK4+^N(01^+^I^A\$R.^L\$S^X^MX^XZ4<^I39>_>9;HJ^<0P%RXRH^IERGV%8OB>^;V_OX^AI^V%CT^JVG^M^3;72Q?-%<
<2ME5)7IVU_2V.0^"I301X>O>=>N^&DMKR^W73;I+I\$D)46.L6\$GO&^WZZL;RVETNYB6Y\$EP;LQG9^OT SG))&3 MQ5KP<
EK<^"FI2W2^2I4WX8(7#^I)CWY7;I1B03.^;=(L8?%_P7FF^T^TNX^MH;2;6IVTH^D^WQ<^@>9&BQ;W>VQM^I^K4429H3R8EV@^OT<

MZM17-UH115U6XLA8Z1+IMFF17D.5NCM<(P' <H1SR/7VK.CC2*8XU"H@ " MJH& .@H X.Q=6\O\1#+-)&A6:1+IF
VAH"JD-C3P4/4UB6MSH14E.9U1 M*SC8? OV8+ < (W9 UKU.B@ #0020S' AK4\VLZL[C19_#_5AJ153(MOYMTQ7&019NXZ8/0B MO3J*
+917L.FQXKHNYHO1&E.QB-9E1H S2AB8Y&#W15)H.<W.P.T&. ME-VB.#K"UU.+:).3IE8-
N'W2LG)STY)KTZB@#C?15H<^IZO9W1W.ZK':B\$0 MZO.1A/M"D.=C1?EWIWW_WOTJJKMY:HOQ=V/W%VYCBN-N;,>)MH(>40&0HQWP
M.E=Y101Y11':Q_<G7H:1Q^1N_+&17W:@1CN.=JH1+6=Y MIWA+11+4+7EO9Q1S\$G/SA #SWY\UK44 %%%%%+1110 4444 %%%%%+1110
M4444 %%%%%+1110 4444 %%%%%+1110 4444 %%%%%+1110 4444 %%%%%+1110 4444 %%%%%+1110 4444 %%%%%+1110 4444 %%%%%+1110
<1XZN9=1U PMK<1TFD6-S JL M49?RB11)1"1YYP"61/=-0 SPYKC70Q%%1Q4+1F2QMK6U=8KD&61'S"WRL 5X M/(ZBK1+?Q-I-S?
K8QW+BYDB.T4<@ZM'N41Q_NYKS74C+XDUQOZFB)<M.L HUNEK)Y#HLQ429_8@#D' SUSOO6UX.U:PSXFU'3+N'316.KV6Y6G1>Y(T
ME>F1DGTX_1HCJC^+1W7E.1GL.=J/EVLT.8&PY+ M-D/SC'2NL@14:/<7V.W92X\$=SQK-\$17FQCRJ@< X'7YKSJWBFWKPS12M.T
MMPH1=GC<2618.#.GEOCY74-M9QV.J7MB8\WD6>YQIY M#X2FTQ@1#1P)1 HB> M(K?#*#4+K5\AYIE174MW*T+Z5MS.1X/T
%:M_XKT73)KF.1O"AM=OVE MEA=T@W?=@QE4JF1S1Q'1S6#1)&/_ KC3XGBEBDCDG#++&R=9688R.1@CD5R MGBS4HIVS1?<8)1-16-
1E16K;KQ1\$N1)""G*1A@<+ SDF@#U6ZU:RLYHH99 MBTTJ1)%%&TCLHQE@J@G.R.>G(1:Q>*&#FTL:E#J\$FZ%XGT+6GN9\$<A>0ZSVTPC9
Z60?65&C=(G.1@<@YZ9B75= M#TOP-1?1F7<&IVXUD-OOP21Q)Q7\$V=W1%JWQ+12W;+=Z?)1!-1,1F'D.N>5 Y8< 8>,"FK=
M6QT/X6"TB9MY(3.#.P_LMMNR\$M=PV1SWH1#T_Q9H1V1=VNH8;&E:HR(MT9A_..K \$<==>U70G7<2K*PU&Y(O@PM_M.T'V.59-
G."%91P=IVZ#1R1B-MN-G?29?%OQ"BU)9)+&Z@L(W\$&=1X5E^M7&NZ19:EY3Q-/DCHT;)AF4.0-P-M&1SP1P:@NO%FB641T41
1M\$J1P32B)YBBB;&%>0#81'9>"1U'K5?P?V1 P""M_<W9V\$5G#>Y-EPZQJ&(<C(XSFO-%N1HZCX71V*P7%1=Q7S_9UM:L M1(JR) 1\$C!2FW
9SD# P3S01ZE?>+M1TZ_FL+G4\$61AB&KP*C.TG P%1! MKP.G@<1P<_<#XL=.O1J&^VU*016DD<CB51XV#>"G#9!&#@1TKG;34.*X^
M<1VDRB)O#Z(L@1B9F&XP=M&NZD#4+8ZD=>#1J1?FE2?>7.JL>=>1WVKV6G21Q7R&6 M169(H87E(1)N1J2151HK;PRJT7D6&?FW=N
MKF_O_P#A/C3 M+&1F==1L+Q;=H'4W\$42Q%E&1U(&=O7':@#TU1?T_5(K^PL1V.&^BMC.8VB:&
M54<4.HR.C&0".U@>1/&FGS^%O#EKJ61F75KVW41S>9(1G:7QM#8YV DY1 MJL6?B?0?S4=QJNGV;EXD)XY1ZXM6A,*GGR=S
<CNYVJ2C:>F>.AF@B^%GP^MC+*LEOJMDTJ8PT>QSO+<1J.9Y)1?>@#V621(HVDD=4C0?F9C@*1U)-95IXDTG
MAKU:"VO&E U+*YT20\$19D CZ.TWJ_X1QD50^(&GWVL31#6:2P9+J.VEJH U@ M11^C> (&JGA_Q7HGBJXL1NWTR87UK\$PG>YM&C<
@*OS+YC*!DD 841CGH* M(1.N&'PMJ1K.HR2+1JMU)KABS8\$11%&.IZ #D170)X@TJ_MM12.^>1K M-.7.^-H18 RY#%74\$<<@XP<5Y68ZO#1_@:
1D:UCG7_A1#1)1 91:(TY9:C9 MU(1/3)'7D5K:#2VD'CIQ1<2W%W);W6F6LD=S=0LHE51(&:1H 7D<^1QU MH_Z72Q\$>@Z5X:T8S>
(7NX+1^VO;LG?<GEC@>AY..1^4)X11^21W;+J66M M'31^1)YBD@D83;N8\$ G(1&7F1C/ GPZ^&T,KJ)+Y1=1T;K\$%F2P_A W+
MDG1D5U^FW51?76G\$.SS1^1TRV42.O1E619222R LL81%&XXY.Y1TR#D_1U MX501H<211/KH1@H3.Y1(1<Z/K\$D110>:_.%K,2/=P72\$P
4:Q84CV11 MA^%&TGC+07TJH11UC96.IAN1?LGH1O1X.N1C(SQQW1J)JEG/9JDR?V MBO1HSQQ-DY7=G1OR1<-BN-
GT61MO^<K;7#N=%126HN+1F1>%A=1.J/K(C* M1L1>=>#61HGAI\$-M1B4X\$1>0PD^GEB\$^S4.^ C:P2P=H\$. MLZN9-
402T>^70"1 OYK1KO10^1 MB&WL+E1/=>"%MY5.Y2?W2_1D;E./3F@#1(O.BS7UO91>CS;EG2W8QN(Y MF1720C.Q/1
)ZNT1>.>+1QXF"BP696\$OKLT\$33;1#*\$%C"YVCYR3Y2D MFF"> "\$6F:AHNAZ#<Z-M\$1JM1H5_O D\$8N(Y 'K?FYFJ=R=P*#<D=>=?
PKSK7O&A MUOX=>1)1_F2_L)K#SDBE\$+Q_1(4_RX1SGC(8#KCFNT1_2QS>)%1*>@R_9 M(AD>H4 CZ@15Y7+>11_#1QYHT@E34%OKX^2T3
MODRF#C1W Y'7GTH1^TC MQ3H11@:0.5%1'R:<@<2."K8<58C.V"><X1U/XHT:WNXK>1V1+>1H MG1H9C9NR".9SD\$=Y#4KNU;QGV1
(9H_+2&Z193P@:#N?3+& SW&P M'1FC3-1X113Z=1VN06DOEM9JRT41^5E4@11O0Y.130ZU1L.FW.D1
MRUM\$<FW1&&8^>1O(K"T_Q%H6C^%&SK1Z-VB1VUY=DH1D9#<#&1DY.M.E;LROPZ)22N1(CRS' ^Z1HBN:S(O PCHT;1Y&02&-"
<^H<5ROB'Q'1<=>)"\$ M6EZE=>=>=WY5T6-TBN(O+1^_EG11KRZT6WBA5 M3_K64R:T1
1MM_>13:GXHT71SP/861V#;ZFOVB\$6DF8-8^2ZE&^7JZ=AG1 M0'W1 P""&_TR1EO+5SRE218D)?*(ZCU11WGB_O_1N;2XU M11\$W%Q&4
MCM+>S;5YWK'LR>@W8:16@#91ZC8-9+K2X=80-5N=D@;J?Q=F22JL=HW M1OZG&::=7TK4/\$>ARPZY=1R3P2O.V1JR)=
(51WNI7/R@91..OOSDZ_1_9> M1>1TO";7Q1\$=/U\$^V1+9%1)1A:18D7_OFE11361V011^1AE188;U6 X\$> MZ_@/89VD#UO01JS?&+PI
D1OK\$6VWG.\$S*CL1W&1B1P1F'S'CWK9N=7L2 M2&^2?=>+1>*>J&D=U&L14\$X&1STY1^1PAN+5_7Q1="UQ=W9B&90T"1H M4?Q L'
1U12G2ZY81JWA+69KHJ3H)M1;BD.(KF.X#11QO'AAR'.671QD 1+ MTG6M.URV-OIETES"#&N@.1?3GN""U4=219>1)O9K1U1)(F&(2O\$9V"D
MX&H.31G@<AK_<1DNC H=RND:1P?21J1Y+<7314"2RL71X^1RH&<#17%9MW2V M6G_&1S+Z.1&1JRRG:H\VAN'OX&?UH
Z:Q9H5SHUO1UO1T2J1'REV#121@1LX-4-3FC7P13;4?;MS+=/%)1HB=7F1B0_1@KMU9C1DY M)^M>;ZNV41F7^H>&K1VNY-
0"WGA^10.EVX=5+Q_1P-VY.O&4>M:M.UG.O:1^#2>4K1.GV1@1"Y1)QQOBUUT_B'2H(6*4W7F"~3?;
MK1&TK3(C=N541)&#&G&1ZUO>G75HOC'XBRO+&(Y(K8\$5APL151OAN'COO M6'X>UJ&OTKP:72M:*+>.ZBEL99DE&P&W7Y3L9L9.02<
#1..H1=1+GXM M>2;SH.J2H1N\$866E"12MPMPNOEA&+X&G29&3^SKI=ZG^YLZW1OA_39-0U612UM8H1&1QZ#
MR3533_%@<:KK\$VDV61Q2W12EC#AE+*."5) #CW4FL7XN?1DKU1_KBG_HQ:K.MT+??%?A:1T15N7TMYYY1(>1/B,17RF_NLS1M1//XXH
Z2W16.)=7=O:PW N MYKEVCWM.3B.9ESD)(1L8V'H3T-2Z?XCTO5#1+93R2M8N81E7(D4Q1.2N'HR? M8S=C#Y9-812<5V.LZ3?6? MCF?2
3HR;#Q'1DU<1?>+&A+13^O3Z1-.UM.Z;1T^<1MV=>1>110+8%EZ M1@12_166WC^04T(ZVU1C35D.33^3)A&#&2&W*_-QR.M;8-4< "O#K^1
M6'X4>1" S071U6+41BIN1MNY15KH.K9QC1&#GGM01JH/CPIH-Y17NIQQ1M.M.S8DDB5&=@11@#D1?1SP?
0U9M_1FCW>B1.Q:W14UA.0D81MO8G-4*DMG MC:C>5R+Z1HK19WN:N=+>.7P1%YATJ1T6:PU^V MF&AKXGN;YH%C.8K>6/RUF*=0H.YNG
1*1/3H1NCW\$1^MZ1?Q_X^DF1HGA M1&@LC_1T_>U413QUX90KJRMK;58Y)+X?Z=CAG#C.W<1@-CG.3GVKGGK.
M#Z1=:EXCM)XSI47AIK2>X1LORRF01J@1C1TW 5S1J01?3X#H1H_U&12Z MN91+Y;QQW\$8B8A@64:QG^0D11NKRUN-147%FJO\$D;
MNR@YQPH1O1XQ576.EW&CB'4_7BS3M8GU+L.R6RF;.*1YFD1U"68R.D.MD QXGQCI1N:6#XL^<TDD<+1=KN9OE10N77<N11G1-
Y1/AJ1K)1T3 M+?E5MW5&*.S?>4MC^L>P8@U9U'Q1H^E33Q7=V5:VC62XV00(1%/OR%5(0'1/ MS8X&>E>4020Q?;218:5G348RT0&.&+S>?
EZ1)S1^V1\$FKP7=UXVT_R1::2 MP<1>6S_<H@P\$B1H #E1G:."8.2(S1C1708 MY& <1H@=3D8S31#Q/HN1-
JUKJ\$36.#1FK@Q'6R>=>#1@1T1H1WKS 2KZUN M/\$_PZ81^G1YHG+H5V.8X>2.D1XCNK.*2ZAM?%T6HW-O MNYIK51'N95_B&Y<1?
W301UW1M2_17LK"WOKX6FDSR2VDB1^1V1KA6531T M+81?2%NB.S)K>1^1Q1HY8".1)2_#1X.UB1_1#&4XXR>X'+PZY8:U15
M1\$O111VJWDW\$7GBVD11BZ\$#)7V/L.G6KB_11816U3#29;#P_%%<%>TKR M8).U3P>1.JKSSQL=71Z1974&N71N;G5H(9#E=HCDDY11MX
1P#UXKN-M+U&WU?214:7S(N8Q)YB&P?P4D5Q7Q9GCG30M^C+9D&KVLN0>6V*^6;1M=30 ?\$*5-#1\$1J-EKNH(4MXS^1^&Z-P^0P&<\$-SS
C>=N1?<C:GJS MZ51.WR2WJ1^Y85&@&0'196(PX1.#M)Q71#6.X6ZP(G60SPJ(0AW>82ZG^X MZ1_GBJ1FW-OA1_136=S\$#&
C>H1JY4+K Y>2.F2#=@14=4WBC1D08+51S;M1Q*8(9C<122#(*)1C86R".YR.U;=>=>9\$M#N1TWPOKVF.L\$&GNB-8RO MV>^PT %%%%
1110 4444 %%%%%+1110 4444 %%%%% M%1110 4444 %%%%%+1110 4444 %%%%%+1110 4444 %%%%%+1110 4444 M %%%%9>L>(M^T1H+
&1=BV*U*(8F961+GL21@24XZ&@#4HKGK#QQX>U*+4'M M1Y1Z>N^ZCD@DCDC7LVQE#\$>X^L?1AK44F>WU-"D-JEX1O&Z*(FZ-D@<^F1
MNR'QC_1T5D-VYB31+N^DL4DFCQ\$A11^R12_1^E5E189XS@1159>+& MU'2+V5:6XE>SLF=+AS.2*4?>^TJ1<1"=1"=HKG11W3;KQO
\$U74%OCIK_..M8.D)B+K^1^E0-X) ZYQOBK<'BC2KF1MK.*69C=21R?9Y^E90S.%?M'1L M>O...T;.%PZW=75M1?3YEOG8"V(&L9)H\$
M@F@GM5N(B1#BI4941P;.#56MIFG/9+)+3R>3 M6(Q'1\$1QUO)O)CG-O+1+4K'X(71X=N\$&3C+81^M;4/\$.G.9)%<23.14 M0GE\$.#R<5&
<@_VP'.UL9ZXH1_-2BH1>>.ZMHKB#MT41T.91&162WB01D MGCC>Z94F@SI<1&1).7-@DQLSZ=>O'7B@#H:HKB?>O'15O1A1 MRV*8;
1\$&.609(8113C.1*U+BY7P_X'GN1JYU'54LGD161R:0#+1_M0.PXW'L.F@#HJ1XUWQ1O@:50MEUP975V%NHOGB<C&1P5189_QUS1UT6
M_3Z)K6AZP1.H7-O%:(15VXADAGMLKH:RA@<1Y4='6+K^C:A1EE1CU MVZTR&1V^T1:QJ3<(1C:N'*\$P'YZ\$SD@=92J1>=VUE=641DG1FM#3-
+738WS=7-W1CS+BY<1XS@<9'M)137"Z_?NWB;PH5S:W44K33AH^&9_1&8C'HO'1^<VY %.D:UX11)1V& MHPQ61#1J-E(FV=4*LC8QX^6(1-
'745S=EK^GVFDZ1)=9WM:NG:A;K9)=VC.T+R@O&R\$6*1K \$\$\$\$=Q>+*1X@:OH6OZE<9<1N@TN+SC#1\$5\$SAA@.Q M1/#9'1KJ1?>
1M\$B77+UHGSY(O'4R1V9&V811U'XX XQ14_1^9-1XFT MB1@O1DNQ1^1V16X1HF@XS1RL 0".0>A15&GBK21)KJW1KDW=M+EK5K619F
MC)P&5&+1#1'01<4_5%:38."Q5_21GC)ZGCK01H45A3^O M#1OH1KJTF11_8+118HIU5BIHKC/\$WB*%M1^1Z19ZE<0Z? M1J4D.X+/\$KJ12
AT.#D.O0C1^0'H7&EQRZG1J4+>3>1KY3.1D21\$Y*.XS MR#U1B0:=GXNT_110NX1WRHM.+S13\$1#019RRN-0".0<1=U_1238 M99X1P0"?
R9H1APCH^HK&C14:5=-061"06TAGE90Q8^1W: M>#>OS@XS43>1"101O63=R R+2YX+B31+U)F.U.#+MW#1ZG&*-ZBN=U7Q\$X
M=T6YDM1^<T=MHJ911Q1K&X84Y1ZSP3T1JHUB2=7U?T1RGEDNK1%> M9M\$SV1PR1RR@1Y&M
&Q17*ZCK.C:C<:#*=7U&S1R_VVR0D\$MU(NY31(" MO*\$1X1OUK5L_16F7^LWND61L1OK(KB)K>1@/W3EE.
<^&VCG5Y1R9'CCC^SR>81+G=M3.N1(&#SC^04NDZS8Y->?#0M1M7CML.P@&G:N11P.&ROX1^#7># M&EA1V@R1ZWJES)=5N1<32K1)
(OYS+&1) (0= -0% 1^9F1.1^E(MR1 MS-%Y1P018TY^9@<1P>O71QT-7+1MM0LH;RSG2>VF0'+&S3U1Z26^M76D".071K1 MJHEA".0?
N1XW^E_1<1\$T_U%8\$WC70+RL+RXO72@U1MML1UO1C.C.2F481D.G.3DXX1.S1X^1M-32SU&56LT1(N51F2\$\$.<#&90WN^1..CHKE#Q1X?T:P
MSHCRZS<7%K=1D5K=W2N1DY(X+G.P2_3SCI5FU1..#?61M-9W.UR.A9^CBAM9 M6D*QMMKE-41>9:6&B7ED)KVWU>ZC@EAA=E).XG
SNLPS>UR.GH1\$=Z=M<=>=L>1W.P1Q_LW<=<1L(B+@^5*1@D+USC(QO1T5>12K.GB1H1462198GG^S+<E%<C.N<1/M-
QPKD\$=>HOUX1E1XRT13M2F1VXN1#20Q'9K>*YDD3R:S5170>X.E.H0F.K56V46Q_MSL#EP=<1_KD_W>E.FDZM8Z1&G1Z1<+<
<6<1@1@<@C1H*KZAXCT31 M9H19Y96D@C\$LPZ0/8D.S_<1P>.#UZX101JT576GB10^&PFN-1C\$H1>1L MB\$SK+P6X901T1-7=(U>QU12X-
2TZ8S6DV=CE&4G1*G(8 C11/101>K"&@WD_MGB>741K61B?3_D>#3#&1QO21<BPY:N0#P1<1X&R>*1&AN8(9+1D\$1YMH1V
MA<00+1D68).3VFHWYAG@<1TNGDR.7+1R1N\$=>3VSTZ_U="RMA M0_#D%1D1E.C#&C&8YR
114S>.H1C1=1NYKQXD1T17B2021"1#D919T1H1 M'G.C>?#HK^TCO1H.07%W1MUYTE1X>6R@P2N"0_0<1G151?%L3^>Y1#
M0M+D&*T\$13&1R&+1/M&1"PO#9819143>O1#TOBOPQ=Z+>19K=^*K0^<0 MP/ W+SQ6W\$)5A03.CR_?R51/L"3C1S60?
%FC1=6L#W3*+N7R+>9H7\$.1G1 MU9"1P<1X5523Q1X:BU\$Y#ZB11)Q^PR%/R1^>G_2UA+H-Y M11=7FHZW<1^1N1+
<2Q1JBV1^1P1>1X^S^&#Q:1WA_+1_9W6-N M9A;21CW#<1.VW?>Q1V.U7L?>C.CK#Z5.73F16(S17A=0D0'19&817&2.5) MH_V1Y30\$7A_2-
1UG57UR1N113(F11MR%17^&C#G6M^Q1Z M1J6KC2161KMXS+&K0NBRH11R_KXSSMD1H BC1.W2>Y2\$C.A\$T=5T1 M1M1E=Y1K-
W1P%<69(KR1+1.QD^X^Z&81OE R<#%:%MXCTNZ-XJSNDMDH:XAE A M=)(U/C8P1/8@&@#5HKF+7X@&+V2P6WU\$NM^XCM1?

[illegible]

```

HOBWx7N$!^2VM+;Z2>XCM)&B!H7:~X7'8_30 M7>T4>?>~.8+K3_%>D>(#HD^M:7;2V=W;V17FRPFI1ED5/XONX/M6?XE@BNO M TTF?
PO>6(NM2MIA'8,J0DJI,CH@)7@'IW/N'~1HH^1^UAIU/PB4=0L=,N MK@+X=GAB9I60I/9%=C/;@9 YR>.G6I&YDNIF \#B=
(UYI+29D0C)9/I&D+ MM RI$BP JIC@~"XOEB IK4+I/PT9=.L9+M_M$(F$4 FDBBW@M(D9I#;H&O_6H5R=B9C/&FNWD>E M:X;^T6-
89YI+5V9D3)G..XIKI'fI(G;J<^I2^&A:Q^KVC0.E;6;75JLN&X'ICIN6-E8I0 MRICD&M&HX&(I+)8HD'HTJ>Y.23ZDGDGO4E I+1110 4444 %%%
I1110 444 M4 %%% % I1110 4444 %%% % I1110 4444 %%% % I1110 4444 %%% % I1110 M 4444 %%% % I1110 4444 %%% % I1110 4444
%4=2UGVTMT8I-O>:YD$-OI&M.E.O^<^<^8 DDD $DBKU<3XIMJ5M=5I^~),LMI1729YI1D2V,I7.SRVITV.R+N&9/WBTDU8Z5 M3Q#XTI:
-QI:WD#KI$5S-IO;^Q:1 BOA6 M+J3@<?^44 2CXE:VCGH^@U+{#H-M+^I=OY-.DMP9JR?~N?&QNR#&UO<^G SPLNG:E)I#I8TI=*U#I?~R/
M;FU<:RM=>8"ICIMY 3K73S1W0^9O5L+IK+4=$2UCGN8X%GBD$K=^<^%8;~MGZ=>~J.QEIHNIHT=REC>SBVM/HI>0D@#.=PI
((#$:3ZX(JK<^I+MSJ MJ9ZIV:Y+PA;8V-GX9U?P#YNIV3")=1-E&U MK(JGY9C*>:9"B7GV?4RM+TVY$&CE=P0,>Y+!&O:
%I5I&WY4OJ:66>VALKF808;93^UJ993,I" MKDL 2I:~T'H#TJ B#O:ZYT X@:K;V5TQUNWAMK.V6%O.E.<=>W40EHH
ZN/OYIAJG@J"NUOQ:6Z26Q0W3R^67RRV.PP.M)MM(U+4 MB^B-LF3RKR PH(FVAAITWDS$$.<@>I9B&U^1?#CVFG:A)9M.BWYMK8FY
MA01D?^A&YN6VE>I>PRW<32VLLIN4CN HI8(3U(IIZ=,1FF77C32D8 M+I+B+E=.FNLI:@$AIS M+I+X'L^I-VW;IUB:FEQ<^I
UW^8WQ@MHKD7$@M9 M:IY)DA"KNXXY'MWXK^*6.FF6$7A;6?^VO4;1C^O'DLXGM9U;RLK2^H0;9' M+<=>0% ^H
IXFM:6I2-VNIP6(I0&M8PP@R-Y#PD@I=ISA03@CGX0YQ^Q^NEBZT6 M^DXM9SICN8@&CH0X=-M%IG.T^05 ^,I6L"#PUJ?
4PYX%EE<79TFIEEO(K>I->(2KT4>XUHO@:CC80YI.L);%5@>,$S($/C^I^M^I V Z8Z@C@6PU6STSO/86DNJW^ARZ4Z627MO(B;=E9?
^0LH=TP5Y(P@.9Z MT->K>)>JL2M I?>=P?;S:G8PIP3^H*%*(I9B>#CGGKVS740:@MOJ-U9K I,M#;=I^I^6&0
0HKC;K1)6^&A:L I^I^4=(L8)X^G0QM;W, " @G/ M3E2^0FNFJ/PW2;/#~?HJ7IT/M%RH%D8#Y?>^C^CV44 3 M^30YCGIAW2;V$L>
J9P#C/I^2:3^6VF:EHJZEYX#7IMPLIQXF&X8JR0J MLC@>^>9+LVD@D2VI^VIE E2-2(CI^P&BG^76N-ETC6#HJ^YI>P%<?CV?BIF
4_I/N8^GVIV<N5#N#1&RIUXZ4>@R>~^MH-7;IBO+>?28 MQ<=VSPH(CQ#C2&4@>I QSBBRK?;7QOR0I^7^81^YEL5%R902@B)X^H<
MGH.$YQS7.7Z0ZXK^I12Z7X.N=*ENM.EMD$E@L5S/(RD!=J9.T'NV'D^V:7Q^MIVI77@OPO?66DO?RZ1+#+<:9/M:5!$T;f%8?>^XD?3C/%
^03>.=MI?5VG-MM;Z.XTEI>6IC4RI&1D2###S.N>5)Z5+XOL8I^5K>ZV:UM#I^4HDKN 8I MN#MYI^VJ^&DTI5(IFY@I(OH;T7DR I:
^I)9>=J5YVVCWZYXKCU%;Z @6I MTR7<+@O0G;@29RS^6 F1N?Y=73YLJC +X&XY M^YZ8^K^I5:7J5S^I0@-A+K&IHDI+^~G997<4X^I%>^7)
I^N^NEJ54@I@MZOIMK<6^YB=GIAOIQL&>3B@&@I^J7POXOD08I2N>WU^X+R MIH DL(C F9B?
NCGN3@=I.BD2:))8V^QNH96^0@I#7ET=I?P9I^K;^S;I3 MZC>WDEI&:20&99(EI^..YI^G7%=3I&OFS?P H6IEIC(=<5<^<I^H
I8S6=IIM,U^ITW3+I3M.34WTB-6ZELP? MM$>OT90#P6P^I^I^&U^SCLIS6K+P5>:9LAP4.P2^ZN&SPBHN2IH@I(N8ID:~MM;
^&#NA&06R1D?FPN3CG^(RZ^O3IU $MOK-EIH(F=ZS/I^2A1Y,==@EVAJFG:O.EU M:SV$2N$?RU1HY.DI!HP2<8JWJZ:C8>
~#MS:5>3P"OGMUL(S+Y$CE&4# MG;I&HGVH DUWXA);%4U^P3=;N19K&I^I^9)-B^3+N1W L2^M6YN>~>W0PE 6EC$T+^?E
(VZ<^L373:O+<:CXYI%ZC%IFHL0^I=GM7 <MB2;FI "2.G4=I4 7)OB/H5KJ5RMJDL6FW#07ACL V<I0^SMG&%;ZIC M K.FU^S2ZM+2#?
=7~W"UQ#%I@C)B&N2Q ^9IR>2:X&^UO3X2^I(M 9NH^4 M;JI>S0VD@.RR0IJB%>I 3O27-Y+I$J>%K^WTG6&OHM%;%P+<^$SD("@IMXMR
ML^&0V<^<8^~I^W&A>(+@+Q09OR:Y9YG+&38V^LSENZ$@!<=C69R7,MDVO6=6^~21X#)
CIB5RHI/IGB@#&LO&^EFT^F^D5VEOJG.MC=2I@I5E03@8) M9<@SGH7I^I-97I2$=6.1RX.CD (06.1R?0'N 7.6ICTSXF^*YYI93;O::RE
M&D+AZS?>7U;3%O@NSM;~>RD:WD^SW,L7F;XF&,$$/@U^IK6U^_O->M-MO:UX-%U2^I:5H;FIMVM)";=0CJO)VX(8M34K>I7V/ MA:W
+I/O+ZLMIIMV\I^IHOYI08I^B:~2V&@TG@YZ4/D/C^SGM;E2Q0IVC M.4NXC&N$+N.I.T;OF&WGCKV55IV0VM IVDWEM;I/<6^?256;+I
JQSC.YI!50V<VJ6&IVK^YY>I>E)4KD$&YX\XKSLZ MK%UX-U^C K7IYY;NWJ32;K^8W<^C)W#YXN^PP 37EI;RNY(I(B7.PX.2<#D>=><
$WBG50?>?I2I@Q6VHVZ3.F#) ME8EYH +<I&KX=IPX I(UU^XPTW3X=2G9+BVTO@EI/^98#@.01G)P&I^T M&?
K7(ZCJ>I^-(CPA.OAG6+>6QU)+Q);?:(L1.IP2?F7)^.L.G:397LEGVMQ^TC+;R?Z.GE-$%<8RI#?0>1@YI^U M@NO^I1=VGWX^WN\6F;23H#
(QMXY^88 7I0IV<^I#F.K;LIU+I4IFM8H0 MTD84,7YI #+R2.H6ETQ^9#>((HEK-9U M.T$RRQ?2DBG#)Z$@I<^JHIL^M^CP>+I^I)U+^MH I#
X&.>I:~L^W&G::A#;V^YH MJY)=>WB:A:~NSRDGQ^05*7QH=I=IHUTK74L.L^I^H5NS;GM+8.UX(VIG/
M:LS69I2;QQ):7.E.C/V^BU>QCPLLYMRS52 C QA200)SDXKEM;IIL2@T^X M=6T^C.G)G)HEVYNPUH IM=CKN:TRP-GTYH
I^TIQCI= #JLDHN+IM^P.R;IC MIMHE^I@QY/I&S2*YK6=4;I^I^@?%KJ^H?7NF G^5)4IAB#M# $ C/I@&YK+I0: M^J^L:A;I08;"SN5E08H!
IY862.X:ET#&# ^INHQ?~M9MXK.X+T+BWV>47A^8Y/(R>O0IIT>@7II:98RWEW^X(AEF0I)@ I^R23@ M
#DDXKA+R>X^+WAM3;7H6L.MGBN^IQA-I5BN?O9Z^ID=V2B#INHXCZ7
MSI4)N+NTNf>I6VW8^I2^Y3/J<<>X%8LUW>ZIX^I.G#H>KVUTP.W<4TES^ M68F<I@9I/;&=>~I-^IWC+3;1K62>.Y2QNK@6T^4I:A:0G
&O=PI((#$.3 MZXP:QM^802$G0LQOWM#;JE?^8U< M.%XYON^I9H CTCQ5X?T^P)HH80:G)HTI06X)/G=6.A4.RS9 +9P3P.IQP
M^ZYFUFWL^I6LZ2(I/LSW3SG;Y<2)K8YR.HI<I^AQOQ6A^PVVJ IM?>~JVLH-M)%-%Y/$4-C(S(P$UQF6X^?DLI^#UI7OAMJ<^&L^+?
7M0I^9D>FQ2BY/HS5 G M;M)I4 =^GBVQ.M.SL.BWO+5HV>S>>I^~W&T.B^P20V.=K ^YH I2=7N5M MK2U0.U^0^I^TBV;
I8WB/IW^Q^IC@X^7Z9^8WA2XBO7LX\IWX?R;JEF.W%W+8OK M%&RC:I)ORO/.. YW?AXLIAH>K+>65Y;L-3NK@+I;I>Y^RLHOELCL.?@I
MFB>#.#A^I$NK+>I^?NIGI+M^CRN&5ERY).INSU3H.U.FF>+I/U+4KW M3S%=V=S9Q+Z7LJBW^I($BY AR#UPIW^>0-
I2M33NYI/O-.EV_6TD^EIIW$CLR;B
```

6DCP&X1HQ&M5=00."CMS\PX P#K5K4%%%% 11110 4444%%%% 11110 4444%%%% 111 110 4444%%%% 11110 4444%%%% 11110 4444%%
%<1XN?;3XM&CMJN2*E M\$>U<OLWE0'_%A)Q'RC'(W9J5T~'GGQ'1+R)H=HJ.@PWIOK6F7<5Q8Q M~)H@2&5Y2&8@ KGTZ 58U\H04_?
@I4TTN.CMI>Z&Z*TEXD*P-UBA5;15(R.MCOTKZNZ*P-K>T0A9?513IUZ&U*25K;@IOWP-1C'IX=>O2LOQ1-U2WA+Q
M+X6FUFBSBT6+3+ZRI A6GMI\$P0ZH_WNT@>7?'"A^9Y F5W>P)._#J#47B/0M0UQJ7XEAMK:XBB0_#PL8+EXF6.MS;W~;3C@88<1.M>F44
>8:AW1WM97144+J5E;<4E9R.FTDC/L.F75**M_.M4U;POXXU.X?1.F^T_5H+;RGTY5*VL4>POE6(VJ>H?0?RO)PSLK_30!MT=H-C-9W""7-
P~R7'(>9W1&Z;N;"B@>#@KL74/OACUB9M<1VJ M.OFFB@/#)&U;Q4OABV5&G;A16*FTVOEQM%)H%L%Q;L@<('X<@)Y^M^0UW%%
'1:#QJH%\$~+>V+;HC7)6">2<=>BCG1'CL1+U6 M#X;^\$~/2+_[98ZU%8LKN5R?9AST'=7Q1;WKR^&KZLT;B16PU;.>.>W4
M.XCV.I8#1."PKL.C;C/I2T<3IBW4?Q+UO4YH/O8K2;3K>)&A)!="Y91G.M2-PICVS7?66AZWTWACPC?MX;DU\$Z1>17^ES1\$S#~)N#H&X8@
'CUQZJKH MH P;P~22WNHO#PT2&4KLADBCCF?&F<(2IUP/G/7UK)11W.GQ!W<5C=R MVEBEV+P>.%F6.R(H0<#G)I;Z9QWK M
00"#D'H;.%T&TWU#PMFWB>UNI'YNI?2M4+34;*.R?3S 8FOI@;HJEL#IZUB:=X9U#PVOP L MKBY_LHB2IE@C+I M\$94<8SW 9!<=AF05:
..DAN5^+JZB;Z^PKHK6IN!Q3S?_#I P.D6276?M7K>1G&1D=j6@C-M
3T*6Y#20;=:H1I5DW+G.#R;UYW_8NK:A)T#7.G30ZFB1V32I.P>6CK M^<^G0C8.X^JGC%>I44<303GK
M70>)O(C:58HH98I;26*..)'S.S(O)<=>_?H6M5>5M(MJ9M5MKF2ZC17#@VM MU) V<\$?>1@2>F<4
>6.#2IGPUX.M8M.T#5H>A>S7.<=>K08IXRG#>1D>M"1T?>1K4=[XK]QZ/IVD7\$-S;JL) 8"ZV*V*Y7JR@*IG^+D19K6_X0+2/^M?
07/_IU=P#QRC_A M(C_Y^I<P#IU= _IR@#>#./BA?@fKOA?6-%05OH+. M.VL6\$1(N\$=2J@>X)QSCC'H:P7L^(\A A%OAQ:#1+ISZ/?/?
((3^Z7S@P/O MD<19KUK_@+2A GIUS_P'5W IE>I?1"1.P>N2^#HJ_/GE) P@>CY^V;YD=OI M;N_(Y0IP&N^\$=6L_+&EM;V5S>P:."%%
I2_Y^ZOP.<8K7Y)Z+K& MB-&+O7AZGC.>*ZI_ (0+2A GIUS_P'5W I^G(C<^10=MR0T8 ML^1(XKU_Q_1Q^&+3?184FU(6I_9XW(9!<=<@_0I5F
@I^1/AWK @Z MN_1X5YK30">G:7?)>07&I^P#<+G<3)R.M'730= M961+6X(NHS:9=I1.7RWJR!&QT7.F:3IBZU+1/%7AL;=K>K<73PLP4)
<MHC(OEG.3E3Z>U>MT4<#?ZEK%WK^DO+H.L'L)K-LPPJ2_~PPLV&+U-HZ9 M-)@ID)IT/1-1M=IN6NM!U6\DEL'54SPS,X)BYY*JPQP.YXS7L1%
'MGOC">25_%PXUJ_0+ZVDNHDBM;69_AVW98LJDA1@#&3C@<HJO4K4\$S'CGPG M=Q65Z+6&UNXIB40_IJ(\$SOZJ?
IWKNIJ0\$;"#CK0IY5X1+L+W2K.V1-GX#C MEOI;B'51!\$;1%RRLY;1..? 23Z=KD\$>M:(/%VBR:)?7JZE<7-Y97=N%_M-A*OW")
@E3QIGV5Z52@>=2I0!@<H>Z_L_VAVELRVUS;Y44.D4N.AEO 1M"22N(O PUJYVK60Q/VK8W+ZH6U XOC!QZ2=-64IAJ_-2S;=:L)B5LJK='W;0
5)&D;DXK;1=?:=MX M#URPLHC+=W10M0UCP)>#1M2ACLGE;Y\$D';0_ Q@ MLIGJOZ=<NRO>*>1@620 2/%O/EFP_Y7&?WMOJ5KIGQ M;6F9)?
=%%@.S@J1GNV.%A2MHLHE+LX97=8IG& M 68DG=P=QXXZUZ139(TEB>_0;D=2K#U'H_+LI=%\$JN2!><~PN3TR1UZI3C+VLTO/M'6T.8K;S4
125X;K(KOG)Z56MK2J6+XAAM.O1 M_-+NUGF!OWP_C&_/PIPX>E>CT4>1^2J3TO^FLR^&)=8M;?1H1.OH!_M M/ ZI2'I'X;D\$<=JU?
\$%I<7.B.\$ICX9FL0NNVUJH;NI(48&GD'94-OT)QOC MT/2**..&DLINX@)N1726 R+2XT;2.X;@GFB1V4Y(I&/3MUJY1-E0;P-
MHFGW^FW5C<6.*V1BW.W.O!X)R.G/O76T4<)<=?CXCZSFONS::MH450> M1*"D3*9 VXDC!
8\$>M9")JU1)OX%NM.FBU1\$2R.I0F#RU<8F\$G0C;X^IG MC%>I44 5Y<6FGMA9)1%@I5+VIZ#I.TL?#FL76P-LP%CLFAUBS\$<@M+M-J
MR"/) ASP0P&N.>=>I>ID@ DG %>1%@H;R9;O A;WTDH(SYELUM&KEL?< MBV99AIX'3&#GC'T:SU"/X8>)M.FTR^BO;E!PP- VYQ;7*8QQSN'?
C07E% M'E%YHIV4A'7A)A)A)7@L1+GZAIKP9JHN\$;1%?>D.A'4>QR+NN;JDVE
M:1K^>@&OL4VFZB+S^RBL<4L10HY(4E0^&.IDG^OO7I((!!!!Z\$4M_'ZI< M;IXL#;_10H=W8<~?#;P7FU9I9"C#IH8A1G-63DYZ
#G9!^3S3^&~/%Q8W MS5E%#1\$8KE0KY30">G SGKZ5L\$A022-U)1;_7+?4=IU7QW;R:12'I+&
M>VN8HPT<@=:4VGI5NM#51_>3FJ;Y&HCP9V/3^S+XW&F7MG>1BIB85BB9) MJ>2.F<IH2HH
1KTPVNIUG5="U+P0VLOW#1_>=66HQ0Q.K)*Y?;SD%-DYY MJATSAZ^GEV!<=>U%VH%VQC"CCL.PJ2B@#OJUT+7_&~;)9+X?EDU#PIJ'GRV5
MV\$>ZFZ4.L9I(ROD\$C IFNANT_M;PIX@_G^>#9I(FN=.FM8XY+6-)YX&0@ *MA_%IMCKYQ7HE%_G7BBTOHX0V>G6VFWDE14LT-
N(304Q0&SYL;13W15HW M=<=Q+14V^U%+*I^IBGZ5VA;1D1'16**&4@>@I""/;=- MTXOI6OV6L>&IVLI010SSFDQ;K+
XRLR!#D%1T(89Z9P*TG@JSU2P_M2VNI J-M'NM+29?I_EU_I1LVC>R@>1%@AGCTQ75T4<5?;7N@>?C5M6DM;BYTO6+6 M!2-
@C.C6IL(*A2IY;P:0.9ZXKGM71~G;_ Q156T5A<2ZAKNHS7L5G\$NY MHP!BD*Q'_U.<9SZ5Z#10!PWA72+O2?TD>ER.DGAIK0YM-0#?Z-
/N&U82_P VY~NR M.5'&~>WU^+;)KN16WQ&4ZE*WJ MF^>K4S;C<~%H2<!)%HBKGW_.U=I?ZW'9.G9Z8I?_?7BN14*8&\$0#2_QM)&AV_QNC
RDD^<#U7Cf_?2?XAV-OX;U36WTS4?L M^F3-W* 1%UD4I6&- 8XYIP1FKD7C&WD=HWTW48)7N/(M4GB"?ODWTF)-H M4\$DG&8QD@50FIP-
JOPX12Z+16@25#JIV VB6?IB59)H?7R 0VS;A'XY@ M8Z9W&NG;I>CP_K?C-2ODTV5/IEQM518I%VMC=QN7 (-SD U+7QSHK M-
~/WFG3QV1IH^TN7DQY04@E6#Y&#GZXP:5?&MHN17^FW% E=Q7H;?;O(&QS M-
#G!9^K\$&@!\$@>USNMZ1J0B+PLUSIGAJ#2IJVNK>IMK&Z\$;M=&-B6632H! MP 3ZYQFM'3.B!OM;O9_<+>?1V%D&4*O&660@ *FP =ZY+8J!<=
<#X0B180! MHHM)HJ1?JY1+>[>]2OFL'5C*ABV3C&0H/0FM'Q:64ISJHM?VEW14VEPB MXN\$0-C^IO!%#P(<4IBN0D&NG@/P)8?
V3=FZIR_LY.N;Q1Q6%UO MC;L^C(1#FH^C)B_*VGMH1T+""Z=<IYRLI8<@#YASCUH Z5Z&=JFL?I
MMW97=K)J*.UFTFPB0JNXH=K\$JV.0#C/KGBLM_B?8)I=QJAT;5086ETUK>3F) M+XB;9(6+;AQ>?D;J3 MT.%HNLR "WQ9I0T>[%?
ZA%7YN;ISTX%=97#HJ4'Q.T15X)NYK;XT;I\$SKM'D M2><'.1\$C QZ9I@;ZK2;ZIOXKA!O39K;HKAXD25U8R(IXD&WH#Z4 7719\$9'4
M.C#&#PR"/OUP/PLMH5A13B>9'KIJY CGDK&K#;@/91Z=VYV(X)S V@G(C) M/TK@? OJHZ;Z!M_HFHQM=ZS=7D(\$MNC D(*IX/2@#K-
6UY2KJPL (FN+ MR_D;WABP_VU2Z\$SEB A;O:GX@Z;=^+169;<^V6Z%&IA54+Q2AE7GYL M\$99+03P;IZS>=7D+30YWT;_?399YS?6EHZ+;BH
QWCY3U8!O8DC@M=Z!KD M?@SQ;HVARX26UM;RUC A;90QIX6P#N'0(V>@S@#-'H=EXL@NO\$;)/IUJ8 MSFW-U
IRI19X@P4D88E2"1PPIQVKC_B%K<L^>+ZMM(N)+35+46I=NT_O ME^&#&X*P!_!AZ'9!<G7M139H1"IBL)H-
B;G^X24RB.#Z'KTSW&(AT#6;CX6_XNM M/D2^5!9BZP#_8@X(F#9_N_P>8;IT="JGCRWTW6!O2T5!VMMH\$N&2T@5 MJ!;-
MW+V12!@XJEXUN"1P^&(+?3IBXAM;6>&6>LGE""HE@3L)I_XIR^M)HA=VWQ1NK0I@< P!GG2C_Y8#;71Y8CKGHPYQBL\$Y7B'2O#?
BSPM_8-W M>_;/MLMC>P/Y>?^10T3_KP@_J%K4VN:S;:IL MWITLGH'2-4B7+;IL%51G R20.2!6!J6K;CHJX8TBYT""RVB0W%QO0K;2*H
M4*PI.EVRW+6LCH;C-E65P2.2^0>XOT&@;7@I5IK7?2'6F;E>6I0 MSW_M^Q W#EE!RN<#GO@^U9_K"&M)W^X/M0!%?;7
M1^XUE+32+IM=CT^Y92X59XMQ""N6P.<1X'XU6!>.>9+P:=K.HV;LVZ=(M@W!CUON MSMWWF6C39/AR/E(YSVH Z/Q98
MW<~.FG3XYKR;4H# 2E;=>..PKG0)OM/BK6+00VOX+>1)TTWAVE7HJZ9;7IYE23!WHA81MGW0-Q MZYIRDV>3<=XP.<I20/SH
QI?5A\$;V;_6Z1;QQ;YJ.C6NBZI>7IC\$DS1PI& ZMG15F<#
MMW32V1KAI5L\$VVKZ+>_ARIGUFUU;X:4R1F(PK;46XW@Z5X2U5=%N9YM^*V6HIX^B7RYI'P>^VL1A MI?0# OA0I&1EHVR1OMY\$3 !GE
_TG6?E&>P?_HGO#&TIZL\$C=7\$%L'K M7)G;-KNVY=V2V;IGI'/<~'3I;_UTN_DTK58="U HB.A)'OEIN_W0V&R M>_X(SWJMX;L-
1!+I2QX8;SN)=@1Y_06^561+1/SDX<~CD&L70L I13_M9TPPIHQ&TZ6PDN' \$<=<22*Y<GDD+@*Z);MZC%W*RW-Z=6TD(K(MP"P*-
D!IC.QSGMOD159'BF%(9/M-C=VURMX+*.VDV M;YI"@D^4AMI7:24MQ<GGH(51HGG@<9Z32IXZE1=K>FWDMS/&KFS&8Y"1T./MRH
R/OY5#J3V16A+2V-SE>* M9GTN^GL7Q!>F=6V1=EO'04 GBY('7?7K;1KU=TI5!TS4-%09KK? MJHJ'V2>+!WN5R5WGC&-DIJ;IG2-7?
PIXYT1R+P7>1A=RVDP95%IOXHU&MRUY/PIK-D'9KK68B&EPP1H#MIRJGW%+NN76L);7NA7MSL;Z9%;1JZ+% M'/@B3I0"W/EQPPP
2;R+2M;B!> K*70IU.C2=2BENT^0E8T212W#Z;VUFVNY1\$!L<=>L\$>2/7I0!=MO%R7442#2=0AOY!*PLKE4BD5\$;
M:68EMNTDC"&ZMDN&N+BZ>R2RYKYPG3)="IJM)SC' M?I6+XLT_4I3QC8^);301KEBIEIBNI!/">.%1Y=9\$#1D\$?Y\$&N;KNS0/\$ND
MUR;BL+717?_A.263&TVI@N(N+NSM+N1=IK1.(?2JAL8 SVR<=K%_8WB M30Q'X=U.V.U:0?TMS-YZ!7+LFT1J 3GI22..3G@
ETGX@66KR!HM.U.&U5 MIA)I(N6)1#;M#G<)&#&'<4="P/&>I+J>H">+D:9=0QRZY;M! 1VYP1BI-\$1ZG>_#7Q%X?
N+6;PO+NO6HDSX"U!79D.03QR>XJ""O) MK.F^&%(92""UH=-7JMM+>9DAV\$1HP9HSOY7G.3CL;_10M7U6UT32;G4IUREM M;C7?I
1+8VGVQP&B?;1Q.TA!\$@*<@XISFK^OJ MSH9J8;8-3W@ (UD=OJY2P#+IQJTGJ<5Q%IX6U".V1:5I/V^0.W29(+>TU" M0GR+E@R18MQ+!
""XR>_I@#J9?7U+X4VMT4USV:0!(3&9_<^@<= M14@!IXVLK_!%E=3Z!="TF0855D1HVPD+G_1K/A@>?*?IN_#I@27D(NH;4UF0
M0^7(Y?>Y.X\$%CD \$GMZT %O>G2/BEXL>TTNIOIGLK-(M%7+IYDDL54?B MOW_9KI-Z"1=K#G!!I""/PKG_-@OK7XD>(M1FT^Z^Q
MW%G;IQ3A1B1H1^X 9S_<T 3) M9TECU& SV=ZVP03_*&@HLL\$1^2N3M+&50#0B36+;2P>NMV>H7TE9W7TE M?YART~?Q79+H-
WXR6L=K MO?>01 H+D#B/OA>I&D8 M&>M+R&GBB\$Z9:7DMC=P>2^5-V1NP23!; (PO &U2V21P*JP>_M*(UA+Q9K
MXT68;J0Q!CAQIA0J2W=ISGC KEM4@I5ZYX>T'5Y_#ZR;WHUR7NM.G*BI 1MD99?9IR<#J_=%XI#M;M-I<^<DW%ZMHLCB<(+1^G:0&#%0P
02.HZU57QYH^'= M%UO+;I.SU>*>WB^5-T;2-M7>-W3/IFI="UC7<0?;O#1^COK&1-HD1BIXQA M I/RJ3N..@:R2.\$MM)1KX1.Z?#EYHJT?
4I9YV.D021(E=0..IN1CUVB@ M#LM;15W=UXS1;9=V+6IC&1JM/N\$M?&GPO0WH M^?D\$5A=&#YSEAP?RI/WIL""QTW40!\$-
C>V>U)1I/E&@<E28XLV/3)R3 MOB@""XGZ5?P'PUU VUA<7-G&K1'179L\$BOM) W;B P'D@=<1I57HD'A?9I6 M*F_@C@C%>2S?7XEM?
AEJ<@<^INYN8UECMKVL2;R9XYD+Q)<=&YQMQ^OY MKH!H PI'GPO+I\$X&G2)L%E.GRD@GZ&@#SSP#HFFWJUXQCNK2-98==GAB+I8
MD"H0JH&3C&4_0=0NM#1;_P"#+R;IU.P2R&H6(D(L3EN3ODYO MWJ?P=-.6BW'BB6IT+4CINUB;IME14R!;0.2P
IYG@D59T0=2B!0_UXQUV MV7IY">+VL8&C06ZIA21P78@X;IZT 3>'0\$B6?@_PI_8EA<1VFH\$P;29LP MWIV;YF;X1CU/IR;U\$150>00G6-
W!>27;6<5DX3S9)-QQABNW;EMV<8%<9YXH O?5\$157F AIXLM;U>WNM 7 M9+&_HRK_"LK*P)!!!Z5F-6NETIQ9#&KEH=OIU_.2W-LTUI-
<(H2X5;MH#% MER#@A@#BLQ8^N^N^OAOQK4*122IE5FR(IOP\$PIQIHZ=>377>
M%K;^A1;^++NZT^XM!>_FMY+>20#;X2%4;H>_1WQF@<'S<^<K"WTTZHMI=3Z9I MK^QB YCV8;3?Y>0"P^?7
1NIUIN:NWBB6;I>>&PN;PYMH%GN(IFC#1ALD+EF M+<@<I.O(SYWTBZ6^F A37YI#_M&2IBBLTAFB(\$Q=0&WIF3<^<1B1UT
MIN&_L2&_UKIOX9/B1=23MXX)>>2."RI M1^Y;IT^ITEX1_V-M9W5HHAQ=7B.C'D&_DY.2>@S@5Z#++Y4+2I!_SM1
MMW_AAM.T'7IVFTI5(O+I%!(2=KD9-LY/<9^4GJ/8=-I^E>& MH_<^IW"QVJO!??RIRY46%4#U9N!>=O>FV?ARQ^Q_K;0I;LH=E@6-E<2
MOR\$;4C(R#R)/ZUS1\$/\$1L VM7TR_GCFUO_12Y@FVI="(1^?3<5YST@_M#L4!01ZS;3?Z?>V-U>1M);_8QE9RHRR IQ
<#G!QI\$USU1X1.N%"/%\$>OZ M;I^I5ZIL;OQ3KWAF!PN;A+&2Y7NKC!O M-&E JOX@G=R.QK318M/#CG2)-%NS+=W5_+R*43B?EA?FSGG
MG& M_56.N.2;_HA&GYLK&M\$>RLU(WK\$J^G3I_L MI4=I#R(LJGSD)DX_3JUY^HT7\$=EXAKUM+UN#1(GNJ.O1D)X^Q1I;2370ENT-
#0XBH58Y-M5C\$TAIDA^0%';)R>>IWH;GIU_IWO(M?%T%M+=V\$VG'3KI(>7A(D)Q_05@22 M'"R.N*

```

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~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fJM=VMI ML.LL1K8(4%20171@1#10IYNVE.Y\XIL4T6>+5C)+7'2QA'WP'+@L'# MN'.0IC/3'S3K3:3X B71KDRZ3-"UZGF1?NPD+1GG? @/G>*>'IKND;.IL M%11EF8X %'FVB6'B3PU=WNAGPO;ZI90=2S66I>?&JDCFE\2@ -E2OZ YI'O M0;JOB0\2YI'I>&XA.&4 8W*RX/TX)J47- N3"/1$3.O?/W@QG^<O'%2D MX&3TH X7PDFN<$.<C\W^D7.H6IGF.SOI.XR8LDJ5F4HP\ ICGK4GCRRUO M7/5I96VY- +>W0L)BMHY$C19$<IV9@N<*>G'(4)G%-/SLB21N.JZ.'M&J''*0?QHVFJ12-(UNWTJ.XM'TV6SE^R1J=VDP17RW3'G\N?QHGV+I M2UOK6=5LKRU64.2'YW36'D
```


[illegible]

```

%==_X13P7l@M{4SZ)=VT|R?M:VLL2%3M.WDG.><5I6&C M:YIOBSQ=QVUI-8:J8YHW-P5D#+"(A7:CJ.YSTf/MV5%`F@|^\($^&A^~
M1:9F^L+L^F^21OM$)+;+<X.W.3C&.<5Z4D12R16(Y&L61M.O:W."Q8 $=H0J#BNQKF?&NAZ.MAK5El;Z6;8W6GZG?|?+<.,420)G*E@"1PW7!Z4
Q%/P^J1`%~^|LZVM);UO^L& MXSRF.)3Yf22.6/L?P?<?>.)+OP)I602+;2M-J$=K/!-D02).RBR*=V&M&1Tf5jVVBZVGC^?
0"/IY@DTI+>8EP^I>KL^<%,8);7&2.N?>@CQ&D&A.M!+=+TJJOYVG^U2;-GGF.=9SVZ> M0i0QZXfMM&8?0i1=2S.M"UMEGAMKM
MRC7i8$XB/3 QC//)Q@=:ZT<@9ZUQ?BCPUJ7B>UU"QO=..TJX@D43YWF99..3 M8.6!"9..R1@.@GH>..G5PQ7%Hi<4*N+jYBA5-
|K%6/-8#&6(QD^QH^X^XCP>L MYVU.9MWY..A14OX5#8VZ4ADUOCB.^COYJ^E=(OC^P:P#..PERJSYBLOM9iL6.MX7)3Z@|?6GZ+H6S3=VLZ?
fTNRiD|D?|U79CGAF4?Z 8X CKK;2.6!#~!MO%N?|G61TTEVGTCV8:581*~+~ZLB@KN8=~YSQ0!TC>!)M3MM^T39!^TD&LPR
M2j23.00b%5F4`#=#~YJSDKM^!Q&N>K#FHKWx?7"6.Nj.=IQ0f2&Z.VT.#E!ZIXYTB&UT4!i2IM+LMJfWDB7f3+>fN;j%2-H.M
3D|>fJfMHWASOGX3(RXQ|>>U9D^Q#U2;PSHWB M5M&MX|+NYXf>Y4W).R.TGEED 7!4-ZG)fJv:1-8L`6LZV8f|6fM(8(5^T MOYf8fV"PiO
SNf$XQWKGt5>=<(8 ACf AD#3#>6MVD|2:9!+~K*YO^fO.3fZM>|+&WJWC&+ZU:WTNWBGETO^O^DAiA0/L4Hf"~RiG/Q@8S4#^-=4N-4T
M*RL$=16U>RDN4Y.T3PL@7^R+LR.%NV2?0=..BDT^Q?fBS4-4fSZ5+8ZL4E MNK2^:0>1.fJ2R.J."%iO^%7HfUJ3QIH.KO)9SP6%K~#(TC))
(fNW+*@4 M@>|>NZ^K00!fS^R^fPU32fXZ?=&-f3R#=&=>..B08fZ5Z9 M.;2Y".2+|+~RfJ2PS7GEWxUVH>..=-MfCFUB+LL|N%8%RFG?
*#^~K MZC/7VKOK)KYK!&OXf|=+P@EXX+1J>P# $GZX^TH^MT?Q#JOAKPOXGU:UTZV MN+&SUZIDN3+.4=Uf|f$8"D9 A1^TKMM;fIwMA-
<~1.V1%K;V@N!>WK%8YW. Mf$28 BPOfYQD<&N~>P5X@E|~>)>f8:8MSJfUf<7$+BYD^fLKLH^fISD=..fSf5 M*~17-Y.P2j2WNfCM5.TfC-8D
A>+&T.PQ:3Rf1.GH*)SXfCfL# M.ZBWL?|=MVf2:f8>5P53Y>1C+&=QR/NGZ5U&DWf|=;+fJ.M#;7f9P<|fU M#D @X&00
@ZUR.D>&fL=fL"6DZfP=fAHVH6@ M.;75LlK;7QM$.*3&1D4f6&f1-9!7.CWw@ZZMfELK..=Lf21Tf!0fU6>?>+>f12MfU;P&PB1Z M;+NV"
fZYSP.C">(<=H6>)O VJ:9>f4>H7R)&D4U3>~O#U_K^EVC:1>1VfJZ?>f=1>6DLfDH74 M$%6Q_"0Q% %6Q!3ZS?7.KZ?
#f:27=f$LUf<..DD50=@ P989f1@>?..7-A>+>..MOQf1%92V=K&K$#+JJ3.E:fF4@&(#$S-G/f@'N 9f0>.&fTNYG@fHRZEY>RVMX
M9)/(#=W=RI8^R>@O:12A|ZKfBZ55M%~R.9.N'9K$Q<.#-fNRIA^XfYR M> 1Q@=:*UYf09UL3JNG:3C^&R=Uf>.#<fQfI&G7NER
M>Y)WEMYHfVfUfVt;f4#..Y^3B>D 7fHX|^~K="f6:fP+&C2Y=U>19YX;R MfK>8 *73:f/fL S&D=AD=;
-8>);P>+>fT>6Q6*+4;"2fRfS(63.E&Q>_Z@ MfJY?7O&>MS>$..GMHf6UN+~65TN1U9FWH7B7QMYK.Y6fD;+Sf)M^<%5;f!7fCO6<~>f!f$ A?
Q-fJ7&G&fU5A)= MLX+A.AXYVN.f$JW78GK0fT5 XGN+;4VT>..6WfHf16PNf!#"(f2fF8(Hf")@GfVM MDGfGH2
M<~$Yf1fCCB?>M)XUDN8O"W@Af!f|GS@Xf10R2.%)-N?O^X^O^3H.UXDT3A+WQXfJ>UG3O;R Mf4LO~:~0Q^8LD>PX8
K(ZXfYf1G6f) fOXACL $-fH=M.VBfMPOU^0f12 M#4 D-V.Yf^4$=1COO?T=AKDNfXf)-8fWEAOKVfL2S$#fJ.f37fHZ?;187LME<--M8W-
U(UB/X8f?P7B+>2f.8W#..20"1G^7fJKfA1 $fH)QA@&D+fE.L)^'+&#G M"@ 8XY>.< KW/C.^TW2M)UW4."%-(U&2)&$?
$/Q184MfLUE9+K&H8:5=;CUB8D^@J%2">KZAX4fTWPK=6:6=G) M)fJ1BUO%~P9fL*~QVJ&~8XYOG?~VVT36f|AH X_P$>)-3fA PWf(3-
fJNfE3SfV.P^~$/$PXT+PXfH7>G7D.DAN9 C+>+YGfI.O.3TZ<>f>B RM<~ MV+111M/MXf1~JD^fFf|f.?%?~H?~O2.#~SW"
~>DKKf|6"4W#N/fLLO8M)f$H7Y@+NK+>f=1US5%GfNY+6&OUNUMX89(f6)X&.G2G:=K%KX?1f?>25K MTD6fUf..20M?O+>P+f>+&KS5?

```

0%32+AGF.&:10/C%*%@"@V MGG.WGZCI3Y? HJLWC2WU0VL5EK_9A">"9GDB*1A 64HHZJ&X/MIT:-WXH MU#1:013K-
G:I9ZM.MJKVIA)MIG&45LCY<=<\$:ACI155L/%V07^MZC:JHUDEGI
MFH"VO\$>Y80+<#>URHR10"8#>K^<=7UJTT&TUT6:H=S=2RP2LYN9(@ M0F%*C:"2&/Z8YSFGZ*XP:J<8KTZXE.%K+&I
M3RM&A81H/F<@9P/+(EBCSE5SD^X4+@C M0Z8QSF014M;N^T&M;:X^RWLJL<+M-F18B
WE_)R>IR<=N#3+&PGXHBN/"5P1&BP1*#DD44TA\$N^(QF7=L\$S\$G=M MOUZMSP_ (0WQ_@WQ;Hf+IHN-
:O:EXA87+E\$68YPWIO.1CL.?:@#16U^<^U MDZ51^0M-%I=7\$T^<=L2R9IM<#DLVUCU&.<^5C?^H7LZ@Tl:Q\$6+TR(K:M@K>:
<@C(SWJ)>/%N\$>(X="L3L4V:PD)JW@) #VJ&.*26R%K(UY=5.W& MX\$A<C.4.9^BW40V>T^QDPT307RA 08(O+611D+(S)@J>FX8YI5D+0I
M:7PK<>(<V76R6QLQK>Z3I6QD*%K.Y9.R8..OS8SSQW:UX;M?%M%>:1<+I M:IM6XMFDIVZ(<#W9&S\$D9^E84G@CQ%+1-7-
^S%N/VADGCD\$S(8U5YO-MY=YR.G3F@#HO\$B6 TEJ2:UMX+:QMA.LIZY5:MR&E1Xf@+R>>6">J4_C M>_>?
PDNG6H^&XBMFFORRW)0Q\$0^<%/RGCD9HR@>#QTT^<^>IK7M9N=+>VU M2Q6V22.5V>P^QJZ(-HW^Q.1.5YZYP1.4.G>/%\$D\$O@9KA-
+V^H^AG"7.F7IA M/D;P/W?;W.%<K8ZUHf8Y)(G:2.JR/U<.@-AN_0H MJ^I0IC<(>@>N.O/FLW/CJ1K&)=?1P5+,%6(1@_M-
@P#C:1G^078:&FHO>f1Zf1W:(%9+9V=1@?>(<I3/0>=<XNF^>+?Y@/MR^009J<JCSUOX^77&@ZAIC0HILSZDMED+>IYET^F
M\$BK)IOR84;01N&_M=)8:~KD^CK4=>GBT^PW-A%:(D=P^f>A9LD&/!+8Z MG
>@>("2?/UG0H/G@M%6BU^6&ECCM^RYL1BW>:Q(C^&WCU)4<9>PGIK_X6 MGXR%["LPMf\$;H2=L@VR8;Y^"&>64UGZ?
X\$2:7HOAV6VFTT:SH=Q171:HFMYOC+6-.G2@#4UK5:RQ0+6WMf>-(94DDFOIDX@MPN;H1RQ:CD=#Z8P?XC/BC0? Mf0:1(9%GEMW6-
J\$3QN5W*#<#XS^4_4 \$&CZ1<>*)U;3?L-U:VL4D:VEI(R^- MV(Q.156RP (Yf\$X(R:~X&T+5?#NGWIG)>>:N7^BZQA0I-UR&:Q-
A:6DMLP>X<2L9"IRIL(XV MhJZS+KPMXABOQ%D5@VG-8ZZAD669W\$D.AA\$978%P0<<(<9Z10I70H1.L:
M_P##+5&B\$37AFN^@.0N^T+8S^<2>)>P/>P/B-H\$F4JXL5@1<4C%5D890XU
MZ9Z9J2+PKTfT^1C3F7P_4AN#H<2>9FROP^E_C\$CTHJ2E=HYH?BWQ/AAU: M.3K?3+L:29C.D@Q^0^2N7W*%&=WKOfT 2Z)XHN-
>1^J%K%>.-0.\$T1+8@_M^@8/7^D;>>I(Z9K3)0ZY%&G) M\$=&L;6M=U73H3Z?>W1.V5^&C1V53.4(ZAG49I)AJX\$S.^>1^M97@L10
MMXIXN\$N.JDT9RN1Z=1^/2I012L\$YVK7FL7^DHZ/+BYM+SR18I>4YBP8WW M^#N#CH3D/%1>^&S-
IXE6VBMJ\$<^1^@>6/+>8L9.9P^IXGMV(R>8HIG M^:M93S:HFBB2(I.VIM)Y3RG_&Y: VZ1R&6XV M-L12R1 #H<9)Z: MAP>
<9&6^Q&^A5510MM(MM)FT.INGND-YGMFVC2=IR^4ISQ^1^HCO5?1QOABON+>S+K M4\$SR1RQ^IMGC0.5.#UOVK
I3>.=.X13OKID2VM:019/(\$X+N5D5MP&&P MW^4 ^M:6N>^M:FU+PWJIA:-7=J3S>_N C^5PP(X&5Z@GUQVH W:KQ)-8SV6E.UO^VC+:
MM>@2PIW05740#_BJM2TGO^f>OB^3.MK^#BV^:FOXL >P5YW8ZD)= "OH90?^MA<NK?+)%TFV^O#G:Z^9)S@>J>HQDf.O-
=+K&MM8ZGINDVL:27^HM)Y^F\$A M(TC+NV.3C^<=21R.361HVB:~GCFI0.FNG1Q75A%&=&WF=VC9+9NI4;A/W
M7CZ<9+&7AS5M20F5UP_1T^Q DWBV TS39# MJVD^5?MJ2Z>9HLF(HQG(V.IY^K@DG0&Tf.FB2^L0%_A_4H.WQ>VSSV\$ M+LLZ?
MQM+H=U#;16LED+VQN5.5R.C)X(-V^T/B?3=(U^<^T?3++&48DU/3IH#Rf>16DC^*8F M1P#E5..XR>Y7UH ZC1KJZOM+ANKI(D:8.T6/-
A^23GH2.\$CMG>=>V&JZO MHT Q_0I^1^UN4M-2>XF^T3F/@#4F37=PFGRV M#^V5U8^I_ O MF(A0MMVQ<\$2=V>O_0UF0_\$.<Y1-
>M4>."P&L3/9KER8=TW @L.9RR8 M<=<O&^BL?>#BC3I4T^Y7^RIXK/28I/>=>0K:RKP9HOL^8LH(^418SBEI.^M&/\$.C>)%
f+0IRVT_LXVNI(N8I)&V\$A=6&4.#1Q&T^OZ_8/102W4M^GJ^XJU2^7K^YNI.DET^CNDZ:6YBL M.B.6L3^N\$K.N&A1@_O(Z=2N8=
(U^TTB>ZT_4)45X(K&?S8(G M^f+YF.C #1:(&9X)OFF3>./\$D^<^L>G:80IA2D\$RS.1^HB\$F!@#YB#U.. MO8
f^L_7+S2:1fB;6Y+9-.Vf90M(f1@>QIZ 2GZ^P^ZQH>GZFD9C6MHf@C M3DF4-Cf:Jh:ZW?>(<A9XAU+3TM1I9CEAC\$@8R3(CfD# X7D\$A<^Y
Y&_M#M=1+<^<=D^Wi&CV.K(ZI2PP^K;3VfQD#VJH?QIVF3VDfI>1057+FVL8IY97M)KA07R\$3;&C.PDDGCC^/7-7NM<K7MP/?
WNWF&FW3^f(=9:6=&5D8^49&X&A.#X&Z&@#T^f5;"75fM^2ZC: AB6: M2^YE1C\$^E_G-
7^YB/6KR7QYJ6AK:6<31.;J>+Y6>&S@UJUOVL^M@&+&f("9SD@ALCL>AQ0IV5%<7J7B^_#ZO^I M5L+2F\$31_8YY/M4HC5V160\$1L_1N>H
Y->f19>0M4TK3L72WCGU+3) M+R+4C^>1=1N4D&WCL^&4A(4\$D@ H Y.A^>IK6+ZV23I7f=M8)>700H(Y)M M@Y(6.H^1^DALIC 70D4
>fZMI^LP23Z=Q7444K0N1R ZIHOC-7:X7X6F M=M^UW24HEP=20?6.Y4.OY^ZC-M?ZR?Bf_&H(MOH>D?2.5A.)XW316R= MW+>
>P>@>fJ2=K17^R>-KY_1HV=S.#>>1^5.4.G.#@%MA^3 M^+<=8=3M:HYU7SS5QE9&D(V.HXW3QC/INL^M2T59+RfM;2&1-16U6RD8-)
(3((Q_ M#@_DY^f_>_JH^L.G&P15NM1G^<O(A.XALA4BOIM)Nf:WN) M<+>QHfD.5SCIOUINH/1.YWPAKHWMKGJ^ZAI^#>Z=?RV_D\$F-
V3!#+GD MAAP:Z^>HHHH ****"BBB@ HHHH ****"BBB@ HJ6E?K-F/4I^M1BP8 MQ3QAU)^(.5E\$2^8XU5\$41551@ #H^*=10 4444 %%%
1110 4444 %%% M^ 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110
57OK&TU.RELKZVBN;68;9(I5#*PJP:L44 16UK;V5K%>6L< M\$52A(XHU^J@0 #H^EHHH ****"BBB@ HHHH ****"BBB@ HLD:RO-&^=K
M#IP2/U%HH HZ7H^GZ):FUTRfCM;H75_6.O#>76/MM\$Z1@/CIN/4U=HH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ MHHHH
****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"N M=VZ#>Y:Z8UC) MOIVHPWZ1.2\$E/O/R%>@5SGK@_2NBHH
Y#5/1A132ZC<: MT8X9+G3FT^&W(^MR^TW<1=NFV A26HU8A L_1/&9H.30^DB\$?S?Z#^TfZf@M@#>1^?=
M:1X7TO3+SR3/9VL=NS0L65MBA)f+7;70#1_IH09+..SU^UNU<03 M:f74KE@PR15S70#VNZM:ZfI^C+=6&H:A<:
f^C&0PV(fH#8&P^3VYSFNP MHH YBWT/4X_B+=Z)H^Q36^68196.@VNSLH<^M(5E^f^AN_TLZ?JLBS7-MJ^2\$P RMA0f=-G7(49fH)X>U<^<=
=UCSK6>^RLY+>H9Y&624R027^A2!@KTSWf5UE\$ M^2^&C^M1

.GAW3'QAX=671M.V&>Y#&#FPL.E'5U97VTV5 MSCJHY&.G|+?%'1K.'*316UIPO"J-.RZ;.4B8.6W+M8G#<@D\$YW5VNLHJ
MLUDU:WMH80ZHSB03+L0JA1@Y)>#&BT/6-+U5JWTF1#S\$UA+JGGMW@.1A:&0 M-I XP001P-.JUGO)X>N%>G^(-
))::|||:26DR73^8K1NRMD:64H@51>>((H11H1:H1RTE68:L1DX"J1GUGUK7-^V/V MH47-.WWK^N2)GPS\$*
=H..D@9.155B1T0311550;&VN0ARHGA51OTR*//K M7?1^NZHLU1Q1H:Q1936450!(>:LP\$TT;:DC89P/NJ"P)R/T&:Q1F;P0:5_NCJS;?
61.N=-N+&B=C?6T252QM'R@Q(1(P1P&EC"&3/S(W8XP>=W>JH5_NC1J1 W1^5_E5EJOA70 MM;BU31_&6D2_1A#8WD-WO
ZUZ_M7^Z/RH^J:D@4.2%\$W@KPOX@KOJH^@:"C:O1T?E0XC:/4^@:MHB_*#PHEN_-W0R5M^S>.>#&W1Q+H5KXQO!>E18>?M5E^:6LVS#
(6ZJ">6"88Y M/T_0!<=Y56:YK>G>=>IGU346:J@-UC1\$TFW1%1X1^J+7^P+0=#CM M?FA1:SH=S/:7/F9BD29BTD/F?>O?2O3@%8
@#1Y24NU?IH_*#@>-719^&10U32YI_M_#>A?8;2:SY89+CY16(7D'VDJN_(-3%4/'O>%_&G6.5AXPT2TO+1GOC(M+F2<8W018
(SG)1YK0K751IU>-TN\$L:NP\$9G4O.H&1\$KAB-P.U.U?7IH_M_#>S35/%FAZK%=6UWXH+1W5C=VRQ:SR96.0_LN^<|CE?E.#1OWA54ZSX:BT
M9=#B1PH16233HK(071H)M#(&H8R#SD?&EX^Z%5Z5ZKM7^Z/RHYK="Y4>30: MEX8LM7^SV_C311+70+22U FLRYDP=#4MD'
Q1&16:1^>K>>10=3M0%7@XQW M=Z1PL1Q.DF%:\$995D^Y 5<\$KGH>M>X15_NC1J1^2=-1%\$X=/M#>Y1PKO_M_>L9H
1VMO#NB7WBK2_2%QXGT"W:/33:RVGYCY@SE78@GI@K@ CIUY1+2? MT01X1W1/X1A1K6)=28&3^LD@Z1@NTAO:IV/K.U?IH_*C:O1="Y4
>>> M&X:XCU1_"&OZ.FHWUQ=H 7K731NLD:R+G:P1&1C@^U.H.Y1A:-G:ZOXIU_*M1:-_2QB-_)0^1^6_-W1CGMS6?1X(U6#2^5@+RR/
C1RREMK?OJH_@_M^SPQ1:1VLW4=1^*OK"SNY^2_E1FW B8AGP3CAO1^H1:R2.FG20Q7:(1%)194 M16_N2K5%&:IVG/;>8_E2&1X1?
R6'.R0XODY1Y1Y2GZGK7GEY1^X_>%S> M^J2UFPIB6X2UMKF6 F...23)27?1D&P1Y(O-5_X5U:YBF@NCB:B.W4J5\$KL_0YY1:CZ5T6A#2I=(MK1116"
M^TO(DN(^*A\$>Y64%20_<&M*#@#D=T^Q:1QVGB#71:4+&12B^&U.\$K):NSW:1+M(7^MB2RXS&1C^(->_>O101PUOXA0Z
KFH/H.OV1Q1H#W#74UO<60FO1(W M+F1(1.3SA@0/0H^&PIJ^OXXFVJ)=X&T;187+;E8L&+>R2<BNHHH |C M_1.K%X1M_*34/198ZL-
4MYC\$WEE0-.38RYSCYB.@UW317+7L5MP&SOR.C)OR^325TMJK5EUIHGHZD(0D1NN1:"\$1 MH@F>34B23Q6/G BM+PHOB:MY*MXBUJO?
*7:&M1:&+>>F^0DG)1@_>.&BHH M P/P?A^?71:33:W.<%Q1^H17?FH61RF?E.""=W71^:NA7 MS^QVR*Y4\$1CDJ6):1P.%
QU)Z&B@#SZ#P1J1UOX81+M1J9\$Z%>QW?FE\$ _M2_-Y%Q_#G>>>>@1Y1/@>76=-GA^P.O8)9_&#YD>PL5<\$1\$Y_-A7:T M4(-
ZGFKZ>15CUC MO5?KW918Y)(PC#=#NQM^41 MG&11UWE^_FEQ9ZAI0Q_1V\$&1K/=6NCW;,%D:-)%7RATRO71UYZ=/370_0
MU\$SO9Y1T1ZU<716H=QQY6B+11+1+J^>=5(0 M4C9SN=@1J^>H1X1P#1R1@2P1-B LBH?14%P8WPP\$QF1<1^1OG/2M_P#L
M^_O1GB)IK80#3OL#0_6Y<.<#=#.HOC^2NEHH |WC^FMQ^%K+PZ_.LA9Z=> MQW%H_P1D8NR)+Y@&GSX)1?
+CMS71Z3H&H6^C+6=:GN+62^4HX\$:*P9^5@# MD1_X1=O>NEHH X21/GB^0)Y1-TSQ##X5(7MBUQ:AB2R1ONP!DG1(-M;1^
161M50K^XM^8JD1+1U 8\$?UJ>B@#&@;7P^JB>M1M4Y15M1JF@21;"XBM MV^(-5V%) 6R=R1\$C&_>16A2^Q+XAOVB-
1HMG^"DI\$&3D1L68@YP.M1ZDIE%11110 4444 %%%%11110 4444 %%%%1110 4444 %%%%11110 4444 %%%%
17\$ _\$6:483X:6ROC:1SZW:02H(PV1\$EA MGGH"H_1=M71/^+O#UQXALK1:1CM;NPOX;Z%Y8C(A9_1_0<\$1"*_N8=5 MD^+UU%1JW:07).PAKB: R
?OY.O8=3 M<@>1/TGQW>W^@>1DH375=1N+BWE M.\$1=51@N^95SSG:N 3QNSSC1YK;PW14/C_Q#>15M^2_2Q1H6Q71K1Y=1
MYCQCH1U@CX:WR>K&UMJ>6VU13KZ61H1^&VP%G.SHR^CE31NOUZ#ZY_B1.M:CKMU=:G:Q9.D-O(OV1?E2:8V&3E.G#11@1
<@&5@^4H&3XLZ2FES6T% MTVC7(\$UO&9%0>?_SM1&X^V1USVP>KT.PU2SADDUC5%O1R3)BA1F_X^KD^O MR12>?_F^IZIX?
NY_%>AX@L_N%)K:YDM7AGC+^Z.RMD\$%%\$%1Y_-Y7CQ5>_M.XTC51> Z1J1D>G>9:Q1T<@>RK(\$SG1BGY<1<59NO\$7BG31.12326:&"PLF
MO+&1N:8H)1JDM&Z1^O^#P>G%6-7^R:H5R^2_2VU1_345U/QF=.%V)A M_-<1?
+CXY1:3PSX@U#PUJ=A1JBW^Y1Q+YU>T62.TV11(P9M@+>24G QP1S MD S17Q(CXMH6)O1\$MA+8ZZA1X8865X1GS PM;WA#4)?
^5/1H6H.@D\$ Z.W1 M^68_P"1O1SWYJKIW@?6M\$O1NWTQO?_?0+J=YS9M:AY82YRZQR9^4\$D1CC/MKS01%-?
O1:X0MXBK_83NJF.U3<+E>O7@<_14=WXAUNYT Q1BW<%M<_YBV MTUO#@A11.C.?
FYQO1*WGL7Y1>Q^>1%OK<018FO^&1BQ0N'W:1W71^1V @ MRY">+(KK48GA101B^1J1+R^181N #VYH T1PN1X1TAKFX\$SM9PL&";<
MOKP>3D^19D&N:OX@&O2Z^_0C21N2SABFA_&B6-51CN&U23MA_1C1<5L M^&M-
OM(T^TT_4+R&ZFMHEB62&\$OKM50HX+^GCDY116:;^%1W112U>1;1^&& MVU68W.L4)BW<-THFA.K2M^DX)#+C1))K79)NV+O(+X^;..^U
'BDLVH71P^N+1J0/MMH1Q7:GO1YVC>)=_UJ:SGLGTN744-M R_*Y3_F2Q MWC#9SOR.@1@?AW1H1W7A@:Y.BT11^WO+>(061=&QR_#Q01F6?
B7Q>+>H6H6VG/<6M^1 M9N1<6^P64@R)M^D+?_MR1^2-U-%>CC5110/1F1ZM1Q@<1TVD)E43H74X181% M9/AOP=KV@#3614@9N1W:
<18K^<6M^Q1IVE1^16S115J:=19N1B2 MSE9" P11^_YC1O^1MSW501G^&WNM6T1U19X=2^<S2W<=17V7KH1HSD=@1DX1(X
MIUUX1U\$6^AZ;3-<6RUK1+86B72V^Z^XAV1^KOEN^T^KP<^V-R/2=>CLK9CKD M=<2/8BD38R^6J1@57)!SDG(SSTH E1:C1JMA/=1J5E1-
LTY%HS?>W6(1+N+1VE:1_111E^2O).B KGI3QZ M&NE1^&X1 EU2X4Q+>1.S1HDBMTV11G:%^5&R1^KJ>1O<)*81BZH(&9795 MSSDA<
GC<3SC1BU?Q9XL1T:PEXA0Y1%)-.EC^R71N56ZB=#1@Y64G1/01 M<4Z/X:7TAS212WUY:25M(NIKFOOXK_'FLS.CH6.Y3NQ1U#1+=6111.M: X-M
=U+789+V1V1A13:1JL&2_-UR.23SGV H 6ZUS7M^QK;31L1UD=3N7^MR18X&0Q:D#892A/LHS^=0
MZAX2U71^1JZ3K.MK1>W1O1C1^W1N^1: M&ZB%X1B1H<71AZ1APBA5SC))1SPO3GA_ACO#=#CJFMZ121_P1HZ1&DDL*
ME4FCD7=#X1)VD@&\$91Q13PM1+YK1FOQ_1HVW1N6D#6T1BW^P7\$1.S;N1?1 M(3SGG1P&W>@7^GZ=K=1^1J);
H2G6<1+YF1NO1957#2_#W4W1):YK1761=+4+B66C^C9D0' MLDGF&_YCG@=-_7@ O?VYK.E>1+TW4Y_*6QU.TGE18(F5K9H@K\$%BOW@A
MCSA>T2125MX111E:83K.EZ)=2V/G1V1_1 M^F^Z1P121^1M311ZH@K1J2>+>+&144D1M(A1D111)(^D&+>+1Y1E1Y-G\$1(5E M2.Q1E301/X1T 80B16?
\$ZOX<10H11%60: M2>U\$Z&0_#S\$^888@?_KZ4 OZGXQO;*YTN/52GAZ&1L1^UQ=0^;ET3@PNX(5 M01SR1NSP1CDFUWQ0?&B.)%<-
1237VDMB: MC^MUO@:ZL1:1>6VU1W.N1P6D)1#
<1AE<@U>:>1810MNC:M^R:U:1#H1FKESXNUGP^Z1>:MT1LVEV51+BUNFB\$#2.3M1EAD1Y(PP&
M.W%2ZG1/6U;31S:D1.LW511^1Z1>1/EC4+^M4GE548Y12>163X2U/62^# M1_1GBK6A2F1@-N#_VX@6_1WXR=SY_3P.8
Y.O1\$OBB/5H8Y)>_PGME.L MRQ1&MIAC&UIST1QOU15Q&BZ1K^E_1C4/\$^7T1U>PR74H-S 3DBXD#161'
M71.PZ9KK_*#@_1BP1:UXB&IPV11=1810EN1H#DECCZ#N1R14R?>D1SUSZY_-#="U+7Y?>Y971G1C^F^%9;..>R6WY MPT3+DY<..*H^_P#D-
^O^PVQO_HF6MG_P1NNYBM1KVM1.C.%Y1(+80(H1MDC)ROP>_PZU#XEV7>N7^B7>O_PVX1TR1WMDA+F0A67:D;##UH OH1Q1
MK5^FLOX?MVDETZY>VAA-J9N1):P-RL^X1(MKK6-1)<=>E91HD+1%Y^#0M(DD&1D:H1DC/1P<5%#16M^>)M1TX-4TF.72 M+1)
1XL15C9W^1;:=F1MN(RK8R_<=<?@S5H1OQ_=:MY#KL1(^ZSOY<@C1 MLD81N1.@Z1DX.O#51_1D11-1 8^M?_12U@V/B#Q>Z1K&1-
TF:=1VLK:W\$1(4#A1^@X)1#@_M>M9VA^&G3=5U^YN1NWN-7F\$S0K4*?
(SODL:MO\$SE^6%3GD_KNSQ@<@U1QO^KTE1H1C) M3(1EN1)+S:6^ M2Y_11RP(31^OR>1CFPG@91+4011NFWL41H1.\$77Q7-K_(-DT1;<7-E1Y
MR\$%MJE.L2U &%X;U+61? MX<>&K019_+M8?M-W1P:5=>14ZQ?> O&T<=X>YTB0 MQ)84PZ1 M1EL-
1X\$81#04LOP^O.JS166MUK221Z1H81+7:T<@15SH17Y>1UQU1/_%\$4 MM8UC1_P1">UF@U&Z^SSDP#71MF&WY11H1OH.2U11A9>M:T?
6K1V2U15 MO1&1(21>+D2%CN.2A X^4^1O^1LZB_AV>ZU:S_&DW^VA1EHP65MA3^_Y1 M@GKGGT^7O\$A.VU 51%U&25H1=-
G9SM_P16T3+AH\$1A^78\$>Z_00\$6K)>_MZ^HLP1U@:Q_&N7AM=1B4L15 N1&^*51HNL6SN21JYTO6+1_H2_+S8YH MF.2CKD<9&0?_*Q%U-
UV^TM2_>CE05N#-VMS< M3QQ1<(-&1(P1(7/N>^XR7PS1WA_21MO#NH6UG?WVH_1)(81/?"WR1?1<_# MM1+<-
%1LM1@GNM.N1>UN#;7\$1+1%1GRG^D1L=1G1^_11^1SQ DDEK MK\$G(R63M: MPH2AW12AW2M\$;Q1:FUT1^BN;1A9^<5CWRI?QH
TCK>NZYKTW MAUK17TN1:S@>N\$S1IEC^73WLCK3K2&6 M=Y%1W11^H1H1G1D10011+8V1R1>1M7M1+B7&&>_
MD_*6QW1UX+1J7@G480\$D>N^&M&G73VR6EVES1H2=\$>ZQ^8>1/71Y1R M>1>8222-(O+5;55KFSNDK16L?
GB+8RKA1GN7SDYP1CG_12>_*>G^9+K6-M>V_H_9Y:R.W9Q1EP2+CR@21V1&3C.>1Q5S6_16H7DNE:E1>ORVFMZ<)%^U
MRPB1A911ZN@P.9&1C1^6^*2^?CM+9ECK17#C (R<=>17^=1)7FD1J1<?>10 M;0X1A1F10H 31S1@#N1Y&XGMQ01>1MZM8>+61.WDEO-
1KLGNK11DC#(0210 MW/4\$%<<>18F1&^%&5 X1^7Q4T1A<12>1B6=0 YEP.P? 8^/1=QVCG<@11=0 MN@WD^L_VU>W-NU_-%>VR1Q;
(H1Q1=CDY8D1O<8 OWS5;0#&1Z1X&MO#1&K M0_?7:GP6Q V1V1&3?SOD19H1?X4UOM=EN9161/1A1>?>6T42ES12Y> MLBYXXVR
>07K73UOMSX8O>1U?7K: M;#6+JS6V2:WM^R AL^8R\$DNYS@>@ MXYKI='W?V-9_P1HLK7WDKY1^NT%1FVZ;_1R0326KN?WB
M.VTKO&3P1NSQC1O1%)PAUK^Z1H_1"0V106FHK?VCM9\$9NS">S3YOW_1R3TVG MU_1NG^&=2L2^6NZN1V61TU6&1RS;1+2E0<1^<1B2_*
110&MYX@T_P+MPP)#ZAK#H1W.Y4LL<> O5<@1DLP R1>1DG_1%0@1F1Q1XZ2ZF2:871F1\$V M1AY QOD1XQGW1.E06OPYU#3M1(^PUN^+6-
15XH+HVL1T+1 HY11V7Q1XK M1^&1M0TCQ1K>K7NJ0W1U4PL1=1F1Q1C1Q1A1@1C1UX13TY1^>O1.E2V1J6=M1M%
1:64LY(\$LKRC&V_+6)19B0#PN.YKF;O1H\$O@?2M;NX1_DUY+71 MW#;M(MLB-(OF>7G11^*#G.W<@^\$M1_Z196FN61D-
1U+LEM#B6.1F_1^&S9_X8^M3K01#?>+>+S3_#U17^EU=Z1>E.35+1&S4AMH1D^*3SN 4GH.DXZ11H514 MZM8#>#DUBT12H17U^&XAC+)+
1B1/1PXW17D=15_3^5H1<^2K^1UMS/M^RWES_9CY#1UO1^6JA1@5 V@Y1YSQ@X1A?#N5_*EYIEG?6UHU1JBZE+MMB8H_MV5D8(B1A@?
6.6/3P11^QO<1>5>77622P12>1^1HRWG.G.FNS5_NG:SW_M1R_1MXU12X^T/7DCTY1F_U\$*EDA%U78TOEY5MYZXRP>P>1^&1^Q1="11> M361>
(M&TVXL1"/R=6M04DWD1YB8N1C1(^1>F6M;5K^B_P19V5ZC1^1Y&H MPSPW5E;8+A(MK*\$7P.Y4D\$CCB@Y1_P1(^Q3JVAXM-
1FCTO1TK.VL1U MDG406/1&#&G030^B6X10W41JH11K1;VS1AN+6XR1^DY11^?1Z1<M6-
6+OPOJ4_BR1U1581F7H1Z=&BP1=&=Q82.M0#1^CH^DC1+V1OB2V1XN1+ M071K1R6Z1RMN8S.7Q1TF6.0.<+GC)YH_Z>B16D61_Z3;P1I?+?
7R+B.Y2(1 M^0YZ1P1_5=H ***** BBB@ HHHH ***** BBB@ HHHH ***** BBB@ HHHH ***** BBB@ HHHH ***** BBB@ HHHH ***** BBB@
HHHH ***** BBB@ MHHHH ***** BBB@ HHHH ***** HKBUM1N.1W,\$4R Y^R(&?H.EHH 9%%1 M\$14.1OKP1(H T1H1%11110 4444 %%%%
11110 4444 %%%%11110 4 M444 %%%%11110 57:PLWN1LW2Q&NBZQ1V1W1DN81S1+&S.R0^<@ZLA=1NTH Z&BBB@ HH
M1G1G1V6D0-?7^Q1B1_8+(-YZ1J1C19CZ \$T 7^*Q1F36\$ Y.6ETEUE.SWDGE M6ZSYV1D1P31@<G< G1^2:MF@ HHHH ***** BBBW#<#R-Q&O_1
GF@!:"\$1 M)U>>6(KB2^ZAS\$P1NPN(3&69#@E0>JGL:T^* BBBW L5R-P&2_>^% HK(-MU1Q+1WAJ&_14FG2>588VC@>3+M1U?E1Y

:D4@EB60*ZAAG*#K@CZB@!1%>% M!1110 45CZMXFTH1+^QLKTW GOG\NV\$<#N)ZXR 0#CUI8?=\$C/KUYHR+<"!MM+;B4-"P!B0-
O=NAZ"?#7HK+T?7K+Q)I0U&PWL9.)AYJ:&RC#3P>1R#6 M10 4444 %34B?RG!27&@HDQ>VJNMR<Z,JFPFMM">O(3CBI=(UB#6-;JB
MAN;>)9*0K=1&AL);#YXZT-%%#%1151^U>WL+!^VDCN9IU=T6"W>9Y5 MV@DE0*7K0!2HKF!7QSHMY;=P&I>YV?
!HLV=j2;MH.WC!;">@JHHOB M&RU^344LUG!L+HVLWG1%#O!.;&TU>PTUX+Y;T2%)(X M2T;="!#AK*A4.? !X?KZ&@ M^Y1110 4444
%%%#11110 444A8+C R<#- "T4570IV+3K">JG\$AA@0R/Y M.%VP.3@#DT 6*!;HJOK>CV>J6F P^SW<2S!H0AMK#(R^NT %%%9!H060!3C
MP^1/JN-JUWGRB\$!JG#=#SEATS!H?B"R!0QWLEB@MG=O9RB;H?;0#>P><< MH4.M%93^(+)!\$T7A!B?;)-(!#HM-CNO.8ZC<
MLVH1EE+JWRW0#@GKVIH U!^**BLK0#X@LO#;CR;H!&O:55QO!C+G+?>? M3DCDX%;M 11110 4444
%%%#4=0U2#3W@A97EN;DL(+>+&^4JH9L9C^4D#I MW(H 0450T:5!P7-2^MH!B)&9D.=Q\$8Y\$925964I^"##4.I^C^2;K3+>X!YG MU*
<6JNT<99"Q!(RW0<C B!-6BBB@ HJH616FDV9N!V;RX@RH/E+!#F8X554 M*.* U&UM(H+P M+>6YN;2Y:JS.G!RK G!P0<.< &MR@ HHHH ****
"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J^Z&28'_ M
Y)M^*!ANXI9!26*U!58!4JKNF!+GOC(S^= !*?Y%YD^%F@ (ZAE:S^*L.@C M)JOJNHW%MI4-
"CU/IT^QRQSV^G7T4^XK^RAF^#KM&J^R> 7ML^~#MSX?M!T.@V^I@R6!)BMH6X!3T)4D@D\$^P-26VAWLW=J!8/F@FW!E-Y4J
M78;FRVTL!@>?.;F.#O MT>?>^T?I7HU<^XSN^#MSJMI;B_OI M/US2WVWUY.V\$TICW^J<(<5=2#R_E0!VWU9P7JO+!&@J59D/=74Y!^>A<
M7#K^L!X>UG7M)O5@<^PW%Q^VC1^T.=D;Z MKKEQ<+&P8!>D=0*Y^!Y^YD.X.#@<#US67#J^A^Q35K3=;O;3>D>::Z> MN3R#S\$AB?;-
N>N^&/3TH NC09K.N:QX3&E74%E9:YHURR26_F/\$R*AZY^; MIO Z#C)STJA?>+O\$MCX^!57^VZWDU/0!2-HMTUL/WT>8!\$J#@-B3T(XZ5*=1
M-1>(-"U"RU.YM!31K9!6WM!J&NF!1@H.6V!<*N./SK+05T6!T;O!HK^(!E8 M!;O!<S.N@W.Z.;+J!8O!B!?! #K^UG6=#!
<6UAJE #?>6%J!87%R\$C\$MQ&=>X MMH(4Y)92&Y.15:QUOQJEEH#M.;8W\$T%Z4MU;3&V6%=>QDF@ F.E!7KS MP.E5+S7-
%00&F;U^K\$Y^Q6!L!&AW6V028FW>N.C?7O69H\$8W>W6R@8 M.W!H\$POZ=SD Z.WU30#XETO4=3T^!MXK!;DMK6
MTG0>5*L3!6!UL%>6PQ&TC^R!>33+5;Z3XPZG\$=5NO)BTJ^5(2\$*+ND?*\$VYQ MHYSN/KTOST.NBZ?KE!GOZ/P.C?>*.8!O!N^!GT(XQH
M2:QH">.4U^QUN^M5-FEG!;V<L.BHQ9<\$H04@M^WU!H FM?>NJO^!<0EN!8 M);!^ (GT;UD.6V;RB-6*#@!&#18SSTS6!<Q^).&L2-
3ZYB>WF9M^5.T! @8 ' MDUJZ1KVE6!M^FN^!M4UF5X6MU9J&FA5\$;K!JQ!L<#+\$GIOC)R 6&!3ZO_P (-MSX^U072B;5JIT@O\$!<KB6-
F8CC^G^8!>J^Z7K^!&VC5;NX2WO(8U24) MC:858#A1@L<8Q!Y^L>26A31UTG0!F!7;D#HMY%<6A70YE(2;.%10W9R<< &M!T^3G-
>G.WH.F^+=5UF^7-0^S:D8Y);Z//_K\$0)NW^7G!^OC!N.*+WQ M5_Y
6C2IARR !K\$W=>.;>+!LT^Q39V=LFLW=FEM=1W8!BW.A9XSE!IT<9ZU9 M!D!76-W^M.L)=)FEODGFN=
M;2PNK;WB#VL4;R;@R!03(!M^8Y!; K0_M04K/OCKVB:EJC10&P% IDXA3Y M\$!;(D!&F^MCCT/KS?PVVCPZ)8Z2/%!FVTV^CO+\$.
H4Q^%9^X#G9ESR>>< M&NEU76?Y!L.MHNI7YDGT!H0C3;D>;&7!8C^X^WU6@?2PMXEU/7=#TNV MN+B2^6UOL;4E\$;
Q^5DOE<\$8.8P.?WQR>_6Z9;ZG!)?4?Z^22Y9J41P^7 MY.6!A#S!Q/^-<5IVK^#J!<6.KX@AN! SM12-6C_LRYVH5&&8?N^K83/^X?>H
MG62SL!3UBZCKFH7U!.*+42;L.GD@!H.L!2*:@!D!D@T 3^/^!1M!"2!A5O_M \$4U36/ "676A L^YV-HV2LGQ^K>B;H^C7!>M7-L^N/M\$<9T2Y?
>Q&TA MC@<8>ZG3H>T;#QC>^<1K5P6N;1;7R#HEUA0D4YOR#-M;2-GNM2UVIMD^AV^B6JO=-EN;&
M5M#6(QOOH!U:NO\$!EX4U;7/B76M5U66W;\$16DRYWDAN-R@!X!WB.MQ).%XQ0!T2:OK^^(#%K!H^7=JHM)
<7>."GRPBJP92N.*Q?;SGMSUK-UCQ5.MK6EHU;Z.62/6\$M9+2^(!/I TH0!H-N1+@AB-W!W<5SV@^K/3+F)M!8VN MIV!)C^N 8!XP;\$
DC(3!S3GMM&O!<3%QJ2V^W!H0+6;Z%;3\$ MWG>0!L.N.YQJWKSF@^!H0Q^<_HA^W_C!^!D^!VVKF^7UO6M6^%5U>W
M.IO=1ZSID=K-462;70BVD\$@8!>+!D516^N;!!XPFI0^7!>Y+!>RGTE M^YR2P8D*.=Q.< #^!6LK^AY_!5_P!^?5%6!365!K8Z(=0.;Z#19+
MFX@GNYKEI89YF;V4!HV1 X7!&=>V-V3V(L.G@>2!>=&=;!OX;O!^!O;R4!L MJ;9/\$R?O ?-?+MOD?0#)R;ZZWQ?Q!81P^!M3N;+;
(NWY)DW1@_ZL^5 M1P0.9^2@#I^3.NI=M&I&X.YQ2TV02&A\$RK)QX69=P!H0D9_@#A/A2BR>%= M11U#*=70_0!D^!Z;PH9=;L!?
XB;EI&H066C.I37.UK<2>;4@C8J23P!QQSS MUXKN!/ AB;PKIUQ9!/"WB2W.ESN!GRV#;I5;EK_ \$V^D?."WD? M3_N.H;W\$W
F3>C&Q4!>TZYU!;G3!6!%GDUPAC;R!Y52_ W^H!^UKN!=Z M^T^736>;&8;DGR!\$8;RNF.V_ GQ^XG;PT7!Z!S3V5HM10;W%SC^Q12L/
MWGIT.!GC)<^!J6>H.Y)XOUS2!?!R6EG:Q2PSR6X+!@;*,5^<XVAA@#&C< MYKND2^\$?_D^!SQ!.;+>N..B;\$D.2!F^S!J2P9^0%0=;J
UH^\$YMUFF+W.MTWQ!HFLY\$BAYDEO!8B6!L<N.C;O)P-O!HJ_ 2?%2B=/ UCXKU^M.B.I@ MC@BLTM@I6XDG^L(7W#(P220_X.SU-;SK?
B30)16U^!LKJXT^WTZ2Y9!HVZR MQS^C!A1Y3_8?P#=#0NVNK7+>2>./R!P^VY6ZD@V#GVZ5 M+I^A*^2QGL0\$B^XURWD@.W6.2!
(0\$8;26VNY;DJSW;_*E2>+Y_.\$Y.MCM9H^Z7_3UG^X\$K^8!>+8Y<@LVXD@AK F!J!>+6!>^M83516;70M2N8TC
M^F^!LT<6WY6R<@9\$Z^!2T\$0VDOBFIOM)M@!@UK7+!Q? MX;CN;V&>PUV^;LL 7!R1>8!5Y;C.C?J_@I6_B/O7KFB6FO;%8SS>=<;E MM^
NMO);IRN-Q?S ^T9ST5OMQ6!X4NK64_#E!VIO!M5\$PJBU!BZ>622GX^M7H^O2L 3?A_>7\$&G>KJWVT">516TL0HVW<-^/;
D^G;"C4X!X\$2\$?7!MV>I(F!RS)!HOVO M3KVW6^YML#JH5?EQN?MR<=KJG->;<645Y+;SRPF;I0-Z;1C>!P.CK6
M^<>Y!W4=2NK^!M1^P26;4T5H4^HY!8L-YW^!8Y&3QSO!Q_A!M^T!PEV!M!H7+Z??-V\$ED+
<#^"R1G;^=-P^CT^/2K_BGO5K6B6&N;DE!&TVG7;"RMX MA+^Y!\$#J^!W^R^K_9L.MAA@!E&..G^/6IO#^AV;P!<4.E!EU_%)?>B^R!COC('S^!#?>
W_>J(6.MZX^+!E1;==QVD!;+>=L3;)&90^QB#%1%Q6&2.00!<JAV;Z!2V.OV5^MM=VL\$EL4EA!V_2.R M^>
RD^CG/X5GZG^K!5=NK;N(1N+Q=0.H0861+A0 C^P50% !.;>_M+7A^>O^C;O!25+8Z7L62TN;@PB4_T^A\$Q!^0@X^!<+K>LW5OXKT+1(G^S
MPZ@L!OHM;H&I5YX MR23&5;5R?QO!O(1K^CVEUOK!8ENDALHJRC>UDDR!HWC;W^J!P#IT^MC36_!>Y>7.PW;UOK!TEP9HMBR>J+
(Y!YON.<8&4(&.VO?>KJ?A_Q9HFFW M5!H8ZOYD^F\$B!R6!RIN!7;"I&1@D\$=3TK/T5!W!5^!<0T74M7@U72^2.V MM_96?V4QR!B?
DP2K;2%1.QR15VZ^*#P!J6G;AK^<E!<.*4_0MC&#Q!G!CM4 MJSK&K7FM;GHFG27!ETR^\$/<0!VY9Y1+>N^!MP!PH!GD8K9N?^!G<^+Q*
M6=;JVMGMM@Z2 D!6^2W^!^A+>HJS=9!W-UXF_XC^R>0!>GT_ DB6^ZV0+!<(^MOW!5@!T"(I98-Y9U5B%#\$(!@G^).#C!M MS^(_ \$GAW3!L-
6LF>V26^2YHDQ^24Y6;2%9B8C^L0^RY+>5Y+^C<R>..*T9_LNK^!+W2_6N76IS72!OYE8D@ MG;=RE^7@%
23G_3B@#)UBUO;XJ>"3<B!W&R7V!)&BE&ID9OM ^4!<) M&IS5!XM9_X5GJE9WV^<_17>.I8?NIR;QH>J;GXEE0+G20-"E;1(Q0)" MG.">
<#D_D!WV?%&@!>?#MWHITD^7&T^&_2!5@X.#UY44_?K8FB;C;W!H!9\$+C;DMN4@!V^!6^!>UB!TN_TB_O!>+74OL<
MCI^BC830615QC@8@S<I2^*W6TH;N7^JDY&00.GH;5YV>1B2_?WX!%;MHY-2TUD=00A.MDP.*2!H6!^!40!^/4_N;^4L(HB)XF^!0&!!Q^=
<=O@_+#!VZ9+KZRC M1;JXA=K(#!Y2!44@...DYR?>@G_XNU7PS>^+!+25.E-273.&* M7!D!Y!
MR^6VWGC&Y15UP>J.U!<>*X_ \$=@#;W_!DS(XO6NOLR&!@;HT?EN25)R^#DC@YI MUYX)34!UB!O!Q9;75%;&V6 J51=V^KIC(V6)SCTI?#7A/5-
\$6H>?;S5 M.;T&+6^2!(HQ@>V^S\$S^ID@=|<#15^+7_)M7^L_H^K>O:A!46NFTBU\$ M6EN;(RPLQK^!C!E0!;L)R;Y?^!PX5_M@P
&1GE1ZUG6)7K^Y)=M!>=Y!M8!;JBCME/F!"2^A8G9JF_WNOXT !+>A8K^X^EACU>-(EVA;WS 2^5_&1Z^C^&^*K63^&^MZ9J!+)
M8^R;Y!JEB1?FC^Y^W64Q!"BG.M;=P>7=HDXFBD!R!ORD;&/?^3!C MRS06*#;H)9<=CU%4-1T?4+N!NH(-3B6TN;9=

(/U"/O@&^@U**XUB>WANV>W5@Y>)>G) MOQCE>@QI-/3**VEI6:M9X9F86VHWGHC2K>VN+262)(VS-N7-VW (#>AQ MWK5%
[XFTW68I/-.1FT/::5[XWOV8"/RKN5%*.2#@/@/0!O!>@-@-IX, LHK MN\BN\BDGC@/DINPSL%&.1CU2-, 42?H E0!T#6K7
MQ\H5IHJDLJVUT^_2@L19(Y)1^T^<1+W^LZ^O_!HP:F/LDUU>Y>7M_XMO_-IC,Z^ZG#13VA.A&ID46Z329YQ(BG:3HDD
M^*5M:12ZU::U_8QNOM>G73V=N8DMQI))&%W>.)&W@,O/W<84C&30\4V4JK#K MEKI9L\QVNI(GE%PD.84VXX9^Q.>:16A7&3:QKD7C?
PS87\$!<66H6\$!M%*BL\$F M14-, 4@%STOTKFKC7_67_(">*M9375231-2NHMH8Q:1D3)\$P 5\CH1Z8.3U/0 M^K%(S:\$9L\$X&<9)J_VF-O:13:<&1
<1(3S71<=&M1?Y9Z=JN17%AK2M(M:S2;N125-K8-W<+Z@1XJG_..1VZ>.)_9QSI\$H(21RA6W(O5N M3W\K5KQ?310H0Q?AMJ&OZ?
J8BCL=7N&-IY"LLZFZ18Y(X)QMOCWKL%&K:MM-W+M+ZF8?LNGB>SM**)9-X#EGGW0H0JY-Y&0M\J^HMH106FF:U16E3Q7M\GU:
WG@=\$R@#J6.XYXX4).T=XAM-2UW5=(ABN\$N=-JKSS(FU6)P.5V1Y"/G MMW%<=ZC+J^H_- 4U59KMGGD"!S6C,<>V36GX<_P"2I^_~^N6G?
^BY*J MU+4K1Z2+2)O)-D*%03C+@.0J@#N22/K5;2I:74IV^LVL+ZSGLF4.MS& KA@ M2K(RDJPX/0Y^<"N8^*L.DGANR9+J)1J=FH
F&S.F%\$K= M1KJVA:G%?;2!N+B-Y\$"L000K%?YP.HXKT4K35%YJZHEH).7A9;<1>4 MA~3)S@=YP3S@/T:5%?;+ _+ _+
K6C:=X@U"WU\$&XTZ=#+1.VL2R0K#1G\$!N M0!F^56! VD#UTJ00M>N?B4NA6NK"TL)M:|^2W1W1Q^J94L#S@JPIR>_A+MV1%>62^(?
%4GPIJNM7M10=H01H@00#@C TR*4AV *D^VSGCC@|=+IC3-1. MLJUW97S2:6EK^A55=LDCC>#G&{(0H>N/GJ^NBN;16ZAK=OXL1~9I>D):
M0ZFUS'N@60C96\$#</'G3(&_BJD_IZ_3WNE6T'37ME!:(991 M%+;V25L!<,>%"HGI@ (ZBN)74O\$8MM^AUF>'3KJ:'717#849KB652 OEJ58
M;_sLQI9-R^J BKQ!<=J K34C%=3ROZE+;7M!C3K;HBUJ34ME4! IX+&S M#T/2**YB19/1;_9Z;KJ:D-9U4VUO>FJ5>WA6_ZLNT\$S-00_5_B!
(H5H0 MJNL:9XNN/#UUS#==;H9W9"Z,%=&^@*P^8\$!/8YH J6JFIZA%I6EW M.H3I^!-M&TKK\$NYMH&3@5YK8>(<\$P!+>#O\$5SK"S?
VE>6UKW>N\4\BAK7_7A/ P^BVH MZ5).KZ19:EJZP7<"3QB0,%=0P
MSC/1#5NO)K"12>=&"7@I6EU:YTF6.QM:C3C*H2:1561_0%@2,Y.#Z#16 MJ==13Z_I=YJ/AZ.Y\$!<
1+%;0D6_V.18!^!\$A9O:18?3D80D8Z9(Z)138V9H MD19V:5191V4.O;2J2/TW9(C^IZ J^ (M:71=66.6MIX@ENK8#.2MNL4T@1&
<'15"GW%,D1_#Q#<+K>DW0LKJX@2"Z1HO M.BF5/N\$KD\$H) (/3J#704A. 3@G'84 ^!OM,T^QM;Z2W%IJ(U.21HPI MW%P'+IGZ<%B20;=@:
58N?^EQ/XCO=-;75!^=6 L"GV<%40\$!&S">RQZ!>U M7_#_ (@M_ \$5M>36(\$!V6/DLY\$G"AM)9PW0D8S[IT3^G>W44V?AH>X^T7<\$
MDI0"TABY0-STY.<8S0 MT|HW@&.#Q#>ZGI/B34=,@0J^_~^OK2!\$9)Q@LA8'83W(YIZI^26.&)I975(T& M69C@>I-I.H X_4O
@EUZ+6=&UJIT6\$!"VLYMT219XE^ZG\$P1N X#_XVK*TG^5DWA;A@ELDYQP>U=611%XAMY2%< AWT/1=&1
M6@NS(P7RV0MM&#"G.O>H^2@C^X1C.O:UJ^U=?;8-7MDM;BU:+F-F0RCG.U5_#?@F?P_Y-L_B+4;_ \$RU/^AV4ZH%B ^IN8#<^WL"
<#CC@8ZVB@#A M1HX<_++7M.CUVI@TS5YGN^M4B0^7OY+!^F(V^)"F^4&P_ O M&SINFYU>^H^Y>:SE4>0AQB<#H|HQQWYJ^VXJ0I^!M!(R
:6B@#C+?P)!H/B33_17+1Z!-<=>9C;4!7V?TP_.YJS+X/EE/ALG M5_0L&(<9Q^!P.Q_1W1TFL<^U=;%270L>=>Z:"2584+E@;B;R<9("ZUD0>
M^HKKP1H&LVNFZAY MSUDKF;V\$%;2%02\$3&6IAG K-1Z!>H MM8LXYH!>XW;F.#C:Q7D D?P^M^M M&^>+M=4T34KQO?<=W%UI221?<
(C59(W"~K@#C|HR>2?;C%J#PC(W1CKJFI MOJ"!2XEMW>\$+*SA"@+N#R.,>IG R3WZ2:3RH9)-COL4ML099L#H|ZUSUSXQ
M@LM&TG4KK2H@74KB*V6&6-5DA>1@1^8"W7MF@#;T?X?H=T%EXAU%~!1ME72=I%6);2@O^C MBA2\$-N?
%Q!&WNNA9&J\$!"6R1PG:SG.3Z=JUZ_2A^7R>(<779O\$5Q!\$ M-HHHJ^1A)>+!AH VC^XY/J^JV"G@FT+KJL 9I6X6=>C-Y^R>8
>JNE=010!O5YI?C?>1VM;B:XT2>6XN96MVCGE4X^T>W\$@#;C.XU4#J.30H(Y^:XXPR^X&T=?F MMMPK_H-
H6Z74I=N18NMGEI+(&D8C3K@*@)P.DY)P*W:~/60#<>J.HVJV MJRHH>GEA#JAE9&&&1UXW*?J^#R*17_@N+4-
IURV06%WK8"WET(AG8^YA M47/R@#H6/4G6=>310!6T^VDLH M1:683/#&\$P)MW8& <9-9\$AR:#Q?>((
M10DFW=LEL86(RHJA)4YV9)RQSZ^U=12,RH19B%4#)/_# \$CX>E?I\$7A8:N M.P|FCN!LWD#?
D2^!_UOJ_ VZ<5K?Q)!XAFUW3[X6U!P#>J8=14\$S(K!<P M^LID Y(OP0=I_BJ4KVOCM!OVLK^)!6_ \$8,+@#/\$S\$*9^(W-9^O%>1^ (MW?@2^33-
JL;_>W33H:CYC1AWGG#_Q9SP.2S\$X H8J7Q^X-MZI9:S8ZM< MZ3K-I&8ENI=%8/&3DHZ-D_1@174T4 4M+L1TZR6&6(F0)R=TMQ-C=(WKA0
M_P-9%#FLM=U^5=(U!K)12">XFB\$B,ZC D09&U!>=H&171T4_P M413STZ#"/>M>A;L.SWGB#1=8FU>?;I<NBHH XG
M1_AZVAW+V1EXBU!>1.0RC2<(<47R4\$A&X)G^&\$9IGDYVO&U7^*U.ZI^PR:3C>O)RAI^O6A0\POA+13 MJWA+PM+>ZBMU:65O;SPP)&%>K&
OF,"=VPYP_%Y SDBMK0?#IT;6&DO!=Q M:K=>=2O_""NP"LIR?EPHX.?K7044.^DET!91(EFZ9<*WB
MR(R9YCW=L9QQFM3Q+X9LO%#A.YE|N^P7;=PK)P5^C\$64^N\$C&MJB@#^13^6 M126UE
+TVJVMW%=>K&+&R@Y/3/7^E513+>W6JP2M:3ZNS6&J+~.M.AO* MEJ9>42?E)YYY#8)RIZI+10!SL7A40^+4UQ+SY\$T!<
<+>4Q97R@VX9;=V>_I MV/U^M^<0OHC^A2ZM:2?>+HP75_~M;Q9G_5Y18S@XW5U1% /Q^&X8O!M MUXA2^F3V:V8@_RHBDLISC.OV0>N'
MIG2TOI(6O+T7UW<>6>&64.KCC@_951CT^O7744 8#^!)H/&%KXB>_FP6C6 MGDK^A65F#,<H@Y48H!ZUA1_#9H-"M1+@107:>8WXOM.?<
R8S1G8,I8(Q!<? M;_3Z=->44 9#&1E0RA@_IC Y1%5%EF^F^C1XLMML816X.RQ_>V5^Z5GS^Y8_ \$EWJ^C>
M(M0TA;@H)O)&DZ2MC&Y=X.OB.I KH^4C>WM_&QO+>6D@C\$!>U)J^#NC.M?F
SCZU6U7Q^Z1K&ZD;LW#R.G^T_!^BL%!'<2KTN&G>80>+13S.M^SCW5Z/XFGU?5;S^W;I*5X\$BOK>*).538^K-DH.=0/SK5E12)HFL7
M1^EZE%#L^R^X>((H1=Q>)/^9<9P>_XJNWC&S2V1.SFTNO+UXOK;L N(RZ;P M^<C@IGIO!1@!RP1>&4 MJ1SH_7@X(XV)>N>"136%GIN-I%<
<1W!^*Q M1RS(P91R>F1S3;WPRT^O6FOVUZ+15H8#.22+!+=%\$3NVNF<1-R^&!O7055U M_32I;N;^2^66.WC:5TB+%0.G&2!TIZ
^U/P)J^AV^TLZ2)10N0>7EUY M89Y_ RL#H-B@#G@>O=7\$)P642NKR;RKM!TR<5BQ>?)HIC2-#U^VTV N M(=7_P0Q!C
LBI@IGR1JYK;#H9#&&1;5SR Y:Y\$27Y0.1C)7(V1Y26M6#PM**8>?DBU^H.B.P-CL>W4E M+1RQVD<10/^!O72T4<1\$;#X>6.EKJ1UJ^ZO?
32HD-DSLTLF69,+G@G@9_M_5M>#M-B!>%K+38XASR*7D0-NVNQR55W SM!H^W*~;6/#DFJ^(-&U9;f MR&T1Y^BC|H^+KL;
<<1=,8IAK7@F2^1C71^URIF:47B\$%P!\$;2)@ZD<\$ M93UUM%_1*77@N5M9T_5;#7_VTN!V>TFD^9XV>Q.X8#N<@8H<4S2?I
M5SH=DMM8;=#D=)1B2)&#&#YC;H61+Y)SGYIC%==10!QIO/;"Z@GDDN)(M13EU=36!@O)Y5PH^@JG(VX&^#G.22<UI#PI+!>?7&IW-
ZLNIR6ALXY5AYOP MQDY;EXDH0)8H^X^>3&PMHN@HJB+2+P^YAE_1.8YVW&YQC7UX MZ=>1O;_0TVYH;ACV^>T^A3@X8\$17^6K-
%1^6A P:2I6G7^H&JL=*;6 ML7DB.L8OB.R\$\$(MO!& HR 3FJ4?@2RUR|N)1:CIUA?S&XN/A5^CR^I01 MF!>1OMYI",=H10 B^fJ(*%48
^84M%#11110 4444 %%%11110 444 M4 %%%11110 4444 %%%11110 4444 %%%11110 4444 %%%1110 4444 %%%17#=\$MH2-X5\$+JDA116@5F7<
<1XA;32H+>#3IO+V.1HFW2)G M;G(Z">*4)ZCXN@NK^75(<#38M0M3<(BLCN74H=BJ^N5;Z9 K9LE M4KX@TV=7EFTJ2-
EOA=O#UQE^BL9/1L;_#>MS^<#6IUW411O.F2XCU^R M^%C<6K(H0Q%#<@>_UUK;+J173V,+N.K&TLX7>1WP^3CO@5HW-G/9_&#P1YN
MH7%VC;:=11.5RH^GR^4;UK_S!M22=F#; MDC^& (SFIK/P7-%KNFZS?>=(10KROBDA4R)\$JNCI<@A4_V>O4GOVH_H%I_ M5Q
LCQW412|M01\$P<_BX;CD<1/SS5TP1U>@_9/#4>HW\$4=GIZW4TZA!+ M1N549VX^42<9)HFV^TA0GOGD!D8@*)7<#10_!M@0/R/X=1/2-
&M1^BN1\$SR374I7Q)C=+(<#)P_1U^T^4ISPV9?Z\$^+M_ EM;W1^+12B0&08L.#R&!)Y!_ T<7FC72;PI>2_+376+G3I+R%\$C M;..&
(2;@&57(9078"~ZIPTOB*&^&U+>6"7L-Z-822NAG"D?KJ!>=AZX/M-5=3^NE:EHB6!GNX+F;L^!CU^&0+MP229;@8R2>*
_K7=2U\$S^<A.R@O&6PO M2W%OL4 MABD6Y3NQD3D MGI7;ZIX_M(O)1&L^EBDTOS##^J*48R+M;=D9Z=,\$8K/C!#JFE^<K_ZK<^!
MKLDDERQC3^10C;.../E^>E&JNNZK8W7A^79-0DCT4#1^V7R1L1Y4S&M^XKN^1^#SW?7M101333-
0U&6\$MK>6_CAA:=%/EPAPC^4%0FYX8&LW9RM;5 MYX4M=1\$MX7O9Y)KP.3YXKB MTF@P6B>_87A@0PP3P;_#218U"YU:QCI%U+=
<6%M.H16\$D>L P.02..XQ74P>"C|JFLB-M;OGN-1M\$MIDR+&0Y4_ ^HQ@<8?^D0 4;>&-&Tf;M=+H_4!\$OEIO8Q M^*IN.8^TYH
EMI0NO\$B+7=MI^<QATHX%_#H6>5D#EYV1#<_TX<18I_M_"2^H1@QRYVLGU_7/5^YI;O\$DVMZPK%HTFW&D=IEN\$*7.T85B^4I6 XR.
MU4(O!5WHWAS2M^T;713A^Q7I65&PX)>+9/E4R0..2>G/8 Z^165K^80S& M78=L@4\$J<=<'@UY9=1>_U1+1>1A.9KNXU>P>60fjW^S_0
5ZK=1//RQ M1RF^W4I) 2N>X1XKD1/HET\$;5X235KL23+B.XAE\$R4;<@&/_W^_ \$M;MO190>O\$K^X9D@<@=
<"X4U5TW40%NMZ7H6NZ=YF+EHYHJ^2\$6[6HJX&+ M.H(P.\$1M?RF9:(V1M_+7RS&6W^MG.X>M96C?#R0KHQV>N M:H-
&\$H322Z^2A)MSMC=LS_#G|YYR 9FJ^<M6>P19RQW\$V.H.1+LL+544^8
MNQ02^2^7IQBRCZ8&#DUK7FEUJB7>D6D^I31^=9O)>+VZJ;R6;Y>>1EGW^!)6FD12ZYHE^UZ_E6C:4+G^15;-C\$V5H+D13Q6^N>LM_"NH
M7HVO7.LWEHJ=JUG<=&%&OVB#\$S^R1D8.\$<1\$XZ\$D4_52;J^*="OM2? MS+LZY;Q2M^EMEWL!
(7@!"C...UZCJE^FEZ1>ZA(A=+6!YV5>I^J6^Y5R8^M\$S\$?AV/0XJ9OEM(KH!%E49D82&0**5Y&XDDG)=FT2RV10SA9#=-K@CA@1@ M1>I
'G&H>(MZN^8GDM*#R@HG&X%=XPI M^A 7=(M/\$+V=19Q6=Q%_HL:E=QG/7.K;>1K:VTF^1^OKB?1 MOEEBL^Y0IP%?>L9?&60_0#SP
21O5ZR1_8_%H;^+^5Y+Z..2^ HNP^F=F M^C.1N/7-G^3XB:C?^1X^U:4M-NWM;NUA\V.1%5N01P0P(QS5?5-3U^W1=>%
M;*&^D6TU&WNC<01\$11QJ58^Z+OBNAU0217!G=O_>V|A)RAPP!4M>XZU@Q")/I2T4KKQO!
S>Z4DJ12.L0#AU"X90N.8^7J<1>10!OMSKGBE/M>O>(AXCF_2-1N(XHOLT6R9(YMNV3Y/EV^O=3=ZOJ>L>19TC3VNX11
M1&M6A#^252X9O.SD 8-&SGC#V^L3^%51/JUTUM1\$=PIQ_1Y;U+MN M8+QC/MO313^BIUB#6K+7-0TS55@%Q<7%H\$Q MJ^"M/O)
4(K^1U_74>H)!&DB,T<1(=21D\$1^0"1^ P5M+O5+C30^&BWNK7- MR=+8K!<LD:RLCP^JH84^<\$D9_1K?N"/2ZIH=1F172MHYD;0;YE1=KM(2
MDD\$1,OTU6<K@G NDO^A.@_O UC!>R MB;64MK=99%0_9TIG>VSY<C7 W9Y>.><U;PKVIA37MP_19C18W8^K1^T^W&^X0_ M.1R#5Y?
#N^FU"YO&FU)H8VB3^6H\$.9.2%7U)P223T^88H X33_ \$?B.O^%I MXPOM;%RHU9O0K.O:(L:323\$BS%A@|DE>AHZO49-8).J>L2ZG1OTFVTR2=
MK>X51+YZ ME2I@64^0CCOQ3!P+I>Z> SX(O)YKS3O^E6?LBPBQ^@8R#>@ M@X!^G-X_%A.R6^IZS&M1F%K=\$OF7.D;#1&%
R2;"OR<=9.0#_Tz;Q7<7> MAZA|DME.H.H) 24H(U+*+& 8R5)LPK\$JH?^W@>^!H4U_5;K3+F2! MN8H^L<#CC@51C^&:
<6CV^E+XAU3D197B7=>@A\$?H H1^!<1E %)_M_U/4_B3XUATW61=#D^O1A^Z^X^J>J28^~^!_07(QD)Z08ZKE0W0@BTGL=>%LK2ZFLI2;L;R%4
>9VGEM"(O(BJ;13VNY_MFODCBO6A4 MS1\$=RK)@;@H.C.<5S\$WX11O\$ESK6EZJ>DR7NW1=#;FR<@8W893M^<5U<= MNEK;QV1(*QQ(\$3))&
&|R>30I>^>);\$P19Z@NKR21+U>>WMY|JCR(E9 M^D;=<=&L_YKH^MFL:51^T^XU>2IM-5M+AY(A1\$A>+808HJW_21ABWU1 M9?
AY%>X>UK19^ZNCIK^YHWG3^G0ZEKMEK^R6?6L^F6T^*YMFAC5\$/D&16L=M.P.ISDG.M>Z>4_318UB3QO+X>2+15)KCAE\$=F>_>=
=T\$N\$0@*H1^29#%@ULR^#O-/AYF MU2?>H2;1\$;?0#L^?Q_>=...>M5M^6TIOQCXM>ATVIA.E)-DUW;M^Q=R OH M/4^?IN^?
_5+1^*MD(M4K2A-OVAE7>3CIV_N2PQI5Y9I7B301_#B+QE? M.V+DFE)X/LC6R^AD;YM.M2PP1MSR.F=H7E5VB98WV.1@-C.#ZXKFM;1#6%
MIXD)@>1|MHKJZ^00% (H^FRZ3);NTOI(2Z M3_91D1M@>I^!#P.HK!>1>WVK66EZGJ18:ZL#F1TV@15E;1YD#1<H;H D
M^>.O(YVM&2Z3^Y5UXBU34XX\$X>=;N(5^Y4 LV^1EB2^43Q^&X!>YTV M_P14U26_L^F1\$2SJB^2R;&=V+3MR.PYR03@&
X^#50&3_#0^,\$11F2ZL^N M)>+1I6(17\$<YNE5;O+>DV7 48!^LI_&?_ *J\$%HJVKGXBMO M#E<"PNX-

(2I06LRI+RLQ3""@<*"I3/(&>#G02VFN10>"H=6UEFY+|^VT@F.MELP\$20;9&5RI7&|^"KQC.<"N@UGP";C>Z=J&GZG?;5J5A\$8\$N|9PS21^DI^
M^?SDY/FP6-Q:6|H+8".S8(KS|".JG.M1NOG SC|4|H6H6_BN6^M>^GL6M5A:UGV+6&W#)@ Y/\$\$GISCv%|4=.GO+ MNTNK:49K22VW|
(|LB@:~#(H0G6|SWH.X>:Q)=G2?#-17B|H0MHV7H|227R MBP(7+^8ZE 590-1^1=^6ZCX<|0^+>X>ZL|/TB^|MH|9T4|)U;9UE0&V
MY4=2>|;Wx^LKG1FLTO+ B^I.HC51>1=PNLYWA2-N.V.=/?FE3P);/JFH7U_ MJ^I?G4;(65W%/LV2H-W. HV_>XVX^U/
%BQLM=BU^3:S^W^N|^1^2W(O8HU& MYR 4>+;HOSD\$S^D8QU/>:QH?PQN_ \$%AJSQBQU:=A+|^ACF4W95A(6|;D M;+2N/?K7?>^O|+;
L4;|=1;J5LH:ME^6XQ@Y^Y_..DX Z 5;X>0MX M-N_#+=&TNKAIWDH/|;L.GF\$%C&W^M0|V3|6C958HQ: 8-9^OS7E4GB;Q#_ M_ *E_ME-
68;DF|W.QAC|/M^PE8(YX^RGM@|=;|35|1;|^#+NEYX|S;U/KBN- M_P""=1^1(D?^#AUB|J;O|69+|CWO|W^3&- /3VH_?7&M67Q&:0KG6|YNT
MOM^DNU9H8E:WE615^3"=PW1MW3|;KZ|K&KS;|^>@ZG|LS^(+74S9BX\$<2L8 MV>)(%)%"I<=>4&-.2|KH|F-F3Q>;(7U^7SX+0VGDB-
0C(Q#;3WR2H/6|E|-V M^+^7|2|6%Z|H+5AGY2 QC^|HG&?3B@_#D_>L.O8|1>|HK75Y6ETVT\$U|9QH MWd|8|S-
<%"EY8_P@YV|@9J2^NGOO^/PZNY|H>2LZ M;+3C|ZOWOP_BN| MG7MFLW|O9:VK2;K2;)|M|H|W|BNX< '&<^|/%3Q>#|^?^|QM7ND)-\$B>^*
M^?B0.H5MV_P &8QWH PYO&H:&OCZZNYS>1Z-)^+.-T50N^)^2%.T#C9:F019 VE=K^9 MW|P2LN:26=
M^%7A77;^5KPV|E|6N;J:U|Y|P>^|I_@2 M+PH|Y=61AMD@2XL|>..9^Y|DYR3ZGD=V;AN;?2K2&|G;JU^"BRRG&78# MD|>|H X>VU+4+ PS|0H-
00&NOL4W;0-R^I6.6ZD^Y0.^|F|J\$W (M_ "G_KYL M_P^#TE>NHM_!^V>Q|0VHU:X|U226=C&F8V=0C;./H YS22^1)I_ AVS&|JW^ MKH4D^1-
T:4Y|H|IAAD.H=%=@DM?2>P6C|LG&V&46QW^<|XL2V|@5P6TV|ZMH=M-M-Z?%;.SOVGVE^?+\$/F|PK+M3))RSOK_5UBGN-0|DW#PJ
M&EMO(R@P(J+NH| (4D8X|+76-0NT|>.:3>27#P.?;J|L;I4\$|JK+ S\$;4X(R.M.C|;#S4|^AS4?^FE0?;=?
Q9&LKV_1TW46LD@FW|2#NC^X*;_0^J|>V^|2@_M417>MW2ZY|2;Q;H|G3|S|;I.C|2@+X;|87C01 MW4VG6ES&4B2-
XOD9(RN|C|O5W2+2|N/B=XO7B6+Z+9;V6PKY;|0RRD|^D(M^|)(|>+;7PWK&L7^E2:~?ZK;/\$=G|JMKN M=8X^?+|^;@D^
|NSTO6|HVEG^MZ3=-9 M?Q^6TN8S^*F<9H|W/V|<@#E;=U65?^NL>";4|M0LM2O5T^ZCG10|@E)\$^J M-N^|R|1CWY|JMX6E|1ZSK6K0-
XA<6FE-W+|^2:6.^?\$(T.OB_8+9|^3(3)DKN4|^?#.FL:SU/7|71_ M 6NS:|3GH.^/5:~Z-P^)|O\$|CJMUH M4QM|NVU^:VM2TZB|^?^?;B1-
I+|^L9>1N&5;5TFMZE|0|C1GURZL|H&BNVCM M1&3^|TC^P1RAX^7|03Z\$4=G|NJ6NBZ5R;+;W0NYR?H^|W);/K5;3|6
MN+K5+NPN=)|N|0P(LB3N T4RMG|K@>_&5/3W^>8ZU?7VM_>Y|^N|09L|J^Y M-N|BX7S@EX\$|8
8S@#HWK|KF_N7|=67A^;IN8X|HFFHSS|AY|O|P|L8;+2 M3CG@<|<@^8T5Y/K3B77M.V^/^-74YA=;89+6 ")O>.5=P|K@E>1N-|^X
M|U=ZKHVM:/45QKDTY|073^S7C1^L|H|Q%VCCP/XF SD@|13S0^WM%<1K5|K M^A|2|UGU\$7<=U^VT%>9<>9;)*ZHYVB;-@EB|(/;+>L?>
BG3M0U^X-W.PZ2U@ M|G^X\$A@N5|^I?4?N|<8H|^B0H(4L0@ZFLCPYXAA|2:~>06TUN(K
MF6V;..N#1MMW|W21U^K7(Z7K.IP>+O^UHLOKFTU2RN#<2W2@)|&B;)(U;&
M09)X(4\$4>L3;36X_1^B+6)=U>^OFT|4|0N(K98D;NR5F829;8Y(&"/M300|Z|D|4|J|^|H|TZZ:~2|IC>|JH|E^""|L)SG<M M+I-
S+;X4RRNB|O@.1SNP;.QM.U_4_ P_AJO7E|U|JU+6_AC|/|%V)+NVE>4|@)%_LF=V;8 MW^<>?
0FM+^<UKWPYXVU/3M4O|HZM+ZR^T2ZKE0= R<20@>#1^Y^D9|&@>#QJ0G+|MP3|^O573+>T|VW@NKE|H|X1>)>GOEVI@#C<+|FNWL?
B6RTW7KS4_U9|N7 M\$?7\$4B.WO9H;6+V^R7LME|)/MW;X|^ MONDC&3ZULU|XK;K8>+>^M;K%Q9RZ?KM|/0%\$B%)^"L@)#|E|X(P"/OKK|7
M0|V|U2;~#4;@*+6>^SL~*61BQ|V|F^4+@^*/X^X^~|6_46AWANDV|UK M|_5VMI^*FW:CD\$-DYZ>^>@2BT1|PW?B|J^T
6MQ%/901SM+)|MV2^Y(&W^)|M^KBN%N-6N=<|^;#4|HUE:ZN=5MWE91@;WDRY;.V.WM_P"2QZ|^_@BT|^M1DE^T5Q_CR^U.OE|
C3=1DM^M>L0VDP^RNC^Y_@PKSO^J^A^|MH9157UQ|L.G;=#?6WV|N61RZE245?ER%;<FTT2(TC|AU+H 64^D|^M|Y&N^UC4-
6|6 AK5BU>^>6|O+>TOH90|243<T V%3C_!7|6E|S6C|XR M|9LU= R^5|J^%DDW YAO|H|=L|<^@OJKWH|Z9H0?7DHBK@-197A^J.D
M_D^PO\$UU<|ZHH|M^?M##;TOFVML^HJN<^H0C|H@G+L_2_1GG|A|2U^4-9^# M_C\$;A7QBE|H|WV_2;ZV@>&6WN-J MLD0Q=46/(RR%F7Y3VR-
G5|?-(|K|I=NU;|W?7|W|X|N|O#EK)=_EE8Q3M(ERL4 MKM(SC<25.0H0=;MSGB@#M^+|(D;3RRN|J|H^S.OP^WK@+35/45_P^|/#&O
M7<4>H7.W.MU^4_3R^/3Z^B@B|B|S+|^M.CD.6/U>9^K^KV0_"/W MD>|37KWFMK9W5Q\$|HBDQ=G&R;^T|
<H0E3EC0|ZE1^FS2ZY|K>;.7 A|H|MZVATQ|N^2D0928|@G9RN3TP>^Y|XU_5X?#W@WQA<A NG2|8-0*\$E0 M 2|@*Y|
(|Z&@#TVB|O23+>3WU|UQ^*|LQ2WC8C:B)|H(X_B8>|X(K%34|H-M>|<^UH0N|BTM|^M|=O|^1V^M+)^*&<6QG@*^F2;~92/M|^1^P(|Z^K
M0|Z|16#X9L|2AMFO+ 6|K|7D4.B12|H@.SY@F|^)|7GC|H^74YU|U;195^PWR|H;97C|Q\$<8V
MD_PDX^4K6QX>UL^X^K70;NRNYX^?;+|^|3N^X^VR_N|J9#G_IGZ&@#H=*U^M74HKEY=.NK\$PW#PA:E0#
(#^#K@GX3V|JW|FFZ590EUMX^R2\$=E^M^K7#;7JGB6|H|>)(GM|IM0U^TUN:VC_U;2-|QRJ&5_H29NOQU|^7Q&USX;16
MWVC:Y|5U|H|9;W|L0^Q8R^C.58.IR&P>^>^#Q0|Z1|(9K>^5HGB+H&;XW+ MD=#CN^DKA|^7;G4_ \$6B^~^8EE0(^VY+<|>L#7_>OZ9
MX|<^>N|3^|T^R9;6^)|ODBE&0KY7|^C<^>#10#U>BN<^XU72/B+H=G|H MQ>6VK6MRTT\$|C\$>(|RE^H^CYB;G\$W|<^C77;G1K72>T?
RH4U_3Q/M M^|D;268|^X4@9XR|U|H Z>N>N^2K~+3+S4(+>|>E)^<#|^3^%9E>)(H MM5U06^6UG@FT|XDE.NW#
|UW@KM|XOCKSSTK&/%U|1_12|NHDE>^RL4F M^"L|P0;=>2_AK2.R0:KQC1#;~M8A;^MU3>SBU|2P|^1/K0|Z|J M&HRV-
U80OZ==72W4WE@) H^P#^|.IG@<8J_7FZ>)-7N|(^>H_ GC;59XH|V M)\$4+|^F%F)Z9\$|^0?^KFNWFF|^P=W>^AL;UU&
^U^|0UFT^%_ =R8^V|6W@_MEL=^>4>BUFZAKVKGZ7|>F=^=SA+G4^CMD_0%5+|^@^I%;5>3^X^1Z3JF
MKV=O>^4K^X2;1Y4M790(^3D;1CYR9.L45Q>K>+Y|KX6?^)|HBYD MF@BE&5%WF\$%U60X|E 7|T^M|^I<7T_CW|^TVKW\$^B?
V;Y|K(R2A)R^&H|E^>9<MMDS_ YZ^%~45Y+|NM>6.3P7?7BV|U>Z.FR7TOLVAC\$Y60R?+E^B^T^ISU_#^TH|^B.O.M^N M_%NN;1H.OZ?>
&&N&CN+M);A3|^77=00?^L/\$E|^N ME.C6C|)\$^N8|(%/RZT.ZCK@/0WU^4;B2ZMO^\$T5DR\$)|YP2YV|^MF &^<^TR.T>RUC>
(^47AY=^;UGF6|O8K-6BVX<^>1@H+9C/H#TK6BC|H M^|(HOM^YS|DGV<^5|3UD;2M^6|PDAUZO^N5W|3Y|QWH|BB0&DUS0?&Z+
M|KEW|^J|AB63W4.DZH|K:6|KG|10^I^W^C^_UZFB5^*T0=3|JAF7|^S@_C@_E2251P|E&=44|J L<@) M^C|XUPGA6T=?
B;XU+7MYXBDM^4F0=F|_#Q|T|P^C^|%)^N|MUX29;JY MB#|^S5BDV@_@F2R1W^C^&E^OYOB^Y|6WOAH|<1SVMLEER97Y|^5F(&W|)
M|^KBK6K:E+ID-O)^IUU?&6X2\$|^*8POP7;|^RCO7%2Z=<70Q;U^UAU.ZLA_ M8-N&F@>^;W|V3NP(|J>_2LY?
\$N03_#^+P^JAU_1+XZM^9W4B|H/M^Y^1SD<M9@|8|T>K45YXOU|^T6S|K;GP2_G\$10H;2#_D8^ ^G^ZBM^O-O M&=C^XMM|;A\$%XTMK\$?>
3|8;9V5;A6#LX8#^=40^FOQ6M.T|77^|>3Q^IE MMYX|K9.3|HPP|QW&6@#M|^X.T0|VZ4>8|UJXO-NK^2P4^ M4|H
5^%|^C^G0B;1CH<8P;S+|^M^?7C|FUFYU^ZEM|U M^Y^CQ<1|Q A^C^M48|80COU\$P>G|T5P6FG09>CP|HUK^O\$^@_P|M;%^&
(O|F)Y^RW^B^RTE&-TVD|H|RD45P_ M9UC6/^7B71_ \$@O;6TAM;66^R^BW1X?(5B03CN.G Y|<^TUIQ^X|^Y^M M|TN=|U+49!
M^A0^HRRY&23|H/300|Z#|^*D;3RRN|1H|H9F8X ZDTZO=>N|H0^AA|XIMKW5 M+N=|U|L6<4Y8^L0EBP|H_ AR?^KV&WA-O
L1EDEYV>^4Y8|H50|(3@\$X) M|A6|X<11>|>^EBM9|8V|^1921S|=V^/8_2^9^K|Z=KEZGB:STW7K\$4_ M.U9|N4K|(H-G20^M6|@^0^AOD-
D;3;S6L|G|H7;VDW:GD\$C=DYZ^M>@/2L/5;^|O_2DCAU^X_F+|^%?>@2Q2;6S|)(S?^%P^|/L^X^*P+C5KK7?^| MWPT2|196NK65|9Y648#-
Y4N3@=|^L_ZM|/\$<-WXXOO#_DN(HLW2X:63;L M=7)^YX|8|<5M5Q5A_R6360^P;_ ^C^*|6@_HHHH ****_BBB@_HHHH ****_M^*^BBB@_HHHH
****_BBB@_HHHH ****_BBB@_HHHH ****_BBB@_K|^2 M^|>?Q^IT5K/<3VTD^Q^=6|Q;D|^X|4.589|!|A\$=ZV^%~.4'|6#^T+|^LZHU MU?
Y0LY&Z;|E&?E^*8|^8|/2D;P;_HVA;8-5U^8=^FCF6ME;B|T83=|F M^|"1QC=910|QTOPI|O>N|3LM7U?
3TOG|R|H+2X^130W8|94GN5/(TK2B|^MPP>^>=>BO|H|W|L09^1^Y2|J25P^F<@DGK6_10|QC_#BSD|(3>&3K&|789IS M|^PB3<9|.(SY?3?
STK6U#PQ#?WNGZB;RYBU2P+|^>1A S(WWD==NUE^&_ M9&^W^*_9U^P18;GH>JZ9=W;G59|>W2%/EP_5(50_!P|H29>^Y67
MB/L;73|Z|O|^M^66WOHG6>^*1>C@>8S^&^Z^B@#F|)^G|WG|AN;5KN^U+Q M5|S=2YE.TY7:0%VGD ^KG;|HQ|^|Q7744 XX;W1KV?
7=6N;K2@ZOR2O|^T^%\$|^1_8 Y&^M^KTO^X|M(+;L^U|^L^EWA|H|F2FUB|YRZ|MN|8W<9|X|SBN|HH|PI|^%GBF
MTU|^VZBEM;9K6.WC\$8B|LD\$C&W/51W|52A|^P0;7KU@_6U%HL|EDEN6/E;E_ M10K|DP;J_..E0+ M+;+>?^\$-
O\$^<^7T2Z|^O|H08=BO|HE^<|LYRX|^G_&16|^P|^B@_KG|^"90CT M^&ZU^*|Q+^23YA;15<^7|LB@A3N|^@D+DX|^|^10|RA^P@%H?^~^LZ^YK;BUO
M|H|Q<7+GRMX;OY<^?+P^H<=|^2|^|+|^NK/QO:QJ<33VT=K>1QNB|Y5_018A_M|J0^1E2M=710|Q|P|^M;^2M#T|=9U/RM&N^N+8DQ9+^%#?>
N^@|H;P>=>^U|M;P^U%;>+^+OQ^+|^+XNH4@>^%MGEA%)@<87=2P>=>MNB@#\$|0^&H0\$4FFO^?7=M M_9|VEY\$+^?9S(N0-
VY3D3P;97&N;GJ=U4T0S@<^ M^&WCSG071T4 WATRW^N+|^O+72Y|)9PW|^3^H(0L0H+;03C|)^|^&
(=|3;EK4%|^C^T^K6F5|KS^0)O^@|NS@=^X|XZ8W^*_#7|^L^L;O|^I_MK1;C>Z2?6^O&DM|J4>^>|^E8.K#L.W%9G_ "NK()K6D+|V|^+;M|^|Z;RES
MEPI9>?4Y|O7944 YHH YJW^&O6U\$K MMPEJZ|7UE56W>4=FU-^@?^|UVC?^7K63=V|M|E|C6WP^BL=5U+|^FQ-O=<@.K@^D|H|^_4<5MT4
^O;^G|C|B36|PQ+|^H|J;3^=SRH0E|_*N5V|3T3&2W|2NKHH K;29_V?HO M9?>+.(4\$8DEVF X&=H_2N%2&2|^>J26U<60_!^H81|&K|
(P=RR_!^M89|XY^YUZ^10;RUWX^L;FRTRUCO;VW6POA|^O&8RTUOEB7D+|^O0(ZD\$|^L>016U10|GZ5H|MI(N6B+ MR3W>O_QTU%
^R>\$+90D)GCO+|^+4^*MG_-O>J\$WM&|^|HXY|64@#L1D8-0ZGX^L=5T35-GO+M6U5U>|NDV>;+M 7E M2_>|^D/444
8%QX6K2ZUW|17E2U^YTN.2.(8B^R|^P|^;X4>=U7?^MT&R|1Z6;^<^@3>LL@Z#BHO^GAF/PV;_G4+RZ6^NI+R5;CR|^5R^O&U5P_ M.E;M%&
&K^AB^7KS3+W|=V-W|LKR0361F=AUV|W^1|C^V|^#PA%;^AKEZF| MW_FZRB+|^N|HA|^J^%>^U|V|V=W|J^Y
H|H|^T|^F^PIU|^VJ=NY5)^/K@BNCHH K:A M;?;?;I=SVC2H4|Z#;O3|^=P(|^H|TX;H&G0SR%((1#^P7<|^@<|^>M|CMV|H|10|YK|JWA)|/^?
@^?ZTFPN=O^&XNT;L<^(TMJ|C2|H^O@|^|^|^7|^3&_ M|^K>3;G VE>|^J|^U^URWVA-1TX|1H|Y^M^%SAW9Q@#N;5Z|^10|SNC^#;2M!
MOM^DN+^F;L;UY^E2ZV|^+ODN 45>^2?I^JX=|^#05_?C4;S|U|^JX^VMK>3A MXX|C@_G^SG Z5U5%&Z1|^;#1+QOL6JZLFE^9ETDW ^S^Q.
<8W>^<M|^F^*AD^EDOB^ZU6QU^5L^Z^F7MK9W 2^X M^N|Q&V3W^D^Z5V^& G^A6^+Q3_!5|^1S^R^BD^B|RBDB@>^F<|^H;S3; M|^+A^9-
&J;CM-^0CN^8_ B|F|SS;KA_..N0|KL;*_3W;|S@_#G M8_A|91Z58Z8=U=K|3|M+|JRC;D8|@H2R|^L^89A63QOQBNWHH PK7PO#9^<|^I
MW7H;^5|H|U+|^+^5(R^55C|N|H(Z XJ3Q|X%\$M?>^<N+|^E^|U;+|^%9+|^A^%R0?N9SDDYSW|^MS^%^A^
FGANT=8U(6MM>?4;|S0;GF&3D^?@C<2>E=G10;S|U|^X^WC5|H=70 MA;ZFH2Y^M1E2|^+9YV3^DA>
<^OQBMG|H|=^+2VD>V5(Q^T>^8P|^@8W_CCW|^ MJQ|10|0T^2QH^DPZ>MW/?<8ZUZ#10|Y|GX^%P|^V^XG|^W|^+GGVV MHZ;
(X^D;ISM\$F&VYQ@YSC@C==H0A6VT9=53|9HH Y#0|A|9^U6VU^5Y=^B2S+^239KG=|^V5S|X|XON/<C^T^XK|J^&W|^|^|^|^I
M3UN+4|T7^H|H|)(A\$11 F=FT;^C;U|ZUF+|^|^|^5EX;75M2^G9SK\$^P_Z M1S^004\$^7C_GI78T4^1|HNU^M^10QE&QNW^E+G;G#G=FNAHH
X^3X>6.YB;H|H=18VSVEG|^=374B#^YTYM|N|SZG M_/R^6^%~^1.U;=10^R8|^PHS7|6LZG\$TUK M^W<^<H|H43|40F5|
(R|6H@AU;V^DZ^IRZS|GDZ^&HK;O9=>|^1?W;W^%S MN|^|^+|^"25 PN|^@DGKWK;HHH *M^*^*^BBB@_HHHH ****_BBB@_HHHH ****_BBB@

[illegible]

MLRZG&BRZ/>#'\$&B&@.88CGG.3@YX'3J<|+>'M8:S^Q37^GW5DIA'.26MO M9LT9==P. @.& N^N5.?NCD54A#7.FWOAF'2I55/I(L6L)'M\$F&:
(/+=1AAM;* M<=1ST.'\$ KZ'J BW7-6U2)+G2HK;3=6DLYJG?=>M(UVC<<,"V>2=C*;GR>|NR*CGJ>Z;PQX>O-"O-.FN+V'X34KU MKW:'
4..JMKMR6.1A1Z5SK #G5#X5D|-OZ _P|T=X+FT(LLRL|AW;YWX;|RM|U+|Y|4 7I0I2ZO?7.N0:%&WFZ7)Y\$8^REF59IA&KD:=PVK|X7C6@G/K-EXA
MU/6-5MM(6)=.0\$T^|.I0Q(|(T+|.2JQKS@|JQ).>...>*UQX-UNU|376L>_' \$4 M=@-1"&_MYK/SHWD500F(-PVG Z9/OFI_P (7Z>
C/7M\$UA;4\$MA;7?YN\$S MHJ|<|"P5PEP)R".N.10!5^& F6P1K<-.CS*Q?>|"T7-K-N&2|DX'MDU<|I
MZUJEA>WD<4UO:00V7GYQ|OSY;F4;MP|M3N+|AAVX|<|B2""DG%&?XZG&@&^-3NR-1=4M/NKX0F6.WD*H50_W58LWS'^
M|COD==H5Q=76C6|Y<6MO_Q^X^=;?ZJ1=QVLO)X*|3U.8.B^&^;T:J01+FE.M9 M74-G;-RPRV;".9?E""|+4Y|=QX%;_A2P_#X8T&+2X)-
Z(|DGRKM4%W+D M^N3M4%L 9.IW-;&HNL;KJ?B+Q3I4TULGI\$F01VTDN?"OAFWT.XO(KM;Q0|F^)|%<MVD^(|UTVX08=
(MY;97M+VZ@+P3SDL^&|Y 7"G&03NZC'.UMKFK#QU9Z'OL3YDF5T0X;."OS\$|OJYK.B.EJCZA.NRETU|@6(VEW:F0I|MESE=PS MU^RX|F#D5G?
+""%7>GW^@WFC.K#^+HFG -F2?|<D^<S=0;A2X9SR.)>6;ZZWAF=|7L.O+I.HWEOGS@_**Z'OEJ|HG@_5=5T M|P^|Y|1Y\$9=3M&
<8I^|ZSI ">HSW?A;Y_M^U#Z&W#|V)R8S&?X_E^4Y|_MUK^*=^F0>&=0TB&X2W;|A_ RO&7VAA@G(Y^&@#G|3|0Z|FN>%+"QDL%76
M;=>9Y6F4A9B(\$&R..CYON)=.HS5>SUWQ7=Z|XHLX9&7-%N3^#(+=A^M^_M_#UWH^MZY?
SWD\$Z;I<+Y:0E\$#0@3&2QSPH|F@|/1M>FU_3_#IU8W.96|_M_M5UF+|R
%1S|K;R|WX#>E8.OC#6;&YT8W;VC37NK#3|JOAC+L;Y8+^<4D> M8_%|ZY|KH_#?A.WI-G5!;|D>W+R0KT\$\$. \$MY;^P=Y&_X%7.P?#06X=|TC
M2CXAM6BT?4(|NT8V;R^UF;|H_S'YCTV^<^<1_1|(?BAXV\$+(DAMK#;SKN-M.R3&0",_F*AT/QM?ZCX2-SS"W&KZY21S6Q|_A
MS4;#Q5K>M#4+3^TH88Q\$;=@8S\$"%). G.XY&|6); #B|F|_&CZ?K2I2GHU MRUS97T=MA&<9 MSGICC%=_7V_AG6;?
Q'=^((K6|1K|3;|9E8|(|D;X\$&7+DX|X<|C@#9|_M_KJRZ#_NMW2W5Z"P=8|)QH7?CGQ%HUR8#;V\$5K
M);F.JWP.3|N8Y|RCIGZ5X\$O.MH'7RG|>|*%\$LO#M_9>+|I.UU;ZV9=2AB-MB6
V|9C|H,%);=S|XYX%8G_"O=0'PV3P@-8MODF\$GVK|W03>=C.OZ|N.YZ4-M-NI>(+R?7M0T?3;CDL8(G>5+7S|O)N*@C<,*H)
|G/48Y|6-BG6Y|X6T_4 MM.&EZG|H3K;0GN8|ZT.FK?170MS\$22.V\$#LZ'|AA|FL:2M2|5^&M1V|VQHLU ML?+EBO| 2;-GSD@9ZY)YQC(P_0_"2)
Y)S8?>|O_TIE|NLWNL^|=8T?3+P*TD-MDI\$)99(<+RR*6 QD84<=>Y)ZC',_@SP|<>O#L>DW%Y%=<5)*Z21PF/AW9R
M""QZ%4>=&KFSI67FOZ3=Q1|J\$*1WMO/\$61V0820\$\$. 2".A!0!S#^|H.N MO#VCW=K;V4-|KBZ-?P2\$S*)-Y5BC9\$|_I(7VY|Q|H|H7CTF)K4H-
>AWS); MQLB%=QV_*Q|QC|:-W+FXGWESP&T\$|L?7 M%-LN=HW8W8YQTH_|'BS6O|A#?&.I&2U^V:'>W4.#>0=LB1*K#6|
&3|_CG4ET|H.Z.&75EUUV315D@B.R0IEO.V9SIP^MY<|<|(?%GZ?XEEDM%|BOL60+&|N;8^J2T3H'Z|<..#|Z<4R7X;W%U
M|H&|VLVB^ZGU=M8L|NV@*M.SGIP6.X_9';T:3#7B#4#@6|Z?|_M^"YN|VU M>T61+|RXHD<\$;VP-EF|J3@8X YR
9|MXD|OV^I>|I+|.PELM=3RW@B@97A?T-M|(#E0FR|H-HQG|K/<7.G^/_|=|>7RM;6<+I+!|RR""VP|FQXSYKZSYK6F|
M:C^OA7_B96H.02)&^S-B/PK_|UIV|AV|M/&^|Z^U|V|!% M^';<0\$;@CW;3OW<_>_*Z'7=?UW2KG5_#ZVDBPWSV|E-OGQOR;'+29^5C MAF"
QD^)|/B75KV|URUT_O-TMQ*_*95FFM7(8|AM7Y@Q'4Y|5'W M@:5M%6U 32QSC6^AWURIS)9FV?2Q_+|3/R@_OX|<|U|=^#-6M?
%M%UK|A0?7MTTU+|4%|I:SVHGC9E&T.GS#;V|CWH EEU56Y|L-M%O%HPN+|S9 RBXF-SD9B2 M-3E@|EB0|OCQI7+|KU|XG|>=
=9;&WCOKC7KKS#W.#1+|.28X&5^|'|X&G+|+M|M|DY&=H^>_="PW0C^#&@6= MIK@MM8T\$M|B0X|?Y2K##*98Y##@|IOPH
Z'POJ&N7;ZC|K5B8EMY@+6Z*>7 MHC(SDID|6^0|CU%9NL.OXB_X3V^PHEO|H\$%O|LETBDTUNSM&RR^IR X#=>+! M07G..?
T2Q|_S@=|7U.7|Y)G_.\$M|H|Y#<0V|JL.9K&GW.V.O+NY6 M78Z?_A^MMW5T|JLZ;|SWAV^NK|H|U^2X6X@A8+>|1@&#86^2V.I&|GG
MO#|J?@*YOM^FACU;+^ZU^*4KJZ>Y+|GC*\$|50XPH^Y|/136QK7AN34M3TC.M6%;2ZWU;3^X1S&6CD1UPZ.N0<J#G(HT.9>(<
>EO/\$7AV(VIUS3H%N;IZI M9^ZEE|O*1^L2NY5<|26 &3@|B#2_# BU^)=5V((K;Y\$|N6/8\$9'3=G^*|R#P M1D>E6KWPC?P;|I)=PKJ|KV?
Y\$S>22D\$.U@%5=V2(X+ MOPAOM60|TFSQ.=N(+)>WTYHK."2+>9I\$C|?<V.M8G<^URW|X|F\$|N^NWWSGC2_X005/4-9
M.E.Y%|IVL%|FWM|9)F7.SQL&(&|)! H O|PZ_YO|X;P^=|Z^YV M7Q^XNGB|V0;7.E1?V#_WEI|K5V|H5B|F7C?+|D^ELGKT&.>O|+Z+|X?LZ?I
M\$UTERUG L(E6+R|P48&7-L2P^=J44^BM#J=|6UYH8;+5AY&Z.LH_S2\$;_MF@|HEXIN=>OM)T^Q_+I=Z0FISR.OF&
'(|HHX&22V2>@7ISD;Z.R|%76F2Z?VFH0C4M M.T;_*S0GR|J 8P"-V5((W @GOQ2ZKX"75/#_B&TDO0FHZW(DL|VL7RJT>T1
M|J\$SIU0@7)R3WQ0|UMLDT<"K<3+_*Y=4V+|F37E.DS>^33?&-H\$VGI+|M7KZ9K>YA9VN-H^A@P^"<#C@Y|I7I.GQWL5C\$FH7\$5Q=@?Q)
(8C&A|L(D(XF MN;MO^H6<6XN-OJD^V.L7.ZVWGLK\$F52_@8 7GUSQC^VWB|6IUT?3;I3'L-8NK>:XNTCC|T MOK&ZH^YB+C).|D^_00
=W9Z0;.IX3U=>=(FALTL98);?SX9H4^YD9|#+Z MY_KF76_1.H;@=*USQ|O2VOB#3MX%|I 9)U&^|CR|MXX&V|SS0|EZGZ475
MX00;^YL;:"ZMM1CMHGGA^BZ@>145PH8|&^G.IOTK8T_6-O9/'%KXB;|MPD-BUFUN(&RVYE8L&W<F^RM2|0ZX9T049=6AMIS
M|LBMM.F0|?ATA1YBC|INTDYOU_X|JXO|*XFM|&6SU^|U|3K@7-G=*@<^V M.\$;IOE2.H+|U&O>^#KG70\$5UIWB#5VN;V78RW-O"
(EMV0|D;9|0DDY/L M^76N;KH7B5|D|OYH+NUUA9(X|UA;0SHN|&XYIAG<\$7L.H3026XMG_TB..78<
O^3CG^+GOV|KLWE|HFF.E|H;3W&F) M|G6^\$HAE=ID8%CVR HZ9|XQAO|I0D|\$.UXPV M|>A>ASO!
(9=2D^_R0#4|/\$&B>>D|BX4&=0P/4|I\$^E5KGOAJ^GW&DO)TL/L-W|F+> M8FVE#N^4YXYW<5@P_#K6HM TS2|^\$BMC#L.H1WEHQL26?
9(7>G?OY/W=O MOG/|LVNNZQ<+>+O\$^D;|/986L\$UFWMUD^D|_FY^Z|QBN?T|OEXF?P|X511W MDFG;
_I=0VMQ.10.&FL5#ARW8X^73N.Z2W;ZG;>)=UA=2M6;4K;*4.V M;|WY88^Q(?Y|B2;"LO/^H1^#=
|HJUM_Q;N&Y\$YMG>B|MRKMW|94Y-M "WOBCKZ/69-M6DETZZ>V@>L72Z;|X;X_E69_".HYVG0;U|H.L;R36T=K>Q7EN9UG\$>0DG**
M0X|Z(X..*OPH^W_(1^X|H9O|3O);*A=WG-G>V;|BN>|'|+>CPOI4E|_M?K>>9=2W"N(?+|QRO|Y(7|/A70T%%%%!1110-4444-%%%%!1110
44 M44-%%%%!1110 4444-%%%%!1110 4444-%%%%!1110 4444-%%%%!1111 M0 4444-%%9FK; 8Z)-817K2|U_U;+>+|06;2V26?3;B-
_UNY)XHD%K(K(RC%D)44">?"IR1QS0!_M^V%>8;?XO|3)X5O|6H7-A)8V#7D4EJD|HF20I&0V3M&0 1SQDY>_M;WQ M6GB^3XWLY|H(N(W%Y)-
%|JFD RK)M-MY>V2SHEC)=#@XSU^N^T^PN_&7B^W|>+>+6%Q9-DU6;UB|E=ACID487=P.M?FSDD_C6NK&Y|WCI3-
*O|NUN;|5+6>58XH^AMWBV'|<2P;C'(SOTH|& MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **CGM\$F/R|B&6;|I9%#%|C4E% #8XTBC6%.1%&J-C^X MAZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
NMOM1L|6TDPWT=J|OX|X M|H8R9POWER.37044_~|J>O Q>W|H+9Z|8+82VJ0%65 6(8/O/6/M;TH.^%M>TA8H=0|5RZG;VJE;6)
|H85TPIE8\$F3^G/AKK;*2TGPOEKX1U M^PWJ=XEF;7K5;S1PF)EUBS?Q-TX|MMWT?#A27-^F4O%4IV=|J6T36JQ MMTPOF."2^|J>3FNLHH
X*2X>7EQX6|O;(^MPXUF>|DF%DM;_UX;O;OQ3HNN2.E&TV&6)HEM3B75 H8Y|SY?NC?7O7244-4)M+^S MM4U#44C?RM;
H(85CY(3E4P.NT<9|U?HHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "H|>P.? M9RW=RY2&)=SD*6^L "3^0%6^BNO^/2;_&_E0|6T;5I37M^MM4L&9K6Y3?&
MS+M)&N.U13Z_HOXBM->4G4+J%YDC49PBXR2>W7CZ&N2|N#ZO;H|P4TG5+E M6.*VLOY51DLSI|_D\$4*|9Y7|449+V%7YXOW;2|H?2
M8+H_N+70Y9K0-TU|KD>^P?D*.L?Q-VIY9VEI-WMG>R^5;B6^NV<E M)4|/C/M6U4-S:07QK&^\$T5P.G^+|I5O\$?@^."9XM|UO39F;T9%
M(1T5)-C=U8|<^L25O%|B.R|^N#5CW>KFZM|5L9Y5^X5JFUEC^H<^X M.HVID=;YKPOK-H?@;".5RZNIK4=>EL(-|MBK;
<29<\$@98A3|XXSCC%'K M5%<29_%UJ^MM(TJ:E.SXOM/A4WBX M^HVEETRVF2 6.?|N1BNYMW?<Y|& >G%'K-%<)H1(%6S
MC9|F65F3^R>X;DY|A@YOA;YUVU^&J|A?;E>C4+@&(B+@N2)&3^--M)LW\$ DC...U_15%Q;S<^@PIY-8|7C.PGDU^*RU^H-|V5
M+?C.W=C_//X&Z0|^2 2.GM7^!_1V|>P#81A_|\$B@#H=+|46.KZW>Z M5;1W FM(8IW>2/C+)|DJ5.U6I4U5=^@Q|K.IN?M5REL/LL/F>66S|
L-W M4&3VR^XE+^N.BEXFM|U.Z-W|F68Z.%9&7F3^V5QZ|23%5HO^N7?@7P M9K^W<5Q?ZL;V|MA4B53^4;&?NYV|O7C%'IU%>?>
(O\$M|HNOWUEJ&HW&B0 MR>6NE7A@1|28E1E97\$.5=N^P 1^@T4;_5|3+BQ@N|A8I+Z?|I;@_00 MM+8_)3^>
IU>KR|OW.CO);ONO&DMO|^7I7.3^|VLO.6+|8(1|@>=0AW9_P|T=617&K?ZJ|NF;2;ZM M)>:=#UK^T|Q|XB32M=|0WN|L1RV6AWM_#F M+5
+|H@>+C&P@&=|HYSP>GT5Q-A<+>9+T;ZC2>PG7_B8+<_9UC4.N0|_MEDMP>S\$Y^OS6=::|XNUW0K^7=#N^N?;?S/LLMO|^O(*YSY@8^O|
>SQC M@_H|J?>2;|SF|)O&E0;HDCY|9|H|X2-F0GO&SX\$X\$9.) M\$;^/|O6674T^E=6M|HVID=;YKPOK-H?@;".5RZNIK4=>EL(-|MBK;
MM!%U|87DEG;B.6YA9XP;^YAW|L3|W&%OCFG3;AXGNO^GZ.VHOZQXH|QW2-&>1E1%&2S^IU>.ZUJFKZK|+M;|5
M)C=Z=XA73D)X^2|2|H?XOCH=(|H?24@_M|@*);*|CD|2^D^&|OBG^VP9|& >H/L82X07|E;7.CCH5QTIUU_5_K6F
M_\$.RTF|U3|=9ZC8S3^68\$C\$D;)|P@9VD;>@&|O0|V=>9CQ|K=K|KD9CC0 MR(3M^A1EQ(5^>^#B@#NF;A;|I;G
&2.R#<^OYOB3360K..>|9Y(^LZA6|MW(Q5N;GN#5VOAN+>P@BNK|KX1|)V55+MW.%&E=I20?MAX^U7^UB!
M-.U^_N#8R6|LEP|J3.SAW/S D VXV_J^V2BN|C|3;IXFN-0@TA;^V-M;6|H(U ML+^*4S^BYCB8,@<<9^8|?;- M^C17G.60>*O\$&A+K?
AZ&X;5K|)M|EXM9(EE%G)F|MJDY&T|8|QXBU_M6|^OBF W=XTVBZLGV;VR(E-E=\$@6.W)C.1RB>^M5NK|H0+FWFGN+D)
(E8|H1A5;#?)?0D|??(SY>|3Z+I26NK&4F0|8|BL_N MYI&9%)DH%0|Z46 Q@&XXZT>@T5Q^K+XDT?2OET=9\$MK#8M1|H=7E6F;O=>&
|+Q_K M=>7C66IND<=P4^LQCB^D\$""0 M_@8^3071^|3;K\$5W^=S.&MM^H|L^S|XF5=RM^Y1R0<\$\$^..#0|N^<|C M-
IX;L8KR|BN^BDGC@DINPSL%&|D8|7D5FB94?8Y!"MC.#ZXH IZ|JBZSI<5^MMI=V@D+?
N.R+RY3PQ^JLXR|8BKU>5#Q7XCD^M.DZVFI|C49=2%O-(UNI#H;MMH@=|H36WSS7I7?7
Z\$8.#>0+4_|I0M9|+>WOLT^1F%6Q+L^C;5P0>O>Y;T\$O^I^XK87KQO00^2K1N K88 @X^Y\$S0|Z|I7FEKKOB.WLO NK7
M6KBYCUH>WNK3|B)^|A9|X8#<^!7GG^05.VN>*\$F&A^2^DN%N;V6^UB M(C_|L|K%6(4(DW\$S.MM)XQC(QTR0#T2B|H^|G;^<E=1%?
LULTL.G-|JB M>_0UPU_XFUG3|^F^&03?^W-
Y|_EH(^F@K&0N|N8)8YP^4|Z_YHIGKL=G;6<=I<19LTD.URVY#GL0I&^(|+QIH>G_P|MK);_W;3|D;U0?97C
M56W|19.02.2_|U4\$|;M|HND;-7|TET66KQZ;74D2INT(4.0+@?+N<= M8SB@#TVBN.OMIU_P_P^+|L|I=0D0|UWF5^ZL|H5|4@\$\$\$<8R#Y
MK^TGO|XD&@ZKXFO|82;ST>XU|+|6| W^Q;@F7^W2^|T^KG>_#TZBN^LKCQ M9)JFCW;27.^G3K_IZW1ME5-5RKQ>6=W|H-GCWYK4|7.Y-

HMGR=LRI<:EJ\$-MA*PR(C(3EL=R#@>N* .AHKBM>U76 !6D^(~90+R/4M~M[9]+)~5"S+~3M* MML55*9*G/7DTS6~4UGPM=^+!F? 46U+VU&BZHSN!<A>)%/*#MDC*J"~",8);(/ MKS0!W%>?1;IK+;#X15!N54~60 C;@C)/49Q4?IM^(;S5 !+MMH!JJP)J~DR7?R?LR.0ZOQG< ;!N? 8>AZ4>B.ZQHSNP55&2Q.~ZFM>.>(M~M4UFI^&C*Y0=76DN~)U(V.W.2)ST1.6 X48Z2\$~C;K6GL 5=03Q*OANVF~MU&9XI#19+ <0"W\$S;I&1!IX"~#.W12?N^0#L*!VU'5 &NFZ~X?6IF@M=0N= M7~MM*~;TR~.PR 2#T(I(Z%17FUKKWB2R~X2;1;W5K.2YTI;U.>J7\$8BS!R6Z+ (A8/G*~+E)M2^~UWX@_0_\$!~.W>:FFB>1G;K4K~WCE>*3!/_0.@1XW

5G34;HW"1!L 8 !J 5!S?EZ4 8L/BK7A#XS _%AO;G!HQ!0VT3~M~NIC5^5W\$!LNS@~\$9Q@8S4FG>)>IG4=&UG4M+UK3!1@MK02PEK
N.GU~M~.WJL;Z\$7XLE!>?9YCIHSY;X+>F2"1W.~#Z"%7PI0^6_P~K\$9QZ^0?2K1>52>*\$.#~.XU8.DG!HP;PUH9~M/LZ89/M(BQC&!P?K6S~KNK>? &=W~;C)U"P.BS:GLA(S\$T3@%4VC.T@!&)~M'/6@#0*R~(1VFLZGJMA;Q7\$(LH9O&HC6*1~P\$1"IMRD@?V#SGM6\$+IYL=2^*5!9W#07~JL4!4B! MK89+0..A@01D4>FUGZYK%OH&BW>JW<D#5FC2!C~M~LF8#(3!W!G<.Q~K)0ZC?1~BGX7>*9BU#f;U~N!B@MDC0!~MT419#0)!;Q+< MZ<2W!V"6<9WA(5DV~D~Y>3!f!>U~J%<#5XEO!4=3!+6;/B@U;3&09)HU~M!+J4A(B4L!)"PS~TSP?>KO@?4~5U!3KZ?4!DW BOH!~EF!M4\$T4!E5D&T<L!2!M3CB@#1B~T!BQ?#ABN!>~>~!RFR@8*~GDY8=2A4UHVYOKOXNV4#A2~89~MTF&?2!~&4>?~T~Q~GIU! /!5E7&O^~.XO#~.O*~0\$N~J^&KT"XD@MXP+ZVVYJ.~MTJ0K!~3QOOT~!J!%86EZG~>IK>6%!\FEK;1MM"KMDDD&~.P(3:<9Q!XK~M=H~***~"BBB@ HHHH~***~"BBB@~HHHH~***~"BBB@~HHHH~***~"BBB~M@~HHHH~***~"BBB@~HHHH~*ANXI9!26*~412.14.4W;~!9&~FJHJF16NCZ~M;f% /!Y=O~NYVQD^@~'

7(>"ZX^ZW)Y'~6M(I29YQJDI6~+B3~M8;52%6/R!LD~!UJY#/#<(7@ECE4!~*,&&?PH~H3^='N=)?2!C3;;Q
7%(R;6V^~. "M?2BEN!~BN~\$~F.XTSK+80S0K&~K"3;DGZ?UI^G;RIHJ=Y83;7?6>~O~MT44~% <+XRFT*!U*W6Y.LVNZ;~_F6M!8;9!8BRC(#+&R.HP5Y~;K7=44<#~M;~*K1FC.IWNM7;Q;&6~+P~0JS#D%OD))!YZ@>U9T=IHEH~ 5MM.N=N=M=U61~M;BW&@W3?<@E;L;ZRBZTV~!tP6~VBUOC&#~"ZX!P2#E"000&~S!>*~.U*!T"~>XT~M.XT!7M+FT=&AMS%~H~S(ODLJHR\$~ %Z~N~VQWK+NK30!C!:=TS~U?%0&.S="Y~MN&DT&X@~1MZ~RAR=BY!>#?>Q44~+;W&M;~;=>*~+UV6GYCS;"&2\$1~X>NPKB3 M&1GY;@~>G60A8~#~)9+>*~Z;IM0FB7?/9R~R^Y6\$620QZGM7~ML%%~E!EJ=M%I=U;ZAKOB74KJ~V~YCN!) N%\$~;8SA~B&YC@?;Q/O>X~+XLU~M!2=^~#MQX~BGU;61+>~.VMGGTFX@WA67)9~N<#KQ7!L2~K!;@N5!+!;D#&(+?Q?7~Q~P3P~VNY;1TG ~#!XSANA(QGWH~XVQ/O!HFIW%I?ZC=;O~MJ^6T3K;F+0K!P^~=ID)"^~^TD9&~R<~FL~"TTR+2M(TZ~XG;+!fM+BR~P~"~ M>?EJ@83~Y^~8X8C!~.G609~*~!~.UK2M&UG10;XUJX~M.59!8SH5!TH1U4~M*~IV=;9S^E4+~XTW2!2fM;+62\$!~O>fMT70;C!P6DWLN? *RP)R>O!UKU~M~B@#S.ZG!H;6~Q+W7~;5M4BCB>~M=NDH!YVE5~<~.~%Y=#UK6~1~4?M#~K;YHS#M"~.IM&TYX&/73K7~MITTA=D# NH!90>1GL~%#!M~#DIKXIU/7H!04RWT\$1!5ZM!%(<~G=7+!J&^&L>F.WXIQ10!S;J>~;C5K~M?5;~YU9GT!4R/MV@!;2!54B)~L+G;GD~ @GC%~!T\$GV%~H+286H~DOXU!5~ZFPUY=+~PWA4VON/MGE~NAVW9NS!~OC~2@~(T32M&M!~W~G>~"~M/8!FCP7~!~IAGDD!D!9~.X~^!~3^~"~ NNG6M;~;7DQD~M;+!Y2FN~!~(D!~M%!)~XOP#@C;DHH!~S!+S7!U~"C;XQ35K~HYUM~8R0H\$!LTB~NT@<@!T!C~MTT^C>~<8!~ TW5!N!H7U!JEQ//CQ;~90QJ~!OIW"K72T4~PR~#CBH~^~^C.3>3Q6/B+4H=~FE;5M)~M0H"QR55R~RH23D#~7K7;44~%Y!76!~=U1~2!EU= (U=&M~EB!M2H!FYX)~MSGJ23!6>0@#D!~Z)H2ZJ!#I!S%~M~J=~\$;9!8~!~!V~;27FM!2!IB!56FMP7Q46MB;~.W~.M/X"D&~M>1~ S>I5<#~L~WYU8HH~XAOAZ6!~W7A)~+~69!0&~UM!~A!0!;A9%DOO=V0?E&=>NB=BJ~P4L0~!1U~97A~MW7!Q+I9U"UAGAC\$TL!2< ~!R1Z\$CJ#WH~Y>#X.S0Z3!G~Q+>M#1%VEO8~MN(AY8<~IX^8X8C)~*K4Q!Q!C/Q!13P6ETS^Y!Y@!Q/!T8\$F~FP9~W9/S!~.~MB!BNTHH ~Y*V!\$~"VTV^T<~G(VCW/MQ)/+8@)!&+!~Y@/W"21!W=@XS76UD~M>)O\$~OX6T&XU>fM!B>W@QO6~*6&2 ~#R1QDB@#U7P~T~B<~YHFMW>B7~BWC!%YYYPV>#D#T~!OUS!QXK@CN"MMH!>P1WHL9Y!6;L~AQC*YWM~M%06~)~.P~&5!P~24= (TF?;7U@~6T@G!J!A9@~"~KCHX(STSCGOFQJ~M~+2+6?~694CV1~.~%55~">Y.2<#~TK;@~^!RP;#%<^~(Z<~)~.KVI\$4~M.X14*!2~O)P<~%CD!<8R; L~H+!Y2Z~C8SW3!22K!A0K~BR!@C;C~.1FM~@#@~!M^@9~.~#&A+XEU~!~>L~.VYBC+0!7A~#A=Y&6~(XSTH5W9206Y!)?W~N~D>~<8!X~MZD#&? P04E%~#~)!~.V3P?~>~&OK+~9!~!%VLIMUWLPE;H4!XQO)!~.~VAXM^B@#&U~P!KOV*8S26U!83BXM+~F~M;F~!8((!4C((!CTJM<~>%C=~_PH7~ Q>~*V!7!G!A;X6"~Q0)~*B9..6!R2><~M=@!714V~TEC62~@R;RLIR~#W~W%)X(E;2~P~FGC5B%T&~*~!~LXS(8U!*&~^~M;IM)SC&?~HE! /9Z!>WVD~(M2TVRU~8SWEA~\$~(P(O;C;~"8R>Y~H!OCM**M(6M8~LVM~B5K~H~*9Y!7&~;?3%)~(H=&@~T&~>XT~WE5XK62~;HMO2~G~MSIR @<8!P~2~YZNB@#~L?2MDGXOU~!7~+?O~.~%~%~\$~!>=F#G;2F<~!~M!4~BG0?~<~F!;7>C~=&VBNUV22?~9MO4@9~? >MBFOR)+&LD;JZ;AE.O;~.M>N?#~\$!UKNAZK)!^~!~I*2(B+~X63S%~"L3W"~&~#Z!~!X~M;R~Q!;ZE=M<0~M~U;MQ(\$C!MH9%~A6!LG&~ H!>1^~=#A10!A1>~H;YQO=3OQ>W.GJXM6!@1!~M9=ID<~.Y.CC~Y!~T73PA%~>BZH~W=~&^L!HEEE5XPA~G\$EUX623DX!CUH M!B&WU~Q!J!NC);W\$5OIBQ~*T@7;XD#~2N<~!+WOUK7H~Y!PWK(N?~Y@MY?~M~M!7^F6!~T2RG~"~!X~!N8#<^~P) &!OP*UO%~A!S!5!~HEX!L0+K+!>~"VV2&1~M3E74~H!H2%~B*W!~**KK6;NWN!>V+K;@~%L\$XSR1QDBND~BX%O>~(H+T22WN~M~U&~62&4!~ +O&H+~G<~!CMWH~HVW@ISM(N!~Q#JUUKANH#;O)!J!A8SU"J@&~M#D~!CDY~YX!KX58)H4;L~B!~!+B2T~Q!6+~J!56D(SLH)Q@+~SR037251U/ M5K72Q~+~N>;!F\$O\$F~TCD~%L#~!X526>PH~YV!~!XN=7!C6KJVL~M;1OM~JD~M~*~0Q~<66#~L\$~9?~6!+3P4!GJ? A~!75Y9!HMJUI~DL*DR(RJ~K~B;~#~<~!U;P+~<E~<~J<7B~M~>LHV~B.HQ11~O~MHV;2CQXVE~!H!VZ!B@~#E~ 0!&27UH<3~Q.TUC?J#7\$T~N!R@~;L8~7!Q@~M~<8Q6/XLEW?%P;~%#J!~OU67.<~@X&03C@UU~EXD~O=U? M2(!22%SID<4DFX+~B02~BNSYQJDI<~.~E!~Z!>~)!HMM8M(HHH+@N%28~.KLA~MR~2~JGO0!B;EX~BU.SN6;4YXM5N+V&^~!B~+~)!@!@~> M2@<~2>D)~*O@FY~M35H!5/PN7N.ZQ%I<~>9!&58A=^!C~8X~!@~D!YZ~B@~#~E!X!B?X>~X~N+Z2~M2V^S? 9DN%~C~NJG&TDP92>~P+V;MPZ?T!@E~B"2;9!#~#~+Y!LICEYSN**5P!T&#~M!M~?PY!K;6!EM~M!V!DOK&0KE09~"9!U8.P~&5!~0XZFB@~#AC!~W;P!~ X?~LOY~MHM;L~^~_MS/~QUOC%FO/%4.N7%ZC!+~!f2V!CY)CW(+Y^~.21~^7/6NCHH~X~MWPI~X#DV21VT?B'4;C!H~!RVTV4)MC.<@%~!F4~D# (~K!KEKK;6~!L\$75Z;~MB+7EVW\$0B"~.~(+4Y!A/KGGFNH!H~XF#X?S+~#H=~SXC0!~!F\$~V!\$4;~*~*~M!3!O/P2%~#~JUK~ U;W\$!LXNYTMP~V.F>2+TXH!~+D@!~!~0P!H~;~?PA(=2!~W@~MUR61CH<~<QQ"2%29>Z;C&WD8~W0.8~&H!0!90LXS\$70(=MGS=~HXS666FNMMH /!2YR;3J&A~>>(+03>?PTWRX;Y!6;WE.(4*59642!~M430PW&FNR!RZE)/W~N!5~M6R4)IENS8BU)!Y0HP&487# =H~M!7!W53>32;A@GY~BOJ">3M~*~@DUS!G!WB?6OA/~.~F8M6~MM3+);I2~4NDBE965!L!0F!U7~!JZ;~!~)277B.WUV+6KRUNUM?L=QY")MGBW MEI;IVG)/YT2!~*Z!~HEHMOK%~X!C;7~7?2JCI@6+A"~<9!#;3G.<@=AB@~"M7PAJ~K~);63Q~E!~!CN?DAL"~?Z;5X8~@;M^X(O!P!BNFKED) (#3!H7KZQU6!~MM1~JRLTL~NBXCEV!~?C&A~Y~+VT+3Y)C93RZ6!>R0J~TA67R0JY!~!L&8GKT!OIAJ~74&C~!P!J MELL!W~GRT5MR>2JEXR!U!R!~CG!6=^~+~.CRZ!~+~.W~D7?DQ?9!>XMMK!HCU!~MPX<~KSWYH~Y2+6~?7Q*A>~G;6/4+HF@EKF6;? IUNP\$FWY!Y2!#~"UR~KVG@9+~P!UVUCUF~?~VG9!AY1&Q!9~C?~E~M&~0!TZ~5MZ#~I7!AZ)9Z6+~F2YCM(EABDD4!MB@~XX)P.M~!66H7~BG6~\$=I M;ZE/TT.ES+~0>0B%~C!L#~(~Y3D9(~!P~GKQSD/C#O!K&B>~#J!~6RNK!5~T~M~!5(E~.R@D!<9&1R@(&~<=H90~?ZP!>ZOHE!~8SWZ\$~EV~BHKH(5&% <~CAP;~!M~W!JG/X%LS~.~%~Y~V>6D~C3~&B~*8)O!ALERPYSN8G&30!M25;7FF~*~#J~M6HOJ~Q\$&~+W31+~T@R2~JO&0~#CKC~ <~)X@U40AG@XYL!H;X!L~U+~\$HA@!F~M~FS\$>V~JMG.HQQ?I2~N2A!HVEOI~WHL%1~0!G~Q!UKGHKC6)~!~ M^+ME9Q~^!+>~&8T%~!5NFM!5N9+B>38F!6D;9MU?^~8!~MWP7!U!J;5E?Z@~F"~\$\$.2(2D3%77~!~!C!QTSV(K8U+~P\$MYJMMJ!GKFH;9JL5 MN+~;ZM@~^T!GHC@J2.QQ~3%JYV!S7~T~AW<~>I7<~ZOTCQ~MKF5Y~0!2\$C!R"~M>F~M~&E~USH?ADR.C>~ J!G;~!OUY8C.VT\$D!P!P07);>~+~M5LO~M~VLV+~R7~M3137TU<~=H7PIAT~X\$~M5KKFJMH~+~#6;6!GFT98)!J"7;PE@0N4>~+ROU)&~#"QC!5U?!5!D M?>(9!VYENX>~18H!U55~5~B!2!D2+~H>;~C!~^6DHGDQ~5=3M;86;6VO4~M!S;8YPH+D~D#)P/2@~GHAYOZ~HF@~^!~6(X~M3K<7E!~(BFL~Y; M3R0<~!<#)!T2~M!SXA7\$~L7HFMKIG&TFO^!~J!P)!7MT~&~!CM6WHGP!M!~N3~;MZSJ9T=9C%~!32+Y;9W8SC<5!YVYQZYJT?!@34M=NK? 5KN&+6!F~W~H45!~0~MN"~!G~T=;XSS@~!4~!5!D~.Y!~!~!Q!5X>~"K"7~MP!~X5O!Y!BT@B2~*~A)!8F~C~@8W+~@~&VE>~5~M\$>~&Y!H7Z<~\$!~> G(YU)KWBF+X=WGBD~(96N~.U"2;0?9XA~!MSY9\$GR~MY^!TV!>~YK!H!6O!XD!S7CMIC;~+~FWV+A9~E1<~@XW~@G@GO4+?~#R%~!U M!X9;5KLVEF<~^~+~L3S~6D!P>~@8ONH!U!X98^~+~\$~F!3!<169L0~M~C(6#~\$~MGC~2P!ZT~8M~W>O~")~T7Q+92M!F>C37%P!F6Q)!C7 W;U&F\$U!SQP~_M0?~7=CX~UFI~L~EK>ZM;~*6>*155L~B%APP(!5C~!~!20KMDL!9U;~YQG323~M(ODJQ!& <~MF>~N<~OGFNCS2QK>AWNEM(!~!~W~!02NFMHG!F!~;HA!~!<F!D;~!~P!U)!~%~WBG5?~#2>~K>!0!~2~M&CFU;TGN417~GKC#; JD*W/0<5TAZ<~Z&08~Y;?O\$~*?Q\$=...M>M>+X&LKN!H0S7US=(8@U7PEOU;6~34YY(+Y58U%K(WELP~M)~JV~5X8#!~*K~M6~PZ;~ OHD46B/4Y3HTH~S8K\$~D80!LH\$P?E~.OR>;~4~84FI~)9~#WC>~^7Q)~M<1/H=[3D6H~60\$U~.QZ5J~^~!~ST~YTY99;~!3X~MA)!GN&P~ K@XG5MN07/9<~!~M?~N3U;PK!X9T!P3H~!G!~7TR~#6M&O=~M+N2XM(N!X)"APP5@0<~UYH~X;3M?U5!/%A~T~H7~W;K~W~VF66)%BDD2~7# MP~*K!D\$C~&~8V384~(XZ?~HJWZ8!X!C~X1W6!M%~5K!H=8N)!BXDV)O~M2~YPO&~#CTXH~?9ZO<~>)/\$!~ID~U+96VGVEO+~Y~WS M))@S#E@<~#J!@~Y!YX&~!~!A73P8Z(9?74~P~Y~!8^~.~!Q5R7P!HJKYU~MK~!8~A~K;W\$T~OD7~2~#JRE=PL!6AX6!P^~#~FLH+RYN8Y+~B2X~? E3M+~ML6(&~#C)!YH~P;05M9US5~\$6GZ4U~VFLEO~UNT(E;8?>XDR2.L!@<84!SQ~M(IYKSW&C6FTWJ6US)8NUS~;8~!LX~C<"RE5B SR2/F(635C5?~D=XYDDU!3~M=;U"1VX18!LV;~(5N%7@~%E92~P~_2W@~J.ZY;~K8~M?V~!~HBF!L!~(9XMY~M?YBX)#;B3N~/~.~;#XRU75=(!~6~ S!Z?O<7<4!VT~&6Y?~!@J&~;H28~MS8!8!~HJ!E~%~<~!C~>P%~XWLF~@2!&9\$^5!~X<~"TZUHGX76"~!~O~4N MjZBCV~VJW8~.HEM78F8A3CD\$~L<~LY~8OW~(74~"IWHU!K~<27NP7~!~MLKA3D~HV!5/8~N>Y50!66!U?2OB~ I>FW~K27M!JEE!~!+~O(BPR1%~#~M&O~M"~&(PQ8^YJ~XRUVXTB/2+2T<17&JZC%8K.5!E6R68~!~L*0.19(ZXQ4UOX9~MZ!2~5K%~L~M202H/K;PI~? 3W5CJEE+~!+~(J>;2QXW8(4~!0P!~M~#!~!<55^&~M)~Z~!~UY<~2@~Y?~(429M)!S!OPH~2QOI5TEMH.S4~!5N!MKK45M~MS.12M&~%6)"/~! M4N~VA9~G#=#?)~\$1~EQLCW~XPN5.3R~1Z8KJKS2KJ;55O!75!9A#Y+0!>~)~MODG<0>W"~@~#~M~N~N^~!~4~BF!ITS~!JK864DRB~3~*F6.T# <~<~W>~?0~NFG!~8L!M3~750M~D~M2>~P6~X5?2<~Y~(Y~5~!NQZ8%59!ASIES;~;7MY>W4M~DDZR~N4=54!U(M7(~@~^G&~*~M;9X!GLK"~&Z!O~EJ~P!+6!<~!V4)A0!~H)~!EFR>*~.~)T~!~MU?1!~GP~OXM6D~WO)!6PDL?0!&~.12.YQOWC~.=V!85W~C37W!>~\$~2UB~ %>~M6WC~EA~N!F8~!~L~P!A6;?~4!~PCV~AZ~NK70AT~XBN+>3RTWLT?W~W&~!~D~M! U>~JZ5~;UI~S!F>H!B~UN8S#~O3(!Z!O0!B31ZQH5P~^J2ZPUH4~C!U!~M~BB!H5&X~&54~9~(Z=;5SMWX@URU~^!~IXYCU!H9? +CO+BP~Y+0N!F)ZEW~MJ&X!~.1SG~!~T7A~P9~8J)~#~ZJW6K00H!&~!92L2\$;>@~W~2;MG@G&~CM?~MEK~;~NA?~KF30DE\$B63A3A0V!E!9>

IMUQQG%#-U#4+GX@^(>F-E% M96TIT'IS!A:00NP=O/W1H->%/XLNVNJWEE+1;K:744-0K.BDEI@XJ*RI7X<06>D-M:JL.LWWDZ1>?;8-ZQL3)EC@_+IWVYXZ|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

MP3!0TFT2D>=KL54L.CY2*RO&.HZA16L+=7<.IMX=%IAKC2W/F6D^XYD M=1RR;=O9@.('C.Z/0!^BT.W=%O+Z^GDOYEU?3F65P@.SP!D!:#
MHJU>^BU2_M7G=6WDCA,91E4L0<.C8/SGD>U'_..Y-0NM/MX;N=2A;1XY\$ MBT!S%(!A_P#7F23(4@<^3R=W!QOY6/B#7=3!..?
#RL;5YXH2N3!:=F-4Q^2-MGSS\$8Z%#*Z9J!NMB^!^DVNI6IYHIS1%>L5HEDIO:SH9YHDSM#Y!;(R>00?>H;M/X;G3;4!KQ-XK!OXDU
M86=DMO!4O%)Y6E1B1OV_:=!7('Z:=.VB^+-6U?1_!-G+(KW6K6 ML%OI?6KJ& MXB!_298F.LJ1!^!V*KNP0<^DD=3O5&ZO:Z/XKV&GK?
3BRGTF>8V_R!%:=9\$ 8 M<9)P3U56!HNC1+!9F%>N!O)6.Z2YUO9C+!(>V3T_H!H1W4\$#6Z1H8+_V.02""A)R0#U!4->..W-
[KPI^!]=^B341=Z!F=TM!4_R!L M7>Z8O!)HL!6>6;+76;NM8N+SQ!J1BT!6KRU6%"BB2_!B ""_@G&.=Z M1!->FC5-
+OI2>1L7TZU>Q1QVTH57?R"%>0!<="560/#<^ATW_-GO+N<7 MUTIW*^@H!YK_'B-JC<^<C!O!P;C/NZM^!O^&L!J5S!OGOI6;4/CS4>;.P8
M=#D5H%[N!>..O&>E/X@U&S^YMHK!H8O.B=\$7!V(IY!CZG R35!AEI%..#IH MU#5OL_O+=+6L^V@;:=E?>%3Y>F?IV2.O^..MMX4AM-
8U75(M2QO<^FB).N_9 M-A OFW*^<8!7<.<IYH_X*^TUC7&L>=>#/%<FMW;W=U>6EM<0?*(98Y^!MLKCECU MW9Z!^BMN.ZUSO1<^>)(^*G%M<?>=.
6GB!+R76-6Q&S8."5!V!A_8!X.MA_8!X;TS05U?45L!-G2XMR&BWAD.N.ZXH R97UZZAW_P_!8MIQU^!N9_*!1BRBG_4!B.D:W\$8F^>;CACU
M!>HKTO_(L.T3Q#9ZS#>7<.MG.FSA@0!Y2Q^!&!j2>5!SGM5!_A!HLNAZMI.M.MJ#P.G=F!E.8LK!TF(08Y53@>@CB@#J8(L.PK\$K2,%&
TGEF/U)Y-25D MPZ*(M1L.UM3U!5!2%XMDEQ!DVX@EY%_+!#&.=ATK6H_YWQ_P#!DH2?!)@R.MX!+!4_P!R3!2?
^P5#_P^BA5!7=^BU_!L!2KHXB@>@ND_4K0!05(O!<1^M<@<9 M!^M^L!R!6P!V!Z!%>W1BC@\$\$? 6K6VK7 M>)>KNULY;3*^0T.K%2-N;
[NAW\$YSI<^HGNZ\$^BP!T!>X6UNK&_EL!23!T.P.KF@&R!80AP!R!3N!>P>_8K8!@&P7PH6B+!H.K!<7<)<6O^1.MR*9.SD_GWS3
M+KX=Z9/X@GUFWU'5!]>|^!..(I&L_:=T0.9<9SCN!^?UH_Z 7D!GX?^MM!(MWN(7S9Q.DE&8)EMA/;C^!S!3^?K^PMTQO!<7UPUS>7-
C2L>)-9!2Z=>AWD-!KQVINR7K0-&(!M_*F%5!MX);&XPO3!>@O!(!7?#E=7DMY-17!MR!N3Y;+<@D9_E6QJG@# M3M2UU=^AU'5M-
OS\$L!MA=>4.E%Z?3@YOZC!_2KMSX2L!C4!&ODNKR!M#"U.MCC92OS+M;=N4LO(X))!O-&!W^!^!+!/&^D3ZK>>3_UJMJZL%WWP!SMP-
MH!>R!P.A(LS!SY+99L_7W!1C MIQTKH!+P.M.7KVJ;Q^W@>^28Z!JL!P!;W4%6C=L!
M8!"CTX(SZX!O!Q:W/B7Q9!^JW>BW4=K>6^H36UJ!7K*^D7E2;=KQ".AMP&3G M)^.@CBENH!^".!L/ABW@!4OX@CN!H7^VRVAA_#B
M(!*2P4#;G@DG.W5U!N!MUN=&_!QYR=C0@^H=E>NUL MYXKM!H4.EZ0JO!+!M.MK*738YKH M.1+YQTTLA@!+!RH^7<+>+!
^!<=V.HQ@D5:O#%>YXF.M>4+V.YM(GBAC0Q^6% M;:&X8\$>G.W!4 A %:=U+9>%MIN<2ATV58ODNYDWK\$20.!)>YYP!@Y!^!KF+ MOK!?
B\$<C!>J=O87&B&Z\$S.R022B02A.2.7<6^Y#?>=J!T5UOB!0;Q-H=SI%<9 ML\$A!R!6W8^88P;S!NHV.VY.V.SDJO#M.MH!P2Q!>1V
NM*!6Q^";Y.G78XM5L!WFM)TN^5D@&&6.<!5R2.J6_8YZY.MO7/PVTFYTK2+7VIP3Z0NRR0!>98!B).8V!@N",=16HGA6W2SL!8:AJ#+.W-M
N9&DE6!K!J08P92RGTE;J9+U!A!1^NW?7.G..YR>15?#O@^P!-3H.74M7 MGM8L_9!^ZNR!%OG^ZN!TR<S.B;JMJ!#N!M!^L5Y!;S!
(YPH(4MOG(!QPI04U5!P-LT^MCX67!>W^X?#>1+>75E!\$MG:2?6C\$#18_WOA=>V>^XQ6R!A.MHJ:3HEA!?!
ZE!_8TF^!N(YE!Y!9S!%)D8L..>=<#K2Y?2FUBU!U!5!FN=O.MVN*QO#&S!&8R_&YSO_S3!^!UWQ>+!+27+0_Y986LDPLIFC\$TH8LP
M88;8NT8?<^TC_9GW6L6VJVM-MU?9>00^V+V.H02PCHC@>@>@>CP!ZU<!.>@!PQ936EE-U)A-S*)!^!@%3E0^&)(Y(!#N!ZMX^TW4_\$!/
MNQ7V!Z;2O&(!WT^Y^K!K0@Z!^!#G!J^W!H!^!%>^/N+K3KNW>>QNI.0Q6!O;_P.MC(P4;<^#*>OQSR^#0Y_KGB#6!^POXYL#^!
S!H!W\$+6=|K;7..4*RJ^&.(M#\$SDW\$=M?6=V9H!V5+!(\$VL<@>C;C6!X!1TNZ!4 M!^N5DFCU.LUY.S#S)7(W\$>+!<@<8!<@<54A!#VL>IZ;J^-!?!
4?2\$>PUUO?Q?>?>H>?>Z9!JQH=^>CDL!G80Z4?F.MRO#8C^>^CFACMOC!J^T9+!A^X!Q?2Y^>=L\$B9Q!>M..84?+TS\$6!^YH!>%+Q
MPXVHZDUC=SM/*2T6!LS!V_.SH6Y_!M5^7P!3>);77FO!H7D_J+60)(J!<1A MBX\$@_"_WB3!N!O!<4_VT4D!1W-V9+UVADA;EX_*!O:FO M\$^(O)Y-
2;5.ZUK^C7O!>XFU&^WTO4+!9H8XUCPR-\$9&7^W^G^U>_*M^D;+!#S6-JL=BTQG#2Q=G!<(KYSDC^C.X)Q!5!;X=M!%U25M72^O)9-09
M9;E)=A3+M!4^>@>(PHOUH!A!B2!]>OK!7BK4^ODN!KQX\$.SRYAD!Y9YV_M-E5QQ@>CCKG7O!80=4MKZ!O!C!LRC!1HKJ&SL!7V&1HV%>R!Y
M!G@;0!43!;K.W!^!PVMQ!=TUC)Y22QM^Q^WDW!67&0&_&XG/!W?>33KK6 M_450=1MAJ\$^PWEK;SA(!H5)&P-C^!
<^F@#EYU3618F^!BC6KJT_MK3 MI7O!(5!EA;JYV?EX;+<@<@<6^*TAJ3XN?29K4!^!DA!PNT!H!>V!)M^..;C!WKT MNO%50XA%U>07D-
O!F9(9 L!<8R<^SP!Z!(H!L^MTTF^VLV)Y!+<4U^!C>9F4C!^MD\$X)!^M^C(R6X^)!@G=/^#2?9!MZN!>W.EW^MP4!4U!F&UO!ITZ=^77?#-
K!KU!IMW)=7EK(-7O-M#<^!D)D?4KF&^!C0^%F5\$!SGC5!>@>@>E=9;^>VOJ908!2U!SM75N^6
MC.W:NO=N4X(7CG/OD!U43P#8QV&AV2.GJ0AT642V@W19# \$#>^!Y^P^1^&+ MJ^KWFE^C!B/7YMI!+!;B_L!4K9RUH!K^K^ZE4<*O.X%F^!7!
%>C5SMQX!M.MN&H.C4+^6PNI@W\$UF\$8(YV<5!V@<N0_P_4ULZA9G4/GM!>3VQF!4.UN0 M)!>Z!200#!X!H!S!86MSX@T?4!9L;&!?
4K.XCN^!G6(%56W)(C>0Y.ASW#+ MZ5T.L!>^!F!^&^>)"#<KB^55FC7>T\$9=1)>P=W\$!5U-G8BRT^PCN) M2(HA\$DK!^X
&!P%!"#VQO7!>QX3POX^FTG2VUV!LHKR-Y\$MG5KH9#<^>C!<M@G!HWGDYQ!UH U^!<^>2!N?^DD.FZK=3!";<KNDJS(MR7(#!&.2GS;<!8!QSSR
MNG;MKMEV!>OOC<.>7.UF.R%;;55.3_OV1<9)4!|8&!C YSN>&F.ZEU2&3 M3>|67% M!PN5UBV^!>JE3C.YD2L6#;
<8R.#GWZ+2!^!G.X?>NM^!6XO=/N3!9 M(KH?H82?^JO4L3!>L4 9<5MXCT_6+34UNHFTD6!GVZ&6^>X;
<H!O69!4OBK7M!&T%Q!HW=0O8!F!FV^=H9(6'SO^7Y>U".@.6!01R3S
M6!X<!"V!AN!1U>5KN&S\$6UO>W9DBM!P0!BX!8D;7.RWM^T2*Z>S=0^D!1E.OBN0!EZ!<=>*T!OAU!3_MZ=ZM;7^<K6)O6WWEK9W9BAN6!6
&"2>OZ<4>;SW%|K7@;PE-J!>S:992AE5;AD#.#P^V M%!/8!|:JA.V5K.VODEVE-F!2\$<C&[NN?^K7+^X>;/!#JZ_-OU(11WHOX9O) M&)>89@Y?
M=7;P_9!>..S)!>B@;Y&W.WN3ZT>0>^&3N^#&GAF^MTN!TFUG6#8_!A?X5.XEW.H;(#\$!1GU.><5U_P!LO=^!&FZ_7!B*
M=2;D).3D!LD<5L6>@>PVVIC4KBZN;Z^6#!D!D!RD9.2_550.D.DXR<^TH U:X M3X9_?9!>C!>?R2NZ8%>D90Q4D8#&^!1!UA^?^"UOX.DU!
L^>O9Q?W+!W!D!&ZG M=GAN.5^6UF_!>JZR7UOLHJW.M.;>=A0H!W>2!S^>N.5=>16^>S^!M7MU6!K&Z7<0.78L!T^R^#Y2""..MH!DU!
#*S2W7Q.RS7+!>O(@)9V<8#+@G).3!H!W?>^O-?Z)>!/ _YVC* MRVV%AMR!&+9SE>;..?GS4VC>&+70!3U^!M;N!9=0N^N9+>20&)>^ON90_#5
M@>2=<=L9H_VZ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***
&3.O;V.VF6T!Y.M!O3E!VTM9)_GEBVD?^VO@^MRO)-6OI.5_#?AR33!1OI5_X2NWC\$>?M%JYVLQ!S!RY!Y!>M>^>L+R!T!O-XKTPZ!<1V!1?>
0W.H!YPM)^9%+^#A!R!>93CB@>#?T4G!JQGVK M!>=O^VOZW_9.W_!SGN9X);<2KN;RL!EST_Z^O2LC3+Z_L?&_ANT2^439ZC!T
MYF%|S!F9XPA\$@!B3^G<..N"!BLR+ _DF?O_!>^&J_P#H_!A=2;M.M;L!L M!>))=N<^!>P!OG!>L5G;#_P BWIG_?Z1?^@>"O.9!-6F!>=2/B^5EGT?
4KS M!&4GVA1&JEQV!R!M!XZ9YH!2!XGBM;2>>4>18XHU+!>@>N!L!7N!75C-M=&N9YX+6#1X;QDMY6A..64X+!EG;H&_!6.Y.K^TD9EB(#!2
S!7OD^QZ!T>T.2)>+&#H.180A?O^!\$EA=77V!M!4V!Y->^!>IACN;3D<=>?K6M;P!0+&^&FC^O0R2-(W!XLO)!XFO(-!TK4)!-MBC5!U-4-
/NM/U74B".P%(24D9B)!Q!X..9+MXC^BD4H9_F!>A!G!>P!<G-3Q3^X!H M!P!+!>DLVMM&T4T4U@>8&E!9H8V=59^D90S^K!K@!P?>
B@#U.BO!>ZUO!>XZ2 M;H>O.H:35K&X>Y!H!6C\$%&C\$9.X@!0..F#S65!XDU32!%O=..+T?B@;_M1#>74QWK^P5!>@G)!3>@>D9!4>KUA;
!XD_L!5=>6!VL9!EU2!P!>@X58FVE MN!U!^G_&N9U6Y!O^<^37!%P!Z!>^!FZ<^!>#T!B!7Q9%!MZ;4UTR0!
MV8O_!\$!LQ!4H!R!YV."O30!F!F2>!"6K;M#&S);2U>5%0!>OGV5UH_VPM3!02V!_M=;=I=B-OU^!M1=RO&;ROE!(50<YCM;
!>Q!R!FN9UNZOO^FD^!>L!M!N!F2>^MZMH+R..9GCDNF^50G";0!L_!>6!>TC38^!7Q\$A!RZ^2QLW^!E2!29@/!>^!>#4/C&[N+!B73-
!N+O!DX8!R!V!Y4F=TS!R!K@ABH<9^82_!>EQ(ZD^0F^P+8;4!Y!%=>9=>X@>5)U.WU^M).DB^W@>249+@7(>=1L=>%;C.N?EP#G&_
_VK#UKO?_8!L+8-90^4N#;B8 M.(R\$9N!U!^G_&N9^>U!KJ6!Q5!F7!3F-H!>L;K;_#%#>@>D95WC)&@>!8P! MCKFQ!O!7N-
=!>0QSR0_!>J!+^C!O!KGA!>S! M!RV!>EKZ!V5W-.OGM!2DM!WCEER_X!88!X!U67O!N!D6T!TU!%?>67354^TN\$ M!R!>..>0S9<9SPN!>
'2>)M=7PSH!UK\$MK)>06!>Y4B8!>OJ.X!JY!EX^H= M!>O.M;^<@<1LP8@>9\$<<9KG/BC_R3#Q%P!>?TK>T!J!>?UE+>(Z!>EK&S.O MP
@R30!H45Y7XQU/4!>2!>6FIV&7!M02>O_>EY^V^O!U^!>K!B^T\$>U\$!S2E!W!C_9B3C(SR>YH_Z M7PIX@7Q!X=M!76U;Y\$SRY3.&*<
&D&3!7!G!V!A!>..S!>OPY!^6.CPC5= M;FL!D!T!&1#<3\$A3V8!>H!>)(YQ72O-?>3!1H_!AO.N33-4TZ68+)>97M!8R M65W!R=I# 8.1G!B@#N.PI2!1?
Y=XHT3!6!V!Z?>U#.#N^X^H8T!>D8ZGH/3K7G.E.M.MJ^F_.NW!9S2_WWY!>290+N^#0(SW_192!+^#G)!>3!Q6!K&EKL_O!^N
MEW>3.C>JXN+AI02+<..Q^4G)SC_Z<<4>B45@>^..A!>PW.T>IMISO+&%)DC M+N=S!J^B<!V&5&.03FN4M!H4HO\$7BG3%GU^TMH!
(CO+>..>Y!Z6%SY@)#\$M.C.MT<9(^F!4=U\$Z!H!M!H!0MWN!>PQ.8DB^6^C)Y^05YK;76!V!>?#W7&UO4 M9!G4;FTM;J.6;4DH;&>^U#J^M1:7
MH^!H41NVTZ-GFAC!H!AM3>1D!>2#^>5O!8SX\$!C_J&6W_H!X/2;^&#PO! M3G!H!>F!U!>H!F!P!H!G!O!>L03!GGWH!>TB_>JZ+8.B<^%W;QSA!
<^!>ZAL9 M!X\$3+&!O+^F^U^>YTV2UAMY0D\$!2^PN5^!>E@>!R!N!Q!O!UY!8&!T;X=74.J7KH M!>16EQ;0^>Y^>V+^#>#>@%2HP>OJ36C93ZH@>);
>Y<86>..M..;F!>3K0!Z#17#^\$=5ANO\$=Q8S?VOI^!0V@.^E.C!P^!>YT4A9@Z_PY!>M!>SGH_!>J8Z!>.>^>G@>M44 DR-P#@>D!>ECST4T-
T3O!H!W!>XU2&PEWO M!MVUI!>X)!>L!D!C!L!U!Z!P@5?^Q^TF>+3KJRTK6+=+G.Y0@W\$8S^Q^L<
MLPW+56_J^H2!X^@T.4.F6UT.32WEAD29H0!P!>=>2#D!00;R!>HX.PHKR: M!N!>UG!>=NKK5K^#4H!7AB!R3_9H6GV!O7(RFTD<=>V.KC!?
!P;B_3_Q^M!>W!>2>175!7O;YH9(9_EED!>+N9L#^0!>OBMRG!>L3RE_V!X!NT-C)!>((77;7O!>H?A?O=>H!AM?>L37-C^!>M>H/!
>R!>IW8D=0VPG!>QV!>8S0!Z!117FERF!VWB3P9Y6O.E_P_3F^6^!510R86#_MS_40C^L!>O=>?7-5)_\$.H^>@!>QO!>J!>Q<1Z;=VD=K!>R^8!
G6..2Y!R!>+!>DC(M;)>@>#U.BN0!L!>00>@>H!>720.3!>M%>M!>S!>ETFDQ!E9(S!>@>VGKD_X!>QO7^V% M!>K!>PPT3Q5)K^!>SW!6H+&Z23?
NYHVN&S&RNO!>60>IY&C!H!C!>37+VXD4S(C M!BNR9Y^L2_?Q^M^!>1J2N!>V;7_?V_!>G!>F7);<@>Z@W.A&667(CW8(!>!>VQ6U
M!XR.L+8V!M!>O!>FGA!>V!>WR.S.5;&1G&H!>@%C@>XB_P"#=337 M!>D!>P!>M!
0V6Y7^B.R.#>#>^>@>Y5N5Y^K&H6NK^>^!>DL+^>N8F^Y.5Z!YZCKUK9^U=Z^XTU_3!>N!>9G0QJ^SW!>GFK;R!>W0L!>1!>X!>!. M^
0OZY.#QMYM_Q!>O!>49RG!>F>?2#55+Y2!V;0<^!>STK TR_U^T!7>^>C(M!>G47M=2L!>@7#WDS_H!>9(T82K&S!>R^23CY3AL\$#%5!>!)\$;X!>P?
^!>B^H!W!>M!(TN^>^!>IZ197XCL74?3;YV!E!>OGOU!>JW61X\$Y_1/O^>#>^>K7GTD>JWM MEX_E^Q!>R!>1S^!>GYEZ>=>(O;B!>=S3112^8!>J5F;\$C1!>^*
!>N-RD\$?<C!>89 MZ5\$>BV!O+GP!>X!>T!>4)!>YE=\$N(C!>LMRTK!>GCDV.J!0!>O^>XYSG@GGF@>Y!>H24!>L!>YK65_-9.CN&);@>S!
<=3!>UJVMNEK!>I#>FC^O0RRM(C M!WKRS\$D_G7DNGZ!>?7F@>^!>^>OU!>4=.N;+7-1FMQ;R!>8!>RMN^<8^<^<^<^<8!>=<@ M!>L%>9Z-
K^<K>K.O!>K!>3!>HHG=>?>R6C>9.A9G!>12!>H!>I!>@X!>3!>P0!>H!>K!>MX!>K!>G!>M!>^>33P!>=P3M!>X!>N!>C>M\$>@>^>O!>O!>9M#>9O!>H!>ET+9M!>AMY^
M!>L!>=>X^>X!>UGN5D5!+!>D\$@>!>MD!><5Y!>H!>7&N!>Z!>XX!>M2!>6!>H!>TOX!>3&UE(C!>B!>H!>OEA_LYQ!>N!>C!>^>H!>U9OAM?7-Y.CZB;A+R&H
M!>YBD+X8@>=MN>U!>H!>?N_5\$X9TF!>N!>8A/X?35;H!>7.37\$C%5!>EP0_2S\$C/!(C!>NV!>BNX_MU^T!>0O.Z-
J!>U!>P!>H!>M!>KYR!>KA@>BL_HN=V_!>Z^>W!>DDE!>M!>H!>83#(Z!>H!>FB8@E^!>1 M!>R!>X..G%>3V2W&E%>?>B<H?>W<<H?>7\$>L5OYF9_5MT9!>3.R M!>O!>H!>G2!>D-C!
<^>Y!>H!>2.PR>6V@>L!>6/2MNS>Z!>Z!>=>=(U^!>N!>M^>P!>+>Y!>G!>1!>+N M7R^>6R0Q&^!>YZ#!>);T5S;C?69H!>T!>38K>4P!>J!>IV!>@>9QC.2R!>S#>?>H!>S
M!>@>U67<IYH!>Q_T72K.ZNY=UN^X5TF!>5K>2) PD!>G!(R!>@>@!>9P4=<4)O3Q=8F M!>..!>@<+G&?>QOQN^!>UFW^>R>^6!>O.G+J%>C!>+^>JO^>H!>E3!>9Y95U
^8%3WZ<8Q7 M!>L!>^>C_>%>^>+>24C">UMUE>\$>H!>^>Q!>TQOE!>RX<+YKR!>R!>57#+C!>P!>1P=17D

[illegible]

```

MH9!*S,F64J?E:(3OZ)-,YX%T6IM+&5NK:2OG>X@N;>X9)A(=I%Y);)SG-MK0:P.I:GJIOX%<(^O+>72FW%J7R:N*LD9V0_.,1QO^F:T?
&AQ+33I(N+MC4I3O9:G7H:CYITVY(EPK>6H(V@P:MBNFF^>A36^JV_P#IJP:H5-W&+HR)M"
!GDGD!02W4XZG.GJOAFQKX0KM*O9:IXX7CDCF64K*KHR1DDY>14+/X=^/UF34K2.IA$DOGM9I=,+8RI=YB:VDYVJ/;@#IU>_MO-
(U>37_P"TB1/GU")KJ+5K&X3-&45@J6(IGD5Z36I)X1T^43MO2R-MW"BBB@HHHH"***"BBB@HHHH"***"BBB@HHHH"***
"BBB@HHHH"***"BBB@HHHH"***"L M#Q+XAFT",1E2S2>/4=1BL6:..XHKG5-2O/1^J>-HJ,N+J2*1XKZ&.YG>?RIF+JS N2<<
MJB.G%:HEHMMVKZ5HJKH46GRQ>+EU+>+Y77Y&18L..H8FN6",4 M 9I2*!< GZJH=TV2^T X;YK*ZMG<5^1>=>1 MV %=AINCZ@NMZ3K-
HJ^>+13+&MO+&MZK+E&^MI 74L5:5S;-8EDW>?7(R>P.YVYZ5NUXE9:/) PJ?4/$%KJ^HV>HZ;<7US M-
%H3>&/%>D^<=1ENAFILV@N(6F=DM;O M:O4JA:IO 9<=0/6@#TBBL1+/%1^2XHYF(7-IYFN7MEH^K.TS^L2N^MT^DC1.T^G&.IT
>KT5YEXMEM4^H:MHF7LOFO<+1WJW4@=BS@H^F^)&SH M.F.*O7D,(RD^3M4D2*.>E^?T5Y(Z MIO?
@W PFL>HW^ZXD7.PG69M@99#F+9G:LP-NW^OUYK5U:P0&NCG:U2S7.D MZS90:W4.DIF.VN OF^ON<L R!M^M0:Z-6H/B&:42%>NZ++9I"-
+#+&+LN S M1^&.2;#..?K75>+&KF_5K_.%ZE+=H#7T=U"ETI2^SD^F;+YR@1XR1O.MDK4I1WJ5QH^B^XFZE9KN+33:6+
(SAA#)@GUQU_@#T^L^QEXAF+>+&G6(K M+KR^@-I?+X9@N0<="PXX^M8=CIFH?;I^06>K1+9^5 I^+<2S^1U^7I0
MON;Y!/:IO7):R^(O@9+XEN;F:6_N6CG=EF8(A-PJ^4%SC:HXOCL;)>+M**XW4HY#X>U00S?V0VEH98BVWS?(D)^H;I^NWG-
<#>ZWHWA_P0IFK M7.R7J7WCI=RW=UJN.%=HHV;^ELI@>@8R01W-15%>I=-/+3DE,4.YI":213G MP5416(P2,2
M;U0U6+SP;+10$T^YNI&+ULYI^F={CR}=RNP+DDC(##8)Q00!W>M>(9M)!M0:#HILTEBU2>X3.9<&JCA=QSG:ZBM^O-
1=TFILO&@*XMKBXFWW=Z9-J=6I03ITZUB>UBDD;I^SEN3JS>8RACGA2>0IC.Y-4M.34 M=7TWP@;Z2G_&B9Q_3^+=&&0(WF-VI
(WA=F#T^IQF@#U&BO_+29-8^O MBNWWGU;5HJ>PGL9I>*&1<..8RY)/RDY^7HR2;%14UGQ?X2L2$-MK$E7^UMYHOZT 8Q
MBKQ>NA^#1U 3H(M16Q^78H+JGOQ^T^L M9IE.VC 6Z(&3@?A797%>?OB7HRQ:C>+WU.QNS?^YN6D0M$99&+U$Q^O^MZ_=I
_I0#>VTHW<6L4JO_?>42P^AD ^>2P^?7PW=W:S^K^UNIR>^U M^RI=06G9&OT>_1LF^0X17)I&1@MGP^HUM;^_&SQ^ZE-
0BQ^I8CYH$)! M^R3R..LUW6H="L8KB5^JSW$5K#&#C?)X516L.G)H#UHTJZU>X08=4TZ M.V$.@$$.F)<16(&5Z$??
0EN6^H)H#^<GDIS=-ME^LC*^3G@K^M1:7684GURIT^UN+J-KH^V.7#Q1VA8N1^H)8NP&%&"1MSP#0!W=-%5Z!X@ MNM4@I
7J;Y.T6I:=+<3R0JOU+&H4+&#D!F(IX>#>=O4=M^3JFT_114.M494U(7(LHY;^G+&USN2>QOI^!XH
ZK6K4:32I9M^T+!&4KLMWF0<=K M#@#IOX&ID A5I=:1@UF55IOAAXKOT^76=:02YC:6TN+AUEM^E+L#!CF-AD MCKOIQP!71Z!O>?%JVTI
IV^2SGT2:26^*Z=%8B6-LV5O:HZ2Z?DAN+HSA3^P V@)C+9YZ=*ED@N5^&OBN_+7U4SZ%J-Y% MIS_-9 85C?Y@#-T#Q#-
K&KZ183V:6I:7K^4XM4@ATZ;)HIK1B29;HE2 MR.I<L;SDCJYH I^L 6+G4K6S232I/2^G.R^T3SB(*A.&)&ZX^:192C M9K^R.EH5I
MW>1(3LY^XV;3I)=O:YB^MM(M%W+V&KV.TU&RNDN+N+E)=!8D82.F2$/(8M!O:OTH I)M^RWNS,+M>59)D,4FTYIM
^1H1D57C%91Z3^2&U0927.MM^7^H^M^X&F1#^LD.W&^I MNO?Q75.E-OC7P$NKA5NX;LA^F8+^!IAN7."03G6/@#O^&CTH^V=15
M>)/44U6XN^I^U5!;00=L1;*(59%.=X^YH6H&F:C=2^!_!!:Q#!%-% MR?M$DHOD=0 &#^&W^'(Z^CIO0!WU%>9Z?=76E^)=M_$<=XD^H
H:3516X.M2UO@X29^NIY#@C (RG:Q70_ $#6+CIH&L^H(T2WNIVUE^APT,4CX=@>QP^M;HLYZT=717^WR3Z%1=1+^X.G:Q;W;5U;M;
H;B0;LJDG<L<2016(HU M4^&F27FEV^MW6K:I^X ML^L/2ZBEG^73M.(CP.H16^UHU08V9U.S@64W>FQ7^DRR
M@I=LB@#U;B0.I6E0914B6EXUYH2U1M^gJ7RH,9QLV=J;1SGG&X^KZE M;E.W2PILK04-
0ANIAGBU^R!QSYC_9V9YI)^.^#U^8CB@#TRB0^O.=^P"$ M_P)@N7UC8VCVOV6=I^N98#-&"RH6:<2S<#G@MFK^GK<+1KK1Y89I73;K0?
MM#6:7C2>)>MNX^*QI(C^TD^4^>=7<#I^BXM5IEB+H=3D$JQ4X_&HJ4 MTZ.V^P/V7U1Z^F M0J<_HR0W7G0QCM8-
$U6SUE=3M19M12QFM^C>SDTD?2DH+G(QDD?>6 M#M^@NKRWLHTDN95C5Y$B4I>KNP50^&X8
<#CI5GXG64%ROA9Y58L/$%H@=(EP&8YQ@I>.06@#O^M^VU^13JGO.N=#.K:O:6#;%M^VI2LGGE=RDDXX4?7^97BRIN8?#GB;6-
M.U^N^NKBRU!0FH.T2V05XU;$@G>IR&)&W^DD4>O45P^U8G4OBU>Z9?@>M+H$CG>WBOH(U^F9E)&T@KPH^Z1G^>RM^D!0:A/M-
SE:4L+4KA)U2>Z M.M-I5C5SL0^&3+&O(IK 47^@>N6U;I^U6>I 9TG%1WC6H^LIR#^WRIO&I^NEI>L^%Y9;?_BHYK-
I6F<+&#U^KTJ.W7Y>33PIYU76I0:OX4&I^CMX+Z3I^H(FEEL-$LJDRS=9%+GC&8..HY^1^1)O$;Y>2Z;LIGU$48K^E.MNTQ:R?F
P=W0IQVK0UN_ETF0H4G=;A16IYA$TFS>%)!&I^OP2O/!$5A=M.V:FMS<3W$^LV+R3-.S^8N^O8C..O3 X!P.#BN!4?BEK7_7A/P^BVH F
MT^4CK/AW3-4.(1>VL5P8PG76B>#_1/B3-3U^LXT^W MEMGN6&XBE^8Q^IT8IX(Z$G)YK32XN^#BO7?#1US=3+K.SZ^HPIE68B M-
X@2<@<S!^&.BY>@#TZBL^Y/J@>IVMUDF.G:LR^1R1.54D9Y)M..M<H5H MNMZ1X1@26NLPPN3%=>S>?(VI6XDB9=H.XX&ND8%_5:5XAFU?
6I>TV.S2M;2IXX=R2I..#C^I2#%1>47NL7&@O4-3M^5G@N+;X&=F8(U+8J@<A M6VUA)>EWD^B&SU&#
I$ME^9+1+B6<7O!LO&P^AAM)W^D@F@#O^KPWMM<75S;M0RJMLRK.H @)&X ^^^#<(KB_#5L>|>.&$XURYBO^V3WY@E@GE:-
XKF165OLZOG@KNYSUH_17HKR@X X MT^P1X2U8:MJ3W&MC3+JEEN2RQ^SHX&VDKN^J^UY:12B0?B#X?L=JDN# MH^LO7.5W:M;
H#&@&995).5.GI^<(SD>=..YK/Y@S7I^OFU.GI_9?Y>^>=W MFIL>7Y>XQS_N^O^9FO^X3W7B1=5U.35->U9Q:R27LA^T@C^LN<."I(X$
M.AQ7W^B^PKX M>13G7+F&+^K>X81H^F218.W7 MRPQ(7KU)=10CQZX8TO1M,N-M89&LIAG:6&5I580G7>1>XJ.3D53A M@30/#-
R9I.MYD(R(FEN9)$A:Z!%8D+GU^..J2WT&EW.NF6T=S?+&3##+&)L5 MV^ MVK&U;O%>Z7K^AS3WL82NJRM#-OB3^ROE1^?F^7(^E $MOX-
T>U22M.M^P);AK-IW:S^YXG83TW<[2NYIYQ5>Y4=UZZ2;S03 H=G<17 OH%99 MR^4(HYI#@9SVI^Z">XGLWM(DFN5C8Q1N^U72^)^G--
T^21ETVVDX M$&O&B4SO10O5^OR>X^HT F6.Y.X^ANZCU^6WN?^OY3/+ +N01K^6#%T3= MA6) YINE=910$S&I^<^VVK7UM>B-
M<+>V18A$
```

```

+UJ+VYKQ.R20L.M>I5UC)R<[-GG-7K3K738Y%MHRIEA:9XCTN33=7M$NKK20(E&)*M&#"A!&#"#
|BLT>|/#@|V$:-9VZOF97D#2N9&92"K&OG=D8&#GB@#$/V&YL_B_MAJ6G>2MG:2.1#_M:M.N+R;:=NSG?G|W/7K50!AW(IK6?4!%L;BU79%.L|D
+2"Q|>=K;#<-(DU+&8M@&#%C|)#_P_%C=M+I=A-J4.HRV5NH|C)%<#&-(BG|W4_-UJGH.AC2-|N:NYTVF;.UY0THF5W_MAP"=Q//7J>2>M;J
'GGC3K32?>#4M=->#Z7|/KL<4B6+F6#%JY;#K|D|C|M>#>."PM?QO/AlK7B!="#GNWLVTF%KX07$SSB"X$HC%>+&DGHQ|&=>=I_#J_B%IES
MJS<"(H|_YNHK$5XKJ;|VF;|5>#%V0<#%M?>#%Q5Z5T=MH.FVXNSY|F|>|01W#W+M_M"TF;|526">7D|=:.3ZF@#A|>T03K77/-
U9.TIDU#;|N#*6.X;#D.QS|Q/7|H3_MCK5K1-LQ|7?|F!&/FY-UKL;?|F;3RK"7%G-YULKWJMJ2Z1>J^W2_?|LIP#U|7KWR;|F#P?
HEM$;E|0VTRZ5$&_M5K7|5?2E8D;|L@|R<^|Y|Z-|>9>Z>X|E|2|>2|17N;6;.&|G|>U7M;@DM_B5#|3|M6Gv33|W0F|ELO|>AV65%#...@?
#5%|G|Z;X|<|=OJK7-G)=65400JS"PE.M"=X+8#|8G;U9^>#_IL-1M+0AN93>6T9C2>2YE+66|FEF_|ONSC_OG_H_MQ?>9V|O;--
EBB"/(9@<#<0"J_C1.VTU&-U$XL9-6T7|*L4BV4^VZTYA_MN+2<N|G(8'(|Y|VKKM$-Z7X=CGCTNW:".0R.AE=U4DDD*&)"C)|P.#FDN
M_#>FWMW%|1|MK1R_#9D.RXR5G;|!|QGZU3T.LGAO3|N;^|G>+7KJSM4|N>|BB9|1R.0R$M480|/10-+J
3P0!$6LKJT50>|>L"TXYY%581T0?>6Y+9YPIUK?X>>+&GL_MUM?L4ZHER;N-EO|>|2PK_P"NTA_Z7-75|X$|.QC4A'8O&N|HB*|7$J_MB50.40.
->YXXYSQQ0!+XM_YM5W7|P?#;03|VYH_M;SS2A>+>9.M.RH2?"AG"CKR.CH370ZEHO;|HOBJ32|H8|>66YM;M/+46T91AW1G8|0PR<<M
#9|Z-Z?-AT>+W/-IWF;4|F_|L|LTD<5B8Y)|"IMN3@&@&"SL)+SOCHEH4.HVFE1V+M>I-M*98%>3*>4&4XWO|?
R3GGK|U%$X6.0%#_LDNR2YC>4|HHR1JW7G;-V@^&8UU_VN.T-O%>HCPRA|KWNJ%>XV4YDV"5|1D<@_9MSG(K=7X;^%EMGMUTZ00F<7"
+|J4'-0%-NS%|W|OOGGY<9HJV?|>9|5_|EM_MZ.DJHNEB>^T.O%>9Y.BZ8H|6+L+&Q(D8GA%$X8|EVFM|R_Q.M!#*M)|$L+^_|"IC'1=L;|@=N*;-|
5XA-HVHP2)-2&2WEBG>&2-B_#(M01D=->#M4N+Z+X<+>|H6N9X&T_5MELL+Z%|E$HK<$H|<|<8Y25U-L"7?#0
MQ+TIK*6|E%|HUX|U^&M+EU6OU.2.X>|L4=O*UU*=BG&01NP;|O(C|!M;Z|U|-7*3?_M#;PI<+>1OIC"&|D$TT"W|Q%PP;
<#%;5.0|QD=>740QK%&L;9VJ+DD|24MT>+&6.D&U^&|AXHLZ^@UC3U;6V9+ELAO.PIOR|2&SC|DD|3TKO;022?%K5_M+62;Y$;NAPR-
%|H?";TK@>E?>EX<^|C|G|Y9>#&_T|XK.VD6WBE|ZV>+;|H8WMSG*QEBHYV>+>1@U;?#6F2VY-K(CG74)H?(>9_J49C|&*P.&D$X/-DMG
M|+|H|M|K|2C4-025;24E"3>R'Y3>+&F-YVP0036G|K7>+>|7B2Q%|XJM=1+>|MSITM;=>2$3"AB#>B_8'AF8MANN%&#TOX%&|0C|100%|
.CE|U(|>38#;MV<|M_M>YOGKS4MWX-T*^U9-4GLW-X(Q"V|J3R)YR#HL@#_2#_>S0|YKIADB^$PIEB_MN)XF_M>TC81RLH=6F;(8
X8<#K720Z3#K'Q|A;?>W%|J|D+T?L.MY|H|F|M_M_-D#CH#CVZ8Z?>GAY-JL+2SE6SL|A;|K=2CRY-G7=OK_(ANW%W'IX3-|7)W(S
M%#*=^>#)T|?>=S&".8Z;D+Z_*OFRMU_4G-&R6SCC(X);B^F^VEB2_NTF@|4_MK9J|=R^+|J*|23|<#
<#T%>#H.MX6TG610M+^&MY#=#VH*Q203Q3VYH5|0C<MIQT-15|(5|X9+&+821P&Z^>V?7=2HJRYR&_5AC|Y'/_@#EM0N92!WB_M_P
|_P|EM<21)X;|>1/|P_X61P'^AN+G0-0_M@M+U;#YE@=<G|C@1.LIAG_D5Y_9W0A.LZ9|DSZ1K*+;S11S&6UND_L9S_MJ|&<@-
R.YQ7H|_H|K|>G3Z?>1-9;SH8Y$W$;E/|Y%9Y1*Z2ZSB6.XE;|W-MJTDMU*SB(G)0.6W*#@9P>#<#2@#M6NPM?|*?
#5K6|S=A-W.MG:3%KARCP;_ML2FS.WVC"/7FF^&|QX<|0ZW1=Q<36NK|LU.24QM"1-4AA49W(O'G.P.T
M)|S=;|L.P9H.V.F61MY|1^F.LEF@|O|AY+*_*0=V3@&@9Z"JM0|_O|TNH|+-MISM?R&:>43*%PD$NJ|L(QC$*_*_*|);HO^Q81-|0%UO$4K|EAYD?
M|92#CZ$?2ED5BZ7=B#P|>:1<A?&#W40H|G"CIY+|B-6#K;EV(P|&D)^Z">_ME>B3>'M_GUZ+6Y(|3$41A247$@>H">2NT-MP<#M6;+X
|+36<|H|G_YB|MMNRK>X(H^Y|0K"34?&7C?P|=YMK.IVCP6UPS|+&^&3V%*|MJ#@<#_#A%W1UC2M-T*^7_HH_
<|XB50D|3YF0>>^UJZK?>BZ|HJVI_M6-F8KN;-8Y9#;|JN<#&D@MR?E|Y|Y-Y7|3?>O%YMH=(H|B=7N)|UD?J%_M&#H|0|YK&H>-
/55JD>M6VG.E|?3%K0#F6S.LNI7$-_M@_Q3X|32|+AHQX;|+&_VP%PKNN_P"&XM-MI.2SG%K;3K
M<0Q_90W|;L|U#HG@PSX=OS>Z7|@<@FRQ3;KNL9_M/78K$A^&|<6G9>SMX+&ANH(+M6Z?_YCER48;2N=BD<<=<Z|6|&#%|F%G-
.W=K)|HDG>9Y|/O.$82;MP*K_M|@<^<M1#P%$<MU(+&+&VXMKAA=2@R|H;CYCNR6PQ;8|D$|F@&A38_AO_MJ<_J"7E^>UN|!=O^>B>V+|%
<9P.1P0_1U|U>?>7|SX1F<|E.D2W@_L&K|U_M=)|6EIEY%<Z|B3V#8H|0O|VB|;7;&#X|K2V5K|1=5#R2|@>?S<#<#>.*M63PQ|ZG?Z@.9WN-
0C$5WYDSNDJ_|2A)7_|OCN;_3M$G37=(URS|JTC|MI8V22&W#LM^&7*2SG+#!;=@DC.3BCX|V4WPOUUY$#-
%&D/H0|@|0@8D+GVQ6EK6B6'B3)_|YK27_61+&8-9S@_M|2_1|4_PS21VL@E@?|3Q8W"(D#;P<#C_MK4">."M
C.I&R_#J<8B0"EQ(E4+MP2|L|ZG)SG(H_XV|Y$SX6_P#7_IW-M#3M7|T$5S_T;R|XW&4|ZQ9|VB2V6F6.P7|@TMU>S07QVY/_;Z04X7|A
C|PW;Z5YB6>K"XMHVY5VVD|064<_*P.06?SSVX_MH+PCH>GZ+H+&#EG2Y50T-VFE>5;5DG&G|G|XU8LHL+&198UGDF6(P|+|
M<22NB|&55F)(S@9QR<#|04>7.5%<=<X&U|Q3%2;C<#H_|^|>#;Z|0S*_MRDX;&-V3S|Q|'96&F6.46B^<M/U.XR;0@QB7>-2+IN7?
G|9@06|'(Y|5N;5X_M;TKL*XLK*W86URS/+&+|JL6SNX&K|KG2=>#%IR%+2NX_MC|ZA_Q(7|MB@#C_#U|?^&#&A|>8-1|MRJ%QG|W|T"W|N
MY3R|P|S;LMC_QG_#&#>|>|>|PT"/0Q:3#38|?2#|7-A7W;LYWY+|SC/7F_M@#*TUH?%?B7Q9;ZBSM_9|<K;Q|0J8$0;S<P>+&9BWS=<#
*Q4GE|Y9H*_M_Q_P;L#M;|&Z>#ZNFJ56;_5C$R3R|GGG|BR_|L|H-7M%T33_*VEO_M;IRU"/>966N|J3NPNXV-9<@>DG@G|'6@#K-
008=>FVZ0|@D06L+S2_M$#G;H|Z"N2N0%<K=HL/B"ZL+632+FRCGC5)"LL4TA41Q-G(8$N|N&_BL_M|4_#(TCP;XTM|B_@08|L|N"R6W")9-
Y3CY
```

MNSNY...G"/2NAHH...&DL;1R(KHP\$LK#((/4\$5F6^AO2=...VMLRBRWR(\$>9 MW2#(P?+5B0G^R@<<=<M6VI6EY>WEL\$+)+9LJSA3G8S#
(4^<^115N@#M/M#FEV.L7.K6)JWUR.Y3<2-Y@ P-P+8.TXXJ5/K&C?K^F2=J=L+BTDP*ED
M+>00000000.AH10I:C0>=<=MM2BU&YD2IB@<S)@+B3(CZL;LBS5I>=>O-M5F#>?7R?37L9&LKB?H+I+J4IF=VX-USSHFNBHH
R) #.EW-PIQ)%<> M=) "L\$CI=RIJ9\$7%;#<#.3U5U:2VT*6@M8T\$4"YX:1%FU<8 7&.8'3'2I.*M *6E.39:+8K96\$;Q6ZDLJ^\$X).3@L2>O-8.J>#
f6WTI7.G0K-/I8U&W^..S-M<2^..Q4@:P6(I&LQI)*ZNB@#RIH_15N9H#>=>2V/W414.:VU@ND>/HJ^V M_P^C^>I=HWA_3=)OKRIH9(HB;:=
<.9Y1Q04AF(SVSZ<5TF4^87\$<C_NXW8-I)M(P.#R..I_P^\$<^..Q9-&
DYTZ27\$MSQOQ3K=3P%8<I<1R.@ZIHJZ^@#GM9J^&C \$\$\$\$UK/NF)=3VJH(FFE<.%I^P M8%AUZD13ZU;D;Z/?>?>FVS:5;QC^J7+^168D6
M135NB@#^3P?H<=H-HMK+Y&L SWB&YE(F9N&+?U(X/H.*C/P/X<=>ZM+EI^# M36D(MXF:0_N@&#HB:/_9\$7V&.;SXXP[OOG.Y
M75NA 0BKFE^<?T6JGO-/L\$@N:A5664.S.X48& ME:.\$%&#H@/WPIJ929=(TN^V\$PVR^&W^N^I^G(YV@9Z&I=8^)>&=>O(+S4M(AGN(\$ M)
(&9M^1M13M(W#V.17144 9-SX:TFZ0=(O)+4B:3AMM^*Z^#8P0HJ0QQTZ< M=*28Z1NG:J>:E.P.EW>D&YD.SMYA
P.@DC@<#C@<5F:AKFIW6LZHHV@L?; MM/M8KAFO^8I(TA;^H7A#1W/WAQ70VKS:PMXHTM 10:=9VUJ=7L-NB7-
WL^4#F38.+GZ#BL>|I^<^| 71K5SHTSFH9I:7+ .1T M+^*#M8|.#I#TKHJ^ R/P-IL6NR:VD.@U&2(RWT^0IDF\$5W;<#L<5GWG@+PM-MJ&N?
VS=+;RWY(+2<^Y0LH.UN@Z@UIAM6_MJ8H/A L?I-D:N;S_/W=?= MV;?QS6A0!BZGX2T+6-4BU^*TY)+V)+\$P=D+)=;107V;
(J.+P7X=@TZST^M/2XEM+Z6(C#-A)E)(?K5MIK7EEFYND:N.M4:=5+9YW8^C^#55E: SXHJWE MRHIG-R:10T^Z E03CZM4
9<7A_3XKV^QEE^\$@J2-f\$9 MP2.XIUEGX=>\$S%/_%8T8CFE\$Q42N C|MV4&YX.0|<9KJ^*,>W+Z1.WUU> MVJO+<7<Q3.EQ<RJ^*.;L#
X&.8f552P-I.X;DT2#1WTQ6L>3S((S+I)F%NN M4:=N7I^*Z^B@#^&ZL;2:CHZO_21B^Y=)7#2^C|<I.HY.^-ETZL7MV:~R+G.S|YN-
N?^Y.N..3TXZ4DOAO2 M^# /8.IDLVF>6(Q;S.S@.%)&.#/&.*U:IVVJ6=WJ%Y8VRR3V>SSPI-MSL+D ^<^IG^N^
_W3?GA12.^<^L15+N+^R4F>1^Y^9SC+&D 4H=JH:WX M=TKOQ#1JEIYXMY/A82-&T.IJRD\$?G6HJ0ISDG@/PO(EI&=*14O@HN4CD=-M%D"@
@.IV&?7 SFKC^&=)EO=/O9O)FN=/4K:R.A6..S.D&C^*I.WG"7(V@#IMQGWH R+GX>>+N.;EGT;)C>OYEP@D<(
Mf9SNVIMH;CD@9/I-Z2&S.WA2&) D-^JCHJ3Z^*F^L-Z5J6K6NJ74\$CWMH MGI^+B13%D8;..P R.#ZIZDUSP_17B33C8:Q8Q7=L6#;R-
K#N^*.\$W^K2HH M_Y_ (OCPX_.AC35732XD>197F."""Q#98|3Tf5J;PSI-QJ4HS64DM-MU!\$88Y^N)@PAZJ06P0>^#=-N(=,AFL-
Z:7D6>Z9R8@1@K6=DK@>3D8&.5LG MUMJ^EW6FWB;LZB;&5256&#^<I KBG75=*7P^+L.W2/5-3AM)(Y2QDA20\$1 MN-
Y%>P)OSC)ZBX.XMW-L(S;E!(2%)!1T^O./0I^* ^&?6-\$MM^*1VHN-MS8NIAN%#PYINB7%UJ&C:5\$NH7^+&O#E5; PI;P M/<@%CU?TC58-
8L1BD4E610<\$?ZHP:O4 97AW1(I TA+>9/M-E9WFN)B;69V+.^V23QV&I2R>=,DULZRT.OI:1A-OYZW\$@C(I-T-@#/M/3KSUK4HH Y_A^/#-
8DNC?87.G2R>I;N.F7:S9W/S>O/UYYZ9D;Z/I MJKJTMIOO!6(OO3M^*Y;8#D|N:FP>1NS@UKT4 %^C M+;RC^TO^S/
\$J7HQCQY93CCMQTK:HH Y^ MXJ\$>^K3J^OFH^=H+I QZ\$1^CQ^N&W 8&C.XX?7-).Z1H3W+Z98QVS7 M+YBF?E&AGV%;E%
&7J7AS2=7U"ROK^S6:YLBWD2;V7;NOD\$ @.#@<^J. M3PMHLMU:~OX^)!S6Q10 4444 %%%% 1110 444 M4 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 4444 %%%% 1110 M 4444 <^35N(1^T+EPDGB&U5BC%6P0_0CD^W^=S5+4DL-9M1;..C|<I M^XD4-U10T92.58>HYH
L10VD @;6?3;^*K+L;2^Y;R-W1V9(9PX595)P MO7>?783VKH!T6SFU700\$>GZS8QPO&T:I8VI3I90I:C&IY.#W;O);CCDUG-X+I
^Iz:JG116TN900T:AX4 M^?Z88H-OOBLN-P4\$R1NU^S\$5..AWZ=*PI:TH^#-IM;77A:*59;W3+Z6IM1 M(TBRM\$@:*1@2?F+L%SW\$|I
(U^3++5f&2RU^UBN;3&Z:1<@X.O?J#R#VIEC MI-EIS;IM\$WF;H1H9)&D(E%I.MXO M^MGGDD1)\$=NK EF:4|
<#T#0)1\$>6L/B=XR@FBB@)0)964COLHV-D2|B1T/N;Z: MV;L:3^Z:Y^1XE.ZOAFM2F+U=8f5;D|@9Y.%YX:T:4-6AU6fTz^..A3RTF M8<|O-/(SG%
(DNCP)>=>^M@9)29-2^V25E7\$Q(R#f|!#GK5W4KB3P2) M1XJ!5&YV;M^*.*+)\$+2IEDD4=CCXQJM>AO^?3D-D-0900Z7%0%92>+>f(H
M(W_OC!^!^A@N)1^M^*CU&10Q: W-ZGEW+NI-YRXP%8\$X!)&..U_#ZQIFC M6GC+X77>EQ0*LMQ.%FC;R&W8AFA9YSN.3R76N@^>)G-
_3/Q%_UXR?RJQ> M-O^MBI^Y^AVBM;R>.%E2YQO).J.P@SQ6f=6MO?6DMK=P1SVIRE)(f%#*ZG MJ^#U%_FU_XWY46%A^H? MB#6? QME-
HJBIJGV9D.<3H3V^8.WT+7>6:@Z=I>U.VQ)(&8X(C)*6GEI
M=<4LM7@<#C@<E41#T?>MWPUP3Q^IUK87D4;006\$WfI59@68MC^+G;:UY P-M#8N.;UDTN2S>YA:UHIY+('FW'3;TOI5XY:VELGP%I;*&
(GGNI(RO\$ K.?M-M+21SGWKVVN=3P)X9CL?L4>DQ);83B)&90^!R#P>O)(L.G&T <=JXCD(5R#G+8..IZLZ%HJKJ\$AGQ^9Z|8P|/+26EL5
MDO-P.^9C(=YSDG(R#D)0)VENT=%SIBH=XOL;G4M>SLINWMIH2:(QB MY;4Q5PWE;R5<J0.OH^<U-|6?P5X|LY=%?1=4M;2W-K#*#
3L8OR1^M8&0VTF;R:1G>I:AIMGJML+>@6;C.L4D4DC%#<@I=P>;IR^&=(N+^YI9I0RP M71N)H^f-
CH8G23VD9D.Z^W;P\$;XPI|R|@<=JWQ%GA) MKO5M.SX6MJUM&@BA^U^7^Y8G@&1NM/L0#WQ5^T6R#0^IL+PWKF1F.WE
M^6RLY).2.GD|UST:Q10^!M5TX;8fO655;Z=@;RICD60L92H P>/EY AS@C%> MGOXE1>='AUN;68H/A749D^23@AV@B2<7^'(5R%
<9P0#T)XZ>U^Z/X>L=0<^>)XIH M.-U^VN+//^1@GU-4O#=-BGBCPGVBW%G=M|f6 MYEEN.N^U(N? M.S|13N9.0Q-NW|&W
Z5398Z#INFW|U?6EN8f(I)QYCDRD<MDX) X^H^I M1>?#&O-KD6BVB:DS\$S^Y^W^JV.@;WQF@#C>@.C.G>:JF^G0ZKHL^HQS#4
Mf9AHJIE=5^#RT89A:(YK)B1J5 H.PIU^TQ66fBA&U^IBE@&8>X4 ML2PK5_X1K2&E.L;1=4&ZAX;C2^ZU".fFI CI=6SQISEI?2
P%W;CD@Y/>N66QU^IDM6>5CY+I;HRLO/#9QSUXQTKU33_1I6EM&UG:~ M/R5^P@NS^%3U\$8)
(0^CA<#BJZ>\$M^C^M.ZY6R(AU|BUVGG28G)X;YN21P?7O M0I:T^=Y_#>F7\$IED+2)W<I22@)>4L8(f.I);SI@=77B^*OJ-PP-Y=D)(X M;.>0!A^-.
DX^Y QBO8+*R#M^T^RBLF5^D\$A(T+^W)MJCH 22<^L^/AJX32)HET. MU\$;3?>.<X.05Y49f# JF_.030=U3Q)18;Z%IX8O<.-Y&^JOMMVX#/?
MRY^YH855:6WD^PH>.^?>U2Z-.03W61N;.>W^9.^K^*0I/0@<M^BQ>#&E MOI(KQ00^<NF69QYH P?FI#>@<XZ5E6F:E8FAV;~K-K%X?
F@>:Y>Y.ZV M;."J1G>G(HIZI%W"W&MQ1H&U)Q^*L@7!;\$ +|X^@-S_ 'C6%#); M:W12M^<f5SVQCC)SVD;)%&L<:A44!54# M
^L&K5O^VAZ|>V|UJ>FP7%Q;@B.5@9P|ZKD=1^B@#RO1+LV^@ PHZDC2KS MQ-O;W3%B0T2FR;48<C.%S3XP>IK^(!^X=N;R2BTB7|VD)9Q M^C^!
8YQOQU05V17A30<^GTN+2.5^XTC MV1HR0!7EDD:21@<+L2O R#.#.IDT <@;X% _\$-O>;ESY05I89!NO M2D3#I-P2YV98@I^!"">
#7.7^0I) B^C&fJYV7PA4@#RB&B;Z=1C^K7fE> M#f#>AZE-J.F.;6MW+G+&F^f|PT52QEVY2?Q8OR.X|QV|URTVCY2?K MQ91Z.YE-
HL;^_5N;D MZW|0+K0M1ET_8=+@EM+>_MC.LNXOYK(-ZC=G;YP.HSVYN0f(601R^9D;?N=SG/&U=UJO@SPIKEK;VJ;5#>QVHQ_92Q9;Z!
MEL>V.FE|Z+;.#?8(HF^V-8V9%@QW4^0?>@#S:~TVRL13XJZ|1;1KH M8
MQ7\$%LIE(f&MG8LH/0Y4^CN^I&!)6UK>\$!\$%K!\$%CVD3L(D^AF+&D4GUJ5 M;#>D)>7HWC#3:@GEW;f-YZXQA@3@<@ D^T^J;2-
&T0;L^2f5+V4Y^D M|IYV| 4>>Y\$&C.K=KJEC|fB3.G^N6f| 766NLBf8|T8= M6R*9;V@;MXIM+W4K^UOK34H_~DMR^FSC0_NGC?
SIL&T.@8SNSG)KOOX:T M@7#S?8QF2;f1(GF-Y;RYSO9;f2V<\$&CC QT%5|2V)>&M7U>/5=0T6TN+Y.8F M=3CIN^IL>^~.272+34_~BHMK?
NUH|J;BDEWLRfWGS;F3;..\$fZ>E+M83;H7=^X|SSCUYZU5@WPI=(N^*38VL;B7SI(6=B#)G;fD;GG(YH-V88 MK>#8(fCBO;51%51Z
^f7AJ|MX=L)>@S-X:450Z\$8RW+JG=QS.C#;AHJX MPQXCDGUKY^VMH;VCMK>8X8E^HBf16;.>9fJMDQ;Y^1@S>?Y2LWE^3.=
MXCSL^9YRIG-&H^<^019=^XGELLPSZ;78KY-1N6^N2?H^LS9KFJ>(9;4-M(%)MDFMYQ-O>Y9 M1E^MOFUOFSGJH SR-Z@#SO2;2fX|>+
fB2fTM8EMK.SF\$@A7.1Q^68<<C M)-8-JD=M+X|U&P01QWE^56fB8&fO(GC=BTQ4<f|W;D\$8KTV^PYI-OJEQJ
M4=f1>7^SRF5R90!@f3A@fZfZ50A|>%>+>."/041Q\$<%(0VN.XOD#D_M+TY/%
\$&FF>=>#UY76fL|VYfYJ3^f1U2J2>Q\$W2.YC1@FYH^99HMP>#&X^4Y=A<=>^#5WKR:W<+;2: MDA!\$DR2.A(Z\$CC!
(SP^L7/A02;RZN+B>TW27.^<8D<+.'4^#C Q@<B@# ME;V|U7A+ SM;W7AE91EB.AR9QV..=*XB32f5?@Q/K(5_f2LM3D:UN3(Q>M_:=ORH
<\$Y|>|>Q X>TMf7.JYV87-DE#SUE=6\$?P8/SS@=>M52A#/# M_P#8fZ1_9P_LZ23\$MO^?8S9SDC/KS|>:=LRTT^XN:9T:0K?
Z7COX=TR34K247 M@<=KRW3RXIC(61>X^W=>W|>|0+X0T)/O-/6Q_T2|>*=T&fFLDM9=CEMHKZ;T4Tf;7>H+!0N.YP^f.IKK^!^D-V^
Mf5VFC53^P71A3M(\$.&0R2<+GCDX|QVJ340WA 6+MM-U3XJUM;2f0L M9C^fY=P^XIAZ5fZHGf5C%96%M%6L(VQO1+M51f^
^T6^U15^)&5IKU MND|U|E=K;0Q2C_46YC|1DH6.YMPYSCT^N;f5O/#VEWfZ;R>U^VEH^*>6-VC:1/fCE2-R^OR^>>+&I M(OFLC/9^?L.#A^9!
1P^@4@_XXR.U_#f#3+;PIH^Y&E0.(+>O(B9R_J0.D MDJ37FWANQC1^\$f5!0^7K^YOK;.>YNX;4BZf|SPR^fT2&)QMQ@C;@8P^f;MK|A|&^&?<
7FUR^f;~29BYG^ICU8#H&fJ9H XG6+^fTS7?B=?<6W|f5f M;^5(CE^8?0<A6E16C6<fJH7B73=9L4C;B+8VQC-^&7fDfC;B^"V2.@&D
MIZf|WT#3+74fO4H;:=W@ N)M^fQIT@<@<@<@<@<G;JFC^~#>@7fMH6C6fEM=2Y#21H@<fJ^=L^4>X0BTG0.XTCQf|
WKPZO|>>=4VMK%HP.TWO-?>S^U^YM+UO+L3OE;=fEW\$#..!@&#\$(SUKKM8T M^<f1^?A5f^A2VCU^fIK;f|@MOL2.\$f1@f|
<94CANO.UUUH.EZ?HfTWLXUTX MJ4^S.ETVGJN&SQf=2QfT3=-P:6W92L2E(S2NYC3^ZA8DJO X&fP2@#QVYf
M;S_X5CXOU3\$OVf3M6O&LIS.Q^W*3#4>#Q@GJ>~NW001^f7NZ^>271KDL MNXX)1XXZ^#K70#P=H^Z7#S7V2>22-W.3R?7
STfPOAO2EU M^WU\$6SFMH^BF.9RR)=Y;fZ=Z.^%|f|BKP9fFOZC>#K-C@>?>74;fU M6G60@PL<f|f""=P0f78^XUDf;~NS|NGSN^&
f((C8@>Xf8_?AN^7VUV/1 MK1=39MYN.G.INV.FfWQFM2_L+4f&6RO(S);S^4DCW%0ZGJ#@C@<^E^E4NBV M<(^&U^f)8KN|NWN+A)f#RQ-
\$E^<=<X&G.%6%G>&fXDP6@N+C3)Mf;T ME7fS<~L^AFCfX#_00XUWC>%>#&PB;S)CTX@V;^>^X(Z%?FXP.f|<=<67
MPHf<^H336^2OJ>?>fFV83^&8\$X.WfVQO!ONF6C=|>4-M4M+3XKG1)O M-MK9f|fMKH%0@;~)Y YX4-8Q
ZX>D;fO+HfDP;0f1>=>C6W@KPW9R6D MEOL\$#M 7f2GfHX+PW4AEG@fUfLCGDE MAGG)Y/K@924_5f1\$MM:0M(E>(%4+#+9P-L?<
ZF74L.<=MBAF7.?<(%;WA/3)M8TO4;HLVfHLMYS(YD5>?DY3GOGfJHK>CVNOZ=->7>MfO)N\$VEE.&0@Y5Af@<@<@<XH Y;XfOK^"8^A)/\$-
fK^*M@<K)T^Y^U0^>)H MLAKXf3V&BK)#f5WfHfNKfUWEHXYA^*5P^3@L-UVGTJ9^*36=*CLfPLX9Y^M75Mz
NO25^fO f;f1DCBV8;^3fO6L;7?@<L7D>4C@<G8DG fG;fTf^* M6f&GCQWfIGfH M^GfIGY0^9Y+4.O0VYK+&M3M?^2)GM=+43f>D&WM^8N
MOZ+D f;f4<fJfZK0f1(72+28.RR75U.f5S=2@8#RL><<P^CV45>^>^M^U^ M5Xf5O.;@FOD01B5QU4^fL^D9fQ0fYA9f2VSHOPL-f
f(fP7BF;S6f=|_M;=>X&^>O06O!HDf&MfX.+6=E;=|_9UGJ+7>-BYD9.R#D^f)Y.%&8= MA^X(f.6L=G^Z8D2V3f2W\$^N;f|
<=<=<GWEUPEH;R3K6FEVfXf|_M=M^<^?Vf&#<^CVZ4^f)6f|TKPW;=>VKfJOV8Q^fK<@<@>?>Y^<
M>#POKfMZYDODM^M7;f;YR^ARfR6QG@D@9(P30f|>)>2L M^A7QW9>(H=6L4MfL O(fW/X#?&0.Y<^R>P_HK+|+6S65S<^MfLXf^*M M-M-
f^A-R^97>..?O19^GfH^f*^?3+>f6WM6M8C^NCPQE>\$9#E2/0@BfL5M MJO MWDHf|KR?QfVS=^N^3/_C BYK;7PKXfUG3/f;HH74KEAYf
MW f747@3PQ=37fL^BVSO^MRU=1MK;fZ;Mf1^9%#D;B f69+6-N3;9B8U/FE=N C|V.V>N^R+P3X9U364U>fT6 MSGOTf1.Zf6.D^Y
M^<V3K&U<1VT^DfN|fWZY/L65ZN\$^>fSMX3>?WAD)06L9;B_>^>5Yf M^X H8_2OCf1+SO9UMA8Q;fF^fH^<+2%>2<8^4f|WKf2RA=Q8f|
<9R3Q7G MDVCZ9JGQ?N;2fM(BS7Pf|f RYB^<^0>A f9ZSA>&Y+27P63fTB<2W_|M.UY^9VSfRf89%Q>7fDfY5%P0.Y^@<
>fZKK%CHND7&f7fPD5Hf&7>0D8QZ# MU)Z=S5U6#^*AKPW5HHO^>=>fJf;f;f;ZB6@6)1Q;5B+;2=O)0f2^6O M;

LWM:U6&UABA^12A5&>>@H P-9IG(GAKQJ&BRVJGHJHRKY)+1F1(QC-M5X(SU-ZV/I6UI%XUHF%C6VIG96_@WXL-:6I4
MFJW>H1(4158H)G0F1I=15;72F1+>3<^<@JPY+=W0.*XG1.^9#E:EMKMUR89 P#T MOQB@#U(NH<(6&XC(&>33J)=TJWM?
%A6UEU+7+2PU2U0I9+N80 7EPDQ(QP-M2(&T1QC:Q7JBNIO)#P-K%YIP9KV&REDAP.G>S)IQZ^U+P-P4L5-L.HSR*MR)M>MYI-
7LI.GBDOM-A5Y0WS(C,&(4X.WB)I>S)T:7573/L MO*GB P19<>=5\$B.>K;LL6SW&>U7)JLK&+QY0G6VMTD1+7RV\$:@J6MB6QZ9YMSZT
=9X/UE;7-^DZK=B)+FMEF=(P0H)ZXI)^VBZJRJS %N@JZU(XMI^F65 MEX%&-&KP0*NHOJ-C^UUDF3JWRWKNZJ2-03YK2@&M?%# B13-
5U.RM;V4)8 MVA^&X@A7E21N7&T \$%#&L,ZKJY@,^FEKRRXJ,Z5KGQ^L;40U^M;7A:1=75%>-MN5V5YXV>PJ/O-HX3UW6=-VC9KB6;VZ8-
UDFBYD>C.RAGU^F.T@Y&12^%#BZJE CNPN/M&CDU(P1P^4J- GW M^,CN>,-1.X8SD8^M1(4@76O:/L;N(1^>HVD;2^%IAEE9HAMD
^CN.MWS*Q.URGO75>0#<BOP1PZ3B&26(FIV^KE^1AZ7^ZV44^Z(4M=6=88-M;SY4H^M\$=K#V8I,&MCO=86Z^\$-U)K2.*IO-L;HR\$^L-
R;XJHPFU3^*J? M7;1/B^0%K^?VYL9-+>15@K>8^614P3G&3VH1^PZY%K7HJ);K8;K8IY^D M^R(%P3DGDY-9I+R6RR-P^O?F^IOT?#KKXL^J&-
LJDH1HF52O;H32.ZMKC=^#TIG/BKHEK?6_FP76EW;SOIB(8I-X)OJXS^+RUK6?M#0/AF^NK&U-
IY=O.0W4^F216@A0(T3.XQ@IFSR02^3TH1+5=OK#QXS>T=M MS9.DERTA*GS%,21A@YQ@IAV15T>Y3T8<>I>=SQ^QE1.81>O?JEF1(+J0?>-
M1#&Y1?>D0Q%*+>03H%F^CJUH1^M.R.BDWKOV;ANQG>>52N(CINAS1Z7;(K6JNPMH\$7^Y^G:H^UQ7E5TL=U1\$;M#O+88_X2&
(0W^7J^H1951U)ZMN)92IXZ^H1A9U7Y@,)#R>@IU>+1+MIFK?%C7H-2L8KB)1+M9)O.M&7+2 DKT)XX/M6M^*9))AKI(DD9S^YT2ES
MDI4F=5&8-9#*O.B*VTNH<S^S1I=PPY^O7EWWB;W2+S5M7OJ/MM.T&+1 M26>XBP+53F38O&O-2V1#&S;CUHU80V76@#T5)=#;
&SP2*W81{MZXK115:7L.G>%;3M M^N)7MAA);4LHFLR1#^K&..C&U1G@#IF@#U(K\$@\$S\$C@X2AF5%+P51U).M
*X+21.LI&^=W;;QVMO<=S^D140VK)ORN^CNV.1.U&6GWNH/IGFSV M37MM^IPEA?#.-VH7:P/H1N!P<M0!M.HVIF+W.DO9! M\$?
GFZW?2)S1W- M^XZ9XJISF.S1O-C-8WG&S2S1H+7/9^K.F#^WF.X+JC#@K MW&.*Z6^VA^+5X+1@&I6DNE1+^#KA.)9PRE2?<
E.G&Z^R1B@#NR0.1J^M^ FGZEM. CUNS2XEBG7F@#YV<K.P5@2O4 1^1(A8J M^7V<H.SR^1^TC2M)O-2V1#&S;CUHU80V76@#T5)=#;
MM^USP1JEC.ZA;7%Q(=,U^SXDD>2-SMG4C)+*6.X\$@D T>I4UG1.F5+^A4JZ#-IO MRHG)/M#T.(6KV&H0W+V^9%>15..YQCYAVKAO(55#(\$3:
<M#ZGJH136D73=4\$ 9GU^Q\$S>7YF?>.<H Z^SDN^M^EO\$2&1AN.8.2+^H3 MW(6I4.I7=O.V#7E1\$MR(AYCO+JZ1
.0AZ.NXSP>G&XW&3 5O<^J^6KYXQRV^XL^M6JX^T121^M^VTJ=GB>Z>2^&C@=P^ M40#A1^%M1;L1Z^-O.Q?>
4K^WOK.59:XC66^1>C1D&L^OM^P^KOJ3XFTN^%L M6L6ERVZPO^PDCW_#9)YY XQ6=1)3 P@%NASY^75REN3WC\$S1PZBL8Z)H MNL^+?<
B0FI6D=TB+^E\$E&Y5V4?>T#^L>H14>GLRHI9B^4=23BC<9R.>N: M1T76)+D>1.#5:VVCMI00B1+WT7FQS7^*#18#<
<\$S@G^>YTWB#P-9.X8L1M^WU(WD.^1)H8H8AL6TR12T4>^=JG.O;9H1=,B1^Y=0HZG/ KG/&NWWA0: M1-
9+;NEWJ=M9R^>DV2.)7!^,IGIN:1S5^7=\$M=),V&EV^J>6Y156A9Q^NUM=BDQ1X.5 M49R^#D9H 1:~H0<.#@X.#T+^N7&)M M?<
\$AR^TBH1ES&RJS#^EOCY7N#&@UY6=2D0^&MT^Q6=1B2J1)MY&JKY7S9>3*B 1B@R>VY<=Z^12R@SE@.O/2JU^UV^EW#;.M6UN:PQ-
JG.^3%OQ^N1;SC/7%<JBZ9-;1/-%IS7-56Y@&4K%\$S:1# M1_6A-T8E1R2=A?^S<1BZ/17BFUUFQFR)NK.O_9=/@6 M.^XC^D81CG:P
WOC04 B1L:7?#66GRQO>7D1Q+>6.KN%MY-D9W+D^4^H M.SNOJ^6IUV:IPVXS6/&^RDB:AE>HSTKPS48D/PQ>0.T+K.Z^1 (1M2/+
MP9V#)VC+^QGN:4^1M.TSXLZ39VD44>H:7=K+>C/VG.T>#)G1Y)R>+10 MMRXSD8^M+7E^>Z9%1>IZC^))&LCZ8^MS;VC&
(H4XON^C1G1^&+>2O-JUOP1VOY9V-0QOLMP! M+J1C-E<^1^W1K1^ZA1R17G DBUYKGUGHB;K1^S2X1;S^NH 1S1XW2QF\$SD
MGJW.#DYY/O5&TM17QA8^1(25=7L1&_M=3G\$TCP@7J\$D)B9)^XVJ\$^X(&OJ M: 1U77)8?&GZ19M%1=WD\$T_G2H76-8JH^Z^,DEQWZ U?<
TB34O1-MUOUO1F MP1<^6M)C1;1^NIGD8.V;XN.P1.L9 BQX=1^L^V@G:72:AY^E@4&5@8L.P(Z-
MRK%LK>T8Z;XAMJ5UBRL=1MJ2G^T2^1^3VH+J1RP^XSDGB0-
AHFF;K16KB^>MT00/#T\$LB3+1LK>E9WANPO+ P1HUM875J;FPU2Z^S6>H9:ZCC>51\$W7Y5.0><%0<<<<^
MK6Y2I8;.#OFA65E#^P^GD\$^BO^FU^VACTFUDL8M M^UR>WU2WN5\$MO%<>3N1 M>^H^2K#H<H^VY_1.5CX@L1^#O%;0RZC+;RBW6
+^PRIOA=@81E<=,1Y/ MK0?Q^KHXRC^PJ09^MMTCRIS^R\$7JQH1D>^P^1KF?1=QMU M16K&1T^2=8BC@>Y6U<^
^W1>=>E3@92PP(CSP>JVN65C)8^#TD1M.L6TJ1 M9FDC4Y^F1/>=>O2@#O^ZA181CT1)IU>76%O>(< WBB1U\$75H+N1\$EPW-M\$MH1)BV-
U4^H0C^OZFNVI)SWNH^1IGU=,WDIE&UP^7YBHS> <>1=>XC M17?9?FMZUH4MM<2;04F4%HV9^,A1&
<\$XZ10:Z6TG1^UA=BOF&KL1VR^1 M=CM+^*X0>.WAMX(YA>:G&2B_1%Q^123X%AGOK:IC MNI-3ON (59=^FEL@>G10/Z1O?7
LW#<C.W1^=7CWAVUM^OA&S&1UNULM5 MM:L7R.6X%W#^1^1#80Q71B1CS8P5;RP.1C^\$=AVJK^X1^2V^6+Z+^1
M+YR11/E1^1#T)SSCK6TMQ T^GK^&8<91P-N/72E\$T32)4+H 74_KGQ^M;@#3PKH\$;WJH1D1W7B8N0L^D0^*2;
^M5_31/L1^L8K^PMH1>VB&\$BC M7 %&=%86 M(C3X2+^ (1.Y 7N M&1^KCK01E2^\$O#T^N+K4NC63ZDI#^Y(WY^0Y11Z1:V:C>XACE2)YHUD?<
1B MP1;Z#O1)/#%GS)43.NX1F P/7Z4 4:3PH1A)K6PA4969T^CY49L1BJ1)R M&=\$NM3EU^*3+>1V6+RGG^_R8QC/TX^G^2M#131^Z?<
1.O21P1D M^?Z>M+>0VX4S31OACM1=;GTYH RCX3T\$V%M8G21P1R>91#>1(G1.H1\$>
M170P^>AW5=2AU& T.RN.R6:6^W3/7^O6PTB15# JECA03C/>P1AJ M^NZ1&B7&KW=W\$ME A=10P(C.PI23P1ZT^*^AZ8^L+J16<9U14V+<
<1POJW/MH1=^XAAAN+KPYJ5M:P-//211H&5 MXA29(7FC65_NH6 90H.1^<#/#-O1^AW1TN=-6#4:UCB?+!PL@0^D)@D#< M<1C1.;M2^?<
#S1E1)+H=BJWQSSU\$A:21#<B.1^51@H17=1TJHFCI90?Z1HFCV.WB*2^M1DWR>C P\$^V^Z 5DZYXRD&A:1^A36TEM?E:6S^>A8F^20+E<^<
IQSR#UK ML4ECE9Q^(CE#M8P^T^A1^,W0K61BM1+K5\$&34;M0:DI)21^J@)Y:1SW M)X\$K6K4:7\$DKO)&^TB??<
161^4=JHZWK=AX>T14=1G6&^=61+>BCU)1M% \$K:78/3V+6D)M+>N98=>VN71+Y^2))>M1/M.UJ&^4K^ZBC8J2#(M
M#H<>HJRIU;OP>>12Q?1^X^_G3S)&%5BZ@>0%)/4GIB@>=1TLZJFJ&SC-M^D?E+<1.)=SZ>U.TW1=-T?<
S1LXL1SW.DOE1;W/5CZD^O6K;W\$+^*K+&O MX)4AAR1UQ31=VQB2471C<14?>20^0015GT/3+G58=4FLXW0X1MBN#G>@1 M
>P1N15M)1^1=O6:05=^LKRXA&SDFB#%#KCW^L>*U9IX;<918XPQV@NP& M3Z^M.M9NB0Z1>7 MS7WB^U1;9119ZX&UO^LZP-)&)6&5C+^<
<1^L/7 M2\$?Z6KZ^%+>^<8H Z^LV+PH\$%YU1%80I M^TOG^+YGL.TW16.^11Z1J^AHTL B.ZL1#S7.&4C.O1R1P.HQYUQ
M#JWC&5K^PMJ6C20/9.O1-O.2^6.EQ^1V00WRG^1^#UH Z:1#1ZC1^V+> MW^1)9U)1#NOH3G1^*1.TFPT6T%HMK^VX)(BB&1)P.U6#*)HI?<
LTL32+E M0<1@K>AQ ^J>E37<^AVNM75D1VFPZ1^DK^6SVW=J^&X\$0>L01^*D_A^PHYHOT/OURQA^20IM-MM-D1JU-C:D-
#A.)&1T1(4>91Z;X3U^M/OX6T^6(U^&XB1DC^+0.<OX.^*U6N(5F6%I8Q^PRJ^AN1A013701.75E MU46:2^UC1H71R7V^<G7%OI
(T^5^>DO:5)1(3^YX^G@E2.5^N1.M2311 M2ZR5^4^M1S<#P139+^F1)HJUDFCOR1^F W^V1.ZX1.)=6<5G/AMO;PR M^:D+>P.YW^19YR>>37^>
(1^5Q2^>R1O_1.EZ_921\$EK^UP(18%5>5;(^+ M^CD^,^#M7H^1=+@TN^V MO=,MPD5P;FWM5E>6.T1^1MFP>VE30>&-
^#MCF1A1T13^12QO.1#1^N^1N1M1V1&^&D)K9K M1;1)K4(&6G1H1V2#U1P1^>^NZ;HFF1+HUE%12L7DCC&9CU1)^> MK3=5URP10>+<
{39TE1S)(BNI1SL=DR^E20>XK^71Z^XE1)WM5TS^R&O@<^MPJZN150AF1QC)Z#K14.&E>\$O^YAWLUY1>C65G@IA4MCX>14=)1
{DYCL1^V6YF.S00 A^&)>Q3D1.^1KPMH1^MJOU2ZTBSFOBPSPR1 L1C^/QQS6E^C3.FGS6C&YU6VL1J.12SJDC8R;1X1@1Z
MJ@#1#L01WAO31+62T2QB>U+ PB&8RV.D\$1^1S15/AU5@2OU^>D>Y@CSOFC7#13N8#1/026@# M-N-@U1I08>1(M1L
^K+1N1V1U1Y7/U1R1=92Z;HJZ7U^O.V>^D9C M0^L5PHZGOCN>IK5KD1^81PEX@U/0+NUGGTE)>7^F(S1H8&1@2.49SU1 MZT
=>1>FVNCZ7Z=91^7.6T.O1K1= 4^HJOA01TEO94L(EDOABZ89^F^1U M5SSZ<1N^FT1^%HMGG)&F6VC1N^>P(W^*G1HFK1N(566
S1B9AD1EAN(1<4 M9%QXA.W>D1.3<12V\$)W10^E8S_L_W7PJ27PMH4VFFVG/15K1BM6W06XC M-2-O4<91^M.S1^6=^1JCJ2<
5R&AZ1H B.&RU2Y1H1=>ZFCGM1E. R4=D# MJP/WSMS@G&#CMD@&HWA 2=14LM5T^1^MT(1.N1:1OD\$1@^1C1#NBMHR;.
M+=M+1/3^&V1H;M^P<O@>=CGG7F.7X;B&X&6.0#1^*P^S^1^Q94+G1RA MAGCK^5&H:51^Y)H5E^H^F.3N1YK 2^U)H^M1J
@DO18BMXK3 MN<@OQV1DB51JH1H1^1JOK36N(99^CGFC=XSALU5@2OU^:CSX7ACS8_O MN1O<V17%
\$E531MD:6YM3:O>1=%S^M&)" WMWK604TUQ#J&GFCB4G+L% M1/1S5+6CJ2V)^1-O903^1>1V1^&P&#1XC10^KH&DZW91V>IZ?1=6131
MXX1%R8<CT1J1L1^AX&Z^Z/9K1K6&29%1Q% 4X18^&85K23Q191R5\$ MPI81F P1W^E1R.O>O7R1M^>N22@O:1=9VFGKH1%NB61Y:P@?<
*Z;<M>GM3ULK5;6(MXOL@B1D004Y8QMOTQCC%2131QB21%1/1D8\$^116+XM1O MKX:T)KT1F&F:6&17&Y&W5 2,C(1)^G:1@^?1?#&A>1?
-122K2R.QS(88P1;M1)ZXJH201.U^1%5T^W0%>??%Y19V-ZBJ^G2ZL7%1)JU 1V1Y0V<18;M1O^Y9.G;P<81//>MA18UC1OG41XSN1XOZYH
Q)/GAJ5+1T2R^73^TZ^4) M^N.9^0XP.;1HKO^SDU^P@DU.UA^6DDK^1<+NZA3QFM+SX3TE31VSP1^1MZ?7V1OVN1V1Y?M\$7EH<^184^A:1@#<
(1.P.O.K:GX@M12WU&2.1^1V1/4L3D1H1V56XZ+(CZAE88^D91^13)9XH(C++^D<8ZNF1^ZK7FBV^1H)@K<20@MD=?<
4CMG14VCKK^1>#41FSN81.S9S6ZE6;CHXY M&0@;@1CL^OKF1^>QVSG=1M^1BJS2H PR^6^1(QG^5)=612HTD12+(0\$+ M&STOZT 9+^# 1(11
1Z1%K1MUT1^_UOQZ=ZY113S41>1^>RG:PB.MB-MM1YSE>BG1^TK4HH OQ^21V^7Z1;+&LO13SN^T^2^1^1G1U1^M;1% M1110 4444
1%1%1%1110 4444 1%1%1%1110 4444 1%1%1%1110 4444 1%1%1%1110 4444 1%1%1%1110 4444 1%1%1%1110 5PGC_4OI^N^<81RZ6T
MTJ>ZE6>5 T.R1/W6^&EL9Z\$ 1LW=5M0TZRU6SD1JOM(1^JVD^1%>=3^1MH1G19^15A1V0&+VFH1?>=1)A:0V_VS31U;DHH1GP8R-
YZL1^1&D+1(T^P.LX-N^K1G7R1^NW M&.^12-X?T=1JWNFTRT.XMUVORF%>1@BG1H^1<3;=X9^>EWHUN&C;ZE
M1>3^G:CD8&2>1KNL1V1H1(751#)M^M26G<SD0_6&11^1N@7M>^9M;M9120MRUYN(96^WCN)(V1^F85Z^9Z+1>GW<1W9 MZ?61Q<^M-
UW7(+&Z@U.83^1(UEBC5_W+H1<@10N^G/K6E1HVFWWQ9D@O+6 M1^CD1:01(+F^SF1YAOD4C1^4.W14IT/2CJ3ZD=.M^MTB&1GRAYC^?<
X2W7M01XRVYD\$^P0OK1+611M^H.MGX4(QY4 9&1H.ZR1NK742B)XAT16=0MK56M(1^1742.LL1 M0^9M11^2?)SCK@>G^9^1
^*^1P^SWL1/L1O1YOC6_V=+904KC&741^1^@Z.M1MNNH2-8W8MAB30^MECT179P1M^@#SR70=^77 AU8^T:(WA32K>3J5NB(5_?@10^S?C01+
M1^VZ:71)B)8QO&O\$0^1^ZYKS71XK37^AUXKGUO4&1H75X;R91+>2.DQE EGT&19PMQZ5Z=1^G66E64=EHK#^VL8PD4^157OP15>20= <
(N:UKR:3.62Y?O MD:(\$OM^1N1<=L1^#F.21N?A?<:O1&1/G1498QN9OLK\$ALH1O601M4@B
MDT61A)&1C1A@#C@<@<4R1T+2=2NH1^1TYUN B.YBEEB#&1D1G1^171#&.<M>E.C^PVDGP<1\$1&P;_31^8CM8_O<SDCG1Y1Z15ZS;MX?<
19^1T1.6L1=1^M_A0W^Q6R1O1TZR21ZVJ1H1^1A1+46RZ^1H@&1G68MDYB31C17WJXF6B1C6 MICADT^V%1O12(A1XFTW=<U>U^1^K70=7_<
_57URRU^+SX%1P0VR1D)N7 MYX1^F(C)^>F?>M/XO1Q1+>2>5\$EO.D.P1V OX1GVXK1+1#PUH>EW1U_8.M18VMW-
GS)H8%5VSR=0.17:VRM=1L1Y:1MX1BVF71%#H96^H0: U1LXOB M31H1%U=VEG8R:7FQ\$1^_1HD<2J-WRAL;13ZUC.MX2FTFTKP286EXVHVJ>1%
MA2=L?7&C+(6B1E^@XP/3^O2+KPMH1^HMO1MUHUA_96W^1@>W41^NC^X5+ M<>1^M^NXXK6^XTJRD1C^&W1H%#PXZ1^CY?PH
X611+>1Q1Z:Z7:Q6361^M6@1^Y5OF1L\$J.L3@<1^Q\$1J2O @OXD1^G61+87M1+60%;\$1^1^1^Y^>1^M^T%>LRZ+1<1^HPZA-
HM>PC\$5PT0.B#V;J^>7PSH20W4^Z/8B^1A1 N)C MZN.2^<17-JE1#HVIZ8UA1=1^HT8N=*U1/1^C2Z/SM8E2^2^#QG1%=3X

M+O+P#IFDW&GVLEK&W58H.6C">+MSWOCKWJPWAG0V6)3I-F!#Y46(0-B M9)VCT7D)*THHHX(DBB18XT4*BC!0:@
I!@#RFS2WUCX/ZJH&HH&SUNH!V-X MG(O-!=1NYCPW40V% 18%7+J!HOQ9-9=8M83J%Q9W)O!8RTGV9*01P!//TK
MO7T12LYKU!MFNG*LTAB&6*-=)12(Q/2BIT*2:^^BO:03;2>ZB-U+J!H1K+D<*<5Y<=>TE^<+PUA58P)=2T P X1:2 M3&X)Y'>#S7L1-92K
\$\$\$8(>L6/P?X:BMHK;/0=-6*7SHXQ;)A9/IP&.&Z<M!-.6TO3+^Q<(WBG3+6RMX;"2K:62VCC"QLV9%)VCGH:67X:L+K4/A?X)&G M7MI#J-
N#>VJZA:&Y(5PR-IR)JB01DC<&5Z,WA1GO)KMM+M#:AMM)TZRO+BM;W&W&:AYF MFCC"M)O\$>?QH XGPP!ASQIK/ARI2&&4ZM8H%
(64,3MF0\$>?O-C!)K% MNM/77-%17^RT%\$?W>LR-WGG)MG&Y"N23N!C"D=L#1/2K6P-HYJ>HW M6EV43D M@*H!>+J\$FK>=(O)?
BMHFGW5C:O:R:~LD00^L!@SD8 (&XZCT(12446E MZKK/BWPSJV16UCY!)!#&A^V2DHS;"/Z<=>A>|=YIWA72!&1K^WFO;M(1173Q
R^V5CD@=/(H6H1!&K%W#>ZEI%C=W\$^JY9X%>EJLD*=/H M+JY3QC:Z+J&LJUH=\$@&G7%_\$_CBZ&YQ(2KO^(&8)IT<#G&2S-
8&B:PUOX^&T+I7ZVVG7M-C.3SH^C\$Z1\$&W<#Y=>MX&?5ZT-T<7=S M+3+07%TNV>41+NE^HOZD?6HSX8T%M(CD^I!^SBVH+Y^
M^7GUVXP#IT>9+!=+!TK30-!66H!>?^HVMPT50(!65HPPVC<^>=>M-P#LGC3M+^+UA!8V5O:Q?>BW^VA(XP!1+!@Q:O)/Y/!
=:WAC07TJ/2VT-P-MG0GB^>JH4I-LB^T73-26BGO;"WGF MA!\$YU&?^L!Y:~DOM T?4M-MCTZITNSN+*,@QV!D^E\$(Z8&.#1^B/A?0&Y.BZ>?
M")-HZ?7O3&Q3QOR!M^JAZ4>8Z JHWI6F^)(=0T>#3M52.Q>IN=-/>^&YM//^EPN;@X.BD-DXIX%;# MW!8VOYVWQ-X?UR*ZUOZ-
(+R2!)JH61G5>NUL^>H^>N-MI(TZTAF&LH^C MG&5"5*#\$@QC#>HOQ@JHBTGPIHV@B4:3I5G8^!HVV>_7FNZA>76H67@/7+G2!P!MCLW:
(HY M>6^N!DCZ5.G@WPPDDDB^J!#R2^5R+5/F<=>=/^?>8-P,=,4><=>(+!U@ MPTP7JGAF..*X-MHHH^
!FMY%)D1L=5*@L<-W/O4K/0!T^&S;/3K!^<&.,+MSR<>F>^>M0IX9T M.-+M\$TBR5,S_<^0(% F_P!_CYOOH
9X6D-Y!&Z+),QD:73X&=FYW\$QKDGUK MS>VAM(OAW3+^C@29;I54&U0&"XR!ZXZ<5Z59V5KH!V5O%;Y18PD42A54 M>@_Z50D!+Z!-
+>2R;-8)>X^U.T^DS0<<C0!PQFV6F>)/AQ=V5M^H!X-X@1#DBCBF,^V.R1SC&?8FO:188YXFBE17C<896&015*RT+2=,LI+^RTRTFM!2
M4\$!/%"JHP4/0.T-3U>OCL B5X6;2H(HXJRWNH,^!)0\$EMT0%T^&9%0 M2!K!X%UW3K,^#6;&4DMOAXA4OU(3!0!;LHM%TS3HV2
MSL+>!63RR(T^3LOTINE.TH1-TB^2+3;"VM(Y&W.L\$00,?4@=Z-)T2SVZ MCF?AW7=-U^%GCC;^V@M\$CC,R.O,A%8=KI>(>?7?JB^K>XU!<>?
M^TC+&RLJW!9L3N)Y9CVX!X>+J^T PUHFECW\$JUI6DV-E==TF.#W7G/K4EWH6 MDWIE#9W>F6DIK#CRID(59\$QTPN.#%
'&7.BZ9!QJN(KRPMJ^1 21XYX#(I M>>P!93POP!UST!7.ZS650PYTB.=M/M;O,T?V5Y OGPK\$H&ECC9AJ-FJEE!(!G3(^U3>% "4.G:H-
37PHNA.L!F\$K MQG.AESCJ^JN!C@8//1C!Z74M&TS6(TCU.PMKQ\$;(6"-9!HOY9E.N)2HZ.MN<#J!XG7!#R/ GCFRV.Z78ZS"--ST
M@)DB.BQ^B@L1@=,D5!^=-IM!#1% M_9OM6F6D_P!E:~S(@WE^_9ST_"E&@Z2+RXO!IMJ+JX7-,(AOD^HOZD?6@# MS3PM9W^J?
#CP+8WUJ=3LQ+!WZEKE5+1E21R^JL\$9QZ8S79>~N^ZT&X M2+2C!4L%6!%U@C@A3.V-0H&3D!WYH XPH!>(+,=60B&&*6Y3
M4^@99@,QV?EYK.WW0F;(FY!6N>O M3E-HZ!6N!#TJ NAGVTT^SR5(8+&H/!<O XHU#0!^U7R!^OTZM!)Q(C: M+SHET7!ST-^K9%1!;%%
BB13@<C!15YEGH\$EFAZSX^Y03N!2T 3SF03A5&B\$04!+>MVH!E4+PIHVG6K&EVEN54H MGE1!=BGJ^QTSOWH!NAB+X5>+8;+&U5-
>N552WEJR^Y7,0/;(4M(H1-,%JT^<6S/(7SG"D@;5RN>^I X%6O\$A)&!.RV^AW3 M-)B!ZYCGN;6:\$)%=>*K!F!BH."<#G!K.T/P5 NJV!^A/1!"
L2UE<&224%2 M!0X1%!"IYSG^0+~%2=,MO@QJH!PVP^W!CJDK6EUM^F0!S^A&ZJ8<Z UW0!*>^AH!>=\$
MT163OYC6_P!G7RRWJ5QC.D!+!+!>DT:P>Z57DB9K=2VS&N<=,O<T!1_8X;+XJ03>0BB5W!ML?~MKM,/<J4UWS^%M DM+T?T
!;K:R.2!W4K^JWHQO3IGPWEHJ#WIS!E-+>/M\$86G>12YOC!&[&<8)TH!SM!+T!5=1^%15U:Q317!&AS);^J!HMXL*WJH!M59@M!^?
Q7XC!^WY!~?##;06!C;7\$;#9^2!B-G!&W9!_I7H2>+&ICEM94T: MP22T&+=EMU!A^SQIOX4!5#FB:Y+!)JNDV5!#_*MKB!7*^P!^3VH J^&
MT-2!^T62XJ!^UYB,=K+<2KYERJ=U-O-#(!8~M39=-L9JNUNY;JBTW^WE M;~H=PPVJTL@8XJU0-4444 %%%%~1110-4444 %%%%~1110
4444 %%%%~M!1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110
4444 %%%%~1110-44-44 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110
4444 %%%%~1110-4444 %%%%~M!1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110
4444 %%%%~1110-4444 %%%%~1110-44-44 M44 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110-4444 %%%%~1110
4444 %%%%~1110-44557CK6;W00#15U8-B3R7MO;J MG3<-LDBJ!^/7H Z6BN+!7ZOK2A!^HK*^@D:4=4CL!7N!+>@&X!67D<8!I
MZ^!M3T!XB67A?4%MKJ& M^N(+F^,OO&4SE74LP(;">F*~QHJK^)%%t>VUU96.MN+5X%7-!>H@G/OQG/M0!UU%5+75-/OC^+2_M:@Q?
MZP13*^SZX/%+>ZGHW^L5M^26TTC(9-D!C)!#9/0W&LZX-O.D!-V!Y-16O M!D-V@CO:EV#>Y>T_~COV-^9T5R/A#QA)K-
OK<6L!;6MUHMZHM=-9WIGJ\$)ELKN^YB#%2!@<^FIWH L454BU33KB0QPWIK)(M.H!IT!HEU/3X+R.SEOK.ZDX2!YE#M!M%SDT
6Z*9^KMSRQOLL>=CK6NM=G\$#<2Q JOE(@2!DY+>3CUH!&B!;MITDMS^FH6K26H MS<@<LRDPC-&?
E_&J6@>*)>26\$M!UY%)!^(ZD!QD!6*!B.P.TD9!4;-,%5+ M?5=.O(99K6-M9XHCBI1XIE94/N0>*2+5M-GN(K>+4+22>;2OO)I9T/X#-2 M/?
I0!D>X!58T.XEA!V!M^IZM:7LB1DS7T06.)\$!CG Z=>U&K!5.WU"RO+9KFVO+>>!20T!4JLHOUR M0<5%K&F3\$-0%J5G);GF1!K.L!2
IRC.2/<4 7:*IS:MIMM=I:3ZA-17+X M^POJNV>F%)RPO^TH ZFBN/X!+>19XO\$#ZJH!JBV6M364,K;84V M^B1R>O)ZDFNG.HV(^SYO+>_\$_G-
%J!MU?WO@!\$!SWX4 6*Y:XB.YJ!AKP3?ZUICPBXM C!)HRZN^ZK@X(ZUT5FLZYD-M8N9EFFV@LZLH!L.G^YT
3T54GU/3!ZCM;B^MHKB4@1Q23^KN3TP"*A.OZE!90-/32H!N^8MI5FE9#D!D_!N02@#J!^J0:KIUS=O:07!MK+=1^!P#LZ>P1OUYH
O45RUO MK&HP \$RR?SX P^SH-FN3&6!5T4\$MG_!6XNKNZ8UD)=KJ-H;~XDF\$Z! M\$D-2!56>HW>F7ME%6VQM6255)R<#@GUH LT57?4+*
HA)=VZF7=Y8:0#?>@G^!_3!";E-M87MHUW:WMM;+G=-%K(=?F!QQ0!;HK/37=(DL!B!CU2RDMK9=TTJ3JROCK M!Q!XJG!B-0!9TVWOK?
K458!A!ML2R3*K!DA1@GOOQ?7F@#M!)ZD+!MM7BE-VN(8S&13QKN8.NY@01C!&M M="JNG37K645-O=KG=LREOCKET9W L<=<
NY!;5:MM0M-2@D?3KVVN-N5WQ.)%5O?! 3-!%JBO, M)?% B!>@W?>(UNX!J=O/GF&W!4JMP8P N<#C?7XUZ/=WIGR(FO:N^VB)Q
MOFPD+GTR;+!%65!J5TZU@BGN+^UBAF UE=K7>J^N0\$A.QV= MF^31W<%P!8A2(Y Y&0^1G&E^!40CR^#(WE>_O^#0!C<1;
!9M.MM22.75!+A+M>="HF^C&G&90?TJQC:C?>M-15 M>("TV62!D N3-#&);8JHB9&="3A0.AX(!ZT;33="X LZ=VJGOA@^V@K-
M3^H:08Y;7(K09M(TRXN(+B23K26>W\$;CP^S1@=-!R/PIS:7!5W9NW!+5K MDCHE^ER-8^!C/2@#QB?3M!3X-
^Y4M8!);ZE>J^X09B^W&553_!^G(!>N MMU34!D!7:O)!TNX!B2YN;N3=YL;ERJ1(2!U)RW)!48=J^T<0/_*L1 M"
!HFC@NFUB.AQ@FGC!H+!\$!XTVSZ!ZW79#Y!"!HEP!~@2Z+=+3^"O MA9^!)HJ3MX6<\$%E=2?3U^VTK?TW2-*O?B!X!6YL;65!V60!;G&Z*3
M.FNX L!0^BB_LFPN!)B3!F5R 0F!+GU-1!P MPMA3YM(EC<+>=8RR^U^L6BV!YY Y!XWY!=(K#5!/Q^>K79 MLWB\$M^5!@C)\$R@(!
_!NAQ47P>TG3!+!J!D=G!H!_L9N0H!FTRME=W7^MRCCBNUMM&TNSAFAM=LEX!+D4!JLG^!_PQJTL+3XS^96DM^M3DK#&\$ M!K@4
!%L?H7ECCVSZUD0P/0 %%%8<HP M5FMP.\$68VY9!P!)(S!YKTB!LK2 A!FM8:F+G-9&7(Z!HKZ=8R68LWLK= MK4=(#5!0?
!QB@#%\$!3X"!E2^#HEMR/^N2U5%Y MW!>+!^N:W;A&H!T+A M6_X^3QR#YKO!6SM;R+2VAMXLYV!(\$7/T0 P!D;J!M^V?V=;?L!OAE=^
M?7=C-^@!H!A A#P-RUG^92)=ZS ZO/<=>R6WB=R26^R9?/7^48^W M.\$L^?R6K!6!Z!3K65H!LUM>VT-S WWW
MHHPZGZ@!5DZ!X=6HT^M0M)6TL+ZXMA;K<-9P<(!X#C!VXR.#QG(H Y!OLB M6!/_VL^FO!Y!6(KV!>U#^TC&JA4"!PE7:6R<\$87CKC\$T?Z1-
=T#5M\$!3^<(MKBQU&+4!FNK!>#*TGG%HYBRA=B1L P2>PXP^ZK3 _!UJH:R:GX>+!+6+02L
M+<38BTI9&#&2B!LURW&1WS77R5!ITNH)J\$EA>O>H!<="ID4>S8R^+*9\$ M:YW9P!INOXUX8JVAW!-!T@C:RHRK!VGI8:0>QP?
UKW^6*")HHHTDQ889 M^0!J!@U!A_11^81H%<@BP8H3:2.^>=,1N+^OTVXOZ MG;06PFTFZ!UA M4+O57C^@>=>2.Y&UU5+^X46S+
<=8K777?4EA"O)%B!H^_8_6@ M#\$^XMO#6HC7!7L==;6+J?1!)(f@!+PA%19&<1H^SG!/_23C*CL!&S!*_R M!MX(KB2!LE:9%
=MUN^X%NISQ^E>HPZ+!5O9264&F645K(P?2!DN);B2PM M6GF3RY9&A4LZ7W6..D>OHCTO3XK)!^PM4M9.IX^A4!V>N5O@T<+J-C_P 7
M*^UQH\$M!FV!M10@%#81^ATW; WX#Z5S=K86-M!W/OA!P0V!5TVJVZ=5 M=MP(8%NIR..>P!^!>CTO3XK!L.PM4M7^J
L^A&^JXQ41T+!VACA.E6BC)9 M\$-NFU2>I OQO!YXQU+3!GP^XZC&G/Y@74BL4LF^XN!XVC!8-GY&T8 !X7 M!TKL!B?&
XQ:/N%.DB/H5QM96!#?OH^A _E75MHFDO+<2OI=DTERGESN;= M^95_NL-(TP7=P.M!&J2^0NY0!@^&O.*.&+Z39^>(+!>Z M1>J^MJK7KJ-
QU^Y2!^N^R/<5>+!W&HZH!%K+!^T^82NP^6:8>>8O_78 M<+135V!M4TH!L-E!A^VTBSU^W4EKB B-USV!9@YQFM?2!2OL5CGF\$J!RQ
M.D!H7^!LA9OE^M8)/ OVKI:S8GQ7+!1L!EO(NA^<!(WGF/IWOP<-OUV.VE;=<7T5!86LMW^J
MYWA5!\$<C9%)!LFS78NY=(M)+D8O!^EQ P+&~0!&W-MXW!VCS1+A!(N!^!="S2^>^6T M@6!>0C7 C D91T!&2!F7FEZ?
J!4WMC:W)7HFA5!3(H!V!>V47A!Q^X; MU?1.B>YUR2^6V2RN;AKS(6_UA42%C'@_99<=>=>M:5_>V!H5-6B!;1%C;Z;C_ MDKO/&O8STH !FM-
3L!JOPVEAOK^&S02B.YBE#&WCV:Y: DD)RS\$@+!R#P<9 MH32=JDI(?62!K.U8Q7E!Y,%!<^P!PV^F&YX!UZI!H6D0!H^!5C!""YZ^E MN@^R?
WP_&^!M^Z!^OROKI5B\$E_UBBW3_#48YH !LUF7!>=!S;Z2:FWA MEI^CLOTHXWPT5OX789_L?S^V^K^<6!+>=W:V<@.E0DT^X
JQ_&4<^HP?M!>_WXM\$TF!""+2!P_6.81TMT+!>^CBHIO@^FM936L&GV\$3\$&0?94M@Y!^MXP2.HS@H-^&XYD!>E!>E!
E!D.01V(J!QU:POHGB>VN?&A!4VT+7+8RB M:IMY0\$WODAEF7H!O)XR#DY>EVEN%96<%K NV&^8T&>75<_JWPOU;4!9+?4FZS*
NTY.#_(@X/> MF:CE7.F6!>^!M+=V-M!^!OY8E8K!^!O7&7A36^UK4KQ2_#&LVUW<@6.74(F6)<1^!C!>MH Y&?QH SI7T73H?
GCPVL72VNXM!CQ\$92BD3!;8GU!^!IDUDZ+!D2?>W MN;O-HOI ?9H!O!)^RS#JEL^CGH#P!)TSP0!6GV-M VGV+R0!F1EME
MC+!7(C!SMT4C@9XJW-8FDGS!Z79?ZO^LW^CI^!YVPW/XT<@#97LE4_9L^A<3A0.G)!H!P(KNT?X%>?W6>A!>=B!P0P!D@3@M^_=
MH!+@>TK3K62&2WT^UB>)/RHFEA53&G7!X L^L^Q(TV^TFM(!M\$MIR6EA6 M^0DA/4LN;^O0!P!W>EZA!9!\$!^UN(G!<-
^XW^RLZ^V^AXYQ7Z:HK9?_MQOURS4 Z+>~NXAC#3-2%;Y!<1M4!^P/208UT?3\$0^NG6BH(O)!"@^J M;=C3!N2>_G-
2VMA9V+0VEH!Q:&J5!56NN^XDEU2- MFT6V^2^A)S^!54C#8QNYS^O- K-P@RAGV!MOM!G.#_K5Z5=M=CI>GZ8KK M86-K:~
(=SBWA6!&8^B%Y%I96UR\$>Z)XE?^TR*_Q?FFV6K X@G^ MTWFHOP+D!TA6=M:~J!PVHFWRPQ L MNXRR^YR>_&21SC-
>TQ11PQ+%%\$BQQJ^J#^!A5)!T>~B:38JAE\$Y5;9 #M.C!H/O>_6@#S.IGLKJ+QWX>DU+3H=3O"(HBI^C00EHHUVLK\$^!P^H(3@ M@XT-
37!UT#QOWHMC^2RVRG:9)H E6=X!\$WF#YD!9U9064(<127FKC>=>9!7!M0^!+!Q#
<7+5)=WT3="=0!^R!&#^!A1A!P!7466AO3(="MDN;^TNK^EA\$M) M!C5B2WRH_200HXXX8EBB14C0:55!@>=>
M@%51L.FB!^V#3!076=WG^2N /KNQF@#A_UM P!(H/AFV5Y^T.WUF 7!R.6 MQ#N8J9>JARE2>N!FKMQ;NOQDL
!#^"K!LAU^9T90X\$);WR6P>N>U>E!"" M\$T4J!&C:RL@>CT!GO:986=NJO=V-M!^XPI<42JK#&0!@!4>3.G_ SG MK)W!@75P.O!T^&NW6Y9?
B^T^Z(W4FC!>9ONDB0<^%VL>63WP!720M^L M:858^06W+L!FTMXOQ-2SZ7HS;1VTIC:RV!9!2^2%65<=>C H!YT PU M-
K!AWQOHTRV!U^5M(A.4J@=>GHHE!>0PIENN@O:G!8^<X/NXH!E!IN!YL8P>_X C!O!T(K%U^>^W2 M!Q.6TO-.GA^WY
<01/OC.HD)=D;N!8D^W(!5Z3=Z=8Z@%M!9V!R%SM\$T2OC.M.XR/8?E6^XNT!U?PE>:!L!E#%>6S0!D)!#&L6>F^%5#D?B*~S3_!D&6O!

[illegible]

[illegible]


```

ZS#F7D^(-N?Q"JH=&VNP9+93P$BC)5 MX7WA@#(YZIN 3ZKJ$6EZ7<7DLV-,@9+H IW).!0!/=P733+##KF&3RYM
X6P#CIB*FKSGOKU=#761N+JYK368BTA-@!>*68@#Y@3P/I005L:OKE M!KM 9Q7$=G%96VM&>/=Y^>^ P%=HSCGYAR*.NHK@9-
9!37<^X@I09WM.J13-.CVY (VEO=M/2M= 811H11*(Y)BNXYW."JX MOTK!5P. HKA+CQ#KU?7HC:=%61K%).(O+8B5P2)=@
HQV:SG&1BH- M2J22ZAI&FVIMG>W-B!MR2GF".12@->>I01<#M%1UN?5ZB>T:R-HTH!YL: MT6LP%NW&D8FLLF!3J/7H748U-
2!0ZM>ZCJMCHT.0G:7L08B5T>0JPO)R% M(8#COGGM3 L:BN).6/$-UXB@TB%:6TVE+=NL9D,$A:1PP#8.>./QK*DUO M6-
4TKPI=2-%AN9M5-VGM!M894+ 9/RQOIT>ET50U:HL!N%)K6-9IN( CME%<I5=@.YI"N8LO$J2WJQVHH&RP%W%=(IER70/S#*@9XYH4
=M17+M>#M:EU?S.HI<?J+YL#P?7-RIU8<<=>F1ZFIK V OKWQ#-HJA=160V>+U$LA MCWOEB0@)QCY23U!C#:-
VYNH:W>XD6!)DELOJMFV&L18W"RB-BCC M5F8B=F4X(UW%<#K6JWNM^&+5+HQMWN!K$K< )D.XD 4KSOU#8 "NZ%O-:7 M:2-
B6I9"SSO0I0S <:2>WJ30!8N=2L!6WBN;F**2X?RX5=L%VOG L:M5Y7 M)>CP:X9G:Y,LTFLVTJHJ!<$R,3DCD@YZUMS>*=3T=VO+>5M/
D2XEA6.B3:"G**XY?K MG/G6KJLX$5QJL=D9E@*F5&D0 A2G45QMIK J:;S3:-FXL M:>-V>*YV>=>2H0D!5^7G0! -U&.>DTB!N+
I2K:YNH!H6X= 9(7ZJW)? #^=#M R!1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4Z* M*4444 -HHHH ***** BBB@ HHHH
***** BBB@ HHHH ***** CK110!CV M AZVM$U$0/IU!VDFD+?PP6>G&!^J %91OZ>EG)F:4LE<S0&.<^M$JVM-,@CGUX)K0W#.-C-
0P7EOH3=C!FQ@J&YT**Y0VFLO)YUJCQOH/NX8?- (5K9%)D>M & M3J>@QZJ^F7L!BG3W:2-%O@L5VY/X$U9U3HJ
@#7$L0AE64>7CYBIS@YX M #P-#MRN5C8H-S +1365!NJSKIFGG6TAM-1NCL"-D#<3M7UX&&?P-%C5=(M
MM7AMXIG=>^N(KE&0X(=&#P-!53E!0-K!NM!H-W.O?>20B E6&WRP X1+!M#H+H7X^GRDH=BA!#*EESMW^X)X!8KH(IT6*-8U&%4
>@9B76QH/AVZ MU98Q.(%IVYZY3#K<^ZG(H S[K!K!U:RU.6!S9AQ$>^FX8.7?C>9IUE!%K M87M!P=PMFO9%DE^!P4*^T_R:OT<
9)Q0!D60A<^U!1WNM)+B!C2.121M MVIG:CC/<!^!>VQV^O7^K)HB2)NT! 0N.YY?06N74$ D<I*#=0!S
MFF>#8=L7L!+4=0CA=F8YD0D,3DD^Q4G .66BW.DW!37 DTP.(B7SOWXW^L MCDG%10 &0V@6XUMM@EE@N)$"3"-OFF
Z!>XYJYZK:X8&D6!S#8ZC=OK M*9FYU.0Q.60GE>Y!J!>I0!C3^K&C?ZJ&QN3! T+!5+EGO^!) P M PZ-G!VM.<4+>0D-Y#^!P";MC;@
!V.C)YY.9-U% &5:;%6VO7>L*T MAN;I% C7+94*H& !VZ9 &HM:TYU" ^TR>WN!FW-IYAIN3"...JZ_Q @?C6U M!0!UC28-XTVZ>18+A-
DAG(#8!B0:HCPUN>2YFU749K5553!A74=F0 M.>G//M% *S<^!>G!N:U8+FX^U-DH"-D">YR<D>U:5A7!TBN!0
MNEGIV @2^4<^*JEICW9P3S6U!0!S+^#;86>G06UV=6UQ80^!&!(0RRIM/GC!FX$8R.Q! #BF P#"+V:OZ6!^C:=(9(!%YF+ AMOOSN
MRU7I(TR !I^!M!MV MN<5-9 MJZ"/UN$P!KJXEAU$=LT3$=JC:<#7C.<#J!M(Q) MMS(%!))&B.<88#MD5H:
HUOHEFIK.YB:5Y<E)KF@VNO:>+6Z.BLC"2"-RKQ2 *#1W&:U:* M.9F!V=OHQTV:~U"0^DLEP!^Z60HVY06(^Z"IP.GUJO?>%K/4;^ZN!B6X)
MNK-K"2.. GEMUQOD*WS6H!0!ST^A*VAEAG:0!B*K?S7E&6L!<$ 8XP.8 MZ4O_B=HNEZ78!SW"Q:~DL!W DL03)(YZUT%& &1?
A^VTF(U"ZM")?I-G M-P!9.Y%<@!B/H!U!^?)(H5C)XA36S)+J2W-LHR-H0G)XOG.>?M2B@#EX !& MG0P:7%!=^UA+>+R+( RF3.IH
!4=Z0Z9X:L~LRTA$KVYU!D0P$S$;3:3VC.HG.6!ZBGKFET/PW%HA+?>Y8+ MY<74V RD NJ. !P?>5MT48>O>H=&:GM;N.YGLK^U)-
W:D:U!ZJ0005/H M:=X=BM!+$Q75QLM=f.KON!V &^0GDL^2K!^MJB@#E(? !K!^!-ICW=PH=M2F:-A3:OG.8R.G//ZZ?
9>#8ETFFZL!609!6ENH *DGN<9^=0% X7!Y!20"> M@KJ**!6.7TSP:MI975K?ZG>:HBD+0+!K;EQL_H^OK3=-!&T.39:S5!JG MTTD6!N
@%"0NT<@<@GKS75T4*1.P!>I-YIDEY:JK)<X&M5(4&U?<7RI R M3N)@!XJO PAZ7>A3Z=JHV75!VW;ML9=N^NT!@<+W/6NFHH%8Y?
22^4UE MK50!UJH!H-PVAM0SH%4D?Z!YUWOY+^SE.@<#W94J58=M-HZAXK(OQZ!O2IX79+00) M!R(7B M4W<4@3!OTX2NDHH
YNS!S07>G276H<2R1M^N!S XYR.8Z!ZU**.'Q+X>EU^&S6<^:SDM:E:E M)%C#G?RKDO$$/XMF>XU!K-XHX5B$<G?.$EQN+
^U!D9QSE1GH* MJ+!^JBY* @!0!RMGHV!CLSZ+4=(UJ.3)!0% C MC602HD4X;@9!..!6X #1AU^PU*Z.VSM&M5C=-S.&08N3GJH!5T-% SD;
MGP<=77AN!TB35A CYO?M?FBX?E?WHEV@;0!PZ+!U4!X4NGUV;5-U!P-U&$ MNXUC5Q*5&89^ZP^&ZBB@#G!F
PXIMXB75$NMR8("S6U)AMVXOGD A6:0@ M:~!M/LX!59+BOQ60@!@0!LLS.2!)DS!Y!^NRHH R>T:360#=#SHNVB>_M.(9!N3D$)
QG..16:X7U)!J:776ZELQ:~H!955.$E649/3<>?3FNIHH MPM.V?9==DUFZG6>I>V6V+!^L&T^))&3DD_E2W^A^!0$7!M6E)!T^D21%0
MTFG7D=S#K!P(!5YGGK!T!V-0! M^!JEYTEY? T&H#PQQ$*~.8JARI#>G!7444 8^CZ!>=O:QU:ZOV^!4! MT(H4?10.GW-
5!>V37VKYFKZ=>+92A!&TD>+S+>(G)4KB=^!Z"B@#C?> MTQ@B!C5Y(KF!4GU$2F%77>@Q&02H!^2BE85CE;CPI?M?H-GK!IG?
ROF>RQ0QELMP%SCY6!^D9..!UK! M:..!W6)69!E9QCDDDY)U)-2T4QA1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110
48HH% #J*** &T444 %%%%1110 4444 %%%% M!1110 4444 %%%%12.1@TM&L !/X=-!H+0&S%Q:PO!PLOY4EB^5E580. M;AR.1FG26QU^5?
#5BJ$<10S23/YPAE9"W$(&#P!N!/7WKJXG<^EPV=I:V:~M+!W!&Y25FN+!10!@G.5)4G@Y<^M7/4M-N04R!J2VU;FX
M#&0&3^N:Z?3PU!NH&&>US<&1920!6%<88J!@#D8?185:~)HCW5!6:GBX MN+HM!^Q!PI>N:XHP:IG~*C 8WBK2=2D)R:~)&+&./1~!R4!R?
Q)H X!PMPN!6^O:JY07-0?7<.(!P%#&21 M@G!^0H5B:9:07MG!7ND.TKH(2S.3QY+^S~. P"=>C6.BV&G&Z-HY?V MJ0RS#
<2^8!3R>/PJO!X7T:3H-/DL(VM:=_AC):$GD<^YH X&XNFTA?^!MVT+!%C..XJ&Q!(Z#IKSO9:7:P-K)
M(8UP2L2/89D).0TTF6R!$ZA%+!H0:589V9V(=?P)!<=1D# K!&3P? M8!AF>
<&_ BC2.3@(!/Y).3QM(S!^OCPU!B^GP+9I-(!<26B!B!PZ$2ZBN7B5! MH0PC<I5!QC^UP*//2LH!7?&LZ*+ZWLS D0LA-
Y)YBMR9(R"C/3ZU MW.C28TFSCEOH!R41A3.O^FE>^V/K3-5!..K4L4NHZ?^H6M^>9?M-I&T<#@&D;%&0!T!@"1110 4444 %%%%1110
4444 M %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110
4444 %%%%11 M110 4444 %%%%1110 4444 %%%%1110 4444 %%%% M% 1110 4444 %%%%1110 
```

[illegible]

[illegible]

[illegible]

J>HZ5T=A<74YN1=6GV<1S,D1WAO-0-8?CIG) MXHJ5D+E16&E78*G^V+S ZC9'S_XJ3/T6Z9IRZJ]*#T40D?K&:V**+(-C&&B7-M@;
(1:1G&:;+?_ HJHETJ@)AM40A;+?8?P@?I?6G13&97?E70(VZM=@ C@ MA^+W%TN^C_UFZ) RJ1C?NGFM6B@?1?1HG?Y\$.H(01P^<9HT2<_
MXCU@/R1/Y1YUM448AT2^_X@U_Y1+W%Q^2^A=(U;#^N3LIQD^2@_A1MP^YZ^5D^?QB^1+S#1=;06R,9PAQ^8IRZ3J2H1_DY;?ROACYL_U;
%*%>2,4Z-M+?%MW-"1ZD1_=[NWQ_Z^IYTB_P_]>(>F8H#_13K7Q10D,RI+NW^XU>Z4@ MC.\$C^/133INHA %UF7=6DM"ASU|A|?E6013^?QE?
Y=J#^_KS#G.4A010^ MB;2=4W/M0W2@GYIHGA_!_WQS6U12 QIH^_1^1WHH#1^#^L9%/32M1C#?
M3VIE)Q@RPP1?H^V**8&)_9>K(9DZ)DLW9_9XP<?<F5(=-U+>#_1@>7^CMAE;UZ^30K&+?#6_"/f84^FZU7^AIOIDZD0W_1/L\$1_)AX^GR?
SK9HH20S%M;2M6V83Q@#G %%%11110 4444 %%%11110 4444 %%%11110 4444 %%%11110 4444 %%%11 M110 4444 %%%10.M% ZT^>B@1^*
"BBB@ HHHH ***"BBB@ HHHH ***M**"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***
"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***
+FN(N611;QB25Q"?BGN2 0_E%_X)16Q146NNYDC6TRN6 MN43.VX&OE(I;Z9&>O17/GPIK;V3+=6.LUEJ7VQ:EXBLZ16RKDC^_1^?OT?
M=3-PE6F;J)1.9(15I08;=QF-<9Q_1/S#C.;OZ=J5OJ6G6M1^66.YC62.2 M+M;1&>0>^_1.PJ+6^BVV62\$-K#L1;1L9^;U M\$F;R\$15PNXYSO-
1O+^"4M<6943H4(VIADE7Z M16.T/23\$VDW@TN2XM9=%B^I9FA6XC.3.H1(4^&?; M-%&SN^A^*VOLH-
1A63=U^Y01O^*Y&^_O15C1^A<7;K<7^?00^(NW<87.1 M&N.CTY%=@Q1^PZ FD_-)B6_V<2@_?V10?3(>9B>#;..PT>UCOKM6TEIT
M\$N5+;215OEQ:OITH_Y^U?P<1^7WZ\$2?%;VKJ4+4HS4E@<1^M M^J;.<#\$/<133=#1^QZ=SWTY>F%)+8W3IC
AQ\H/X^F@5C5TM+1+^5U.6^6ZW/M/N>12J=OV^OMP#IYJY5+2.&73M.CMIKR>1D4L3/1N;)YQZ9P/85=H&%% M%%11110 4444 %%%
11110 4444 %%%11110 4444 %%%1110 444 M4 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 M 4444 %%%
1110 4444 %>BCO0 IZFE*>M)0 4444 %%%1110 4444 M %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 M 4444
%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%11 M110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
%%M%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 M %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
%%1110 M 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
1110 4444 %%%111 M0 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%M112 G)XXI-"BBB@ HHHH ***"BBB@
HHHH ***"BBB@ HHHH ***"MBBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@ HHHH ***"BBB@
HHHH ***"BBB@ HHHH ***"BBB@ HHH MH ***"BBB@ HHHH ***"BBE14 IZTE*>M)0 4444 %%%1110 4444 M %%%1110 4444
%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 M 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%11 M110 4444
%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%M%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 M
%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 M 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
%%1110 444 M4 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 M 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
%%1110 4444 %%%111 M110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%M%1110 4444 %%%1110 4444 %%%1110 4444
1111F@1324H^"BBB@ HHHH ***"BBB@ HHHH M****"BBB@ H14401RSZG>1X@NM-TJH6VM+\$ 75RBAW1P^6:AA@8^41 M^G6KEO-
J6G7TZZC=1S:9%;B07+1/%\$UF9H8Z0(60GRFE(7L6Y^H M19=:TYGLD^1 60@6M1O&9@1N)7UXY1\$UO39+X627L#7)5B;R<=0/4CTKSF
MPU1+15/45M;W61;DDN.H8@1^6JL&IV^HZEK7FC22W_K2+ M8K;D1VTC+(<\$1?>?L6@KQ7)O&SW^_7@D1/\$LLMJ5Y#1MH 4=1VJH0?
1^(M1EN MK64;9IY4R-1/G7KDH^;214.E^*U2.JECG6.TD=1@_1^"WL,UQ=C M9B/2?1P%1AFW2XA88E;W>G)H2^61H@>^ZV2&Z-
S8;M1X<1/F6\$31 ML XPP^X&>G2F1WUMK.G7C2K;WL\$K1*=5<\$H&02/0^M1:=XBTG5K@06%1 M<2>4LVV-
LG8>A_1^H1;YJ91.5_%%KKFEW^_=(101%<^?7TWQ1>V5_>1PZ91B7^AE M^G&TMKI;R^H+G^D.K9\$N1D1?7@1Z5RL12O1314N6@
M+&+0TB4^7G)QV(IQUP>G07.V:76FZ5X2U^1LH1#%#;W<=<\$K>K1 M1T^C&>2^T 46TNZM8TCEL?VHX+;E9807(Z^1^M>^18K?
Q/81M1A321/DN MBW&Y4^>V1@G^M7_A^*OGG04EA01)MY(P75W1;1^H1OH^Y.WM;3_3
MVD<141G1^5(D:3(SK^YE4JK\$YP=N>#TZ5_/#C3^\$1C@#0&>1EO_1NPQ_ M^&0@1N2N><<=&@#N5N8FN6MPV954.R^@.0/Y^1JKW^K66F1?
M4P5F1^HH1_0 M.1^C)C^1JS^2C2WVEIK5Q&T4^HQO5>4QR8UVC.O1SVZUE.Q_1/HZVU2YM9 MY=DL&MO.AB.GE1OW8(R
<#Z_A01TG1N=1BM1P7>361Q@0NK91S/R^O0_MD.C?Q1\$>FQ.BU1#1DED\$2R@Y4N3C^0YKD@1X9GTG5+3C0L6B^RFMH1V8%
MHYD1;H^1N OTXZ&L55_N871UQ9W1M+OQ1S11&3F;1A&A203^001 MWUMXDT1XMO=1U(F1TRH^6 YY QDC@C<6/\$5Y1^BWW1Q>
(%TFVA>591):MEPD6XJC#(Y?Y<1^N.5KQ1/Q-O:AH)5M_P"R8T\$HB8J6#LO&<8)QBL.Y@DN/M@_1.51=1A1^
_QNO%>BZ2PMK_4X4FC@<\$K1N#MX^8 MCMU%1E17^1=7;51.4EEF.4E19Q6Z&1;21313(H9^91M)M\$H2261-M YDSM)
(P#M1&LR2V)T^Q_P=92^--EN#^2T@=4@.WMO#6E7>1 M^3X+1Y)H L\$Z@=2/7M2VWB2KN16S@O8GG6L#49^8K1X
1#COBN=;_P#^M0^0%9%9M1L5G&D\$1PL8^5CCE1^8KA^#<1CX@LK3XY1=JE.662WN1H8EACW1TP1J13^3_>=HUC^S6EO(TSY0?S1Y_=
M:OJ.G+YJM8,\$EE>E3=@D_1@1^!>I_#M5#QO%+^*>7;33^FJPR2>5\$S14< MDXZ#W-94^?9=<16P.A1U1^1?63R8&=9(O)P<\$#&
<@1=00^K1LAVDD1AN R^0<\$5/>_E:6)07\$RHSYV+U9L=<1L7D9.F2V^Y;10^R+ M=P^1Y00_1J25^HR3Q;K D^&8-
2TS4(VB;1MT=>1&4H95^C/TR^TK?Q1NM M61W1H>11_4(8J1NCXX;PZ1A@UQUH1XN@ZA^EK<^?778KR.14^9(5D0LV
MW1W1V;9YH1U;C^15W.OVL1L1;UKN:1\$TKYD101&XX&R1L1^U6100# M^ABZN M;2WN1J96EW1J3=9WRQZ^7B.126XX^9@.?
6H=0W?;_<^C^Z@ MME15V&DG6R><1DH@;4R.01C^GDYH 1Z?Q3H1MNB.1HP%6B13T1VK5;B^6/1F1-8W9MH=+>U=E@8E)&\$8_
MXR.X/04D1Z02M0A226KB76U1N>^X(9&01+3^C^\$1 6K<7B+3)1+1^E1D1Q M^_C1J5&30V^11QU&?2N@1L+YK3Q1Y5A.1G7H1L0LFTZ;
_G111&1UOC^ M-11MKN03Q81RBVBTF>UWLCHTKOR^M^D.G&O1?F.Z&P16Z1J5U#6;MADDL
MZ1XU^L@C&C.XYQUQYK1U#41+3+1KJH5^1D1L24D^#120/QKS3K^#PS.MK&SHW\$1K=K1H06KAHSL<6&W(18C)XKK&0N6T2-
_Q^UC13^9 %WM\$@<\$R M^O1 \$5P11^@1^1#XET1>SN1H;R-815^<>9E#P^_1P15G315M-31W1+^* M1+91@1@1<9P0?O-
13319D15VNI66K0;WLEO*MOY(65TPH1Q@8W^1G.C1TK MK1H1M1UZ+107478>5>^1Y33C^19^1O X^% (OM8O-214^0)G6V;UB6XO; MHH^1Q(6-
0>-QP22@>QUS5F^W1;PU:\$1(NH1E82^BK)&P51^C1^#QUZ5E MW1A=>O&EYK15O)E^1 MCG%27/B/2_16TN+V..8NL>#G
90N1J1H^8K7G^H6NH0^&132K^6ZL14^M&T51D1^1H\$1^#MWR&^Y1TYOBFZY?<_U^FC7.\$W<_TL=G_+=14F1G0D0 MQC Y&AZT
=Y/XMT6VOGL1U^N\$D2)D(1YB0H2=13R1FB12:3>1VD=1\$T MTK.L81X=EZ@H2^Y1015H&6M7EQH1PW1K)#+^#C11^1ST(1^\$5551JX
MDVC2R:5?P81ZUG6D5L3^\$K+(H92HRV=RDG)1BA7_1QCX^66;_G Q>_R.M4)91G&UF^1G1^)%GB>T^Q/H827SHXA(SF191)
SC^8G.U1TO@1L>M&C@UKO_U@5911.T.L.X.9(810&+ 81^@O12M=CH1F4)YC M1\$4 EF7Y Y1^@JN1\$&F1R1^EW&M=L3J1ICSP.N91H
Q^96-W1L1R6F17V61@B);_MTC+(R@<1^#18PPIZ/2K^*M10M^NK659(6)^NO?1P21JG%X@TV;418QW&9 MB11CY&VLZ@EE#8VD@Y1P
A^M01^SHQ1H(1B781<1B1Y-Y(D^1L);1 MYV^VNI+6(1^ M#8.YSN^T M^R2V2TT241U224;1W61HY(81K^N^X^VFB1 M1RSPYC.PQN\$8\$-
T.26XSD1^>)76^7=+T2+419=+&3S9D1VETPHV^P(RS_..MH181U>LM8@TR1V17U:W1FU^EO1J%1=LG&>H4D8XSU^HJEKS1^7AUU\$F1H
M1Y52091U^1@1P21LD&D^)=OM^GNK1FEM56-F6X#X^1TH1OUQ1M1H1M1G:7WB31M.G;1J5M1^\$E7<A2P41R16%K^BO+OP_X@ETBZ:~
1TT2^L@CS MED16)P1C&6QSZ&L1V1T7.XYTFWU^V>1610A.W\$1T#.DDH=2.L1MSPQ1N.B+Q
M1G1V2X=KAO.AC2)B#^0(11@1=^P(1:6+Q^X1=+65=EE-%1L3 M+E\$15CCCYE. <=1T^2\$.DVB6XBA>65+ZWD7RUW.NV526^T7<+1W1XGT2PEF
MBN14M8)2(HD620 H6&1G1F1M.S10@)P.;KNW#D8ZYKCX121O&7B^6S)A> MRARS^P#L 1^1(PW
7X^M#PQ1X1TMOQ15@1^NLP(81#GVOCVQ01C.OXV1^M(WN1Z11)1#)1=^S;+1JOF^C@1W;Z8KK^6=.;OY8;1@FE@1U4D1^27%> MGXT
=M;1QHW=-P7<.DZK01M7&2O3(C M1>_C1VL^O^L1>S^"VB9MJD1V81E Y1ZY3P1ME>SZ.#HFIH-A\$(Y9+DR^ MEL0H1^).#V
SQZ5K^1=OJ1TV.TZU^US=>)G13751\$<V=PZ.N161K V MLZ;EM.W+7H1%P<OR-H60XSA3GD1X1^O_+DDM-*VY1IR_990UTEHSR(
MQ89B_@9N?F(Q@<8SD065NTGA+PE9W-1=M1FUMWG66U<14311);EOM&=VZ-3@1@R1DXS1W45#H@CN-81(M+^;OD;5/FPL1N1J^&G9F4
1O MFPY3@HL\$2515T^O172;H1 B31OM>Y46<1IAG27^EL0^TDXZ MUTUE+96\$5LK%A&4L>K^N31DV015U.22X2;SH.Q:79UY+OS(C L1MYH-
T.M.2 XQ@11^;_K%SK.F64PANM0M8)?E^2655/S9^13WP<>N^1CO1S>)FT)9 M01A(CV.0^31TXZ^ S@1J11;W(G:Q1^L4UK^;_0H(68WD1&)
(@+R_1K MGV11;2X198GE1^ 141Y12);YFW1M^U^W2>^1B2XB 5W9&8*51X1Z5S1A0V&H1M1E);ZAXATE-H ^D+H1VD&3W2&
(C1YZ50.HV5QV1E14V1C6X+U1MM1JL^1M(L@G1>1L^1DY1Z41/8GECAA.DC1B^LS^121J61LZ=);1Y^#1(55WR< M?<M?
^N@GV1ZH>+B_X1431M=PM O1T^E@7411Q5>1<5.SV5F1F1R1U.WM^C11^;V11641N\$21S1S1=CGM2111+1+6_U5HK11@GD101+1^1O1Z-
CT..#W M121U.OTY51O>Y5CA3^J1C19-0^X1F?5Y(HK66Q1.6;"OJP=C(NX1CE#CT^M0116>8%=MT1+NVGA:6YD2.W=CN3YF +<=0
Q1.UW=V1Y&6)%N(1MW1 M^ID^C M1^U>=W1D8^_102)\$MQRV11RD F14=@_X1 UZPO04+1110 4444 %%%1110 4444 %%%1110 4444 %%%
1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
MDV1HHH1#>5Y1R=00 B#-K89EM)KE-NE^53)SC1N1_O#3_+81^7Q_1P^Y< MR64%ME+^#4111V1=14^B@ GWB#E1;
10H111M^H^YK60^4VCR71_LXM;M6OE;Y7DVF3<0^Y;X1&>Y^163XC1GQ1_8JU\$D^1^=1.TAQ+C.Y0.81&1> ME &180CDBD8^9 H1KV-
S+3@4X^XK&UW1=-U)21U.N1_9 M3>5^D16&=V.Y^_<^H1^E^*1&01B011MEMX9T+3+EK@Q1A1BPL+GF3L M79E1CZE0H12^OQ00#A-
6T^"6^RN+&Y1H1M1+1M1^W=R@=1/17&+HMO1OC.4Z08M.2VY7^J.V1HLC9MR0@11B1/7K6^-?B+>6 M(21A=QORRYOT2^@1&^19B
H2D1H1O(C1BNA5E895AR^1L_Q1)^0^&M3D MO(311RM^1P70^<@W&Q^Q1F1L#21TO^1_1\$ SH%:78L2H184^3C#M#D1E^6X1
15C.YX=37^M3)27EM^6WQV1TNP3^<95^1Q4N@N^1LZ;B6V^MSR11)#(F1<R.02^0@XR1UJD1U^1N1H27:6L1K;71M1?F^2.PV1MO&_1MW?
KB@#H\$4H1&_E^0#U>P^P7UV1N1^1M=+M(IG&1W#2N5\$#SKN1V11)(ZX&M135)&S^MWT>@HP12N1QQ>11> MWTFG0M<6.F1V?<M?
&DQV1=RKN0D>K+P?>K2^1&0> M.0/FR^YQC^15X11M&@KEF13ZG+11&11.51^1@51TCZS=3Z116EQVX MDM>^*5Y1V>86^1J19&A>M
108112@#TKB(1^U<1^21C1>GWT4^SV>4VG_@0H ZD8G=BD1U+(?F10^1#3PB986D42N^RH3R011\$?G1 MG61ZK-ING^+1W3;2UL1NWQ\$22>^1
13Y5>3G R X1>17136_7QMX^CB11X1/MN<22 11S^R0.3VXR1J^_YP2D.U51_11C1P1H1VLZ4TURD:7\$4TD\$@C1VY1 MBN1N6GG&P1K14_6?
M=K=7.E.C1K&(#G1C-FZ1B1C^1_@H192DD892^M4C@16N^P_1^0214+FYM=5U^VGN7>26WBG^ONW54D1J^H2N1N=1)M16GZ+X-
MM72U.POK(1C=Y1L16=GH1G1C^O5B18ZU15L1C1^ER3P37110^Y1PL D1^M1^<L1\$C1S141.W@MH1V2)H1@1G1?1VJ1D^FW
+P3C156U_O/K&FOW1O^HM1J^)(#&7W0MMS(S_1R71A M=SWH1K1^*XW4?%>_1^+S3P1TCB6)12ZC(CN0<P1)@1AR1KTVYU_6 MKVXU:3

P:PNB2\$OY\$XPI8L20IU,'MSUHN:V>I24N_U5:FYEBTN6YBB\$D MRQ%UC+A0S8SC/0?6N/TSQ1J=JFT5A-J)...G3#=-1R1PM@3
 CE54E<2)84#2"=-6'BCQ'EAHNNZC)82Z3?^7%)%QL(G?A3DGG MYN"/_KFKNF>)=U6YLKZULTDTN6=HYUP@H067<"SD@A2'D56!'9Y&?
 2N4T 6M6UOL:KRENNG+>203VYW#6A*%PP!<M_X&X&_A1B-N+WQ39VOM:XA@C1H98XLLP;D:B3R<@X1*_-EUW28+CR);M^VCGE)'4D
)Z5HC&|SCNH_<6AZRD5GYD<'9O;\$MS*_ML<18;F3X'6N213^>=:J9.A=,2S(AMA;HJF>3)8\$*P#&P/)ZTEF<=I'M19>#
 IQHBI>WNB\$SG:61Y/F5V^ZOID8/X4_<T=<@"YQ6'JFMS6VNZ?HJJB>?>D(995)540=...I.M)C_<VJLVZK%>Z1FRMMBEI>2RY;+
 <L:Q1G);#N:5X19/7%_2D*TL"N)U_M/OA|&EP^<(H9+6'2ZTJ&...P"t_&.>RDN8S_M"C'HHKJN'2<_/FH0JFW>N:382>7>;A:P-SQ+*%Z)?
 \$\$\$B81I_>9X M12KEIXBU9=8T2&%'FIKJT#2(L*_'B(16Y8DAAR>P14=C@>E'f5QNA^);^MIU-
 OWAM+Y7E.MG)REXQG:T3Y(ZC9/H@L:A(A7):6FCB^>%'S-SC MFT.T7GQ1U-Q-1VDM'D4:EG81I_ZFFVEQ;7UG#=(6K))!>@-UZ;I&017.
 M1W&MS6UO<3364EE3GHU@&K_6:#0/"#QR.PXYH_(*KG<0.CO663,4V13L7'"UZFL# M1I=D-0X1CL8A;6&HQ28MW/FLJ*A9?
 G^@%...O:FEKKF.R%7M156TADE0 QOL(MR<*OL S;1SDX-;TWRU+;MHSZXKS?Q6JMEH?B'4%)KC2KF)\$>>H9(WQ MC(&-
 R>GMQ61<7WB.TBMH|ZL(6N)H@<5G=(4+J)B\$?V1R>@&_P'>^MH&_4V1O>7H*YA8ZZ^EZ2P2U>U3ZP^FR&6)EWJ-V&
 SX1YZ1ZAU5O*KW_M C7B^SN9X(KW3=(JA+BT4)K(XSCYB2&QO^%_IH49SBD|M_VX*.G07\$GJ
 MVB7&@&ZO(KC3KEO(NI3%M9'93Y9SG&TGC\O6M_1FYO(Y|B5E,#S-JG^K@<6_M_1DYYS0!H%01@CCTHBB0'(09Z=*XVZUOQ!>7>H-
 HJNKB RN_LZP.q0+@*6W-MN^7IV1CTYSG%UKO+J.AZO#1<L;381H3RK)C1W_"R".N3U_<N7 f(\$f M@8-(T...H;J*KK5)-9C15>&
 f0ZC&EAF>;9;DOLZJ.DC>#CYCP3W-)*XD M07R1W^FZRL1#8>;224_F<9"A
 M01QC00|NVEW;WUNMO:3QSPMD+J&P93@X(IZFKRCPYKUSX?>^V@2% EG/G64@U0P0:E(DQ3R@Y61 M0HSN)SM.P?
 +QI\$4_48X=WNGNM/FCGDN6A*1LF\$5:6'W#*XR#^5=> M6"C*).5/(OS18_@+M XJ^R+WP|97EQ8RBWMT6VG,S+Y^G^C+CV^<#^%<^M1V-
 8USKK0>*K#1A;|ENH99?_W?>V8XQC0GUH_ELP4XM;09)KM^TUEC^S0("M^T3_8;YAUXXFF^MZ+J&I:A9W-KJ-V16VXB-K<2_L1C=R1T&?
 SK<9@HR2_*M.P|FV@#G1#UW>;7#J>HBZO+>7-03GVKH=Z1H^XQP<2@<6M%T36=-,M#K
 M00/9PH08H|>R>^>2_235Z1VB|27&KFX1>=;K(=PH4DYSU|U4MM M\$R;=VW#)_U*N;N;35KZWMKV7S;
 MFS4H8W)&&P2NY<JR^*Z8.IQ|PYZ5#9QGT5@U5|;W^KFA_MV6H%#A;ZC|P1;|D<^<O>@#*G|VLIE>VOVJ8)=Z@<1DR%.)_5.TK%
 MYX1M=1U_<N|Q\$+>#V8M)P?<51SD\$#1>|&S-E=7|P^V:QO%'<_N\$5@5/*|S|P_2_23C-2;/X8;1Q|'FJWTE;M+M@MIE3;@1#<#%#<@<#)-
 AGB\$8D.B1'>|BPOCZT|>N.H<#FYJ^EK-H=IHS WMX&Z)(CW)^Y)|>NU2HP_#3|?M5DZC9)6-W|M@_P1;M3&(<P>#>|Q1-
 U.SU>QCO<8302#%'L|CP>11#01#^A6.MI^M^f02<@_MX/U;A;IZQ9;1#>?>M3K3)!'>0'fH|ZUFVYWBS>>K13@<6M09Q7*SB3);>6'8#C|_<
 +NCZ_H MZW^0S2.D|S3;QOA'QORON|TS55;7PU^VLW.IPWEEU;R7!9XXRNROA2JL00>0#
 M1;1D&M6XO+>TMS<7\$144(QF21P|H.3Q4DfN_>?IZ9)?L\$=B(SYJN26W@D<8!SS6V5*B|F('4F@'EJV6 MC5)-N=;AC2XB;V4 D*PP<9|X-
 981^JVDQZ7J-Y+H@C9'54N@XVD@ X?_M%=)S\$P^XNSO3N|T3D9B;G+>A<8ZT18YN|V=SJ^H07E190=(\$NH|
 M...LX^S#MOOD8/O3;WP)IM_)J^F7%ZD-|@RP1SXC#A0H<#<41P>L;^IDU+?7V|MJ^VBUBD^ELV;AD\$@<1#H<
 M<=-M.FO:TEBV44Q7>||=O&X&YVVC/M6;)K>L0WL&ER6M|+VX.K02AR8VC1_M5.6'!);&/_<HAB_LXV1W&(Q>426Y|QCKZUD-
 H50H80YIKF|FL|5XH7F MPSJHY;T#>.%X#WSJ6\$S;6)+P+>@8E2)LKGU>><'KS5IG0\$ D<1>1^<M^<#J
 C(A/1>BY+6|RK|2%1^>=HYXSP^TJY^X(FT^ DGCEUN@EF\$|V@E_"M;L1HENX+O\$EG^T^<_<DR<L<67GZU>_L^7NHW:SSB
 M6_14DY7^A1@>N>M4_\$VORZ^>F^2(F^TW|M+O+W\$=L%NOX?B^N>(|4F MT;P|>ZE!\$DLEM\$9-CD@\$\$KDCGIF@/L"/66GPs:="<
 |W#V=J|O^F3#X0@KD@>#PC\$+V M^Y:23QS^26WH5|7TZ-F@|GV:#PG#?WD4.HWQO|QSH(X8Q(ZNV1D_2+P|A5S MPH46E:56!
 (99Y&GE5_<9CD@>PZ58U234\$MT?3)(8Y3)>#99GV86&XC<#>#) MOJ5=WJN 2_?3-<1KWARTUXVLLD T^U_9+>Y@>?9/VV<1D&FS>&+..QMX
 M6DG|ZWE|<_ZW_O2|LJ3T)0@C^M6Y6#_XF@<1V^<N<G^<XG^<10)9)03CS|SY23&2H M+>=>@_5\$IX1M;I3|ZVTFGV^*_2;D\$;W8VCI@<CL^O^1\$;68-
 4:XF;15N;_M'R|64D\$DC^7(|XQTK2>1(T+P^@9))P131/\$8_WKL_O9X_@#|A|6D/AN_MT(7=VUM>>;YC.R:QYA);VXYR>H-
 30^<HH=6LM1\$YU|F7D2-SL?7M1Q0|<3>;6\$;#7(FN;EEUD8GRP^3Y= MOR|<8^2I4O_ CAH&G MB5"S.H4=23P*_*Q1+);7JG<27|S16?&A)K
 MMK;1FZGM9+X2XBAF0N5ESZ@CH3VK4DGCBB;LCJL8&2S\$?6G;O^L>E^&)_M^X;BCN-3F%Y=%M0@6^0.RD(4J^O&<1GDD|H0>"
 (131HEU&JB^R6GV|E67_M;L771..#G^X#=#=>G965E|>7.5%#%;1@EY&@8JT^...3A|<Q6^E...0:C= MQ2:=*7MYU*
 HU4;G3H!>>O>MO5=-.FU^Q2^JEM94=765^&Y41^#U|BM^B@_M^FO^\$2BN;48=0G\$UQ?E3+/%Y6-H^7;G!KS3H^%NMJ=75W=W5Z|W:79)
 QO.RX9_D_P@8XXXP|QYKHZ*_9TGP>FE0^_ZG27;4_1VR3;A|@<(X^7).#C) MSQ4L/A2^#3M^LHKF98|D5XCA27P^_<OH31TQKH;#
 G.FUAO+62VN(UBDD7P^M;AAZ5@P^>H2P_L@T^UJCLL1+X20JAZJ&(SCZYK1^...?PA#9;Z?M>7%E_9(VV1+AJ5VD-
 N^%1MX^LFAE7|9>^510&HK^&7_1>XL13MWU&|U&=>XE9BA^NA4@CY>^Z^TK3U^PZFHSV%SINN<@_IL@ MPCFAV9.X-
 D;1/2MNB@#Df1#6#K6^26_M;K1ZM&L3J^f)<C?_M7C^2-0W)+J_P^|_#J179Q1)!^L4:A401551@_#M3L#.<4M^3>\$(#JUUPV
 MVH7U|HK;Y@<D-CE&(<D\$>@<D\$>J|A>WU;@MKV62;UN8EA2(A0<_Z\$#_M_UM;J=;M;74J+3)Y#++IZA=AB6G)PV-P4GJ
 >:ZFB@#F92?T;UCKMHU|>7K^L|O>?NR M5VD+OZ=>0>Z>U+>4;5KJWNA;LSN%1A<G3<^"N>O(Q

[illegible]

ZK1M4?7IP[C].BHKGO^M\$HD Z>[?]^-1 C0?S\?+H.L 8-&?YYH"YT-?<1 PD=[W\A^ P) M'>G^AW4MQ^IEIC/N>U '0T5S@U_6"-?#-
U^@_RTOIOZOW.W?X2]._BHKF_MH_10?9AF3'-RO^%&MZ?^99D \5H Z?BN<L>[V(R)&#T:Z6@<MXX)Q_M_P(VH \?TH Z.BN=:4?
%#%#=F@1C^Z4Z R^*+I03NYT6UQ_UB@#H:~P/O^/M\$^UJLPWO<9H^VCQ5 SX:= W^@:#?HK%SOBBK OZ:8# P1=G \B::LXKR MC1<=SF7
H W**R?7Q)GYSI0'L)*#XB+\$FYTT#L!"Y_P#9J->BLM8=>YW M76GCZ6IG PIGH^RZXS9.HV:#1:1C_-Z-2BLU;360>=4M2/^O_ %TK6>K;
M1_Q-(5 ZL3K^&@#1HK%?EJ?255 P#9?I&E:ROV7 U1EIQ_N: +1%9 \M9UIG\KW_?]/ XF1L-SMP=3N<^H2,^?RT 7**SU7J8#G5KICZGR-
XBH MA@Q P3&U^?1 Q_ %RBJ1TO+IC?7O7IYN!_ *1%L?7_EXN3IS4T 6:#JMI ML+2;VEN2<8P+AP/RHXL80@H2BG8 Z"B@:M%.HH; M13J*
T4Z4B@ HHHH;1110 4444 %%% %%% %!1110 %FBBB@ SR**** M'DS110 HYHHHH **** "FN^P9QFBB@1G6<9V_K2/<;
(6DVYV@G&:*8&>FMI ML_Z/C^W_P#6J1=5W8< P#C P#1:BB@9FR^+!D=16=K%<^UO^%_BI/_ M "X_~1?
+&BBB(IS^_7BN+&GJ1^@6VVQ@#=#B6)5 M_P#A9.I8^AVN?1 @7^%#% 7_A9&HD?1>=MG^7YQ1:C P^M^BZO_+13 OA_MQ1:**OKA_P
+&U)V>TQ_NM_C4G_<R@SBU MUC/^3P+>_NTIU_B" ^XVB#A_T44P)>^SDUP_C1@ _7_O1_Q_C4J^P M^"O_&O5L= MV=B?YF44
!1:# T#T_IZ_&GQ^\$M"C4@:=>0?>FR3^HHHH 4^\$M"/738?U_MQ18">A1MN7382>GS#=_ _BB@^"3_A&M% ZIEK_P1^A2KX;T96##3+7(-Z9"BB
M@^"OZ%11_YAUL_P1^5_P1H/TG_H&VG_?E?1 "BB@:_^RI/(YLK?_+1+ A2? MV3IW_/C;?1^E_P_*)5L5%":Q^HZ_(*71+;_P#/"^IY% %%% #E@A0\$
M+\$BY1^Q2^3'_ _U_ *BB@ \$4:G(C4V^+L0_PCJ^**RX_IB_E2X'H*** #M !1!>E% %!>E+110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444
% %%% %M 1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444
exhibit101-terminationof007.jpg begin 644 exhibit101-terminationof007.jpg_M_IC_X 02D9)1@+ @+0+ #_VP!# @&!@<@!0@'!P<^!0@*#10-#L+
M#ID2\$P14'1H?AT:'!P@)"XG("L(OP<*#7I#A(6&AXB)B1^3E)66EYB9F?C1^6FIZBJHK^SM+6VM|BYN1+!#0.7&M|Q)CRM+3U_
76UQ3QV\BX^40EY?HZ>KQ^O^TI?W^/GZ_10^P\$P1^0\$!M 0\$1^0\$! P0%1!@<(^OH+^10 M1\$ @S^! 0\$!<10^0^0)W^\$!M
Q\$12\$Q^A!3E>A=1.B.H\$<3^B.H\$<1^2.S4O 58G+1^A8D_>E1^&8!HF MR@<1^C4V_S@Y.D^149'2\$E4^14U55E=8651C9&5F9VALG-
T=79W>'EZ@H.\$ MA8:'B(F^DL4E9:7F)F.HJ.DL:GJ^FJLK.TM.:WN+^FZPL/\$Q<:'R.G^TM/4 MU=:7V-G.XN/DV>;GZ.GJ@/T1?W^/GZ_IH #_! (1 O\$
/P#W^BFYHSO MZBFT9H =13U)2GH: =*6D^2EH;1110 4444 %%% M%% %!1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444
M4 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444
% %%% %M 1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444
% %%% %!1110 444 M4 %%% %%% %1110 4444 %%% %%% %1110 4HZ&DI1T_ .E+2#12T-HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4 M444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %111 M10
4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110
4444 M%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4 M444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444
YBBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
^BJ>GZMIVK1MDIU_.WB(C<M<U.O.L@4^<#O4IQ<06EO)<7.T<,,EGDD8^J@=22>@H EHJO971GJ5N+BO NH M+J D@202!UR.O(XJQO 4444
% %%% %1110 4452U25<^C^TJXU&Z\$A@MT+OY: MJC@>U^VYBJ6DZIK.EV^HYH2R)UW)O7!QJ BKM 1110 4444 %%% %%% 4VU6Q354 MTQJH;YX_-2
M\$S+SRIZ<^V+^E4?17L_I9_LK\$31H3;A^IDC.<8IK&KU M 1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 M%% %%%
1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 M%% %%%
H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
S;O71+L+R.TNKR M>?3D^ZGH/OJ236<C1O=>0CS\$1Q/F\$+>^MT F?7*RI+Q^1.HR11VE1#* MTPB_<
[X4CUJ^IS#<^1P/(RRYV(3RV.N!01+15+4-6L=>6-KZYC@G\$;4WG MQQQ_1IV BK1KD(8KQ2^EA6*L 9.D;AH L5G;^B2>'M223=L.UF#;>N-
ASBM&H+^V^" M?4?"IS=*U&!&93:~L%T^J<>:CL_9^@8GZCZUU^Q&1^T MJOT^T)1_5+M(6^AC!W.O10.#CO7)Z5:7!^\$,%_!2M6FSF1@R<#Y?O#
(JBW-MM_NTM+JWUIQ3#~9%1^JUCHUL^LL=K9HE.XW.O_P_M.F*~*Y6Z7^&1XKBWR26+(KKY.Y9MQ "@>N3BN^G^(&K6>A)Y)YSO!<12>=
\$T4Z:86\$FJWF\$FVB M@D 5U&^6WSZ5K)A>>P_V/(H_N_>1QOD>Q19I^GAV_P1+2^NK;6+&
MXNEMVD>=1RQ^CAG1^_SSSO!U+O?1+>+K0!TU+R1MX5DE>=7RXHR<1\$X) MPDZ>OM4GA_Q7^WNLRZ+KFE#3=12/SHPLHD29<\$J?J?
1X-0L-4US71^&PFC MTRTMY%2;YBC4SW# XY!PN#@^KP>?2GI^E&U^>GF/27=[FF\$+/4:Q<8' M&W@\$1LY/7L 2W7C?5+W7+O3/#_A_V@+_
+N+F6811JX)RHXVZ\$91>U1W7B.7 MQ#X0!OZ=>6.FGZM;6M: _JNG2/KMK! 5N;>S9H@1J ?E.%W=R/R%_&=015+X4L M5T71K1(6=O\$J
WERO1_~5^CY1G_<E6V1^TL @JYUNWM+NV&K4^E0C C<M^?3!SGTQ1^L^&#>^M.(C@1T44 M>G6@#O81^>Z1+J^LB<2VHFB7DJ6^9-1
<9KEH&1_J P@5EK_YD4UI^V=>0K2U1V=W1(4MHK!^L_P1?^<#.AXO1^Y\$01.TWX: MV6^K0QBZLGE.1^*@LS<-CJ_F1^<
&D=1V;4NM1L1.O+3@1)J_KNNWD5U8:71^Q_<X%E>=&VPH:DLR@9JL^"Z8K.NM^1;FNJ^&MUNY"PR9\$K^<F>GE@9X&3J>E6=2M(KK4-
NKZXDM5F@6+;3O\$ZRSYPK_Y7.<M^VH_K?VEXD1_7MN=>N8-0TRY29IS#Y;6SGID#JH&=>W7WL.EINN_1216-2;
MQ1Sf.Z6Q=6VB;_#)J#6PS=..16CK&Z79006DLVJWS7H1+<7KRN?1KYVY^Y MZ_3KQ6G?0@+^M^G+E0D.POU!_1U1_ZT 9S:=K#>~9:Sf5:OR&
^A68>2).MX(1C6C/M^MHU1<,>_C3 M<-K-V:IF)TRUR77^<DXPR>1U1^W>7<<B M60B=EIEA<@GCIC^1_JFT+H.K.PVG:G#&MY\$
T#2':SJ1Y&^!X&@#3T^ M34Q?W<-J/ &WV1>1E3 "PZIAZ1"#6G7)+*Z^9J73|WJ51<=N=^7:3RIM M^H8DCIG@>G=;0 4444 %%% %%% %1110
4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110
4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110
HHHH **** "BBB@ HHHH 10K4C^OB/5K^IT^2_P#M^URR M220CS)<(&^O?W?E1^IS6W_Y^EQ^1QJIT^FM^TX1#_P&XQ13C)P^F6TC6HYI
MGHJT^VURY=H|BWWF+(-_P@COD_-GK4Z^X13PHVAZ?(D^SM^LDJH|^E>-&>TC;E1E&V;3CT."1^>KE?^\$KQ#7HM?2_C1 MD70B^HC_#-
^IME:KE@?HE=E16AWEF^\$C^CUI31^>0ET@N@#_W/8>16 M1HRCPT=(+A01^N7(X.5VYQ0(NB.&=HHH!&8(=C^OQT^X^N71^01W^AJX2>_
M7_U_1#1+QD7#L1/QOBM0+NM^TWTZ>1^TUN@C24KM)4=CGIT1A_19^T MY6T^PRIQ+^NV1<81RY71)H&ON.YC3_ YXD7J21-
IK&E;NX<?>Y(8@ M#^HXX%=>1%G C-86^Q7-S1H^S22RXC^AFBDG_1ISP_1^@#E2\$NYGMH>16D>Z1BU^*1 #@NDF59Q1S6WKQ1@K1M
M1XIC;71H_F6UR^W&^19RN<,"&JZZ1=7NM6FI:K>+1J1%Q\$FV-9";SSD MG<^1T"N8=M6L9:3RUVCG1.%170=.COR//MNW>81R";\$8
1A1P1#X>M1(M9Y)E+9!D+1^M4^M\$!P=0C^>Z^>E+P_1)3HG&=3MAG^1^YTG1(+D^GX3LK;2=0TR9Y+T
MVOY1^1D_>M\$D@>S^AYJ&P#="Q64YK.EBC0U4\$ZM9_1^7G1:8OBW06&3JELH_P1H?SH3N1!8^\$2RTFYTMKJ1N+ M2?)VS29;DDY5@
0Y1!10SZK;^&Z;GQFD/BO01UU6V_1H@+1^ANQUF^WCF_T+VQW036^AC>XQ MP1H5#>#>:WO(HJYO+V.EA.Z190)\$< 948&#P/UL_ FAW
/1LV81Z9E M_J3_(2KP1.3KFG#MS=(ZT 5=0^V% J\$M1MS2V<1P.E-G_O2^Q=H(C_11#Z@_P^% \$_1^<#+=+U_<8W5M=N^#S6D1LX&1L=>@^K@8J
MUI_AO3M.TB33(C1W:WE#~7S^1L^L>Y_D'BK0\$S%+8^U+XIS>)M\$5=QU M2TQ12K_C2N@+MC8V^G64=1J4AC1^J6+\$^M"(S_1UF1ZF9?&
&HXET1@NJV91&01.O31Z+@9UAX\$T+3 MI@2OP32A+OOW\$S21\$Q.255B0#J1:UET73DTLZ;+5#9_1A8;E/(7K5=_%_@_MH_?16LSDX^64-
^M&VN8;RW2>WD\$D3C^LAI@<+J&@:3H7C307M=/C\$-11T4
MRDLPW1=R.%P.88>P/TKNKBU@NX&@N(DEB889^4\$1#6%)DTRX>XLK""9P0TB(C_11P?P?3WNEY6 MHA/MEM^LSM+KDKD8.^MT4
5YK"UN?+1^".00 =+1J#BFW>FV5^NV1M(A<8Q_M+&Z^U:HH AMK2WLXA%;0OPQ<^&OH_ (5-110 4444 %%% %%% %1110 4444 %%% %%% %1110
4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110
4 M444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110 4444 %%% %%% %1110
HHHH 3:" M>E,,9.2BD^N^DHH C1F^<XOY4>1%_SS3JDDH^PP0Q@>@A/R:G%0>+10 P MQ1L#N131131:VZMN6"-ZA1FJ*^&\$_NC1J78O1T?
E0^#T+01^Y\$0:=Y.Y MI<41RXSU1?R1V11D10% A@AB71&@<BBES^*65K^K^G74MH)P K8P.G3-
&M2;AG>~7M7GE1HMO\$4E="2XT^6_A6&^M9L:L M'51/9>Z^P0Y8H=P8^&2.G@_M#KP#R/K7V+1/3>Q^K^1%65)8B@K512>
M+&TBF1M1^TYR.HZU<+OBM1L&P9RS.1@#C12S_10>=^TTS6--TFRABN;Z1D;
M:51N/NQ(!1^<#651@CB^+FM;NR:2RB1@DXW)A=V7D#UZ@<^WH/C2ZN18 M71M=T672-1D00^K2B1)0.Y^L_>=
<#U1#5/B1L B" T_2+1V1O1=HUBC@P_MWFEES\$ J(8/6M_4DT01=^N180H2!L_5CB1E:Y1Y19J1V15=1RG +G/M819_ M@131#CG-
0_#98XCXB\$C+1M_J2_'IP' (!&1Z9W?K0!L^%_%)B^Z.BEM)M/O M1L;FUN:&3CJ.A^<^!TZ=^QY?B//_M3_M_%(H-5/1?73B9R%*MY1
_B/3WSO6QX^1 PA6DFS8B-JF0G3?CY MQOW93S VV8V5WX_N%#M%)#>:PO+&?>A0993SC(P>19VD?\$.TUR_L+731 M+O1Q<
>2.B@QVAQVNW3.1V1WXKGK&W1R+XDBWR13F5%0\$D^MC1AC1/ P15 M=1HD31_18DTMN1?K0 EU0FEN9TT30-0UBWMSB:Y MMP
F1D\$1G1Q16%1-FBN_7B041+?<1\$S_Z^P*GYW=L8/0CZ5UG@<K_<^+1R MX-B1AW5_P"
(W^S6/X&EL\$XO1610HDA)Q190EP1@_+C1:Q(O\$UW1GBN?2=^DA M^QR13:7B1L7>1GRG)-O^>K1_.OHKG1V^U?^V+NRL1;~.ORP^8#P1.RG=
MST 7-91LZ1XG01^1H+VYMPND^PW&XMV^1VY_4KL#L^XO5^@Y1^R22L5=4U;PH1JWL ML5S:QE1>QQ1X^G&1>QR@GCTH
Z1BN130Q1G1^>M^T129K6N1VTLXEGA=MR_@4C&^7@AA61HTF1O-3FLY6G4K);(R^5P.H+00VX=22@3HHHH **** M "@1J#/#
(O\$^OZ316;J^>+^1DTR+4^D1LOE(XWSMR D \$\$^VSZU1J31ZF MGZ5=7SJ62WA:5@O4A027R3T^LO2+^T^&\$1 M(Q#%;/%)JY(X#
#V^/KS^=8%AJ^S8^<O&U_9RA)A1\$H5AGY07^D@<N^31301 MW\$WCGPW>OH16L0B_0N MP^X&Q1=2SJH1O1V1(VEHVGYC+_
^TD@C7+51+NN<1#VYXOTK@ENKE(A^M^H)1HUH^GC1_<0<1/O^\$H?8;19;@G^>4WGN^SU/M MUK&14/<^<^\$1\$B_TSGH:00&Z:U#JAD;153ER
0>_1_P1Q393KXALX8X?1^E MK>VH1!>=2%E)P_<1/7 SB@#L=<12Z1X.ABEU16W65BL8VLO8XSP%1A MD>M1^TQ5H_B+SHMUYCQ
>9&R.C+GV8#/U<=<X@>@U6W^<VG7R65KJ EM^6W@ MF?^P^G+2-M%1+14U^=S.P#+\$FYR.XSZ<115K1/\$^E^<=>^TZ^<
110=C397E6UD1N1S&54G_9)X^/1/60A_Q:E0H.O7:Z/< MM1_LVHQQ16\$2%E&_Z\$1E/KR>F1#1_Z91^E>1^TTLAK_@810=X(SN) M1D1:~BD/
KE=#U^4%\$K1H;XUA8VP.XO&^Y136U=>(MK+25MXM3F^3L^184C9U06NQ (091MCOZ4_#91ZUH8JTXRG168C.(PCV:L44
%9WT@Z710%HAA^R\$S N#N O^Y1ZUHT4 91>@Z9?F^CM M64C^1X\$1XYR<=>1FK-186MB9C.P1Q0>0RR.%QQ<@ L?2^59HH
CG>2.GBB M.CCH@(&:SCJ&I=M@DRM6BBDP.H7NJ_P6DMTSQ.G^+_.H ?HUR M3C/R2Q=73EQ61H0D^E.J.HN^%T6=6C/^FB^1V2&1^X

[illegible]

```

#0=#Y:;C$+J,"8I&"+9)D&TX)ZAB:SV;L1KJ=,43W8VM;Wf1Sj"(A@JCV MW*OZU=U2:0^,2%4$,^S98EB OW,F1B2,="#R?
0F@#1L$6L1Z,HFGZ=;$&DB M=GEDP4P&D 4-GC 3)IO?@P:IXHUBIT<%f,W4QL8YRT8E1S1Y88 YX R)%/N:S M64MW;-
H6K);0/4#6WV>1TEVfCYLlC;HSSCD&NCBBUCSPKK5+2*10%# M"O)@:102 3QZKP/7KS031TRXUC4B/Z78:8A<6>FOOMC,%5>%&T!@<'<2?
T MXKN L&f1P8106;WS'9W=;'JSEF1@.#'H1<HJ3ZGJ=F5:;#H1"JF M&6/L Q-5<1XIGLJ-04-OAG<6BVJ3Y>9B13/T239&-W)>ISBFY-
Z"L>JW-M%W;VD+37,1<.,#+/(P4#ZDU*CK(BNC!E89!R"XD0:7J/C?4/M,<-Q'-9-N MX$Bf@1OEYQW^OO6IX#*6BB@#-U-5DT/
M0f046C:4PIE(EEZR,%6>Y8@?C5;0 $5MJGA:TUN>2*WCEB*REGPL=;&DQT-M(KE==U:/SOCW3_#=#C2R6OJGLIW%OB#X M:U:Wf+))<1
1PQ#@A<8UOQ6Uf4>O3:18PR&6ZA601&;87&fRQ;U/H/6 MN/O;MlX$B#0S LHN$C>;Y$S>5VC?>0?3M6:H^H65_10-"FMI8K@'P
M5,B+O(fV%QV=)CAH;M3MXf;F9S^N^TAV4f;WZ9H ICA MN(U)BE23;<$HP.#Z<4f;18f;1<5Y5fJDMCQ2@B P74>F6S;8/E>OY9P M
>H5ASUX%:"0:>?%O@^XT:8HS8RW%TZ ?9FC&WS">N7.02C&Z6.ROH8f$D_@>5R%ODC(T.# $UH:E;VE-/ZIUHW_$SOM;
MB26>1R/LEFfEYfC@.2=H/KCL#0?Z7N f&ZEEBM9'MXA_ fDI&7fVfCV&><5Y> MY.O^C-FF^MTMC;METXW+;fLA:ST<f@2.MUX'-7M>10-
U33M7U#X&X MFZ5;fT4K(O&C)3;fG)P&3G6Uf'POK6 "1">753.FV.X;f)?=M(8fJ)M<#?2LZ;OYf<#>f10>?V>MOJE^WK$&A,NX)MX;
fQQNQMR#S1XfV60PZT=B"J M+19+(03D@8SCBN+AL+WPfHMG?;920:MX5OKfQ87$7fQ/D4f8f<#$D>31G
MF@#TNSU=;S5f0Tf6E5&;RfSRfXCEW+N^0H=ZTOH fH$ f2UYfHVf;C#K7A,3-K-2Z% MJfEWX=;fHK*W;WKRZO<0fVS(
K5M"$5RfWfQW(f>NBFfCfM&UfVfH04$NfO M-fNc;Af<#RfHP_fY"D93D6fYXODfX_XJ"-fM99Yf(fB)YHf>9&K@Lf>f1U%
M>23<fOB%+Xf.OfL6CVfF.RQ;)@2Q4f_#@$?0V>GfXJGfLWYKfZUHD.KK;f MUL0fJBZ_Z5%W0_-f;fT&6.Rf700fZf=>f(=1U#4f4f_-S:XTXf1?)
<$XG9@_M6900?E 7/f>*>U_$.f/H6A7&f"TDN?<7.HfP;f%#XENK?8TL^NMNC MYRfHP+>fZK;2D)96M@DfE495f89P&Z$YH MWf
f43ZSXBfU33)M:fS%Bf<2.&=BW7;..f4'OBMG5=4M&fTV>_O9+f@A7""f2N+f(W4-Q)f12%;f1+fVYXPFU@<@#f
(K4<f)&Fw>f>f"KR"R5Y)D9)fI&G5 MPK D>_ SCVfH$=^UCQ)J^f+fJL6GV44$R>9f;R3MYCH>020""&)>O45fT2C M9fTG3GDTV0ZMfJfP6)?
&fP=S8X_R=;ZEf+>fM"$PQ8D"U=FANH+ @?+fVS46N^f=3fTWQf>f6L<K-fJ8 =2.&WfXfCfX88(fQfZfRfB=;f7f6#0fGf""O:
Rf2;f@Wf80;Y3S:K=1>f+GSI%(Cf16)fXVDfT: MO_4Mf7B*XT3f1HTDDM5S5+>R&YMYf2)D#-Tf<fYQf&K_M(f3:Gf?C'5M,N)HGL+ OB80f6?
#8)SCCGZXH^XN@^f14UQMf0;296f64f M0HfKf)&=BfJXPG(f_&NOTBfN+12K>YfNf0VEQ(f9(fQ.P^f2fGfVf1<f;fJ M-
fJUfHfUOIEU"YV";f3K^C673$U" M/3H(XfHf7D0G2,"(O.8P.P)IOQ7f(ZfHBNZfNI:UfHfY_9&M6$fLODP2@E9&f MW8;_Y
QON7<XUPH=M8OYKf2;f4A2f0BDSfUf>fOAWQ3fWBfP MfLM0fCTNfWBMf9YSfCfG9Wf1fN^&fT#fLO?N:9fGBK6-3f0:Wf45E9AM+fV#>fK@2f@
M2/X3CHf;f1+7C_X0"R(8fH">fOYf_#N.MK?4f5f4^f-T#46M+fL/Tf48$P M4;f76Vf^N*
-WfHQL=5f)7^K6fJf7=^@fT6fLTA4^RC<1NP>WMWYfJ8^=;U? MPlfL66GV^R2+*f5fLTFNfGEE@54f1DX7f(YfO>L?PYfJ>E7fPGU6RLXf1;75K93+
M=00G=fYAf0fFYfZYQ_3M5P+P+8Z-X7T_7fW5 MO:QSORPR2C:C&OXYKV8fPYSO( MZOQ^XHU+2fFE:3;OVK4f1PB>3=fE"N,Y/f4'MZ5-
_P6KPSZA&fCLfZWQ "G@62;1Y%0D:1?>0%N^XfJf8YR^ZWP M0;3?9&C=+>7f4E=1HUU+&fZQ^+&R@<fD-X(f307f;G)
M/CMfK(fJf=;5?OX^;_N1^f3Z5VfI>)M.TG6=fFNZ9UN+fE8""RfL0.$fLD M@?C0.V;_U^0_1110_4444_%%%_1110_4444_%%%_1110_4444_
%%%_M.M.fHZTZ@fM%N%_1110_4444_%%%_1110_4444_%%%_1110_4444_5 M9=-fLKAf6EM87fJfD^R fUfJ#ZBN>fA5KCOfN<f5C:fEJ&Hf1?
%&QTL=0.#_f50#DNH^* OT>f;f+3;f7@87_ fHQ^5f;f:YV98f1G^9XR0C#_RfH ZfZ?9&W^S&UA;_#S#&_f72GBU MMP&
ACGPORPVCD^fKf(fT^@NfJ33f4N5B2;=6R@KZ5E77BfV=Mf1GM;f4PMP@OV MF;f 4@W#(WHfH U MXSfFfWfGV
^RfL_P"M*1K7fSV0fMK%4M5f86&D7$7fJ$-Rf;f47%0$@;_#=# 2Y MR;_XfP"#$CN_&E.C;f1fYMKR26_0M(8X2P"2$@.<=;f""5AEE(f=(f>ZfT^fBV?
fLZ;MuxA MZf3R^fN3Y f10JAL%<G>ZK=;<fO6.5W@Y29?2%<fJ B^f5 MXfL;26f5;37:QBfOEBN$GfXf(f&fR.13 ZH?
YX$Y^P^O8;_fHfM%XA;f% MURf<@fVfG_OL5=U+48+L6N9fO PffHfSL3A57f2RNK;f M.X%LMO;H#NfY56&;&C#&=0<<"TH fV?
X2^<f+<D%AJE@ME$260^8&4(8+Mf(8 M^@8R;V+SX>Z5;-6445 fR;f@<0>f+&fG#DDfSR&4$>G=+<fWEGM+ZQ@82f05>;f5;@&fCH;
M+B9CCX>ZD+fJMUBfA>1K&fC6QWX#fYfW<fDfN_6KTO@_4f2^L>@>6AAB% M)f^8^fHfW0/fC/2M^PfOYMHfE+f;W%Q)9f+f#%LW^6
fN.fJfVGA+fQ/f1 Mf@OKfT^&fRf-fJ3$K(f<fX^C&f 7f2V 8B(fYfZ M^X Y.#Cf0fSUGX^U.fTVf33@<D?9Yf7$DA:"9W+ 9R9f08QfZ^fJP?"fJ 9D;
MF^2f+V<G6fIPM8N0&R3GF4^fL_NfT 4;f5=AOf^02fVfD8@<C_67^VDT&f;
MSK5fJ;7UK_9UfNCNS(%%NBfHfQ0D$ *222.@)fT/#NH%_D fLefACW_9 MFR5P5P+&#fL/f;8Y>5fJX$^O?7KBE
M8+&KH&fJ0fVM>7f1TMR=QA fLY">N^M3fELRH$GfE=fQTYfCL8G)M(f><fVfYfJ>+;35#fJS#;-R^0UPADVE7f1O^$DX(f@fTR#QA9SRV^BUQ
fH MD_8Y+f1$H R3UX^4=N>P50D@&fTf7X.fHDVfDf1L(QD44 MKf)f6U;@8Y BfHfXfKLK)6F;f>T23RfJf;f;#&Y>@YR>G&M.DN=;M/f
M=O=L fTUVB)7^&f;fDfXVC_V2>GKfJ86%6VY3PUWfC6^3R" fLUN9L^O$ MfO6fJGW= fNfSHHf;fL74YXW-CGGCM6A9^>=fO;BP2^WOf#?
#fS+&fPM;VZfJXN(f+417#Pf2$8@f12.XR^fE RYfHfBf6F@6fM; M5f&#.'9>5fLLf$ 9.fT^f f5?;4F2R^V>#D9R^8K_+<(2/f">f;f;fAD=# M@XS^
fJG^4f_#>2@8fL%& M2.902fD>D>(PfJ^G^%<f#XfTL;f1AK6f@>P=4E@GB^29; 7 SCG(fU5UKQ;=V M.B3Wf;5<173PPf92A_C f!@0<#&fC,fFP-
fHO$>fE>3S 08-N3_P^C^D^S MZXHf4+1f.K^fGZYf;f^fJ^C=^K>VG:;f3K^fYf62f1N^f;fVOC=^
```

[illegible]

[illegible]

[illegible]

[illegible]

#MUT,DB1(7D=44=20P*=45Q;07D+0W,,@,"ZC9*I8WEN% M'4F0?XT@U*P8?+>6Y^DJ_P"-*.LF.3:0\$XODQC15=I+T>OY2DCC&3 IX
M<?"TMJ:,I9:F\$J,I#:@5% -VFY ^WYN3 PI-E QJNOA00T.5T>P3LIV "I M&T'2'SNFTJR:OS:J<-IO _MC3,@?VA:Y/O>/U
MIAT/2NSI=EIWOWW\ 7B@:JE.ON6PME,U\$0%)B=<'6I*\$GEG4K0A/W/7 MY9J4:E9\$9%W 1G^L1OH^FRS:I&V: 'HE-1MX?
T=SIVEV9QZP+ AIJ^N6 M#JI-DJF^FNH H&23G >M1P?VYI/I O,K/GK^ 7 &HEJ-Z(AI72:\$\$.=6Z_P%%M3#1I ^GVGHOP,QKOVJ^1A_&F#_F(6O_?Y?
!)-9TR&\$RR:A:I&.KM,H,Y MYJ,> 'M&#;AI-B&/4_9TY_2GKHNFOD:>+V7^R,1@4Q.XV/7M)E^YJ=FW^f.I MK4R:I82+N2\MV&-L-\$@
MG6>"2+",9>DB6ZI^(&:J_V:8P^LD&?^N8_SVH&0KKND.1MU2R:/3%PA_K4B-M:KITLBQQWJHL<*JRI2J#--DT:39FW26-
NY_PJ,"^E.S.\$..RK+*8V7I)9M;EL='B_*_8IBY?_GG^&P8?^|^|O/Q:ND P_4@1020 M">HU PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *4=:2E'6@!.I%>B@ H MHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ JCI=O>W.,.6%+|.02JSN8A)N0 YEP?4<9I5>K.UC2(M8MX899
MJB\$13)&.&D\$E3G10>XH T_.#%<=XLU^*_L-1B:2|M-'\$!+WEFBR&:7)_U ME20F.,+^_.VU%Λ>LYΔ*_AHK/I/B[3_NXK_M?
\$X'^@S'/OPIXI/^\$ML@0#...L,X_P^89,.4A2:S<>@^PS<^_TP->BL'_A^f0/M-JC^OMIBD(^Z4X>+M_-+;=EJVQ_H\$WA_Xf0!N45AGO9I8;??
M@:LIL9DIJ>MK-OHUEIHU>_,S;&;D<8_-S@XYX_M.31#?>I0_G#8ZC:0A)(E-W#(C^+l0KE2I&1H/7L.PY95TGXRW=1#^7NG1 MQ0W.G"+
(KL3NZ D/-=#K)74_QOMIM US-RIOC#^X%//OOI2T_O'=S MISZH=DLEAF_*:60HP4D\$JNW@"&3SWO4-QXP27PW::SI42W\$=Q<10%)F;9
MIG8)SP>5)&IJD)"W*1^K^VF0P7-G^(+B&O_-ZC||I2>HJB^Y*SLY<_4N_
MJ!&6&76OI289Z0^XSN_IY>:_#@T76=OGTW3/M4<22_C0JS\$YG"!<=LUG7_MOBJ/20\$EH.IOK^EVA&Y\$F5W @:6R!M!)X_#UI_B&Y@O=
5>.:OSS6YC^-MDL-I08JK-SIMGK^BI=U&)K:73Y/D)P2I(AR,JQ:Uf>E3Z9:OSWL+S/B!+>5M RO^J_F.3!#=
M67HD816OB>TF:6DFGDMEE.VU#_*7\$6%L^XXS_>HFWK3^FXH>"9E6.6UNH_MESCXFPIQZHFDI_JWBK4\$I+L+6Io="I:=KHP73KI:6
MK:I>0W^GV.FH+/V=OJ^E+:7<*2VJf%)(W&OP/M45R^PVC_TJC^FDIZYLKR6O.C8+"_L(N>X_7_#.K-1U^VTk39I^IDV00(7<
M^P_K6%-K^K6^D_VU)IT^V%4UX%L>+\$+JVEWSJ_M\$=6^I.L_?2^6K&A\$O>+!""LACE:5?:@HPZA@>,=(I3_M6_9f.OKK3X8IJVU:X2"
VD^+=XRX<*^<!UKVM\$SJIOV@Nf2%8?+#++%6R<J_U MO5&.HPN!3.5=2f.2<18W=R,>M>E:7IB:8D_MZI<7>X^FDI_S-Q(78<8H/_U-^%^BBB@
HHHH **** "BBB@ HHHH **** "MBBB@ HHHH RKW56Tf5K2^Y5I.WC=5%#IV7H(5L_WL<^U&:JM^fVOZ^J+29C=7K7UH_MAPDJ_2 V
_@YXZ_EF@#H6OJ8>UU*(+6^MT^D2R.6@d):OZ\$ \$8<_6KG^ MKVT>I6^F32HMEA::O3:I)_ABLCQ9=66I>="_\$,4:1SF83\$L/N3=L8@_I
M^00/IQ7.3&V_X2+P=WJP@W5A^DIDRCYWNDA)_ BW9QWSO!Z3YB%=P92OKG_MBLC6=40+6ZM;33H^FN9EDDG(H)^_?I^&?
2N4.G+WIFMW4A.TM&F:H5O_M4~3^1KN_63VSA<>AVP%=>I9CO=?UZA(-LJV2XZ^ERS^W&Y1f%30^F^VWXB_M_P^M'A=-IGF_8?MK2^4^-
S:C.W?T?=HEIQ_I^UGK+R>-2BUUL:2^LATN=6-8Z^Z CYP2A I=3:B87I=)#JBQ_8_MY_-94RD:6V^2K^6Q>6ICY47B^8JQPCIP
MX&5:3CNA8G/RXYQO!Z09XP.EU_ZY)J3K7_G1I+NO&.JV5Q:OR6MMI5MB&0_MIPTN"!T&_/Uf5M>I6E\%:87FUA"%W:LXQQC/MT^H_Z2BBB@
HHHH **** "MBBB@ HHHH **** "BBB@ H-HJ^6B@-I_HJ^7_HHH_3_HVCTI.*\$P/2C_I-*M\$P^HVHCTI.*\$Y^>HHV+Z4M%_#=@!^B^@IU%
"8^IIM^I2T4)M&E)L7FI MU%_"8^I2T4 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 M%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!
ZF4^K0_K10>M%!"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 IS0QSOF.5%=>#P589J_ULK:RCINV_M@CA3&.(H_3ZU8HH
I7&CZ>=W^SWW^E!+*ARKO&"08D>PJUY2;-FT:<8VXXO_M3Z^*D&F6_JRM!:0IE,I2D8&W/7&IOFI3:0&Z^T84-P^V^7-P7-<9I_U-10 M
THI8.5&X=#CI4,UA:7%6Q<36T^DTIS(^Z_LAJCVJO10 A ((OU^O^QUE: B MW@CB#)?>ATXG-G_90V<4&=WKI?>KM%>%Yf.2I4+
M=6T.ZJ<@2H&/XU8 &, 444 9MZ=:6?_0%L6A(I&:H^H^P^"),9>_TS M/HME)Q^/FULT4_9077=B_RZ>6_B(B<#^/FIP:6AC^6+<#S_Y_ICI:TZ^OC
M.YZUR/LLYX.QN/UUD@UHC.IT^<_K_5\$6M13&8O/B.J_HBG^/\$A_E3XSU_U MY3F>XT^2V2W=YN:UJ^_IOL=#\$@6#+V!C_C_||J>I^<^
<(FG@O&14H7Q_0&73C)GJ(G_+=6M13\$96=? X&GL<#DIQSWI?)>FIWB(S&CT
MT19&Y@fEL=H^J:UZ^f=>.:3%I^J:SWIR^U<2QI8X\$HSASZD_GY^E:2BB M@ HHHH **** "H,BTMIN_OW\$,2H
M(3)V4B2-I/EHJ@DL=HODGI?10_PPFO.44N.C8&139I6^ZCN)=?SG:Z@BI_M:*&f%v:=HVXCSS&Q<8
QTH=10!%f@^OI^/*3>PVLVT9(I#2PP16^8CAC5_M\$15&*DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *M*** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHM **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
H^6BCO0_K12GK24 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!
%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!
%%%"!110 44 M44 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!110 4444 %%%%"!
I365F="*A3R!_QO3)* "BBB@ HHHH *M*** "BBB@ HHHH *.I%>@I3UI^4I:2_HHHH **** "BBB@ HHHH **** "MBBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "C%%=%<=_X.10_ZBBB@ HHHH **** "BBB@ HHHH ****M^BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIUI^_%/6DI3UI^ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^BN+I^fTA:XE2*>K_M<^tY+4E^V2&C1I2?>=WLHR_-I&4.B
D=#A7:f@#HK34I.I=D@N\$>1/O_MH&I@>XIZMUR^C(FOOM_U&V^fJTE^L&3^T:JP8\$#KT!^HJJ^BC7(f6KV_M\$ATff-U_J
M^N9IHUUS_P5_(B\$)^_d5YI/fW=W18V_M\$P>HSS6GVVH6L=S:)3^fZ^<1=W^K>?,2_MJU9W^M^16IUF6QSLD:8"
(ROV^3R_MIUW<<21)M1%4=<*_4 /HHHH **** M *** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M9)+"/C(ZHB@EF8X_IDU%_WIG^2fES2NH+A<^G69_XSH3,*^wU^*_07<8E

M:YAU&C.R9 FFJFKJO T"1AG (NHOGWZ)U Z\$ZOFU16&=5UD\$ 14Y M[-X:>M_K3(&&CQ D9"M=1CV.%Z_3_#9HK&H:P" ^C+CGE+H3_ "D_M35 M%W.#(P_V% 7-FBLAM2U4\$8T5FIPI08IK:EK(Y@)/TNTH_V:~QT MU/5F8H~1=1G/VE#^~#7VLJVH\$38)(NL#_~ H75V.%9#9:AJR@+1\$F+~ MMMN%Q^N~/I2U3G_B1RYXO^ CQWZ_2BX7>BL?I=K@8#^QH>N"?MG_ OFG_? M:RJV&C1L?1:L?_ \$TQFM160=0U<~VY_16^H+P? \$T M^N:5%8RZEK)7YM"96G1[4AH&H7ZF T(CT+W:A?QCU Y T^~ FBL319XCP~" ML<#4&_~ 4/2 ZVANC1NV#PMV_9^I6E<3=C95U9V4_"5Z@^I7G_B^YN&O17C_MLKV[EGM]_:0641B2V_"1(6/RS" P>G;~1H>AQVFM7NL>6(KB^1%EC5B1I MHZ1^2_ @J>^1/3J5XEW>642<\$MO"6AV@JWTV66.DM=_.90F(W MAQ4S3.6W>^IY/I+1%9#W.OASY>G.2 MD=TQ^ZH* -6BLR2ZU81V\$(7+3Y^HONTUQG6%; L<=<=)H(S^E^K166MMWJ MPQOL(O.+C_1&I&N-2*?N1&#?C^X(&?%J/-"BL4W/B_ =TO3,^AU^3_X MS(QO) T^+~Z_P#00D?_?F@#;HK&2;Q\$@S^/JL^C^SD7.CY/MBU/AVLAAE MMJ0C0^1_ "E<3=C5HK"%SKF>_2TZ_P#/5NGY4I9M:?)%I9J.F:UQ_12--L9K45B-XFD) M^NUTE_ =&N)Y^NP4BR>*PW0Z2!WQ))_ P#\$TP_ RBLU9-9_~%92L?_ "F_M^N^N%#3R_Q&1(W\$BC>5PPZ@1H0Y<1E MWX+13V&O7=MZ==;A:K1=VZ31^2R^KC(#*<@_4&@#TVQF.PI?>*!<1_P"= M+(K\$T^J^YV3J7R1:H8OSU+>17-S1O_PQ^1G10Y^1GNNZ1?^1%? M7O^IVZ33JA/HV?IPR^EE1\$6UQ1^QV1VK5OB@RSG@B>6IN+~:(5&69V48 MQCTY)H>1?M?1_P&C^E&#8R.051>U51= T2_Y:AHF^#Y(O1964.8Z M^X)/@#S_PY.2?WC?>QECFTK21VG-Q1 IS1D<<1^1CGU6KE_HVM6_B^4I_ M1(WT:NH2_L:D<_ZJ#1OOM(I.O6NUU+PH6L21O)%E%<_&04,@SM(1^7^P=-M%Q+<1;~LTR(9)%#_# /60^1O=16B6HVVN11_M2FDH *****BBB@ HHHH *****BBB@ HHHH *****BB MB@#D=137A PDIGX7THHXKVC1DEN4+^*3;HZN^N_>M4_#B34_1N1^4 M+B8.C6WK^02(L15(>@)3CKM+9 ZHUO^M.DW>K^\$KC3M-MU>;7,M7>\$ PP/24(FI/Z1K5_KKVGCV75K:8PP037JK^K&0_ M=JL#1I&W?J^BNO\$6PJ_ \$U_ ^TVZV.EGYX+12_K?QG/W:=9VVKZ=:V4=AH MZ1>R061%Y=&90HK%P2!_ \$<_P^X<15G:GX6N=8^(K:E?8M)>T_H0F^S9^8_ ML\$1=>_ "><^N&%S7V)^C(3U;6=7M+AK>ZL;*01QWT^1I^1(\$W MCAM^U^PAI\$?3OM_@OI<9_~N4^1^U^VOZUG>=&_1>4> \$J&G168U?3>Y>S;S M51P2.C:B1CZ=ITN1^KC5^16V.J_ =16WGM7MD^1H4CD_ M^GKC^NBI^*K-MX6BHFSD1G^18RHD1G_#ZP(.DBZD.IT.1@184^1^G\$SXU^O6XJVGAI+O.GRPF5U^M^N417_V.F0^ET:Q.M^J?B? QEK&G6TZVNG:80F4C/DF8DC.XY^5/0>E5IG017.XK1>10^1D^1O81P_9R M1^NXY1^X&#3D>>?#QTF:R1W_A7QCFJF6^DU_1^J^?^)% (J20N.G@.0&1^+N M_>AH+^O+1J5E129^#%L ES;7\$FP2B.(388I3CAA^N.M8Q19Z/X_10^36Y_MVN1^NKF%)^O^53;1)709(IX0\$Y^CIBM3^_#U1=^+S07JMN89Y^C9EU+ M1H0^08J2NXY4#S V1)*TBL^A^X^B^+F1 MJ^N:Y17A76K^UEEO9H+TQ(7C3IS;9;"J.XI 1_6K7AWQ^8^((KZSETO76F^JW_MVFSN_JR_H=8^#UQP<~Y^KZ1H_0^?^JM9V@AN+F^4^W^P.F1_20>00<^ MJ.M+^X0AD15V6N6&G1Z4MJD@D53L.X<@;257C^_D16/L^_1K@15U?4X/B MA1VC0W<@L) I7S9(PJ>S)T;^1HU:U^1VJZU14&H1ZY%K<6MTT2R6^?+D&> M">N^20X5A:CLM7^O4LM>329FL+6_VY:SHLG_62^IOSCYOUYH^7BW6_\$WA M66[C5I^X?:1H6_~XLF13PR@ELXR_22.O1_1506?BBWFU^5M3BOI^MM,@O M^MC71+~.19SB(#&>_>_T.MKZYU^6?11FU8L1<:1+(KIU^"A149 1P3U1 MUUC>?_?_=>1;OOTK4HT6?)^GS-R85VNU^OGVH_~X^OM^716)=K=JH MM M^)*R06END8510+2M6Z_>W3IS71Z+8ZC8RWXO1YIR_ YIUNTF_RQI^&#&?> M#*=Y.PG9:WX.LI^ETHOM%E9I:Z@=5ZXX9^1T9).HZY^HJY#:"">XN98VE\$4^L\$4@%C MDCC)^41A658:GKI;WUA=Q0M1P^D^9I^C1M:A818).H7.Y3@XJ/6@S^1^F-XAT7>VHQ7%S_1L_89DB81_7EV%E2RL MFBO+@N_3(R^4%MOHDM_ +UN-2@-1R^1VVPV_CW:J9=VX<10^?QAI1Z6C0+<+275_MH12_LJ(N_~V1@#E.OKZL=L^1^U^YO&6ZT+1^J^EVWS@>9^ZV_1Y4=(#1 M2_~NCZ48:7#~FE0V^JHLJIRG(96Y^4G_Z^> 90IX^T_~YL915HJEY^1A6 M^1^LQ^#++<C^H5N1Z1^=&12B2^WCSVY^K(N-QW#M(Q5DMAK#>). 1N9:/S(MJ<3<~"Z+^%O415^_W-C^7^<^PZ^6UO7T_173_AOF480!_N1<9H1:~?XH@_MO1O_6YBF>T6B1U&9(CZ8_0< @^HJ^U1_V%TVG\$6M^D^%0L1P\$)O_<3V M^7HJUCZ1LMVOB6VUJ^1A44Z>1\$V+SS&1<R5\$98DCK1_F6NA:M;^%O^UF_M;1? M^%C<1/(D7PHK<M^>_Y-N1;W<~R^0KPI^<@1_M9<#C=~T@MJ^MDFSY=NI=N>R1GGFN^ETCQ%8Z7KWA^VTT7=M^R32P7GVA M5VB7HDKD\$GGW_/O@LZ:2\$1&N^N1%C9NR1^3) XSWQ0.HV2B>TNX/MIAN<8 MP. <+1%V%1UY1.#WP:CM/%MA=7HM&6:"9X/M\$2RI_K\$7&">1D<>XKEK:PG? MW\$-1#;6.FA6EQ8R1RV+S))":AL:6C^DA5!^9X&6%M\$T_2+B M^1XHI1%)2IE0%90H^Q9R2^1#U1_VG^+<K;4+0M;+1^=P&1@^T6TDH^D3UX_M0<>H^X3UN^2::~UM#2V>17^T+9WS^# M^6W(21C=ALVGRW^OHRV\$&1Q^%9R^21WS1^J_1^1H;X5O M^ "<5LCP31_>Z@95PL316RZ1_0&2_><@>U^?B11J(M&:GQ:2UF9MZ81P MRC^WH5E7&M^7.G>1J9K6 M^N41^ICE^OPG>48R&_&^VT<@1^=COM^1K.BQ16^1(Q1=PW(1FVIPC;BH18 MG145M1^HGQ? ZG<6P6WFTZ_1%\$H8IP22>_G\$>281^~XXTIM+TVIAD4_P1H MJ7MTE=81@?>W\$1^1ZT^#OB.R12ZZ1=2_~L8+19%:*79L MYT^PO96M;E8+B6_~%0AE#~1CGA_KI&H1^OH5YJUK8^Q^NRXMY1(C+5YO MA6+^2.1N L1/L1H5XD2Y1C^2D+PNK D^RQ1P_X^M^W^M5#~1EXDL^1+3+& MULDAL1L^VU)^S7;K@87^R_1X%1^EZ7QE^1T^75C=364UR;6^XCYD/(X^1 M#;_~E89_E37GBA8#~FWL1^F2QQH(^(#Y_21>8 Y(C<1H1FHPVD_ W)^2Z M1^YH5T&F:H+~M196L=U.ZG.IS&DNQHGD_M W1A@Y_ZC^TOWIA1(C^F^FY..E1^QQ:BW% MRNGWYMTN_LD1AC4^"IVWYANSU(Z U^H^QOIN^&DMXVGM=^MGMW<_~(W^1@1 M3U^1V/X52.BZO)X7O1^0)=2ZE15.PP4.PDX:UOD=N2^@#2U^Q/18W5U^MM <9^7V^%9HH(ND_~"=Q>=&A6GINH0:KIMO?VXVJ7\$8DC+^1!D9^O71:R_M3N?&S&L+I&G?C+>Q6MV1^U(G416^#E/(#10>AHNO1^IS% <~198;IKI_MV_Y8L&S9012_1PIQD)^X\$1C^0V6D;2K^S^E<1P;@8YEE7)C1VCY1<@&L1 MVWC^TEOKVTNK6LI+6V. V3<1X#P@D%UP3T(K\$N1^UBIT7Q^9FR59+S41+^7F M^SD6\$8G^"G@XZ_A5Z1T74V85(K6^6W;1VL1KOD^7<6_8=U/2F1^=>8X_M&N_ 133+UDCL MD890%1D3^#9_~9&22EQ>~\$BLM_WIU_1LOO)4A2(\$N44_P M_SWWORVEM^SOM^AE1&UEMKD1 MR(^#~2^3D9^Z_ #U1H^FJWCR^OK=18_BT^2^5^K/39+16BGF^OQB6Y_2

L:("OY4>8MIVE+ #X9M+ .MZN:JODUB5UFD8.#\$Y.PJ!&3D#")/U/+!-133:7JET=-T=:8f2+|fE M8D2# + X8Y00@X%>ERV5K.4.MO%(8SE-Z
PZ:=!^5+!+:P3E#.#(4.5+J#M/MMZ4"/M*6#3-!A:6-D):-L!4L&OR#O:>2 7'S:=O7G ^M9-&80A[K1N/ M*&G2YV/!+,KH/Z@5-0 4444 %%%
!110 444 %%% %%% !110 444 %%% %%% !110 M 444 %%% %%% !110 444 %%% %%% !110 444 %%% %%% !110 444 %%% %%% !110 444 %%% %%%
!110 444 %%% %%% !110 444 %%% %%% !110 444 * M2E.DH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** MBBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** ** MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH ",C%% %%% !110
4444 %%% %%% !1110 4444 %%% %%% !1110 4444 %%% M%% %%% !1110 4444 %%% %%% !1110 4444 %%% %%% !1110 4444 %%% %%% "G12AIZ4E M-!110 4444
%% %%% !1110 4444 %%% %%% !1110 4444 %%% %%% !1110 4444 M%% %%%96IZ-5J>G6.Y(8-! M-GHHMF1+JX6W5X5!"NOPND&
!/\$=L BH!"F=:M81/EE 0!TR*GGGCI0! ML45EMK<8 M+!:S- 9 \$N/F.PA>>3AA56W4VUW;VYUO#N&O/67-(16&M2 M7-
N!)5=DB'&N#GK0!K45A3^*+6UAU::>WN\$BTL@3.54A@0#E< M\$DX!SS@T)XF3/\$EY+IMJ#;/LO*RHPVP,"L3CGTH W.*QY!/?C6_FM+6VENWM
MTWSF!AOT7W8CG%1+XLT^32!6^C2Y<74K0PPB<:SF2&WMC:#CL.O7!>6\$FER:HEC!MM812+@+L.DQL!Y=VX#>=>=O2@#J!R-1
M1V6G6-E>L'EMKR6.**2@!KE.NDDC<UJ9M66*[M]>6UGC.Y(5R 4! S@D^ MUGL!M5B+XD2XU+JLK*QY:IK&@3R)M".B,1%)S-
CMT&>34D/B*VN=&N-1MK M>XF.ON66V50)E>=J\$@:/A!<>1 O!7/6GBQ+ NGL:5?QVEYL7?#^5M7?HW< M Y/)C-/6NAH
**R:K78[37!+(2)+>3S+Q7.*08VD*,MGN,M "T4F11D>M "T49H) H **B M6XB>=X5D4R(S*#RH/3/Y&L "BBB@ HJ.6>*!0TLBH"P4%CCDG
<XDU)0 4 M444 %%% %%%9!Y!T5GJFGVY#L.SWK.\$9<87.I8Y *@#0HHS1D4 %%%&16=J6LP:7S_9XS&N0&VEN>?F%-&C1129!HT
+11D>M9VK:Q#1!6KSQR+&BZBM M5V"#2,1%/MDT:~%&:"BL&?Q3:17+(EK=S6!>G6@#HZ*E!2G124 %%% %%% !1110 444 M4 %%% %%% !1110
4444 %%% %%% !1110 4444 %%% %%% !1110 5QGCIAX@)!-Q(M-2VA@>=HLC@/P'#\$S&U+1+5H!>ZC+26.M:&KVA1ZUX@ M?
RW:WOX:17M[M.YB;ZMC(YLXKJFTTV-5?4=SF=X1!)-&L^KZP 'F30L(S_7O!_XKS@ZW>WEK!BES*@T7R:;+ M R%_DN>WRML/7C!-
>N'FLIO#NF/5YIK6JFTO'D>>)>A=G.YC^>,"KHA MJ@O+V6Y:Q!+HW0H1A<@^J!<^^J_!JGP#H!3!HW.2/F%>="G"IB:;5@ M,?
E!5+,C&,_2H=:TFUTG2X!L.E.VC!>BP@>@G_?QH YSX<@+0+Q5.8U* MZV #@\$S<#1S<1.IX:FGO)=H.PLBC.8WE;SI#(WF2%L\$>F@>HJ
=&JKK/A?Q M?&M?&H7AHEY;=A!T.NP@/I?HUM^H 4!A!0WY Y.MLL:S(T9!;#F3D?E6S M-H&FSO.C UL!L3=I6!PEOI/XZ5"?
#%@=/.GEKHV101F\$W,A&P8&W.< MXP.8SS2%8Y_5_#US<.:<[X8U9:74XPD5U#(N^&? # -Z:1R/7!KM!#X! M-0"
[C.E:F%=N898CNV7\$9.64!>@3CV4760X>THZ!>15)8!BX" B5XIW3< M!P#CH
9)X:TH&WLUM!%%,7A!BAC<!"#G/6F!C:#JFKQ>C!HENV!M MELT.HO<+,F! J5O!H&5SVK<1!6:-/7VG'_!+!Q!UNJGZ@X/X5)9Z:-6
M5Y+H)9+F10AEFE!@H.A!8G SS6A0!=FUVZN!T?QDNV)!H1B@NHR.7.3Y) MQDY&4Z!^BEN6Z!&7Y<@!E'@CIG/K6M_PC^E.V:=;
M=H/(&_F/Z5W,&B6=O MH2;.BR?8DA!A4.C9V8QMR#G!Q!K2>%)FTZRL9(9!LBP>W1,B1?+(Z8(8' MCH/2@9)8Q:A:7\$CZCJ\$\$.!B1*D/E8?
G=U8YSD=^U>76SWT?A2^9W;>Q):N.MH!H!WROQ&7!<G@8YXS<->H0^&I'&@!N:ET M!O.TJSGM+2 B"=VDD22!H.S-
RO.XGK0!S'C1+!P=IS.GNJ6P0K%#E.0\$W.MJ^<HOBNHJ!AU S27R&T!0!E IPL/!TR,57.PE13=5IGE2?8X9%EC\$S M?<RG*X.3^<BWJ32
MAKZ4+D7?O.O:&1VRN!>LW3V5X@!>7\$158!<HVN!NF00C2CMD= !UUEUX MAIO MHA!HFGPV5I&\$\$\$!

[illegible]

[illegible]

Q#C8[!@&(*-2BL[5]@XJ%\$VDR:RFD+=@:Z>8L#*0Q7<@B@#7HK(E)Z27#>W5FJP2M*I-MYDZ"-CL7U#%0Q>+1%GC@>.&@GC.L@R-B60!&.E&f17/XTT*2.VD2f9.MHHEML+%"2'&<XYZ&K^EZYI^M637>GW-FA5V1B.00R!\$F@#1HKGF:Z"F

MKS7S7NYVU@DJ24Q/M5LXQTLF1)XHTHFUM+=9+MML&L*%AQGG@D8Z4!-%8-M-QXRT*U:Y\$MX0EL-ESR!)BD;>A8#

/6G5fJHVR013SGS9U+OOHQ.S.*%1.M!-2BL2M:T.6DG73f@3!+81"1M<=CGZBH73:3JDFFO=8O(C.L&+MSM4!<=

>BLBR3:1J5E<7=E=K-L;Y1QU4X74<=U5E!>F%L1J4?^D-ZC-MY6->?O!-045D7OB:2=^NK>UNKH1W%R.PQE&W/H/BF)XFFF2XGMTN6>:!(

MHJ+Q*%C/G%&U16!+XST&^QBO9=1!>9S&DA5L.P."HXZY15=L=>Tf4J6U.MMKD/<1\$&>(J581#&@T

:5%8G%5Z09)XEN?>2!HDJ\$!%#C/L0Q4!+PD&E.M.P.V.NK&C%BPRLQ/L.KGVH-U**R+3Q+I=(=):1S.LT@+H+!\$9<#KMW-9-"HF-M6:2E-8O-

(HJ?DOD-G3HT.F&4M+U6S8U+UBS>:"9-V"/F4X(Y)MZAUG7f/T"W2XU?R(8\$;YC2H/10HT5%W?7=O"/DHXW-D8Xf:@.HHJEJ-MVTVFBZ;-

f%J+Y5M"NYWP3@?A0!=HK&Q/B:CIU@IQ6YU"/S(*GYEQG/M6O-MF@!>.*S-5Uf3f&FLX;V?RY+R40PKM)+>U+G61VHH

****S=0UJ1+O."SNI-MMEQ>2"!!>DLU+E15#4M8L-(CC>^N5A\$Kf\$R"20QG^E9R^O^QK^C.G\$P\$M@B.>)Q@|<=:.@HI.P/OTM!11FB@-HJ-

YHXW17=59SA03U7BjN/M9Z/M.I/I>RB-.Y%64X)RS"/OO!>HI/R:6@.HHHH**T4%^%FEH**%*#0-44U.M)\$F+S0%/"9OG-76F1"H9@<O

MT/HK/T56K35VN214WFBWE,A'D-HR>M(C:&L&UOM&6;-D/JMGOM/M"/9QG2/M@#1HH2DPTT+15:ROJ74(=>3f+3?>RGHP."P-6:"BC.*T

%%&.:T.M%%%%!!144=S#)-"/(K/\$=K@<HOG!-T2T4"B@.HHSFCIO-45AZEXNT;2-M7G6/NBGV?>)BL:-(HWW=Q-^<:VB(fAWC#C*^&>)*.Rf

(U^QUMKH6.C.M2!+2F&1BI-W#f1FM3-116=>ZU9V&f6&GS.PN:Yf6%I.f.GGMQ0Hf45#-M#>0SM(f%9&)&HBR"<8&9/7MUK1K.U=Q"%

f.HGC.M:5AD'+>A^OX4-Z"Ef%Q4M!4-M-JV-P!XU-4-MHOQIXT@)****8!1110M444%%%%!1110444%%%%!1110444

%2!%PiU.JOC-O!E=26-M#Xf-GZ!>QVDMJ+!>*P-TB-Rf@KDLG!-T1BJV@>(3XB4>^SD/7.0#26PQ9+17Q^<X-DNA;N-!(QIOB@!OC

M#1\$0>=0Tf1.1!)O!BLJ?S-K50>*FNM8!+>(0B^386ZVVHOC6F.S^Uf3-M)SZUf2>17"P!8-!(YJVC(X6+4.EKAF"<8)^F*

(fM.M.C:KfAR^IB1-MXP>Tf253P-C3?I4:IX#L+IRE^U-L-EE3OM&2f737FE!<=>*FOS!QM%Y6-MZf#(7&#/'2f-EXL!^O!<=>?>2M#T\$;

M#HJZ7!>320QKMB+A#<)>BNO.VHOK.DC5+2UBT^*fL&R&D&F2O.fF.M.P#^O+>)%Y-#R74T5C+>+55DM%UCPCJ4DLMNV9K0=)fZ

MTG&#%+M-(@U7f6EJ)17^>:5&L&2-8W1/38-*D-1A^M=#H2A^WTf.ADEGD-MN;J35;BXE(W2-ZD@<=>)EXHf6-BCPI-Z1<

CCf6KXGLOf&1!>.&RB1UMYVC12<.<1\$=2-M2NP^A6T36M*U)3M;3K5K;-HQ@XYfL8-6JVO>)%H:UW3H474FMVYXfH>1AA-MO/#%Lj<@XH

P-\$5Q=0!>P=IHM5@fF7!WAL(*6RGU2W15^VTNATM)!+M3YDFW&G@#CFN@U@?PK-^NZ?JfHf3Q2Z?N."1HNU2P-.1SG%);>%fK/4f0U

M"WUBY2-.96FfEQD948&CCB@#CfI=RG@WPX%MTBNWfUVEN("LK-N8\$=LD-K-M6AHBMKWQ.O-

7N\$>Q?EP&R^QDY9U8fA<v#SBM^X^UO<5FSV!#>)/^E7**V9)KJ2'-RfP!H68XKL-M+3PK>4:1\$SK^Y7!#OC&^JP>&-

U545-P!^A0.GZTMM-MX:DM-\$T^MG4fAY9XUA>)D39f4DA1OGJ>M-%KPl:K:Z/3&L&C(%>GK8W-Y!>AUD98E7f1.HRfRfV-&O^fD-

f%08+Jf@9.GTKSVPl6-M:#NZ3%)54B-A10&^f6P-M&6!&GKWKJ9-"S7MS9R7^f7-Q%:DLd)5-M4MM^@G-R2:5f67PlCLVXfC5fZ0:=G/fJ>:

:3Q5XDM-#T-MFKF^B>#>N&LFB>1-%9Df**9f8S0QBK2BC5Kf6-7?C0f5\$K9Z2%)>+RP6D)3-M!>6GMXQ6W/H9=>GfDZf="6^&^W%>fJ9#

fH^!QfW4-4?%M?>J>S4fVVBUL-M7<497:(V;NfP<#M0!BZFW>*O^fW82SE)XXXC7OZU-P)+K\$>AFSf5-<"M6TGG7?

9K\$>MB=1@<f7(X/6MR7P:/fED7LNH7#-V9\$8HXV"D-."\$MOfRfJ-WM\$106T5C-^R^fF17fVB.T8+M7fW!#>#D@>VB.T;=%SC)1Z-M-OQ3?

W>FZf1-.fN=M;J-M+V;=.:>)/MW=PP>f7(>%)>WU.P46MW&89=6M-RfJfJ-Bf17%ELfK\$8S@<M8?AWPW)MH^VL4)+fJ9fY!

(BCYVOD)=f.9fL0S&B&^>K>V5HfL-Mf02M^fL"DKNW\$Y-M+<9J^f6<^HMFU54ELQfTG47A!OG.D09fCKP<^fULf7?R&^<N675;T/<

M?>Tf(fK=G/7&<9YQFDE!&0f5THZ0:(=2N3^55?5+I(M3MXXIXT^CYD-8^&PZ5f%>X>)"ZO9X=5F7f78fM92#RUZ^f4...O)H-Y-M4U3Q-

fJO@344N4M3=Q3RfR@P20fX)&3TY=5X-fJ-M%>H=HfYA>6VW>."\$>:O7fTG-PK<:UL/#%A!Jf3:0S(LQ49-^&3KCH-W-\$

MAXZfL5@+V2W+!f.YN57S-V!&G/RfJ:U=0!>G\$M0NfFfU-MW6ZL?L+QB.#"YSDFUSSH@ZYL-\$EJLNL7fPUO^fV92BfJ)G(S@<4-86E>

M+P!PW-MER(=3NXM+NYS<7&GfJL=RRN:B^).#YD9PQOOSW<1^&+&O)H9TRXWfJH-M5HfH^&B9R<C#Z5BR>KB>QD2Q!>RWDH2-

HPNfRE.=>R>fZT4*!>ZAJ-M^Af42\$8fO!&96VfLY3#M.H^?)SIW/2@>O\$>NGVSW^H6^fQ33Vf9V0)^&XVJ^M&5.22M9/

L:MF@PMPXRV.H0^3@Y-.30-QfO/36<7%Q-9/RV^RDA<DP&OJ@GYAC^55K3Q-fK-M\$^G^&+H8-LWEW^B(C!>P\$!>=>KVE^fLH1-fU-

fU:&."Q6LW4HN.NT^fCGKUZ<f6K:KHWA9fY+YfTNfMRXUf2fC5TfWfY@0G(Z="S^U4")=BU1MfTU@B18ULM9-%LCL^fVE0QXfY

M5>:X202VfJ6P-ZT9-f4WB09-PL-M+P@D5Y<CW^fLH^PB/fOUK2fTOPG=660PQZ>S>3Q6GV7:T-.*N<AUS5fG-M7-%>UfEDfWZ>?26D^G-

f44-NWKM(YH-&M=5fUG0M)4ZE8+&:"UUF5fSd4-MfLSC\$BfX1fOJH-fD.fEGfQ9%CP00?<#V>:WP

MCXGU36=2MH+FXM=RVf&fM6C.5Zf2MCOKK;>X?D.#f!<^506X4-M5G7-M:fVB8fA-fD99L=2<fMfV7-fXHL-M-7^VH(f)&6.W+>(RWf!>N:*

8^<fT.EZMK^AR^XFEA0!>VfDZLK^f3f#-M\$X8>f7-H0f9ZfZfO26TfJfLEfO14fA)9E)="#<f37MK24FMH+P-4(@PD4G)!S-D5P5M9WA?

4+Z^YU^"UU22fED^K>L&LX7#E>MF.<14=(<K>)fO%UfH=O>6fQV<5M<6BQF^3Y@fD=f3-12^)-6-GfJO-MH+N9V#QE5-2^)-8-

G):@>BMW2/#UQ%Kf^O7=P2M%Y:QPSV^T.5^>=#1<G5-M-RfP6-Z-DZC=V6fWV^A=WB^RTDSG@f<9YQG%&19>*\$>HQP:S-VX;37G8/

M^ZBfS(N.XS23^f8ZU-fJPM8M6664LBfD(OPO-M3^f4-f4fMfB+4:74H9X\$

<=46R;MOQQOTQCF@#TO(H:CUOO+XITC40°FGSZ@;>YU.X.WN@85(C.M.5MH=U^T)*@5X3_6QQ+K%`H=&;
MICA4ZS\XN1J3Z=>;Y.EAH*RH=O&9.SCB.XY/6M+7>713Z+V/6U<~&7IE_M3#(85\$S1EEVDKI>|L1I8Z<'1ZG==SOPW5U?
9TV>2S13@_M_|JZ@16BZXWP!-%;W1NBSC.YNM5+S'8494A9CM.<9SC%'E_K.76BN>JT#7+?7 MIA_NZ.ZTUK9&B=@H*R9.X8_-%/SJ6@_HHHH
_BBB@_HHHH__BBB@_HHHH_M*Q]=#)JJH=O^FIDMN R>-7/3BMBL77EIGTL[4.+Q.6)&W@/17TH VITI M.0=#6@ J'T U?
IQJ8I#@M<^4?]>-%BBBB@_HHHH_***_BBB@_HHHH_*M**_BBB@_HHHH_***_BBB@_I' BEHH \>A) ZBTGB/I B0Z?IZ3R:(RY M.^8\I#_=
/((I:#PU?)>"Y3-YO-U.NIV-W-RFW)#%<.;O.P I788HQGB@#QJ MUBN:7P)X'E:SNE:QU://SL3%U_U.F.C1+=?)>* A_P>Q"SG(Q)?).7' MRCY>:
<\$=-JDPB-HH IEGV67B".24M.U*) L=3M(C@FM ^ORIM*;O>3SS45U.M+91)>S Z=O7'I C'H\FU%+1+1Y L+&M-7
M(MHL OFF:I0I<IL#:"W(Z8KOK#4I>?O?Z>FG313VT<9.Y>.\$E!'-WO6W@_M48 H 44444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110
4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110
UZ!2\$@#RKQ_8RZSX;ZG:Q226A=M=127*A)&5<M \$XZ=L^Z^K(V'B+Q=XCNPT5I>7.RW9E/SJ/X@->X>EG:%Y(O[U&)]? Q+C MMPIH
1Z"@GGP:/I=M=12PRM?RS(DD94I&)/Y%1_% P>2ZW<+46-K+=G2KE M6GAB6,>X'C(?I7IPQVJ>.>>WG.DTJI.H.K.P.H.Y^3Q.%
<"UCTVONIFXG9?D M.%Ds:GJ78CY<5Q_A?2IGP+X_UYK^%FTI6Y/,@NT&5C^ECM?TWL>-+B&6VTN!/MVE4@S':6_/.*H?#/4TT+50
M%=QJ#@>POWEK)8&^S.2.7YN1@>|>T8%&10IX;1I 5?S@NR=K>26?4S+%;MI'P>.W4G18#N<=-6NZN_%X=(L-'BO&GFEN(HYF^S.%CC&"Y)
(QT&^C:*.4_M>"06-O?O^#8S2+);6-W%&(F2)RC2+(K\$CUYIK>9:7J?O!,S76GQ>6VF7 MI>SDCD F=%4;N#W)SCZ5ZS)-%ZH/HK.<^I.'?
I2QS12EEGD5BIPP4YP?OT M>6^-/%NHW@RSOO#=\$S^6^L^I^C6;3@&@>GK6318;Z72?50=1W-U^6 MUS<7NR.LRC
W\$1OSFO:IHDDDD40!DD5-2!8XR3VH X/P/>#2=3M]STO== M17=W/>3RF.@L2-EMNX_Q:B*M>+NUDU33I
(U.R^UZ\$=QRFX582YB(QM5_*W05T/QSK\$>CW%Q-X>^RH4:0DH2>2OIZ\$X^6H-M.^A3X\ZA?R+*MFIBL^7IC:87&W(SC'.O5GF@B=
(FD16>%N8CY M#:9?G^IL^C>E_D'A^XN=V^64EA.W*:DA-DULUF_\$P<@2,>F'^.H-A9VES!^E>E?V:36J3W.O>XS Y^EOQF3"/K5G%M
7%3KN.IT^&YBR5=0>5(Y17EOCAYIWZF^&+RVL;Z.VTR9_M4B6CG)IL^C M_A7KG %&!0!Q4_BMKKO#IG6_BTVMY)^IFM&E8X"*C)
(Y%)DGCC^QR\$NI.PIQI5I%@4:0_/&\$^A>/(%AZ;XL@M&DU6 MPNVN%MF^5O(WHE7J
172)XRCNX8(I.L+N XO02FZ\$XF019QN+1,@8YKJ<#%& MT4.8.D>*[35]>U+1XX+I*B^XL;*\$F%D[IJ>XK?K/L=&L!'N;R)&-QH%+#+.,MYIQ^%
&R.E+O.E%>E514_NV_WC5@I^KYO.I WC0:8HHHH_***_BBB@_H_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH
MB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH
*YOQ_XDNM\NH>UL.M1(FWDN)9)+1.E,X\AKI^XWO)H&K:CXD BN]^UGM!920*EQ(P\$4C^TX4#G
MCB@#T35(\$7AVTU@8@<(KN\$.8UYQDT047131W5HLBP.U-%X M=jf%7_/^371>#+=U30?^0OH_I'S,*4187.UFI9)!K.V:9XFT4ZT?L%
MDS:CRWB;.H NP(V+HAL%<K.LIUN MHF=UPCRI.13WYXI=5T^Q3VA.FER+/I9)^""1S_Y.O4Y+9(R2?IZ4-6=M7W7A^W98M-
66VL+*>26:RIP(R)ORP)J<^KEI>M=.2QC6.LL#>VTSS8 M\$@_R5(OP>"2'S<^4J:M MOSCD @?F*9%XIF?
5I^VDTY(X+VZ>VAW3@394YBF.%TXIJ7I_HZ.XPU/40 M0MDZ*..B)R.)&J3M6L+3_ZXDMI-G.T=@I6.I<2S;R7G0AN2<=<S;NGM
M0:K+X/O/LI/Q>R:)(EE/O^*6 MRZ;#U4DJ_*IO^<X=O=N^N":4%U>W/O@K;U_2M4O#FAWH\$JM8LS2EYI28>|CG M^6L6^I^--
=3.N\I/VRK=RP M^9?9JTERXE0^#.Q.A) OS55=36ME7S2G=R5;JC^&UA6WA77X0#E>=:VI26VK& MJ(E^79YA><&4.3(KAI CCI M@S4^0?
\$NLZ8ICK@L:6/(H#?926:9R;B2_.900!NIRZU:OCX2OI02?L: MRO(T4K2AF^E/N.OHIZV?B5\$DGAB%F0.4OI8J3V/FK5.ST.Q3=WGAMJ5ALD&
MER-YK12%C)FT.../6QXXTO4=8T.FTV^*2;I3%^??:-\$8-UP23% %%\$7%O M;.\$Z.FF;D:8?2Y\$I9I4/RA<<.#KD]>EWNGOO+?V\$ES&OFFVO+U61
M<#IY3:AHM&AXFN+^(Q6L9TQK2.592760G.<8Z-IZS)>-(C-T)^N8.-@
M6WLVI6X6IFD)?SYAD@130E>1_\$^H+X6I)03285T.Y7LUXTR@R6<1..MRILGUJSJTEI<^OB1;1Z8MO-#DSOYTSE.6X-
i8&.*T=+|^ZS#HFAZ!"S:P MTR99GE5R3/M8LHVX^7DCN>E)=>%=N+3QG&(.16UT@0_OC|@>\$>SYOE_&@"X MFABUOP!'_9@ED>
B^+IUFXO)PE,8K9%T@9N.2DILOL_*OXYJKH|^..U"V11WM M@FEW=U;1.W%FMS-/RECA5"!0.TF
MJZY-V^KOZ7IUHEQ!*SOAUHOTOPU+*)/N27S.V6S8%\$ M:^V%Q3O\$>AZVWB^RUSP)+\$=-W2WL26;7MUJT>H3* MTA"1K&
5%3CDX^6@#0^C#62I9NM&_L_7TNMT-UT-GE\$DM M=M^1.WEKL3J6G&""2A3&=I/ZI..M#ZKA PF>IZVL%MY4VF+9PH9CDL&+9 M/R|#YO?
I7/SV&JZ^IO@:3IHK9KVUOMFU93L91&_?"7TH VX/5YIFU2*ZT9 MXM4L)XXC.K+N#K(0%?=CfO)SZ8]"I^(-S^X^I07<5C%)=5RW^KHUNFI7-
QI_HWF\$Q!/\$>\$9L9.AX^7I..@3Q5I+.S>Z1_9D.W<=D+VVIGXE7."&X M^4YXIU^8>-
)M3T:0HJTM(GN=3G.;0.=J0N=YSGC:X'XU+7FE<+I^5VIK9 MV^FHJVTTAE.8SNW\$1.1DXJ#P3IVGSZJ^M:<(R.?);1:\$ _#..6@44-%%%%-1110
4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110
I@#BEHHH_***_J%JHYG:E-I>6DAID#HF<9*U M%7Z*\$_P.4M%% %\$W9VJ_.R6MU^DT\$@VO&XR&^N?#1%;Q+%"BOOH_JC J M2B@_HHHH
_BBB@_HHHH__BBB@_HHHH_***_BBB@_HHHH_***_M^L7787GNH1\$#!;P2.3GY0JD^GTK.Z5BZZI+=Z043/6@_M#9+0.E%
>E06G^JA_O'=3I41 JF_W%.@>BBB@_HHHH_***_BBB M^HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_HHHH_***_BBB@_OUR
M16G10!@?)WT#5Q_VQ7_XJC_AW_Z6K J^!_156_BB@#_P"\$G?I_Z6KM_P#?>XT?)_P#T M7_..P.W48H P/^G? HI:Q WX^O5_"3O-T
MM7_I#&M_%&\$*_?P"\$GDIZHX I8K_/%40_"3R?I_O U<P#_%?I_XJM_M%&\$*_#A)W_Z_K_/@?_?4?I)_P#T M7_..P#BJW48H P2^&F? HI
M:M WX^O5^C'\$S_E'4%U P@^H^<^3K&# PDYZ_VJ I T S?_%Z3 A*<P# M\$U@?INI OK?P*."_@#_X2C J^ZO_X^G_HI_X2G_*@FL?_@*?
1.WI#TI<4 M">9_L4%UPK2100 44 M44-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110-4444-%%%%-1110
I^WI-6T^_U2Z:I@\$#N(UDIP:2Q..??-%VBJ MIO?6UU-/%! DCP/LE53DHV.X/X&K%_17->+I;OM"(L)K187%S>16A60@R-MC=D'MZ5^XFUG

#XJC A=" "YHO_F3_P"KH:.*->X0G00^?>P)MD+BJ0^"/6VE/UN)/BJZ*B@#GAX)T(#BUD^-)/JC A=" "Y19A MP(D^*KH:.*S3-
 IT 2)7LHF11 Q:IFSCIU)TZ**"BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
 #)%BEHH *AZ+%%/%%-%1110 4444 %%%-%1110 4 M444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%11 M10 4444
 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444
 M%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4 M444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444
 %%%-%11 M10 4444 %86MJHUC0V?M3\$1#^Z?GZY "MPU@ZIN:M>1L47KDDGI^XD M P: -!*=1THH 1ONGZ5!9 ZD !Q 64!?
 =/TJOY)@-IS?SH LT444 %%%-% M 1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 M%%-%1110 4444 %%%-%1110
 4444 %%%-%1110 4444 %%%-%1110 4 M444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%11 M10 4444 %%%-%1110
 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-% M 1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 M%%-%1110
 4444 %%%-%1110 5@ZYC^U? &<7K' R#)6!6!KP UOPV.3 M>.NWO6O7GEI+!-!NF@TUKXG18LQJR*1^2GYB!0!WEI>6!H:
 MK:S1S0MT>-@PXBIZKI+7>HVFA^Y+2&5/GZ2;4RY%<6>G! B)XXS7 M2:1XKFUO4M)AL?+D@FL3>7E<%,G:H'H=VHJ
 .PHK^T^U L4GIM"W!QOY! M2(SMV9?7KWQ6K0 444 %%%-%1110 4444 %%%-%1110 4444 %%%-%11 M10 4444 %%%-%1110 4444
 %%%-%1110 4444 %%%&110 4444 %%%-%11 M10 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%16!K!>9!>YA M_P"09*WZP-
 >P=9!9!7KBYZ N9* ^B@=** (YGV1.PK2 3B!6C=[K4 Y3S4!X3]M?Q5Y.2:ZHUS M5EXOCF52^KZT>R0!K)80!A!)Y4CZ=* !>R!
 66HZHMO<7EO?3)HE MCAR !SGLK& U 6AMG!Z?9(V!#)GY00>GEWL?AVY-EK^OORWCRO(C3.PL=HQ M!BKG "7>MN!^VK!Z^+--?M
 MBV?7 384! A="!Y P"JO9! !?@UT!#S^Z3G &11Y\$?/IM>>3QUH ROX M!T MM&L66!>@*2&UBR!Q@S+UK3\$SP!M!E)G:
 <1!0:\$\$Y =)R< M="6@#.'B00".C6+(!? ELO:KWH_X2O0/^@Q9? !Y?T.LL^/S/O CO MUH^S0XOY28X A: @#_X2O0-Y#K%EG.>G8 :O:C(G
 M)^<?>?M86=L""(PIW"GM!^C^C1@#D94F/^#BS0 Y0ZM:9 S_K!2!M9H/EK).UKM:>?O!60L?^Z/RHM/H!X4 8Z^+O#
 !>7C5K7IYIWX^?&A MX\$C^U!7D?ZP5!460=1\$5!1Z^ZOY4 8O "8^B&U^U^49!ST7 "8>1^W^RUK7<8!S06UL3^ZOY4:\$ NCJ
 ^A/#W! !-I3G H!#3 (3!PIG!U>U^M ZVA&@ A^Y4:\$ NK^5 &) PF?AP?QBUZX^1 PFGAO_HVG ?=>Q/H E M!L3^ZOY4 87-
 FOAO>\$ M>YR>?O4G "->Q4:M.G R<\$UO>6F<5! *C8G!MT?E0!S!GCKPW<^583 N@G^0K:L;ZWU&SBN!24202CF"??
 M:;X@>6X!27>?>997EAI<4-VZHUP9/F3/4^BJFC -L79+!P!AAET RE4N2 MSNZGB!L?>8Y!5Z9-
 H>G3W5<2VR!>PK#G/D2!X!X!F!DQX)T&T.6!BL 1 MPO=&G<4;J!1ZV:6K202!D7>6+?/M M7!/O5VW!7P7GB^!L.OY5X+9!W8V=
 !\$C&8P.9S6? !QUN!/L#Q1M-NO:9 MUV*6!(&)P/8\$U:7<=M!5!3>2*:9BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@
 HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
 HHHH *0@=2*6B@!NT\$8^C%+M!T4)M0 MQVIK1HZE712H\$<4^B@ P!1110 4444 %%%-%1110 4444 %%%-%112\$@=: M4F@ HHHH ****
 "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#UH
 M9US0!MRL/6E#YH).K-4U30X!O!Z2Z.R-U!>J!>f".<@<L!E!1H#O+Z.2U-D+JW41!6 M:YL\$Y\$Y\$?BO@CW+^!KD575!K1M+!9-
 M*.8FOH E!@!>J8>2^!M^=5XYL7!7!FDZ!7-7!Q7HF17:0.6FHPRS7\$9EB13RRCK+!MJKDY+ZSM:B+JANV^D7FDO^4VTE?
 W:NVK^TF>PM="!2!HHBMS^!>C!(50S MWZD^@#TO A)M^M!>P!>G:AI#>XWCJN>F?GIXBTA!H!NH6YN?>KRI .M_&OUO7D^D!>?
 M.D7L&IR.Y:B9DM!@B<^!6S@/3#&S6E9W!L=8L!+<6!MQJ4!D!V!G3Q 0:61 Q:12-V0.#>H!P!A!2:<7.6D!HVSIN6!H!Y8KH!TJQ!
 M>K66LVGVJPF\$T.JHP!^!V(C,&O! ECBUSO(D)EO!3)OM\$BQ2O OM^!>M#\$=B21S7?>[S2!H23!Y!N8+99!\$*&9/P8!CCW:--NBBB@ HHHH
 **** MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
 J/M&U!>V MTT/V?R93\$5#Y C C=VR#6G>?>P!M6>KZ!>=VEQH=O.01-72?G^S<@_ M&LXJ75M< #Z> **97:XE@>HW+>2H21!H3+IM\$T?
 QHM !4S75Y^QM!>T.O& M^!>22<:0! ^OP XOO!O\$E!H>LK DB2!>YBR\$N!H!90W&1GFM:PI2.G2W MVJO>30FWMHK&:-
 ^Y<^<3GT(KDM/T>U!5)JL-P(M0M!2FN:66!6C:/R MD^T:..BTKQ^Z5X-UN!ODCM-3G0Y(8X,YVS812?<9^Z4=#1GBR2+!B%>Z
 M!TL4@Q:5XEE!L2:3WQD#^!A!2>+!0!+!>M8M!N!(H!&O!N!B!N!R ML\$SKG?5F62?>=\$!VZK%>1W\$VEW?^KAKA9!>0>5M7-
 W/6LJST4!/#WC:0!O\$VC"XFL9!W50C MRR#&2GBM3O+J4\$Q!&)X!VZ2!V^X&48^A/&*-W2=6NK!>:Q#>PWL!MU)!>?>?
 E\$Z> *5\$3VKH^P.NM&@UG!H!H!M!O!>33.MDWE!MC!>1!G!>3 Z<="EHH !L7.L^N^N^00Q@!>BY!<4^B@!BQ!H!M**&^!
 "@.F!TH(B!OK^5244 .&=7*^LOW21R!M%&6R44GK6%/HH C%> M""22-WC5FC.48CE3!5!110 4444 %%%-%1110 4444 %%%-%1110 4444
 M%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%1110 4444 %%%-%163!A R&M^*8?>-
 T)SCIO>M8UC:IO!>T? M!39NEW CD +OB@#9HHHH 1ONFHK.4CZG=2M!TU!>ZG3! #H FHHHHH **M** "BBB@ HHHH **** "BBB@
 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@
 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** K A M^VVEY\$U!>2B^WA4OQZ?/6@ "S15.XU^VMM-^!L?>W!H8D^H<#G06^<Q M#>Y
 9X=20PABC2,K!5;T)(X/-'2T5BZKXKT3!8K>6 OXH8D^R!D!>QJV/<<4 MV!5Z3!H!A;WU!>W!V!ONT3F.F^FTWOAH>K!>IEG?^!J!>9("I5EP<^!T
 M!>8^G>)M+U349!T9!F M#(D00L OUR^NM!5H!H!H!Q47.OF58NY4!>ZT 6Z^S!2!UPTDPK>3B-YVVO!>M 2SGV INF!HVL2S1V!R!FAOY@
 (V9Z Y!T:5%4 4UBPT> 3W!RD^\$X&X!L M3V ZFH+>O)!>H7DEG;W:J-!0L!5!OK@!&

[illegible]

[illegible]

and 31.1KS57MFA0LBYA&O M>=>3<@DUV^G6=[9:!!90-)%=0PB,2!2%) P#CK7*60@G6;?3,*R-M*S*VE P#; M4?R6R3N+>ON:-
 /PYKJVW'B/5M'U=-+?1:)<1R09P8Y.XISW&I>^LN^IO M7+>|HR|J-|E=(A\$0%(HR<FMK2_#U|:~+|0UVZN8^UV<E1H1M"\$D')
 M^M+J7ARZN?%UEKMI-)>#Y%NTS;D:Q|MZDYX|@:#B/#^LZO&AV\$*60ID_VK)9 M-C9.CAI2!
 (Zi00UM7/C379IS4FTC2N?K:NK:NI;JH@=-C,5QYGS X7&;@,FX# MIM7_.\$>L)24+UUMIT79E|DAB0^YX|BHCPIJB:M?R:9KTEGIVH/YES;"
 M/)#\$88HW).*-#QUJHOI7@34+ZVC=9S#M4|X|W&X_3.:@BLM|_#0@%%BT|_M7E|:I_*VYD79EF^8|YY_.NCN|_MKW29-
 _N\$|RWDBH|E;G*XQ7.Q^%-9MO#_MDWA^WU>=&2Q>(P))/'3+&1@C6.#P<T_9AG0Q|C|FHF&*2|HC
 CRO|@Z%00I7?CBLZ^X=X=WUKIUG^%JFZFMM-1D08Y^ARI^YR^O M<|G|H J+|+U?2PS|J_5L|JRV\$AVLNY2X4\$+_#WK3O_.\$6B#2&AMKY_9
 MH6|S>:P/R^|Y&S1R3V|MQC|U^%UDU%|J|A@00Q^|D|H5JZGX M0NHQ_6AU 0K-9FTN|VCW|H|HX30|E|XPUV_NO^264-F@U>S>:02|OD<^
 MC^;G|5|^|UC5|=-T005FN|(W_MLV5R%C.)&C+88P J^P-JZ:2MNNI6T=S%|C:C|L1(4L22"">>IH MS^M_*2TCQ'=Z?
 K|MSM4L6N|>6^)>9=OWAROP1QOWS6U|6I7O_""|H>K">Y|GD M2(8^"KCC"><5R-L^W6^(-=,T+R|Y9|D)NA>+W4D)1^H7|H|0AB1Q|5Z^_17%
 MJ|H0(4B%&7^H|4+7Z0?_KK.G>@|QY|/BM;K5|9C@(-1.Y+W+Y)XK M3U;O|H6G;W,H^S^S^=QVWV3;N:6!^7D|U^#X U"*&RL1K9.G:7>+
 <6 ML30/NB YV^&N|U X=WMTN|Q0_0704^W>^|C4Q999 P^&NO^|4 11W^L;XO M4ZA6R|DPS;1W|SWYJU8^|O\$;4|M=ZA9|M-
 GM&N)GB@*BV^|M7#4.D>";RSV6N|U:M-?Z;,*4M8&7.0^,??.XL X^:@#F|80M7U;S|:(M?M:_9;W5|>6.WCC(-)2&* MG=GG(Z|5W_B;4|K2-
 ^FN|^%YU^A?_<*BY|&22_K7|Q?_#_484TZU MQGT_3; MU+|BTA>(\$JBY^4GOUX;NB|6^>3XET3|EP8|HY4FB MMQ+>KCF|:RXL|
 (-G6:DW0OCYO+Z|X|)H5T^435C5I6>62|M+RW4JL_O.C;M^7YMYR.TY|5G1>#M3AOKR|CUV03W/E2C%&H8@Q@^|J\$?P^1.7AOPR=%N+^|
 C|GG22|OW5Y^>3RXP0_2^O|_ZZUS7^>ZUDZ,UFL&E-LVR^6.XD^|F3.1M^(&M>36|1FJW7B.+P5|EN4^7EWN|C+|^M|YYY (KH;OPG=QZO?
 WND;BM|F|0 MNXVW|B#(&-Z<^BH9O|MR(M(MK&|CMK^2|IR^M08|Y=MI^W|^YZ>M^46-HEI|M M^1+
 |QW2M\$F^YZM^C|W3|PPC4.06P.D;T^C^ HHHH **** BBBB^ HHHH **** M** BBBB^ HHHH **** BBBB^ K|<@^|HN|_O|SW^*UJR7+?
 |);\$H4?_7LK\$ MG|(-8=J_-BBB@|K|C|D3+?_U""22GO|O|3+?_U""22D+1113 **** BB MB@ HHHH **** BBBB^ HHHH ****
 ^BBB@|LA94)1=S8X^K7->%O&=MXDN|2 ML|(>VO| 3|3%|S| CO&5/<<5TQZ5Y-/_PC;V^BT_LT=J=VM^JKG;S-M8-MXZX8#^|Z
 OUKOK|HGBFP|_06K75->(S**<#18_O^Z9=-0K@X#S|L=-UY^B2K MXX^75W^MN=4N+|F?|Y5=N(U)Z|1Q4\$U_<+M_70|U_-5=@&VF-\$ MZ;|TH
 |A|U#T=3OGK3@P89!!^M7E>|JORZ|X@U2(C|L_#HT|_8^6@O^5U^> M@&2|=S|N|A^|)21Z7;R75U| (X\$|RS-C)^S^9H 8%-1+P3P|I^EG%N|TL@
 M|R|@<8^O_<QX>4;4.SUYT^C^2Q=OCHYUW_MWL FMH|YHCD;T8_CKR^2_UX^A6^GRSR1Z52W>G6K^&B^&0&-AU^7|QW(K
 M4U3Q0EG+96|C;O^W5W&9HX8W^_NP.ELGZCZYK+|4SBIAD|^Z2L44EVA^TRX M2^_OO\$ _|Y^XU|TZ^&W^>D+P.C6#;^Y=K(&R|^_-P^;T-
 &M+XXMW|TBPO+|^_MQN;ZYO@OALX<^|K|H|/P>^MZ|XMMO\$&EW-W|_W;@#2|_Z|GB+3|+O>2|4N|(-DF-V4;&>*36-5O_0M+AMM.ENH
 M|NX_4TB^B<^9W&LCX^&G54U;4^N;_O L\$?F7#0>+J|5Z(C^>M_|M9|V M|^>\$ZG^QC3|C6R|<\$|^|G=G|STZ4>L9
 ZFC(C^|P|G^|J|K6|FV\$|EY_18KA M8FE=|1|(O|9L|020|T|ZCTV|YD00\$.CZ^|J6NM=0Q;?^RS0NT0N|E?8Z2|?7G^|H43ZUJ&F^?&=Q#_-S|:T
 M|^R.O8P168^1GH_-/5.CUIM9&AO>0V^|f41?W/#|9P2.#GK0|ZT<9HR.957^C^M?
 \$._PNY_#_W|A|_MU8.MUR^CE9|13ED.#R^;UQ^S+|T|DZA>/\$=#G#@SMRRE^Z>Y^8\$%A_M;K|M\$).D|SWEL^C2M(S|F;O^;|)P>M
 ^L;MN&I3_K;1.DNG;|UX|+3+|M48|_4USGAH2V/C|O|H|V|>W1+>Y3S|^|*7#@9Z^Y^YU|H>;^XP6LS^>K|_M2V?|E8#<0|W_2@#>|+>(&|2;7)?-
 ^;J9Y(^?=&6&TXR<5M;8|<+^N^G^_M^VLEO| AS2^NM^VXCE_O|IG95D2|H|WTF(8%>A|VQU^6FU^&K|K16AS|F^T|7-4DT^29H+|H|H0J?>-
 &^G_1&@;|ZW+K^E0Z@;^_M2TAG021B1U8D^Z=*CU^7?X.OY=VX-9LV|U^7K53PG=0Z^V^_*N;J18H8K%&= MV/
 6#@#IBPSC(S1D5Y>2ZAKN^H+|^F^6H+4V.RF&1Y^5K>.(#&|0=I|YZBH/ M\$F|SS6?B^|M|H0N|9K6^V|^5X4MVP|VA0?F^YZ=^/8|BCQ?;
 MKZ|OKB3|+^;_SVDS^33Y^H|0\$9|W Y|Z>#5;_OO\$HAU>+S>PG58|)9|+M^H8,%|/44@#^US^D8SFN9|0WR|^| W=R+^2\$S+3BZB4|@6&
 5^9S07 M\$BXU^&O=-M/N|^_A^+2L9N3|D|WGA^YBNK|X>|T>9YH|Y2X.Q^M|H^SOHL.ZFVQO2NVT^B1A0>O|3|+|U>U
 |E.DW<.%QJ6EWR:A91RVLL081^F MRK9.589.^/9.CL>_1VKR063>>&M1UZ^3M3N^B?2^NFV4N890<^AGID^GC_M|T|
 YM4T|AY14MM4@E.VE|^|"%|F1@?^&XG|^|)QCI0|ZE=3#^;S2Q|&9T0 MLL;GEB|P/QK^E|5BQ|^|KYV6.|JY4_K4N|^|0OXDBL^W@MK>VEM-
 =N8|_M \$N0^M^N^<+N|W=GY3CT07^J|M^OP/TZ|N|)H|^+O^Q^?^*GGG|_..|T MWQ@J|MSK_/9EWX^N+K+1&0W?F|H|8/<|G|JZ0^?>
 ZT9|_|=Z5^8RW^C|L MN|D^N9696==|4X|Z|F7A^1&|C|O^&F^P_K>|G2IB=*NVMI|(N3@+|ELL^?7+;.%>WZ^|) #1_P_Q<=<2_@#B>^TNM5|F_.5V
 M|F1^W<9&^FR_U>^ZQ=W^A36+^#53|)^9ZUG|C\$|9BJW_8R|_M8VUU6AV55H.MGA&*^>6.XO(X6DD;5BS0@L|D^_%
 &|D9OGFC|^|;|Q^T^9;W0|^|0MK|^|)=M^?Z7\$9^|NN|&KY&S^|QC JK+XGO|UMX|D(^YCZD|^|5YWK^7EU?>|)FU6 @6TT^_MYBBCG^A).
 A;M^N^>N^H|IR^P|H7 M|_76WB>G_92J|Y|^922<|2.H&_0070;@|XKRW6+J|AU^X|C+>702VT^V;+|^|MH|6&J3|=7%F^_|L
 MLEP1|;2\$9|XH^_PQ_*@#U|F55|) Y|^N>N^|UHEYH^M&US^J=P|^\$XEA>>|^|E M<|@-C\$@S|L^?K0|^|D>M07M|Z^9S7=U(CX(4+NYI
 5Y>|U|P9Z^|E@=400|>_MNBV|MOWA>65^&H;3GGD9SP^|W8ENO^OC|JRO&N^6SVO#\$^|W|D|F(\$|N|R>3|^M_/8B|5FB61#E6-8^V_-#
 |#65911VGAQ5C\$^09|R1|VT|>D|^|

[illegible]

[illegible]

4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 44 M44 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !111 M0
4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % M!1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110
4444 % M%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 V3 M 5MP2+ %2 2ED U;22DA U2 2@!% % !1110 4444
%% % !1110 4444 M %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 M4444 %%% % !1110 4444 %%% % !1110 4444
%% % !1110 4444 %%% % !1 M110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % M!1110 4444 %%% % !1110 4444
%% % !1110 4444 %%% % !1110 4455 M\$N\$VNI=H98U\$UW>W- %JBBB@ HHHH *** BBB@ HHHH *** M BBB@ HHHH *** BBB@ HHHH ***
HHHH *** JPNU^VFVVMN^|XXQG%6:C/E/! MS:-^9QSBB@2BBB@HGC;22DA U2 2G/!P 2F0?ZF!0!)1110 4444 %%% % M 1110 4444 %%% %
1110 4444 %%% % !1110 4444 %%% % !1110 4444 M%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4 M444 %%% %
1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !11 M10 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % M
1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 M%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 (W#!?9!_J4-E?IC?2F0?ZE/0!
M)1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 % M%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% %
1110 44 M44 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !111 M10 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% %
1110 4444 %%% % M!110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 % M%% % !1110 4444 %%% % !1110 4444 %%% %
!4&R7!5OI>5MOLOQW!7-6HAX !3V<M^Y>>O&^G!UH N4444 -?IC?2FP?ZA/I3W^X?I4=O !\$^E \$M%% % !1110 4 M444 %%% % !1110 4444
%% % !1110 4444 %%% % !1110 4444 %%% % !11 M10 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % M !1110 4444
%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 M%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4 M444
% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !11 M10 4444 %%% % !11 M10 4444 %%% % !0?E % % \$K=QW<9DCW;0!)RDD Z4M !5<&#I<
M5" OMF=VWVG!HK%50" M ?V>7ZC;G!US0!;HH2B@!K M;9=SDZ!9!B*3)QQU6@#42B@=** \$!A^E!V !MJA3W^X?I3+? %0H EHHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** M"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HH MHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB M@ HHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *C;S2HWXV/N^>DHH * M*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HH
MHH *** "L^15U!VVB*(6>)V#\$<@ CI^=,%9=P/^>M" ^1)VYZK0!J!H10 M.E% #7^XWTH!EM !%I! <Z4RW U(! EHHHH *** "BBB@ HHHH
*** "BB MB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
*** "BBB@ HHHH *** "BB MB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M "BBB@ HHHH *** M "BBB@ K.FQ;EKEQ*M?X4
:M%% % #7^X?I3+(Y8 \$<AZ?;+ MU= #7 ^)=&M?2?B?=-+OYM !Z; "DB7?2=9&R0K#>^)*+EMXSO;VYCL!1G^ MU&ZEMW224!L!EA26)QT
!BJJ^/=2!G4;A!O!MWJ!ENF6Y!(((R5& !1PJ_X M^U^>U+3+T.K%; "M+V2VEFMUPLS^%>ZV^L^% M8!>3)+?V9-M=%3SO0XS^;T
58 &N?J?0KMO!H?F3/L\$BK/GS^!G^!X; C6; B>? !0W.BZ/K+?;*#P42F%G)26;1^XZ?UJG8>=5U/PA^X@M^C=78!>9"7.V MG"!/T?9UWLW?
XFW.I63C!>I>FR6!S+ !CY4'N1C^!K*70Y-0!>V! M (!:W4CRO% D^!T%Z^OR^/45.0#2T=J^ "BBB@ HHHH *** "BBB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
_BI?^T4T^A!X;A2LT M=E^L@/4;\$&10!KT444 %%% % !1110 4444 %%% % !1110 4444 %%% % !111 M0 4\$XHI&4.I4C(^!0<@TM-CC6*8T&%48
!>=0 4444 %%% % !1110 4 M444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% %
1110 4444 %%% % !1110 4444 %%% % M !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% %
!>6273!^&VDD&)&C7!G/S>H\$6K10!F67A M2!N7N;RBA);^9@PSY;?F4 C4+>\$!>=W!>M7=V+!>L@LQ/4DI36S10!
M6Lk^TTZW^O9V!4\$(R0D;A1^0J#4=\$TS5MOV^QMIG;JTRH^!^% %;78!>M_912P29^OE^6-N?I3K33;QW?9+;#>U!>+G!JM44 9NK^6
L!TE-FS^!>M! Q16 Q!>O!;HAO^Q!OR!ET@>P#BZ<+>#Q M^6!3M9!2 9U044 87V^Q^D !3NUQCC 0N !WW208^>=
MAV.S;MO&C= WUTKBNO!& (KSQ 99Y+RQN;<R0V^>4H!4ASN!U)E;#KBN0H *** "BBB@ HH MHH *** "BBB@ HHHH *** "BBB@ HHHH ***
HHHH *** "BBB@ HHHH *** "BBB M@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ K.FC)06KY M.!#
(WJM;=9LJ>=ME/WA\$X^7U^VQ^M &E!110 C?>TJ^V U!Q5 N^Z%#; MZ@4 34444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110
4444R6; M^!>75\$49<+<4/HJ^!MIF58BK-V8;E^L^D M-DU^SAF6&6ZA25ONR@\$ MA0!9HJ^2Y@B!R;C^W !D4C7=NL;NT!85ONL7&#1*
)!^AANK>X_T<@!M48^51/I^=A!3WD^R(LK2 ?A0!HJ4; E; QU^TVGOYH P^" !VLZ8K^! MO!B,V^!J;G3H
0452N=7TZSG2^Y08!G&5C=P&8>P!U;B!Y8!<9SGC% M #J^H6^N;7=W^D6!>R3F?;KP.; %HHHH *** "BBLW M4M=L-
*DAAN!29YL^5#&!>WQUPH!H T!P?7Q9IU!>W^E +>CJ;PF.2WD49" M@XS!PU/PB^OU72/459H!H!A8EG&QF8H!OQ0!KT4@/!%9.0>
63P !!+=! MRLTOEC9R1P26QZ F@#7HKFE!;UY#; "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
4444 %%% % M !>E8VE6&JYVZK!<7VH^XMB;B13;PA<2H^H(ULT4 5-3M)!>+3+FUAG;"2) MD651DH2 M^C
T^!>RW5XD4VW=L8^/6H!XKT1C@7!9.<< !?RK7,4^<44GU(MI)C!H WR^;S_A)M***ZW)96!(*Q.1^>IC>*M&5U1KS:S#(B<\$!6N(D4 M !0
/04&)"<!%S!^G (2G2L9;DX !>9? (FD/BK2AUDN/PM)3 !>60M^ MH^ BCM0!C^Q07HY\$ESC *YO B;#X!TH?O7GU^PS !>Q%6T>@HYCTH O?
@ M\$KTKUO^ !G P#B^A A!>+P^GW P_G !B^VMH!^HJ^; ^A^=>)?Y M^Z?12^> (I5!3V\$>\$ 1ZAS _0?>^ XBMC STI<@=#^B.S;V#4^3T T&8?
MS7V?>SUNOP^4R0;D28H!6GM^H1M^&+ P))&5!&FZH!C9%>B48-MW2=58XSCL16!ZV^>E; &PN^SUYZ Z;K53!2R^Q T+5V;B?>
X MUOX%&!0 B-O16P1D9P>U.HHH *** "BBB@ HHHH *** "BBB@ HHHH *** M* "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
&Y;@!\$XZ>Z!5HUF7 M;GEZY9AI2IRZA< !W! EF@#3HHHH 10NFHK7 4!T6^Z.AM^F!QH GHHHH M*** "BBB@ HHHH *** "BBB@ HHHH ***
HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
!H0!6MYJL27 MMH\$(FGGF&YR6<+!H<@<5!0Z!F!>FUFU2WCMQ!HLK9BZ;XRS;IGCV%4= M^T/Q^XF0;2HKH!>UUG;36!8;*>9!>6J9HMH
X M^!S MUH YWQ+WMEXSAU^05"366F;9+2(5ND!S#<=P!D>12DZ3XU!364! S;7N ME3+R+M<\$H^G(Z!H74#2=2/BXZLOM!>?
90LNP^M^C^W=NSTQO&JNG^4ATCQQ M<Q9;5M+!W^ROQ!ONR;LY4=LIZ;5^*L/^%Q!>38H!&A!>GEC;GS2.XZ5)XC
M!\$&QTF6RN!>OR;C!SYN;=9,\$R)DDO?3?3!U ^\$>U?^!> (TN+4P&T^Y)!>@ MN!>NSZYK=U6;!GL9(;%H4F<%=TN< \$=>.)^&57Q?JZ^+>X
MM^8+>!(MY>_! O^>E32>9OHUCIR!>F\$H7T M+^AP^C+?>V!Q6EX T!>Z%#1S
M/#.D&=DL8(+98DY^XU;!1^!>O)H!FGW+O&^P=)^>I&ZG^L!<@&#G?B!EG8 M_#R N;2WC@GT^>2VTD2!6C92,8-8UY=M>^>^!5Y+!Q(N)
!BPDDD^A>24?Q\$=M^Z>^!>I&KEDFFZO?P 8 CSE@C!>+<I&)/?>I&ZCX8U&Y!5Z;K%M;HJ!>+&N!F2> (=W;5!G&^Z6FD!B^C@5L-
K^F#DGE^44;=8819>595.KVN6Y^STW (3;PT^8S;H4 M!>C< P^>O)X;_9M?>OJ@>O#1/6L!X^0!T%8^ FWA0!Z^#K^P!H
M44A;^&Q S#H!>L^E^0455W^;^>S \$8&2R;"E P^SV!8XU6^F PH Z^ MBL>---!H/3!V /Z4X>="9PBWV760")!>VBL^&C^PMC=-+DX!D@=
MD;=VZZQZ299_P !8?>V MCB;MF!X!29 +% \$GC+38!1!>C\$YVM^T^E;C!CH PC \$5!>W!Z!X9TN MD7;IS;ORL!V4&L/Q^JNL;
EGHT47!J4!FB9!>G^LV^F!GCK?Z299!>M!EM8P@B^WB6)!BC H MT444 %%% % !7G^AEC^4/4-6@U;X!J0A^W!L^>+K^=8\$\$/K0
FL6!HJN M^<0; M!HMK!^!PQ!R!G?XL8 6O!HC=ZK8 #H!C4;D=3/Y4>2%89 Q!X%>@0^>HD MEN:B!NK!F!G 2W\$QAM\$!1!>@?E6;W!L?>
!\$TS35U^!>4;YMO.L@H^!5R M_#F@#\$U^6-5T;4\$;D37!U+0 B2>4 @VEY)IUG96R7 6UPK^!>(S^)/H^!G?>UX02!Z!Q!>=50X!N^Q!J!C(\$
M^!SY^D>L;CX8MM0U;5\$N+BTQHHVB.UNP!>#V;(!>W!0!P^>M^MX<=>Y^!>PA!LOA23PZ\$>=+1-KD^>+DY)SZD!U87PY8KJ>GWX3!
!86YMX>!MPIO A^M^G6!RZ0=^F37!NWBTE(6@^9#>+?U!>OK7H AF FU/PS!E! M2SVR2A
4J.UEMX^!EU=Y+!FZ8 N^MX!<8D^0^!QA>^W(T^N!M)MM.MVHHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
M_3RGW46!ERXZ8 Z?JK8K!>Q%#>(+>#J659#>@<8R>>1H4.XZ44#H!0 C<-M0V@Q^E2H^E16G !HK0!1110 4444 %%% % !1110 4444
4444 %%% % !1110 M4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110
4444 %%% % !1110 4 M444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !11 M10 4444 %%% % !1110 4444 %%% % !1110
4444 %%% % !1110 4444 %%% % M !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 5B-ED M^>M^>YH;=P;PZ5MUA;NN?
\$>AG X;?J!D4;H44444 ?!A^E16G^H^ MXU;WW3!^AM?J0J;^Z*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
HHHH *** "BF22!\$A9V^J!8X !L4!4R!HG5P>ZG- M\$M%% % !15;^>MK>Y@MY9XTFG)\$4; SX&3@>=^!3KN!MK& SW4!<0(!>1@H!M!P.30!/12
@C!>E !155M1!UOH!K!F(74BEDA+C>P4@>=<5;H *** "BBB M@ HHHH ***0G;"30 M^4.UFPU@7!L+E)UMY3#(4Z^XY(6KV;%HHHH **@
MN!N^QM9+FYE2^&99W !572!K+^TFZONXA)= "94 MM4@&XR&C(Q!8YH W^*Y^G A; Z4EXD4!DSSM+!1NEU?O!CU^7KTHH7B2
MSUY;A84F@N;5!D!M.FR2;JLCT^!>L!Z5AVOBBQ0%QH-N3)<6!OJ!C!057Y ML;?K6V3Q0 M%8>A>(AK5!HMK!F;M/N/!>C+<Y^P.U;9!>
%HKY^UOQ _>N M; &RAMS<7M^!>L!Q!M!J!N!XDGL^K.BZE)JFG+>E ^ZC^755W^M^M!ZD!JL&^D\$^N^%HI&95&6(!Z0.1)
8"7F@!U^!>K!>Y.V!>QUPP---Y;+ MNS/\$@>#^!PX!HF@^!BH/MEL+H^UZ M4 3T5!>=VLGEQ5!H^T/M# G!Z&F!W!K<220V!S!>G#
!L@!>4^X^2@^!U!7GU MQXPU!>O^E!G!MOM>G7!V!>5=NTJ!N>QWL A7;0Z!9!>E!>6!>=M\$!>WC M_@B@K!G)FP^5!GN06^!>G^Y!
M^!>TJ^Y!>4M;!>06>IZ!>H!N2!TM4?>6E!>S8XQVP^*!>27P!U^M^\$Y\$5
M!>6;4SC;V;E;>>N<50>+>+ZL!>F!JMBRK^!>R;V>..OUKEG!^>(9!>MW MHS16:S37!N%;SB5^F3S^#QU!5U^>KZ9-
K!A2!TU!L4US;F.X.0K\$>O!F@#A90 MMAU^X?W.T44E!L!G5^P O!HGR-S9?2UJY7B&50 !LS?>W!>HBT;W;4 M^>67\$H4.#C)
!>0?>C!>OB!K!P!>="R(TA)!>S-L&4 Q!>I^X5!2CPU>V\$<+>M>GBXDU0?D;5BH& ?@!>3!>M.U:7C!O!P!>3!>5WH!>6W^D!>1CG&!8NL^!>=UB>
!2=>;HH8W!MYRQ\$M!M;MR!>=>A!UT B+29=8!^W^>FOR^LMQ!MSKR<@^!>-%3?1^>^EM!2^46T M67!J!>=P7)>?>
!5ZW!>WU!UH&ENEM\$F!>S);RIAG6;Q!M!>^D?>+M6(!>#V MO#Q/H!NJSO9!>8M;3JA8;RPZCCL0/KFLR#P)KL&C0207EK^>K5E?S7=LXR8F\$

HFWD&:9<2M<-6-M)(WWGDB4D MB: .F\^4VT.O:3I5I-!UV9&E97W>7&BD[CCIS@5YYI&I0M+340&N+J""%&O
MJZ&1PNX9.D9ZB05X1\$TJ<8M/M4WJ58I\$HRIZGCM1-8>E?+ ,_2VT^48"IE> MIZ=*
((O'EY<^(I_)4VMNTFE/JCK*T9W:HPRC\$=^0>E>FW'BK1'LC'BNH MKT71 B@A(D:3/^S-
(ULPV=M:6-D001QPC EFB@+^51P278VTIEM.WBD/5D ML/YB@#)TKQ?HFK>(M0T.VH78*#+O3"GG'RG0@UQ7CB2SCUK5:Q+FWN9H+
M5(IK3:Q<T:86I-SVS7>V6@I:^(+W6)9?-GN\$6)!MP(XQS@>N2IM/%A.FBD6ID^A1X")=,;CCZ@'M7/^\$H^U6+
MPC^TU&^M6M:9XV0VUJ(O^V^*HFYJ.U '\$7ZZ?H?BBZ\$5 M^CJPE%)(\$:AH+51@ M@>4>8Z#9:??>\$H/3H(=L<^&IAB6&IU:9_5ZX88FSF-3GDY%
BC#;@BAO7%'F5GK>E:AXY)2 MV&X1+I!9'DL-APH"GCM@UL^L.WLS?Z'DNHOIM(X))++2ZVAHPX7E7!\$&NQ?I-M/-S^6@'8W5
MMH/LCYIA@F-GJH5:1%CBF10-VLON.C+5ZHI^K+X:L@JL&6W1&5U*D.%((MO6H<
=L4U)8WCWHZE# \$#Q0!XNBS P#"M4T>2PNFGLJ67S4,+\$.HFW""(QS M6KKUE=:OXH)2HUO(WVG0XX824**JY7)IX(KU">WN OADCD
/P@X-.\$D M1E.092-W%<IX|<4-79&6V)M8:C@>M=MQ5=[VSI5I\$B\$,""XXH I4R6-A MXMTZFM9YIM4EEGLY%P+!=")%VHN1T/NCVDS?
C2UMK^V.GEZ)#9L(PED)U M6R55C17H8N[8VZSF>+RF *ON&T^F#3HKFWG)I6-R.3M8!%"DUK8FO?4I& MU:0+V^O^O6GM) |A@F#-
N5PVVU=O!^COD\$FO^<^/D^T1VUUNEPHO/M2VA9.IBZAYX^<US+K:O#\$+BYT.I@R>"1(23RG.TC&0% .L24=JNF7P/OM972M

&P\$8(O&U;SJM+BOH<12;1DA1(%G&=>M";6IC3KU MTFE.(N0F#) 8\$<=>C2QH7IGZ:T^-RDXGB;AV^8DCW\$FN8U6RU"7
M7^+&0Z9=>M_IH@MVV%<%G%3C1QUKLM%1/2f:>*OO(F^R;IY6FV;789R/N1 M5MM?T=>=VI6HP0,^,I(S&H XF6RU<
HMQ(%HTL^Z2):R^Z@%);#<N0 M1521ZU%UGUNKN^PM+N2)M1D46UW@FWF(X2,YZ^T^<O3V=50N2 H6&22>^RH?>
M\$VBW#JD.I6SNS!54..L2<#<KSZ4<=>V>K3IX\$9M%NPFFEN?M)(7@>5LSCA M>K1UK3M5BU;Q/IGT;XBU;3DB@DC90%94=2&R>#1P-
=1)XM/PEUQ/JHHNQMC M9D& WIGU!A^!HJ64ZL";.(@2.6X3/3IG/H XI2L;U;Q1^%HI+N#19 MZ^IDN7&TH);<#GK/O6LMM"UD>^9H!<
(NWNUEUHW2J=>FXQ>8C M9D?>1^1^M?>C M7D@BMJ2MC=AE0^ W?3UIMWXGT73IKI+>E;H/D)^VTDGTI";.E.KI B5 MYXC;_M;SU9A^f. @.#
f=120.2N_3/>GV&GZ0;^(6N9M1^).GDE2^A=XDQU7DIN<9QI;A3QCX>E#&5K9IGWIK9V_ M7TH Y4 31U^FVTCPO?>
fE;VF;HJ(NH^RBN=%YL>&SN3^V;JFFZYX7M8\$BTZ^M%BE ME^KY9^5I&3/3J0^R7C^0J=U2^10PQZ2;J.YLA^92^?1^>EYXS6^?>
%>AB16T&H1&Z9@H@&2^2< M?>ZXIZ_+T;2_&=>7NBW1>DFY3^4SL+J_2^K1,K\$A@2<=>\$KH2AH>H;7I&H MKJ^NL\$MQJ5Q;0^<R+RS^VF/
^R2J2JY/TZ5EVGA%5 MXOAOJVG2P/JUYN@4LZC;.:DYZ;0^<=YK60=>H^KJHOYP@PJ^S^K2P15^M)-06^BK1J2NX;2VNLW;J%UA=&1#J2I(H
RIJfT5M106;ALC%9G2L^YD;M1^R^P;0%SR^K1>^=E^Z1X;GM8XTLB;+>=B0^6BB;5..NXX";O1J3B@#F
M_&VF;Jf@^"VTIOWOG1M(GF>7YD8/S+Nf9%IN-YA@0N^Q2QP/0^K0;PVJZ9XNU01;X7= MK1#^J9/);0W.Y)&_EHO(&=>G-3.7H&NZ+
<7%M;000IMU?7C;..Y-QM&8 M^INDX=9INLVYf;?Z0;+G;>3^C-6S^2;1WHFAZ19^<_19^<A(A)>14V ML&4X^UH^FK/POKD7A;PMHYM83/f=
f/B88^3Jf120?TJ5_!^VMKHfK>&88H M6TZZF9X;J2?Z5NS8%<=<02<5UUKKT5WXCO=&6^59+2)>=G@UK6^/M;1@4<7XA!
(SW^1^<4;XCM3^%X=P>+WVJ^?YE7f;E1^<%=U^W7KP1J8Y0 M;)-W"(EEH^1^34^F>_4J5M+^*WF^W)G^0^N^V)BL^N^E=30YQ;>IM>C
MT50LULZL;G)>YK^f<0Y.Y&X^4\$BKVH>%0%&KV?VRXOI2WU;^XGFM(X OA M39D^/M5LM4TH^(>?6KFSCAN;.\$1PH^f4-ZCD\$M6+X
M=N;JOGT">^9=(OQ<1BT L1AY)H(7VD)1=,UVT C^WDOVM\$TJHN47V.2XBC
M^HND;1(SD@=SCBMVTT03K;WDM+;W=9EVC^&);@#CM&L^>#B;TAM1M\$T6 MYE)B>%6^T&S;^H2>_Q-4KGp-XA?>
1ET6^fT f%;WZW=K(RMOVIR^UATH17I M61C+&0fE;fHNL>&-0TS>J2W=J.fL^RD9^G->34"/JU=7%ENT>W>=&M7R@Pp;N!GV4?>
C7>Y%G)D#C_<GLG@25Y=-O^MJ;VYH5&U&SEBR54D8VMGL M1P<5TWAf2M0LA<76K7BW%;OCF5KB15;5HU4 M-TS^56B0^>
_U3P=>ZO.5NKJX5U!&R&0fE56;fP^TRUJE-X^U;)<10ZM# MY+Z&F-016A^.;159L!@#&8Q7H&X4FX%<@C^>#S>#M1EL^S=F+RV";U(SL2K
MB9W+M;7/>58B1^Z@FN;^F6MfN6fAM&#&#)Q2^<=>+<20W7^1& M&QD5N^H;H;AZ>Z;LS1PJ0&;JOH)XDU?S^BNX_?QJ^Q6#fVOW%YXOU^1G
MMXUAM;*>=)EDW%PY8=.WW;_NRH^?9K;#3YM0;72f;1^V0P^7AB^XOAFSR 3 MZ=)O^+?VI?266LW-6IU^PDN;.(#MT8@GD;@ #79^D>=>
fJN>F3C-(140! M>151Z%GC-&K;APZMX;N1#&#&XMS "G1(Q639^#9K24^JOI=76FGTZV>!
W=Z+AMW46ACZ5U^X0P(CZYTf)E2P6CP.fWCB@#C5^\$";1C74ID3Q7CW MMM=*H5X9)+8OU!R>2NCT+13H\$WG7'<9QIHFS_P1^7H
MZR^fTHH 1ONFH;3_4 B^Y MFfI^Z;AM<=&OJ^YFEU GHHHH(%%%%&%%&1110 4444 %%%&%%1110 4444 %%%&M%1110
5PGB^ZEO%V@^+3M9W!FDD"2;2^V)P.^#&9S7=UQ^B^4)OB^X M>08-N);P6<3SKMP;4 8&95_-4H4!CQR MN>""UN^N;FX>UCM0!N\$ MB9W
G_!CK63KWC6f>RLETRVEAN9-36RF&NT%2.2IG@YQC-8IAH^B73+9;JU MTU8YM;U>...SC<;9f>08^H>=>23M6GK&F>;RTL14-E%G);_W
SMf^OK;QM%=>W51<6.T%Q^ M9?;>fF6W1^AT/L^L^K76-U^74&GE8=4DA& K1 IP&_9KCL^PWJRZN;N^O MTM^M^EM719@Q\$N=S=R?>
6#&H=1=>Q7S7^7TRfHfH-7R0L!EY@N<9HIC6)X MSU0L^W4E08A!EMM1BBB6^&499E!CW1FGV^Y^KQTOP9^VG0^f5H1 MG14^<1/7-0W?>
AGQ;/#%YX;ALf2-W%XL%R!VTNAE\$A!7GD^00!WNLZQ;Z#H M^1I70=H85!^QC+&\$D@ ?4UQEW=32_%#Pf;096L\$5M;7%O<+^/N+>8
MH7(X(XSCM0!)9?&FTNK0Q^V10LMD)Y<_B2AW0!X;B#H;YIU0! \$;WGU^SB M^<R^f)D>3-
#;L@+H1D;G3^D@X;KZ^HOBRO@AT^8VBZ3;_6614YDFA1-G8) M!G;ET^O>#>EJ^#=[3^RH92T=Z&S^T6XGRH^7G&;?Q\$JNN>K6^72+L
M!U=NDP^TGSX\$P!;CIK8XYKT7619MM T>4;K/E1<+C+&G SW)K(SZ5Y^>
M^6!+X;2&U;QLfZ&6WN3+!TD^RHL%>Q&.O>NW15Z^/\$OAJYTSS^>3.R/C.U MU8,OX9 H 10^*+N+6<-(U^3DMfNIA>6U^SfE?;C^DXX;GT-
KZWVfVIZQ9P6QfQOR!(DE\$GFR_-MP^C;9XfZ=X^TK5=#M+NRU&SC027;MRLTfR;H+5AYZO;D)-DUF@VDK@?>R0>=>16M>#?2NH2ZRfFRE6
M!BN;=>1COVJP(CQ_!C!;-4.MfVC+&O\$W08+!H8P5SW/fS\$SYMHP>fTO M5>6ZNBO^XN1S3K>U>6&=D;_7>Q78;1OE^fSfUF!+4f&; MU
4DEK(#AOHfOTh!P!XHEfP^ZC<6#^3HfI(1^#9?<SfSXZ4;GC6Q6+M;FADEB=+1fT>1D(8^>
<@BO;13U&XT_fJfPEMW82S8Q1^_G#28XUZMXCL MfW4\$^NK^QH27;31%Y^0\$# C/f7&;Y;+P#<77PR^f1fXOW^*L-Q\$#R5;<@C/M/O0!BZ^>
fV/Q@-BP;RVD^<Q/H;L0&fZXfP^?>QV7Q156D3RM^9ZP!>D-D M^A2>3fDUOZ^X2Nf7Q)/XCOFA?4L^642f)I^fHY)/N;@T#PIK>6^f_Q+>W%
M_P#4^Q301AAY07W/W/WNE_?2%SO)>=>QO fTICE;BX862R#^19fLY^Y4;M;OZ^f74+6REACN^O+422W^C+;C.XGKG)KH?>6A^S!3Z^X-
<_H_A_P 4;1fT1-7M7LXfE!N!f;fHL M7L=(fX3A2OR3R^<1^YZ&f_UW)X1^>_AC4=-C6;-fT.YCB7_6KN^Y^_N
MOM76;fX>76=+Uf3M0>+5=;BfGS)UWB=f1^GY^f^O@V;5%&KXB!030RW%G^MMM;6%3Y49YRQ);2>..%M^K^TH4!AOH
V^HP3CK7H_B16=5X8U6TN!%fYl M9?5;8)P^>^YM? VM^QZ_B1ZA9+>^7Y^V_DL4VBP6=6-6fCPOXANfS6+J4 M;R;WUWfM!^fV^G<<N3SZT
40^K^>1^K&0(H61L2XGM8W7BGP-M^0#)=1^f4M&525%;K^>1^#H^f_70M@YM Lf6LJfK^X_LfGVGWfX622#F.
MN(f#T<H6f7f)LLL&82WG2#f;fYN 2.WK0_6f<6B7_C^%08KWf+)=7=)K496DN9F3><D^Z5U\$^A.Y77(+BXN+

```

E:RW.$UT120.107.7?*>MNL7600Q/1>44"MD).>I=/PA/!:@#.HHHH1NE06?I/\W$4F?=-5/+4?/!^=%FBBB@MHHHH****"BBB@
HHHH****"BBB@HHHH****"BBB@HHHH****"B-MBCVH$+GQ#P#I=-9.C4(KC.)YLV&T>IK'5/U)I%LKN&=HBX1LE3I^E
M<:XD13I50">50AH:D'TN'74&L(KV)KM?00@./P."G7FLZ?IHU;7=U'#+<<1*YQO/H?FN
M4:7HK/CBJU25PT?QIENR(19L@^A!L.$G3WFI+M!N@:ITN5+V\OL.6M*XC.
'10ZUIMSJ$EA!>P27D8R!N"RCW'.JC^+=#CAN)GU")8K.7R9W.<1OZ-MQQ7GL&OVT/Q)'B*W@C.
++O;/D)+.O4RJGFI+!BKNHV/D!S7;RZ39R@.$9#/RH..10!VDGBWQXMDU".0T8EZ!A3T)XX%(OC#0&A.RZE$T8C;NX!
MC@ZL..0.BUWFFVMM.21Ox80+BX<:V?;#>#>E1Z;IEU!)M)U%$=US.Z.M3$PZ.%R.=Z.OAU.SN-74(OUEM&3>LL2S KZC%93^
O#T5K#>2.BJ6I!8.MH7C<1>@)7DUY.X8FN!FCZ2KC?X>+!S:5WYMW)W7IG^X3CZ5JTF!PU!4M1H(=3M@OS.G+1U!_6@#T'S1Z5?WH6-
M=AIE8S*8RC*0N<9Y.XR14(17Z$9.M8HQJ!9EE!F.MK;7?-H.&#<"^AK)B6!N?%>H/JEM%90Q>.(X9XI"P*27^8@8M(V@UR-O/?
^08K+1$UBL^@Q7;.66K6S9P0?4!T=N<DW?B72K*ZGMIKD^M;H'F!LXC4I"Q.(2KEC!KJ5E>6D@EMYN1U!PPH7G&IQZX>U_6->V
MP0:WHW(HOK0DB6)E&#L/?@!$3P@^G2^%K%)=FLBF8PYR5!YVGZ=*IXS.MT*0WP2I+&P_X^@(_G=?
!W%6#XFTH.$FM?2.-==RSK&Q&WUX&<5Q>O?&PMXW.MOKV3R.LFM:X9-IM?..X"!+90)!O8$MD+1%
'HL/BC2IC4$!H(#+O&)5B,+@E#QNY3WH3QH)O%FE6I^MD!DOVB1=4M.O.QE7^!N!R..X+PU_PD.GPXM;.*VLY+26I7I9N9+7OI
MHTY6C6L5X(M*GJ)H!C&#^&*.YM.$6G7NG3W6U*US%Q218E)=6!YI7KD.M5G+XFT633J?VUK&UDLY+O..N"7?)E.(?3:
..U#Q%I^FS06ILK.MYDM$5C>RW..7G"YME#26!PLDF#T(4C)KF=#.*XIZMU)(48+86WV(^DIW.MOMD+FH>WQ?&#PRUFF$LMK.MRH_BB
!)A/P+&Y&X.MXTFYM9KFC.>?IF25L12$*>1^7C%UG=P7IE#=#VTD@FO&X_B4I#7F>C_M-M-TPB8:.
(GSK$HYD$N02FLVZ9ZUZ9:0Q6MK%POK%$&5448"@#IB@#.U.MGQ+8Z"UNMZEP!<:
(HC">SAG/I>IU.*MWE>HV>F27I4OEQHYC($N!WKKF7B-M!Y?AP.HRV.IFKH!Y.H$P#M)Z":%TC4XM8TFWU"12*X3>BOUOIU
M>R!L.RWNE!(E_E)_JO>Y$B26K8I!6EX$=IYVA76OZC!B$ZFD=M/..M*2LDY9&5G*B-4Y!$9^44>HY%+7DEM=PN@:
!KTFLLW;MI%!=>3#@%9%!"I.M5#^H!YH!ZK;)!(-UMJ-E)CW#;7EV:E>.@#;TSB@#TS(HR*PL=00+F.MU!7HU"Z.MV3#10!ZU?
6TUY/)>$G@#"M@ZJ&Z9_*K&:HO5?1/$C25K>YNF6M(9D5I"MR9Y#U7NIG(%..F7>A.WX8>VOIBAU/5TLKE@R.A(3G1"/O:3-9+9)/Y4EQ&
#5F(8PRMF)"T!Q)Y8->Q77?;$SKX$=WMI>7.X.MM$12.0ANH)IT=D3.M1FO-IC3KD>-I/T^V=1^RZA8R37"-1.RXP01H!T!HJO6FIZA!
HM2M+Z!..MH$X?T.G.AZTA8#O7D1NCKY!$=AEN9+I=P#M$13S?T.T9E9AR6SP!M3)CFUZ!$17>HWK0WFHC3?>#..RB1EP.3COR?
>@#V!L-N<1>M8FA>O-8U+6M+*2S-NVG3K"27W.IJ&JN"X^T^GCTW2M%N.V22S77Y+1Y7E.7C&2JLO/T'MX5UG>)>"T12>+X+?_4B^CV-
G.EDN?UH!8LP306.ZD#O7F/C1DO.$&K6T.MP..WT@L3+!M2WR3AD.Y+G^@JKIZ+KNH>#_MDUPR7FC2>M@#UG<-
N)!%L%J%$WRD!>Q*#(XT=P!L<94.ZI.M6.R<9-9R/6SHME!)&LLUQ<1V2LV!NC!2^VC-A
M)POGJU.VL!^U8CPQOW@WPU>HLLT^KOVZ2B+&J9&Y^@%2?!)XA74M$T>33;1-4<32H)-1XD
VGV+$XYZ50>'M2U&^TV2XUFRL+!A9&!A2<2!5!JP.MXS7)W&G.MM>:ZY!H=MHGB^2I6>"2R$H!P^SPOC"A0.A.FL_P126=PVHY:30:"GS7
M!)(RA^20KG^+M0!W^J^(-VPI9;+HZ6!62GNH+!3?7.J2@SP*Z$>WB.DTJ1.MH.K.<5YRUW:S..V7IZ.Y&MI#G<"3F$?
UK<11%)"PNU&#IHJ5DUMH6I!&(<>8)!MSI!>ZU5U%RUQ$(#TDWC?QOKO!"M+M.73)!4$6G6"ZA)=%
<2P"YOAIVX$KUSZ&KCSZ+0.;5V5U!6CZL!L5Y.2IO!W"U"Q+!I/A235M?>WGO+!O+97#.%!)&:ZE<1HGK7.MALE!GX>)+?7?)<
.:@!^7Y#..AR!V'4@5Z!^(-.NM0P+<H'&MONA!P!-6BBB@HHHH****"BBB@HHHH****"BBB@HHHH****"MBBB@HHHH****
"BBB@HHHH****"BBB@HHHH****"LC6"!PZ.P.MCV..*DK7K&ULXO!%Z?2G?KE)0!LT444.1R!O+!;UQO52.M#0*TC.CSQQY3S-
..@%HK%FBBB@HHHH****(9IUA>)3UD;RS.2H.MN@N+<3^62<+PXJ>@HHHH****"BBB@HHHH****"MC%%%
**OX70=3!5Z=K.7L?IG9!F$QGY@PPVXY+&BK&CZ#267B+5.3NIN"Q.M.Y41(RI3;D#///&..Z.B@#F&A(V^A^*=5U6S*OPWZ(&@^ZK))(^N:Z:)
M9H7B25<07.7)E*->(?)>?WO$A^3O'MHDVDK>?9+>#(5B#$KZ#D8K>HH.Y^ZV75WX2?OGU!^A^SF=81GR!NWIGK
MCO2VN@7%KX430EOIR+!99S&A-NWIGKC06_10!A6!AF*PKX?O76IM8X!M#&I&EO.#(I>M8-Q).3<:H^D+JL5O1430D0@LSH21G)Z=*
!NB@#F+GPK=M.A+=I.KO<+!%D40!5%5G7:N.#R0!<5!/GVIH.ERHNYPM"M#>+F17674.YMKR.N+5YK?L(9B!M6125"Y
/0!5J!HUKH&D0:=9M@B*$8RW3CW)JZT*./Q%X/M$GIGZ.NEE=I=+P#N*PGV+9^+!U4.AKR.MMFEO(HXB.10N?SSQ^5;=%/!+!_G.
(2R/Q=0G.ZQ-!Y>U=AC)SM_/G..M0Q>#H!77M1UB&NDNM001RG(!"CH.<8YKJ*..6L!B.9H9TBTU6^CM#N!K
MN^8Y!/>FQ>IK.#05..OX+RZB?3XO)@12-H0!G>.ZE97=MU?>J/H!%P!M!B!C=M(OGWV!X$&MM&S;28-6U".S8;1C64#AB2><>I=10!@7M?
A*PN)M(GFM;P0!PSO.AMGITIB/8T-R!VIG=7%Z+BXEOYU&ZF8.Z+G.M#R;#TQ6Y10!SV@^%
(!#UQ=2VU!^2"ZE..9)2I#2^6X"2JUGHIW"X^N!57.MI2ED;B-O)N21!%5.APYU5%/_Z.X7B!0RP&YOKR..WE6:.*%E4+(N<-MG&<1U=O-
(-IT9!EOID"1=CS^5$C!><8.2M.B@#F+7P39VK;2!>7CKI8(MU.M9OC!&#<@<4EQX!T6VUB348UG!7SQ>^2)23^!$Z9IUI%
#&I'A+3M(M+MZVC.IT5!S.DTA<6SN.V4D(S=AZ<4LO+!1).**R!N=6.Y-T(EN^A.M=V!U.2?QIEY$S6>#K$EOPO'YR%.E%&"OA'2$O8:P
M1S:.(8C#(GAR50IASTK)O&U0(!-2)HEN6D^T<3MBD?>..>IKM**M.
!0!CT70!33HCN$584MC&XIS^)!JM<>%M+NM1N!^2!OM%W#Y$!R-Z>G^?6.MMJB@#G8_!A^+!+..2!6T1HX5=-@^S-O63;U6?
9L!QT9?7IZABI+Z.S;0181K2/RH&MYC7N!6Q10!CKX6T!>K^RL!S^S^882F5W>N/6K=EI&GZ=+++9V4$D$DISC!M!2OIZNT44+
$3M3$=OK.&=D&%+KD@'M45SX=TB!6!C3!>18>4K)PF0!M=JU**..K_A!^TBY.GP&8.2%?F!T!^0*#@MI>P@6&X)T>P?7SUR.1M.5%
&3AF5FTV8K$Y'DO.X3^Z!M.B@)M!F!A=AY/EV<^0(LCY-3TJ6>TMID^XBY=ARN10<U&FHH.K8+R!#1MEAH!S8.N?
7%*.U.2Q&WB..G*KL&785/10!372I>9BS@Q(^!P!V/E;U.M/O4!M#%)YB0QJ^N!Y5./2I.*"BBB@HHHH****"BBB@HHHH****"MBBB@
HHHH****"BBB@HHHH****"BBB@HHHH****"BBB@HHHH****"M**"LC6=GVW2-Y/VOY?KY;UKUD.SCI9L/JX!P!W)0!KBBB@!&^Z.AM
M/I3.."/AF/0U#<^OG.F.G0/1110.4444.%%%%>1110.4444.%%%%>1110.4444.%%%%>1110
```

[illegible]

[illegible]

M@Mj3@53^(06355?#T.12%-DN6^YAD*2%S&/IW=ZUVMI+.&.\$M7A1H5P1\$8 M18OVH
X/Q/H.^D:~E1NN:A1K1GC2&4S1J2.S@!3'DKCD1>E>A+D<_>Q56) MJ5_H%WT6:
M.&IRVEU8WPNM@.(RC0R\$5@.1.OB17P3XLIT@~"UO8ZKJ.%KJL~>R*3(D.F.MX@DC^/&..T1/<>.?5FGRP61T6B.=:(CSID*&>8
A0%:2T9SF@~N.M.+<4"B@1L.M>+U.L*~BBD50 M%&T.17.S19VTEQ:SNK3F4(7.MCML>:02N9Z97N*R/B)1=RRZL;RV1.D1-M207%UI&M+~"K98
=<QQI5E-<6-1 MXJ361(A+&WTOQ>W&W\$Z=?6NB1:~WASPM>7T+W80K;1A=Q>0H;CO6A+;Z&?PFL>X+*M+B>0Q,
<~BM(Q7H<52U&1.Z27QX~.SOHX\$TR1@HFC+1+~<0V1QG:O?WH.ZK1 M-5/B/PC~.E:7.CDN:=71Q0&Y-CG@1<~<#X615^1?1~"NOZG+JMO#H-U-\$
MH^S5D5%1Y&>..6J7PNUB+PQ=>YX8O19#961PFE=<#%Y;K.%?U..N8T+PU=M>(<?/B2QMC=6N141.VOZ1AT6XBXX(Z.#S^E^H-OX12:O1
~"N^Q=H5C;QM7EDM60.K1Q&>~&HHR.H1.A(KD A.X2ETOQK<E<1.91.TN~.M.C8<RC.X=N..2B+1.VV1XD1TGQUX<1.Q:0074D)G#?
\$)F21^W:~90%1JBD51+1B4MDY^RC.O4GC31?+163#>J6>FZA<6>G1DN9 M(K9V5.D^W11^2NGLEBU7QMK4=W1H6-W:1(KSVS^CE<1ADCW%
~.1J<^1^H.M9+1/6:B321K1?~"M71RP3;1W1.UJEXR1=HOC?0~B8K9Q+<+?S#1J.P0BL>MO1.F63X+1.W7@/QWK22FXN+~<P&2JRV^SX4R9*
#ODH576:#\$WB/P+JU1=4 M.GZIN&NOL2V3YEE^\$.=S= 2G01U.Q133>1&L.B.66&VGN7BN.F106BB/M4C@1^AJ/PI=SZAKJW~
IKOX1=X1VCI.B)=WNA61Y9:1KB:&X5D\$S\$1.M%./~.4Z*3H*6@.HHHH ****.BBB@ HHHH ****.BBB@ HHHH ****.MBBB@ HHHH ****
"BBB@ HHHH ****.BBB@ K"19J61ZF1NR8#1WK^%.M8 M'C?_)\$O5@/2H+H.^14OZ&H.M1K_?1=0)Z***811110 4444 %%%%.1110 4444
%%%%%.1110 4444 %<~MYK7A+15M.M=461N+6..1)H3?<>~>7VYP\$M+LKJ1H.O90<\$W.AW^4^RJQOC1)1YXU
MT0:9X.D6*21NKKZ1U.XEG2+?A7^0=~4~<M+62\$M.X4^PW^B3HE1L1J01Q<M6TA1A=CT# CGZBDDU/QO=V^C23/#D=C1/.49E@G\$1^C/48J1-
U1.6=PUY M>7LLE1)2VX@=Y@%/E8^1@8QR2:S^X~.7.VDH>7UW1NUM&EO.N\$~U>G M.GVJO1^C^ZU&RUU81.BCU+1787-LT1^LH!
(*MCOBJ%G121000^1MKD&DVQ2> M.Y1.2~91&C1^&WG1OO1T.L^@Y@(<^TK^271&1DSNX.Z(HG&..=JLR^~MK^Z1^0>1R>XNG<1Y.S.%DC~=
(1QR^S=41.71EXPTW1P180..10F6^="M.M+1Y+M3+7UO^?>^\$Y95XR1QQU^001.OP.TJ32+NPO.M1J1.ZVH1BXDW2C1W!
181(723215K1NQ.T1.275^EO1G.LTN=Z9R.0.^CM5>..2.PS1JNBV41)N^*2+8..D1#^VW8%72\$JZC1^F0:~QSR7ESY3FDW+M&NTDL2/H0
111V1C226;VFH.Z^=.%RGC/##BL/Q.XQ+PY>2V79:@M1(M.V.F6O4>YVKUZI.R=A?Z.JHXCM+1+1+1H:E7WRL1.XW?='(6HM51Z
MKJ7B+PS1\$EG:@Z@BZA.79P87C7^0X^7GZ4.FF7UCH+1.0C0M5>>TMA;~MK.MEB@ZYZC&OWFN6.%M.8V1QO^XCF?_926"&V.?
XSBE?QJG/O#A.MP27M670KF8.4A0@.0.0223ZTS3&L1^+KKPCJ<=O1J21>..S1Y~.92.CY3R M1.XSVH UG120@K.PC^M1(10).P#%UG:1?<
O&~UT.P+1.TD1+1&~<1D1QR3D.MOHU@11H1S.A1+1=UZVM.832^#8WD^MY1NSQZ4.61H1>1806D6@.S&BW44TEC^&5&W81
MSKP^H08O1Y(YM14W%G).X)&3T)O618ZY1OB2RLW.RN=-.MN(O)50+5&^EE(&P1D1YSGFNL8\$KOP<~.~\$UJY25Q;~P(OK1OM41%1^%1_P
10)=10VMM:Q7.TD.C.M>01P21DM^VYN6~.M=126.A75161H1&1LMM(DBD@D.ID^H.1%O;
M71?)~&KLEH&+6U@M1+<CUVRY(HLU.B1.76FZ3X@UK6.B1K121N2S1&K1H.MLA1R6+1A5G3+SOAJF@KKJ56).N1(-@TY1=C@E=S1L1L>V*
>T31HR2W2.MVU;PO1UE%<3306B^RSN=F#OF3EL\$~08K1LY.%&BW^#JYU@7DNG(16%G=F)M1)A#K1>1SQBNS1.W5U?
>1.NKX+N616F#M+(81>..U1Z4>?Z&~9T.6=2.MU1V17MY1.B5B1~\$C"@.\$R9/7T2K?B:4O\$7AR.TL>12@.ZA%<FA.F.M1.)TXK>~P^\$FT=K1:
718N7=HU31Y92O^H<5E^~.CM1%OK55~MKR;~5 M5GC^ZJEODCXZPD9019AUK5\$A6&/PU2%T0%?2.MJ2@~FM^M~T76+VXLM.\$>GW^1S:"
101)1U1@1..ON^U.W4\$MS:20V^A26TC.MJ011=OY^H111J.^XKT.1PD=~1ED1U.TGSO.HVKW50.6=VLL.MMO&1L0"G#HC.6(.=.7^P>+1J1K?
4K>1N(14B~BB8@<@1JHS^=6..1.0.MTK2WTVS1^JVJL@(<DOWZGS.1=Q^Y~1JGBW1MOC:7ESY)99%DD^W3&1SGVH.R-
+@U31PXTIP39VY.ABE.M^@1^VYJA=^"O.OKR?P%9.Y8N1J"@.3U1)&~.ZN7Q5H>DVN1^161X0+<~MH1+2D1J@9)X1^P2A_K%WK-
1XDN+Z.YBAU\$PVXD4+Y+84\$C.(1)SGH6@1J.MO%K.E:SPV1A^VM1<##F^1>V~.ZXJ2+1#6M.T&UT.PO:750.H4&11LX4.MC;UK=U+Q?
1E74M0<3/OA.O2.F562N1B1@9HU+OGHVE331W1CR.K3ND3.LM(81B1@=>1(S^<2>X^O1ED.H1QO9MUKJ91J8J1NTY^E<61>..M(AA34-
M^M=5WE8..M)MK^2<~F4CIWXXK700&VB=>O.SSN#&(C(ZO.RO/N\$1L1@9K.N+1MJX.M.BH1)^2S&Q:29:@PEL1H0ZC/Y>M.%FH/W?B+5-
/O=5M1.U3:3D2P^42..M=18(8XY@G1.1717^F6>J6WV~MH1B<^Y2#(R#D&LBW1Z<7=1.DD1~.MWV:1XF5)MHR=1CP?
ZTW11&NE.Y>P6UFTK&~22.S&O1~.M891<1J+&A.O1MF)X1=1M621U=E1L.MEZ1^E#T#2K6~.AL881M@.TRK1\$~R2PJ#5?MGI=
MW1D^37%UY9F&~.NR1@X1^0552B.P.7)XZ1T1T:=H1NH8O/A01(S881MF14~1=XD^UR28X1^SY^0RRN1(P1Q#4)2@~1LT.G~*2?
~\$U6MPWAC0-M005?4KR(EYXH)OF>\$!7NC/..1^MN.M+XFLM.N1RSB66&1LRHG@F3.R:AD^W1H1J2Q^*9HVCAT5.MXV&~K&0@C1JP(O
361ZUW#H>@1^<7<~1.21X1U6YN1NE1HK2FO>~M.1U@.TRL1@(<1JFKVG>~=/T1H8X&U^YT^VE^S.J.J.EW.B.3U1(XW~*~M.MM1^O6?
%M9.%#Q."1"MD>~OX31/D21EUXZL+69M+^S7DEQ12L\$A8C;<M1C^C.TYD2C12GN+1(9EMKKZY.UMK@:@1D1OCU1)YH.O1?%(1>21GD19^4
M1XHY>Z620.P~172GBSM.Y+2ZFM1XPG6331^1AC^GC+~1=16T6.F.M^Q74D2G12G+2*H.2.03B@~22OUV~=&8Z.LQ&=D.S#W&31S1J^XG
MP0-3L1OQ.HO~^K^EU'3KCO_IUO\$U1+.X=0%\$BDC.C.31T1^~\$V?B?&J6~7J2.B10V?B<M#G5K\$<1^AZ?1J52O1=M./R65S.PW8LGFC^XZD
3R.D#~.61R^A^Y M>YMYMCV1&2^C>5Y>M.%\$6B<1C6K/M9.P#V5).9.BG~#E.X1?95.MS^@>*12.2#2A>U@LKZ==21HX^1AV14\$@>?
4X~#7T^1(5M.8.S2\$6Q#<6UZ.M/EMG9)P#H1>V~<1.R1^FWBDG.D/68^7C~/9U.MSWB.OEJ^6VG061+~W.FK164P=E1
V)X1(XS6F.C.X.X2621^FFGMVM..M91A\$E>G(4CZT.7014JM+1L.O1A1E&G>~XR^1W75Q&^R.VXTK2>#11@0W40FF1JX1+1=19 M'
S01W^~

[illegible]

M2ZD027&%"E12,L2!WS0!JKUGX=L?MU^15M%...)4C^">K8YQVJ73=5CU+28 M1HBAG6&5/02)AB08XJ?P?B?&?)AOKBDD9ML!>S
TK8J,D?PEHY48!LH<# M_@ H,X=101>(M.DO889(52>2+?)URAP!3660FO";,4=*\$L\$U!U*9(CXEDMOL MJ@>6T;RD,#ZGW!5?
NKS0J?PUHXB+&^DA;3KQHXCH\$<42IXSN3N&+D>?IY MHR/60^;1.76=8>?=BNMW,%JUE:WJB(C!LMDJO?R>F>N?S?TUCQJ.FV?B.7B
MPP?L+D27)?&N4\$83?!"&.!K>11D>M>47=J\$A;4IDU.\$UKXA-M"YF. MjR_5=A/<8)H_?j=J/CAAK=1-/1)I=87
"E8BX'3ID'COF@%#TN74+6"^(M-LY)E6XG#%?GE@N_P_Q5G/>6640H^L^MU6=IEFN?%OVHK"*R@-E3Q@1YJMU!-%I%
'C6WOKDZEHH\$DD+3.T3J90+!LH3@ !N>+?/6!4F:P%WVY "U MTF7<=K>2*%BDD;DCC)Z\$C!XO:7ETG3YI2*YU"R>?4+6UNK:YF9C9JW
M5UER24;ZT>O7VH6FV.MY=S+!%\$NYZ=>G5PZIEYIY%>+M-N<1^C!(M*740/MC!M>J6MG ND?8X991&5^A^Q<9Z_3D M&@("^(R.C.
&X>HKQ62I>^?PGX500I9U%;J!U.K.63SN?9I5L_*,>O.NG M.;U_J/C+PXMJ=K!;M_UH_P!H??"19X8G_XH I*#*<F02K/"^@6SPWOS-
B2X)V13GK-P?JH5 M!..K9+GQKX.1S(H:6Y1F1L<>5DC/49QVH IC<N2110&NX)>+^0/>8HHQ#<0B.R94 M_.2!D!/:0P(X/TKG0^\$BG;QP-
%HH@-F.D?7F9SA@NW&*X741N30Y?UC M:W4T5E&H"6E8F)92!(02H94 E@ 3@<1.XCOYT!%D)6EEFD9;7S-D4RJOS&K<
M@SG^>N+LF>ZT73+6.^F(@!7!KYUK(K#(8\$>H-8;_W-MC)=%S1^0!FURDXDR3AE7&,<=?60-M3F;1.?Q9I^GW.T>GOZE:(QCE):WC<#
MS2.@U<XHQ<^/#VG7S^\$S;A9F.9^!+H&U6 D@>M%F\$B)(^HP3CGI7?Z<=>.&J^T.M72KIKB>XLG@F@(@E!4)M!9YAUUR_ GU-
8>F7M!NE@6C?>10?>1YD TO!D!>[XS1IWA:=8W6G103)<7<4#0N!F?=#MC(ZUU)8*I9B_.DGM7B M+7DH!>=!JG=0M+;W4.L.;>=!
^P%+!;ME!);JEC!>1+9K9&[N!4FM00R=60.1G/KFKIO-X=MM-1WM!>SJM-M;M>AF^SLD<<8YJH/E46Y...*
/4IM02TZXTDJM99D4D'=O4'&><#JWA+5) M!;^Z.J5SM\$US)"^C R?2N+!7UE^XROA'=V9230X2/L_RQ@SYQS!OQC)K MH?!"M6%AXA
#%C/<*MQ=P.(5ZIF)(H JBB@=** BBB@ HHHH *** BB MB@ HHHH *** BBB@ HHHH *** BBB@ HHHH *** BBB@ HHHH *** M
"BBB@ HHHH *H.V.Z?7C IW?OCM5^LW7PI/ZANSM^S29Q_NF@!VA#&@.^*7TUB+Z?UBLMK+L.XBY=USOPPYJ;^P=5?Q9;X1Y9XBMC;
MM\$!+&O&#K^2&POKAW\$579CVOHY?1U_2N HH YC4?#FH:F MMI:W&JHB@GBE!+?T@OYVEMOX)
/56A!WT.D7.DC6%^PW1E.BFV!91(22 M%>.IZ@UVV%"+0^%)!.ODN.*U!D=E'91%)#YBE4S@MR"3SZU>V/>8!H6 M?SS!)!A2^!KS29VV)
<)C>1DJ0<@ F^M12>?;1M M%5B!+!+M.;2.FZAX.F0?56GK*ZG)%+1.0^%&@5PV-V>YZ"NBHH Y33O^_U! M_..9.6DGSU.VQ@8 M!7:44
%M%DU^+7(+Z6VU!8?)E_4F7MN6JAX.GTZ!U"YMM=NXWOYS<M3A8TP7!QD"!>=910!RQ!#>^C6M)<=..3M3W!JL16W\$P2(GJP4#
!WO70T4 \$HK.Q-KZZA=F641R@E=C M(NKC^&K4N2I)% P"!+="#U"TFFAALY8W#";.I @V#IQOR>E=70!B@#)0
M:##XCTN33KJXN8K:4.95@<*7H3@U)IVD+I>EKL-UZ8=+_+!;OS#J^K^V@^: PESG.<>O-J^PWT/4M2EOY608Y9! M?:%@N61)!WU"#5U!J%
&+!^\$K^R!0R;U#!= "XDBS+@9/W?ECHH?^4;2X=: M#;ZS_<^W^YQG^SB=O(W WO+Z9KK;*.300A!HVVH2W32M"!+
!K5IQ=?7BMJ!+!L=K#&.!VXX ^NGHH Y^+P%!41TLK+=YT MU#% WG\$R!@A">X&!^5/C!#:-#>O.JS^4TXN?LOG-Y(ESG=LZ9SS7344 9NM
MZ+!..!C6%ZK&%F5_D8J05!((H(Q5&+P9HPL+RTN&NEO !3_ ROYX! M5T!%>1+V?&#0!+0!S2(X)&MKP8E.DA=R.PW^GC K7L=\$M-/TA=-
M@Z0A-NX.M=Q!3GKFM&B@#FHO NBPV5K9HD_D6DQG@4SO^!<1YZ^I/YU7U?0Y=%CO!9!6 M)N-
N63>LLS;9<\$#YGL^ZVB@#&1;5<.;!TFDEI?V^!F:XXN?+^Z;L#W&1 M4FI>.&1U74K34+D3M:1%_!.(H)MH=[5Y(YH)C2^^M5F(FV!)R#1*/
WJ?T.6Y C1H4F98G9_77IK!ZC%=%10!A1X1T=:F&N&MV ME+!3R!@2RLZRC&K&!.#Q2!;X0T+2+J^ZLM/BBGB0QHXY*]>PSVK=HH RJ6/
MZK7QV! M^SCN#>OOBW_)HJ?AX12QC2I?)/H/RD/PI!#?WJ^P MPSH=Q>SBOB.EZ"MR2.B4?
!0!TS3?"NBZ3<17%A8102Q1M\$C+G(4G)!YULT4 M 5-0TRRU6WAB^MHYXP<@.N<^U^H?>JR^!^73!/.LVU:SSN;+!E8^HZGW M-.E%
&2 AC0Y(XT2?JD.C44P!J0H02I8=#TNWNFNX^/MDN&@U15B_8CI@GT MK!HH RK+PWH^G+;+33;6'S@1^4B+@G)!/2K2IX=T.?8\$TNS6)9/
""%#H? M^!CK610U?F2>M(EA&+T3;5XGDUD:(\$%_!V7WJW/9YUQ:&UG@CDMV48F M4?2/3!6**=>K16G4306ME;POR?=
2..*&^H6DATC3;>UDM@&VCMY.[XDB M 5L!<@=:NT4 4A!GAOHLK<1>2 (Q!S^!H:G1Z78Q!^L=I @8M\$%C V\$! M2/2K=% !BBBB@ HHHH
**** "BBB@ HHHH *** "BBB@ HHHH *** "BBB M@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "LI7MO! 8&HIAE?L MTF?
^<36C6=K^X>M1*9W_9!N.N=IH 70!V%88Z?9X_016A5#1.C0!#>G/MV>/.?I?5?H *AM^5;_?2G14-MJUO!XT@)!Z**8!1110 4444 %%%
!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!:OJMMHNE7.HWC;8+>.R.1UP/2HK36K^T*#5Q.B6DL(FWNP 52;T :5%8= MGXN!T6^N:WAO%!VZ! *LI7?CTR>E:E !1110 4444 %%%%
!2:ANVY>N^4 M!Y;1KJ34?<O.6)ALDAM4!D.V_4B@#J: "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
**** "BBB@ HHHH *** B MBB@ HHHH *** "L 72?0J?7 CWDZ#&36A5#6Q60K OZ_"" \$T.MYT*P.Z.G&?PBM"LI00^00Y Z=T !H%>
>E06WW&_WC4 :H;:IC^S&@ M".BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
HHHH *** "BBB@ HHHH *** "BBC.; M^BBD+ =; %HH!^0!S0 M%^#TL "BHVN(E<(TB!ST4L.FGY% "T4R25(HR MCJB!JS'
%16E!TWT9DM:B.9 2I-@1F@!Q115#4=8T_245/Z!B@#!&O?&?IZ MT^?U3K!A>73!E9T!MK%<1'WS6A0 4444 %%%% !1110 4444 %%%%
M&1XBEUR?2YD/P6LIZ&@HJBL (HUS.U!X^2 -+86R2@9Q:QK(H!T 7Z= M1!B@#K76O&#W^L216<*&09O&H9E>H36MD
MY%1@>E&!Z4_N;6=967C)XX)YXJOI?C71=4G%LL!VU MV1G!|=1-\$/HW6NBQ6;JFAZ7JT174+^<8QND494>OZB@#1!!&:P/&NLW&@>
M\$!H4K54!^KMWC@98@)!F< A7?7B^?PEJ.D&CWK!L!@#N=1LM7M+^SE!N_M_NYK5UFO;J9C!\$2LV?PDY;7I57X.V3^(-\$T6-5D3!-
A*.DBKBXN_-D^MRKS6W%KZZ? !VTU#> FELDBA 4#;C#-;K4?PPLUT?J0>4D*+!S<6^);!@QNO(QC!JTM^NFO+=MKF1!+>2;
M.RDYP_-42%UXEAEX2U6X=V79;28*69VG ^O4OA>6^PKI4?T'G)!H=XYH W!B*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
**** "BBB@ HHHH *** "B MBB@ HHHH *** "BBB@ HHHH *** "L 721X?U!< 9L8./X36A5#7!G0M MO?_!R#_LF@!N@+!(-
T_KVC!Y A%_9^A8 L^PQG^V=-.IR>@KOH ^@M MONO +Y!<P^M!B_P#?-\$!%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
%%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
0@8.3.LVP+MQG^Y?V7V-7H AE52+!;"IS >XDS_Z?40_KPKPU!ELW MYG8GR;+>C^+!+U>.<2B!>?2+E.#!1ZBI=215:HD*M=-
(SR,5CBC.YW(! M?A527P#X;FD\$CZ:A@Z#K0!/A@2Q2#2(!394!GZT MYXS6I8)/M!NH!M!ENZJ"ZRC;@G?
!WJ!PB!A_9L&CVO7?MP(O^D7PMH^7 M#3KHHD)6QE(O)7A *%&#UQXB+!HEKNMYEO!ACM2^AR?4GTKG_!^*!<K;99D_C0^*X "LWO-
T?334NYH@FC65(PJ MO+E=S 9Y150+4AD^@OAB.8Q^\$+@!3A2>A.Y?50B7?J!>31Z""9PK!T MD>IC!P&=>H&C1US7WCU+J?O-TX M!G:S!D9'
K<@OGL!SH_V>26^Y!T!%)6!RYS!>U MC5(!BXT2PLS;0NR+>2G;K#@!0HXJP1CF@#C=1>C."X1M3Q?Q?6LS.H^C C M0!N.8YZ5VQ-
G>F2QDVT%_*&C%G(>?"3VJP_B.HVC)<6+6_H!%UD\$S!3 M#M4G!Z@_G4%KK!Q=P.KJ<.;_V7!1G!63#2LN=S#_9Z_?3-'&W?B?Q;JEZD
MH:7UT!\$V_R5MC@J@!>YW+EL!<5T^G_KM!4&[T#4V=5^9X;1!T 2S>=26VG M_PAV^!Q=O&=>XG5+2Q?X^N^S-WI=J
=>ZRH8M#"JH<Z10!DYY!J_1 M-50+WPU->6NH6XDYG^K!HD7T!T-RQ?7MBFY7CP?5F'S M@>F!_/-2-6!6V!P?A221 DHE3.;!N?
!T!FLZEXNKO(K^0!3S)0(A-M.W!>X)ZUVT#L!^P_8J!_DH !ETNVC!>(BSN!O9/!)RT<!RD\$Y^0!N.#L!7 M3W>I^G0BUT.UG.<O<
G&H!>U=GLB@#QZ^!\$>M3U3!/?#;2.3!YVGX/T MX!W=/M?B+9PK&&L)4C;(\$H!R!Z9"G^=>B8HQ0!YCK!AWQ!XBM#;ZA=ZM44 <@K^M/?
_Z+1-F.#R9^Q2O.O.CZUIBQ.EXANX+TSR^3\$(F(LDDX^C;BO=*U!M.AM!T6<N:.*\$B<@NXX(V!M!L;I<5U/G@!UP05;OP>U!+!1110
4444 %%%% !1110 4444 %%%% !11 M2\$XKF=2U?4);S!P!#3 3W3>ITV^ENOJ>N684 7M;26.AQJL!;Y?B!U^M60^@7^M?
L:8#M(^1^2^M=-HWANUTJ22!>WNM0_MFOYUU_R!^WH!H"M&ITZROP@O+6&X"HPSZ1!"MU" L^#8L;6\$BKC!W_.NFUJ;PUH5L
M?L+H<\$Q6T^"F20^BKB! A30:BWN;O6=1@@ANKM56^UB0!;(9(3W.22./M=&U&TFL
\$TOY9;JRTZ[N!K9^FLD)=IC @:X^M70V&M7E04+JZL&NPIU MI2-Y M_HY^5L9.<1.U!X^2_-&S9=8!&_9/XV.P4_D%:%WJ\$6C_!^O+R! M?
!#HHF#&N4N!4UNINAW1Z;Y.O:L68X!^J^ MZ!_!PI?KSG3!CQ#HFLMKH6!UPV!JPKFUM4!HP;Y5VDC/RGGW!K>^CFVD
M^K%HVMR3^@O^Q8%3!DX7!_JHKDQXEU^Y^R^\$KQ!DY.ZGCC_0\$FG7_".W.M94P#2;^0!/^N!H;.
JHKCVLO'OS!>9T8!_#90TSW^;J!5L!..85(=\$ MN7_Y8R21Y!Y!_M0!U=->EV!E?YU:=9!5K)(H!M-0.%?MP;@E "T44 M4 %%%% !1110 44=Z*
"BBB@ HHHH *** "BBB@ HHHH *** T4 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %4_!_P"0?>1<6!G_H)
MJ_5'6<#1+XLJ!>3.A=-#=#>Q_8ECC_GW3_P!H%;%9/AD!O#;F-QS.1GC_M !HEM:@!J^U_P!6W^!F-16W.9/N;)!*** "BBB@ HHHH *** "BBB@
H MHHH *** "BBB@ HHHH *** "BBB@ "O?7<5A83WDY(B@C:1R/0#)KR+P;KY MU!XFOJ=S 5-U!M@PV3&_@!GN.GI7L.T^7\$#PRJ&C=2K*>A!
!5Y^9.EV8EDMS&9!O<RU96X!0\$>GXT>P4444 %%%% !1110 4444 (>_FN^4 M.C;U9RZ!V5REXFH0H 8BR.H97W\$XP%P#^5=W2;1G;..
..>;00&!=S6= M!;7UO^%:V@:4(R;LYVC.IVKG!S2-2_X5\$?J!^Z:YN!5^U!_LHWHC3@!H< MX=S?ZL!MXBT 3@=\$7\$TKLW7Y-H
X!L(RK)BUC?XDA2!+T3) M="GTG4!R2-3V#@?26^LV05/O75:QK^9H4VH!&5CWKL4MVX) YQ570- M.N-7G08WMMRB612.2%2N!BH+8!H#-
'+2!(HJ)QH7A^QU.*6X5+XS7*3YHU. MX@%LY_!0#6K^HM-I=YJFGV<J2KVW>2\$*0!!*1@K@!B3D>E6-2U?5M-?I7,E MNMM!H\$4=J
6EE4G&X/7OC^304EU?ZK8ZY;_&B.\$YES/Y^0B.C:N="QINS MQM!H_FUT5M!^"ABLUFDTV%TGC!^02F.#Z6==WM?T?MFGFS^D;RA!P
M_"L:U>1M!6NNVR7!M!M<2NC1>5!D: MX)4AO7CIH^T?0G@U;6!R!B8W2Y^D!CY6TCHU!_3V^K7P.A!#76;M;R!#R F-H)
(3?;5!M!L)!XD M>#5;N80!NGA8+Y8+@?=>SGOUH @LO#>WU!YH073R6=!\$6 >OF19B.\$YQT(MQ^59VH^&_V_VZ9Y!46IVRQQS;_
D45@2AOC@&5J6UW?67B"VT^YFEG\$T;_M!C)B_-G@<EUYT!(FEV:A7!H&#"#&3CKSVXKMZP_"NN6NN;3V!C>J!)^A1@.\$55N4 %%%% !6-J
M6NR="!"=(!U&H?7=YEM\$K^DCEMFN>13>#HK65G;PK<E2R^5.0.VT>D M8 _!< (NHK04\$VFW.FB>
M^QN8+FXCA?15H@0^EAD>M9Z@O M#86Z_7H?2+7=+N+!6\$!R7902>4L@+!76@#/_B>14_P#^!;SR.CY(O_BZ M20:SH)_8S_PC>J?
3!U_739!\$6!*J>7X8UH!F!Y.D0!>C=T MJZK>=">?S>4N!>U>RED;B?>(G_>2<?05IS>*!^!LX;N75+9+>8L(Y" M_#8.#CY%>+>?
%NOV7AHD@T&Y!LK6"QOSRS1%\$9F!R&(3)HVFZVN@6) XE M!N!D!6?AF^N2255H98V3/NV<8J#4 MKWQUJ3^5!H!Z9;J&>YADE8^T).%
(^AZUT\$BWPY^D=O#J=IN>7R\$1!&C_NX MU!>^4Z+IEV+6!OXHH.JQ^!GDIH!^!_Z9#J!>DO+!X/N!KQ\$5>_B:2
M0>D)!T%#3.YXH^X2D!Q!U^W1<^ZT+OQ=H.A@U.W610!S!L#(S<@M!T?C M6C?C;;9O=WD20N)K!>+>E
^T7A0Q!^HMI#H5Q!JEM+!)!^0WD082.Q9 MLJ3@f<1@^E7-T;7K;Q!KNH:##>EJ+1+!\$KS7D""BCT5<#HUV?_EFD2:=
M=WD5YK;C.HP0RG&1D8R.US7@G5=312^SUE!8;9)&SW5CY/L DA-C>V>M M&P.;138Y!/_..!7^<_<
+7B;MX4_P.B OK!UCQU+>6GB^YTRF>?28 T\$! M0EF=:6;3!@5T7A0Q5!FI6UG9#48YMI!^QQS2KWRC<>F.M_1K!B4D^#02/M?
!>3!OJ0B!J/K>14JHNT2!OULH+YTFD)8(C\$7.2_*SO^N03!H!MUE+!+;WGNAT;K.NB.YRW_N@V-2!2.X4>XE!/+>+@#H!FE>12J"
MZ->LPY!%UP?_!VLS3;_%!POI+!F4FU!PXE@9TNPBE@X;D\$KU^7)Z5K1>= M\$E.EI+EF75%+6C>6V)=1G^!HCO GVKO^1DZ989!M1_^H#

[illegible]

@@G(EQAOI:RISXD^(-.98KIH8.5FYVYGW*N<MG&#1.&.0#D:HUQ^=-F=M01>U/5%MI)T^~^C8#)BC;MY>N06+11R/7D5H2ZIXYL+F^6IT-
f0Y5:9@S*.F."?K_6N\@M8+92L\$,<0)MR0B@9J7% 'D?'@O:E^M!%&Q68IY(4^9(">|C'.G_-=O<11UJ6@#RC4?%GBK2Y7BO\$EMIS"-
M>%7&2/O:A@G_..D7OC76(KVXMV@BC^5:9KM&0-UW\$ #J|<1.\$-&4.M/0C*-.4ME9>J7/CI18H6G^W@D C8VB,^HJ
fM:,|H/HQ0/Y=86^C:512;+5+ROL5V M-O^G0F7-X+U2[M].MOB2|>YE_..40 YP/G/ MX15VF^*/(+O0/..AW,1M)IM14,
(T^2<,>3P8CKTZFKNB^/\$\$-<7%JHNW M6G1SDD6L@9UR,8ST&|QQF042 TM'G6J #Z_#@NG:YJ\$MX\$ *SSD;SW,1W M^M6^6Y?
M:AIDF#MSGJ",5CZE|f|>1)38:A<^CAW6YC44>>^"?&N> M&J5-Q=7^V5D^M!\$S^6L_?>> ?#R MZ786VH:|!+6W6&U-|=2:7)YT-
@Q/EHP,1SC)/08UUM% "%# MP+G3=3M=0U:;BZG:LR8U^ LIR.#L% "#KIO@VWGO^O):^1-S+;29)5P R M^23^N:Z:B@#E|P196TND2)=7>
f249+8EQPK#!!XYX)0A-ICZ-J6&>1-MJ% MSHF^F#(?8E3C6D^NMHH NYN|&=Y+!+;MDE,2^N/UQ72TA NWCKOU,31744
f&M&Z%|KYVG&P)QO/Q(D:|=XJ" M#+&Q^DEWJ4DS+HZ0R7:~!00%3U^%0S^=(N:~!M)WNY(KJH^V2\$S8:S.V&M-PKJ|^+1X:N)_B+!+))JR:<:
-CM(fQ;DAG=78G\$M<^65G\$A/4D\$X| MJHSK+X=^&K#14(-/%PCQ,#(Q^HW55Y^4?2NHH P#X,T3RKA/LSH7H(SM,M,|
(OIH+X\$X;UA8PZ=86|E:@#K&|&L2 G)V|.#FK% 11101E0+#+..=M"
MHJHU&J31@ *Q7.&^N^MBSL:..XB>+&N^DB=2K(PR^#UH2B@#%L^16A:,,LUMI ML^RH,(f#>4H^V|-%%|28L.*&L^5.#@XK;VZ^FA:XXN
M15)GFA#^3D;,YOCZU%9>=%#T^Y6YM=-+MHYUZ2^6^XULT^4&1110 4444 M %%%% 1110 4444 %%%% 1110 4444 %%%% 1110
5^2LSA^934EOW08 MYLH7&f8<9|<4 90A4E0^~G\$|3 M.%8 _A92OAG3E(P1" 1600 ^5>T_U3TQ MJP>E5I7B-O|>+J8HHHHH@%%%% 1110
4444 %%%% 1110 4444 %%%% M1110 4444 %%%% 1112,1JTH 6BFQJ4C56G4 %%%% 1110 444 M4 %%%% 1110 4444 %%%% 1110 4444
%%% 1110 4444 %%%% 1110 M 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444
%%% 1110 4444 %%%% 1110 4444 % M% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 444 M4 %%%% 1110 5#=?
|>LN/IC^RI:H.KBUE/^P^Y4 90A/ ^PC.G|B2)&<1 M:~YQ "W^AG3SGK^Y^*U6M.8F WS5FIUE JF WS2Z@6:***8!1110 4444 M%%%% 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4 M444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 111 M10
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% M 1110 4444 %%%% 1110 4444 %%%% 1132.7S-FINOCG.H ***
"BBB@ M HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "MBBB@ HHHH *** "BBB@ HHHH ***
"H:OBTF W&^E4U07@S9SE M:=->E5K+ 4G_>|^=63TJM9ZEOHOYTNIH^FBBBF 4444 %%%% 1110 444 M4 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 4444 %%%% 1110 M 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 444 M4 %%%% 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 444 M4 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 M 4444 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 14< ^I?<3;G6I^9-CR75TP|:4(\$A 9=OIG96BV#:438^IVJ_0
AZ&H+|^5M MOG^=6^TJO^?ZIO| ?+|J8HHHHH@%%%% 1110 4444 %%%% 1110 4444 % M% 1110 4444 %%%% 1110 4444 %%%% 1110
4444 %%%% 1110 44 M44 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1111 M0 4444 %%%% 9YMY-|JFO:Z?
J(#XCL9fK|f%+."X>#9^P)0X)XXZYK>#5/^"WA:5 M:FZU2ZUF^EHE:\$|LD|5 51CKSTI+7POJ:~&M)LK37KC3YH4+7,D42.9F:EL M|f^T\$
MHQ:D&+^RX,1BIZ \$/2H:3 5M O&ISTJ^U^XW^1:74"> MBBBF 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 129I:YKOKJ<6V
MCVS^NUQ^ WV^V5FC."5.B@fP8@T=^GFER^|H4.Y>PZW=%A,=3A\$SGIKICMY(E+9^|B_ (^O@4 =+D4N17G.@MJ&
MJ_<1N+W7,JW6WO:B2,X7B0QIR-A03TS:HUQ63:MK9T:RMC<7LRI;JEVRS 3 M&\$N7+&#^9Y:72@#US-
&:~VGENCXATC4+36|Z6UND>_D@# (END8PNW^,21D M_6JVB:W=>+9UJ+^VY:6Mf.6**|N8\$Y9QZ:B,GWH |2S03Q7E<2>6CP0+
M^~ZOYX6NY+G8+G9.Ul 0@5R^UP#TKH \$=O|7@K3K^WDFN4NO^A@>9LN2_0L M<=N2^H0|U|U^E% 1110 4444 %%%%
145S:Q74^PS^C<893W% M2T4 (JA0_@.I.* "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
MXW^1:F0U#:.ZMO|XTNH\$|I% %%%, HHHH *** "BBB@ HHHH *** "BBB@ H MHHH *** "L_6=&M=6
M=468^9@)@OW=X B &K&6AVL^L3:ISTPN)HEB<>8=FF9Q|O3C)K3HH P:PEI MMHHEWIS^VCI^=J2(TS\$ _%+=U^XGFCDD5HX3;CRI^FZ,XRC
M8ZKQT_-=&^Z^8V=^R&C^|)G6V49^58UZ ^H.M12>|>fOKH|LDM|() MRC%=R@#^IT.^6010!BW^A?3KFVL(=C<)&#^1^5^0.R I@#^P:1^88
ZUBCT6T M@N4DB^1&D0B2_?4^H|A>@/O6E103T53+2.%+2U4KSD^|4DG^=7*** "MBBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH
01#4-K|OO|ZICT-0VOW& WJ74">BBBF 44 M44 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1111 M0 4444 %%%% 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% M1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 % M% 1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 44 M44 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1111 M0
4444 %%%% 1110 4444 %%%% 1110 4444 (>A|&U^XW^14QZ5#-.P^K M, >+|J/1113 *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH M *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** "B MBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M* "

[illegible]

[illegible]

HHK#17ZI=Z+X8N10LC\$)X=F/0L,%PIX)/. #0!N45\$'B'Q2FEZO;Z6L@A+ M6fWEU)%7DYZ8I5 7FOZ;XA0:GJFGR;B>8)
H:**S96AC3&YAW;55U:JMKH/-P&VM3 7D*ABN'f9 M^hHSGG#924 =/17(Z3f'B'7O"E0>6H865WfJN5GfDfMfE0)-(@K07LHY)f

[illegible]

```

M+@.$HQ&#P2""#T((((KR>33I13XL^/-1.DZD;.VT9I.VG6.MRE*RR".(5(7GE6QZXKJ0@O8WFF?#:SL=0LKFSNH9I=15S"?#:+DCA@.C' M(H
P/U>0?PW14>J.C#IMF.F2XMKIZ5(W:H5@.?:=7IC4NC.H=O)=+MGPHFWH.H#J#ERX2:9IQ:OLSPISD?.@B) _BIN*WC672YI2^_AV^?
I.ZITBVMM3I>=RBPDDMI)EX/RX(->9-F-MI)>-&UKX6:$YT-XT_00.JID2+).P/+E:M.MNV@GGH?5<J.J4
>AZAXIT'3+N!AGN)"E@127MPB.HK5I#A I->YLXIXJ36G&MFCZ<<8R2 <8-'4MC%1 MGOWH7-"W?
B))Y)+*SD.=T%C/F0.#@JR=002/SSTKCI7T"ZL_B9X.I3P:5+MHUK:26DEKI#O.GE9-A*1YP#O..@8ZUST'A:6I?X<=>AY-/O/URI:6SLU@9
MBIGF#9%.KG/<#ISOZI1HOQ*.K?P6EM>2:I.K-KT2O$SQOB-IELL>0.OFT/M%/:f5-+C41"<1O)"EQ$.P:/YX&X#IPH.UU6D>HJ
MJ<HL6AQGSVFH2:2IMY<1TB99RM;E-(.OIYKS?6-JUSA AX36V/P>M9_M'M3+!"ZOV:15"B3I/#"@Y&O.Y&1D
I2NI3L.^%OV5DVM:I%>"P.:I2K *.-M/F:S"FF&2Y%I(8T:1S'.9H2@1P<%?"7VKRKQ=Z=X>@^&VJZG.MIMTR_L.$1F>.:S=T39&JM$I?
RMNJ$@C@)YXKJOA#=(%)=(-770M8?4=1NK@WE.MHD#0G+$XVH>B@DISUY2/@#/-~.?Z7?-%/I-/U*L.M5IY.XMIN2-73*$#@M=SSIT>
(I:U'O?BSX.TKPJV5W>17OOJ.GRW+7?'TN'W.Z4'W<>"/NCU.A-4-MG7VK7GAB*QTN^O5M.TS7'D6DDJHF5ZD*1V/I#4+00-5^?Q)A\I^&-
*(O+WP.J.M.P.MJ96MNS-IDY)3R.WYAOZKKOOI29K/C2-OY.&=YIK'I'UN(I)/>8%MZR/Z-VZGL$YQA\SVVTO5/#=#CIEFO/>+K$D
MJZ9>Z9I7M2UF^T+6=4/VZJ9+#NL$FWTB#.(JD#$Y2"K8X;/8U8\7^IO3O$M.PIOM.V/W@TI3IG$MK:(9VM@64@-C/OSG (/2@#T+-A-
M*X2>PXR7:2D_M_-4@:@$CXIH9_$GP1^2+@WQI.R7+Z:92^3?)C/7K7+2>&I#UUJ^MOBI2:C1=3BU&YO2-IUG)OD#"/I4:>1K=-.F/<4
>H6GOA-7TZ0VDUS.IV.M37RI+>L-EIAGIN.ZC.I.O5K?XO>$KF*PF2ZO/LWL_V>.=KIQ&LF?NLV_I
M>GJ?7PU9R67P.M:9J."YBNXM")K/'$FPU"^\^&*@V.M+Y&YM-/FIKJ&SD=(QYH.=24?#PZ3%)<07$=UJG48:50&M!4
I_FSCV:LK66DWVM_&F'Q1\7-MI5H2VY>XA:(R2-N.P*PI_-V2<8!&*M.ITG5K?6:62XMDG5(YG@(FA.ID:IP&'3(ZU?JAII_YK:R3_8KRSV3/#LNx
MMC-M&X#W3U\HBKJ\1110 4444 %%% %% !110 4444 %%% %% !110 4444 M %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 5DZOH(U>..0ZKJEGL7:M MLIGRE;W(QR:U)*-8_X0L?OR>
(-P#P8"-L+6_A:-WJ%A>S>)M>|VP:S+M)?$=.Y*M"I2.8W8J+HWL1GD5T%!!110 4444 %%% %% !110 444 M4 %%% %% !110 4444 %%% %%
!110 4444 %%% %% !110 4444 %%% %% !110 M 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
!110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 444 M4 %%% %%
!14"W=LTCOK<1&2.9=0XROU'.H "BBB@ HJL=IL5OEL3>6XO&&I:MF52.(I=NA\H M<4M{I3})HHH>9(B9Z:F.S2<@JBNTF85NC%A@T
244U'610R.&4I"IR*=0.M4444 %.EEG@B:6618XT&6=S@>I-IFIM('J%Q/JW@>I9^7UXYXH GH.MHI.2>&
(XDEC0GG#.I0)1427.$C:4FC9O16!-2T %%% %% !110 4444 %%% %% M !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
M %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4 M444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
%% %% !11 M10 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% M !110 4444 %%% %% !110
5PWQ'U>Z@.@:±3/MKFH):S3OMM=(I@RI3V8_M@@9IS7S_PGO)AUZ4_I4:3X6_MT_P9=6^HV45H:0E#):V8JP_C&I_2"N?
SJ2:QG81+8P6UN\I$:4:~E-MHICX8IE+L>@VGH?OI^)$U_Q/X+OI&@R6J>P-9/M.36Z$;MVJ>5_P"M9JHZEHP7B0I4Z>DV5.$B:C$ MA
I2(OP.Y3FKJIMU@U)XSNO#=Q9RO.NFK86HOOR.L.C.O#ISM&IL?6@M#BK-HJPCFUJZL+>IJS?PMM=M0<-
YL&VTVVN+:8%U62.'G<%3M/(I_B&35C1=#URO^$EI[X>GTIOJ4D%MU$B+/&48S-(0=VIH-XSWI-.74-%UN?POX,LX)E-QI?Y9S72F:
(#:"FUMIW<MY)X^G.*4>-7C6"UOK"WTW5I(Y)GM;Z_2-$17**2_.=Q&1@=,7QO/X>LH=-M162S%E>Z?+.6)*ARZNKG(R"Q)\K:FL62IM>#
IJSI3_KK7+<I2)-PMU_MR"(XXK@-G_YIAOJPTVTVLW-FMNGDO1HS3B)WMGY-N.H\JZJ?UI=6U!="#MTNXO60R&-?DC'61R<(I@IV8@#W-
4"/C>6AJT.M4S:E.@FNy2.%I"U\L_J.M.P#_AUNRN=6US3:2236GT>(M/Y=<K2@8C4IMBJLOXZA>M^-IYMO7QC
MKGA36+HW.TX&K6DI(<>8).>@/0"3H/OFO1*X#Q7X5N8-<I:UX6TB/I=87I._MELD2R6I*OZ)&3TOQ@I
(OIFE69N+B6>3F1$50DBNQOV."Q^8G&1RI/DT_N&*V^K^->OVT36NN(3!)<K_N.M/AWB>+C2S+=JJE*A6T67/"12EXGH""K744>?A9+L7S-I:
H64E.MM.V:=TLI#K'6>3Y5OR.I.G@<R<#N=#UEXO.NS2Y"==&OITOV@OF,X<GD_MY^GOO0/ZI7GGO4CMM.@>~>9-OB*V5L1;V*X?*@
$G@:ZUUL&GZKD B34M.MO+=2WM(C516Y2X#F93P=RCE#G.;I<TK(I>:5JFK?>3IM@IR-U")F(EI\ML3<"HW.MSI/>@Y?;
Y%>^(I:.UTN2"ILXVN#F:Q:WX8&J'R@L#N)(3-I_M^{62ZS);SV.GI-IFMU).M.EQF2 INYDCV_*5_Q$,N<9HJYES>VD<.C36.ML9?I_?F:I.D T-
5)=O9>&K_Q*:6+Q2+0LI+I/HV-M:86I+LS=W=D_M9)!((XSYVMMN16JIFO%)=TWQ'X:<?B#PW>?;R:99POJFU);D9DB.FX QX MSO&
<H/KCGU>7&I516WCL8FTOK8M)=&#(C).(SQR.G.?_XH4444 %%% %% M %%% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110
444 M4 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 M 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
4444 %%% %% ! M110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444 %%% %% !110 4444
%07%Y.VFWI3PN.C.WR"(M#H+VTNB1.W4.Q'41R/L?E23WIG-R".XNX(G(R'K MDD"G'XFN5^('AIQOO'EI?6I26FJ.?IU9WI
"21.BEAAS@XP1TYKEMOU,@) MKX7:O=PIHN=01HE&WEMNOH;ES^5_K2LKJ&5@RL.@Y\#K#J#+.@9) MIG@4M<I0I+4_%G-
INC7#PW.FQ+J09.KSJVB8_?5R?0A/6@#NZKW%I:6K!M:BZ@a8C($D@4D?C5'POKL'B;PSI^LV^EU""C^!NC+^# C)*Y7XK"(6GA62
M6.J^((H/R:CC+9&:R?IOWD\+OYDJ2)>1@1^8K&NM%-^+)M.U:>"TU M(V3LU.LFF%);&Z'#G^&FMJ2XO3:28K>15$)-PT>X84 Y(S@#J>O>
M@#T.BN+3OY)8-Y<+XDTAM)M+VWG(P)DEBC&7?P!M<#G/UZ9("Z2:K5 MJJK;O#J>5B>UO!\+XRFE0*N>F02
>+>@#M#A+I+VUM"HN;F&MTRIO+GIZY M:P_XQU?7I0.47AUX&I^N+ZNC=J1"T6<$+@%@2<=,CKSB4TH8IO(ECYL_M/C5K3&X9QF0_H2?
.CECFC62)U=&Z,IR#^0Q:C8SRB**IMY)#T15)/X9 MJR -.8%8.GI-.ZGNK>UO/<3O0J3@&1PH)_M&D@N;Z:I-O<13=?+<-
CJY.XI*K #*O"$4%FQ&1WXKMEM&U/G/DOAVQN M(IZUBD>IO$MGB1+78-Z_O#_NRH_6@#UBJAVH65LYV)-IMXFSC#RI3ZISICI
MZO_VO2>&_"H5
```

[illegible]

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f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|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~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f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~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|WY.Z^-)M>@0>#;>+3!7OM2TBZN.M.FO MSNNDMMACEP!O!75@Y!Y(QGOF!M!)Z?H5G>Q>=H5U? 2&6YOF97GE<Q\$!L" M.YXQ@9.10!YW^SA_R(&H_P#84?|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

[illegible]

S-@?Q:=S24UA:##>Z6?P^NK..SBM)OMJB,2 MHYEWQ\$Q=3R9^9V,M@K/A@4I\$ \$ @Y/Z\$5YMINDRX+XB
MU3P4EH3HVJ2'4=U3Y\$A)VB\$<V\,H'1+I5WFL1Z@<CW>DF%+YDVPF9RBJ3 MP3D^M?G^"YQQO'E6WB@W?CJ30(K<&VCLGN#D614*J/O,B"?
43=JZ,O- MM-36:7XJ6M+HFF6<=>AO^MAOY)LOF3Y@6B4ELXX7J,IM7=Z5K.FZY:-,M?>PW<"R&TDP<,@&'426@#60\$/B/Q-
I2WNHV6@VMQI-@T"OFW12XF51EVC7:0 M.<:CDXXZC-NY4>=J&C:=I<:/K 7I/M 5VWJRW*HVP18QD16'J 24BL^2>W3XHZ;KD; :5J&BRVE
MM,IM3<^651STR@)J10IKYWB?47T42:JL4FJ+=2V/Q#1,5AMIR(20X9PD) M/Q@9.X=-<6/#"JL:4J/U73TL14TV58YFBE\R0,N1B
<=\$B,BN8I?Q M8^&+JUS7-5NH:VU?7:FYL2,D""5&(5"">Q/L,LL/2NCV?ZIH=-,?3-4M- M2O16%Q>S6KIUV(VJN1P?#7-17"YBDT6?
#6NW.MOK^75L/T^HO9I8Y3(&") MHC;LD#KOZ8K=KCO-ID?VIOBVI<+KTN3GIB&^ UTTE:OI^MV""VVEVD-W:N2%ME;+;0QZ;<<5T/G1>9Y?
FI-MYGHW<_E7E%QIV@7WB#XD+KD%K(4,+1><73-LH#1@ABV-"O)(J66QU+PY MIWA/QI=6TLN16MG%8Z5&J19(9 HW"N71HIF@#U-
9\$?;QU;I^P<,"33"/,M-Q 94\$I&1&6&XCUQ5/I(K)K3EJ+P9FGN-O>1SN;GN;G I@^*A10ZAIL57UW-M,2VIO+I/XJ@ I0^Z4+I(B,X,1Y<0 PISQW&
<4>U//##GS4J43;IF OGI^<?# MTTF<1>61U/G;JIN;JH?PTJ U3XJRR6IKY?GP31DJ&JL2>5SOHM7M1+UBW+VPOZ>\$6\$ AN%
I*6Z(MI@X)WYFXW=OO@GU-^8>#>N?>AR7U MW%#^EW;/I8L<1R,@J19HNB:J2>(M-O;0Q:9/I#"ZL07R/SDJ><<
M5D?0VXI&316S1^5J5VJAX4>K2510)OFE2-2<9@<IG;J7>M:29;G9Z>J;C%& M6&2JC)8^W;ZD5Y-9WKZ5J,BV7CB 23XY= ACMYKJ-
^BHWGSD/N=,4>J-KZ;N^+;G&=XOF MG^6,L%\$BEB,@9Y(I:JU)PXTFN>)O1\$5JYV&OA=4@G\$>4MVX68GWW@A I%ZG MN-1UW6?A?
JFLBSGAU>"T^QO,,8DS^&+EH=O# 8 N"@#FV.;?#Y4JL UM MK X/H:SGBE=TCE1V0X<^P4^>J7DXN+U/3MOU,P5K5Q>N-\$EACMK6*,1K
MC*[I1:B0^A0>>3@8S5KPM+X5UNITJ^TW6)9JF&QEAEL5BC0)\$5^9;@+I%G^+^A9@2%##) X)K;4:M-H7AC4M7@CCE>RMWGIMR0""@D
MC(Z=-M>3>K6RM0""PPU&^*#JEU187N%QYC^5F10MUQP;CI7I7Q%94^& B0 MLP LZ89)JE^I0K;>SZEH5C2W^1H+=0)4CSA-R@XR>N;J;N-
^LRPM+&) M6&50L-Q^L^Y00M^Q^TRR(J;^>)P\$ 8=4C652SN44^BC/+&X J;Z187^GSV MGB:ZM9+>WNK77+82?;^WW+/@^*ITYEQ@=-N?FY&<4
>TR3Q1F25\$QC.Y@, M9XJYTLT<<9DEB2^18YUY-266E:CK O.DD@M5A5TNEVC) 8 FWD.1=IJ
M#NZI]>ETC5+=-8I\$C7)XAI DOAI&MI+EAY379;LDI;IF<9J6I;-XJ>ZM# MX%UW7I9V1NM-U22Q\$>6V%5E6/=UR3IV>U>@2SPP13-
*D88I078#J1;V/E-R MB^#C^TDA=NFORK\$88"?HJN;2NYMY+2XJ?>+Q&L#1;0&R6ZQL:UV M'S-N>/OIMW <JH;IW+R^C>ZKG;-
QQVS_(53U34L=+FN8Y#((F>2A/7 M&O/?^DI3A=W/PUM=-B[I;J486Y^S20;3Y2MGDC9MX/7O6JWC66M>+J\$ MU9+6W2+3X8=+AN"
QV00XQ6 P^FFL;J)Z5JUPD<9GR,9(^Z1TOR;J#/"K16EO.6V M8+&P[V;X^N-U1WMRMK; F1+(01&6P&^ KO/5I^P@>XD7JPO^YM=D:WE"
MC="P1@H?X3G/(QFNOFOM;Q P") +3Q\$JLJ2:2--^UDJ)("K>L)XSO/..3 MA?2@#J/NMS^)/!^F:S=JG@9YK=KC?A1(DGPNVE&5L6VTX M-
<\$SY@=E0 4444 %%%% 11110 4444 %%%% 11110 4444 %%%% 11110 44 M44 %%%% 11110 4444 %%%% 11110
44500I.EOKJW<7US;P1^<^<JGE=-N MTDJ<#<=>I %>BO/OA I VEKWAJ4;K6;YKJ/495),F5>..8C85QCE1C/7072
MKXLTHW5KJ9)5BOC;VURT3Q4THS;JMZ *^H<<<T;E%R1Q;R6PD^X7(MJ>O&<#DX% ^045@W B 2M/U6;2W%W-?
16PNC#1;O(OC)OD8&#R#T^SKJQI; M)-X- LZ">JMM;=C^/2 @C9NG;W9 XOQSG^% ^7U"UL;+YK6J32==Y0\$ G M6;XGUZ+PWX:O=8DC;GD(-
D6<+1V(5%JLL0)ODHFLJ;V;I\$W^MUJ^DL2) M-S2R125^Z^H/7@ T966.HRLK6;HJ2PKVXH EBMK>#JDP1QINNQ _E34LK6-P;0
MK^3DOK&I KBN00 ^IV@S>,-2BN=4O(C3XX7^M)^5^>+T1@>I0P&YB,C MOI5U.E7S:AI50=N%Q)TD.LRNA4YQDX^I0;9)B^R#IY4?DD8>T;
<>F8&;U; M^OFYA,2?>38 J=O JVOOB)X>6(3--="V^VRDN^M9I^%*VX=B/EYXU-E6A; M>*M^NIG4;I1\$UIV?
BG3+O4KG3JIT,IO;^6^T0M&KPQYBDCENUU!%86G^J)U.YM]W^T^9=6INJ0/RBYB& M,LF?J;#@I@XJ73_%FZIH<>L6?
GR6DDWD+^N7W^7C>+IHW/UZM9>H>+^TPSMN.C.*?QC;?>=H;^>2>+3YY8I8FVLK+&S @_4^@#6 M^0
I+I#^B4YD&T7/QCGUXHAM;V&((H@>I^D G7^<^&G.W50NN ME7\$MV-0N;^2,2X@=5N6\$8+D&)&ZGJ^U:XLTHW-
G\$9)5BO9C;W+ID13 M2#R/JWJ<^Z-C@F@#6BMX("YAACC.C;G^*INJ<=33I88IU59HDD^L&=0<\$ M\$=#SWK(D)5;7%/"CR2+#+
<_9(IHQGR6FRLH>N01GHD8SGBJ%\$S100#IH+YY9; MKRK^Y%M=RBTD^P-QROQPN6 S^5 ^226MO+^')\$;L?W^9 67Z^M4M,EECAA
M>:5U2I%+LY/2&Q;A8;3JMU;P&X5FU;Y>9 RB>CYTI>HXX/(XH XU
M869I!M;G^BY^ECEU/UJZ=JDMMSMIGAW;"&P98J#ZUS.(Q1;7\$;GW^3W7 MV6 E;^WN&M)!T@+^#9G^#;^<#J;T^Q7L1%J;B:2W LQ17B7431-
\$-NX,0P-MS@CD&@#5CM;=>%E;*)"J>615,+Z#VJH?%#%;QB.&-(T^144 #J16;7%NEK< M3VIOJIMIX;4WABFMW#0".Z@-DX(CIPXR;4.G>-
M%U2ITVWMM=2A,UG); MNB3+^N^JO&^PIR1J2@#=-M UPMP9(S.HVB0H-P^IGK0I0I).DSPQM+IQRH M+I+IVK@?B^XJ5^UPVE7%I^)?
PVPN<I>L>_SE5TWCYVW-GID8SGBNKU-O-IV ME?;FGH(XI-0H)M#76W4C.7QIWF^MQWAF7^-.GE@Y8^MALLW 18KM=^A4Z9?H^E^H=W?;1YI+
(L6=I&^(PRY^I_10I100P B&*M;^DA\$ S^51M86;L6?T)9BV5JKRH;J6:RDDC^L^ M^<(Q1PQI&W5%4 ^*+U%KIE^M^+?
&^V^9CZ=*X#Q3JNOVO@/O1?30W>EWM-MA(S6EREPK+^N1AE4=%Q@88>-6MGX;7EWJ?P TG4;^ZFN;NZA\R665LDG<1P;
M@-"@#HUM;=22L\$0+^%)#D#H/H^G;^WB,4,\$<<9SE\$0<I>I6JGC71-(O;MJTN:AVDLXEFQ#%\$SBV1C@-(HSG;N<8YI-
4I;^I7VL27)G;SMUNKE;=?;M,43=?..W?C)QSC%&M-IMO)HV44<=<+1%8XUP>P(OG^GMK>*TM8;^I-D, M^+&B^B@8
^L27OHHJKWB30=OJ;#7-K;QEWBD R6QUX;I.08 T3>M,BATI MDDFFU6\$;LWBB+2R1H=Y;V^KCTZ;V^JL53+&085FW%P@W\$X(SGUP3^
M=#65J2,UM^3^09^8QIY3/KBN?CGD^IWNB;JH6LW#;41^1)S/Y2><5VF3-V/3/7%)00-(T;,<2'7" %MC<^N"?>GRO1SQ-%D##
(Z@<4&L33 ^!AHVHV% MU=152Q09)A!<03PM^I^2JE^V6R,8'>*9<>=&L;5)KQIBW73\$62IA>I MC(B-IU@IG^GU&0;^*P6MNI8B"(%@
Q)^D#H#I^6^W@M8+MX8XDSG;H4 M9^@KC=3^(UI;R6\$=C8WTYNM1BLRIVSHH#KOW+G&^*@<^9^IC.I?^M^T26Z
M6XDG(6;1)=RK^5);M)C8^IG<F<9&<4-IJK;W.S1L^Y2,0 M/J1^I) M;^<@S01R\$=Z X ^L26L%I="ZAJVZ3/D-BH8YVBIQ?
WFW&&?VC)OD M8J&P1?;#J1TPV\MSY.INT=K;JLZO.XSIFXC 8J3@>WK00;TC100^Y;(I3-I M^&I21PQ0ILBB1\$SG;J@#-
^V74J2D^P1PO>VJ,T5JH1B#\$NW MN;N8C(IJYIWB 2=3U;#3X&N\$GN;I5;F;D6;C)1B-C(SCUIT^V2VJ MSOL7FYSOV#=#GZTSI#;HFQ;>"
PO=&J0^5R/O8I;OY&NBQ>0J23FWN+EK2^ MXC@>1)9E)I=H)RK#;^<U;I3;ZGAOP^;PIO+<+PMOY48Y;WI^ZF@!
ME@;9JMI&T^NZC^JH;L OEB6&RBD5 2Z,V6(HWP 6(I;Z;CDD^HWP)I552=8M;M7N+^OLY6AEIU^Q^O(IPR;IY% M^W68GF>9M7?C&F^/3-
5K#3K?3HY5@109I#+(54+N; <=<=I^KS52X165 MO>RVVRXE;L<ID4198G?&U6(I0RGT OQ69??\$0;"24(9607;3G^7ABLI7 M\$ (#;FPO^X.
<I^V<@#H7L+1RIVD#;3DDQ@DT^6W@GAI^F;2+CY^4>;G1 MK&O ^IAI@0#++<I^IO;I^&9EQ P I^#CMZ8Y;#@<59D^0V
AM9+>I+MKN# MI3;^H69XL I=AR.N.H^6@0EMH)U59H8Y O0;@/SHBMH+<\$0POQANNO; M E65;^M^O=I+VOE>I2_5GM8X4>0+IXX;.
=3C(I4BKFD;Q9;YIZWMA^ M9(BS1H4JR;IPRLYH\$&#0;8CM8=QAABC9AR50#UJ3=-M1+MYAMU WNM^M^T#=#CLM8NW-
P(M^D)V^2=)Y((GFC^Y(R LOT/45DS; M7JUUX@;6XU;%M\$^ENEDMOB35%>9;IKN;,@=F<I^8>+I3-(^VNG2;KK%
MOJDKQO?MT^I(KH=B6)2PWRX OTZ^%IXNCT3Q5XT;5)H0FLK;V9\$2-YA;I-F M;S\$>N22? ^*U HM0-9VKM(C(S6T+^*09^8P=^F?
7%8FH7YG(XJ/HVIV) M=O-?);6I;8072I 6.G&VCI SDB\$U QI TPKK+=>0;PV+3FUD\$<IM8KZ1S2")YH N2,@++I#VK\$B;Z+))HMOJ
MAFFCBM(GJ+%)PE6?<%\$>S&Q+>+CZU2UGQI9=^X;UO4I>VN9KK2?DG M&CVO M^(0^NIMPM0=P)XZ9%
'4SVT^GRH6XACE4AJ.QNC>644YBDC+C)61=I^X5EQC;DO+;#5)0EL T%K<,&^5-(NT;MVIG&T I1@ 9SQ6^XJTN&>)))%AEN^LB71C(DF)79N!
M<@C/3(QG/049^VB>+W-G+Z^XN+=K;5C;1ML@3@>G&I^D<G /J; 30IT<MM;IAI#^\$;D2TMIH-V6I2^<?>UKE^I^=V= X9TW5JH^
M>J1D\$=M (R6EQM0Q55)PE^XJZ4FM^);^U^PJ=J)>HV^H^G;XGLU=+BW ME\$P^O)4YPL^K0ITWY&TVJOV6#"G^EC=U+>#%;FR-
I%)SG#J^/UK\$Q_%V MEZ;JZMK5;ME M5,AHF) 93T<^J+YLI4LI&VA)I^QI^?I^6A^UD@6H;^HE.X1M&^H/KB MN;O=?T;5K/PU?
JHHA^I>QM9FV#(+EL-B.3CIA&20<9Q572M5>WJ?>1?7I M@T^QMK^91I-(+@I256(IX _GZA=IQZFB6SMIE
MC66WAD\$1S&0^8?;TKAKSQ#)=>?KPE;VLNH6J0I); M@ICC(^7K^O1H;D=K&H2-MJ-QJ)JIVISW;WD35^E-(HVO@L I;#)YH ZQ M(>^219)
(8VD7HK,H)T-M&K;SNC5012 F>@;I7K?E9=AXITO+Z LD>;& MXL466D;F;H2(SG^C#SI5;,>M(N;C3H5-TK;G^YMB6MG(N\$&LN<#H!
M^<!!Z4;ZJJ^%50J@8 P^A%E;@DBVAI;GFD^6.7 O27WJ#5M7L1%LUN;V MOJIKRI#&JH6:21SM55 ZDDUE3>=
\$MM&U+4IB6>*+39Q(O^V@8Q^& 0>2NY>M>G/6@#;^PV>UE^RP88Y(ILO^YCW^H^GI699>)I.OM6NM+1 MYHKJWA%PRSPM&&B)
(I02P&5R;URVO>#MGBP;^GOXK;IU _%9(KJRV M?<9VD9QD0197+PFX20-G;A^JG@G-A;Z5XAURQ;O;8C2+J5(SIK6H^ M^<(HW>9)P9GSD
^I@8 Y>J^4<3;6FH^X2ZQ+IES^9MH26VYH/FB5G^8 M^H;^>G;^<H^@>YIGAWX?F72+EYI^N91>6I)00;DB@C+I2;L<I2I3N;F"
MRM9;FZFC@MXE+R2R,%5%4DG@G12Q51)+\$ZR1NH9^4Y# I@>I00;R7Q,TZY MU/P%>998FDN+9XKQ8EY+^4ZNR^YP#^;7Q)J-
Y=>;G3+2;TB5W>ZDLR@G M^M^I^P;O1522=04@XH;Z^H;T@LXC%;QB;<6^ G SZ#L/8<4>925X9G X M1>XTG5HUS1 VW<7\$OS=#S78^"X
9M=I;M32S2I M<2B^2"^^&I^HV9-O& ^7;YK3\$>M;D ZI8^2KCI9/XA-I^E MGS^K@>I M=M;WUI?)(H=0W^XN8W;^0.8=5^A&I04I
^FF@;9JH>M\$U>2-22)M(DM M+J2ZDCS+O1ONAL^ORG 4>U;F@>H+I8ZK12(="25+1MX1UAN)0RNGIM^I^XJ;0787UG^J-
A<65P&,%O&T4@5RI^L;I^<HJMHVBY.@;^8?&Z0ISF21 MI&8^I9B23@ ?0 =!0;B _\$C3KW5 _&JZ=IULIS=W"(L<2\$ L=ZD^D@#@^K6?J
M=EK#>I9M6T 3FD3 _I(16VA; C-R9 ZHPSG;IOR>G0777^JZ=I2^<H7IM;(W
MIH50^H.YI0^<6P0P!!!!Y!>@#S^0I;UG A^ "VJW&C-BGEV\$IM>O)B^0 M;L^I^GRM@*J^W-%I-WVE^--6PJ P!@S3+J5N;K61:J>G;
IK>FWG@NUURU&JDNJ2-DHHHD;XL&Y 4^@/85W6GB33YH1Z MOIMHM<7-A I^SOW07;JH#)%55%)H9^DBD4;CH00>XH
X^#1+ 6I;PA;36-Q8#1562YEFVAMZPF,(F"<MY+9)Z8^7)O6?X.T74-/BT_0=4I\$V9GTV1 NLGRFB=\$/RR+ ^YF.G^IY%)>H4 M4>7>@M;OI-
D^A4 I^I>>I P#^WV^%7Q L>= M1%;#>+L U6SVS@&N#T33I8^BKPSJHOHN(=-FMIQYGC^20^7TQ-A4^5L;0^ M17IU^
'DIX>UJ^P^X1T^32KA;NOUY+NYBRI,40GD^X/H(&@ M^S^PS2XV2M^N6H^@I^@#D=-203;^/I.MJW4=,099?D.C7 MRV\$L+2
I^ILC+C9\$5YVD^DD@=-O)\$-AHFKQO #59-G;TIBDOON N2;F26021^/C;C1?%603**^IM+ M^5 #7B-49DT=
IS3I4LL;V^15M9(4^>658KA#G(I(Z=^U^ASIUH^P T3JH MM7MKNWA^R1.RD@IB?X21T=23@9-06E;W1ELHf&XC5BA>%PX#J;CN^/+
MM2T7^4>/M^MCT>Y>24=1FNK1PR)5?RHH;W91^5LY QU56UJ^A7^K^<S^E MO#^9W/AR3^3VN2I^ZED92 IG/ IY%=>I10IYSX-
4(CVTZQ3P19V5JH^2^K M^Z9^VKM^8Q^>)P2W^=0E=UJFAZ7K2QKJ= MC#=#+24\$JYVYZX _L;PEX^EO);/2I>+Y44^"H4N@/0D=1G;H
X) ^LZ7 MI1-APL^I(I\$ P^"\$S^I^J&Q P^="^>?M^@#8 P#?N@#52;P=-SXA/6&HZ+J=AJFZ>I;ZC:NAD@G^Y&4-RIP""I.W
MOFE00^C^Q^I^<\$S^EW83ZK;Z;I^48+^Y\$ L9^E2^7WQGI2H\$&O20^<\$ M^I^&Q_HTO/I^A&7=Y>BZ>^UBK;4PIUHZ+OAG2I?
I^AM+735TV\$G6 MT63?Y>XDGI^>=>G3K@>I;7\$?7IE,4CHJR@9R<=>WX^U67@I=O;NS^<QQ8B1^>B>A^4J=MQY MSTG;^
3^97^58;D9;SR.#45W>6UA;N;7^7XEUW3Q(IK)H^XTIRP2M ADBC6^X^9;I#O+IK^Y@O.#&IUI;H6;W4;J N 7\$ZEH5C^I@9)4=2.59 MH
XUK6 /O0AUDZ=N!U&1GO7-;X>UJWJ#^!+^73) MUNM,U=+BIC4F^&7+9S@_?7@9/Y5ZO10YMIJBZK/=?\$@Q:=ZZM810V+#+ MB9Q T9

YXPS*KBKD.EZB/\$ ^@BZ.C/^TV>^I4U5^YVM\$M|MGH|MGF48DA|Q2P|XY7|KWH|ETV22TL=|2|I|ZZ=^#T 49-3MFMEAEC3YW
M96WA|SOC>6&R>.HX/HWC73KG6/^MZ?9|YES(KC5=|M-1L=9|^-1^HM;^(|-QF4G V@L,X#?*, M9JK83SGO+1|,*3|HHF*./8%V%C,*
K\$GY1R.3QC>?FUBVNG:5H6|WU|H| MJYU617E\$P.D=0%&T^VP,*&F|..|9V(|.M87%W91>^UM+;XM2-9+<^*P8
M2L6#;1@H^XF61R1)&LDJZ,AE.0?QH \X|OZ;K@U71/ M\$8|,P.C%1;7FD*Z|,*ZLK(3|H8;1NQ^|=CX:M?LVED_V;Z;H|6E^QP MA
4SCERGRES|Q|G|HXS6Q10|Q.H>?H|H|Q<74(3^Q=8L1%|T9."|Q\$|/^E M8|F|E3|5/X&T/4Q#^BR1ZLYGGM|VELRL|UK\$S>5G.;
O|/?I753PVTIEGE M2*?=7=@H^XFH_P^T+|+H^UV_V?;|P;M\$B@#R|2= US2 _" @R:1W1+\$?+^86VED@GCYQ-M7^K7HT\$|
S\$|8|8Y8ST>@P|XBI* _".F.B?\$/>^Y^P3^IUG/>@N6>?>M4^GGE2|, E6|X>U| _|V^Z5>6;06-/7C.IQ7T% '%E|Z?
XGL;Q%)9Z5*WY0Q\$EU@+&TCVFS#/\$& XV< M9Y^7K52|,ZU=:=|0K2WT>|G&|J00R69GG5S(5B4%2Q.G6<^06_4T^&X@N\$#P31R|5#
HP8\$^H>_W|_*@M|DEU432VT|H M|FX.O&.=|Y(UQO|E|>)=|L+<#PQ|A|C3F\$;ZH94,Q*>49W;RO&,<^D MGM7H%%
^EWA0W^T250^Q^>+2|5^T-D|M2>4T;F0N^<YMXSC_4#D#FN@_M+Z926VI^+VN;621+_4#;.,^2)Y2KG@|#@UV-% ^E>CVOB73_!7A72WT
M&H+&;R=0\$31>>%"L TIW< D@%@0V">M5Y_#>MGX<^&|B|T.Z%\$>ZK+|;|T MB-
YJ.Z/FW^H%.23^|KURB@#C4L|W A9|L&L&QG@VAK;^4@+20&^AG2I7EUN^N)+2F_.G31=3T^Q>)+?3|B LY=|ATZ>.-E
66)F^D@<%(S|?|)HH|ML M| UJ#P9|K*32YQV*6.5VEYYSQ8 MC=T11MPY+|D6G/|UK&O-UN3PSXCMH|N6GN_ \$XOX(E|> 21-OSG
X1N#<M|_18|1|(^4FH;1M=1M|(NRN8;FVE&4FA<C.#IP1P_|+O+*/QKXBU2| MLG:29M#2^S9\$|^5.A9^Z2U)=&A|I93R0Q&*M\$RA8|R%+^C"
X&VYW6IU\$KA@^1RK8|P|I|U5T M|PS8Z;(C)|/P|C|J6EW?2S^F.F%9B,CL3DB@^|XT.K#3;%M*M^N@M|S;M8E0 MRK_|FCW>H&<8/
<6|7A07|O#OCRPM^M^00^IW4\$MFLDR.7 \$6W4U|*10|P.NZ#|L^-=0DAAE@M+SPS-IRW;# 29WR1UX; <8|=-SHH; MO|2Q^";?>
PY=VAVC7B^17M6%DW(= *G(3OCFO3Z* "BBB@ HHHH ***M "BBB@ HHHH ***M "BBB@ HHHH ***M "BBB@ HHHH ***M "BBB@ HHHH M
***** BBB@ K^U_5+5S35LQ:6|12;9|=7#|8K5.L|1^1G| 4#|(Y6MBN)+1 M;12.KJFBZC8750+ILSR&*XA.L4H=:=N2H92F7|J#GN;..#XBI! ^6|JW.50:?
M|3-1-GN^9F@A*EAYTX|VG;_XP6&3W|J|C&33-TV>^ETZW2^N^A6_A>U5-M0^4<.,??P.D 9|Q|RW2|^6|JZ187EJFIV5Q|^9DK|)^N+1M_JP.1
MTV|H#FETSP9-H^D-HK-8|37\$|UQ936|W(D((C1=WRJN|2.3P|_1M/\$=W+ M>Z:I^Q6JZG>P37)=9#)"D2_#%<C|;=N7 XZGTP;
<7CEU>XTVZLXTUJ#4HM.;M|9#Y;M(N|) <9^E S8ZY4CWJ#30A|VAC|C2|Y\$O-;\$9\$D9.4L4S|VC W94 M^<^>3C;^EU7P% _=K=W
U\$YVVMSTG6H|WT465BEB79&A^A<@<GG<3WQ0_ MJ^L.I9>& \$TNK;^7.6GPJ^N<^&^BIOWL M;VM|H^*X|9WYQM|MR+>.#G=@\$YYP.
<&K4WA06|2|^ZKIVJZW<^7VH6S6WG1-MVVR%"" JF|/S\$DD|:=.53?P|H|VZ;^5H/+;1Q|4JR6Q9Q|C|A5K_ (3NYGC% M|H^DW5Y8B|U;.<
L|C(LAC:56^L_@G;GH;H%)9^"-1LU|2|)M|L;C0;2 MT+&U;+&R^G WY##8.V1GCGF@#^+;ZW=:YX%|9?
8>;W=:QL\$FLY#*QWR.BCS&7LH4GC.=O4| M.#7<2; E^+&|YK-MM(SM49)^0<^N3O?>IM;+>_T|6+>+2M=:6:2*>U+R02 MR#^E#&@;2>
<=<5Y-K9RVYCV0G|G|EB@90F5-HR%&PQDX_<^EM^9W&MZ5-JP_MHVFSQQV4D|D49;S+&B&53SG|FWS8^W>E+>+>
^FZC|&2FRA6/Q^A.@WG;+ MHR<-8R6|SU/^0"EIG@3 M4|0>%TN=9M|(^ #S.(5CM^OG(8S&-V7.&P>HX|CV.^T:7=6|;^XKU2RTNVN-MM,L_\$%
|I>=|9RDVS>_QC7.CYISR>>?QZR;QH9=?ETNR>Q6=4AD@MHS|>)>|MQ>|G@X|Q|R25(XZTQ|_IR+|7-
)DU&Z5|H+>S|8B|P60@O\$&W8P<8W8S@GC M|(F|1^#^1P|8W\$M^+ (21O-|F|GV84+D10NX)*G|P.9|H^+ (SOK=VMGXRE M^G^S^B"@+;\$"
<>4);?|HYQW|+>O^K9UNPTG2M|H|W82FOXWGN2BA@5|4X7\$>M^P-|UDCIS3-7|)"WH|XG2SU6""R|00@3|);%Y(|H^Y>5.N;=;T+7
MPK=6_B;2=6>_BD6PTPZ>T?DE3|)DJ2^=QQ|T<|<|^.;6Q%_?_!|0V|VH0V|D| MN+M|HY+>=77RV,I^C|I|)YX|^6M|)9W(U\$1=^O;^UM?
|0MYT^O#|E|Q^&\$<MG8Y4|H8Q|TU+X7N0^&|UK5K?|D>IV:6@2^J;P-APV>3Y|H#M63|T@35;_MX|+R7&K64BZ|^<
%CLV7SHY\$ "DGY OG;DGD|H^0|H;XBU;58-(U.STR;2M= M1<@<|FQ+|^0\$2D|K9X|E.O.C=U;^HP^|F|2VOK2^J|T^+^N44M|FD8\$?
X<|&ZQX>>3|H_ \$|D|V|HDM|OVX\$RC=N\$9ESR@|MDCC@4F MB^+|8T^+|EM+&Q|X=>=IULM@98|S^GFCB|^N^DD|LX|^&S0|N^*|T;=X2U>|;
MRAO4M|265|;#ZUC67A|IM-?T? M5#>P-;TLZ<8Q\$|YF=I|WYWI#3;E5N M&+K(93^O3Y<^OPSRG65|HTO9%<12RL1+_.8U=HT8#@^#XZ|H
^T|>=&|N_ "I|Q%;1K|O^QZ|M.Y|>=&5)|HATR2&|/H|J>?^*WLHK;^R27|H|V0CC=|HBL6D95|)^R-@#K|
MO(I)\$>I>12X|N^VOANQ|+0V3126VE|EXI48 YG^13NS.O&P\$GA#^U|TV# M2|H|+O=^D66PN50.(R|E=K^?O*5|)^_ZB
9.H^/-4TW0=00)="D.MG>PVP>5 M|((H|A)651(@=0>^V^O8C|G|BCQ%_<^K&.;TH|9.VB7L\$GVE+;BPVMA^N=
MV5OQQQWXZ&35?^6LZ|YX8;3M|UR&6|E|GAEDG6|UYQ|L|AP|&X|R1R22>?H|=^AN M|_X2W4=^W_/M6G|8K^8C|A5F<3GGECQ@?<
6@^A_<4O|+|VR|MJWZ6|LV57^ (M3R|D|A B@;B0^W^N^S^ITSG.1C^02^_M5AL>_306BN;K6|H3+<%X0V02L|HGR-M48#N..>N^*APZOK70?
^L6FZX+76=^1RH+P0;HYHVON|XR>A-^&TK_PG|F|M6^C&|UE;H=3CU&1K^R^M5^B%#?>(N#UR|J6GGO0|C|XSNUR|POXSC2^TM=5 MT;^<
C9GC^21AU9<@<^<|9&>>E;H|XKGT>2M.O;C3K6>|MVD2Y|NV989&4 M|H&L_O_G#K|^00#^/8K0|T5G)--8P27,2Q3O&K21AMP5B
M.1G0@UYUX+U|(^T|H%\$LEWTB&|MK;G^C\$CL\$V55|QW^X^?=>|HNF+HF@V M.EOS23+9VZ0+)^?F?;H&3^52H8Q|<8U&TU;35+2Y6 |59V|>.
EW9 M^D.0<^I|Z4-6K0OPVB7>K6&LVR&ZLK>^Y@-W^W22Y^X|^1^XWf84@D|0^O/DGM&M8|K:U\$|3<+> M8_S^KPR,Z1^VM\$ _J5|)^((SZ)
M|7ASQC|^#?#<^H%;G4=9W&|)DBD?^|H|JR|^3G%|1T^T|>E;^+|5; MG4;(B+2C|D|L^M&:=EX^F7;G0|S^XOAWJPV0-7
M|4K(18|MRG|OCH/O_-|&MVEY5S|4L.H2ZDNGVGG120Q7)8;A^*Z|@H4.2_M\$@KC|(-4_#@NO|6_\$XO\$@S|O|GV?
SPY^R#F&P>0>V.G|S|4O|^IZOHUK|MUP M^7+2|2|MJR.W^Q|1R(^O EY|Y0AFR+|7UNZ|W>G^3;6NL&62;|RS\$LL+G.6&J#STY(|K|
4;7|UXMM;ML|HAB|;|J.2"> R|0S;M|>&U^O^Q|SP|6>-1T|2O^L6KVINM DDV2>L4 MD1T^\$%=<^<@|<
<A|0W^K^4JP|4C|I|Z&N|1^3_P|D>#O%>Q|1(OV35>3>*5P MHV2.0_3|><5W|W7@Y_.|8|ASP+|H|H^M=5Q74=|27%WA8RH42L6*).<9|/ MZ4
^|=GGN|Z5UFM01+|4_"LRQO M7M+X.X4.F \$6-3WQD_G3|P#4|M\$HVGSWJS:5HUP;BSB|LB1B-PC#MG|!"CT'
M;.%&:=+4=#N;WQ9H^LQW;21Z=^/(&86C|,@E^@-GG&T=CF@^YX@U^|32?#>J; ME\$@>2TM|9T0_Q%\$+^16^V|!">FW4Z+<7.IVR75|_*
S3R2+N;<3U^.. MP_%5+&^/|^4|XW4JRLA@>#7;+X=UPGW;K|@FZL;R|H53|F2|MV>6W0G M.S0^W8@CGK73ZE8FN-ITG5K_*Z
MG|QD^7|UGGD^&C_8\$Y(|QH|3P%4|51%2;GHGB^W|B34=^K|>>42D;JH5 M55-M^N^PN=3M;""6T@UC^R^G|H|(R2|S|Q&9|)"SG|NTG|>U6-
3|9WD5QJL&F<^M|U-L;D8D@FE|^4H;2,B\$*<O+>2>@ZUQ|H|/=ZE>C9>(^ #?VB2_DG73|1 MLV%PD@8|@;-9_?."@ \$+NZ=375-
X3UY=>EUWIM;327U2^M2L87""55-W1 MG(PV|CT;G/2@<KK)GU#28YF2;T>X@#A9%VR1%ES@&|&=>G|^T^44|VNF
M>@O^6%T^U&UAK\$8WY|Q^L@=6+14 M.O^ELYM9+33;V;.<+>PR2MUYY|ODXZ 8%0?X|U67PY8^Y?3;Q6N|D EFL
M45O(9I&QM90|T^YN.G Z9;|K-X7OHO%6LZM;7|^V^K644T;D|9E>_752K1P^?>D|>=NW6J9|V|+V-;R;HT5|UWEO-W|>T|+&^STQ
M|ZVU^2RFC@8|H#NC(<#YQC(Y|<@>Q%6|GP?JFN^&+O3?60&XNY@GDW%|B%8
M&1@RN^RDS7LBR3R6D3EP22V4|R2>_K5+X@;9;O:OX.NK&|3;4 MTL^@;|N3J#-5^|V|L=I&^"?<MGICM;_HUSJNEM;6L|4\$ADCD|R1^X&OU?
H^NW6#@SH|OMA>?P|?B>3S M-2@TNX;R0&^H6X&^?7|="Z;O?GDUUNQ|>7M;.;1"=655#;5 M1<|J2;16Y|3 X.;>^>?|HGXSTV(X^X?
^N4>^WN8_00OC&1Z|>A<55UIP|H=S MXEA|OZ|K2Z;?9O;W^W^36_G13Q|BPRN00P|);?>@&^QG?-<^&6N|)23|63| M#
(MTK+;7^@E4|((80V|X&<=>?HW^?25SUBY;VCU&PU\$62Q^68.K5);.QP M06/^0>M7M;|^C7#>E7.H32;8YH|A+X^1)5MRT9CLA;F|?
NL5X1S|HK;OT@="7QF;^!|/\$^/A Q+G_P|!^7%W^P&T_TMN^?|WMW|F;G CW^H|H_-3=K^G2ZQX^PU#3(944;|MY+?S^4L\$#|J5SC(6
MXK63_PKG A%3>0^9_9W|G_&KRCC;Y>S=LSUOYQ6G;5JMYIG@H|C; M;P6|
<\$^FO&^1N6Q%|MA3;I&02S\$X&|0U63XB74GAKPYX@.GPOV.I7@L|PF0G M|^3(T>_..|E=RX|YOC(|H^X.U2UN?#5Q|H|E|T>R-BRRVS,DBE4^F*
XVOA=3 MP;+^#P%|7PYNO^&H7D=S%)A^D.PI0=65B.G+|B^VZ^"@#0U^Q2=|@OKE|X|^# M^6^0\$|..9&#DZAXXU|2|UYXF;64;=;"
|AN&@FMX9 MOT9/G7(=3VYR^GBM^4|B;EX(B|34J2)N8|D|PZWCYQ|T|)(ST|H>= M\$|?P|G|J6E;SXAAN;|MS;+^>7^&IZL4#?QP.X|H^KD-LZ?
XGU&3Q9;^M2V.O%>Z>U|^1;9EVLH^N^X@>@/BSUKJZ?_AS;P>#M^UHW^CHV312 M30+30;W<8^CCGZHU&AK TA5UNXBN;L.P\$TOX
^C.*.1% M3^7O%?BO5KY|H|CJ3Z;|^?>(BC49V^FXG)?^CT^>^K-I0@V5/\$55L.O#|& MT\$>%\$TVXHG|T|+@<^@S36|^7N6>
(+W5|H|OH(|0^M>6=5^7BD=1@2^58%&QP>_MH|GE|H=;|ABT^|T^4K|O|N^C)+FU8^1MR.BDGD_3D|H;P|C^<+^_3_\$
MMGHNHV|LSA|^1)930LR|J9^P|T;Y(X.0PZX/K^TGX@G?;=X7U6YTNUBL<MN?LFU|V;6-
S0M^C@K|A|YSSG|VKH4T^NM3L=4U2YM9K53XQ9|800.Q;Y T MAR2>@P.F3RTT_Q^J^39FWT&|F8-F1@^G%*
H|^7=WHOB3CJ4*_V_ZNR6NG;?|FU|=^CO;B^_5E); X..R|O7O\$M_W\$UO9RDNRR(@RK,IP0_&XR?;U|@W5EUFUUK00\$^V745M1
M;7:7=N)DND#M%<@Q4%<."2>..<<"K5|X4OIM6|VZG|H|FZTL7^RO<0|_\$.P&X@ M^AM(X^O#CM0|07Q;|HVK^*Q|H-O#|975LAX6&^DF51^O;..?>
>4=|@/6M^ M4=&PL#>P7;D1RE58M\$03N^&|W|W0YZ=J|W_P|S|J|OBDW> MH|5UN2WEB;".H|J^J\$8\$GYN5|H=Q5RU|W>+>
P^AXDUY+XW5|D|9;U\$J^MKGAK(R=S|/0#GGF@H|^673ZKX8LUM8=NN6.MS|D|W3|&CX|P<^>W2F?#K5-6 MUGO(KW598)?N\$|C|&-LK+G|Z
#|ATWP;JL&J>&KV^U>VE-L.VEME2^T M^B5614|)+G#87|/3T%0V_A|Q^X9;7=EH^K6I-
IYDWE|D#W#6T^S^S^&|TA52=H|JSC63D|H|3WD5S|T|50.M0=20LL9|W2^3C;C^Z2.G-^EHWB|N^X MU^712T.6.RN|H|TCNDFM|H|Y;
|BRE#UP05QD9SGH.E4|/7BY+|P|X|M1-TV|L MKK5HY98K|H&VBC|W-@_9Y^@_8R6|8K0L|H&|VWB|J729M|LFDFTY+X(K5M1 M61F(*.
<+>|W3G|V^K^2AW?3|AP-2J^*KH0ECCG>W|BN(|H#ED=V|VP0>" M/R)_AUY P^>C^H2L;S^VX^X1\$|^<5^R_&O6NZK6?^ AVIT^YUFXN|Z^Y?4
M|S|6R0Q&_1L552|ECD?^/_KUT5_1110_4444 %%%%_1110_4444 %%%%_1 M1110_4444 %%%%_1110_4444 %%%%_1110_4444 %%%%_1110
4444 %%%%_M%&_1117>+|/54;6X|Q;2|FU+55X|68Q^IWR;3U|YR|H0A&@#L;^D|0ZM
MKWAVP;Z;K5Y.MA907MG=RI6EA.A96C+>1E21QD^M04+C5=(UK1^+^+6F M0#K4LT&S^YGS^WXR^U_1NB\$|^26P>_9ZY
/0**|SUNX|4;|FFV|QK^)|X^C MMK=6MWU-LTC#49\$#<1^P3ND.>%XQGU_7|H^FU_4Y MX?AU=BI>^U6C_Y&@
67=.%SGG/WO0T|ZS>6^C**RUPZE;M<A(ME=QOOLKJ M_|O+A|^<K#<49|4X.*^/0;^V|;ZEXD|1Z-I7B.UO+2\$276Z661|^YH| M)0|G-
^5ZYK|H|H^V#7;|<O.V^RC.O|VO(V%>9(X^F.UJX^XG^Z=^X>2.OQN MWB^Q^N^5^F=^<BL^7?2\$M^>_3|0V|G|J|HFFO^T^E|FM622?R3R|C^X)?
M|^H|H|5|PI."@H^Z|J^H;K14|H|E=6+2@DV|YER5^CYADX9_&L#3+778 M=9\$DNH0^2|F5(6.7C|H|H^?|H^HP_IY^W>F^Y2|>UR|
^W|P|G;6+E|H4 MNVC0|)"\$RC;(^>?>RNY|RYTF|6DLVUY4C M9(V;G&&^AG^Y|A56|HKZ&XWNQ;7M|H+>C|H|HG7SAE3<6^*<C^A0|H(X)^"
M@#L.*X|Q=>A#X|H|Y=H|S|K|774T5PL07Y|P(68=0=0|H;N0QM3URR|(^<K MN^7K|R^|29+^F9264^MLAVY;+509|Y|>VM=AN0
M0#&^TCR.P+^ASA0&H.XRQSGBN5DU_P_O3V>C6;Z|H^|XGDT>_YC1^F^>^M|Q@-P|OQD^/2@>M^U>BO.HIM9N\$;H^%8=3DGD|TRRB;*>XO#|
^TA8^2D9P.WAPE7^J0<=IH905|H-H3N+>_6/9<36_K^0<|P^>^&BO=IUK4U3^R MM755>75 MO.W5|T^%|j6.5|APH&0PR#G|KVX
|Z|4:P0F^95BC61NKA0^?OKSBPU/Q^XET MZZUC3KZTM9K74I4837CB.&*>0T4D0C(R4&=Q..8X8XF&=Z9


```

@HJR=FX8QB@#K#U)FUV33/L#V%2W$ VPH/(8EB-M-@;WAC;=*Q+WOO%!:MSFP.BQ3I$!"/:5U+*%M$Ff:1.413N:HK?3SKLMY=V^D2/
%#R&:8-M^T.V.MF:73=7MM.M3UG5M+BA6CGTMTXF.@&UBZ(UVX)R.8ZXZUP$NIW6LZL-109I)=7&HP22N.M1N8P29:Q55N"QO=213-!
(MM.O9+-.9L.V119QLD#L-N24$1V-.T#<9X.M3JO2=>*K2G5I89-.G4HMYRLX)C\MO7YED:GGY51:M^J)I5GAU\PYHD4SV\>J
MM$HFFOX:9:7V*=>Q8X&1S@"/- &EINOVJ:JVEEQ0SQZ61:3&0 *Q==P*X
MDR.8ZXZUK5X +JEQX2U'XA7.%RSNM\HT2W%P^?)61$7-.ZW((&X.Z#"$..#D.XXP<4=017EL;@PTK4V
M+;GIU.%+9P7%GJ9PV:R2I&G1SD:1#^IR1E1P<5N>(X=2T-Q*$MY;..$1.MN2XM0.220R1J2SAVR2IRG&-.Y*.HU:46TJP.
TEC=WI#HGDVB+W@9@.XR:1MG)IA5>2U^VO$F#H:4Z-77-C%#&+((@&63=MVD')Z@50&KRZU'@&VUE'&-M-N>@)J8Z7-
JWQ14V1.J7FVG<5K+1Y:0^0?W.MF=TP/300/1Z1E7AWQ9K2B3^P-.N7C^239KB9A1:1#8<%BH\^7W-6:K.MJMK=QID$.13Z==FTFT
9<*K9">..*UJX3X.M5'C)I'X^>^*N0W<_B#OCXATB2fN;2#2XK=81;R>6O:1&U>.P1%<:C-;/>7%:WC0(BB?R53Z@UL:M4B5.M&C-
M+29@:O&M71/U)=0:X0VMQ:2VIA^CG41@#$8M)/4/L:XK44NW^.=H+M.M.&3^A7RTf)D&M\XP&7GISEfN@O:34;CPW?
65UK6fJA9)50:8>6(EW.8V.M^DGY0_02>AYH.WKf<6UK+49Q&AA:Q:~("LM7M4D2"IB$I
M.R:R!@#ZX)&:Y+PEKEWXBTK51)39f.4f*W^R7&GfC(83Y15L^YP44IEV&QPO5fSG/7MQ0fWVJ>+(M(L=;O:MO3-16VTD*S2>6H$ZE<*5A:
(.K.MOX.VC^$CGJ:1^76&KK>6V#FZ5f5OK&D6>I6C;K>ZA6:~$S#YT6?)MCfWS?+3S.8Wf1G^UH80BVf?3_"FHW>H2;(L6$NWC.@B8D
/0)P1ZD=M:X>6^U(W7C#1Y;C48K2^0UNX%N)S1N1("=ZDD;MHL:1>W2@#TP?2=N889f1^L80YMHb<;/GD8fH%Z9=+Y@CZ1#8CB
M1U.C^#DL.C^@>17U^Y)KKZN2:~OE.ND.D1:N(=;S%O0P*)XPIUQ2#Q#";Q:~(WY.XN.L10Y*CRS'O8fSG.3ZM=JYOPfHE4>H2-
EEVZE%AY6W-CR$P">^_F3SQS46f63:A18Xf=;RXMOWA\MTJELP5f?%;X#8:/P1^/Q*Wf1T3Q9K.IZ-X+LH4)+C5%O1@YfMVf.#;54.MJD>GfOP
3MZh.M.U\XfTG3^*MK6GD2:3Q)!:A19A^WY:0Y$^OY+6f.MTHfAY.HC.LJL@fY$.?+1#Y3CMEfBLK1-.US.A&?VN3ZU=SW&HZH+YBDV^
M6f;F4^@=fL&#GCZ<4>E>C;M.#f@fWFKW44TMO:QF2180V/)6M^*030.Mf^H(#J&/O7D.BfGf6f2
#GQMf4MW<1&fN+BTfBMXPWB)fP4AEZ.6Y)YfX80B.MO3XMOT9-CLC29QAUQD^;U&FYU:Z%M=*0A1D9
M)#G;MON&T8f/L^UHM90f3^5G+KSP+IMTB6E=)YSPB2-#C^S2.V%&6fYMOSGfCMWK@;CQ5fWARYf78%MX\Af$-Y.P7T@D=)&+f6f)P2
2N3C^f5N.ffMOB^XfG.H7-YfL=X7:63<^M;f/G>HZ+GfO83B@#TFB0-7fNI>C^fVD:1XCM+ZT@66f#7:27CE#0^MfY7E.MX5QP.fQG&34J-
f6H?&f1.M&fLWMGHZ(URRV6VQ6#<^R&*D@Xf\^V.T=S17E.D:WJUY86&FZAJfMSfJU.MY9.ELNRXU*.*<0X^"19LC..9R<&G%X@U^?
P=H.YK%<=OXG&FR2X5f>+S.MG4fCGG&^>XfSfOZRTL2)&SfT.02>60UQ69XBf06WAGK34OKN&>6fHXW.M(f19VfJ3DCC%)
<6VC2V7Q3T^U6U74KTC3KN3S9Yf_K4(&#P.AP>.0fGH*Uf/MBL@/@@A6VL;^SP<9P?M^4=M17F6J>=(4^ZGfXOBCO:B.CM-)BU^W%T0WE2f
M74f/EXfQT&#C%>fHKf5U%>Jf4fF7%FX?_fUKAY)=NYf8fT85><@?+CH.M.*.fTHKR3f;UNR^NA^KC7fB>XU8VMf^+AD6&?+@R
f25:19.SG^%:MVN.GXC(Z?f=U=6PM)fSfIUPfQ);^BOR2%G090f@0#GfXZ?^HU8f14M/?>1.Vf>f01>89KBWCf1#+@9W#;
fL.X+8P#67>S7FC>.M^fTX&fNfKf5XPF.M>..0N8WC0.LB>5SR^f.GP1f5X96BPfXEDfTfS.f2fH7E+>@2Gf1^1^9W>
MH06f^fJ5f9MM&TF.P1fF#QVf+33QPX+A0-MQX^89Kf1/GDN_C%K^39VfE6f=NH)f9G8?4JH.X^*YN:9X?10WUfL-R.MRO?f
fQW2f1X:Q^7A5B^_M@DYS0fZf1110.4444.%%&%%f1110.4444.%%&%%f1110.4444.%%&%%f1110.4444.%%&%%f1110.4444.%%&%%f1110.444
M4%<=XfTBZUB:PVEO:SS1VVKQW-PT+f#&#<%LYfR^PZ?7f13TF.MRN9f1=1F.43M&SfG&(-HX8fN">.T.N^f.CWFEWVGW4$LT.H$&
f9YWR;M.M.SYS@.#fP=K2A3f1Q56E1:=fMHfB^fY$AHE.C^2-AT8.#NfNfHUS&O^Q?>T.Mf#;OXCTPbVfFF7f@GM9H9%*L7f1-A)
f^8.LD@f$=NV37/Q(OM.O?fZMZ9VfTMMX.MFBC.4EKN5f>1@GRLDfW#BC(f=fJ.J.P9H;..96V:7R+.Y6fBQ<2.O.7D
M.S;LL1.M$U^A729+G5KAHfO.U>B;UA<./15%<=2EP^1N.M7FfU;35f4fM+4^f(f9.S+ASCIYXYXfJ22^LXKN.UDNHfSN9fE(6D=Af#f;.P^$f)
f.D1>3-MLT<@VfP.P^PZNT=f^f7CG6f/3POfBW<=P4G?RfEfM(Y+1BfHfU8fL2X4G.68.M@=fG(-79.4fTZfY4EOf5&A&Z4-
H^#fU;G+1HB@#M^7ANPUZ36:730^NYf95E?RO_0^7G;NH5=3PUHf7<5P4.MGD.4fZ<K.CfXfMU&OE33Qf4$"-#
^3^KX^N#0f!%K&BY&NY2VNH0f2%)fF0fH.M(TXfJ.P.fBVfYX#).%X^ZNRZ:X8R.N:16+9X^XZ#f)H.MVf_9.MW8D-M=P3^X(D.<@;8?
0X^9Nf;SYNB7D^@7FEW-Y^H?>?>Y7f)^QH.M@TP3H7AD5fTJUEAfQ^N:XBD9%Zf1+&f(fGL=1Z46W@C0K2fTfTU@MfDATE
MARV22:9#Y3.3HGF>#GK4=GJGB&ZU6&^2fL(+>3EG^<fIRP5G5=>fMYC^M/RGWQfK>M6VNH^YXQ2H<N>XZ$N^*WH
PfGA$.+fJHTS2.MW09=3N8fKZ$W:(TH5ER4+A7.48Y.Xf14/ACPX+/58KVSLf?TR^PEAUf4?/M28$$.0GF28P<=D^C.37<44.9VH.%8:GfA?
74G75Y.7K.M+>6f1@2XBG=)f#&>J.P.Sf#fGGGK3)^ND7$6GfL.f=HfM@DSKMEY^<MXfSfIFR6SGfSUK9HH.Y.70f6@^fYWO=2fLV;
fMP5CGAF>#fHfJ60@D>=>ZGfU.MK.Mf^TM8f6WB6^*)BfH.15.P^EHH.P80^fFZ=+&f17fLEfL/#K<+22^M4f1f!B<9fP/GTXZ5B_#fPFNF^$-
#BUZUN(fH2R3>=>M.6fHfVQRIEV3.B3%>A=0KXfJ?>NEHH.SfH&GCT7M;"2C4>6SfRB9f>6#D.MfK$S(8)fSCf4fH.16A1^f!RfVTWfJE3EC)
fF0YW-NfYfMVfDG/6N@HH.YS5_MOA_79;..M6N+2/RHfXfB2.39_=fJp+fZGfUfENfVAV%L;WAM7BE@M^PL:B.M^9XE.#fJCV52
R@fC6fH10fST^G0f>RfTHC@G$.E2B6SfNfH^Y.@f1JSP2^fC.MQ3f13SX>4f;f1HM2U2>+f1+3SYfNY010.fZ5f.9Q7f1f4.9.>@6-MKF9.MfJ>^*f
fOAFUKY02fDfVP.9fD$Mf/<@G03f;T^30S-G^;C.SK^fL3f1CfTQ2#HR.Mf14CUfK3HH.Pf?>@Q1ZG&UFVZfZHJk>_9Y)?."KM&=S^D=>M1:7X#f/;f
MfQO8V=LfL.PHfIRUS(fA.%f)U^H&NH97fL(f1+N.N3fNfP@RP.XX^4fJ2Zf+Z9=;E)f+M+14WfL@fFAN9fC^0-
M(SC)YzfGfMfFB@#GfJ9$^M>L^fVO=)48_>C6f.MM^T.PfA60@8.XZ<4Zf+Z%=Z:96+6Cf11V+^9.R0Sf"/+_=A(#NRC^M-
T%KMM/BDfKN7fSVDF>0N^_QW$X.YfH22
```

1ZTH/#=-#XAU+2M8-M2.XTW-255(O;H54E"P50I)C/7D/><<5A1-M7=OI(^+X>7D\@M-&94-M"XBA5U63R2(VD!!!&_/^)P>H%>OI96L=N;>-.VA6
M\$G(C)&?RZ4HM+80-+>(OMJZ/8-I^HH\B10V6BCPAY^FZH^H65SX@M)1-E M!\$CM(HD\$)4=SCC)/P-
.:O+HWA3QMUG..CO7I9L5H4A:VA-2<A087ZM#M3K;XBJ>+&6/@!0...GHH\H L6 M2(=>^ME!<27^GM-?B&6IV-O8-*)^C &8IG
&,\$8ZC%4ENDTCPIKFQ"NGV7C M(BIAA7^0Q6F4+#+/X-Q!(Z8S7LCVUO)(LCP1LZ?=9D!(^AISM+>.(.I>)_#A-M4-W?7UH\OJ
\$EIH0-^UK-A6:2YMHJTDU>2Q:SC)5@="KJW=L\$S^HJZMM?P>V@WFO7FJ^K&M-I^Q^ZP*1H#21YEM?9H(>)6&TNJ\1Z9H
XOKEPP2MX1\$RH<^(<5,G@X/P(MSZ^BN6U#2-)0Q06MA8VHAM;2..%1C9#<Q&DNBJ^8D Y^Y%>O2VT?OMZ&E- M3;TWJ#CIZ;.*T) OFI:GU MKV;
I:9B/V\^J)C^02)GKCT^P-D-E-..9FM83;..(QOC9USTZ=;^%6!>6V MGZ^XGD\)-C(6)>+>FU42;4K&68+R^TF!&,\$ C1H7/@U-^%FU/4I2T369-2B
MNUC.YC""W5P.#50-Y^WN^N>U=7P^VWK=/?#8I9=0^\$EA/KGQ-M9#=Q+DX^TK>B<^Q"N"1QSVV^U>O-
!\$J2O\$C21YV-5!^*YXZ^D%K;KKS7T^EJ87+D2^3RV^+@OWN=H^DX^K&YKP-MK<6T/Q5U^""&ITYDN-
"MV5+!"OLRO@.#DIB%&G85ZK0I2QM^BNC##PR^M0BF1VM^RM%\$!\$C^GE@J@!" W2H4-8FO+L^SYZH-IZ\DI?J>WJ\$EM!+(LDD
M\$;NO1F0\$C\;D95;&Y0<^(R.AH\QC^Q^7VG>+7Q!Y0U&.(F^W^F+H^V=H^MX&-N^X\IS4.C)IF^(<?AR3Q"(\$U&7PP@E>
<*&>Y\$LBZGJ_ZUZ??:6TL<LEO-M\$!T^TW)&0%E^A\4YX(9)8Y7B\H(I^902N>N^VH\^UKINA^)+A4/IQ0>="V
MHK\$N0+8>7OR\U7-.CN,BM+O>Z?^VMZQX4F>Z@GN+235Y+!MZ>2C-.?#NI^MR-O^#HZO4(I6WB#B.WB0/PP5-
WU!:=#;PVT@ACBB^1\$&4!^H XSP>V@M7NOW>J^KT1)U1A1%<3;2D+!5&);CGG YQO3KVY^%6&TU8)@FTH-8M/OY;3^3IZ\GC?
MV>^T^WKL8+>"UC\NWACB3.=L.A1GUP^2>V@NH^+N(CYH\MYVR(&&?H-/&M=MEM_A)XJ69\$&GQ.TPTO>!M6-SQ<1^B\MX&.WM7LT-;
O\$LM<\$;1QCHL;@?@26V@F14EACD5>BLH(%\$4:Q^6\$41XOM XQ)*///ACJ-C% M8>)O.O+^>G;UOFE X+YZI^J>(O\$=@?
&6CW>I;B;0+NP66TNYT>H\O,P2-M2P^C=&0WH?_02P120C&(W01)C1O0Y@G\A-MZ=+X4TN^I:X@-P\+FL+S5)%^SA,
""#;.(09&R0<8S0\1R7-(T^3^1-M6Tz+4K^4+OK>VOEW038DE41L,Y^Y&R.<@#HBO7Y+>80F6&-S&VY-R@J3ZCT-M-..QM^A:%K6
Q,22AC&TDG)/K0!X^OB^VBN?#5QJD/I@Z&RWL(^JDMM%>^=MR=O4KL(#I&QP"<<9KT/P1;Z?
9^O^TF^GO=I\CP32XVD,*8H7MA=Q>^U\DNVW^:A-M1W46Z<>Q9P3SMXXS^7K,EE;S3>=+;00+MV\VC\1/3/I3GM;>27S7@B;3:4WL@
MNVGJ^GM0/Y=IUQIV,EHR7^APA^I^ISDP>+1/5Q>9-AF\TK6H/-MM=8UJYMO%EJADELDCC6X;X#G.#MW-&5//.O!P!7L^V2V<-P^CQ?
D1J5I@M-=I8^7T^E%M-M+BW@C@Y&X&TR\N(I\I<4>=>G;S3K0X9>.(=6-V^B+496FMADELF(\$PQ,/^**Y^*~7M
QQC/O7K^NWMM;>%=1OI3+);QV>SM99C-);00*0%+L@+&\$9SC/IFIR.C\Z4>.^;K3K7QIH+VJU8P6DOAR2-4MLW!*&-&55G-Y:2
\$G.IWXK7%M2R2ZQXBTV29QINPHOLC;2K%B-KO&CRD^<MG.A@<\$@IR-I\$CLK2<(H6%&!"\$^Q@>0>H\IGO3HK6W@=WA@BC>0Y=D0-MJ<=
M-.0117^D_&+PW\J^T:1+#+<+9/I7K^79NSQG9OYV\DXKE=LT@&?&A(UC-M.BHY>P\^*)8E\WR^P^F\$CC^+&86@-MB>)<4^*J/H*
^NBQ00Z+9BVC2D-H4B-0-*Y126TL^M<^+M;7S;IP-MK.TB1IG\DMR^6;+^YJMM>H\Q1Q1B-_%1H51@?E38K6WAW>5!%N^H\O#-M/UH
I\NUJ^X=I#WM\^*OJ2UIKJ^-SIR Q\$)'_P_178H\GO61XOOI-FM/\$=S-M.R06UW;.:1/7I2^ZY9TDA7>G^N.#IUSSTS7L\ML3N^FMXI&'+H"?U!L;
M1YD9I6IC^)*8P=X^3KB@#S16\$G!^..DUH\I<7%KXEA%!*QEI=@\$P2\$C^%MAD\$C7>V%BNF;5#96P^*""(I;C<0.IQW)VUK-MM(U5)=EO-
4U^&Y\X&FZL+M-.W\LO94KEVR-O+<#J3Z8W;.^M9B)3V-X3Z2TS26NGU@RM^FI2^SYC\+MG=F
:5QT^@#JL;IZ\ZOIMH5YIUM>P2WEGM^T0<6BW#(R^N;B.5+^*K3;E-M21G\H56^3(=(3GU^*#<3\$)"@84=N\SVR36H*
_SQ\XLT0098K;U:OLKRX-M4F/I5;J1%I\N02,CT^<_B1Q^M?V1+I/A74=#N4NM(T;6H-M%PC;EPP^*M^6Z-A-MG\9AQDMZ&O2);UG??-0R-
&Y\I/ZT\H(4A;*1(L1!0^O/7B@#A+ZM+7^MKA>*E=U1P:5:6=M9OISP-MF&WMYUE;&59Y;3^@H
I\I.W6F7^BG4&8V!^Y^H+>^MN\HW9OEBXCRY^MGC^CI-MI8^D8:QJ7P-M-SY-VSZ/<)(?>5ABX8=V\H(UZ\IM);LLD;RH""=E!^*
MI0#3%L;12A6U@^EC^8C^RCT^I0!XW:74>G^X8^IX>M_-Q-I=^#K%%;AV**W-M8I\RN<I=ZGPG)IA^*WBTF;+^-.63+AE^LP\$@8C^IG^MK)%
(.)+P^..2/<9I5STS;^K^B;PYXAU>32IOM^RCIM-I6P!H^Y#;I-(M;G-!SNR<9)KUIK;YA.T;2KT)=#I<3^0US%">+22I;TEL8E&
(V^X&2R001HJU!^WEI?;I8ZY&LT-MFF6S;?^\$&M?>I7=2VUO^)+I^I9S5&4/J#VHGM>Z^M^BX@BF^G^P+?#Z74HUK70S-M9SQ-
2;GWK\IWM2M\I;I6J\MUX2FUGYDEN;+IG^K^M^D)F(41^0OCL^&15>UMY\I;13308-ID\7-Z#^2G/P2YV@DAC>G;8V4K0<<F.E^I^9+
^..";>I\N83>VH(^-IS^N2,S^~3ZTL(^-AG<(P\F-MG7IG(&6^I0-I^ZUVL4\$4^E88DC\QD(H^08^3V^X4CVMO)O)(GD-P&9-3-M^=-B^E:6%OX
T7488&NX^%01+A0-Z+IK8;0W9=I^XY>F-\$G%9-AQXB5H-MQ(IHS^*N<\$<(3D>I;V^SV;/D&W.=OEG&?7I4Y52NT@%<8QCC%-'EDJ;I^I
MB^X:00BTGM7AN\<@>THS?9E)!X/;(XUC&I&D^&M1^T.B6?C^.;I;8=8+M;DCY;.\$I(5;^A7LJV%FGEI?2!?
+&Q&M^CIG3DM+^75>+>5<8<@^Z^M-M+^H^M;I;4;Z^UM+QXWE9@MUD^X.S8H&X@+N-#=#(88K>)8H(DBC7-MJ(H4#Z-4^@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N1;ZY>6=I\H.@Z=*8
M+&6KLO?;3#^@W2,N>-V_9I<IJJZN6I9>+O5Y=(U72YB&J;I;=2;(\$E;D-MRD8DC)YV\AT.#@B@Y<>G06KZ?
I.H0R17\$3R>9>22K+I=6#D1IGD8X9% M86E:HNG^./2BQLTIG-DD9Q&#\$Q(4PZFNDL1U^I^J^BW.GD\$WN-MH(F7<+Y;L2?
3;I\WCONK^I^7UF^I=Q+^+I/5H\I;V\JRN^I&^I(8+&^Y\NK6\MI\NTN>T-I^J;S20@X+I+L9<+<@C@C(XKD%&C^+7?#EA-MT;.
<I\WMFUD+B\$3(C^)"EWX;=CHI-MQ@T=Q#>I\J37EM^EPD<>8OM2I0K-CG8LK74;N^O-M\B6G%;7BS3(M7TN^RN^-I6TDX\Z-11)&
K\$2(Q9<.&V\I^M#@F@#2TZ;2H0I)GGMV21HWBG4IE8?0D\$>A\I:P^X70-0F8ZUKL\I0%I\NEWS
M:=;P6\SI\$G0\$S^)*92""M/U;2I^FM=5N^F8+>29J/ME-?>=>Y6TL6WM;U-Y^VA8719O^V\$@=(E!5L @^Y^M(QWH-BM=;NM&I?
Z^ABOW^I;3;1VA9;G#2H0^QXMS\$;AT8C;D\$S^>K>P>2)<1W""@6E10R;4^43^X&Y4\$9YKM\T2IG\877BS4K?MRIA9BRLK-
75G2+=09G(.W>S=@2!U;.>M?#6N0-!&I-/ACC59(IXEB\Z/I-MR5V\W;L8PPS0!8%MI-CJ\AR^O9-?MKN^FBBAM-M1.*68(?GD-8CD\$YYYQR*
MZZ2H8;29N&>^Z>T^UK9?>1H&B28MMVGG=PWRD@<^19X;O7M)U2_P^\$;&G-MR^S\^XN@9(P8U6-
DA7)RW;/2J>AVOB_PIAOZ3;W6FR7DTIKJANU40Q-MRN7(>C;X;R\LYEANKN-5-<?""WLD;0-RY*
M@>9YZ&@U=WEM86;U=3I^%01F625CPI@9)^*O.X^N\Z5XDU;W-XL217T4-M;UIN^49Y(PUMYARRR^P+;98IKFW;<MPH88(S-MCMD^VH
DC\36WJH6NGW-K=V<I\ZC/?;?4"?;E1ACA@.=K8/7T-UC\I+9R<<#&3O)X-TW4=U^O+^763VZ7VJ>=6I&M1&W1E\$49VL<Y2<&@^4\$)Q:~.
A/I:9^Q:R7#\$S^R=^#KQE@<#>SWZ8S-MS7^%T6BVFL^VF-1GMQXCN;316V9\$MP90D89E;..@XSCC;BM16-U/B^
MHNM6E@U:OV<H;5E1#79\$5B&(RORGID^U%M>E\^I^M;33^U^UWVO?0-M(9HN8C<)+DG=@;I\X\I-WU3Q09;6+YV@NKB+3T^WLENJL+
<%=WS90I(7YB)%M(&..15N_P^M;PW3\;FVE6%>H63;=MH^#DXH P^=RO#>ZC\$+G;I;=21I\I;S(BH^X4CD@DG;3;10Z
M5;>+I+7;4;B\5%2WN(\$&^=)ER@EQ@;=O5>G^I?^XUIPYHUIH-IHTUZ+);M;P7UI^Y&U^PIEK\$=Y<<4ZJH1A7&MX@L1N^UP3@=*(<+?
QY^M^UXHD="O\$LM\$D^;8O+>MH0.S\$1_OYP;I^GGBN@U-MRVN;22IX8Y734@&AV\3M4H7W-SP.=QGD@=ZPI\TN_P\A6^*60+^3I2N(YX
MKDR(49?5^H7;I;W&=^U;I#;I-HIOI@I@3V%E2YVE\I^M>9+92A^?;02K@I\MK<^D>A^7BHO^ND:A=WVA;QIB>YTF\K6Q<+YT;H4<^*
M3QN-ID@>XJK+HE>);SK>O-9R127-E+H0:%TQI^%V+;0VT9+@#GH#ZXH-C\I-M-P2;KH>C^<KQM02-EL@9V>><?7=%P&W%Q^I^PI
_8K&OM&01^L5OVI\$ES>7=LB\FV95=SC:6^AL#!SD-M@<=17-W^PZN;F^Q3IC3HFEW^;ZLM\$MUU-M\I;E;491YUVR\#W+>P^Z/8^@#E-
1U1+/@EK;7>JRGVGHK36F\9(3)@H-M^V\I<I4EKJ7WQ<KG-K9ZL\QPT^W+0PWA>\$3^<+NP&QG>E7Y=*U-OBW\K8L7
M.FH#61GI0/I890-W=V<8^71W&E;P^B^KKEO8XLOH36<I@RCO.WC^M^VW-M^2%_%3?^&E;I=;?#&I=I^JH^I(A-BAD+D1>V-D<;
I98FX34H\N)BQ-M>+I^0L^//10-1G\O<H\KX8O;3XA7U\I&4&AW@CO9(I;.%I\GZ>A7;Y\Y10\;M\;GXL=+CO9I(+I;WT^V^V;%%9?(<#?>R^<*P8I0<
U7O\^G6M-=V45K^WD-M\K+>..MM^-G#^20^M^T\;GBN=D\ZSI^BI5FBI+9KFG;K<=ZCNKB6-M7
M^JK^*Y22ORY&T^I^T8M^U2#QIK%_I@+6DNC16^+OM&H>1^Y^C\I\I\F&I<4-M=9I>I6NLZ5;ZE92>9;W42RQ-
G&S(I-U97GBZTYS);C^ITE\I@U^I^BLP-M&X8VD=<5C%Y^9\;..IH5WHGL##I\GNUN8-W#@<84\$EP>3D=-"36E\O\I
M^OM;I\ZMI>FVYGN\J(IQIO5>=P.26(C^@6\76-CJFNCL;A=7T-F+ORH(=MQ;DC@D@9X\4IO7-K4T;5K37M&M-5L+VMU&)
(RPP<U^8USD.FZE/B<=>RV-MG2BR^I(I17;D>?61G^XW>C=>F15KX>;52;X^TG2I2MS!>6L\CD3>K#XG(-M^DCO0\CZ1P%&F7<23Z\I
MXANR(3HY6CC\$DIF)(X1MD<^3@9<..I\T48FJWQ\A;CK>GV\H3I^KFEW-M7%G(^
_I74Y-A^G)2;BK/B#PF=0^5UX8L)O^8V@AAD<I67\I8^Y)J\$0!-M=B\2VQU;UTVZM;NRGO\$9I4W^T%GVC+^%6&
YVM@XSOP;Y3PWXCCT.Q\37>I-MRW<I">)>I;1&+F5HPOC5^QSM\(^2M;33\3I^1WGAR?4M-?3GTN?I7<?%I8VWR-M^-D")M8_2Q;3C@
8YXYVY\Z\<>?%2%6LFG\NYI0?V\I;L\F)HO&P&02Q)M^M^KCM0\VMQXK^T^U^5+&9+A9=MI>S\$1H@8CGE<^>Z>..E4(^<^F3W.EPK9
MZDHU6W;I\B\6-RS84;4&#D>X^YQS6<=1K\I-K-(CU-M^I;4^6S@C>XC-M;GFC?IK8;_UR\I\H@ZSVZS%";
<5PD_@I7;K0\$26<=XWB@ZQ917+HT5-MR@<^<^<9^L^U^X=7X4@O6\$EU>^<+^0^I^ADCD=SU)+@OH.DG)SC^(I-M#1Y\NT\&SW=E>W%K-
%/_-^VTL&F12">N;.>F%&JW\$&I>=^M97A;5KXO-MS2OL580QH7<*1R"<9^I(..>G\>Z=?>OX2N+^3K5KBYEE@8^5^0;C
MFD\Z=J&GV^MI>6SVKW6JW-U^2R/E&RI^4GGV;"">%8UN^US3M;DO;Q?>MUEP\$KL5S.OA;UYP40G;@IHPNP<8)IYLRZH%_XA7>
(QJEO^;H^H7^P1^M9A^5D^;W^H\W6^M^2022W^I^A^F^H8^>I^%>%GM#;ZMHU)-=ZL)4^W+;I;HP-M\&3<.&QEOQZ^Q-
X^M^%YVUN=I^M;6>+I&O\XHG3HAR\$3(SC8X^C\ISP-M=7I-X=1TBROBGEFFY@2;9=W^*#C\Y^XFWAUE^&Y&G;ZYLTFUVUMKAH;EX@T+
MEMZL5(XP.O:NACU;I\B\3_P\I^C23^8^UAV&I69^&((I3RQIR@9^2LCQ-I;I-MPOAY-LFN?L>M6U;1(B@1ODEOO;GGIO\DZ?XF.E^~\$8U;2H+?>
H\W4T^MIN90LX\;R+^+I0;B\$EAN;X@M^%O62Z51FJL<%688R^M^Y^IAGB6#56)W\7AY\HM3\$;9U<^&C\GXLM<=TEI8^>H7KW1#
M;Z5+X2;?PUI>HY#HJLE8;O.OO;C&G0^36OC;3KJ^T28A;7R?VO&9;I\B&M^T)X)^*OWS^HCB;7QAH+P\IDGLYK&IEJMR3-N^
I>N\I&X%=VW;GO7-M\$^<=(5TN;PIVM>=>46#3HQ;VLYO>+>5;S=I9VKAR;^Y(I7U;35GPIU;UG;I-M@Z<^<^%N;2*X=X-
<9XRWE;Y8;D(+F09P.W3GCD-I_5;XU^Q;UM\IV6RIP@/M-#CS-G<^3T)Z9I9..<5RVBQW^GASQ\H6\JUI?;I(8)=LH^9GMI26RH<I^D%5
MW8\3CUKI^=NM\H\PEETG3OMH\PI(X^?6;9\I-M.EVMM;RB>IDQ(Y)9^&WHG2^I\X4^#&.&X2I5P\I9ZAK<^<6USJ;^F6-M\I(H5B4I#>
%ED<I@<D\I<#I\XURU;^I^J^*Q&9O\$@<^66UTV+3OU1UBU2^XD\I\$A\$F&Y&W^?XADGUSZT>@5E;KKUOI@I9-M6/D7%\$>WOF&^W@I^IF"
%CEF50ID=3W%16VIWJ>)7T;73)9I;B6^4&N%?S2-MH8.GWE/4I<&L-Q%K4WB32C;V4EYHOERK=10SI\$1(=NQG)&+IXW949IP>I0-M\;M?
&&G7^E;9>Y\$5Q=?VD7%O-BJLA^9WYWL-NT@I_3-YGWR;C2)=)%+&\$+M^8YEYN5BH^U\KSG1""%T\FFZ%KGAV=VM9\AUDM+N-
I^K=X(S)P>P<8&Q^U MSOR^LPG;M8^&K6VUIY>Y04W^R2\$>S<=>@6-M^<178@O;I2SMK\HOE2RQI@RC#;ARK\$J^<FJH\$1=(M;..NGM=1-
KHUX-I-MG\$^RP-IO\$R5RXZ.GYQBN8700P=U-X7OMIT=YM4L^7;H^>UQ\B\ID^I0-ME0\ER;N.C^I^H^<M^N^2IGCC38I;2I3VJ\AV\H\T@;&
MV>I^GD=ZSO\FBZWIL=GI>I^%>@.G^J#6(GC8W^H_53&X.<#)8CN?;@#6@^<(MVC7\$5M.MOJ^VBI;#I2I0B;..=M-G(I(OG\QWQ3?

&7B5?)/#WB2ULEFOGGLK* M3SIFS(7!YC+!+EMP:&(&T'(SUKG2!A%M?/4Z;_9;_VU_P"W>7YT7\$V MCS2#POH-
OY5S?)/<^DP7?^O0E2^S8H+L78#D#G).<9P_N6_B_2!^ST MDZ?3?OVU% DMX8 Y5.)W%0H4D Y(Y..M<5)X8U_2!00=3B!..66MB/1H..O_M;">6-
7A>^0\$B_>5(^8@BM:31M:TCQ+17B&QT>WGC^Q265YIME(D?D?TKFHRR MVU6P>#1W/7Z_%6X:7DUH.M2SR7+%=;NT07+EG1_X"J
M+U/2K/65U2T%LJUHS=Q*) M5?;Z6+/4+FM+9;IX!>#=-F.DCQ(C!)ZXJLGBIH_%6G7%A! =U9 MB;L5(-M(8@_HKMW\$G<0%
!&22.2IU(C%8T>F:L_CK51623?)\$MKK1XK;/H# M3XBYL\$XW?I8YZ<FL+10#GB3P!>^s=2BTLW4^G:2)IU_8+!&^L58;Q:8>5 M&02.B@#
!<&1Y/>P^JGG>Z.S7KB_NG+!/H6/"0KYJN3X4 M#.WH?EI=-T04/B3KFJ2V+87=+G:Q13T.6C+Y&T^(_!W8T_7)%(^Q26S.MDZV=S=?
8XKTJQDM+DJ\$ZL%00&Y!2>_(!6/Q!>=5!97DLVEJ312DBH8_-3 M(93!VXLZ),NAW?A:2KBUMYV;7>;L8BY8;D(+F0_XI M.L!>A!:
:@OC!^L.K29WOW:4&2Y0VEY;@MSIH2.8;>=HP2/8!^PYX@OK73KE MK_1@%GM)MBF.LH96)\$\$%<\$Y2315B0Z3XMT01-
8LK<37W;P!>)%TN(U:XM9) M=S"D(^*^WNVW;GD5!KP?K509>+6WTG!/"K-O"UEON4;.\$&_7)W10^2;?D-C^Q!>^_+OK+3!C
M3_0_U?#2!G@B4!0!);AB NT1?); IBN4UG1>;7=+1!P>+;4U+@+&ZTN!MFB\$D6&W+!(K^9R2"3OC!+OZ_XB!&MI EM:7FEVU_%GX;7D!
!>(WG>Z.S7KJ_#N7+&H^83DGITQG%41K!FC?>?Q5_MYD&J7! =G9R);6JF-L&)"O4\$X7MP.9! UK^!+U33\$UJM3LQ.FIUB>1A7S5<MF-IN;
!>AX-1H8W1M7!C616BTOIVUUSMXX6BFC78!6(<_P(W#D)!*+EIX MYTB^O=%M!7!1(F!P!O+9SA(W"#+*23D..XQ6W:WR7<JW%"(LTOE;!<
_6;_M: M?WYON_UO=DJX.H#R:7!+_38J:SI#^"LYU"VG>6V!=K=R.FX(KN! MKM8Z?% !Y>7E<#>1B6=0Q8DT8NJ^<_<
+TB:4%GBNWAUHD=O)B)*0&3?B)! M!CPRD!0<9K!M8^>_!1K!KXHLGTFMKLRO\$^E2^ZC2!8U\$%\$KL)!SBL^YF!M0X!
X/!+O)"CR1&V4\$QD@E?8D<9^E_#Z***"BBB@_HHHH ****"BBB@_MHHHH ****"BBB@_HHHH ****"BBB@_HHHH ****
"B_MBB@_JC>ZSINFW_M;WU!#;RW+!B_2.MMAOQT4\$!\$^U7JY3QIHUKX(T:STH!#^1 M?>3^!+<%WL#C)(^XD@#W-6_0R@C..!MC%>70;_?
VEL?>70B?>3=K=I!>V;VMT!>J%N+!F\$@_VOT8>V?6NL36+!%K6!;TS_M2!B&T_E&*R20>9YDKIOY&1A^"H12<C^(!TU4K75!"U.^TVWN_Y8>7!HB
M"D>?W&Y>2^C^O.\$!2.KXEY3P!>PW^V^WLMXLIH!W!H)HHY\$8YR^!G=^>E.YX MK80&MYI=-XR%0%_21ZUO!O#!HJX8I=6FUB72
!HKD!7UG6"HJV_MIZ@+6!TNUL#<1O&#%)YX)S&1DC81@!@!1SUJ32!2!1MKMO!>V#2;_!S27)C2_M+R)1@!@_!V+*PSCN".2<!
44CJ!7=@!J.DBX%8.KZW+!XCTG0;4!^?QS3_M_-Z!O+2,+G !DEA!#!ZURWB#6!3N_"WCS1.J6%;W2;)W^T!1\$+!/)!"S+QGY6 MX8^G&1D#G%
_!V/B^2M2W!6Z6W^PK<^_HV00\$3@.NX#&-+XDCED-I%M98!F^V+!A!S7;?2V MB!30W/AJHHA!FX5XHW^!TG/D@E0>F^Q^NAH
HHKA;^OG=W_P@E!3VPB&H.MYMA)!_A(8!2G>I4\$\$(?S!R0;#827&G&+6!>X!A;MFVD148_Q? M_"Z?+^F"=-17GMGX!UO#O!HJX8I=6FUB72
T4>)\$C9!R!^W!U#N!HJ?2DU MSQ3XJT3PSKU!+8Q1FREM_L5OPL+Z_MRLKFY6.YO7,=O&029&+\$<=,>M,+NUFAAL+1K-8FBW-*(R%=
MBV>_MG_Z_\$YSP>GB5?)"024\$!@0%"M_UR7^0KBOA^R!L+V\$!O_P!&M0!WE!30=-MB?
S(G);J29(E26=E5<%EX&PD_4^CK54ZJXB>UT5;^!VT>YN89C=1;?M,OFJ_M0!6-.22RGEB><#
)6@#H!M7T730\$;ERZ;JML+FSF(!QEBN<\$<=<@CD^K-L6_MJA906E!T!-O^H2_-1@^!7GLQ^"NY!_!AW7+!L-K?D)!M08;9!H!9U.U05SE_M58!OF<
<8QWR-O%-HJWNA6!VMV^*V6H_L!^L^O#\$!A@G (P<9_XJ#Q1KCZ)9V8@5# = MW!H!%8V_F_E% =S!Y@!"00%#"?&_YH_OQZO83_Q-L=RK7T,0FDA<
_50G>_G_M4&KM><0-J5C!4?\$.C207EU\$X2B>#?2K&D>^*M600\$!T5!N_MYE.YC&^6ZBM658Y0X5@F3B1!FR"!H!H!^BO+^"OB?
5(!/A199C>7^ML^!_MH!D 5Y^E;#&8XXY&_YYO@ZTOB67!"WCM+_3UAO+55(!"PN95_61";S&17_M^H5AC(R0.@/!UD:L?<
<:OHPNUY>1VS3!V@P%!_55C_MNY.<8QWS7;Z5?_H%O?G7?S;3EH2>=>UYB<8SN3D!>G)H-T:5!4UO3!F&C+WTY
M3;_&T!"1M(P1<_G(4\$A1D9/09KC!GQEFJ7@>V);J!G-@!>+8F/+^"W>0^"M_*P@GC^48!TX!WK_&V9?MIKR_PJA!
(S!L!RSRNGB;VYUGC=56_4E^!&MP^RE690!Z^"MUDDO!H1^47S_H!^!IFG5!UO4#0!KP^A%?J-(6!C!PR5060_MRLF_"_H_M)!#HKS;!H>
(3P9K!N\$V32Z!P^V%&A;L\$G03)!7^_WWGIC!4!;W+!SQ#J!MGX MVU+!H>^"YCAT4^T!>+^C0!S!UO)!NSC!VGMW!H
ZVBO_Y!%UWK^!@IQ#^IQ@G^!O!XKLO"(G^A#2#<3^5S9PD;V!;!@>=3D^!M_%^T!^T_L%Y;_!RS+!G#&@R!_0-Q7!DCGWIE_K.FZ6ZI>WD4#;I?#^D<
MK^T49&6!+YZZ_Q>TOCKHEU_Z_AK.TD?_!H0D00^CG@M+9%?M^868CZ_M\$LOH!\$_.000>01574M3L=^L9+
!4KN&UM8!;I9^J!#!_YSX77%Q_#?#P_M+XA20P/YL>19V@_CL_MOMFDW!%Y;MI>#PPI#Z^V+9;UINI3_9WL_H!^V\$;_5!P2!PSQD9&>*X3
M7;1M;V!>2\$VG6;?2!9!8=@QO!N(9!>I+^!A!5!>DOO^!>J^PR6S&UCFUVK_MWA-N^P^GRJ?H!0!V%MXN!7FLO!%MK-E+!^J\$;=9@6R.H^J!W
Z4M_XN!>9 MJL>EWWLV50?/C;#);%GIGTSVSUK_UWP!8W!V>Z59VL<7!GWD5X^C4#!/^<M^U<@+CN^Q!5-
XJT>RN_#6!5#90R7_K!HPI7_Z5ACS&7^<_GL%_84=-1 M4%G;_5L>U^O!(8UC#N9R^>_7PA!%_!\$EHUW8ZZ+!2P@EC.B^\$YRC8<9SGH
M^>O77C34!#M_XH@UC!>1Z781ZA_UO\$8BP?WY!0BDDGD!L/6M^O_-2351!10_4FWH_O_YBWC\$11%+!/?H!_MRV99U)!61PIP0>#SUY^E
3U!%<6!M_L!2VMU!"DUQ.A22.12W-G;=>6TC)!C_O MP2E.XY8=IU!HW!6!^!TO1_ZUBTO5Y!2.ZN!<5!&N!P!H;MN^TAG^3_5K=25+^<
+BNQ^_@!6S7^C7=AZ5XK@M)=1T46!L.YA.R:&8X&_M5W<_&^!Y<X!4>D52L-7L_4FO(K^Y69!7R9PH/R/@!^7@CI7.2ZOKUIK_MEAH=U-=:O-
^T!3!BS\$!V!6UMOD+?)!%)&\$.GKS6^7B7Q+^_C^U_ML!M.BCT.UAN;22SZE=2^>2Y0;P7DS_M^C(%+!M)87N.2!^X_X%_ME%
<#>=>10V/7_B>#5S;WD>F:??P-!\$82=Y=M?>3#6;NHY!S6KI6H^!6UVU@O+R:=;LTMP8TB!B48(^@.Q92^XOUYH_Z.ZN
M@>RMI+!FGC@&G^Y96^"JHJ23P!H0>=(=)N)XH\$08P^?2W^2_HTO!N!@_PIQF_MN5!7S<=>GP3HIQ_R#Y9+FZ=#!V66*/8(KM)W8!
<5VEW8VJZ;=EXPS6\HFB_M;NCC(R/P)!H_BLM8T_4_V!L!2Y66>R=4N44!VQ&0">G3TJ!7F!JNGP!XD_M!>
WT<QEG: T^"%"#T.DD;+GIP^V3R.E.M_K_(!TNQO^YDL5_K9Z6!H;7=Q\$ M!YF0\$M\$R+(200_0>,<@YH_ZW4=7L-(%L^Y6\$7.Z6T.03OD&U
MM!;BXD6!&^!DCG_50.DD^<@>6>+!J6)/#A_5M;FM!M6TNYBCM8^WQ!G_M!Y_MC^<8Z5WN@>@WB#2?142Y@FL+U-
!M&L>=B\$8PYS9R;_MOB6\$RP7?RJS!N!85!>0KZ!5R<^>_5+9WUKJ-N+BSN(KB\$DC?&P89^4?4>E<3 M!+Y70X?&TFW?
S:C/K!_Y;JBOX5(^8^@!S45G!HMOG_KUC82B&^!TB&^!ERF MY%G#!^VW(Y^*#GUP/2@#JF!6;\$EZMJ^HQI(RRLC.K+&XBSYFV0C:Q7!R>_!/
M2HH_&GA^36H=&^&^PH_2E;+^20R(!?26R_RCC^!OXZUY<(!YOV;M&NXR!LV_M8_P_9&##=NZG/7!L!>@ZAJN!5XE^Z>SVDR;G+!<2?
9RKX2^G7=QQS M^?PH_ZZBN!_6=^OJFB^)_L+V;_Y!M=6,D^R")4;=+4+CC M^<=R\$!ACJ^!R_-6!2.18WD=K=;<8Q02L_51G_VJQ!";.1ZUJ\$@_M
DG_%<N!_HKM!GQ4_FYCFC77!@.IAP2X8!&^R<#<@LXO?1_2ZE;26H!O^&FFMY!&XBSR!)GX#H!HQ/KM!<V
MGAZR.SZ7!FCB;_LL!H568.Q=2H^>_#C&^C^ZC^G!DRRS.02^_CH#STK2KDM7O9/#YX7TO38K=;*_M!OS.LCH28TV.XV\$&
8QCH>^PM^N_%4!>_9!H!OX+!J_L!10+!+6&>W)5ME49^###_M_QD#W.2350!Z517^<^!\$!>+!+O;FOE3%\$;M<7@*_!4Y!8^NUE6GB72+!44L+>1^W\$D
M1FB4HP65<0%D8C_X!_NDUSMSK>JBZ!1!^KF>(75K!XO;6!2(C?^P8\$;N>+&#^M!D^G(.^*M_#;&5?A!X?>2.3_B7P^A5B^44H;_Y?K00!UE%&%
!110_444 M4_%4%&%!1110_4444_%4%&%!1110_4444_%4%&%!1110_4444_%4%&%!1110_4444_%4%&%!1110_4444_%4%&%!
P@;_>5S@_VY^M;%QXN_NX!NVF7!R;C!B!HV_M\$?U_IC^&O^!0W6M;?26=Q>O!>^Y;NDNP\$^&#T<XSTQ!J!4=<\$&BP;HIZ
MOWT^N!QD3;?82NJ^P(4!>?6LN=HW_XY_!_6F!^V+!H_TZ!N+!&C!M@_5R_F^5?>N!&3DG/J3Q1<^<^!_N\$;7TL!&O\$!MQ%@+Y?<
EKM0H>D!P><^!>? M2N!JH!Y2Q!&@;_#6.MZS?ZY!%;M.C!657RXFZ@;0.L<^YCD!<8YS+X;)3>^M!B3Z_!6J0P+!M8H!KB%<8Z@<
L<<9)X^3%6/7B10^A!>US!&+M+7;7B!W83 MN=5X_#W;HO^OB>^PGX3EUR73TN#^8Q)D^WEW5!AMO!+!#L^+6M^>^HM60!>U
M^_XDM=1TYW.WG10P^V_N.C^?O^1CT/!(M>>#H;W2-M)!N07&LH8!RZ"#<5_MV_JCH_X^7!3R3FN@C+!F3^JY^S^K;@#J
<#^/Y4Z@^K!MF=.TNULO-T!62 MQ^Y7!4_GWXY!2M-DTU;K\$;IKF2YN&G9V0^_DA MT_O)8KJLXMM?>62>RUO^T@PYGLCUST?74!)JFJZ?<
&S)HJHK\$OEC&B_MNJ2W0A^!>=1^!0!QDQY!+CP=;5?7K6Z4^U;ZB(CEM!AF+D!H^3CQV_X MT^H!O!>AFITC4>=O!R!;767DJHO^QL&554
^HR/0DY/3!>=J.SWHU^T MBMU2Y9+8OR!_#8<#;YX&TDYX!J04<!=^\$;4!/\$S!JEL.9ENM..F3VVS^/\$ M6+^YZ@Y!H!SK-
L_A^!M!HOG^(!=0N8=%E+V2.D8^KM^!&;EAM;_!E_BCO^M^X_N=^!T!Y!_NTM^N3<_!IGY2PVG@^N>M;_&L_K!TNGPVUK^2H(S_MFZ<5^!<
PYBNH!M+!+6+RSTW66:6ZLT!&42M!YT+^*YQDCU!^L!4_%\$NG^M+!^T06B/%!J7#&?<
S_#%\$H;W^_0%6;XCSN!D5@58EB6S3C!3!5;P.J.WT^JYFK7D\$Q;6SVLK\$)(_M9T!P!\$EAPQ89R!H8KIZ^_3T.P9-
H.CV.FV.MW!AM^YHPDT^_DBR;&^9<#_ M^!S_!^M05;X9V45M!^D;I?7?Z7T.5Y!M+!&S^F5U(VD%B2!C_KMW8!C_M_%+\$#
(48R2;FL70/\$<#M^_JDTL!HX9YX!&D<_M!V!B2_X2;_*LFB;C.76 MC+8.M?&_WD9KSS=C!)M^%E<2S0!^*EQ_W\$<
M!O)!^ARKKGN/ZFLVP!>=^HTT!B>OULLM;9.L3M+^7_V!U!(P3TP<5>U!M_QO+^H=Y!>H8&GFO!N_V.5L^)(.2.3?D<#O@^AP
9.W@!+>4Y!3UJ!N!M!TT= M^R!F&@+!<^J^YOHUSGM8!H!CVFMV6K3ZU=7-S;V!L^#1!JLD98;_O^(!<M^!>U_P.3.O!4MT^G^&IM!LK-
=US+^E8FZ;B(TO_N_0BG2ZBU-B@ECF3.PJ-H_R1_MMQ@!CGDYK2!_Z_K!M=P-
>7=ED^%WT!Q#&^!MGBFWUZ#4KB!TGC6M6LY4C5&66(MN!O_P.TY^45@V?Q!W>^!_!0ZAD!M_MM^U.585EBN^;_!H8!HD4!N^R_H!DKO!>_5T.P2-
H.A6&E66M3M^9Q20A9X\$=) M%<@<X90!TP<^<_O^!Q6QH6B6GA_O!>2W;_W4JN_C3DDDDG")!>Q6E10!RE_MKX&M;726T!H7+!H/G>^EBZ
!H!W^70ZF!>=SCKVSCBKZ>_06C^3Q!H!TKV<^CG(%4!>767AE!%;C^VSWDMHUK_1W<44T^M@N!LB?=(SP.M5!S07^!)732!6^7!U_VLF?<
RR6V!RD8VG>%FN?>\$D&NQ!<6UT_M+!/%<")%VS1;MXZ@E3DGD>MVK^X.D_MBXU>?7+V6_M_6TW^&SVE5(T^YFWJ_O!!;C^ISG-
=310!S\$W@NWOH!N=1NWN+!HTY!;9(U_MC(A;_2<=6SCGH<_UTNQB;EDJKY+QA<+DGYM!M&?7ZW\$&D7&MZ!IC@U2XT!+@O)
Z.B;S!>H^&WXYZ=";U^>_T_PQ!&E MY^K&N7NLPW!;MS%&V-5!)&D!_W4TFG>\$XK^ZT^>>JENVTR:WL_M-4#R58^CC!S!0%SQOCC))!44
!>ZF@#GDTG4_ML;7>#5!U!^V!MVC=0S!6686VGC!3;#^+X@!_!#7+3!J!&FLK03_M!>SP2Q!K!5^L^K @!>@GZ5N48<2_PZB?
3M0L3K%>V5J!ZFY;_!(D#^V_." M4&?TQ6A>>^!4M7U;JOYGGBU2Q6QGMJNU1!&N2!"I(.6)S!^Z:B@#D+!+P+!J
M&B7E!W!X@O!O!Q&O!42!Q!<NFS#D+ECMXXU/MSG6!>^T!V5M_R7+VZP745T^&M1026C(O!J^WJMGK^!HEY!6KVL9A6!M=IWO\$Y^*K
AAGD9_MZ&H=4!PWT64FRVKNZAZK!YB@8!FYZGKFNKHH_P=;!6!O_0OYK!5=-8%(WAF4^*=^JC!&T!>U=6!0R_M8!1WGAZ!TK7=8U#55=
(C_M\$Y5&B_(9@>4_A@#DY)!<^!BI+^!PA!>Z!8Z5? M!>7!W9VS!Y!J!XHT^HO!^!P^E/_JNHHH_QQ\$GAI\$=G_VTE!HNM0%Q78^M^*6;_<
MR@Y!9^4!/^"R7OB_Z_(!UVW2W!F_C&(E5&0%/?#KGG!JZ:B@^CHV_MFKH^B6.F)^94LX\$@!V&^RHH4\$^&^*Y@_#N+^PY!&L70LWO_<
+=&AC3_3>;Y_MN<9!S>O_NUHH_YNZ!&V=K_J!H^T!6!V^V_Q_<+Y;Y(!4YCS!^C!>#_MY?^YB6?
7!2U_!V4!0W3!>M@7&X0^QUODG@9P!744_9^B#PY9>(K>6WX&6_MXM91!W4!>198)!_H!H!^"W%_M;O5;ZAJTEX(R^JB#8@2A;_UYX^VZ5
M!T4=U0\$^!<U!^XEGBUUHHWF0^8FC4^A0CH!M4!YX^X4V^P1_85_INH_M!<!(M!U)KNT>R\$!SMS#&XPVT_#^CYFR>17744=) M@S(T_FX=;
<2YE_M;#%#2_JW>L3=&RFO2&NHG&)(H7_P^V!\$CC_M!(SW!J330!&6FO2W4=O)!J5!09!V8_LV!A0_*HZ^?GBDD!%%"!>P?_M!<
!>S^T9Q9;_!>8OFL^!>IUXSCI^<=^X<_M^5M^X+U6!99M^>W0+&_2%T M^*=_P\$GIWK=HH_X^R!QZ=JMQ+>U!_DW\$!7.NE^5!DR_2H(!^G
M!>^>8!7^KR^L^M_U^T!>+4SWFFO.OE2R^Q!(W+N!H!2^45V%&#%#6!&L^&B MW>DWZ%!6ZC;A3@CT!&@&?2!5KX?
D%U8W6HZ@!>_8^RVS/^J89EVEVOJ!Y!MNI6@!^XZ^4RMV!Q_!>D!>2;T_VN^@.8_A^4=>?>FW_AH7?B

MJRU^ GM:FWMVMV71\$5EEB9@VTY^*J1\$CTK=HH XT #^\$^9=&I3>5)JA M:)D|M=PD|SS-OIMW#ZXIUWX#^>+G6=-
U14M+^X+0KLM"HP&K'8V.C MGZ5V%=% \$0MXZ?LOV8R4-G&E!&05OC|SU&*YI2 "EQH4/V+2M;NH+4DQ6LD2 M2F \$YVQNP%I
VP%=-10|@ZIX7BU*2H1=RP_PIE7AJ|@.9P0=Q/7(9LH MFJEL> "9M9UYK4|H2+5GELH>W\$161@P%AM&XC@<=>N=M=910:IS7A#0f:2X
MJ2U"&U>U;5;MKKR7!C0= &#1W/S.51%R*N> (#L&O"RD>:6VO+ "X%S:W.6 -MT;@8((/4@D\$=Q6S10:AGPX)\$U::Z+ZAJ_ML;D1@:(P& 5%I
/F0)YSP_M!T#2%T0+24G::*SA6&-W4BJC SCC=:5%1110 4444 %%%>1110 4444 %%%>1110 4444 %%%>1110 4444 %%%>1110 4444 %%%>1110
4444 %%%>16% Mxf1\$>TJ.159U"U)654D,"&X(K=J)O=6%G>F,W=H<C)M?FQAIC>HST/00!Y9 MJ-G>+ M0M!\$ACDG\+ZKJ5J:(CDZ?/HHIC\$?
^F:8)7T/N9M6N!\$5/&BCIM< MU>PFOHXH0+WL751PF,\$RP.9%"L+&D#.0.PP/498(IXQ)\$DB!E8>Z@%2" M#100"/<550=&T04YX)|
\$V\$NIH#F&2>17:_P"R2./PH|U<X=U PYX@8 M3.E:ZE8C2KS="AH&0-"Y7LSD?310*E|VMU;3R<#12C\$K%=&Y|_2LL;C=
M#R>IRS^|_JKW12>2*4)(U<^P9=PS@CHI|T"96E")& #,IR0_X1/MD G0-M/P_OEX^\$^N7\$8>VS^L(C5OW)4K&W;H!F"O
M=JLM2@B L|>ZASGRYXE<=0BF7.DZ>6BFEUHI|)JV&6661?HHS*_* MO8W^C|:HNS\$EU8Z&7873@0P!BY5XEZF4D
LC&%YSQ5"IG.21|^"Y9&E2WM MK>WU9S|Q...|YV>I5R#Z-714VA:<3Q3S:58R311F*.H="R">J@D<#D|> M13)HEA'IZZ?96R62C:MNL2B.#
<_<8ZT>?>^KJH&LO#K|U)D#86>IZDTN|_M/\$7C4O&YCGE 92E!V">0/ER>YRM?M(+7PLMCKBWEM+KEDRI99C@MBTBAHX
MR>_>#YXW9XS7K-W9VU_-R6MY:Q7%O<_/=%R'Q'N_P_PJ_V#HYL(C Z5F8SA M.Z.W-NGEH?4+C-'(Z&:300B
X@&65+33DL2ZDSDF(T<^8&A!^451NM#TXY@R6TQ_U\$Y4LDELK^8OIUNA M8>Q-3Z;R&E=>Y%LNVS!& B# "T'T H|>U;= PK_P
=8GF5HO\$^U&\$K M9 IR|<9STP2.5V&DVT6E?W4K"RW1VMQHT-U+>%+HO,==YR?O\$ 9/>N|P!MHK0RPMH^6F*:3S94-LF?<
^|PQR2) "VH:(0IN8B(W_N2#E&_!@#7_#15;SQ:L&K:E_15QI=N=>E5 MQC-UN_2M^21X/>_N_\$PPFU=2+^6PO&N PP2Q
M@CSD=CZB0W;C1|N|M:NYTZFTN5 FDA5G IR;D/C6DM L;B|A0|K^*WDNH_M^5_|2EX|_P!UW;C|"/#=#1P_#NV1YU2>^Q7Y0!>#
(!<G^CT&WMZ5H9HOM? M:G14OM(>46UC|_&DB8Q)_P!91G@AN1Z?C7I+>M>XFN&TBP:>=E>60VR^I M&R'QOR0?61#HNE,IRf:99%
H=MPQ@7.P!X^8?6@#SW3\$^S>*>A|>1R2_-M4TN?I=^*TC.UQB&-QOR><_21Z50V/7<@&OVMOAD!E* ML
01@@|ZKV>GV6G(Z65G;VR.Q=E@B5 S>IP.30!YD0-51+ "RTL|_<=VL|H M.D|_PESZ8/RGW_*XAD|00'19K_\$(?)M?
MY2ZWBS,10"1+Z*%XSZY4FO M38+T^UNY;JWL_>XESYDL<2J|Y.3D@9/+-336T%SY?GPQR^4XDCWH&V..C# M/OCUH PI=U?3VBDT:?
4K6RN;B'\$QDG16AC88)&3|X|@2GT.3Z2+8<=^PBK0 MM6L|*2K1H72(GF6|EKTYY##& N00?SKHKKPOH\$IAZ9+3R+RRVD;LW
MU)&35L;8K%|\$+_.W\$=O@0H(AMCQTV^C'&/_@#B_22.5I>IZ|X@GBLI=[5>F@BN87AGB26)QAD=0RL/0@|:/+ (>^%H?\$/PR|+VE>W\$M
MC;XN%LE"+&H|:=Y W\$ XSI+|JWD>|U:316|<^Q/L;M=W;H|_KHCQ1 M@8VQ 9X).66XMI&T@M81R(X(PBC|.54E|_<2W;L^C:?)+=
M%3.SVR\$RX.1N)S8(Y|"/_>+>|XOLVNK:XNKFTMTN3|7"&_*38<VCJUO|,IE@GGWD2D\$NHW8VD9)(! M_9K7O?%"WSW>B>#M8M|B0-
?_?H5FMT"@_#RV# 8XY7J-WX|NCKHMM M15UUG=VUNO>_*16C0D(K9V@9PIV&10 GA*#1+X8LK==425\$C#EXXYE4 M_<^3D8P-LN4C_<
(7#;#|/|@2 ^E\$==+^PR^JR6=W!8JDD|LZAT./F9=P/&<|X_*ND%K;B MY-R(O.1M;NT;L>F>N*K7FA:1H-
W=WNEV5SNK>#9OW"ROMA64.RD14<#YE"D=<15U=075E.WL21W=M#|SCK(MJRH&"LIR<^<H.GH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "M BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBN0U7QPN@>_!+1=7M8X+* 7 1K|925F_#HJC|HUEF^<_+|%)D%=P(QU\$0"&
((0B@!:_Hf34_P"W MA^Y5K_97V;=YF|^=YVHMOC;MHN<14%E)+# ZG/M2@!:_Y O)X@N_\$O=IAAMX18|3U!+W9R#&"K-D=?NGO6^&##
(((0: %HHI M"0H)) ZDT +15747O5TNY?3\$@EO1\$3 L\$51L^_Q_*EMFF:UA;Y\$;SE%_@ MC.5#8YT>XS0!+12\$> DD8%&X;=V1@|T +12
@YPO<<52N-6LK;5.33))E^V M78=HHAU^J.LQ|T^U_*ZBN?A|<_9M?AU-KF"*H4YI%5C1V"|_7/T!-%RBN>L\$/_ISXUUGOYH(8H+ "WMYHYOY+/
WY|KT_<|FKH&8*10ZF@!:_**YK0_*MWJWBG7|&FLH85TAXD;JS%C+YB;P<_M1CCW_-T4\$@ DG ->DW+MW9&W&GUH NT4@922-02.H
MSTHW+>_YT+12.EY^8<=>>E4=7DU./37?1XK6:1W+M6Y|! \$F MK98 @\$\$@!\$GK0 M%415O^T_2;N|B1))887D2-
WVARJDXS@<^G15;PSJLEN^%M M^U...8Y+VUCG9\$Z^64_ \$I_-6BD*#6^AAN^49YHW+NV|ANI T+1133(@C_MEX;_Y% #J^YGP|KVJ>)(=,U6"UM?
!&OHGDY2A6;_!+#+(C_M G5N@_HI-RIMN1N/;TM 112E498@#U)JG/JUE;Z|...:OVRZ5VBB!<8J_MHR6OZ=|30!>=HHHH
**XRI8;SI=S;W>H>1%15H5Q_*SHKFEM03SHJV!<=DEWIEJMS=[Y2G+HBD;X!<8A2_M0#9?
\$NHZEIMA>>%M+BU!+NW%SYEU<>1&B^HN0K\$N>>_&2..@'3T5B^&_ \$4 M?B#01J4EN|C)&|D-S!_P)@DC8JZENA (/I47ACQ*?
\$;ZMBT_WCLKS!_O/S M2+Y;_< ASOZ=1WYH WZ*1F51EF_3DTN0.9/6@ HI-01D\$>=HKGI/O#/<^_M_03!"+>VLHK)EM97AKO#K5UKD-S!#
=U)K)CEMX"(V23CGY07%6(652 6)X M&3UJF^K64>M0Z09E-!+ PLOY(C4J)Q1.6 "KSZ4 7_*H:A<C%+>1Z?9PSF M1CKYK3&-8U
Z1^Y23@8^O17.Z1XKU67|>_G@T^T5_41+^52MC%F|MG@&=2W>_M#P20C;4=C12;ANVY+I&<9YH+!#>B9Z%_#HH'RKCRTL9KN=4-
U<1VT*YY>1V |HCZ?XA|0S21J42S6 MUQ1#H3R/WHPP1)"#R#ZBNKJ#|'_:OM7V:|1C'F|!OOZ9ZT>=>>)&|&_#W;NGV%RUEJ+=+N M""W?
LXPWX W.22V|?H3"2!_761S@R@#12E MZ|_!HG_03:0.E>P&_#(4A12Z@A6(Y /7!_?E4 T^R%Z;T6=N+LC|GH= MY^<|C-
""Z:Z_16_*SVI6DEO9&_BAF9DEW!>YSWOU|U AW5K3;/W@_M%16=^%T&2XO\$NY)>8EEWOY7F9XQG=UX!/:O9 L;22Y-RJK TY3RS*8P6*?
W<=M|<>U_LRP^FIGIAMOL_ "H*78WU^C7!&_#<=0_*T3:3_P|T^X\$9FUQWOK@# MSL;NC\$*_/*\$FW@?2*#
|@BNM1V^G0MJDNDZNHV=O.LO^CA/L4A7YECV!# M. S#U/N:Z3!_8 L?V:|+MV>3Y8V;?3;TQ3K>V@M(\$@MH8X84%&CC4*JCV M-X%
^ZEY_?Q?N6>|86#+>ZC66%X=0#10RKCX^<_XICQ7 M&K2G1 "KQ% (T&U77-M_8|Z06X9MBE?^>8SR65K<)<2VT+SQ_M_1>+*72%|
^+>G2=92 M_@FNK&4FU""WMY#;BMY>W@_5P6N#WK7|20Z3X5|4Z;2-HFA7WVF666=/_ M@:_|E@_^XX!""V">_DGU-
>B>2M_*FMF+^U"0HJRL^DKL T7\$^DN+&TN|7!+_#%H-|XJA|MG|>E1V_AJ2PL9DD4@7\$!+9_ \$J8A GOF@ M#G_+|
<^>4MK|4K/R+O2(F19E9_?Z4#B4K!_N"/H#M2_ \$ZALKCPW=7EN MEJFH|HK6XE6_A1&_ =B%RIPP#\$
D#0BNJTRP&FV^6 F&1S22R\$8;DC\$LS8| M9)|_163XFT74-4N+>R>PECBM_F66H0EXI2P_#9*^LHW <88T<_JC91_#
M'QW>036L=T;NX@2VF27H&8C(BD).06P#<@N'MXZD/AI?""C_#Q77;X7M+/H1-PZY/LMO|
9UM (BIA<8|@VCIR;IP10|YQXJE_X1^PT=2>_ST^|OI9= M4F:(21+Z_4#CH5#_!X&U3VK^U^QTN/PHO|G;K_&A93>(<1T>-JL3-(H=
M(2AX<@')?/79|>@Z@>"XACFA<8_10RL/<K4+;98/16S6-LT\$7^KB_M2E4^@Q@4 <X8M;3/B?XJL+^*_WM#;Y%MT32(&*U4GH?10:XEJ-
G9CPXW4Q1_1KQY5(8D_?@VJ|_ M8?X<@XQGO5SXWB.GW4?C=|HEOK*WMTDDNW#2^P&1L;KP4'S9+9>T>O6-
M|(TNRGB L^TMVYW.GDKACZD8Y+|J6G2R-)86KR|Y+T^DM_)Q1WY24 M<#_#2IR(C_#2+9L90!&4DK130E^T.NX^NW09Z|N?
\$ZWM)4|+274.#HOB^U M5FE4\$!#NR"3V.!FNT_L^RL\$OV2WRW7;" EC.81%..H*=P&"Z@BGB M)!DZKXP|9QS6UM<6L>AVIA7-/DEVLHZ
@8P>W;K6? M.ZT@C|S^KXAU""VTVZT?+GO8A)|\$S|F|>6X#_A|PUZY=-L#)(<^Y+RKM MD8Q+EQZ\$XY%)>G568LY+^U>U4Y\$+0J4|H=N,4 9?
@VUMK+PU|V6HRZ9H M|<1<28PR;B0\$&(ZH.BGT QOCLM^PC+&B=|0)+ZMH+2WL<6@B|GMJZDC\$D^GB-? M+W=BH)<9/
92-49DT&QT 3L_4S|5E?ZYMI1(D=DLH0L8R0)*\$\$.|LU?QBL MP<@>F3K\$V1LC9VYM#P8#\$OE6GAW<8ZTDF6\$UFEG+8VSVJ8VOM\$H1<=,+C Q
M0!Y3H400Q#WB#3+75M-AGC|3;-)4S;R8".(RF3B-CNP>O3)H&IUPVME8+J
M.GPZ8PZ|:ZN(51ZUSR|D8#>@66^D@1\$^/KUMM.FIEE5K&V\$S-OEIA7#M MG&6XY...</LELC9"SMQ:\$8_BEX|N.4
<|X^MM.@74WTG5UU&SGN!# M%&SQ.1RQ>_>0D#@\$^I-U@2"WACAA086-0J|/8#1339VQO#NS;PFY5=@F*#>%|W7'M0!YC MX-?
PIK&WX?OK?Y+Y+>XIK&15ED#)|XN1|X@_!FZL1R=W/VFAZ6?V2HS M6C;JVH_8+J|07.X+H8|>N.94?KZG+M46FV\$D|D-
E;1R7^<N9(E|D_WB|S M^_TS3UM3:BQMA;DY.(B783ZXQB@#SM-"TI?B;IS_LH3#>Z#(UW\$1E;EE>/_ MD^1S|QY;/Z5A.0/@.0S92VU;RHBQSL1;|
#Z!>H7L(TVQ\$)2BRMA(B1%2R_MERJ^@_!3?D)TW|JG_L^T|@MNIOR5VY|<8OF@#SW4_*T14OB+XMAO:6&X&G&
MB0Y<@RN|OS8Z9^&#U^L_2+RQJ+2_MJ#QS7IT9Y@VH.#!<C;RG_62= M@C+&F05|L;L>3|#;Y%V.WE+EE|<J M<^Z4>+Z;.&|+?#6-
M/Y>H3020|H;H6;_3T""T%_MUIJZXKETO M7<@<TN^2\$;HE&X@_3R6MWW|@W)X^GUGRVG#<=174MH|<1<1S/&"Z?
0|10!YG<7%A?KXXL_\$3PF|@M(ULUN MJLL|@SNCST)D+>E>^05UWP|=7^&_APJP8#3H<^/09%MSIUC>31S75E;
MSRQ@A^EB5BN>N^1Q4|<<_0Q(|J_!JC1_*_/%&_ TOKPI9J^G3PPQ?_K MW|=YY%|<=7\$18S_8&0!MG;
%YXK>MEETCQC82SVMJAGWNJSBTUW^6|MYG M\$FZ4?QJHW+D^*_C@5Z\$ND:8ARFG6BG\$?R(|S^T^H|?^IMC#=-=16
M5NEPPC(RQ*_*2&_7)>W;M;M;_<^I^37EOL^DK<|VVG;T#%H^D 12>U=U_#%<00#&_DD3C#(Z@_MAAZ\$K46GV4H;2\$SMX|8I84C_0_P# <8H
Y/X36MM#|_!#EA@BCDFME;KH M@!<@GEB.I^M;.%|+>71K%9BUF@TI29DG8X|BX X|^!&3P?^>H|^Z"WM;_>
MTB|VY@BAC_N|H%Y^DALLWEDEAMX9Y#Ew1"QIR.M "GGP^+;_XAI^7OE M23:5(S6H_X;S#>@&>3@L0?Y^O1KYR;PO|+HH@-
S^?17<^>D^ER@<@G^C M|HBO9T^R2|TEG;K7ED7_MGVLO\$5EZ@^:0_<5U\$&BZ=|V;V23&3|#\$L5NL89XU_!\$CC@=J+^+M
MKN_<^@R72Y|NKRWL9F.F;C\$S#>JE0Y|YVNO_1QQO>_*^EL9M^O_!X|U\$Z M?196TNE76V.YV684L!_Q^ICG?>
3G07J;NDZ;_QV|VGVDD.8Q^&*E4^H 1 M@5))8VDI@_EK YMSF\$M&#Y1Z97T_"@Q455U "6EW;WH!%=VD|<10;H>_6-@RN
MIZ\$5\$S;R?>^*VHHW@O>TQ+33YQ|>\$URA>_Y50NO#>Y<65!<O\$|S:PS_VZ-I(PQ0^HST-1W.F:7>R_2ZL; M:=P-
H:6%G|DB@#E(TCN_#109>9+1+6+_Z;T-WL\$|XPWJK |G<@>_ M\$KWXA|3ZE+KWB7ECL;H3UM|+RK;_>
M^*!<=D2!1GZ"G)9#%\$SM^B&1MSE5_W&GU_*_!8R;9=<_&TZY\$+74>CS M2C|>P-LD;_%>5#RTN5QUG(PHYQ7_Z)IGU>/X4+=.MT7MH|;
<^XMBV|RMZIN M#V/O7L;UE:7\$|4UK#)_#GR|C;9;_!<L^("HDTG380)|O31|(<U6V%1Y?_M?EXXY!*_<DNETKP_J=J0Z|XT-
M=HO\$<%H=K%2|H>0^>T).F&Z&NE/KI4 M^QBUM=-_JL6>LM|N:3G|T^M^A82^A>+I>I^Z/
M17M5Q9YV8SHSTO^0)FG3ZDBB3|4I^=TB<2N^/3;30!Y M^XN-O|&^EHA?>C@G06!"DHH63@AB<9?/4+P<5:L3HMQ|2/#5|=9?)
M^F.E /DVDO.)@#N/5OR/601WTK3D|(|A:LBX.(9H5)|L4SCIOMTIWIG6 M6ZW;|;

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

[!E9X_*C2,SH!T4.26-8!4FF:%IFCV4EE86:0VLA):$$E"3UX)(-MYSSZT)8M/M?+2!0KD;-G;)7&0>HY!ZUS^GZ+=
MZYX8T.W'G.O:ZOYMJ&I/$LK>8_F?QJZ!<^@P.CNM,'Z'X>:IN-TBR MLKR="6/C/4#V7...!C!7!.../5:WBM:SP)96VH*NUI3AU'&7!R*J88<A<
M#TR!0!NZ7#.^(!?BW3=:M8KA+):. &TMYU#+'T9)9>A9LY(YX!["N65!RX M^'WAQ!Z66=K:Q1#;VL!C$M) MSM4D!^%OD^@KU2?P !IUU+!
<7.)DNX80)%R' M9)&3NK.H!OYP>+!PYI!6EK:75A$!M.LK00C*I&5^Z0!@ CMZ=L-.DT?3-M=6^+^L6U;."XMGT>WD>"1V*.OD<*YP>/Y!O.

```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

A:264D1JL@:IZTYM:TQ)C"]L;K^05;@:R.HH OT5GZIK6GZ-8^OH(C:M8LJAR">6Z8K(CV1)XDN$FOX/L-JDT3%=H4EMOWNX-
3T54FU2PMX8YIK MRI(Y2N.S@:IOIZU.MS^IN^A4.$KN$AOEQZYH EHK+M.$>BW=TMM.ZL2SN2J MQI*21U J.;6--MYS!-26!>)
I29;+31MG6+N5ZPP8,N&XSVVY*2T56M+^TOT=K2YBG5&*L8 MV1VGT-1W&L:=WBVDH!^<-C$3. QSP.*+M%8FGZG")M2>.+>XBBF!+?
M-8)SR.S+1R7OC24M2 MH^WM4F&P#*20=U M7<5CD#*%UXHY5E1^WB9=10,N^8P&.+5%8M>+(K23)2JHMY43595A1VD
MP@8GJ3H^L138FU.MV?)439"A-3!<4.=9%F.WB1"5IZW6.R M"(S@-N>@^H+G7M+L.MHGO84.RB1ZX7=S&F.@D4.-%S: KMA=-P
MD$=DXIEBB@X90>?7&:FM106MG801:OK-DIVZ^O#A-!>>P>@H Z2BL^77-M+AF$4FH6R2^RF09YZ476NZ592>7K9F!@^TMTBWC1HF-
6^8DY.M1+I(=2^NW"(L.EF;L(C)H NT50@UK3:FQ2JBO8&MG(C^R1 MQ@DIOK5BVO+;15FMYXY0IP2C X- $1%4I-7T^&!(%K)>0+<$A?
+.;@9J08LNT-MT-%%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444 %%%1110 4444
%GO=P6K MR><$) (&W@GUKKJ^/*=31.WMSIOBZ230I)KRXO@JD3C=M(4!EY!$90QTJ^M=N.WU!55U?1.^L!Q(C!$N!@*49=PP0>.!HH
1ZM-!$?B+O.1QH5RI6>6 ML$(2H8215P5$=1Q^50VFD.OJH&B7EHEQ>:=8;.-:6@DSPVTC!RO&<15 MZ710!YY!GDI;
f9R6_A^&E&R.2O6K^P/O)(8!AU!K1X+.*+PBHJ 9TPB.#K MJC=MID/RY)Y^M.E% ^G.F>&S!..XH+1Y:748 +.6-D ED96SUSSO!U0!8
MZJ^!O6NMK%>X>O3JHMF58077YRDA+ C. <&O5.*/*=7F9Y+ZYC@T*8L HGV7M9?V5J!^OH MZS2!
<3+;ZS+O?;B8.U^OJ1570#I=W!#XNN&TR;+!+=VTIO&.?O60 .P&>> M1TFUZO6?JVD0:Q#%')-&89!*CPOM8.E
^>+2KWO7=-RUPLU^Q^5$1 MFT+0JHC^OY!>.-%666=(MO^0R.G.^00 V3D1=JZ5A M91!-%FLY+L;@#%&H8!>N">U6Z* -7T^"33!-
%581.N$AN&7%N@:1.1AP7VY MP.!E!HIDB^P!<O&%(G9BU$#0EO!).^=V @IN1^!KJ** 3Q!HOJXMY+74^MLYK=BR$1JX)(QT-
ME7^E23X)$Z>.-D& MST 6NOHH 1VU!0M0BAI26.EI+>#58D0%,$"4(CP23!&?76A34+K5>TH1XT340MRLFO+!H4IUY8?37H-%
M'.^$(=6 LE9!>BC34O! 5/LY^5>!SH?OJXNT^YOKG;Z4)!LHA=Y1.98 M<)>@L^OM76T4
8VBPW2>X>VE22^Z2W!L^9P0P&^!UKC(=,U^+PYI&GRZ<= MF!LH3R3H!O#DLP).F^*LOI>NOJOA:INK-9C90.MPT0 (5AA6(X/!H7H%>
^FIE&J)XAT MBX717M+&W.U!$1(96^*QR&SG)WQ>=-(L9UFM-7ZJ-N!^O)W2M^>BT4 <3HHC?Z9=Z=Z9(TLEY+!^?H%
<$.25=1E!AAD#M53PHLZ=8666H M.%;+RTE=>1J!^HHH YCQ+IEU=ZYH-!^HDMK*=VFCR.C(P&P M>N^Y17?#^!E!XLDM!-
^QWT<.=O#P#R=9#Z=0/PKTBB@^CIGN^AW6TD+!& M%3 9R!H5SNL7<>+(!;B&QDLH+H7$TTH 8*H(V<^ONKL**/Y#NK1>' MIS00LX:1?
40M50-Q^*JC.^0YZ.ZM?Q7ICZ 1 V^3^CUIYE5+N10-@4@EPP M%>G3ZUVM%&Z55KJWFTB>6" (L;RIMYX!^!Z81ZR!H$EQXKO-3DMWM=-;
MRR%O="Q(C!)8@>@:Z^B@#E=J.T.0ZR-5N;1!%;P&V!^YHXRFP+>Y.P..MV^?QCHS=V.ASGUDUSIEOEF? 2B@AK=U:1K MS42%F7L-
H(6TM)EGR<&75% $8 ZX(IUV-% ^GFFZ#=V/ASPI^V5Y% MY5!7Y%RV6W^0UBZ9!26ZIK.5SHMKJLES&98!ZR.F.TF0<?FKUPJ&4@C(I
MP.R8?#EC19+8CS6LU(MW?#8)SMOQ#L.U &7XZFN!O!PW#^EOYDUOX;27B8?3V@65R.6)SC^NK P.44 >7Z=X7U3D3V37!MA=-6JG;/R6L3
F)R!;W+>?>P@C^1D^K6L:JVKZEKDDMHM5U#3EMXJ2=ZG
M$S@^8XKTPBB@^#C.#E6G15.W?^A97+4@G6F9L8XR0G7^YJ.ZT>^3XA0:WD3 M.>%;K9H^IB?>NW>AOBNJHH !E!..!9:A=I:Y:S5(IH+12
8T7 Z1B0+M>M>@Q!OJ=NW(^!Z4ZB@#^U>2ZDOC9S.;+I29^792^V /W=H8KFM.)ZAI D MFDS^TDMI:7LKQV;$ $PPN.*!I=?
OKT^B@#577 ".KZS/XBO;3$2W:0OP0EMK M.8SDOGL>PJ!>Z1!>1.EHJP;%E@NM%L@=ANP$G! /K7>44 <1;Z;>7/ ^"-M-
I$13Z=D3+M)3JWMSG!-;GABTN+(Z1^!F!9+Z66/4AE8!58K?HH XNQV
M P#%#8ZU=WNF1SVZMR&*8@^S!U^#1.M0.EX9! ">=>02V+IEG:ROLV!C. M05P#V/YUW=% $G1.Z#3/$ML-BEE0IG."0_K
XP^WIM 12V6C7FF^H)F MLC<*NEI:R7 Q!TB^H!>NUHH X^#1+1>%YY+!X !ED.L(PY(92!C/09/X5 M3ET?5)=.M;+
&DM8K743>W16KX=T#^S%33H1!+B>*>6!4 MYB.6)5SDY!P2NGM #6GVFGH/!F9QL^L D.T#.=2>^M2P$ A!Z.GVM!@CS01L +
!O.R>REF)FOV 3-9-5M!IG;K6KH XDV^V8OQ^TJZ5(==E^36! # @ MK@2*!UVGFK^@:9/XFUK6&1H;>+!H8XV& "=@(+8!BNGHH
!H1/!5J!UTU MGICQM=VTI2Q$;C8P)R>.-6 600$19)H!&S!H13^ "BBB@ HHHH ***M "BBB@ HHHH ***M "BBB@ HHHH ***M "BBB@
HHHH ***M "BBB@ HHHH M ***M "BBB@ HHHH ***M "LC4?5EIFH16$PF.ZFB>6&-(R=X7J^?7FM>N9
MUDW(8;JG!HDPW.1!<=EQB@>^/QCHV6Z?IG8>?JF!O80XE N$H:IZOXH MT>;3-9AFO+NU.GA?M+1^5DC!
(PR!MOK5PL!<1!VD:DG:B^VXL?<^E &W+XNTRVN!81^YNKM;M=9 +CA8L8R.&SC1R>+!H3(15)H2@KM^Y2?="#G.>GTI+!2-5@UF.ID^J
M8TL1D G<6^!^I1X=UG3=-TD!&LY!FQDFR@H!5@0Q&.>..COM9LM TY;Z MD3.3.0H93N+!HN/6LRA!9Z9:6D$POE ^7BV03RR&$A!$5?
UNWU&ZTHH!QMD MQ!0:A=RCGG^OZ5RMWX^U&=;C$T+8U6+4H=Q.3M RI/!2.M ^87.H.Z/f)
M1PD.32!6&#HISC^X^Y4G4C ^VYPB!MX:FYVR0!3!X:-B...6RDW>?3^8I5/57^!H7-WWA/
M5KMKJ!)H!QI?"=J&0!H$^KCZ5U&EPW<5NQ0$<CE9LE!A?KZT 8K>*=^TQ M!N)YKH19SK.K*6PS#Y=@^8U93Q=8LMYOAN(GM;;
f4R2IM+!H!C!YH6?> MLZG ^V$N+!^?3P3H!V5!LC^@K90?#EW>ZUJ
M!M4#X7U<6FC3)D9 _!^DH^W&6+!%Y!&XSEK!L%JH!YCRQBP62$N&C!GH M=HXP-N/KWH OV/BJTU+!^RVTF$TS
A9^T>WRR1D@>+!Q22>.!#AU#f!>H^X M MPPW52!(SMSZ!53NO#-!>ZS^JG600?<$ZE)H009(SDL+EI!)F90K!)IGDVT..^BRONKB-
^!YG@DF!>F^M^O^Q(O9 M8;^R+!Q7I6HZ7 _!>M.M!J^O3P^!HO@;#H; M.5V%@:IG2=X;XN9D3!>9.3W!O4EUXOTZ&-C^L!UV LY+!0RG
MS^5^#$CCK0!TEG!- ID=-AVBD3>H^X.Z8!Q$!RNWB>6+(W1 @8)! 6N9UOP+>2ZDNGSL6IVZ MW8520RW8(<^!N!R!^!W5M>L!VM?
M(U&S^4DMT6+Y2.DOP&C^AP<U2!O> M)TU+P!XA6SCN!>L.W!E6^A9?/!SEF^4!#!<+!HEC!>H7MHJ.XGEN-S&3:
MF:W A36K!Q!96EY+!J.E7J.60D^3/W%&UHFN?7S0V:1SQS 9DF M!E7 _%BD=0.S!SVK7Y15Z!X!E!&^$DMS.^@940?>H9-
6.70M4CUC3+Z>Z MME2UM3!^JYVR<4MIV3Y^!VIOGGKZ4 MW4+U76$009K9.F@*3^3N$C.50P^PSS5).PG=WNE:1!U/#!GL!V9,AW!
MO!F#VZ>VNL92W8WORB! MF^($AQ<=>2>:Q1X^UM9)"MHVU!7!G.C.3YR#G:UK3T PHFE.E<^3U!PB:E.H5 ^?PIUMX!T&I
MU^*OAN
```

[illegible]

```

(Y"TH Z">#3;>WNWNE,C2LH3+No1,Z9Z5;+MZ$&N<;Q'MUZWT23IB1+43?;"E?"*YPI1X@BTKPW8Q74-WY-Q>21+=2J=N
MXN0N2>>>@H1%)ZFD!Z$&N7<CP9JTB-LDBMG="2K'D&N6!:@UUXF-MTNWTEI8EALD:4XKABH<F495AWCGJHT
>E45@1780>Q:P9F$1DR=L.MGTF1Q.061W15Y3C.DIG<9989;=V,Y,Y?..BH=1P6YTD3,12LZ:&(R5S.MG%<1-1%E=?
$5$XQ)1.FM$TP7W:=VWZ>9HJ[D$91R9*N1>?>7P=XWTS3,M>2YET24XI2V9B.V>1HD;1A2.U6A+H1=O#>?>"- (INFCQ&"C8VD^M
M'2$X&31G/2JFJ&.:5=F6/S(Q$VY,XW#2N,1%:A)1*7F@WMZ998E$S:2W,F6.MDB?&844=ID9QFBN!:.PUOI&KW=-(U=Q:A)WEY?)W?
*J^V3WZ"MB.P#&MMHFF75Y=6=UFUN%MY8XDWD.V.8QUZB@#HJ0$H0.Y6+Q=>SZI8V2>IR)KF.M.20F&235WLO$&A.IOR22NK^E
">4FX#N*R=M*UZ/4101>WDM[NR*B5Y!##((=55GB7CEW>&:=781W4=QIHB#;:(%E2*ZN$M.1A1C,<#(1*S-519/8;K4T=@S76F2(C1
M.XP2?&#1&H.ZO$(S24M)=M=7-014G03TP.PJ;27MTEFD1+2C=;UO2.M>;46-C/R#>1M(D#?25520%CVQ^M
'24$@=;Y&Y>P0W&GV1.E:C/70M.M+"BPX)VGI/3U^E2?$.66/X?M&TD.RV^X&..IXIT=26&21B@.IZ$<^
M<;HNHZJXFI/1).BF@A0R6T'Z.7&O#N1IBIWN*TOQ2EHNGW(GM1>6)XR.M64Q@C*A<>Z4=917V/CN..AT^I32KN/31^?R6.B3
.XYP2O4#CK440Q$M.(MUBN(I/NKREO&LXYK<V.01$Z10..R)ZD^EZ1Y^Q.FY.WUR@FB=(A(.M8ZIC(IN^DU#Q4FAWAUHHOI?
1=33V121>2GRCJQD1^..JH=0%AGZTV1^MIK>;1XVB9E1*U7V>.>:6CVB^+EH7LKFYAETN2661^1.G$%XSUIJ/3P01MD^
%>>?>$0$,&@>%M5N-2EN$^SWI5,*F6/@&?&K_6N1;O+JGNH;6^LVMHJB.M%I8.9.PD*C+("X%&-2!@PRI!"*YF3Q?"9-
"3J%*T.M$%:AAAYVPP^G>L.MO1=7CT/0+2V1@22RW-PD40DP=JLS$DF@#NZ^YFQSL.MK>P@&$M&$0YIGWJQ10.4444.%%%%!1110.4444
%%%%&3<>@LNM.M.BUF6%.M!..95E8?+G..X(S6M110.4444.%%%%!1110.4444.%%%%!11.M10.4444.%%%%!1110.4444.%%%%!1110
4444.%%%%!1110.4444.%%%%!1110.4444.%%%%!1110.4444.8.K>+>WVL6H1=0HD.$D0C>(MDOC)SG.MV%0;U%
(Q^%-0MM)T.SAU%=(UP)6D1K.07)RN1<$U7E1.LUKJHE1%?W.M?VU"1>UH9.@C/(XKMJ*.70M1UG50#U.IEJ<DN(*66*WV1W1&&>32WG6
MN:HTBRTV1K=C@PJ4=VA^1N%=>?E/(Q73T4)=5L+BVN;765>?>Q6TE.M.XA1SS2D)=1CK4R^&R.V102ZU:7Z1W5U;1#=#8-
R.5Z1D81^M=110/RMUX.M9U&..Y^ZAU.(O10MUAGC..9KJ**..7P5=(PFUCV.5N)0^W3NT6X.0.10.C.K4TC0103M=U74K.MY98HD?
R1^CRV500!SZ.5044."I80",^B?VF6EF41MO?I6MM0MJOBC>*T%.MLZO/NW=-1R.52A1%3+X)=*ZP8IVMN^XSZUV%&9X@TEM=T*1
MTP7'D2:8S&TFS=@KQ6.W@R1+G1VYU1XK.3XO(>..R@1-8ZFJ6=U<&X:IX.Q5F^JALJ$STJT1.;/Q0^IPS1+>6>?>?^-(M/NM^1Z5N44.5+>")
ICQ+F6:ZD$A$E1.;>7@1HUB2>&M0C/%1AU=4#6PM.MQ.;AE"YSG.INXXVBMT"(H0>Y)1"1^&.BTKPI.MJ6BZ16%QJHDN)YD)HK@P
>67;R1LZ>B@#N&KXN="DLMO1XJ"=DSD.MXP6VY92^*X'N="NHJ5+K3D1J80+YB$?>8NEHH.X^U&WJCIJ6UKK.M.127IV;GSE@:
(D@D#GGICFH.GP)&91126&L&K?K%)M8"00)Y.1X.XYYZ5TE%'.KX7O=6MY5FU)?I9:558FS-J8?LXV.MJ
<1LYZQ4./A1.MH1+D@U41=V*R(9#1E)4.L5SV^M=510:SLOARFUC213?5.M-TUDCHP.(QOON1=1BKWB+1OK^@7FE.-85N81AD^Y(%E%
+;IX.74;+3C.M>^&UU2Q@OR1^1O(7^&CNH#51@1V75Q1.VHOM^+5181;?>@-YZ^H%=#10.M.R$A&XTHPH^G1.BK1Z?
(9@16X9F2F0.04UR^E3).61UA1F6NE6ZAV1J.MRODL$R41RN37H1BWA"E1$&3G&T4.5NW1L9R<^PK;J/2OV+N.O8YH1%"SM+R
M#4+V>^>1M.5..10#R<#D91@UD.CX6N+OQ=^<(K24A1^VS6R1-#N4J3DD1C.MG=-10/R);16EQIVH17UPIQ=ZA.MQ-<00SIC9A708Z5=61.G4-
4LHAKOS7.MLD98%&C38.S1.M9CUS1#M70T4<6O@B^5M^QK8V.231F46PYXQAN>>3%.B1#S.M126.RNH1VRFDECFN.1JG-
MFOE.1@F*U21X7BV1@VX8#=>H5T51%Q>+>F+^TBF1.M.M+DTR)H8VX^96&>?>B7PA.OO!O:9JUCK$DMA<+D4K0N0-KKU!SWHJ7
ME5HJ.K47B+4K^XM5BAUM.WNM31VD5U9Q02TC1^<3N#Y3<02F1^<2.M>*1UC61/216.WLB^FK>22RH1Q1O1AD#H
1BBN.U#4.$(U8.1HWIYGCLA.M.1LZ$>808@84'@<>M;7PWI.MVK7%W..N:$O&L1^&QY&=W)1ZJ>1)%VM.6=-1+8.EHUN(7D1^3S&VD-CKC
MK012%03@&UQJ^<716VU.9+JTNIXM.Y.L1M@!1P0PSR.U#CH.LUY18>(M9>VT.M2);JT+WFH3V.DDBS$DH@9AC1ZX&*<B15+6+74?
R9GT^BMO."10J.2Q78.MUYH1^BN>T/4.10=404EECEL8=OE3+&1YA(Y+^M.;O1SO+J1C%>1VUO:0H.M1E=6?B.41^X1/0B2*1+=+
<0S1JLFX1&26NH1C=7PU.M1&1ECEEM+MX01J0RC13SS01F5Q6M>1)1W3-8A@6YMF51^&HMA.V-^6S.M1@-15K>+1+N:
#T1/7.^7YKSQ0A102JHV.R6P&G1#)#YD><OR"0>2.B@#T&BN&U.M^U12+2.^ZU6..REG1.MEMPHC1A0GTO3.;C>XU">1HK.MGA/*49
W+V(WZ4=1165H0U<63C69151@2;8DKLXQG?K7)6^N.M.CQ+>M=M.T)Z8(H7&$&C7@DYI9YH
1HKD3JM1/B02=ENOML.H1(Q:9AHB@ISQ."@<MTOB1JOH=71.6U1PFT2Y0&64A<1@&P2;B@#H134V2XCBW11>3RY.RXP>M6
MJ.U>^U+3+7Q.1%KJ1**R.<@W1N1D1KDGC-1GQ^XBUK57M)=>PM^BLHH@MTFY>@>0AA@=R*/1^J7FH0V.D^3+)^&8A5"PW>AQ7JK?
W=Y.^&9H1.^JLCM.MB^4&Y2X&>>Y.Y+=+6&L1U^75HW61^YL.C^14Y.YSW^Y4=X3@&$XQ6?1M&M6NMP2RVOF.0RM#(LB.2KKU%
=<XCUR17Y>.V$S1.O^M*T763M1CZ(79-77?L1T1P1%?>CZ4>19&&9YJA)JIM^K.6E.ML1<2QF1/E4@>+YC2FN).B?KP1*(88+&?&
E.MTJ;7%EE1%..PHK@&U541^#LCOH1FZU"TNK:1XYB.AMBN1$11GM5.MNN0+0+O5=*X1H&U1Y.NV58C.621SZ-66^FMZN^B)K(UN-
Y$U).62'R@M(HIE"$=^*BHKF<6MK+RLPC0N509)&>17.M^*14NK^XU6^XO).F.&91.TR.V%0>152ZU2YUG61>T.^T7T^+38P1(H.4L
MFI<2>W.B@#KM+U^WU23(+^U+>3.NY=RX(^HJ.76.678-(2S1SV&A)HTEBC6.DYF7.8G?<0%1CGHR36Q1AR1Q9H.2W43W.M:9<H4^?U.H1
R**1T1Z1V_@C3JHUQ2UZ^V65QF161)&H1Y1E=#1.M/M7O.81^T2RB6YBFD4.0$98*Q)QQG%545YY?>(2M0?IEOU2V^R.D+2
MUB).&49@6SSOX1^HCO9K.N%P..P1K/62?P.#Z.C.MH2^62^41B1L8FY8Y&LBX13Z5P1Y.MXA001-2.3/YI&E&=VIP3GLZEEF-
N.4PYXUVLA8C(1TW2%FZR+A87DBFMONFAN$.HO.MJ0>W07.Z3-#=.JWB#4FAAL5@AM&C#RWD0DEESV1/L.U=*L89.$H=U/
M:S7$%Y4.2.96^OZY-&C^XCTRXLHKJTN16.M^02NVY2HW1C8#1500C.D#%MC'S=1<X$M811+BTNM&M.V
```


[illegible]

[illegible]

!NUE;&?ZU0UHQ!M9Z08VAZAJ!T!T*PWC+*0B\$.?P23WSZU5;PMJ-EK.L7FF750IGU4.M.S0S*2D<+M)!J*^*F>*>I70_#FBVUWHNKKJ.VPKK
,94"YW-Z&M!)J91_M&6D7T.UREM.V.UM.UZR12:0FI6!6.8'9EPXP05."#<-<_8>\$M6Tf0M-T>48?
MELUD~8Q0/2M+P9X=F+>.&VF23QS*H)\$9\$V1.R38N)6<CG*XR0@9?2?K5)!VG.KSBBWA91W9M&N3'A0^X*/PR<9JK?>\$
M=8N!;BU!M1MY/LUZ+FW62+.Q=I:4<!=)YKZJ98/M47E1R.M'H:~*!ZDHJPX;.,24I9U)K."H!<[A;I=^4="."64I~!-WX#N=<74-1^Y
MKX+>+W%.?JL.U.B*.*048ZB@#L~UV#6)+N.*"XB>UD"!)HNR#6HQUXJ*Z%I^>SJ>ULKB6\$0Q'9(QWL.#WZUA)+GLI!&G7<44>DQ/&<+>
MXON&?"SYQ0'4W4.DUA+>C.2.A3<1P.C&~.8!R.CKO@P+?74R)YU/G704;BN.M2#CL#CC-1^&K.Z@OI5H!&JNY-
**8MYI@HLL^!%8IL15RT1.V76^\$;+1.35@MDD)P.DVX^9'A!H>A8WEI;Y4N9.SVR9RJG/W@1CK4WB#Q/(-\$YBQVN
MJ6R6*Z@Q@D@W.=C@W-.HX_&NFT70!HVHZCJ4IR57MRFIU38!J"J!G!R.MM7^FBZCJ.GWD-E.P;W@N9L1YIT8.0?J2^%&)%XBU*~
"6I^(-?VRVE!M*MHH!C'EAINUNQ&_7TK6G!ZA?6FKD7T!QOY8I88TE!O&G;/H5!_!6.MGVNF0W#*3KR!^T-1!JQ6!53Z\$-E76JH!HZ-8%
%2YNH!+L!)?<-(0.5)9.MF/!&ZEFYB-Y#K45P5@E/EMH3?+*5.K(UKEI?WNSD6^FW.VET^LK+N.M&>>A/5!HVS5HMQ?
M+!%E@%#0&/J!D@Y!H.T.J!<~!BSYJ2&#W>.>#IB@M!^OZ!J!K!>+6MXMO)J"^3>KPC+@!~?PGMGK4FF^!J.TVYOS';Z@WfZN+.7>MY<)*V..?
N!;?..^M4MM\$T.2?J5@>VL9DDB#0\$MM4*3GGC03/!5!8!&L*MTUSJ4>H(WD8\$;*0<8SSD#%&Q=^!J"PDU=+B*=3I81H+G(?
H!6HG^!KJHHU.MPD@OH*J6((3>MNHVQO<?I62XOX;WGN.L!9.EXAPC-9^YQ6%-MJ.B!=-1%NWI!;FSG@G'ZT'C'6?2"!M*?
8MPJ\$R+!~"SY.2+!&!)ZLITK6G(QPBTG5!-WVUO<001V4T?ER6Y8@.3!MG%=UKNBG6K;W3SC#);SK!&P\$1N4HQW!9=5X-34O!0DU"Z+RW?
ED"=-J1M&Z+J=QI^GRJOM.EN9XF;KJPR!Z9!P>G>".DU!7.F.-)K" M\$6T:J2Z?>M?WIO'Y6Y6LR2!4P.3(V.1D!#7H-QIDMXNGBZDCD-N
MXDD^7=-(@.9IS5*Z!S2!)#K/%C3!>JDIH5C5/#6H;OI.N=2!+ZVG2>"6\$;ORIB">4;U.KFHO!NJ+.%MK.3.T"NHJ).2C@8SUZ9%VW!
<6#ZM!HW;75E)+&ZB>X4*K1C!>O&/2L.MK6-9^VZIX7GAAO&H(BZ(#!D3.2-PZ0/6H0!S.KJEE8H7-SSP:..CU75XM*?>&::2=RD:
M1+DD@>^G3K60GK2VT*P4QW(CO90;1Q^!<V.8PFTNT8ZUG>*~"VJ"!N.8;DD.GS6X18IAW!R!+?7
MGD"@~WC*Q.MZ31H;6!FNHBGF&+*(K#('M340+>2PA9MC-&?VDD!3VIXS0!TM%%%~!1110-4444-%%%~!1110-4444-%M%%~!1110-
4444-%%%~!1110-4444-%%%~!1110-4444-%%%~!1110-4444-%%%~!1110-4444-%%%~!1110-4444-%%%~!1110-4444-%%%~!1110-
MM+EX!M0.A8&BR!Q7+V#S;..NGV-6!8U.MP.9!VDK)=WMSDQ0(ON0.I+@#ZT:~!@2N%U!Q.IQX6U46MG.-1M94MIB
MU4@L48C^+H@COHUT7A!2;73~V73-L!\$S!Y%YF-.WUR:-?(!P.0@-0UR.M&@6!P!4>*1KYVD3=-4!E.HM!2U@BDE@B17?AW
Y./4U."#G!!OUKA.OQ';Z!H%SHJB6AU@7\$=MMN.6>1^M!)Y~."MGP!>6D%I=;T.LS.G!~)9Q!TJG@./4=J.A+!1DD>H0H-
%AXRL8!VWTS3=+N9+&3~."XCY5&!MP>..!G>1'9TSRL'CBWN!4%L!;?2PM.UNMRH&PN!SH!D8S5SPMKUWX@T.P"V.M3Z...E@NZ0-
N(8CMJ(UH.WJ*Y&:ONMKXAU>ON+>+8Z7"LL!WYH^7(R!MZW^!9.M6U!5M2!2P&HV\$ME%?R*~WD=U8%B.J!"!JW(S0:T=%9NKZD)H\$;0V4MW-
(VU(T.M(4^+>+>N;..H.M!Z!H*W43!Y9D;L&PRG!&I!P>:-2BN;CYH!Z09M#N
MTMK.Z>VNW#JOAV@>0.2O;M*3Q2)-4N+&3!JGO)+.%JG5@B*&&5)ZDCM0.M!T&1G&>?
2EKBO<~SKTF!UK2+M.SN!F&M;AH9.A38!00H!Z59T.P.KJ\$.G7;..M57IH;12E.?N!M>H.WXH?Y190FEW%S%"@>6565.O/09/S"/%~"OY&<=Z6N!?
5+!+0?&OZM.7.M6#I##(PW\$!F.P!TR.W&6!-WEE:~C92VCWL;Y=7VWLHR4X.BQ0!K1Z581.MKQV<%"KF12J.88C!/U(JY7&6OCXS1Z?
=3>+6UA2!2-9XKB1EX)!"DJ#D-X!M&C^VF^RRH7+VMMV=26LB;Z@~)UOP>..PHHD!F*JP!4*!QO\$6N7&BV.M=I;V!H)N!C!AGH600!Z!
M17*MXU26WLV!L=NKJ;ZM!K=\$@R*>@)J3@_E6M=K+X%>25+>QF6D6'S!~
M<~!J>@#4HKD!QO'=7&E!H9.L6!6S3!3M!H56499~N14^~.9C;VR.V=27.MT!S"WB("X!)VNU_!2!4TCR2!2;[MN8F;9!J36@
#>@5R\$;CDW#6!M#8C2;BYN!150^>.(BP!P0N>I'H*M67B*_O?N!H2!FCG+!SV;IS';G<~!F3C.M%~2FU9\$9F56!9;H!Z5S>M^+?
!~UF^2TM"!LH!Q)(X1&R<5)ZM!5EP>~(T.MWQ.XEGEL)G;NV;..64-DW!9!L_0=<4=P)\$+E.P+CDK6D4ZO!3QWL'MGJ.MVHVIL(!3)
!B1!)O.P&W(XXR.UT>B^+&G5;NVBDT!MX.F(S!SLOR!>H#~L2.M.U_2T5B.KXA2QU6UTEFWC\$~HW*~)~\$6VC804DUSOBCQA<1>~M.%!\$!KY
42.M!Y!Q=RA&HC%>=!S!RYM!U;7;?%~HSZ-IDDOF>P.MMYD+BOC<^M7N@P*Y!&8M+74FU2PFML#82BD.90_"E<~%7!%UZYU!GM
MKG2;J9.S2AUDD&4<~!\$ZB@#6~W;G;L?#;3!PX!4W60.12CTZ#XE7FEW9RW.M220YCCG+&X?PHZG!ZTS2-6NO!N!..M.OFM!V!5C;A("'
C.U&J9/Y4>MCT5RUOXFU&N#9P.3MOH8EDN8D!B.MG"ANYP*BA!;J!TY=..TH&O/0AW.MJ2!IRM.C0!U!U%DO?'#Z;.4AN.M!-
E^UY"QR.J*~M&W!>?HHT=C17)XS9=LYDLFN;J#M!;S5=5QR.V" M*EMO%TEU:6!TFZM!1N1(PMYUV!53?7).NDD?
6W@#18HHYAF^17!HS3@P!C(M!~7G!7\$~#IYG375FC+!+J+G<~!@<#!J^~#M!T\$W=H!ZW.E\$TLO.M=BS;G(.V."@#0.\$~\$W!-
PW8SC<~?~WCG6!A.Y0V.M(Y?#M;D*98-L&2<=MN?&~P+&C3KM!NTEFO7>.&0!A49R0>2#0!UE%<1)X^FM=&GU2!THH;1^Q.MW;"0%HWV
AV*~.4DOCC'4.M~LP6VB!NF&)&#X.J.N!^<^~.U_8>AD!L.N.M-&N>:~7G".IEQXTM/\$\$+\$0/HSQWNI&VEMY"IM.MH&Y92#TZ=*~2**XY?
&EXWB;1T=&=IK..*~75S+&PY!<46WCHR\$W4YDW.ML>EX=M?E\$J+GYB?OXH!&BN!L?&5Q?O4T~%&K)!L4!J!\$+M.R.D.WNU;'
MA'6;GQ;X!M!3N84B*U+T+O0?X3Z^!&JVH6:*6>Z45!U><+>+>#%~LZ*XFY=W4=J!O#HTA.LZR2!N;M<~0&14C!U*EE!=
!5L\$=B!37UNL!N3Y.MG^~TW<~J~.N6.Y^C5U+HY.M0!H>?%W'B6S734/\$-U!FQ!R.TT!1.P7~@^A!TSXBGM40CL!ZSV~#9KXZ4-6Z***
"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **YK6?#-OK6L+//>PBP^S26!6-D.M9);2R+1Q;l63C+~!V!CTK+!F!M7!%KHAH#ML^9!M(!N*!ND(!&~.B@#RK08!HNE6-
!O~E);SN8-M?<N2'_>D!8!8#!7Z9K;O_FH7^G:O8Q.S!9ZG<~.MC6N7C8L!1NW#/?3%=P.ML\$~8VQ(N.1A14E+WA^Y.Q59.P;Y+MK1K
5RY)SNW9X!<8JSJ&BM=ZU8.M.G#=-!+AD=NY94;JH.0#GVK6HH.Y.Z!R76G7T37R;+Z=HIS%Q!F.H5.M<8.ZUTL"2!BS.KR.P8
M'S9YX!5^VTZ.VO;RZ&#)0.P!K'M5.MY!;KR<<50Q.M"VN!H.MK<~>^5M1N9DF2X6\$1%#!@~"Y^N>>?4.MY.<!UN44
8MWSHUB<~\$;000"!VCO\$~"KGGH"Y:X8U#2)C;6&I0KH!M2-(UM+&E!F.6.DW#)!^ZFB@#F\$.W^A7!M=40Z!YC2);M;YD7<<!F;ST.MR?
2K/A_1+S0U>W.H+/9>9!<9APR.FW;L!XR>W>MVB@#D!4!#P.CJ6J\$O=\$.M6VJPK%=PE.3M&*&MGCL;G.X15!FXTS!?
>^=Z9L.WB"8W2\$~.G!>..U=+10!MD;H-SJH0!%!>BV?2AW!3>LBC^&G!#PMH\$~ARPGL!+X74!E:6<4\$9.QR0<~M!Y^E.U%
FVA6.GB6'Q190ZH(K';4I8Y56;-(5*-ALXY<~<=JZO^P+&BTO.M+&C2!U;R=X^OYV!F!TQ5#6_"!ZO=2S+&P!F(20&~8P^S/=<!~M.Z.B@#D9?
Z7H!U^T+U!OMUK!;~%3;MV=&!)YJW<~%O.W3KF!NVE.FJWV7Y<~M88KMW.SSQ!Z.B@#BO!A!FM!TW38!08187?VL\$Q9+X)(7KQR.Y?7
1F.SAM!M.&=)T=1GE3D.CN*JKX;E;4=10)K!F!L.BW9%3-7.ON?/7FN@HH.Y"~T!\$R.MZ.UA;8;K)%=VUN+62!TW+~\$#D.KG
(!ZN)!6%5D<~X&&~.GZ5!10!Q5?#R.MQ^<)>?7^K!M.Y"1^Y+?24?I+<15H.CX7_&K6N!ZJ\$UA9%?I4/EZC>!/0.1C%D.M#!MHP"~#U!K=HH
Y!6-#)UUYXKBY3!%#B@PF!E<~#9X.9MU.K&J!N!6GN.N-MX?I.M#R&P#CRGB&#8>IX%=G10;Q^H>!WUFI!MH5U!A(;6V;-8@N!7&~2?7
MH?PK8T32+S24\$N!J27=K&@2%)\$ 90/5AU.2MBB@#)OM.MKW6K/5!S!VHEHK(G
MCH5;J"/PK^U+P+%J\$&J;OX!G5"HN9!F247!J@9P>M=-10!7M89H.58IYA*MX&"X7;G!Y2?P+<3Z4FFG69!;Q7GV!)?)7*X?>%)!JZ!B@#EK_&
&KJHU.M7UZI"~!\$S&NTQ!&S&M02!Z!H!RKN!^UL!NOY>T@5>HH.P9?#LC^~!C=COF.M1.(6WAK8!~FD)?#MJECKN8#8!6X*
!EZ;Z!UAWNF0;3X@!~6%E<~"VZ&X>20@%&I9.HR?Y5W~.~M'8.R*6'0D7!5VZ7E.MR!HO*AE6;2P@5MT4?I9/Y?#M!M.M8@XQ!/\$>A2>
(+~*T^VO;0B57E"~?7D\$~L<@69)MYUY*Q&#D="~*~K7A?J!N!O.C4!C=6!9E944*Y88.1!Z*~B@#C!SP!M=M?Z>Z?J!HEWY!J?;!G-7)!&00'
X'Y53TV"2Y!8^)+."DARL0!~OOL.SGZ.M<8KO*~(T5RX50QZD#DT*Z%+!Y?2TF;@C&*ZVB@#B!6!T?B6.UKSI6DO;=+>6(G
MY=JY.7FP!IX>VTZ?26U6>3290Z.9BHR\$~.5W=<@!FA\$~0%54SQW"6G!H&EV@&J!C8!UQQWK)89?Y~PD13QD
M8Z^!>+10!S3^#H)5UB^!&W;L!K;R!<~*1Q!&4!J.C!0W;=510!RLG@2PGJ+<3SRI?B;~!1B.R!N8!DC.Y!>=>8!N
MYM+HJ?I39PM"!~%&9AC=CN;VZ~.8.X0NU^R!+UY~.~E\$T!+&D#H>.E7.M!\$353<~E!\$K>1+<9M874!HHH~"JOX?Q'#I^V*9&MXS"/F0
M@<~D45YQJ5H^~K6YD0^+L<46F"2.9E!H.MMO4N6&1CHUU!<2P^"YWU~.MHS!IC&W<<<~!VH.WJ*!SL;Z!P"~\$8TKO.M!%K!<~
=S0_6WF@#78!+7!BXFTT?;2.K!&~RN!W%7M!U)!>?>D*M=4E9-0TH9X!Y03N-7!HCR?2@#L!NWO&~XDM!9G5F~889><(KBPTW4(;?
499H.768X=V_2?Y+&\$~M!JW^Z!YH!3HKE_#%0>+J!H\$O>WDBU9!T2=@HW=5X?L-2.U.R;C!0M!G!MH54_(Q.Z.M9-
=X20%QECOF!7OVD6MR!;~\$MN8+VR>6@#J!~YUC6&A!76QC!N!B98!0BAF.M96VQ!P.4!G!H2?>N@!<~!L@!L%~=&N(XY!E4DQOD_>~<=<=Z
FH)ZG.M%<)>SYNG6%O=Z=KES;KJ4'G.TV!1CA@3=QS6-?^!Q!U+QD!J!~!BW>#
MYU(L.E;INGM0;ZH!7GVJ6VLE<7>267C'2=.TFX>ZL!H&O&O6.GE!HQ.MG)~M0^/?%#Z!X6BDO)8+M>6!J99-
LFP\$~1T!YQ!U6F;H=0G086MYA;U6.1W.#NXX&Y56G7FV!56GX.MJOX-5E!H-UDC.A.Q@BC)ZY-
GU34=6U*.VN=F540;R2T.W"6LLXEE\$&/_EF#.\$?;L;7!A!P+=S&FBE6V.+GA~MW8X!/0DUSD5U;VMCH5PNN337-W=P&?
S!AB4QM0V"3B@#T;~%8WA!Q*~X@.MH!~%~3V.RUM*~KD!Y@>#ZEW-!K5POV+4!IX!P.G*EY.L@9\$C3^!<~M5D(7LK/OEJE!
W!M!&ZPK(JR.C^~D\$QEKM(Q!U)WLW=U+H@<~U5Y2.R;#J!U>A!6!P\$~VMW.M0~&L;BX..36DZE46QZX)=!M!35S<72W\$S;Q0B3;(Y!C
MM+MU&U!<~7)!~02%~H!B2!JFN+>W81W!JN2&4+N/NH!>~SW.L55#&ELB.M2#J&\$!S5G>?7#6~G!SH;#4!N*XDN&FF@GN-
Q".#PPZ8!~YNVU.XG!7!B.M"YU2Y!M!\$;+<~0OE>~%(VCC!4GJ*~9;~!MN!10!6U75H+&ZE.IV!ZD.4L.M\$P\$=O\$0"
<@!\$XSUIYKLO\$MP^>?%Y)FOI8A\$%#S!0689.OGH_@O@~#H*!ZE@O.M8Z;&~!\$&~E!#~.FN-
^FJ0W~\$SK5C'8S'RX!P10^;US0!WNDZDFK.3.ZA&C!H<M1B0(W5<1C5*?7Q!XLM~.K(3;+IU3!>D.FROFXV;2P8_?2>^1^?6@#TH;~
M@<~CV!H!HYN!T6PT~*R4KH37=Y+~%~#HD9Y.P4\$Y^O<9R.9K!2AH=QJ?@M&YGDEG@GEA!FG+J!8A0WX8H!P^C-
>77^KV!BK3)P"TI7N8M2^RWDC.44*R.MG^~7G&W./FK)EN?~T740\$)U>~!AUP102O.P41^8H*!~ND8)!4>SUE6.MK>
M;YJ.EF!HY+!+8=Y8\$;K#@<CTHUQ+Z4>~W>49_!8!2=;X!GMO!H!1FN;!)1V!6L!EEK.MU&VE<~C;DC(&~22>>O)K"FM9.4UCY(=<=>Y3!&=VG+&
!Q8C9W*5.&Y!~W5Y!GRH@<~+NP.DDGH!E.M.6NEFIU!9A%W2@ON">V>J><0.MLFL7_A_~(2)!5ODMW.H64QE&8)~NVXY(^M=+!0%2!
LK3ALE.U74(GNF09.GRQ@!EO;~..X!3VUGHS.M=QRO6A95A#KAY!QP.V3C^>~!@!UW>6EY.R6T!MM\$).
!@!9!@CO!5SY@M_.\$%UKNG7%U+!H!NT4-R7XAF&6(4^BX4!^M7!H!CO+MWQ+>7MP9'MK>W6TAE=0!<~(9G!X%
%G.A+X!H!A0!#3;Z!DG#B.W6!VY#M@AL!>!5T!>6.^F0SP0R&!EN?L2V!*ZSXR4!T%6/\$?B3M"\$5E.VTL!VX4^M2TYPI#N!Q_P
!FL>2_#HJ>%Q!V!OAK6!^UOJ&X&?&C;T!1O^~&A@>+>~MTM&EFLYO@NEM;N%;T3-T!C!O#D59U^Q4^F.S965S!5T+!E\$~72X*B0!@\$=
M<=>!5?^YD0+~ZIK_~ZA.LD4.VOCY;O9?~%0>~>2.30!MVN;UP%Q?ZE0!<~SNM4NA#~RQP!<~\$~\$HW<8?~XYQ^<~
!6Y!6M1#;8XRS@^~HZ;/05Y&=4N+N67560H?MGFLZE7(;~M*\$X

[illegible]

Area Code or City

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_CityAreaCode Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Cover page:

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_CoverAbstract Namespace Prefix:dei_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

End date of current fiscal year in the format --MM-DD.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_CurrentFiscalYearEndDate Namespace Prefix:dei_ Data Type:xbrli:gMonthDayItemType Balance Type:na Period Type:duration

[- Definition](#)

Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_DocumentFiscalPeriodFocus Namespace Prefix:dei_ Data Type:dei:fiscalPeriodItemType Balance Type:na Period Type:duration

[- Definition](#)

This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_DocumentFiscalYearFocus Namespace Prefix:dei_ Data Type:xbrli:gYearItemType Balance Type:na Period Type:duration

[- Definition](#)

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_DocumentPeriodEndDate Namespace Prefix:dei_ Data Type:xbrli:dateItemType Balance Type:na Period Type:duration

[- Definition](#)

Boolean flag that is true only for a form used as an quarterly report.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-Q-Number 240-Section 308-Subsection a>

[+ Details](#)

Name:dei_DocumentQuarterlyReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- Definition](#)

Boolean flag that is true only for a form used as a transition report.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Forms 10-K, 10-Q, 20-F-Number 240-Section 13-Subsection a-1>

[+ Details](#)

Name:dei_DocumentTransitionReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- Definition](#)

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other':

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_DocumentType Namespace Prefix:dei_ Data Type:dei:submissionItemType Balance Type:na Period Type:duration

[- Definition](#)

Address Line 1 such as Attn, Building Name, Street Name

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressAddressLine1 Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Address Line 2 such as Street or Suite number

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressAddressLine2 Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Name of the City or Town

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressCityOrTown Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Code for the postal or zip code

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressPostalZipCode Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Name of the state or province:

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressStateOrProvince Namespace Prefix:dei_ Data Type:dei:stateOrProvinceItemType Balance Type:na Period Type:duration

[- Definition](#)

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityCentralIndexKey Namespace Prefix:dei_Data Type:dei:centralIndexKeyItemType Balance Type:na Period Type:duration

-Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+References

No definition available.

+Details

Name:dei_EntityCommonStockSharesOutstanding Namespace Prefix:dei_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

-Definition

Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+References

No definition available.

+Details

Name:dei_EntityCurrentReportingStatus Namespace Prefix:dei_Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

-Definition

Indicate if registrant meets the emerging growth company criteria.

+References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+Details

Name:dei_EntityEmergingGrowthCompany Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

-Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+References

No definition available.

+Details

Name:dei_EntityFileNumber Namespace Prefix:dei_Data Type:dei:fileNumberItemType Balance Type:na Period Type:duration

-Definition

Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+Details

Name:dei_EntityFilerCategory Namespace Prefix:dei_Data Type:dei:filerCategoryItemType Balance Type:na Period Type:duration

-Definition

Two-character EDGAR code representing the state or country of incorporation.

+References

No definition available.

+Details

Name:dei_EntityIncorporationStateCountryCode Namespace Prefix:dei_Data Type:dei:edgarStateCountryItemType Balance Type:na Period Type:duration

-Definition

Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such

~~Rule 405 or Regulation S-1 during the preceding 12 months (or for such shorter period that the registrant was required to submit such files);~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Regulation-S-T-Number-232-Section-405>~~

[+ Details](#)

~~Name:dei_EntityInteractiveDataCurrent_Namespace Prefix:dei_Data Type:dei:yesNoItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC;~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>~~

[+ Details](#)

~~Name:dei_EntityRegistrantName_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>~~

[+ Details](#)

~~Name:dei_EntityShellCompany_Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~Indicates that the company is a Smaller Reporting Company (SRC).~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>~~

[+ Details](#)

~~Name:dei_EntitySmallBusiness_Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>~~

[+ Details](#)

~~Name:dei_EntityTaxIdentificationNumber_Namespace Prefix:dei_Data Type:dei:employerIdItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~Local phone number for entity.~~

[+ References](#)

~~No definition available.~~

[+ Details](#)

~~Name:dei_LocalPhoneNumber_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

[- Definition](#)

Title of a 12(b) registered security:

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b>

[+ Details](#)

Name:dei_Security12bTitle Namespace Prefix:dei Data Type:dei:securityTitleItemType Balance Type:na Period Type:duration

[- Definition](#)

Name of the Exchange on which a security is registered:

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-d1-1>

[+ Details](#)

Name:dei_SecurityExchangeName Namespace Prefix:dei Data Type:dei:edgarExchangeCodeItemType Balance Type:na Period Type:duration

[- Definition](#)

Trading symbol of an instrument as listed on an exchange:

[+ References](#)

No definition available:

[+ Details](#)

Name:dei_TradingSymbol Namespace Prefix:dei Data Type:dei:tradingSymbolItemType Balance Type:na Period Type:duration XML 28 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) - USD (\$) \$ in Millions Sep. 30, 2024Dec. 31, 2023Current assets: Cash and cash equivalents\$ 85.2\$ 311.7Restricted cash0.05.5Marketable securities1,036.4949.3Accounts receivable7.30.0Other receivables7.57.2Prepaid expenses and other current assets13.16.5Total current assets1,149.51,280.2Property, equipment and leasehold improvements, net6.811.5Operating lease right of use assets1.02.5Collaboration contract asset and other assets9.810.4Total assets1,167.11,304.6Current liabilities: Accounts payable and accrued liabilities75.992.2Deferred revenue199.2163.0Current portion of operating lease liabilities0.81.9Total current liabilities275.9257.1Deferred revenue304.5386.2Long-term debt0.60.8Operating lease liabilities0.10.5Total liabilities581.1644.6 Commitments and Contingencies (Note 13) Stockholders' equity: Preferred stock, \$0.001 par value, zero shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively0.00.0Common stock, \$0.001 par value; 68.7 and 68.0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively0.10.1Accumulated deficit(1,486.5)(1,332.7)Additional paid-in capital2,068.31,995.7Accumulated other comprehensive income (loss)4.1(3.1)Total stockholders' equity586.0660.0Total liabilities and stockholders' equity\$ 1,167.1\$ 1,304.6

[- Definition](#)

Collaboration contract asset and other assets:

[+ References](#)

No definition available:

[+ Details](#)

Name:arvn_CollaborationContractAssetAndOtherAssets Namespace Prefix:arvn Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

[- Definition](#)

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits:

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(19\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: <http://www.xbri.org/2009/role/commonPracticeRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2>

+ Details

Name:us-gaap_AccountsReceivableNetCurrent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 14A-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-11>Reference 3: [http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: [http://www.xbri.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\(a\)\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbri.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(23)(a)(3))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 14-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14>

+ Details

Name:us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(30\)\(a\)\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(30)(a)(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

+ Details

Name:us-gaap_AdditionalPaidInCapital_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-48-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-49-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(ee\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(ee)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22>

~~50-22Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 12: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(12\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-03(a)(12))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-599-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.6-04\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.6-04(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-599-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.5-02\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-03\(11\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-03(11))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-599-1)~~

+ Details
Name:us-gAAP_Assets **Namespace Prefix:**us-gAAP_ **Data Type:**xbrl:monetaryItem **Type:**Balance **Type:**debit **Period Type:**instant

- Definition

Amount of asset recognized for present right to economic benefit, classified as current.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(bb\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(bb)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-10-45-25)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(g\)\(1\)\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(g)(1)(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 6:** <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 7:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483467/210-10-45-1>**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(9\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(9))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-600-Paragraph-1A-Subparagraph-\(SX-210.12-01\(e\)\(1\)\(v\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-600-Paragraph-1A-Subparagraph-(SX-210.12-01(e)(1)(v))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Subparagraph (SX 210.13-01(a)(4)(i)) - Publisher FASB - URI~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 470 -~~
~~[SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) - Publisher FASB -](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~[URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 470 -~~
~~[SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) - Publisher FASB](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~[-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 -~~
~~[SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) - Publisher](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~[FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 -~~
~~[SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) - Publisher FASB](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~[-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 -~~
~~[SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph \(SX 210.13-01\(a\)\(5\)\) - Publisher FASB -](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~[URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic~~
~~[10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) - Publisher FASB -URI](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 -~~
~~[Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) - Publisher FASB -URI](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 -~~
~~[Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) - Publisher FASB -URI](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 -~~
~~[Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) - Publisher FASB -URI](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 -~~
~~[Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph \(SX 210.13-02\(a\)\(5\)\) - Publisher FASB -URI](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 852 -~~
~~[SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 7 - Subparagraph \(a\) - Publisher FASB -URI](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~
~~<https://asc.fasb.org/1943274/2147481404/852-10-50-7>~~

[+ Details](#)

Name:us-gaap_AssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AssetsCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>

[+ Details](#)

Name:us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(17\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(17))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(15\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(15))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>

+Details

Name:us-gaap_CommitmentsAndContingencies Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>

+ Details

Name:us-gaap_CommonStockValue_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479837/606-10-45-2>

+ Details

Name:us-gaap_ContractWithCustomerLiabilityCurrent_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479837/606-10-45-2>

+ Details

Name:us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(26\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 11: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(14\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 22: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 24: [http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)

Name:us-gaap_Liabilities_Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(32\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(32))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

+ Details

Name:us-gaap_LiabilitiesAndStockholdersEquity_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 8:** <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-5>**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 11:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 20:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)**Reference 21:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)

[+ Details](#)
Name:us-gaap_LiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[- References](#)

No definition available.

[+ Details](#)
Name:us-gaap_LiabilitiesCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)

[+ Details](#)

Name:us-gaap_LongTermDebtNoncurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of investment in marketable security, classified as current.

[+ References](#)

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.5-02\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)

[+ Details](#)

Name:us-gaap_MarketableSecuritiesCurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1)

[+ Details](#)

Name:us-gaap_OperatingLeaseLiabilityCurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1)

[+ Details](#)

Name:us-gaap_OperatingLeaseLiabilityNoncurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of lessee's right to use underlying asset under operating lease.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1)

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAsset_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.

+ References

No definition available.

+ Details

Name:us-gaap_OtherReceivablesNetCurrent_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) -Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(21\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(21))) -Publisher FASB-URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>

+ Details

Name:us-gaap_PreferredStockValue_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(9\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(9))) -Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit

Period Type:instant

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 3: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 360-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1>

+ Details

Name:us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>

+ Details

Name:us-gaap_RestrictedCashCurrent_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(3))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(2\)\(i\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(2)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(h\)\(2\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (h)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(23)(a)(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(17\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(17))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>

+ Details

Name:us-gaap_RetainedEarningsAccumulatedDeficit **Namespace Prefix:**us-gaap_ **Data Type:**xbrl:monetaryItemType **Balance Type:**credit **Period Type:**instant

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 5:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)**Reference 8:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 11:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 12:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 13:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 14:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2)

+ Details

Name:us-gaap_StockholdersEquity_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_StockholdersEquityAbstract_Namespace Prefix:us-gaap_Data Type:xbri:stringItemType Balance Type:na Period Type:duration XML 29 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - \$ / shares shares in Millions Sep. 30, 2024Dec. 31, 2023Statement of Financial Position [Abstract] - Preferred stock par value (in dollars per share)\$ 0.001\$ 0.001Preferred stock, shares issued (in shares)0.00:0 Preferred stock, shares outstanding (in shares)0.00:0Common stock, par value (in dollars per share)\$ 0.001\$ 0.001Common stock, shares issued (in shares)68.768:0Common stock, shares outstanding (in shares)68.768:0

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

+ Details

Name:us-gaap_CommonStockParOrStatedValuePerShare_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

+ Details

Name:us-gaap_CommonStockSharesIssued_Namespace Prefix:us-gaap_Data Type:xbri:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-05(4)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7)) -Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)

[+ Details](#)

Name:us-gaap_CommonStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[- Definition](#)

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>

[+ Details](#)

Name:us-gaap_PREFERREDStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:

na-Period-Type:instant

-Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>

+Details

Name:us-gaap_PreferredStockSharesIssued Namespace Prefix:us-gaap Data Type:xbrli:sharesItemType Balance Type:na-Period-Type:instant

-Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>

+ Details

Name:us-gaap_PreferredStockSharesOutstanding **Namespace Prefix:**us-gaap_ **Data Type:**xbri:sharesItem**Type Balance Type:**na **Period Type:**instant

- References

No definition available.

+ Details

Name:us-gaap_StatementOfFinancialPositionAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbri:stringItem**Type Balance Type:**na **Period Type:**duration **XML 30 R4.htm IDEA:**XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD (\$) shares in Millions, \$ in Millions	3 Months Ended	9 Months Ended
Sep. 30, 2024		
Sep. 30, 2023		
Sep. 30, 2024		
Sep. 30, 2023		
Income Statement [Abstract]		
Revenue\$ 102.4\$ 34.6\$ 204.2\$ 121.6		
Operating expenses:		
Research and development86.985.9264.9284.5		
General and administrative75.822.6131.373.3		
Total operating expenses162.7108.5396.2357.8		
Loss from operations(60.3)(73.9)(192.0)(236.2)		
Other (expense) income		
Other expense, net(2.6)0.0(2.7)(1.1)		
Interest income, net14.310.041.926.6		
Total other (expense) income11.710.0		
39.225.5		
Net loss before income taxes and loss from equity method investment(48.6)(63.9)(152.8)(210.7)		
Income tax (expense) benefit(0.6)		
0.0(1.0)0.7		
Loss from equity method investment0.0(0.1)0.0(2.5)		
Net loss\$ (49.2)\$ (64.0)\$ (153.8)\$ (212.5)		
Net loss per common share, basic (in dollars per share)\$ (0.68)\$ (1.18)\$ (2.14)\$ (3.97)		
Net loss per common share, diluted (in dollars per share)\$ (0.68)\$ (1.18)\$ (2.14)\$ (3.97)		
Weighted average common shares outstanding, basic (in shares)72.154.171.953.6		
Weighted average common shares outstanding, diluted (in shares)72.154.171.953.6		
Condensed Consolidated Statements of Comprehensive Loss		
Net loss\$ (49.2)\$ (64.0)\$ (153.8)\$ (212.5)		
Other comprehensive loss:		
Unrealized gain on available-for-sale securities7.93.07.210.0		
Comprehensive loss\$ (41.3)\$ (61.0)\$ (146.6)\$ (202.5)		

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(26\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-599-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5>

[+ Details](#)

Name:us-gaap_ComprehensiveIncomeNetOfTax_Namespace Prefix:us-gaap_Data Type:xbrl:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)**Reference 12:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)**Reference 14:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 20:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>

+ Details

Name:us-gaap_EarningsPerShareBasic_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-599-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>

[+ Details](#)

Name:us-gaap_EarningsPerShareDiluted Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

[- Definition](#)

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)

[+ Details](#)

Name:us-gaap_GeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- Definition](#)

Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.

[+ References](#)

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22>-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>**Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>****Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>****Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>****Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>****Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>****Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(8\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(8)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>****Reference 8: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31>-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31>**

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix:us-gaap_ Data Type:xbrl:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of income (loss) for proportionate share of equity method investee's income (loss).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)
Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)
Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(10\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(10))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147481664/323-10-45-1>
Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)
Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(12\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(12))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)
Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(13\)\(f\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(13)(f))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)

+ Details

Name:us-gaap_IncomeLossFromEquityMethodInvestments_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncomeStatementAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 231-Publisher FASB-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.1.7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph \(a\)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (a)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h))-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)

+ Details

Name:us-gaap_IncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-48-Publisher-FASB-URI-https://asc.fasb.org/1042274/2147492795/280-10-55-48>Reference 2: <http://www.xbrl.org/2000/role/commonPracticeRef>

~~**Publisher FASB - URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(7)(b))-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>**~~

+ Details

Name:us-gaap_InvestmentIncomeInterest **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef>-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 250-SubTopic 10-

Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>

+ Details

Name:us-gaap_NetIncomeLoss_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(7\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(7)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>

+ Details

Name:us-gaap_NonoperatingIncomeExpense_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:us-gaap_OperatingExpenses_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OperatingExpensesAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 33-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-33](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 33-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-33)

~~30-Subparagraph (b)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>~~

+ Details

Name:~~us-gaap_OperatingIncomeLoss~~ **Namespace Prefix:**~~us-gaap_~~ **Data Type:**~~xbri:monetaryItemType~~ **Balance Type:**~~credit~~ **Period Type:**~~duration~~

- Definition

Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.

+ References

Reference 1: ~~<http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>~~ **Reference 2:** ~~<http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 20-SubTopic 10-Topic 810-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-20>~~ **Reference 3:** ~~[http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph \(c\)\(3\)-SubTopic 10-Topic 810-Publisher FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph (c)(3)-SubTopic 10-Topic 810-Publisher FASB-URI)~~

<https://asc.fasb.org/1943274/2147481203/810-10-50-1A>

+ Details

Name:us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(9\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(9))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>

+ Details

Name:us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 912-SubTopic 730-Name Accounting Standards Codification-Section 25-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479532/912-730-25-1>

[+ Details](#)

Name:us-gaap-ResearchAndDevelopmentExpense **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 5:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 6:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 11:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)**Reference 21:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 23:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)**Reference 26:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 500-Paragraph 2>

[+ Details](#)

Name:us-gaap_Revenues Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

[+ References](#)

Reference 1: http://www.xbrl.org/2002/role/disclosureRef_Topic_260_SubTopic_10_Name_Accounting_Standards_Codification_Section_50

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 16-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16>~~

+ Details

~~Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType-Balance Type:na-Period Type:duration~~

- Definition

~~Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.~~

+ References

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>~~

+ Details

~~Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType-Balance Type:na-Period Type:duration XML 31 R5.htm IDEA: XBRL DOCUMENT~~

~~Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) - USD (\$) shares in Millions, \$ in Millions~~

	Total Common	Accumulated	Additional	Accumulated Other
	Deficit	Paid-in Capital	Comprehensive (Loss) Income	
~~Beginning balance (in shares) at Dec. 31, 2022~~	~~53.2~~	~~Beginning balance at Dec. 31, 2022~~	~~\$ 564.9\$ 0.1\$ (965.4)\$ 1,549.4\$ (19.2)~~	~~Increase (Decrease) in Stockholders' Equity [Roll Forward]~~
~~Stock-based compensation~~	~~54.9~~	~~54.9~~	~~Net loss (212.5) (212.5)~~	~~Issuance of common stock under equity incentive plans (in shares) 0.3~~
~~Issuance of common stock under equity incentive plans~~	~~3.9~~	~~3.9~~	~~Common stock issued, net of issuance costs (in shares) 1.5~~	~~Common stock issued, net of issuance costs 36.0~~
~~Common stock issued, net of issuance costs~~	~~36.0~~	~~36.0~~	~~Unrealized gain on available-for-sale securities 10.0~~	~~Ending balance (in shares) at Sep. 30, 2023~~
~~Ending balance (in shares) at Sep. 30, 2023~~	~~55.0~~	~~Ending balance at Sep. 30, 2023~~	~~457.2\$ 0.1(1,177.9)1,644.2(9.2)~~	~~Beginning balance (in shares) at Jun. 30, 2023~~
~~Beginning balance (in shares) at Jun. 30, 2023~~	~~53.4~~	~~Beginning balance at Jun. 30, 2023~~	~~463.6\$ 0.1(1,113.9)1,589.6(12.2)~~	~~Increase (Decrease) in Stockholders' Equity [Roll Forward]~~
~~Stock-based compensation~~	~~16.7~~	~~16.7~~	~~Net loss (64.0) (64.0)~~	~~Issuance of common stock under equity incentive plans (in shares) 0.1~~
~~Issuance of common stock under equity incentive plans~~	~~1.9~~	~~1.9~~	~~Common stock issued, net of issuance costs (in shares) 1.5~~	~~Common stock issued, net of issuance costs 36.0~~
~~Common stock issued, net of issuance costs~~	~~36.0~~	~~36.0~~	~~Unrealized gain on available-for-sale securities 3.0~~	~~Ending balance (in shares) at Sep. 30, 2023~~
~~Ending balance (in shares) at Sep. 30, 2023~~	~~55.0~~	~~Ending balance at Sep. 30, 2023~~	~~\$ 457.2\$ 0.1(1,177.9)1,644.2(9.2)~~	~~Beginning balance (in shares) at Dec. 31, 2023~~
~~Beginning balance (in shares) at Dec. 31, 2023~~	~~68.0~~	~~Beginning balance at Dec. 31, 2023~~	~~\$ 660.0\$ 0.1(1,332.7)1,995.7(3.1)~~	~~Increase (Decrease) in Stockholders' Equity [Roll Forward]~~
~~Stock-based compensation~~	~~64.9~~	~~64.9~~	~~Net loss (153.8) (153.8)~~	~~Issuance of common stock under equity incentive plans (in shares) 0.7~~
~~Issuance of common stock under equity incentive plans~~	~~7.7~~	~~7.7~~	~~Unrealized gain on available-for-sale securities\$ 7.2~~	~~Ending balance (in shares) at Sep. 30, 2024~~
~~Ending balance (in shares) at Sep. 30, 2024~~	~~68.6~~	~~Ending balance at Sep. 30, 2024~~	~~\$ 586.0\$ 0.1(1,486.5)2,068.34.1~~	~~Beginning balance (in shares) at Jun. 30, 2024~~
~~Beginning balance (in shares) at Jun. 30, 2024~~	~~68.6~~	~~Beginning balance at Jun. 30, 2024~~	~~\$ 600.2\$ 0.1(1,437.3)2,041.2(3.8)~~	~~Increase (Decrease) in Stockholders' Equity [Roll Forward]~~
~~Stock-based compensation~~	~~24.7~~	~~24.7~~	~~Net loss (49.2) (49.2)~~	~~Issuance of common stock under equity incentive plans (in shares) 0.1~~
~~Issuance of common stock under equity incentive plans~~	~~2.4~~	~~2.4~~	~~Unrealized gain on available-for-sale securities\$ 7.9~~	~~Ending balance (in shares) at Sep. 30, 2024~~
~~Ending balance (in shares) at Sep. 30, 2024~~	~~68.6~~	~~Ending balance at Sep. 30, 2024~~	~~\$ 586.0\$ 0.1\$ (1,486.5)\$ 2,068.3\$ 4.1~~	

- Definition

~~Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-12>~~

+ Details

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue **Namespace Prefix:**us-gaap **Data Type:**xbrl:monetaryItemType **Balance Type:**credit **Period Type:**duration

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)**Reference 4:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)**Reference 6:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)

[+ Details](#)

Name:us-gaap_CommonStockSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInStockholdersEquityRollForward **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 13:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 17:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>**Reference 18:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 23:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 27:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 28:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 29:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)

~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI)~~
~~<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI)~~
~~<https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28>-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35:~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36:~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(22)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>~~

[+ Details](#)

Name:us-gaap_NetIncomeLoss **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>**Reference 2:** <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 20-SubTopic 10-Topic 810-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-20>**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph \(c\)\(3\)-SubTopic 10-Topic 810-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph (c)(3)-SubTopic 10-Topic 810-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A)

[+ Details](#)

Name:us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOffTaxPortionAttributableToParent **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

Number of new stock issued during the period.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)**Reference 7:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType
Balance Type:na **Period Type:**duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 8:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(d\)\(1\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (d)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

-Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2>

[+ Details](#)

*Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant
XML 32-R6.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) (Parenthetical) - USD (\$) 3 Months 9 Months
\$ in Millions Ended Ended
Sep. 30, 2023
Sep. 30, 2023
Statement of Stockholders' Equity [Abstract] - Issuance of common stock, offering costs\$ 1.1\$ 1.1*

[- Definition](#)

Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_StatementOfStockholdersEquityAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration **XML 33 R7.htm IDEA:** XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (unaudited) - USD (\$) \$ in Millions 9 Months Ended

Sep. 30, 2024

Sep. 30, 2023

Cash flows from operating activities: [Net loss](#) \$ (153.8) \$ (212.5) [Adjustments to reconcile net loss to net cash used in operating activities:](#) [Depreciation and amortization](#) 3.53 [6 Net accretion of bond discounts/premiums](#) (17.1) (11.6) [Loss on sale of marketable securities](#) 0.00 [9 Amortization of right-of-use assets](#) 1.51 [4 Amortization of collaboration contract asset](#) 3.62 [0 Net loss on disposal of property, plant and equipment](#) 2.60 [0 Stock-based compensation](#) 64.95 [4.9 Changes in operating assets and liabilities:](#) [Accounts receivable](#) (7.3) (14.7) [Other receivables](#) (0.3) [2.2 Prepaid expenses and other current assets](#) (6.4) [12.3 Collaboration contract asset](#) (3.0) [0.0 Accounts payable and accrued liabilities](#) (16.3) [16.0 Operating lease liability](#) (1.6) (1.5) [Deferred revenue](#) (45.5) (117.7) [Net cash used in operating activities](#) (175.2) (264.7) [Cash flows from investing activities:](#) [Purchases of marketable securities](#) (600.8) (665.7) [Maturities of marketable securities](#) 538.08 [73.4 Sales of marketable securities](#) 0.05 [2.3 Purchases of property, equipment and leasehold improvements](#) (1.5) (2.8) [Proceeds from disposal of property, equipment and leaseholds improvements](#) 0.10 [0 Net cash \(used in\) provided by investing activities](#) (64.2) 257.2 [Cash flows from financing activities:](#) [Repayments of long-term debt](#) (0.3) [0.0 Proceeds from issuance of common stock](#) 0.03 [7.1 Payment of common stock issuance costs](#) 0.0 (1.1) [Proceeds from exercise of stock options and issuance of ESPP shares](#) 7.73 [9 Net cash provided by financing activities](#) 7.43 [9 Net \(decrease\) increase in cash, cash equivalents and restricted cash](#) (232.0) 32.4 [Cash, cash equivalents and restricted cash, beginning of the period](#) 317.28 [6.8 Cash, cash equivalents and restricted cash, end of the period](#) 85.21 [19.2 Supplemental disclosure of cash flow information:](#) [Cash paid for taxes](#) \$ 1.6 \$ 9.1

[- Definition](#)

Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares

[+ References](#)

No definition available.

[+ Details](#)

Name:arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares **Namespace Prefix:**arvn_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Proceeds from maturities of marketable securities:

[+ References](#)

No definition available.

[+ Details](#)

Name:arvn_ProceedsFromMaturitiesOfMarketableSecurities **Namespace Prefix:**arvn_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Proceeds from sale of marketable securities:

[+ References](#)

No definition available.

[+ Details](#)

Name:arvn_ProceedsFromSaleOfMarketableSecurities **Namespace Prefix:**arvn_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.

~~item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.~~

[+ References](#)

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>~~

[+ Details](#)

~~Name:us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration~~

[-References](#)

~~No definition available.~~

[+ Details](#)

~~Name:us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration~~

[-Definition](#)

~~Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.~~

[+ References](#)

~~Reference 1: [http://www.xbri.org/2003/role/disclosureRef-Topic 340-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(b\)](http://www.xbri.org/2003/role/disclosureRef-Topic 340-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479483/340-40-50-3>~~

[+ Details](#)

~~Name:us-gaap_CapitalizedContractCostAmortization Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration~~

[-Definition](#)

~~Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.~~

[+ References](#)

~~Reference 1: <http://www.xbri.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4>~~

[+ Details](#)

~~Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:~~

xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 1-SubTopic 230-Topic 830-Publisher FASB-URI https://asc.fasb.org/1943274/2147477401/830-230-45-1>

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: [http://www.xbri.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbri.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9)

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1)

+ Details

Name:us-gaap_DepreciationAndAmortization_Namespace-Prefix:us-gaap_Data-Type:xbri:monetaryItemType Balance-Type:debit Period-Type:duration

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_GainLossOnSaleOfPropertyPlantEquipment_Namespace-Prefix:us-gaap_Data-Type:xbri:monetaryItemType Balance-Type:credit Period-Type:duration

- Definition

Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22>
Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2>

+ Details

Name:us-gaap_IncomeTaxesPaidNet_Namespace-Prefix:us-gaap_Data-Type:xbri:monetaryItemType Balance-Type:credit Period-Type:duration

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInAccountsReceivable_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInContractWithCustomerAsset_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 912-SubTopic 310-Name Accounting Standards Codification-Section 45-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478345/912-310-45-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 912-SubTopic 310-Name Accounting Standards Codification-Section 45-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478345/912-310-45-11)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-References

No definition available.

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of increase (decrease) in obligation for operating lease.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(g\)\(1\)-SubTopic 20-Topic 842-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(1)-SubTopic 20-Topic 842-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) in receivables classified as other.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase (decrease) in prepaid expenses, and assets classified as other.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

[+ References](#)

Reference 1: <http://www.xbri.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25>

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInOperatingActivities **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**na **Period Type:**duration

-References

No definition available.

+Details

Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

-Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 13:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 17:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>**Reference 18:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 23:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 27:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 28:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 29:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 30:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 31:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 32:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)**Reference 33:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>**Reference 34:** <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>**Reference 35:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)**Reference 36:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)**Reference 37:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType Balance Type:debit Period-Type:duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-15>-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15>

+ Details

Name:us-gaap_PaymentsOfStockIssuanceCosts_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType Balance Type:credit Period-Type:duration

- Definition

Amount of cash outflow for purchase of marketable security.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-11>-Publisher FASB-URI <https://asc.fasb.org/1943274/2147481830/320-10-45-11>

+ Details

Name:us-gaap_PaymentsToAcquireMarketableSecurities_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType Balance Type:credit Period-Type:duration

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-13-Subparagraph-\(c\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-13-Subparagraph-(c))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13>

+ Details

Name:us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType Balance Type:credit Period-Type:duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14>

+ Details

Name:us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph \(c\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph (c))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-12>

+ Details

Name:us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 15-Subparagraph \(b\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 15-Subparagraph (b))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>

+ Details

Name:us-gaap_RepaymentsOfLongTermDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_ShareBasedCompensation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 34 R8.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation9 Months Ended

Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business and Basis of Presentation

Nature of Business and Basis of Presentation

Arvinas, Inc. and its subsidiaries ("Arvinas" or the "Company") is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.

The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended ("Exchange Act"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission ("SEC") rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023, forming part of Arvinas' 2023 Annual Report on Form 10-K filed with the SEC on February 27, 2024.

The preparation of the Company's unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.

Risks and Uncertainties

The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company's products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.

To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately \$1.1 billion as of September 30, 2024.

- Definition

The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235/tableOfContent>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/275/tableOfContent>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/205/tableOfContent>

+ Details

Name:us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-References

No definition available.

+ Details

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 35 R9.htm IDEA: XBRL DOCUMENT Summary of Accounting Pronouncements and Significant Accounting Policies9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Summary of Accounting Pronouncements and Significant Accounting Policies Summary of Accounting Pronouncements and Significant Accounting Policies

Accounting Pronouncements

Recently Adopted Accounting Pronouncements

There have been no recently adopted accounting pronouncements that have had a material impact on the Company's unaudited condensed consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

Segment Reporting (Topic 280) *In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting-Improvements to Reportable Segment Disclosures," which requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures*

required by this ASU and all existing segment disclosures in Accounting Standard Codification ("ASC") 280, "Segment Reporting." The requirements of the ASU are effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact ASU No. 2023-07 will have on its condensed consolidated financial statements.

Income Taxes (Topic 740) *In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.*

Significant Accounting Policies

There were no changes to the Company's significant accounting policies during the nine months ended September 30, 2024.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023:

September 30, 2023

(dollars in millions) September 30, 2024

Cash and cash equivalents \$85.2; \$113.7 Restricted cash —; 5.5 ~~Cash, cash equivalents and restricted cash~~ \$85.2; \$119.2;

Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as was required under the terms of the Terminated Lease, as discussed below in Note 6.

Right-of-Use Assets and Liabilities:

- References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-1>**Reference 2:** <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235/tableOfContent>

+ Details

Name:us-gaap_SignificantAccountingPoliciesTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**XML 36 R10.htm **IDEA:** XBRL DOCUMENT **Research Collaboration and License Agreements 9 Months Ended Sep. 30, 2024**

Research Collaboration And License Agreements [Abstract] **Research Collaboration and License Agreements**
Research Collaboration and License Agreements

Novartis License and Asset Agreements

In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of ARV-766, the Company's second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of ARV-766 and has all research, development, manufacturing, and commercialization rights with respect to the Company's PROTAC® protein degrader targeting AR-V7, a splice variant of the AR.

In May 2024, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Novartis Transaction (the "HSR Termination"). As a result of the HSR Termination and satisfaction of other closing conditions, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of \$150.0 million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional \$1.01 billion as contingent payments based on specified development, regulatory and commercial milestones for ARV-766 being met, as well as tiered royalties based on worldwide net sales of ARV-766, subject to reduction under certain circumstances as provided in the

Novartis License Agreement. There were no development, regulatory or commercial milestone payments, or sales-based royalties received through September 30, 2024.

The Novartis License Agreement will expire on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.

The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be evaluated as a combined contract in accordance with ASC 606, Revenue from Contracts with Customers. The Company determined the fair value of the assets sold under the Novartis Asset Agreement to be \$20.0 million, which was recognized at the time of sale as revenue, and the fair value of the Novartis License Agreement to be \$130.0 million, which is being recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred.

As a direct result of the Company's entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling \$3.0 million. In accordance with ASC 340, Other Assets and Deferred Costs, the Company recognized an asset of \$3.0 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the Novartis License Agreement and the Novartis Asset Agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the Novartis License Agreement and the Novartis Asset Agreement.

Vepdegestrant (ARV-471) Collaboration Agreement

In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. ("Pfizer") (the "Vepdegestrant (ARV-471) Collaboration Agreement") pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company's proprietary compound vepdegestrant (the "Licensed Products"). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of \$650.0 million. In addition, the Company is eligible to receive up to an additional \$1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, \$400.0 million in regulatory milestones are related to marketing approvals and \$1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through September 30, 2024.

The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.

The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.

As a direct result of the Company's entry into the Vepdegestrant (ARV-471) Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling \$12.9 million. In accordance with ASC 340, Other Assets and Deferred Costs, the Company recognized an asset of \$12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the Vepdegestrant (ARV-471) Collaboration Agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the Vepdegestrant (ARV-471) Collaboration Agreement.

Bayer Collaboration Agreement

In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company's collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC® targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of \$17.5 million in exchange for the use of the Company's technology license. The Company also received an additional \$12.0 million from Bayer AG from inception through 2023, including \$1.5 million received during the nine months ended September 30, 2023. These payments are being recognized over the total estimated period of performance.

The Company was also eligible to receive up to \$197.5 million in development milestone payments and up to \$490.0 million in sales-based milestone payments for all designated target proteins. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. There were no development or sales-based milestone payments or royalties received through September 30, 2024.

Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024.

Pfizer Research Collaboration Agreement

In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling \$28.0 million in 2018 in exchange for use of the Company's technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional \$37.5 million in non-refundable option payments if Pfizer exercises its options for all target proteins under the Pfizer Research Collaboration Agreement.

The Company is also entitled to receive up to \$225.0 million in development milestone payments and up to \$550.0 million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the nine months ended September 30, 2023, the Company received payments totaling \$1.0 million for additional target proteins and services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received through September 30, 2024.

Restated Genentech Agreement

In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Restated Genentech Agreement") with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of \$34.5 million (in addition to \$11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period.

The Company is eligible to receive up to \$44.0 million per target protein in development milestone payments, \$52.5 million in regulatory milestone payments and \$60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through September 30, 2024.

Changes in the Company's contract balances for the nine months ended September 30, 2024 and 2023 were as follows:

	(dollars in millions) September 30, 2024									
September 30, 2023										
Accounts receivable related to collaborations	—	Beginning balance	\$1.0	—	—	—	—	—	—	—
payable related to collaborations	—	Beginning balance	\$13.1	\$5.0	—	—	—	—	—	—
Collaboration contract asset	—	Beginning balance	\$9.4	\$10.7	—	—	—	—	—	—
revenue	—	Beginning balance	\$549.2	\$623.7	—	—	—	—	—	—
		Revenue recognized from new collaborations	(93.5)	—	—	—	—	—	—	—
		Ending balance	\$503.7	(\$506.1)	—	—	—	—	—	—

During the nine months ended September 30, 2023, the Company changed its estimate of the duration of the performance period under the Bayer Collaboration Agreement and Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and net income of \$8.2 million and a decrease in net loss per share of \$0.15 for the nine months ended September 30, 2023. The reversed revenue related to the Bayer Collaboration Agreement was fully recognized through September 30, 2024. The reversed revenue related to the Pfizer Research Collaboration Agreement will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline. During each of the three months ended September 30, 2024 and 2023 and the nine months ended September 30, 2024, no changes in accounting estimates related to the Company's collaborations were recorded.

The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of September 30, 2024 totaled \$503.7 million, which is expected to be recognized in the following periods:

	(dollars in millions) Remainder of 2024 \$									
84.1	2025	153.4	2026	105.0	2027	57.6	2028	59.8	2029	43.8
		Total	\$503.7							

- Definition

Research Collaboration And License Agreements

+ References

No definition available.

+ Details

Name: arvn_ResearchCollaborationAndLicenseAgreementsAbstract Namespace Prefix: arvn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration

- Definition

The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Topic 808-Publisher FASB-URI https://asc.fasb.org/808/tableOfContent>

+ Details

Name:us-gaap_CollaborativeArrangementDisclosureTextBlock_Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 37 R11.htm IDEA: XBRL DOCUMENT
Marketable Securities and Fair Value Measurements9 Months Ended Sep. 30, 2024

Fair Value Disclosures [Abstract] Marketable Securities and Fair Value MeasurementsMarketable Securities and Fair Value Measurements
The Company's marketable securities consist of corporate bonds and government securities which are adjusted to fair value as of each balance sheet date based on quoted prices, which are considered Level 2 inputs.

The following is a summary of the Company's available-for-sale marketable securities measured at fair value on a recurring basis.

September 30, 2024 (dollars in millions)	
Valuation Hierarchy	
Amortized Cost	
Gross Unrealized Gains	
Gross Unrealized Losses	
Fair Value	
Corporate bonds Level 2	\$1,028.8
Government securities Level 2	\$1,032.9
Total	\$1,032.3

December 31, 2023 (dollars in millions)	
Valuation Hierarchy	
Amortized Cost	
Gross Unrealized Gains	
Gross Unrealized Losses	
Fair Value	
Corporate bonds Level 2	\$934.4
Government securities Level 2	\$931.3
Total	\$952.4

The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.

The carrying values of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these assets and liabilities.

-References

No definition available.

+ Details

Name:us-gaap_FairValueDisclosuresAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 107-Publisher FASB-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 100-Publisher FASB-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2E-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 940-SubTopic 820-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/214748119/940-820-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 940-SubTopic 820-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/214748119/940-820-50-1)

+ Details

Name:us-gaap_FairValueDisclosuresTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML:**38-R12.htm **IDEA:**XBRL-DOCUMENT
Property, Equipment and Leasehold Improvements9 Months Ended Sep. 30, 2024
Property, Plant and Equipment [Abstract] **Property, Equipment and Leasehold Improvements**
Property, Equipment and Leasehold Improvements

Property, equipment and leasehold improvements consist of the following:

December 31, 2023	(dollars in millions) September 30, 2024
Laboratory equipment\$19.4; \$18.5; Leasehold improvements9.3; 11.5; Office equipment2.6; 2.6; Total property, equipment and leasehold improvements 31.3; 32.6; Less: accumulated depreciation and amortization (24.5) (21.1) Property, equipment and leasehold improvements, net \$6.8; \$11.5;	

During the three and nine months ended September 30, 2024, the Company wrote-off leasehold improvements totaling \$2.4 million resulting from the termination of the lease for its laboratory and office space at 101 College Street, as discussed below in Note 6, Right-of-Use Assets and Liabilities.

During the three months ended September 30, 2024 and 2023, the Company recognized depreciation and amortization expense of \$1.1 million and \$1.2 million, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized depreciation and amortization expense of \$3.5 million and \$3.6 million, respectively.

- References

No definition available.

+ Details

Name:us-gaap_PropertyPlantAndEquipmentAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

- Definition

The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/360/tableOfContent>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 6-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-6>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 7-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-7>

+ Details

Name:us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML:**39-R13.htm **IDEA:**XBRL-DOCUMENT
Right-of-Use Assets and Liabilities9 Months Ended Sep. 30, 2024

Leases [Abstract] [Right-of-Use Assets and Liabilities](#)[Right-of-Use Assets and Liabilities](#)

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets and operating lease liabilities in the condensed consolidated balance sheets.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments, which ranges from 3.0% to 7.5%. Lease expense is recognized on a straight-line basis over the lease term. The Company considers options to extend or terminate leases in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised.

In August 2024, the Company entered into a Lease Termination Agreement with 101 College Street LLC (the "Landlord"). Under the terms of the Lease Termination Agreement, the lease, by and between the Company and the Landlord, dated May 4, 2021 (as amended, the "Terminated Lease"), for certain leased premises of approximately 160,000 square feet of laboratory and office space, was terminated in full, effective August 15, 2024. The leased premises were expected to be occupied by the Company in 2025. In connection with the Lease Termination Agreement and as consideration for the Landlord's agreement to terminate the lease for its laboratory and office space at 101 College Street in full, the Company agreed to pay to the Landlord a one-time cash termination fee in the amount of \$41.5 million and wrote-off \$1.9 million of prepaid rent, both of which are recognized in "Lease termination costs" on the condensed consolidated statements of operations. The Company also cancelled its previously issued letter of credit in the amount of \$5.5 million.

The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than October 2025. The leases have a weighted average remaining term of approximately nine months.

The components of lease expense were as follows:

Nine Months EndedSeptember 30, (dollars in millions)2024-2023		: Three Months EndedSeptember 30, (dollars in millions)2024-2023	
Operating lease cost	\$0.5	\$0.5	\$1.5
	\$1.5	\$1.5	

Supplemental cash flow information related to leases was as follows:

Nine Months EndedSeptember 30, (dollars in millions)2024-2023		Cash paid for amounts included in the measurement of lease liabilities:-		Operating cash flows from operating leases
				\$1.6
				\$1.5

Maturities of operating lease liabilities as of September 30, 2024, were as follows:

2025		0.5	Total lease payments	0.9	Less: imputed interest	Total	\$0.9;	(dollars in millions) Remainder of 2024	\$0.4

-References

No definition available.

+ Details

Name:us-gaap_LeasesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB> -URI <https://asc.fasb.org/842-20/tableOfContent>

+ Details

Name:us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 40 R14.htm IDEA: XBRL DOCUMENT Accounts Payable and Accrued Liabilities9 Months Ended Sep. 30, 2024

Payables and Accruals [Abstract] [Accounts Payable and Accrued Liabilities](#)[Accounts Payable and Accrued Liabilities](#)

Accounts payable and accrued liabilities consisted of the following:

										(dollars in millions) September 30, 2024																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
<u>December 31, 2023</u>																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
Accounts payable										\$17.7	Accrued liabilities										Research and development expenses	29.1	43.1	Employee expenses	19.9	25.7	Income taxes	4.1	0.7	General and administrative																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
and commercial expenses										2.7	2.4	Professional fees										2.4	2.5	Total accounts payable and accrued liabilities																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			</

-Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20)) -Publisher FASB) -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24)) -Publisher FASB) -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1-Publisher FASB> -URI <https://asc.fasb.org/1943274/2147483384/720-30-45-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB) -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_PayablesAndAccrualsAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type: duration XML 41 R15.htm IDEA: XBRL DOCUMENT

Long-Term Debt 9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract] Long-Term DebtLong-Term Debt

Debt obligations consisted of the following:

Rate September 30, 2024 (dollars in millions) Maturity Date Interest
December 31, 2023

2018 Assistance Agreement Debt 09/28 3.25% \$0.8 \$1.0 Less: current installments (0.2) (0.2) Total long-term debt \$0.6 \$0.8

In June 2018, the Company entered into an assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed \$2.0 million under the 2018 Assistance Agreement in September 2018, of which \$1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of \$2.0 million plus liquidated damages of 7.5% of the total amount of funding received.

Minimum future principal payments on long-term debt are as follows:

2025 0.2 2026 0.2 2027 0.2 2028 0.2 Total \$0.8 (dollars in millions) Remainder of 2024 \$—

During the three and nine months ended September 30, 2024 and 2023, interest expense was immaterial.

- References

No definition available.

+ Details

Name:us-gaap_DebtDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(c\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.4-08(c))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45->

~~2Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1C-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1E-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1E-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1I-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1I-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1I-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1I-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1I-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1I-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I)~~

+ Details

Name:us-gaap_DebtDisclosureTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML 42 R16.htm IDEA: XBRL DOCUMENT**
Equity **9 Months Ended**
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract] EquityEquity
Equity Distribution Agreements

In November 2023, the Company amended and restated the Equity Distribution Agreement with Piper Sandler & Company ("Piper Sandler") and Cantor Fitzgerald & Co. ("Cantor"), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately \$262.8 million of the common stock registered under a universal shelf registration statement pursuant to one or more "at-the-market" offerings. During the nine months ended September 30, 2024, no shares were issued under this agreement.

Stock-based Compensation

2018 Employee Stock Purchase Plan

In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company's then-outstanding common stock, effective as of January 1 of each year. As of September 30, 2024, 3,035,594 shares remained available for purchase. During the nine months ended September 30, 2024 and 2023, the Company issued 85,119 and 78,528 shares of common stock, respectively, under the 2018 ESPP.

2018 Stock Incentive Plan

In September 2018, the Company's board of directors adopted, and the Company's stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company's initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock, plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Fourth Amendment to the Company's Incentive Share Plan, which was terminated in September 2018, that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right, plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company's common stock, 4% of the number of shares of the Company's common stock outstanding on the first day of the year or an amount determined by the Company's board of directors. As of September 30, 2024, 3,434,422 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.

Compensation Expense

During the three months ended September 30, 2024 and 2023, the Company recognized compensation expense of \$24.7 million and \$16.7 million, respectively, related to the issuance of incentive awards, including \$0.1 million and \$0.2 million, respectively, related to the 2018 ESPP. During the nine months ended September 30, 2024 and 2023, the Company recognized compensation expense of \$64.9 million and \$54.9 million, respectively, relating to the issuance of incentive awards, including \$0.6 million and \$0.7 million, respectively, related to the 2018 ESPP.

As of September 30, 2024, there was \$75.1 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.2 years.

Stock Options

The fair value of the stock options granted during the nine months ended September 30, 2024 and 2023 was determined using the Black-Scholes option pricing model with the following assumptions:

	September 30, 2023	September 30, 2024
Expected volatility ⁽¹⁾	72.8 – 75.6%	71.5 – 74.2%
Expected term (years) ⁽²⁾	5.4 – 5.5	5.5 – 7.0
Risk free interest rate ⁽³⁾	3.5% – 4.6%	3.4% – 4.3%
Expected dividend yield	0.0%	0.0%
Exercise price	\$24.85 – \$47.00	\$23.23 – \$36.27

⁽¹⁾ Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.
⁽²⁾ Expected term is calculated based on the Company's historical experience.
⁽³⁾ Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.

A summary of the stock option activity during the nine months ended September 30, 2024 is presented below. Included in the table are stock options granted to employees and directors under

the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4);

exercise price)

Options

Weighted-Average

Exercise-Price

Weighted-Average

Remaining-Contractual

Term (Years)

Aggregate Intrinsic Value

Outstanding as of December 31, 2023

7,933,794

\$45.22

7.2

\$62.6

Granted 1,145,629

\$41.74

Exercised (269,028)

\$21.53

Forfeited (855,007)

\$56.63

Outstanding as of September 30, 2024

7,955,388

\$44.32

6.9

\$12.2

Vested and exercisable as of September 30, 2024

5,219,887

\$44.42

6.0

\$11.8

Vested and expected to vest as of September 30, 2024

7,724,552

\$44.45

6.9

\$12.2

(dollars in millions, except weighted-average

The weighted-average grant date fair value per share of options granted during the nine months ended September 30, 2024 and 2023 was \$27.69 and \$22.51, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2024 and 2023 was \$3.6 million and \$0.9 million, respectively.

Restricted Stock Units ("RSUs")

A summary of RSU activity during the nine months ended September 30, 2024 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4);

Weighted-Average

Grant Date

Fair Value Per

Share

Unvested RSUs as of December 31, 2023

1,151,856

\$38.16

Granted 1,722,239

\$44.69

Vested (316,065)

\$39.01

Forfeited (201,028)

\$42.62

Unvested RSUs as of September 30, 2024

2,357,002

\$42.43

Shares

The total fair value of RSUs vested during the nine months ended September 30, 2024 and 2023 was \$12.3 million and \$6.2 million, respectively.

- Definition

The entire disclosure for share-based payment arrangement.

+ References

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-718-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(b\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(b)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(h\)\(2\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(h)(2)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(l\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(l)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration

- References

No definition available.

+ Details

Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration XML 43 R17.htm IDEA: XBRL DOCUMENT
Income Taxes **9 Months Ended**
Sep. 30, 2024

Income Tax Disclosure [Abstract] Income Taxes

Income Taxes A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.

For the three months ended September 30, 2024, the Company recognized income tax expense of \$0.6 million, resulting in an effective tax rate of (1.3)%, as compared to no income tax expense or benefit recognized in the same period for 2023, resulting in an effective tax rate of 0.0%. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended September 30, 2024 and the Company's overall effective tax rate of (1.3)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended September 30, 2023 and the Company's overall effective tax rate of 0.0% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.

For the nine months ended September 30, 2024, the Company recognized income tax expense of \$1.0 million resulting in an effective tax rate of (0.6)%, as compared to income tax benefit of \$0.7 million resulting in an effective tax rate of 0.3% in the same period for 2023. The primary reconciling items between the federal statutory rate of 21.0% for the nine months ended September 30, 2024 and the Company's overall effective tax rate of (0.6)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the nine months ended September 30, 2023 and the Company's overall effective tax rate of 0.3% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

- Definition

The entire disclosure for income tax.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 231-Publisher FASB-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>**Reference 3:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12C-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>**Reference 4:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12B-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 270-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.I.5.Q1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.I.5.Q1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)**Reference 7:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/740/tableOfContent>**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>**Reference 11:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 21-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 11.C\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 11.C)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2)

+ Details

Name:us-gaap_IncomeTaxDisclosureTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlock**ItemType** **Balance Type:**na **Period Type:**duration **XML:** 44 R18.htm **IDEA:** XBRL DOCUMENT

Net Loss Per Share **9 Months Ended**
Sep. 30, 2024
Earnings Per Share [Abstract] **Net Loss Per Share****Net Loss Per Share**

Basic and diluted loss per common share was calculated as follows:

<u>For the Nine Months Ended September 30,</u>					<u>For the Three Months Ended September 30,</u>						
(dollars and shares in millions, except per share amounts)											
2024		2023		2024		2023		2024		2023	
Net loss		\$(49.2)		\$(64.0)		\$(153.8)		\$(212.5)		Weighted average number of common shares outstanding	
— basic and diluted		72.1		54.1		71.9		53.6		Net loss per common share	
— basic and diluted		\$(0.68)		\$(1.18)		\$(2.14)		\$(3.97)			

The weighted average number of common shares included in the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2024 gives effect to pre-funded warrants issued in November 2023 which allow holders to acquire up 3,422,380 shares of common stock at a nominal exercise price of \$0.001 per share and are classified as equity. The shares underlying the pre-funded warrants are exercisable for little or no consideration and therefore the underlying shares are considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted average number of common shares outstanding in basic and diluted net loss per share for common share.

The Company reported net losses for each of the three and nine months ended September 30, 2024 and 2023, and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:

<u>For the Three and Nine Months Ended September 30,</u>	
<u>2024</u>	<u>2023</u>
Stock options	0.0
RSUs	2.4
	1.1
	(10.4)
	(9.1)

- References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrl:string**ItemType** **Balance Type:**na **Period Type:**duration

- Definition

The entire disclosure for earnings per share:

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/260/tableOfContent>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-3>

[+ Details](#)

Name:us-gaap_EarningsPerShareTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML:**45-R19.htm **IDEA:**XBRL-DOCUMENT

Equity Method Investments9 Months Ended

Sep. 30, 2024

Equity Method Investments and Joint Ventures [Abstract] [Equity Method Investments](#)**Equity Method Investments**

In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 44.3% and 45.2% as of September 30, 2024 and 2023, respectively, as a result of vested incentive units.

Net loss of Oerth Bio for the three months ended September 30, 2024 and 2023 totaled \$1.2 million and \$3.2 million, respectively. The Company recognized equity method losses of zero and \$0.1 million for the three months ended September 30, 2024 and 2023, respectively. Net loss of Oerth Bio for the nine months ended September 30, 2024 and 2023 totaled \$2.7 million and \$8.5 million, respectively. The Company recognized equity method losses of zero and \$2.5 million for the nine months ended September 30, 2024 and 2023, respectively.

As of September 30, 2024 and 2023, the Company's carrying value of the investment was zero.

The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and nine months ended September 30, 2024 and 2023 were immaterial.

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/214748156/740-323-50-2](http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/214748156/740-323-50-2)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 4:** <http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Topic-323-Publisher-FASB-URI-https://asc.fasb.org/323/tableOfContent>

[+ Details](#)

Name:us-gaap_EquityMethodInvestmentsDisclosureTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML:**46-R20.htm **IDEA:**XBRL-DOCUMENT

Commitments and Contingencies9 Months Ended

Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract] [Commitments and Contingencies](#)**Commitments and Contingencies**

From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred. The Company's accrual for such matters totaled \$5.0 million and

\$10.0 million as of September 30, 2024 and 2023, respectively, related to the Amended License Agreement with Yale University ("Yale"), as further described below.

Clinical and Preclinical Development and Licensing Arrangements

From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.

In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.

Yale University License Agreement

In June 2024, the Company entered into an Amended and Restated License Agreement (the "Amended License Agreement") with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of \$14.95 million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, Research Collaboration and License Agreements, for a description of the agreements). The Company will make another \$5.0 million payment on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to \$15.0 million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined "collaboration products," and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined "meaningfully involved products."

The Company's obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the requirement to pay to Yale a minimum license maintenance royalty totaling \$0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately \$3.0 million for the first licensed product and approximately \$1.5 million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from \$0.2 million to \$0.5 million.

FMI Agreement

In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement with Foundation Medicine, Inc. (the "FMI Agreement") for the development and commercialization of one or more of Foundation Medicine, Inc.'s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.

The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine, Inc. may terminate the FMI

Agreement with respect to an applicable program, (a) if a reasonably necessary third party license is not secured by Foundation Medicine, Inc. or if the Company does not consent to payments for such license, (b) if Foundation Medicine, Inc. reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain licensing and other rights and certain obligations of Foundation Medicine, Inc. survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine, Inc. and may also be required to pay a termination fee, if applicable.

ARV-766

In exchange for the development of FoundationOne® Liquid CDx as a companion diagnostic for use with ARV-766 for androgen receptor ("AR") metastatic castration-resistant prostate cancer in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars in addition to certain validation fees per sample and related pass-through costs.

- References

No definition available.

+ Details

Name:us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type: na Period Type:duration

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContent>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent>

[+ Details](#)

Name:us-gaap_CommitmentsAndContingenciesDisclosureTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType

Balance Type:na **Period Type:**duration **XML 47 R21.htm IDEA:** XBRL DOCUMENT

Pay vs Performance Disclosure - USD (\$) \$ in Millions3 Months Ended9 Months Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Pay vs Performance Disclosure **Net income (loss)**\$ (49.2)\$ (64.0)\$ (153.8)\$ (212.5)

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection v-Paragraph 1>

[+ Details](#)

Name:ecd_PvpTable **Namespace Prefix:**ecd_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 13:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 17:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>**Reference 18:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-599-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)**Reference 23:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)

URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>

[+ Details](#)

Name:us-gaap_NetIncomeLoss_Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

XML 48 R22.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements 3 Months Ended

Sep. 30, 2024

Trading Arrangements, by Individual Rule 10b5-1 Arrangement Adoptedfalse Non-Rule 10b5-1 Arrangement Adoptedfalse Rule 10b5-1

Arrangement Terminatedfalse Non-Rule 10b5-1 Arrangement Terminatedfalse

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

[+ Details](#)

Name:ecd_NonRule10b51ArrAdoptedFlag_Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

[+ Details](#)

Name:ecd_NonRule10b51ArrTrmntdFlag_Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

[+ Details](#)

Name:ecd_Rule10b51ArrAdoptedFlag_Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

[+ Details](#)

Name:ecd_Rule10b51ArrTrmntdFlag_Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A

+ Details

Name:ecd_TradingArrByIndTable_Namespace-Prefix:ecd_Data-Type:xbrli:stringItemType Balance-Type:na Period-Type:duration XML-49 R23.htm-IDEA: XBRL-DOCUMENT

Summary of Accounting Pronouncements and Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024

Accounting Policies [Abstract] Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended ("Exchange Act"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission ("SEC") rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023, forming part of Arvinas' 2023 Annual Report on Form 10-K filed with the SEC on February 27, 2024.

Use of Estimates

The preparation of the Company's unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.

Risks and Uncertainties

The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company's products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.

Risks and Uncertainties Accounting Pronouncements

Accounting Pronouncements

Recently Adopted Accounting Pronouncements

There have been no recently adopted accounting pronouncements that have had a material impact on the Company's unaudited condensed consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

Segment Reporting (Topic 280) – In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting – Improvements to Reportable Segment Disclosures," which requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures

required by this ASU and all existing segment disclosures in Accounting Standard Codification ("ASC") 280, "Segment Reporting." The requirements of the ASU are effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact ASU No. 2023-07 will have on its condensed consolidated financial statements.

Income Taxes (Topic 740) – In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements. **Cash, Cash**

Equivalents and Restricted CashCash, Cash Equivalents and Restricted Cash

Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as was required under the terms of the Terminated Lease, as discussed below in Note 6.

Right-of-Use Assets and Liabilities:

- References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract_Namespace-Prefix:us-gaap_Data-Type:xbrli:stringItemType Balance-Type:na Period-Type:duration

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name:us-gaap_BasisOfAccountingPolicyPolicyTextBlock_Namespace-Prefix:us-gaap_Data-Type:dtr-types:textBlockItemType Balance-Type:na Period-Type:duration

- Definition

Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-03\(1\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-03(1)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-599-1)**Reference 2:** <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-1>

+ Details

Name:us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlock **ItemType:**Balance **Type:**na **Period Type:**duration

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 825-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478898/942-825-50-1>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)

+ Details

Name:us-gaap_ConcentrationRiskCreditRisk **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlock **ItemType:**Balance **Type:**na **Period Type:**duration

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name:us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlock **ItemType:**Balance **Type:**na **Period Type:**duration

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9>**Reference 2:** <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 11-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 12-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>**Reference 7:** <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-8>

[+ Details](#)
Name:us-gaap_UseOfEstimates_Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 50 R24.htm IDEA: XBRL DOCUMENT Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023:

(dollars in millions) September 30, 2024

<u>September 30, 2023</u>	
Cash and cash equivalents\$85.2`-\$113.7`Restricted cash —	5.5 — <u>Cash, cash equivalents and restricted cash</u> \$85.2`i`\$119.2`i` <u>Schedule of Restrictions on Cash and Cash Equivalents</u>

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023:

(dollars in millions) September 30, 2024

<u>September 30, 2023</u>	
Cash and cash equivalents\$85.2`-\$113.7`Restricted cash —	5.5 — <u>Cash, cash equivalents and restricted cash</u> \$85.2`i`\$119.2`i`

- References

No definition available.

[+ Details](#)
Name:us-gaap_AccountingPoliciesAbstract_Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the components of cash and cash equivalents:

+ References

No definition available.

[+ Details](#)
Name:us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType

Balance Type:na Period Type:duration

- Definition

Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(1\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(1)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 8-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>

+ Details

Name:us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 51-R25.htm IDEA: XBRL DOCUMENT Research Collaboration and License Agreements (Tables)9 Months Ended Sep. 30, 2024 Research Collaboration And License Agreements [Abstract] Schedule of Contract Balances

Changes in the Company's contract balances for the nine months ended September 30, 2024 and 2023 were as follows:

September 30, 2023		(dollars in millions) September 30, 2024	
Accounts receivable related to collaborations	Beginning balance \$ — \$ 1.0 Additions 8.7 21.7 Payments received (1.4) (7.0) Ending balance \$ 7.3 \$ 15.7	Accounts payable related to collaborations	Beginning balance \$ 13.1 \$ 5.0 Additions 43.5 31.0 Payments made (42.3) (6.7) Ending balance \$ 14.3 \$ 29.3
Contract assets:		Contract assets:	
Contract asset	Beginning balance \$ 9.4 \$ 10.7 Additions 3.0 — Amortization (3.6) (2.0) Ending balance \$ 8.8 \$ 8.7	Contract liabilities: Deferred revenue	Beginning balance \$ 549.2 \$ 623.7 Additions to collaboration agreements 130.0 1.5 Revenue recognized from balances held at the beginning of the period (82.0) (119.1) Revenue recognized from new collaborations (93.5) — Ending balance \$ 503.7 \$ 506.1
		Schedule of Transaction Price Allocated to Performance Obligations	

The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of September 30, 2024 totaled \$503.7 million, which is expected to be recognized in the following periods:

		(dollars in millions) Remainder of 2024 \$
84.1 2025153.4 2026105.0 202757.6 202859.8 202943.8	Total	\$503.7

- Definition

Research Collaboration And License Agreements

+ References

No definition available.

+ Details

Name:arvn_ResearchCollaborationAndLicenseAgreementsAbstract Namespace Prefix:arvn_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10>

+ Details

Name:us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType
Balance Type:na Period Type:duration

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)\(1\)-SubTopic 10-Topic 606-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13](http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)(1)-SubTopic 10-Topic 606-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13)

+ Details

Name:us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock Namespace Prefix:us-gaap_ Data
Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML-52-R26.htm IDEA: XBRL DOCUMENT
Marketable Securities and Fair Value Measurements (Tables)9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract] [Schedule of Available-for-Sale Marketable Securities](#)

The following is a summary of the Company's available-for-sale marketable securities measured at fair value on a recurring basis.

September 30, 2024 (dollars in millions)	
Valuation	
Hierarchy	
Amortized	
Cost	
Gross	
Unrealized	
Gains	
Gross	
Unrealized	
Losses-Fair Value	
Corporate bonds-Level 2	\$1,028.8
\$4.4	\$(0.3)
\$1,032.9	Government securities Level 2
3.5	—
3.5	Total
\$1,032.3	\$(4.4)
\$(0.3)	\$1,036.4

December 31, 2023 (dollars in millions)	
Valuation	
Hierarchy	
Amortized	
Cost	
Gross	
Unrealized	
Gains	
Gross	
Unrealized	
Losses-Fair Value	
Corporate bonds-Level 2	\$934.4
\$1.5	\$(4.6)
\$931.3	Government securities Level 2
18.0	—
18.0	Total
\$952.4	\$(1.5)
\$(4.6)	\$949.3

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9)Reference 2:
<http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 3:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(aa\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (aa)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(aaa\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (aaa)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 9:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 10:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 11:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 12:
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML:53 R27.htm IDEA: XBRL DOCUMENT Property, Equipment and Leasehold Improvements (Tables)9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Schedule of Property, Equipment and Leasehold Improvements

Property, equipment and leasehold improvements consist of the following:

(dollars in millions) **September 30, 2024**

December 31, 2023						
Laboratory equipment	\$19.4	\$18.5	Leasehold improvements	9.3	11.5	Office equipment
					2.6	2.6
						Total property, equipment and leasehold improvements
						31.3 32.6
						Less:
accumulated depreciation and amortization	(24.5)	(21.1)				
						Property, equipment and leasehold improvements, net
						\$6.8 \$11.5

- References

No definition available.

+ Details

Name:us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1-SubTopic 10-Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details

Name:us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML:54 R28.htm IDEA: XBRL DOCUMENT Right-of-Use Assets and Liabilities (Tables)9 Months Ended Sep. 30, 2024 Leases [Abstract] Schedule of Components of Lease Expense

The components of lease expense were as follows:

					: Three Months EndedSeptember 30,					
Nine Months EndedSeptember 30,										
(dollars in millions)					2024 2023 2024 2023					
Operating lease cost					\$0.5	\$0.5	\$1.5	\$1.5	Schedule of Supplemental Cash Flow Information Related to Leases	

Supplemental cash flow information related to leases was as follows:

Nine Months EndedSeptember 30,			
(dollars in millions)		2024 2023	
Cash paid for amounts included in the measurement of lease liabilities	-:-	Operating cash flows from operating leases	\$1.6
			\$1.5
			Schedule of Maturities of Operating Lease Liabilities

Maturities of operating lease liabilities as of September 30, 2024, were as follows:

		(dollars in millions)		Remainder of 2024	\$0.4
2025	0.5	Total lease payments	0.9	Less: imputed interest	-
				Total	\$0.9

- Definition

Supplemental cash flow information related to leases.

+ References

No definition available.

+ Details

Name:arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock Namespace Prefix:arvn_ Data Type:dtr-types:1:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4>

+ Details

Name:us-gaap_LeaseCostTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_LeasesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-6>

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 55 R29.htm IDEA: XBRL DOCUMENT Accounts Payable and Accrued Liabilities (Tables)9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Schedule of Components of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

December 31, 2023										(dollars in millions) September 30, 2024												
Accounts payable	\$17.7	\$17.8	Accrued liabilities	Research and development expenses	29.1	43.1	Employee expenses	19.9	25.7	Income taxes	4.1	0.7	General and administrative	and commercial expenses	2.7	2.4	Professional fees	2.4	2.5	Total accounts payable and accrued liabilities	\$75.9	\$92.2

- References

No definition available.

+ Details

Name:us-gaap_PayablesAndAccrualsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name:us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 56 R30.htm IDEA: XBRL DOCUMENT Long-Term Debt (Tables)9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Schedule of Long-Term Debt

Debt obligations consisted of the following:

<u>Rate September 30, 2024</u> <u>December 31, 2023</u>		<u>(dollars in millions)</u> <u>Maturity Date</u> <u>Interest</u>					
2018 Assistance Agreement Debt	09/28-3.25%-\$0.8	\$1.0	Less: current installments	{0.2} {0.2}	Total long-term debt	{0.6}	{0.8}

Schedule of Minimum Future Payments on Long-Term Debt

Minimum future principal payments on long-term debt are as follows:

2025 0.2 2026 0.2 2027 0.2 2028 0.2		(dollars in millions) Remainder of 2024 \$	Total	{0.8}

- References

No definition available.

[+ Details](#)

Name:us-gaap_DebtDisclosureAbstract Namespace Prefix:us-gaap Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69B-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 3: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69E-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.12-04\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.12-04(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3)Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 470-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6>Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7>

Name:us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na
Period Type:duration

~~**Tabular disclosure of maturity and sinking fund requirement for long-term debt.**~~

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification Section 50-Paragraph 1-SubTopic 10-Topic 470-Publisher FASB-URI https://asc.fasb.org/1943274/2147481544/470-10-50-1>

Name:us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 57 R31.htm IDEA: XBRL DOCUMENT

~~Sep. 30, 2024~~

~~Share-Based Payment Arrangement [Abstract] Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted~~

The fair value of the stock options granted during the nine months ended September 30, 2024 and 2023 was determined using the Black-Scholes option pricing model with the following assumptions:

- September 30, 2024

September 30, 2023

~~Expected volatility σ~~

~~72.8 - 75.6%~~~~71.5 - 74.2%~~~~Expected term (years) ⁽²⁾~~

~~5.4-5.5~~

~~5.5 - 7.0~~

~~Risk-free interest rate (3)~~

~~3.5% - 4.6%~~

~~3.4% - 4.3% Expected dividend yield 0 % 0 % Exercise price~~

~~\$24.85 - \$47.00~~~~\$23.23 - \$36.27~~

⁽¹⁾ Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.

⁽²⁾ Expected term is calculated based on the Company's historical experience.

(2) Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant. **Schedule of Stock Option Activity**

A summary of the stock option activity during the nine months ended September 30, 2024 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

(dollars in millions, except weighted average)

~~exercise price~~

Options

Weighted Average
Exercise Price

Exercise Price
Weighted Average

Weighted Average
Remaining Contractual

Term (Years) Aggregate Intrinsic Value

Outstanding as of December 31, 2023 7,933,794 \$45.22 -7.2 \$62.6 Granted 1,145,629 \$41.74 Exercised (269,028) \$21.53 Forfeited (855,007) \$56.63

Outstanding as of September 30, 2024 7,955,388 \$44.32 6.9 \$12.2

Vested and exercisable as of September 30, 2024 5,219,887' \$44.42 6.0 \$11.8

~~Vested and expected to vest as of September 30, 2024 7,724,552 \$44.45 6.9 \$12.2~~ ***Schedule of Restricted Stock Grant Activity***

A summary of RSU activity during the nine months ended September 30, 2024 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

Shares

Weighted A

Grant Date
Fair Value Per

Fair-Value Share

~~Unvested RSUs as of December 31, 2023 1,151,856 \$38.16 Granted 1,722,239 \$44.69 Vested (316,065) \$39.01 Forfeited (201,028) \$42.62~~

Unvested RSUs as of September 30, 2024 2,357,002; \$42.43

-References

No definition available.

+Details

Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of the changes in outstanding nonvested restricted stock shares.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Subparagraph \(c\)-Paragraph 2-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Subparagraph (c)-Paragraph 2-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)
Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)
Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments; (b) expected volatility of the entity's shares; (c) expected dividends; (d) risk-free rate(s); and (e) discount for post-vesting restrictions.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph \(f\)\(2\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (f)(2)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML 58 R32.htm IDEA:** XBRL DOCUMENT

Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024

Earnings Per Share [Abstract] - Schedule of Basic and Diluted Loss per Common Share

Basic and diluted loss per common share was calculated as follows:

For the Nine Months EndedSeptember 30:	For the Three Months EndedSeptember 30:
(dollars and shares in millions, except per share amounts)2024-2023-2024-2023	
Net loss\$(49.2)-\$(64.0)-\$(153.8)-\$(212.5)	Weighted average number of common shares outstanding
- basic and diluted72.1154.1171.9153.6	Net loss per common share
- basic and diluted\$(0.68)\$(1.18)\$(2.14)\$(3.97)	

Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share

The Company reported net losses for each of the three and nine months ended September 30, 2024 and 2023, and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:

For the Three and Nine Months EndedSeptember 30:

2024-2023	Stock options	0.0-0.0	RSUs	2.4-1.1	10.419.1

-References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

-Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)

+ Details

Name:us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration

-Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)

+ Details

Name:us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML 59 R33.htm IDEA:** XBRL DOCUMENT

Nature of Business and Basis of Presentation (Details) \$ in Billions Sep. 30, 2024

	USD (\$)	Organization, Consolidation and Presentation of Financial
Statements [Abstract] Cash, cash equivalents, restricted cash and marketable securities	\$ 1.1	

-Definition

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

+ References

No definition available.

+ Details

Name:arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities **Namespace Prefix:**arvn_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

-References

No definition available.

+ Details

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract_Namespace Prefix:us-gaap_Data Type:

xbri:stringItemType Balance Type:na Period Type:duration XML 60 R34.htm IDEA: XBRL DOCUMENT

Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation

	Sep. 30,	Dec. 31,	Sep. 30,	Dec. 31,		
(Details) - USD (\$) \$ in Millions	2024	2023	2023	2022		
Accounting Policies [Abstract]						
Cash and cash equivalents	\$ 85.2	\$ 311.7	\$ 113.7	Restricted cash	0.05	55.5
Cash, cash equivalents and						
restricted cash	\$ 85.2	\$ 317.2	\$ 119.2	\$ 86.8		

- References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract_Namespace Prefix:us-gaap_Data Type:xbri:stringItemType Balance Type:na Period Type:

duration

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbri.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://www.xbri.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_CashAndCashEquivalentsAtCarryingValue_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbri.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gAAP_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gAAP_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.5-02\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>

+ Details

Name:us-gAAP_RestrictedCashCurrent Namespace Prefix:us-gAAP_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant XML 61 R35.htm IDEA: XBRL DOCUMENT

Research Collaboration and License Agreements - Additional Information 1 Months 3 Months 9 Months 12 Months 38 Months
(Details) - USD (\$)

Nov. 30, 2017

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2018

Sep. 30, 2024

May 31, 2024

Apr. 30, 2024

Dec. 31, 2023

Dec. 31, 2022

Jul. 31, 2021

Jun. 30, 2019

Research Collaboration And License Agreements [Line Items]	Contract with customer, liability	\$ 503,700,000	\$ 506,100,000						
\$ 503,700,000	\$ 506,100,000	\$ 503,700,000	\$ 549,200,000	\$ 623,700,000	Revenue, remaining performance obligation	503,700,000			
503,700,000	503,700,000	Contract revenue receivable if milestones achieved	8,800,000	8,700,000	8,800,000	8,700,000	8,800,000		
9,400,000	\$ 10,700,000	Collaboration contract asset and other assets	9,800,000	9,800,000	9,800,000	10,400,000	Revenue	102,400,000	
34,600,000	204,200,000	121,600,000	Net income (loss)	\$ (49,200,000)	\$ (64,000,000)	\$ (153,800,000)	\$ (212,500,000)	Net loss per common share, basic (in dollars per share)	\$ (0.68)
\$ (0.68)	\$ (1.18)	\$ (2.14)	\$ (3.97)	Net loss per common share, diluted (in dollars per share)	\$ (0.68)	\$ (1.18)	\$ (2.14)	\$ (3.97)	Updated Research Timelines
Research Collaboration And License Agreements [Line Items]	Contract with customer, liability	\$ 150,000,000	Contingent payments	\$ 1,010,000,000	0				
Revenue recognized	\$ 20,000,000	Payments received	0	Revenue, remaining performance obligation	\$ 130,000,000				
130,000,000	130,000,000	Capitalized costs	\$ 3,000,000	Pfizer, Inc.	Research Collaboration And License Agreements [Line Items]	Payments received	0	0	Pfizer, Inc.
\$ 1,000,000	\$ 28,000,000	0	Pfizer, Inc.	Collaboration Agreement	Research Collaboration And License Agreements [Line Items]	Contract revenue receivable if milestones achieved	\$ 650,000,000	0	Collaboration agreement direct and incremental costs incurred
12,900,000	12,900,000	Collaboration contract asset and other assets	12,900,000	12,900,000	12,900,000	12,900,000	12,900,000	12,900,000	Pfizer, Inc.
12,900,000	Pfizer, Inc.	Regulatory and Sales-Based Milestones / Maximum	Research Collaboration And License Agreements [Line Items]	Contract revenue receivable if milestones achieved	1,400,000,000	Pfizer, Inc.	Regulatory Milestone Related to Marketing Approvals	Research Collaboration And License Agreements [Line Items]	Payments received
0	Contract revenue receivable if milestones achieved	400,000,000	0	Pfizer, Inc.	Sales-Based Milestones	Research Collaboration And License Agreements [Line Items]	Contract revenue receivable if milestones achieved	\$ 1,000,000,000	0
0	Pfizer, Inc.	Sales-Based Milestone Payments / Maximum	Research Collaboration And License Agreements [Line Items]	Contract revenue receivable if milestones achieved	550,000,000	550,000,000	550,000,000	Pfizer, Inc.	Development Milestone Payments / Maximum
225,000,000	225,000,000	225,000,000	Pfizer, Inc.	Option Payments To License Agreement / Maximum	Research Collaboration And License Agreements [Line Items]	Contract revenue receivable if milestones achieved	37,500,000	37,500,000	37,500,000

[Bayer Collaboration Agreement](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Contract revenue receivable if milestones achieved](#) [\\$ 17,500,000](#) [Bayer Collaboration Agreement / Sales Based Milestone Payments](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Payments received](#) [0](#) [Bayer Collaboration Agreement / Sales Based Milestone Payments / Maximum](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Contract revenue receivable if milestones achieved](#) [490,000,000](#) [Bayer Collaboration Agreement / Research Funding Payments](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Payments received](#) [\\$ 1,500,000](#) [Contract revenue receivable if milestones achieved](#) [\\$ 12,000,000.0](#) [Bayer Collaboration Agreement / Development Milestone Payments](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Payments received](#) [0](#) [Bayer Collaboration Agreement / Development Milestone Payments / Maximum](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Contract revenue receivable if milestones achieved](#) [\\$ 197,500,000](#) [Genentech Research Collaboration And License Agreements \[Line Items\]](#) [Payments received](#) [\\$ 34,500,000](#) [0](#) [Additional upfront non-refundable amount received under previous agreement](#) [\\$ 11,000,000.0](#) [Genentech / Regulatory Milestone Related to Marketing Approvals](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Contract revenue receivable if milestones achieved](#) [52,500,000](#) [52,500,000](#) [52,500,000](#) [Genentech / Development Milestone Payments / Maximum](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Contract revenue receivable if milestones achieved](#) [44,000,000](#) [44,000,000](#) [44,000,000](#) [Genentech / Commercial Milestones](#) [Research Collaboration And License Agreements \[Line Items\]](#) [Contract revenue receivable if milestones achieved](#) [\\$ 60,000,000](#) [\\$ 60,000,000](#) [\\$ 60,000,000](#)

[- Definition](#)

[Additional upfront non-refundable amount received under previous agreement.](#)

[+ References](#)

[No definition available.](#)

[+ Details](#)
[Name:arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement](#) [Namespace Prefix:arvn](#) [Data Type:xbrli:monetaryItemType](#) [Balance Type:debit](#) [Period Type:duration](#)

[- Definition](#)

[Collaboration contract asset and other assets.](#)

[+ References](#)

[No definition available.](#)

[+ Details](#)
[Name:arvn_CollaborationContractAssetAndOtherAssets](#) [Namespace Prefix:arvn](#) [Data Type:xbrli:monetaryItemType](#) [Balance Type:debit](#) [Period Type:instant](#)

[- Definition](#)

[Direct and incremental costs incurred to obtain the contract.](#)

[+ References](#)

[No definition available.](#)

[+ Details](#)
[Name:arvn_DirectAndIncrementalCostsIncurredToObtainTheContract](#) [Namespace Prefix:arvn](#) [Data Type:xbrli:monetaryItemType](#) [Balance Type:debit](#) [Period Type:duration](#)

[- Definition](#)

[Research collaboration and license agreements.](#)

[+ References](#)

[No definition available.](#)

[+ Details](#)
[Name:arvn_ResearchCollaborationAndLicenseAgreementsLineItems](#) [Namespace Prefix:arvn](#) [Data Type:xbrli:stringItemType](#) [Balance Type:na](#) [Period Type:duration](#)

[- Definition](#)

[Revenue, Remaining Performance Obligation, Contingent Payments](#)

[+ References](#)

[No definition available.](#)

[+ Details](#)
[Name:arvn_RevenueRemainingPerformanceObligationContingentPayments](#) [Namespace Prefix:arvn](#) [Data Type:xbrli:monetaryItemType](#) [Balance Type:credit](#) [Period Type:instant](#)

[- Definition](#)

[Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.](#)

[+ References](#)

[Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 340-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479483/340-40-50-3](#)

+ Details

Name:us-gaap_ContractCapitalizedContractCostGross Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)

+ Details

Name:us-gaap_ContractWithCustomerAssetNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2>

+ Details

Name:us-gaap_ContractWithCustomerLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period

Type:instant

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>

[+ Details](#)

Name:us-gaap_EarningsPerShareBasic **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-52-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482635/260-10-55-52>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(g\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(g)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1>**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-15-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482635/260-10-55-15>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(e\)\(4\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(e)(4)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-7)**Reference 12:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-2>**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B)**Reference 14:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 15:** <http://www.xbrl.org/2002/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-2>

~~20-Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-200-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-200-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\(25\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03(25))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-04\(27\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-04(27))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-04\(23\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-04(23))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-7>~~

[+ Details](#)

Name:us-gaap_EarningsPerShareDiluted **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 13:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 17:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>**Reference 18:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 23:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 27:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 28:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 29:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 30:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 31:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 32:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)**Reference 33:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>**Reference 34:** <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>**Reference 35:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)**Reference 36:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)**Reference 37:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)

[+ Details](#)

~~***Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration***~~

[- Definition](#)

~~***Cash received from collaborators during the current period.***~~

[+ References](#)

~~***Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-25)***~~

+ Details

Name:us-gaap_ProceedsFromCollaborators_Namespace Prefix:us-gaap_Data Type:xbli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 11.L\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 11.L)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4)

+ Details

Name:us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> Name Accounting Standards Codification - Section 50 - Paragraph 13 - Subparagraph (a) SubTopic 10 - Topic 606 Publisher FASB URL <http://asc.fasb.org/1042274/2117470906/606-10-50-13>

+ Details

Name:us-gaap_RevenueRemainingPerformanceObligation_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 5:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 6:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 11:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)**Reference 21:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 23:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)

